{"id":{"674":"100000000000000000000675","6842":"100000000000000000006843","4917":"100000000000000000004918","5394":"100000000000000000005395","9227":"100000000000000000009228","8418":"100000000000000000008419","656":"100000000000000000000657","9903":"100000000000000000009904","3203":"100000000000000000003204","9994":"100000000000000000009995","4890":"100000000000000000004891","6855":"100000000000000000006856","148":"100000000000000000000149","7371":"100000000000000000007372","1183":"100000000000000000001184","7177":"100000000000000000007178","6727":"100000000000000000006728","1133":"100000000000000000001134","1916":"100000000000000000001917","7490":"100000000000000000007491","9947":"100000000000000000009948","9726":"100000000000000000009727","9081":"100000000000000000009082","9749":"100000000000000000009750","6308":"100000000000000000006309","420":"100000000000000000000421","5759":"100000000000000000005760","2171":"100000000000000000002172","8891":"100000000000000000008892","6513":"100000000000000000006514","1409":"100000000000000000001410","777":"100000000000000000000778","5636":"100000000000000000005637","9948":"100000000000000000009949","4203":"100000000000000000004204","6790":"100000000000000000006791","9589":"100000000000000000009590","1505":"100000000000000000001506","2363":"100000000000000000002364","1604":"100000000000000000001605","2743":"100000000000000000002744","1099":"100000000000000000001100","1553":"100000000000000000001554","3177":"100000000000000000003178","9166":"100000000000000000009167","3412":"100000000000000000003413","1161":"100000000000000000001162","1140":"100000000000000000001141","2664":"100000000000000000002665","6271":"100000000000000000006272","7714":"100000000000000000007715","6197":"100000000000000000006198","7397":"100000000000000000007398","4255":"100000000000000000004256","6419":"100000000000000000006420","749":"100000000000000000000750","9651":"100000000000000000009652","7115":"100000000000000000007116","4474":"100000000000000000004475","7883":"100000000000000000007884","9121":"100000000000000000009122","1392":"100000000000000000001393","2933":"100000000000000000002934","5705":"100000000000000000005706","2037":"100000000000000000002038","4726":"100000000000000000004727","6891":"100000000000000000006892","8178":"100000000000000000008179","6351":"100000000000000000006352","9831":"100000000000000000009832","8067":"100000000000000000008068","5650":"100000000000000000005651","5908":"100000000000000000005909","6965":"100000000000000000006966","2227":"100000000000000000002228","8502":"100000000000000000008503","8232":"100000000000000000008233","6464":"100000000000000000006465","3546":"100000000000000000003547","6275":"100000000000000000006276","4596":"100000000000000000004597","9857":"100000000000000000009858","5221":"100000000000000000005222","5685":"100000000000000000005686","4061":"100000000000000000004062","5435":"100000000000000000005436","74":"100000000000000000000075","7760":"100000000000000000007761","449":"100000000000000000000450","4281":"100000000000000000004282","3551":"100000000000000000003552","10057":"100000000000000000010058","3641":"100000000000000000003642","6949":"100000000000000000006950","368":"100000000000000000000369","4658":"100000000000000000004659","9178":"100000000000000000009179","969":"100000000000000000000970","9148":"100000000000000000009149","5272":"100000000000000000005273","4080":"100000000000000000004081","7388":"100000000000000000007389","4908":"100000000000000000004909","658":"100000000000000000000659","1284":"100000000000000000001285","8091":"100000000000000000008092","3308":"100000000000000000003309","6775":"100000000000000000006776","5001":"100000000000000000005002","3341":"100000000000000000003342","4420":"100000000000000000004421","5547":"100000000000000000005548","5506":"100000000000000000005507","4791":"100000000000000000004792","6931":"100000000000000000006932","4207":"100000000000000000004208","1833":"100000000000000000001834","2001":"100000000000000000002002","9435":"100000000000000000009436","7064":"100000000000000000007065","1206":"100000000000000000001207","933":"100000000000000000000934","4144":"100000000000000000004145","7668":"100000000000000000007669","7076":"100000000000000000007077","5215":"100000000000000000005216","1177":"100000000000000000001178","2321":"100000000000000000002322","5842":"100000000000000000005843","8888":"100000000000000000008889","2332":"100000000000000000002333","5927":"100000000000000000005928","1216":"100000000000000000001217","995":"100000000000000000000996","6520":"100000000000000000006521","7188":"100000000000000000007189","2165":"100000000000000000002166","1629":"100000000000000000001630","6948":"100000000000000000006949","6185":"100000000000000000006186","8566":"100000000000000000008567","2256":"100000000000000000002257","6673":"100000000000000000006674","7565":"100000000000000000007566","421":"100000000000000000000422","6355":"100000000000000000006356","6382":"100000000000000000006383","3211":"100000000000000000003212","1288":"100000000000000000001289","850":"100000000000000000000851","5235":"100000000000000000005236","7750":"100000000000000000007751","6911":"100000000000000000006912","5550":"100000000000000000005551","465":"100000000000000000000466","9953":"100000000000000000009954","5180":"100000000000000000005181","6653":"100000000000000000006654","3875":"100000000000000000003876","4437":"100000000000000000004438","3024":"100000000000000000003025","1662":"100000000000000000001663","6613":"100000000000000000006614","225":"100000000000000000000226","3425":"100000000000000000003426","8980":"100000000000000000008981","5817":"100000000000000000005818","8386":"100000000000000000008387","6251":"100000000000000000006252","9209":"100000000000000000009210","6546":"100000000000000000006547","4888":"100000000000000000004889","1077":"100000000000000000001078","7537":"100000000000000000007538","4391":"100000000000000000004392","8622":"100000000000000000008623","8937":"100000000000000000008938","1690":"100000000000000000001691","4876":"100000000000000000004877","2353":"100000000000000000002354","3330":"100000000000000000003331","7933":"100000000000000000007934","3872":"100000000000000000003873","5404":"100000000000000000005405","3230":"100000000000000000003231","5832":"100000000000000000005833","1663":"100000000000000000001664","3724":"100000000000000000003725","433":"100000000000000000000434","353":"100000000000000000000354","2863":"100000000000000000002864","7723":"100000000000000000007724","5338":"100000000000000000005339","4887":"100000000000000000004888","4120":"100000000000000000004121","7432":"100000000000000000007433","7454":"100000000000000000007455","4103":"100000000000000000004104","8443":"100000000000000000008444","584":"100000000000000000000585","3838":"100000000000000000003839","7272":"100000000000000000007273","4984":"100000000000000000004985","4260":"100000000000000000004261","216":"100000000000000000000217","8498":"100000000000000000008499","8838":"100000000000000000008839","5984":"100000000000000000005985","7678":"100000000000000000007679","4150":"100000000000000000004151","9213":"100000000000000000009214","8026":"100000000000000000008027","5549":"100000000000000000005550","7256":"100000000000000000007257","5317":"100000000000000000005318","432":"100000000000000000000433","3464":"100000000000000000003465","9060":"100000000000000000009061","10108":"100000000000000000010109","8573":"100000000000000000008574","7736":"100000000000000000007737","309":"100000000000000000000310","9402":"100000000000000000009403","9":"100000000000000000000010","5023":"100000000000000000005024","4471":"100000000000000000004472","4680":"100000000000000000004681","8045":"100000000000000000008046","305":"100000000000000000000306","3514":"100000000000000000003515","6455":"100000000000000000006456","1944":"100000000000000000001945","7716":"100000000000000000007717","622":"100000000000000000000623","2732":"100000000000000000002733","9405":"100000000000000000009406","6517":"100000000000000000006518","3890":"100000000000000000003891","9499":"100000000000000000009500","7889":"100000000000000000007890","1057":"100000000000000000001058","8887":"100000000000000000008888","3342":"100000000000000000003343","2556":"100000000000000000002557","7612":"100000000000000000007613","3":"100000000000000000000004","3395":"100000000000000000003396","2707":"100000000000000000002708","10133":"100000000000000000010134","6535":"100000000000000000006536","2286":"100000000000000000002287","1987":"100000000000000000001988","2658":"100000000000000000002659","4229":"100000000000000000004230","5679":"100000000000000000005680","1894":"100000000000000000001895","1516":"100000000000000000001517","9885":"100000000000000000009886","5415":"100000000000000000005416","20":"100000000000000000000021","3704":"100000000000000000003705","8684":"100000000000000000008685","3421":"100000000000000000003422","5256":"100000000000000000005257","8564":"100000000000000000008565","5093":"100000000000000000005094","6316":"100000000000000000006317","2346":"100000000000000000002347","591":"100000000000000000000592","4071":"100000000000000000004072","805":"100000000000000000000806","1771":"100000000000000000001772","7208":"100000000000000000007209","6479":"100000000000000000006480","4223":"100000000000000000004224","1266":"100000000000000000001267","5835":"100000000000000000005836","5104":"100000000000000000005105","6833":"100000000000000000006834","5129":"100000000000000000005130","809":"100000000000000000000810","4861":"100000000000000000004862","8901":"100000000000000000008902","2635":"100000000000000000002636","4005":"100000000000000000004006","5304":"100000000000000000005305","2660":"100000000000000000002661","4480":"100000000000000000004481","1405":"100000000000000000001406","8918":"100000000000000000008919","5595":"100000000000000000005596","6703":"100000000000000000006704","1783":"100000000000000000001784","1105":"100000000000000000001106","10125":"100000000000000000010126","4736":"100000000000000000004737","6536":"100000000000000000006537","6892":"100000000000000000006893","4170":"100000000000000000004171","8481":"100000000000000000008482","6956":"100000000000000000006957","7012":"100000000000000000007013","9918":"100000000000000000009919","7724":"100000000000000000007725","7844":"100000000000000000007845","9198":"100000000000000000009199","7811":"100000000000000000007812","8382":"100000000000000000008383","2442":"100000000000000000002443","6519":"100000000000000000006520","7212":"100000000000000000007213","8164":"100000000000000000008165","1847":"100000000000000000001848","9224":"100000000000000000009225","6804":"100000000000000000006805","2485":"100000000000000000002486","6750":"100000000000000000006751","6555":"100000000000000000006556","5577":"100000000000000000005578","2570":"100000000000000000002571","1066":"100000000000000000001067","5026":"100000000000000000005027","2320":"100000000000000000002321","1387":"100000000000000000001388","7552":"100000000000000000007553","5021":"100000000000000000005022","1086":"100000000000000000001087","8452":"100000000000000000008453","5413":"100000000000000000005414","6648":"100000000000000000006649","7680":"100000000000000000007681","2669":"100000000000000000002670","4534":"100000000000000000004535","8073":"100000000000000000008074","8261":"100000000000000000008262","9891":"100000000000000000009892","8767":"100000000000000000008768","5849":"100000000000000000005850","585":"100000000000000000000586","6359":"100000000000000000006360","2307":"100000000000000000002308","9359":"100000000000000000009360","4351":"100000000000000000004352","9674":"100000000000000000009675","9944":"100000000000000000009945","3450":"100000000000000000003451","3290":"100000000000000000003291","9301":"100000000000000000009302","5330":"100000000000000000005331","998":"100000000000000000000999","6958":"100000000000000000006959","1851":"100000000000000000001852","8755":"100000000000000000008756","9799":"100000000000000000009800","5781":"100000000000000000005782","5178":"100000000000000000005179","9766":"100000000000000000009767","7505":"100000000000000000007506","884":"100000000000000000000885","9564":"100000000000000000009565","2695":"100000000000000000002696","447":"100000000000000000000448","6416":"100000000000000000006417","5389":"100000000000000000005390","3460":"100000000000000000003461","4218":"100000000000000000004219","5969":"100000000000000000005970","4812":"100000000000000000004813","3864":"100000000000000000003865","6411":"100000000000000000006412","10008":"100000000000000000010009","2774":"100000000000000000002775","9156":"100000000000000000009157","3496":"100000000000000000003497","1204":"100000000000000000001205","3442":"100000000000000000003443","1802":"100000000000000000001803","49":"100000000000000000000050","9356":"100000000000000000009357","9978":"100000000000000000009979","8389":"100000000000000000008390","1477":"100000000000000000001478","2539":"100000000000000000002540","7264":"100000000000000000007265","9875":"100000000000000000009876","3397":"100000000000000000003398","3126":"100000000000000000003127","7536":"100000000000000000007537","210":"100000000000000000000211","5690":"100000000000000000005691","6037":"100000000000000000006038","5069":"100000000000000000005070","9219":"100000000000000000009220","5133":"100000000000000000005134","7270":"100000000000000000007271","5500":"100000000000000000005501","3406":"100000000000000000003407","7872":"100000000000000000007873","7749":"100000000000000000007750","4235":"100000000000000000004236","4552":"100000000000000000004553","6957":"100000000000000000006958","4438":"100000000000000000004439","7227":"100000000000000000007228","8496":"100000000000000000008497","7717":"100000000000000000007718","3647":"100000000000000000003648","10141":"100000000000000000010142","8842":"100000000000000000008843","9833":"100000000000000000009834","7625":"100000000000000000007626","7449":"100000000000000000007450","5359":"100000000000000000005360","9557":"100000000000000000009558","800":"100000000000000000000801","1125":"100000000000000000001126","6510":"100000000000000000006511","8854":"100000000000000000008855","4236":"100000000000000000004237","1664":"100000000000000000001665","10043":"100000000000000000010044","3448":"100000000000000000003449","5854":"100000000000000000005855","2413":"100000000000000000002414","9702":"100000000000000000009703","332":"100000000000000000000333","4424":"100000000000000000004425","1546":"100000000000000000001547","2265":"100000000000000000002266","8973":"100000000000000000008974","333":"100000000000000000000334","6565":"100000000000000000006566","6430":"100000000000000000006431","2715":"100000000000000000002716","4085":"100000000000000000004086","9697":"100000000000000000009698","9299":"100000000000000000009300","4048":"100000000000000000004049","2032":"100000000000000000002033","1525":"100000000000000000001526","5173":"100000000000000000005174","3396":"100000000000000000003397","7307":"100000000000000000007308","3806":"100000000000000000003807","10129":"100000000000000000010130","7779":"100000000000000000007780","9133":"100000000000000000009134","2471":"100000000000000000002472","2672":"100000000000000000002673","3698":"100000000000000000003699","2054":"100000000000000000002055","7634":"100000000000000000007635","7340":"100000000000000000007341","6562":"100000000000000000006563","4869":"100000000000000000004870","6189":"100000000000000000006190","2674":"100000000000000000002675","8936":"100000000000000000008937","8344":"100000000000000000008345","9003":"100000000000000000009004","4985":"100000000000000000004986","5088":"100000000000000000005089","4169":"100000000000000000004170","7602":"100000000000000000007603","806":"100000000000000000000807","7052":"100000000000000000007053","2703":"100000000000000000002704","8929":"100000000000000000008930","6900":"100000000000000000006901","6966":"100000000000000000006967","8556":"100000000000000000008557","2747":"100000000000000000002748","2360":"100000000000000000002361","7846":"100000000000000000007847","5057":"100000000000000000005058","6433":"100000000000000000006434","6655":"100000000000000000006656","1832":"100000000000000000001833","8168":"100000000000000000008169","9623":"100000000000000000009624","6474":"100000000000000000006475","9451":"100000000000000000009452","5265":"100000000000000000005266","8910":"100000000000000000008911","2082":"100000000000000000002083","8243":"100000000000000000008244","4627":"100000000000000000004628","587":"100000000000000000000588","7514":"100000000000000000007515","2826":"100000000000000000002827","3371":"100000000000000000003372","9170":"100000000000000000009171","4327":"100000000000000000004328","605":"100000000000000000000606","6498":"100000000000000000006499","9672":"100000000000000000009673","3319":"100000000000000000003320","8222":"100000000000000000008223","6086":"100000000000000000006087","616":"100000000000000000000617","6380":"100000000000000000006381","8359":"100000000000000000008360","9031":"100000000000000000009032","7294":"100000000000000000007295","3147":"100000000000000000003148","9913":"100000000000000000009914","114":"100000000000000000000115","414":"100000000000000000000415","8953":"100000000000000000008954","3789":"100000000000000000003790","6318":"100000000000000000006319","8995":"100000000000000000008996","1760":"100000000000000000001761","6402":"100000000000000000006403","9053":"100000000000000000009054","6716":"100000000000000000006717","1494":"100000000000000000001495","1619":"100000000000000000001620","8217":"100000000000000000008218","5538":"100000000000000000005539","6393":"100000000000000000006394","4490":"100000000000000000004491","7796":"100000000000000000007797","4478":"100000000000000000004479","5098":"100000000000000000005099","962":"100000000000000000000963","6932":"100000000000000000006933","1713":"100000000000000000001714","9471":"100000000000000000009472","5640":"100000000000000000005641","6372":"100000000000000000006373","5326":"100000000000000000005327","134":"100000000000000000000135","7180":"100000000000000000007181","4981":"100000000000000000004982","6155":"100000000000000000006156","6132":"100000000000000000006133","1426":"100000000000000000001427","9724":"100000000000000000009725","3871":"100000000000000000003872","3675":"100000000000000000003676","1096":"100000000000000000001097","86":"100000000000000000000087","9174":"100000000000000000009175","3485":"100000000000000000003486","9904":"100000000000000000009905","3994":"100000000000000000003995","10052":"100000000000000000010053","5804":"100000000000000000005805","9782":"100000000000000000009783","7238":"100000000000000000007239","3532":"100000000000000000003533","9196":"100000000000000000009197","6459":"100000000000000000006460","2961":"100000000000000000002962","9349":"100000000000000000009350","1433":"100000000000000000001434","8675":"100000000000000000008676","3650":"100000000000000000003651","7707":"100000000000000000007708","6072":"100000000000000000006073","3231":"100000000000000000003232","468":"100000000000000000000469","4856":"100000000000000000004857","182":"100000000000000000000183","7387":"100000000000000000007388","9228":"100000000000000000009229","2293":"100000000000000000002294","8124":"100000000000000000008125","1782":"100000000000000000001783","6159":"100000000000000000006160","2027":"100000000000000000002028","8356":"100000000000000000008357","1397":"100000000000000000001398","9445":"100000000000000000009446","4612":"100000000000000000004613","6330":"100000000000000000006331","4205":"100000000000000000004206","1643":"100000000000000000001644","604":"100000000000000000000605","911":"100000000000000000000912","2575":"100000000000000000002576","8783":"100000000000000000008784","3597":"100000000000000000003598","4692":"100000000000000000004693","8110":"100000000000000000008111","8551":"100000000000000000008552","10109":"100000000000000000010110","8088":"100000000000000000008089","1656":"100000000000000000001657","9378":"100000000000000000009379","6547":"100000000000000000006548","4193":"100000000000000000004194","920":"100000000000000000000921","8364":"100000000000000000008365","3365":"100000000000000000003366","27":"100000000000000000000028","2830":"100000000000000000002831","76":"100000000000000000000077","2322":"100000000000000000002323","6813":"100000000000000000006814","7709":"100000000000000000007710","9342":"100000000000000000009343","4764":"100000000000000000004765","3031":"100000000000000000003032","2365":"100000000000000000002366","8343":"100000000000000000008344","3621":"100000000000000000003622","3476":"100000000000000000003477","878":"100000000000000000000879","6286":"100000000000000000006287","3738":"100000000000000000003739","3920":"100000000000000000003921","9022":"100000000000000000009023","3262":"100000000000000000003263","5922":"100000000000000000005923","9717":"100000000000000000009718","8118":"100000000000000000008119","7202":"100000000000000000007203","6988":"100000000000000000006989","382":"100000000000000000000383","9514":"100000000000000000009515","7461":"100000000000000000007462","4252":"100000000000000000004253","8778":"100000000000000000008779","3320":"100000000000000000003321","1152":"100000000000000000001153","6482":"100000000000000000006483","95":"100000000000000000000096","9679":"100000000000000000009680","8736":"100000000000000000008737","5292":"100000000000000000005293","6442":"100000000000000000006443","2358":"100000000000000000002359","3358":"100000000000000000003359","1768":"100000000000000000001769","6553":"100000000000000000006554","4292":"100000000000000000004293","7605":"100000000000000000007606","3050":"100000000000000000003051","9332":"100000000000000000009333","9599":"100000000000000000009600","4280":"100000000000000000004281","9016":"100000000000000000009017","6704":"100000000000000000006705","1616":"100000000000000000001617","2918":"100000000000000000002919","8658":"100000000000000000008659","2233":"100000000000000000002234","8020":"100000000000000000008021","2621":"100000000000000000002622","6055":"100000000000000000006056","9794":"100000000000000000009795","264":"100000000000000000000265","2060":"100000000000000000002061","1168":"100000000000000000001169","4611":"100000000000000000004612","528":"100000000000000000000529","2389":"100000000000000000002390","1222":"100000000000000000001223","6732":"100000000000000000006733","8186":"100000000000000000008187","1872":"100000000000000000001873","4763":"100000000000000000004764","1029":"100000000000000000001030","2150":"100000000000000000002151","8100":"100000000000000000008101","8163":"100000000000000000008164","2549":"100000000000000000002550","2501":"100000000000000000002502","7798":"100000000000000000007799","5787":"100000000000000000005788","9190":"100000000000000000009191","255":"100000000000000000000256","7433":"100000000000000000007434","673":"100000000000000000000674","2831":"100000000000000000002832","9581":"100000000000000000009582","4982":"100000000000000000004983","6489":"100000000000000000006490","6893":"100000000000000000006894","9760":"100000000000000000009761","9972":"100000000000000000009973","6278":"100000000000000000006279","9662":"100000000000000000009663","8782":"100000000000000000008783","3607":"100000000000000000003608","2330":"100000000000000000002331","7288":"100000000000000000007289","2343":"100000000000000000002344","8714":"100000000000000000008715","6571":"100000000000000000006572","3301":"100000000000000000003302","9937":"100000000000000000009938","3754":"100000000000000000003755","3372":"100000000000000000003373","4282":"100000000000000000004283","2500":"100000000000000000002501","7166":"100000000000000000007167","9550":"100000000000000000009551","8726":"100000000000000000008727","5125":"100000000000000000005126","7982":"100000000000000000007983","2393":"100000000000000000002394","4058":"100000000000000000004059","8046":"100000000000000000008047","7148":"100000000000000000007149","6662":"100000000000000000006663","84":"100000000000000000000085","5176":"100000000000000000005177","8290":"100000000000000000008291","5493":"100000000000000000005494","5258":"100000000000000000005259","6065":"100000000000000000006066","18":"100000000000000000000019","7521":"100000000000000000007522","7579":"100000000000000000007580","10077":"100000000000000000010078","9916":"100000000000000000009917","851":"100000000000000000000852","8442":"100000000000000000008443","3747":"100000000000000000003748","6304":"100000000000000000006305","2764":"100000000000000000002765","1179":"100000000000000000001180","689":"100000000000000000000690","4831":"100000000000000000004832","154":"100000000000000000000155","3377":"100000000000000000003378","2950":"100000000000000000002951","298":"100000000000000000000299","5659":"100000000000000000005660","6181":"100000000000000000006182","2368":"100000000000000000002369","4256":"100000000000000000004257","832":"100000000000000000000833","3726":"100000000000000000003727","9344":"100000000000000000009345","6814":"100000000000000000006815","9909":"100000000000000000009910","6346":"100000000000000000006347","7980":"100000000000000000007981","929":"100000000000000000000930","1052":"100000000000000000001053","8847":"100000000000000000008848","6097":"100000000000000000006098","7120":"100000000000000000007121","4436":"100000000000000000004437","7191":"100000000000000000007192","9186":"100000000000000000009187","8523":"100000000000000000008524","7147":"100000000000000000007148","8095":"100000000000000000008096","7317":"100000000000000000007318","768":"100000000000000000000769","2761":"100000000000000000002762","3169":"100000000000000000003170","8125":"100000000000000000008126","9507":"100000000000000000009508","8650":"100000000000000000008651","1230":"100000000000000000001231","2545":"100000000000000000002546","4503":"100000000000000000004504","842":"100000000000000000000843","4919":"100000000000000000004920","4696":"100000000000000000004697","8293":"100000000000000000008294","4141":"100000000000000000004142","1200":"100000000000000000001201","9565":"100000000000000000009566","10110":"100000000000000000010111","4409":"100000000000000000004410","2421":"100000000000000000002422","2895":"100000000000000000002896","8096":"100000000000000000008097","3781":"100000000000000000003782","2767":"100000000000000000002768","4854":"100000000000000000004855","667":"100000000000000000000668","9173":"100000000000000000009174","2372":"100000000000000000002373","10114":"100000000000000000010115","8683":"100000000000000000008684","5263":"100000000000000000005264","5895":"100000000000000000005896","5111":"100000000000000000005112","9570":"100000000000000000009571","5864":"100000000000000000005865","3346":"100000000000000000003347","4191":"100000000000000000004192","6631":"100000000000000000006632","7133":"100000000000000000007134","5312":"100000000000000000005313","3219":"100000000000000000003220","5772":"100000000000000000005773","1716":"100000000000000000001717","2129":"100000000000000000002130","9294":"100000000000000000009295","2892":"100000000000000000002893","4469":"100000000000000000004470","9576":"100000000000000000009577","4146":"100000000000000000004147","2063":"100000000000000000002064","8673":"100000000000000000008674","4633":"100000000000000000004634","9275":"100000000000000000009276","3693":"100000000000000000003694","8824":"100000000000000000008825","8017":"100000000000000000008018","328":"100000000000000000000329","8361":"100000000000000000008362","2384":"100000000000000000002385","6946":"100000000000000000006947","9624":"100000000000000000009625","7800":"100000000000000000007801","7159":"100000000000000000007160","9711":"100000000000000000009712","9960":"100000000000000000009961","1137":"100000000000000000001138","2758":"100000000000000000002759","9652":"100000000000000000009653","785":"100000000000000000000786","1928":"100000000000000000001929","8378":"100000000000000000008379","2475":"100000000000000000002476","5642":"100000000000000000005643","9212":"100000000000000000009213","7224":"100000000000000000007225","9824":"100000000000000000009825","9615":"100000000000000000009616","5982":"100000000000000000005983","5189":"100000000000000000005190","1679":"100000000000000000001680","7659":"100000000000000000007660","4822":"100000000000000000004823","9669":"100000000000000000009670","409":"100000000000000000000410","7111":"100000000000000000007112","3912":"100000000000000000003913","577":"100000000000000000000578","554":"100000000000000000000555","4545":"100000000000000000004546","6087":"100000000000000000006088","9648":"100000000000000000009649","6652":"100000000000000000006653","218":"100000000000000000000219","1325":"100000000000000000001326","5460":"100000000000000000005461","9993":"100000000000000000009994","8859":"100000000000000000008860","6778":"100000000000000000006779","5686":"100000000000000000005687","9556":"100000000000000000009557","1292":"100000000000000000001293","6788":"100000000000000000006789","1091":"100000000000000000001092","5108":"100000000000000000005109","8003":"100000000000000000008004","2817":"100000000000000000002818","2012":"100000000000000000002013","7807":"100000000000000000007808","7420":"100000000000000000007421","7764":"100000000000000000007765","3351":"100000000000000000003352","4232":"100000000000000000004233","5880":"100000000000000000005881","3658":"100000000000000000003659","6112":"100000000000000000006113","3679":"100000000000000000003680","935":"100000000000000000000936","7143":"100000000000000000007144","683":"100000000000000000000684","3584":"100000000000000000003585","8376":"100000000000000000008377","8458":"100000000000000000008459","6131":"100000000000000000006132","2154":"100000000000000000002155","2073":"100000000000000000002074","1403":"100000000000000000001404","4307":"100000000000000000004308","3618":"100000000000000000003619","303":"100000000000000000000304","397":"100000000000000000000398","3575":"100000000000000000003576","9470":"100000000000000000009471","3973":"100000000000000000003974","3232":"100000000000000000003233","7903":"100000000000000000007904","41":"100000000000000000000042","3527":"100000000000000000003528","7962":"100000000000000000007963","10031":"100000000000000000010032","5284":"100000000000000000005285","1931":"100000000000000000001932","6700":"100000000000000000006701","251":"100000000000000000000252","6521":"100000000000000000006522","3531":"100000000000000000003532","1597":"100000000000000000001598","9704":"100000000000000000009705","6453":"100000000000000000006454","9083":"100000000000000000009084","2434":"100000000000000000002435","7644":"100000000000000000007645","9734":"100000000000000000009735","8969":"100000000000000000008970","4270":"100000000000000000004271","7713":"100000000000000000007714","6383":"100000000000000000006384","6634":"100000000000000000006635","9103":"100000000000000000009104","97":"100000000000000000000098","8823":"100000000000000000008824","5840":"100000000000000000005841","589":"100000000000000000000590","4023":"100000000000000000004024","5801":"100000000000000000005802","5066":"100000000000000000005067","9548":"100000000000000000009549","8586":"100000000000000000008587","5935":"100000000000000000005936","9987":"100000000000000000009988","512":"100000000000000000000513","4052":"100000000000000000004053","2132":"100000000000000000002133","4084":"100000000000000000004085","8181":"100000000000000000008182","8240":"100000000000000000008241","538":"100000000000000000000539","324":"100000000000000000000325","3340":"100000000000000000003341","653":"100000000000000000000654","862":"100000000000000000000863","8476":"100000000000000000008477","9525":"100000000000000000009526","4067":"100000000000000000004068","194":"100000000000000000000195","1906":"100000000000000000001907","91":"100000000000000000000092","5414":"100000000000000000005415","2779":"100000000000000000002780","9867":"100000000000000000009868","6003":"100000000000000000006004","3101":"100000000000000000003102","5580":"100000000000000000005581","4958":"100000000000000000004959","4190":"100000000000000000004191","5551":"100000000000000000005552","4715":"100000000000000000004716","9258":"100000000000000000009259","9407":"100000000000000000009408","6528":"100000000000000000006529","253":"100000000000000000000254","8528":"100000000000000000008529","4400":"100000000000000000004401","5913":"100000000000000000005914","5171":"100000000000000000005172","8230":"100000000000000000008231","8816":"100000000000000000008817","6031":"100000000000000000006032","2755":"100000000000000000002756","8374":"100000000000000000008375","695":"100000000000000000000696","8986":"100000000000000000008987","1296":"100000000000000000001297","379":"100000000000000000000380","6198":"100000000000000000006199","3507":"100000000000000000003508","8363":"100000000000000000008364","4066":"100000000000000000004067","9092":"100000000000000000009093","11":"100000000000000000000012","2714":"100000000000000000002715","5262":"100000000000000000005263","773":"100000000000000000000774","1864":"100000000000000000001865","7046":"100000000000000000007047","1510":"100000000000000000001511","5216":"100000000000000000005217","7606":"100000000000000000007607","7350":"100000000000000000007351","1888":"100000000000000000001889","1730":"100000000000000000001731","1935":"100000000000000000001936","8831":"100000000000000000008832","3707":"100000000000000000003708","4891":"100000000000000000004892","1925":"100000000000000000001926","2762":"100000000000000000002763","2133":"100000000000000000002134","3520":"100000000000000000003521","61":"100000000000000000000062","2473":"100000000000000000002474","8139":"100000000000000000008140","1554":"100000000000000000001555","6082":"100000000000000000006083","4222":"100000000000000000004223","5828":"100000000000000000005829","8500":"100000000000000000008501","6603":"100000000000000000006604","6497":"100000000000000000006498","4002":"100000000000000000004003","28":"100000000000000000000029","10091":"100000000000000000010092","4402":"100000000000000000004403","9925":"100000000000000000009926","1686":"100000000000000000001687","5928":"100000000000000000005929","9368":"100000000000000000009369","1060":"100000000000000000001061","4885":"100000000000000000004886","1796":"100000000000000000001797","5484":"100000000000000000005485","9360":"100000000000000000009361","7383":"100000000000000000007384","9036":"100000000000000000009037","5632":"100000000000000000005633","111":"100000000000000000000112","7704":"100000000000000000007705","1254":"100000000000000000001255","6588":"100000000000000000006589","4830":"100000000000000000004831","1518":"100000000000000000001519","8268":"100000000000000000008269","3119":"100000000000000000003120","642":"100000000000000000000643","1838":"100000000000000000001839","1135":"100000000000000000001136","5688":"100000000000000000005689","1742":"100000000000000000001743","7674":"100000000000000000007675","4185":"100000000000000000004186","2555":"100000000000000000002556","7960":"100000000000000000007961","3217":"100000000000000000003218","3366":"100000000000000000003367","4173":"100000000000000000004174","7867":"100000000000000000007868","8457":"100000000000000000008458","7174":"100000000000000000007175","5225":"100000000000000000005226","8391":"100000000000000000008392","9552":"100000000000000000009553","3364":"100000000000000000003365","4498":"100000000000000000004499","2883":"100000000000000000002884","7126":"100000000000000000007127","3997":"100000000000000000003998","4398":"100000000000000000004399","9376":"100000000000000000009377","6539":"100000000000000000006540","4566":"100000000000000000004567","4458":"100000000000000000004459","2480":"100000000000000000002481","506":"100000000000000000000507","4964":"100000000000000000004965","7273":"100000000000000000007274","4416":"100000000000000000004417","9997":"100000000000000000009998","5243":"100000000000000000005244","1709":"100000000000000000001710","6936":"100000000000000000006937","4930":"100000000000000000004931","9290":"100000000000000000009291","7055":"100000000000000000007056","9074":"100000000000000000009075","5613":"100000000000000000005614","7860":"100000000000000000007861","2907":"100000000000000000002908","4261":"100000000000000000004262","5621":"100000000000000000005622","8574":"100000000000000000008575","1840":"100000000000000000001841","3529":"100000000000000000003530","8068":"100000000000000000008069","8289":"100000000000000000008290","5186":"100000000000000000005187","5353":"100000000000000000005354","5896":"100000000000000000005897","2053":"100000000000000000002054","3209":"100000000000000000003210","6592":"100000000000000000006593","2857":"100000000000000000002858","8660":"100000000000000000008661","378":"100000000000000000000379","2250":"100000000000000000002251","8307":"100000000000000000008308","4208":"100000000000000000004209","6898":"100000000000000000006899","8686":"100000000000000000008687","5663":"100000000000000000005664","5672":"100000000000000000005673","3911":"100000000000000000003912","545":"100000000000000000000546","7382":"100000000000000000007383","8719":"100000000000000000008720","7620":"100000000000000000007621","3559":"100000000000000000003560","476":"100000000000000000000477","8264":"100000000000000000008265","1274":"100000000000000000001275","4725":"100000000000000000004726","7309":"100000000000000000007310","5335":"100000000000000000005336","7228":"100000000000000000007229","1654":"100000000000000000001655","120":"100000000000000000000121","5156":"100000000000000000005157","1386":"100000000000000000001387","6846":"100000000000000000006847","9105":"100000000000000000009106","8593":"100000000000000000008594","4638":"100000000000000000004639","4044":"100000000000000000004045","6253":"100000000000000000006254","5348":"100000000000000000005349","221":"100000000000000000000222","8805":"100000000000000000008806","124":"100000000000000000000125","8176":"100000000000000000008177","2998":"100000000000000000002999","10094":"100000000000000000010095","8647":"100000000000000000008648","5786":"100000000000000000005787","8394":"100000000000000000008395","8984":"100000000000000000008985","1148":"100000000000000000001149","8116":"100000000000000000008117","9111":"100000000000000000009112","8160":"100000000000000000008161","5487":"100000000000000000005488","6987":"100000000000000000006988","9512":"100000000000000000009513","5992":"100000000000000000005993","2547":"100000000000000000002548","197":"100000000000000000000198","3344":"100000000000000000003345","1218":"100000000000000000001219","1933":"100000000000000000001934","3100":"100000000000000000003101","7972":"100000000000000000007973","999":"100000000000000000001000","12":"100000000000000000000013","7763":"100000000000000000007764","1252":"100000000000000000001253","3783":"100000000000000000003784","9884":"100000000000000000009885","5839":"100000000000000000005840","7400":"100000000000000000007401","2815":"100000000000000000002816","6113":"100000000000000000006114","7380":"100000000000000000007381","6774":"100000000000000000006775","3190":"100000000000000000003191","3030":"100000000000000000003031","2226":"100000000000000000002227","6614":"100000000000000000006615","7029":"100000000000000000007030","939":"100000000000000000000940","1411":"100000000000000000001412","6837":"100000000000000000006838","1785":"100000000000000000001786","1919":"100000000000000000001920","5518":"100000000000000000005519","2131":"100000000000000000002132","3243":"100000000000000000003244","8975":"100000000000000000008976","285":"100000000000000000000286","1199":"100000000000000000001200","1999":"100000000000000000002000","772":"100000000000000000000773","6237":"100000000000000000006238","6199":"100000000000000000006200","8882":"100000000000000000008883","8745":"100000000000000000008746","8234":"100000000000000000008235","9306":"100000000000000000009307","7885":"100000000000000000007886","3851":"100000000000000000003852","8259":"100000000000000000008260","8806":"100000000000000000008807","6593":"100000000000000000006594","1732":"100000000000000000001733","3567":"100000000000000000003568","9496":"100000000000000000009497","1320":"100000000000000000001321","2147":"100000000000000000002148","90":"100000000000000000000091","7378":"100000000000000000007379","5718":"100000000000000000005719","6733":"100000000000000000006734","7435":"100000000000000000007436","7320":"100000000000000000007321","9613":"100000000000000000009614","9131":"100000000000000000009132","425":"100000000000000000000426","6904":"100000000000000000006905","537":"100000000000000000000538","3027":"100000000000000000003028","3748":"100000000000000000003749","1677":"100000000000000000001678","4992":"100000000000000000004993","7985":"100000000000000000007986","1786":"100000000000000000001787","6728":"100000000000000000006729","7670":"100000000000000000007671","2122":"100000000000000000002123","1141":"100000000000000000001142","5364":"100000000000000000005365","350":"100000000000000000000351","10090":"100000000000000000010091","6156":"100000000000000000006157","3550":"100000000000000000003551","8428":"100000000000000000008429","755":"100000000000000000000756","3345":"100000000000000000003346","6139":"100000000000000000006140","3130":"100000000000000000003131","4792":"100000000000000000004793","9020":"100000000000000000009021","9631":"100000000000000000009632","2754":"100000000000000000002755","9353":"100000000000000000009354","17":"100000000000000000000018","2656":"100000000000000000002657","6930":"100000000000000000006931","6870":"100000000000000000006871","5375":"100000000000000000005376","7568":"100000000000000000007569","956":"100000000000000000000957","4967":"100000000000000000004968","310":"100000000000000000000311","1150":"100000000000000000001151","9295":"100000000000000000009296","1049":"100000000000000000001050","2185":"100000000000000000002186","165":"100000000000000000000166","7614":"100000000000000000007615","5160":"100000000000000000005161","5795":"100000000000000000005796","9200":"100000000000000000009201","7219":"100000000000000000007220","5695":"100000000000000000005696","4492":"100000000000000000004493","4639":"100000000000000000004640","7310":"100000000000000000007311","8614":"100000000000000000008615","7538":"100000000000000000007539","6781":"100000000000000000006782","9253":"100000000000000000009254","8248":"100000000000000000008249","4881":"100000000000000000004882","1726":"100000000000000000001727","3482":"100000000000000000003483","3979":"100000000000000000003980","5403":"100000000000000000005404","3053":"100000000000000000003054","4158":"100000000000000000004159","7415":"100000000000000000007416","5603":"100000000000000000005604","9417":"100000000000000000009418","8708":"100000000000000000008709","7826":"100000000000000000007827","6563":"100000000000000000006564","3414":"100000000000000000003415","7696":"100000000000000000007697","3110":"100000000000000000003111","4547":"100000000000000000004548","5989":"100000000000000000005990","1093":"100000000000000000001094","5117":"100000000000000000005118","390":"100000000000000000000391","4128":"100000000000000000004129","6604":"100000000000000000006605","6118":"100000000000000000006119","2875":"100000000000000000002876","4481":"100000000000000000004482","3430":"100000000000000000003431","7396":"100000000000000000007397","4382":"100000000000000000004383","8002":"100000000000000000008003","8632":"100000000000000000008633","9862":"100000000000000000009863","5110":"100000000000000000005111","8461":"100000000000000000008462","7661":"100000000000000000007662","4463":"100000000000000000004464","3250":"100000000000000000003251","561":"100000000000000000000562","9485":"100000000000000000009486","1870":"100000000000000000001871","5269":"100000000000000000005270","9433":"100000000000000000009434","6216":"100000000000000000006217","5544":"100000000000000000005545","8769":"100000000000000000008770","3273":"100000000000000000003274","5572":"100000000000000000005573","2939":"100000000000000000002940","6643":"100000000000000000006644","2452":"100000000000000000002453","196":"100000000000000000000197","6441":"100000000000000000006442","4953":"100000000000000000004954","752":"100000000000000000000753","6917":"100000000000000000006918","6805":"100000000000000000006806","4145":"100000000000000000004146","2721":"100000000000000000002722","2419":"100000000000000000002420","5209":"100000000000000000005210","1038":"100000000000000000001039","7743":"100000000000000000007744","5053":"100000000000000000005054","2924":"100000000000000000002925","9413":"100000000000000000009414","4388":"100000000000000000004389","10015":"100000000000000000010016","4164":"100000000000000000004165","6664":"100000000000000000006665","8012":"100000000000000000008013","5339":"100000000000000000005340","8284":"100000000000000000008285","8165":"100000000000000000008166","4465":"100000000000000000004466","5853":"100000000000000000005854","7401":"100000000000000000007402","8090":"100000000000000000008091","10137":"100000000000000000010138","8808":"100000000000000000008809","9473":"100000000000000000009474","8236":"100000000000000000008237","2260":"100000000000000000002261","3646":"100000000000000000003647","2276":"100000000000000000002277","3573":"100000000000000000003574","7014":"100000000000000000007015","8347":"100000000000000000008348","4226":"100000000000000000004227","9138":"100000000000000000009139","6766":"100000000000000000006767","9678":"100000000000000000009679","2530":"100000000000000000002531","6532":"100000000000000000006533","3054":"100000000000000000003055","3829":"100000000000000000003830","8365":"100000000000000000008366","250":"100000000000000000000251","9722":"100000000000000000009723","3673":"100000000000000000003674","7471":"100000000000000000007472","9185":"100000000000000000009186","6186":"100000000000000000006187","8592":"100000000000000000008593","3436":"100000000000000000003437","5295":"100000000000000000005296","3519":"100000000000000000003520","8990":"100000000000000000008991","1025":"100000000000000000001026","1737":"100000000000000000001738","4392":"100000000000000000004393","2425":"100000000000000000002426","5016":"100000000000000000005017","8639":"100000000000000000008640","3350":"100000000000000000003351","6165":"100000000000000000006166","1834":"100000000000000000001835","5779":"100000000000000000005780","2565":"100000000000000000002566","6066":"100000000000000000006067","9598":"100000000000000000009599","2665":"100000000000000000002666","1269":"100000000000000000001270","9825":"100000000000000000009826","1682":"100000000000000000001683","7234":"100000000000000000007235","520":"100000000000000000000521","2975":"100000000000000000002976","583":"100000000000000000000584","2940":"100000000000000000002941","254":"100000000000000000000255","213":"100000000000000000000214","5259":"100000000000000000005260","2373":"100000000000000000002374","6672":"100000000000000000006673","1953":"100000000000000000001954","6124":"100000000000000000006125","9297":"100000000000000000009298","3264":"100000000000000000003265","2431":"100000000000000000002432","1375":"100000000000000000001376","5845":"100000000000000000005846","1127":"100000000000000000001128","6052":"100000000000000000006053","2091":"100000000000000000002092","5633":"100000000000000000005634","6908":"100000000000000000006909","3312":"100000000000000000003313","3977":"100000000000000000003978","6289":"100000000000000000006290","3700":"100000000000000000003701","5868":"100000000000000000005869","4962":"100000000000000000004963","9740":"100000000000000000009741","3741":"100000000000000000003742","4647":"100000000000000000004648","4326":"100000000000000000004327","9340":"100000000000000000009341","1721":"100000000000000000001722","2113":"100000000000000000002114","132":"100000000000000000000133","8346":"100000000000000000008347","5830":"100000000000000000005831","1646":"100000000000000000001647","7223":"100000000000000000007224","3363":"100000000000000000003364","7265":"100000000000000000007266","7090":"100000000000000000007091","4212":"100000000000000000004213","9261":"100000000000000000009262","5763":"100000000000000000005764","10078":"100000000000000000010079","4358":"100000000000000000004359","6309":"100000000000000000006310","8940":"100000000000000000008941","7766":"100000000000000000007767","5535":"100000000000000000005536","2690":"100000000000000000002691","1645":"100000000000000000001646","9743":"100000000000000000009744","8076":"100000000000000000008077","9444":"100000000000000000009445","3452":"100000000000000000003453","7472":"100000000000000000007473","2859":"100000000000000000002860","5970":"100000000000000000005971","5802":"100000000000000000005803","6040":"100000000000000000006041","7184":"100000000000000000007185","6744":"100000000000000000006745","4375":"100000000000000000004376","499":"100000000000000000000500","9638":"100000000000000000009639","2730":"100000000000000000002731","3441":"100000000000000000003442","330":"100000000000000000000331","2709":"100000000000000000002710","1508":"100000000000000000001509","4712":"100000000000000000004713","2057":"100000000000000000002058","7413":"100000000000000000007414","9443":"100000000000000000009444","7226":"100000000000000000007227","4057":"100000000000000000004058","2100":"100000000000000000002101","5728":"100000000000000000005729","4147":"100000000000000000004148","1393":"100000000000000000001394","8299":"100000000000000000008300","9688":"100000000000000000009689","1976":"100000000000000000001977","3408":"100000000000000000003409","8143":"100000000000000000008144","7085":"100000000000000000007086","4644":"100000000000000000004645","8468":"100000000000000000008469","5172":"100000000000000000005173","9583":"100000000000000000009584","5806":"100000000000000000005807","1627":"100000000000000000001628","7804":"100000000000000000007805","3975":"100000000000000000003976","3671":"100000000000000000003672","2156":"100000000000000000002157","2253":"100000000000000000002254","5188":"100000000000000000005189","1753":"100000000000000000001754","5028":"100000000000000000005029","7986":"100000000000000000007987","9912":"100000000000000000009913","4412":"100000000000000000004413","6211":"100000000000000000006212","3630":"100000000000000000003631","9305":"100000000000000000009306","9853":"100000000000000000009854","9279":"100000000000000000009280","5789":"100000000000000000005790","4933":"100000000000000000004934","6710":"100000000000000000006711","3900":"100000000000000000003901","9962":"100000000000000000009963","3723":"100000000000000000003724","1496":"100000000000000000001497","5367":"100000000000000000005368","6705":"100000000000000000006706","1240":"100000000000000000001241","988":"100000000000000000000989","1868":"100000000000000000001869","6964":"100000000000000000006965","2278":"100000000000000000002279","7318":"100000000000000000007319","5182":"100000000000000000005183","7841":"100000000000000000007842","6666":"100000000000000000006667","1752":"100000000000000000001753","5297":"100000000000000000005298","1744":"100000000000000000001745","8408":"100000000000000000008409","6074":"100000000000000000006075","1871":"100000000000000000001872","7810":"100000000000000000007811","7236":"100000000000000000007237","3157":"100000000000000000003158","475":"100000000000000000000476","4843":"100000000000000000004844","10099":"100000000000000000010100","7106":"100000000000000000007107","8651":"100000000000000000008652","9561":"100000000000000000009562","14":"100000000000000000000015","10003":"100000000000000000010004","4713":"100000000000000000004714","9135":"100000000000000000009136","6202":"100000000000000000006203","1":"100000000000000000000002","3083":"100000000000000000003084","6048":"100000000000000000006049","297":"100000000000000000000298","5040":"100000000000000000005041","9900":"100000000000000000009901","2397":"100000000000000000002398","5370":"100000000000000000005371","5274":"100000000000000000005275","4788":"100000000000000000004789","3495":"100000000000000000003496","4114":"100000000000000000004115","5517":"100000000000000000005518","2752":"100000000000000000002753","975":"100000000000000000000976","5903":"100000000000000000005904","457":"100000000000000000000458","837":"100000000000000000000838","6191":"100000000000000000006192","4483":"100000000000000000004484","1466":"100000000000000000001467","6910":"100000000000000000006911","4672":"100000000000000000004673","9371":"100000000000000000009372","471":"100000000000000000000472","4991":"100000000000000000004992","5726":"100000000000000000005727","10140":"100000000000000000010141","1843":"100000000000000000001844","1970":"100000000000000000001971","4616":"100000000000000000004617","6018":"100000000000000000006019","5963":"100000000000000000005964","9440":"100000000000000000009441","8302":"100000000000000000008303","8106":"100000000000000000008107","9883":"100000000000000000009884","5523":"100000000000000000005524","9126":"100000000000000000009127","687":"100000000000000000000688","4206":"100000000000000000004207","5401":"100000000000000000005402","4670":"100000000000000000004671","6293":"100000000000000000006294","9358":"100000000000000000009359","1875":"100000000000000000001876","845":"100000000000000000000846","3895":"100000000000000000003896","6379":"100000000000000000006380","5714":"100000000000000000005715","6757":"100000000000000000006758","5":"100000000000000000000006","9492":"100000000000000000009493","1528":"100000000000000000001529","9392":"100000000000000000009393","1248":"100000000000000000001249","6689":"100000000000000000006690","7509":"100000000000000000007510","8297":"100000000000000000008298","677":"100000000000000000000678","2085":"100000000000000000002086","4300":"100000000000000000004301","2948":"100000000000000000002949","5255":"100000000000000000005256","6140":"100000000000000000006141","4064":"100000000000000000004065","6226":"100000000000000000006227","5987":"100000000000000000005988","5412":"100000000000000000005413","6894":"100000000000000000006895","2198":"100000000000000000002199","8654":"100000000000000000008655","6826":"100000000000000000006827","8065":"100000000000000000008066","6454":"100000000000000000006455","4875":"100000000000000000004876","2336":"100000000000000000002337","8203":"100000000000000000008204","1309":"100000000000000000001310","3309":"100000000000000000003310","5513":"100000000000000000005514","2491":"100000000000000000002492","6767":"100000000000000000006768","3664":"100000000000000000003665","8492":"100000000000000000008493","4708":"100000000000000000004709","5956":"100000000000000000005957","8489":"100000000000000000008490","5738":"100000000000000000005739","786":"100000000000000000000787","7506":"100000000000000000007507","1533":"100000000000000000001534","1947":"100000000000000000001948","8414":"100000000000000000008415","7497":"100000000000000000007498","1377":"100000000000000000001378","4328":"100000000000000000004329","9848":"100000000000000000009849","241":"100000000000000000000242","8588":"100000000000000000008589","4006":"100000000000000000004007","8852":"100000000000000000008853","8691":"100000000000000000008692","9038":"100000000000000000009039","9023":"100000000000000000009024","3778":"100000000000000000003779","934":"100000000000000000000935","5224":"100000000000000000005225","4466":"100000000000000000004467","5910":"100000000000000000005911","5161":"100000000000000000005162","8596":"100000000000000000008597","7663":"100000000000000000007664","1162":"100000000000000000001163","9075":"100000000000000000009076","6640":"100000000000000000006641","2396":"100000000000000000002397","5145":"100000000000000000005146","3222":"100000000000000000003223","5257":"100000000000000000005258","2688":"100000000000000000002689","9034":"100000000000000000009035","4676":"100000000000000000004677","4381":"100000000000000000004382","7182":"100000000000000000007183","623":"100000000000000000000624","8399":"100000000000000000008400","5079":"100000000000000000005080","6348":"100000000000000000006349","2297":"100000000000000000002298","5409":"100000000000000000005410","9650":"100000000000000000009651","3131":"100000000000000000003132","3223":"100000000000000000003224","4590":"100000000000000000004591","6358":"100000000000000000006359","63":"100000000000000000000064","8796":"100000000000000000008797","505":"100000000000000000000506","6194":"100000000000000000006195","320":"100000000000000000000321","4609":"100000000000000000004610","5018":"100000000000000000005019","3534":"100000000000000000003535","78":"100000000000000000000079","802":"100000000000000000000803","6762":"100000000000000000006763","6347":"100000000000000000006348","6258":"100000000000000000006259","2756":"100000000000000000002757","2026":"100000000000000000002027","9892":"100000000000000000009893","915":"100000000000000000000916","6114":"100000000000000000006115","5226":"100000000000000000005227","3952":"100000000000000000003953","2266":"100000000000000000002267","4516":"100000000000000000004517","7110":"100000000000000000007111","6545":"100000000000000000006546","2315":"100000000000000000002316","8917":"100000000000000000008918","6313":"100000000000000000006314","8331":"100000000000000000008332","2636":"100000000000000000002637","1026":"100000000000000000001027","1586":"100000000000000000001587","8174":"100000000000000000008175","9232":"100000000000000000009233","7853":"100000000000000000007854","9296":"100000000000000000009297","293":"100000000000000000000294","1561":"100000000000000000001562","2128":"100000000000000000002129","10034":"100000000000000000010035","3268":"100000000000000000003269","3548":"100000000000000000003549","3391":"100000000000000000003392","9588":"100000000000000000009589","887":"100000000000000000000888","5241":"100000000000000000005242","9951":"100000000000000000009952","1809":"100000000000000000001810","3039":"100000000000000000003040","5416":"100000000000000000005417","7626":"100000000000000000007627","9449":"100000000000000000009450","9932":"100000000000000000009933","4097":"100000000000000000004098","6584":"100000000000000000006585","7574":"100000000000000000007575","290":"100000000000000000000291","9347":"100000000000000000009348","1992":"100000000000000000001993","6937":"100000000000000000006938","3734":"100000000000000000003735","5419":"100000000000000000005420","2516":"100000000000000000002517","5764":"100000000000000000005765","8038":"100000000000000000008039","3080":"100000000000000000003081","7000":"100000000000000000007001","5846":"100000000000000000005847","5954":"100000000000000000005955","2616":"100000000000000000002617","4767":"100000000000000000004768","3200":"100000000000000000003201","6651":"100000000000000000006652","5119":"100000000000000000005120","7899":"100000000000000000007900","2340":"100000000000000000002341","9004":"100000000000000000009005","4554":"100000000000000000004555","8256":"100000000000000000008257","8198":"100000000000000000008199","9735":"100000000000000000009736","3886":"100000000000000000003887","1089":"100000000000000000001090","4246":"100000000000000000004247","4789":"100000000000000000004790","3276":"100000000000000000003277","4310":"100000000000000000004311","7470":"100000000000000000007471","4285":"100000000000000000004286","5886":"100000000000000000005887","9861":"100000000000000000009862","58":"100000000000000000000059","1247":"100000000000000000001248","6046":"100000000000000000006047","6410":"100000000000000000006411","4040":"100000000000000000004041","1010":"100000000000000000001011","261":"100000000000000000000262","2820":"100000000000000000002821","3631":"100000000000000000003632","9114":"100000000000000000009115","7186":"100000000000000000007187","4243":"100000000000000000004244","31":"100000000000000000000032","5373":"100000000000000000005374","2677":"100000000000000000002678","1107":"100000000000000000001108","2797":"100000000000000000002798","6611":"100000000000000000006612","2028":"100000000000000000002029","517":"100000000000000000000518","7879":"100000000000000000007880","6220":"100000000000000000006221","5033":"100000000000000000005034","1042":"100000000000000000001043","567":"100000000000000000000568","1434":"100000000000000000001435","4440":"100000000000000000004441","1715":"100000000000000000001716","3093":"100000000000000000003094","34":"100000000000000000000035","248":"100000000000000000000249","7421":"100000000000000000007422","9432":"100000000000000000009433","8438":"100000000000000000008439","1826":"100000000000000000001827","1912":"100000000000000000001913","4339":"100000000000000000004340","7981":"100000000000000000007982","5766":"100000000000000000005767","8059":"100000000000000000008060","163":"100000000000000000000164","2967":"100000000000000000002968","8971":"100000000000000000008972","10014":"100000000000000000010015","8453":"100000000000000000008454","4810":"100000000000000000004811","8601":"100000000000000000008602","8911":"100000000000000000008912","2078":"100000000000000000002079","965":"100000000000000000000966","5327":"100000000000000000005328","1514":"100000000000000000001515","7113":"100000000000000000007114","2477":"100000000000000000002478","4265":"100000000000000000004266","6508":"100000000000000000006509","7037":"100000000000000000007038","6230":"100000000000000000006231","399":"100000000000000000000400","8321":"100000000000000000008322","7091":"100000000000000000007092","8759":"100000000000000000008760","30":"100000000000000000000031","3506":"100000000000000000003507","8380":"100000000000000000008381","5730":"100000000000000000005731","5011":"100000000000000000005012","2029":"100000000000000000002030","10066":"100000000000000000010067","5540":"100000000000000000005541","9197":"100000000000000000009198","6690":"100000000000000000006691","6512":"100000000000000000006513","4934":"100000000000000000004935","5746":"100000000000000000005747","2503":"100000000000000000002504","6974":"100000000000000000006975","1907":"100000000000000000001908","2536":"100000000000000000002537","2917":"100000000000000000002918","6534":"100000000000000000006535","8194":"100000000000000000008195","3214":"100000000000000000003215","1712":"100000000000000000001713","6244":"100000000000000000006245","9310":"100000000000000000009311","435":"100000000000000000000436","9515":"100000000000000000009516","9323":"100000000000000000009324","2468":"100000000000000000002469","5014":"100000000000000000005015","9696":"100000000000000000009697","8585":"100000000000000000008586","7008":"100000000000000000007009","1046":"100000000000000000001047","8772":"100000000000000000008773","5707":"100000000000000000005708","9379":"100000000000000000009380","6506":"100000000000000000006507","7733":"100000000000000000007734","10051":"100000000000000000010052","1124":"100000000000000000001125","1647":"100000000000000000001648","4597":"100000000000000000004598","5344":"100000000000000000005345","9474":"100000000000000000009475","2644":"100000000000000000002645","8517":"100000000000000000008518","8762":"100000000000000000008763","5379":"100000000000000000005380","8711":"100000000000000000008712","398":"100000000000000000000399","4678":"100000000000000000004679","8167":"100000000000000000008168","2168":"100000000000000000002169","4258":"100000000000000000004259","2247":"100000000000000000002248","5127":"100000000000000000005128","5236":"100000000000000000005237","1526":"100000000000000000001527","668":"100000000000000000000669","3580":"100000000000000000003581","8722":"100000000000000000008723","1688":"100000000000000000001689","748":"100000000000000000000749","6036":"100000000000000000006037","6083":"100000000000000000006084","1924":"100000000000000000001925","2359":"100000000000000000002360","7019":"100000000000000000007020","1381":"100000000000000000001382","8740":"100000000000000000008741","1750":"100000000000000000001751","735":"100000000000000000000736","5426":"100000000000000000005427","1603":"100000000000000000001604","9870":"100000000000000000009871","450":"100000000000000000000451","4167":"100000000000000000004168","1324":"100000000000000000001325","4961":"100000000000000000004962","6177":"100000000000000000006178","8049":"100000000000000000008050","4422":"100000000000000000004423","6049":"100000000000000000006050","8799":"100000000000000000008800","7652":"100000000000000000007653","1578":"100000000000000000001579","3820":"100000000000000000003821","2459":"100000000000000000002460","16":"100000000000000000000017","4279":"100000000000000000004280","6017":"100000000000000000006018","1329":"100000000000000000001330","8419":"100000000000000000008420","6057":"100000000000000000006058","2390":"100000000000000000002391","3173":"100000000000000000003174","3299":"100000000000000000003300","6866":"100000000000000000006867","2495":"100000000000000000002496","572":"100000000000000000000573","2141":"100000000000000000002142","974":"100000000000000000000975","6978":"100000000000000000006979","8371":"100000000000000000008372","1190":"100000000000000000001191","7128":"100000000000000000007129","8607":"100000000000000000008608","215":"100000000000000000000216","9952":"100000000000000000009953","9084":"100000000000000000009085","6123":"100000000000000000006124","2792":"100000000000000000002793","9837":"100000000000000000009838","6174":"100000000000000000006175","9015":"100000000000000000009016","1014":"100000000000000000001015","9072":"100000000000000000009073","4355":"100000000000000000004356","6109":"100000000000000000006110","406":"100000000000000000000407","9331":"100000000000000000009332","8429":"100000000000000000008430","9627":"100000000000000000009628","4569":"100000000000000000004570","984":"100000000000000000000985","7730":"100000000000000000007731","1460":"100000000000000000001461","601":"100000000000000000000602","6450":"100000000000000000006451","3841":"100000000000000000003842","246":"100000000000000000000247","3178":"100000000000000000003179","8221":"100000000000000000008222","9582":"100000000000000000009583","3570":"100000000000000000003571","4591":"100000000000000000004592","7042":"100000000000000000007043","1680":"100000000000000000001681","8674":"100000000000000000008675","1607":"100000000000000000001608","5408":"100000000000000000005409","8196":"100000000000000000008197","9503":"100000000000000000009504","5797":"100000000000000000005798","9333":"100000000000000000009334","7134":"100000000000000000007135","8536":"100000000000000000008537","7966":"100000000000000000007967","8136":"100000000000000000008137","8182":"100000000000000000008183","8480":"100000000000000000008481","7651":"100000000000000000007652","4456":"100000000000000000004457","10073":"100000000000000000010074","2072":"100000000000000000002073","559":"100000000000000000000560","4123":"100000000000000000004124","3651":"100000000000000000003652","2000":"100000000000000000002001","5658":"100000000000000000005659","2140":"100000000000000000002141","1452":"100000000000000000001453","6573":"100000000000000000006574","5943":"100000000000000000005944","5116":"100000000000000000005117","3314":"100000000000000000003315","6272":"100000000000000000006273","9889":"100000000000000000009890","597":"100000000000000000000598","214":"100000000000000000000215","9826":"100000000000000000009827","7686":"100000000000000000007687","8270":"100000000000000000008271","2631":"100000000000000000002632","7569":"100000000000000000007570","3949":"100000000000000000003950","6323":"100000000000000000006324","819":"100000000000000000000820","4928":"100000000000000000004929","7816":"100000000000000000007817","3040":"100000000000000000003041","2590":"100000000000000000002591","6029":"100000000000000000006030","4777":"100000000000000000004778","3848":"100000000000000000003849","6030":"100000000000000000006031","1083":"100000000000000000001084","2263":"100000000000000000002264","9377":"100000000000000000009378","8685":"100000000000000000008686","779":"100000000000000000000780","6660":"100000000000000000006661","9922":"100000000000000000009923","2951":"100000000000000000002952","9703":"100000000000000000009704","4442":"100000000000000000004443","7638":"100000000000000000007639","4139":"100000000000000000004140","3090":"100000000000000000003091","6310":"100000000000000000006311","5625":"100000000000000000005626","428":"100000000000000000000429","8695":"100000000000000000008696","3107":"100000000000000000003108","2991":"100000000000000000002992","4449":"100000000000000000004450","708":"100000000000000000000709","9752":"100000000000000000009753","7259":"100000000000000000007260","4112":"100000000000000000004113","7640":"100000000000000000007641","484":"100000000000000000000485","130":"100000000000000000000131","8412":"100000000000000000008413","4704":"100000000000000000004705","6227":"100000000000000000006228","5680":"100000000000000000005681","201":"100000000000000000000202","2312":"100000000000000000002313","3542":"100000000000000000003543","5619":"100000000000000000005620","5784":"100000000000000000005785","9664":"100000000000000000009665","5765":"100000000000000000005766","7619":"100000000000000000007620","4273":"100000000000000000004274","7734":"100000000000000000007735","1257":"100000000000000000001258","6821":"100000000000000000006822","9911":"100000000000000000009912","9315":"100000000000000000009316","3672":"100000000000000000003673","5662":"100000000000000000005663","8269":"100000000000000000008270","3045":"100000000000000000003046","8933":"100000000000000000008934","5378":"100000000000000000005379","2357":"100000000000000000002358","4445":"100000000000000000004446","6859":"100000000000000000006860","6777":"100000000000000000006778","8206":"100000000000000000008207","9590":"100000000000000000009591","8483":"100000000000000000008484","8568":"100000000000000000008569","2663":"100000000000000000002664","10075":"100000000000000000010076","116":"100000000000000000000117","3762":"100000000000000000003763","7036":"100000000000000000007037","5483":"100000000000000000005484","7636":"100000000000000000007637","5446":"100000000000000000005447","6637":"100000000000000000006638","8162":"100000000000000000008163","56":"100000000000000000000057","5041":"100000000000000000005042","7856":"100000000000000000007857","3018":"100000000000000000003019","4228":"100000000000000000004229","6452":"100000000000000000006453","8421":"100000000000000000008422","7200":"100000000000000000007201","4025":"100000000000000000004026","6448":"100000000000000000006449","5519":"100000000000000000005520","3445":"100000000000000000003446","4795":"100000000000000000004796","4283":"100000000000000000004284","3868":"100000000000000000003869","4975":"100000000000000000004976","3407":"100000000000000000003408","2361":"100000000000000000002362","7917":"100000000000000000007918","1103":"100000000000000000001104","8781":"100000000000000000008782","4852":"100000000000000000004853","4414":"100000000000000000004415","4018":"100000000000000000004019","1577":"100000000000000000001578","1863":"100000000000000000001864","7793":"100000000000000000007794","1879":"100000000000000000001880","3946":"100000000000000000003947","617":"100000000000000000000618","4518":"100000000000000000004519","5058":"100000000000000000005059","4844":"100000000000000000004845","9192":"100000000000000000009193","5624":"100000000000000000005625","539":"100000000000000000000540","9475":"100000000000000000009476","5135":"100000000000000000005136","9049":"100000000000000000009050","5909":"100000000000000000005910","2498":"100000000000000000002499","1118":"100000000000000000001119","1560":"100000000000000000001561","5465":"100000000000000000005466","2269":"100000000000000000002270","3289":"100000000000000000003290","9612":"100000000000000000009613","7089":"100000000000000000007090","8036":"100000000000000000008037","2182":"100000000000000000002183","4443":"100000000000000000004444","2432":"100000000000000000002433","6405":"100000000000000000006406","8889":"100000000000000000008890","8893":"100000000000000000008894","4213":"100000000000000000004214","5594":"100000000000000000005595","8583":"100000000000000000008584","5574":"100000000000000000005575","4073":"100000000000000000004074","3415":"100000000000000000003416","1331":"100000000000000000001332","39":"100000000000000000000040","1144":"100000000000000000001145","598":"100000000000000000000599","7112":"100000000000000000007113","3909":"100000000000000000003910","2443":"100000000000000000002444","2061":"100000000000000000002062","8664":"100000000000000000008665","5729":"100000000000000000005730","7515":"100000000000000000007516","6336":"100000000000000000006337","9847":"100000000000000000009848","8519":"100000000000000000008520","5929":"100000000000000000005930","7170":"100000000000000000007171","1960":"100000000000000000001961","387":"100000000000000000000388","4460":"100000000000000000004461","8985":"100000000000000000008986","5645":"100000000000000000005646","9414":"100000000000000000009415","3313":"100000000000000000003314","824":"100000000000000000000825","9282":"100000000000000000009283","6023":"100000000000000000006024","9984":"100000000000000000009985","669":"100000000000000000000670","8019":"100000000000000000008020","5614":"100000000000000000005615","3263":"100000000000000000003264","715":"100000000000000000000716","1672":"100000000000000000001673","671":"100000000000000000000672","2098":"100000000000000000002099","4857":"100000000000000000004858","5240":"100000000000000000005241","9594":"100000000000000000009595","4195":"100000000000000000004196","4028":"100000000000000000004029","2763":"100000000000000000002764","4669":"100000000000000000004670","6389":"100000000000000000006390","707":"100000000000000000000708","418":"100000000000000000000419","5147":"100000000000000000005148","4194":"100000000000000000004195","2195":"100000000000000000002196","6720":"100000000000000000006721","9530":"100000000000000000009531","2009":"100000000000000000002010","2833":"100000000000000000002834","4762":"100000000000000000004763","98":"100000000000000000000099","8334":"100000000000000000008335","8932":"100000000000000000008933","3378":"100000000000000000003379","660":"100000000000000000000661","2694":"100000000000000000002695","494":"100000000000000000000495","9872":"100000000000000000009873","4152":"100000000000000000004153","5512":"100000000000000000005513","7462":"100000000000000000007463","2375":"100000000000000000002376","8306":"100000000000000000008307","7603":"100000000000000000007604","7152":"100000000000000000007153","7650":"100000000000000000007651","412":"100000000000000000000413","1003":"100000000000000000001004","1153":"100000000000000000001154","4842":"100000000000000000004843","4679":"100000000000000000004680","8657":"100000000000000000008658","6254":"100000000000000000006255","727":"100000000000000000000728","1321":"100000000000000000001322","7003":"100000000000000000007004","3907":"100000000000000000003908","2354":"100000000000000000002355","291":"100000000000000000000292","9188":"100000000000000000009189","1938":"100000000000000000001939","2203":"100000000000000000002204","5599":"100000000000000000005600","2517":"100000000000000000002518","7329":"100000000000000000007330","7701":"100000000000000000007702","6092":"100000000000000000006093","2245":"100000000000000000002246","4019":"100000000000000000004020","4979":"100000000000000000004980","7331":"100000000000000000007332","5482":"100000000000000000005483","6620":"100000000000000000006621","2689":"100000000000000000002690","9469":"100000000000000000009470","6982":"100000000000000000006983","2303":"100000000000000000002304","5230":"100000000000000000005231","7230":"100000000000000000007231","795":"100000000000000000000796","8267":"100000000000000000008268","9158":"100000000000000000009159","9123":"100000000000000000009124","1180":"100000000000000000001181","2080":"100000000000000000002081","6636":"100000000000000000006637","5247":"100000000000000000005248","8177":"100000000000000000008178","8760":"100000000000000000008761","2428":"100000000000000000002429","5248":"100000000000000000005249","9436":"100000000000000000009437","7167":"100000000000000000007168","4016":"100000000000000000004017","4333":"100000000000000000004334","6151":"100000000000000000006152","3266":"100000000000000000003267","8171":"100000000000000000008172","147":"100000000000000000000148","3188":"100000000000000000003189","827":"100000000000000000000828","6427":"100000000000000000006428","5964":"100000000000000000005965","4347":"100000000000000000004348","5866":"100000000000000000005867","1427":"100000000000000000001428","9816":"100000000000000000009817","8785":"100000000000000000008786","1849":"100000000000000000001850","7160":"100000000000000000007161","6339":"100000000000000000006340","8841":"100000000000000000008842","7303":"100000000000000000007304","7591":"100000000000000000007592","7813":"100000000000000000007814","2720":"100000000000000000002721","10126":"100000000000000000010127","4886":"100000000000000000004887","6527":"100000000000000000006528","9453":"100000000000000000009454","10103":"100000000000000000010104","3824":"100000000000000000003825","8690":"100000000000000000008691","26":"100000000000000000000027","8742":"100000000000000000008743","6850":"100000000000000000006851","8957":"100000000000000000008958","3255":"100000000000000000003256","5062":"100000000000000000005063","9943":"100000000000000000009944","5331":"100000000000000000005332","7015":"100000000000000000007016","4851":"100000000000000000004852","5587":"100000000000000000005588","5762":"100000000000000000005763","1575":"100000000000000000001576","2617":"100000000000000000002618","9705":"100000000000000000009706","8351":"100000000000000000008352","9976":"100000000000000000009977","2864":"100000000000000000002865","2058":"100000000000000000002059","9586":"100000000000000000009587","1021":"100000000000000000001022","3091":"100000000000000000003092","1428":"100000000000000000001429","3161":"100000000000000000003162","9834":"100000000000000000009835","1158":"100000000000000000001159","2654":"100000000000000000002655","3416":"100000000000000000003417","6424":"100000000000000000006425","1590":"100000000000000000001591","2052":"100000000000000000002053","9795":"100000000000000000009796","747":"100000000000000000000748","2994":"100000000000000000002995","444":"100000000000000000000445","4635":"100000000000000000004636","3598":"100000000000000000003599","1115":"100000000000000000001116","2972":"100000000000000000002973","8123":"100000000000000000008124","7082":"100000000000000000007083","6193":"100000000000000000006194","5719":"100000000000000000005720","4096":"100000000000000000004097","8069":"100000000000000000008070","7751":"100000000000000000007752","3166":"100000000000000000003167","5060":"100000000000000000005061","8615":"100000000000000000008616","8914":"100000000000000000008915","2568":"100000000000000000002569","8373":"100000000000000000008374","6061":"100000000000000000006062","2064":"100000000000000000002065","9329":"100000000000000000009330","5799":"100000000000000000005800","4920":"100000000000000000004921","1355":"100000000000000000001356","6864":"100000000000000000006865","9354":"100000000000000000009355","2528":"100000000000000000002529","3856":"100000000000000000003857","4034":"100000000000000000004035","7129":"100000000000000000007130","2534":"100000000000000000002535","9066":"100000000000000000009067","8208":"100000000000000000008209","4125":"100000000000000000004126","6748":"100000000000000000006749","670":"100000000000000000000671","655":"100000000000000000000656","8109":"100000000000000000008110","343":"100000000000000000000344","5733":"100000000000000000005734","1336":"100000000000000000001337","3171":"100000000000000000003172","2879":"100000000000000000002880","5745":"100000000000000000005746","8582":"100000000000000000008583","3179":"100000000000000000003180","395":"100000000000000000000396","5458":"100000000000000000005459","2051":"100000000000000000002052","236":"100000000000000000000237","2456":"100000000000000000002457","7566":"100000000000000000007567","1401":"100000000000000000001402","1349":"100000000000000000001350","6241":"100000000000000000006242","7608":"100000000000000000007609","4030":"100000000000000000004031","1820":"100000000000000000001821","3064":"100000000000000000003065","1867":"100000000000000000001868","1815":"100000000000000000001816","629":"100000000000000000000630","169":"100000000000000000000170","7146":"100000000000000000007147","680":"100000000000000000000681","1880":"100000000000000000001881","3980":"100000000000000000003981","6062":"100000000000000000006063","5333":"100000000000000000005334","507":"100000000000000000000508","1720":"100000000000000000001721","9341":"100000000000000000009342","9383":"100000000000000000009384","4855":"100000000000000000004856","9350":"100000000000000000009351","2584":"100000000000000000002585","1245":"100000000000000000001246","2645":"100000000000000000002646","452":"100000000000000000000453","4741":"100000000000000000004742","3354":"100000000000000000003355","1943":"100000000000000000001944","5771":"100000000000000000005772","7428":"100000000000000000007429","9938":"100000000000000000009939","6671":"100000000000000000006672","4572":"100000000000000000004573","4269":"100000000000000000004270","5611":"100000000000000000005612","8094":"100000000000000000008095","4254":"100000000000000000004255","2778":"100000000000000000002779","9796":"100000000000000000009797","161":"100000000000000000000162","5991":"100000000000000000005992","3151":"100000000000000000003152","1480":"100000000000000000001481","3318":"100000000000000000003319","5950":"100000000000000000005951","4907":"100000000000000000004908","473":"100000000000000000000474","547":"100000000000000000000548","9804":"100000000000000000009805","643":"100000000000000000000644","5485":"100000000000000000005486","3993":"100000000000000000003994","6658":"100000000000000000006659","2006":"100000000000000000002007","4094":"100000000000000000004095","5902":"100000000000000000005903","4987":"100000000000000000004988","5289":"100000000000000000005290","6504":"100000000000000000006505","7136":"100000000000000000007137","5139":"100000000000000000005140","2484":"100000000000000000002485","3252":"100000000000000000003253","7902":"100000000000000000007903","8212":"100000000000000000008213","3540":"100000000000000000003541","1058":"100000000000000000001059","3533":"100000000000000000003534","9303":"100000000000000000009304","4607":"100000000000000000004608","3379":"100000000000000000003380","556":"100000000000000000000557","8253":"100000000000000000008254","10059":"100000000000000000010060","2296":"100000000000000000002297","4568":"100000000000000000004569","713":"100000000000000000000714","3068":"100000000000000000003069","4505":"100000000000000000004506","3561":"100000000000000000003562","4673":"100000000000000000004674","2139":"100000000000000000002140","9660":"100000000000000000009661","5123":"100000000000000000005124","2862":"100000000000000000002863","6141":"100000000000000000006142","6633":"100000000000000000006634","4068":"100000000000000000004069","7527":"100000000000000000007528","9839":"100000000000000000009840","1632":"100000000000000000001633","8503":"100000000000000000008504","181":"100000000000000000000182","7221":"100000000000000000007222","9832":"100000000000000000009833","6154":"100000000000000000006155","7618":"100000000000000000007619","3220":"100000000000000000003221","3656":"100000000000000000003657","7931":"100000000000000000007932","3557":"100000000000000000003558","7690":"100000000000000000007691","4665":"100000000000000000004666","3883":"100000000000000000003884","6209":"100000000000000000006210","5081":"100000000000000000005082","3113":"100000000000000000003114","6985":"100000000000000000006986","6754":"100000000000000000006755","710":"100000000000000000000711","8758":"100000000000000000008759","5529":"100000000000000000005530","2901":"100000000000000000002902","5454":"100000000000000000005455","2107":"100000000000000000002108","8055":"100000000000000000008056","5418":"100000000000000000005419","89":"100000000000000000000090","5876":"100000000000000000005877","4000":"100000000000000000004001","4348":"100000000000000000004349","8578":"100000000000000000008579","8529":"100000000000000000008530","5270":"100000000000000000005271","3006":"100000000000000000003007","3823":"100000000000000000003824","2200":"100000000000000000002201","4862":"100000000000000000004863","8134":"100000000000000000008135","804":"100000000000000000000805","7512":"100000000000000000007513","1195":"100000000000000000001196","4322":"100000000000000000004323","8533":"100000000000000000008534","4108":"100000000000000000004109","2120":"100000000000000000002121","2489":"100000000000000000002490","3187":"100000000000000000003188","8786":"100000000000000000008787","6830":"100000000000000000006831","4581":"100000000000000000004582","7843":"100000000000000000007844","2290":"100000000000000000002291","7365":"100000000000000000007366","7782":"100000000000000000007783","6993":"100000000000000000006994","4368":"100000000000000000004369","4394":"100000000000000000004395","1050":"100000000000000000001051","7557":"100000000000000000007558","5004":"100000000000000000005005","4935":"100000000000000000004936","2952":"100000000000000000002953","6889":"100000000000000000006890","4924":"100000000000000000004925","2339":"100000000000000000002340","8694":"100000000000000000008695","3152":"100000000000000000003153","6493":"100000000000000000006494","4330":"100000000000000000004331","3852":"100000000000000000003853","422":"100000000000000000000423","876":"100000000000000000000877","5137":"100000000000000000005138","2802":"100000000000000000002803","7815":"100000000000000000007816","5190":"100000000000000000005191","8579":"100000000000000000008580","9481":"100000000000000000009482","8811":"100000000000000000008812","3227":"100000000000000000003228","1013":"100000000000000000001014","4613":"100000000000000000004614","6486":"100000000000000000006487","8320":"100000000000000000008321","8309":"100000000000000000008310","7077":"100000000000000000007078","3478":"100000000000000000003479","6119":"100000000000000000006120","8818":"100000000000000000008819","3389":"100000000000000000003390","9352":"100000000000000000009353","8991":"100000000000000000008992","2490":"100000000000000000002491","5220":"100000000000000000005221","3501":"100000000000000000003502","8247":"100000000000000000008248","4159":"100000000000000000004160","3899":"100000000000000000003900","5812":"100000000000000000005813","2355":"100000000000000000002356","7078":"100000000000000000007079","2056":"100000000000000000002057","10028":"100000000000000000010029","963":"100000000000000000000964","2236":"100000000000000000002237","627":"100000000000000000000628","2003":"100000000000000000002004","6208":"100000000000000000006209","1313":"100000000000000000001314","3226":"100000000000000000003227","6167":"100000000000000000006168","7436":"100000000000000000007437","3524":"100000000000000000003525","2557":"100000000000000000002558","9593":"100000000000000000009594","5155":"100000000000000000005156","6456":"100000000000000000006457","9246":"100000000000000000009247","113":"100000000000000000000114","8358":"100000000000000000008359","5560":"100000000000000000005561","1044":"100000000000000000001045","7544":"100000000000000000007545","3769":"100000000000000000003770","3606":"100000000000000000003607","3247":"100000000000000000003248","5575":"100000000000000000005576","3465":"100000000000000000003466","3349":"100000000000000000003350","8938":"100000000000000000008939","625":"100000000000000000000626","3988":"100000000000000000003989","1454":"100000000000000000001455","5546":"100000000000000000005547","9193":"100000000000000000009194","8943":"100000000000000000008944","874":"100000000000000000000875","4983":"100000000000000000004984","371":"100000000000000000000372","1734":"100000000000000000001735","8422":"100000000000000000008423","3419":"100000000000000000003420","2905":"100000000000000000002906","3797":"100000000000000000003798","1359":"100000000000000000001360","2308":"100000000000000000002309","9128":"100000000000000000009129","970":"100000000000000000000971","2045":"100000000000000000002046","9244":"100000000000000000009245","3079":"100000000000000000003080","3705":"100000000000000000003706","8043":"100000000000000000008044","5813":"100000000000000000005814","9974":"100000000000000000009975","3277":"100000000000000000003278","2597":"100000000000000000002598","2728":"100000000000000000002729","1277":"100000000000000000001278","849":"100000000000000000000850","157":"100000000000000000000158","8280":"100000000000000000008281","1950":"100000000000000000001951","1633":"100000000000000000001634","1893":"100000000000000000001894","9634":"100000000000000000009635","972":"100000000000000000000973","2381":"100000000000000000002382","7123":"100000000000000000007124","5031":"100000000000000000005032","761":"100000000000000000000762","10119":"100000000000000000010120","6832":"100000000000000000006833","6494":"100000000000000000006495","4387":"100000000000000000004388","3674":"100000000000000000003675","821":"100000000000000000000822","1175":"100000000000000000001176","341":"100000000000000000000342","7487":"100000000000000000007488","4211":"100000000000000000004212","4012":"100000000000000000004013","2160":"100000000000000000002161","3360":"100000000000000000003361","8295":"100000000000000000008296","7997":"100000000000000000007998","6182":"100000000000000000006183","1703":"100000000000000000001704","5654":"100000000000000000005655","823":"100000000000000000000824","8757":"100000000000000000008758","2683":"100000000000000000002684","21":"100000000000000000000022","52":"100000000000000000000053","490":"100000000000000000000491","6531":"100000000000000000006532","1267":"100000000000000000001268","3889":"100000000000000000003890","8156":"100000000000000000008157","6296":"100000000000000000006297","1628":"100000000000000000001629","7728":"100000000000000000007729","7955":"100000000000000000007956","2179":"100000000000000000002180","1747":"100000000000000000001748","3108":"100000000000000000003109","8053":"100000000000000000008054","7323":"100000000000000000007324","3876":"100000000000000000003877","4468":"100000000000000000004469","880":"100000000000000000000881","6091":"100000000000000000006092","8718":"100000000000000000008719","3102":"100000000000000000003103","3825":"100000000000000000003826","9744":"100000000000000000009745","3681":"100000000000000000003682","1957":"100000000000000000001958","7684":"100000000000000000007685","9868":"100000000000000000009869","7989":"100000000000000000007990","8939":"100000000000000000008940","474":"100000000000000000000475","4847":"100000000000000000004848","3792":"100000000000000000003793","8369":"100000000000000000008370","906":"100000000000000000000907","6200":"100000000000000000006201","8080":"100000000000000000008081","8946":"100000000000000000008947","7905":"100000000000000000007906","1588":"100000000000000000001589","6306":"100000000000000000006307","812":"100000000000000000000813","9665":"100000000000000000009666","7812":"100000000000000000007813","7247":"100000000000000000007248","4332":"100000000000000000004333","6802":"100000000000000000006803","7756":"100000000000000000007757","212":"100000000000000000000213","8216":"100000000000000000008217","404":"100000000000000000000405","6496":"100000000000000000006497","2388":"100000000000000000002389","273":"100000000000000000000274","1250":"100000000000000000001251","5038":"100000000000000000005039","7153":"100000000000000000007154","4526":"100000000000000000004527","7540":"100000000000000000007541","7440":"100000000000000000007441","9738":"100000000000000000009739","3521":"100000000000000000003522","1683":"100000000000000000001684","7452":"100000000000000000007453","9518":"100000000000000000009519","5736":"100000000000000000005737","1317":"100000000000000000001318","4399":"100000000000000000004400","185":"100000000000000000000186","2216":"100000000000000000002217","10054":"100000000000000000010055","9250":"100000000000000000009251","6741":"100000000000000000006742","4909":"100000000000000000004910","6067":"100000000000000000006068","2414":"100000000000000000002415","6579":"100000000000000000006580","2173":"100000000000000000002174","9217":"100000000000000000009218","5321":"100000000000000000005322","7277":"100000000000000000007278","7976":"100000000000000000007977","5999":"100000000000000000006000","9959":"100000000000000000009960","3097":"100000000000000000003098","6835":"100000000000000000006836","9641":"100000000000000000009642","6740":"100000000000000000006741","8522":"100000000000000000008523","5858":"100000000000000000005859","1759":"100000000000000000001760","6944":"100000000000000000006945","3213":"100000000000000000003214","3020":"100000000000000000003021","9067":"100000000000000000009068","2773":"100000000000000000002774","6522":"100000000000000000006523","288":"100000000000000000000289","3454":"100000000000000000003455","6843":"100000000000000000006844","4577":"100000000000000000004578","1611":"100000000000000000001612","6905":"100000000000000000006906","3767":"100000000000000000003768","8169":"100000000000000000008170","994":"100000000000000000000995","5977":"100000000000000000005978","9967":"100000000000000000009968","5009":"100000000000000000005010","7745":"100000000000000000007746","3574":"100000000000000000003575","4779":"100000000000000000004780","8960":"100000000000000000008961","8521":"100000000000000000008522","1587":"100000000000000000001588","7669":"100000000000000000007670","7703":"100000000000000000007704","384":"100000000000000000000385","3601":"100000000000000000003602","4290":"100000000000000000004291","1570":"100000000000000000001571","8086":"100000000000000000008087","10062":"100000000000000000010063","7916":"100000000000000000007917","4418":"100000000000000000004419","7210":"100000000000000000007211","716":"100000000000000000000717","2108":"100000000000000000002109","5162":"100000000000000000005163","1396":"100000000000000000001397","4749":"100000000000000000004750","4593":"100000000000000000004594","9616":"100000000000000000009617","1718":"100000000000000000001719","8098":"100000000000000000008099","7402":"100000000000000000007403","2244":"100000000000000000002245","5203":"100000000000000000005204","7888":"100000000000000000007889","10146":"100000000000000000010147","8499":"100000000000000000008500","8890":"100000000000000000008891","5796":"100000000000000000005797","3225":"100000000000000000003226","2436":"100000000000000000002437","6149":"100000000000000000006150","1081":"100000000000000000001082","5863":"100000000000000000005864","7279":"100000000000000000007280","1323":"100000000000000000001324","5904":"100000000000000000005905","9055":"100000000000000000009056","5782":"100000000000000000005783","6408":"100000000000000000006409","6989":"100000000000000000006990","6711":"100000000000000000006712","9175":"100000000000000000009176","6170":"100000000000000000006171","5420":"100000000000000000005421","7911":"100000000000000000007912","10013":"100000000000000000010014","3815":"100000000000000000003816","4942":"100000000000000000004943","1229":"100000000000000000001230","3284":"100000000000000000003285","1658":"100000000000000000001659","4801":"100000000000000000004802","1300":"100000000000000000001301","568":"100000000000000000000569","8930":"100000000000000000008931","2878":"100000000000000000002879","1213":"100000000000000000001214","3834":"100000000000000000003835","5889":"100000000000000000005890","5933":"100000000000000000005934","10079":"100000000000000000010080","6000":"100000000000000000006001","9622":"100000000000000000009623","3381":"100000000000000000003382","503":"100000000000000000000504","3154":"100000000000000000003155","8978":"100000000000000000008979","1291":"100000000000000000001292","1915":"100000000000000000001916","9776":"100000000000000000009777","902":"100000000000000000000903","9797":"100000000000000000009798","1447":"100000000000000000001448","4484":"100000000000000000004485","7687":"100000000000000000007688","0":"100000000000000000000001","4318":"100000000000000000004319","8249":"100000000000000000008250","7781":"100000000000000000007782","2234":"100000000000000000002235","1653":"100000000000000000001654","5316":"100000000000000000005317","1354":"100000000000000000001355","1078":"100000000000000000001079","6105":"100000000000000000006106","7797":"100000000000000000007798","4055":"100000000000000000004056","5985":"100000000000000000005986","3616":"100000000000000000003617","909":"100000000000000000000910","2019":"100000000000000000002020","5495":"100000000000000000005496","5261":"100000000000000000005262","2973":"100000000000000000002974","4001":"100000000000000000004002","4531":"100000000000000000004532","5997":"100000000000000000005998","6341":"100000000000000000006342","119":"100000000000000000000120","2144":"100000000000000000002145","8897":"100000000000000000008898","1858":"100000000000000000001859","8510":"100000000000000000008511","7425":"100000000000000000007426","8313":"100000000000000000008314","6896":"100000000000000000006897","9466":"100000000000000000009467","1438":"100000000000000000001439","3999":"100000000000000000004000","4605":"100000000000000000004606","2395":"100000000000000000002396","9068":"100000000000000000009069","9110":"100000000000000000009111","6399":"100000000000000000006400","9721":"100000000000000000009722","7919":"100000000000000000007920","3556":"100000000000000000003557","7475":"100000000000000000007476","9516":"100000000000000000009517","566":"100000000000000000000567","1390":"100000000000000000001391","4999":"100000000000000000005000","9682":"100000000000000000009683","5793":"100000000000000000005794","3484":"100000000000000000003485","7314":"100000000000000000007315","7840":"100000000000000000007841","1068":"100000000000000000001069","1343":"100000000000000000001344","635":"100000000000000000000636","1363":"100000000000000000001364","535":"100000000000000000000536","4013":"100000000000000000004014","5362":"100000000000000000005363","1986":"100000000000000000001987","4457":"100000000000000000004458","9488":"100000000000000000009489","8633":"100000000000000000008634","7422":"100000000000000000007423","2119":"100000000000000000002120","3684":"100000000000000000003685","6935":"100000000000000000006936","8620":"100000000000000000008621","5194":"100000000000000000005195","3037":"100000000000000000003038","1185":"100000000000000000001186","4126":"100000000000000000004127","1817":"100000000000000000001818","6906":"100000000000000000006907","8129":"100000000000000000008130","4770":"100000000000000000004771","6016":"100000000000000000006017","5888":"100000000000000000005889","5959":"100000000000000000005960","2836":"100000000000000000002837","453":"100000000000000000000454","8535":"100000000000000000008536","462":"100000000000000000000463","4439":"100000000000000000004440","4107":"100000000000000000004108","9272":"100000000000000000009273","1391":"100000000000000000001392","9351":"100000000000000000009352","9501":"100000000000000000009502","8665":"100000000000000000008666","5644":"100000000000000000005645","6407":"100000000000000000006408","488":"100000000000000000000489","9409":"100000000000000000009410","4259":"100000000000000000004260","256":"100000000000000000000257","4989":"100000000000000000004990","1524":"100000000000000000001525","6623":"100000000000000000006624","6447":"100000000000000000006448","5980":"100000000000000000005981","9338":"100000000000000000009339","3709":"100000000000000000003710","1824":"100000000000000000001825","1651":"100000000000000000001652","5752":"100000000000000000005753","6045":"100000000000000000006046","1687":"100000000000000000001688","1897":"100000000000000000001898","3922":"100000000000000000003923","2264":"100000000000000000002265","9736":"100000000000000000009737","1120":"100000000000000000001121","1996":"100000000000000000001997","7768":"100000000000000000007769","2834":"100000000000000000002835","3497":"100000000000000000003498","7069":"100000000000000000007070","2559":"100000000000000000002560","5861":"100000000000000000005862","2412":"100000000000000000002413","4905":"100000000000000000004906","6696":"100000000000000000006697","6897":"100000000000000000006898","4289":"100000000000000000004290","9808":"100000000000000000009809","3286":"100000000000000000003287","8318":"100000000000000000008319","2784":"100000000000000000002785","8768":"100000000000000000008769","7149":"100000000000000000007150","4504":"100000000000000000004505","1128":"100000000000000000001129","9919":"100000000000000000009920","3628":"100000000000000000003629","6701":"100000000000000000006702","355":"100000000000000000000356","9544":"100000000000000000009545","2791":"100000000000000000002792","9788":"100000000000000000009789","8550":"100000000000000000008551","7469":"100000000000000000007470","9901":"100000000000000000009902","1978":"100000000000000000001979","7975":"100000000000000000007976","581":"100000000000000000000582","1289":"100000000000000000001290","9591":"100000000000000000009592","9108":"100000000000000000009109","6809":"100000000000000000006810","3164":"100000000000000000003165","8549":"100000000000000000008550","6818":"100000000000000000006819","5097":"100000000000000000005098","9528":"100000000000000000009529","6477":"100000000000000000006478","5564":"100000000000000000005565","5785":"100000000000000000005786","1571":"100000000000000000001572","3715":"100000000000000000003716","1063":"100000000000000000001064","178":"100000000000000000000179","1927":"100000000000000000001928","5674":"100000000000000000005675","7979":"100000000000000000007980","6947":"100000000000000000006948","1520":"100000000000000000001521","2013":"100000000000000000002014","688":"100000000000000000000689","4345":"100000000000000000004346","1126":"100000000000000000001127","4337":"100000000000000000004338","5305":"100000000000000000005306","8011":"100000000000000000008012","2237":"100000000000000000002238","4649":"100000000000000000004650","9602":"100000000000000000009603","2342":"100000000000000000002343","2735":"100000000000000000002736","9563":"100000000000000000009564","7205":"100000000000000000007206","5505":"100000000000000000005506","2341":"100000000000000000002342","3719":"100000000000000000003720","8087":"100000000000000000008088","2486":"100000000000000000002487","5437":"100000000000000000005438","5245":"100000000000000000005246","3095":"100000000000000000003096","8827":"100000000000000000008828","8858":"100000000000000000008859","4757":"100000000000000000004758","977":"100000000000000000000978","2999":"100000000000000000003000","1270":"100000000000000000001271","6314":"100000000000000000006315","2254":"100000000000000000002255","6984":"100000000000000000006985","3218":"100000000000000000003219","6610":"100000000000000000006611","3943":"100000000000000000003944","3721":"100000000000000000003722","6345":"100000000000000000006346","2213":"100000000000000000002214","8928":"100000000000000000008929","3138":"100000000000000000003139","1388":"100000000000000000001389","3343":"100000000000000000003344","8885":"100000000000000000008886","9562":"100000000000000000009563","1788":"100000000000000000001789","5918":"100000000000000000005919"},"title":{"674":"20e562776262c6cebe19de217cd8baa5","6842":"99f95b08b9381ec9c076c4b05afcdbad","4917":"aff22404c30f84162684c76505243562","5394":"d7e7038f470864005402b44df6e16300","9227":"a43e02e6a6e00207823f7e1f7ab9a446","8418":"e4642dde22d5c71f0909a4a9f389e5ac","656":"15775fcb96e2d28e58af78fb3a77ed70","9903":"1c0e0011da19e1df35c1264ef6b3d4a","3203":"be22c05dd597d0a5186ddb62b990f4f8","9994":"be763c5ecacb827d3b1c0f4ab01ee07","4890":"1cef68ecbd3bf796cb522e52f21a8c61","6855":"46dc87713ede3cbf016b05805902b557","148":"11df74a8cf591564413db47aae7ad791","7371":"84bb06e66df4819a7f2e20f8637b6ea9","1183":"25e94f4c53144a8e6d9139368f391c1f","7177":"926f4f798459fe738bc0513734582010","6727":"f6aaedfff362e93bf37d59de602a1dfa","1133":"88e67e4c6c0ad1bf0ab0c069541a90e6","1916":"9d9dfc083ebc17d5bc1430d1564fc1f5","7490":"ccdae1b9f56f267ab89c472e986d6c03","9947":"291051d94392816744da59dcdb9b889c","9726":"9b10e49651098a5ce67c5574122341f5","9081":"4bc4fb342bed8ca5e2a193c6a525b9c5","9749":"fb9027aa70ec54b6142d154d0d3535d2","6308":"85fe249c5ed5a967b10dfecc679dd3e4","420":"77ec1b28c1032f5cac5eb8e8e227a525","5759":"95658bc65bb9d06dd083f4f8f307bdc1","2171":"41a2662584a011de1cae019f5c654a21","8891":"4ba48e4dc339b4d29b085ba14f128922","6513":"9a26576bedcb19f44dc8f74bc141c3f3","1409":"ccdab60c22301347a9e3b6fc924d877b","777":"781f2eba0475a8f046007f0de3bba82c","5636":"a47258bdeddcad4f4267098715b39e7f","9948":"291051d94392816744da59dcdb9b889c","4203":"16fbdbdb85a5db3a55401076248314bc","6790":"d5c269fcd1e24bfb2290cd9941cadee8","9589":"7558e5154ff4611427faf0214f123e8b","1505":"a69103d2a24bb8e7591be24699728d73","2363":"475a93627cccfe89b999e08e8581f63d","1604":"12b09723bb79199c49df9c9abce16dfe","2743":"1fafeb043737d92826d1635b5d7eb3c7","1099":"eb5a12f3a1f643d3abbe8340bada70e7","1553":"d85538623e7c76567e1b8fbf26a72a28","3177":"d694856682b3acd9415cafb1ff2a009d","9166":"624014b17abac4096af9ee255e55fbf9","3412":"977eaa47c8a374cad76d20562c18a602","1161":"951ee567eaee0b86954de4811a4548a4","1140":"351306fc709ce9643a6af254e36ed99","2664":"37e5df81ddb6c6e247616d3aa0ed76de","6271":"2783fab90228130146bf571ed6098d53","7714":"ae43e1e844d44d8ca6704d5d0ee4f4a9","6197":"cd8f7ab86219d64ab495a13541eea902","7397":"3e65eb2434d859694ea4a805fa445be2","4255":"c4e33aac3e286af79e1c3ed226e85b4a","6419":"f6f3b567c57c7229f2447bef44d3c950","749":"73d952632d927c1714c249b334b25d13","9651":"37d1d5ee1c7f4472d27e0b52b6b4ca3d","7115":"3cd729a404bcb4df0aff4604a911dd78","4474":"af861ab341708d39362e5c591b1226ed","7883":"91302acdc2fd07ba1804e3728126baa9","9121":"1d9a84a48c228dd001eef0403c29ec98","1392":"1db23be6142ad4eb8cbc633fb16d4cc0","2933":"b66530d82297a3c8c065e6759c028c5f","5705":"b8d01a499de538f81b41b1e7c28122ef","2037":"c93a131f0a5fab8509a6ca008ac341b3","4726":"a056ce0c9a20d14eb7efaade73833523","6891":"4bd610196254becc9ef9dd539aacf1c4","8178":"ef990b64941a5c70403844363fb4fbf1","6351":"ddbe91e1b949ffb156c019a962e22e53","9831":"48a53858060d221094ae9640b0b9813","8067":"fcacd500182eb07cf3c3ce1689d66336","5650":"fda65f6c8a820c6ae814683afc89fdaa","5908":"d55ac82c4a5527830e1449f14aa1a7a4","6965":"1aee85db34074444211d6feda1b4de1b","2227":"1a42ed18d9ae562fed7f0e9911ceeded","8502":"4bbfdbce6119498e1ac7524da67d090a","8232":"80f2a62d93d01f09109482c00d04ec06","6464":"93197097f97b8fb0365a0a34b5403a07","3546":"52f4c6ca200909d97efb4e5c700cd9aa","6275":"ba6be2f95278b443b9b66abd248dad88","4596":"277073a1d59274c183f424f6a7c8c9ba","9857":"ff2913a9f0c74ded818075c55a96000b","5221":"20c180dff81d128b4034c17e389b731f","5685":"fcd5e4e6853426099d117e135e7a1a68","4061":"3c03cf20eca31c9d5750c6056f784e05","5435":"a645430aaf469802deacc170dadfbf8","74":"7f367bb0227a59b0bf5f06f13849d734","7760":"94a024b9e15fffc21e3a9a9ed986a572","449":"4992ee0de077a6c984d86a31347dac8f","4281":"77f0cf42de33ef88370e954176c4d8f6","3551":"2387eece719d57a1a8759d5796d310d4","10057":"1091b69c6ab91be0d76cee88ca4e2b6d","3641":"81bbefaef018606f5ea8233aaeb67751","6949":"bd25788b87c3627e6b1c6e4befba88da","368":"103cca277e47b87f0ecd8e4ec249bbcb","4658":"e9d0a64ff097f130fd7de4dbc95502ad","9178":"7ae209c31f8a880b3dafd4c18c189de1","969":"aae8d731b6e4258b36cd172f41759804","9148":"9224e8e9be384d38fbf2b4e356e3eddb","5272":"e3bb0499ad7790c27467bb4f1ed0049a","4080":"e8a40a7e02b4c6070a616b8097c4e2b2","7388":"d2e711807b58df5de9e519a86a728f9f","4908":"ef54ed4a4a1286fe884dd0fdfa858c16","658":"15775fcb96e2d28e58af78fb3a77ed70","1284":"fa0b95297584c107fbc7b4263b6689d","8091":"45f13b3020a1568355a13aa67c5fcdd0","3308":"d9444afd3dd2c9b4656598a159c102ff","6775":"5cbc011a82c6a3cab48273fb448381cf","5001":"84849a679dcd8639044483bf4f0f2e03","3341":"3c42d11c599a2bdeeb7777b39fa067fe","4420":"96b30132289c43497aca14e0ae5d619","5547":"a99fd1bc45d7cb7a7fd65bd7759ba8b2","5506":"23ac0e85ff616858a07b48c76bb0489b","4791":"14cc9653da9f9b4a3a6384605ae8ad90","6931":"af0480ae13741e2fbc296c12c1426ed3","4207":"16fbdbdb85a5db3a55401076248314bc","1833":"ea891ff8c77d2250ec9f6b51e6e17162","2001":"b973f410fc1d3a85985d0574386c1e1e","9435":"36337480369bcdb21d40ca56ea52c885","7064":"a4b59719c379192ca6f7dfaffd176f98","1206":"566cb4f384f59f3027af4c4d4e136afc","933":"9c16e8b5645eb7f0e67e9e693e1256d","4144":"9d2990d9c99cd5b0e33ff1d708e9c7a1","7668":"eb1ec9e768aae2251821e5d20eecb7b1","7076":"ee431996004004b15c3e5a2235e69b8c","5215":"712513a264623145ecc2ad4fd4df3bdf","1177":"93dfc31acd0386e5de68bf427b6b32b3","2321":"e123a6b2eea13d846e41bd4feda36e2f","5842":"9d98b3374a420a7007fd2dd4ebfcb805","8888":"4ba48e4dc339b4d29b085ba14f128922","2332":"e123a6b2eea13d846e41bd4feda36e2f","5927":"42edf0fbf8d69352aa6ea46593df7892","1216":"8bae3524acbbc9781cc36dc77111beed","995":"12a5f2b2e040abf2773730c225a657d1","6520":"53d706cb807fe5d878478f1fd0a0e316","7188":"1355a1dd599dd9f33cc9f5e123d4d83c","2165":"bff81642b7a6bec60dbc63bfa4c353b9","1629":"8133b423a3b6187781d9866c2ee269d","6948":"ce022185500042314f8802d6201d1e60","6185":"85a96d45e288ca22d7199e85cbab090b","8566":"9a17b13c1ed8c7b93cd2990a9e3ad708","2256":"3ca39cfe37550e6fe3ca8ce0f5acca71","6673":"3048b1c6b2ce9a694cc7a6bd3bf83170","7565":"530270efddf24e51ee98178e4beb4f40","421":"77ec1b28c1032f5cac5eb8e8e227a525","6355":"98abd760f74c65fa3c450969e3e8006","6382":"c57d3aff8fa831944fd81ab931072b2e","3211":"b624859d3eff932d038b6b02855d5ccd","1288":"fa0b95297584c107fbc7b4263b6689d","850":"dcd4f0c2cba9b7a586d64f40e10ad59d","5235":"28fcab701147e22aa62207d6bf6f1598","7750":"4556eb3592d528cfeaba174b71a312ce","6911":"80a54ae20a643b634f49736bce960dfe","5550":"c49dfe8bdf58433c8f9ddcea1742c140","465":"87d5f1c5050590117a60c4156c9b5f6d","9953":"968df9af06dbc3e54c5222b38defe88f","5180":"7f99ac9975f6bf190c748d5c44b441de","6653":"b3795b0197bba243ae164d4ce5ad1d14","3875":"b1381b909bf80d20be72401c91061b7c","4437":"16d18fe762f809fd57993be2e9317cf1","3024":"80154fde26256a1dec1f6ebbd6380516","1662":"940280692f10d1951f8b172a84ec1292","6613":"2349ee6e6d34acd219b9b76439185e75","225":"8088dde892089a20ea5c1e85e1613273","3425":"68088100f6f27c5619d5db405a89d4ff","8980":"cc4935a135e2124423641382243836ea","5817":"c0bc0226ecc90c9ff4a68952e2a93eee","8386":"4cf236f6436c6e90a28157d6a2ceb011","6251":"e2c3cbe58dc80dec1f0bc1b55b4e5bd","9209":"96c66ad20b1bd9a8cd54fbc12fd21d96","6546":"49ee8a95dfa3fa0e3033ee3d44b6d3c8","4888":"1cef68ecbd3bf796cb522e52f21a8c61","1077":"b880cc5dbbef2e3972969041df285bb8","7537":"7dae7dbe3df5113391387b85ee5af7c8","4391":"bda5da7e4a33a783e31fc636e168bbca","8622":"e2bac44944c7bf43f4031c60c838dc60","8937":"bfdfca0b4505a210897d3cb4d428a751","1690":"7508864e8f2985166accc5ac569144c9","4876":"55e3a610558a605c673477db1e3aa203","2353":"63d380e5517d8be2b85ba4f10dd99a84","3330":"fb9a18fb0d1c31432c28a82fd32b8646","7933":"22db8bdc52ee6ba41f4a8efd756115ca","3872":"b1381b909bf80d20be72401c91061b7c","5404":"42094fb53aceac1bdf6ab50a767f9bd7","3230":"a588f2daca10338fa8b5ce3a49f0dd68","5832":"6c566646fc0104e56dd987264489398f","1663":"940280692f10d1951f8b172a84ec1292","3724":"2b4351bbf231e76c58cfb1b019a0740b","433":"14977aa09fe67799cd08faab196484b5","353":"af26c4dbefd895c8827afd8b35cb5f7","2863":"bba430f21e38599a5b9efbcd0d45c187","7723":"510c609be46708b0aae6595e933552fc","5338":"4f80ce6e2945a5c50b77624bb3f6855e","4887":"86d4fa920b02891089e197066cedbdd3","4120":"e902bd55ebfd0600bd3f69e221c1cda8","7432":"f2d091e53e41f317bf9d8a164e22c4d7","7454":"1c2c07e041a24410f289b1b8ae05c943","4103":"74aa44cbad90eafddda8b509bee65a39","8443":"e73999cb7f181a4b6233af82e02a2eaa","584":"f5d44cecd710bdb17057ef49138daf7f","3838":"2a61be567266b273a6a838dd5bf386","7272":"2f1f4954af75db07f1627845c97c1436","4984":"7de9f22477057e8b1d31fb4de7860d72","4260":"ebb6a12ee4d57677dbf2f97f51ef4e70","216":"9a06ef81d3fb0c37a081191e1fed0e47","8498":"13975bab99e3364bcabb647914b1179","8838":"9b33c983027c777909964a5913c345c8","5984":"b3690b41cd13e5ac7275542d1e0aa57a","7678":"ae27efcd50752fcd5a7781b13e260e80","4150":"fd9a56f4d4d29289e24bb26813176283","9213":"da390299092298a09545c175d5415fc","8026":"70cc0c104b5cb77cbdfb39444e221c22","5549":"c49dfe8bdf58433c8f9ddcea1742c140","7256":"52babc1f70a26e279370603f64201a83","5317":"12b69c1ea91a15a9389823a58a12f72a","432":"14977aa09fe67799cd08faab196484b5","3464":"5307ccbba5b4f803949c33edbbde930b","9060":"57a5b9e06fa78f1096619ede4d153b8c","10108":"f6ad14a14517106f58240e713d54426a","8573":"a47b59fb0176d83589534ddb95a562ca","7736":"9d86bebfda551d246d83a009349f95b","309":"14c3deb96d3642d9a6a9908e1e553df0","9402":"ece61975a4cd294fe623ad488fdb3c65","9":"d7bba6b692a38859debc1bf7955686d5","5023":"84849a679dcd8639044483bf4f0f2e03","4471":"af861ab341708d39362e5c591b1226ed","4680":"dafbcd76a994eaa901c263798c2927a","8045":"3ab36ff161581e6f6781179c2ca2b8ac","305":"14c3deb96d3642d9a6a9908e1e553df0","3514":"8ab43cd5fc3114211a75f84a5357e303","6455":"f43695bc8a080c3dfc545d5906ef526f","1944":"25e906641e63e8cc0e95e199ae190c0","7716":"ae43e1e844d44d8ca6704d5d0ee4f4a9","622":"36aa1344b985eee32539045e329443b4","2732":"f4c04c19c27ccc97e1f957acf17dbb8f","9405":"cd854c8ebb1d921807242687b0dc65d","6517":"53d706cb807fe5d878478f1fd0a0e316","3890":"29a000919d07acd8b87f5bc88f9603c2","9499":"bcaa0db1d290f93fe1bc8cea14ebd595","7889":"5da2e6d2262b1a0d06ccf2bf5ee49a82","1057":"a4f4d203ce28c6e4754994d6b851b8b1","8887":"4ba48e4dc339b4d29b085ba14f128922","3342":"3c42d11c599a2bdeeb7777b39fa067fe","2556":"142914859998ebcc4fa65fcc60d4e39a","7612":"692eec1de67564a3f54bd8f2d2126e5a","3":"f059e215ee14a89be75d577ec5ad4eb2","3395":"406504dd868a47b735e5350991a12041","2707":"d10af9756bd29658195c1bab0de0b868","10133":"23a47d740ee78593077b8e9c3b95e0ba","6535":"2cf36221c0ec3d36088fcbec15216084","2286":"c8e6421c22c7025eb3349167a9685c22","1987":"39e8a31c6634444323ed3cfd53d0f2ef","2658":"58b0553f74e8870a00e502b3b2d0edb7","4229":"51159230085127eb04e8052539ffc605","5679":"acdb289ceca1fc562ce1a06f176e6575","1894":"24bbfe0c4a3366a7381a9b55625164ac","1516":"21f475eb49d34a61614b5e3b3531aad9","9885":"346d72b6d24d5844f07b2581f540b4ea","5415":"dc52f40a626dae7da89b7c6bf62dc81b","20":"81fd262a74141ee213c771449bcfd8a4","3704":"e2b1523b26cb6fc8183778d32bcdd6b6","8684":"6db0404cf47f3de821c33f1af6ae434c","3421":"3e6e38e3a8296e45311e21cecd316e4d","5256":"68159231a21d495e3aad16bca97208e9","8564":"dbf0f795b97953006f5d419f046501fb","5093":"890361374dd2a4c6d09da4f23f84081e","6316":"39288f8f077a22fb6ed55463d7e14b7b","2346":"90b3ed2d1dad82574cf3c43a526059b7","591":"933187e32706f98d04a93c3f7c62255e","4071":"43fd357c7e9d87d671bfa705687a9d8d","805":"be5aac7f0f716ec0e6648066ecb13c9d","1771":"6ff542c1c046c0646187a06c68af7269","7208":"589ea53368668397c4cf2ed7a8f8e5bb","6479":"d9d7eb56b1509cfff2daeebc12307964","4223":"14f60da20baf05d226781c519fe51e96","1266":"1e1030957deef426a3b34953be0ac56","5835":"fdd8ae11e376145337d963be8a9a5e06","5104":"39a4139d58a3df206d6591c8807e77be","6833":"a3b7d0642ecafbe24abc57f5e6852ba7","5129":"d1eae314ffc3139ee604f34f59308999","809":"16ace4eabe59de6188f96c4678f5c03d","4861":"b10f2434ba780c088dd5466a6afa6da1","8901":"57fa1fb446b9241963f04e14a17cd92a","2635":"54efdd623dec2ee2825f83cc047c3e5e","4005":"12ed64e0d8ca9bd9de5bfeab481e6e3","5304":"f580ff0a573f969ebcc2ffca7f9fdfaf","2660":"58b0553f74e8870a00e502b3b2d0edb7","4480":"de030e96fb0a49c1acf7f7514940a15","1405":"b7bdadd532d6f5ed496634ecf9ec6be6","8918":"82346f83941dd66898d97f257df97f6","5595":"383930507c8ae2275c00b716c42adb99","6703":"2a8cb96f3fc1334fae021242f77ae3c9","1783":"9d3671361e2579561bd32f7a27692547","1105":"68d52f30590d5f92747cae7f724618ad","10125":"9d384193cc3b62a17bdc01e06449daf8","4736":"f914d31ce21d13345694fdc8ed49695b","6536":"2cf36221c0ec3d36088fcbec15216084","6892":"4bd610196254becc9ef9dd539aacf1c4","4170":"7d3ac66eafa9b457f8ed6ccee87d1b24","8481":"16fc1a58de600ebe144f8a27c79387ae","6956":"1d4974ebafc6ef10c7f030962e5c315c","7012":"12bfb4d5b33cc5c7eaa699cf6dc72b80","9918":"f501309a7dd5c4bddb03caa0a59dd4c9","7724":"e8d3a1817ca6f0036aef14589a61df18","7844":"df67f194f49fbdce07fc4c88dc5086aa","9198":"8075e5d732f330668cef39c568d54a92","7811":"d802cb3b95923ae4d7f51043a3cbe37f","8382":"4cf236f6436c6e90a28157d6a2ceb011","2442":"986b98e6cfecc927756d5f24331a8bc3","6519":"53d706cb807fe5d878478f1fd0a0e316","7212":"c1dee9c542f570c18480cbfacbae0249","8164":"24ae80d65b27d4b8acdfe801ecaeff87","1847":"ae2c2142b897744f41e1d05ad6975aac","9224":"c6b31849f0c1d74de6e8a263521ba262","6804":"b031dc1608a13f31b39ea1d82b4bca69","2485":"4ba1ecd061e0129873e59cf94711a680","6750":"93003feee612119b9922b936f0f01c08","6555":"34a2726c580fe282fbb53550db6e3aeb","5577":"5a2efd2b389bb5483a63a882498baf18","2570":"d14fe26eef0f104f67c2bb69b2837ba1","1066":"578bdb7a5dfe9b8fac854ddad2864d41","5026":"84849a679dcd8639044483bf4f0f2e03","2320":"e123a6b2eea13d846e41bd4feda36e2f","1387":"db47ba4f8911530304190516f15c7abe","7552":"b1ba2692d7f55f0a7f92eb3912a081d1","5021":"84849a679dcd8639044483bf4f0f2e03","1086":"4ecb7a8b3bea03031e6a888d99a5f3e6","8452":"68385e71b80aaa94cd5f598ccf52b118","5413":"dc52f40a626dae7da89b7c6bf62dc81b","6648":"8ecf27d49e7b9b98861671bc34560491","7680":"ae27efcd50752fcd5a7781b13e260e80","2669":"6956c75fa0485b3c1a6f7b2b7057d71","4534":"24e9ddf52e9b176502323c9d346ee36a","8073":"fcacd500182eb07cf3c3ce1689d66336","8261":"73cfb7863df134baa3e5a40d88baaa7f","9891":"25e03ec93c6a95fbaeef50f37aa10b37","8767":"acd2700d073990d78ef7865cf26c6b72","5849":"7da129c72d73e8f8adc2a3577f6ee622","585":"f5d44cecd710bdb17057ef49138daf7f","6359":"d67bebac569654e2fefdc81d10dc2b23","2307":"7aa0d008fc8ff274d275b0002055bcf0","9359":"7fa4ec28ee947be14736e651b62630df","4351":"df5784616b9a240c5b0cdcfd6d9c27d","9674":"ddfa33da99bb672ab01bc3527fd6c9cd","9944":"67535473e5701844797dce87de814966","3450":"47c81ce148aca647cb88175aae58f564","3290":"e5a8331bf393564ddd71f2b59680a314","9301":"23a6591132487e73438bf73c7e6e4987","5330":"9c7c76a74973e8714d2d22cb1a1ececc","998":"12a5f2b2e040abf2773730c225a657d1","6958":"1d4974ebafc6ef10c7f030962e5c315c","1851":"ae2c2142b897744f41e1d05ad6975aac","8755":"b40742461863a8531b39fe33ca869cf8","9799":"229fbe93e83b4a69ef720f3fbe556e75","5781":"ee808d18ac83a219778293338062229","5178":"6a9c6ee3c0a0720ba70e6c4d0cbee99d","9766":"f7f9ac7286c425511a60ee2b51e79661","7505":"1747d462d4ec959f32128457bd3d086e","884":"18faa5d7c58bc73d5b05a9316da907b5","9564":"b2dcc7aab30c84d68b030ebee5ab3b07","2695":"49bc31ce7b2a56cb109cf6fa293c669c","447":"a5833cbac5ccec1cbacd3a30ec48db5e","6416":"f6f3b567c57c7229f2447bef44d3c950","5389":"d7e7038f470864005402b44df6e16300","3460":"18627117982c4acda224842012110fb7","4218":"646645fc9bca4128a626599f13637de3","5969":"7cc4f9ff58eede95b5747f07ae2cf178","4812":"2e4b123147526e90f8b3c8a9020f205e","3864":"f2931ecf23270165c7bca23c540fe7cc","6411":"5cb03253fcc7e4d7c436677149b9630a","10008":"6b00aec36f2ebf1695b2350499035bfc","2774":"d6f9c6ef2b1090992ea5471b4eecacb5","9156":"fd329412efe75e0252851dce7cab1378","3496":"e9ee89a5a589875acaf25578aece19a7","1204":"20c1c6ec014cf220c9f4ee55dc797252","3442":"7b3c1971c8d114650be25acc24b3a9a1","1802":"459f27d4d584cc5344dd3510ed848030","49":"e34dcd35e8a2caef68ba59a67638ebb3","9356":"4fdbda72fca4a2ffff9ab66c32d5c4b5","9978":"29646875e22ccd7f337a54e18472755","8389":"e35a277d424b480aadfd0555bb53ba9d","1477":"4527f2e9f7e8f19ac47f275f2741ea81","2539":"e76d82e6b55ee4ea699c7367b65770ed","7264":"359b5e7bee18bb78ac6ca844abfe744a","9875":"d794401a3fc771e3a0eaaad1d576157b","3397":"406504dd868a47b735e5350991a12041","3126":"e7ccd11ed243fe0dfbf35474a426ca84","7536":"ad37c4df832bd4084335abdd034259fd","210":"2147d681250bf28a35f5d2219155002b","5690":"d14e0e1394eccd0892f1210899e494ad","6037":"46892bc58560e1a55300c577a2b84108","5069":"d19f379531d904caae147e93d10bcf11","9219":"53bc5e4a5ffa3004a0d8d9989802959a","5133":"d9eb3610e76b711ee436d30d98d73748","7270":"2f1f4954af75db07f1627845c97c1436","5500":"f31d547d3b2e076ad4d021b0626f4dd5","3406":"315b87d2b426712222f7a8e250844cc6","7872":"9bb90e846b8209d65dcf5ae4c72dc05d","7749":"4556eb3592d528cfeaba174b71a312ce","4235":"7dde4846513ba46cdc8eb10a5f0ab624","4552":"a05bf554bd5787730e7fca4de7021cdb","6957":"1d4974ebafc6ef10c7f030962e5c315c","4438":"16d18fe762f809fd57993be2e9317cf1","7227":"a6b682c76e29065d80f77edac5acb3a4","8496":"13975bab99e3364bcabb647914b1179","7717":"ae43e1e844d44d8ca6704d5d0ee4f4a9","3647":"5057be08371c424cc130dc750040cfb6","10141":"38ea1d417afb05e16a38cf84012530cb","8842":"9b33c983027c777909964a5913c345c8","9833":"11f46290afdfb1708cb87e7a6270f266","7625":"420ed9323a7ae1ec8357f1d732675d63","7449":"8f325a2b66bc9ebec08890bbf50961ba","5359":"9883be53e4116b1301dfc7c339740ea3","9557":"c1bb9185ef8d696fceb4dee26eeae4c7","800":"be5aac7f0f716ec0e6648066ecb13c9d","1125":"fd6e7d5d28762061adcdea16605292","6510":"23e30014754e0087e43b9e76b536caf7","8854":"83add000389acc93161703fde67073cd","4236":"7dde4846513ba46cdc8eb10a5f0ab624","1664":"940280692f10d1951f8b172a84ec1292","10043":"7964c2b5259d91e70266a197c09b46f2","3448":"8d15cebdf0278b4493f09808de983eb5","5854":"6328b70b8965440a33b0154c86539a06","2413":"220b6266493a61b8d1394e8ced0062a3","9702":"4758bf5196e3e448560dd66ed09c2aee","332":"df58e259be88799fdc1d34991a7ea6f8","4424":"1c36194a2630164aa436c499aacad280","1546":"e510a6c97d1ebbf4dd7d11641ffba94","2265":"145cef7af50e6816086718fa5507ce31","8973":"9e859f1f2637bd5f2b44ec146f9cad0d","333":"df58e259be88799fdc1d34991a7ea6f8","6565":"c0bd90a1d6d9b6add8dada7bdb8691af","6430":"6f76cdd9d0576bcf3921b0449b1ac9b1","2715":"4df9a7eed61e35bf908eadaa7854a9cf","4085":"32c7cef9d6757a9571d6ae4274f09286","9697":"1f99e7afb83fcfa11ef9b12f3c436033","9299":"23a6591132487e73438bf73c7e6e4987","4048":"60d53522869375983a2bdb69da941c43","2032":"c93a131f0a5fab8509a6ca008ac341b3","1525":"e01243f4d985f82137d9c3691ed2c65b","5173":"f53ba657d303fecda7c765091481c25c","3396":"406504dd868a47b735e5350991a12041","7307":"69b225f5bd85478be9ee5376f0b4794c","3806":"68a2faf066498a9282be7b44cd71634f","10129":"202b8ff82c6e9903f8f42a28f145826a","7779":"ec309214fc62b71ce37398a74f5847db","9133":"6a8262c7e4999a5381da9121a1eadfb8","2471":"578f8a37c59832d76859460f3f5a376f","2672":"6956c75fa0485b3c1a6f7b2b7057d71","3698":"abca474fb83fa861ab2ae8ce8fd625a9","2054":"562378080b4027a2c56aa0b5d29d6609","7634":"e4f0ad04d8d2e2b2814df314531f3352","7340":"fff7dc5b8c5e4d4507d4bacbf0b5c85f","6562":"c0bd90a1d6d9b6add8dada7bdb8691af","4869":"6b2f5455665dc1904fbbcb9d10ef0459","6189":"85a96d45e288ca22d7199e85cbab090b","2674":"22f3238a9c9e3f96ef75f17263dfa9ff","8936":"bfdfca0b4505a210897d3cb4d428a751","8344":"d65e177620d359a8f6a5d388bc12639c","9003":"73b74d40846f1b580c3b46fd0d95fbc9","4985":"7de9f22477057e8b1d31fb4de7860d72","5088":"d3c330b99b9e2f703e61788f22f77285","4169":"7d3ac66eafa9b457f8ed6ccee87d1b24","7602":"2c8f2979f57d9d80947058c7ecd51587","806":"16ace4eabe59de6188f96c4678f5c03d","7052":"2d00362ec0d6ed5d634ced0696953bfe","2703":"bc35e9843de745faf285cbcb9cc295be","8929":"d51cbb6627722010fd556158cd8faab","6900":"d8993c76e37f8c487ac4b6f31a202cf","6966":"1aee85db34074444211d6feda1b4de1b","8556":"fdd12473f5dec69eca28cc75218ae277","2747":"1b2e2fca462c2448fe8cc6f0ce00c77b","2360":"3c5088db0d18aa93a3aaa4ea4acda140","7846":"df67f194f49fbdce07fc4c88dc5086aa","5057":"65b7b078f5cca0f7158a77ccf9943829","6433":"f29a42dfa53194cc1e701b0239e32f57","6655":"d010e80043b2a3392173b5ca167f2636","1832":"ea891ff8c77d2250ec9f6b51e6e17162","8168":"9fa641c42af8e0d308c0be4221905ead","9623":"57cb5e7615877ec0035c3b95f4b3b8d9","6474":"74a24ee4d27d4185e037c57edf089348","9451":"8a4402d74079db8bf63887c64880009","5265":"e77b874d0a59b366f2c2c42ad2a3fbe2","8910":"93139a624fa3bd6a89f0b80c5afb7070","2082":"5d9c41545257e1297be32ca58aae9a2b","8243":"3d799e3d4fe5a46785ec4be53c93dd92","4627":"e0ac9c05f47644460f01970713aa1ce1","587":"933187e32706f98d04a93c3f7c62255e","7514":"348c3837a80338dec87c071244021c1c","2826":"6fb483d107214f20297e1eb4ea4a5cd7","3371":"bf714e56934cd4033816c9b40d7c346b","9170":"6f526486869d858fe1b7fec56f3a2bad","4327":"a5d4fed986b6d8bb6c5aad0fb784c310","605":"5e536128c75fbdc0754302a03859aa9d","6498":"c2ef094eb03df79cbdad198a54794bf8","9672":"3db49be8caf11f7ca91a76700495edb9","3319":"8412d609fbb2be18f4b7242a7e5ab58","8222":"4ea2fcffd4de7c00bcac1d9e4aebe3b4","6086":"1f359e13dcfb58aa9f2bab70b274c08e","616":"9970b3471fdfacc93e41ed7a1cec0b9d","6380":"225fd30e1866eb863f97e978a93a9a4a","8359":"1c40d9fe48b30347cd94e096845a1658","9031":"e6e26db058fb913691392f28655f6a73","7294":"ff5029fc8397198214a791412d2c4e6e","3147":"5ef4110517113a10d8b4cca23cd71d7e","9913":"deb30df7c7435a231388fadcd5bf5b25","114":"8aad37bad5e1f65c77e0155868940a8b","414":"86965f7225f29f4fb089bb1f274576fa","8953":"3b38425610a8af91fe5d1a21625e8c96","3789":"9f8373eee7efca7afbb37acb7f2dc76b","6318":"b2d242090ec0a65a4047bfba5ff7435b","8995":"e26614bd91d69ed1bc1c316b820723f1","1760":"d6b9782360a98675a786939fc435fdc7","6402":"5cb03253fcc7e4d7c436677149b9630a","9053":"bc60d80e8a293cb2ef4c63561a0f540d","6716":"c3774fa8a643432ffa21b12ec8f6e362","1494":"acbc620ff476f6ff4a3e5b96cd0369a","1619":"970369a5f3946e7e5511dab979f69f2c","8217":"3f14f7c137c499480998a84382756b76","5538":"861b5b6e0b67ee216978fc8eab856df8","6393":"cf736b83e63eaf5cbf130ec663bc40ca","4490":"d722d3f2852c312bbaa46f904c12f826","7796":"f4ea37a646ebe595c8b74534d2549ab3","4478":"de030e96fb0a49c1acf7f7514940a15","5098":"634bf682b8752d90e7f91c915d7dc4a1","962":"e93de8fc05f27bac972e4a63bec12691","6932":"af0480ae13741e2fbc296c12c1426ed3","1713":"bed9df3ea5a66bbbcf7387ded634c5b9","9471":"2451ed561f6b5c3c57fdf0e5e01a7121","5640":"e03d25f3d9e0b80e8be563fd4defde50","6372":"a7e9b606956152408ae3cfb3bd3b0092","5326":"41cd4f3a276d59d9bcb1871e0e32c0d6","134":"b06129ce4bee31b367178f3956c53e5c","7180":"dd0292f339a5fea0d1466465689c538e","4981":"7de9f22477057e8b1d31fb4de7860d72","6155":"b31fc24ec3daa090c596c0bb33ee91d5","6132":"4730984234387cb0d5f009e969ff6816","1426":"8ca75665a711ac362596649cd3c0d673","9724":"6fba4d3d2536053b8828f42d43e4307b","3871":"b1381b909bf80d20be72401c91061b7c","3675":"225fc0772f843c8e8e1627b4a7fe18d0","1096":"eb5a12f3a1f643d3abbe8340bada70e7","86":"8e49fd6e064ee564dea7a243c32b0b3b","9174":"7ae209c31f8a880b3dafd4c18c189de1","3485":"29baeea6fa26d15c6544a530ca87ab8b","9904":"1c0e0011da19e1df35c1264ef6b3d4a","3994":"3ee5d3bcad83570b2d350b2f34021875","10052":"7964c2b5259d91e70266a197c09b46f2","5804":"4a658080ff7548f1552508cf50602e98","9782":"81a670f7bb709b367340a4d45aea9172","7238":"de8ecc05b066cda5781c485e7e74d701","3532":"8942d9bac954bc7ae0ea988fc65c429","9196":"8075e5d732f330668cef39c568d54a92","6459":"93197097f97b8fb0365a0a34b5403a07","2961":"c67382a84a98b8cc02f8caeb9964135f","9349":"c0cc9c53df437da8b64cb626ec076ba5","1433":"485c260be5cd3041f22acca2c83397da","8675":"9762102c8f891da0a4e341ecf6fe8a73","3650":"5057be08371c424cc130dc750040cfb6","7707":"d8ab57b62f69b9f4e51190548b2aef1d","6072":"d2cdebb82e1afc9954b8d6e74f11a673","3231":"a588f2daca10338fa8b5ce3a49f0dd68","468":"87d5f1c5050590117a60c4156c9b5f6d","4856":"3204032079017f214ef4037103300dc","182":"fbfc8570be618f0cf8b459c2eb2c8f7a","7387":"d2e711807b58df5de9e519a86a728f9f","9228":"a43e02e6a6e00207823f7e1f7ab9a446","2293":"c3f43ed961dee05c0f7d77f4d207c2ae","8124":"8558ab89431f95d086d1f1f3a78bdb06","1782":"9d3671361e2579561bd32f7a27692547","6159":"b1d29528122107e030b5b917d24fbc2d","2027":"fb63f0563e3bddfd56374f8ac2ea621e","8356":"1c40d9fe48b30347cd94e096845a1658","1397":"2033aa338775a6f172268bc98e5f6e6e","9445":"9927a5023011596b9b1cc234f205018f","4612":"81089b699b38110a7eb908ae7af13085","6330":"ce49d051adc3fc2ec968df2b2366ec0e","4205":"16fbdbdb85a5db3a55401076248314bc","1643":"8acb08f326a421393f920acf0e3a8803","604":"3c601b841064012aa32d3c2020e9db65","911":"d812752c43a43b87d13a933e67cc940a","2575":"d14fe26eef0f104f67c2bb69b2837ba1","8783":"52e33308e569765789851daee8697c88","3597":"d721de93217d02bff085d3ef26153336","4692":"6ea2c5fb8403b3d410327811519c3cea","8110":"2d8339a16d87e5208f6012f1c2d71222","8551":"d409f5c95c7c684a1b37f6ee63289275","10109":"edb2f5df6449fffbade5e9c9313c16c5","8088":"45f13b3020a1568355a13aa67c5fcdd0","1656":"940280692f10d1951f8b172a84ec1292","9378":"6f2941ef3cd666aa0e88e0e4e0807b5e","6547":"49ee8a95dfa3fa0e3033ee3d44b6d3c8","4193":"ea4537acb479769079ccbf098f72bb6c","920":"f42f20f2c8b413e651d909a8a723ca2","8364":"c79fd3a56b4997fabfe4764634627567","3365":"2e0daa3b56cbbdaee1671e1b68decea","27":"5ae09f6b7c89da2d1b5973d4cf686c0c","2830":"5c82b52e3e78b456f798f56305dd518e","76":"7f367bb0227a59b0bf5f06f13849d734","2322":"e123a6b2eea13d846e41bd4feda36e2f","6813":"f2cb64ec01af3ef53125df67eee4287c","7709":"d8ab57b62f69b9f4e51190548b2aef1d","9342":"ceefe54fcc480ebe53e3ca4ba72c2ab1","4764":"c8b3a6ba7cc39f126a1f82647be73d46","3031":"d32a8ee62fbd31bb5fbad61ca344cac3","2365":"475a93627cccfe89b999e08e8581f63d","8343":"d65e177620d359a8f6a5d388bc12639c","3621":"9f09ca29a2171f252451a2b54b3e7b00","3476":"6eb5e22681e02d63e6bad8e72cc3f51e","878":"18587d30d64ede630bb981613dcf8f5a","6286":"8aa72b1af65e90713668bb4fb4f2a5af","3738":"ef6fc2ac6bfa4dcb408ccb8389a0ca0e","3920":"e3cf365ab7e8b9d207c856323deb9593","9022":"51ac75dbc5e043e8df2c7fcf749ce259","3262":"36e92a17c0dc78ca50f225718d439cf0","5922":"eeeac3d0833410ffd405d4e54c52a490","9717":"310e26583852456385abdfb4576fe745","8118":"2d8339a16d87e5208f6012f1c2d71222","7202":"d73ad47b44a6690ee13afa904358fe35","6988":"78cab76378eb5827b589b018e3ec2936","382":"37aa05585acbf6dc29f4e1878b315712","9514":"f9e09591c1ba83c3b8cd11ba70d7ab11","7461":"1adbbd88be5b4ac1242e23df26054a13","4252":"2a8b9f744f931c21871767b58cb8725e","8778":"52e33308e569765789851daee8697c88","3320":"8412d609fbb2be18f4b7242a7e5ab58","1152":"280b81415d3a7d8feca9111d17710beb","6482":"d9d7eb56b1509cfff2daeebc12307964","95":"2ad87233769032e29ecca90d80ffa575","9679":"db68698c7240eb0ee7636bdb0cf0518","8736":"30d8468f0f5882abc3b352f3074f4d1e","5292":"b06541b0a28343d8e6acd5e9fd2d880c","6442":"a498e79b77d2c1ec0e7d0e136f7b1288","2358":"63d380e5517d8be2b85ba4f10dd99a84","3358":"c1aa7b6c1999c77a97d3a1cb9bcedeaa","1768":"564dbe707fb5e84b22921f240c434ea0","6553":"b741f22ba02b38272aa1563857647b42","4292":"a29cc507c9120d57280609f848bff08f","7605":"2c8f2979f57d9d80947058c7ecd51587","3050":"fd478c290f101c698b79e12bf7a23dab","9332":"440a14df37910f5343b695ce454f9ee0","9599":"4a49655f89c89c68a3932a894628f15c","4280":"cb3ffcb2db9932526a1627056375abe6","9016":"4c7bee00129c4760419038feacead074","6704":"2a8cb96f3fc1334fae021242f77ae3c9","1616":"970369a5f3946e7e5511dab979f69f2c","2918":"4a6bb562c723333d087b4be3e47edf49","8658":"3be5daa19daae36c683110f834c52005","2233":"2e56372cc3e19a77f2226e35f878902c","8020":"12467700fda7f733335adc4547fec4af","2621":"a168bdcf83c1130b7e121f7c303d253","6055":"906c769a657770a043c2edf1525c13c8","9794":"30d0f1095380baca5a840e4abcb019cd","264":"9cbd59f7f6ae3cd74ffbbf0d735cdabb","2060":"92b480a88e47594488b3d6175d411a5f","1168":"7430c2f840eac5b99a27b5c14b8840d7","4611":"81089b699b38110a7eb908ae7af13085","528":"e405db48caa19b765c2ac483e13063ec","2389":"c926569034651308916317b92849a21f","1222":"cfee1cb4e63332be99688336a79654ac","6732":"16ffc8a033c1962d1962db280c10d038","8186":"d908577a188309e1b3ab87d7bef17508","1872":"9ccafbf6caf7a6b2d4df00fe320c5ab4","4763":"c8b3a6ba7cc39f126a1f82647be73d46","1029":"93b63faf641102c321366fa70ad04b7a","2150":"49d11d9a436c3fb902d9202caa5ed293","8100":"4293e587c0bafb469c261c09ec69b76","8163":"24ae80d65b27d4b8acdfe801ecaeff87","2549":"9d409afbe041eb5902c9d3fbf0123496","2501":"4d2da4401f080ae3b9662e1984490c75","7798":"f4ea37a646ebe595c8b74534d2549ab3","5787":"ee808d18ac83a219778293338062229","9190":"c2a03ff81cc2ef3c35a191b3d8833ace","255":"f747b76c19a8e3e83792ec6152cab1ff","7433":"f2d091e53e41f317bf9d8a164e22c4d7","673":"20e562776262c6cebe19de217cd8baa5","2831":"5c82b52e3e78b456f798f56305dd518e","9581":"94f74181056cf605b06ade1aaf400f95","4982":"7de9f22477057e8b1d31fb4de7860d72","6489":"dc3317d94154967ff452ad112e9196cf","6893":"4bd610196254becc9ef9dd539aacf1c4","9760":"51cb8fc3e12a6156cda1a32cbabd9e1f","9972":"8059e6e339583db612c4b190a825fbcf","6278":"387244b6291eddd26f607d902e2a1c05","9662":"e998503b0138aa6aa966553a43690442","8782":"52e33308e569765789851daee8697c88","3607":"2625c93da21257212c14e6e21d0afb63","2330":"e123a6b2eea13d846e41bd4feda36e2f","7288":"ce89d2dd3357bb668610b682e380c73","2343":"90b3ed2d1dad82574cf3c43a526059b7","8714":"b0332df72643cd3b67bd857eb35f32c0","6571":"8b5f43954d1a80ed7e7bced9073c4d0f","3301":"d601ea4a9efa4be4213b435ea48eda88","9937":"1cfd94a2d8d36237c523cdf479a3dc2a","3754":"db346246d1e80df991de1460ddcb9997","3372":"b4dfa89ad2ebc4de1c7aa43666c1fbd9","4282":"77f0cf42de33ef88370e954176c4d8f6","2500":"4d2da4401f080ae3b9662e1984490c75","7166":"2656f18b518bb203d3f7a1fc35dcff7d","9550":"4a291b3fd683022c11afc012cfc898b8","8726":"3e5fcbdde489fa1686b83a4824a69835","5125":"d1eae314ffc3139ee604f34f59308999","7982":"4f4311cdb48efa3a92f87fa0246c7c47","2393":"7365a77925092d51b34ba3999b7658dc","4058":"cc5b22a0f15545533be9df232eb1616","8046":"3ab36ff161581e6f6781179c2ca2b8ac","7148":"410af1a82cb9565a85c3da89eddc6d3","6662":"55067cb68aa7542e3e5f30302330dfad","84":"bc13643233cbdda84af71544d63d64ed","5176":"6a9c6ee3c0a0720ba70e6c4d0cbee99d","8290":"8f8fbeea9fce98a9eba119c7ee521c81","5493":"b4535a6a5e16cdebb2a145e5197601b4","5258":"68159231a21d495e3aad16bca97208e9","6065":"cd8fa30759baedf7bcad5b53ac1395e1","18":"a2ebbe91c5fbc2888446cd5e8e0e63c8","7521":"d29255e6eea236d531fc2465df471bdf","7579":"1620785766891cb2aa2c48cc3c86283e","10077":"ae58523d9b02dfc6b40d6b63acbe49b0","9916":"deb30df7c7435a231388fadcd5bf5b25","851":"32ec16ce3d319db5efd0e8fbbbe48d67","8442":"e73999cb7f181a4b6233af82e02a2eaa","3747":"300abf2c6bd1b36245d3c1f0d4aee16c","6304":"61c2724e55857fe06399db210f64599","2764":"792695072b0e3689f8b692f13f8c98bc","1179":"25e94f4c53144a8e6d9139368f391c1f","689":"4b0fe4bd8c040c89044d4159a5f4d387","4831":"fdf9d0c094625b619e2005c0f71b9c2a","154":"b90829ff3c739f76090ba19ee477ffb","3377":"b8baf89e74e40f7a8e1dd51f485b2f87","2950":"8e0a15b90d56499afa3a2839d0a2d9b5","298":"8c378d30f5442b9bc3acae2e5423bd3","5659":"33f5c1db3b26671e26bcc2eb77c5c284","6181":"559dfc34e66415901d64fe89ff38667f","2368":"475a93627cccfe89b999e08e8581f63d","4256":"c4e33aac3e286af79e1c3ed226e85b4a","832":"be38140dfb3e540fe2447880e499535a","3726":"2b4351bbf231e76c58cfb1b019a0740b","9344":"ceefe54fcc480ebe53e3ca4ba72c2ab1","6814":"c4f67a28d4488ceeb534cf00d1b05149","9909":"70842c2986687dedbf5271ecb000f086","6346":"c712eaf95d7c8629d2c7ca175e8331fd","7980":"4f4311cdb48efa3a92f87fa0246c7c47","929":"4b30a35cd194acd878e922aefa99c993","1052":"71924d5575606b2d03fafb349be02b5d","8847":"3757103854b0f7dd3d6db8f7a719a0ea","6097":"a52be3ac8ad6e86e27739d1422319ff8","7120":"454cb2724ba238610fb484e06818f1ae","4436":"16d18fe762f809fd57993be2e9317cf1","7191":"1355a1dd599dd9f33cc9f5e123d4d83c","9186":"c2a03ff81cc2ef3c35a191b3d8833ace","8523":"de28d13041713de626c6d8a6b9c491e1","7147":"bd1b9e684f9debd9edf6e23ae06d78","8095":"553a751b1d7cd95714b7e01750284cc9","7317":"b46ccf0bfeb6c300a03360df1c5e38af","768":"56c7a16bdcb3dcc8006fb432c4684c99","2761":"792695072b0e3689f8b692f13f8c98bc","3169":"9b03c83edba2689f2328b2b4e29a7fa0","8125":"8558ab89431f95d086d1f1f3a78bdb06","9507":"f69648d2f519cc94fb252868449bf28a","8650":"e20ccb0f914fa2ddd701d7ee489effaf","1230":"7a2905706ade3e1e10c1767b54fa2637","2545":"c2de9c0f4668ea75ff375513ea3d24c3","4503":"be4a361cc469d56aa01fb904fc5f9c85","842":"209c807964fc17d7150b0d3c00452078","4919":"aff22404c30f84162684c76505243562","4696":"7855d3c51fb972a2fb05e5b06278365","8293":"1646f2dc75ca1f4513b42e0b6a153d90","4141":"9d2990d9c99cd5b0e33ff1d708e9c7a1","1200":"1854bcac3fd8f793020b1ddbc60bee2e","9565":"b2dcc7aab30c84d68b030ebee5ab3b07","10110":"edb2f5df6449fffbade5e9c9313c16c5","4409":"62bfb1c9ef621bd5ddcc1a68db150e55","2421":"97c95f755760a62f991cd8cc653483da","2895":"3f3d0b7f84f8285035a9846cdd9b5c9b","8096":"553a751b1d7cd95714b7e01750284cc9","3781":"9bc4f17ab7ff2785a613ebf2fb7d14f8","2767":"792695072b0e3689f8b692f13f8c98bc","4854":"65fb74791543d9171c4393376d50ac5b","667":"fa156fea936f1967ac2e70a996baf69d","9173":"7ae209c31f8a880b3dafd4c18c189de1","2372":"6c79295b91cb8f6b255baac6f63ca177","10114":"a8ccce3717bbd7cd92f04cfc3f204abc","8683":"b4150daaa123a73ba08e93f3b919e0a2","5263":"67c1aed00bc7ad0db1d81accf5721b8f","5895":"479720cb8b781a7a72f9a69245a5f3cf","5111":"b6032cf44c48a3a3abecba440ad05a58","9570":"96d017061a2fe3cb903b28a94b31e50b","5864":"83719aa1f49dfd9345442ac151fbcf46","3346":"de11829465633ae1d77f45ab7b182907","4191":"ea4537acb479769079ccbf098f72bb6c","6631":"d21b78be144c5b557652872bf36f8596","7133":"f8aa82fa833b00cf91bbc4fc8b551343","5312":"b73b947562cf26d427f43e39bc67c8ac","3219":"4380a7aed0645df263f3132cc82d384d","5772":"280365e44750fd07f4dd883d6512d94a","1716":"bed9df3ea5a66bbbcf7387ded634c5b9","2129":"96f2ecfc85a53f7cc90722421671a588","9294":"eb447d35f14e501a49b130d0944f89cf","2892":"3f3d0b7f84f8285035a9846cdd9b5c9b","4469":"94b76987f6660d64caaa4eea67bd6a3b","9576":"94f74181056cf605b06ade1aaf400f95","4146":"fd9a56f4d4d29289e24bb26813176283","2063":"92b480a88e47594488b3d6175d411a5f","8673":"9762102c8f891da0a4e341ecf6fe8a73","4633":"e1ff85db33f78e670b9ecacff0035afd","9275":"394be57f78697202f69f02cb69df3254","3693":"665e545efca8192211489ed075c225a9","8824":"eb4afa1a9fa78a003e96323f6c8ce896","8017":"12467700fda7f733335adc4547fec4af","328":"50b296455f503a6fdafd680e286e5590","8361":"c79fd3a56b4997fabfe4764634627567","2384":"70fe1a274d310ee30323624652ae4df","6946":"ce022185500042314f8802d6201d1e60","9624":"57cb5e7615877ec0035c3b95f4b3b8d9","7800":"f4ea37a646ebe595c8b74534d2549ab3","7159":"a07e2dadce1438ffcdbe6e59f97e9403","9711":"f25960fcabb65f9531e8f1fa7dc71194","9960":"41a92c2c8a23d11156e3c2c6bbc28fa6","1137":"4f97235cb4f7f12d2b2f6f405f48c906","2758":"7b014282343681490b237fe462bf7d6e","9652":"10c9d6a7e94ac72e00530c348b88b913","785":"10625cc12d799b1ecfa63527bf897d56","1928":"13fe5b7ef8677c01cad389346393d160","8378":"50829584ed1dd038c13c4a2a4e700f42","2475":"b92ec273c6d74826b69863534d26a76c","5642":"12d10aa73462009a56179df9abfd329f","9212":"da390299092298a09545c175d5415fc","7224":"8285fc049b9102e9e928eeb0530fbc78","9824":"9e3bb3955bd7ea4b2a917abf901ef645","9615":"2d97ad3b03cc7313f88c83ca2d6d4d62","5982":"b3690b41cd13e5ac7275542d1e0aa57a","5189":"3f1fa694601df5f1f775053e3be95e61","1679":"84db693bf6b39244bcced3f7ccf7a528","7659":"d488fa5804361db8a2c4953f62318a5d","4822":"5e1624af5a72c2e5175eb7eec3ef9e6a","9669":"3db49be8caf11f7ca91a76700495edb9","409":"52f97c46db8fe1697fac7d17b2068fbc","7111":"5a42cdc2acef93994c1652bb2f84b677","3912":"59956d1a8f1964c739e7b4c89547dc67","577":"c3a8b438008e9089095e8d06f96609e1","554":"a30b45352d42e2268d0c3b7dd0c74a53","4545":"26c0eea2ac407954ff8d6973423f6c57","6087":"1f359e13dcfb58aa9f2bab70b274c08e","9648":"37d1d5ee1c7f4472d27e0b52b6b4ca3d","6652":"b3795b0197bba243ae164d4ce5ad1d14","218":"9a06ef81d3fb0c37a081191e1fed0e47","1325":"f23acaa394ae43607c81895df3d0a62c","5460":"14b62f7fb00af6f5270cf309fa26e1d0","9993":"be763c5ecacb827d3b1c0f4ab01ee07","8859":"f981f8a5dec2a4434d3d5a40b6e3d7bd","6778":"9ed655183eb8523e4013e621c713e0b0","5686":"fcd5e4e6853426099d117e135e7a1a68","9556":"c1bb9185ef8d696fceb4dee26eeae4c7","1292":"aa96c516354b1b2938bb0bee635f0626","6788":"d5c269fcd1e24bfb2290cd9941cadee8","1091":"7eb758a025f7f5405058ca12fba684e7","5108":"fdedd72111b1570f15fc3115058a3a5","8003":"47213e6ead2c3ba6dc02d55366f7ddf3","2817":"834636093c0f9fb2bc13b05cf8f3d300","2012":"e71006be8a1fd92adf702af0494e07b9","7807":"777ab7f6942c5e20d187979682e5b3c8","7420":"cf980971ea6ed383f2fc788e35a7467","7764":"6172504579a2c342e05b2845a26e1624","3351":"ce7c9b37a5e6ca37235467215291c64e","4232":"51159230085127eb04e8052539ffc605","5880":"a43ba393ce41195c5305c84c03eeeea","3658":"57d7fd12a20ad9c2fc04f2a437e5aa79","6112":"d89b817d008e2febf87f6bf394cb2d3a","3679":"e2640cc4f11f0f97eae5ab116039a8b4","935":"193177fa63ffc8d878ed68e3c3cfc305","7143":"bd1b9e684f9debd9edf6e23ae06d78","683":"4e09ec2e9071607d012b71f0c4ce5fb4","3584":"3ced07d7865f1800d2b689c8717b05a1","8376":"b2bd758ed542393c9a2b2762c8574bf6","8458":"7364302006445fd24cfc49bbcc16b3e7","6131":"4730984234387cb0d5f009e969ff6816","2154":"e4c0777b39840dd9e92d568c3001c040","2073":"de533715920e6e74b860cba021dee542","1403":"b7bdadd532d6f5ed496634ecf9ec6be6","4307":"ea9e91a966fd5535c8acbe3fd5e6f6f4","3618":"e52c23f934e697fea670dd918e317394","303":"8c378d30f5442b9bc3acae2e5423bd3","397":"a6343530c25251f1ccdc94c2998fc7dd","3575":"696e5e62ca2c4c9343dafda10e829cfc","9470":"2451ed561f6b5c3c57fdf0e5e01a7121","3973":"beec4948c607e2f3aacd5d8164988798","3232":"bee45fbbdb5ba2906d392cf8ff3f38f6","7903":"f62760f1ce85477557d8ae28d0466ec0","41":"cb7973e637cb213634c54a9aa03f5427","3527":"8942d9bac954bc7ae0ea988fc65c429","7962":"dd0818c0bade571e28c28592311798fb","10031":"f019ebba426701a374d64aba854085eb","5284":"8f97d083bbf9a5ae19f0a8bb7714fba6","1931":"13fe5b7ef8677c01cad389346393d160","6700":"2a8cb96f3fc1334fae021242f77ae3c9","251":"71036bc151fa235eee1ec42899eea3e1","6521":"53d706cb807fe5d878478f1fd0a0e316","3531":"8942d9bac954bc7ae0ea988fc65c429","1597":"2ed3612fffda75704d01968558f55117","9704":"ce5bb8c15743957d23441d54dc48b9d","6453":"f43695bc8a080c3dfc545d5906ef526f","9083":"4bc4fb342bed8ca5e2a193c6a525b9c5","2434":"4cf2a7e81ad18709049cfdec88c0a775","7644":"384704d1c9ecb505b82eeb4dbcc4cd54","9734":"f2164398ced4bffc0061a836aa49c0c1","8969":"9e859f1f2637bd5f2b44ec146f9cad0d","4270":"491a7a4f0b9aab0d3f2aee53e7be6bc5","7713":"1009e6503e836968d153c949ad43a6df","6383":"c57d3aff8fa831944fd81ab931072b2e","6634":"d21b78be144c5b557652872bf36f8596","9103":"711071d46d0e34ef70587cbb5a395a98","97":"2ad87233769032e29ecca90d80ffa575","8823":"eb4afa1a9fa78a003e96323f6c8ce896","5840":"9d98b3374a420a7007fd2dd4ebfcb805","589":"933187e32706f98d04a93c3f7c62255e","4023":"f5646fbb07425daa93a2de4be216cf4e","5801":"86d1974990b3269ef1f4f7b404c7f475","5066":"d19f379531d904caae147e93d10bcf11","9548":"50725feea96b5a97a27d3424684b179","8586":"bb8968bb502073a319a87520d6afbab","5935":"1d7866fa1ee30f10d8ad4007e4f2f605","9987":"d948bcc6841190d382e8518d65c2cce5","512":"ce3095518f128aede04e1987efe4ce59","4052":"d4f43ea562d06564d9bf3ae9c4173ddb","2132":"c7d695d23319b6d082860c1917258092","4084":"e8a40a7e02b4c6070a616b8097c4e2b2","8181":"ef990b64941a5c70403844363fb4fbf1","8240":"3d799e3d4fe5a46785ec4be53c93dd92","538":"97524fd1a08979c64e6526dd33c257f","324":"50b296455f503a6fdafd680e286e5590","3340":"3c42d11c599a2bdeeb7777b39fa067fe","653":"984060e0ec12c5beb4e6bb14f68f5423","862":"aa1ecda78ed5afefc2267e2b3683e763","8476":"c07d7fcb1594964fc442b239d9a9d39","9525":"2031b938ceb3792d6a3bb0a217a37d72","4067":"43fd357c7e9d87d671bfa705687a9d8d","194":"9e0f7d3a3c6e6d02df95f7668928f2e7","1906":"d1de91bee7bba9d72b334cde1d6bb2ed","91":"2d2d93f3f938c4d227de4e00cd007b9d","5414":"dc52f40a626dae7da89b7c6bf62dc81b","2779":"99a74749c39768971d100807361de47c","9867":"83b88f39b961c02251e906e991f0bcc2","6003":"a05d1dac5f838d06416cab02d8ced4f8","3101":"8544a81b94c530487e9aaf6515143264","5580":"5a2efd2b389bb5483a63a882498baf18","4958":"7de9f22477057e8b1d31fb4de7860d72","4190":"ea4537acb479769079ccbf098f72bb6c","5551":"c49dfe8bdf58433c8f9ddcea1742c140","4715":"d99b0fadd3157f8277f7905d02c267c6","9258":"6c5a7c370bb262832218829b3fcb0dc1","9407":"cd854c8ebb1d921807242687b0dc65d","6528":"c5d5e52b81fe3ea36fbc6fcb3637776c","253":"f747b76c19a8e3e83792ec6152cab1ff","8528":"7b1c4f4f0d51653d5e6adc549dfb036f","4400":"6e4bcc62ff5845afd3cac29737b53157","5913":"612bd8ce839b1f7e6f5ef70ed0aa8f6e","5171":"f53ba657d303fecda7c765091481c25c","8230":"8c1cd5ea7378862dc09d746be19ccddb","8816":"49eca868224160330a6f91000451385f","6031":"a9e328d73539692a05e628069d31eab","2755":"7b014282343681490b237fe462bf7d6e","8374":"e9d7be2d74929ffcec0790275c728a2f","695":"c3cb4fe21de18457b5367c2e8450f474","8986":"a7e2d6335e67bf5a8e1bd1e6d81a8b68","1296":"aa96c516354b1b2938bb0bee635f0626","379":"37aa05585acbf6dc29f4e1878b315712","6198":"cd8f7ab86219d64ab495a13541eea902","3507":"a71c6961ade2f39a227ee7bd300606ba","8363":"c79fd3a56b4997fabfe4764634627567","4066":"43fd357c7e9d87d671bfa705687a9d8d","9092":"3d16439daae7a90de0a471eea812230a","11":"d7bba6b692a38859debc1bf7955686d5","2714":"4df9a7eed61e35bf908eadaa7854a9cf","5262":"67c1aed00bc7ad0db1d81accf5721b8f","773":"697d545cf4a7a01e4bb6034a7f8d3cbd","1864":"9ccafbf6caf7a6b2d4df00fe320c5ab4","7046":"c9e3970da65966336f3e147a354c3679","1510":"95ef4ba0d8b4d0713af400d9005d43cc","5216":"712513a264623145ecc2ad4fd4df3bdf","7606":"2c8f2979f57d9d80947058c7ecd51587","7350":"6b266495fc8bf5e35940b06a60f1acdf","1888":"d26a4de8f94b180662e3b78b04045a05","1730":"69bbc26847cc5059701bc87f9afc27b8","1935":"a0e58f7a03ba4fbc5fdb3e17355148b1","8831":"ed29307f41bcaf7dca82f4a6fd46c52","3707":"e2b1523b26cb6fc8183778d32bcdd6b6","4891":"1cef68ecbd3bf796cb522e52f21a8c61","1925":"51660f7be8fb838073041e22df134084","2762":"792695072b0e3689f8b692f13f8c98bc","2133":"c7d695d23319b6d082860c1917258092","3520":"2ace86789e1a69b3c817391fb83726e5","61":"eaa55a44539a58015dfeabf50ee6816f","2473":"b92ec273c6d74826b69863534d26a76c","8139":"a14be2767063b1b291b96de167f4e23a","1554":"d85538623e7c76567e1b8fbf26a72a28","6082":"e04808227774c5991dfc7ec3e49b2d30","4222":"14f60da20baf05d226781c519fe51e96","5828":"6100d6f23fe6e784762655e6f94e68b1","8500":"4bbfdbce6119498e1ac7524da67d090a","6603":"a79e091119c8946d075f706101d5ed8c","6497":"70470d44e6154b978c4d6ac695cd9e23","4002":"12ed64e0d8ca9bd9de5bfeab481e6e3","28":"5ae09f6b7c89da2d1b5973d4cf686c0c","10091":"5ce21d6cbc651c4aebf3b694b854fe74","4402":"6e4bcc62ff5845afd3cac29737b53157","9925":"286accff807bfb81356061d881f249c4","1686":"1507a4cad9e990ac9f961289ea224f54","5928":"42edf0fbf8d69352aa6ea46593df7892","9368":"2c2c6fc066bcaf84ebeaa3f0705e3ad","1060":"b9d94d7d086d1261aa5ab10ad11e772e","4885":"86d4fa920b02891089e197066cedbdd3","1796":"8e425430dfd61afbdec396f63aff281e","5484":"dc0e73e1071a6f2bca19ac4d82354898","9360":"7fa4ec28ee947be14736e651b62630df","7383":"2eb3718309c0ef4f657ed2b00051df0","9036":"284ef2458eabb1d3f3645f32b606688f","5632":"5827963d8e080d29eb49f91709e31073","111":"8aad37bad5e1f65c77e0155868940a8b","7704":"1de308c4ab060740e905a63ed27ae789","1254":"ba49e4e8d8df31bbfc3e30aa39629b39","6588":"bd2c40c38e704520d38165b2affdc0cc","4830":"fdf9d0c094625b619e2005c0f71b9c2a","1518":"21f475eb49d34a61614b5e3b3531aad9","8268":"19c5516633a9a86e2b762b9de7f58e29","3119":"d16190037de6d089ecddfbdfc273b0dc","642":"59ab111c26bc5b01c29bd38522edc358","1838":"39d8b8834d3861c389dd29e47b592e8e","1135":"4f97235cb4f7f12d2b2f6f405f48c906","5688":"d14e0e1394eccd0892f1210899e494ad","1742":"f09f04f77262cb7be574ce8c79a82d3f","7674":"eb1ec9e768aae2251821e5d20eecb7b1","4185":"b26917d604cfcfd903ff70726a903bcd","2555":"142914859998ebcc4fa65fcc60d4e39a","7960":"359166c9409a77049434a946349179cb","3217":"efabe80ebaa08cb5fa6df141473a6d4d","3366":"2e0daa3b56cbbdaee1671e1b68decea","4173":"7d3ac66eafa9b457f8ed6ccee87d1b24","7867":"9bb90e846b8209d65dcf5ae4c72dc05d","8457":"68385e71b80aaa94cd5f598ccf52b118","7174":"926f4f798459fe738bc0513734582010","5225":"20c180dff81d128b4034c17e389b731f","8391":"e35a277d424b480aadfd0555bb53ba9d","9552":"4a291b3fd683022c11afc012cfc898b8","3364":"2e0daa3b56cbbdaee1671e1b68decea","4498":"6710d6b2af86b559eeb1e9d27c6b5a73","2883":"b72ff91dc1f1f6a6c3154dc9af183ab9","7126":"691747821a5addb2fc220220138d7898","3997":"3ee5d3bcad83570b2d350b2f34021875","4398":"1f9f1aa94c25162c35a38ad43c272a7f","9376":"6f2941ef3cd666aa0e88e0e4e0807b5e","6539":"d235d7cb5649a4cdcd4231694566771f","4566":"81f7e2a8b5d5182e57d36a841567d2b5","4458":"65bec555558bce677a123477e9f42136","2480":"c91c50cabab2df78da691c3d157f1ea9","506":"5e7d38de844a33ef39c0b93eb4292d6c","4964":"7de9f22477057e8b1d31fb4de7860d72","7273":"9c7030fb68db17a2f8cfa29b58a3182","4416":"17140cb86dfeda80f98d96ac8cf37717","9997":"1995c522f8dc0b0f5779aa8f069d85d4","5243":"297a9c38d2d8fb729c1c16ba510848d","1709":"e9d91258c30cef424d00adffc1d259d9","6936":"167c332009e6e416a008d679d23f3f7","4930":"ac96b3af539102d1d31897d51f67e71d","9290":"cf28268da492e4412c7b6749b26d1e14","7055":"1562292f81cf8744d08029eb25639568","9074":"687f168908e53985e7fdc999d8c0951d","5613":"59ce7155cbb7bbb6ec08595e2bf6e843","7860":"6455d1a58401ba4d1f2de11572896887","2907":"576469dc68e25cbe8fbd764da041388b","4261":"ebb6a12ee4d57677dbf2f97f51ef4e70","5621":"e9f6253e43062db5a49447162e76ab40","8574":"a47b59fb0176d83589534ddb95a562ca","1840":"39d8b8834d3861c389dd29e47b592e8e","3529":"8942d9bac954bc7ae0ea988fc65c429","8068":"fcacd500182eb07cf3c3ce1689d66336","8289":"8f8fbeea9fce98a9eba119c7ee521c81","5186":"3f1fa694601df5f1f775053e3be95e61","5353":"a998c0b82196ff01a7bded813d072488","5896":"479720cb8b781a7a72f9a69245a5f3cf","2053":"562378080b4027a2c56aa0b5d29d6609","3209":"b624859d3eff932d038b6b02855d5ccd","6592":"a15c6a144e37f8bdc4535eb348b6f0c0","2857":"ec8ad215ff6856d4cb1077fc52a349d4","8660":"3be5daa19daae36c683110f834c52005","378":"dd3857878a7ba60c41eef2b82cbe361b","2250":"75d370caeac2c8392731185871922e7c","8307":"e33806ba0f3d9889a82ed7ab424cfe45","4208":"70782590b2a3c214cd7da9aa704eceb1","6898":"3fd225756f69d5dec3a5e87247099ef0","8686":"6db0404cf47f3de821c33f1af6ae434c","5663":"af0aed89422a5a608967c4c84ee89e2","5672":"f322337e4b79e0b369309a74d26a267e","3911":"59956d1a8f1964c739e7b4c89547dc67","545":"cc4367bed4549907f4c39294c5fe5e14","7382":"2eb3718309c0ef4f657ed2b00051df0","8719":"8748e43d1432e08a998d616c8be8d42b","7620":"83c5d6f63169e7681e03423cebac5276","3559":"ea70835f719f3608f5693167f57e3a3e","476":"b6625481d6431daee7e06445ff8a19bf","8264":"c2338c68b82f4e014d882c6c49026e75","1274":"47aa4f9b358692806600a16f82759016","4725":"a056ce0c9a20d14eb7efaade73833523","7309":"cbe10c3fcfb14784fc78c926c9d6c66b","5335":"4f80ce6e2945a5c50b77624bb3f6855e","7228":"a6b682c76e29065d80f77edac5acb3a4","1654":"e4fcf225a39678c8c7ee6e23cb4deac5","120":"72882d2ae816b477bfdc8b82b72c3827","5156":"189d359660fb2e9f00d5a85d594792be","1386":"db47ba4f8911530304190516f15c7abe","6846":"5ba56a4adaa3f39d7d4a102fb40ddf29","9105":"711071d46d0e34ef70587cbb5a395a98","8593":"5e2d843ecca2747ffff96ecfb129681a","4638":"a494d52febdeb2724bc588cef8e3ebd8","4044":"60d53522869375983a2bdb69da941c43","6253":"33d98e760b265771a71027413a432fa8","5348":"637f4246802ec5523e186a004a14db3c","221":"8088dde892089a20ea5c1e85e1613273","8805":"e1dbb862c21ad1d66f63fdd8bb57d678","124":"2d1d238b3ff66b07dc27e6073b9e840e","8176":"ef990b64941a5c70403844363fb4fbf1","2998":"ba220eeb6826ab5196a0b8d77503b8ce","10094":"5ce21d6cbc651c4aebf3b694b854fe74","8647":"b4bff841119ea0fec16136df7b409eba","5786":"ee808d18ac83a219778293338062229","8394":"69a11cef940340adf40b8b63607c9d79","8984":"cc4935a135e2124423641382243836ea","1148":"1e1873068e5bf7c3fcd336fb8e8d7219","8116":"2d8339a16d87e5208f6012f1c2d71222","9111":"f78d64b62130ff220e127d31aed8f0d7","8160":"24ae80d65b27d4b8acdfe801ecaeff87","5487":"965fb4f4e2d9af734ee8cd7af6fff3dd","6987":"78cab76378eb5827b589b018e3ec2936","9512":"f69648d2f519cc94fb252868449bf28a","5992":"3658d5eec6c958880730bc5717688f0f","2547":"c2de9c0f4668ea75ff375513ea3d24c3","197":"f61515ed5c4bd6ca599f43df3d23bd2b","3344":"de11829465633ae1d77f45ab7b182907","1218":"cfee1cb4e63332be99688336a79654ac","1933":"13fe5b7ef8677c01cad389346393d160","3100":"8544a81b94c530487e9aaf6515143264","7972":"9f7f2b201160a8018760f15c5774fc3c","999":"12a5f2b2e040abf2773730c225a657d1","12":"d7bba6b692a38859debc1bf7955686d5","7763":"6172504579a2c342e05b2845a26e1624","1252":"2da61c0e1cce68543a750a5ce558e41d","3783":"9bc4f17ab7ff2785a613ebf2fb7d14f8","9884":"346d72b6d24d5844f07b2581f540b4ea","5839":"fdd8ae11e376145337d963be8a9a5e06","7400":"3e65eb2434d859694ea4a805fa445be2","2815":"834636093c0f9fb2bc13b05cf8f3d300","6113":"d89b817d008e2febf87f6bf394cb2d3a","7380":"6a7fc181cbce8d7659e9d08f55332565","6774":"5cbc011a82c6a3cab48273fb448381cf","3190":"c97ed82fcfa05e25f0bc6ef90b1a1be3","3030":"d32a8ee62fbd31bb5fbad61ca344cac3","2226":"1a42ed18d9ae562fed7f0e9911ceeded","6614":"2349ee6e6d34acd219b9b76439185e75","7029":"78f1466a201c92713b96625a335a75b6","939":"193177fa63ffc8d878ed68e3c3cfc305","1411":"ccdab60c22301347a9e3b6fc924d877b","6837":"cc2879556fcebf869662b9bde44179c5","1785":"db88a990c2c65663ee4a6960dd28cb5e","1919":"9d9dfc083ebc17d5bc1430d1564fc1f5","5518":"268b2346cbb0264c04dcfed69b0a4c53","2131":"96f2ecfc85a53f7cc90722421671a588","3243":"320c2db2f396dbef7a414f6f8422f450","8975":"8f1689c0d75763d958c3e5570088c838","285":"a6810db92255ec1494a1f5352d947af8","1199":"1854bcac3fd8f793020b1ddbc60bee2e","1999":"b973f410fc1d3a85985d0574386c1e1e","772":"697d545cf4a7a01e4bb6034a7f8d3cbd","6237":"e5b4320338a742b052dffb8217943de6","6199":"cd8f7ab86219d64ab495a13541eea902","8882":"7425074c928278b0fb0a3d0703c3da43","8745":"476aa136efffa2322b4ed7ea06b5c2bb","8234":"80f2a62d93d01f09109482c00d04ec06","9306":"876d3bc711fc1d0a83c3db40bb94d881","7885":"5da2e6d2262b1a0d06ccf2bf5ee49a82","3851":"c72a3636dbbe6c44e32c5491dc5786f1","8259":"73cfb7863df134baa3e5a40d88baaa7f","8806":"e1dbb862c21ad1d66f63fdd8bb57d678","6593":"a15c6a144e37f8bdc4535eb348b6f0c0","1732":"ae73f672e5d5909037930d069f602967","3567":"58115c8479e907e0f6b9b608a08fd24e","9496":"bcaa0db1d290f93fe1bc8cea14ebd595","1320":"f40a7426bd2d9432a0a468345583c631","2147":"766686bf2d6f9fcd4f9b4098dbe2b7c6","90":"8e49fd6e064ee564dea7a243c32b0b3b","7378":"6a7fc181cbce8d7659e9d08f55332565","5718":"3359f7059d6ee9a192661952eb940956","6733":"16ffc8a033c1962d1962db280c10d038","7435":"f2d091e53e41f317bf9d8a164e22c4d7","7320":"cde7784f42df57503b8fc9be69f4c2c","9613":"2d97ad3b03cc7313f88c83ca2d6d4d62","9131":"6a8262c7e4999a5381da9121a1eadfb8","425":"f8ecdb9a228fe7b7892748066829c6e6","6904":"16646ef014a40117af791bcbfd6b3c8f","537":"97524fd1a08979c64e6526dd33c257f","3027":"80154fde26256a1dec1f6ebbd6380516","3748":"300abf2c6bd1b36245d3c1f0d4aee16c","1677":"616ca847de0b16bd48ecb9a34ba4323","4992":"84849a679dcd8639044483bf4f0f2e03","7985":"4f4311cdb48efa3a92f87fa0246c7c47","1786":"db88a990c2c65663ee4a6960dd28cb5e","6728":"f6aaedfff362e93bf37d59de602a1dfa","7670":"eb1ec9e768aae2251821e5d20eecb7b1","2122":"3fc3f7a4e5e3ae160dcdaa8c2548fd1a","1141":"351306fc709ce9643a6af254e36ed99","5364":"9883be53e4116b1301dfc7c339740ea3","350":"af26c4dbefd895c8827afd8b35cb5f7","10090":"5ce21d6cbc651c4aebf3b694b854fe74","6156":"b31fc24ec3daa090c596c0bb33ee91d5","3550":"2387eece719d57a1a8759d5796d310d4","8428":"1a9958fcce12535af67d3902b7a59f70","755":"c663406059f0fa2148679fbdc22345c7","3345":"de11829465633ae1d77f45ab7b182907","6139":"219a9f7018cbfba24fde0b2336e2d853","3130":"d6acc662d339716a255b7bd93e15aca","4792":"14cc9653da9f9b4a3a6384605ae8ad90","9020":"4c7bee00129c4760419038feacead074","9631":"15781ef40602929e63c636ac4c38b852","2754":"7b014282343681490b237fe462bf7d6e","9353":"4fdbda72fca4a2ffff9ab66c32d5c4b5","17":"a2ebbe91c5fbc2888446cd5e8e0e63c8","2656":"50c8fe6bac93768aae158339735bd7a0","6930":"f7257dd3a0d4d65c0b7be48567bb3cac","6870":"4b51db16e7554cb6eb1ed0cda9972d7","5375":"c863189f8953bd424517abccf22018c1","7568":"c4d0d245742922cb2be306321d402ad1","956":"8b510468e336c169680a6fd9e9891faf","4967":"7de9f22477057e8b1d31fb4de7860d72","310":"14c3deb96d3642d9a6a9908e1e553df0","1150":"280b81415d3a7d8feca9111d17710beb","9295":"eb447d35f14e501a49b130d0944f89cf","1049":"991932a93df1eb2ac51069607c2045e5","2185":"19b63c71411e767286e267027cdbeff9","165":"1d3b1c63a6123b0a9188b7b3d6a888ac","7614":"e66270e8f3a6353636ccf3a06d73ce20","5160":"b6a476f906c0f3a3795a0b1b5ab969ba","5795":"971c1e7c74f8f6e9d6de5956b1f158b2","9200":"fb153dc2238b24df400a80d405bc3125","7219":"db9b0e98d8d63ea0a9a439c226dc2e75","5695":"5b3c7e257d9b1f5e89c7795b77ed4ec8","4492":"ab70edfe1f3559fc965dcdb3138d619f","4639":"a494d52febdeb2724bc588cef8e3ebd8","7310":"cbe10c3fcfb14784fc78c926c9d6c66b","8614":"ebf85775c6fffda39647e1f4e8c44fa","7538":"7dae7dbe3df5113391387b85ee5af7c8","6781":"9ed655183eb8523e4013e621c713e0b0","9253":"4839977b0e4457e4f6e3f3970e75b5b3","8248":"29905df143a5fea778d559b7f132c24a","4881":"94cef21a51aa1aa4f87ffef98adb5e5a","1726":"69bbc26847cc5059701bc87f9afc27b8","3482":"1226ba725c533d00892382e491118a1c","3979":"c10abecffb6f2b7c4e937060b84b35a6","5403":"42094fb53aceac1bdf6ab50a767f9bd7","3053":"fd478c290f101c698b79e12bf7a23dab","4158":"dafd3a0cc942630d28cc9b8750a3bcc","7415":"857585b4200a8cd4c0cfc48ef54579a0","5603":"d903d96298b039f6972fdd3d9fb4692c","9417":"97da7ca71189e77f56f49df66a1b7296","8708":"5d4f5b7e3b2cb4a360fb1a2a1ab95fa8","7826":"5f4021cf2cf6b4612e399ac7967f8469","6563":"c0bd90a1d6d9b6add8dada7bdb8691af","3414":"804987ebe8e692785962d111f9bfe16e","7696":"5386daa018657eb607bd87313b3f5cb6","3110":"d16190037de6d089ecddfbdfc273b0dc","4547":"26c0eea2ac407954ff8d6973423f6c57","5989":"52c4ac1005af8269b93508226e1411c4","1093":"7eb758a025f7f5405058ca12fba684e7","5117":"1364a9b9f9fb7c24fe7bd129372f4b7a","390":"78c61b4307736bfa928cdeaaa5b2a437","4128":"d7fb3b1aa2632fd5c34ec8adb9610fdc","6604":"f9349ef4b4acb92a2b6ff14272f6c426","6118":"d89b817d008e2febf87f6bf394cb2d3a","2875":"5f9c31794b32739d9f9b52e9c531a1e9","4481":"de030e96fb0a49c1acf7f7514940a15","3430":"348bc082790b41a77d7be82bcf27790b","7396":"3e65eb2434d859694ea4a805fa445be2","4382":"26dbfcb20606be19a757f3e01cf8a1d4","8002":"47213e6ead2c3ba6dc02d55366f7ddf3","8632":"c215d088de150978e1efa18f506833b6","9862":"83b88f39b961c02251e906e991f0bcc2","5110":"b6032cf44c48a3a3abecba440ad05a58","8461":"7364302006445fd24cfc49bbcc16b3e7","7661":"d488fa5804361db8a2c4953f62318a5d","4463":"16b2b0423fa0a7281b57ece13713d4cf","3250":"f1cb78d586fc0be0faace5287a1236c8","561":"5de73d696d642874fdaa9a911cd185b2","9485":"30eba48f28bc78e49d47165d6349e827","1870":"9ccafbf6caf7a6b2d4df00fe320c5ab4","5269":"e77b874d0a59b366f2c2c42ad2a3fbe2","9433":"36337480369bcdb21d40ca56ea52c885","6216":"a5b4e41f15a08f4d1d937534762c2ef9","5544":"a99fd1bc45d7cb7a7fd65bd7759ba8b2","8769":"acd2700d073990d78ef7865cf26c6b72","3273":"71a64c3588a6bd6496707fd8653e10b5","5572":"26e0fabeb8b9777dbc09cfa026fdbffa","2939":"2671f59ba5df00f836adcb782960e3c6","6643":"b57bb983bf875e8528270b0f50d080e0","2452":"413aa3779dc2ee4fd8eb15597e7ff42a","196":"f61515ed5c4bd6ca599f43df3d23bd2b","6441":"b8a2503efb63b5f2fd312b133c9e4de3","4953":"7de9f22477057e8b1d31fb4de7860d72","752":"73d952632d927c1714c249b334b25d13","6917":"e5ecc0f0d8c8bc58ac94c6a031460e59","6805":"8b6436824727aed824a2be9dd4bfbbd4","4145":"fd9a56f4d4d29289e24bb26813176283","2721":"4df9a7eed61e35bf908eadaa7854a9cf","2419":"73fcaf51c28bb6da7465a14dac472123","5209":"734e8cb9d5ebd3b4cd784816f4aad294","1038":"5afa0d71ce8da77d3c98ff058d26a07b","7743":"bf57ff7d438ce5a2dae51856e5e16117","5053":"aba0e3e3b4f0283b6ea857101f35196b","2924":"273d531a54061274aba4050007d9d420","9413":"70cf37a3dd7a93ece48c02c924f342ed","4388":"bda5da7e4a33a783e31fc636e168bbca","10015":"a8cf5b1fa28d7559da96e016ce3b4558","4164":"ed2c8e92d5a1748bdfd7facb06907e8a","6664":"55067cb68aa7542e3e5f30302330dfad","8012":"88125204df946730bab17dae13d0f91c","5339":"4f80ce6e2945a5c50b77624bb3f6855e","8284":"aa5beebd1e4b056cd6657675bf130d07","8165":"24ae80d65b27d4b8acdfe801ecaeff87","4465":"16b2b0423fa0a7281b57ece13713d4cf","5853":"6328b70b8965440a33b0154c86539a06","7401":"3e65eb2434d859694ea4a805fa445be2","8090":"45f13b3020a1568355a13aa67c5fcdd0","10137":"56d3446bec7634f5248bbe1fde5464f3","8808":"cd3023aaa5c6b5bf102cf8dd0c2cc7b7","9473":"2451ed561f6b5c3c57fdf0e5e01a7121","8236":"80f2a62d93d01f09109482c00d04ec06","2260":"398fccc6f5e48b78e26b21cd2efcc83c","3646":"81bbefaef018606f5ea8233aaeb67751","2276":"f7fd4eedab9cfef4c585fee363a97bd7","3573":"fdbbaeea4dd21c50eb73a2c2a0d2edc2","7014":"c930a2d10df8393161d1283e93604e97","8347":"75f5822b7654a59d1e666e178db2f45f","4226":"d40bc9d29f212d32a228c67b8cd300ce","9138":"ad14600400c3c3242576b2e10ea897e0","6766":"89642f6fa65615e9c069c0d0fe25030b","9678":"db68698c7240eb0ee7636bdb0cf0518","2530":"e76d82e6b55ee4ea699c7367b65770ed","6532":"c5d5e52b81fe3ea36fbc6fcb3637776c","3054":"fd478c290f101c698b79e12bf7a23dab","3829":"bed63159a7f270dc58a6a9c5d6467d5e","8365":"b19d3bbdc7bf48a4faa7389e8515f6ea","250":"71036bc151fa235eee1ec42899eea3e1","9722":"6fba4d3d2536053b8828f42d43e4307b","3673":"b78ee0a41d216dfe0e98ec3b6016eff9","7471":"230080a5b829e74d07a3744e320ffe4d","9185":"23c402b8f0d1ad219b664018d6410ee7","6186":"85a96d45e288ca22d7199e85cbab090b","8592":"5e2d843ecca2747ffff96ecfb129681a","3436":"725e247cff44b08186fcb304b0261765","5295":"aba81c2c7887a27318130ba5ff3f6ae9","3519":"2ace86789e1a69b3c817391fb83726e5","8990":"a7e2d6335e67bf5a8e1bd1e6d81a8b68","1025":"e3c2e69a1ef435d4d637889660c3d72c","1737":"ae73f672e5d5909037930d069f602967","4392":"bda5da7e4a33a783e31fc636e168bbca","2425":"79498d603ca64875d72299084fcdb0c9","5016":"84849a679dcd8639044483bf4f0f2e03","8639":"627af4531bf2074203bd3bf708d3ddac","3350":"ce7c9b37a5e6ca37235467215291c64e","6165":"e922f7907c79c833c68c957f316fba74","1834":"ea891ff8c77d2250ec9f6b51e6e17162","5779":"84f000d703a4d7a39d89b5b3f907b0ec","2565":"a3e732581c46078608c4fe7ee9e18a99","6066":"cd8fa30759baedf7bcad5b53ac1395e1","9598":"4a49655f89c89c68a3932a894628f15c","2665":"37e5df81ddb6c6e247616d3aa0ed76de","1269":"6a0c3d3897e37d8fd238546fd14bed90","9825":"9e3bb3955bd7ea4b2a917abf901ef645","1682":"1507a4cad9e990ac9f961289ea224f54","7234":"90ce8b14304ed81e21b517b535f79db5","520":"d9bec67713071ab47d9678f9dc367cc1","2975":"e276514097e15900055acc5d50f52b96","583":"f5d44cecd710bdb17057ef49138daf7f","2940":"2671f59ba5df00f836adcb782960e3c6","254":"f747b76c19a8e3e83792ec6152cab1ff","213":"2147d681250bf28a35f5d2219155002b","5259":"68159231a21d495e3aad16bca97208e9","2373":"6c79295b91cb8f6b255baac6f63ca177","6672":"18a6e731d2d8a2d8da1cf1bb697bfdca","1953":"1ab1f4995281d9f5fcdc403cb6f156fd","6124":"a5c39cc095d0ba7819577ae5aed01eef","9297":"23a6591132487e73438bf73c7e6e4987","3264":"a247ed645f1f888ab70fe4b6a4262543","2431":"4cf2a7e81ad18709049cfdec88c0a775","1375":"58e1921d4acd23272655f4274e46d299","5845":"9d98b3374a420a7007fd2dd4ebfcb805","1127":"aa268638a7b5982ca9b1a71487b78e97","6052":"906c769a657770a043c2edf1525c13c8","2091":"f8a0ba3ede38c840a1f973fa80ca7f4e","5633":"a47258bdeddcad4f4267098715b39e7f","6908":"16646ef014a40117af791bcbfd6b3c8f","3312":"d9444afd3dd2c9b4656598a159c102ff","3977":"61541e82ba7157ae8a9f01570eef5c0b","6289":"9ca68d19a603dc5adc6404f494a16304","3700":"abca474fb83fa861ab2ae8ce8fd625a9","5868":"9f12a9568347dd5e969ec05d5e7b85cc","4962":"7de9f22477057e8b1d31fb4de7860d72","9740":"b9709e6c54bf79ae30eab7eb58eb3e41","3741":"733268130beb3d542c4b79ddd879932","4647":"a494d52febdeb2724bc588cef8e3ebd8","4326":"13549cfb73762eee481fcf3c595e049d","9340":"ceefe54fcc480ebe53e3ca4ba72c2ab1","1721":"78daac88f4ea001faefe4f77a35ac8bb","2113":"1ddf44d80ed3b78be5f182489c380fc5","132":"b06129ce4bee31b367178f3956c53e5c","8346":"75f5822b7654a59d1e666e178db2f45f","5830":"6c566646fc0104e56dd987264489398f","1646":"bb874e01828353ba46e841acf64e4bc4","7223":"8285fc049b9102e9e928eeb0530fbc78","3363":"2e0daa3b56cbbdaee1671e1b68decea","7265":"359b5e7bee18bb78ac6ca844abfe744a","7090":"2b5a364074c442661e11ea1e73b9478c","4212":"70782590b2a3c214cd7da9aa704eceb1","9261":"3e861300b3accf28bde928dd491af717","5763":"95658bc65bb9d06dd083f4f8f307bdc1","10078":"ae58523d9b02dfc6b40d6b63acbe49b0","4358":"753bba8beefa815b4236e1a57a2c2c05","6309":"85fe249c5ed5a967b10dfecc679dd3e4","8940":"aa08ce482c0614ba4cb904e4fe9df7de","7766":"6172504579a2c342e05b2845a26e1624","5535":"59a130f1c205431f0f0af76233f1c1e9","2690":"890064a99bec799d4416e942eda0b77c","1645":"bb874e01828353ba46e841acf64e4bc4","9743":"ceae429603d9866b56931941c21ee52","8076":"1eb03ed46f2f515659e5c1aa64add309","9444":"9927a5023011596b9b1cc234f205018f","3452":"7048834e2c2589b10a577dcacfdbab27","7472":"230080a5b829e74d07a3744e320ffe4d","2859":"bba430f21e38599a5b9efbcd0d45c187","5970":"7cc4f9ff58eede95b5747f07ae2cf178","5802":"4a658080ff7548f1552508cf50602e98","6040":"46892bc58560e1a55300c577a2b84108","7184":"dd0292f339a5fea0d1466465689c538e","6744":"fd944896a257056439619b04e36ca1e1","4375":"482b8793d0d444f7defc28b69816fb86","499":"1c0190e6a5c4094bf3c1ba49416b613","9638":"a49f85231026a79d49353b81d2cc0b7c","2730":"f4c04c19c27ccc97e1f957acf17dbb8f","3441":"7b3c1971c8d114650be25acc24b3a9a1","330":"df58e259be88799fdc1d34991a7ea6f8","2709":"d10af9756bd29658195c1bab0de0b868","1508":"a69103d2a24bb8e7591be24699728d73","4712":"812c133bd0265286a28dca7f10737a5d","2057":"8cb1a4d63b3af999448c3b633dd5d45f","7413":"4f2da0fce33a0bd0445178d4355db283","9443":"67afa00590fa84f47447a1b550d67176","7226":"a6b682c76e29065d80f77edac5acb3a4","4057":"cc5b22a0f15545533be9df232eb1616","2100":"caee4e423e533f3aecc5087168da7ed8","5728":"8f66197ac74b5b05161effd3fdeb0aeb","4147":"fd9a56f4d4d29289e24bb26813176283","1393":"b7a76ec216b065583a7d942d2c9e8357","8299":"4c329053c5cd464dd5391014f4912a1a","9688":"9009d90b1ecfdf1984a417d326dae495","1976":"1675c247a26bad19d57656101c545250","3408":"315b87d2b426712222f7a8e250844cc6","8143":"3bf2eff2399cec68700ce42ca8a13e30","7085":"3f47099e7298dea3a6173f309c89b16f","4644":"a494d52febdeb2724bc588cef8e3ebd8","8468":"488702a6ae244598b7544a4224e47b65","5172":"f53ba657d303fecda7c765091481c25c","9583":"482a9db8c8c5ef28c0d9ef3e86635f62","5806":"4a658080ff7548f1552508cf50602e98","1627":"8133b423a3b6187781d9866c2ee269d","7804":"f4ea37a646ebe595c8b74534d2549ab3","3975":"beec4948c607e2f3aacd5d8164988798","3671":"b78ee0a41d216dfe0e98ec3b6016eff9","2156":"e4c0777b39840dd9e92d568c3001c040","2253":"3ca39cfe37550e6fe3ca8ce0f5acca71","5188":"3f1fa694601df5f1f775053e3be95e61","1753":"fadb06da8c02e6455b201fc02331fc96","5028":"a7f3e32a6322f818bb0b8073a2a2a694","7986":"9e77253d2d43898902afdbda36a3daaa","9912":"deb30df7c7435a231388fadcd5bf5b25","4412":"17140cb86dfeda80f98d96ac8cf37717","6211":"a5b4e41f15a08f4d1d937534762c2ef9","3630":"909615b5c435e4438eea4eb7cc5bb6af","9305":"4a8b06ce80902ea67228b46eb9bd9b5a","9853":"ff2913a9f0c74ded818075c55a96000b","9279":"ce624d2a8a477c2ffa863490f4d56d0c","5789":"33d76e35ac8bc79ed8316d68ce7175ff","4933":"ac96b3af539102d1d31897d51f67e71d","6710":"87fa2ec2d125250103c780e387759d83","3900":"633a4252d0bd151d009ddf902661bb59","9962":"9ac2762dfca951e4de15b2c8e34b6c8a","3723":"2b4351bbf231e76c58cfb1b019a0740b","1496":"acbc620ff476f6ff4a3e5b96cd0369a","5367":"51ef2bc3372d5657844283d9b4a4b4d","6705":"3936dded58c81a4a1f8b5f6ffcdfa6bc","1240":"9884f7279643a62acd47e3dd2e972be1","988":"2681fa9875a2afae6e3131dc43c85052","1868":"9ccafbf6caf7a6b2d4df00fe320c5ab4","6964":"465fa531797b3644d7fa1cb77a3dd17","2278":"f7fd4eedab9cfef4c585fee363a97bd7","7318":"b46ccf0bfeb6c300a03360df1c5e38af","5182":"7f99ac9975f6bf190c748d5c44b441de","7841":"e1daaa32a7a2267bc4f318c6832e815c","6666":"55067cb68aa7542e3e5f30302330dfad","1752":"fadb06da8c02e6455b201fc02331fc96","5297":"aba81c2c7887a27318130ba5ff3f6ae9","1744":"c6ba88325fb55c335859be6b378ec1cc","8408":"4d735e9f499518e3ac4ad9a72fcbce12","6074":"d2cdebb82e1afc9954b8d6e74f11a673","1871":"9ccafbf6caf7a6b2d4df00fe320c5ab4","7810":"d802cb3b95923ae4d7f51043a3cbe37f","7236":"90ce8b14304ed81e21b517b535f79db5","3157":"b73c2345b4c044d7a886ea6a41a9abe3","475":"b6625481d6431daee7e06445ff8a19bf","4843":"1add7f94d3c87d0bcf5b24ff8ae4dc2c","10099":"104a33b1b73b00d78659703a30116200","7106":"5a42cdc2acef93994c1652bb2f84b677","8651":"e20ccb0f914fa2ddd701d7ee489effaf","9561":"b2dcc7aab30c84d68b030ebee5ab3b07","14":"a2ebbe91c5fbc2888446cd5e8e0e63c8","10003":"6b00aec36f2ebf1695b2350499035bfc","4713":"812c133bd0265286a28dca7f10737a5d","9135":"6a8262c7e4999a5381da9121a1eadfb8","6202":"d85ff6f2a85146d81a13e5f0a6660545","1":"f059e215ee14a89be75d577ec5ad4eb2","3083":"e550d869eb5d62fb5e6210987927e45f","6048":"c1b571df1cbb67c5d053581bf6eaee81","297":"ed155ea265a9fef431a8a197415bd6c3","5040":"cdc01e85c2a29acc82a0cdd4ad13d9a0","9900":"7ccd3381c7d6cd29393b5a82a2007f43","2397":"45667969ca8ea606094ab9f3442761b7","5370":"2ab73997fc3e387446cfa84b2171128e","5274":"e3bb0499ad7790c27467bb4f1ed0049a","4788":"b221052100e20135834f0b0c2b519be","3495":"e9ee89a5a589875acaf25578aece19a7","4114":"ef1022d8241df8a54d5901a7e854b5a8","5517":"268b2346cbb0264c04dcfed69b0a4c53","2752":"20d97cb7127f75f3b1626f98b88b1ae","975":"b92636ec6eae37a28fb5384925320a59","5903":"9603684575703ec666611a674d5326ed","457":"78c2f6002f20eeb1e44868b0e6c66c6","837":"8e0f5baf29d8d4ff90efbd40439cc76e","6191":"7d1683d1b0faea180c835c80ca13a2ed","4483":"90bf0c15511b37bdb5de7f400ee7fd73","1466":"d638fa89f1c9805b02992dd4babed2cd","6910":"80a54ae20a643b634f49736bce960dfe","4672":"7364b9e0a1d394868b7233619157772a","9371":"6f2941ef3cd666aa0e88e0e4e0807b5e","471":"ceb412d766b4cf5c5ebbecef5ac9eac9","4991":"84849a679dcd8639044483bf4f0f2e03","5726":"8f66197ac74b5b05161effd3fdeb0aeb","10140":"56d3446bec7634f5248bbe1fde5464f3","1843":"ae2c2142b897744f41e1d05ad6975aac","1970":"7be3b7fae503f3bf992643c66b90b913","4616":"12b378508207299df85df41e494cd004","6018":"ffcb7a456fb47caeaffcb7299a6e7ec7","5963":"9bc64bc2bcfffca49695499f4769304d","9440":"67afa00590fa84f47447a1b550d67176","8302":"4c329053c5cd464dd5391014f4912a1a","8106":"bebbc954039d75f7ea4a15a490bd4a4f","9883":"346d72b6d24d5844f07b2581f540b4ea","5523":"3e18690b3efd16182f24d1aa1c384753","9126":"3c4f13d76babaa79a58028adbc3e0081","687":"4e09ec2e9071607d012b71f0c4ce5fb4","4206":"16fbdbdb85a5db3a55401076248314bc","5401":"a634b6358767065c6d59b0da4e5b567f","4670":"9c17953f397e97eb535dad8bff204b4e","6293":"a656a102ea0ec3ea43d84f8acc5a6dad","9358":"7fa4ec28ee947be14736e651b62630df","1875":"9ccafbf6caf7a6b2d4df00fe320c5ab4","845":"209c807964fc17d7150b0d3c00452078","3895":"7343fab455296bf70dc78c58aeb341f5","6379":"225fd30e1866eb863f97e978a93a9a4a","5714":"3359f7059d6ee9a192661952eb940956","6757":"66477e70697d9034a7001fd217304343","5":"f059e215ee14a89be75d577ec5ad4eb2","9492":"2968b8acbb1f8b69ef9f5a226d7fbbef","1528":"e01243f4d985f82137d9c3691ed2c65b","9392":"90960c6c2dd17c5e1c030beac9697fb1","1248":"2da61c0e1cce68543a750a5ce558e41d","6689":"8194fc5c6e614919732662bdddea7a75","7509":"1747d462d4ec959f32128457bd3d086e","8297":"4c329053c5cd464dd5391014f4912a1a","677":"f898b06a6ea03989a766354bc1c7d03","2085":"300734cc3e2d4a564caa82ae261c7c4c","4300":"73264bfd7bc941e3b8b1519b4aacd26c","2948":"8e0a15b90d56499afa3a2839d0a2d9b5","5255":"68159231a21d495e3aad16bca97208e9","6140":"219a9f7018cbfba24fde0b2336e2d853","4064":"3c03cf20eca31c9d5750c6056f784e05","6226":"4833a72ce2f9469e377f35d8c08b9f2a","5987":"52c4ac1005af8269b93508226e1411c4","5412":"8ece99c432b669758a884ab89a7bab1b","6894":"4bd610196254becc9ef9dd539aacf1c4","2198":"2da6d9e1fd0626f55ce6932753c11e8","8654":"e20ccb0f914fa2ddd701d7ee489effaf","6826":"2636c9b88cd2e33ea2f2405ecd2dcf37","8065":"961f0f6a8a30fd5c9e7976b53cf6702","6454":"f43695bc8a080c3dfc545d5906ef526f","4875":"55e3a610558a605c673477db1e3aa203","2336":"e123a6b2eea13d846e41bd4feda36e2f","8203":"2da94c75a8b46c2400ea6a6a224e1500","1309":"2e4907eca6e131ac66f74408971d8e47","3309":"d9444afd3dd2c9b4656598a159c102ff","5513":"d613b8d25607f829d1aba51ecb5d6fc4","2491":"e412e5346a826a59f1474ae83d07730b","6767":"89642f6fa65615e9c069c0d0fe25030b","3664":"d331dd013a02f976f8089274c2f3d08f","8492":"c27226441bb65dfadff372c466f2ea71","4708":"7a1f79f3ebcee566a1ba70a5e94935ac","5956":"961b1c9a33b8a62d5624249883ed331a","8489":"c27226441bb65dfadff372c466f2ea71","5738":"e0b29c85e2b8d9d3b51ed6a60be8e814","786":"10625cc12d799b1ecfa63527bf897d56","7506":"1747d462d4ec959f32128457bd3d086e","1533":"d1b729c57b9b0c26b574ee52f3945329","1947":"25e906641e63e8cc0e95e199ae190c0","8414":"4d735e9f499518e3ac4ad9a72fcbce12","7497":"83f8cffca7db082b2f42b1731ab3bb64","1377":"219d9a5335b93b5b700d0a0352282032","4328":"a5d4fed986b6d8bb6c5aad0fb784c310","9848":"a306c65c390a15fbe5ea2ff9343cc889","241":"f2c7065f4a720a22bd21460e6231c0bf","8588":"5e2d843ecca2747ffff96ecfb129681a","4006":"12ed64e0d8ca9bd9de5bfeab481e6e3","8852":"83add000389acc93161703fde67073cd","8691":"4bb6dd3e8090ac98397371276a8dd774","9038":"57588ff8c678e37105e0ff13257d6b4b","9023":"51ac75dbc5e043e8df2c7fcf749ce259","3778":"9bc4f17ab7ff2785a613ebf2fb7d14f8","934":"9c16e8b5645eb7f0e67e9e693e1256d","5224":"20c180dff81d128b4034c17e389b731f","4466":"94b76987f6660d64caaa4eea67bd6a3b","5910":"612bd8ce839b1f7e6f5ef70ed0aa8f6e","5161":"b6a476f906c0f3a3795a0b1b5ab969ba","8596":"71c0430a3740d750b7b9feb944866d16","7663":"a146b983980ecd57d475b2c0634eafb1","1162":"781a09b1c62743f3733b33a0fdc6583a","9075":"687f168908e53985e7fdc999d8c0951d","6640":"b57bb983bf875e8528270b0f50d080e0","2396":"45667969ca8ea606094ab9f3442761b7","5145":"a06fd7cd2f1fdb69f8e690abc43b2f4c","3222":"4380a7aed0645df263f3132cc82d384d","5257":"68159231a21d495e3aad16bca97208e9","2688":"890064a99bec799d4416e942eda0b77c","9034":"284ef2458eabb1d3f3645f32b606688f","4676":"7364b9e0a1d394868b7233619157772a","4381":"26dbfcb20606be19a757f3e01cf8a1d4","7182":"dd0292f339a5fea0d1466465689c538e","623":"36aa1344b985eee32539045e329443b4","8399":"1408849e1c843e540e83d9a89da8b724","5079":"771d812ecdb2db9ca9cb1926af97310d","6348":"c712eaf95d7c8629d2c7ca175e8331fd","2297":"c53d7c5255790d63a7faa1dbb3c7ab56","5409":"8ece99c432b669758a884ab89a7bab1b","9650":"37d1d5ee1c7f4472d27e0b52b6b4ca3d","3131":"d6acc662d339716a255b7bd93e15aca","3223":"556c32b0037839628a0c633026400f91","4590":"a759939f87859ba932744a15bd598fc0","6358":"98abd760f74c65fa3c450969e3e8006","63":"99f603a81c35490975e6c53a77505766","8796":"1b65fe9c0705b94194545314f70489e","505":"5e7d38de844a33ef39c0b93eb4292d6c","6194":"7d1683d1b0faea180c835c80ca13a2ed","320":"58a7715990ebd8c64678f1efa8f9ff8d","4609":"81089b699b38110a7eb908ae7af13085","5018":"84849a679dcd8639044483bf4f0f2e03","3534":"50142f1cc3cb7b7586a68b36766b0c85","78":"a591319cbeea9146749734234f05d143","802":"be5aac7f0f716ec0e6648066ecb13c9d","6762":"f2621e37427aaf2dc5e61323f516bda4","6347":"c712eaf95d7c8629d2c7ca175e8331fd","6258":"33d98e760b265771a71027413a432fa8","2756":"7b014282343681490b237fe462bf7d6e","2026":"fb63f0563e3bddfd56374f8ac2ea621e","9892":"25e03ec93c6a95fbaeef50f37aa10b37","915":"550a95abf3395f2f31e5ac04dac410bd","6114":"d89b817d008e2febf87f6bf394cb2d3a","5226":"20c180dff81d128b4034c17e389b731f","3952":"32065d3deae20bb806afd7dec13dc1e5","2266":"145cef7af50e6816086718fa5507ce31","4516":"90be8ef4540671cf4fb8cf73d36dcba0","7110":"5a42cdc2acef93994c1652bb2f84b677","6545":"49ee8a95dfa3fa0e3033ee3d44b6d3c8","2315":"e123a6b2eea13d846e41bd4feda36e2f","8917":"82346f83941dd66898d97f257df97f6","6313":"85fe249c5ed5a967b10dfecc679dd3e4","8331":"c50ddaac2ab3006487405c8dbca3ab5d","2636":"54efdd623dec2ee2825f83cc047c3e5e","1026":"93b63faf641102c321366fa70ad04b7a","1586":"64f8d1884b8a98126f0e9215cb59d182","8174":"ef990b64941a5c70403844363fb4fbf1","9232":"af0579d5016a237e369b3168cb73eb19","7853":"899d2a18692aeb450cd2d2af150e8041","9296":"23a6591132487e73438bf73c7e6e4987","293":"ed155ea265a9fef431a8a197415bd6c3","1561":"96f3fc949e4dcdc61d40aea7e57328b1","2128":"96f2ecfc85a53f7cc90722421671a588","10034":"f34f11a3763ac996010a776d52fb7aec","3268":"a247ed645f1f888ab70fe4b6a4262543","3548":"52f4c6ca200909d97efb4e5c700cd9aa","3391":"a8af940f6c956b4916ad7e701629d5c9","9588":"7558e5154ff4611427faf0214f123e8b","887":"18faa5d7c58bc73d5b05a9316da907b5","5241":"297a9c38d2d8fb729c1c16ba510848d","9951":"291051d94392816744da59dcdb9b889c","1809":"18e2afb67e896ba47e1821158a7a19a1","3039":"c230ec199d51a003b09fe8f1ea91bce8","5416":"dc52f40a626dae7da89b7c6bf62dc81b","7626":"519b9c63ed274e31cc9e2ef0ab4efdb0","9449":"9927a5023011596b9b1cc234f205018f","9932":"286accff807bfb81356061d881f249c4","4097":"42371bc17e60cd751fe3ea94c87ff25e","6584":"bd2c40c38e704520d38165b2affdc0cc","7574":"a19fad03499ff062db11588ea16fdec6","290":"3dcb2d94bb72cd774d4b582ec03eb863","9347":"c0cc9c53df437da8b64cb626ec076ba5","1992":"4b400983065ca5256176e317012f9155","6937":"167c332009e6e416a008d679d23f3f7","3734":"28e9147cd7d7680127f8f0e767ba85d","5419":"9abf4fc941148316598676e1e856535f","2516":"f4b39659f7c1a6e4b8508fc46bb6cc16","5764":"95658bc65bb9d06dd083f4f8f307bdc1","8038":"3ab36ff161581e6f6781179c2ca2b8ac","3080":"e550d869eb5d62fb5e6210987927e45f","7000":"db766d90a6564ce8e5bc0bb1fa1c0672","5846":"7da129c72d73e8f8adc2a3577f6ee622","5954":"961b1c9a33b8a62d5624249883ed331a","2616":"a168bdcf83c1130b7e121f7c303d253","4767":"e3f9626519a8540093aadcf9232facaa","3200":"17a45a981ec6909d52fe1bb798e778ce","6651":"b3795b0197bba243ae164d4ce5ad1d14","5119":"f0d974964914ca23d8c299c651f94d94","7899":"ebba2d7d5adcd572d64c3d1122a4ad47","2340":"90b3ed2d1dad82574cf3c43a526059b7","9004":"73b74d40846f1b580c3b46fd0d95fbc9","4554":"a05bf554bd5787730e7fca4de7021cdb","8256":"88d0ae01304e444453b61269c71cc7b7","8198":"9e41e4d67e72379f0353b240a04c461c","9735":"f2164398ced4bffc0061a836aa49c0c1","3886":"cd13dc020514f9e272782bab1ccf695b","1089":"7eb758a025f7f5405058ca12fba684e7","4246":"6b0acd31a8405ff01feed8d224a3a7fc","4789":"b221052100e20135834f0b0c2b519be","3276":"25188a0c067fa176f630e0fbd212c39a","4310":"cae289fbaa2ca9cbf83c5d1411955591","7470":"230080a5b829e74d07a3744e320ffe4d","4285":"3a4873159e9da79fe784ed631e3f34ba","5886":"9a11056c0f7f6649d1abfff85db55d90","9861":"83b88f39b961c02251e906e991f0bcc2","58":"ecaf712d2fb2b519784ccb0aca7b73d5","1247":"179e89a37cdaeb9ebaf1616fb37a62bd","6046":"c1b571df1cbb67c5d053581bf6eaee81","6410":"5cb03253fcc7e4d7c436677149b9630a","4040":"c3e45684d462e4ab0f2284136f24c7ba","1010":"29913cc86bfaafa4a39069e4e6508056","261":"9cbd59f7f6ae3cd74ffbbf0d735cdabb","2820":"834636093c0f9fb2bc13b05cf8f3d300","3631":"f8fc31a2829b5c8c45d339043d79a0ea","9114":"f78d64b62130ff220e127d31aed8f0d7","7186":"1355a1dd599dd9f33cc9f5e123d4d83c","4243":"f4c0431617e6a61268c803c018aba665","31":"948373cea621f6816d541c171e687f1b","5373":"2ab73997fc3e387446cfa84b2171128e","2677":"22f3238a9c9e3f96ef75f17263dfa9ff","1107":"68d52f30590d5f92747cae7f724618ad","2797":"342476e9629b2a7bc5a7fd9f2182999f","6611":"2349ee6e6d34acd219b9b76439185e75","2028":"d99ed3a119d5c646ea1c3276465a25e8","517":"17e669e5ccf6e6e99652bdbd7a701f3f","7879":"91302acdc2fd07ba1804e3728126baa9","6220":"40e632ea2ea2c9797fb9988af7945c2c","5033":"a7f3e32a6322f818bb0b8073a2a2a694","1042":"5afa0d71ce8da77d3c98ff058d26a07b","567":"5d8e67350c9c61e56c7564d237196d2d","1434":"485c260be5cd3041f22acca2c83397da","4440":"16d18fe762f809fd57993be2e9317cf1","1715":"bed9df3ea5a66bbbcf7387ded634c5b9","3093":"ac9b669f06258c03006d4558eb2381f9","34":"948373cea621f6816d541c171e687f1b","248":"71036bc151fa235eee1ec42899eea3e1","7421":"cf980971ea6ed383f2fc788e35a7467","9432":"36337480369bcdb21d40ca56ea52c885","8438":"943e5da90b42d7d62c890c991a650605","1826":"64bbd792d77b03512c001e8f3d8fbce","1912":"de22455f006e5820153f2518677767a3","4339":"3541149f8b5ca7c3cc8fda331689b8f1","7981":"4f4311cdb48efa3a92f87fa0246c7c47","5766":"74ead9bcacbae811fa152e2cd1640263","8059":"780d0963ec74509f98a75332ea904054","163":"1d3b1c63a6123b0a9188b7b3d6a888ac","2967":"dd70acb7f440c478b24ee4a7078bedc5","8971":"9e859f1f2637bd5f2b44ec146f9cad0d","10014":"a8cf5b1fa28d7559da96e016ce3b4558","8453":"68385e71b80aaa94cd5f598ccf52b118","4810":"83d309657e74429d974743799c64c876","8601":"33ba2922112722c51a5c9c8bead79166","8911":"c4b624600a0ee9b1884094ba4e17a54d","2078":"de533715920e6e74b860cba021dee542","965":"e93de8fc05f27bac972e4a63bec12691","5327":"9c7c76a74973e8714d2d22cb1a1ececc","1514":"95ef4ba0d8b4d0713af400d9005d43cc","7113":"5a42cdc2acef93994c1652bb2f84b677","2477":"b92ec273c6d74826b69863534d26a76c","4265":"8901f72331c0bced4c7ebb3b2cbad1c0","6508":"23e30014754e0087e43b9e76b536caf7","7037":"ce1211ac80ee864ab8da4aa59c621861","6230":"5b8df3b1729d37c7ea2fd8ca7c045f9a","399":"a6343530c25251f1ccdc94c2998fc7dd","8321":"3ebbfceec4ae529a78c6019aac229e33","7091":"2b5a364074c442661e11ea1e73b9478c","8759":"13b188d26445b678daf203cfcc5e41cb","30":"948373cea621f6816d541c171e687f1b","3506":"61c3bb909004056a9b0ff01d2f759dcf","8380":"50829584ed1dd038c13c4a2a4e700f42","5730":"8f66197ac74b5b05161effd3fdeb0aeb","5011":"84849a679dcd8639044483bf4f0f2e03","2029":"d99ed3a119d5c646ea1c3276465a25e8","10066":"76666ccdc0cdac566ec8033bbf37ff4e","5540":"861b5b6e0b67ee216978fc8eab856df8","9197":"8075e5d732f330668cef39c568d54a92","6690":"d90133b395fb02a9b58f0864293ee25a","6512":"9a26576bedcb19f44dc8f74bc141c3f3","4934":"ac96b3af539102d1d31897d51f67e71d","5746":"f58c82f36721e70a6c0ddab51217b83e","2503":"4d2da4401f080ae3b9662e1984490c75","6974":"26cfe5c281702f62d8241d1463767acd","1907":"d1de91bee7bba9d72b334cde1d6bb2ed","2536":"e76d82e6b55ee4ea699c7367b65770ed","2917":"4a6bb562c723333d087b4be3e47edf49","6534":"2cf36221c0ec3d36088fcbec15216084","8194":"4823ba88b9211b9337a53e8c05265b2d","3214":"efabe80ebaa08cb5fa6df141473a6d4d","1712":"bed9df3ea5a66bbbcf7387ded634c5b9","6244":"52129cca219a220ea14e2628a4d272a7","9310":"6f7d0911851c531ce0cdec89401c204d","435":"47054ab6ed4f489001007bcf3422d00d","9515":"f9e09591c1ba83c3b8cd11ba70d7ab11","9323":"e522cbbbfade3e21d6f3e0530fbe1dc6","2468":"578f8a37c59832d76859460f3f5a376f","5014":"84849a679dcd8639044483bf4f0f2e03","9696":"1f99e7afb83fcfa11ef9b12f3c436033","8585":"bb8968bb502073a319a87520d6afbab","7008":"12bfb4d5b33cc5c7eaa699cf6dc72b80","1046":"991932a93df1eb2ac51069607c2045e5","8772":"6130c676393d3082b034e99070c85b6c","5707":"b8d01a499de538f81b41b1e7c28122ef","9379":"4983b411e01832d342fe1d72cd08800b","6506":"5238ab434cde377559e94876435778df","7733":"44d6d08ab2f43590294900628b99563b","10051":"7964c2b5259d91e70266a197c09b46f2","1124":"fd6e7d5d28762061adcdea16605292","1647":"bb874e01828353ba46e841acf64e4bc4","4597":"c0c97af98369419263a3fe9e0bdeeb6d","5344":"f3370e74721aa1dbbc1308b6cc51777e","9474":"2451ed561f6b5c3c57fdf0e5e01a7121","2644":"90375bf8850dfc1a5c6dedea82f0033e","8517":"f47c5db6e1f37e332dcce5681e54205e","8762":"13b188d26445b678daf203cfcc5e41cb","5379":"c863189f8953bd424517abccf22018c1","8711":"b0332df72643cd3b67bd857eb35f32c0","398":"a6343530c25251f1ccdc94c2998fc7dd","4678":"dafbcd76a994eaa901c263798c2927a","8167":"9fa641c42af8e0d308c0be4221905ead","2168":"bff81642b7a6bec60dbc63bfa4c353b9","4258":"ebb6a12ee4d57677dbf2f97f51ef4e70","2247":"75d370caeac2c8392731185871922e7c","5127":"d1eae314ffc3139ee604f34f59308999","5236":"297a9c38d2d8fb729c1c16ba510848d","1526":"e01243f4d985f82137d9c3691ed2c65b","668":"fa156fea936f1967ac2e70a996baf69d","3580":"7e3100824a573bc7c9ae262ca0147154","8722":"eaed3a149cdc4ec6b9f05042fdc4e9ca","1688":"1507a4cad9e990ac9f961289ea224f54","748":"cc8ac970c7a5dafcc42be0bccd52bf51","6036":"a9e328d73539692a05e628069d31eab","6083":"e04808227774c5991dfc7ec3e49b2d30","1924":"51660f7be8fb838073041e22df134084","2359":"3c5088db0d18aa93a3aaa4ea4acda140","7019":"b677a633b34a569e69de5108d7bb9315","1381":"219d9a5335b93b5b700d0a0352282032","8740":"41987febffadb48539a25f623109f6fb","1750":"fadb06da8c02e6455b201fc02331fc96","735":"c5e25a79d0926990ce5aef7c2a03845a","5426":"13142adc2a6d97b936882fec094a2290","1603":"9d6ab4fa4537b3a38f6f24de2f55cd7b","9870":"51833cc0c3c4989ea2e5bcd7aab5ef75","450":"4992ee0de077a6c984d86a31347dac8f","4167":"7d3ac66eafa9b457f8ed6ccee87d1b24","1324":"d178d13d3df6b2446ab52e3c6cd6c2ad","4961":"7de9f22477057e8b1d31fb4de7860d72","6177":"559dfc34e66415901d64fe89ff38667f","8049":"3ab36ff161581e6f6781179c2ca2b8ac","4422":"96b30132289c43497aca14e0ae5d619","6049":"c1b571df1cbb67c5d053581bf6eaee81","8799":"1b65fe9c0705b94194545314f70489e","7652":"908a92a8feaf65d46ac0c813e3e4abae","1578":"96f3fc949e4dcdc61d40aea7e57328b1","3820":"a63baad0045e5705db50a86755caaef1","2459":"c1a4e58a597fdb7c59bd88c6a5d399c4","16":"a2ebbe91c5fbc2888446cd5e8e0e63c8","4279":"cb3ffcb2db9932526a1627056375abe6","6017":"ffcb7a456fb47caeaffcb7299a6e7ec7","1329":"f23acaa394ae43607c81895df3d0a62c","8419":"e4642dde22d5c71f0909a4a9f389e5ac","6057":"7903f734dfee2f80b6d44b55b42fdba","2390":"7365a77925092d51b34ba3999b7658dc","3173":"41324445a37d8cfdb180ea37a88ae58","3299":"9b29e3696dee354a2d3fab4672868436","6866":"4b51db16e7554cb6eb1ed0cda9972d7","2495":"a853d067b9f4a199698a6d8c37a439b9","572":"c3a8b438008e9089095e8d06f96609e1","2141":"404f120b8aeb8d03e4bf7cb54de3c4c6","974":"b92636ec6eae37a28fb5384925320a59","6978":"78d57b61740fbf5725940ae91c7e6952","8371":"e9d7be2d74929ffcec0790275c728a2f","1190":"cf7b69afd82d43a83e1d68526e56ff3f","7128":"f8aa82fa833b00cf91bbc4fc8b551343","8607":"9700838d6813b762ec5aaa97fded10ed","215":"9a06ef81d3fb0c37a081191e1fed0e47","9952":"291051d94392816744da59dcdb9b889c","9084":"4bc4fb342bed8ca5e2a193c6a525b9c5","6123":"a5c39cc095d0ba7819577ae5aed01eef","2792":"61cad46c46e2d9f9b43ffc8249be8da0","9837":"11f46290afdfb1708cb87e7a6270f266","6174":"559dfc34e66415901d64fe89ff38667f","9015":"f7a37712fecb3af94c1dcd30210c1bb","1014":"14943386829f84c40f885cb102285a0e","9072":"687f168908e53985e7fdc999d8c0951d","4355":"476a1ddff74850e3a8f567be18492876","6109":"e2e73e6638bf0f354ffa4b8576a0e254","406":"52f97c46db8fe1697fac7d17b2068fbc","9331":"440a14df37910f5343b695ce454f9ee0","8429":"1a9958fcce12535af67d3902b7a59f70","9627":"85b9b97ac2133e9f510413f14a0b8378","4569":"96c7fc6ec5146462fe8798125ce80094","984":"553d9efdf41153049d6a697e62c0d5ca","7730":"44d6d08ab2f43590294900628b99563b","1460":"1372983d3f48de479c9d71a70f13acf8","601":"3c601b841064012aa32d3c2020e9db65","6450":"7c18530bb7d88fee325160db8f587f57","3841":"94c42634acfcd42aeeda8cd4ec490512","246":"71036bc151fa235eee1ec42899eea3e1","3178":"d694856682b3acd9415cafb1ff2a009d","8221":"3f14f7c137c499480998a84382756b76","9582":"94f74181056cf605b06ade1aaf400f95","3570":"fdbbaeea4dd21c50eb73a2c2a0d2edc2","4591":"a759939f87859ba932744a15bd598fc0","7042":"814a32a4107f3194dd9dcc719cd5b1d2","1680":"1507a4cad9e990ac9f961289ea224f54","8674":"9762102c8f891da0a4e341ecf6fe8a73","1607":"12b09723bb79199c49df9c9abce16dfe","5408":"8ece99c432b669758a884ab89a7bab1b","8196":"9e41e4d67e72379f0353b240a04c461c","9503":"9154bdd3a0d02082c59db89b5884b56c","5797":"971c1e7c74f8f6e9d6de5956b1f158b2","9333":"440a14df37910f5343b695ce454f9ee0","7134":"fab4159cd7c7f9512437eb0d930c0f45","8536":"a2f28305da35046ef4d2049f09b424e2","7966":"dd0818c0bade571e28c28592311798fb","8136":"a14be2767063b1b291b96de167f4e23a","8182":"ef990b64941a5c70403844363fb4fbf1","8480":"c8b6bfdd7528c369af74a6f6d86e299e","7651":"908a92a8feaf65d46ac0c813e3e4abae","4456":"65bec555558bce677a123477e9f42136","10073":"1464ea18b19ec3447a2eccbe26aada3c","2072":"de533715920e6e74b860cba021dee542","559":"782d3b7953c287ccb59c8979c8d9928e","4123":"d7fb3b1aa2632fd5c34ec8adb9610fdc","3651":"5057be08371c424cc130dc750040cfb6","2000":"b973f410fc1d3a85985d0574386c1e1e","5658":"33f5c1db3b26671e26bcc2eb77c5c284","2140":"404f120b8aeb8d03e4bf7cb54de3c4c6","1452":"1cef40af9292c243b52ce8ac2c3ff80f","6573":"8b5f43954d1a80ed7e7bced9073c4d0f","5943":"d3968154498ced594150c18a16876036","5116":"1364a9b9f9fb7c24fe7bd129372f4b7a","3314":"d9444afd3dd2c9b4656598a159c102ff","6272":"2783fab90228130146bf571ed6098d53","9889":"25e03ec93c6a95fbaeef50f37aa10b37","597":"5a3f1eb475e83101d593cbca79216262","214":"9a06ef81d3fb0c37a081191e1fed0e47","9826":"48a53858060d221094ae9640b0b9813","7686":"8270d705bec56940ec2fcef14620b40c","8270":"19c5516633a9a86e2b762b9de7f58e29","2631":"432050677905f863f55e7be9625c290d","7569":"c4d0d245742922cb2be306321d402ad1","3949":"32065d3deae20bb806afd7dec13dc1e5","6323":"4619bd1b3ce4468c1a5a60e00ca986d0","819":"c05a6dfc60a5a3c98c3dc1580c8a59ea","4928":"ac96b3af539102d1d31897d51f67e71d","7816":"d802cb3b95923ae4d7f51043a3cbe37f","3040":"89a642e47561b477b5112d5a011d6ef3","2590":"9104f42d534f2ba8c85f80c2fecc19bc","6029":"9d1fc862ddffa9a9e602edc8bab856e1","4777":"98b11cde318360cf129dfe9a67be0922","3848":"c72a3636dbbe6c44e32c5491dc5786f1","6030":"a9e328d73539692a05e628069d31eab","1083":"4ecb7a8b3bea03031e6a888d99a5f3e6","2263":"145cef7af50e6816086718fa5507ce31","9377":"6f2941ef3cd666aa0e88e0e4e0807b5e","8685":"6db0404cf47f3de821c33f1af6ae434c","779":"781f2eba0475a8f046007f0de3bba82c","6660":"d010e80043b2a3392173b5ca167f2636","9922":"f501309a7dd5c4bddb03caa0a59dd4c9","2951":"8e0a15b90d56499afa3a2839d0a2d9b5","9703":"4758bf5196e3e448560dd66ed09c2aee","4442":"dafe607ba86ffa2f795216d67da6ede2","7638":"96f046720d2f648a8c023d00f8941b3f","4139":"9d2990d9c99cd5b0e33ff1d708e9c7a1","3090":"1863b4efd76afa3aec6e161e88aa28b0","6310":"85fe249c5ed5a967b10dfecc679dd3e4","5625":"d4816e2ebfc46a774b6a93889c043e3b","428":"f8ecdb9a228fe7b7892748066829c6e6","8695":"8e385ce00d6e109a38768946761ce8f5","3107":"aeb92f022ba80cfb6b6ac288c4809614","2991":"18e6c4185e5bcbd9d7a52cf90b40f4d2","4449":"2d6d3598289d5e399eae1cdc6ae5cd04","708":"a197fbb6ada9c34f59986cb52ce6de16","9752":"fb9027aa70ec54b6142d154d0d3535d2","7259":"618fe55aa3276beebd0ee394efe9710d","4112":"e3b070129df4f168c1cc33602890c57b","7640":"96f046720d2f648a8c023d00f8941b3f","484":"53b0dab0eb7743e9168d7eab6aa80483","130":"2d1d238b3ff66b07dc27e6073b9e840e","8412":"4d735e9f499518e3ac4ad9a72fcbce12","4704":"fa99a1d1e2d835afb4f6be2acc7f55f","6227":"5b8df3b1729d37c7ea2fd8ca7c045f9a","5680":"8f4fbfd4a2e4d168f3ddc7e7533ca53c","201":"1a7a8f69193639eb536a4da7801d6788","2312":"e123a6b2eea13d846e41bd4feda36e2f","3542":"52f4c6ca200909d97efb4e5c700cd9aa","5619":"bc2ec5955752e80a315ed67f4616f2b3","5784":"ee808d18ac83a219778293338062229","9664":"32f8edf620ffb1555e68f1d937a18867","5765":"74ead9bcacbae811fa152e2cd1640263","7619":"2f56306976c06fd725c2326789457f5c","4273":"491a7a4f0b9aab0d3f2aee53e7be6bc5","7734":"44d6d08ab2f43590294900628b99563b","1257":"ba49e4e8d8df31bbfc3e30aa39629b39","6821":"1dd4fb814e35492ac20a0b03c1eafdbb","9911":"70842c2986687dedbf5271ecb000f086","9315":"6f7d0911851c531ce0cdec89401c204d","3672":"b78ee0a41d216dfe0e98ec3b6016eff9","5662":"33f5c1db3b26671e26bcc2eb77c5c284","8269":"19c5516633a9a86e2b762b9de7f58e29","3045":"89a642e47561b477b5112d5a011d6ef3","8933":"b206cfb580fc33cb5e29b168c00ebc86","5378":"c863189f8953bd424517abccf22018c1","2357":"63d380e5517d8be2b85ba4f10dd99a84","4445":"dafe607ba86ffa2f795216d67da6ede2","6859":"faa7382f468a195b015974e35a75e984","6777":"5cbc011a82c6a3cab48273fb448381cf","8206":"a5cefb788905018301e1bb3628531b12","9590":"ad7b7d6e103ccee6333fc673ca71169e","8483":"16fc1a58de600ebe144f8a27c79387ae","8568":"cba32339c28ab29995e0a4b017887787","2663":"37e5df81ddb6c6e247616d3aa0ed76de","10075":"1464ea18b19ec3447a2eccbe26aada3c","116":"72882d2ae816b477bfdc8b82b72c3827","3762":"786c210ee97bdbf69a42fe4313424fdd","7036":"ce1211ac80ee864ab8da4aa59c621861","5483":"dc0e73e1071a6f2bca19ac4d82354898","7636":"e4f0ad04d8d2e2b2814df314531f3352","5446":"6447be818d45ff6a92c3d972d38a7c51","6637":"d21b78be144c5b557652872bf36f8596","8162":"24ae80d65b27d4b8acdfe801ecaeff87","56":"ecaf712d2fb2b519784ccb0aca7b73d5","5041":"cdc01e85c2a29acc82a0cdd4ad13d9a0","7856":"899d2a18692aeb450cd2d2af150e8041","3018":"964aa9365ed7a09e670b213600fe405c","4228":"d40bc9d29f212d32a228c67b8cd300ce","6452":"7c18530bb7d88fee325160db8f587f57","8421":"e4642dde22d5c71f0909a4a9f389e5ac","7200":"d73ad47b44a6690ee13afa904358fe35","4025":"f5646fbb07425daa93a2de4be216cf4e","6448":"7c18530bb7d88fee325160db8f587f57","5519":"268b2346cbb0264c04dcfed69b0a4c53","3445":"8d15cebdf0278b4493f09808de983eb5","4795":"14cc9653da9f9b4a3a6384605ae8ad90","4283":"77f0cf42de33ef88370e954176c4d8f6","3868":"15f8a7ddf88a7f37eba6b320a66b3777","4975":"7de9f22477057e8b1d31fb4de7860d72","3407":"315b87d2b426712222f7a8e250844cc6","2361":"3c5088db0d18aa93a3aaa4ea4acda140","7917":"39d3a5b451736b829c3127bde9bde5b0","1103":"a3a845370e9747534f8cfe26083cfb7a","8781":"52e33308e569765789851daee8697c88","4852":"65fb74791543d9171c4393376d50ac5b","4414":"17140cb86dfeda80f98d96ac8cf37717","4018":"4eb62f3d1ae3860607ea9083e684acfa","1577":"96f3fc949e4dcdc61d40aea7e57328b1","1863":"9ccafbf6caf7a6b2d4df00fe320c5ab4","7793":"4c658d5e64a825f97866a4b6f0212d48","1879":"693270e90e93fc9dc70e7e2abeca1fd","3946":"374a7b10e844f57a4f2193c8e4716db4","617":"9970b3471fdfacc93e41ed7a1cec0b9d","4518":"90be8ef4540671cf4fb8cf73d36dcba0","5058":"65b7b078f5cca0f7158a77ccf9943829","4844":"1add7f94d3c87d0bcf5b24ff8ae4dc2c","9192":"8075e5d732f330668cef39c568d54a92","5624":"d4816e2ebfc46a774b6a93889c043e3b","539":"97524fd1a08979c64e6526dd33c257f","9475":"2451ed561f6b5c3c57fdf0e5e01a7121","5135":"d9eb3610e76b711ee436d30d98d73748","9049":"b7d75a69d072c6876bfe147f681fa4ca","5909":"612bd8ce839b1f7e6f5ef70ed0aa8f6e","2498":"a853d067b9f4a199698a6d8c37a439b9","1118":"dabb8248c3d5cfdb88a80bfa7298fbe9","1560":"d85538623e7c76567e1b8fbf26a72a28","5465":"14b62f7fb00af6f5270cf309fa26e1d0","2269":"3b68ef9b6b635e51a07d78fcda4efac3","3289":"e5a8331bf393564ddd71f2b59680a314","9612":"2d97ad3b03cc7313f88c83ca2d6d4d62","7089":"3f47099e7298dea3a6173f309c89b16f","8036":"3ab36ff161581e6f6781179c2ca2b8ac","2182":"19b63c71411e767286e267027cdbeff9","4443":"dafe607ba86ffa2f795216d67da6ede2","2432":"4cf2a7e81ad18709049cfdec88c0a775","6405":"5cb03253fcc7e4d7c436677149b9630a","8889":"4ba48e4dc339b4d29b085ba14f128922","8893":"839557399dba7df50ca68c9a6f0226ff","4213":"646645fc9bca4128a626599f13637de3","5594":"383930507c8ae2275c00b716c42adb99","8583":"bb8968bb502073a319a87520d6afbab","5574":"26e0fabeb8b9777dbc09cfa026fdbffa","4073":"dde15a6efd232d0c1f80cd4a8a31fdb0","3415":"804987ebe8e692785962d111f9bfe16e","1331":"6dad045b6b0a9a528f0825856dd22945","39":"cb7973e637cb213634c54a9aa03f5427","1144":"351306fc709ce9643a6af254e36ed99","598":"3c601b841064012aa32d3c2020e9db65","7112":"5a42cdc2acef93994c1652bb2f84b677","3909":"59956d1a8f1964c739e7b4c89547dc67","2443":"986b98e6cfecc927756d5f24331a8bc3","2061":"92b480a88e47594488b3d6175d411a5f","8664":"8cdbf14b8489b08b6a344c38d5d48b7b","5729":"8f66197ac74b5b05161effd3fdeb0aeb","7515":"348c3837a80338dec87c071244021c1c","6336":"1f47486fda250b86002fb547c56edaff","9847":"a306c65c390a15fbe5ea2ff9343cc889","8519":"f47c5db6e1f37e332dcce5681e54205e","5929":"42edf0fbf8d69352aa6ea46593df7892","7170":"a87bf5db8c85f4212632ada0d0e3d503","1960":"a63b7a16431a638903688c052e9b444d","387":"78c61b4307736bfa928cdeaaa5b2a437","4460":"16b2b0423fa0a7281b57ece13713d4cf","8985":"a7e2d6335e67bf5a8e1bd1e6d81a8b68","5645":"12d10aa73462009a56179df9abfd329f","9414":"70cf37a3dd7a93ece48c02c924f342ed","3313":"d9444afd3dd2c9b4656598a159c102ff","824":"bdcaacf8e6d26db830f4658333aab69b","9282":"ce624d2a8a477c2ffa863490f4d56d0c","6023":"f3caa1152e06ada95f9fd8415a4c368f","9984":"d948bcc6841190d382e8518d65c2cce5","669":"fa156fea936f1967ac2e70a996baf69d","8019":"12467700fda7f733335adc4547fec4af","5614":"59ce7155cbb7bbb6ec08595e2bf6e843","3263":"36e92a17c0dc78ca50f225718d439cf0","715":"960799369dc2077444322bca33d80dbe","1672":"616ca847de0b16bd48ecb9a34ba4323","671":"20e562776262c6cebe19de217cd8baa5","2098":"caee4e423e533f3aecc5087168da7ed8","4857":"3204032079017f214ef4037103300dc","5240":"297a9c38d2d8fb729c1c16ba510848d","9594":"ad7b7d6e103ccee6333fc673ca71169e","4195":"ea4537acb479769079ccbf098f72bb6c","4028":"d5139f75c3023b0d49d881b429541016","2763":"792695072b0e3689f8b692f13f8c98bc","4669":"9c17953f397e97eb535dad8bff204b4e","6389":"f340a0b795ebba6fe9080708b0e6aeac","707":"a197fbb6ada9c34f59986cb52ce6de16","418":"77ec1b28c1032f5cac5eb8e8e227a525","5147":"f08f2ca798532ba8a5c500c39d36fde1","4194":"ea4537acb479769079ccbf098f72bb6c","2195":"5503f0e8fb98abf3160eaf9e8f56ff3e","6720":"a6e28801cfc0a6dc68c03098ed44bbbd","9530":"455707b51b21bddd4f6c319d1ef326f","2009":"e71006be8a1fd92adf702af0494e07b9","2833":"5c82b52e3e78b456f798f56305dd518e","4762":"c8b3a6ba7cc39f126a1f82647be73d46","98":"2ad87233769032e29ecca90d80ffa575","8334":"dfe057c09719f5ae7959b33729b33399","8932":"b206cfb580fc33cb5e29b168c00ebc86","3378":"b8baf89e74e40f7a8e1dd51f485b2f87","660":"15775fcb96e2d28e58af78fb3a77ed70","2694":"49bc31ce7b2a56cb109cf6fa293c669c","494":"1c0190e6a5c4094bf3c1ba49416b613","9872":"51833cc0c3c4989ea2e5bcd7aab5ef75","4152":"dafd3a0cc942630d28cc9b8750a3bcc","5512":"931b0d1a12a013825da85a762dc3a07c","7462":"1adbbd88be5b4ac1242e23df26054a13","2375":"6c79295b91cb8f6b255baac6f63ca177","8306":"e33806ba0f3d9889a82ed7ab424cfe45","7603":"2c8f2979f57d9d80947058c7ecd51587","7152":"42c7086de40a85c99e2cb1d06edba92e","7650":"908a92a8feaf65d46ac0c813e3e4abae","412":"86965f7225f29f4fb089bb1f274576fa","1003":"deab6d44d98c53fc742a082ce034cdaa","1153":"280b81415d3a7d8feca9111d17710beb","4842":"1add7f94d3c87d0bcf5b24ff8ae4dc2c","4679":"dafbcd76a994eaa901c263798c2927a","8657":"3be5daa19daae36c683110f834c52005","6254":"33d98e760b265771a71027413a432fa8","727":"48212e82d8556c3fa5a030520754f3e6","1321":"d178d13d3df6b2446ab52e3c6cd6c2ad","7003":"9f4379e3fef80ddb42f2fc025b2902e6","3907":"59956d1a8f1964c739e7b4c89547dc67","2354":"63d380e5517d8be2b85ba4f10dd99a84","291":"ed155ea265a9fef431a8a197415bd6c3","9188":"c2a03ff81cc2ef3c35a191b3d8833ace","1938":"8961723a08e6c11d322e360d0e95e3f","2203":"2da6d9e1fd0626f55ce6932753c11e8","5599":"f40649f89fb77f0f6ee9d630cb74cd52","2517":"f4b39659f7c1a6e4b8508fc46bb6cc16","7329":"7a65e652d4ac69900c7a4011dd6b0ee7","7701":"1de308c4ab060740e905a63ed27ae789","6092":"a52be3ac8ad6e86e27739d1422319ff8","2245":"bd10a2e62695ef9f655345811602df84","4019":"4eb62f3d1ae3860607ea9083e684acfa","4979":"7de9f22477057e8b1d31fb4de7860d72","7331":"3e53e9242c4ebdf0ae7522321a23dcab","5482":"dc0e73e1071a6f2bca19ac4d82354898","6620":"188f0bf9b820b27e2e055ec58daa4e72","2689":"890064a99bec799d4416e942eda0b77c","9469":"eb696975e84e3ad6d261eaf9c34e1c0b","6982":"c8f04349a9020296eb3a3f46942a6292","2303":"410f58af6f4ed5a74b0380a4c8ed32a4","5230":"28fcab701147e22aa62207d6bf6f1598","7230":"a6b682c76e29065d80f77edac5acb3a4","795":"5b3dd12cda151519679f3931e354b48b","8267":"19c5516633a9a86e2b762b9de7f58e29","9158":"fd329412efe75e0252851dce7cab1378","9123":"1d9a84a48c228dd001eef0403c29ec98","1180":"25e94f4c53144a8e6d9139368f391c1f","2080":"5d9c41545257e1297be32ca58aae9a2b","6636":"d21b78be144c5b557652872bf36f8596","5247":"703c27228a24971bfd7b10e2027f8b2b","8177":"ef990b64941a5c70403844363fb4fbf1","8760":"13b188d26445b678daf203cfcc5e41cb","2428":"79498d603ca64875d72299084fcdb0c9","5248":"703c27228a24971bfd7b10e2027f8b2b","9436":"36337480369bcdb21d40ca56ea52c885","7167":"a87bf5db8c85f4212632ada0d0e3d503","4016":"f19ebe6e693b7faf2808a3bc7c9f4839","4333":"f332803fbf9407cd8ddd9c6d1f61b28a","6151":"fe7923af2c6991935380b103b58525a2","3266":"a247ed645f1f888ab70fe4b6a4262543","8171":"9fa641c42af8e0d308c0be4221905ead","147":"11df74a8cf591564413db47aae7ad791","3188":"c97ed82fcfa05e25f0bc6ef90b1a1be3","827":"bdcaacf8e6d26db830f4658333aab69b","6427":"6f76cdd9d0576bcf3921b0449b1ac9b1","5964":"9bc64bc2bcfffca49695499f4769304d","4347":"7f5e1b24692cfe47491e824dabd7b212","5866":"9f12a9568347dd5e969ec05d5e7b85cc","1427":"8ca75665a711ac362596649cd3c0d673","9816":"7dfa5f08b44e2909bb97609ee84d57c8","8785":"43ed18643c179378a0839de6447b27bd","1849":"ae2c2142b897744f41e1d05ad6975aac","7160":"a07e2dadce1438ffcdbe6e59f97e9403","6339":"1f47486fda250b86002fb547c56edaff","8841":"9b33c983027c777909964a5913c345c8","7303":"ec676b563e9e8a0197bc39be2be9b759","7591":"18ccf06090c51d3e531a7744dc644a14","7813":"d802cb3b95923ae4d7f51043a3cbe37f","2720":"4df9a7eed61e35bf908eadaa7854a9cf","10126":"202b8ff82c6e9903f8f42a28f145826a","4886":"86d4fa920b02891089e197066cedbdd3","6527":"c5d5e52b81fe3ea36fbc6fcb3637776c","9453":"8a4402d74079db8bf63887c64880009","10103":"f6ad14a14517106f58240e713d54426a","3824":"1ea8d79c2dcb44bbf7483fd5545bc6ac","8690":"4bb6dd3e8090ac98397371276a8dd774","26":"5ae09f6b7c89da2d1b5973d4cf686c0c","8742":"7d1e1541d319416ab02b8197e77c063f","6850":"5ba56a4adaa3f39d7d4a102fb40ddf29","8957":"cad25871946a42e2659d82147f8b7707","3255":"a7ab7ef3da57925e47eba587f471b6cd","5062":"1c66731b2555b63d3a90ee978358f02e","9943":"67535473e5701844797dce87de814966","5331":"9c7c76a74973e8714d2d22cb1a1ececc","7015":"c930a2d10df8393161d1283e93604e97","4851":"65fb74791543d9171c4393376d50ac5b","5587":"bd7923450a7f5f6c43dec83c153f7682","5762":"95658bc65bb9d06dd083f4f8f307bdc1","1575":"96f3fc949e4dcdc61d40aea7e57328b1","2617":"a168bdcf83c1130b7e121f7c303d253","9705":"ce5bb8c15743957d23441d54dc48b9d","8351":"7ec367cf56bb927be47941cdd980cbfd","9976":"8059e6e339583db612c4b190a825fbcf","2864":"bba430f21e38599a5b9efbcd0d45c187","2058":"8cb1a4d63b3af999448c3b633dd5d45f","9586":"7558e5154ff4611427faf0214f123e8b","1021":"e3c2e69a1ef435d4d637889660c3d72c","3091":"1863b4efd76afa3aec6e161e88aa28b0","1428":"8ca75665a711ac362596649cd3c0d673","3161":"7033ec552ac292ead56ba35fc9f64c67","9834":"11f46290afdfb1708cb87e7a6270f266","1158":"951ee567eaee0b86954de4811a4548a4","2654":"50c8fe6bac93768aae158339735bd7a0","3416":"804987ebe8e692785962d111f9bfe16e","6424":"19ebe365fb9b6eeaa829c4155e60241a","1590":"64f8d1884b8a98126f0e9215cb59d182","2052":"562378080b4027a2c56aa0b5d29d6609","9795":"30d0f1095380baca5a840e4abcb019cd","747":"cc8ac970c7a5dafcc42be0bccd52bf51","2994":"e195d2c1de553f791c3581c3075c606c","444":"a5833cbac5ccec1cbacd3a30ec48db5e","4635":"e1ff85db33f78e670b9ecacff0035afd","3598":"d721de93217d02bff085d3ef26153336","1115":"fdfac301cc6447614438074a8848ef22","2972":"513f07a1f0eca6cbe69568d3d0a1d02e","8123":"8558ab89431f95d086d1f1f3a78bdb06","7082":"d1dbd3fe5644afe29b6c75d06cfff52","6193":"7d1683d1b0faea180c835c80ca13a2ed","5719":"3359f7059d6ee9a192661952eb940956","4096":"f2ff7e4c447c979544fad9cac009e141","8069":"fcacd500182eb07cf3c3ce1689d66336","7751":"4556eb3592d528cfeaba174b71a312ce","3166":"ef43b9036c93d1b50e168edf91a22d0a","5060":"1c66731b2555b63d3a90ee978358f02e","8615":"ebf85775c6fffda39647e1f4e8c44fa","8914":"c4b624600a0ee9b1884094ba4e17a54d","2568":"a3e732581c46078608c4fe7ee9e18a99","8373":"e9d7be2d74929ffcec0790275c728a2f","6061":"7903f734dfee2f80b6d44b55b42fdba","2064":"ff528527630320e09c2fb8228acb6bae","9329":"440a14df37910f5343b695ce454f9ee0","5799":"86d1974990b3269ef1f4f7b404c7f475","4920":"aff22404c30f84162684c76505243562","1355":"40132ec5184301fc3da2ab93ef34b949","6864":"368403645025e18b0870c8faac727607","9354":"4fdbda72fca4a2ffff9ab66c32d5c4b5","2528":"e76d82e6b55ee4ea699c7367b65770ed","3856":"8836df77dac9bb613eb939e19993f246","4034":"8d44277dd8c86429e83f2cc4503db643","7129":"f8aa82fa833b00cf91bbc4fc8b551343","2534":"e76d82e6b55ee4ea699c7367b65770ed","9066":"4248f61d2295e30c9650bca0c8c68501","8208":"a5cefb788905018301e1bb3628531b12","4125":"d7fb3b1aa2632fd5c34ec8adb9610fdc","6748":"93003feee612119b9922b936f0f01c08","670":"20e562776262c6cebe19de217cd8baa5","655":"984060e0ec12c5beb4e6bb14f68f5423","8109":"2d8339a16d87e5208f6012f1c2d71222","343":"e179505353f1c5ca302a473d7dc97e7f","5733":"553ce19789e4fe122c2a18637e6b4cd5","1336":"6dad045b6b0a9a528f0825856dd22945","3171":"9b03c83edba2689f2328b2b4e29a7fa0","2879":"5f9c31794b32739d9f9b52e9c531a1e9","5745":"73c6b609b5b60678be76da67bb556a09","8582":"bb8968bb502073a319a87520d6afbab","3179":"d694856682b3acd9415cafb1ff2a009d","395":"aa4a73fa8daaef07951c25aa881bbd0f","5458":"e1906b68143bee3199382919547eab99","2051":"562378080b4027a2c56aa0b5d29d6609","236":"4c1e6694c39d9a0e825277bf1b32a3e5","2456":"c1a4e58a597fdb7c59bd88c6a5d399c4","7566":"530270efddf24e51ee98178e4beb4f40","1401":"2033aa338775a6f172268bc98e5f6e6e","1349":"7a8e71a13035b3572680bf3089483644","6241":"e5b4320338a742b052dffb8217943de6","7608":"692eec1de67564a3f54bd8f2d2126e5a","4030":"d5139f75c3023b0d49d881b429541016","1820":"84b53941a69c1f4d0660e963355ce662","3064":"f0a9606eb350229f55a59a8e6480a399","1867":"9ccafbf6caf7a6b2d4df00fe320c5ab4","1815":"e16fee7fdf9d30a4dbf0bf30c2f47b70","629":"72558d93d8f4bb4a66e57f4c2e5ebe50","169":"8f2d869d86005bae756cbe5cf44ac6e5","7146":"bd1b9e684f9debd9edf6e23ae06d78","680":"f898b06a6ea03989a766354bc1c7d03","1880":"693270e90e93fc9dc70e7e2abeca1fd","3980":"c10abecffb6f2b7c4e937060b84b35a6","6062":"e5c70eec49bb94ec4a3f145fd6620896","5333":"4f80ce6e2945a5c50b77624bb3f6855e","507":"5e7d38de844a33ef39c0b93eb4292d6c","1720":"78daac88f4ea001faefe4f77a35ac8bb","9341":"ceefe54fcc480ebe53e3ca4ba72c2ab1","9383":"4983b411e01832d342fe1d72cd08800b","4855":"3204032079017f214ef4037103300dc","9350":"c0cc9c53df437da8b64cb626ec076ba5","2584":"f2c2f50b0984960ad89f56b4a072ace9","1245":"179e89a37cdaeb9ebaf1616fb37a62bd","2645":"6612c759e513806aa5131c5846298b16","452":"4992ee0de077a6c984d86a31347dac8f","4741":"d3292438ff5b60c13da4032b6e7c2c4f","3354":"ce7c9b37a5e6ca37235467215291c64e","1943":"25e906641e63e8cc0e95e199ae190c0","5771":"280365e44750fd07f4dd883d6512d94a","7428":"3210bccadb9f998d228aa6dd9cd1d34d","9938":"1cfd94a2d8d36237c523cdf479a3dc2a","6671":"18a6e731d2d8a2d8da1cf1bb697bfdca","4572":"96c7fc6ec5146462fe8798125ce80094","4269":"8901f72331c0bced4c7ebb3b2cbad1c0","5611":"59ce7155cbb7bbb6ec08595e2bf6e843","8094":"553a751b1d7cd95714b7e01750284cc9","4254":"c4e33aac3e286af79e1c3ed226e85b4a","2778":"99a74749c39768971d100807361de47c","9796":"30d0f1095380baca5a840e4abcb019cd","161":"29f05dec404999d3cd435185664abe1b","5991":"3658d5eec6c958880730bc5717688f0f","3151":"8284cfa6dcb3c9c3e97223b50bb2a84b","1480":"4527f2e9f7e8f19ac47f275f2741ea81","3318":"8412d609fbb2be18f4b7242a7e5ab58","5950":"3bc48e874fdffbd0ba69f90470209ba2","4907":"bd893d9b5c0a0bd2f30703fd2f6615ab","473":"ceb412d766b4cf5c5ebbecef5ac9eac9","547":"cc4367bed4549907f4c39294c5fe5e14","9804":"e260129c343aa2cc65e5798191feb021","643":"95e4e8b05d82e8bc89762ed47f8c4f6e","5485":"965fb4f4e2d9af734ee8cd7af6fff3dd","3993":"bf813318d04b7d7dd65edd4ad61780c7","6658":"d010e80043b2a3392173b5ca167f2636","2006":"5abd0f8491fa775c0de7922c9c9034c9","4094":"f2ff7e4c447c979544fad9cac009e141","5902":"9603684575703ec666611a674d5326ed","4987":"7de9f22477057e8b1d31fb4de7860d72","5289":"8f97d083bbf9a5ae19f0a8bb7714fba6","6504":"5238ab434cde377559e94876435778df","7136":"fab4159cd7c7f9512437eb0d930c0f45","5139":"cec591363ae1a3aaf03586bbbb70d3e5","2484":"c91c50cabab2df78da691c3d157f1ea9","3252":"f1cb78d586fc0be0faace5287a1236c8","7902":"f62760f1ce85477557d8ae28d0466ec0","8212":"fa6b166b4ab2dffcbd6c88fb9946040c","3540":"50142f1cc3cb7b7586a68b36766b0c85","1058":"a4f4d203ce28c6e4754994d6b851b8b1","3533":"8942d9bac954bc7ae0ea988fc65c429","9303":"4a8b06ce80902ea67228b46eb9bd9b5a","4607":"81089b699b38110a7eb908ae7af13085","3379":"b8baf89e74e40f7a8e1dd51f485b2f87","556":"782d3b7953c287ccb59c8979c8d9928e","8253":"88d0ae01304e444453b61269c71cc7b7","10059":"76666ccdc0cdac566ec8033bbf37ff4e","2296":"c53d7c5255790d63a7faa1dbb3c7ab56","4568":"81f7e2a8b5d5182e57d36a841567d2b5","713":"960799369dc2077444322bca33d80dbe","3068":"6c1d92c660212f12a6dd2ce3d612bcf4","4505":"79af8c9a0547488b9e816942ef181900","3561":"ea70835f719f3608f5693167f57e3a3e","4673":"7364b9e0a1d394868b7233619157772a","2139":"404f120b8aeb8d03e4bf7cb54de3c4c6","9660":"e998503b0138aa6aa966553a43690442","5123":"f0d974964914ca23d8c299c651f94d94","2862":"bba430f21e38599a5b9efbcd0d45c187","6141":"219a9f7018cbfba24fde0b2336e2d853","6633":"d21b78be144c5b557652872bf36f8596","4068":"43fd357c7e9d87d671bfa705687a9d8d","7527":"8471b1885556c9e97f4dbe76d98e5bb4","9839":"11f46290afdfb1708cb87e7a6270f266","1632":"8133b423a3b6187781d9866c2ee269d","8503":"4bbfdbce6119498e1ac7524da67d090a","181":"fbfc8570be618f0cf8b459c2eb2c8f7a","7221":"8285fc049b9102e9e928eeb0530fbc78","9832":"11f46290afdfb1708cb87e7a6270f266","6154":"b31fc24ec3daa090c596c0bb33ee91d5","7618":"2f56306976c06fd725c2326789457f5c","3220":"4380a7aed0645df263f3132cc82d384d","3656":"57d7fd12a20ad9c2fc04f2a437e5aa79","7931":"7b8e6c1e95fef107f5d2ce01a4431f04","3557":"6a0489fccff01a9ed04985d49014ed76","7690":"8a32db8038628066eb9e74798b1f93bb","4665":"d067d6d3c14effc2af7c3a9c9e5d3a14","3883":"cd13dc020514f9e272782bab1ccf695b","6209":"9dad4321a1014af3a30ba578c61a258","5081":"771d812ecdb2db9ca9cb1926af97310d","3113":"d16190037de6d089ecddfbdfc273b0dc","6985":"c8f04349a9020296eb3a3f46942a6292","6754":"66477e70697d9034a7001fd217304343","710":"960799369dc2077444322bca33d80dbe","8758":"13b188d26445b678daf203cfcc5e41cb","5529":"1352051624f663033e29f6c180003d","2901":"9b81e17a5cdf07e2fb6d6aaacbd2fb92","5454":"5d7ebaa5cf13a4057f3d96cec15cdd66","2107":"721eb8aed18c6bcd24279094ad70af8f","8055":"c81ca55af39eef53942def692fb4b3fd","5418":"9abf4fc941148316598676e1e856535f","89":"8e49fd6e064ee564dea7a243c32b0b3b","5876":"d1463a6001d7b79125627be6e5ab33f2","4000":"3ee5d3bcad83570b2d350b2f34021875","4348":"df5784616b9a240c5b0cdcfd6d9c27d","8578":"ce8af0675926f711fd05c1bef254ba1f","8529":"7b1c4f4f0d51653d5e6adc549dfb036f","5270":"e77b874d0a59b366f2c2c42ad2a3fbe2","3006":"634c8d0bc8deb68fd44240d5bbb0b1c1","3823":"1ea8d79c2dcb44bbf7483fd5545bc6ac","2200":"2da6d9e1fd0626f55ce6932753c11e8","4862":"d4f4e189529498328c64058f0883e693","8134":"a14be2767063b1b291b96de167f4e23a","804":"be5aac7f0f716ec0e6648066ecb13c9d","7512":"348c3837a80338dec87c071244021c1c","1195":"1854bcac3fd8f793020b1ddbc60bee2e","4322":"13549cfb73762eee481fcf3c595e049d","8533":"71b164736fd0f6bc7c2a1dcb37b33691","4108":"e3b070129df4f168c1cc33602890c57b","2120":"3fc3f7a4e5e3ae160dcdaa8c2548fd1a","2489":"e412e5346a826a59f1474ae83d07730b","3187":"c11ae325f1d3554f145f036017e0efd8","8786":"43ed18643c179378a0839de6447b27bd","6830":"a3b7d0642ecafbe24abc57f5e6852ba7","4581":"766f69d878380ca42ad36a2f8fa3bbc1","7843":"df67f194f49fbdce07fc4c88dc5086aa","2290":"c8e6421c22c7025eb3349167a9685c22","7365":"a47e2ebfb129f28cfd66f63efe29272c","7782":"c4043cb05b4e526ea60d21e718bac11b","6993":"78cab76378eb5827b589b018e3ec2936","4368":"3ef967a2d03857af92ff7fe465ea4fee","4394":"1f9f1aa94c25162c35a38ad43c272a7f","1050":"71924d5575606b2d03fafb349be02b5d","7557":"2888de75067d252017d6845a1e33a193","5004":"84849a679dcd8639044483bf4f0f2e03","4935":"ac96b3af539102d1d31897d51f67e71d","2952":"8e0a15b90d56499afa3a2839d0a2d9b5","6889":"4bd610196254becc9ef9dd539aacf1c4","4924":"ac96b3af539102d1d31897d51f67e71d","2339":"e123a6b2eea13d846e41bd4feda36e2f","8694":"4bb6dd3e8090ac98397371276a8dd774","3152":"8284cfa6dcb3c9c3e97223b50bb2a84b","6493":"ddd85976ef4bd5700ce6384cbe76c028","4330":"a5d4fed986b6d8bb6c5aad0fb784c310","3852":"8836df77dac9bb613eb939e19993f246","422":"77ec1b28c1032f5cac5eb8e8e227a525","876":"18587d30d64ede630bb981613dcf8f5a","5137":"cec591363ae1a3aaf03586bbbb70d3e5","2802":"37ed07fcde9df8114ab4e9ecccfd68e5","7815":"d802cb3b95923ae4d7f51043a3cbe37f","5190":"3593ddc92f8ee1cbbf9c977ca94449da","8579":"ce8af0675926f711fd05c1bef254ba1f","9481":"2d6b536b1740258da82768e96e2283af","8811":"cd3023aaa5c6b5bf102cf8dd0c2cc7b7","3227":"556c32b0037839628a0c633026400f91","1013":"14943386829f84c40f885cb102285a0e","4613":"81089b699b38110a7eb908ae7af13085","6486":"dc3317d94154967ff452ad112e9196cf","8320":"3ebbfceec4ae529a78c6019aac229e33","8309":"ede00e9b246f86bc50da6400c5f2103d","7077":"ee431996004004b15c3e5a2235e69b8c","3478":"1226ba725c533d00892382e491118a1c","6119":"d89b817d008e2febf87f6bf394cb2d3a","8818":"49eca868224160330a6f91000451385f","3389":"b502bc91a5202f76216b495629607802","9352":"64d77eed2030e85dbd2edc01c6c1fbd5","8991":"e26614bd91d69ed1bc1c316b820723f1","2490":"e412e5346a826a59f1474ae83d07730b","5220":"712513a264623145ecc2ad4fd4df3bdf","3501":"61c3bb909004056a9b0ff01d2f759dcf","8247":"3d799e3d4fe5a46785ec4be53c93dd92","4159":"dafd3a0cc942630d28cc9b8750a3bcc","3899":"633a4252d0bd151d009ddf902661bb59","5812":"615ad3d60ca5cf567cdaba8761e3ec14","2355":"63d380e5517d8be2b85ba4f10dd99a84","7078":"d1dbd3fe5644afe29b6c75d06cfff52","2056":"8cb1a4d63b3af999448c3b633dd5d45f","10028":"fe07e78d0869a30132e3af785347c2a8","963":"e93de8fc05f27bac972e4a63bec12691","2236":"b80ec2cfa9198a8e73a3401c4f3c8b51","627":"72558d93d8f4bb4a66e57f4c2e5ebe50","2003":"b973f410fc1d3a85985d0574386c1e1e","6208":"9dad4321a1014af3a30ba578c61a258","1313":"d1f9dacf84057a98fb3e7de29a92b0d1","3226":"556c32b0037839628a0c633026400f91","6167":"e922f7907c79c833c68c957f316fba74","7436":"b6886050940f5b41a6fa6c896bd91b76","3524":"2ace86789e1a69b3c817391fb83726e5","2557":"142914859998ebcc4fa65fcc60d4e39a","9593":"ad7b7d6e103ccee6333fc673ca71169e","5155":"189d359660fb2e9f00d5a85d594792be","6456":"f43695bc8a080c3dfc545d5906ef526f","9246":"f9ef0bb91da748378cff444f80b58a58","113":"8aad37bad5e1f65c77e0155868940a8b","8358":"1c40d9fe48b30347cd94e096845a1658","5560":"ed9de254fc10d81009c9870fb72b2497","1044":"27fff678ac42f3036da6678d8a10f7ac","7544":"1b1cba4be00be3bbdc1e4178269506d2","3769":"e258c105a58b82fe0a39c5c6069c9426","3606":"2625c93da21257212c14e6e21d0afb63","3247":"f1cb78d586fc0be0faace5287a1236c8","5575":"26e0fabeb8b9777dbc09cfa026fdbffa","3465":"5307ccbba5b4f803949c33edbbde930b","3349":"de11829465633ae1d77f45ab7b182907","8938":"bfdfca0b4505a210897d3cb4d428a751","625":"36aa1344b985eee32539045e329443b4","3988":"70338208975c9e7591381d113b856f01","1454":"1cef40af9292c243b52ce8ac2c3ff80f","5546":"a99fd1bc45d7cb7a7fd65bd7759ba8b2","9193":"8075e5d732f330668cef39c568d54a92","8943":"aa08ce482c0614ba4cb904e4fe9df7de","874":"3823cc900b38fbbd5c6cdb45bee8df56","4983":"7de9f22477057e8b1d31fb4de7860d72","371":"103cca277e47b87f0ecd8e4ec249bbcb","1734":"ae73f672e5d5909037930d069f602967","8422":"1a9958fcce12535af67d3902b7a59f70","3419":"1c5b7bc8f5aa109d9240b7f00b8d831e","2905":"576469dc68e25cbe8fbd764da041388b","3797":"24ed6ba11bc9018e184b7aade252f303","1359":"40132ec5184301fc3da2ab93ef34b949","2308":"7aa0d008fc8ff274d275b0002055bcf0","9128":"3c4f13d76babaa79a58028adbc3e0081","970":"aae8d731b6e4258b36cd172f41759804","2045":"c93a131f0a5fab8509a6ca008ac341b3","9244":"f9ef0bb91da748378cff444f80b58a58","3079":"d086419a3f83bd6e1363868e7988893c","3705":"e2b1523b26cb6fc8183778d32bcdd6b6","8043":"3ab36ff161581e6f6781179c2ca2b8ac","5813":"615ad3d60ca5cf567cdaba8761e3ec14","9974":"8059e6e339583db612c4b190a825fbcf","3277":"25188a0c067fa176f630e0fbd212c39a","2597":"bd96be1302ca7f960fc7c2e35e9e5a66","2728":"15474f9533dbe55ac732a5118deb844c","1277":"a0bf91a1f3d3ded02b840e0f7a9c41d6","849":"dcd4f0c2cba9b7a586d64f40e10ad59d","157":"29f05dec404999d3cd435185664abe1b","8280":"22e121230cb6a59f60ff38750a91a742","1950":"461c08b722df52a0db52dcaf305aa2eb","1633":"4272f9f5059a95b1ccea67ceaafa7731","1893":"24bbfe0c4a3366a7381a9b55625164ac","9634":"a49f85231026a79d49353b81d2cc0b7c","972":"aae8d731b6e4258b36cd172f41759804","2381":"70fe1a274d310ee30323624652ae4df","7123":"691747821a5addb2fc220220138d7898","5031":"a7f3e32a6322f818bb0b8073a2a2a694","761":"c663406059f0fa2148679fbdc22345c7","10119":"a29fa7591a0d90200fb0b5b1c7a5a9f3","6832":"a3b7d0642ecafbe24abc57f5e6852ba7","6494":"70470d44e6154b978c4d6ac695cd9e23","4387":"383396efe7a737edfe2db6358a3625b2","3674":"225fc0772f843c8e8e1627b4a7fe18d0","821":"d3e1c9b1aaf5db03980d73789dadb149","1175":"93dfc31acd0386e5de68bf427b6b32b3","341":"5f6d3976c629d511e34e8a9a557eff52","7487":"267caadd3d1d2eb27887457aa202c9cb","4211":"70782590b2a3c214cd7da9aa704eceb1","4012":"f19ebe6e693b7faf2808a3bc7c9f4839","2160":"19417da43e567049584539b117445a1d","3360":"c1aa7b6c1999c77a97d3a1cb9bcedeaa","8295":"4c329053c5cd464dd5391014f4912a1a","7997":"e812ca827f8fb579e665d596463d8f0c","6182":"f7d86cae7db93b0be2703d3537aec4d1","1703":"be3dd29bd6314fb35db2d3b367f7ffbf","5654":"fda65f6c8a820c6ae814683afc89fdaa","823":"d3e1c9b1aaf5db03980d73789dadb149","8757":"b40742461863a8531b39fe33ca869cf8","2683":"524b6fe94371e23a2902929b02f02fcf","21":"81fd262a74141ee213c771449bcfd8a4","52":"7ff7f8b5d8e85b1fdbe91110fda87436","490":"1c0190e6a5c4094bf3c1ba49416b613","6531":"c5d5e52b81fe3ea36fbc6fcb3637776c","1267":"1e1030957deef426a3b34953be0ac56","3889":"29a000919d07acd8b87f5bc88f9603c2","8156":"3e4be242b2dda8ac9193b8560a468c1e","6296":"40a79cddef89d530d8915ccf6a4e0bb6","1628":"8133b423a3b6187781d9866c2ee269d","7728":"e8d3a1817ca6f0036aef14589a61df18","7955":"6d0859c21fa8497620f27466c3a33aa0","2179":"dd1b96a71fab92b133f273af2f017bb2","1747":"c6ba88325fb55c335859be6b378ec1cc","3108":"aeb92f022ba80cfb6b6ac288c4809614","8053":"db7735eceaff19064ef2772c5109eefe","7323":"cde7784f42df57503b8fc9be69f4c2c","3876":"bd6dea207e9084658c92626b6379728b","4468":"94b76987f6660d64caaa4eea67bd6a3b","880":"18587d30d64ede630bb981613dcf8f5a","6091":"a52be3ac8ad6e86e27739d1422319ff8","8718":"8748e43d1432e08a998d616c8be8d42b","3102":"8544a81b94c530487e9aaf6515143264","3825":"4a5d6e20d40504faa9b984bb185dd736","9744":"ceae429603d9866b56931941c21ee52","3681":"e2640cc4f11f0f97eae5ab116039a8b4","1957":"b68a621c1ab90fbcc5e38fae1a956503","7684":"8270d705bec56940ec2fcef14620b40c","9868":"51833cc0c3c4989ea2e5bcd7aab5ef75","7989":"9e77253d2d43898902afdbda36a3daaa","8939":"bfdfca0b4505a210897d3cb4d428a751","474":"b6625481d6431daee7e06445ff8a19bf","4847":"6efad447f9a574daabb725227106f291","3792":"5692dc75f47ba602d1b66a8540d1b474","8369":"e9d7be2d74929ffcec0790275c728a2f","906":"a5c987b8ad8d6266ac3971ecc29cdd51","6200":"cd8f7ab86219d64ab495a13541eea902","8080":"58cf2d7cebd2d3f1ebb17db0f1e1874","8946":"482997e889a803a2e0dc00baf6df5eb6","7905":"945d94748e6f992932930e264990ca5a","1588":"64f8d1884b8a98126f0e9215cb59d182","6306":"61c2724e55857fe06399db210f64599","812":"abf8d066819a28430617180bed398dd","9665":"32f8edf620ffb1555e68f1d937a18867","7812":"d802cb3b95923ae4d7f51043a3cbe37f","7247":"ab3d9a7c06877c116370641c6e20cf71","4332":"f332803fbf9407cd8ddd9c6d1f61b28a","6802":"b031dc1608a13f31b39ea1d82b4bca69","7756":"4556eb3592d528cfeaba174b71a312ce","212":"2147d681250bf28a35f5d2219155002b","8216":"3f14f7c137c499480998a84382756b76","404":"671c55b03b7d3edc37b752ce78e1c18b","6496":"70470d44e6154b978c4d6ac695cd9e23","2388":"c926569034651308916317b92849a21f","273":"4dc8f03626a94ae92913efd47a0ec7eb","1250":"2da61c0e1cce68543a750a5ce558e41d","5038":"cdc01e85c2a29acc82a0cdd4ad13d9a0","7153":"42c7086de40a85c99e2cb1d06edba92e","4526":"d0cbdf5060a2fbfab19a6955b1a19d6a","7540":"9f53f19a6747aaac7f75435f398b71a4","7440":"b6886050940f5b41a6fa6c896bd91b76","9738":"3047dd55a820566d07dc1345d5f1f871","3521":"2ace86789e1a69b3c817391fb83726e5","1683":"1507a4cad9e990ac9f961289ea224f54","7452":"8f325a2b66bc9ebec08890bbf50961ba","9518":"f9e09591c1ba83c3b8cd11ba70d7ab11","5736":"e0b29c85e2b8d9d3b51ed6a60be8e814","1317":"d1f9dacf84057a98fb3e7de29a92b0d1","4399":"6e4bcc62ff5845afd3cac29737b53157","185":"fbfc8570be618f0cf8b459c2eb2c8f7a","2216":"158ca84d28055631b00806887002a7e0","10054":"1091b69c6ab91be0d76cee88ca4e2b6d","9250":"4839977b0e4457e4f6e3f3970e75b5b3","6741":"fd944896a257056439619b04e36ca1e1","4909":"ef54ed4a4a1286fe884dd0fdfa858c16","6067":"cd8fa30759baedf7bcad5b53ac1395e1","2414":"220b6266493a61b8d1394e8ced0062a3","6579":"26540191e18c3d19336c523591947fb2","2173":"41a2662584a011de1cae019f5c654a21","9217":"53bc5e4a5ffa3004a0d8d9989802959a","5321":"12b69c1ea91a15a9389823a58a12f72a","7277":"9c7030fb68db17a2f8cfa29b58a3182","7976":"4f4311cdb48efa3a92f87fa0246c7c47","5999":"1f3a19713c2790a34e04a208241595ef","9959":"41a92c2c8a23d11156e3c2c6bbc28fa6","3097":"ac9b669f06258c03006d4558eb2381f9","6835":"a3b7d0642ecafbe24abc57f5e6852ba7","9641":"b8b28edcea37661a72b742cde6c8bf5f","6740":"fd944896a257056439619b04e36ca1e1","8522":"de28d13041713de626c6d8a6b9c491e1","5858":"1dd87d5d8de81c6c308fc3d4f1d2a0f5","1759":"d6b9782360a98675a786939fc435fdc7","6944":"ce022185500042314f8802d6201d1e60","3213":"efabe80ebaa08cb5fa6df141473a6d4d","3020":"964aa9365ed7a09e670b213600fe405c","9067":"4248f61d2295e30c9650bca0c8c68501","2773":"d6f9c6ef2b1090992ea5471b4eecacb5","6522":"3273a3fb8cf6eca76db879a4155a671f","288":"3dcb2d94bb72cd774d4b582ec03eb863","3454":"7048834e2c2589b10a577dcacfdbab27","6843":"99f95b08b9381ec9c076c4b05afcdbad","4577":"bc6ad91c697964c0816045c44ad333b6","1611":"67010c1f428ee506223ebd4d03bbd2d4","6905":"16646ef014a40117af791bcbfd6b3c8f","3767":"e258c105a58b82fe0a39c5c6069c9426","8169":"9fa641c42af8e0d308c0be4221905ead","994":"12a5f2b2e040abf2773730c225a657d1","5977":"84758391539a84fd83599665b4c5927a","9967":"9ac2762dfca951e4de15b2c8e34b6c8a","5009":"84849a679dcd8639044483bf4f0f2e03","7745":"bf57ff7d438ce5a2dae51856e5e16117","3574":"696e5e62ca2c4c9343dafda10e829cfc","4779":"98b11cde318360cf129dfe9a67be0922","8960":"cad25871946a42e2659d82147f8b7707","8521":"f47c5db6e1f37e332dcce5681e54205e","1587":"64f8d1884b8a98126f0e9215cb59d182","7669":"eb1ec9e768aae2251821e5d20eecb7b1","7703":"1de308c4ab060740e905a63ed27ae789","384":"37aa05585acbf6dc29f4e1878b315712","3601":"ab3c09ccbc1ba25001b195a46c05c054","4290":"3a4873159e9da79fe784ed631e3f34ba","1570":"96f3fc949e4dcdc61d40aea7e57328b1","8086":"45f13b3020a1568355a13aa67c5fcdd0","10062":"76666ccdc0cdac566ec8033bbf37ff4e","7916":"39d3a5b451736b829c3127bde9bde5b0","4418":"96b30132289c43497aca14e0ae5d619","7210":"589ea53368668397c4cf2ed7a8f8e5bb","716":"757c2f70f0a95577a4d5d411bc758742","2108":"721eb8aed18c6bcd24279094ad70af8f","5162":"b6a476f906c0f3a3795a0b1b5ab969ba","1396":"b7a76ec216b065583a7d942d2c9e8357","4749":"6959e4ee5fbee286181636c0d34bd5a1","4593":"277073a1d59274c183f424f6a7c8c9ba","9616":"2d97ad3b03cc7313f88c83ca2d6d4d62","1718":"bed9df3ea5a66bbbcf7387ded634c5b9","8098":"553a751b1d7cd95714b7e01750284cc9","7402":"a5396fe729b8b948857ab99593fbdcb2","2244":"bd10a2e62695ef9f655345811602df84","5203":"37202414135829f322ab4bcd44939b6c","7888":"5da2e6d2262b1a0d06ccf2bf5ee49a82","10146":"84171aee554ca1b8dea2756ce5a292df","8499":"4bbfdbce6119498e1ac7524da67d090a","8890":"4ba48e4dc339b4d29b085ba14f128922","5796":"971c1e7c74f8f6e9d6de5956b1f158b2","3225":"556c32b0037839628a0c633026400f91","2436":"4cf2a7e81ad18709049cfdec88c0a775","6149":"fe7923af2c6991935380b103b58525a2","1081":"b880cc5dbbef2e3972969041df285bb8","5863":"83719aa1f49dfd9345442ac151fbcf46","7279":"9c7030fb68db17a2f8cfa29b58a3182","1323":"d178d13d3df6b2446ab52e3c6cd6c2ad","5904":"9603684575703ec666611a674d5326ed","9055":"bc60d80e8a293cb2ef4c63561a0f540d","5782":"ee808d18ac83a219778293338062229","6408":"5cb03253fcc7e4d7c436677149b9630a","6989":"78cab76378eb5827b589b018e3ec2936","6711":"87fa2ec2d125250103c780e387759d83","9175":"7ae209c31f8a880b3dafd4c18c189de1","6170":"de1d80bff6b92148bee49d2351f32d74","5420":"9abf4fc941148316598676e1e856535f","7911":"f0a8b68ff3d46190479c8bea78577216","10013":"a8cf5b1fa28d7559da96e016ce3b4558","3815":"a63baad0045e5705db50a86755caaef1","4942":"7610c9453c1dee5e9c5be1b2db0032bd","1229":"7a2905706ade3e1e10c1767b54fa2637","3284":"270be6d71ee255910c71fdb8e1b5e71c","1658":"940280692f10d1951f8b172a84ec1292","4801":"58638f226e1a3258109d6a5322110a39","1300":"6f97395c0287df1ed5f79eb83204ed1f","568":"5d8e67350c9c61e56c7564d237196d2d","8930":"b206cfb580fc33cb5e29b168c00ebc86","2878":"5f9c31794b32739d9f9b52e9c531a1e9","1213":"8bae3524acbbc9781cc36dc77111beed","3834":"2a61be567266b273a6a838dd5bf386","5889":"99a851a9a11e38f61ceecfb4297f5a61","5933":"42edf0fbf8d69352aa6ea46593df7892","10079":"ae58523d9b02dfc6b40d6b63acbe49b0","6000":"1f3a19713c2790a34e04a208241595ef","9622":"57cb5e7615877ec0035c3b95f4b3b8d9","3381":"700aeffc378c8f544f54747fd6bf90df","503":"5e7d38de844a33ef39c0b93eb4292d6c","3154":"8284cfa6dcb3c9c3e97223b50bb2a84b","8978":"8f1689c0d75763d958c3e5570088c838","1291":"aa96c516354b1b2938bb0bee635f0626","1915":"9d9dfc083ebc17d5bc1430d1564fc1f5","9776":"ab6728d3475fead7f353952daedcfe01","902":"a5c987b8ad8d6266ac3971ecc29cdd51","9797":"229fbe93e83b4a69ef720f3fbe556e75","1447":"653d4247556e0929fa5e6a3664f0138","4484":"90bf0c15511b37bdb5de7f400ee7fd73","7687":"8a32db8038628066eb9e74798b1f93bb","0":"f059e215ee14a89be75d577ec5ad4eb2","4318":"329e71d4eb9e15145d58670b20dd8592","8249":"29905df143a5fea778d559b7f132c24a","7781":"c4043cb05b4e526ea60d21e718bac11b","2234":"b80ec2cfa9198a8e73a3401c4f3c8b51","1653":"83ae723a3d0ee160f71b5b503d4f451","5316":"b73b947562cf26d427f43e39bc67c8ac","1354":"7a8e71a13035b3572680bf3089483644","1078":"b880cc5dbbef2e3972969041df285bb8","6105":"1a4e9e05ee49d22341b856ca1920dccd","7797":"f4ea37a646ebe595c8b74534d2549ab3","4055":"cc5b22a0f15545533be9df232eb1616","5985":"b3690b41cd13e5ac7275542d1e0aa57a","3616":"e52c23f934e697fea670dd918e317394","909":"d812752c43a43b87d13a933e67cc940a","2019":"bb9ae953d98fc1d0462f2f3e6fadf051","5495":"b4535a6a5e16cdebb2a145e5197601b4","5261":"67c1aed00bc7ad0db1d81accf5721b8f","2973":"513f07a1f0eca6cbe69568d3d0a1d02e","4001":"12ed64e0d8ca9bd9de5bfeab481e6e3","4531":"27006fb9eef6b33ff9f774d8cf0e82ff","5997":"1f3a19713c2790a34e04a208241595ef","6341":"a2863c6a8500676b8321bf8a37e97940","119":"72882d2ae816b477bfdc8b82b72c3827","2144":"766686bf2d6f9fcd4f9b4098dbe2b7c6","8897":"57fa1fb446b9241963f04e14a17cd92a","1858":"ae2c2142b897744f41e1d05ad6975aac","8510":"ff65cd2c1e04d061f49b0e0f04972934","7425":"3210bccadb9f998d228aa6dd9cd1d34d","8313":"ede00e9b246f86bc50da6400c5f2103d","6896":"3fd225756f69d5dec3a5e87247099ef0","9466":"eb696975e84e3ad6d261eaf9c34e1c0b","1438":"9ead4d22ff96e409aa0d43bd657adaaa","3999":"3ee5d3bcad83570b2d350b2f34021875","4605":"d4b0e91073ef31f95bccea77981f580f","2395":"45667969ca8ea606094ab9f3442761b7","9068":"4248f61d2295e30c9650bca0c8c68501","9110":"915af6be2725c9ce91c7c0f20bc36a40","6399":"15afeb4c7b78571f63a78c00e41e94f2","9721":"6fba4d3d2536053b8828f42d43e4307b","7919":"39d3a5b451736b829c3127bde9bde5b0","3556":"6a0489fccff01a9ed04985d49014ed76","7475":"230080a5b829e74d07a3744e320ffe4d","9516":"f9e09591c1ba83c3b8cd11ba70d7ab11","566":"5d8e67350c9c61e56c7564d237196d2d","1390":"1db23be6142ad4eb8cbc633fb16d4cc0","4999":"84849a679dcd8639044483bf4f0f2e03","9682":"db68698c7240eb0ee7636bdb0cf0518","5793":"971c1e7c74f8f6e9d6de5956b1f158b2","3484":"29baeea6fa26d15c6544a530ca87ab8b","7314":"b46ccf0bfeb6c300a03360df1c5e38af","7840":"e1daaa32a7a2267bc4f318c6832e815c","1068":"578bdb7a5dfe9b8fac854ddad2864d41","1343":"15ad17a0aa8459816df323bfb1fb3d54","635":"a4c747372f002b2bd543206523b9219d","1363":"c6168cee6c38ff34606494bb0b4e3c67","535":"97524fd1a08979c64e6526dd33c257f","4013":"f19ebe6e693b7faf2808a3bc7c9f4839","5362":"9883be53e4116b1301dfc7c339740ea3","1986":"39e8a31c6634444323ed3cfd53d0f2ef","4457":"65bec555558bce677a123477e9f42136","9488":"30eba48f28bc78e49d47165d6349e827","8633":"d3ded76c938113350be0a569071255b6","7422":"3210bccadb9f998d228aa6dd9cd1d34d","2119":"69b7541e7152dff5e7d57fefc99034e9","3684":"1710c000895b8f80f24a76061b33cb5","6935":"167c332009e6e416a008d679d23f3f7","8620":"1265ff3241abb6fd6a36118be634227d","5194":"f9a90311601a83f6e08320378c968b2","3037":"c230ec199d51a003b09fe8f1ea91bce8","1185":"25e94f4c53144a8e6d9139368f391c1f","4126":"d7fb3b1aa2632fd5c34ec8adb9610fdc","1817":"e16fee7fdf9d30a4dbf0bf30c2f47b70","6906":"16646ef014a40117af791bcbfd6b3c8f","8129":"a14be2767063b1b291b96de167f4e23a","4770":"e3f9626519a8540093aadcf9232facaa","6016":"ffcb7a456fb47caeaffcb7299a6e7ec7","5888":"99a851a9a11e38f61ceecfb4297f5a61","5959":"b00d48381af2270901d7bd14fe1b8b3","2836":"f72da330adf52e902421b7d16ca68b26","453":"4992ee0de077a6c984d86a31347dac8f","8535":"71b164736fd0f6bc7c2a1dcb37b33691","462":"78c2f6002f20eeb1e44868b0e6c66c6","4439":"16d18fe762f809fd57993be2e9317cf1","4107":"e3b070129df4f168c1cc33602890c57b","9272":"a4a772ad1e01962840e2a88de88f8e5b","1391":"1db23be6142ad4eb8cbc633fb16d4cc0","9351":"64d77eed2030e85dbd2edc01c6c1fbd5","9501":"bcaa0db1d290f93fe1bc8cea14ebd595","8665":"42e6088990689e1b8f53c2767ceb3125","5644":"12d10aa73462009a56179df9abfd329f","6407":"5cb03253fcc7e4d7c436677149b9630a","488":"a77214ebf44bdd677a644070fee4c017","9409":"4bd5b01dc863231b3292d11876d6891b","4259":"ebb6a12ee4d57677dbf2f97f51ef4e70","256":"f747b76c19a8e3e83792ec6152cab1ff","4989":"7de9f22477057e8b1d31fb4de7860d72","1524":"238d416520471e246b6b964a92be9aec","6623":"bffd8a4f18b59dae09d7581b1b25da05","6447":"7c18530bb7d88fee325160db8f587f57","5980":"84758391539a84fd83599665b4c5927a","9338":"ceefe54fcc480ebe53e3ca4ba72c2ab1","3709":"e2b1523b26cb6fc8183778d32bcdd6b6","1824":"84b53941a69c1f4d0660e963355ce662","1651":"83ae723a3d0ee160f71b5b503d4f451","5752":"f58c82f36721e70a6c0ddab51217b83e","6045":"fa0f1ce78d7be1681d336b50f98ea0f9","1687":"1507a4cad9e990ac9f961289ea224f54","1897":"fde2ac9b29e8b84dd58b7c8cac083c8d","3922":"e3cf365ab7e8b9d207c856323deb9593","2264":"145cef7af50e6816086718fa5507ce31","9736":"f2164398ced4bffc0061a836aa49c0c1","1120":"fd6e7d5d28762061adcdea16605292","1996":"4b400983065ca5256176e317012f9155","7768":"6172504579a2c342e05b2845a26e1624","2834":"f72da330adf52e902421b7d16ca68b26","3497":"e9ee89a5a589875acaf25578aece19a7","7069":"8e84b8cc49e274229d8edf7297e4c7cf","2559":"8dd72a93f7e8b0f517f2e48eff8cdb5f","5861":"83719aa1f49dfd9345442ac151fbcf46","2412":"220b6266493a61b8d1394e8ced0062a3","4905":"bd893d9b5c0a0bd2f30703fd2f6615ab","6696":"d90133b395fb02a9b58f0864293ee25a","6897":"3fd225756f69d5dec3a5e87247099ef0","4289":"3a4873159e9da79fe784ed631e3f34ba","9808":"e260129c343aa2cc65e5798191feb021","3286":"e5a8331bf393564ddd71f2b59680a314","8318":"3ebbfceec4ae529a78c6019aac229e33","2784":"e50d3b5e5bb57f0a47c8683044c89261","8768":"acd2700d073990d78ef7865cf26c6b72","7149":"410af1a82cb9565a85c3da89eddc6d3","4504":"79af8c9a0547488b9e816942ef181900","1128":"aa268638a7b5982ca9b1a71487b78e97","9919":"f501309a7dd5c4bddb03caa0a59dd4c9","3628":"909615b5c435e4438eea4eb7cc5bb6af","6701":"2a8cb96f3fc1334fae021242f77ae3c9","355":"da71acf0bff66206457a063103bbaee8","9544":"50725feea96b5a97a27d3424684b179","2791":"61cad46c46e2d9f9b43ffc8249be8da0","9788":"de9cc30caf2d50c29b4b8eabc0722b0","8550":"d409f5c95c7c684a1b37f6ee63289275","7469":"b8de7dc869c24f8d03e7ac8837a81f27","9901":"1c0e0011da19e1df35c1264ef6b3d4a","1978":"1675c247a26bad19d57656101c545250","7975":"4f4311cdb48efa3a92f87fa0246c7c47","581":"f5d44cecd710bdb17057ef49138daf7f","1289":"fa0b95297584c107fbc7b4263b6689d","9591":"ad7b7d6e103ccee6333fc673ca71169e","9108":"915af6be2725c9ce91c7c0f20bc36a40","6809":"f2cb64ec01af3ef53125df67eee4287c","3164":"ef43b9036c93d1b50e168edf91a22d0a","8549":"d409f5c95c7c684a1b37f6ee63289275","6818":"1dd4fb814e35492ac20a0b03c1eafdbb","5097":"634bf682b8752d90e7f91c915d7dc4a1","9528":"455707b51b21bddd4f6c319d1ef326f","6477":"74a24ee4d27d4185e037c57edf089348","5564":"3adb19fb409ce8856c6b0c92c671ef72","5785":"ee808d18ac83a219778293338062229","1571":"96f3fc949e4dcdc61d40aea7e57328b1","3715":"855020fd421a34b81e0edb2c86f292e9","1063":"b9d94d7d086d1261aa5ab10ad11e772e","178":"fbfc8570be618f0cf8b459c2eb2c8f7a","1927":"13fe5b7ef8677c01cad389346393d160","5674":"acdb289ceca1fc562ce1a06f176e6575","7979":"4f4311cdb48efa3a92f87fa0246c7c47","6947":"ce022185500042314f8802d6201d1e60","1520":"238d416520471e246b6b964a92be9aec","2013":"e71006be8a1fd92adf702af0494e07b9","688":"4b0fe4bd8c040c89044d4159a5f4d387","4345":"7f5e1b24692cfe47491e824dabd7b212","1126":"aa268638a7b5982ca9b1a71487b78e97","4337":"3541149f8b5ca7c3cc8fda331689b8f1","5305":"f580ff0a573f969ebcc2ffca7f9fdfaf","8011":"bc4153d0c65d00313c7fb444c867cde5","2237":"b80ec2cfa9198a8e73a3401c4f3c8b51","4649":"13447810da183628f0ab34b66d3749b9","9602":"c137d9f7e9fa18496c4c0cf7c00cf58b","2342":"90b3ed2d1dad82574cf3c43a526059b7","2735":"f4c04c19c27ccc97e1f957acf17dbb8f","9563":"b2dcc7aab30c84d68b030ebee5ab3b07","7205":"d73ad47b44a6690ee13afa904358fe35","5505":"23ac0e85ff616858a07b48c76bb0489b","2341":"90b3ed2d1dad82574cf3c43a526059b7","3719":"855020fd421a34b81e0edb2c86f292e9","8087":"45f13b3020a1568355a13aa67c5fcdd0","2486":"4ba1ecd061e0129873e59cf94711a680","5437":"a645430aaf469802deacc170dadfbf8","5245":"a70bd16f6c30b2b9e58c61000c04f94f","3095":"ac9b669f06258c03006d4558eb2381f9","8827":"60210fd3b9539b7ae6be919d462a7f9a","8858":"34c7a3f5fea59fa321f7745aafd0609a","4757":"725efdf0c25249c8f0a16349d0c2a1b7","977":"b92636ec6eae37a28fb5384925320a59","2999":"ba220eeb6826ab5196a0b8d77503b8ce","1270":"6a0c3d3897e37d8fd238546fd14bed90","6314":"39288f8f077a22fb6ed55463d7e14b7b","2254":"3ca39cfe37550e6fe3ca8ce0f5acca71","6984":"c8f04349a9020296eb3a3f46942a6292","3218":"efabe80ebaa08cb5fa6df141473a6d4d","6610":"2349ee6e6d34acd219b9b76439185e75","3943":"374a7b10e844f57a4f2193c8e4716db4","3721":"2b4351bbf231e76c58cfb1b019a0740b","6345":"c712eaf95d7c8629d2c7ca175e8331fd","2213":"158ca84d28055631b00806887002a7e0","8928":"d51cbb6627722010fd556158cd8faab","3138":"7c2e364455d05d5a137b80b054eba317","1388":"db47ba4f8911530304190516f15c7abe","3343":"de11829465633ae1d77f45ab7b182907","8885":"7425074c928278b0fb0a3d0703c3da43","9562":"b2dcc7aab30c84d68b030ebee5ab3b07","1788":"11e1278f6d86b5a092cd25e7475b4e3b","5918":"4831277fa5421d4483651c6fc206f73b"},"context":{"674":"February 3, 2022: Alaska made updates to data previously submitted to CDC that resulted in a decrease of 3,945\ndoses administered. January 28, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n26,796 doses administered. January 28, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 14,973\ndoses administered.","6842":"However, vaccination providers may seek appropriate\nreimbursement from a program or plan that covers COVID-19 vaccine administration\nfees for the vaccine recipient (private insurance, Medicare, Medicaid, Health\nResources & Services Administration [HRSA] COVID-19 Uninsured Program for\nnon-insured recipients). WHERE CAN I REPORT CASES OF SUSPECTED FRAUD? Individuals becoming aware of any potential violations of the CDC COVID-19\nVaccination Program requirements are encouraged to report them to the Office of the\nInspector General, U.S. Department of Health and Human Services, at\n1-800-HHS-TIPS or https:\/\/TIPS.HHS.GOV. WHAT IS THE COUNTERMEASURES INJURY COMPENSATION PROGRAM?","4917":"Ability of the patient to be vaccinated in a setting where appropriate medical care is immediately available for anaphylaxis. For people\nwith a contraindication due to allergy to one type of COVID-19 vaccine who are receiving another type that has been deemed a precaution\nand for people with an immediate, non-severe allergic reaction after a previous dose of COVID-19 vaccine who are receiving vaccination\nwith a subsequent dose of that COVID-19 vaccine type, vaccination should only be undertaken in an appropriate setting under the\nsupervision of a healthcare professional experienced in the management of severe allergic reactions.","5394":"KEEP YOUR VACCINATION CARD\nWhen you receive the Janssen COVID-19 Vaccine, you will get a vaccination card to document\nthe name of the vaccine and date of when you received the vaccine. ADDITIONAL INFORMATION\nIf you have questions or to access the most recent Janssen COVID-19 Vaccine Fact Sheets, scan\nthe QR code using your device, visit the website or call the telephone numbers provided below. QR Code Fact Sheets Website Telephone numbers\nwww.janssencovid19vaccine.com. US Toll Free: 1-800-565-4008\nHOW CAN I LEARN MORE? \u2022 Ask the vaccination provider. \u2022 Visit CDC at https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/index.html. \u2022 Visit FDA at https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-\nregulatory-and-policy-framework\/emergency-use-authorization. Contact your local or state public health department.","9227":"Video and Print Resources\nWatch Video\n10 Things You Can Do to Manage\nCOVID-19 at Home\nVideo Length: 00:01:32\n[PDF - 484 KB, 1 page]\n10 Things You Can Do to Manage\nYour COVID-19 Symptoms at\nHome\nFile Details: 484 KB, 1 page\nView PDF in English\nOther Languages\n\uf20c\n\uf20c\n[PDF - 361 KB, 1 page]\nDon\u2019t Delay: Test Soon and Treat\nEarly\nFile Details: 361 KB, 1 page\nView PDF in English\nAdditional Languages\n\uf20c\n\uf20c\nMore Information\nTravelers\nSpecific Groups of People\nPeople Who Are Sick\nHealthcare Professionals\nHealth Departments\nLaboratories\nLast Updated Mar. 22, 2022","8418":"Core Competencies:\nRelevant information contained in the EUA Fact Sheet(s) for Healthcare Providers for the vaccine product(s) in\nyour facility\nPreparation requirements\nStorage and handling requirements\nTransport guidance\nVaccination documentation and reporting requirements\nRequired and additional information for vaccine recipients\nCOVID-19 Vaccine Administration Competencies Assessment Form\n\uf209\n\uf20c\nCOVID-19 Vaccine Training Routine Vaccine Administration Routine Vaccine Storage and Handling\nCDC Training Module(s) for the\nvaccine product(s) in your facility\nn\/a Recommended if storing and handling\nvaccine: You Call the Shots: Vaccine\nStorage and Handling\nOr other vaccine storage and handling\ntraining offered by a worksite, state or\nlocal health department, medical\nprofessional organization, or\nmedical\/nursing school within the last\n12 months.","656":"February 18, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 20,754\ndoses administered. February 18, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n12,473 doses administered. February 17, 2022: A federal entity made updates to data previously submitted to CDC that resulted in an increase of\n4,251 doses administered. February 11, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 58,355\ndoses administered.","9903":"Interim recommendations for use of the\ninactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm; updated 28\nOctober 2021. Geneva: World Health Organization; 2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-\n2019-nCoV-vaccines-SAGE-recommendation-BIBP. Zhong D, Xiao S, Debes AK, Egbert ER, Caturegli P, Colantuoni E, et al. Durability of Antibody Levels After\nVaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. JAMA. 2021 Dec","3203":"Localized axillary lymphadenopathy on the same side as the vaccinated arm or groin, if\nvaccination was in the thigh, has been observed following vaccination with Moderna, Novavax, and Pfizer-BioNTech COVID-19\nvaccines (4). Infrequently, people who have received dermal fillers might experience temporary swelling at or near the site of\nfiller injection (usually face or lips) following a dose of an mRNA COVID-19 vaccine. Among younger children, particularly those\nyounger than ages 3 years, systemic reactions also can include irritability\/crying, sleepiness, and loss of appetite.","9994":"Additional information\ncan be found at Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination. 7. Has the person to be vaccinated ever had anaphylaxis after another vaccine (other than\nCOVID-19 vaccine) or another injectable medication? A history of anaphylaxis to any other vaccine or injectable\ntherapy (i.e., intramuscular, intravenous, or subcutaneous\nvaccines or therapies not related to a component of COVID-19\nvaccines) is a precaution to COVID-19 vaccines. This also\napplies if the non-COVID-19 vaccine or therapy has multiple\ncomponents, one or more of which is a component of a\nCOVID-19 vaccine, and it is unknown which component\nelicited the allergic reaction.","4890":"Severe allergic reactions include:\nPossible anaphylaxis, a progressive life-threatening reaction that typically includes urticaria but also with other symptoms such as\nwheezing, difficulty breathing, or low blood pressure\nAny angioedema affecting the airway (i.e., tongue, uvula, or larynx)\nDiffuse rash which also involves mucosal surfaces (e.g., Stevens-Johnson Syndrome)\nNon-severe allergic reactions may include:\nUrticaria (hives) beyond the injection site\nAngioedema (visible swelling) involving lips, facial skin, or skin in other locations.","6855":"An EUA is supported by a Secretary of Health and Human Services (HHS)\ndeclaration that circumstances exist to justify the emergency use of drugs and\nbiological products during the COVID-19 pandemic. A product authorized for\nemergency use has not undergone the same type of review by FDA as an\nFDA-approved product. FDA may issue an EUA when certain criteria are met, which includes that there are no\nadequate, approved, and available alternatives.","148":"Finding these mutations in mink on the Michigan farm is not unexpected because they have been seen before in mink\nfrom farms in the Netherlands and Denmark, and also in people linked to mink farms worldwide. To confirm the spread of SARS-CoV-2 from mink to people, public health officials would need more information on the\nepidemiology and genetics of the virus in mink, mink farm workers, and the communities around mink farms. These results highlight the importance of routinely studying the genetic material of SARS-CoV-2 in susceptible animal\npopulations like mink, as well as in people.","7371":"U.S. Citizens, U.S. Nationals, and U.S. Lawful Permanent\nResidents\nThe Presidential Proclamation and CDC\u2019s Amended Order do not apply to U.S. citizens, U.S. nationals, or U.S. lawful\npermanent residents (Green Card holders). For additional information on actions to take before, during, and after international travel, visit International Travel to and\nfrom the United States. Immigrants and Other Non-affected Persons\nThe Presidential Proclamation and CDC\u2019s Amended Order do not apply to immigrants (including Special Immigrant Visa\nholders).","1183":"Although Texas still reports vaccination data in\naggregate form, Texas and CDC recently collaborated to update the format of this record submission to improve COVID-19\nreporting of Texas\u2019 data on CDC\u2019s COVID Data Tracker at the national, state, and county levels. Previously, for Texas, CDC estimated the number of people with at least one dose and the number of people who are fully\nvaccinated for the populations ages 12 years or older, 18 years or older, and 65 years or older in the metrics for Texas alone\nand when including Texas in the national level metrics on the\u202fVaccinations in the United States\u202fsite.","7177":"This Vaccine Information Fact Sheet contains information to help you understand the\nrisks and benefits of COMIRNATY (COVID-19 Vaccine, mRNA), the Pfizer-BioNTech\nCOVID-19 Vaccine, and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent, which you\nmay receive because there is currently a pandemic of COVID-19. Talk to your\nvaccination provider if you have questions. This Fact Sheet may have been updated. For the most recent Fact Sheet, please see\nwww.cvdvaccine.com. WHAT YOU NEED TO KNOW BEFORE YOU GET ANY OF THESE VACCINES\nWHAT IS COVID-19? COVID-19 disease is caused by a coronavirus called SARS-CoV-2. You can get\nCOVID-19 through contact with another person who has the virus.","6727":"Children\nwho will turn from 4 years to 5 years of age between any doses in the primary series, and who initiated a\n3-dose primary series with the Pfizer-BioNTech COVID-19 Vaccine authorized for use in individuals\n6 months through 4 years of age, may receive the Pfizer-BioNTech COVID-19 Vaccine authorized for use\nin individuals 5 through 11 years of age for doses 2 and\/or 3. 4 You may receive this Fact Sheet even if your child is 12 years old.","1133":"10\/30\/22, 9:35 AM COVID-19 Vaccination Data Systems and Data Sources\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccination Data Systems and Data Sources\nCDC reports COVID-19 vaccination data online on COVID Data Tracker and in vaccination datasets. Sharing timely and\naccurate information with the public is one of CDC\u2019s core activities. Timely and accurate reporting from jurisdictions provides\nthe reliable data that can be reported by CDC. All reported numbers may change over time as updated data are continuously\nreported to CDC.","1916":"The v-safe COVID-19 Vaccine Pregnancy Registry is a registry to collect additional\nhealth information from v-safe participants who report being pregnant at the time of vaccination or a positive pregnancy\ntest after vaccination. This information helps CDC monitor the safety of COVID-19 vaccines in people who are pregnant. CDC: Vaccine Safety Datalink (VSD) \u2014 VSD is a network of nine integrated healthcare organizations across the United\nStates that monitor and evaluate the safety of vaccines. The system is also used to help determine whether possible side\neffects identified using VAERS are actually related to vaccination.","7490":"What if I have tested positive for COVID-19 antibodies or have recently recovered from COVID-19? Do I still need proof of vaccination? \uf1aa\nAt this time, CDC\u2019s Amended Order only requires that noncitizen nonimmigrants are fully vaccinated with the primary\nseries of an accepted COVID-19 vaccine to board a flight to the United States. A booster dose is not needed to meet this\nrequirement. Does CDC\u2019s Amended Order require noncitizen nonimmigrants to be up to date with their COVID-\n19 vaccines, which includes a booster dose when eligible, to board a flight to the United States?","9947":"Has the person to be vaccinated ever received a dose of COVID-19 vaccine? COVID-19 vaccination is recommended for everyone 6\nmonths of age and older. For the primary series, Moderna,\nNovavax, and Pfizer-BioNTech COVID-19 vaccines are\nrecommended; only monovalent vaccines are approved or\nauthorized for primary series doses. The same vaccine product\nshould be used for all primary series doses. Moderna and Pfizer-BioNTech are recommended for booster\ndoses. People ages 5 years and older are recommended to\nreceive 1 bivalent mRNA booster dose after completion\nof any monovalent primary series or previously received\nmonovalent booster dose(s). Use an age-appropratie\nproduct.","9726":"Finally, a study from Chile\nexamining heterologous boosting with AztraZeneca or Pfizer-BioNTech among Sinovac-CoronaVac primed\nindividuals demonstrated higher vaccine effectiveness (VE) against infection, symptomatic disease, and\nintensive care unit admission compared with homologous boosting (Araos, 2021). WHO\u2019s Strategic Advisory Group of Experts (SAGE) on Immunization has noted that although data are currently\nlimited on the safety, immunogenicity, and effectiveness of heterologous versus homologous additional doses,\nevolving evidence suggests that use of a heterologous vaccine for an additional dose may be more\nimmunogenic than a homologous series.","9081":"10\/30\/22, 9:43 AM Wearing Masks in Travel and Public Transportation Settings | CDC\nEspa\u00f1ol | Other Languages\nWearing Masks in Travel and Public Transportation\nSettings\nFor people aged 2 years or older\u2014\nincluding passengers and workers\u2014CDC\nrecommends properly wearing a high-\nquality mask or respirator over the nose\nand mouth in indoor areas of public\ntransportation (such as airplanes, trains,\nbuses, ferries) and transportation hubs\n(such as airports, stations, and seaports). When people properly wear a high-quality\nmask or respirator, they protect\nthemselves and those around them, and\nhelp keep travel and public transportation\nsafer for everyone. Wearing a high-quality\nmask or respirator is most beneficial in\ncrowded or poorly ventilated locations,\nsuch as airport jetways.","9749":"Recent studies indicate that additional doses in people who are moderately or severely immunocompromised\nare safe and can increase antibody response. Small studies in solid organ transplant recipients in Toulouse,\nStrasbourg, and Baltimore demonstrate immunogenicity of a 4th mRNA dose when administered 1\u20132 months\nafter the 3rd dose (Kamar et al., 2021; Benotmane et al., preprint; Alejo et al., 2021).","6308":"10\/30\/22, 9:42 AM Patient Tips: Healthcare Provider Appointments for Post-COVID Conditions | CDC\nEspa\u00f1ol | Other Languages\nPatient Tips: Healthcare Provider Appointments for\nPost-COVID Conditions\nBefore Your Appointment\nWhat You Need to Know\nPreparing for an appointment can make all the difference in getting the proper evaluation, diagnosis, and\ntreatment. To help get the most out of appointments for post-COVID conditions, download the Healthcare Appointment\nChecklist (Espa\u00f1ol [PDF \u2013 72 KB]). Try to arrive early or log on a few minutes ahead of the appointment and ensure paperwork is completed on your\nappointment day. After visiting your healthcare provider, review your notes to prepare for your next appointment.","420":"On June 30, 2021, data review and reporting adjustments resulted in an increase in the number of vaccine doses\nadministered for North Carolina of 621,198 doses since December 2020. The adjustment is the result of updates to how\npharmacies report data to CDC and\/or the jurisdictions. On June 25, 2021, data review and reporting adjustments resulted in a decrease in the number of vaccine doses\nadministered for New Jersey of 331,640 doses and a smaller-than-usual increase for New Hampshire of 6,449 doses. The\nadjustments are the result of updates to how pharmacies report data to CDC and\/or the jurisdictions.","5759":"\u25aa Received COVID-19 vaccine dose(s) during treatment with B-cell-depleting\ntherapies over a limited period: the suggested interval to start revaccination is\nabout 6 months after completion of the B-cell-depleting therapy\n\u25aa Received COVID-19 vaccine dose(s) prior to or during treatment with\nhematopoietic cell transplant (HCT) or chimeric antigen receptor (CAR)-T-cell\ntherapy: revaccination at least 3 months after treatment\nThe COVID-19 vaccine by Pfizer-BioNTech can also be used under EUI for similar uses in persons ages 12\nyears and older as an alternative mRNA COVID-19 vaccine (see the Pfizer-BioNTech EUI Fact Sheet for\nRecipients).","2171":"Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-\nGestational-Age at Birth \u2014 Eight Integrated Health Care Organizations, United States, December 15, 2020\u2013July 22, 2021. MMWR Morb Mortal Wkly Rep 2022;71:26\u201330. DOI: https:\/\/dx.doi.org\/10.15585\/mmwr.mm7101e1\n5. Moro PL, Olson CK, Clark E, et al. Post-authorization surveillance of adverse events following COVID-19 vaccines in\npregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 \u2013 October 2021. Vaccine. 6. Sadarangani M, Soe P, Shulha HP, et al. Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety\n(CANVAS) network cohort study [published online ahead of print, 2022 Aug 11]. Lancet Infect Dis. 2022;S1473-\n7.","8891":"10\/30\/22, 9:21 AM Vaccinating Dialysis Patients and Healthcare Personnel | CDC\nVaccines & Immunizations\nVaccines & Immunizations\nVaccinating Dialysis Patients and Healthcare Personnel\nTake action to protect patients at high-risk in your jurisdiction\nCOVID-19 vaccines are effective at protecting people from getting sick. By allocating vaccines for outpatient dialysis patients\nand the healthcare personnel who care for them in your jurisdiction, you can protect patients who are at high risk,\ndisproportionately affected by COVID-19, or might suffer severe consequences if infected. How can jurisdictions support COVID-19 vaccination efforts for\ndialysis patients and healthcare personnel? Make sure you are aware of the dialysis clinics located in your jurisdiction.","6513":"\u2022\n\u2022\n\u2022 TM\n\u2022\n\u2022\f10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nBased on the current evidence, a person with any of the conditions listed below is more likely to get very sick from COVID-19. This means that a person with one or more of these conditions who gets very sick from COVID-19 (has severe illness from\nCOVID-19) is more likely to:\nBe hospitalized\nNeed intensive care\nRequire a ventilator to help them breathe\nDie\nIn addition:\nOlder adults are at highest risk of getting very sick from COVID-19. More than 81% of COVID-19 deaths occur in people\nover age 65.","1409":"Below are three scenarios and the recommended action:\nIf your patient received the primary series before or during treatment: Revaccinate the patient with the primary series\nand administer 1 bivalent mRNA booster dose at least 2 months after repeating the primary series. If your patient received the primary series and 1 or 2 (or more) monovalent booster doses before or during\ntreatment: Revaccinate the patient with the primary series. Do not revaccinate for the monovalent mRNA booster dose(s). The patient is recommended to receive 1 bivalent mRNA booster dose at least 2 months after repeating the primary\nseries.","777":"The spike protein is the part of the virus that attaches to\na human cell to infect it, allowing it to replicate inside of the cell and spread to other cells. Some antibodies can protect you\nfrom SARS-CoV-2 by targeting these spike proteins. Because of the importance of this specific part of the virus, scientists who\nsequence the virus for research constantly monitor mutations causing changes to the spike protein through a process called\ngenomic surveillance. As genetic changes to the virus happen over time, the SARS-CoV-2 virus begins to form genetic lineages.","5636":"The information on this page is about N95 respirators but also applies to international respirators, like KN95\nrespirators. \uf20a\f10\/30\/22, 9:39 AM Masks and Respirators\nMost publicly available respirators are disposable and should be discarded when they are dirty, damaged, or difficult to\nbreathe through. More information on these two types of respirators is provided below. Respirators that Meet International Standards\nSome respirators are designed and tested to meet international standards. The most widely available respirators that meet\nKP100, P2, P3, PFF2, PFF3, R95, and Special. What to know about international respirators\nThey are designed to standards that do not often have a quality requirement.","9948":"Has the person to be vaccinated ever received a dose of COVID-19 vaccine? COVID-19 vaccination is recommended for everyone 6\nmonths of age and older. For the primary series, Moderna,\nNovavax, and Pfizer-BioNTech COVID-19 vaccines are\nrecommended; only monovalent vaccines are approved or\nauthorized for primary series doses. The same vaccine product\nshould be used for all primary series doses. Moderna and Pfizer-BioNTech are recommended for booster\ndoses. People ages 5 years and older are recommended to\nreceive 1 bivalent mRNA booster dose after completion\nof any monovalent primary series or previously received\nmonovalent booster dose(s). Use an age-appropratie\nproduct.","4203":"You may consider delaying your vaccine by 3 months from when your symptoms started or, if you had no symptoms,\nwhen you received a positive test. People who already had COVID-19 and do not get vaccinated after their recovery are more likely to get COVID-19\nagain than those who get vaccinated after their recovery. Learn more about the benefits of getting a COVID-19 vaccine. If I already had COVID-19 and recovered, do I still need to get a COVID-19 vaccine? \uf1aa\nCan I get vaccinated against COVID-19 while I am currently sick with COVID-19?","6790":"A\nsevere allergic reaction would usually occur within a few minutes to 1 hour after getting\na dose. For this reason, your child\u2019s vaccination provider may ask your child to stay at\nthe place where your child received the vaccine for monitoring after vaccination. Signs\nof a severe allergic reaction can include:\n\uf0b7 Difficulty breathing\n\uf0b7 Swelling of the face and throat\n\uf0b7 A fast heartbeat\n\uf0b7 A bad rash all over the body\n\uf0b7 Dizziness and weakness\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the\nlining outside the heart) have occurred in some people who have received the\nPfizer-BioNTech COVID-19 Vaccine.","9589":"\u2022 Delaying the second primary dose in persons ages 12 years and older who recently had SARS-CoV-2\ninfection, by 3 months from symptom onset or positive test (if infection was asymptomatic)\n\u2022 Primary dose(s), including for those with certain immunocompromising conditions or those with\nincomplete primary series, for persons ages 12 years and older who received primary or booster\nvaccination with certain non-FDA authorized or approved COVID-19 vaccines2. \u2022 An additional dose in persons ages 18 years and older with certain immunocompromising conditions\nwho received primary vaccination with the Janssen COVID-19 Vaccine.","1505":"Mask Distribution Initiative (January 20, 2022)\nAs a subcomponent of the CDC COVID-19 Vaccination Program, designated enrolled providers are authorized to\nreceive from the Department of Health and Human Services Strategic National Stockpile (SNS) N95 masks (also\nknown as respirators) that are approved by the National Institute for Occupational Safety and Health (NIOSH) for free\ndistribution to people in the United States. 1. Designated providers will provide shipping and other necessary information to the SNS to receive shipments of\nthe masks, in addition to the name, title, and contact information for the individual who will coordinate the\nprovider\u2019s participation in this initiative.","2363":"transplantation or taking immunosuppressive therapy)\nModerate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined\nimmunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)\nAdvanced or untreated HIV infection (people with HIV and CD4 cell counts less than 200\/mm3, history of an AIDS-\ndefining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)\nActive treatment with high-dose corticosteroids (i.e., 20 or more mg of prednisone or equivalent per day when\nadministered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs,\ncancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and\nother biologic agents that are immunosuppressive or immunomodulatory\n\u2022\n\u2022\n\u2022\nIf you are moderately or severely immunocompromised or severely allergic to COVID-19 vaccines, you may be eligible for\npre-exposure prophylaxis with EVUSHELD .","1604":"Similarly, in lieu of a separate COVID-19 VIS for the licensed Moderna vaccine, FDA has issued a combination Moderna\nCOVID-19 Vaccine Fact Sheet for Recipients and Caregivers to address both the FDA authorized (EUA) Moderna COVID-\n19 Vaccine and the FDA BLA approved (licensed) Moderna SPIKEVAX COVID-19 Vaccine. The vaccines have identical\nformulations. When administering the Moderna COVID-19 vaccine under either the EUA or under BLA approval,\nproviders must give each vaccine recipient, adult caregiver accompanying the recipient, or other legal representative, a\ncopy of the combined Moderna COVID-19 Vaccine Information Fact Sheet. [Additions to CDC COVID-19 Vaccination Program Provider Agreements, Paragraph 1.]","2743":"If your child has a post-COVID condition that impacts their ability to attend school, complete schoolwork, or perform their\nusual activities, it may be helpful to discuss with your child\u2019s healthcare professional and school possible accommodations\nsuch as extra time on tests, scheduled rest periods throughout the day, a modified class schedule, etc. School administrators,\nschool counselors, and school nurses can work with families and healthcare professionals to provide learning\naccommodations for children with post-COVID conditions, particularly those experiencing thinking, concentrating, or physical\ndifficulties. You may also request similar accommodations for activities outside of school, such as day care, tutoring, sports,\nscouting, etc.","1099":"Preventive medications\nThe FDA has issued an emergency use authorization for tixagevimab plus cilgavimab (EVUSHELD ) , a medicine that can\nhelp protect you from getting COVID-19. EVUSHELD contains two different antibodies and is given as two separate\nconsecutive intramuscular (IM) injections at a doctor\u2019s office or healthcare facility before you are exposed or test positive for\nCOVID-19. If you are moderately or severely immunocompromised, or severely allergic to COVID-19 vaccines, you may be\neligible for EVUSHELD every 6 months. EVUSHELD may offer less protection against certain strains of the Omicron\nvariant. It is important that even if you receive EVUSHELD you take multiple prevention measures.","1553":"Novavax COVID-19 Vaccination of Persons 18 Years of Age and Older\nPursuant to CDC\/ACIP recommendations and the July 21, 2022, Secretarial Directive, as of July 25, 2022, CDC COVID-\n19 Vaccination Program enrolled providers shall:\nIf they have the vaccine in stock, make immediately available and administer upon request a two-dose Novavax\nCOVID-19 Vaccine, Adjuvanted primary series for persons ages 18 years and older. When unable to fulfill a request from an age-eligible person for Novavax COVID-19 Vaccine, Adjuvanted, notify the\nrequesting person that providers having the vaccine can be located through the website\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nhttps:\/\/www.vaccines.gov\/.","3177":"People who received Janssen COVID-19 Vaccine after a dose of another COVID-19 vaccine should be considered to have\nreceived a valid, single-dose Janssen primary series. Booster vaccination\nFor booster vaccination, bivalent mRNA vaccines are recommended. Any homologous or heterologous bivalent mRNA vaccine\ncan be used if a booster dose is FDA-authorized for use in that age group. COVID-19 vaccines may be administered without regard to timing of other vaccines. This includes simultaneous\nadministration of COVID-19 vaccine and other vaccines on the same day. However, there are additional considerations if\nadministering an orthopoxvirus vaccine (see below).","9166":"If you need to be around other people or animals in or outside of the\nhome, wear a well-fitting mask. 10\/30\/22, 9:41 AM What to Do If You Are Sick | CDC\nTell your close contacts that they may have been exposed to COVID-19. An infected person can spread\nCOVID-19 starting 48 hours (or 2 days) before the person has any symptoms or tests positive. By letting your\nclose contacts know they may have been exposed to COVID-19, you are helping to protect everyone. See COVID-19 and Animals if you have questions about pets.","3412":"A positive anti-nucleocapsid antibody test result\nindicates prior SARS-CoV-2 infection. (To test for current SARS-CoV-2 infection, a molecular diagnostic or antigen test should\nbe used). Anti-spike protein antibody testing cannot be used to determine SARS-CoV-2 infection status in a vaccinated person\nbecause a positive test result can be induced by either COVID-19 vaccination or SARS-CoV-2 infection. Decisions about administration of subsequent COVID-19 vaccine doses in people who develop MIS-C or MIS-A after COVID-19\nvaccination depend on timing of MIS in relation to vaccination, clinical recovery, and epidemiologic considerations.","1161":"When the denominator data are not available for federal entities, these metrics are displayed\nas \u201cN\/A\u201d or entered as \u201c0.\u201d\nJurisdictions and Other Reporting Partners\nNational and jurisdictional metrics reported on CDT include vaccination data distribution to and administered in the following\nlocations:\nJurisdiction (state, territory, tribe, or local entity) partner clinics\nRetail pharmacies\nFederal partners and programs such as\nFederal Pharmacy Partnership for Long-term Care (LTC) Program\nDialysis centers participating in the Federal Dialysis Center Program\nFederal Emergency Management Agency (FEMA)\nHealth Resources and Services Administration (HRSA)\n\u2022\n-\n-\n-\n-\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\n-\n-\nPopulation Data Sources\nCensus\nCDC calculates rate and percentage measures for vaccination among the entire population and among select demographic\ngroups (such as people ages 65 years or older).","1140":"Vaccine Distribution Data Systems\nVaccine Tracking System (VTrckS) is CDC\u2019s vaccine order management system where jurisdictions (states,\nterritories, tribes, and local entities), federal agencies, and pharmacy partners order vaccines from the federal\ngovernment. VTrckS Provider Order Portal (VPOP) is CDC\u2019s platform where federal entity providers report their on-hand\nCOVID-19 vaccine inventory each day. Immunization Data Lake (IZ Data Lake) is a cloud-hosted data repository to receive, store, manage, and analyze\ndeidentified COVID-19 vaccination data. \u2022\n\u2022 \uf209\n\u2022\nVaccine Administration Data Systems\nImmunization Information Systems (IISs)\u202fMost IISs create\u202fa centralized\u202fdata repository for storing\nvaccination\u202finformation specific to that jurisdiction.","2664":"Caregivers should quarantine\nKeep a separate bedroom and bathroom for a person who is sick\n\u2022\n\u2022\n-\n-\n\u2022\f10\/30\/22, 9:41 AM COVID19 - Caring for someone at home | CDC\nCaregivers and anyone who has been in close contact with someone who has COVID-19 should stay home, except in\nlimited circumstances. Learn when and how to quarantine. When it's safe for a person who has been sick to be around others\nDeciding when it is safe to be around others is different for different situations. Find out when someone who is sick can\nsafely end home isolation.","6271":"10\/30\/22, 9:34 AM Myths and Facts about COVID-19 Vaccines | CDC\nVaccines work by stimulating your immune system to produce antibodies, exactly like it would if you were exposed to the\ndisease. After getting vaccinated, you develop immunity to that disease, without having to get the disease first. Learn more about the ingredients in the COVID-19 vaccinations authorized for use in the United States. MYTH: Receiving a COVID-19 vaccine can make you magnetic. FACT: Receiving a COVID-19 vaccine will not make you magnetic, including at the site of vaccination which is\nusually your arm. vaccines\ndo not\ncontain\ningredient\ns that can\nproduce\nan\nelectroma\ngnetic field\nat the site\nof your\ninjection.","7714":"10\/30\/22, 9:32 AM Selected Adverse Events Reported after COVID-19 Vaccination | CDC\nEspa\u00f1ol | Other Languages\nSelected Adverse Events Reported after COVID-19\nVaccination\nSafety of COVID-19 Vaccines\nSome people have no side effects. Many people have reported side effects, such as headache, fatigue, and soreness at\nthe injection site, that are generally mild to moderate and go away within a few days. What You Need to Know\nCOVID-19 vaccines are safe and effective and severe reactions after vaccination are rare. CDC recommends everyone ages 5 years and older get vaccinated as soon as possible to protect against COVID-19 and\nits potentially severe complications.","6197":"Active\nmonitoring includes reviewing data and medical records and evaluating the relationship to COVID-19 vaccination. Information about CDC\u2019s ongoing study of myocarditis after COVID-19 vaccination can be found here: Investigating Long-\nTerm Effects of Myocarditis | CDC\n\u2022\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nSeek medical care if you or your child have any of the specific or general symptoms of myocarditis or pericarditis\nespecially if it\u2019s within a week after COVID-19 vaccination. Healthcare Providers: For additional recommendations and clinical guidance, visit Clinical Considerations: Myocarditis after\nmRNA COVID-19 Vaccines. Should I Still Get Myself or My Child Vaccinated? 10\/30\/22, 9:31 AM Myocarditis and Pericarditis After mRNA COVID-19 Vaccination | CDC\nYes.","7397":"Categories of noncitizen nonimmigrants that meet the criteria for an exception under the Proclamation and CDC\u2019s Amended\nOrder include:\nPersons on diplomatic or official foreign government travel\nChildren under 18 years of age\nPersons with documented medical contraindications to receiving a COVID-19 vaccine\nParticipants in certain COVID-19 vaccine trials\nPersons issued a humanitarian or emergency exception\nPersons with valid visas [excluding B-1 (business) or B-2 (tourism) visas] who are citizens of a foreign country with limited\nCOVID-19 vaccine availability (See list for updates effective June 28, 2022)\nMembers of the U.S. Armed Forces or their spouses or children (under 18 years of age)\nSea crew members traveling with to a C-1 and D nonimmigrant visa\nPersons whose entry would be in the national interest, as determined by the Secretary of State, Secretary of\nTransportation, or Secretary of Homeland Security (or their designees)\nIf you travel by air to the United States under one of these exceptions, you will be required to attest that you are excepted\nfrom the requirement to present Proof of Being Fully Vaccinated Against COVID-19 based on one of the exceptions listed\nabove.","4255":"10\/30\/22, 9:30 AM Getting Your COVID-19 Vaccine | CDC\nEspa\u00f1ol | Other Languages\nGetting Your COVID-19 Vaccine\nEveryone 6 Months and Older Should Get a COVID-19 Vaccine\nCOVID-19 vaccination has many benefits and is an important tool to help protect you from severe illness, hospitalization, and\ndeath. Getting a COVID-19 vaccine after having COVID-19\nEven if you or your child have had COVID-19, you should still get yourself or your child vaccinated. Getting a COVID-19 vaccine after having COVID-19 provides added protection against the virus that causes COVID-19.","6419":"Since your immune response to COVID-19 vaccination may not be as strong as in people\nwho are not immunocompromised, you have different recommendations for COVID-19 vaccines, including boosters. Learn\nmore about COVID-19 vaccine recommendations for people who are moderately or severely immunocompromised. COVID-19 pre-exposure prophylaxis\nTake extra precautions\nEven if you stay up to date on COVID-19 vaccines and receive Evusheld , taking multiple prevention steps can provide\nadditional layers of protection from COVID-19. Wear a well-fitting, high quality mask or respirator. Properly fitting respirators provide the highest level of protection. Avoid poorly ventilated or crowded indoor settings.","749":"July 23, 2021: The number of doses administered by a national pharmacy provider decreased by 14,187 for the\nFederal Long-Term Care program. July 20, 2021: A federal entity made updates to data previously submitted to CDC that resulted in a decrease of\n159,648 doses administered. July 14, 2021: Utah made updates to data previously submitted to CDC that resulted in an increase of 6,028 doses\nadministered. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nLast Updated Oct. 28, 2022","9651":"\u2022 A second primary dose of the COVID-19 vaccine by Pfizer-BioNTech (30 \u03bcg in 0.3 mL) may be delayed\nby 3 months from symptom onset or positive test (if infection was asymptomatic) in persons ages 12\nyears and older who recently had SARS-CoV-2 infection\fPfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\n\u2022 A primary dose, including as an additional primary dose for those with certain immunocompromising\nconditions, of the Pfizer-BioNTech vaccine (30 \u03bcg in 0.3 mL) should be administered intramuscularly to\npersons ages 12 years and older at least 28 days after primary vaccination with certain non-FDA\nauthorized or approved COVID-19 vaccines.","7115":"Call your healthcare professional if you have any concerns about your pregnancy, if you get sick, or if you think that you\nmay have COVID-19. Do not delay getting emergency care because of worries about getting COVID-19. Emergency departments have steps in\nplace to protect you from getting COVID-19 if you need medical care. If you need emergency help, call 911 right away. If someone else is driving you to the emergency department, call\nthe emergency facility while you are on the way. If you must drive yourself, call before you start driving.","4474":"If you have symptoms, get tested\nand stay home until you have your results. If you have tested positive (even without symptoms), follow CDC\u2019s\u202fisolation\nrecommendations. These recommendations include staying home and away from others for at least 5 days (possibly\nmore,\u202fdepending on how the virus affects you) and wearing a high-quality mask when indoors around others for a period\nof time. 10\/30\/22, 9:39 AM How to Protect Yourself and Others | CDC\nSeeking Treatment If You Have COVID-19 and Are at High Risk of Getting Very Sick\nEffective treatments are now widely\navailable and free, and you may be\neligible.","7883":"State of Vaccine Confidence\nInsights Report\nDate Range: May 3 \u2013 May 31, 2022\nSummary\nMajor themes identified from social media, news, and other sources that may impact\nvaccine confidence:\nConsumers continue to express their concerns about actual and potential COVID-19 vaccine\nside effects. Continuing and evolving themes that may impact vaccine confidence:\n\u0083 Consumers continue to express their lack of concern about COVID-19 despite rising cases\nand over 1 million dead Americans. \u0083 Parents continue to express concern and hesitation regarding COVID-19 vaccination for\nchildren. Emerging Misinformation Theme Affecting Vaccine Confidence:\n\u0083 Consumers have questions about the relationship between COVID-19 vaccines and\nmonkeypox. Ways public health and partners can take action.","9121":"What are other ways I can reduce risk in travel and transportation settings? \uf1aa\nDoes CDC recommend masks on school buses? \uf1aa\f10\/30\/22, 9:43 AM Wearing Masks in Travel and Public Transportation Settings | CDC\nK-12 schools and early education settings should follow guidance for schools according to the COVID-19 Community\nLevel in their area with respect to mask wearing on buses or vans. Does CDC recommend masks on school buses? \uf1aa\nOperators of Conveyances and Transportation Hubs\nOperators of conveyances and transportation hubs can take steps to help keep travel and public transportation safer for\neveryone.","1392":"The monovalent Novavax COVID-19 vaccine is authorized for a booster dose in limited situations. People ages 18 years\nand older who completed primary vaccination using any COVID-19 vaccine and have not received any previous booster\ndose(s) (including any previous mRNA monovalent or bivalent booster dose[s]) may receive a monovalent Novavax\nbooster dose at least 6 months after completion of the primary series if they are unable to receive an mRNA vaccine (i.e.,\nmRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive\na booster dose.","2933":"Children age 5 years: A 2-dose primary series and 1 bivalent Pfizer-BioNTech booster dose is recommended. The primary\nseries doses are separated by 4\u20138 weeks and the bivalent booster dose is administered at least 2 months after\ncompletion of the primary series. Currently, only the bivalent Pfizer-BioNTech booster dose is authorized for children age\n5 years who receive a Moderna primary series. Children ages 6\u201311 years: A 2-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is\nrecommended.","5705":"Moderna COVID-19 Vaccine EUI Recipient Fact Sheet, ver 9\/02\/2022\nEmergency Use Instructions (EUI) Fact Sheet for Recipients and Caregivers:\nModerna COVID-19 Vaccine for Primary and\/or Additional Doses\nThis Fact Sheet describes Emergency Use Instructions (EUI) that have been issued by the Centers for\nDisease Control and Prevention (CDC) to provide information about the primary and additional doses of the\nCOVID-19 vaccine by Moderna that go beyond its FDA-approved labeling.","2037":"COVID-19 vaccine safety in children aged 5\u201311 Years \u2014 United States, November 3\u2013December 19, 2021\nEvaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age\nAdverse events among children ages 5\u201311 years after COVID-19 vaccination: Updates from v-safe and the Vaccine\nAdverse Event Reporting System (VAERS)\nThe Advisory Committee on Immunization Practices\u2019 interim recommendation for use of Pfizer-BioNTech COVID-19\nvaccine in children aged 5\u201311 years \u2014 United States, November 2021\nChildren ages 5 through 11 years\n\uf1aa\n\u2022\n\u2022 \uf209\n\u2022\n\uf20c\n\u2022\nSafety monitoring of COVID-19 vaccine booster doses among persons aged 12\u201317 years \u2014 United States, December\nChildren ages 12 through 17 years\n\uf1aa\n\u2022\f10\/30\/22, 9:31 AM COVID-19 Vaccine Safety in Children and Teens | CDC\nSafety monitoring in the Vaccine Adverse Event Reporting System (VAERS)\nMyocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021\nCOVID-19 vaccine safety in adolescents aged 12\u201317 years \u2014 United States, December 14, 2020\u2013July 16, 2021\nUse of Pfizer-BioNTech COVID-19 vaccine in persons aged \u226516 years: Recommendations of the Advisory Committee\non Immunization Practices \u2014 United States, September 2021\nUse of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: Update from the Advisory\nCommittee on Immunization Practices \u2014 United States, June 2021\nThe Advisory Committee on Immunization Practices\u2019 interim recommendation for use of Pfizer-BioNTech COVID-19\nvaccine in adolescents aged 12\u201315 Years \u2014 United States, May 2021\n\u2022 \uf209\n\u2022\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\nFor a complete list of research, visit Vaccine Safety Publications.","4726":"People who initiated vaccination outside of the United States are\nconsidered to be up to date with their COVID-19 vaccines when they have completed the recommended actions described\nbelow. Age-appropriate Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccine products can be used. For additional\nguidance on primary and booster vaccination, see guidance for people who are not moderately or severely\nimmunocompromised and guidance for people who are moderately or severely immunocompromised. Table B. People who received COVID-19 vaccine outside the United States\nTable B.1. Received a COVID-19 vaccine that is FDA-approved or FDA-authorized\nVaccination history Recommended actions\nReceived all recommended primary dose(s) Do not repeat primary series.","6891":"The COVID-19 vaccine by Moderna can also be used under EUI for similar uses as an alternative mRNA\nCOVID-19 vaccine (see the Moderna EUI Fact Sheet for Recipients), and the same or similar\nrecommendations in this EUI also apply to the use of the COVID-19 vaccine by Moderna under EUI. What is COVID-19? Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a coronavirus called SARS-CoV-2. It\nis predominantly a respiratory illness that can affect other organs. People with SARS-CoV-2 infection have\nreported a wide range of symptoms, from no symptoms to severe illness leading to death.","8178":"COVID-19 vaccine recommendations are based on three things:\n1. Your age\n2. The vaccine you first received, and\n3. The length of time since your last dose\nPeople who are moderately or severely immunocompromised have different recommendations for COVID-19 vaccines. You are still up to date if you receive all COVID-19 vaccine doses recommended for you and then become ill with COVID-19. You do not need to be immediately revaccinated or receive an additional booster. Boosters are an important part of protecting yourself from getting seriously ill or dying from\nCOVID-19. They are recommended for most people.","6351":"Focus on talking to your provider as this can be the most valuable part of the visit. If your provider still needs any of your\npast medical records, ask to sign required forms to give your permission to have these records sent. Ask & Answer Questions\n\u2022\n\u2022\f10\/30\/22, 9:42 AM Patient Tips: Healthcare Provider Appointments for Post-COVID Conditions | CDC\nAsk questions, starting with the most important ones. Don\u2019t hesitate to ask your healthcare provider to clarify the\nanswers if they are not clear to you.","9831":"Consequently, the benefit\/risk balance for the use of the COVID-19 vaccine by Pfizer-BioNTech for booster dose use is\nexpected to be less favorable compared to the available alternative bivalent booster vaccines. Accordingly, these EUI are\nbeing revised to no longer provide for the use of the monovalent COVID-19 vaccine by Pfizer-BioNTech for certain booster\ndose uses. Refer to the CDC\u2019s Interim Clinical Considerations for Use of COVID-19 Vaccines for additional information. Available Alternatives\nCurrently, the Pfizer-BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine are the only FDA-approved\nvaccines for which EUI provide for primary, additional, and\/or booster dose administration.","8067":"In addition, CDC is communicating with key medical groups and continues to provide updated reporting and\nlaboratory guidance for clinicians who may identify hepatitis of unknown cause in children.126\n\u0083 When will vaccines be available for children ages 5 years and younger?d\n\u0082 As of June 18, 2022, everyone ages 6 months and older is recommended to get a Moderna or Pfizer-BioNTech COVID-19\nIdentified misinformation themes that may impact vaccine confidence\n\u0083 Some social media users believe authorizing vaccines in children is only a ploy for pharmaceutical companies to make\n\u0083 Some social media users claim that COVID-19 cases in children are always mild.129,130,131 w\nWays public health and partners can take action to improve vaccine confidence\n\u0083 Encourage primary care providers and other medical professionals who care for children to explain the benefits of COVID-19\nvaccination to parents and guardians.","5650":"\u2022\n-\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nNIOSH-Approved Respirators\nNIOSH approves many types of filtering facepiece respirators. The most widely\nand R100) offer the same or better protection as an N95 respirator. Lists of\nrespirators that are NIOSH-approved can be found on the NIOSH-Approved\nParticulate Filtering Facepiece Respirators webpage. CDC recommends that specially labeled \u201csurgical\u201d N95 respirators \u2014 a special\nsubtype of N95 respirators that provide additional protection against hazards\npresent during medical procedures, such as blood splatter \u2014 should be prioritized\nfor use by healthcare personnel. Employers who want to distribute N95 respirators to employees shall follow an\nOccupational Safety and Health (OSHA) respiratory protection program .","5908":"\u2022 An additional dose with the COVID-19 vaccine by Moderna (100 \u03bcg in 0.5 mL from red-capped\nmultidose vial) should be administered intramuscularly for persons ages 18 years and older with\ncertain immunocompromising conditions at least 28 days after a primary dose with the Janssen COVID-\n19 Vaccine (e.g., 1 primary dose of the Janssen COVID-19 Vaccine followed by an additional dose with\nan mRNA COVID-19 vaccine at least 28 days after the primary dose).","6965":"Similarly, for individuals who received the Janssen vaccine for primary\nvaccination, an additional primary or second booster dose of the COVID-19 vaccine by Pfizer-BioNTech\ncould improve protection against COVID-19. The COVID-19 vaccine by Pfizer-BioNTech may not protect\neveryone. What are the Risks and Benefits of the COVID-19 vaccine by Pfizer-BioNTech? The FDA approved the COVID-19 vaccine by Pfizer-BioNTech to prevent COVID-19 based on safety and\nefficacy data available from clinical trials.","2227":"10\/30\/22, 9:33 AM COVID-19 Vaccines Work | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccines Work\nCDC is reviewing this page to align with updated guidance. All currently approved or authorized COVID-19 vaccines are safe and effective and reduce your risk of severe illness. Vaccination can reduce the spread of disease, which helps protect those who get vaccinated and the people around them. COVID-19 Vaccines Protect Against COVID-19 Infections and Hospitalizations\nVaccines reduce the risk of COVID-19, including the risk of severe illness and death among people who are fully vaccinated.","8502":"What should my\ntravel companions do? \uf1aa\nHow can I protect myself from COVID-19 when using different types of transportation? \uf1aa\f10\/30\/22, 9:43 AM Travel: Frequently Asked Questions and Answers | CDC\nAir Travel\nFor additional FAQs on the vaccine requirement before air travel to the U.S., visit Requirement for Proof of COVID-19\nVaccination for Air Passengers. Maintaining distance between yourself and others is often difficult on public transportation. People may not be able to\navoid crowding on airplanes, trains, or buses. Protect yourself from COVID-19 by staying up to date with your COVID-19 vaccines and by wearing a high-quality mask on\npublic transportation.","8232":"Anyone wanting protection due to high levels of community transmission, people ages 65 years and older, or people\nwho are more likely to get very sick from COVID-19, should get the second dose of:\nPfizer-BioNTech COVID-19 vaccine 3 weeks (or 21 days) after the first dose. Moderna COVID-19 vaccine 4 weeks (or 28 days) after the first dose. Novavax COVID-19 vaccine 3 weeks (or 21 days) after the first dose. Staying up to date: If you have completed your primary series, but are not yet eligible for a booster, you are also considered\nup to date.","6464":"Isolate until it\u2019s safe to be around others. CDC recommends that you isolate for at least 10 and up to 20 days. Check with\nyour healthcare provider to learn when you can be around others. Monitor your symptoms. Call your healthcare provider if you develop symptoms that are severe or concerning to you. If\nyou notice emergency warning signs, call 911 or call ahead to your local emergency facility. If you test positive for COVID-19, oral antiviral and monoclonal antibody treatments are available for people who are more\nlikely to get very sick. Learn more about COVID-19 treatment.","3546":"As people receiving doses are attributed to the jurisdiction in which they reside, the reporting\nmethod might change between doses if they move to a different jurisdiction. Also, CDC may lack information about a person\u2019s\nresidence. These issues can cause CDC\u2019s dose number estimates to differ from those reported by jurisdictions and federal\nentities. CDC has capped estimates of vaccination coverage shown on COVID Data Tracker at 95%. This cap helps address potential\nover-estimates of vaccination coverage due to first, second, and booster doses that were not linked. Other reasons for\noverestimates include census denominator data not including part-time residents or potential data reporting errors.","6275":"All COVID-\nvaccines\nare free\nfrom\nmetals. 10\/30\/22, 9:34 AM Myths and Facts about COVID-19 Vaccines | CDC\nLearn\nmore\nabout\nthe ingredi\nents in the\nvaccinatio\nns\nauthorized\nfor use in\nthe United\nStates. MYTH: COVID-19 vaccines authorized for use in the United States shed or release their\ncomponents. FACT: Vaccine shedding is the release or discharge of any of the vaccine components in or outside of the body\nand can only occur when a vaccine contains a live weakened version of the virus. None of the vaccines authorized for use in the U.S. contain a live virus. mRNA and viral vector vaccines are the two types of currently\nauthorized COVID-19 vaccines available.","4596":"Keep the exhaust fans turned on for an hour after your visitors leave to help remove virus particles that might still\nbe in the air. [PNG - 225 KB]\nWith good ventilation, the concentration of virus particles in the air will be lower and they will leave your home\nfaster than with poor ventilation. \uf20a\n\u2022\n\u2022\nUse fans to improve air flow\nPlace a fan as close as possible to an open window blowing outside. This helps get rid of virus particles in your\nhome by blowing air outside. Even without an open window, fans can improve air flow. Point fans away from people.","9857":"Fact Sheet for Healthcare Providers Administering Vaccine. Emergency Use Authorization of the Pfizer-\nBioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019, Revised January 3, 2022\nGruber, W. BNT162b2 [COMIRNATY\u00ae (COVID-19 Vaccine, mRNA)] Booster (Third) Dose. Advisory Committee\non Immunization Practices meeting, September 22, 2021:\nGrunau B et al. A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute\nRespiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval. Clin Infect Dis. 2021 Nov 30:\nJoint Committee on Vaccination and Immunisation (JCVI). JCVI statement regarding a COVID-19 booster\nvaccine programme for winter 2021 to 2022. London (United Kingdom): Department of Health & Social Care;\nprogramme-for-winter-2021-to-2022.","5221":"This information is intended for a general audience. Healthcare professionals should see Ending Isolation and Precautions for\nPeople with COVID-19. This CDC guidance is meant to supplement\u2014not replace\u2014any federal, state, local, territorial, or tribal\nhealth and safety laws, rules, and regulations. Regardless of vaccination status, you should isolate from others when you have COVID-19. You should also isolate if you are sick and suspect that you have COVID-19 but do not yet have test results. If your results are\npositive, follow the full isolation recommendations below. If your results are negative, you can end your isolation.","5685":"If your child has a hard time breathing, gets dizzy, or has other symptoms while you are trying to get the mask to fit\nbetter or when using an ASTM F3502 mask or a respirator, choose a regular cloth or disposable mask. They should\ncontinue to follow CDC guidance to protect themselves and others. Consult your healthcare provider if these symptoms\ndo not resolve.","4061":"However, public health\nexperts are seeing reduced protection over time against mild and moderate disease, especially among certain\npopulations. If we need a booster, are the vaccines working? \uf1aa\n\uf20c\nYes. COVID-19 boosters are the same ingredients (formulation) as the current COVID-19 vaccines. Do boosters use the same ingredients as existing vaccines? \uf1aa\f10\/30\/22, 9:18 AM Frequently Asked Questions about COVID-19 Vaccination | CDC\nAdults and children may have some side effects from a COVID-19 vaccine, including pain, redness or swelling at the\ninjection site, tiredness, headache, muscle pain, chills, fever, and nausea. Serious side effects are rare, but may occur.","5435":"Post-COVID conditions are found more often in people who had severe COVID-19 illness, but anyone who has\nbeen infected with the virus that causes COVID-19 can experience post-COVID conditions, even people who had\nmild illness or no symptoms from COVID-19. People who are not vaccinated against COVID-19 and become infected might also be at higher risk of developing\npost-COVID conditions compared to people who were vaccinated and had breakthrough infections. While most people with post-COVID conditions have evidence of infection or COVID-19 illness, in some cases, a\nperson with post-COVID conditions may not have tested positive for the virus or known they were infected.","74":"You had an immediate (within 4 hours) allergic reaction that was not severe from a previous dose of that type of\nCOVID-19 vaccine. This vaccination should only be done in a health clinic, medical facility, or doctor\u2019s office. CDC Is Monitoring Reports of Severe Allergic Reactions\nIf someone has a severe allergic reaction after getting vaccinated, their vaccination provider will send a report to the Vaccine\nAdverse Event Reporting System (VAERS). VAERS is a national system that collects reports from healthcare professionals,\nvaccine manufacturers, and the public about adverse events that happen after vaccination.","7760":"Myocarditis and pericarditis after COVID-19 vaccination are rare. Myocarditis is inflammation of the heart muscle,\nand pericarditis is inflammation of the outer lining of the heart. Most patients with myocarditis or pericarditis after\nCOVID-19 vaccination responded well to medicine and rest and felt better quickly. Most cases have been reported\nafter receiving Pfizer-BioNTech or Moderna (mRNA COVID-19 vaccines), particularly in male adolescents and young\nadults. A review of vaccine safety data in VAERS from December 2020\u2013August 2021 found a small but increased risk of\nmyocarditis after mRNA COVID-19 vaccines.","449":"On May 27, 2021, the New Hampshire \u2018at least one dose\u2019 values posted to Tracker appeared lower than that reported the\nday prior (May 26, 2021). This correction is accurate and is due to New Hampshire and CDC collaboratively correcting\ndata transmission errors. On May 25, 2021, the 7,836,063 administered doses reported for Long-Term Care Facilities (LTCF), were fewer by 4,105\nrecords compared to the 7,840,168 reported on May 24, 2021. This was due to an error in data processing that has now\nbeen corrected. The data for May 26, 2021 accurately reflect total LTCF doses.","4281":"Biologics or biologic response modifiers that treat autoimmune\u202fdiseases\nChemotherapy or other cancer treatment medications\nAntiviral medication\nAntibiotics\nStatins\nIf you regularly take over-the-counter medications, you should keep taking them before you get\nvaccinated. \uf1aa\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:30 AM Getting Your COVID-19 Vaccine | CDC\nBlood pressure medications\/antihypertensives (amlodipine, lisinopril, etc.) Diuretics\nThyroid medications\nAntidepressants\nMetformin\nDiabetic medications\nInsulin\nSteroids (prednisone, etc.) This is not a complete list. These are some examples of common medications. If you have questions about medications that you are taking, talk to your healthcare or vaccination provider.","3551":"Previously, CDC had capped estimates of vaccination coverage at 99.9%. CDC changed the cap to 95% on December 9, 2021,\nto account for differences in the accuracy of vaccination coverage estimates between different jurisdictions. CDC encourages people to bring their CDC COVID-19 Vaccination record card with them to their appointment for another\nCOVID-19 vaccine dose because having the card will help ensure the doses are linked.","10057":"For guidance on respective record\nreview, scheduling and administration of Janssen vaccine see Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendix A\fSummary Document for\nInterim Clinical Considerations\nfor Use of COVID-19 Vaccines Currently Authorized or Approved in the United States\nAll currently authorized or approved COVID-19 vaccines\nCOVID-19 vaccination schedule\n\u0083 See the Interim COVID-19 Immunization Schedule for Ages 6 Months or Older at https:\/\/www.cdc.gov\/vaccines\/covid-19\/downloads\/COVID-19-\nPre-vaccination counseling\nPrior to vaccination:\n\u0083 Provide the vaccine-specific Fact Sheet for Recipients and Caregivers Pfizer-BioNTech (https:\/\/www.fda.gov\/media\/144413\/download), Moderna\n(https:\/\/www.fda.gov\/media\/144637\/download), Janssen (https:\/\/www.fda.gov\/media\/146304\/download), Novavax (www.novavaxcovidvaccine.com)\n\u0083 Screen for contraindications and precautions. CDC's Prevaccination Screening Form and Guidance document can be found at www.cdc.gov\/\nvaccines\/covid-19\/info-by-product\/index.html.","3641":"10\/30\/22, 9:42 AM Domestic Travel During COVID-19 | CDC\nCOVID-19 County Check\nFind community levels and prevention steps by county. Data updated weekly. Select a Location (all fields required)\nState County Go\nView CDC\u2019s full list of individual and community recommendations for each level. \uf3c0 Testing\nRECOMMENDED\nConsider getting tested with a viral test as close to the time of departure as possible (no more than 3\ndays) before travel. Make sure you know your test results before travel. Don\u2019t travel if your test result is positive. Find a COVID-19 testing location near you or use a self-test.","6949":"Limited data are available on use of the COVID-19 vaccine by Pfizer-BioNTech as an additional primary dose\nin people who completed their primary vaccination with a non-FDA authorized or approved COVID-19\nvaccine, or as an additional primary dose for individuals who received Janssen COVID-19 Vaccine for\nprimary vaccination. Side effects of the COVID-19 vaccine by Pfizer-BioNTech include injection site pain,\nfatigue, headache, muscle pain, chills, joint pain, fever, injection site swelling, injection site redness,\nnausea, malaise, swollen lymph nodes (lymphadenopathy), decreased appetite, rash, arm pain, diarrhea,\nand vomiting.","368":"On November 14, 2021, a temporary network outage at CDC occurring Friday, November 12, 2021 resulted in vaccine\nadministration files from 13 partner entities not being properly processed and resulted in 281,912 records being\nomitted. The omitted 281,912 records are included in the data for Sunday, November 14, 2021. On November 5, 2021, population estimates for all territories and protectorates (excluding Puerto Rico) have been\nupdated using the 2020 US Census International Data Base. On November 2, 2021, CDC recommended use of the Pfizer-BioNTech Vaccine for children ages 5 through 11 for the\npediatric population ages 5 to 11.","4658":"People who are moderately or severely immunocompromised\nAdults ages 18 years and older are recommended to receive 1 primary dose, a second (additional) dose using a\nmonovalent mRNA COVID-19 vaccine, and 1 booster dose; a bivalent mRNA booster dose is recommended. The primary\nseries dose and the additional dose are separated by at least 4 weeks. The booster dose is administered at least 2\nmonths after the additional dose. Safety considerations\nAppendices\nAppendix A.","9178":"If someone is showing any of these signs, seek\nemergency medical care immediately:\nTrouble breathing\nPersistent pain or pressure in the chest\nNew confusion\nInability to wake or stay awake\nPale, gray, or blue-colored skin, lips, or nail beds, depending on skin tone\n*This list is not all possible symptoms. Please call your medical provider for any other symptoms that are\nsevere or concerning to you. Call 911 or call ahead to your local emergency facility: Notify the operator that you are seeking care for\nsomeone who has or may have COVID-19. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\uf33f Call ahead before visiting your doctor\nCall ahead.","969":"If you test too\nearly, you may be more likely to get an inaccurate result. If you are in certain high-risk settings, you may need to test as part of\na screening testing program. Consider testing before contact with someone at high risk for severe\nCOVID-19, especially if you are in an area with a medium or high COVID-19 Community Level. For guidance on using tests to determine which mitigations are recommended as you recover from COVID-19, go to Isolation\nand Precautions for People with COVID-19.","9148":"\uf31a Stay home for at least 5 days\nStay home for 5 days and isolate from others in your home. Most people with COVID-19 have mild\nillness and can recover at home without medical care. Do not leave your home, except to get medical\ncare. Do not visit public areas and do not go to places where you are unable to wear a mask\nTake care of yourself. Get rest and stay hydrated. Take over-the-counter medicines, such as\nacetaminophen, to help you feel better. Stay in touch with your doctor. Call before you get medical care.","5272":"This may mean you need to continue wearing a mask and testing beyond day 10. As noted in the Food and Drug Administration labeling for authorized over-the-counter antigen tests, negative test results\ndo not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management\ndecisions, including infection control decisions. \uf309 Removing Your Mask\n\u2022\n\u2022\nAfter you have ended isolation, if your COVID-19 symptoms recur or worsen, restart your isolation at day 0. Talk to a\nhealthcare provider if you have questions about your symptoms or when to end isolation. Last Updated Aug. 11, 2022","4080":"Use CDC\u2019s COVID-19 Booster Tool to learn if and when you can get boosters to stay up to date with your COVID-19\nvaccines. If I have received a J&J\/Janssen COVID-19 vaccine and a J&J\/Janssen COVID-19 booster, are\nadditional boosters recommended? \uf1aa\n\u2022\nGetting Your Vaccine\nAn employer may require that their workers be vaccinated. Check directly with your employer to see if they have any\nvaccination requirements or rules that apply to you. Am I required to get vaccinated for work? \uf1aa\nThe number of vaccine doses you need to complete your primary series depends on which vaccine you receive.","7388":"\uf209\n\uf209\nAircraft Operators\/ Airlines\/ Crew\nFor additional information, resources, and FAQs please visit the following webpages:\f10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nNoncitizens, Nonimmigrants (Covered Individuals)\nNoncitizens who are nonimmigrants and seeking to enter the United States by air are required to show proof of being fully\nvaccinated against COVID-19 before boarding a flight to the United States from a foreign country. If you are not fully vaccinated against COVID-19, you will NOT be allowed to board a flight to the United States, unless you\nmeet the criteria for an exception under the Proclamation and CDC\u2019s Amended Order.","4908":"Healthcare professionals and health\ndepartments may also request a consultation from the Clinical Immunization Safety Assessment COVIDvax project. In patients with these\nprecautions, vaccination should only be undertaken in an appropriate setting under the supervision of a healthcare professional experienced in\nthe management of severe allergic reactions.","658":"February 18, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 20,754\ndoses administered. February 18, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n12,473 doses administered. February 17, 2022: A federal entity made updates to data previously submitted to CDC that resulted in an increase of\n4,251 doses administered. February 11, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 58,355\ndoses administered.","1284":"Doses administered at any time after the recommended interval are valid. For more information, see timing, spacing, interchangeability, and coadministration of COVID-19 vaccines. \uf209\nIn accordance with general best practices for immunizations, routine administration of all age-appropriate doses of\nvaccines simultaneously is recommended for children, adolescents, and adults for whom no specific contraindications\nexist at the time of the healthcare visit. This includes simultaneous administration of COVID-19 vaccine and other\nvaccines. However, there are additional considerations for Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines if\nadministering an orthopoxvirus (monkeypox) vaccine. For more information, see Coadministration of COVID-19 vaccines with other vaccines.","8091":"However, monkeypox can spread to anyone through close, personal, often skin-to-skin contact. Anyone who has been in close contact with someone who has monkeypox is at risk.137\n\u0083 How do I know if I have monkeypox?d\n\u0082 People with monkeypox can get a rash that may be located on or near the genitals (penis, testicles, labia, and vagina) or\nanus (butthole) and could be on other areas like the hands, feet, chest, face, or mouth. \u008f The rash will go through several stages, including scabs, before healing. \u008f The rash can initially look like pimples or blisters and may be painful or itchy.","3308":"In age groups where product comparisons can be made (i.e., 18\u201339 years), some evidence suggests that the risk of\nmyocarditis and pericarditis may be higher following vaccination with Moderna COVID-19 Vaccine relative to Pfizer-BioNTech\nCOVID-19 Vaccine; however, findings are not consistent in all U.S. monitoring systems. In post-authorization surveillance , cases of myocarditis and pericarditis among children ages 5\u201311 years after Pfizer-\nBioNTech COVID-19 vaccination have been rarely reported, primarily in males and after dose 2; the reporting rate of\nmyocarditis in VAERS following dose 2 of Pfizer-BioNTech marginally exceeded the background incidence rate for male\nchildren in this age group.","6775":"WHAT ARE THE INGREDIENTS IN THESE VACCINES? The Pfizer-BioNTech COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent include the following ingredients: mRNA, lipids (((4-\nand cholesterol), tromethamine, tromethamine hydrochloride, sucrose, and sodium\nchloride. HAVE THESE VACCINES BEEN USED BEFORE? In a clinical trial, approximately 3,100 individuals 5 through 11 years of age have\nreceived at least 1 dose of the Pfizer-BioNTech COVID-19 Vaccine. Millions of\nindividuals have received the Pfizer-BioNTech COVID-19 Vaccine under EUA since\nDecember 11, 2020.","5001":"Added considerations for an 8-week interval between the first and second doses of a primary mRNA vaccine schedule\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nUpdated guidance for moderately or severely immunocompromised people\nClarification of existing recommendation to receive a 3-dose mRNA vaccine primary series followed by a booster\ndose for a total of 4 doses\nNew guidance to shorten the interval between completion of the mRNA vaccine primary series and the booster\ndose to at least 3 months (instead of 5 months)\nNew guidance for those who received the Janssen COVID-19 Vaccine primary series to receive an additional dose\nand a booster dose, for a total of 3 doses to be up to date\nUpdated guidance that it is no longer necessary to delay COVID-19 vaccination following receipt of monoclonal\nantibodies or convalescent plasma\nUpdated guidance on receiving a booster dose if vaccinated outside the United States\nUpdated contraindication and precaution section to include history of myocarditis or pericarditis after an mRNA\nCOVID-19 vaccine as a precaution\nReorganized and condensed multiple sections\nUpdated guidance for use of Pfizer-BioNTech COVID-19 Vaccine as a booster in people ages 12\u201317 years\nUpdated guidance for administration of a COVID-19 vaccine booster dose at least 5 months after completion of an\nmRNA vaccine (Pfizer-BioNTech or Moderna) primary series\nUpdated guidance for use of an additional primary dose for moderately or severely immunocompromised people ages\n5\u201311 years who received a Pfizer-BioNTech vaccine primary series\nUpdated recommendations for people who received COVID-19 vaccines outside the United States that are not FDA-\nauthorized or approved\nUpdated information about a second formulation of Pfizer-BioNTech COVID-19 Vaccine that is authorized for use in\npersons ages 12 years and older\nUpdated information on vaccinating people during quarantine after a known SARS-CoV-2 exposure or during COVID-\nUpdate to alert providers of possible false positive Rapid Plasma Reagin (RPR; non-treponemal) test results in some\npeople after COVID-19 vaccines\nUpdated information on vaccine administration errors and deviations\nUpdated guidance on use of Janssen (Johnson & Johnson) COVID-19 Vaccine\nUpdated recommendations for receipt of a COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 booster doses in recipients of mRNA COVID-19 vaccines\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nRecommendations and clinical guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children aged 5-11 years\nincluding updated section on Vaccination of children and adolescents\nUpdated guidance on COVID-19 vaccine dosing and schedule\nUpdated guidance for myocarditis and pericarditis after mRNA COVID-19 vaccination in new section on Considerations\nfor mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna\nNew guidance for people who received passive antibody products in section on COVID-19 vaccination and SARS-CoV-2\ninfection\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial in the United States\nUpdated guidance on Considerations for COVID-19 vaccination in moderately and severely immunocompromised\npeople\nUpdated guidance in section on Contraindications and precautions\nUpdated Table in Appendix A: Vaccine administration errors and deviations\nUpdated Appendix B: Triage of people with a history of allergies or allergic reactions\nUpdated Appendix C: Ingredients included in COVID-19 vaccines\nUpdated Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects\nfollowing COVID-19 vaccination\nUpdated guidance in section on Considerations for use of a COVID-19 booster dose.","3341":"Until additional safety data are available, experts advise that people who develop myocarditis or pericarditis after a dose of\nModerna, Novavax, or Pfizer-BioNTech COVID-19 vaccine generally should not receive a subsequent dose of any COVID-19\nvaccine. If, after a risk assessment, the decision is made to administer a subsequent COVID-19 vaccine dose, the person\nshould wait until at least after their episode of myocarditis or pericarditis has resolved (i.e., resolution of symptoms, no\nevidence of ongoing heart inflammation or sequelae as determined by patient\u2019s clinical team). For information on potential use of Janssen COVID-19 Vaccine, see Appendix A.","4420":"Select a Location (all fields required)\nState County Go\nPrevention Actions to Use at All COVID-19 Community Levels\nIn addition to basic health and hygiene practices, like handwashing, CDC recommends some prevention actions at all COVID-\n19 Community Levels, which include:\nStaying Up to Date with COVID-19 Vaccines\nImproving Ventilation\nGetting Tested for COVID-19 If Needed\nFollowing Recommendations for What to Do If You\nHave Been Exposed\n\u2022\n\u2022\n\u2022\n\u2022\nStaying Home If You Have Suspected or Confirmed\nSeeking Treatment If You Have COVID-19 and Are at\nHigh Risk of Getting Very Sick\nAvoiding Contact with People Who Have Suspected or\n\u2022\n\u2022\n\u2022\nStaying Up to Date with COVID-19 Vaccines\nCOVID-19 vaccines help your body develop protection from the virus that causes COVID-19.","5547":"10\/30\/22, 9:39 AM Masks and Respirators\nEspa\u00f1ol | Other Languages\nTypes of Masks and Respirators\nSummary of Recent Changes\nKey Messages:\nMasking is a critical public health tool for preventing spread of COVID-19, and it is important to remember that any mask\nis better than no mask. To protect yourself and others from COVID-19, CDC continues to recommend that you wear the most protective mask\nyou can that fits well and that you will wear consistently. Masks and respirators are effective at reducing transmission of SARS-CoV-2, the virus that causes COVID-19, when worn\nconsistently and correctly.","5506":"\u2022\n\u2022\n\u2022\n\u2022\nPreventing Long COVID\nResearch suggests that people who are vaccinated but experience a breakthrough infection are less likely to report post-\nCOVID conditions, compared to people who are unvaccinated. Learn more about protecting yourself and others from COVID-19. The best way to prevent post-COVID conditions is to protect yourself and others from becoming infected. For people who\nare eligible, getting vaccinated and staying up to date with vaccines against COVID-19 can help prevent COVID-19\ninfection and protect against severe illness.","4791":"To file an electronic report, please see the VAERS website . Determine how the error occurred and implement strategies to prevent it from happening again. A discussion on\nstrategies to prevent errors can be found in the \u201cVaccine Administration\u201d chapter of Epidemiology and Prevention of\nVaccine-Preventable Diseases (Pink Book). Additional resources can be found on CDC\u2019s vaccine administration web page,\nincluding a job aid for preventing errors. Follow the revaccination guidance in the table below, using an age-appropriate COVID-19 vaccine product. Then continue\nwith the recommended schedule of subsequent dose(s) unless otherwise noted (see footnotes to this Appendix).","6931":"You should not get the vaccine if you:\n\u2022 Had a severe allergic reaction after a previous dose of the COVID-19 vaccine by Pfizer-BioNTech\n\u2022 Had a severe allergic reaction to any ingredient of the COVID-19 vaccine by Pfizer-BioNTech\nWhat should I mention to the vaccination provider before getting the COVID-19 vaccine by Pfizer-BioNTech? Tell your vaccination provider the name, number of doses, and date(s) of COVID-19 vaccine(s) you received\npreviously.","4207":"You may consider delaying your vaccine by 3 months from when your symptoms started or, if you had no symptoms,\nwhen you received a positive test. People who already had COVID-19 and do not get vaccinated after their recovery are more likely to get COVID-19\nagain than those who get vaccinated after their recovery. Learn more about the benefits of getting a COVID-19 vaccine. If I already had COVID-19 and recovered, do I still need to get a COVID-19 vaccine? \uf1aa\nCan I get vaccinated against COVID-19 while I am currently sick with COVID-19?","1833":"10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nVaccines & Immunizations\nVaccines & Immunizations\nCOVID-19 Vaccine Effectiveness Research\nClinical trials are conducted to determine vaccine efficacy before the U.S Food and Drug Administration (FDA) determines\nwhether to approve a vaccine. CDC and other partners assess COVID-19 vaccine effectiveness under real-world conditions\nafter the FDA approves a vaccine. This helps us understand if vaccines are performing as expected outside the more\ncontrolled setting of a clinical trial, which tests a vaccine before approval. Below you\u2019ll find descriptions of current and planned vaccine effectiveness evaluations CDC is conducting with partners.","2001":"New studies\nhave shown the rare risk of myocarditis and pericarditis associated with mRNA COVID-19 vaccination (Pfizer-BioNTech and\nModerna)\u2014mostly among males between the ages of 12 and 39 years\u2014may be further reduced with a longer time between\nthe first and second dose. In children ages 5 through 11 years, there were 20 confirmed reports of myocarditis out of approximately 18.1 million\ndoses given of the Pfizer-BioNTech COVID-19 vaccine between November 2021 and April 2022\nWhat You Need to Know\nCDC recommends COVID-19 vaccines for everyone ages 6 months and older, and COVID-19 boosters for everyone\nages 5 years and older, if eligible.","9435":"You should seek medical attention right away if you or your child have any of\nthe following symptoms after receiving the vaccine:\n\u2022 Chest pain\n\u2022 Shortness of breath\n\u2022 Feelings of having a fast-beating, fluttering, or pounding heart\nSide effects that have been reported in clinical trials with these vaccines include:\n\u2022 Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm\nof the injection, swelling (hardness), and redness\n\u2022 General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea and\nvomiting, fever, and rash\nSide effects that have been reported during post-authorization use include:\n\u2022 Severe allergic reactions\n\u2022 Myocarditis (inflammation of the heart muscle)\n\u2022 Pericarditis (inflammation of the lining outside the heart)\n\u2022 Fainting in association with injection of the vaccine\nThese may not be all the possible side effects of these vaccines.","7064":"Certain factors can increase risk\nOther factors can further increase the risk for getting very sick from COVID-19 during or recently after pregnancy, such as:\nHaving certain underlying medical conditions\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:39 AM Pregnant and Recently Pregnant People | CDC\nBeing older than 25 years\nLiving or working in a community with high numbers of COVID-19 cases\nLiving or working in a community with low levels of COVID-19 vaccination\nWorking in places where it is difficult or not possible to avoid contact with people who might be sick with COVID-19\nBeing part of some racial and ethnic minority groups, which have been put at increased risk of getting sick from COVID-\n19 because of the health inequities they face\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nEffect on Pregnancy Outcomes\nPeople with COVID-19 during pregnancy are more likely to experience complications that can affect their pregnancy and\ndeveloping baby compared to people without COVID-19 during pregnancy.","1206":"10\/30\/22, 9:34 AM COVID-19 Vaccination Data in the United States | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccination Data in the United States\nVaccinations in the United States\nCDC reports COVID-19 vaccination data online on COVID Data Tracker and in\nvaccination datasets. Timely and accurate reporting from jurisdictions drives\nthe information reported by CDC. All reported numbers may change over time\nas updated data are continuously reported to CDC.","933":"Fever (a temperature of 100.4 or higher is considered an emergency)\nLethargy (being overly tired or inactive)\nRunny nose\nCough\nVomiting\nDiarrhea\n-\n\u2022\n\u2022\n-\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\n-\n\u2022\n-\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:41 AM Breastfeeding and Caring for Newborns if You Have COVID-19 | CDC\nPoor feeding\nIncreased work of breathing or shallow breathing\nSee CDC\u2019s webpage on Evaluation and Management Considerations for Neonates At Risk for COVID-19 for more information. Breastfeeding and COVID-19\nCurrent evidence suggests that breast milk is not likely to spread the virus to babies. COVID-19 vaccination is recommended for people who are pregnant, breastfeeding, trying to get pregnant now, or might\nbecome pregnant in the future.","4144":"\uf1aa\nThe COVID-19 vaccines for children have the same active ingredients as the vaccines given to adults. However, children\nreceive a smaller and more age-appropriate dose that is right for them. The smaller doses were rigorously tested and\nfound to create the needed immune response for each age group. Making it important for our child to get the vaccine\nmade for their age group. Are the COVID-19 vaccines for children the same ones that are given to adults? \uf1aa\nSafety\nAlthough COVID-19 vaccines were developed quickly, research and development on vaccines like these have been\nunderway for decades.","7668":"To view the current total number of COVID-19 vaccinations that have been administered in the United\nStates, please visit the CDC COVID Data Tracker. COVID-19 vaccines are safe and effective. COVID-19 vaccines were evaluated in tens of thousands of participants in clinical\ntrials. The vaccines met the Food and Drug Administration\u2019s (FDA\u2019s) rigorous scientific standards for safety, effectiveness, and\nmanufacturing quality needed to support emergency use authorization (EUA). Learn more about EUAs in this video. The Pfizer-BioNTech, Moderna, and Johnson & Johnson\/Janssen and Novavax COVID-19 vaccines will continue to undergo the\nmost intensive safety monitoring in US history.","7076":"If you have questions about getting vaccinated, talking with your healthcare professional\nmight help, but is not required. Getting vaccinated prevents severe illness, hospitalizations, and death. People who have not received a COVID-19 vaccine\nshould get vaccinated as soon as possible and continue masking. To maximize protection from variants and prevent possibly\nspreading the virus to others, people who are up to date with their COVID-19 vaccines should wear a mask indoors in public in\nareas with a high COVID-19 Community Level. With the emergence of variants, this is more urgent than ever.","5215":"10\/30\/22, 9:41 AM Isolation and Precautions for People with COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nIsolation and Precautions for People with COVID-19\nIf you have COVID-19, you can spread the virus to others. There are precautions you can take to prevent spreading it to\nothers: isolation, masking, and avoiding contact with people who are at high risk of getting very sick. Isolation is used to\nseparate people with confirmed or suspected COVID-19 from those without COVID-19. These recommendations do not change based on COVID-19 Community Levels. If you have COVID-19, also see additional\ninformation on treatments that may be available to you.","1177":"Reporting Conditions\nJurisdictions currently collect demographic data and report it to CDC. Not all states and territories report to CDC demographic\ndata on vaccine recipients; the laws in each state or territory dictate whether the state can collect or report demographic\ndata. Jurisdictional Reporting Conditions\nTexas\u202fhas historically provided COVID-19 vaccination administration data to CDC in aggregate format, which impacted CDC\u2019s\nability to report metrics requiring information at the individual dose level.","2321":"\u2022\n\u2022\n-\n-\n\u2022\n\u2022\n\u2022 TM\nPre-teens, Teens and Adults Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nAGE GROUP\n18 YEARS AND OLDER\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nModerna\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nJohnson & Johnson's Janssen\n\uf1aa\nPRIMARY SERIES\nADDITIONAL DOSE\nAt least 4 weeks after 1st dose\nand should be Pfizer-BioNTech\nor Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nor last booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nNovavax\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nA monovalent Novavax booster\nis available in limited situations\nMore details: Novavax booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nChildren Ages 6 Months-11 Years Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 8 weeks after 2nd dose\nUp to Date: 2 weeks after 3rd dose in primary series, since a booster is not recommended for this age group at this\ntime\nAGE GROUP\nModerna\n\uf1aa\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nIf you have completed your primary series\u2014but are not yet eligible for a booster\u2014you are also considered up to date.","5842":"\u2022 Revaccination of moderately or severely immunocompromised persons ages 12 years and older who\nreceived certain therapies (indicated below) and received primary dose(s) of COVID-19 vaccine prior to\nor during treatment. o\no\nReceived COVID-19 vaccine dose(s) during treatment with B-cell-depleting therapies over a\nlimited period\nReceived COVID-19 vaccine dose(s) prior to or during treatment involving hematopoietic cell\ntransplant (HCT) or chimeric antigen receptor (CAR)-T-cell therapy\nThe COVID-19 vaccine by Pfizer-BioNTech under EUI also allow similar uses as an alternative mRNA COVID-19\nvaccine to Moderna, and the same or similar recommendations in the EUI also apply to the use of the COVID-\n19 vaccine by Pfizer-BioNTech under EUI.","8888":"10\/30\/22, 9:21 AM Vaccinating Dialysis Patients and Healthcare Personnel | CDC\nVaccines & Immunizations\nVaccines & Immunizations\nVaccinating Dialysis Patients and Healthcare Personnel\nTake action to protect patients at high-risk in your jurisdiction\nCOVID-19 vaccines are effective at protecting people from getting sick. By allocating vaccines for outpatient dialysis patients\nand the healthcare personnel who care for them in your jurisdiction, you can protect patients who are at high risk,\ndisproportionately affected by COVID-19, or might suffer severe consequences if infected. How can jurisdictions support COVID-19 vaccination efforts for\ndialysis patients and healthcare personnel? Make sure you are aware of the dialysis clinics located in your jurisdiction.","2332":"\u2022\n\u2022\n-\n-\n\u2022\n\u2022\n\u2022 TM\nPre-teens, Teens and Adults Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nAGE GROUP\n18 YEARS AND OLDER\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nModerna\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nJohnson & Johnson's Janssen\n\uf1aa\nPRIMARY SERIES\nADDITIONAL DOSE\nAt least 4 weeks after 1st dose\nand should be Pfizer-BioNTech\nor Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nor last booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nNovavax\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nA monovalent Novavax booster\nis available in limited situations\nMore details: Novavax booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nChildren Ages 6 Months-11 Years Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 8 weeks after 2nd dose\nUp to Date: 2 weeks after 3rd dose in primary series, since a booster is not recommended for this age group at this\ntime\nAGE GROUP\nModerna\n\uf1aa\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nIf you have completed your primary series\u2014but are not yet eligible for a booster\u2014you are also considered up to date.","5927":"The EUI apply to the FDA-approved formulation of the COVID-19 vaccine by Moderna (supplied in a red-capped\nmultidose vial containing 5.5 or 7.5 mL of vaccine). The formulation supplied in a red-capped multidose vial is\nthe same formulation that is FDA-authorized under EUA and FDA-licensed under BLA on January 31, 2022. This\nformulation provides primary doses (100 \u03bcg in 0.5 mL) and booster doses (50 \u03bcg in 0.25 mL). FDA has\nexplained that the FDA-approved Spikevax and the EUA-authorized Moderna COVID-19 Vaccine supplied in\nred-capped multidose vials have the same formulation and can be used interchangeably without presenting\nany safety or effectiveness concerns.","1216":"In the snapshot below, CDC provides administration data on the\npercentage and number of people with an updated (bivalent) booster dose by age, sex, and racial and ethnic groups in the\nUnited States. Following these releases, over several weeks, COVID Data Tracker will add bivalent booster data to all vaccination sites,\nincluding the addition of demographic data trends (planned for release in early November 2022). Once these data go live on\nCOVID Data Tracker, the snapshot will be retired.","995":"You can order free self-test kits at COVIDtests.gov or purchase tests online, in pharmacies, and retail stores. You can also visit FDA\u2019s website to see a list of authorized tests. As noted in the labeling for authorized over-the-counter antigen tests: Negative results should be treated as presumptive\n(meaning that they are preliminary results). Negative results do not rule out SARS-CoV-2 infection and should not be\nused as the sole basis for treatment or patient management decisions, including infection control decisions. Please see\nFDA guidance on the use of at-home COVID-19 antigen tests.","6520":"The number of deaths among people over age 65 is 97 times higher than the number of deaths among\npeople ages 18-29 years. A person\u2019s risk of severe illness from COVID-19 increases as the number of underlying medical conditions they have\nincreases. Some people are at increased risk of getting very sick or dying from COVID-19 because of where they live or work, or\nbecause they can\u2019t get health care. This includes many people from racial and ethnic minority groups and people with\ndisabilities. Studies have shown people from racial and ethnic minority groups are also dying from COVID-19 at younger ages.","7188":"COMIRNATY (COVID-19 Vaccine, mRNA) and the Pfizer-BioNTech COVID-19\nVaccine, when prepared according to their respective instructions for use, can be used\ninterchangeably. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is made in the\nsame way as COMIRNATY and Pfizer-BioNTech COVID-19 Vaccine but it also\n3 Monovalent refers to any authorized or approved COVID-19 vaccine that contains or encodes the spike protein\nof only the Original SARS-CoV-2. contains an Omicron component to help prevent COVID-19 caused by the Omicron\nvariant of SARS-CoV-2. For more information on EUA, see the \u201cWhat is an Emergency Use Authorization\n(EUA)?\u201d section at the end of this Fact Sheet.","2165":"Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N\nEngl J Med2021; 384:2273-2282. DOI: https:\/\/doi.org\/10.1056\/NEJMoa2104983 . \uf209\f10\/30\/22, 9:30 AM COVID-19 Vaccines While Pregnant or Breastfeeding\ng J ; p g J\n2. Zauche LH, Wallace B, Smoots AN, et al. Receipt of mRNA COVID-19 vaccines and risk of spontaneous abortions. New\nEngl J MedPublished online September 8, 2021; DOI: https:\/\/doi.org\/10.1056\/NEJMc2113891\n3. Kharbanda EO, Haapata J, DeSilva M, et al. Spontaneous Abortion Following COVID-19 Vaccination During\nPregnancy. JAMA. Published online September 8, 2021. DOI: https:\/\/doi.org\/10.1001\/jama.2021.15494\n4. Lipkind HS, Vazquez-Benitez G, DeSilva M, et al.","1629":"It shall be cause for immediate termination from the CDC COVID-19 Vaccination Program and\ncriminal or civil prosecution for violation of 18 U.S.C. \u00a7 1001 or other relevant federal statutes. Prioritization for receipt of COVID-19 vaccine in the early months of the CDC COVID-19 Vaccination Program was\nnecessary given limited supplies of vaccine. Supplies of COVID-19 vaccine doses are rapidly increasing. Effective May\n1, 2021, in conformance with the Secretary\u2019s March 17, 2021 directive to transition beyond priority groups, all\npersons qualified under the terms of the applicable COVID-19 vaccine Emergency Use Authorization are eligible to be\nvaccinated.","6948":"Has the COVID-19 vaccine by Pfizer-BioNTech been used before? Yes. Millions of people have received this vaccine in the United States since it became available starting in\nmid-December 2020. Also, in clinical trials, approximately 23,000 people ages 12 years and older received\nat least 1 dose of the vaccine. There have been some studies in people who received the COVID-19 vaccine\nby Pfizer-BioNTech after completing a primary vaccination with a non-FDA authorized or approved COVID-\n19 vaccine or Janssen COVID-19 Vaccine. What are the risks of the COVID-19 vaccine by Pfizer-BioNTech?","6185":"10\/30\/22, 9:31 AM Myocarditis and Pericarditis After mRNA COVID-19 Vaccination | CDC\nEspa\u00f1ol | Other Languages\nMyocarditis and Pericarditis After mRNA COVID-19\nVaccination\nMyocarditis is inflammation of the heart muscle. Pericarditis is inflammation of the outer lining of the heart. In both cases, the body\u2019s immune system causes inflammation in response to an infection or some other trigger. Learn\nmore about myocarditis and pericarditis. Both myocarditis and pericarditis have the following symptoms:\nChest pain\nShortness of breath\nFeelings of having a fast-beating, fluttering, or pounding heart\nMyocarditis and pericarditis have rarely been reported.","8566":"Being closer to someone who is infected with COVID-19 increases the risk of transmission. Crowded settings can raise your\nlikelihood of being close to someone with COVID-19. Distant\nLower Risk\nModerately close\nModerate Risk\nVery close or touching\nHigher Risk\ni \uf209\nLast Updated Aug. 11, 2022","2256":"These\nmedical conditions and living situations can make residents more likely to\nbe infected by the virus that causes COVID-19 and to become seriously ill\nfrom COVID-19. Children and adolescents with intellectual and developmental disabilities living in any type of shared setting, including\nintermediate care facilities and group homes, are also considered LTC residents. This means they are also more likely to be\ninfected or become seriously ill from COVID-19. If you live in a LTC setting, you can help protect yourself and the people around you by getting a COVID-19 vaccine as soon as\npossible.","6673":"COVID-19 Vaccines Information for Specific Groups\nVaccine information for older adults, long-term care facility residents, people with underlying medical conditions, people\nat high risk for severe illness, people with disabilities, and more. COVID-19 Vaccine Information\nCOVID-19 Vaccine Information: Vaccine Considerations for People with Underlying Medical Conditions | CDC\nAdditional Consideration: Flu vaccination is especially important for people with asthma\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:39 AM People with Moderate to Severe Asthma | CDC\nFollow the recommendations below to reduce your chance of an asthma\nattack while cleaning. Follow recommendations for cleaning your home and\nin your facility.","7565":"You will need to show official documentation (e.g., clinical trial letter, participant card, or modified vaccination card) of\nclinical trial participation that includes the following information:\nDocumentation you participated in a phase 3 trial of with a qualifying COVID-19 vaccine candidate\nDocumentation you received the full series of an active (non-placebo) qualifying COVID-19 vaccine candidate or an EUL\nvaccine, with the name of the vaccine product and the date(s) received (showing it has been at least 2 weeks since you\ncompleted the series)\nHow do I know if the vaccine trial I participated in is on the approved list for an exception?","421":"On June 30, 2021, data review and reporting adjustments resulted in an increase in the number of vaccine doses\nadministered for North Carolina of 621,198 doses since December 2020. The adjustment is the result of updates to how\npharmacies report data to CDC and\/or the jurisdictions. On June 25, 2021, data review and reporting adjustments resulted in a decrease in the number of vaccine doses\nadministered for New Jersey of 331,640 doses and a smaller-than-usual increase for New Hampshire of 6,449 doses. The\nadjustments are the result of updates to how pharmacies report data to CDC and\/or the jurisdictions.","6355":"Be prepared to discuss your activity levels, what activities make your illness worse, and any medications that seem to\nimprove or worsen the symptoms. Answer the provider\u2019s questions. Explain how you feel. Be straightforward, and don\u2019t be embarrassed to talk about\nanything. Let your provider know if there have been any changes to your prescribed medications and supplements. Know Your Next Steps\nMake sure you understand the next steps. Bring pencil and paper to write down instructions or use your hand-held\ndevice for notes. Repeat back what the provider has told you to check for understanding.","6382":"Remind your provider to share any test results if the expected window for receiving the results has passed. Set Goals with Your Healthcare Provider\nYour provider may run tests that return normal results. This does not change the existence, severity, or importance of\nyour symptoms or conditions. Healthcare providers and patients are encouraged to set achievable goals through shared\ndecision-making and to approach treatment by focusing on specific symptoms or conditions. Review the Healthcare Appointment Checklist\nConsider reviewing the Healthcare Appointment Checklist for Post-COVID Conditions before your next appointment\n(Espa\u00f1ol [PDF \u2013 72 KB]). Many instructions apply to follow-up appointments.","3211":"Unless people have a contraindication to vaccination, they should be encouraged to complete the series to optimize\nprotection against COVID-19 even if they experience local or systemic symptoms following the first dose. People receiving Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines, especially males ages 12\u201339 years, should be\nmade aware of the rare risk of myocarditis and pericarditis following receipt of these COVID-19 vaccines. Counseling should\ninclude the need to seek care if symptoms of myocarditis or pericarditis develop after vaccination, particularly in the week\nafter vaccination. See COVID-19 vaccination and myocarditis and pericarditis for additional information.","1288":"Doses administered at any time after the recommended interval are valid. For more information, see timing, spacing, interchangeability, and coadministration of COVID-19 vaccines. \uf209\nIn accordance with general best practices for immunizations, routine administration of all age-appropriate doses of\nvaccines simultaneously is recommended for children, adolescents, and adults for whom no specific contraindications\nexist at the time of the healthcare visit. This includes simultaneous administration of COVID-19 vaccine and other\nvaccines. However, there are additional considerations for Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines if\nadministering an orthopoxvirus (monkeypox) vaccine. For more information, see Coadministration of COVID-19 vaccines with other vaccines.","850":"\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nAfter vaccination, continue to follow all current prevention measures recommended by CDC and based on latest COVID-\n19 Community Level data. Learn more about protecting your family from COVID-19. Related Pages\nFacts about COVID-19 Vaccines\n\u203a\nFrequently Asked Questions about COVID-19\nVaccination\n\u203a\nCOVID-19 Vaccines for People Who Would Like to Have\na Baby\n\u203a\nHow Do I Find a COVID-19 Vaccine? \u203a\nLast Updated Aug. 17, 2022","5235":"Isolation & Exposure\nFor Healthcare Professionals: Ending Isolation and Precautions for People with COVID-19\n\uf3b7\n\uf285 When to Isolate\n\uf6eb IF YOU TEST\nNegative\nYou can end your isolation\n\uf6ec IF YOU TEST\nPositive\nFollow the full isolation\nrecommendations below\nIf you had no symptoms If you had symptoms\f10\/30\/22, 9:41 AM Isolation and Precautions for People with COVID-19 | CDC\nIf you test positive for COVID-19, stay home for at least 5 days and isolate from others in your home. You are likely most infectious during these first 5 days. Wear a high-quality mask if you must be around others at home and in public.","7750":"Based on a recent analysis of data from the Vaccine Safety Datalink, the rate of GBS within the first 21 days\nfollowing J&J\/Janssen COVID-19 vaccination was found to be 21 times higher than after Pfizer-BioNTech or Moderna\n(mRNA COVID-19 vaccines). After the first 42 days, the rate of GBS was 11 times higher following J&J\/Janssen COVID-\n19 vaccination. The analysis found no increased risk of GBS after Pfizer-BioNTech or Moderna (mRNA COVID-19\nvaccines). CDC and FDA will continue to monitor for and evaluate reports of GBS occurring after COVID-19\nvaccination and will share more information as it becomes available.","6911":"\u2022 For people who are moderately or severely immunocompromised:\no\no\no\nPeople ages 12 years and older who are moderately or severely immunocompromised and\nreceived their primary vaccination with certain non-FDA authorized or approved COVID-19\nvaccines at least 28 days ago should receive an additional (third) primary dose of the\nCOVID-19 vaccine by Pfizer-BioNTech. People ages 18 years and older with a moderately or severely immunocompromising\ncondition who received a primary dose of the Janssen COVID-19 Vaccine should receive an\nadditional dose with the COVID-19 vaccine by Pfizer-BioNTech at least 28 days after\nreceiving the Janssen COVID-19 Vaccine primary dose.","5550":"Some masks and respirators offer higher levels of protection than others, and some may be harder to tolerate or wear\nconsistently than others. It is most important to wear a well-fitting mask or respirator correctly that is comfortable for\nyou and that provides good protection. While all masks and respirators provide some level of protection, properly fitting respirators provide the highest level of\nprotection. Wearing a highly protective mask or respirator may be most important for certain higher risk situations, or by\nsome people at increased risk for severe disease.","465":"This error has been corrected. The correct number for May 13, 2021 is 2,340,538. On May 13, 2021, CDC updated its methodology for calculating age-based metrics for Texas. Effective May 13, 2021, to\ncalculate age-based metrics, CDC assumes: Residents of Texas who receive a vaccination in a different state or territory\nare not attributed to Texas in their population-based metrics but are still included in national-level metrics. All people\nreceiving vaccinations in Texas are considered Texas residents of Texas.","9953":"Janssen COVID-19 Vaccine can be administered to persons 18\nyears of age and older in certain limited situations due to safety\nconsiderations. To determine previously administered COVID-19 doses, check\nmedical records, immunization information systems, and\nvaccination record cards. If the vaccine product previously\nadministered cannot be determined, is no longer available, or\ncontraindicated, any age-appropriate COVID-19 vaccine product\nmay be administered at least 28 days after the first dose.","5180":"10\/30\/22, 9:31 AM Investigating Long-Term Effects of Myocarditis | CDC\nEspa\u00f1ol | Other Languages\nInvestigating Long-Term Effects of Myocarditis\nHow CDC Is Investigating Myocarditis Health Effects after COVID-19 Vaccination\nParticipating in the Survey\nHow did CDC get my contact information? CDC got your contact information from the Vaccine Adverse Event Reporting System (VAERS ), a secure system that\ncontains information needed to check in with patients to see how they are recovering after they experience a serious event\nfollowing vaccination. The U.S. Food and Drug Administration (FDA) requires healthcare professionals to report to VAERS certain serious adverse\nevents and hospitalizations that occur after COVID-19 vaccination.","6653":"Ask your primary care provider if you would like to speak with a professional. Getting\nregular exercise and being physically active is also a great way to reduce stress. Accommodate dietary needs and avoid triggers\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nHave non-perishable food choices such as canned goods available that meet your needs based on your medical\ncondition (e.g., kidney diet and KCER 3-Day Emergency Diet Plan , diabetic diet).","3875":"Cases of multisystem inflammatory syndrome\nHealthcare providers are encouraged to report to VAERS any additional clinically significant AEs following vaccination,\neven if they are not sure if vaccination caused the event. Also report any additional select AEs and\/or any revised safety\nreporting requirements per FDA\u2019s conditions of authorized use of vaccine(s) throughout the duration of any COVID-19\n\uf209\n\uf209\f10\/30\/22, 9:17 AM FAQs About Implementing COVID-19 Vaccination Program in Provider Practices | CDC\nvaccine being authorized under an EUA. Vaccination provider requirements can be found at COVID-19 Vaccination Provider Requirements and Support. Yes. Healthcare providers are the most trusted source of health information for their patients.","4437":"Improving Ventilation and Spending Time Outdoors\nImproving ventilation (moving air into, out of, or within a room) and filtration (trapping particles on a filter to remove\nthem from the air) can help prevent virus particles from accumulating in indoor air. Improving ventilation and filtration\ncan help protect you from getting infected with and spreading the virus that causes COVID-19. Spending time outside\nwhen possible instead of inside can also help: Viral particles spread between people more readily indoors than outdoors. Actions that can improve ventilation and filtration include:\nBringing in as much outdoor air as possible\u2014for example, opening windows.","3024":"The COVID-19 vaccination schedule for people who are moderately or severely immunocompromised is detailed below and\nsummarized in Table 3; see also COVID-19 vaccination and EVUSHELD\u2122. Table of Contents \uf426\nCOVID-19 vaccination guidance for people who are moderately\nor severely immunocompromised\nView the COVID-19 Vaccination Schedule for People who are Moderately or Severely Immunocompromised \uf20a\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nPeople who are or who become moderately or severely immunocompromised should follow the COVID-19 vaccination\nschedule according to their age and immune status at the time of eligibility for that dose.","1662":"COVID-19 Vaccine Administration Fees (updated 4\/8\/2022)\nAll organizations and providers participating in the CDC COVID-19 Vaccination Program:\n\uf209\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nmust administer COVID-19 Vaccine at no out-of-pocket cost to the recipient\nmay not deny anyone vaccination based on the vaccine recipient\u2019s coverage status or network status\nmay not charge an office visit or other fee if COVID-19 vaccination is the sole medical service provided\nmay not require additional medical services to receive COVID-19 vaccination\nmay seek appropriate reimbursement from a program or plan that covers COVID-19 Vaccine administration fees for\nthe vaccine recipient, such as:\nvaccine recipient\u2019s private insurance company\nMedicare or Medicaid reimbursement\nHRSA COVID-19 Coverage Assistance Fund for underinsured vaccine recipients (unavailable as of 11:59 ET on\nApril 5, 2022, due to lack of supplemental funding)\nHRSA COVID-19 Uninsured Program for non-insured vaccine recipients (unavailable as of 11:59 ET on April 5,\n2022, due to lack of supplemental funding)\nmay not seek any reimbursement, including through balance billing, from the vaccine recipient\nFor additional information on filing claims for reimbursement of COVID-19 vaccine administration fees, go to:\nCMS Guidance \u2013 https:\/\/www.cms.gov\/covidvax-provider\nCDC Statement on Exhaustion of Funding for the Uninsured Program and Coverage Assistance Fund\nDue to the lack of supplemental funding from Congress, HRSA stopped accepting claims for reimbursement of costs\nassociated with administering COVID-19 vaccines to uninsured and underinsured individuals as of 11:59 PM ET on April 5,\n2022.","6613":"Get more information:\n\uf209\n\u2022 \uf209\n\u2022\n\u2022\n\u2022 \uf209\n\u2022\n\u2022 \uf209\n\u2022 \u00ae \uf209\n\u2022 SM\n\u2022 \uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nGet more information:\nSmoking & Tobacco Use\nTips From Former Smokers\nHealth Benefits of Quitting Smoking\nSolid organ or blood stem cell transplant\nHaving had a solid organ or blood stem cell transplant, which includes bone marrow transplants, can make you more likely to\nget very sick from COVID-19. Get more information:\nTransplant Safety\nCOVID-19 Resources for Transplant Community\nStroke or cerebrovascular disease\nHaving cerebrovascular disease, such as having a stroke which affects blood flow to the brain, can make you more likely to get\nvery sick from COVID-19.","225":"I have COVID-19 antibodies. What does it mean? A positive antibody test result can help identify someone who has had COVID-19 in the past or has been vaccinated against\nCOVID-19. Antibody tests are not used if you have symptoms of COVID-19 or for diagnosing a current case of COVID-19. This is\nbecause it takes most people with a healthy immune system 1 to 3 weeks after getting COVID-19 to develop antibodies. A viral\ntest is recommended to identify a current infection with the virus that causes COVID-19. More information about the role and\nuses of antibody testing is available.","3425":"Considerations for people diagnosed with MIS-C or MIS-A after COVID-19\nvaccination\n\uf209\nTable of Contents \uf426\nConsiderations involving pregnancy, lactation, and fertility\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nStaying up to date with COVID-19 vaccinations is recommended for people who are pregnant, trying to get pregnant now, or\nwho might become pregnant in the future, and people who are breastfeeding. A growing body of evidence on the safety and\neffectiveness of COVID-19 vaccination indicates that the benefits of vaccination outweigh any potential risks of COVID-19\nvaccination during pregnancy. Side effects can occur after COVID-19 vaccination in pregnant people, similar to those among non-pregnant people.","8980":"Requesting Permission to Contact Your Healthcare Provider\nParticipants will also be asked if they would be willing to provide permission for Pregnancy Registry staff to review their\nmedical records for additional details about their pregnancies. Personal information and responses given to the registry are\nconfidential and will be protected to the full extent allowed by law. Having information on details, like medications or clinical\nlaboratory results, provides a complete picture of your pregnancy. Your healthcare provider(s) can help provide this\ninformation, which is important as we try to understand more about COVID-19 vaccination during pregnancy.","5817":"Based on available information, the use of the COVID-19 vaccine by Moderna as described in this\nFact Sheet could help improve or restore protection that may not have been sufficient or may have\ndecreased over time after the primary vaccination. What alternative choices are available for primary and\/or additional doses other than the COVID-19\nvaccine by Moderna? Currently, the Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine are the only FDA-\napproved COVID-19 vaccines for which EUI provide information about primary and\/or additional doses\nfollowing the COVID-19 vaccine that you received.","8386":"Who needs to be trained\n\uf1aa\nIt is critical that healthcare professionals and personnel are familiar with the specific COVID-19 vaccine product(s) in their\nfacility\u2019s inventory. Guidance for vaccine storage, handling, preparation, and administration may differ for each vaccine\nproduct. Therefore, all healthcare staff members need training in COVID-19 vaccination even if they are already\nadministering routinely recommended vaccines. While many practices are the same for all vaccines, whenever a new\nvaccine is introduced to the U.S. market, there are nuances that healthcare professionals must become familiar with to\nensure the vaccine is stored, handled, prepared, and administered correctly.","6251":"FACT: Anyone can report events to VAERS, even if it is not clear whether a vaccine caused the problem. Because of this, VAERS data alone cannot determine if the reported adverse event was caused by a COVID-19\nvaccination. Some VAERS reports may contain information that is incomplete,\ninaccurate, coincidental, or unverifiable. Vaccine safety experts study\nthese adverse events and look for unusually high numbers of health\nproblems, or a pattern of problems, after people receive a particular\nvaccine.","9209":"\u2022\n\u2022\n\uf1b8 Clean surfaces in your home regularly\nClean and disinfect high-touch surfaces (for example, doorknobs, tables, handles, light switches, and\ncountertops) in your \u201csick room\u201d and bathroom. In shared spaces, you should clean and disinfect\nsurfaces and items after each use by the person who is ill. If you are sick and cannot clean, a caregiver or other person should only clean and disinfect the area\naround you (such as your bedroom and bathroom) on an as needed basis. Your caregiver\/other person\nshould wait as long as possible (at least several hours) and wear a mask before entering, cleaning, and\ndisinfecting shared spaces that you use.","6546":"Chronic lung diseases can include:\nAsthma, if it\u2019s moderate to severe\nBronchiectasis (thickening of the lungs\u2019 airways)\nBronchopulmonary dysplasia (chronic lung disease affecting newborns)\nChronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis\nHaving damaged or scarred lung tissue known as interstitial lung disease (including idiopathic pulmonary fibrosis)\nPulmonary embolism (blood clot in the lungs)\nPulmonary hypertension (high blood pressure in the lungs)\nGet more information:\nCOPD\nAsthma\nPeople with Moderate to Severe Asthma\nAmerican Lung Association: Controlling Chronic Lung Diseases Amid COVID-19\nCystic fibrosis\nHaving cystic fibrosis, with or without lung or other solid organ transplant (like kidney, liver, intestines, heart, and pancreas)\ncan make you more likely to get very sick from COVID-19.","4888":"Severe allergic reactions include:\nPossible anaphylaxis, a progressive life-threatening reaction that typically includes urticaria but also with other symptoms such as\nwheezing, difficulty breathing, or low blood pressure\nAny angioedema affecting the airway (i.e., tongue, uvula, or larynx)\nDiffuse rash which also involves mucosal surfaces (e.g., Stevens-Johnson Syndrome)\nNon-severe allergic reactions may include:\nUrticaria (hives) beyond the injection site\nAngioedema (visible swelling) involving lips, facial skin, or skin in other locations.","1077":"They include:\n\u2022 \uf209\n\u2022 \uf209\n\uf209\nTreatment Who When How\nNirmatrelvir with Ritonavi\n(Paxlovid)\nAntiviral\n\uf209\nAdults; children ages 12\nyears and older\nStart as soon as possible;\nmust begin within 5 days\nof when symptoms start\nTaken at home by mouth\n(orally)\nRemdesivir (Veklury)\nAntiviral\n\uf209 Adults and children Start as soon as possible;\nmust begin within 7 days\nof when symptoms start\nIntravenous (IV) infusions\nat a healthcare facility for\n3 consecutive days\nBebtelovimab\nMonoclonal antibody\n\uf209 Adults; children ages 12\nyears and older\nStart as soon as possible;\nmust begin within 7 days\nof when symptoms start\nSingle IV injection\nMolnupiravir (Lagevrio)\nAntiviral\n\uf209 Adults Start as soon as possible;\nmust begin within 5 days\nof when symptoms start\nTaken at home by mouth\n(orally)\nSome treatments might have side effects or interact with other medications you are taking.","7537":"\uf1aa\f10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nCertain categories of persons traveling to the United States for reasons related to official foreign government travel or\nbecause they have been invited by the United Nations are eligible for an exception under the Proclamation and CDC\u2019s\nAmended Order.","4391":"10\/30\/22, 9:27 AM How Do I Find a COVID-19 Vaccine? | CDC\nEspa\u00f1ol | Other Languages\nHow Do I Find a COVID-19 Vaccine or Booster? Find COVID-19 Vaccines or Boosters Near You\nThere are several other ways you can look for vaccine providers near you in the United States. Ask your doctor, pharmacist, or community health center, or visit their website. Contact your state health department. Check your local pharmacy\u2019s website to see if vaccination appointments are available. Some pharmacies may offer\nvaccines to those who walk-in without making an appointment ahead of time.","8622":"Besides being used in vaccines, viral vectors have also been studied for gene therapy, to treat cancer, and for molecular\nbiology research. \uf426\n\u2022 \uf209\n\u2022\nProtein subunit COVID-19 vaccines are given in the upper arm muscle. After vaccination, nearby cells pick up these\nproteins. Next, our immune system recognizes that these proteins do not belong there. Another ingredient in the vaccine, the\nadjuvant, helps our immune system to produce antibodies and activate other immune cells to fight off what it thinks\nis an infection. This is what your body might do if you got sick with COVID-19.","8937":"Learn more about\u202fselected adverse events\u202freported to VAERS. How VAERS Reports Are Reviewed\nVaccine safety experts review all reports of serious adverse events submitted to VAERS. A serious adverse event after\nvaccination is something that causes:\nPermanent disability\nHospitalization or an extended hospital stay (if vaccinated while in the hospital)\nLife-threatening illness\nBirth defects (congenital anomalies)\nDeath\nImportant Things To Know About VAERS\nVAERS is an early warning system used to monitor adverse events that happen after vaccination. VAERS is the\nfrontline system of a comprehensive vaccine safety monitoring program in the United States.","1690":"For those provider agreements not specifying vaccine administration data to be recorded or reported, the following\napplies:\nAfter administering a dose of COVID-19 vaccine, record to the extent not already recorded in the vaccine recipient\u2019s\nrecord all information marked below by an asterisk and report the following required vaccine administration data, or\nother data elements if revised by CDC, to the appropriate entity noted in the agreement:\na. Administered at location\/facility name\/ID\nb. Administered at location type\nc. Administration address (including Company)*\nd. Recipient name and ID*\ne. Recipient date of birth*\nf. Recipient sex*\ng. Recipient race\nh. Recipient ethnicity\ni. Recipient address*\nj.","4876":"\u00a7\n\u00b6\n\u00a7\n*\n\u2020\n\u2021\n\u00a7\n\u00b6\n\uf209 \uf209\n#\nTable of Contents \uf426\nCONTRAINDICATION TO COVID-19\nVACCINATION PRECAUTION TO COVID-19 VACCINATION\nNO CONTRAINDICATION OR\nPRECAUTION TO COVID-19\nVACCINATION\nAppendix E. Triage of people with a history of allergies or allergic reactions\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nCONTRAINDICATION TO COVID-19\nVACCINATION PRECAUTION TO COVID-19 VACCINATION\nNO CONTRAINDICATION OR\nPRECAUTION TO COVID-19\nVACCINATION\nHistory of the following:\nSevere allergic reaction (e.g.,\nanaphylaxis) after a previous\ndose or to a component of a\nKnown (diagnosed) allergy to a\ncomponent of a COVID-19\nvaccine\nAmong people without a contraindication, a history\nof:\nAnaphylaxis after non-COVID-19 vaccines or\ninjectable therapies\nNon-severe, immediate (onset within 4 hours)\nallergic reaction after a previous dose of\nNote: People with an allergy-related\ncontraindication to one type of COVID-19 vaccine\nhave a precaution to the other types of COVID-19\nvaccines.","2353":"Examples of medical conditions or treatments that may result in moderate to severe immunocompromise include but are not\nlimited to:\nActive treatment for solid tumor and hematologic malignancies\nHematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status\n(e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\nReceipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\nReceipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of\ntransplantation or taking immunosuppressive therapy)\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nTalk to your healthcare provider about COVID-19 and your medical condition.","3330":"People receiving Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines, especially males ages 12\u201339 years, should be\nmade aware of the rare risk of myocarditis and pericarditis following receipt of these vaccines and the benefit of COVID-19\nvaccination in reducing the risk of severe outcomes from COVID-19, including the possibility of cardiac sequelae. Counseling\nshould include the need to seek care if symptoms of myocarditis or pericarditis, such as chest pain, shortness of breath, or\ntachycardia develop after vaccination, particularly in the week after vaccination. In younger children, symptoms of myocarditis\nmay also include non-specific symptoms such as irritability, vomiting, poor feeding, tachypnea, or lethargy.","7933":"Online rumors continue to spread stating that COVID-19\nvaccines cause vaccine-acquired immune deficiency syndrome (VAIDS) and HIV.22,23,24 The State of Vaccine Confidence Report\n#24 detailed the evolution of the VAIDS narrative to concerns about HIV. Social media users are further bolstering this false\nclaim, using it as a rationale to resist vaccination.25,26 However, there is no association between COVID-19 vaccines and risk for\n\u0083 Impaired Immunity.","3872":"Cases of multisystem inflammatory syndrome\nHealthcare providers are encouraged to report to VAERS any additional clinically significant AEs following vaccination,\neven if they are not sure if vaccination caused the event. Also report any additional select AEs and\/or any revised safety\nreporting requirements per FDA\u2019s conditions of authorized use of vaccine(s) throughout the duration of any COVID-19\n\uf209\n\uf209\f10\/30\/22, 9:17 AM FAQs About Implementing COVID-19 Vaccination Program in Provider Practices | CDC\nvaccine being authorized under an EUA. Vaccination provider requirements can be found at COVID-19 Vaccination Provider Requirements and Support. Yes. Healthcare providers are the most trusted source of health information for their patients.","5404":"However, vaccination providers may seek appropriate reimbursement from a program\nor plan that covers COVID-19 vaccine administration fees for the vaccine recipient (private\ninsurance, Medicare, Medicaid, HRSA COVID-19 Uninsured Program for non-insured\nrecipients). WHERE CAN I REPORT CASES OF SUSPECTED FRAUD? Individuals becoming aware of any potential violations of the CDC COVID-19 Vaccination\nProgram requirements are encouraged to report them to the Office of the Inspector General, U.S.\nDepartment of Health and Human Services, at 1-800-HHS-TIPS or TIPS.HHS.GOV. WHAT IS THE COUNTERMEASURE INJURY COMPENSATION PROGRAM?","3230":"Antipyretic or analgesic medications can be taken for the treatment of post-vaccination local or systemic symptoms, if\nmedically appropriate; these medications should not be used prophylactically for the purposes of prevention of post-\nvaccination symptoms. However, in general, aspirin is not recommended for use in children and adolescents ages 17 years\nand younger as an antipyretic or analgesic due to the risk of Reye\u2019s syndrome. Pre-vaccination testing\nAntibody testing is not currently recommended to assess the need for vaccination in an unvaccinated person or to assess\nimmunity to SARS-CoV-2 following COVID-19 vaccination.","5832":"Moderna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 09\/02\/22;\nEmergency Use Instructions for Healthcare Providers:\nModerna COVID-19 Vaccine for Primary and\/or Additional Doses\nThe Centers for Disease Control and Prevention (CDC) is issuing Emergency Use Instructions (EUI) to provide\ninformation about the use of the COVID-19 vaccine by Moderna (Spikevax), which is approved (licensed) by the\nFood and Drug Administration (FDA) for the prevention of COVID-19 in individuals ages 18 years and older.1\nThe CDC-issued EUI provide information for the use of this vaccine that are beyond the FDA-approved labeling.","1663":"COVID-19 Vaccine Administration Fees (updated 4\/8\/2022)\nAll organizations and providers participating in the CDC COVID-19 Vaccination Program:\n\uf209\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nmust administer COVID-19 Vaccine at no out-of-pocket cost to the recipient\nmay not deny anyone vaccination based on the vaccine recipient\u2019s coverage status or network status\nmay not charge an office visit or other fee if COVID-19 vaccination is the sole medical service provided\nmay not require additional medical services to receive COVID-19 vaccination\nmay seek appropriate reimbursement from a program or plan that covers COVID-19 Vaccine administration fees for\nthe vaccine recipient, such as:\nvaccine recipient\u2019s private insurance company\nMedicare or Medicaid reimbursement\nHRSA COVID-19 Coverage Assistance Fund for underinsured vaccine recipients (unavailable as of 11:59 ET on\nApril 5, 2022, due to lack of supplemental funding)\nHRSA COVID-19 Uninsured Program for non-insured vaccine recipients (unavailable as of 11:59 ET on April 5,\n2022, due to lack of supplemental funding)\nmay not seek any reimbursement, including through balance billing, from the vaccine recipient\nFor additional information on filing claims for reimbursement of COVID-19 vaccine administration fees, go to:\nCMS Guidance \u2013 https:\/\/www.cms.gov\/covidvax-provider\nCDC Statement on Exhaustion of Funding for the Uninsured Program and Coverage Assistance Fund\nDue to the lack of supplemental funding from Congress, HRSA stopped accepting claims for reimbursement of costs\nassociated with administering COVID-19 vaccines to uninsured and underinsured individuals as of 11:59 PM ET on April 5,\n2022.","3724":"\u25aa Updated on February 11, 2022, to allow an additional Pfizer-BioNTech COVID-19 vaccine dose in\npersons ages 18 years and older with certain immunocompromising conditions who received\nprimary vaccination with the Janssen COVID-19 vaccine; revaccination of certain moderately or\nseverely immunocompromised persons ages 12 years and older who received certain therapies\n(i.e., hematopoietic cell transplant (HCT) or chimeric antigen receptor (CAR)-T-cell therapy) and\nreceived COVID-19 vaccine prior to or during treatment; and the ability of healthcare providers\nto administer the Pfizer-BioNTech COVID-19 vaccine outside of the FDA-authorized or FDA-\napproved labeling and CDC recommended dosing intervals based on clinical judgment when the\nbenefits of vaccination are deemed to outweigh the potential and unknown risks.","433":"On June 14, 2021, CDC corrected an error in the Census denominators used to calculate percentage-based metrics for\nthe U.S. population ages 12 years and older, 18 years and older, and 65 years and older. No other population groups\nwere affected. The census counts for the population ages 12 years and older increased from 280,216,744 to 283,545,812 people\n(+3,329,068). The census counts for the population ages 18 years and older increased from 258,130,580 to 258,259,833 people\n(+129,253). The census counts for the population ages 65 years and older decreased from 54,696,898 to 54,696,581 people\n(-317).","353":"CDC is actively working to address this issue and the data will be updated\nwhen available. December 30, 2021: CDC updated 349 incorrect census county-level population denominators. This update does not\nimpact the overall number of people who have received at least one dose of a COVID-19 vaccine or the overall number of\npeople who are fully vaccinated. The update does impact the percentage of populations within 189 counties who have\nreceived at least one dose or who are fully vaccinated.","2863":"The following COVID-19 vaccines, categorized into three vaccine types, are currently approved under a Biologics License\nApplication (BLA) or authorized under an EUA by FDA (Table 1):\nmRNA vaccines\nModerna COVID-19 Vaccine\/SPIKEVAX (1) and Moderna COVID-19 Vaccine, Bivalent\nPfizer-BioNTech COVID-19 Vaccine\/COMIRNATY (2) and Pfizer-BioNTech COVID-19 Vaccine, Bivalent\nProtein subunit vaccine\nNovavax COVID-19 Vaccine, Adjuvanted\nAdenovirus vector vaccine\nJanssen (Johnson & Johnson) COVID-19 Vaccine\nNone of the currently FDA-approved or FDA-authorized COVID-19 vaccines are live-virus vaccines. Overview of COVID-19 vaccination\n\uf209\n\uf209\n\uf209\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nJanssen COVID-19 Vaccine is authorized for adults ages 18 years and older in certain limited situations due to safety\nconsiderations (see Appendix A).","7723":"Although mRNA vaccines (Pfizer-BioNTech or Moderna COVID-19 vaccines) are preferred, Johnson & Johnson\u2019s Janssen\nCOVID-19 vaccine may be considered in some situations. Millions of people in the United States have received COVID-19 vaccines under the most intense safety monitoring\nprogram in U.S. history. CDC, the U.S. Food and Drug Administration (FDA), and other federal agencies continue to monitor the safety of COVID-\n19 vaccines. Adverse events described on this page have been reported to the Vaccine Adverse Event Reporting System (VAERS) . VAERS accepts reports of any adverse event following vaccination.","5338":"\u2022 General side effects: headache, feeling very tired, muscle aches, nausea, and fever. \u2022 Swollen lymph nodes. \u2022 Blood clots. \u2022 Unusual feeling in the skin (such as tingling or a crawling feeling) (paresthesia), decreased feeling\nor sensitivity, especially in the skin (hypoesthesia). \u2022 Persistent ringing in the ears (tinnitus). \u2022 Diarrhea, vomiting. Severe Allergic Reactions\nThere is a remote chance that the Janssen COVID-19 Vaccine could cause a severe allergic\nreaction. A severe allergic reaction would usually occur within a few minutes to one hour after\ngetting a dose of the Janssen COVID-19 Vaccine.","4887":"However, some\nof these people may be able to receive Novavax or Janssen COVID-19 vaccine after a detailed risk assessment (see footnote 5 below). An immediate allergic reaction to a vaccine or injectable therapy is defined as any hypersensitivity-related signs or symptoms such as urticaria\n(hives), angioedema (visible swelling), respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occurs within four hours following\nadministration.","4120":"\uf1aa\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:18 AM Frequently Asked Questions about COVID-19 Vaccination | CDC\nDespite these temporary changes in menstruation, there is no evidence that COVID 19 vaccines cause fertility problems. Learn more about COVID-19 vaccination for people who would like to have a baby. Getting Children and Teens Vaccinated\nParents and caregivers should get their child vaccinated as soon as vaccines are available to them. Getting vaccinated\nprovides the best protection against serious illness if a child gets infected with the virus that causes COVID-19.","7432":"10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nAll forms of proof of COVID-19 vaccination must have\nPersonal identifiers (full name plus at least one other identifier such as date of birth or passport number) that match the\npersonal identifiers on the passenger\u2019s passport or other travel documents\nName of official source issuing the record (e.g., public health agency, government agency, or other authorized vaccine\nprovider)\nVaccine manufacturer and date(s) of vaccination\nHow the 14 days are calculated:\nYour last dose must have been given a full 14 days before the day you board your flight to the United States.","7454":"If you are a noncitizen who is a nonimmigrant and can show acceptable proof of vaccination with an accepted COVID-19\nvaccine, and meet the definition of fully vaccinated, you meet the requirements under the Presidential Proclamation and\nCDC\u2019s Amended Order. Are noncitizens, nonimmigrants (Covered Individuals) allowed to board a flight to the United\nStates if they can show proof of being fully vaccinated against COVID-19? \uf1aa\nCDC\u2019s Order requiring proof of COVID-19 vaccination does not apply to Ukrainians who are approved as part of the\nUniting for Ukraine program .","4103":"All COVID-19 vaccine providers in the United States must be enrolled in the CDC COVID-19 Vaccination\nProgram. To participate in this program, vaccine providers sign an agreement that states they will only administer COVID-\n19 vaccines in accordance with program requirements and recommendations including those of CDC, the Advisory\nCommittee on Immunization Practices (ACIP), and the U.S. Food and Drug Administration (FDA). Your provider can\nrefer to the CDC Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States for specific information\non administration of COVID-19 vaccines. These guidelines are based on safety and efficacy data and are updated as new\ninformation becomes available.","8443":"10\/30\/22, 9:42 AM Travel | CDC\nEspa\u00f1ol | Other Languages\nTravel\nFind a COVID-19 vaccine or booster near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. Domestic Travel\n\uf698 International Travel\n\uf1c8 Cruise Ship Travel\n\uf4fc\n\uf1c8\nGet Started\nTravel Assessment\nA tool to help you know the requirements to board a flight to the United States. Travel Requirements for Non-U.S. Citizen, Non-U.S. Immigrants\nYou must be fully vaccinated with the primary series of an accepted COVID-19 vaccine to travel to the United States by\nplane. Only limited exceptions apply. For more information, see Requirement for Proof of COVID-19 Vaccination for Air\nPassengers.","584":"August 11, 2022: New Jersey made updates to data previously submitted to CDC that resulted in a net increase of\n37,096 administered doses. August 11, 2022: California made updates to data previously submitted to CDC that resulted in a net increase of\n202,640 administered doses. August 4, 2022: Idaho made updates to data previously submitted to CDC that resulted in a net decrease of 42,051\nadministered doses. This contributed to a decrease in overall US figures. August 4, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 77,754\nadministered doses.","3838":"Visit Training and\nEducation for COVID-19 Vaccination for training information and core competencies for healthcare professionals. At a\nminimum, CDC recommends all providers complete the training module for the vaccine(s) they will be administering. The\ntraining modules can be found at COVID-19 Vaccine Training Modules. Additional vaccine preparation and administration\nresources can be found on CDC\u2019s web pages for each vaccine product at U.S. COVID-19 Vaccine Product Information. Your\nstate, local, or jurisdictional immunization program may also have training requirements. Providers who are enrolled in the VFC program may already have completed some of the training recommended to\nbecome a COVID-19 vaccination provider.","7272":"Data have not yet been submitted to FDA on administration of COMIRNATY\n(COVID-19 Vaccine, mRNA), the Pfizer-BioNTech COVID-19 Vaccine, or the\nPfizer-BioNTech COVID-19 Vaccine, Bivalent at the same time with other vaccines. If\nyou are considering receiving COMIRNATY (COVID-19 Vaccine, mRNA), the\nPfizer-BioNTech COVID-19 Vaccine, or the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent with other vaccines, discuss your options with your healthcare provider. WHAT IF I AM IMMUNOCOMPROMISED? If you are immunocompromised, you may receive a third primary series dose of\nPfizer-BioNTech COVID-19 Vaccine or COMIRNATY (COVID-19 Vaccine, mRNA). Individuals 12 years of age and older may receive a booster dose with\nPfizer-BioNTech COVID-19 Vaccine, Bivalent.","4984":"New booster recommendation for people ages 12 years and older to receive 1 bivalent mRNA booster after\ncompletion of a monovalent primary series; it replaces all prior booster recommendations for this age group\nRecommendations for use of a bivalent Moderna booster dose in people ages 18 years and older\nRecommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 12 years and older\nUpdated guidance for observation periods following COVID-19 vaccination\nUpdated guidance on COVID-19 vaccination and multisystem inflammatory syndrome (MIS) in children (MIS-C) and in\nadults (MIS-A)\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adolescents ages 12\u201317 years\nReorganization of Janssen COVID-19 Vaccine guidance into an appendix\nUpdated guidance on COVID-19 vaccination following exposure to SARS-CoV-2\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nPrevious Updates\n\uf1aa\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nUpdated guidance on COVID-19 vaccination and myocarditis and pericarditis\nNew clinical considerations for coadministration of mRNA COVID-19 vaccines and orthopoxvirus vaccines\nNew guidance for use of Moderna COVID-19 Vaccine in children and adolescents ages 6\u201317 years\nNew guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children ages 6 months\u20134 years\nNew guidance for use of Moderna COVID-19 Vaccine in children ages 6 months\u20135 years\nReorganization of sections on COVID-19 vaccination recommendations and schedules\nAddition of new section in Special populations for infants and young children\nNew guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5\u201311 years\nUpdated guidance that the following people should receive a second COVID-19 booster dose:\nPeople ages 12 years and older who are moderately or severely immunocompromised\nPeople ages 50 years and older\nUpdated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-\ndepleting therapies\nClarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults\n(MIS-A)\nUpdated guidance for primary series vaccination after SARS-CoV-2 infection\nAdded considerations for the option to receive a second COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 vaccination after SARS-CoV-2 infection\nAdded guidance that people ages 12 years and older who are moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that people ages 18\u201349 years who are not moderately or severely immunocompromised and who\nreceived Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster\ndose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose\nFurther clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C)\nand adults (MIS-A) and myocarditis\nUpdated information on the availability of Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL\ndosage volume) and Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL dosage volume) for\nadministration of a 50 \u00b5g booster dose.","4260":"People who already had COVID-19 and do not get vaccinated after their recovery are more likely to get COVID-19 again\nthan those who get vaccinated after their recovery. If you were given monoclonal antibodies or convalescent plasma while sick with COVID-19 you do not need to wait to get\nvaccinated. \u2022\n\u2022\n\u2022\nWhen you can wait\n\uf1aa\nIf you recently had COVID-19, you may consider delaying your next vaccine dose (primary dose or booster) by 3\nmonths from when:\nyour symptoms started,\nyou first received a positive test if you had no symptoms.","216":"This level is called the\n\u201cthreshold of protection.\u201d When antibodies decrease below the threshold of protection, you may become more vulnerable to\nsevere illness. We do not yet know what the threshold of protection for antibodies is for the virus that causes COVID-19 or\nhow long it takes these antibodies to wane. Even after antibodies wane, your immune system may have cells that remember\nthe virus that can act quickly to protect you from severe illness if you become infected. These topics are being researched by\nscientists all over the world\f10\/30\/22, 9:37 AM Antibodies and COVID-19 | CDC\nscientists all over the world.","8498":"Remember, requirements\nand recommendations in other countries may differ from the United States. You can travel back home once you have ended isolation but only if you are able to wear a high-quality mask or respirator\nwhen around others indoors for the full duration of your trip. If not, do not travel until it\u2019s safe for you to remove your mask around others. Your travel companions should follow CDC travel guidance for people who have been exposed. If you are in another\ncountry, also follow local guidance. What should I do if I test positive during travel? When can I travel back home?","8838":"Sign up during the waiting period after you get any dose of COVID-19 vaccine or at any time\nafter vaccination\nAdd a dependent and complete health check-ins on their behalf\nEnter and report how you, or your dependent, feel after first, second, additional, and booster doses\nAvailable in multiple languages including English, Spanish, Chinese, Korean, and Vietnamese\n\u2022\n\u2022\n\u2022\n\u2022\nPlease note:\nV-safe is not an official record of being vaccinated against COVID-19\nV-safe does not give medical advice\nV-safe cannot schedule COVID-19 vaccination appointments\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:31 AM V-safe After Vaccination Health Checker | CDC\nEnroll in v-safe\nYou can enroll in v-safe after any dose of COVID-19 vaccine by using your smartphone and going to vsafe.cdc.gov.","5984":"Effectiveness of a Moderna COVID-19 Vaccine (0.25 mL [50 \u03bcg of mRNA]) booster dose in individuals who\ncompleted primary vaccination with another authorized or approved COVID-19 vaccine (homologous or\nheterologous booster dose) is inferred from immunogenicity data supporting effectiveness of a Moderna\nCOVID-19 Vaccine (0.25 mL [50 \u03bcg of mRNA]) booster dose administered following completion of a Moderna\nCOVID-19 Vaccine primary series and from immunogenicity data from an independent Phase 1\/2 open-label\nclinical trial (NCT04889209) conducted in the United States that evaluated a booster dose (0.5 mL [100 \u03bcg of\nmRNA]) of the Moderna COVID-19 Vaccine.","7678":"This monitoring includes using both established and new safety monitoring\nsystems to make sure that COVID-19 vaccines are safe. Common Side Effects\nSome people have side effects after getting their COVID-19 vaccine, while others might have no side effects. Side effects may\naffect the ability to do daily activities, but they should go away within a few days. Learn more about common side effects after\nCOVID-19 vaccination. Adverse Events (Serious Safety Problems) Are Rare\nIn rare cases, people have experienced serious health events after COVID-19 vaccination. Any health problem that happens\nafter vaccination is considered an adverse event.","4150":"All vaccine development steps were taken to ensure COVID-19 vaccine safety and effectiveness,\nAre COVID-19 vaccines safe even though the vaccines were developed rapidly? \uf1aa\f10\/30\/22, 9:18 AM Frequently Asked Questions about COVID-19 Vaccination | CDC\ny p p y ,\nincluding:\nClinical Trials \u2013 All vaccines in the United States must go through three phases of clinical trials to ensure they are\nsafe and effective. The phases overlapped to speed up the process, but all phases were completed. Authorization or Approval \u2013 Before vaccines are available to people, the U.S. Food and Drug Administration (FDA)\nreviews data from clinical trials.","9213":"Clean and disinfect areas that may have blood, stool, or body fluids on them. Use household cleaners and disinfectants. Clean visible dirty surfaces with household cleaners\ncontaining soap or detergent. Then, use a household disinfectant. Use a product from EPA\u2019s List N: Disinfectants for Coronavirus (COVID-19)\nBe sure to follow the instructions on the label to ensure safe and effective use of the product. Many products recommend keeping the surface wet with a disinfectant for a certain period of\ntime (look at \u201ccontact time\u201d on the product label).","8026":"\u0083 Disseminate messages about community-level risk and corresponding COVID-19 mitigation measures. \u0083 Continue to encourage vaccinations and staying up to date with vaccine boosters by suggesting employers offer time off to\nget vaccines and recover from side effects. \u0083 Monitor and update the public on the COVID-19 vaccines\u2019 effectiveness against variants and communicate any concerns in\nreal time. \u0083 Create messages that encourage people who are vaccinated to support their friends and family to get the COVID-19 vaccines.","5549":"Some masks and respirators offer higher levels of protection than others, and some may be harder to tolerate or wear\nconsistently than others. It is most important to wear a well-fitting mask or respirator correctly that is comfortable for\nyou and that provides good protection. While all masks and respirators provide some level of protection, properly fitting respirators provide the highest level of\nprotection. Wearing a highly protective mask or respirator may be most important for certain higher risk situations, or by\nsome people at increased risk for severe disease.","7256":"Please include either \u201cCOMIRNATY (COVID-19\nVaccine, mRNA)\u201d, \u201cPfizer-BioNTech COVID-19 Vaccine EUA\u201d, or \u201cPfizer-BioNTech\nCOVID-19 Vaccine, Bivalent EUA\u201d as appropriate, in the first line of box #18 of the\nreport form. In addition, you can report side effects to Pfizer Inc. at the contact information provided\nbelow. Website Fax number Telephone number\nYou may also be given an option to enroll in v-safe. V-safe is a voluntary\nsmartphone-based tool that uses text messaging and web surveys to check in with\npeople who have been vaccinated to identify potential side effects after COVID-19\nvaccination. V-safe asks questions that help CDC monitor the safety of COVID-19\nvaccines.","5317":"\u2022 had a blood clot along with a low level of platelets (blood cells that help your body stop\nbleeding) following Janssen COVID-19 Vaccine or following AstraZeneca\u2019s COVID-19\nvaccine (not authorized or approved in the United States). WHAT ARE THE INGREDIENTS IN THE JANSSEN COVID-19 VACCINE? The Janssen COVID-19 Vaccine includes the following ingredients: recombinant,\nreplication-incompetent adenovirus type 26 expressing the SARS-CoV-2 spike protein, citric acid\nmonohydrate, trisodium citrate dihydrate, ethanol, 2-hydroxypropyl-\u03b2-cyclodextrin (HBCD),\npolysorbate-80, sodium chloride. HOW IS THE JANSSEN COVID -19 VACCINE GIVEN? The Janssen COVID-19 Vaccine will be given to you as an injection into the muscle.","432":"On June 14, 2021, CDC corrected an error in the Census denominators used to calculate percentage-based metrics for\nthe U.S. population ages 12 years and older, 18 years and older, and 65 years and older. No other population groups\nwere affected. The census counts for the population ages 12 years and older increased from 280,216,744 to 283,545,812 people\n(+3,329,068). The census counts for the population ages 18 years and older increased from 258,130,580 to 258,259,833 people\n(+129,253). The census counts for the population ages 65 years and older decreased from 54,696,898 to 54,696,581 people\n(-317).","3464":"\uf106 As of July 18, 2022, CDC\u2019s COVID-19 Program for Cruise Ships is no longer in effect. CDC will continue to\npublish guidance to help cruise ships continue to provide a safer and healthier environment for passengers,\ncrew and communities going forward. For more information, please see the Frequently Asked Questions\n(FAQs). Before Cruise Travel\nDo not travel or board a cruise ship if\u2026\nYou are sick with COVID-19. You tested positive for COVID-19 less than 10 days ago (day 0 is the day your symptoms started or the day your\npositive test sample was taken if you had no symptoms).","9060":"Scientists monitor all variants but may classify certain ones as:\nVariants Being Monitored \u2013 No risk to public health; Circulating at very low levels in the United States\nVariants of Interest \u2013 Potential impact on spread, severity, testing, treatment, and vaccinations; Evidence it has caused an\nincrease proportion of cases or unique outbreak clusters\nVariants of Concern \u2013 Evidence of impact on spread, severity, testing, treatment, and vaccination\nVariants of High Consequence \u2013 Clear evidence of significant impact on spread and severity, and reduction of\neffectiveness of testing, treatment, and vaccination\nIn the United States, CDC uses viral genomic surveillance to track COVID-19 variants, to more quickly identify and act upon\nthese findings to best protect the public\u2019s health.","10108":"\u0083 People who recently had SARS-CoV-2 infection may consider delaying their next COVID-19 dose by 3 months from symptom onset or positive test\n(if infection was asymptomatic). \u0083 Viral testing to assess for acute SARS-CoV-2 infection or serologic testing to assess for prior infection is not recommended for the purpose of\nvaccine decision-making. \u0083 Additional information at: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html#infection\n\u0083 COVID-19 vaccination is not recommended for post-exposure prophylaxis. \u00a7 Additionally, people with a history of an episode of immune-mediated syndrome characterized by thrombosis and thrombocytopenia, such as spontaneous or classic HIT, should not receive Janssen COVID-19 Vaccine.","8573":"\u2022\n\u2022\n\u2022\n\u2022\nCOVID-19 vaccines help our bodies develop immunity to the virus that causes COVID-19 without us having to get the\nillness. Different types of vaccines work in different ways to offer protection. But with all types\nof vaccines, the body is left with a supply of \u201cmemory\u201d T-lymphocytes as well as B-\nlymphocytes that will remember how to fight that virus in the future. It typically takes a few weeks after vaccination for the body to produce T-lymphocytes\nand B-lymphocytes.","7736":"\u2022 -\n\u2022\n\uf209\n\u2022\n\uf209\n\u2022\f10\/30\/22, 9:32 AM Selected Adverse Events Reported after COVID-19 Vaccination | CDC\nAllergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine \u2014\nUnited States, December 14-23, 2020\nThrombosis with thrombocytopenia syndrome (TTS) after J&J\/Janssen COVID-19 vaccination is rare and has\noccurred in approximately 4 cases per one million doses administered. TTS is a rare but serious adverse event that\ncauses blood clots in large blood vessels and low platelets (blood cells that help form clots). A review of reports indicates a causal relationship between the J&J\/Janssen COVID-19 vaccine and TTS.","309":"CDC and DC are actively working to validate this increase, and if needed, data corrections will occur in a\ntimely manner. Vaccination data submitted by Texas on April 20, 2022 are currently under review by CDC and state officials due to the\nuse of a new reporting process and are not reflected on COVID-19 Data Tracker. The data will be updated when\navailable. April 15, 2022: New Hampshire reviewed data and made adjustments to the vaccination records they have reported to\nCDC, resulting in a decrease of 62,163 vaccine doses administered since December 14, 2020.","9402":"You or your child should not get any of these vaccines if you or your child:\n\u2022 had a severe allergic reaction after a previous dose of SPIKEVAX (COVID-19 Vaccine,\nmRNA) or Moderna COVID-19 Vaccine\n\u2022 had a severe allergic reaction to any ingredient in these vaccines\nWHAT ARE THE INGREDIENTS IN THESE VACCINES? SPIKEVAX (COVID-19 Vaccine, mRNA), Moderna COVID-19 Vaccine, and Moderna\nCOVID-19 Vaccine, Bivalent contain the following ingredients: messenger ribonucleic acid\n(mRNA), lipids (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG],\ncholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), tromethamine,\ntromethamine hydrochloride, acetic acid, sodium acetate trihydrate, and sucrose. HOW ARE THESE VACCINES GIVEN?","9":"Even after your COVID-19 vaccination, when you are in a correctional facility, it\u2019s important\nto continue wearing a well-fitting mask, try to stay at least 6 feet away from others as\nmuch as possible, and wash your hands often. Side effects may make\nyou feel a little sick or\neven make it hard to\ndo daily activities, but\nthey should go away\nin a few days. vaccination rates and\nensure that staff and\nresidents stay up to date\non their COVID-19 vaccines. COVID-19 vaccines may\nnot fully protect you\nuntil a week or two after\nyour final shot. It takes\ntime for your body to\nbuild protection after\nany vaccination.","5023":"Added considerations for an 8-week interval between the first and second doses of a primary mRNA vaccine schedule\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nUpdated guidance for moderately or severely immunocompromised people\nClarification of existing recommendation to receive a 3-dose mRNA vaccine primary series followed by a booster\ndose for a total of 4 doses\nNew guidance to shorten the interval between completion of the mRNA vaccine primary series and the booster\ndose to at least 3 months (instead of 5 months)\nNew guidance for those who received the Janssen COVID-19 Vaccine primary series to receive an additional dose\nand a booster dose, for a total of 3 doses to be up to date\nUpdated guidance that it is no longer necessary to delay COVID-19 vaccination following receipt of monoclonal\nantibodies or convalescent plasma\nUpdated guidance on receiving a booster dose if vaccinated outside the United States\nUpdated contraindication and precaution section to include history of myocarditis or pericarditis after an mRNA\nCOVID-19 vaccine as a precaution\nReorganized and condensed multiple sections\nUpdated guidance for use of Pfizer-BioNTech COVID-19 Vaccine as a booster in people ages 12\u201317 years\nUpdated guidance for administration of a COVID-19 vaccine booster dose at least 5 months after completion of an\nmRNA vaccine (Pfizer-BioNTech or Moderna) primary series\nUpdated guidance for use of an additional primary dose for moderately or severely immunocompromised people ages\n5\u201311 years who received a Pfizer-BioNTech vaccine primary series\nUpdated recommendations for people who received COVID-19 vaccines outside the United States that are not FDA-\nauthorized or approved\nUpdated information about a second formulation of Pfizer-BioNTech COVID-19 Vaccine that is authorized for use in\npersons ages 12 years and older\nUpdated information on vaccinating people during quarantine after a known SARS-CoV-2 exposure or during COVID-\nUpdate to alert providers of possible false positive Rapid Plasma Reagin (RPR; non-treponemal) test results in some\npeople after COVID-19 vaccines\nUpdated information on vaccine administration errors and deviations\nUpdated guidance on use of Janssen (Johnson & Johnson) COVID-19 Vaccine\nUpdated recommendations for receipt of a COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 booster doses in recipients of mRNA COVID-19 vaccines\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nRecommendations and clinical guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children aged 5-11 years\nincluding updated section on Vaccination of children and adolescents\nUpdated guidance on COVID-19 vaccine dosing and schedule\nUpdated guidance for myocarditis and pericarditis after mRNA COVID-19 vaccination in new section on Considerations\nfor mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna\nNew guidance for people who received passive antibody products in section on COVID-19 vaccination and SARS-CoV-2\ninfection\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial in the United States\nUpdated guidance on Considerations for COVID-19 vaccination in moderately and severely immunocompromised\npeople\nUpdated guidance in section on Contraindications and precautions\nUpdated Table in Appendix A: Vaccine administration errors and deviations\nUpdated Appendix B: Triage of people with a history of allergies or allergic reactions\nUpdated Appendix C: Ingredients included in COVID-19 vaccines\nUpdated Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects\nfollowing COVID-19 vaccination\nUpdated guidance in section on Considerations for use of a COVID-19 booster dose.","4471":"If you have symptoms, get tested\nand stay home until you have your results. If you have tested positive (even without symptoms), follow CDC\u2019s\u202fisolation\nrecommendations. These recommendations include staying home and away from others for at least 5 days (possibly\nmore,\u202fdepending on how the virus affects you) and wearing a high-quality mask when indoors around others for a period\nof time. 10\/30\/22, 9:39 AM How to Protect Yourself and Others | CDC\nSeeking Treatment If You Have COVID-19 and Are at High Risk of Getting Very Sick\nEffective treatments are now widely\navailable and free, and you may be\neligible.","4680":"Most systemic symptoms were mild to moderate in severity and resolved within 1\u20132 days. Overall, symptoms were more frequent in people ages 18\u201359 years compared to people ages 60 years and older. Thrombosis with thrombocytopenia syndrome (TTS)\nTTS is a rare syndrome that includes acute venous or arterial thrombosis and new onset thrombocytopenia in patients with\nno recent known exposure to heparin. Although the condition is rare, currently available evidence supports a causal\nrelationship between Janssen COVID-19 Vaccine and TTS.","8045":"On May 17, 2022, the FDA amended the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine, authorizing\na single booster dose for children ages 5-11 years at least five months after completion of a primary series with the same\nvaccine.101 The FDA committee that reviews and evaluates data concerning the safety, effectiveness, and appropriate use of\nvaccines, VRBPAC (Vaccines and Related Biological Products Advisory Committee), meet on June 14\u201315, 2022 to discuss the\nemergency use authorization of COVID-19 vaccines in this age.102 On June 17, 2022, the Advisory Committee on Immunization\nPractices (ACIP) issued interim recommendations for use of the Moderna COVID-19 vaccine in children ages 6 months to 5\nyears and the Pfizer COVID-19 vaccine\nfor use in children ages 6 months to 4\nyears.103 Some parents have expressed\nenthusiasm and relief about childhood\nvaccination.104,105,106 However, a recent\nKaiser Family Foundation (KFF) poll\nfound that only 18% of parents with\nchildren younger than 5 years will get\ntheir child vaccinated right away, while\n38% say they plan to wait and see how\nthe vaccine is working for others, 27%\nsay they will definitely not get their child\nvaccinated, and 11% say they will only do\nso if they are required.107,108\nPerceptions, Concerns, and Threats to Vaccine Confidence\n\u0083 Concerns about side effects, such as myocarditis, may negatively impact vaccine uptake.109,110\n\u0083 Some consumers believe vaccines are unnecessary because COVID-19 rarely affects this group.111,112\n\u0083 Some believe infection-induced immunity protects children better than vaccines.113,114\n\u0083 Some social media users do not think there is enough data to support vaccination against COVID-19 in children.115,116,117\n\u0083 With cases of hepatitis in children rising globally, some believe they are caused by COVID-19 vaccines.118,119,120\n\u0083 Some are concerned that immunity from vaccines decreases rapidly in adolescents.122,123\nCommonly asked questions and queries from the public\n\u0083 Should children under the age of 5 years still wear masks?i\n\u0082 Wearing a well-fitting mask or respirator consistently and correctly reduces the risk of spreading the virus that causes\nCOVID-19.","305":"CDC and DC are actively working to validate this increase, and if needed, data corrections will occur in a\ntimely manner. Vaccination data submitted by Texas on April 20, 2022 are currently under review by CDC and state officials due to the\nuse of a new reporting process and are not reflected on COVID-19 Data Tracker. The data will be updated when\navailable. April 15, 2022: New Hampshire reviewed data and made adjustments to the vaccination records they have reported to\nCDC, resulting in a decrease of 62,163 vaccine doses administered since December 14, 2020.","3514":"Additionally, cruise travelers have access to\nrecommendations that allow them to make informed decisions about cruise ship travel. While cruising poses some risk of\nCOVID-19 transmission, CDC will continue to publish guidance to help cruise ships continue to provide a safer and\nhealthier environment for crew, passengers, and communities going forward. What happened to CDC\u2019s COVID-19 Program for Cruise Ships? \uf1aa\nThe previous color-coding system under CDC\u2019s COVID-19 Program for Cruise Ships depended upon each cruise line\nhaving the same COVID-19 screening testing standards, which may now vary among cruise lines. Therefore, the cruise\nship color status webpage has been retired.","6455":"What to do if you test positive for COVID-19\nEffective treatments are now widely available and free, and you may be eligible. Contact your healthcare provider, health department, or Community Health Center to learn about treatment\noptions. Don\u2019t delay! Treatment must be started soon after you first develop symptoms to be effective. If you don\u2019t have timely access to a healthcare provider, check if a Test to Treat location is in your community. You\ncan get tested, receive a prescription from a healthcare provider (either onsite or by telehealth), and have it filled all at\none location.","1944":"If an unexpected\nadverse event is seen, experts quickly study it further to assess whether it is a true safety concern. Experts then decide whether changes are needed in U.S. vaccine recommendations or clinical guidance. This monitoring is critical to help ensure that the benefits continue to outweigh the risks for people who receive\nvaccines. FDA\u2019s COVID-19 Vaccines website includes important recommendations for ongoing safety evaluation after any\nCOVID-19 vaccine is made available under EUA . CDC has expanded safety surveillance through new systems and additional information sources, as well as by scaling up\nexisting safety monitoring systems.","7716":"10\/30\/22, 9:32 AM Selected Adverse Events Reported after COVID-19 Vaccination | CDC\nEspa\u00f1ol | Other Languages\nSelected Adverse Events Reported after COVID-19\nVaccination\nSafety of COVID-19 Vaccines\nSome people have no side effects. Many people have reported side effects, such as headache, fatigue, and soreness at\nthe injection site, that are generally mild to moderate and go away within a few days. What You Need to Know\nCOVID-19 vaccines are safe and effective and severe reactions after vaccination are rare. CDC recommends everyone ages 5 years and older get vaccinated as soon as possible to protect against COVID-19 and\nits potentially severe complications.","622":"May 12, 2022: California made updates to data previously submitted to CDC that resulted in an increase of 25,505\ntotal doses administered, a net decrease of 646,951 people with at least one dose, and a net increase of 472,028\npeople with a first booster dose. May 11, 2022: Alaska made updates to data previously submitted to CDC that resulted in an increase of 3,118 doses\nadministered. May 10, 2022: Wyoming made updates to data previously submitted to CDC that resulted in a decrease of 12,716\ndoses administered.","2732":"10\/30\/22, 9:42 AM Caring for People with Post-COVID Conditions | CDC\nEspa\u00f1ol | Other Languages\nCaring for People with Post-COVID Conditions\nHaving a post-COVID condition or supporting someone with a post-COVID condition can be challenging. It can be difficult to\ncare for yourself or loved ones, especially when there are few or no immediate answers or solutions. However, there are ways\nto help relieve some of the additional burdens of experiencing or caring for someone with a new and unknown condition. If you care for someone, remember to take steps to protect yourself and others from COVID-19. This information is intended for a general audience.","9405":"SPIKEVAX (COVID-19 Vaccine, mRNA), Moderna COVID-19 Vaccine, or Moderna COVID-\n19 Vaccine, Bivalent will be given to you or your child as an injection into the muscle. for the primary series for individuals 12 years of age and older without presenting any safety or effectiveness\nconcerns. Primary Series: SPIKEVAX (COVID-19 Vaccine, mRNA) and Moderna COVID-19 Vaccine\nare administered as a two-dose series, 1 month apart. A third primary series dose may be\nadministered at least 1 month after the second dose to individuals with certain kinds of\nimmunocompromise.","6517":"The number of deaths among people over age 65 is 97 times higher than the number of deaths among\npeople ages 18-29 years. A person\u2019s risk of severe illness from COVID-19 increases as the number of underlying medical conditions they have\nincreases. Some people are at increased risk of getting very sick or dying from COVID-19 because of where they live or work, or\nbecause they can\u2019t get health care. This includes many people from racial and ethnic minority groups and people with\ndisabilities. Studies have shown people from racial and ethnic minority groups are also dying from COVID-19 at younger ages.","3890":"\uf1aa\n\uf209\nYou are required to provide patients with a COVID-19 vaccination record card, included in the ancillary supply kits for\nCOVID-19 vaccines, and an EUA Fact Sheet for Recipients and Caregivers for the vaccine product administered. Vaccination providers should also provide vaccine recipients with information about participating in v-safe, CDC\u2019s\nsmartphone-based after-vaccination health checker that uses text messaging and web surveys to provide personalized\nhealth check-ins. What information am I required to provide to patients? \uf1aa\nAs we learn more about COVID-19 vaccines and how to best implement the CDC COVID-19 Vaccination Program, CDC\nposts updates and amendments to the COVID-19 Provider Agreement on its website.","9499":"The Countermeasures Injury Compensation Program (CICP) is a federal program that may help\npay for costs of medical care and other specific expenses of certain people who have been\nseriously injured by certain medicines or vaccines, including these vaccines. Generally, a claim\nmust be submitted to the CICP within one (1) year from the date of receiving the vaccine. To\flearn more about this program, visit www.hrsa.gov\/cicp\/ or call 1-855-266-2427. WHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)? An EUA is a mechanism to facilitate the availability and use of medical products, including\nvaccines, during public health emergencies, such as the current COVID-19 pandemic.","7889":"\u0083 Clarify the benefits of COVID-19 vaccines, including boosters, in preventing severe disease. \u0083 Work with community members and trusted messengers to create and disseminate messages that explain that some side\neffects are normal and expected. If a vaccinated individual gets COVID-19, vaccination will increase the chances that it is a\nmild case. \u0083 Develop and amplify messages explaining why vaccines are still important in the COVID-19 prevention response. \u0083 Disseminate messages about community-level risk and corresponding COVID-19 mitigation measures. \u0083 Encourage local health departments, public health experts, and healthcare workers to explain the absence of association\nbetween COVID-19 vaccines and monkeypox.","1057":"The Treatment Locator (hhs.gov) can help you find a location that offers testing and treatment or a pharmacy\nwhere you can fill your prescription. \u2022\n\u2022\n\u2022\n\u2022 \uf209\nIf you test positive and are more\nlikely to get very sick from COVID-\n19, treatments are available\nthat can reduce your chances of\nbeing hospitalized or dying from\nthe disease. Medications to treat\nCOVID-19 must be prescribed by a\nhealthcare provider and started as\nsoon as possible after diagnosis to\nbe effective. Contact a healthcare\nprovider right away to determine if\nyou are eligible for treatment, even\nif your symptoms are mild right\nnow.","8887":"10\/30\/22, 9:21 AM Vaccinating Dialysis Patients and Healthcare Personnel | CDC\nVaccines & Immunizations\nVaccines & Immunizations\nVaccinating Dialysis Patients and Healthcare Personnel\nTake action to protect patients at high-risk in your jurisdiction\nCOVID-19 vaccines are effective at protecting people from getting sick. By allocating vaccines for outpatient dialysis patients\nand the healthcare personnel who care for them in your jurisdiction, you can protect patients who are at high risk,\ndisproportionately affected by COVID-19, or might suffer severe consequences if infected. How can jurisdictions support COVID-19 vaccination efforts for\ndialysis patients and healthcare personnel? Make sure you are aware of the dialysis clinics located in your jurisdiction.","3342":"Until additional safety data are available, experts advise that people who develop myocarditis or pericarditis after a dose of\nModerna, Novavax, or Pfizer-BioNTech COVID-19 vaccine generally should not receive a subsequent dose of any COVID-19\nvaccine. If, after a risk assessment, the decision is made to administer a subsequent COVID-19 vaccine dose, the person\nshould wait until at least after their episode of myocarditis or pericarditis has resolved (i.e., resolution of symptoms, no\nevidence of ongoing heart inflammation or sequelae as determined by patient\u2019s clinical team). For information on potential use of Janssen COVID-19 Vaccine, see Appendix A.","2556":"\u00b6 An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines may be optimal for some people ages 6 months\u201364\nyears, especially for males ages 12\u201339 years, as it may reduce the small risk of myocarditis and pericarditis associated with these vaccines. A shorter interval (4 weeks for Moderna) between the\nfirst and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is\nincreased concern about COVID-19 community levels or an individual\u2019s higher risk of severe disease.","7612":"How does CDC determine whether a country is designated as having limited vaccine availability? \uf1aa\n\uf209\nYou will need to show a U.S. military identification document, such as a military ID or Common Access Card (CAC) or a\nDEERS ID Card, or other proof of status as a member or spouse or child (under 18 years of age) of a member of the U.S.\nArmed Forces. What documentation do I need if I am a member of the U.S. Armed Forces or a spouse or child\n(under 18 years of age) of someone who is a member of the U.S. Armed Forces?","3":"cdc.gov\/coronavirus\nWhat to Expect after Getting a COVID-19 Vaccine\nThe COVID-19 shot may cause side effects in some people. Side effects should go away in a few days. On the arm where you got the shot:\n\u2022 Pain\n\u2022 Redness\n\u2022 Swelling\nIf you are sore where you got the shot:\n\u2022 Apply a clean, cool, wet washcloth over the area\n\u2022 Use or move your arm gently\nIf you have a fever:\n\u2022 Drink a lot of water\n\u2022 Get plenty of rest\n\u2022 Dress lightly\nIf you have pain, headache, or fever, ask a healthcare provider (or facility\nstaff) if you can have medicine.","3395":"Clinical recovery has been achieved, including return to baseline cardiac function; and\n2. It has been at least 90 days after the diagnosis of MIS-C\/A\nCOVID-19 vaccination may also be considered for people who had MIS-C\/A and do not meet both criteria, at the discretion of\ntheir clinical care team (see Consultation for decisions about COVID-19 vaccination). Experts view clinical recovery, including\nreturn to baseline cardiac function, as an important factor when considering COVID-19 vaccination. Additional factors, such as\nthe risk of severe COVID-19 due to age or certain medical conditions, may also be considered.","2707":"Clean other surfaces in your home when they are visibly dirty or as needed. Clean them more frequently if people\nin your household are more likely to get very sick from COVID-19. Disinfect if certain conditions apply. Clean surfaces using a product suitable for each surface, following instructions on the product label. When Someone Is Sick\nIf someone in your home is sick or someone who has COVID-19 has been in your home in the last 24 hours, clean and\ndisinfect your home. Disinfecting removes germs and reduces their spread. Immediately after disinfecting, wash your\nhands with soap and water for 20 seconds.","10133":"\u0083 For more information see: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html#myocarditis-pericarditis\nConsiderations for Janssen COVID-19 Vaccine\nJanssen COVID-19 Vaccine is authorized for adults ages 18 years and older in certain limited situations due to safety considerations. For more information, see https:\/\/www.cdc.gov\/vaccines\/\nPersons with a history of Guillain-\nBarr\u00e9 syndrome (GBS)\n\u0083 A history of GBS is a precaution for receipt of Janssen COVID-19 Vaccine. An mRNA or Novavax vaccine is recommended..\n\u0083 Persons who develop GBS within 6 weeks of Janssen COVID-19 vaccination should only receive an mRNA COVID-19 vaccine for subsequent\ndoses. These people should receive a booster dose of an mRNA COVID-19 vaccine for subsequent doses.","6535":"They are not in order of risk. CDC completed a review for each medical condition on this list. This was done to ensure that these conditions met\ncriteria for inclusion on this list. CDC conducts ongoing reviews of additional underlying conditions. If other\nmedical conditions have enough evidence, they might be added to the list. Because we are learning more about COVID-19 every day, this list does not include all medical conditions that\nplace a person at higher risk of severe illness from COVID-19. Rare medical conditions, including many conditions\nthat mostly affect children, may not be included on the list below.","2286":"Safe, Easy, Free, and Nearby COVID-19 Vaccination\nThe federal government is providing the vaccine free of charge to all people living in the U.S., regardless of their\nimmigration or health insurance status. COVID-19 Vaccines Are Free\n\u2022\n\u2022\n\u2022\nTo find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. 10\/30\/22, 9:29 AM COVID-19 Vaccines for Long-term Care Residents | CDC\nLearn more about how the federal government, LTC providers, and jurisdictions are ensuring access to COVID-19 vaccines in\nLTC settings. Learn more about possible side effects and what to expect after getting your COVID-19 vaccine.","1987":"10\/30\/22, 9:31 AM COVID-19 Vaccine Safety in Children and Teens | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccine Safety in Children and Teens\nClinical Trials and Ongoing Safety Monitoring Show That COVID-\n19 Vaccination Is Safe for Children and Teens\nBefore authorizing or approving COVID-19 vaccines, scientists conducted clinical trials with thousands of children and teens to\nestablish their safety and effectiveness. Learn more about how COVID-19 vaccines were developed and approved. COVID-19 vaccines are being monitored under the most comprehensive and intense vaccine safety monitoring program in\nU.S. history. CDC monitors all COVID-19 vaccines after they are authorized or approved for use.","2658":"If possible, have the person who is\nsick use a separate bedroom and\nbathroom. If possible, have the\nperson who is sick stay in their own \u201csick room\u201d or area and away from others. Try to stay at least 6 feet away from\nthe sick person. Shared space: If you have to share space, make sure the room has good air flow. Open the window to increase air circulation. Improving ventilation helps remove respiratory droplets from the air. Avoid having visitors. Avoid having any unnecessary visitors, especially visits by people who are at higher risk for\nsevere illness.","4229":"Some vaccination providers and health departments may offer you access to a QR code or digital copy of your CDC\nCOVID-19 Vaccination card in addition to giving you a physical card. Contact your vaccination provider or local\nhealth department to learn if you can get a digital copy of your card. CDC does not provide the white CDC COVID-19 Vaccination card to people and does not maintain vaccination records. CDC distributes the white CDC COVID-19 Vaccination cards to vaccination providers and only a vaccination provider can\ngive you this card. How can I get a new CDC COVID-19 Vaccination card?","5679":"Although\nrespirators may be available in smaller sizes, they are typically designed to be used by adults in workplaces, and therefore\nhave not been tested for broad use in children. Selecting Masks\nMasks and respirators should not be worn by children younger than 2 years. Choose a high-quality and comfortable mask or respirator that your child can wear properly. A poorly fitting or\nuncomfortable mask or respirator might be worn incorrectly or removed often, and that would reduce its intended\nbenefits. Choose a size that fits over the child\u2019s nose and under the chin but does not impair vision.","1894":"10\/30\/22, 9:33 AM COVID-19 Vaccine Effectiveness | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccines are Effective\nCDC is reviewing this page to align with updated guidance. COVID-19 vaccines are safe and effective. COVID-19 vaccination helps protect adults and children ages 6 months and older\nfrom getting severely ill with COVID-19 and helps protect those around them. Some people who are vaccinated against COVID-19 will still get sick and have a\nvaccine breakthrough infection because no vaccine is 100% effective.","1516":"Providers may direct bulk quantities of the masks to long-term care facilities for free distribution to their residents\nand communities at no cost subject to the requirements of this section. 4. USG will have the sole responsibility for any reporting of inventory throughput or other data. 5. Providers distributing USG-purchased N95 masks provided through this initiative agree to provide the masks at\nno charge, for use by individuals. Receipt of masks cannot be conditioned on purchase of other products or\nservices.","9885":"Rapid Review Update 1: What is the ongoing\neffectiveness, immunogenicity, and safety of COVID-19 vaccines in persons who have had a prior, confirmed\nCOVID-19 infection?. Hamilton (ON): McMaster University; 2021. Available from: https:\/\/www.nccmt.ca\/covid-\n19\/covid-19-rapid-evidence-service\/36. Parry H, Bruton R, Stephens C, et al. Extended interval BNT162b2 vaccination enhances peak antibody\nPatamatamkul S, Thammawat S, Buranrat B. Induction of robust neutralizing antibodies against the COVID-19\nDelta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster following a primary vaccination series with\nCoronaVac. medRxiv 2021.09.25.21264099; doi: https:\/\/doi.org\/10.1101\/2021.09.25.21264099. Payne RP, Longet S, Austin JA, et al. 2021. Immunogenicity of standard and extended dosing intervals of\nBNT162b2 mRNA vaccine. Cell.","5415":"The EUA is supported by a Secretary of Health and Human\nServices (HHS) declaration that circumstances exist to justify the emergency use of drugs and\nbiological products during the COVID-19 pandemic. The Janssen COVID-19 Vaccine has not undergone the same type of review as an FDA-approved\nor cleared product. FDA may issue an EUA when certain criteria are met, which includes that there\nare no adequate, approved, and available alternatives.","20":"10\/30\/22, 9:34 AM About COVID-19 Vaccines | CDC\nEspa\u00f1ol | Other Languages\nAbout COVID-19 Vaccines\nCOVID-19 vaccines are safe and effective. CDC recommends COVID-19 vaccines for everyone 6 months and older and boosters\nfor everyone 5 years and older, if eligible. Learn about the different vaccines available. To find a COVID-19 vaccine near you: Search vaccines.gov, text your zip\ncode to 438829, or call 1-800-232-0233 to find COVID-19 vaccine locations near you. Benefits of Getting Vaccinated\nFrequently Asked Questions\n\u2022\n\u2022\n\u2022\n\u2022\nGetting a COVID-19 vaccine is fast, easy, and free. Learn how to find a COVID-19 vaccine near you, and get your vaccine\ntoday!","3704":"1 The COVID-19 vaccine by Pfizer-BioNTech (brand name Comirnaty) was approved by FDA in August 2021 as a 2-dose\nprimary series for active immunization to prevent COVID-19 in persons aged \u2265 16 years. FDA also amended the EUA for the\nPfizer-BioNTech COVID-19 vaccine to authorize an additional primary dose in certain immunocompromised persons aged \u2265\n12 years and a homologous or heterologous booster dose in persons aged \u2265 18 years following primary vaccination with the\nPfizer-BioNTech or a different FDA-authorized COVID-19 vaccine.","8684":"If you have risk factors, have a COVID-19 plan in place in case you get sick, and discuss that plan\nwith your healthcare provider and those close to you. Learn what extra precautions you can take to protect yourself and\nothers in settings that make you more likely to be exposed to COVID-19. \uf3c2 Risk of Getting COVID-19\n\uf266 Risk of Getting Very Sick\nInformation for Specific Groups\nOlder Adults\nPeople Who Are Immunocompromised\nPeople with Medical Conditions\nPeople with Asthma\nPregnant and Recently Pregnant People\n\uf419 Risk for COVID-19 Infection, Hospitalization, and Death\nAge Group Rate Ratios Race and Ethnicity Rate Ratios\nLast Updated Aug. 11, 2022","3421":"Consultation for decisions about COVID-19 vaccination\nA conversation between the patient and\/or their guardian(s) and their clinical team or a specialist (e.g., infectious diseases,\nrheumatology, and\/or cardiology) is strongly encouraged to assist with decisions about the use of COVID-19 vaccines in the\nsetting of MIS-C or MIS-A. For complicated situations, not addressed by the guidance above, healthcare and public health professionals may consider\nrequesting a consultation from the Clinical Immunization Safety Assessment COVIDvax project. An illness consistent with MIS-\nC or MIS-A after receiving COVID-19 vaccine should be reported to VAERS .","5256":"\u2022\nYour symptoms are not improving\nContinue to isolate until:\nYou are fever-free for 24 hours (without the use of\nfever-reducing medication). Your symptoms are improving. \u2022\nModerate illness (you experienced shortness of\nbreath or had difficulty breathing)\nYou need to isolate through day 10. Severe illness (you were hospitalized) or have a\nweakened immune system\nYou need to isolate through day 10. \u2022\f10\/30\/22, 9:41 AM Isolation and Precautions for People with COVID-19 | CDC\nRegardless of when you end isolation\nUntil at least day 11:\nAvoid being around people who are more likely to get very sick from COVID-19.","8564":"Yes, both masked\nLower Risk\nOnly one masked\nModerate Risk\nNeither masked\nHigher Risk\f10\/30\/22, 9:38 AM Understanding Exposure Risks | CDC\nLower Risk Moderate Risk Higher Risk\nVentilation and filtration: How well-ventilated was the space? More outdoor air can decrease the risk of transmission. Being outside would be lower exposure risk than being indoors, even\nwith good ventilation and filtration; both of those options would be lower risk than being indoors with poor ventilation or\nfiltration. See the Interactive Home Ventilation Tool. Outdoors\nLower Risk\nWell-ventilated indoors\nModerate Risk\nPoorly ventilated indoors\nHigher Risk\nDistance: How close was the infected person to you?","5093":"People with a known (diagnosed) allergy to PEG, another mRNA\nvaccine component, or polysorbate, have a contraindication to vaccination. People with a reaction to a vaccine or\ninjectable therapy that contains multiple components, one of which is PEG, another mRNA vaccine component or\npolysorbate, but in whom it is unknown which component elicited the immediate allergic reaction have a precaution\nto vaccination. Updated information on delayed, local injection-site reactions after the first mRNA vaccine dose. These reactions are\nneither a contraindication nor a precaution to the second dose. Updated quarantine recommendations for vaccinated people.","6316":"\u2022\n\u2022\n\uf20c\n\u2022\n\u2022\nIf you think you or a loved one may have a post-COVID condition (new or persistent conditions occurring 4 or more weeks\nafter initial infection with SARS-CoV-2, the virus that causes COVID-19), taking a few steps to prepare for your meeting\nwith a healthcare provider can make all the difference in getting the proper medical evaluation, diagnosis, and treatment. You play a vital role in helping healthcare providers understand your or your family member\u2019s symptoms and how they\naffect your daily life.","2346":"AGE GROUP\nPRIMARY SERIES PRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nChildren 5 years of age can get a\nPfizer-BioNTech booster at least\n2 months after their 3rd dose. (Children 6 months to 4 years\nare not recommended for a\nbooster.) Up to Date: Children 6 months to 4 years are up to date two weeks after completing the 3 dose of their primary\nseries. Children 5 years of age who received a Moderna primary series are up to date immediately after they have\nreceived the most recent booster recommended for them.","591":"August 4, 2022: Texas made updates to data previously submitted to CDC that resulted in a net decrease of\n1,125,795 administered doses. This contributed to a decrease in overall US figures. August 4, 2022: Wyoming made updates to data previously submitted to CDC that resulted in a net increase of 2,013\nadministered doses. July 28, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 91,864\nadministered doses.","4071":"What are the risks to getting a booster? \uf1aa\nYes, you are fully vaccinated even if you haven\u2019t gotten your booster yet. The definition of fully vaccinated does not\ninclude a COVID-19 booster. Fully vaccinated, however, is not the same as having the best protection. People are best\nprotected when they stay up to date with COVID-19 vaccinations, which includes getting a booster when eligible. Am I still considered \u201cfully vaccinated\u201d if I don\u2019t get a booster? \uf1aa\nYes. You are up to date if you have completed a COVID-19 vaccine primary series and received the most recent booster\ndose recommended for you by CDC.","805":"Getting sick with COVID-19 can cause severe illness or death, even in children, and we can\u2019t reliably predict who will\nhave mild or severe illness. You may have long-term health issues after having COVID-19. Even people who do not have symptoms when they\nare first infected can have these ongoing health problems, also known as long COVID or post-COVID conditions. These complications can appear after mild or severe COVID-19, or after multisystem inflammatory syndrome in\nchildren (MIS-C).","1771":"Use CDC\u2019s COVID-19 booster tool to learn if and when your child or teen can get boosters to stay up to date with their\nCOVID-19 vaccines. Children and youth with special healthcare needs require more care for their\nphysical, developmental, behavioral, or emotional differences than their typically\ndeveloping peers. A special healthcare need can include physical, intellectual, and\ndevelopmental disabilities, as well as long-standing medical conditions, such as\nasthma, diabetes, a blood disorder, or muscular dystrophy. Learn more\nabout Children and Youth with Special Healthcare Needs in Emergencies.","7208":"Booster Dose: Pfizer-BioNTech COVID-19 Vaccine, Bivalent is administered as a single\nbooster dose at least 2 months after:\n\uf0b7 completion of primary vaccination with any authorized or approved monovalent\nCOVID-19 vaccine; or\n\uf0b7 receipt of the most recent booster dose with any authorized or approved\nmonovalent COVID-19 vaccine\nThe vaccine may not protect everyone. WHO SHOULD NOT GET COMIRNATY (COVID-19 VACCINE, mRNA), THE\nPFIZER-BIONTECH COVID-19 VACCINE, OR THE PFIZER-BIONTECH COVID-19\nVACCINE, BIVALENT?","6479":"Include how you will adjust your plan if the COVID-19 situation changes in your community. Your plan should include:\n1. What you\u2019re doing to protect yourself and prepare (in case you get COVID)\n2. What you\u2019ll do if you\u2019re exposed or develop symptoms\n3. What you\u2019ll do if you test positive\nTalk with your family, friends, and healthcare provider about your plan\nShare your COVID-19 plan with your family, friends, and healthcare providers so they can support your prevention and\npreparation steps. Consider how others may help you if you get sick and identify the supplies you may need.","4223":"If you are\ngetting a COVID-19 booster, depending on your age and which type of COVID-19 vaccine you have already had, you may\nbe able to choose which type of COVID-19 vaccine booster to get. Learn more about which vaccine is available by age and how to stay up to date with your COVID-19 vaccination. Can I choose which COVID-19 vaccine I get? \uf1aa\nAfter Your Vaccine\nIf you have lost your CDC COVID-19 Vaccination card or don\u2019t have a copy of it, contact your vaccination provider directly\nto request a new vaccination card. They may be able to reissue a CDC COVID-19 Vaccination card.","1266":"10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\nEspa\u00f1ol | Other Languages\nVaccines & Immunizations\nVaccines & Immunizations Home\nFAQs for the Interim Clinical Considerations for COVID-\nThis page has answers to commonly asked questions about the Interim Clinical Considerations for COVID-19 Vaccination. For information about COVID-19 vaccine storage, preparation, and administration, visit the COVID-19 Vaccine FAQs for\nHealthcare Professionals. Vaccination Schedule and Use\nYes. For primary series vaccination, Moderna, Pfizer-BioNTech, and Novavax COVID-19 vaccines are recommended. For\nbooster vaccination, Moderna and Pfizer-BioNTech are recommended.","5835":"\u2022 Delaying the second primary dose in persons ages 12 years and older who recently had SARS-CoV-2\ninfection, by 3 months from symptom onset or positive test (if infection was asymptomatic)\n\u2022 Primary dose(s), including for those with certain immunocompromising conditions or those with\nincomplete primary series, for persons ages 12 years and older who received primary vaccination with\ncertain non-FDA authorized or approved COVID-19 vaccines2. \u2022 An additional dose in persons ages 18 years and older with certain immunocompromising conditions\nwho received primary vaccination with the Janssen (Johnson & Johnson) COVID-19 Vaccine.","5104":"10\/30\/22, 9:43 AM International Travel to and from the United States | CDC\nEspa\u00f1ol | Other Languages\nInternational Travel to and from the United States\nALL TRAVELERS\nThis page is for all international travelers including U.S. citizens, U.S. nationals, U.S. lawful permanent residents,\nimmigrants, and non-U.S. citizens who are not U.S. immigrants. What You Need to Know\nProtect yourself and others from COVID-19:\nGet up to date with your COVID-19 vaccines before you travel. Consider getting tested before travel. Follow CDC\u2019s recommendations for wearing masks in travel and public transportation settings. Get tested after arrival. Countries may have their own entry and exit requirements .","6833":"Remember to bring the card when your child returns. ADDITIONAL INFORMATION\nIf you have questions, visit the website or call the telephone number provided below. To access the most recent Fact Sheets, please scan the QR code provided below. Global website Telephone number\nwww.cvdvaccine.com\nHOW CAN I LEARN MORE? \uf0b7 Ask the vaccination provider. \uf0b7 Visit CDC at https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/index.html. \uf0b7 Visit FDA at https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-\nlegal-regulatory-and-policy-framework\/emergency-use-authorization. \uf0b7 Contact your local or state public health department. WHERE WILL MY CHILD\u2019S VACCINATION INFORMATION BE RECORDED? The vaccination provider may include your child\u2019s vaccination information in your\nstate\/local jurisdiction\u2019s Immunization Information System (IIS) or other designated\nsystem.","5129":"Find a U.S. COVID-19 testing location near you or use a self-test. If you already had COVID-19 within the past 90 days, see specific testing recommendations. \uf209\nCan I travel if ...? I am sick with or tested positive for COVID-19 and\nam recommended to isolate. Do NOT travel. Follow recommendations for isolation. I have ended isolation but still need to continue\nwearing my mask per CDC\u2019s guidance. Do not travel on public transportation such as\nairplanes, buses, and trains if you will not be able\nto wear a high-quality mask or respirator when\naround others indoors for the full duration of your\ntrip.","809":"Getting Sick\n\uf1aa\n\u2022\n\u2022\n\u2022\nSymptoms associated with COVID-19 vaccination vs infection\n\uf1aa\f10\/30\/22, 9:34 AM Benefits of Getting A COVID-19 Vaccine | CDC\nSymptoms Post COVID-19 Vaccination Symptoms Post COVID-19 Infection\nSymptoms Post COVID-19 Vaccination Symptoms Post COVID-19 Infection\nCough\nMuscle and joint pain\nHeadache\nTrouble falling or staying asleep\nTrouble concentrating\nLimitations in physical activity\nFeeling distressed about symptoms\nMental health challenges\nDecreased school or daycare attendance\nMissed opportunities for participation in sports,\nplaydates, or other activities\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nWhile people can get some protection from having COVID-19, the level and length of that protection varies, especially as\nCOVID-19 variants continue to emerge. Immunity (protection) from infection can vary depending on how mild or severe someone\u2019s illness was and their age.","4861":"However, if local or systemic side effects following vaccination are clinically concerning (outside of the expected side\neffect profile), lead to serious adverse reactions, or are ongoing at the time of the subsequent dose, this dose might be delayed, but this\ndecision should be assessed on a case-by-case basis. For FDA EUA dosing options for children who turn from age 4 years to 5 years (i.e., Pfizer-BioNTech), age 5 years to 6 years (i.e., Moderna), and\nage 11 years to 12 years (i.e., Moderna and Pfizer-BioNTech) during vaccination, see Transitioning from a younger to older age group.","8901":"Work with dialysis clinic leaders to establish the number of doses needed to vaccinate patients and healthcare personnel\nand determine a timeline for allocating these doses. Why is it important to vaccinate dialysis patients? The median age of patients on dialysis is 62 years. Due to age and health status, dialysis patients are at high risk for\nserious illness and death related to COVID-19; people on dialysis who get COVID-19 have a 50% hospitalization rate and a\n20%\u201330% mortality rate. Vaccinating this population addresses a health equity issue.","2635":"*Note: Older adults and people of any age with serious underlying medical conditions are at higher risk for developing more\nsevere illness from COVID-19. People at higher risk of severe illness should call their doctor as soon as symptoms start. CDC is reviewing this page to align with updated guidance. Provide support\nHelp cover basic needs\nHelp the person who is sick\nfollow their doctor\u2019s instructions\nfor care and medicine. For most people, symptoms\nlast a few days, and people\nusually feel better after a\nweek. See if over-the-counter\nmedicines for fever help the\nperson feel better. Make sure the person who is\nsick drinks a lot of fluids and\nrests.","4005":"Vaccination data in CDC\u2019s COVID Data Tracker are updated weekly on\nThursday between 1:30 pm and 8:00 pm ET. On federal holidays, updates will occur the following day. Data can be updated on different schedules and reflect data \u201cas of\u201d different dates or times of day. There can be a\ndelay between the time a vaccination record appears in a jurisdictional or federal system and when it is received\nby CDC. COVID Data Tracker\u2019s vaccination data typically have a lag time from vaccination data shown on a state\u2019s\nwebsite. The amount of lag time varies for each state.","5304":"Under an EUA, the FDA has authorized the emergency use of the Janssen COVID-19 Vaccine to\nprevent COVID-19 in individuals 18 years of age and older for whom other FDA-authorized or\napproved COVID-19 vaccines are not accessible or clinically appropriate, and in individuals 18\nyears of age and older who elect to receive the Janssen COVID-19 Vaccine because they would\notherwise not receive a COVID-19 vaccine. For more information on EUA, see the \u201cWhat is an Emergency Use Authorization (EUA)?\u201d\nsection at the end of this Fact Sheet. WHAT SHOULD YOU MENTION TO YOUR VACCINATION PROVIDER BEFORE\nYOU GET THE JANSSEN COVID-19 VACCINE?","2660":"If possible, have the person who is\nsick use a separate bedroom and\nbathroom. If possible, have the\nperson who is sick stay in their own \u201csick room\u201d or area and away from others. Try to stay at least 6 feet away from\nthe sick person. Shared space: If you have to share space, make sure the room has good air flow. Open the window to increase air circulation. Improving ventilation helps remove respiratory droplets from the air. Avoid having visitors. Avoid having any unnecessary visitors, especially visits by people who are at higher risk for\nsevere illness.","4480":"Contact your healthcare provider,\nhealth department, or\nCommunity Health Center to\nlearn about treatment options. Don\u2019t delay! Treatment must be\nstarted within a few days after\nyou first develop symptoms to be\neffective. If you don\u2019t have timely access to\na healthcare provider, check if a\nTest to Treat location is in\nyour community. You can get\ntested, receive a prescription\nfrom a healthcare provider (either\nonsite or by telehealth), and have it filled all at one location. \u2022\n\uf209\n\u2022\n\u2022\n\uf209\nAvoiding Contact with People Who Have Suspected or Confirmed COVID-19\nAvoiding contact with people who have COVID-19, whether or not they feel sick, can reduce your risk of catching the virus\nfrom them.","1405":"Should they receive the bivalent\nmRNA booster dose? \uf1aa\nPatients who undergo HCT or CAR-T-cell therapy should be revaccinated for the monovalent primary series\nand bivalent mRNA booster dose received before or during treatment. There is no revaccination for monovalent mRNA\nbooster dose(s) received before or during treatment. After revaccination with the primary series, the patient should\nMy patient who is moderately or severely immunocompromised underwent HCT or CAR-T cell\ntherapy after receiving the primary series and 2 monovalent mRNA booster doses. Should they be\nrevaccinated? \uf1aa\f10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\ng p y p\nreceive 1 bivalent mRNA booster dose.","8918":"By offering COVID-19\nvaccines in a setting where patients are comfortable with trusted and trained vaccinators, it might be possible to\nincrease vaccination rates for this high-risk population and ensure patients receive a complete vaccination series. Patients on dialysis are often medically frail, and it might be challenging and impractical for them to seek out venues\nseparate from the dialysis clinic to receive COVID-19 vaccines. Currently, dialysis providers are reporting low COVID-19 vaccination coverage among their patients because of\nchallenges with getting vaccines. Why is it important to vaccinate dialysis healthcare personnel?","5595":"Gaps can be caused by choosing the wrong size or type of mask and when a mask is worn with facial hair. It is important to check that it fits snugly over your nose, mouth, and chin. Check for gaps by cupping your hands around the outside edges of the mask. Make sure no air is flowing from the area near your eyes or from the sides of the mask.","6703":"Spray or pour spray products onto a cleaning cloth or paper towel instead of spraying the product directly onto the\ncleaning surface (if the product label allows). Store products safely and correctly\nStore and use chemicals out of the reach of children and pets. Label diluted cleaning solutions. Follow EPA\u2019s 6 steps for Safe and Effective Disinfectant Use . If you feel ill\nCall your healthcare provider to ask about your symptoms. If you don\u2019t have a healthcare provider, contact your nearest\ncommunity health center or health department. Remember to call 911 for medical emergencies.","1783":"They can also experience barriers to getting\nneeded health care and other support, and can have other characteristics that increase their risk of COVID-19, including:\nLimited mobility\nNeed for important support services\nChallenges practicing preventive measures, such as wearing a mask\nChallenges communicating symptoms of Illness or being sick\nGetting Children and Teens with Disabilities Vaccinated against\n1 in 6 children ages 3 through 17 years of age has one or more developmental disabilities.","1105":"People have been seriously harmed and even died after taking products\nnot approved for use to treat or prevent COVID-19, even products approved or prescribed for other uses. Talk to a\nhealthcare provider about taking medications to treat COVID-19. For Healthcare Professionals\f10\/30\/22, 9:42 AM COVID-19 Treatments and Medications | CDC\n\uf2ff General Treatment Resources\nCOVID-19 Treatment Guidelines: What\u2019s New\nCoronavirus (COVID-19) Drugs\nTherapeutic Management of Nonhospitalized Adults With COVID-19\nCOVID-19 Therapeutics Locator\nOral Antiviral Treatment Resources\nPaxlovid Eligibility and Effectiveness Information Sheet\nWhat are Oral Antivirals? FDA Updates on Paxlovid for Health Care Providers\nPaxlovid Patient Eligibility Screening Checklist Tool for Prescribers\nMonoclonal Antibody Treatment Resources\nAnti-SARS-CoV-2 Monoclonal Antibodies\nWhat Are Monoclonal Antibodies?","10125":"\u0083 Persons should wait 2 weeks after COVID-19 vaccination before receiving tixagevimab\/cilgavimab (EVUSHELD) for pre-exposure prophylaxis. Persons who are pregnant,\nbreastfeeding, trying to get pregnant,\nor might become pregnant in the future\n\u0083 Are recommended to be vaccinated according to the recommended schedule. Considerations for mRNA vaccines and Novavax\nPersons with a history of myocarditis\nor pericarditis\n\u0083 Development of myocarditis or pericarditis after a dose of an mRNA or Novavax COVID-19 vaccine is a precaution to a subsequent dose of any\nCOVID-19 vaccine.","4736":"Administer a bivalent mRNA booster dose if eligible. *\nAppendix B. People who received COVID-19 vaccine outside the United\nStates\n\u2020\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nVaccination history Recommended actions\nReceived a partial mRNA (i.e., Moderna or Pfizer-BioNTech) or Novavax\nCOVID-19 vaccine primary series\nDo not restart primary series. Complete primary series as close to the recommended time as\npossible with the same vaccine. Administer a bivalent mRNA booster dose if eligible. *\nReceived a monovalent booster dose(s) after completion of primary series Administer a bivalent mRNA booster dose if eligible.","6536":"They are not in order of risk. CDC completed a review for each medical condition on this list. This was done to ensure that these conditions met\ncriteria for inclusion on this list. CDC conducts ongoing reviews of additional underlying conditions. If other\nmedical conditions have enough evidence, they might be added to the list. Because we are learning more about COVID-19 every day, this list does not include all medical conditions that\nplace a person at higher risk of severe illness from COVID-19. Rare medical conditions, including many conditions\nthat mostly affect children, may not be included on the list below.","6892":"The COVID-19 vaccine by Moderna can also be used under EUI for similar uses as an alternative mRNA\nCOVID-19 vaccine (see the Moderna EUI Fact Sheet for Recipients), and the same or similar\nrecommendations in this EUI also apply to the use of the COVID-19 vaccine by Moderna under EUI. What is COVID-19? Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a coronavirus called SARS-CoV-2. It\nis predominantly a respiratory illness that can affect other organs. People with SARS-CoV-2 infection have\nreported a wide range of symptoms, from no symptoms to severe illness leading to death.","4170":"People with COVID-19 during pregnancy are more likely to\ndeliver a preterm (earlier than 37 weeks) or stillborn infant and may also be more likely to have other pregnancy\ncomplications. COVID-19 vaccination during pregnancy helps:\nPrevent severe illness and death in people who are pregnant\nProtect babies younger than 6 months old from hospitalization caused by COVID-19\nLearn more about vaccination considerations and the safety and effectiveness of COVID-19 vaccinations for people who\nare pregnant or breastfeeding. If you are pregnant and have received a COVID-19 vaccine, we encourage you to enroll in v-safe, CDC\u2019s smartphone-based\nsystem that provides personalized health check-ins after vaccination.","8481":"10\/30\/22, 9:43 AM Travel: Frequently Asked Questions and Answers | CDC\nEspa\u00f1ol | Other Languages\nTravel: Frequently Asked Questions and Answers\nGeneral\nCheck CDC\u2019s Domestic Travel or International Travel pages for the latest recommendations for travelers. Travel is any trip that involves leaving your community. Transportation within your community for errands and work\ntransit is not considered travel. What is travel? \uf1aa\nYes, you can travel once you have ended isolation. However, you should wear a high-quality mask or respirator the entire\ntime you are around others indoors until it\u2019s safe for you to remove your mask around others.","6956":"Common side effects reported were mostly mild, but some people had side effects that\naffected their ability to do daily activities. Cases of myocarditis and pericarditis have rarely been reported\nin some people. Cases have occurred predominantly in adolescents and young adult males within the first\nweek after the second dose of vaccine. Additional information on the common and serious side effects of the COVID-19 vaccine by Pfizer-BioNTech\ncan be found in the package insert for Comirnaty and in the EUA Fact Sheet for Recipients and Caregivers. What are the benefits of the COVID-19 vaccine by Pfizer-BioNTech?","7012":"\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nChildren and teens ages 6 months\u201317 years\n\uf1aa\nAGE GROUP\nCommon side effects can include:\nPain on the leg or arm where the shot was given\nSwollen lymph nodes\nIrritability or crying\nSleepiness\nLoss of appetite\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nAGE GROUP\nSide effects are more common after the second dose\nand can include:\nPain, swelling, and redness on the arm where the\nshot was given\nTiredness\nHeadache\nMuscle or joint pain\nChills\nSwollen lymph nodes\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nAdults 18 years and older\n\uf1aa\f10\/30\/22, 9:30 AM Possible Side Effects After Getting a COVID-19 Vaccine | CDC\nAfter a second shot or booster\nReactions reported after getting a booster shot are similar to those after the two-dose or single-dose primary shots. Most side\neffects were mild to moderate.","9918":"Clinical considerations based on the age of the recipient include:\nCOVID-19 vaccines products (monovalent and bivalent)\nhave different age indications. \u0083 Janssen COVID-19 Vaccine can be administered to persons\n18 years of age and older in certain limited situations due to\nsafety considerations. \u0083 Novavax COVID-19 Vaccine can be administrated to persons 12\nyears of age and older. \u0083 Moderna COVID-19 Vaccine can be administered to persons\nages 6 months of age and older. \u0083 Pfizer-BioNTech COVID-19 vaccine can be administered to\npersons 6 months of age and older.","7724":"\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022 \uf209\n\u2022\nCDC is providing timely updates on the following adverse events of interest:\nAnaphylaxis after COVID-19 vaccination is rare and has occurred at a rate of approximately 5 cases per one million\nvaccine doses administered. Anaphylaxis, a severe type of allergic reaction, can occur after any kind of vaccination. If it happens, healthcare providers can effectively and immediately treat the reaction. Learn more about COVID-19\nvaccines and allergic reactions, including anaphylaxis.","7844":"Healthcare providers can ensure that those who have tested positive for COVID-19 receive the most appropriate medical\ncare, including specific treatments if necessary. In most jurisdictions, healthcare providers who\u202fdiagnose COVID-19 are required to report those cases to public health. The US Government\u202fdoes not want to construct any barriers that would deter the use of self-tests. COVID-19\nsurveillance\u202fcontinues to be based on results from laboratory testing. The primary role of case reporting is to allow public\nhealth agencies to take actions to mitigate disease spread. The public health community, including CDC, is confident that\nsituational awareness remains strong without receiving self-test results.","9198":"Throw away used tissues in a lined trash can\n\u2022\f10\/30\/22, 9:41 AM What to Do If You Are Sick | CDC\nThrow away used tissues in a lined trash can. Immediately wash your hands with soap and water for at least 20 seconds. If soap and water are not\navailable, clean your hands with an alcohol-based hand sanitizer that contains at least 60% alcohol. \u2022\n\u2022\n\uf304 Clean your hands often\nWash your hands often with soap and water for at least 20 seconds. This is especially important after\nblowing your nose, coughing, or sneezing; going to the bathroom; and before eating or preparing food.","7811":"If you\u2019re not able to obtain a self-test when you need it, you might also visit a community testing site, or\ncall your local health department for more options. \u2022\n\uf209\n\u2022\n\u2022\nFDA-Authorized Tests\n\uf6e0 How to Use an At-Home COVID-19 Test\nRead the complete manufacturer\u2019s instructions for use before using the test. To use an at-home test, you will collect a nasal specimen and then test that specimen. If you do not follow the manufacturer\u2019s instructions, your test result may be incorrect. Wash your hands before and after you collect a nasal specimen for your test.","8382":"Who needs to be trained\n\uf1aa\nIt is critical that healthcare professionals and personnel are familiar with the specific COVID-19 vaccine product(s) in their\nfacility\u2019s inventory. Guidance for vaccine storage, handling, preparation, and administration may differ for each vaccine\nproduct. Therefore, all healthcare staff members need training in COVID-19 vaccination even if they are already\nadministering routinely recommended vaccines. While many practices are the same for all vaccines, whenever a new\nvaccine is introduced to the U.S. market, there are nuances that healthcare professionals must become familiar with to\nensure the vaccine is stored, handled, prepared, and administered correctly.","2442":"Fever in pregnancy may be treated with\nacetaminophen as needed, in moderation, and in consultation with a healthcare provider. It is not recommended you take\nthese medicines before vaccination to try to prevent side effects. Learn about other ways to relieve side effects. \u2022 \uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\uf209\n- \uf209\n\u2022 \uf209 18\nLearn more about getting your COVID-19 vaccine. References\n1.","6519":"The number of deaths among people over age 65 is 97 times higher than the number of deaths among\npeople ages 18-29 years. A person\u2019s risk of severe illness from COVID-19 increases as the number of underlying medical conditions they have\nincreases. Some people are at increased risk of getting very sick or dying from COVID-19 because of where they live or work, or\nbecause they can\u2019t get health care. This includes many people from racial and ethnic minority groups and people with\ndisabilities. Studies have shown people from racial and ethnic minority groups are also dying from COVID-19 at younger ages.","7212":"You should not get any of these vaccines if you:\n\uf0b7 had a severe allergic reaction after a previous dose of COMIRNATY (COVID-19\nVaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine\n\uf0b7 had a severe allergic reaction to any ingredient in these vaccines. WHAT ARE THE INGREDIENTS IN THESE VACCINES? COMIRNATY (COVID-19 Vaccine, mRNA), Pfizer-BioNTech COVID-19 Vaccine, and\nPfizer-BioNTech COVID-19 Vaccine, Bivalent include the following ingredients:\n\uf0b7 mRNA and lipids (((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-\n1,2-Distearoyl-sn-glycero-3-phosphocholine, and cholesterol).","8164":"As with other vaccine-preventable diseases, you are protected best from COVID-19 when you stay up\nto date with the recommended vaccinations, including recommended boosters. Four COVID-19 vaccines are approved or authorized in the United States:\nPfizer-BioNTech\nModerna\nNovavax\nJohnson & Johnson\u2019s Janssen (J&J\/Janssen) (However, CDC recommends that the J&J\/Janssen COVID-19 vaccine only be\nconsidered in certain situations, due to safety concerns.) Updated (Bivalent) Boosters\nThe updated (bivalent) boosters are called \u201cbivalent\u201d because they protect against both the original virus that causes COVID-\n19 and the Omicron variant BA.4 and BA.5. Previous boosters are called \u201cmonovalent\u201d because they were designed to protect against the original virus that causes\nCOVID-19.","1847":"For information for the general public,\nplease see Monitoring Vaccine Effectiveness\nProspective Cohort\n\uf1aa\nHEROES\nArizona Healthcare, Emergency Response, and Other Essential Workers Surveillance (AZ Heroes) Study\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Healthcare providers\/first responders\/essential and other frontline workers\nParticipating Sites\nUniversity of Arizona, Tucson, AZ\nMel and Enid Zuckerman College of Public Health, Tucson, AZ\n\uf20c\nRECOVER\nResearch on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER)\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Healthcare providers\/first responders\/essential and other frontline workers\nParticipating Sites\nBaylor Scott and White Health, Temple, TX\n\uf209\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nKaiser Permanente Northwest, Portland, OR\nSt. Luke\u2019s Hospital, Duluth, MN\nUniversity of Arizona, Tucson, AZ\nUniversity of Miami, Miami, FL\nUniversity of Utah, Salt Lake City, UT\nPROTECT\nPediatric Research Observing Trends and Exposures in COVID-19 Timelines\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Children aged <18 years\nParticipating Sites\nBaylor Scott and White Health, Temple, TX\nUniversity of Arizona, Tucson, AZ\nUniversity of Miami, Miami, FL\nUniversity of Utah, Salt Lake City, UT\nCASCADIA\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Children aged <18 years and adults aged <50 years\nParticipating Sites\nKaiser Permanente Northwest, Portland, OR\nUniversity of Washington, Seattle, WA\nHousehold Transmission Studies\n\uf1aa\nHEROES-RECOVER Household Transmission Study\nResearch on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER) SARS-CoV-2 Household\nTransmission Study\nOutcome: Transmission in households of healthcare, first responder, and essential and other frontline workers with\nPopulation: Households of infected healthcare providers\/first responders\/essential and other frontline workers\nParticipating Sites\nBaylor Scott and White Health, Temple, TX\nKaiser Permanente Northwest, Portland, OR\nSt. Luke\u2019s Hospital, St. Louis, MO\nUniversity of Arizona, Tucson, AZ\nUniversity of Miami, Miami, FL\nUniversity of Utah, Salt Lake City, UT\n\uf20c\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nUniversity of Utah, Salt Lake City, UT\nRVTN (Respiratory Virus Transmission Network)\nRVTN \u2013 Sentinel\nSentinel Protocol\nOutcome: Household transmission among community members confirmed with SARS-CoV-2\nPopulation: Households of community members with positive SARS-CoV-2 tests recruited from sentinel testing sites\nParticipating Sites\nUniversity of Arizona, Tucson, AZ\nStanford University, Stanford, CA\nUniversity of Colorado, Denver, CO\nColumbia University, New York City, NY\nUniversity of North Carolina, Chapel Hill, NC\nVanderbilt University Medical Center, Nashville, TN\nMarshfield Clinic Research Institute, Marshfield, WI\n\uf20c\nRVTN \u2013 National\nNational Approach (also known as \u201cTrack COVID at Home \u201d).","9224":"\u2022\n\u2022\n\u2022\n\uf318 When you can be around others after being sick with COVID-19\nDeciding when you can be around others is different for different situations. Find out when you can safely\nend home isolation\f10\/30\/22, 9:41 AM What to Do If You Are Sick | CDC\nend home isolation. For any additional questions about your care, contact your healthcare provider or state or local health department.","6804":"Serious and\nunexpected side effects may occur. The possible side effects of these vaccines are still\nbeing studied. WHAT SHOULD I DO ABOUT SIDE EFFECTS? If your child experiences a severe allergic reaction, call 9-1-1, or go to the nearest\nhospital. Call the vaccination provider or your child\u2019s healthcare provider if your child has any\nside effects that bother your child or do not go away. Report vaccine side effects to FDA\/CDC Vaccine Adverse Event Reporting System\n(VAERS). The VAERS toll-free number is 1-800-822-7967 or report online to\nhttps:\/\/vaers.hhs.gov\/reportevent.html.","2485":"10\/30\/22, 9:39 AM COVID-19 by County | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 by County\nMany people in the United States have some protection, or immunity, against COVID-19 due to vaccination, previous\ninfection, or both. This immunity, combined with the availability of tests and treatments, has greatly reduced the risk of\nsevere illness, hospitalization, and death from COVID-19 for many people. At the same time, some people\u2014such as those who are older, are immunocompromised, have certain disabilities, or have\ncertain underlying health conditions\u2014continue to be at higher risk for serious illness.","6750":"It is predominantly a\nrespiratory illness that can affect other organs. People with COVID-19 have had a wide\nrange of symptoms reported, ranging from mild symptoms to severe illness leading to\ndeath. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may\ninclude: fever or chills; cough; shortness of breath; fatigue; muscle or body aches;\nheadache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or\nvomiting; diarrhea. For more information on EUA, see the \u201cWhat is an Emergency Use Authorization\n(EUA)?\u201d section at the end of this Fact Sheet.","6555":"Get more information:\nDiabetes\nAmerican Diabetes Association: How COVID-19 Impacts People with Diabetes\nDisabilities\nPeople with some types of disabilities may be more likely to get very sick from COVID-19 because of underlying medical\nconditions, living in congregate settings, or systemic health and social inequities, including:\nPeople with any type of disability that makes it more difficult to do certain activities or interact with the world around\nthem, including people who need help with self-care or daily activities\nPeople with attention-deficit\/hyperactivity disorder (ADHD)\nPeople with cerebral palsy\nPeople with birth defects\nPeople with intellectual and developmental disabilities\nPeople with learning disabilities\nPeople with spinal cord injuries\nPeople with Down syndrome\nGet more information:\nPeople with Disabilities | COVID-19\nHeart conditions\nHaving heart conditions such as heart failure, coronary artery disease, cardiomyopathies, and possibly high blood pressure\n(hypertension) can make you more likely to get very sick from COVID-19.","5577":"Whatever product you choose, it should provide a good fit (i.e., fitting closely on the face without any gaps along the edges or\naround the nose) and be comfortable enough when worn properly (covering your nose and mouth) so that you can keep it on\nwhen you need to. Learn how to improve how well your mask protects you by visiting CDC\u2019s Improve How Your Mask Protects\nYou page. A respirator has better filtration, and if worn properly the whole time it is in use, can provide a higher level of protection than\na cloth or procedural mask.","2570":"Booster dose\u00a7: Bivalent\nAt least 8 weeks\nAt least 8 weeks\nAdenovius\nvector\nvaccine\nand older\nMONOVALENT Janssen\nJanssen COVID-19 vaccine is authorized for use in certain limited situations\ndue to safety considerations.\u00b6\nModerna or Pfizer-BioNTech\nbivalent COVID-19 vaccine should\nbe used for the booster dose. Booster dose\u00a7: Bivalent\nAdminister a single booster dose at least 8 weeks (2 months) after the\nprevious dose. * Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate monovalent\nCOVID-19 vaccine may be administered at least 28 days after the first dose to complete the primary series.","1066":"Still, some vaccinated people,\nespecially those ages 65 years or older or who have other risk factors for severe disease, may benefit from treatment if they\f10\/30\/22, 9:42 AM COVID-19 Treatments and Medications | CDC\nget COVID-19. A healthcare provider will help decide which treatment, if any, is right for you. Check with your healthcare\nprovider or pharmacist if you are taking other medications to make sure the COVID-19 treatments can be safely taken at the\nsame time. Types of Treatments\nThe FDA has authorized certain\nantiviral medications and\nmonoclonal antibodies to treat\nmild to moderate COVID-19 in\npeople who are more likely to get\nvery sick.","5026":"Added considerations for an 8-week interval between the first and second doses of a primary mRNA vaccine schedule\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nUpdated guidance for moderately or severely immunocompromised people\nClarification of existing recommendation to receive a 3-dose mRNA vaccine primary series followed by a booster\ndose for a total of 4 doses\nNew guidance to shorten the interval between completion of the mRNA vaccine primary series and the booster\ndose to at least 3 months (instead of 5 months)\nNew guidance for those who received the Janssen COVID-19 Vaccine primary series to receive an additional dose\nand a booster dose, for a total of 3 doses to be up to date\nUpdated guidance that it is no longer necessary to delay COVID-19 vaccination following receipt of monoclonal\nantibodies or convalescent plasma\nUpdated guidance on receiving a booster dose if vaccinated outside the United States\nUpdated contraindication and precaution section to include history of myocarditis or pericarditis after an mRNA\nCOVID-19 vaccine as a precaution\nReorganized and condensed multiple sections\nUpdated guidance for use of Pfizer-BioNTech COVID-19 Vaccine as a booster in people ages 12\u201317 years\nUpdated guidance for administration of a COVID-19 vaccine booster dose at least 5 months after completion of an\nmRNA vaccine (Pfizer-BioNTech or Moderna) primary series\nUpdated guidance for use of an additional primary dose for moderately or severely immunocompromised people ages\n5\u201311 years who received a Pfizer-BioNTech vaccine primary series\nUpdated recommendations for people who received COVID-19 vaccines outside the United States that are not FDA-\nauthorized or approved\nUpdated information about a second formulation of Pfizer-BioNTech COVID-19 Vaccine that is authorized for use in\npersons ages 12 years and older\nUpdated information on vaccinating people during quarantine after a known SARS-CoV-2 exposure or during COVID-\nUpdate to alert providers of possible false positive Rapid Plasma Reagin (RPR; non-treponemal) test results in some\npeople after COVID-19 vaccines\nUpdated information on vaccine administration errors and deviations\nUpdated guidance on use of Janssen (Johnson & Johnson) COVID-19 Vaccine\nUpdated recommendations for receipt of a COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 booster doses in recipients of mRNA COVID-19 vaccines\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nRecommendations and clinical guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children aged 5-11 years\nincluding updated section on Vaccination of children and adolescents\nUpdated guidance on COVID-19 vaccine dosing and schedule\nUpdated guidance for myocarditis and pericarditis after mRNA COVID-19 vaccination in new section on Considerations\nfor mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna\nNew guidance for people who received passive antibody products in section on COVID-19 vaccination and SARS-CoV-2\ninfection\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial in the United States\nUpdated guidance on Considerations for COVID-19 vaccination in moderately and severely immunocompromised\npeople\nUpdated guidance in section on Contraindications and precautions\nUpdated Table in Appendix A: Vaccine administration errors and deviations\nUpdated Appendix B: Triage of people with a history of allergies or allergic reactions\nUpdated Appendix C: Ingredients included in COVID-19 vaccines\nUpdated Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects\nfollowing COVID-19 vaccination\nUpdated guidance in section on Considerations for use of a COVID-19 booster dose.","2320":"\u2022\n\u2022\n-\n-\n\u2022\n\u2022\n\u2022 TM\nPre-teens, Teens and Adults Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nAGE GROUP\n18 YEARS AND OLDER\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nModerna\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nJohnson & Johnson's Janssen\n\uf1aa\nPRIMARY SERIES\nADDITIONAL DOSE\nAt least 4 weeks after 1st dose\nand should be Pfizer-BioNTech\nor Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nor last booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nNovavax\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nA monovalent Novavax booster\nis available in limited situations\nMore details: Novavax booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nChildren Ages 6 Months-11 Years Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 8 weeks after 2nd dose\nUp to Date: 2 weeks after 3rd dose in primary series, since a booster is not recommended for this age group at this\ntime\nAGE GROUP\nModerna\n\uf1aa\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nIf you have completed your primary series\u2014but are not yet eligible for a booster\u2014you are also considered up to date.","1387":"My patient never received a monovalent mRNA booster dose(s) and now only 1 bivalent booster\ndose is recommended for everyone ages 5 years and older. Can my patient still get the previously\nrecommended monovalent mRNA booster dose(s)? \uf1aa\nCan a child who completes a Pfizer-BioNTech primary series at ages 6 months\u20134 years get a\nbooster dose when they turn age 5 years? \uf1aa\f10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\nYes. The child should receive 1 bivalent booster dose when they turn age 5 years, and it has been at least 2 months since\ncompleting their primary series.","7552":"You must also\nattest that you will get a viral test 3-5 days after arrival and will self-isolate if the results of the test are positive or if you\ndevelop COVID-19 symptoms. You must show a letter from a licensed physician documenting the medical contraindication to the airline or aircraft\noperator before boarding a flight to the United States. The letter\nMust be signed and dated on official letterhead that contains contact information (name, address, and phone number)\nof a licensed healthcare provider. Must clearly state that you have a medical contraindication to receiving a COVID-19 vaccine.","5021":"Added considerations for an 8-week interval between the first and second doses of a primary mRNA vaccine schedule\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nUpdated guidance for moderately or severely immunocompromised people\nClarification of existing recommendation to receive a 3-dose mRNA vaccine primary series followed by a booster\ndose for a total of 4 doses\nNew guidance to shorten the interval between completion of the mRNA vaccine primary series and the booster\ndose to at least 3 months (instead of 5 months)\nNew guidance for those who received the Janssen COVID-19 Vaccine primary series to receive an additional dose\nand a booster dose, for a total of 3 doses to be up to date\nUpdated guidance that it is no longer necessary to delay COVID-19 vaccination following receipt of monoclonal\nantibodies or convalescent plasma\nUpdated guidance on receiving a booster dose if vaccinated outside the United States\nUpdated contraindication and precaution section to include history of myocarditis or pericarditis after an mRNA\nCOVID-19 vaccine as a precaution\nReorganized and condensed multiple sections\nUpdated guidance for use of Pfizer-BioNTech COVID-19 Vaccine as a booster in people ages 12\u201317 years\nUpdated guidance for administration of a COVID-19 vaccine booster dose at least 5 months after completion of an\nmRNA vaccine (Pfizer-BioNTech or Moderna) primary series\nUpdated guidance for use of an additional primary dose for moderately or severely immunocompromised people ages\n5\u201311 years who received a Pfizer-BioNTech vaccine primary series\nUpdated recommendations for people who received COVID-19 vaccines outside the United States that are not FDA-\nauthorized or approved\nUpdated information about a second formulation of Pfizer-BioNTech COVID-19 Vaccine that is authorized for use in\npersons ages 12 years and older\nUpdated information on vaccinating people during quarantine after a known SARS-CoV-2 exposure or during COVID-\nUpdate to alert providers of possible false positive Rapid Plasma Reagin (RPR; non-treponemal) test results in some\npeople after COVID-19 vaccines\nUpdated information on vaccine administration errors and deviations\nUpdated guidance on use of Janssen (Johnson & Johnson) COVID-19 Vaccine\nUpdated recommendations for receipt of a COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 booster doses in recipients of mRNA COVID-19 vaccines\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nRecommendations and clinical guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children aged 5-11 years\nincluding updated section on Vaccination of children and adolescents\nUpdated guidance on COVID-19 vaccine dosing and schedule\nUpdated guidance for myocarditis and pericarditis after mRNA COVID-19 vaccination in new section on Considerations\nfor mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna\nNew guidance for people who received passive antibody products in section on COVID-19 vaccination and SARS-CoV-2\ninfection\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial in the United States\nUpdated guidance on Considerations for COVID-19 vaccination in moderately and severely immunocompromised\npeople\nUpdated guidance in section on Contraindications and precautions\nUpdated Table in Appendix A: Vaccine administration errors and deviations\nUpdated Appendix B: Triage of people with a history of allergies or allergic reactions\nUpdated Appendix C: Ingredients included in COVID-19 vaccines\nUpdated Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects\nfollowing COVID-19 vaccination\nUpdated guidance in section on Considerations for use of a COVID-19 booster dose.","1086":"Ask a healthcare provider if\nmedications to treat COVID-19 are right for you. If you don\u2019t have a healthcare provider, visit a Test to Treat location or\ncontact your local community health center or health department. If you are hospitalized, your healthcare provider might use other types of treatments, depending on how sick you are. These\ncould include medications to treat the virus, reduce an overactive immune response, or treat COVID-19 complications. \uf209\f10\/30\/22, 9:42 AM COVID-19 Treatments and Medications | CDC\nManaging COVID-19 symptoms\nMost people with COVID-19 have\nmild illness and can recover at\nhome.","8452":"I have ended isolation but still need to continue\nwearing my mask per CDC\u2019s guidance. Do not travel on public transportation such as\nairplanes, buses, and trains if you will not be able\nto wear a high-quality mask or respirator when\naround others indoors for the full duration of your\ntrip. If you travel, wear a high-quality mask or\nrespirator the entire time you are around others\nindoors. Traveling by private vehicle (if possible) can lower\nthe chances of spreading COVID-19 to others. I was exposed to a person with COVID-19 in the\npast 10 days.","5413":"The EUA is supported by a Secretary of Health and Human\nServices (HHS) declaration that circumstances exist to justify the emergency use of drugs and\nbiological products during the COVID-19 pandemic. The Janssen COVID-19 Vaccine has not undergone the same type of review as an FDA-approved\nor cleared product. FDA may issue an EUA when certain criteria are met, which includes that there\nare no adequate, approved, and available alternatives.","6648":"Follow your current treatment plan (e.g., Asthma Action Plan, dialysis schedule, blood sugar testing, nutrition, and\nexercise recommendations) to keep your medical condition(s) under control. When possible, keep your appointments (e.g., vaccinations and blood pressure checks) with your healthcare provider. Check with your healthcare provider about safety precautions for office visits and ask about telemedicine or virtual\nhealthcare appointment options. Learn about stress and coping. You may feel increased stress during this pandemic. Fear and anxiety can be\noverwhelming and cause strong emotions. It can be helpful to talk with a professional like a counselor, therapist,\npsychologist, or psychiatrist.","7680":"This monitoring includes using both established and new safety monitoring\nsystems to make sure that COVID-19 vaccines are safe. Common Side Effects\nSome people have side effects after getting their COVID-19 vaccine, while others might have no side effects. Side effects may\naffect the ability to do daily activities, but they should go away within a few days. Learn more about common side effects after\nCOVID-19 vaccination. Adverse Events (Serious Safety Problems) Are Rare\nIn rare cases, people have experienced serious health events after COVID-19 vaccination. Any health problem that happens\nafter vaccination is considered an adverse event.","2669":"Eat in separate rooms or areas\nStay separated: The person who is sick should eat (or be fed) in their room, if possible. Wash dishes and utensils using gloves and hot water: Handle any dishes, cups\/glasses, or silverware used by the\nperson who is sick with gloves. Wash them with soap and hot water or in a dishwasher. Clean hands after taking off gloves or handling used items. \u2022\n\u2022\n\u2022\nAvoid sharing personal items\nDo not share: Do not share dishes, cups\/glasses, silverware, towels, bedding, or electronics (like a cell phone) with\nthe person who is sick.","4534":"Even if you cannot get the N95 sealed against your face,\nit will provide protection that is likely better than a cloth\f10\/30\/22, 9:40 AM How to Use Your N95 Respirator | CDC\ny g g ,\nyou are wearing glasses and they fog up, it is not snug. Adjust the N95 and try again. p p y\nmask. Check for gaps every time you put on your N95. Remove the N95\n\uf1b2\nAfter you remove your N95, wash your hands with soap and water, or hand sanitizer containing at least 60% alcohol if\nsoap is not available.","8073":"In addition, CDC is communicating with key medical groups and continues to provide updated reporting and\nlaboratory guidance for clinicians who may identify hepatitis of unknown cause in children.126\n\u0083 When will vaccines be available for children ages 5 years and younger?d\n\u0082 As of June 18, 2022, everyone ages 6 months and older is recommended to get a Moderna or Pfizer-BioNTech COVID-19\nIdentified misinformation themes that may impact vaccine confidence\n\u0083 Some social media users believe authorizing vaccines in children is only a ploy for pharmaceutical companies to make\n\u0083 Some social media users claim that COVID-19 cases in children are always mild.129,130,131 w\nWays public health and partners can take action to improve vaccine confidence\n\u0083 Encourage primary care providers and other medical professionals who care for children to explain the benefits of COVID-19\nvaccination to parents and guardians.","8261":"To find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. \uf263 Learn About Getting Your Vaccine\nDo you need to wait to get vaccinated after getting COVID-19 or getting treatment for COVID-19? How can you prepare for vaccination? What can you expect during and after your vaccination? Getting Your COVID-19 Vaccine\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nIf You Receive a Vaccine That is Not in the U.S.","9891":"doi: 10.1016\/j.cell.2021.10.011\nPulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with\nemergence of the Omicron variant in South Africa. 2022. https:\/\/doi.org\/10.1101\/2021.11.11.21266068\nPerez, J. Efficacy and safety of BNT162b2 booster \u2013 C4591031 2 month interim analysis. Advisory Committee\non Immunization Practices meeting, November 19, 2021:\nSkowronski DM. 2021, MedRxiv preprint. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules\nand extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. Schietzel S, Anderegg M, Limacher A, et al. Humoral and cellular immune responses on SARS-CoV-2 vaccines in\npatients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients. Infections. 2022;8:e002036.","8767":"They should do this by\nconsidering the person\u2019s ability to:\nWear a mask correctly (proper mask size and fit)\nAvoid frequent touching of the mask and face\nLimit sucking, drooling, or having excess saliva on the mask\nRemove the mask without assistance\nPeople who are deaf or hard of hearing\nThese individuals may consider:\nWearing a clear mask or a cloth mask with a clear panel\nIf a clear mask is not available, using written communication, closed\ncaptioning, or decreasing background noise to make communication\npossible while wearing a mask that blocks lips\nTravelers\nWearing a high-quality\nmask while you travel\ncan help protect you\nand others. Learn about the latest\nrecommendation for\nwearing masks during\ntravel.","5849":"See the Pfizer-BioNTech COVID-19 EUI Fact Sheet for Healthcare\nProviders. Refer to CDC\u2019s Interim Clinical Considerations for specific recommendations on use of the COVID-19 vaccine by\nModerna allowed under the EUI. For additional information about the COVID-19 vaccine by Moderna COVID-\n19, refer to the Spikevax package insert or the Full Emergency Use Authorization (EUA) Prescribing Information\n(FDA, 2022). What are EUI and why is CDC issuing EUI for the COVID-19 vaccine by Moderna?","585":"August 11, 2022: New Jersey made updates to data previously submitted to CDC that resulted in a net increase of\n37,096 administered doses. August 11, 2022: California made updates to data previously submitted to CDC that resulted in a net increase of\n202,640 administered doses. August 4, 2022: Idaho made updates to data previously submitted to CDC that resulted in a net decrease of 42,051\nadministered doses. This contributed to a decrease in overall US figures. August 4, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 77,754\nadministered doses.","6359":"(For example, you might ask:\n\u201cSo, I should go to the lab next week with this paperwork to get my blood drawn?\u201d). Additional questions could include:\nWill I need additional tests? When and how will I get test results? When should I return for another visit? Ask for a Summary\nAsk for an appointment summary. You can also ask the provider to write down any instructions, medication names, etc.,\nfor you. If there are changes to your treatment plan, make sure you understand what to do. For new medication, ask why\nit is being given and what you should expect by taking this new medication.","2307":"CDC recommends everyone ages 5 years and older get an updated COVID-19 booster to help restore\nprotection that has decreased since your last vaccine. One updated booster dose is recommended for all\npeople ages 5 years and older, regardless of whether or not they are immunocompromised. CDC recommends that people with moderate or severe immunocompromise get an extra primary series dose\nif receiving the Moderna or Pfizer-BioNTech series. Use CDC\u2019s COVID-19 booster tool to learn if and when you can get boosters to stay up to date with your COVID-19\nvaccines.","9359":"2 FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and one presentation of the EUA-authorized Moderna\nCOVID-19 Vaccine (supplied in vials with red caps and labels with a light blue border) can be used interchangeably\nfor the primary series for individuals 12 years of age and older without presenting any safety or effectiveness\nconcerns. The Moderna COVID-19 Vaccine has received EUA from FDA to provide:\n\u2022 a two-dose primary series to individuals 6 years of age and older; and\n\u2022 a third primary series dose to individuals 6 years of age and older with certain kinds\nof immunocompromise.","4351":"CDC does not provide the white CDC COVID-19 vaccination card to people and does not maintain vaccination\nrecords. Only a vaccination provider can give you this card. \u2022\n\u2022\n\u2022\nWhat is the difference between a vaccine record and a COVID-19 vaccination card? \uf1aa\nA vaccine record (sometimes called immunization record) provides a history of all the vaccines you received. This record may be required for certain jobs, travel abroad, or a school registration. A COVID-19 vaccination card is only for COVID-19 vaccination and is given to you when you get your COVID-19\nvaccine.","9674":"Each formulation, when prepared according to its respective formulation-specific instructions\nfor administration, provide 0.3 mL doses (each containing 30 \u03bcg mRNA). FDA has explained that these\nformulations of the vaccine can be used interchangeably without presenting any safety or effectiveness\nconcerns, when prepared according to their respective formulation-specific instructions for use. The EUI do not apply to the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4\/BA.5),\nwhich is supplied in multiple dose vials with gray caps and labels with gray borders. What are the common side effects with the COVID-19 vaccine by Pfizer-BioNTech?","9944":"While there is no evidence acute illness reduces vaccine\nefficacy or increases adverse reactions, as a precaution, delay\nvaccinating patients with moderate or severe illness until\nthe illness has improved. Defer vaccination of people with current SARS-CoV-2\ninfection. For those with\n\u0083 Symptoms: defer vaccination until recovery from the acute\nillness and isolation has been discontinued. \u0083 Asymptomatic infection: defer vaccination until isolation has\nbeen discontinued. This recommendation applies regardless of whether the SARS-\nCoV-2 infection occurred before the recipient received an initial\ndose or between doses. Viral or serological testing to assess\nfor current or prior infection solely for the purpose of vaccine-\ndecision making is not recommended. 3.","3450":"Table of Contents \uf426\nFootnotes\n\uf209\n\uf209\n\uf20c \uf209\nTable of Contents \uf426\nLast Reviewed: October 27, 2022","3290":"Febrile seizures can occur in infants and young children ages 6 months\u20135 years with any condition that causes a fever (most\ncommon with high fevers), including COVID-19 . Febrile seizures are uncommon after vaccination and were rare in mRNA\nCOVID-19 vaccine clinical trials for infants and young children. In rare instances, administration of certain combination\nvaccines or more than one vaccine at the same clinic visit has been associated with an increased risk of febrile seizures in\ninfants and young children. The impact of coadministration of COVID-19 and routine vaccines on the risk of febrile seizures\nhas not been specifically studied.","9301":"Children and Teens Can Experience Ongoing Health Problems\nAfter getting COVID-19, children and teens can also experience a wide range of new, returning, or ongoing health problems. These include physical and mental health complications that may occur four or more weeks after initial infection. These\ncomplications can appear after mild or severe COVID-19, or after MIS-C. Symptoms Post COVID-19 Vaccination Symptoms Post COVID-19 Infection\nCough\nMuscle and joint pain\nHeadache\nTrouble falling or staying asleep\nTrouble concentrating\nLimitations in physical activity\nFeeling distressed about symptoms\nMental health challenges\nDecreased school or daycare attendance\nMissed opportunities for participation in sports,\nplaydates, or other activities\nLearn more about post-COVID conditions.","5330":"In clinical trials, more than 61,000\nindividuals 18 years of age and older have received the Janssen COVID-19 Vaccine. Millions of\nindividuals have received the vaccine under EUA since February 27, 2021. WHAT ARE THE BENEFITS OF THE JANSSEN COVID-19 VACCINE? The Janssen COVID-19 Vaccine has been shown to prevent COVID-19. The duration of protection\nagainst COVID-19 is currently unknown. WHAT ARE THE RISKS OF THE JANSSEN COVID-19 VACCINE? Side effects that have been reported with the Janssen COVID-19 Vaccine include:\n\u2022 Injection site reactions: pain, redness of the skin and swelling.","998":"You can order free self-test kits at COVIDtests.gov or purchase tests online, in pharmacies, and retail stores. You can also visit FDA\u2019s website to see a list of authorized tests. As noted in the labeling for authorized over-the-counter antigen tests: Negative results should be treated as presumptive\n(meaning that they are preliminary results). Negative results do not rule out SARS-CoV-2 infection and should not be\nused as the sole basis for treatment or patient management decisions, including infection control decisions. Please see\nFDA guidance on the use of at-home COVID-19 antigen tests.","6958":"Common side effects reported were mostly mild, but some people had side effects that\naffected their ability to do daily activities. Cases of myocarditis and pericarditis have rarely been reported\nin some people. Cases have occurred predominantly in adolescents and young adult males within the first\nweek after the second dose of vaccine. Additional information on the common and serious side effects of the COVID-19 vaccine by Pfizer-BioNTech\ncan be found in the package insert for Comirnaty and in the EUA Fact Sheet for Recipients and Caregivers. What are the benefits of the COVID-19 vaccine by Pfizer-BioNTech?","1851":"For information for the general public,\nplease see Monitoring Vaccine Effectiveness\nProspective Cohort\n\uf1aa\nHEROES\nArizona Healthcare, Emergency Response, and Other Essential Workers Surveillance (AZ Heroes) Study\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Healthcare providers\/first responders\/essential and other frontline workers\nParticipating Sites\nUniversity of Arizona, Tucson, AZ\nMel and Enid Zuckerman College of Public Health, Tucson, AZ\n\uf20c\nRECOVER\nResearch on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER)\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Healthcare providers\/first responders\/essential and other frontline workers\nParticipating Sites\nBaylor Scott and White Health, Temple, TX\n\uf209\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nKaiser Permanente Northwest, Portland, OR\nSt. Luke\u2019s Hospital, Duluth, MN\nUniversity of Arizona, Tucson, AZ\nUniversity of Miami, Miami, FL\nUniversity of Utah, Salt Lake City, UT\nPROTECT\nPediatric Research Observing Trends and Exposures in COVID-19 Timelines\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Children aged <18 years\nParticipating Sites\nBaylor Scott and White Health, Temple, TX\nUniversity of Arizona, Tucson, AZ\nUniversity of Miami, Miami, FL\nUniversity of Utah, Salt Lake City, UT\nCASCADIA\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Children aged <18 years and adults aged <50 years\nParticipating Sites\nKaiser Permanente Northwest, Portland, OR\nUniversity of Washington, Seattle, WA\nHousehold Transmission Studies\n\uf1aa\nHEROES-RECOVER Household Transmission Study\nResearch on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER) SARS-CoV-2 Household\nTransmission Study\nOutcome: Transmission in households of healthcare, first responder, and essential and other frontline workers with\nPopulation: Households of infected healthcare providers\/first responders\/essential and other frontline workers\nParticipating Sites\nBaylor Scott and White Health, Temple, TX\nKaiser Permanente Northwest, Portland, OR\nSt. Luke\u2019s Hospital, St. Louis, MO\nUniversity of Arizona, Tucson, AZ\nUniversity of Miami, Miami, FL\nUniversity of Utah, Salt Lake City, UT\n\uf20c\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nUniversity of Utah, Salt Lake City, UT\nRVTN (Respiratory Virus Transmission Network)\nRVTN \u2013 Sentinel\nSentinel Protocol\nOutcome: Household transmission among community members confirmed with SARS-CoV-2\nPopulation: Households of community members with positive SARS-CoV-2 tests recruited from sentinel testing sites\nParticipating Sites\nUniversity of Arizona, Tucson, AZ\nStanford University, Stanford, CA\nUniversity of Colorado, Denver, CO\nColumbia University, New York City, NY\nUniversity of North Carolina, Chapel Hill, NC\nVanderbilt University Medical Center, Nashville, TN\nMarshfield Clinic Research Institute, Marshfield, WI\n\uf20c\nRVTN \u2013 National\nNational Approach (also known as \u201cTrack COVID at Home \u201d).","8755":"These instructions may show how to make sure the product fits\nproperly. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:40 AM Use and Care of Masks | CDC\nSome types of masks and respirators may feel different if your child is used to wearing cloth or disposable procedure\nmasks. Parents and caregivers may have questions about NIOSH-approved respirators (such as N95s), and international respirators\n(such as KN95s and KF94s) for children. Although respirators may be available in smaller sizes, they are typically designed to\nbe used by adults in workplaces, and therefore may not have been tested for broad use in children.","9799":"Vaccination continues to be recommended regardless of the option for delaying vaccination after infection. Numerous immunologic studies and a growing number of epidemiologic studies have shown that vaccinating\npreviously infected individuals significantly enhances their immune response and effectively reduces the risk of\nsubsequent infection, including in the setting of increased circulation of more infectious variants (CDC, 2021). What is the available supporting evidence for revaccination of people who received COVID-19 vaccine during\nB-cell-depleting therapy administered over a limited period?","5781":"Has the COVID-19 vaccine by Moderna been used before? Yes. Millions of people have received this vaccine in the United States since it became available starting\nDecember 18, 2020. Also, in clinical trials, approximately 15,400 people 18 ages years and older received at\nleast 1 dose of the vaccine and approximately 2,500 people ages 12\u201317 years received a primary series of\nthe vaccine. There have been some studies in people who received the COVID-19 vaccine by Moderna after\ncompleting a primary vaccination with a non-FDA authorized or approved COVID-19 vaccine or Janssen\nCOVID-19 Vaccine. What are the risks of the COVID-19 vaccine by Moderna?","5178":"More Information\nRequired Proof of COVID-19 Vaccination\nFrequently Asked Questions about Travel and COVID-19\nHealth Information for International Destinations\nDomestic Travel During COVID-19\nUS State Department Travel Site : Safety and security information by country, passport, visas, and entry\/exit\nrequirements\nUS Customs and Border Protection : Information about what you can and cannot bring back from your trip abroad\nUS Embassies : In-country contacts\nTransportation Security Administration (TSA) : Information about flying\n\uf209\n\uf209\n\uf209\n\uf209\nLast Updated Aug. 24, 2022","9766":"\u2022 Neutralizing antibody titers were higher following an extended dosing (6-14 weeks) interval with\nmRNA vaccine, compared to a standard 3\u20134 week interval (Payne, 2021; Grunau, 2021; Amirthalingam,\n2021; Parry, 2022). \u2022 Among an observational cohort of SARS-CoV-2 infection na\u00efve health care workers (n=334) in the\nUnited Kingdom, persons who received Pfizer-BioNTech COVID-19 Vaccine following an extended\ndosing interval (6\u201314 week) had higher neutralizing antibody titers and antigen-specific B cell\nresponses 4 weeks after their second dose, compared to persons with a short interval (3\u20134 week)\n(Payne, 2021).","7505":"If you have received both doses of an accepted 2-dose vaccine series,\nregardless of how long it has been between doses, you are considered fully vaccinated. This means if you received a\nsingle dose of an accepted 2-dose series and then a booster dose of an accepted vaccine, you would be considered fully\nvaccinated under CDC\u2019s Amended Order because you have received two total doses. The second dose does not have to\nbe the same vaccine as the first, but both doses must be one of the accepted vaccines for you to be considered fully\nvaccinated.","884":"Once your isolation period has ended you should still wear a mask until day 10. After 10 days, you should still wash your\nhands before caring for your newborn, but you don\u2019t need to take the other precautions. These timeframes do not apply if\nyou have a severely weakened immune system or were severely ill with COVID-19. Please refer to \u201cQuarantine and Isolation\u201d\nand consult with your health care professional about when it is safe for you to end your isolation period.","9564":"Either dose may be:\n\u0083 0.20 mL (10 mcg) of the product authorized for children ages 5\u201311 years (orange cap and label border), or\n\u0083 0.30 mL (30 mcg) of the product authorized for children ages 12\u201317 years (gray cap and label border)\nOR 3-8 weeks\nOR\fSpecial Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nInterchangeability of Moderna and Pfizer-BioNTech COVID-19 vaccines\nCOVID-19 vaccine from the same manufacturer should be used for the primary series.","2695":"Practice everyday preventive actions to keep from getting sick: wash your hands often; avoid touching your\neyes, nose, and mouth; and frequently clean and disinfect surfaces. \u2022\n-\nClean your hands often\nWash hands: Wash your hands often with soap and water for at least 20 seconds. Tell everyone in the home to do\nthe same, especially after being near the person who is sick. Hand sanitizer: If soap and water are not readily available, use a hand sanitizer that contains at least 60% alcohol. Cover all surfaces of your hands and rub them together until they feel dry.","447":"May 2021: New Hampshire lifted its national COVID-19 emergency response declaration in May 2021, which allows\nvaccine recipients to opt out of having their COVID-19 vaccinations included in the state\u2019s Immunization Information\nSystem registry. As such, data submitted by New Hampshire since May 2021 may not be representative of all COVID-19\nvaccination occurring in the state. On May 27, 2021, the total doses administered data posted to COVID Data Tracker for Vermont showed a decrease in\ndoses administered. This is an accurate reflection of the data and is the result of ongoing efforts to improve the data\nquality of records reported from Vermont.","6416":"Since your immune response to COVID-19 vaccination may not be as strong as in people\nwho are not immunocompromised, you have different recommendations for COVID-19 vaccines, including boosters. Learn\nmore about COVID-19 vaccine recommendations for people who are moderately or severely immunocompromised. COVID-19 pre-exposure prophylaxis\nTake extra precautions\nEven if you stay up to date on COVID-19 vaccines and receive Evusheld , taking multiple prevention steps can provide\nadditional layers of protection from COVID-19. Wear a well-fitting, high quality mask or respirator. Properly fitting respirators provide the highest level of protection. Avoid poorly ventilated or crowded indoor settings.","5389":"KEEP YOUR VACCINATION CARD\nWhen you receive the Janssen COVID-19 Vaccine, you will get a vaccination card to document\nthe name of the vaccine and date of when you received the vaccine. ADDITIONAL INFORMATION\nIf you have questions or to access the most recent Janssen COVID-19 Vaccine Fact Sheets, scan\nthe QR code using your device, visit the website or call the telephone numbers provided below. QR Code Fact Sheets Website Telephone numbers\nwww.janssencovid19vaccine.com. US Toll Free: 1-800-565-4008\nHOW CAN I LEARN MORE? \u2022 Ask the vaccination provider. \u2022 Visit CDC at https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/index.html. \u2022 Visit FDA at https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-\nregulatory-and-policy-framework\/emergency-use-authorization. Contact your local or state public health department.","3460":"If the virus is spreading\non board a cruise ship, passengers and crew are at risk for infection. Check directly with your cruise line about their testing or vaccination protocols before travel. If your cruise line does not have a testing requirement, get tested for current infection with a COVID-19 viral test as close\nto time of cruise departure as possible (no more than 3 days before you travel). Get tested again with a COVID-19 viral test 3-5 days after your cruise. CDC is reviewing this page to align with updated guidance.","4218":"People who have had a known COVID-19 exposure should not seek vaccination until their\u202fquarantine period\u202fhas ended to\navoid potentially exposing healthcare personnel and others during the vaccination visit. This recommendation to wait\nalso applies to people with a known COVID-19 exposure who have received their first dose and need additional or\nbooster doses. Learn more about how to stay up to date with your COVID-19 vaccines. Yes, depending on your age, for your primary series you can choose which type of COVID-19 vaccine to get.","5969":"Frequencies of local and\nsystemic adverse reactions in the 7 days post booster vaccination were higher with heterologous than\nhomologous boosters and in those aged under 70 years when compared to older recipients. Among all mRNA\nvaccines, the 100 microgram COVID-19 vaccine by Moderna was the most reactogenic (Munro et al., 2021). WHO\u2019s Strategic Advisory Group of Experts (SAGE) on Immunization has noted that although data are currently\nlimited on the safety, immunogenicity, and effectiveness of heterologous versus homologous additional doses,\nevolving evidence suggests that use of a heterologous vaccine for an additional dose may be more\nimmunogenic than a homologous series.","4812":"Age Unauthorized age group (recipients\nyounger than age 6 months)\nDo not give another dose at this time. *\nProduct and dosage Higher-than-authorized dose\nadministered (e.g., incorrect dose\nvolume, incorrect product resulting in\nhigher-than-authorized dose)\nDo not repeat dose. Lower-than-authorized dose\nadministered (e.g., leaked out of the\nsyringe, equipment failure, recipient\npulled away, incorrect product resulting\nin lower-than-authorized dose)\nRepeat dose immediately (no minimum interval). However, if a half-volume dose of vaccine is administered to a patient\nrecommended for the full volume, another half-volume dose can be\nadministered on the same clinic day, and the 2 doses can count as 1 full\ndose.","3864":"NDC (national drug code)\n13. Dose number*\n14. Lot number (Unit of Use [UoU] or Unit of Sale [UoS])*\n15. MVX (manufacturer)*\n16. Sending organization (name of the agency submitting the report)\n17. Vaccine administering provider\u2019s name and suffix*\n18. Administering provider\u2019s address, if different from the administration address*\n19. Vaccine administration site (on the body)*\n20. Vaccine expiration date*\n21. Vaccine route of administration*\n22. Vaccine series\nFind more information about vaccine administration and reporting requirements.","6411":"Examples of medical conditions or treatments that may result in moderate to severe immunocompromise include but are not\nlimited to:\nActive treatment for solid tumor and hematologic malignancies\nHematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status\n(e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\nReceipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\nReceipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of\ntransplantation or taking immunosuppressive therapy)\nModerate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined\nimmunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)\nAdvanced or untreated HIV infection (people with HIV and CD4 cell counts less than 200\/mm3, history of an AIDS-\ndefining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)\nActive treatment with high-dose corticosteroids (i.e., 20 or more mg of prednisone or equivalent per day when\nadministered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs,\ncancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and\nother biologic agents that are immunosuppressive or immunomodulatory\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nHow to Protect Yourself\f10\/30\/22, 9:38 AM People Who Are Immunocompromised | CDC\nYou are up to date with your COVID-19 vaccines when you have received all doses in the primary series and all boosters\nrecommended for you, when eligible.","10008":"Considerations for subsequent COVID-19\nvaccination may include:\n\u25cb The myocarditis or pericarditis was considered unrelated to vaccination with Moderna, Novavax,\nor Pfizer-BioNTech (e.g., due to SARS-CoV-2 or other viruses), especially if the myocarditis or\npericarditis diagnosis occurred more than 3 weeks after the most recent dose of COVID-19 vaccine\n\u25cb Personal risk of severe acute COVID-19 (e.g., age, underlying conditions)\n\u25cb Timing of any immunomodulatory therapies;\nConsult ACIP\u2019s General Best Practice Guidelines for Immunization\n\u0083 For information on potential use of Janssen COVID-19 Vaccine in this situation, see Appendix A\n\u0083 Persons who have a history of myocarditis or pericarditis unrelated to mRNA (Moderna, Pfizer-Bio-\nNTech) or Novavax COVID-19 vaccination may receive any currently FDA-approved or -authorized\nCOVID-19 vaccine after the episode of myocarditis or pericarditis has resolved.","2774":"If you feel able to, try to do some activities you enjoy. Connect with others. Talk with people you trust about your concerns and how you are feeling. For information, explore CDC\u2019s recommendations on how to cope with a disaster or traumatic event. If any of these steps require changes to your routine, diet, activity level, or medication, talk to your healthcare provider. \u2022\n\u2022\n- \uf209 \uf209\n-\n-\n-\n-\n\u2022\n\u2022\nSupport People with Post-COVID Conditions\nExperiencing post-COVID conditions can be confusing and frustrating, and a person who feels sick long-term may feel\nisolated.","9156":"Be sure to get care if you have trouble\nbreathing, or have any other emergency warning signs, or if you think it is an emergency. Do not travel and avoid public transportation, ride-sharing, or taxis if possible. \u2022\n\u2022\n\u2022\n\u2022\n\uf283 Isolation and Exposure Calculator\nA tool to help you determine if you need to isolate or take other steps to prevent spreading COVID-19. Isolation & Exposure\n\uf3c0 Separate yourself from other people\nAs much as possible, stay in a specific room and away from other people and pets in your home. If possible,\nyou should use a separate bathroom.","3496":"Follow recommendations for protecting yourself and others. If you have symptoms of COVID-19, stay in your cabin and notify the onboard medical center immediately. It\u2019s important to report your symptoms, even if they are mild, to protect others on board including\npassengers at increased risk for severe illness and crew. \uf309 Masks\nFollow any ship-specific mask protocols. Follow CDC\u2019s recommendations for wearing masks in travel and public transportation settings. If You Develop Symptoms or Use a Self-Test on Board with a Positive Result\nIsolate yourself in your cabin immediately. Call your ship\u2019s medical center.","1204":"County-level Reporting\nCalifornia\u202fdoes not report the county of residence for persons receiving a COVID-19 vaccine when the resident\u2019s county\nhas a population of fewer than 20,000 people. Hawaii\u202fdoes not provide county-of-residence information when reporting COVID-19 vaccination data to CDC. Massachusetts\u202fdoes not provide COVID-19 vaccination data for Barnstable, Dukes, and Nantucket counties because of\ntheir small populations. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nLast Updated Apr. 8, 2022","3442":"The two approved formulations of COMIRNATY and the two FDA-\nauthorized formulations of the Pfizer-BioNTech COVID-19 Vaccine for people ages 12 years and older are the same\nformulations, and vials of the BLA-compliant vaccine may bear the name \u201cPfizer-BioNTech COVID-19 Vaccine.\u201d The FDA-\napproved COMIRNATY (COVID-19 Vaccine, mRNA) and the emergency use authorized formulations of Pfizer-BioNTech\nCOVID-19 Vaccine for people ages 12 years and older (gray cap\/label vials ), when prepared according to their\nrespective instructions for use, can be used interchangeably without presenting any safety or effectiveness concerns. 3.","1802":"10\/30\/22, 9:22 AM COVID-19 Vaccine Access in Long-term Care Settings | CDC\nVaccines & Immunizations\nVaccines & Immunizations Home\nPromoting COVID-19 Vaccine in Long-term Care\nSettings\nPrint this Page\nThe risk for severe COVID-19 illness\nincreases with older adults and\nthose with underlying medical\nconditions. Because of this, the\nfederal government is committed to\nensuring that residents and staff in long-term care (LTC) settings, such as nursing homes, assisted living communities,\nresidential care communities, group homes and senior housing, have access to COVID-19 vaccines. For additional examples of\nLTC settings, see COVID-19 Vaccine Access in Long-Term Care Settings .","49":"However, if\nyou had a severe allergic reaction after a dose of an mRNA COVID-19 vaccine or if you have had a severe allergic reaction to\nany ingredient in an mRNA COVID-19 vaccine, you may be able to get the J&J\/Janssen COVID-19 vaccine. Learn about getting a different type of COVID-19 vaccine after an allergic reaction.","9356":"Children who will turn from 11 years to 12 years of age between doses in the primary series may receive, for any\ndose in the primary series, either: (1) the Moderna COVID-19 Vaccine authorized for use in individuals 6 years\nthrough 11 years of age; or (2) Moderna COVID-19 Vaccine authorized for use in individuals 12 years of age and\nolder; or (3) SPIKEVAX (COVID-19 Vaccine, mRNA).","9978":"In\nall other cases, an allergy-related contraindication to one type of COVID-19 vaccine is a precaution to the other types. \u0083 A previous dose OR a component of any COVID-19 vaccine\n\u0083 A previous dose of COVID-19 vaccine? People with a severe allergic reaction* to a previous COVID-19\nvaccine dose or a known (diagnosed) allergy to a component\nof the vaccine have a contrainidcation to the same type of\nCOVID-19 vaccine (mRNA, Novavax, Janssen). People who had an immediate (less than 4 hours), but non-\nsevere allergic reaction to a previous dose of COVID-19 vaccine,\nhave a precaution to receiving the same type of COVID-19\nvaccine product.","8389":"Vaccine manufacturers, CDC, other federal entities, public health agencies, and professional organizations provide a\nvariety of training resources, including print materials, training modules, webinars, seminars, and videos. For healthcare\nprofessionals who will be preparing and administering vaccine, it is essential that training programs also include an\nTraining recommendations\n\uf1aa\f10\/30\/22, 9:17 AM Training and Education for COVID-19 Vaccination | CDC\nobservation component and competency assessment. The following sections describe trainings and competencies\nhealthcare professionals need based on their roles and experience to ensure the vaccine cold chain is protected and\nvaccines are administered safely to recipients.","1477":"Which COVID-19 vaccines are recommended for people with a history of Bell\u2019s palsy? \uf1aa\nGBS is a neurological disorder in which the body\u2019s immune system damages nerve cells, causing muscle weakness and\nsometimes paralysis. For people with a history of GBS, as for the general population, mRNA (i.e., Moderna or Pfizer-\nBioNTech) and Novavax COVID-19 vaccines are recommended for the primary series, and an age-appropriate mRNA\nWhich COVID-19 vaccines are recommended for people with a history of Guillain-Barre syndrome\n(GBS)? \uf1aa\f10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\nvaccine is recommended for the booster dose.","2539":"Immunization Schedule for Children 6 Months through 17 Years of Age*\nType\nRecipient\nAge\nProduct\u2020\nFor Most People\nThose Who ARE Moderately or\nSeverely Immunocompromised\nDoses Interval Between Doses\u2021 Doses Interval Between Doses\nmRNA\nvaccine\nthrough\nMONOVALENT Moderna:\nBlue vial cap with\nmagenta-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 4\u20138 weeks\u00b6\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nthrough\nMONOVALENT Moderna:\nBlue vial cap with\npurple-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 4\u20138 weeks\u00b6\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Moderna:\nBlue vial cap with\ngray-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nthrough\nMONOVALENT Moderna:\nRed vial cap with\nblue-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 4\u20138 weeks\u00b6\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Moderna:\nBlue vial cap with\ngray-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nthrough\nMONOVALENT Pfizer-BioNTech:\nMaroon vial cap with\nmaroon-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 3\u20138 weeks\u00b6 Dose 1 to 2 At least 3 weeks\nDoses 2 and 3 At least 8 weeks (2 months) Dose 2 to 3 At least 8 weeks (2 months)\nthrough\nMONOVALENT Pfizer-BioNTech:\nOrange vial cap with\norange-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 3\u20138 weeks\u00b6\nDose 1 to 2 At least 3 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Pfizer-BioNTech:\nOrange vial cap with\norange-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nthrough\nMONOVALENT Pfizer-BioNTech:\nGray vial cap with\ngray-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 3-8 weeks\u00b6\nDose 1 to 2 At least 3 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Pfizer-BioNTech:\nGray vial cap with\ngray-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nProtein\nsubunit\nvaccine\nand older\nMONOVALENT Novavax\nPrimary series: Monovalent\nDose 1 to 2 At least 3\u20138 weeks\u00b6 Dose 1 to 2 At least 3 weeks\nmRNA (Moderna, Pfizer-\nBioNTech) should be used for the\nbooster dose.","7264":"ARE OTHER CHOICES AVAILABLE FOR PREVENTING COVID-19 BESIDES\nCOMIRNATY (COVID-19 VACCINE, mRNA), THE PFIZER-BIONTECH COVID-19\nVACCINE, OR THE PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT? For primary vaccination, another choice for preventing COVID-19 is SPIKEVAX\n(COVID-19 Vaccine, mRNA), an FDA-approved COVID-19 vaccine. Other vaccines to\nprevent COVID-19 may be available under EUA, including bivalent vaccines that\ncontain an Omicron component of SARS-CoV-2. CAN I RECEIVE COMIRNATY (COVID-19 VACCINE, mRNA), PFIZER-BIONTECH\nCOVID-19 VACCINE, OR THE PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT\nAT THE SAME TIME AS OTHER VACCINES?","9875":"Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-\nCorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective\ncohort study from Lebanon. Vaccine 2021; 139:6713-9. Munro, Alasdair PS, et al. \"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster)\nfollowing two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre,\nrandomised, controlled, phase 2 trial.\" The Lancet (2021). National Advisory Committee on Vaccination. An Advisory Committee Statement: Guidance on booster COVID-\n19 vaccine doses in Canada. Public Health Agency of Canada; 3 Dec 2021.\nhttps:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/immunization\/national-advisory-\nvaccine-doses.pdf\nNational Collaborating Centre for Methods and Tools.","3397":"Clinical recovery has been achieved, including return to baseline cardiac function; and\n2. It has been at least 90 days after the diagnosis of MIS-C\/A\nCOVID-19 vaccination may also be considered for people who had MIS-C\/A and do not meet both criteria, at the discretion of\ntheir clinical care team (see Consultation for decisions about COVID-19 vaccination). Experts view clinical recovery, including\nreturn to baseline cardiac function, as an important factor when considering COVID-19 vaccination. Additional factors, such as\nthe risk of severe COVID-19 due to age or certain medical conditions, may also be considered.","3126":"Age or place of residence\nalone (e.g., residence in a long-term care setting ), independent of a patient\u2019s medical condition, should not be used to\ndetermine the level of immune competence. For additional information about the degree of immune suppression associated with different medical conditions and\ntreatments, providers can consult ACIP\u2019s general best practices for vaccination of people with altered immunocompetence,\nthe CDC Yellow Book, and the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline\nfor Vaccination of the Immunocompromised Host . People can self-attest to their moderately or severely immunocompromised status and receive COVID-19 vaccine doses\nwherever vaccines are offered.","7536":"Do I qualify for an exception or can I apply for an exception to the vaccine requirement? \uf1aa\nNo, there are no exceptions under the Presidential Proclamation and CDC\u2019s Amended Order for religious reasons or\nother moral convictions. Can I qualify for an exception to the proof of vaccination requirement under the Presidential\nProclamation and CDC\u2019s Amended Order for religious reasons or other moral convictions? \uf1aa\nCertain categories of persons traveling to the United States for reasons related to official foreign government travel or\nWhat do I need to show if I am on diplomatic or official foreign government travel?","210":"When someone who is fully vaccinated gets COVID-19, it is called a vaccine breakthrough infection. No vaccine\nis 100% effective, so some breakthrough infections are expected. The risk of infection, severe illness, hospitalization, and\ndeath are all much lower for vaccinated people compared to people who are unvaccinated. When reinfections or\nbreakthrough infections happen, having antibodies plays an important role in helping prevent severe illness, hospitalization,\nand death. For many diseases, including COVID-19, antibodies are expected to decrease or \u201cwane\u201d over time. After a long enough period\nof time, your level of antibodies can decrease below a level that provides effective protection.","5690":"\u2022\n\u2022\n-\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:39 AM Masks and Respirators\nAlternative Masks for Special Situations\nFor more information on science behind improving how your mask protects you, see:\nEfficacy of Portable Air Cleaners and Masking for Reducing Indoor Exposure to Simulated Exhaled SARS-CoV-2 Aerosols\n\u2014 United States, 2021\nMaximizing Fit for Cloth and Medical Procedure Masks to Improve Performance and Reduce SARS-CoV-2 Transmission\nand Exposure, 2021\nClear masks or cloth masks with a clear plastic panel are an alternative type of\nmask that may be helpful when interacting with certain groups of people, such\nas:\nPeople who are deaf or hard of hearing\nYoung children or students learning to read\nStudents learning a new language\nPeople with disabilities\nPeople who need to see the proper shape of the mouth for making appropriate vowel sounds\nThe FDA cleared for marketing a transparent medical mask.","6037":"Delaying vaccination for 3\nmonths after infection may therefore help to maximize protection with minimal risk to the individual. However, robustness and duration of protection is variable (National Collaborating Center for Methods and\nTools, 2021). The circulating variant, as well as individual-level factors such as age and comorbidities, can\nimpact level of protection. For example, overall risk of reinfection increased during the Omicron wave, and\nprotection from infection or vaccination, was less robust than against previous variants (Pulliam et al., 2022).","5069":"A new section on persons with a history of multisystem inflammatory syndrome added to considerations for\nvaccination of people with certain underlying medical conditions. Updated recommendation for timing of COVID-19 vaccine administration in persons with a history of heparin-induced\nthrombocytopenia. Updated information on vaccination of children and adolescents. The Advisory Committee on Immunization Practices\u2019 updated interim recommendation for the use of the Janssen\n(Johnson & Johnson) COVID-19 Vaccine. Clarification that COVID-19 vaccination is recommended for all people 16 years and older added to key points and\nvaccine administration. Updated information about the Janssen COVID-19 Vaccine added to background.","9219":"You may also need to wear personal protective equipment, such as gloves, depending on the\ndirections on the product label. Immediately after disinfecting, wash your hands with soap and water for 20 seconds. \u2022\n\u2022\n\u2022\n\u2022\n- \u2022 \uf209\n\u2022\n\u2022\n\u2022\nTake steps to improve ventilation at home\nImprove ventilation (air flow) at home to help prevent from spreading COVID-19 to other people in your\nhousehold. Clear out COVID-19 virus particles in the air by opening windows, using air filters, and turning on fans in\nyour home. Use this interactive tool to learn how to improve air flow in your home.","5133":"If you travel, wear a high-quality mask or\nrespirator the entire time you are around others\nindoors. Traveling by private vehicle (if possible) can lower\nthe chances of spreading COVID-19 to others. I was exposed to a person with COVID-19 in the\npast 10 days. Follow CDC guidance, including getting tested at\nleast 5 full days after your last exposure. Do not travel on public transportation such as\nairplanes, buses, and trains if you will not be able\nto wear a high-quality mask or respirator when\naround others indoors for the full duration of your\ntrip.","7270":"Data have not yet been submitted to FDA on administration of COMIRNATY\n(COVID-19 Vaccine, mRNA), the Pfizer-BioNTech COVID-19 Vaccine, or the\nPfizer-BioNTech COVID-19 Vaccine, Bivalent at the same time with other vaccines. If\nyou are considering receiving COMIRNATY (COVID-19 Vaccine, mRNA), the\nPfizer-BioNTech COVID-19 Vaccine, or the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent with other vaccines, discuss your options with your healthcare provider. WHAT IF I AM IMMUNOCOMPROMISED? If you are immunocompromised, you may receive a third primary series dose of\nPfizer-BioNTech COVID-19 Vaccine or COMIRNATY (COVID-19 Vaccine, mRNA). Individuals 12 years of age and older may receive a booster dose with\nPfizer-BioNTech COVID-19 Vaccine, Bivalent.","5500":"People who experience multisystem inflammatory syndrome (MIS) during or after COVID-19 illness. Health Inequities May Affect Populations at Risk for Long COVID\nSome people are at increased risk of getting sick from COVID-19 because of where they live or work, or because they can\u2019t get\nhealth care. Health inequities may put some people from racial or ethnic minority groups and some people with disabilities at\ngreater risk for developing post-COVID conditions. Scientists are researching some of those factors that may place these\ncommunities at higher risk of both getting infected or developing post-COVID conditions.","3406":"Evaluation of people who develop MIS-C or MIS-A after COVID-19 vaccination\nIn the rare instance a person develops MIS-C, MIS-A, or a similar clinical illness after receipt of COVID-19 vaccine, referral to a\nspecialist in infectious diseases, rheumatology, and\/or cardiology should be considered. Assessment should include testing for current or prior SARS-CoV-2 infection, in addition to other potential etiologies as\nclinically indicated. Obtaining a serum sample before any intravenous immune globulin (IVIG) is administered is highly\nrecommended so that the sample can be tested for SARS-CoV-2 anti-nucleocapsid antibody, which may require a reference\nlaboratory. Treatment should not be delayed until test results are available.","7872":"\uf209\nBD Veritor\nManufactured by BD\nSteps for testing \u2013 BD Veritor At-Home COVID-19 Test \uf209\nBinaxNow\nManufactured by Abbott\nHow To: A Guide for the BinaxNOW\u2122 COVID-19 Self-Test \uf209\nCarestart\nManufactured by Access Bio\nAccess Bio Carestart Antigen Home Test Kit \u2013 Instructional Video \uf209\nCelltrion DiaTrust\u2122\nManufactured by Celltrion USA\nHow to use the Celltrion DiaTrust\u2122 COVID-19 Ag Home Test \uf209\f10\/30\/22, 9:38 AM Self-Testing Videos | CDC\nCLINITEST\nManufactured by Siemens\nHow to use the CLINITEST\u00ae Rapid COVID-19 Antigen Self-Test (prefilled extraction tubes)\n\uf209\nFlowFlex\nManufactured by ACON Laboratories\nFlowFlex SARS-CoV-2 Antigen Rapid Test with Prefilled Extraction Buffer Tubes \uf209\niHealth\nManufactured by iHealth\niHealth COVID-19 Antigen Rapid Test \u2013 Self-testing accessible to everyone \uf209\nInBios SCoV-2 Ag Detect\u2122\nManufactured by InBios\nInBios SCoV-2 Ag Detect\u2122 Rapid Test \uf209\nInteliSwab\nManufactured by OraSure Technologies\nInteliSwab\u2122 COVID-19 Rapid Test Training Video (OTC) \uf209\nQuickVue\nManufactured by Quidel\nQuickVue At-Home (quickvueathome.com) \uf209\nCOVID-19 At-Home Test\nManufactured by BD Sensor\nHow to use the COVID-19 At-Home Test \uf209\f10\/30\/22, 9:38 AM Self-Testing Videos | CDC\nLast Updated Feb. 10, 2022","7749":"Based on a recent analysis of data from the Vaccine Safety Datalink, the rate of GBS within the first 21 days\nfollowing J&J\/Janssen COVID-19 vaccination was found to be 21 times higher than after Pfizer-BioNTech or Moderna\n(mRNA COVID-19 vaccines). After the first 42 days, the rate of GBS was 11 times higher following J&J\/Janssen COVID-\n19 vaccination. The analysis found no increased risk of GBS after Pfizer-BioNTech or Moderna (mRNA COVID-19\nvaccines). CDC and FDA will continue to monitor for and evaluate reports of GBS occurring after COVID-19\nvaccination and will share more information as it becomes available.","4235":"\uf1aa\n\u2022\n\u2022\n\u2022\nGenerally, if you are up to date on your COVID-19 vaccinations, you do not need to wear a mask in outdoor settings. Check your local COVID-19 Community Level for recommendations on when to wear a mask indoors and additional\nprecautions you can take to protect yourself from COVID-19. If you are immunocompromised or more likely to get very\nsick from COVID-19, learn more about how to protect yourself. Do I need to wear a mask and avoid close contact with others if I am vaccinated? \uf1aa\nSh ld I k if I h k i t ?","4552":"10\/30\/22, 9:40 AM Improving Ventilation in Your Home | CDC\nEspa\u00f1ol | Other Languages\nImproving Ventilation in Your Home\nVentilate your home by getting fresh air into your home, filtering the air that is there, and improving air flow. Improving\nventilation can help you reduce virus particles in your home and keep COVID-19 from spreading. You may or may not know if\nsomeone in your home or if a visitor to your home has COVID-19 or other respiratory viruses. Good ventilation, along with\nother preventive actions, can help prevent you and others from getting and spreading COVID-19 and other respiratory\nviruses.","6957":"Common side effects reported were mostly mild, but some people had side effects that\naffected their ability to do daily activities. Cases of myocarditis and pericarditis have rarely been reported\nin some people. Cases have occurred predominantly in adolescents and young adult males within the first\nweek after the second dose of vaccine. Additional information on the common and serious side effects of the COVID-19 vaccine by Pfizer-BioNTech\ncan be found in the package insert for Comirnaty and in the EUA Fact Sheet for Recipients and Caregivers. What are the benefits of the COVID-19 vaccine by Pfizer-BioNTech?","4438":"Improving Ventilation and Spending Time Outdoors\nImproving ventilation (moving air into, out of, or within a room) and filtration (trapping particles on a filter to remove\nthem from the air) can help prevent virus particles from accumulating in indoor air. Improving ventilation and filtration\ncan help protect you from getting infected with and spreading the virus that causes COVID-19. Spending time outside\nwhen possible instead of inside can also help: Viral particles spread between people more readily indoors than outdoors. Actions that can improve ventilation and filtration include:\nBringing in as much outdoor air as possible\u2014for example, opening windows.","7227":"FDA has authorized Pfizer-BioNTech\nCOVID-19 Vaccine, Bivalent to provide better protection against COVID-19 caused by\nthe Omicron variant of SARS-CoV-2. The duration of protection against COVID-19 is currently unknown. WHAT ARE THE RISKS OF THESE VACCINES? There is a remote chance that these vaccines could cause a severe allergic reaction. A\nsevere allergic reaction would usually occur within a few minutes to 1 hour after getting\na dose. For this reason, your vaccination provider may ask you to stay at the place\nwhere you received your vaccine for monitoring after vaccination.","8496":"Remember, requirements\nand recommendations in other countries may differ from the United States. You can travel back home once you have ended isolation but only if you are able to wear a high-quality mask or respirator\nwhen around others indoors for the full duration of your trip. If not, do not travel until it\u2019s safe for you to remove your mask around others. Your travel companions should follow CDC travel guidance for people who have been exposed. If you are in another\ncountry, also follow local guidance. What should I do if I test positive during travel? When can I travel back home?","7717":"10\/30\/22, 9:32 AM Selected Adverse Events Reported after COVID-19 Vaccination | CDC\nEspa\u00f1ol | Other Languages\nSelected Adverse Events Reported after COVID-19\nVaccination\nSafety of COVID-19 Vaccines\nSome people have no side effects. Many people have reported side effects, such as headache, fatigue, and soreness at\nthe injection site, that are generally mild to moderate and go away within a few days. What You Need to Know\nCOVID-19 vaccines are safe and effective and severe reactions after vaccination are rare. CDC recommends everyone ages 5 years and older get vaccinated as soon as possible to protect against COVID-19 and\nits potentially severe complications.","3647":"If you already had COVID-19 within the past 90 days, see specific testing recommendations. \uf209\nCan I travel if ...? I am sick with or tested positive for COVID-19 and\nam recommended to isolate. Do NOT travel. Follow recommendations for isolation. I have ended isolation but still need to continue\nwearing my mask per CDC\u2019s guidance. Do not travel on public transportation such as\nairplanes, buses, and trains if you will not be able\nto wear a high-quality mask or respirator when\naround others indoors for the full duration of your\ntrip. If you travel, wear a high-quality mask or\nrespirator the entire time you are around others\nindoors.","10141":"Persons with a history of heparin-\ninduced thrombocytopenia (HIT)\n\u0083 Persons with a history of an episode of an immune-mediated syndrome characterized by TTS, such as a spontaneous or classic HIT, should not\nreceive Janssen COVID-19 Vaccine. \u0083 These persons should receive an mRNA or Novavax COVID-19 vaccine. General COVID-19 Vaccination Information\nPersons vaccinated outside the\nUnited States\n\u0083 The recommendations for people vaccinated outside the United States depend on the number and type of vaccine(s) received for the primary\nseries and booster doses, whether the primary series was completed, and whether a booster dose was received.","8842":"Sign up during the waiting period after you get any dose of COVID-19 vaccine or at any time\nafter vaccination\nAdd a dependent and complete health check-ins on their behalf\nEnter and report how you, or your dependent, feel after first, second, additional, and booster doses\nAvailable in multiple languages including English, Spanish, Chinese, Korean, and Vietnamese\n\u2022\n\u2022\n\u2022\n\u2022\nPlease note:\nV-safe is not an official record of being vaccinated against COVID-19\nV-safe does not give medical advice\nV-safe cannot schedule COVID-19 vaccination appointments\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:31 AM V-safe After Vaccination Health Checker | CDC\nEnroll in v-safe\nYou can enroll in v-safe after any dose of COVID-19 vaccine by using your smartphone and going to vsafe.cdc.gov.","9833":"Reporting Adverse Event or Medication Errors\nThe vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event\nReporting System (VAERS):\n\u2022 vaccine administration errors whether or not associated with an adverse event,\n\u2022 serious adverse events (irrespective of attribution to vaccination),\n\u2022 cases of myocarditis\n\u2022 cases of pericarditis\n\u2022 cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and\n\u2022 cases of COVID-19 that result in hospitalization or death. Complete and submit reports to VAERS online at https:\/\/vaers.hhs.gov\/reportevent.html. For further assistance with reporting to VAERS call 1-800-822-7967. References\nAbu-Raddad L, Chemaitelly H, Ayoub HH, et al.","7625":"Self-quarantine Requirements\nMariners who are embarking the ship the same day they arrive in the United States, must either:\nSelf-quarantine in a single-occupancy cabin with a private bathroom for 5 days after arriving in the United States\nor until the ship leaves U.S. waters, or\nMaintain a \u201cworking\u201d quarantine on board the ship for 5 days after arriving in the United States or until the ship\nleaves U.S. waters\nPlease see CDC\u2019s Interim Guidance for Ships on Managing Suspected or Confirmed Cases of Coronavirus\nDisease 2019 (COVID-19) for additional information regarding \u201cworking\u201d quarantines.","7449":"Who must meet the requirements in the Presidential Proclamation and CDC\u2019s Amended Order to\nboard a plane to the United States? \uf1aa\n\uf209\n\uf209\nNo, U.S. citizens, U.S. nationals, U.S. lawful permanent residents, and immigrants, are not Covered Individuals; therefore\nthe Presidential Proclamation and CDC\u2019s Amended Order Implementing the Presidential Proclamation do not apply. See\nImmigrants and Other Non affected Persons\nDo the Presidential Proclamation and CDC\u2019s Amended Order apply to U.S. citizens, lawful\npermanent residents, or immigrants? \uf1aa\f10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nImmigrants and Other Non-affected Persons.","5359":"Guillain Barr\u00e9 Syndrome\nGuillain Barr\u00e9 syndrome (a neurological disorder in which the body\u2019s immune system damages\nnerve cells, causing muscle weakness and sometimes paralysis) has occurred in some people who\nhave received the Janssen COVID-19 Vaccine. In most of these people, symptoms began within\n42 days following receipt of the Janssen COVID-19 Vaccine. The chance of having this occur is\nvery low. You should seek medical attention right away if you develop any of the following\nsymptoms after receiving the Janssen COVID-19 Vaccine:\n\u2022 Weakness or tingling sensations, especially in the legs or arms, that\u2019s worsening and spreading\nto other parts of the body. \u2022 Difficulty walking.","9557":"OR 8 weeks\nOR\nChildren who turn from age 11 years to 12 years\nRecommended: Children who started a primary series and turned from age 11 to age 12 years before completion of the\nseries should receive:\n0.20 mL (10 mcg) of the\nproduct authorized for\nchildren ages 5\u201311 years\n(orange cap and label border)\nChild turns 12\n0.30 mL (30 mcg) of the\nproduct authorized for\nchildren ages 12\u201317 years\n(gray cap and label border)\nAcceptable: If the following dosing occurs, it is NOT considered an error and the primary series is considered complete.","800":"Getting sick with COVID-19 can cause severe illness or death, even in children, and we can\u2019t reliably predict who will\nhave mild or severe illness. You may have long-term health issues after having COVID-19. Even people who do not have symptoms when they\nare first infected can have these ongoing health problems, also known as long COVID or post-COVID conditions. These complications can appear after mild or severe COVID-19, or after multisystem inflammatory syndrome in\nchildren (MIS-C).","1125":"Older Adults and People with\nDisabilities\nChildren and Adolescents\nHomebound Persons\nDialysis Patients\nHealthcare Personnel\nTeachers, School Staff, and Child Care\nWorkers\nPregnant or Breastfeeding Patients\nPeople with Certain Underlying\nMedical Conditions\nPatients Vaccinated Outside the US\nPatients Receiving Antiviral Therapy\nResources\nHealth\nDepartments\n\uf426\nYou and Your\nFamily\n\uf426\nCOVID-19 Vaccine Effectiveness and Safety\nMMWR COVID-19 Vaccine Reports\nEquity in Vaccination\nCDC\u2019s program, Partnering for Vaccine Equity, aims to\nreduce disparities in disproportionately affected\ncommunities by supporting a wide variety of partners\nworking to increase vaccine confidence and access\namong racial and ethnic minority groups. Equity in Vaccination\nGet Vaccinated\nFind COVID-19 vaccines and boosters near you. Message & data rates may apply.","6510":"Staying up to date with COVID-19 vaccines, getting doses of EVUSHELD if eligible, and following preventive\nmeasures for COVID-19 are important. This is especially important if you are older or have severe health\nconditions or more than one health condition, including those on the list below. Approved and authorized COVID-19 vaccines (primary series and booster) are safe and effective. Some people who are immunocompromised, or people with weakened immune systems, may be eligible for an\nadditional primary dose of COVID-19 vaccine.","8854":"Creating an account to add a dependent does not require that you enter your own vaccination information or complete\nhealth check-ins for yourself. What Happens After I Enroll? During the first week after each vaccination, v-safe will send you a text message each day to ask how you are feeling. After\nthat, you will receive occasional health check-ins. Depending on your answers, someone from CDC may call to get more\ninformation. You can opt out at any time. Your personal information in v-safe is protected so it\u2019s safe and private*.","4236":"\uf1aa\n\u2022\n\u2022\n\u2022\nGenerally, if you are up to date on your COVID-19 vaccinations, you do not need to wear a mask in outdoor settings. Check your local COVID-19 Community Level for recommendations on when to wear a mask indoors and additional\nprecautions you can take to protect yourself from COVID-19. If you are immunocompromised or more likely to get very\nsick from COVID-19, learn more about how to protect yourself. Do I need to wear a mask and avoid close contact with others if I am vaccinated? \uf1aa\nSh ld I k if I h k i t ?","1664":"COVID-19 Vaccine Administration Fees (updated 4\/8\/2022)\nAll organizations and providers participating in the CDC COVID-19 Vaccination Program:\n\uf209\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nmust administer COVID-19 Vaccine at no out-of-pocket cost to the recipient\nmay not deny anyone vaccination based on the vaccine recipient\u2019s coverage status or network status\nmay not charge an office visit or other fee if COVID-19 vaccination is the sole medical service provided\nmay not require additional medical services to receive COVID-19 vaccination\nmay seek appropriate reimbursement from a program or plan that covers COVID-19 Vaccine administration fees for\nthe vaccine recipient, such as:\nvaccine recipient\u2019s private insurance company\nMedicare or Medicaid reimbursement\nHRSA COVID-19 Coverage Assistance Fund for underinsured vaccine recipients (unavailable as of 11:59 ET on\nApril 5, 2022, due to lack of supplemental funding)\nHRSA COVID-19 Uninsured Program for non-insured vaccine recipients (unavailable as of 11:59 ET on April 5,\n2022, due to lack of supplemental funding)\nmay not seek any reimbursement, including through balance billing, from the vaccine recipient\nFor additional information on filing claims for reimbursement of COVID-19 vaccine administration fees, go to:\nCMS Guidance \u2013 https:\/\/www.cms.gov\/covidvax-provider\nCDC Statement on Exhaustion of Funding for the Uninsured Program and Coverage Assistance Fund\nDue to the lack of supplemental funding from Congress, HRSA stopped accepting claims for reimbursement of costs\nassociated with administering COVID-19 vaccines to uninsured and underinsured individuals as of 11:59 PM ET on April 5,\n2022.","10043":"Summary Document for\nInterim Clinical Considerations\nfor Use of COVID-19 Vaccines Currently Authorized or Approved in the United States\nCOVID-19 vaccine products currently approved or authorized in the United States\nPfizer-BioNTech\n* Booster doses are only indicated for recipients 18 years and age and older in limited situations, see: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html\nAge indication Vaccine\ncomposition\nVaccine vial\ncap color\nLabel border\ncolor\nDilution\nrequired\nPrimary series Booster doses\nDose Injection volume Dose Injection volume\n6 months\u20134 years Monovalent Maroon Maroon Yes 3 \u00b5g 0.2 mL NA NA\n5\u201311 years Monovalent Orange Orange Yes 10 \u00b5g 0.2 mL NA NA\n5\u201311 years Bivalent Orange Orange Yes NA NA 10 \u00b5g 0.2 mL\n12 years and older Monovalent Gray Gray No 30 \u00b5g 0.3 mL NA NA\n12 years and older Bivalent Gray Gray No NA NA 30 \u00b5g 0.3 mL\nModerna\nAge indication Vaccine\ncomposition\nVaccine vial\ncap color\nLabel border\ncolor\nDilution\nrequired\nPrimary series Booster doses\nDose Injection volume Dose Injection volume\n6 months\u20135 years Monovalent Dark blue Magenta No 25 \u00b5g 0.25 mL NA NA\n6-11 years Monovalent Dark blue Purple No 50 \u00b5g 0.5 mL NA NA\n6-11 years Bivalent Dark blue Gray No NA NA 25 \u00b5g 0.25 mL\n12 years and older Monovalent Red Light blue No 100 \u00b5g 0.5 mL NA NA\n12 years and older Bivalent Dark blue Gray No NA NA 50 \u00b5g 0.5 mL\nJanssen\nAge indication Vaccine\ncomposition\nVaccine vial\ncap color\nLabel border\ncolor\nDilution\nrequired\nPrimary series Booster doses\nDose Injection volume Dose Injection volume\n18 years and older Monovalent Blue No Color No\nparticles\nparticles\nNovavax\nAge indication Vaccine\ncomposition\nVaccine vial\ncap color\nLabel border\ncolor\nDilution\nrequired\nPrimary series Booster doses*\nDose Injection volume Dose Injection volume\n12 years and older Monovalent Royal blue No Color No\n5 \u00b5g rS and 50 \u00b5g of\nMatrix-M\u2122 adjuvant\n5 \u00b5g rS and 50 \u00b5g of\nMatrix-M\u2122 adjuvant\nJanssen COVID-19 Vaccine is authorized for adults ages 18 years and older in certain limited situations due to safety considerations.","3448":"For intervals of 3 months or less, 28 days (4 weeks) is a \u201cmonth.\u201d For intervals of 4 months or longer, a month is a\n\u201ccalendar month.\u201d For age group ranges (e.g., 6 months\u20134 years, 5\u201311 years), a dash (\u2013) should be read as \u201cthrough\u201d and\nthe upper range includes that year through the last day before the birth date. 4. The Society of Breast Imaging has developed Recommendations for the Management of Axillary Adenopathy in Patients\nwith Recent COVID-19 Vaccination which includes considerations for patients and healthcare professionals in\nscheduling screening exams in relation to the administration of a COVID-19 vaccine.","5854":"In 2013, the Pandemic and All-Hazards Preparedness Reauthorization Act included a new provision that\nallowed for the issuance of EUI to permit CDC to inform healthcare providers and recipients about certain uses\nof FDA-approved or cleared medical products. Specifically, EUI inform healthcare providers and recipients\nabout such products\u2019 approved, licensed, or cleared conditions of use. The CDC Director has statutory (legal)\nauthority to create, issue, and disseminate EUI before or during an emergency. 1 Spikevax is the proprietary name for the product licensed under the Biologics License Application (BLA).","2413":"In addition, a recent report using the v-safe COVID-19 vaccine pregnancy safety monitoring\nsystem data showed that 4,800 people had a positive pregnancy test after receiving the first dose of an mRNA COVID-19\nvaccine. Another report using data from eight U.S. healthcare systems documented more than 1,000 people who\ncompleted COVID-19 vaccination (with any COVID-19 vaccine) before becoming pregnant. Learn more: COVID-19 Vaccines While Pregnant or Breastfeeding. No Evidence that COVID-19 Vaccines Affect Fertility\nThere is currently no evidence that vaccine ingredients or antibodies made following COVID-19 vaccination would cause any\nproblems with becoming pregnant now or in the future.","9702":"What is the available supporting evidence for use of the COVID-19 vaccine by Pfizer-BioNTech for additional\nprimary doses in people who received a primary vaccination with non-FDA authorized or approved COVID-\nCDC has not systematically evaluated the safety, immunogenicity, and efficacy of an additional dose of the\nCOVID-19 vaccine by Pfizer-BioNTech following receipt of primary vaccination with a non-FDA authorized or\napproved COVID-19 vaccine. Most evidence is with use of a booster dose after primary vaccination.","332":"On January 25, 2022, Idaho began providing vaccine data for recipients younger than 18 years of age to CDC. This\nresulted in an increase of 177,996 doses administered. On January 20, 2022, data review and reporting adjustments resulted in a decrease of 12,298 vaccine doses\nadministered in Hawaii since December 14, 2020. On January 19, 2022, CDC changed the address algorithm for the Bureau of Prisons (BOP) and Department of Defense\n(DOD) to better align vaccine administration counts with the residential county of the recipient instead of the county\nwhere vaccine was administered.","4424":"Although vaccinated people\nsometimes get infected with the virus that causes COVID-19, staying up to date on COVID-19 vaccines significantly lowers\nthe risk of getting very sick, being hospitalized, or dying from COVID-19. CDC recommends that everyone who is\neligible get a booster and stay up to date on their COVID-19 vaccines, especially people with weakened immune systems. If you are moderately or severely immunocompromised or severely allergic to COVID-19 vaccines: Talk with a healthcare\nprovider about whether you are eligible for a medicine called EVUSHELD\u2122 that you can take before you are exposed or\ntest positive for COVID-19.","1546":"10\/12\/22 Update (Revises the 9\/1\/22 update to reference younger children 5 years and older who are\nnow eligible to receive the bivalent booster):\nSingle Bivalent COVID-19 Vaccine Booster Doses\nPursuant to September 1 and October 12, 2022, CDC\/ACIP recommendations and the September 2 and October 13,\n2022, Secretarial Directives on Bivalent COVID-19 Vaccine Booster Doses, all providers in the CDC COVID-19\nVaccination Program shall make immediately available and administer, upon request, a single booster dose of:\nPfizer-BioNTech COVID-19, Bivalent (Original and Omicron BA.4\/BA.5) vaccine to individuals ages 5 years and\nolder at least 2 months after receipt of a primary series or prior monovalent booster dose with any COVID-19\nvaccine.","2265":"Staying up to date\u202fmeans getting all recommended COVID-19 vaccines including boosters when eligible. If your loved one is not able to ask questions or otherwise communicate with the LTC staff, here\u2019s what to know about\nconsent for getting a COVID-19 vaccine:\nResidents and their families can ask a LTC provider about the current COVID-19 vaccination rate among their staff and\nresidents. Nursing homes are required by the Centers for Medicare and Medicaid Services (CMS) to monitor weekly COVID-19\nvaccination data for residents and healthcare personnel through CDC\u2019s National Healthcare Safety Network.","8973":"Even if you are no longer pregnant, you may still be eligible to enroll in the registry. \u2022\n\u2022\n\u2022\nV-safe and the V-safe COVID-19 Vaccine Pregnancy Registry:\nWhat\u2019s the Difference? v-safe is a smartphone-based system that uses text messaging and web surveys to provide personalized health check-ins\nafter you receive a COVID-19 vaccine. The v-safe COVID-19 Vaccine Pregnancy Registry is for v-safe participants who self-\nidentify as pregnant at the time of vaccination or shortly thereafter (within 30 days of vaccination). The registry activities are in\naddition to the v-safe after vaccination health check-ins that participants receive via text message.","333":"On January 25, 2022, Idaho began providing vaccine data for recipients younger than 18 years of age to CDC. This\nresulted in an increase of 177,996 doses administered. On January 20, 2022, data review and reporting adjustments resulted in a decrease of 12,298 vaccine doses\nadministered in Hawaii since December 14, 2020. On January 19, 2022, CDC changed the address algorithm for the Bureau of Prisons (BOP) and Department of Defense\n(DOD) to better align vaccine administration counts with the residential county of the recipient instead of the county\nwhere vaccine was administered.","6565":"Get more information:\nHeart Disease\nAmerican Heart Association: COVID-19\nNHLBI Information & Resources on COVID-19\nHIV infection\nHaving HIV (Human Immunodeficiency Virus) can make you more likely to get very sick from COVID-19. Get more information:\n\u2022\n\u2022 \uf209\n\u2022\n\u2022 \uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022 \uf209\n\u2022\n\u2022\n\u2022\n\u2022 \uf209\n\u2022 \uf209\f10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nHIV Infection\nInterim Guidance for COVID-19 and Persons with HIV\nImmunocompromised condition or weakened immune system\nSome people are immunocompromised or have a weakened immune system because of a medical condition or a treatment\nfor a condition.","6430":"Know how to get tested as soon as possible if you develop symptoms. Order free at-home tests to have when you need them. If you need more tests, check with your health\ninsurance, Medicaid, or Medicare plan to learn what tests are available . To find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. EVUSHELD is authorized by the U.S. Food and Drug Administration (FDA) as pre-exposure prophylaxis to prevent\nCOVID-19. It is a medicine containing antibodies and is given before you are exposed to or test positive for COVID-19.","2715":"\u2022\n\u2022\n\u2022\nTrack your own health\nCaregivers should stay home and monitor their health for COVID-19 symptoms while caring for the person who is\nsick. Symptoms include fever, cough, and shortness of breath but other symptoms may be present as well. Trouble\nbreathing is a more serious warning sign that you need medical attention. Caregivers should continue to stay home after care is complete. Caregivers can leave their home 5 days after their\nlast close contact with the person who is sick (based on the time it takes to develop illness), or 5 days after the\nperson who is sick meets the criteria to end home isolation.","4085":"2 doses of Pfizer-BioNTech vaccine 3\u20138* weeks apart for people 5 years and older, or\n3 doses of Pfizer-BioNTech\u202fvaccine\u202ffor ages 6 months through 4 years, first and second dose 3-8 weeks apart,\nsecond and third dose at least 8 weeks apart*. 2 doses of Moderna vaccine 4\u20138* weeks apart for people ages 6 months and older. 2 doses of Novavax vaccine 3 8* weeks apart for people ages 12 years and older\nHow many doses of COVID-19 vaccine will I need to get to complete my primary series?","9697":"\u2022 Provide a CDC COVID-19 Vaccination Record Card to the recipient or their caregiver with the lot number\nand date of administration recorded for the primary, additional, or booster dose of the COVID-19 vaccine\nby Pfizer-BioNTech. \u2022 Provide the v-safe information sheet to vaccine recipients\/caregivers and encourage vaccine recipients\nto participate in v-safe. V-safe is a voluntary smartphone-based tool that uses text messaging and web\nsurveys to check in with people who have been vaccinated to identify potential side effects after COVID-\n19 vaccination. V-safe asks questions that help CDC monitor the safety of COVID-19 vaccines. For more\ninformation, visit: www.cdc.gov\/vsafe.","9299":"Children and Teens Can Experience Ongoing Health Problems\nAfter getting COVID-19, children and teens can also experience a wide range of new, returning, or ongoing health problems. These include physical and mental health complications that may occur four or more weeks after initial infection. These\ncomplications can appear after mild or severe COVID-19, or after MIS-C. Symptoms Post COVID-19 Vaccination Symptoms Post COVID-19 Infection\nCough\nMuscle and joint pain\nHeadache\nTrouble falling or staying asleep\nTrouble concentrating\nLimitations in physical activity\nFeeling distressed about symptoms\nMental health challenges\nDecreased school or daycare attendance\nMissed opportunities for participation in sports,\nplaydates, or other activities\nLearn more about post-COVID conditions.","4048":"How often are COVID-19 vaccination data updated? \uf1aa\n\u2022\n\u2022\n\u2022\nUsers can download daily cumulative data from CDC\u2019s COVID Data Tracker vaccination pages manually or\nprogrammatically. Users can also download historical COVID-19 vaccination data manually or programmatically. Where can I download COVID-19 data? \uf1aa\f10\/30\/22, 9:35 AM Frequently Asked Questions about COVID-19 Vaccination Data | CDC\nVaccination Information\nCOVID-19 vaccination is recommended for children of certain ages and all adults, including those who are pregnant. Learn more about staying up to date with COVID-19 vaccination. Who is eligible for a COVID-19 vaccine?","2032":"COVID-19 vaccine safety in children aged 5\u201311 Years \u2014 United States, November 3\u2013December 19, 2021\nEvaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age\nAdverse events among children ages 5\u201311 years after COVID-19 vaccination: Updates from v-safe and the Vaccine\nAdverse Event Reporting System (VAERS)\nThe Advisory Committee on Immunization Practices\u2019 interim recommendation for use of Pfizer-BioNTech COVID-19\nvaccine in children aged 5\u201311 years \u2014 United States, November 2021\nChildren ages 5 through 11 years\n\uf1aa\n\u2022\n\u2022 \uf209\n\u2022\n\uf20c\n\u2022\nSafety monitoring of COVID-19 vaccine booster doses among persons aged 12\u201317 years \u2014 United States, December\nChildren ages 12 through 17 years\n\uf1aa\n\u2022\f10\/30\/22, 9:31 AM COVID-19 Vaccine Safety in Children and Teens | CDC\nSafety monitoring in the Vaccine Adverse Event Reporting System (VAERS)\nMyocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021\nCOVID-19 vaccine safety in adolescents aged 12\u201317 years \u2014 United States, December 14, 2020\u2013July 16, 2021\nUse of Pfizer-BioNTech COVID-19 vaccine in persons aged \u226516 years: Recommendations of the Advisory Committee\non Immunization Practices \u2014 United States, September 2021\nUse of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: Update from the Advisory\nCommittee on Immunization Practices \u2014 United States, June 2021\nThe Advisory Committee on Immunization Practices\u2019 interim recommendation for use of Pfizer-BioNTech COVID-19\nvaccine in adolescents aged 12\u201315 Years \u2014 United States, May 2021\n\u2022 \uf209\n\u2022\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\nFor a complete list of research, visit Vaccine Safety Publications.","1525":"In addition, providers will post notice visible to the public at the site of any\nmask distribution under this initiative utilizing uniform signage that will be provided electronically by HHS, which,\nat a minimum, will address:\na. The masks have been provided by the U.S. Department of Health and Human Services for free distribution. b. The masks are provided for personal use only. c. And, the public notice will include a QR code and\/or weblink that can be used by recipients of the masks to\nobtain user instructions.","5173":"Summary of Recent Changes\nUpdates as of April 18, 2022\nAs a result of a court order, effective immediately and as of April 18, 2022, CDC\u2019s January 29, 2021 Order requiring\nmasks on public transportation conveyances and at transportation hubs is no longer in effect. Therefore, CDC will not\nenforce the Order. CDC continues to recommend that people wear high-quality masks in indoor public transportation\nsettings at this time.","3396":"Clinical recovery has been achieved, including return to baseline cardiac function; and\n2. It has been at least 90 days after the diagnosis of MIS-C\/A\nCOVID-19 vaccination may also be considered for people who had MIS-C\/A and do not meet both criteria, at the discretion of\ntheir clinical care team (see Consultation for decisions about COVID-19 vaccination). Experts view clinical recovery, including\nreturn to baseline cardiac function, as an important factor when considering COVID-19 vaccination. Additional factors, such as\nthe risk of severe COVID-19 due to age or certain medical conditions, may also be considered.","7307":"All of these criteria must be met to allow for the product to be used during the\nCOVID-19 pandemic. An EUA is in effect for the duration of the COVID-19 EUA declaration justifying\nemergency use of this product, unless terminated or revoked (after which the product\nmay no longer be used). Manufactured for\nBioNTech Manufacturing GmbH\nAn der Goldgrube 12\n55131 Mainz, Germany\nManufactured by\nPfizer Inc., New York, NY 10017\nScan to capture that this Fact Sheet was provided to vaccine\nrecipient for the electronic medical records\/immunization\ninformation systems.","3806":"Strong vaccine confidence leads to more people getting vaccinated, which leads to\nfewer COVID-19 illnesses, hospitalizations, and deaths. Learn more about:\nVaccinate with Confidence\nVaccine Recipient Education\nWhat is the advantage of signing up to participate as a COVID-19 vaccination provider in my\nhealthcare organization or individual practice site? \uf1aa\nTo become a COVID-19 vaccination provider, you must be licensed to administer vaccines in the jurisdiction where you\nwill be practicing. Your health system or you, as an independent provider, are required to sign and abide by the terms of\nthe CDC COVID-19 Vaccination Program Provider Agreement.","10129":"\u0083 If after a risk assessment the decision is made to receive a subsequent COVID-19 vaccine dose, the person should wait until after their episode has\nresolved. \u0083 For information on potential use of Janssen COVID-19 Vaccine in this situation, see Appendix A at www.cdc.gov\/vaccines\/covid-19\/clinical-\nconsiderations\/interim-considerations-us-appendix. html#appendix-a\n\u0083 Persons who have a history of myocarditis or pericarditis unrelated to mRNA or Novavax COVID-19 vaccination may receive any age-appropriate\nCOVID-19 vaccine after the episode of myocarditis or pericarditis has resolved.","7779":"5-11 years: 22 verified reports of myocarditis after 21,638,046 doses administered\n12-15 years: 357 verified reports of myocarditis after 24,480,644 doses administered\n16-17 years: 308 verified reports of myocarditis after 13,429,039 doses administered\nAs the COVID-19 vaccines are authorized for younger children, CDC and FDA will continue to monitor for and evaluate\nreports of myocarditis and pericarditis after COVID-19 vaccination and will share more information as it becomes\navailable. Learn more about myocarditis and pericarditis, including clinical considerations, after mRNA COVID-19\nvaccination. Reports of death after COVID-19 vaccination are rare.","9133":"\uf209\n[PDF - 439 KB]\n\uf20c\nMasks Are Recommended\nCDC recommends properly wearing a high-quality mask or respirator over the nose and\nmouth in indoor areas of public transportation and transportation hubs. Airplane:\nEnglish\nSpanish\nTrain:\nEnglish\nSpanish\nBus:\nEnglish\nSpanish\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\f10\/30\/22, 9:43 AM Wearing Masks in Travel and Public Transportation Settings | CDC\n8.5 W x 11 H [PDF \u2013 304 KB, 1 Page]\n\uf20c\n\uf20c\nLast Updated Sept. 8, 2022","2471":"N Engl J Med. 2021;384(24):2273-2282. 10. Razzaghi H, Meghani M, Pingali C, et al. COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy \u2014\nEight Integrated Health Care Organizations, United States, December 14, 2020\u2013May 8, 2021. MMWR Morb Mortal Wkly\nRep 2021;70:895\u2013899. DOI: http:\/\/dx.doi.org\/10.15585\/mmwr.mm7024e2 . 11. Aharon D, Lederman M, Ghofranian A, et al. In Vitro Fertilization and Early Pregnancy Outcomes After Coronavirus\nDisease 2019 (COVID-19) Vaccination [published online ahead of print, 2022 Jan 25]. Obstet Gynecol. 12. Morris RS. SARS-CoV-2 spike protein seropositivity from vaccination or infection does not cause sterility. F S Rep.\n13.","2672":"Eat in separate rooms or areas\nStay separated: The person who is sick should eat (or be fed) in their room, if possible. Wash dishes and utensils using gloves and hot water: Handle any dishes, cups\/glasses, or silverware used by the\nperson who is sick with gloves. Wash them with soap and hot water or in a dishwasher. Clean hands after taking off gloves or handling used items. \u2022\n\u2022\n\u2022\nAvoid sharing personal items\nDo not share: Do not share dishes, cups\/glasses, silverware, towels, bedding, or electronics (like a cell phone) with\nthe person who is sick.","3698":"\u2022 CDC issuance of initial EUI for the COVID-19 vaccine by Moderna on February 11, 2022\nThe FDA approvedl the COVID-19 vaccine by Moderna (brand name Spikevax) on January 31, 2022, as a\ntwo-dose primary series for active immunization to prevent COVID-19 in persons ages 18 years and\nolder., CDC subsequently issued EUI for the Moderna COVID-19 vaccine to allow primary, additional,\nand\/or booster doses in persons ages 18 years and older, including those vaccinated with certain non-\nFDA authorized or approved COVID-19 vaccines and certain individuals with immunocompromising\nconditions, similar to the uses that go beyond or differ from the FDA-approved labeling as described in\nthe EUI for the Pfizer-BioNTech COVID-19 vaccine.","2054":"10\/30\/22, 9:30 AM COVID-19 Vaccines While Pregnant or Breastfeeding\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccines While Pregnant or Breastfeeding\nWhat You Need to Know\nCOVID-19 vaccination is recommended for all people aged 6 months and older. This includes people who are\npregnant, breastfeeding, trying to get pregnant now, or those who might become pregnant in the future. This also\nincludes infants ages 6 months and older born to people who were vaccinated or had a COVID-19 infection before\nor during pregnancy. If you are pregnant or were recently pregnant, you are more likely to get very sick from COVID-19 compared\nto people who are not pregnant.","7634":"Non-cruise ship operators and mariners have several options to fulfill this requirement:\nCrew can visit a shoreside testing facility (e.g., testing at a pharmacy or healthcare facility)\nOperators can contract a 3 party to preform testing onboard\nOperators can provide crew with COVID-19 self-tests (sometimes referred to as home tests or at-home tests) or\nask that crew embark the vessel with their own self-test. CDC recommends that if self-tests are used, they should be conducted under supervision of tele-medicine\npersonnel. How should sea crew members fulfill the requirements of the attestation?","7340":"10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nEspa\u00f1ol | Other Languages\nRequirement for Proof of COVID-19 Vaccination for Air\nPassengers\nRequired for non-U.S. citizen, nonimmigrant passengers arriving from a foreign country to the United States\nby air\nWhat You Need to Know\nIf you are a non-U.S. citizen who is a nonimmigrant (not a U.S. citizen, U.S. national, lawful permanent resident, or\ntraveling to the United States on an immigrant visa), you will need to show proof of being fully vaccinated against\nCOVID-19 before you travel by air to the United States from a foreign country.","6562":"Get more information:\nHeart Disease\nAmerican Heart Association: COVID-19\nNHLBI Information & Resources on COVID-19\nHIV infection\nHaving HIV (Human Immunodeficiency Virus) can make you more likely to get very sick from COVID-19. Get more information:\n\u2022\n\u2022 \uf209\n\u2022\n\u2022 \uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022 \uf209\n\u2022\n\u2022\n\u2022\n\u2022 \uf209\n\u2022 \uf209\f10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nHIV Infection\nInterim Guidance for COVID-19 and Persons with HIV\nImmunocompromised condition or weakened immune system\nSome people are immunocompromised or have a weakened immune system because of a medical condition or a treatment\nfor a condition.","4869":"It is acceptable to administer the repeat\ndose at an interval earlier than 8 weeks if the interval is not sooner than the minimal interval noted in this table. As of the date of this update, current manufacturer contact information is:\nJanssen: US Toll Free: 1-800-565-4008; US Toll: 1-908-455-9922\nPlease see the package inserts and EUA provider factsheets for the most up-to-date manufacturer information. Vaccine doses administered up to 4 days before the minimum interval may be counted and do not need to be repeated.","6189":"10\/30\/22, 9:31 AM Myocarditis and Pericarditis After mRNA COVID-19 Vaccination | CDC\nEspa\u00f1ol | Other Languages\nMyocarditis and Pericarditis After mRNA COVID-19\nVaccination\nMyocarditis is inflammation of the heart muscle. Pericarditis is inflammation of the outer lining of the heart. In both cases, the body\u2019s immune system causes inflammation in response to an infection or some other trigger. Learn\nmore about myocarditis and pericarditis. Both myocarditis and pericarditis have the following symptoms:\nChest pain\nShortness of breath\nFeelings of having a fast-beating, fluttering, or pounding heart\nMyocarditis and pericarditis have rarely been reported.","2674":"\u2022\nWhen to wear a mask or gloves\nIn general, people do not need to wear masks when outdoors. If you are sick and need to be around others, or are caring for someone who has COVID-19, wear a mask. If the COVID-19 Community Level where you live is\nLow\nWear a mask based on your personal preference, informed by your personal level of risk. Medium\nIf you are at risk for severe illness, talk to your healthcare provider about wearing masks indoors in public.","8936":"Learn more about\u202fselected adverse events\u202freported to VAERS. How VAERS Reports Are Reviewed\nVaccine safety experts review all reports of serious adverse events submitted to VAERS. A serious adverse event after\nvaccination is something that causes:\nPermanent disability\nHospitalization or an extended hospital stay (if vaccinated while in the hospital)\nLife-threatening illness\nBirth defects (congenital anomalies)\nDeath\nImportant Things To Know About VAERS\nVAERS is an early warning system used to monitor adverse events that happen after vaccination. VAERS is the\nfrontline system of a comprehensive vaccine safety monitoring program in the United States.","8344":"Option 1: Move on and say, \u201cI respect that, and because I care about your overall health, maybe we could talk about\nthe vaccines at a future time.\u201d\nOption 2: Based on the patient\u2019s demonstrated emotions and your assessment of the patient\u2019s worldview and\nvalues, you could spend several minutes curiously exploring why the patient doesn\u2019t want to talk about it. The goal\nis to understand, not to change their mind. Remember: These conversations may take time, and they may continue over multiple visits. If the patient says yes to talking about the vaccines, move to Step 3.","9003":"How CDC Is Using Data from the Registry\nIn April 2021, CDC released the first U.S. data on the safety of mRNA COVID-19 vaccines administered during pregnancy\nbased on analyses of data from three vaccine safety-related databases, including the v-safe COVID-19 Pregnancy Registry. The\nanalyses did not identify any safety concerns for pregnant people who were vaccinated or for their babies. Additional follow-\nup is needed, particularly among those vaccinated in the first or second trimesters of pregnancy; however, these preliminary\nfindings continue to indicate COVID-19 vaccines are safe and effective.","4985":"New booster recommendation for people ages 12 years and older to receive 1 bivalent mRNA booster after\ncompletion of a monovalent primary series; it replaces all prior booster recommendations for this age group\nRecommendations for use of a bivalent Moderna booster dose in people ages 18 years and older\nRecommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 12 years and older\nUpdated guidance for observation periods following COVID-19 vaccination\nUpdated guidance on COVID-19 vaccination and multisystem inflammatory syndrome (MIS) in children (MIS-C) and in\nadults (MIS-A)\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adolescents ages 12\u201317 years\nReorganization of Janssen COVID-19 Vaccine guidance into an appendix\nUpdated guidance on COVID-19 vaccination following exposure to SARS-CoV-2\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nPrevious Updates\n\uf1aa\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nUpdated guidance on COVID-19 vaccination and myocarditis and pericarditis\nNew clinical considerations for coadministration of mRNA COVID-19 vaccines and orthopoxvirus vaccines\nNew guidance for use of Moderna COVID-19 Vaccine in children and adolescents ages 6\u201317 years\nNew guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children ages 6 months\u20134 years\nNew guidance for use of Moderna COVID-19 Vaccine in children ages 6 months\u20135 years\nReorganization of sections on COVID-19 vaccination recommendations and schedules\nAddition of new section in Special populations for infants and young children\nNew guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5\u201311 years\nUpdated guidance that the following people should receive a second COVID-19 booster dose:\nPeople ages 12 years and older who are moderately or severely immunocompromised\nPeople ages 50 years and older\nUpdated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-\ndepleting therapies\nClarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults\n(MIS-A)\nUpdated guidance for primary series vaccination after SARS-CoV-2 infection\nAdded considerations for the option to receive a second COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 vaccination after SARS-CoV-2 infection\nAdded guidance that people ages 12 years and older who are moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that people ages 18\u201349 years who are not moderately or severely immunocompromised and who\nreceived Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster\ndose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose\nFurther clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C)\nand adults (MIS-A) and myocarditis\nUpdated information on the availability of Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL\ndosage volume) and Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL dosage volume) for\nadministration of a 50 \u00b5g booster dose.","5088":"Public health recommendations for vaccinated people have been moved to: https:\/\/www.cdc.gov\/coronavirus\/2019-\nncov\/vaccines\/fully-vaccinated-guidance.html. Clinical considerations added for use of Janssen (Johnson & Johnson) COVID-19 Vaccine. Updated recommendations for fully vaccinated people who subsequently develop COVID-19. Updated recommendations related to COVID-19 vaccination timing for immunocompromised people. Updated contraindications and precautions to mRNA COVID-19 vaccines. Updated information on interpretation of SARS-CoV-2 antibody test results after vaccination. New recommendations for preventing, reporting, and managing mRNA COVID-19 vaccine administration errors\n(Appendix A)\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\n(Appendix A). Clarification on contraindications and precautions.","4169":"People with COVID-19 during pregnancy are more likely to\ndeliver a preterm (earlier than 37 weeks) or stillborn infant and may also be more likely to have other pregnancy\ncomplications. COVID-19 vaccination during pregnancy helps:\nPrevent severe illness and death in people who are pregnant\nProtect babies younger than 6 months old from hospitalization caused by COVID-19\nLearn more about vaccination considerations and the safety and effectiveness of COVID-19 vaccinations for people who\nare pregnant or breastfeeding. If you are pregnant and have received a COVID-19 vaccine, we encourage you to enroll in v-safe, CDC\u2019s smartphone-based\nsystem that provides personalized health check-ins after vaccination.","7602":"CDC considers a country to have limited COVID-19 vaccine availability if less than 10% of the total population has been\nfully vaccinated against COVID-19 with any vaccine, as reported in official source data in Our World in Data (OWID). CDC reviews OWID country-level data on the proportion of a population that is fully vaccinated and updates the list of\ncountries with limited vaccine availability every three months. If country data are missing from OWID, CDC reviews other\nofficial sources of information to determine a countries\u2019 vaccination coverage (percent of the population fully vaccinated\nwith available COVID-19 vaccines).","806":"Getting Sick\n\uf1aa\n\u2022\n\u2022\n\u2022\nSymptoms associated with COVID-19 vaccination vs infection\n\uf1aa\f10\/30\/22, 9:34 AM Benefits of Getting A COVID-19 Vaccine | CDC\nSymptoms Post COVID-19 Vaccination Symptoms Post COVID-19 Infection\nSymptoms Post COVID-19 Vaccination Symptoms Post COVID-19 Infection\nCough\nMuscle and joint pain\nHeadache\nTrouble falling or staying asleep\nTrouble concentrating\nLimitations in physical activity\nFeeling distressed about symptoms\nMental health challenges\nDecreased school or daycare attendance\nMissed opportunities for participation in sports,\nplaydates, or other activities\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nWhile people can get some protection from having COVID-19, the level and length of that protection varies, especially as\nCOVID-19 variants continue to emerge. Immunity (protection) from infection can vary depending on how mild or severe someone\u2019s illness was and their age.","7052":"People who are pregnant or recently pregnant and those who live with or visit them should take steps to protect\nthemselves from getting sick with COVID-19. \u2022\n\u2022\n\u2022\n\u2022\nIncreased Risk of Severe Illness\nIf you are pregnant or were recently pregnant, you are more likely to get\nseverely ill from COVID-19 compared to people who are not pregnant. Pregnancy causes changes in the body that could make it easier to get\nvery sick from respiratory viruses like the one that causes COVID-19. These changes in the body can continue after pregnancy.","2703":"Hands off: Avoid touching your eyes, nose, and mouth with unwashed hands. Learn more about handwashing. \u2022\n\u2022\n\u2022\n\u2022\nTest to prevent spread to others\nSelf-tests are one of several options for testing for the virus that causes COVID-19 and may be more convenient than\nlaboratory-based tests and point-of-care tests. Ask your healthcare provider or your local health department if you need\nhelp interpreting your test results. Clean surfaces in your home regularly\nClean high-touch surfaces (such as, doorknobs, tables, handles, light switches, remote controls, phones, and\ncountertops) regularly and after you have visitors in your home.","8929":"Ensuring healthcare personnel have access to COVID-19 vaccination is critical to protect both them and their medically\nfragile patients. Page last reviewed: August 24, 2021","6900":"\u2022 People ages 12 years and older, especially those at higher risk of myocarditis associated with mRNA\nCOVID-19 vaccines, may receive the second primary dose of the COVID-19 vaccine by Pfizer-\nBioNTech 3\u20138 weeks after the first primary dose. The second dose should not be received earlier\nthan 3 weeks after the first dose.","6966":"Similarly, for individuals who received the Janssen vaccine for primary\nvaccination, an additional primary or second booster dose of the COVID-19 vaccine by Pfizer-BioNTech\ncould improve protection against COVID-19. The COVID-19 vaccine by Pfizer-BioNTech may not protect\neveryone. What are the Risks and Benefits of the COVID-19 vaccine by Pfizer-BioNTech? The FDA approved the COVID-19 vaccine by Pfizer-BioNTech to prevent COVID-19 based on safety and\nefficacy data available from clinical trials.","8556":"Less Moderate Elevated\f10\/30\/22, 9:38 AM Understanding Exposure Risks | CDC\nLower Risk Moderate Risk Higher Risk\nSymptoms: Did the infected person have symptoms at the time? Being around people who are symptomatic increases the risk of transmission. i\nNo symptoms\nLower Risk\nSymptoms\nHigher Risk\nMasks: Were you or the infected person or both wearing a respirator (for example, N95) or high-\nquality mask? If one person was wearing a mask, the risk of transmission is decreased, and if both people were wearing masks, the risk\nis substantially decreased. Risk is also lower if the mask or respirator is a type that offers greater protection.","2747":"For more information, visit the U.S. Department of Education\u2019s Office for Civil Rights (OCR) and the Office of Special Education\nand Rehabilitative Services (OSERS)\u2019s Resource to Support Children, Students, Educators, Schools, Service Providers, and\nFamilies . \uf20c \uf209\nUnderstand Your Experience\nEach person copes differently with a long-term illness, and there are different ways to manage the stress, anxiety, and\nuncertainty of a new illness. Some people find taking an active role in understanding their condition is a comfort for managing\ntheir ongoing illness:\nRead about the experiences of other people with a post-COVID condition.","2360":"People Who Were Vaccinated Outside of the United States\nPeople who are moderately or severely immunocompromised and who received COVID-19 vaccines not available in the\nUnited States should either complete or restart the recommended COVID-19 vaccine series, including a booster, in the United\nStates. For more information, talk to your healthcare provider, or see the COVID-19 Interim Clinical Considerations.","7846":"Healthcare providers can ensure that those who have tested positive for COVID-19 receive the most appropriate medical\ncare, including specific treatments if necessary. In most jurisdictions, healthcare providers who\u202fdiagnose COVID-19 are required to report those cases to public health. The US Government\u202fdoes not want to construct any barriers that would deter the use of self-tests. COVID-19\nsurveillance\u202fcontinues to be based on results from laboratory testing. The primary role of case reporting is to allow public\nhealth agencies to take actions to mitigate disease spread. The public health community, including CDC, is confident that\nsituational awareness remains strong without receiving self-test results.","5057":"New information on the occurrence of myocarditis or pericarditis following vaccination with mRNA COVID-19 vaccines\nadded to patient counseling. Information on cases of myocarditis and pericarditis occurring after mRNA COVID-19 vaccination, particularly in\nadolescents and young adults. Information on the efficacy of the Pfizer-BioNTech COVID-19 Vaccine in adolescents aged 12\u201315 years in patient\ncounseling section. Updated data on local and systemic symptoms following vaccination with mRNA COVID-19 vaccines in patient\ncounseling section.","6433":"EVUSHELD continues to be authorized for people who are moderately to severely immunocompromised and may not\nbe able to mount an adequate response to the COVID-19 vaccine, and for people who could have a history of severe\nadverse reaction to the COVID-19 vaccine or its components. If you\u2019re eligible for a vaccine, we encourage you to talk with\nyour healthcare provider. EVUSHELD still protects people from getting COVID-19, but it may offer less protection against three strains (BA.4.6,\nBF.7, and BA.2.75.2) of the Omicron variant.","6655":"Know the triggers for your condition and avoid when possible (e.g., avoid asthma triggers by having another member of\nyour household clean and disinfect your house for you or avoid possible sickle cell disease triggers to prevent pain\ncrises). \u2022\n\uf209\n\u2022\nAdditional Resources\nDon\u2019t Delay: Test Soon and Treat Early\nFile Details: 361 KB, 1 page\nView PDF in English\nView PDF in Spanish\n\uf20c\n\uf20c\nLast Updated Oct. 19, 2022","1832":"10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nVaccines & Immunizations\nVaccines & Immunizations\nCOVID-19 Vaccine Effectiveness Research\nClinical trials are conducted to determine vaccine efficacy before the U.S Food and Drug Administration (FDA) determines\nwhether to approve a vaccine. CDC and other partners assess COVID-19 vaccine effectiveness under real-world conditions\nafter the FDA approves a vaccine. This helps us understand if vaccines are performing as expected outside the more\ncontrolled setting of a clinical trial, which tests a vaccine before approval. Below you\u2019ll find descriptions of current and planned vaccine effectiveness evaluations CDC is conducting with partners.","8168":"They also provide some protection against Omicron, but not as much as the updated (bivalent) boosters. The virus that causes COVID-19 has changed over time. The different versions of the virus that have developed over time are\ncalled variants. Learn more about variants of the COVID-19 virus. Two COVID-19 vaccine manufacturers, Pfizer and Moderna, have developed updated (bivalent) COVID-19 boosters. When Are You Up to Date? You are up to date with your COVID-19 vaccines if you have completed a COVID-19 vaccine primary series and received the\nmost recent booster dose recommended for you by CDC.","9623":"Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the novel coronavirus, SARS-CoV-2,\nthat emerged in late 2019. It is predominantly a respiratory illness that can affect other organs. People with\nSARS-CoV-2 infection have reported a wide range of symptoms, ranging from no symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include fever or chills, cough,\nshortness of breath, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat,\ncongestion or runny nose, nausea or vomiting, and diarrhea. Who can receive the COVID-19 vaccine by Pfizer-BioNTech?","6474":"Oral antivirals can be taken at home and must be given within 5 days after\nthe first symptoms of COVID-19 appear. Monoclonal antibodies\n\uf209\n\uf209\f10\/30\/22, 9:38 AM People Who Are Immunocompromised | CDC\nMonoclonal antibodies can block the virus that causes COVID-19 from entering cells in your body, which can limit the\namount of the virus within your body. These must be prescribed and administered by a healthcare provider within 7 days\nafter first symptoms of COVID-19 appear. Make a COVID-19 plan now so you\u2019re prepared. Consider the ways you will protect yourself and how to be prepared if you get\nsick with COVID-19.","9451":"V-safe also provides second-dose reminders if needed\nand live telephone follow-up by CDC if participants report a significant health impact following\nCOVID-19 vaccination. For more information on how to sign up, visit: www.cdc.gov\/vsafe. WHAT IF I DECIDE NOT TO GET OR NOT TO HAVE MY CHILD GET SPIKEVAX\n(COVID-19 VACCINE, mRNA), MODERNA COVID-19 VACCINE, OR MODERNA\nCOVID-19 VACCINE, BIVALENT? Under the EUA, there is an option to accept or refuse receiving the vaccine. Should you decide\nnot to receive, or for your child not to receive, any of these vaccines, it will not change the\nstandard medical care.","5265":"\u2022\n\u2022\n\u2022\n\u2022\nAfter you have ended isolation, when you are feeling better (no fever without the use of fever-reducing medications and\nsymptoms improving),\nWear your mask through day 10. OR\nIf you have access to antigen tests, you should consider using them. With two sequential negative tests 48 hours apart,\nyou may remove your mask sooner than day 10. Note: If your antigen test results are positive, you may still be infectious. You should continue wearing a mask and wait at\nleast 48 hours before taking another test. Continue taking antigen tests at least 48 hours apart until you have two sequential\nnegative results.","8910":"Chronic kidney disease disproportionately affects racial and\nethnic minorities; 34% of patients on dialysis are Black and 19% are Hispanic. Many dialysis clinics deliver care to patients\n\uf656 Federal Vaccine Allocation\nGet more information about a federal partnership with dialysis organizations. 10\/30\/22, 9:21 AM Vaccinating Dialysis Patients and Healthcare Personnel | CDC\nin communities that have been hit hardest by this pandemic. Dialysis is a lifesaving, essential treatment that must be done 3 times per week for most patients. Because these services\nare nonelective and cannot be delayed, dialysis clinics serve patients whether they have COVID-19 or not.","2082":"Data from American, European, and Canadian studies showed that vaccination with an mRNA COVID-19 vaccine\nduring pregnancy was not associated with an increased risk for pregnancy complications, including preterm birth,\nstillbirth, bacterial infection of the placenta, and excessive maternal blood loss after birth. A Chicago study has shown that vaccination of pregnant people with a COVID-19 vaccine prior to and during the\nfirst trimester was not associated with an increased risk of birth defects detectable on prenatal ultrasound. The monitoring of the effect of COVID-19 vaccination during pregnancy is ongoing.","8243":"J&J\/Janssen Vaccine Overview\nJ&J\/Janssen\nPRIMARY SERIES\nPfizer BioNTech or Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 1 dose\nor last booster\nst\nUp to Date: Immediately after you have received the most recent booster recommended for you\nMore details: Staying up to date\n\u2022\n-\n\u2022\n-\n-\n-\nMixing COVID-19 Vaccine Products\nDo Not Mix Primary Series\nCDC does not recommend mixing products for your primary series doses. If you received Pfizer-BioNTech, Moderna, or\nNovavax for the first dose of your primary series, you should get the same product for all following primary series doses. Mixing Boosters\nThe following information applies to boosters for people ages 5 and older.","4627":"This size is used because 1,000 square feet is the size of an average one-bedroom apartment in\nthe United States, or about one floor of a larger home. The first panel shows particle reduction based on levels that would\nbe in the air at the end of a 4-hour visit. The second panel shows particle reduction 1 hour after the visitor leaves. If the \u201cOpen Window\u201d option is selected as \u201cYes,\u201d the tool assumes one single open window. All scenarios are compared\nagainst a scenario with no open windows, no HEPA air cleaner, and no HVAC system use.","587":"August 4, 2022: Texas made updates to data previously submitted to CDC that resulted in a net decrease of\n1,125,795 administered doses. This contributed to a decrease in overall US figures. August 4, 2022: Wyoming made updates to data previously submitted to CDC that resulted in a net increase of 2,013\nadministered doses. July 28, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 91,864\nadministered doses.","7514":"I have recovered from COVID-19 and have received one dose of an accepted COVID-19 vaccine\ndose, and therefore am considered fully vaccinated in my country, but not under CDC\u2019s Amended\nOrder. Would I be considered fully vaccinated under CDC\u2019s Amended Order if I got a booster dose\nof an accepted COVID-19 vaccine? \uf1aa\nAre different formulations of vaccines considered acceptable proof of vaccination? \uf1aa\f10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nYes, different formulations of COVID-19 vaccines authorized for emergency use or approved by the U.S. Food and Drug\nAdministration\u202for listed for emergency use by WHO are accepted.","2826":"Evaluation and management may vary depending on the patient age, clinical presentation, potential causes, or practice\npreference of the provider. Summary\nIn April 2021, increased cases of myocarditis and pericarditis were reported in the United States after mRNA COVID-19\nvaccination (Pfizer-BioNTech and Moderna). Data from multiple studies show a rare risk for myocarditis and\/or\npericarditis following receipt of mRNA COVID-19 vaccines. These rare cases of myocarditis or pericarditis have occurred\nmost frequently in adolescent and young adult males, ages 16 years and older, within 7 days after receiving the second\ndose of an mRNA COVID-19 vaccine (Pfizer-BioNTech and Moderna).","3371":"COVID-19 vaccination is recommended for everyone ages 6 months and older, regardless of a history of symptomatic or\nasymptomatic SARS-CoV-2 infection. This includes people with prolonged post-COVID-19 symptoms and applies to primary\nseries and booster doses. This recommendation also applies to people who experience SARS-CoV-2 infection after receiving\nany COVID-19 vaccine dose. Growing epidemiologic evidence indicates that vaccination following SARS-CoV-2 infection further increases protection from\nsubsequent infection and hospitalization, including in the setting of increased circulation of more infectious SARS-CoV-2\nstrains.","9170":"If you are diagnosed with COVID-19, someone from the health department may call you. Answer the\ncall to slow the spread. \u2022\n\u2022\n\uf399 Monitor your symptoms\nSymptoms of COVID-19 include fever, cough, or other symptoms. Follow care instructions from your healthcare provider and local health department. Your local health\nauthorities may give instructions on checking your symptoms and reporting information. \u2022\n\u2022\nWhen to seek emergency medical attention\nLook for emergency warning signs* for COVID-19.","4327":"\u2022\n\u2022\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nWatch Video: Use v-safe to tell CDC how you\u2019re feeling after COVID-19 vaccination [00:00:34]\nYour CDC COVID-19 Vaccination Card\nBring your card to your appointment whenever you get a primary\nseries dose or booster so that your provider can fill in information\nabout your shot. If your vaccine card is full, your vaccine provider can give you another\ncard. If you did not receive a CDC COVID-19 vaccination card at your first\nappointment, contact the vaccination provider site where you got\nyour first shot to find out how you can get a vaccination card.","605":"June 15, 2022: Pennsylvania made updates to data previously submitted to CDC that resulted in a net increase of\n14,201 administered doses. June 15, 2022: A federal entity made updates to data previously submitted to CDC that resulted in a net increase of\n3,354 administered doses. June 10, 2022: Illinois made updates\/deletes to data previously submitted to CDC that resulted in a net decrease of\n15,884 administered doses. June 9, 2022: District of Columbia made updates\/deletes to data previously submitted to CDC that resulted in a net\ndecrease of 59,667 administered doses.","6498":"Contact a healthcare provider right away after a positive test to determine if you are eligible, even if your\nsymptoms are mild right now. You can also visit a Test to Treat location and, if eligible, receive a prescription from a\nprovider. Don\u2019t delay: Treatment must be started within the first few days to be effective. \uf209\nThis information is intended for a general audience. Healthcare professionals should see Underlying Medical Conditions\nAssociated with Higher Risk for Severe COVID-19 for more detailed information.","9672":"The EUI apply to the FDA-approved formulations of the COVID-19 vaccine by Pfizer-BioNTech that may be used\nfor individuals 12 years of age and older. As of December 16, 2021, there are two FDA-approved formulations\nof this vaccine that are distinguished by purple and gray caps with vials labeled either as Comirnaty or Pfizer-\nBioNTech COVID-19 Vaccine. They are also FDA-authorized under EUA. The multiple dose vials with purple caps\ncontain phosphate buffered saline that must be diluted with normal saline prior to administration. The\nmultidose vials with gray caps contain tromethamine (Tris) buffer and do not require dilution for\nadministration.","3319":"No cases of myocarditis or pericarditis were reported in children in the pre-authorization clinical\ntrials of Pfizer-BioNTech (ages 6 months\u20134 years) or Moderna (ages 6 months\u20135 years) vaccines. To date, post-authorization\nsurveillance has not detected an increased risk for myocarditis and pericarditis following mRNA COVID-19 vaccination in\nchildren ages 6 months\u20134 years (i.e., Pfizer-BioNTech) and ages 6 months\u20135 years (i.e., Moderna). Cases of myocarditis and pericarditis were identified in clinical trials of Novavax COVID-19 Vaccine and have also been\nreported during post-authorization use outside the United States. These findings suggest that an increased risk for these\nconditions may be present after receiving Novavax COVID-19 vaccine.","8222":"Novavax\nPRIMARY SERIES\nNovavax\nPRIMARY SERIES\n3\u20138 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech or Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd\nprimary series dose\nNovavax Vaccine Overview\nUp to Date: Immediately after you have received the most recent booster recommended for you\nMore details: Staying up to date\nAGE GROUP\n18 YEARS AND OLDER\nJohnson & Johnson's Janssen\n\uf1aa\nJ&J\/Janssen\nPfizer-BioNTech or Moderna\f10\/30\/22, 9:27 AM Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC\nGetting your 2nd dose: Talk to your healthcare or vaccine provider about the timing for the 2nd dose in your primary series.","6086":"Benotmane, I., Bruel T., Planas, D., Fafi-Kremer, S., Schwarz, O., Caillard, S. A fourth dose of the mRNA-1273\nSARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients. Buchan SA, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by\nvaccine product, schedule and interval. CDC. Science Brief: SARS-CoV-2 infection-induced and vaccine-induced immunity. 2021. Das, R. Update on 50 \u00b5g Booster Dose of Moderna COVID-19 Vaccine in Individuals \u226518 Years of Age.","616":"June 2, 2022: California made updates to data previously submitted to CDC that resulted in a net increase of 37,678\nadministration records. May 25, 2022: North Dakota made updates to data previously submitted to CDC that resulted in a increase of 64\ndoses administered. May 20, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 139,447\ndoses administered. May 13, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 31,945 doses\nadministered.","6380":"Some people with post-COVID conditions find it helpful to include:\nwhether symptoms have improved\nwhich treatments have improved symptoms\nany side effects\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\n-\f10\/30\/22, 9:42 AM Patient Tips: Healthcare Provider Appointments for Post-COVID Conditions | CDC\nany other new symptoms or changes\nMake a note to give your healthcare provider feedback about how recommended interventions have worked for you. Write down any issues you did not have time to talk about at the last appointment. Keep track of medications, vitamins, herbs, supplements, and over-the-counter drugs you take, using a current\nmedications and supplements list.","8359":"And why not a lower\nnumber?\u201d Let them answer, and ask a follow-up question like, \u201cWhat would help you move to a 5 or 6?\u201d\nThe goal is to help the patient become more open to moving toward higher numbers\u2014in other words, getting vaccinated. You want them to talk about this out loud because talking actually changes how they process their choices and can\ndevelop forward momentum. People hesitant about vaccines usually have more practice explaining why they haven\u2019t gotten vaccinated, so it\u2019s good to\nreverse that. Ask them to express their vaccination benefits out loud.","9031":"10\/30\/22, 9:36 AM Variants of the Virus | CDC\nVariants of the Virus\nVariants in the United States\nNumerous variants of the virus that causes COVID-19 are being tracked in the United States and globally during this\npandemic. CDC is working with public health officials to monitor the spread of all variants and provide an estimate of how\ncommon they are in the nation and at the regional level. This data can change over time as more information is available. What You Need to Know\nNew variants of SARS-CoV-2, the virus that causes COVID-19, are expected to occur.","7294":"Generally, a claim must be submitted to the CICP within one (1) year from the\ndate of receiving the vaccine. To learn more about this program, visit\nwww.hrsa.gov\/cicp\/ or call 1-855-266-2427. WHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)? An EUA is a mechanism to facilitate the availability and use of medical products,\nincluding vaccines, during public health emergencies, such as the current COVID-19\npandemic. An EUA is supported by a Secretary of Health and Human Services (HHS)\ndeclaration that circumstances exist to justify the emergency use of drugs and\nbiological products during the COVID-19 pandemic.","3147":"A patient\u2019s clinical team is best positioned to determine the degree of immune compromise, need for revaccination, and\nappropriate timing of revaccination. Administration of COVID-19 vaccines should not be delayed in patients taking immunosuppressive therapies. Whenever\npossible, COVID-19 vaccines should be administered at least 2 weeks before initiation or resumption of immunosuppressive\ntherapies. For patients who receive B-cell-depleting therapies on a continuing basis, COVID-19 vaccines should be\nadministered approximately 4 weeks before the next scheduled therapy. Timing of COVID-19 vaccination should take into consideration current or planned immunosuppressive therapies,\noptimization of both the patient\u2019s medical condition and anticipated response to vaccination, and individual benefits and\nrisks.","9913":"\u25cb Anaphylaxis after non-COVID-19 vaccines or injectable\ntherapies\n\u0083 All other people\nHealthcare professionals should be familiar with identifying severe\nallergic reactions, including anaphylaxis, and be competent in\ntreating these events at the time of vaccine administration. See\nManagement of Anaphylaxis at COVID-19 Vaccination Sites | CDC\nfor guidance. COVID-19 vaccines are administered by IM injection and can be\ngiven at the same clinical visit as other routinely administered\nvaccines using separate injection sites. Other routine vaccines\ncan also be administered any time before or after COVID-19\nvaccination. Orthopoxvirus vaccines (monkey pox) have additional\nconsiderations. See guidance section 8 Clinical Guidance. 1. How old is the person to be vaccinated?","114":"Mink on mink farms. Wildlife, including white-tailed deer, mule deer, a black-tailed marmoset, a giant anteater, and wild mink near mink\nfarms. For information on how to protect pets and animals, visit\nWhat You Should Know about COVID-19 and Pets\nCompanion Animals with COVID-19: Toolkit for Health Officials\nReducing Risk of Spreading COVID-19 between People and Wildlife\nRisk of animals spreading SARS-CoV-2 to people\nThere is no evidence that animals play a significant role in spreading SARS-CoV-2, the virus that causes COVID-19, to people. There have been a few reports of infected mammalian animals spreading the virus to people during close contact, but this is\nrare.","414":"Use of this new functionality may result in fluctuations across\nmetrics on the CDC COVID Data Tracker as historical data are updated or deleted. The functionality will also allow for\nmore accurate reporting and improved data quality. On July 1, 2021, data review and reporting adjustments resulted in a larger-than-usual increase in the number of vaccine\ndoses administered for Arizona and Puerto Rico of 258,590 and 465,704 doses respectively. The adjustment is the result\nof CDC and the jurisdictions actively working to correct data transmission errors.","8953":"\u2022\n\u2022\n\u2022\n\u2022\n-\n\u2022\n\u2022\n\uf209 \uf209\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:32 AM Vaccine Adverse Event Reporting System (VAERS) | CDC\nWhen VAERS staff members follow-up on a report of a serious adverse event, they ask for the patient\u2019s medical\nrecords related to the event to learn more about what happened. VAERS reports are available to the public, but to protect privacy and confidentiality they do not include information that could\nidentify the person. VAERS Limitations\nVAERS reports alone generally cannot be used to determine if a vaccine caused or contributed to an adverse event or illness. Some reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable.","3789":"CDC recommends COVID-19 vaccines for everyone ages 6 months and older, and boosters\nfor everyone 5 years and older, if eligible. Are the vaccines safe? Have vaccines caused any health problems? \u2022\n\u2022\n\u2022\n\u2022\n\u2022\nTo make sure that COVID-19 vaccines are safe, CDC expanded and strengthened the country\u2019s ability to monitor vaccine\nsafety. CDC created new web-based platforms to gather more information about the safety of COVID-19 vaccines. These\nplatforms give CDC scientists information about the safety of COVID-19 vaccines in real time. As a result, vaccine safety experts can monitor and detect issues that may not have been seen during the COVID-19\nvaccine clinical trials.","6318":"Printable Version: Preparing for Your Appointment | Espa\u00f1ol [PDF \u2013 372 KB]\n\uf189 \uf20c\nList Your Healthcare Providers\nPrepare a list of your current and past healthcare providers and your current and past medical conditions, especially if\nyou are seeing a new healthcare provider. Write Down Your History\nPrepare a brief history that summarizes your experience with COVID-19 and post-COVID conditions.","8995":"As of May 2, 2022, the registry has enrolled 23,779 pregnant people in the\nUnited States. Why CDC Is Collecting Registry Information\nIf you participate in the registry, the information you and other participants provide will be evaluated and used to educate the\npublic about COVID-19 vaccines and pregnancy. In addition, this information will be used by CDC and the Food and Drug\nAdministration (FDA) to guide recommendations on COVID-19 vaccination during pregnancy.","1760":"All COVID-19 vaccination providers must report COVID-19 vaccine inventory weekly into Vaccines.gov. In some jurisdictions, providers may report vaccine inventory to the jurisdiction\u2019s IIS for the jurisdiction to upload into\nVaccines.gov. If you have questions about the process for your jurisdiction, please contact your jurisdiction\u2019s immunization\nprogram.","6402":"Examples of medical conditions or treatments that may result in moderate to severe immunocompromise include but are not\nlimited to:\nActive treatment for solid tumor and hematologic malignancies\nHematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status\n(e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\nReceipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\nReceipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of\ntransplantation or taking immunosuppressive therapy)\nModerate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined\nimmunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)\nAdvanced or untreated HIV infection (people with HIV and CD4 cell counts less than 200\/mm3, history of an AIDS-\ndefining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)\nActive treatment with high-dose corticosteroids (i.e., 20 or more mg of prednisone or equivalent per day when\nadministered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs,\ncancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and\nother biologic agents that are immunosuppressive or immunomodulatory\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nHow to Protect Yourself\f10\/30\/22, 9:38 AM People Who Are Immunocompromised | CDC\nYou are up to date with your COVID-19 vaccines when you have received all doses in the primary series and all boosters\nrecommended for you, when eligible.","9053":"As the virus spreads, it may\nchange and may become harder to stop. Regardless of the variant, a surge in cases can impact healthcare resources\nEven if a variant causes less severe disease in general, an increase in the total number of cases could cause an increase in\nhospitalizations, put more strain on healthcare resources, and potentially lead to more deaths. Monitoring Variants\nCDC uses viral genomic surveillance to quickly identify and track COVID-19 variants, and acts upon these findings to best\nprotect the public\u2019s health. Some variants spread more easily and quickly than others, which may lead to more cases of\nCOVID-19.","6716":"FACT SHEET FOR RECIPIENTS AND CAREGIVERS ABOUT THE\nPFIZER-BIONTECH COVID-19 VACCINE AND THE PFIZER-BIONTECH COVID-19\nVACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4\/BA.5) TO PREVENT\nCORONAVIRUS DISEASE 2019 (COVID-19) FOR USE IN INDIVIDUALS\n5 THROUGH 11 YEARS OF AGE\nFOR 5 THROUGH 11 YEARS OF AGE\nYour child is being offered the Pfizer-BioNTech COVID-19 Vaccine1 or the\nPfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4\/BA.5)2,\nhereafter referred to as the Pfizer-BioNTech COVID-19 Vaccine, Bivalent to\nprevent Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2.","1494":"At this time, all COVID-19 vaccine in the United States has been purchased by the federal government for administration\nexclusively by enrolled providers through the CDC COVID-19 Vaccination Program. How to Enroll as a COVID-19\nVaccination Provider\n\uf2a1\nFAQs for Private & Public Healthcare\nProviders About Implementing the\nCDC COVID-19 Vaccination Program\nin Provider Practices\n\uf2a1\nVaccines for Children Program vs.\nCDC COVID-19 Vaccination Program\n\uf2a1\nFAQs for Federal Retail Pharmacy\nProgram Participants\n\uf2a1\nCOVID-19 vaccination providers participating in the CDC COVID-19 Vaccination Program are required to sign a CDC\nCOVID-19 Vaccination Program Provider Agreement.","1619":"This includes\nCOVID-19 Vaccination Record Cards that have been printed by agents on behalf of CDC, including the jurisdictions. USG-provided COVID-19 Vaccination Record Cards remain property of the United States Government until provided to\nthe vaccine recipient following vaccination through the CDC COVID-19 Vaccination Program. The COVID-19 Vaccination\nRecord Cards may not be reproduced by anyone other than authorized jurisdictions or without written permission of\nCDC. Any use or unauthorized reproduction of the COVID-19 Vaccination Cards outside of the CDC COVID-19 Vaccination\nProgram, or production or use of similar facsimiles of such cards, is prohibited.","8217":"Novavax Vaccine Overview\nNovavax\n\uf1aa\nNovavax\nPRIMARY SERIES\nNovavax\nPRIMARY SERIES\n3-8 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech or Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd\nprimary series dose\nUp to Date: Immediately after you have received the most recent booster recommended for you\nMore details: Staying up to date\nAGE GROUP\n18 YEARS AND OLDER\nPfizer-BioNTech Vaccine Overview\nPfizer-BioNTech\n\uf1aa\nPfizer-BioNTech\nPRIMARY SERIES\nPfizer-BioNTech\nPRIMARY SERIES\n3\u20138 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech or Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd\nprimary series dose or last\nbooster\nUp to Date: Immediately after you have received the most recent booster recommended for you\nMore details: Staying up to date\f10\/30\/22, 9:27 AM Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC\nAGE GROUP\n18 YEARS AND OLDER\nModerna Vaccine Overview\nModerna\n\uf1aa\nModerna\nPRIMARY SERIES\nModerna\nPRIMARY SERIES\n4\u20138 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech or Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd\nprimary series dose or last\nbooster\nUp to Date: Immediately after you have received the most recent booster recommended for you\nMore details: Staying up to date\nNovavax\n\uf1aa\nAGE GROUP\n18 YEARS AND OLDER\nNovavax is not authorized as a booster dose at this time.","5538":"Collaborate with professional medical groups to develop and offer clinical guidance and other educational materials for\nhealthcare providers, patients, and the public. \u2022\n\u2022\n\u2022\nCDC and other federal agencies, as well as academic institutions and research organizations, are working to learn more\nabout the short- and long-term health effects associated with COVID-19 , who gets them and why. \uf209\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nRelated Pages\nFor Healthcare Professionals\nCaring for People with Post-COVID Conditions\n\u203a\nPreparing for Appointments for Post-COVID Conditions\n\u203a\nResearching COVID to Enhance Recovery\n\u203a \uf209\nGuidance on \u201cLong COVID\u201d as a Disability Under the ADA\n\u203a \uf209\nPost-COVID Conditions: Healthcare Providers\n\u203a\nLast Updated Sept. 1, 2022","6393":"If you or someone you live or spend time with is immunocompromised, it is important to have a COVID-19 plan to protect\nyourself from infection and prepare for what to do if you get sick. Information on this page can help you build a COVID-19\nplan for preventing, diagnosing, and treating COVID, so you know what to do and can act quickly if you\u2019re exposed, develop\nsymptoms, or test positive and when COVID-19 levels are increasing in your community.","4490":"10\/30\/22, 9:39 AM How to Protect Yourself and Others | CDC\nPrevention Actions to Add as Needed\nThere are some additional prevention actions that may be done at any level, but CDC especially recommends considering in\ncertain circumstances or at medium or high\u202fCOVID-19 Community Levels. Wearing Masks or Respirators\nIncreasing Space and Distance\n\u2022\n\u2022\nWearing Masks or Respirators\nMasks are made to contain droplets\nand particles that you breathe, cough,\nor sneeze out. A variety of masks are\navailable. Some masks provide a\nhigher level of protection than others. Respirators (for example, N95) are\nmade to protect you by fitting closely\non the face to filter out particles,\nincluding the virus that causes COVID-\n19.","7796":"\u2022\n\u2022\n\u2022\n\u2022\n\uf6e5 When To Take an At-Home COVID-19 Test\nTest Yourself If\u2026 Timing\nYou have any COVID-19 symptoms Immediately\nYou were exposed to someone with COVID-19 At least 5 days after your exposure\nIf you test negative for COVID-19, consider testing\nagain 1 to 2 days after your first test\nYou are going to an indoor event or a gathering Immediately before the gathering, or as close to\nthe time of the event as possible\nThis is especially important before gathering with\nindividuals at risk of severe disease, older adults,\nthose who are immunocompromised, or people\nwho are not up to date on their COVID-19\nvaccines, including children who cannot get\nvaccinated yet.","4478":"Contact your healthcare provider,\nhealth department, or\nCommunity Health Center to\nlearn about treatment options. Don\u2019t delay! Treatment must be\nstarted within a few days after\nyou first develop symptoms to be\neffective. If you don\u2019t have timely access to\na healthcare provider, check if a\nTest to Treat location is in\nyour community. You can get\ntested, receive a prescription\nfrom a healthcare provider (either\nonsite or by telehealth), and have it filled all at one location. \u2022\n\uf209\n\u2022\n\u2022\n\uf209\nAvoiding Contact with People Who Have Suspected or Confirmed COVID-19\nAvoiding contact with people who have COVID-19, whether or not they feel sick, can reduce your risk of catching the virus\nfrom them.","5098":"Fully vaccinated people who meet criteria will no longer\nbe required to quarantine following an exposure to someone with COVID-19. Additional considerations for patients\nand residents in healthcare settings are provided. Additional information and updated recommendations for testing for TB infection. TB testing can be done before or at\nthe same time as mRNA COVID-19 vaccination, or otherwise delayed for \u22654 weeks after the completion of mRNA\nCOVID-19 vaccination. Last Reviewed: October 19, 2022","962":"10\/30\/22, 9:37 AM COVID-19 Testing: What You Need to Know | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Testing: What You Need to Know\nWhen you get tested:\nMake sure to test at the right time\nChoose the right type of test for your circumstance\nFollow test directions as recommended by FDA\nIf you do not, your results may be less likely to correctly indicate whether you have COVID-19 or not. \u2022\n\u2022\n\u2022\nWhen to Get Tested for COVID-19\nKey times to get tested:\nIf you have symptoms, test immediately. If you were exposed to COVID-19 and do not have symptoms, wait at\nleast 5 full days after your exposure before testing.","6932":"You should not get the vaccine if you:\n\u2022 Had a severe allergic reaction after a previous dose of the COVID-19 vaccine by Pfizer-BioNTech\n\u2022 Had a severe allergic reaction to any ingredient of the COVID-19 vaccine by Pfizer-BioNTech\nWhat should I mention to the vaccination provider before getting the COVID-19 vaccine by Pfizer-BioNTech? Tell your vaccination provider the name, number of doses, and date(s) of COVID-19 vaccine(s) you received\npreviously.","1713":"Preserve all records related to COVID-19 vaccine management for a minimum of three years, or longer as required\nby the agreement or law of the jurisdiction. Comply with CDC instructions and timelines for disposing of COVID-19 vaccine and diluent, including used doses. Find detailed information regarding COVID-19 Vaccine storage and handling requirements at CDC Vaccine Storage and\nHandling Toolkit. (https:\/\/vaers.hhs.gov\/reportevent.html )\nThe Vaccine Adverse Event Reporting System (VAERS) is a national early warning system to detect possible safety\nproblems in vaccines used in the United States. VAERS accepts and analyzes reports of adverse events (AEs) after a\nperson has received a vaccination.","9471":"Individuals 6 years of age and older may receive a booster dose with Moderna COVID-19\nVaccine, Bivalent. Vaccinations may not provide full immunity to COVID-19 in people who are\nimmunocompromised; therefore, you or your child should continue to maintain physical\nprecautions to help prevent COVID-19. Your close contacts should be vaccinated as appropriate. WHAT ABOUT PREGNANCY OR BREASTFEEDING? If you are, or your child is, pregnant or breastfeeding, discuss the options with your healthcare\nprovider. WILL THESE VACCINES GIVE ME OR MY CHILD COVID-19? No. These vaccines do not contain SARS-CoV-2 and cannot give you or your child COVID-19.","5640":"They filter varying levels of particles in the air depending on the standard they are designed to meet. They seal tightly to your face when fitted properly. It is important to pick a respirator that fits your face and seals well since not all fit the same.","6372":"Ask the provider\u2019s office if they will call or email you with an appointment reminder. Work with Your Healthcare Provider\nIf you are confused or don\u2019t remember something your provider said, call the provider\u2019s office for clarification. Follow your provider\u2019s instructions as closely as you can. Document Your Experiences\nContinue to record symptoms in a journal, if possible.","5326":"Primary Vaccination\nThe Janssen COVID-19 Vaccine is administered as a single dose. Booster Dose\n\u2022 A single booster dose of the Janssen COVID-19 Vaccine may be administered at least two\nmonths after primary vaccination with the Janssen COVID-19 Vaccine. \u2022 A single booster dose of the Janssen COVID-19 Vaccine may be administered after completing\nprimary vaccination with a different authorized or approved COVID-19 vaccine. Please check\nwith your health care provider regarding timing of the booster dose. HAS THE JANSSEN COVID-19 VACCINE BEEN USED BEFORE? The Janssen COVID-19 Vaccine is an unapproved vaccine.","134":"One wild mink and a small number of escaped farm mink\ntrapped near affected farms in Utah and Oregon were found to be infected with SARS-CoV-2. Although there is no evidence that mink are playing a significant role in the spread of SARS-CoV-2 to people, there is a\npossibility of mink spreading SARS-CoV-2 to people and other animals on mink farms. Mink-to-human spread of SARS-CoV-2\nhas been reported in the Netherlands, Denmark, and Poland, and data suggest it might have occurred in the United States. People can spread SARS-CoV-2 to animals, especially during close contact.","7180":"It is predominantly a\nrespiratory illness that can affect other organs. People with COVID-19 have had a wide\nrange of symptoms reported, ranging from mild symptoms to severe illness leading to\ndeath. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may\ninclude: fever or chills; cough; shortness of breath; fatigue; muscle or body aches;\nheadache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or\nvomiting; diarrhea. HOW ARE COMIRNATY (COVID-19 VACCINE, mRNA), THE PFIZER-BIONTECH\nCOVID-19 VACCINE, AND THE PFIZER-BIONTECH COVID-19 VACCINE,\nBIVALENT RELATED?","4981":"New booster recommendation for people ages 12 years and older to receive 1 bivalent mRNA booster after\ncompletion of a monovalent primary series; it replaces all prior booster recommendations for this age group\nRecommendations for use of a bivalent Moderna booster dose in people ages 18 years and older\nRecommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 12 years and older\nUpdated guidance for observation periods following COVID-19 vaccination\nUpdated guidance on COVID-19 vaccination and multisystem inflammatory syndrome (MIS) in children (MIS-C) and in\nadults (MIS-A)\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adolescents ages 12\u201317 years\nReorganization of Janssen COVID-19 Vaccine guidance into an appendix\nUpdated guidance on COVID-19 vaccination following exposure to SARS-CoV-2\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nPrevious Updates\n\uf1aa\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nUpdated guidance on COVID-19 vaccination and myocarditis and pericarditis\nNew clinical considerations for coadministration of mRNA COVID-19 vaccines and orthopoxvirus vaccines\nNew guidance for use of Moderna COVID-19 Vaccine in children and adolescents ages 6\u201317 years\nNew guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children ages 6 months\u20134 years\nNew guidance for use of Moderna COVID-19 Vaccine in children ages 6 months\u20135 years\nReorganization of sections on COVID-19 vaccination recommendations and schedules\nAddition of new section in Special populations for infants and young children\nNew guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5\u201311 years\nUpdated guidance that the following people should receive a second COVID-19 booster dose:\nPeople ages 12 years and older who are moderately or severely immunocompromised\nPeople ages 50 years and older\nUpdated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-\ndepleting therapies\nClarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults\n(MIS-A)\nUpdated guidance for primary series vaccination after SARS-CoV-2 infection\nAdded considerations for the option to receive a second COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 vaccination after SARS-CoV-2 infection\nAdded guidance that people ages 12 years and older who are moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that people ages 18\u201349 years who are not moderately or severely immunocompromised and who\nreceived Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster\ndose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose\nFurther clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C)\nand adults (MIS-A) and myocarditis\nUpdated information on the availability of Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL\ndosage volume) and Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL dosage volume) for\nadministration of a 50 \u00b5g booster dose.","6155":"\u2022\n\u2022\nCDC uses the following platforms and methods to collect and\nanalyze surveillance data on COVID-19 cases, hospitalizations,\nand deaths by vaccination status:\nCase surveillance\nCDC collaborates with more than 30 state and local health departments that routinely link case surveillance, immunization\nregistry, and vital registration data to monitor rates of COVID-19 cases and deaths by vaccination status, including receipt of\nbooster doses. These rates are published monthly on COVID Data Tracker. Data from the participating health departments represent more than 70% of the U.S. population and all regions of the\ncountry. The volume of this data allows CDC to analyze rare outcomes over time, like COVID-19-associated deaths.","6132":"Moderna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 09\/02\/22;\nSkowronski DM. 2021, MedRxiv preprint. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules\nand extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. WHO Strategic Advisory Group of Experts on Immunization (SAGE). Interim recommendations for an extended\nprimary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised\npersons;.updated 26 October 2021. Geneva: World Health Organization; 2021.\nimmunocompromised-persons. WHO Strategic Advisory Group of Experts on Immunization (SAGE). Interim recommendations for use of the\ninactivated COVID-19 vaccine, CoronaVac, developed by Sinovac Interim guidance; updated 21 October 2021. Geneva: World Health Organization; 2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-\nvaccines-SAGE_recommendation-Sinovac-CoronaVac-2021.1.","1426":"My patient is moderately or severely immunocompromised and receiving EVUSHELD\u2122. Should\nthey also get COVID-19 vaccines? \uf1aa\n\uf209\nYes. In addition to following the recommended COVID-19 vaccination schedule, EVUSHELD\u2122 should be administered to\npeople who are moderately or severely immunocompromised every 6 months to supplement vaccine protection. Administration of EVUSHELD\u2122 should be deferred for at least 2 weeks after COVID-19 vaccination per the EVUSHELD EUA\n\u2122. COVID-19 vaccines can be administered any time after receipt of EVUSHELD\u2122. For more information, see COVID-19 vaccination and EVUSHELD\u2122 and CDC\u2019s EVUSHELD\u2122 guidance.","9724":"In a pilot prospective cohort study of healthcare workers (HCWs) from\nLebanon, 50 HCWs who received a 2-dose primary series of Sinopharm BIBP COVID-19 vaccine and a single\nbooster dose of Pfizer-BioNTech COVID-19 vaccine had significantly higher anti-S-IgG titers compared to 50\nhomologous vaccinees (2 primary series doses and 1 booster dose of Pfizer-BioNTech COVID-19 vaccine)\n(Moghnieh, 2021). A longitudinal study of 41 Thai HCWs who received a 2-dose primary series of Sinovac\n(CoronaVac) COVID-19 vaccine demonstrated booster antibody responses following either AstraZeneca or\nPfizer-BioNTech COVID-19 vaccines, including against the Delta variant (Patamatamkul, 2021). Local and\nsystemic reactogenicity was reported to be mild to moderate across studies.","3871":"Cases of multisystem inflammatory syndrome\nHealthcare providers are encouraged to report to VAERS any additional clinically significant AEs following vaccination,\neven if they are not sure if vaccination caused the event. Also report any additional select AEs and\/or any revised safety\nreporting requirements per FDA\u2019s conditions of authorized use of vaccine(s) throughout the duration of any COVID-19\n\uf209\n\uf209\f10\/30\/22, 9:17 AM FAQs About Implementing COVID-19 Vaccination Program in Provider Practices | CDC\nvaccine being authorized under an EUA. Vaccination provider requirements can be found at COVID-19 Vaccination Provider Requirements and Support. Yes. Healthcare providers are the most trusted source of health information for their patients.","3675":"Learn what to do and when it is safe to be around others. Summary of Recent Changes\nUpdates as of April 18, 2022\nAs a result of a court order, effective immediately and as of April 18, 2022, CDC\u2019s January 29, 2021, Order requiring masks\non public transportation conveyances and at transportation hubs is no longer in effect. Therefore, CDC will not enforce\nthe Order. CDC continues to recommend that people wear high-quality masks in indoor public transportation settings at\nthis time. More Information\nFrequently Asked Questions about Travel and COVID-19\nInternational Travel\nLast Updated Aug. 24, 2022","1096":"Preventive medications\nThe FDA has issued an emergency use authorization for tixagevimab plus cilgavimab (EVUSHELD ) , a medicine that can\nhelp protect you from getting COVID-19. EVUSHELD contains two different antibodies and is given as two separate\nconsecutive intramuscular (IM) injections at a doctor\u2019s office or healthcare facility before you are exposed or test positive for\nCOVID-19. If you are moderately or severely immunocompromised, or severely allergic to COVID-19 vaccines, you may be\neligible for EVUSHELD every 6 months. EVUSHELD may offer less protection against certain strains of the Omicron\nvariant. It is important that even if you receive EVUSHELD you take multiple prevention measures.","86":"\uf209\nRelated Pages\nInformation about COVID-19 Vaccines for People with Allergies\n\u203a\nPossible Side Effects\n\u203a\nEnsuring the Safety of COVID-19 Vaccines\n\u203a\f10\/30\/22, 9:31 AM Allergic Reactions after COVID-19 Vaccination | CDC\n\uf2ff For Healthcare Professionals\nInterim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19\nVaccination Sites\nInterim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United\nStates\nCOVID-19 Clinical Resources\n\u2022\n\u2022\n\u2022\nMore Information\nResearch\nAllergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine \u2014 United\nAllergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine \u2014 United States,\nMore Information\nVaccine Adverse Event Reporting System (VAERS)\nCOVID-19 Vaccine Safety Publications\n\uf209\nLast Updated July 20, 2022","9174":"If someone is showing any of these signs, seek\nemergency medical care immediately:\nTrouble breathing\nPersistent pain or pressure in the chest\nNew confusion\nInability to wake or stay awake\nPale, gray, or blue-colored skin, lips, or nail beds, depending on skin tone\n*This list is not all possible symptoms. Please call your medical provider for any other symptoms that are\nsevere or concerning to you. Call 911 or call ahead to your local emergency facility: Notify the operator that you are seeking care for\nsomeone who has or may have COVID-19. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\uf33f Call ahead before visiting your doctor\nCall ahead.","3485":"Make sure you have a plan to get\ncare overseas, in case you need it. \uf3c0 Pre-embarkation Testing\nIf your cruise line does not have a testing requirement, get tested for current infection with a viral\ntest (no more than 3 days) before boarding a cruise ship, regardless of your vaccination status. Get your test\nresults before you board your cruise. If you recovered from COVID-19 in the past 90 days, testing is not generally recommended unless you\nhave symptoms. People can continue to test positive for up to 90 days after diagnosis and not be\ninfectious to others.","9904":"Interim recommendations for use of the\ninactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm; updated 28\nOctober 2021. Geneva: World Health Organization; 2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-\n2019-nCoV-vaccines-SAGE-recommendation-BIBP. Zhong D, Xiao S, Debes AK, Egbert ER, Caturegli P, Colantuoni E, et al. Durability of Antibody Levels After\nVaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. JAMA. 2021 Dec","3994":"Because CDC removes duplicate records, data presented on the COVID Data Tracker might differ\nfrom data listed in jurisdictional Immunization Information Systems (IIS) and dashboards. CDC makes every effort to\nreconcile doses administered that are reported through more than one system. How does CDC manage data from multiple sources? \uf1aa\nEach state or territorial health department is responsible for establishing internal operations and schedules for\nreporting data. As a result, there are differences among states in the frequency of reporting. Data on doses of vaccine delivered and administered include data received by CDC as of 6:00 am ET on\nWednesday, the day of weekly reporting.","10052":"Summary Document for\nInterim Clinical Considerations\nfor Use of COVID-19 Vaccines Currently Authorized or Approved in the United States\nCOVID-19 vaccine products currently approved or authorized in the United States\nPfizer-BioNTech\n* Booster doses are only indicated for recipients 18 years and age and older in limited situations, see: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html\nAge indication Vaccine\ncomposition\nVaccine vial\ncap color\nLabel border\ncolor\nDilution\nrequired\nPrimary series Booster doses\nDose Injection volume Dose Injection volume\n6 months\u20134 years Monovalent Maroon Maroon Yes 3 \u00b5g 0.2 mL NA NA\n5\u201311 years Monovalent Orange Orange Yes 10 \u00b5g 0.2 mL NA NA\n5\u201311 years Bivalent Orange Orange Yes NA NA 10 \u00b5g 0.2 mL\n12 years and older Monovalent Gray Gray No 30 \u00b5g 0.3 mL NA NA\n12 years and older Bivalent Gray Gray No NA NA 30 \u00b5g 0.3 mL\nModerna\nAge indication Vaccine\ncomposition\nVaccine vial\ncap color\nLabel border\ncolor\nDilution\nrequired\nPrimary series Booster doses\nDose Injection volume Dose Injection volume\n6 months\u20135 years Monovalent Dark blue Magenta No 25 \u00b5g 0.25 mL NA NA\n6-11 years Monovalent Dark blue Purple No 50 \u00b5g 0.5 mL NA NA\n6-11 years Bivalent Dark blue Gray No NA NA 25 \u00b5g 0.25 mL\n12 years and older Monovalent Red Light blue No 100 \u00b5g 0.5 mL NA NA\n12 years and older Bivalent Dark blue Gray No NA NA 50 \u00b5g 0.5 mL\nJanssen\nAge indication Vaccine\ncomposition\nVaccine vial\ncap color\nLabel border\ncolor\nDilution\nrequired\nPrimary series Booster doses\nDose Injection volume Dose Injection volume\n18 years and older Monovalent Blue No Color No\nparticles\nparticles\nNovavax\nAge indication Vaccine\ncomposition\nVaccine vial\ncap color\nLabel border\ncolor\nDilution\nrequired\nPrimary series Booster doses*\nDose Injection volume Dose Injection volume\n12 years and older Monovalent Royal blue No Color No\n5 \u00b5g rS and 50 \u00b5g of\nMatrix-M\u2122 adjuvant\n5 \u00b5g rS and 50 \u00b5g of\nMatrix-M\u2122 adjuvant\nJanssen COVID-19 Vaccine is authorized for adults ages 18 years and older in certain limited situations due to safety considerations.","5804":"Receiving the second primary dose of the COVID-19 vaccine by Moderna 4\u20138 weeks after the first dose\nmay reduce the risk of myocarditis and result in greater immune response and better protection against\nCOVID-19. Primary, additional, and\/or booster doses of the COVID-19 vaccine by Moderna as described\nunder EUI may help to increase immune response in people, which could improve protection against\nCOVID-19. Similarly, for individuals who received the Janssen Vaccine for primary vaccination, an additional\nprimary or second booster dose of the COVID-19 vaccine by Moderna could improve protection against\nCOVID-19. The COVID-19 vaccine by Moderna may not protect everyone.","9782":"Countries such as Australia, Canada, Denmark, Finland, France, Germany, Norway, Taiwan, and the United\nKingdom have recommended extended mRNA vaccine primary series dosing for all persons or specific sub-\ngroups, based on their reviews of available immunological, safety, and effectiveness data, as well as the\nepidemiology of COVID-19, operational considerations, and other contextual factors. What is the available supporting evidence for delaying the second primary dose in people who recently had\nSARS-CoV-2 infection by 3 months from symptom onset or positive test (if infection was asymptomatic)?","7238":"You should seek medical attention right away if you have any of the\nfollowing symptoms after receiving the vaccine:\n\uf0b7 Chest pain\n\uf0b7 Shortness of breath\n\uf0b7 Feelings of having a fast-beating, fluttering, or pounding heart\nSide effects that have been reported with these vaccines include:\n\uf0b7 Severe allergic reactions\n\uf0b7 Non-severe allergic reactions such as rash, itching, hives, or swelling of the face\n\uf0b7 Myocarditis (inflammation of the heart muscle)\n\uf0b7 Pericarditis (inflammation of the lining outside the heart)\n\uf0b7 Injection site pain\n\uf0b7 Tiredness\n\uf0b7 Headache\n\uf0b7 Muscle pain\n\uf0b7 Chills\n\uf0b7 Joint pain\n\uf0b7 Fever\n\uf0b7 Injection site swelling\n\uf0b7 Injection site redness\n\uf0b7 Nausea\n\uf0b7 Feeling unwell\n\uf0b7 Swollen lymph nodes (lymphadenopathy)\n\uf0b7 Decreased appetite\n\uf0b7 Diarrhea\n\uf0b7 Vomiting\n\uf0b7 Arm pain\n\uf0b7 Fainting in association with injection of the vaccine\fThese may not be all the possible side effects of these vaccines.","3532":"10\/30\/22, 9:35 AM Data Definitions for COVID-19 Vaccinations in the United States\nEspa\u00f1ol | Other Languages\nData Definitions for COVID-19 Vaccinations in the\nUnited States\nHow CDC Estimates Vaccination Coverage\nCDC estimates the number of people receiving at least one dose, the number of people who are fully vaccinated, and the\nnumber of people with booster doses. CDC estimates are based on data that include a dose number (first, second, boosters,\nor additional dose). To protect the privacy of vaccine recipients, CDC receives data without any personally identifiable\ninformation (deidentified data). Each jurisdiction or provider uses a unique person identifier to link records within their own\nsystems.","9196":"Throw away used tissues in a lined trash can\n\u2022\f10\/30\/22, 9:41 AM What to Do If You Are Sick | CDC\nThrow away used tissues in a lined trash can. Immediately wash your hands with soap and water for at least 20 seconds. If soap and water are not\navailable, clean your hands with an alcohol-based hand sanitizer that contains at least 60% alcohol. \u2022\n\u2022\n\uf304 Clean your hands often\nWash your hands often with soap and water for at least 20 seconds. This is especially important after\nblowing your nose, coughing, or sneezing; going to the bathroom; and before eating or preparing food.","6459":"Isolate until it\u2019s safe to be around others. CDC recommends that you isolate for at least 10 and up to 20 days. Check with\nyour healthcare provider to learn when you can be around others. Monitor your symptoms. Call your healthcare provider if you develop symptoms that are severe or concerning to you. If\nyou notice emergency warning signs, call 911 or call ahead to your local emergency facility. If you test positive for COVID-19, oral antiviral and monoclonal antibody treatments are available for people who are more\nlikely to get very sick. Learn more about COVID-19 treatment.","2961":"The primary series doses are separated by 4\u20138 weeks and the bivalent mRNA booster dose\nis administered at least 2 months after completion of the primary series (for people who have not received any booster\ndoses), or at least 2 months after the last monovalent booster dose. Novavax COVID-19 Vaccine\nPeople ages 12 years and older: A 2-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-\nBioNTech) is recommended. The primary series doses are separated by 3\u20138 weeks and the bivalent mRNA booster dose\nis administered at least 2 months after completion of the primary series.","9349":"It is approved as a two-dose series for prevention of COVID-19 in\nindividuals 18 years of age and older. It is also authorized under EUA to provide:\n\u2022 a two-dose primary series to individuals 12 years through 17 years of age; and\n\u2022 a third primary series dose to individuals 12 years of age and older who have been\ndetermined to have certain kinds of immunocompromise. 1 You may receive this Fact Sheet even if your child is 5 years old.","1433":"None of the currently authorized SARS-CoV-2 antibody tests have been\nvalidated to evaluate specific immunity or protection from SARS-CoV-2 infection. For assistance with patient counseling and education related to COVID-19 testing and vaccination, please see:\nCOVID-19 Testing: What you Need to Know [CDC]\nUsing Antibody Tests for COVID-19: Information for Patients and Consumers [CDC]\nAntibody (Serology) Testing for COVID-19: Information for Patients and Consumers [FDA]\nFor more detailed information, please see: Interim Guidelines for COVID-19 Antibody Testing. My patient is asking for an antibody test to decide whether to get vaccinated (or revaccinated).","8675":"Some people have no side effects. Many people have reported common side effects after COVID-19\nvaccination, like pain or swelling at the injection site, a headache, chills, or fever. These reactions are\ncommon and are normal signs that your body is building protection. Reports of serious adverse events after vaccination are rare. CDC and FDA continue to closely monitor\nseveral reporting systems, like the\nVaccine Adverse Event Reporting System (VAERS),\nVaccine Safety Datalink (VSD), and\nv-safe, which help look for safety issues now that the vaccines are being given to patients in real-\nworld settings across the country.","3650":"If you already had COVID-19 within the past 90 days, see specific testing recommendations. \uf209\nCan I travel if ...? I am sick with or tested positive for COVID-19 and\nam recommended to isolate. Do NOT travel. Follow recommendations for isolation. I have ended isolation but still need to continue\nwearing my mask per CDC\u2019s guidance. Do not travel on public transportation such as\nairplanes, buses, and trains if you will not be able\nto wear a high-quality mask or respirator when\naround others indoors for the full duration of your\ntrip. If you travel, wear a high-quality mask or\nrespirator the entire time you are around others\nindoors.","7707":"Everyone who receives a COVID-19 vaccine can also\nparticipate in safety monitoring by enrolling themselves -or their children or dependents 6 months and older in a\nsmartphone-based system called v-safe and completing health check-ins after COVID-19 vaccination. Have you experienced a side effect following COVID-19 vaccination? Please report it to VAERS . In addition, enrolling yourself or your dependent in v-safe allows you to easily report to CDC how\nyou are feeling after getting a COVID-19 vaccine.","6072":"Reporting Adverse Event or Medication Errors\nThe vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event\nReporting System (VAERS):\n\u2022 vaccine administration errors whether or not associated with an adverse event,\n\u2022 serious adverse events (irrespective of attribution to vaccination),\n\u2022 cases of myocarditis\n\u2022 cases of pericarditis\n\u2022 cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and\n\u2022 cases of COVID-19 that result in hospitalization or death. Complete and submit reports to VAERS online at https:\/\/vaers.hhs.gov\/reportevent.html. Moderna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 09\/02\/22;\nFor further assistance with reporting to VAERS call 1-800-822-7967.","3231":"Antipyretic or analgesic medications can be taken for the treatment of post-vaccination local or systemic symptoms, if\nmedically appropriate; these medications should not be used prophylactically for the purposes of prevention of post-\nvaccination symptoms. However, in general, aspirin is not recommended for use in children and adolescents ages 17 years\nand younger as an antipyretic or analgesic due to the risk of Reye\u2019s syndrome. Pre-vaccination testing\nAntibody testing is not currently recommended to assess the need for vaccination in an unvaccinated person or to assess\nimmunity to SARS-CoV-2 following COVID-19 vaccination.","468":"This error has been corrected. The correct number for May 13, 2021 is 2,340,538. On May 13, 2021, CDC updated its methodology for calculating age-based metrics for Texas. Effective May 13, 2021, to\ncalculate age-based metrics, CDC assumes: Residents of Texas who receive a vaccination in a different state or territory\nare not attributed to Texas in their population-based metrics but are still included in national-level metrics. All people\nreceiving vaccinations in Texas are considered Texas residents of Texas.","4856":"In addition to the minimum age, some experts suggest delaying the second dose for 8 weeks after the invalid dose\nbased on the potential for increased reactogenicity and the rare risk of myocarditis and pericarditis from mRNA COVID-19 vaccine. If the administration error resulted in a higher-than-authorized vaccine dose, in general a subsequent dose may still be administered at the\nrecommended interval.","182":"Related Pages\nReducing the Risk of SARS-CoV-2 Spreading between People and Wildlife\n\u203a\nWhat You Should Know about COVID-19 and Pets\n\u203a\nMore Information\nInformation on Bringing an Animal into the United States\nWorld Organisation for Animal Health: COVID-19 Events in\nAnimals\nUSDA: Confirmed cases of SARS-CoV-2 in Animals in the\nUnited States\nUSDA: Coronavirus Disease 2019\nFDA: Coronavirus Disease 2019\n\uf209\n\uf209\n\uf209\n\uf209\nMedia Announcements\nConfirmation of COVID-19 in a Canada Lynx at a Pennsylvania Zoo\nConfirmation of COVID-19 in Hyenas at a Colorado Zoo\nConfirmation of COVID-19 in a Coatimundi at an Illinois Zoo\nConfirmation of COVID-19 in a Binturong and a Fishing Cat at an Illinois Zoo\nConfirmation of COVID-19 in Ferret in Florida\nConfirmation of COVID-19 in Deer in Ohio\nTexas A&M Research Uncovers First Known COVID-19 UK Variant In Animals\nConfirmation of COVID-19 in a Snow Leopard at a Kentucky Zoo\u200b\nUSDA Confirms SARS-CoV-2 in Mink in Utah\nConfirmation of COVID-19 in Pet Dog in New York\nConfirmation of COVID-19 in Two Pet Cats in New York\nUSDA Statement on the Confirmation of COVID-19 Infection in a Tiger in New York\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022\n\u2022 \uf209\nLast Updated July 5, 2022","7387":"\uf209\n\uf209\nAircraft Operators\/ Airlines\/ Crew\nFor additional information, resources, and FAQs please visit the following webpages:\f10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nNoncitizens, Nonimmigrants (Covered Individuals)\nNoncitizens who are nonimmigrants and seeking to enter the United States by air are required to show proof of being fully\nvaccinated against COVID-19 before boarding a flight to the United States from a foreign country. If you are not fully vaccinated against COVID-19, you will NOT be allowed to board a flight to the United States, unless you\nmeet the criteria for an exception under the Proclamation and CDC\u2019s Amended Order.","9228":"Video and Print Resources\nWatch Video\n10 Things You Can Do to Manage\nCOVID-19 at Home\nVideo Length: 00:01:32\n[PDF - 484 KB, 1 page]\n10 Things You Can Do to Manage\nYour COVID-19 Symptoms at\nHome\nFile Details: 484 KB, 1 page\nView PDF in English\nOther Languages\n\uf20c\n\uf20c\n[PDF - 361 KB, 1 page]\nDon\u2019t Delay: Test Soon and Treat\nEarly\nFile Details: 361 KB, 1 page\nView PDF in English\nAdditional Languages\n\uf20c\n\uf20c\nMore Information\nTravelers\nSpecific Groups of People\nPeople Who Are Sick\nHealthcare Professionals\nHealth Departments\nLaboratories\nLast Updated Mar. 22, 2022","2293":"CDC has information that LTC providers can use to evaluate and manage residents\u2019 signs and symptoms after vaccination. After vaccination, everyone should continue to follow guidance to protect\nthemselves and others. For your safety and the safety of those around you, LTC providers may recommend vaccinated residents continue to take\nprecautions such as wearing a mask or getting tested for COVID-19. Family members should follow facility guidance for visits and wear masks indoors, when required. Learn more about being up to date on COVID-19 vaccination and what precautions might still be recommended in LTC\nsettings.","8124":"\u0083 Utilize proper risk communication strategies when communicating about monkeypox, including creating tailored, effective\ncommunication with trusted messengers that explain both what is known and what is not known about the spread and\noutcomes of monkeypox infection.151\n\u0083 Create and disseminate graphics through trusted messengers that show the difference in the structure of the virus particles\nand virions for the virus that causes monkeypox and the virus that causes COVID-19.","1782":"They can also experience barriers to getting\nneeded health care and other support, and can have other characteristics that increase their risk of COVID-19, including:\nLimited mobility\nNeed for important support services\nChallenges practicing preventive measures, such as wearing a mask\nChallenges communicating symptoms of Illness or being sick\nGetting Children and Teens with Disabilities Vaccinated against\n1 in 6 children ages 3 through 17 years of age has one or more developmental disabilities.","6159":"However,\nwhile these analyses can provide signals of potential changes in vaccine effectiveness, they cannot control for some variables\nthat could impact the results \u2013 for example, underlying medical conditions from prior infection. COVID-NET\nCDC monitors rates of COVID-19 hospitalizations by vaccination status using COVID-NET. COVID-NET is a population-based,\nsentinel surveillance system that collects reports of laboratory-confirmed COVID-19-associated hospitalizations in 99 counties\nin 14 states. COVID-NET covers approximately 10% of the U.S. population. 10\/30\/22, 9:33 AM Monitoring COVID-19 Cases, Hospitalizations, and Deaths by Vaccination Status | CDC\nCDC publishes weekly rates of laboratory-confirmed COVID-19 hospitalizations by vaccination status on COVID Data Tracker.","2027":"\uf20c\n\u2022 \uf209\n\u2022\nLearn more about myocarditis and pericarditis after COVID-19 vaccination and the association between myocarditis and\nhaving COVID-19. If your child gets a COVID-19 vaccine and you think they might be having a severe allergic reaction after leaving the\nvaccination provider site, seek immediate medical care by calling 911. People Cannot Get COVID-19 from Any COVID-19 Vaccine\nmRNA vaccines, such as the Pfizer-BioNTech and Moderna vaccines, do not use the live virus that causes COVID-19 and do not\ninteract with DNA in any way. Instead, mRNA vaccines teach the body how to fight the virus that causes COVID-19.","8356":"And why not a lower\nnumber?\u201d Let them answer, and ask a follow-up question like, \u201cWhat would help you move to a 5 or 6?\u201d\nThe goal is to help the patient become more open to moving toward higher numbers\u2014in other words, getting vaccinated. You want them to talk about this out loud because talking actually changes how they process their choices and can\ndevelop forward momentum. People hesitant about vaccines usually have more practice explaining why they haven\u2019t gotten vaccinated, so it\u2019s good to\nreverse that. Ask them to express their vaccination benefits out loud.","1397":"Vaccinators and clinic administrators\nshould not deny COVID-19 vaccination to a person because of a lack of documentation. How do I verify if a person is moderately or severely immunocompromised? \uf1aa\nYes. Everyone ages 5 years and older who completed a primary series is recommended to receive 1 bivalent mRNA\nbooster dose regardless of previous booster dose history; this includes people who are moderately or severely\nimmunocompromised. The bivalent mRNA booster dose should be administered at least 2 months after the last\nmonovalent booster dose. My patient is moderately or severely immunocompromised and received the primary series and\nthe previously recommended monovalent mRNA booster dose(s).","9445":"Please include either \u201cSPIKEVAX (COVID-19 Vaccine,\nmRNA)\u201d, \u201cModerna COVID-19 Vaccine EUA,\u201d or \u201cModerna COVID-19 Vaccine, Bivalent\nEUA\u201d, as appropriate, in the first line of box #18 of the report form. In addition, you can report side effects to ModernaTX, Inc. at 1-866-MODERNA (1-866-663-\n3762). You may also be given an option to enroll in v-safe. V-safe is a voluntary smartphone-based tool\nthat uses text messaging and web surveys to check in with people who have been vaccinated to\nidentify potential side effects after COVID-19 vaccination. V-safe asks questions that help CDC\nmonitor the safety of COVID-19 vaccines.","4612":"10\/30\/22, 9:41 AM Interactive Home Ventilation Tool | CDC\nEspa\u00f1ol | Other Languages\nInteractive Home Ventilation Tool\nSmall particles that people breathe out can contain virus particles, including the virus that causes COVID-19. If a guest visits\nyour home, improving ventilation (air flow) can help prevent virus particles from accumulating in the air. Good ventilation,\nalong with other preventive actions, like staying 6 feet apart and correctly wearing masks, can help prevent you from getting\nand spreading COVID-19. \uf5bd We need your feedback! Help us improve this tool by taking a quick survey after using the tool below.","6330":"Select your most important issues (sometimes referred to as\n\u201cchief complaints\u201d) and write them down\nList Your Medications\nPrepare a list of medications and supplements you are taking. Most healthcare providers will ask you to provide this\ninformation at each appointment. Bringing your list with you will help keep track. Talk with a Family Member or Friend\nConsider discussing your appointment with a trusted family member or friend immediately before and after you see\nyour healthcare provider. This person can help you take notes and remember what was discussed at the appointment\nwhile it\u2019s still fresh in your mind.","4205":"You may consider delaying your vaccine by 3 months from when your symptoms started or, if you had no symptoms,\nwhen you received a positive test. People who already had COVID-19 and do not get vaccinated after their recovery are more likely to get COVID-19\nagain than those who get vaccinated after their recovery. Learn more about the benefits of getting a COVID-19 vaccine. If I already had COVID-19 and recovered, do I still need to get a COVID-19 vaccine? \uf1aa\nCan I get vaccinated against COVID-19 while I am currently sick with COVID-19?","1643":"These\ndata are collected solely for the purposes of the CDC COVID-19 Vaccination Program and must be maintained in a\nmanner that protects the integrity of the CDC COVID-19 Vaccination Program by only being used or disclosed for the\npurposes of the COVID-19 Vaccination Program and other limited purposes that promote public health, advance positive\npatient outcomes, and promote health equity. This prohibition is not intended to limit communications by health care providers to vaccine recipients with whom the\nprovider has an existing relationship prior to contact about COVID-19 vaccination.","604":"July 7, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 64,066\nadministered doses. June 30, 2022: A federal entity made updates to data previously submitted to CDC that resulted in a net increase of\n732,308 administered doses. June 30, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 27,319\nadministered doses. June 23, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 21,371\nadministered doses.","911":"Caregivers should wear a mask when they are within 6 feet of your newborn for the entire time you are in isolation, and\nduring their own quarantine after you complete your isolation. If a healthy caregiver is not available, you can care for your newborn if you are well enough. Wash your hands with soap and water for at least 20 seconds before touching for your newborn. If soap and water are\nnot available, use a hand sanitizer with at least 60% alcohol. Wear a mask when within 6 feet of your newborn and other people during your entire isolation period.","2575":"Booster dose\u00a7: Bivalent\nAt least 8 weeks\nAt least 8 weeks\nAdenovius\nvector\nvaccine\nand older\nMONOVALENT Janssen\nJanssen COVID-19 vaccine is authorized for use in certain limited situations\ndue to safety considerations.\u00b6\nModerna or Pfizer-BioNTech\nbivalent COVID-19 vaccine should\nbe used for the booster dose. Booster dose\u00a7: Bivalent\nAdminister a single booster dose at least 8 weeks (2 months) after the\nprevious dose. * Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate monovalent\nCOVID-19 vaccine may be administered at least 28 days after the first dose to complete the primary series.","8783":"Cloth masks should be washed at least once a day or as soon as\nthey become wet or dirty. You can either wash and dry your\nmasks by hand or use a washer and dryer. 2. Wash or sanitize your hands after removing any mask. Taking off your mask while you eat or drink\nIf you are taking off your mask to eat or drink outside of your home, you can place it somewhere safe to keep it clean, such as\nyour pocket, purse, or paper bag. After eating, put the mask back on with the same side facing out.","3597":"\u2022\n\u2022\f10\/30\/22, 9:35 AM Data Definitions for COVID-19 Vaccinations in the United States\nLearn more about CDC\u2019s recommendations for a COVID-19 vaccine booster dose. On September 30, 2021, this language was changed to reflect the recommendation for a booster dose. People who\nreceived an additional dose since August 13, 2021, are included in this count. People Who Received a Second Booster Dose\nRepresents the total number of fully vaccinated people who received two subsequent doses of COVID-19 vaccine\nbeginning August 13, 2021, which includes people who received two booster doses and moderately or severely\nimmunocompromised people who received one additional dose and one booster dose.","4692":"People should seek medical attention immediately if they develop any of the following symptoms:\nShortness of breath\nChest pain\nLeg swelling\nPersistent abdominal pain\nSevere or persistent headaches or blurred vision\nEasy bruising or tiny blood spots under the skin beyond the site of the injection\nIt is contraindicated to administer Janssen COVID-19 Vaccine to people with a history of TTS following receipt of the Janssen\nCOVID-19 Vaccine or any other adenovirus vector-based COVID-19 vaccines (e.g., AstraZeneca\u2019s COVID-19 Vaccine, which is\nnot FDA-authorized or FDA-approved in the United States).","8110":"If given between 4\u201314 days after the date of exposure, vaccination may reduce the symptoms of disease, but\nmay not prevent the disease.141\fCOVID-19 State of Vaccine Confidence Insights Report | October 10, 2022\n\u0082 Monkeypox PrEP should be offered to people with the highest potential for exposure to monkeypox such as:142\n\u008f Gay, bisexual, and other men who have sex with men, transgender or nonbinary people who in the past 6 months have\nhad\n\u00bb A new diagnosis of one or more nationally reportable sexually transmitted diseases (i.e., acute HIV, chancroid,\nchlamydia, gonorrhea, or syphilis)\n\u00bb More than one sex partner\n\u008f People who have had any of the following in the past 6 months:\n\u00bb Sex at a commercial sex venue\n\u00bb Sex in association with a large public event in a geographic area where monkeypox transmission is occurring\n\u008f Sexual partners of people with the above risks\n\u008f People who anticipate experiencing the above risks\nIdentified misinformation themes that may impact vaccine confidence\n\u0083 Some social media users believe COVID-19 vaccines weaken the body\u2019s immune system, making vaccinated individuals more\nsusceptible to monkeypox.143,144\n\u0083 Some social media users believe monkeypox is caused by COVID-19 vaccines.145,146\n\u0083 Some social media users believe monkeypox is being used to scare people now that COVID-19 is not seen as a threat.147,148\n\u0083 Some social media users believe pharmaceutical companies are attempting to create a monkeypox pandemic to increase\nWays public health and partners can take action to improve vaccine confidence\n\u0083 Encourage local health departments, public health experts, and healthcare workers to explain the absence of association\nbetween COVID-19 vaccines and monkeypox.","8551":"If multiple factors below indicate higher transmission risk, you should consider adding more prevention\nactions. Factors that lower or increase risk of transmission\nLength of time: How long were you with the infected person? Longer exposure time increases the risk of transmission (for example, contact longer than 15 minutes is more likely to result\nin transmission than two minutes of contact). Shorter exposure time\nLower Risk\nMedium exposure time\nModerate Risk\nLonger exposure time\nHigher Risk\nCough or heavy breathing: Was the infected person coughing, singing, shouting, or breathing\nheavily? Activities like coughing, singing, shouting, or breathing heavily due to exertion increase the risk of transmission.","10109":"These people should receive an\nmRNA or Novavax COVID-19 vaccine booster dose. \u00b6 People with a known allergy to polysorbate have a contraindication to both Novavax ad Janssen COVID-19 vaccines. ** People who develop GBS within 6 weeks after receipt of Janssen COVID-19 Vaccine should not receive another dose of Janssen COVID-19 Vaccine. These people should receive a booster dose of an mRNA COVID-19 vaccine for subsequent doses.","8088":"However, monkeypox can spread to anyone through close, personal, often skin-to-skin contact. Anyone who has been in close contact with someone who has monkeypox is at risk.137\n\u0083 How do I know if I have monkeypox?d\n\u0082 People with monkeypox can get a rash that may be located on or near the genitals (penis, testicles, labia, and vagina) or\nanus (butthole) and could be on other areas like the hands, feet, chest, face, or mouth. \u008f The rash will go through several stages, including scabs, before healing. \u008f The rash can initially look like pimples or blisters and may be painful or itchy.","1656":"COVID-19 Vaccine Administration Fees (updated 4\/8\/2022)\nAll organizations and providers participating in the CDC COVID-19 Vaccination Program:\n\uf209\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nmust administer COVID-19 Vaccine at no out-of-pocket cost to the recipient\nmay not deny anyone vaccination based on the vaccine recipient\u2019s coverage status or network status\nmay not charge an office visit or other fee if COVID-19 vaccination is the sole medical service provided\nmay not require additional medical services to receive COVID-19 vaccination\nmay seek appropriate reimbursement from a program or plan that covers COVID-19 Vaccine administration fees for\nthe vaccine recipient, such as:\nvaccine recipient\u2019s private insurance company\nMedicare or Medicaid reimbursement\nHRSA COVID-19 Coverage Assistance Fund for underinsured vaccine recipients (unavailable as of 11:59 ET on\nApril 5, 2022, due to lack of supplemental funding)\nHRSA COVID-19 Uninsured Program for non-insured vaccine recipients (unavailable as of 11:59 ET on April 5,\n2022, due to lack of supplemental funding)\nmay not seek any reimbursement, including through balance billing, from the vaccine recipient\nFor additional information on filing claims for reimbursement of COVID-19 vaccine administration fees, go to:\nCMS Guidance \u2013 https:\/\/www.cms.gov\/covidvax-provider\nCDC Statement on Exhaustion of Funding for the Uninsured Program and Coverage Assistance Fund\nDue to the lack of supplemental funding from Congress, HRSA stopped accepting claims for reimbursement of costs\nassociated with administering COVID-19 vaccines to uninsured and underinsured individuals as of 11:59 PM ET on April 5,\n2022.","9378":"COVID-19 is caused by a coronavirus called SARS-CoV-2. This type of coronavirus has not\nbeen seen before. You can get COVID-19 through contact with another person who has the\nvirus. It is predominantly a respiratory illness that can affect other organs. People with COVID-\n19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever or\nchills; cough; shortness of breath; fatigue; muscle or body aches; headache; new loss of taste or\nsmell; sore throat; congestion or runny nose; nausea or vomiting; diarrhea.","6547":"Chronic lung diseases can include:\nAsthma, if it\u2019s moderate to severe\nBronchiectasis (thickening of the lungs\u2019 airways)\nBronchopulmonary dysplasia (chronic lung disease affecting newborns)\nChronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis\nHaving damaged or scarred lung tissue known as interstitial lung disease (including idiopathic pulmonary fibrosis)\nPulmonary embolism (blood clot in the lungs)\nPulmonary hypertension (high blood pressure in the lungs)\nGet more information:\nCOPD\nAsthma\nPeople with Moderate to Severe Asthma\nAmerican Lung Association: Controlling Chronic Lung Diseases Amid COVID-19\nCystic fibrosis\nHaving cystic fibrosis, with or without lung or other solid organ transplant (like kidney, liver, intestines, heart, and pancreas)\ncan make you more likely to get very sick from COVID-19.","4193":"However, staying up to date with your COVID-19\nvaccinations means that you are less likely to have a breakthrough infection and, if you do get sick, you are less likely to\nget severely ill or die. Staying up to date with COVID-19 vaccination also means you are less likely to spread the disease to\nothers and increases your protection against new variants of SARS-CoV-2, the virus that causes COVID-19. Why should I get vaccinated if I might get COVID-19 anyway? \uf1aa\nThere is no recommended waiting period between getting a COVID-19 vaccine and other vaccines.","920":"If you had symptoms, your isolation period ends after:\n5 days since symptoms first appeared, and\n24 hours with no fever without fever-reducing medicine, and\nOther symptoms of COVID-19 are improving\nIf you never had symptoms, your isolation period ends after\n5 days have passed since you tested positive for COVID-19. Once your isolation period has ended you should still wear a mask until day 10. After 10 days, you should still wash your\nhands before caring for your newborn, but you don\u2019t need to take the other precautions.","8364":"Be compassionate and curious about the patient\u2019s mixed feelings, both the part of them that wants to trust that getting a\nvaccine is important and safe and the other part that feels hesitant. It is important to show support for the patient to\nincorporate their personal values and the health needs of their family and community as they make their decision. If a patient asks a question about vaccine safety, vaccine risks, or their health or mental health, respond within the\nboundaries of your competence, ethics, and scope of practice.","3365":"SARS-CoV-2 viral testing may be necessary to differentiate between\ncommon post-vaccination symptoms and symptoms of SARS-CoV-2 infection:\nPeople who develop signs and symptoms associated with COVID-19 (e.g., cough, shortness of breath, runny nose, sore\nthroat, loss of taste or smell) should isolate and be evaluated for SARS-CoV-2 infection as soon as possible. People who develop signs and symptoms that could be from either COVID-19 vaccination or SARS-CoV-2 infection (e.g.,\nfever, fatigue, headache, myalgia) without typical COVID-19 symptoms described above, and are clinically stable, should\nisolate and, if symptoms do not improve by two days post-vaccination, be evaluated for SARS-CoV-2 infection.","27":"Espa\u00f1ol | Other Languages\nGet the facts about COVID-19 and the virus that causes it, including how it spreads and new variants. CDC is reviewing this page to align with updated guidance. Protect Your Family Members\nCDC recommends COVID-19 vaccines for everyone 6 months and older and boosters for\neveryone 5 years and older, if eligible.","2830":"There has not been a similar reporting pattern\nobserved after receipt of the Janssen COVID-19 Vaccine (Johnson & Johnson). CDC continues to recommend COVID-19 vaccination for everyone 6 months of age and older. The Advisory Committee on\nImmunization Practices (ACIP) and CDC have determined that the benefits (such as prevention of COVID-19 cases and its\nsevere outcomes) outweigh the risks of myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines. \uf209\f10\/30\/22, 9:16 AM Clinical Considerations: Myocarditis after mRNA COVID-19 Vaccines | CDC\nFor follow-up of patients with myocarditis, consult the guidance from the American Heart Association and American\nCollege of Cardiology .","76":"You had an immediate (within 4 hours) allergic reaction that was not severe from a previous dose of that type of\nCOVID-19 vaccine. This vaccination should only be done in a health clinic, medical facility, or doctor\u2019s office. CDC Is Monitoring Reports of Severe Allergic Reactions\nIf someone has a severe allergic reaction after getting vaccinated, their vaccination provider will send a report to the Vaccine\nAdverse Event Reporting System (VAERS). VAERS is a national system that collects reports from healthcare professionals,\nvaccine manufacturers, and the public about adverse events that happen after vaccination.","2322":"\u2022\n\u2022\n-\n-\n\u2022\n\u2022\n\u2022 TM\nPre-teens, Teens and Adults Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nAGE GROUP\n18 YEARS AND OLDER\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nModerna\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nJohnson & Johnson's Janssen\n\uf1aa\nPRIMARY SERIES\nADDITIONAL DOSE\nAt least 4 weeks after 1st dose\nand should be Pfizer-BioNTech\nor Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nor last booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nNovavax\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nA monovalent Novavax booster\nis available in limited situations\nMore details: Novavax booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nChildren Ages 6 Months-11 Years Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 8 weeks after 2nd dose\nUp to Date: 2 weeks after 3rd dose in primary series, since a booster is not recommended for this age group at this\ntime\nAGE GROUP\nModerna\n\uf1aa\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nIf you have completed your primary series\u2014but are not yet eligible for a booster\u2014you are also considered up to date.","6813":"V-safe also provides second-dose reminders if needed and live telephone\nfollow-up by CDC if participants report a significant health impact following COVID-19\nvaccination. For more information on how to sign up, visit: www.cdc.gov\/vsafe. WHAT IF I DECIDE NOT TO HAVE MY CHILD GET THE PFIZER-BIONTECH\nCOVID-19 VACCINE OR THE PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT? Under the EUA, there is an option to accept or refuse receiving any of these vaccines. Should you decide for your child not to receive any of these vaccines, it will not change\nyour child\u2019s standard medical care.","7709":"Everyone who receives a COVID-19 vaccine can also\nparticipate in safety monitoring by enrolling themselves -or their children or dependents 6 months and older in a\nsmartphone-based system called v-safe and completing health check-ins after COVID-19 vaccination. Have you experienced a side effect following COVID-19 vaccination? Please report it to VAERS . In addition, enrolling yourself or your dependent in v-safe allows you to easily report to CDC how\nyou are feeling after getting a COVID-19 vaccine.","9342":"This Vaccine Information Fact Sheet for Recipients and Caregivers comprises the Fact\nSheet for the authorized Moderna COVID-19 Vaccine and the authorized Moderna\nCOVID-19 Vaccine, Bivalent for use in individuals 6 years of age and older, and also\nincludes information about the FDA-licensed vaccine, SPIKEVAX (COVID-19 Vaccine,\nmRNA) for use in individuals 12 years of age and older.1\nThe FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and the Moderna COVID-\n19 Vaccine authorized for Emergency Use Authorization (EUA) for individuals 12 years of\nage and older can be used interchangeably, when used according to their respective\ninstructions for use.2\nSPIKEVAX (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made\nby ModernaTX, Inc.","4764":"*\nPeople ages 5 years and older who received a COVID-19 vaccine that is FDA-authorized, FDA-approved, or listed for emergency use by WHO\nshould receive 1 bivalent mRNA booster dose. A monovalent Novavax booster dose (instead of a bivalent mRNA booster dose) may be used in limited situations in people ages 18 years and\nolder who have not received any previous booster dose(s). The Novavax booster dose is administered at least 6 months after the last primary\nseries dose.","3031":"For example, people who become\nmoderately or severely immunocompromised after completing a 2-dose mRNA primary series do not need additional primary\ndoses; however, they should follow the schedule for people who are moderately or severely immunocompromised for the\nbooster dose. Moderna COVID-19 Vaccine\nChildren ages 6 months\u20134 years: A 3-dose primary series is recommended. The first and second doses are separated by\n4 weeks and the second and third doses are separated by at least 4 weeks. Currently, a booster dose using any COVID-19\nvaccine is not authorized for children in this age group.","2365":"transplantation or taking immunosuppressive therapy)\nModerate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined\nimmunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)\nAdvanced or untreated HIV infection (people with HIV and CD4 cell counts less than 200\/mm3, history of an AIDS-\ndefining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)\nActive treatment with high-dose corticosteroids (i.e., 20 or more mg of prednisone or equivalent per day when\nadministered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs,\ncancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and\nother biologic agents that are immunosuppressive or immunomodulatory\n\u2022\n\u2022\n\u2022\nIf you are moderately or severely immunocompromised or severely allergic to COVID-19 vaccines, you may be eligible for\npre-exposure prophylaxis with EVUSHELD .","8343":"Option 1: Move on and say, \u201cI respect that, and because I care about your overall health, maybe we could talk about\nthe vaccines at a future time.\u201d\nOption 2: Based on the patient\u2019s demonstrated emotions and your assessment of the patient\u2019s worldview and\nvalues, you could spend several minutes curiously exploring why the patient doesn\u2019t want to talk about it. The goal\nis to understand, not to change their mind. Remember: These conversations may take time, and they may continue over multiple visits. If the patient says yes to talking about the vaccines, move to Step 3.","3621":"10\/30\/22, 9:42 AM Domestic Travel During COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nDomestic Travel During COVID-19\nInformation for People Traveling by Air and Land within the United States and U.S. Territories\nBefore You Travel\nMake sure to plan ahead:\nGet up to date with your COVID-19 vaccines before you travel. Find out when you can get your booster and where to get a vaccine or booster. COVID-19 vaccines are effective at protecting people\u2014especially those who are boosted\u2014 from getting seriously ill,\nbeing hospitalized, and even dying. Check the current COVID-19 Community Level at your destination.","3476":"You had close contact with a person with COVID-19 in the past 5 days and are recommended to quarantine. Get tested at least 5 days after your last close contact. Make sure your test result is negative and you remain\nwithout symptoms before traveling. Properly wear a well-fitting mask when you are around others through day 10. If you are unable to wear a\nmask, you should not travel during this time. Check with your cruise line regarding their policies. 10\/30\/22, 9:43 AM Cruise Ship Travel During COVID-19 | CDC\nDuring Cruise Travel\nAfter Cruise Travel\nSelf-monitor for COVID-19 symptoms.","878":"Talk to your healthcare provider about how you can protect your newborn, such as using a physical barrier (for example,\nplacing the newborn in an incubator) while in the hospital. You most likely will not pass the virus to your newborn or any other close contacts after your isolation period has ended. If you had symptoms, your isolation period ends after:\n5 days since symptoms first appeared, and\n24 hours with no fever, without fever-reducing medicine, and\nOther symptoms of COVID-19 are improving. If you never had symptoms, your isolation period ends after\n5 days have passed since you tested positive for COVID-19.","6286":"The genetic material delivered by mRNA vaccines never enters the\nnucleus of your cells, which is where your DNA is kept. Viral vector\nCOVID-19 vaccines deliver genetic material to the cell nucleus to allow\nour cells to build protection against COVID-19. However, the vector\nvirus does not have the machinery needed to integrate its genetic\nmaterial into our DNA, so it cannot alter our DNA. Learn more about how COVID-19 vaccines work. MYTH: A COVID-19 vaccine can make me sick with COVID-19.","3738":"\u25aa Updated on May 20, 2022, to allow the following for Pfizer-BioNTech and Moderna COVID-19\nvaccines: revaccination for any COVID-19 vaccine dose(s) received during treatment with B-cell\ndepleting therapies over a limited period and deferral of the second primary dose in an mRNA\nCOVID-19 vaccine series in people who recently had SARS-CoV-2 infection by 3 months from\nsymptom onset or positive test (if infection was asymptomatic).","3920":"Underlying Health Conditions\nCertain underlying health conditions you have (for example, obesity\nor chronic obstructive pulmonary disorder) may affect your risk of\nbecoming very sick if you get COVID-19. Often, the more health conditions you have, the higher your risk. Certain conditions increase your risk more than others. For example,\nsevere heart disease increases your risk more than high blood\npressure. Learn more about how different underlying health conditions affect the chances of getting very sick or dying from\nCOVID-19. Vaccination\nCOVID-19 vaccines are safe and effective.","9022":"Learn more about selected adverse events reported to VAERS. Updates on COVID 19 and Pregnancy (ACIP meeting slides)\nMonitoring the safety of COVID-19 vaccines in pregnancy in the U.S.\n\u2022 \uf20c\n\u2022 \uf209\n\uf209\n\uf209 \uf209\n\uf209\nRelated Pages\nCOVID-19 Vaccine Safety and Monitoring\n\u203a\nCOVID-19 Vaccines While Pregnant or Breastfeeding\n\u203a\nBenefits of Getting a COVID-19 Vaccine\n\u203a\nMyths and Facts about COVID-19 Vaccines\n\u203a\nCOVID Data Tracker: COVID-19 Vaccination Among Pregnant People\n\u203a\nLast Updated July 18, 2022","3262":"For information on contraindications and precautions to Janssen COVID-19 vaccination, see Appendix A.\nHealthcare professionals and health departments may request a consultation from the Clinical Immunization Safety\nAssessment COVIDvax project for a complex COVID-19 vaccine safety question not readily addressed by CDC guidance. Adverse events that occur in a recipient following COVID-19 vaccination should be reported to VAERS.","5922":"See Table 3 COVID-19 vaccination schedule for moderately or severely immunocompromised people in CDC\u2019s\nInterim Clinical Considerations for the latest dosing recommendations. On a case-by-case basis, providers of\nmoderately or severely immunocompromised patients who are ages 12 years and older may administer the\nCOVID-19 vaccine by Moderna outside of the FDA-authorized or FDA-approved labeling and CDC recommended\ndosing intervals based on clinical judgment when the benefits of vaccination are deemed to outweigh the\npotential and unknown risks for the recipient. What are the formulations of the COVID-19 vaccine by Moderna that these EUI apply to?","9717":"Additional supporting evidence for use of the COVID-19 vaccine by Pfizer-BioNTech for additional primary or\nbooster doses in people who received a non-FDA authorized or approved COVID-19 primary vaccination series\nare as follows. An unpublished small, randomized trial in Bahrain found that a third dose of Pfizer-BioNTech\nCOVID-19 vaccine after a 2-dose Sinopharm BIBP COVID-19 vaccine primary series resulted in higher levels of\nIgG antibodies against the spike-antigen of SARS-CoV-2 (anti-S-IgG) compared to a 3-dose series of Sinopharm\fPfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nBIBP COVID-19 vaccine (SAGE, 2021).","8118":"If given between 4\u201314 days after the date of exposure, vaccination may reduce the symptoms of disease, but\nmay not prevent the disease.141\fCOVID-19 State of Vaccine Confidence Insights Report | October 10, 2022\n\u0082 Monkeypox PrEP should be offered to people with the highest potential for exposure to monkeypox such as:142\n\u008f Gay, bisexual, and other men who have sex with men, transgender or nonbinary people who in the past 6 months have\nhad\n\u00bb A new diagnosis of one or more nationally reportable sexually transmitted diseases (i.e., acute HIV, chancroid,\nchlamydia, gonorrhea, or syphilis)\n\u00bb More than one sex partner\n\u008f People who have had any of the following in the past 6 months:\n\u00bb Sex at a commercial sex venue\n\u00bb Sex in association with a large public event in a geographic area where monkeypox transmission is occurring\n\u008f Sexual partners of people with the above risks\n\u008f People who anticipate experiencing the above risks\nIdentified misinformation themes that may impact vaccine confidence\n\u0083 Some social media users believe COVID-19 vaccines weaken the body\u2019s immune system, making vaccinated individuals more\nsusceptible to monkeypox.143,144\n\u0083 Some social media users believe monkeypox is caused by COVID-19 vaccines.145,146\n\u0083 Some social media users believe monkeypox is being used to scare people now that COVID-19 is not seen as a threat.147,148\n\u0083 Some social media users believe pharmaceutical companies are attempting to create a monkeypox pandemic to increase\nWays public health and partners can take action to improve vaccine confidence\n\u0083 Encourage local health departments, public health experts, and healthcare workers to explain the absence of association\nbetween COVID-19 vaccines and monkeypox.","7202":"The Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent, or COMIRNATY (COVID-19 Vaccine, mRNA) will be given to you as an\ninjection into the muscle. Primary Series: The Pfizer-BioNTech COVID-19 Vaccine and COMIRNATY (COVID-19\nVaccine, mRNA) are given for the primary series. The vaccine is administered as a\n2-dose series, 3 weeks apart. A third primary series dose may be administered at least\n4 weeks after the second dose to individuals with certain kinds of immunocompromise.","6988":"The Countermeasures Injury Compensation Program (CICP) is a federal program that may help pay for costs\nof medical care and other specific expenses of certain people who have been seriously injured by certain\nmedicines or vaccines, including this vaccine. Generally, a claim must be submitted to the CICP within one\n(1) year from the date of receiving the vaccine. To learn more about this program, visit www.hrsa.gov\/cicp\/\nor call 1-855-266-2427. How can I learn more? \u2022 Ask the vaccination provider. \u2022 Visit CDC at https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/index.html. \u2022 Visit FDA at https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-\nand-policy-framework\/emergency-use-authorization. \u2022 Contact your local or state public health department.","382":"The adjustments are the result of updates to how pharmacies report data to CDC and\/or the jurisdictions. On October 26, 2021, CDC corrected an error in the census denominators used to calculate percentage-based metrics\nfor the population \u2265 65 years of age in Puerto Rico. No other population groups were affected. The census counts for the population aged 65 years and older in Puerto Rico increased from 542,928 to 679,656\npeople. The census counts for the population aged 65 years and older in the US increased from 54,696,581 to 54,833,309\npeople. CDC will update its historical data on data.cdc.gov to reflect these corrections.","9514":"Special Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nSpecial Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nModerna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group\nCDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage based on their age on\nthe day of vaccination. \u0083 If a person moves from a younger age group to an older age group during the primary series or between the primary series and receipt\nof the booster dose(s), they should receive the vaccine product and dosage for the older age group for all subsequent doses.","7461":"While CDC\u2019s Order does not apply to Ukrainians who are approved under the Uniting for Ukraine program, the U.S.\nDepartment of Homeland Security (DHS) has identified health requirements as a component of the program, which\ninclude receiving measles, polio, and at least one dose of COVID-19 vaccine. For more information about the health\nrequirements of the program, how to apply to the program, and the processes to receive travel authorization to come to\nthe United States please visit DHS\u2019 website for the Uniting for Ukraine program . For information not found on DHS\u2019\nwebsite, please contact the USCIS Contact Center .","4252":"Learn more about COVID-19 Vaccines for People Who Were Vaccinated Abroad. Am I considered fully vaccinated if I was vaccinated in another country? \uf1aa\nAnswers to more questions about:\nIsolation\nVaccines.gov\nVaccine Administration Management System (VAMS)\nV-safe after Vaccination Health Checker\n\u2022\n\u2022\n\u2022\n\u2022\nRelated Pages\nFAQs about Vaccination in Children\n\u203a\nMyths and Facts about COVID-19 Vaccines\n\u203a\nLast Updated Oct. 13, 2022","8778":"Cloth masks should be washed at least once a day or as soon as\nthey become wet or dirty. You can either wash and dry your\nmasks by hand or use a washer and dryer. 2. Wash or sanitize your hands after removing any mask. Taking off your mask while you eat or drink\nIf you are taking off your mask to eat or drink outside of your home, you can place it somewhere safe to keep it clean, such as\nyour pocket, purse, or paper bag. After eating, put the mask back on with the same side facing out.","3320":"No cases of myocarditis or pericarditis were reported in children in the pre-authorization clinical\ntrials of Pfizer-BioNTech (ages 6 months\u20134 years) or Moderna (ages 6 months\u20135 years) vaccines. To date, post-authorization\nsurveillance has not detected an increased risk for myocarditis and pericarditis following mRNA COVID-19 vaccination in\nchildren ages 6 months\u20134 years (i.e., Pfizer-BioNTech) and ages 6 months\u20135 years (i.e., Moderna). Cases of myocarditis and pericarditis were identified in clinical trials of Novavax COVID-19 Vaccine and have also been\nreported during post-authorization use outside the United States. These findings suggest that an increased risk for these\nconditions may be present after receiving Novavax COVID-19 vaccine.","1152":"\u2022\n\u2022\n\u2022\n\u2022\nCOVID-19 Vaccination Data Sources\f10\/30\/22, 9:35 AM COVID-19 Vaccination Data Systems and Data Sources\nFederal Agency Data\nOn CDC COVID Data Tracker (CDT), data are individually displayed at the national level and included as part of national\ntotals for each metric for the following agencies (except Department of State, DoS):\nBureau of Prisons (BoP)\nDepartment of Defense (DoD)\nIndian Health Services (IHS)\nVeterans Health Administration (VHA)\nFederal agency data\u202fare\u202falso included as part of jurisdiction, state, or territory aggregate metrics. To avoid duplicate\ncounts, the agency data\u202fshould not be combined with other data.","6482":"Include how you will adjust your plan if the COVID-19 situation changes in your community. Your plan should include:\n1. What you\u2019re doing to protect yourself and prepare (in case you get COVID)\n2. What you\u2019ll do if you\u2019re exposed or develop symptoms\n3. What you\u2019ll do if you test positive\nTalk with your family, friends, and healthcare provider about your plan\nShare your COVID-19 plan with your family, friends, and healthcare providers so they can support your prevention and\npreparation steps. Consider how others may help you if you get sick and identify the supplies you may need.","95":"\u2022\n\u2022\n\u2022\n\u2022\nFor Pet Owners, Veterinarians, & Public Health Officials\nPet Owners\nand Others\nHandling\nAnimals\nPets and\nAnimals\nFrequently\nAsked\nQuestions\nAnimal\nTesting\nGuidance\nOne Health\nToolkit for\nHealth\nOfficials\nManaging\nCompanion\nAnimals with\n\u2022\n\u2022\n\u2022\n\u2022\nCoronaviruses are a large family of viruses. Some coronaviruses cause cold-like illnesses in people, while others cause illness\nin certain types of animals, such as cattle, camels, and bats. Some coronaviruses, such as canine and feline coronaviruses,\ninfect only animals and do not infect people. Some coronaviruses that infect animals can be spread to people and then\nspread between people, but this is rare. This is what happened with SARS-CoV-2, which likely originated in bats.","9679":"Adverse reactions following administration of the vaccine that have been reported in clinical trials and\/or post\nauthorization include injection site pain, fatigue, headache, muscle pain, chills, joint pain, fever, injection site\nswelling, injection site redness, nausea, malaise, lymphadenopathy, decreased appetite, rash, pain in\nextremity, diarrhea, and vomiting. Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nWhat are possible serious side effects with the COVID-19 vaccine by Pfizer-BioNTech? Severe allergic reactions, including anaphylaxis, and other hypersensitivity reactions (e.g., rash, pruritus,\nurticaria, angioedema), syncope, myocarditis and pericarditis have been reported following administration of\nthe vaccine outside of clinical trials.","8736":"If you have household or social contact with someone at high risk getting very sick, consider self-testing to\ndetect infection before contact and consider wearing a mask when indoors with them. \u2022\n\u2022\nHigh\nWear a high-quality mask or respirator. If you are high risk for getting very sick, consider avoiding non-essential indoor activities in public where\nyou could be exposed. \u2022\n\u2022\nCOVID-19 County Check\nFind community levels and prevention steps by county. Data updated weekly.","5292":"The Janssen COVID-19 Vaccine has received EUA from FDA to provide the following doses in\nindividuals 18 years of age and older for whom other FDA-authorized or approved COVID-19\nvaccines are not accessible or clinically appropriate, and in individuals 18 years of age and older\nwho elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a\n\u2022 A single dose primary vaccination. \u2022 A single booster dose after completing a primary vaccination with the Janssen COVID-19\nVaccine. \u2022 A single booster dose after completing primary vaccination with a different authorized or\napproved COVID-19 vaccine. The Janssen COVID-19 Vaccine may not protect everyone.","6442":"Download: Evusheld EUA Fact Sheet for Patients, Parents and Caregivers\nTM\nTM\nTM\nTM\nTM\nTM\n\uf2dc TM \uf209\nTM\n\u2022\n\u2022\n\u2022\n\u2022\nKnow What to Do If You Get Sick\n\u2022\n\u2022\n\u2022\n- \uf209\n\uf209\f10\/30\/22, 9:38 AM People Who Are Immunocompromised | CDC\nKnow where free or low-cost testing locations are near you so you know where to go. Know how to reach a healthcare provider right away, including after hours or weekends. Ask them about telehealth\nappointment options. Have an updated list of all your current medications in case you need to see a different provider. What to do if you were exposed to COVID-19\nDetermine if you should stay home.","2358":"Examples of medical conditions or treatments that may result in moderate to severe immunocompromise include but are not\nlimited to:\nActive treatment for solid tumor and hematologic malignancies\nHematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status\n(e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\nReceipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\nReceipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of\ntransplantation or taking immunosuppressive therapy)\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nTalk to your healthcare provider about COVID-19 and your medical condition.","3358":"History of other heart disease\nPeople who have a history of other heart disease, including congenital heart disease and Kawasaki disease, may receive any\ncurrently FDA-approved or FDA-authorized COVID-19 vaccine. Recent exposure to SARS-CoV-2 is not a contraindication or precaution to COVID-19 vaccination. People with a known or\npotential SARS-CoV-2 exposure can receive vaccine if they do not have symptoms consistent with SARS-CoV-2 infection;\nhowever, people should follow CDC\u2019s post-exposure guidance. COVID-19 vaccines are not recommended for post-exposure prophylaxis. People should be informed that vaccination is to\nhelp prevent severe COVID-19 following future exposures.","1768":"10\/30\/22, 9:29 AM COVID-19 Vaccination for Children and Teens with Disabilities | Human Development and Disability | NCBDDD | CDC\nEspa\u00f1ol | Other Languages\nHuman Development and Disability\nHuman Development and Disability Home\nCOVID-19 Vaccination for Children and Teens with\nDisabilities\nWhat You Need to Know\nCOVID-19 vaccination for children and teens is safe and effective. Everyone 6 months and older, including those with disabilities and underlying medical conditions, should get\nvaccinated against COVID-19. Everyone 5 years and older should get a booster, if eligible.","6553":"Get more information:\nCystic fibrosis\nCF and Coronavirus (COVID-19) | Cystic Fibrosis Foundation (cff.org)\n\u2022\n\u2022 \uf209\n\u2022\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022 \uf209\n\u2022\n\u2022 \uf209\f10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nDementia or other neurological conditions\nHaving neurological conditions, such as dementia, can make you more likely to get very sick from COVID-19. Get more information:\nDementia\nAlzheimer\u2019s Association: COVID-19, Alzheimer\u2019s and Dementia\nDiabetes (type 1 or type 2)\nHaving either type 1 or type 2 diabetes can make you more likely to get very sick from COVID-19.","4292":"Preparing children and teens for vaccination\nIf you are getting your child or teen vaccinated learn how you can support them and talk to them about what to expect. The\nexperience of getting a COVID-19 vaccine will be very similar to that of getting routine vaccines. Requesting accommodations at COVID-19 vaccination sites\nWhen making an appointment or arriving for vaccination, you can let staff and\/or volunteers know you or your child\nmight need some accommodations. People with disabilities can use the COVID-19 Vaccine Disability Information and Access Line (DIAL) to get help with\nCOVID-19 vaccinations.","7605":"CDC considers a country to have limited COVID-19 vaccine availability if less than 10% of the total population has been\nfully vaccinated against COVID-19 with any vaccine, as reported in official source data in Our World in Data (OWID). CDC reviews OWID country-level data on the proportion of a population that is fully vaccinated and updates the list of\ncountries with limited vaccine availability every three months. If country data are missing from OWID, CDC reviews other\nofficial sources of information to determine a countries\u2019 vaccination coverage (percent of the population fully vaccinated\nwith available COVID-19 vaccines).","3050":"Children age 5 years: A 3-dose primary series and 1 bivalent Pfizer-BioNTech booster dose is recommended. For the\nprimary series, the first and second doses are separated by 3 weeks and the second and third doses are separated by at\nleast 4 weeks. The bivalent booster dose is administered at least 2 months after completion of the primary series (for\npeople who have not received any booster doses), or at least 2 months after the last monovalent booster dose. Currently, only the bivalent Pfizer-BioNTech booster dose is authorized for children age 5 years who receive a Pfizer-\nBioNTech primary series.","9332":"If\nneeded, ask the provider to write down\nor print out any instructions, medication\nnames, or diagnoses. After the Appointment\n\nMake appointments for follow up. Record future appointments,\nincluding tests, in your calendar. If\nothers will go with you or drive you to\nfuture appointments, make sure the\nappointments are on their calendars too. Follow your provider\u2019s instructions to\nthe best of your ability. Contact your provider\u2019s office with any\nquestions or clarifications. Continue to record symptoms and\nkeep your journal, so you can refer\nto updates or changes during your\nnext appointment. Update and keep track of medications\nand supplements. For more information on post-COVID conditions, please visit\nhttps:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/long-term-effects.html.","9599":"See the Moderna EUI Fact Sheet for Healthcare Providers. Refer to CDC\u2019s Interim Clinical Considerations for specific recommendations on use of the COVID-19 vaccine by\nPfizer-BioNTech allowed under the EUI. For additional information about the COVID-19 vaccine by Pfizer-\nBioNTech COVID-19, refer to the Comirnaty package insert or the Full Emergency Use Authorization (EUA)\nPrescribing Information (FDA, 2022). What are EUI and why is CDC issuing EUI for the COVID-19 vaccine by Pfizer-BioNTech?","4280":"You may be able to take these types of medications to reduce fever or pain after you get your vaccine to\nrelieve any pain or discomfort resulting from possible side effects. If you do not regularly take over-the-counter medications, you should not take them before you get a COVID-19\nvaccination. Taking one of the following medications regularly is not, on its own, a reason to avoid getting your COVID-19 vaccination:\nOver-the-counter medications (non-prescription)\nNon-steroidal anti-inflammatory drugs (NSAIDs) (naproxen, ibuprofen, aspirin, etc.) Acetaminophen (Tylenol, etc.)","9016":"Anyone can submit a report to VAERS ,\nincluding patients, parents or caregivers, healthcare providers, and vaccine manufacturers. There are two ways to report an adverse event to VAERS: report online or report using a writable pdf form . If you need\nfurther assistance with reporting to VAERS, please email info@VAERS.org or call 1-800-822-7967. For healthcare providers \u2013 Under Emergency Use Authorization, FDA requires healthcare professionals to report to VAERS\ncertain adverse events that occur after COVID-19 vaccination. CDC also encourages reporting of any medically important\nadverse event even if it isn\u2019t clear if the vaccine caused the health problem.","6704":"Spray or pour spray products onto a cleaning cloth or paper towel instead of spraying the product directly onto the\ncleaning surface (if the product label allows). Store products safely and correctly\nStore and use chemicals out of the reach of children and pets. Label diluted cleaning solutions. Follow EPA\u2019s 6 steps for Safe and Effective Disinfectant Use . If you feel ill\nCall your healthcare provider to ask about your symptoms. If you don\u2019t have a healthcare provider, contact your nearest\ncommunity health center or health department. Remember to call 911 for medical emergencies.","1616":"This includes\nCOVID-19 Vaccination Record Cards that have been printed by agents on behalf of CDC, including the jurisdictions. USG-provided COVID-19 Vaccination Record Cards remain property of the United States Government until provided to\nthe vaccine recipient following vaccination through the CDC COVID-19 Vaccination Program. The COVID-19 Vaccination\nRecord Cards may not be reproduced by anyone other than authorized jurisdictions or without written permission of\nCDC. Any use or unauthorized reproduction of the COVID-19 Vaccination Cards outside of the CDC COVID-19 Vaccination\nProgram, or production or use of similar facsimiles of such cards, is prohibited.","2918":"Terminology for COVID-19 vaccine use\nPrimary series: Initial vaccination which can range from a single dose to a 3-dose series depending on the vaccine\nproduct and a person\u2019s age and immune status. The same vaccine product should be used for all doses of the\nprimary series. Additional dose: A dose of vaccine administered after the primary series to people who may be less likely to mount a\nprotective immune response after initial vaccination. People who are moderately or severely immunocompromised\nand who received Janssen COVID-19 Vaccine for their primary series are recommended to receive an additional dose\nusing an mRNA vaccine.","8658":"The clinical trials for COVID-19 vaccines have involved tens of thousands of volunteers of different ages,\nraces, and ethnicities. Clinical trials for vaccines compare outcomes (such as how many people get sick) between people who\nare vaccinated and people who are not. Results from these trials have shown that COVID-19 vaccines are\nsafe and effective, especially against severe illness, hospitalization, and death. 10\/30\/22, 9:34 AM Understanding How COVID-19 Vaccines Work | CDC\nAuthorization or Approval\n\uf1aa\n\uf2a7 Before vaccines are made available to people in real-world settings, FDA assesses the findings from\nclinical trials.","2233":"In\naddition to data from clinical trials, evidence from real-world vaccine effectiveness studies show that COVID-19 vaccines help\nprotect against COVID-19 infections, with or without symptoms (asymptomatic infections). Vaccine effectiveness against\nhospitalizations has remained relatively high over time, although it tends to be slightly lower for older adults and for people\nwith weakened immune systems. Most People Need Booster Shots\nCOVID-19 vaccines are working well\u202fto prevent severe illness, hospitalization, and death. However, public health experts see\nreduced protection over time against mild and moderate disease, especially among certain populations.","8020":"Identified misinformation themes that may impact vaccine confidence\n\u0083 Some consumers believe that natural immunity is superior to vaccine-induced immunity despite the health risks associated\nwith getting SARS-CoV-2.96\n\u0083 Some social media users state that the efficacy of the Pfizer vaccine is only between 1 and 12 percent at preventing illness97\nwhile leaving out the additional context that the vaccine-acquired immunity decreases with time, the vaccines are less\neffective against some variants of SARS-CoV-2, and, most importantly, the vaccine provides protection against severe illness.98\n\u0083 Some social media users believe SARS-CoV-2 is the same as influenza.99\n\u0083 Some social media users believe COVID-19 vaccines are causing a surge in the number of COVID-19 cases.100\nWays public health and partners can take action to improve vaccine confidence\n\u0083 Develop and amplify messages explaining why vaccines are still important in the COVID-19 prevention response.","2621":"The vaccine is made of mRNA\nwrapped in a coating that makes\ndelivery easy and keeps the body\nfrom damaging it. How does the\nvaccine work? The mRNA in the vaccine teaches\nyour cells how to make copies\nof the spike protein. If you are\nexposed to the real virus later,\nyour body will recognize it and\nknow how to fight it off. After the mRNA delivers the\ninstructions, your cells break\nit down and get rid of it. Antibody\nWhen your body\nresponds to the\nvaccine, it can\nsometimes cause a\nmild fever, headache,\nor chills. This is\ncompletely normal\nand a sign that the\nvaccine is working. GETTING VACCINATED?","6055":"The option to be revaccinated for people who received vaccination during\ntherapy would allow the opportunity to develop a more sufficient immune response. Risk\u2010Benefit of the COVID-19 vaccine by Moderna as Primary or Additional, Vaccination for Individuals\nDescribed in the EUI\nThe duration of vaccine-induced protection from primary vaccination with COVID-19 vaccines is unknown. Efficacy data from clinical studies of 2-dose primary series supported benefit of the COVID-19 vaccine by\nModerna in preventing severe COVID-19 and supported its FDA approval.","9794":"However, robustness and duration of protection is variable (National Collaborating Center for Methods and\nTools, 2021). The circulating variant, as well as individual-level factors such as age and comorbidities, can\nimpact level of protection. For example, overall risk of reinfection increased during the Omicron wave, and\nprotection from infection or vaccination, was less robust than against previous variants (Pulliam et al., 2022). Additionally, some populations (e.g., older adults, immunocompromised) may have decreased levels of\nprotection following infection, necessitating an interval that balances the benefits and risks of delaying\nvaccination after infection at a population level.","264":"This section serves as an\narchive of footnotes for historical COVID-19 vaccine data updates. Reported changes to COVID-19 vaccine data can occur for\nthe following reasons:\nUpdates to COVID-19 vaccine policy and guidance\/recommendations\nData changes outside scheduled Record Management events\nChanges in reporting methods\nAdjustments made due to errors (such as syncing errors)\nVaccination Data Updates:\nOn October 20, 2022, the daily number of vaccine doses administered for Indiana was 69,965 doses. This total includes\nrecent dose administrations and historic dose administrations from August 1 to September 30, 2022 that had not been\nreported to CDC by Indiana.","2060":"\u2022\n-\n-\n-\n\u2022\n-\n-\nPeople who are Pregnant\nAlthough the overall risks are low, if you are pregnant or were recently\npregnant, you are\nMore likely to get very sick from COVID-19 compared to people who\nare not pregnant. People who get very sick from COVID-19 may\nrequire hospitalization, admission to an intensive care unit (ICU), or\nuse of a ventilator or special equipment to breathe. Severe COVID-19\nillness can also lead to death. At increased risk of complications that can affect your pregnancy and\ndeveloping baby. For example, COVID-19 during pregnancy increases\nthe risk of delivering a preterm or stillborn infant.","1168":"COVID-19 Community Vulnerability Index (CCVI) scores, which also range from 0 to 1, are from Surgo Ventures . National Immunization Survey\nRace\/ethnicity is not available for some of the records that are directly reported to CDC. Thus, data reported to CDC\nsignificantly underestimate the race\/ethnicity percentages and are not generalizable to the entire population of individuals\nwith COVID-19 vaccination. CDC is providing information on self-reported COVID-19 vaccination status by race\/ethnicity from\n\u2022\n\uf209\n\u2022 \uf209\n\uf209\f10\/30\/22, 9:35 AM COVID-19 Vaccination Data Systems and Data Sources\nthe National Immunization Survey (NIS) Adult COVID Module to supplement vaccine administration data reported directly to\nCDC by jurisdictions and federal entities.","4611":"10\/30\/22, 9:41 AM Interactive Home Ventilation Tool | CDC\nEspa\u00f1ol | Other Languages\nInteractive Home Ventilation Tool\nSmall particles that people breathe out can contain virus particles, including the virus that causes COVID-19. If a guest visits\nyour home, improving ventilation (air flow) can help prevent virus particles from accumulating in the air. Good ventilation,\nalong with other preventive actions, like staying 6 feet apart and correctly wearing masks, can help prevent you from getting\nand spreading COVID-19. \uf5bd We need your feedback! Help us improve this tool by taking a quick survey after using the tool below.","528":"The algorithm used to calculate the age of persons who have received vaccine has been updated to address\nvariability in how jurisdictions report age-related information (e.g., report date of birth, year of birth, age). On March 5, 2021 , doses were removed from the delivered doses totals for Maryland (98,475 doses), Pennsylvania\n(239,900 doses), and Virginia (91,950 doses) because it was determined that the doses, while delivered to federal\nfacilities in those states, were not intended for vaccinating persons living in the region. On February 28, 2021, CDC released an official recommendation to use the J&J\/Janssen COVID-19 vaccine for people ages\n18 and older.","2389":"Fatigue and pain at the injection site were the most\ncommonly reported side effects\u2014and overall, most symptoms were mild and temporary. As with the two-dose primary series, serious side effects are rare, but may occur. What are the risks of vaccinating people who are moderately or severely immunocompromised\nwith a third primary dose? \uf1aa\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\np y y\nFor people who are immunocompromised, the third primary dose is the final dose of the primary series of an mRNA\nCOVID-19 vaccine.","1222":"Graphic: COVID-19 Updated (Bivalent) Booster\nAdministrations in the United States \u2013 October 26, 2022\nFile Details: 1 MB, JPG\nView Image\f10\/30\/22, 9:34 AM COVID-19 Vaccination Data in the United States | CDC\nCOVID-19 Updated (Bivalent) Booster Administrations in the United States \u2013\nPercent and number of people receiving COVID-19 updated (bivalent) boosters by age\nPercent and number of people receiving COVID-19 updated (bivalent) boosters by race\/ethnicity*\nAI\/AN: American Indian\/Alaska Native\nNHOPI: Native Hawaiian and Other Pacific Islanders\n*Among 87% of people with a known Race\/Ethnicity\nPercent and number of people receiving COVID-19 updated (bivalent) boosters by sex**\n**Among 99% of people with known Sex\nImportant considerations\nUpdated (bivalent) booster counts include the number of people administered a vaccine dose with a Covid-19 vaccine\ncode (CVX code) 229 (Moderna ages 6+) or 300 (Pfizer ages 12+) on or after September 1, 2022 or a CVX code 301 (Pfizer\nages 5+) on or after October 12, 2022.","6732":"Children who will turn from 11 years\nto 12 years of age between doses in the primary regimen may receive, for any dose in the primary series,\neither: (1) the Pfizer-BioNTech COVID-19 Vaccine authorized for use in individuals 5 through 11 years of\nage; or (2) COMIRNATY (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine\nauthorized for use in individuals 12 years of age and older.","8186":"\uf426\nFind Out When You Can Get Your Booster\n\u2022\n\u2022\n\u2022\n\u2022\nFor Healthcare Workers: Learn more about COVID-19 vaccine schedules\n\uf2ff\f10\/30\/22, 9:27 AM Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC\nGetting Vaccines If You Had or Currently Have COVID-19\nIf you recently had COVID-19, you may consider delaying your next vaccine dose (whether a primary dose or booster) by 3\nmonths from when your symptoms started or, if you had no symptoms, when you first received a positive test. Reinfection is less likely in the weeks to months after infection.","1872":"National Protocol\nOutcome: Household transmission among community members confirmed with SARS-CoV-2\nPopulation: Households of community members with positive SARS-CoV-2 tests recruited from national commercial\nlaboratories\nExternal partner: Westat\n\uf209 \uf20c\nTest-negative prospective case control\n\uf1aa\nIncreasing Community Access to Testing (ICATT) program\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Anyone seeking testing at a pharmacy\nParticipating sites: 8,319 locations across the United States and its territories\nIVY\nInfluenza and Other Viruses in the Acutely Ill (IVY) network\nOutcome: Hospitalization with SARS-CoV-2\nPopulation: Hospitalized adults\nParticipating Sites: 21 large adult hospitals in 20 cities in 18 states:\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nCalifornia\nColorado\nFlorida\nGeorgia\nIowa\nMaryland\nMassachusetts\nMichigan\nMinnesota\nMissouri\nNew York\nNorth Carolina\nOhio\nOregon\nTennessee\nTexas\nUtah\nWashington\nPReventing Emerging Infections through Vaccine EffectiveNess Testing (PREVENT ) Sites\nOutcome: Symptomatic SARS-CoV-2 infections\nPopulation: Healthcare personnel\nParticipating Sites\nBaystate Medical Center, Springfield, MA\nJackson Memorial Hospital, Miami, FL\nOlive View-UCLA Medical Center, Los Angeles, CA\nThomas Jefferson University Hospital, Philadelphia, PA\nTruman Medical Centers, Kansas City, MO\nUniversity of Alabama Hospital, Birmingham, AL\nCommunity Regional Medical Center\/ UCSF, Fresno, CA\nUniversity of Chicago Medical Center, Chicago, IL\nUniversity of Iowa Hospitals and Clinics, Iowa City, IA\nUniversity of Massachusetts Memorial Medical Center, Worcester, MA\nLCMC Health Hospitals, New Orleans, LA\nUniversity of Mississippi Medical Center, Jackson, MS\nUniversity of Texas Southwestern Medical Center and Parkland Hospital, Dallas, TX\nUniversity of Washington Hospitals, Seattle, WA\nValleywise Health Medical Center, Phoenix, AZ.","4763":"*\nPeople ages 5 years and older who received a COVID-19 vaccine that is FDA-authorized, FDA-approved, or listed for emergency use by WHO\nshould receive 1 bivalent mRNA booster dose. A monovalent Novavax booster dose (instead of a bivalent mRNA booster dose) may be used in limited situations in people ages 18 years and\nolder who have not received any previous booster dose(s). The Novavax booster dose is administered at least 6 months after the last primary\nseries dose.","1029":"Possible treatment may be available for you. \u2022\n\u2022\n\u2022\n\u2022 \uf209\n-\n\uf6ec If Your COVID-19 Test is\nNegative\nA negative COVID-19 test means the test did not detect the virus, but this doesn\u2019t rule out that you could have\nan infection. If you used an antigen test, see FDA instructions on repeat testing . If you have symptoms:\nYou may have COVID-19, but tested before the virus was detectable, or you may have another\nillness. Take general public health precautions to prevent spreading an illness to others. Contact a healthcare provider if you have any questions about your test result or if your symptoms\nworsen.","2150":"To reach MotherToBaby:\nChat live or send an email MotherToBaby\n\u2022\n\u2022 \uf209\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:30 AM COVID-19 Vaccines While Pregnant or Breastfeeding\nSide effects can occur after receiving any of the available COVID-19 vaccines, especially after the second dose for vaccines that\nrequire two doses, or after a booster. People who are pregnant have not reported different side effects from people who are not pregnant after vaccination with\nmRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech vaccines). Fever during pregnancy, for any reason, has been associated with adverse pregnancy outcomes. Fever in pregnancy may be treated with acetaminophen as needed, in moderation, and in consultation with a healthcare\nprovider.","8100":"If you have symptoms, do not\ntravel until you confirm that you do not have monkeypox. \u008f If you have monkeypox and must travel:\n\u00bb Make sure that you do not have fever or respiratory symptoms such as sore\nthroat, nasal congestion, or cough. \u00bb Cover your rash and wear a well-fitting mask. \u00bb Take additional steps to prevent spread to others. \u008f Visit https:\/\/www.cdc.gov\/poxvirus\/monkeypox\/travel\/index.html for the most up to date information. \u0083 Is there a monkeypox vaccine? If so, will everyone need it?","8163":"As with other vaccine-preventable diseases, you are protected best from COVID-19 when you stay up\nto date with the recommended vaccinations, including recommended boosters. Four COVID-19 vaccines are approved or authorized in the United States:\nPfizer-BioNTech\nModerna\nNovavax\nJohnson & Johnson\u2019s Janssen (J&J\/Janssen) (However, CDC recommends that the J&J\/Janssen COVID-19 vaccine only be\nconsidered in certain situations, due to safety concerns.) Updated (Bivalent) Boosters\nThe updated (bivalent) boosters are called \u201cbivalent\u201d because they protect against both the original virus that causes COVID-\n19 and the Omicron variant BA.4 and BA.5. Previous boosters are called \u201cmonovalent\u201d because they were designed to protect against the original virus that causes\nCOVID-19.","2549":"Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine can be\nadministered for the bivalent booster dose, regardless of the primary series product. \u2021 Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic). \u00a7 Administer 1 Pfizer Bio-NTech bivalent booster dose to children age 5 years who have completed a primary series of Moderna COVID-19 vaccine.","2501":"Select a Location (all fields required)\nState County Go\f10\/30\/22, 9:39 AM COVID-19 by County | CDC\nIndividual-Level Prevention Steps You Can Take Based on Your\nCOVID-19 Community Level\nLOW, MEDIUM, AND HIGH\nAt all COVID-19 Community Levels:\nStay up to date on vaccination, including recommended booster doses. Maintain ventilation improvements. Avoid contact with people who have suspected or confirmed COVID-19. Follow recommendations for isolation if you have suspected or confirmed COVID-19. Follow the recommendations for what to do if you are exposed to someone with COVID-19. If you are at high risk of getting very sick, talk with a healthcare provider about additional\nprevention actions.","7798":"\u2022\n\u2022\n\u2022\n\u2022\n\uf6e5 When To Take an At-Home COVID-19 Test\nTest Yourself If\u2026 Timing\nYou have any COVID-19 symptoms Immediately\nYou were exposed to someone with COVID-19 At least 5 days after your exposure\nIf you test negative for COVID-19, consider testing\nagain 1 to 2 days after your first test\nYou are going to an indoor event or a gathering Immediately before the gathering, or as close to\nthe time of the event as possible\nThis is especially important before gathering with\nindividuals at risk of severe disease, older adults,\nthose who are immunocompromised, or people\nwho are not up to date on their COVID-19\nvaccines, including children who cannot get\nvaccinated yet.","5787":"Has the COVID-19 vaccine by Moderna been used before? Yes. Millions of people have received this vaccine in the United States since it became available starting\nDecember 18, 2020. Also, in clinical trials, approximately 15,400 people 18 ages years and older received at\nleast 1 dose of the vaccine and approximately 2,500 people ages 12\u201317 years received a primary series of\nthe vaccine. There have been some studies in people who received the COVID-19 vaccine by Moderna after\ncompleting a primary vaccination with a non-FDA authorized or approved COVID-19 vaccine or Janssen\nCOVID-19 Vaccine. What are the risks of the COVID-19 vaccine by Moderna?","9190":"If you can\u2019t put on a mask (because of trouble\nbreathing, for example), cover your coughs and sneezes in some other way. Try to stay at least 6 feet\naway from other people. This will help protect the people around you. Masks should not be placed on young children under age 2 years, anyone who has trouble breathing, or\nanyone who is not able to remove the mask without help. \u2022\n\u2022\n\u2022\n\u2022\n\uf277 Cover your coughs and sneezes\nCover your mouth and nose with a tissue when you cough or sneeze.","255":"We can also learn if antibodies to SARS-CoV-2 provide the same protection against new variants of the virus that causes\nCOVID-19. Studies show that people who have antibodies from an infection with the virus that causes COVID-19 can improve their\nlevel of protection by getting vaccinated. \uf209\nAntibody quiz\f10\/30\/22, 9:37 AM Antibodies and COVID-19 | CDC\nNow that you\u2019ve learned about antibodies and COVID-19, test your knowledge with an interactive quiz. Test Your Knowledge\nAntibodies for the virus that causes COVID-19 are expected to decrease, or wane, over time. True\nFalse\nNext \uf29e\nLast Updated Nov. 10, 2021","7433":"10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nAll forms of proof of COVID-19 vaccination must have\nPersonal identifiers (full name plus at least one other identifier such as date of birth or passport number) that match the\npersonal identifiers on the passenger\u2019s passport or other travel documents\nName of official source issuing the record (e.g., public health agency, government agency, or other authorized vaccine\nprovider)\nVaccine manufacturer and date(s) of vaccination\nHow the 14 days are calculated:\nYour last dose must have been given a full 14 days before the day you board your flight to the United States.","673":"February 3, 2022: Alaska made updates to data previously submitted to CDC that resulted in a decrease of 3,945\ndoses administered. January 28, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n26,796 doses administered. January 28, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 14,973\ndoses administered.","2831":"There has not been a similar reporting pattern\nobserved after receipt of the Janssen COVID-19 Vaccine (Johnson & Johnson). CDC continues to recommend COVID-19 vaccination for everyone 6 months of age and older. The Advisory Committee on\nImmunization Practices (ACIP) and CDC have determined that the benefits (such as prevention of COVID-19 cases and its\nsevere outcomes) outweigh the risks of myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines. \uf209\f10\/30\/22, 9:16 AM Clinical Considerations: Myocarditis after mRNA COVID-19 Vaccines | CDC\nFor follow-up of patients with myocarditis, consult the guidance from the American Heart Association and American\nCollege of Cardiology .","9581":"Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nEmergency Use Instructions for Healthcare Providers:\nPfizer-BioNTech COVID-19 Vaccine for Primary and\/or Additional Doses\nThe Centers for Disease Control and Prevention (CDC) is issuing Emergency Use Instructions (EUI) to provide\ninformation about the use of the COVID-19 vaccine by Pfizer-BioNTech (Comirnaty), which is approved\n(licensed) by the Food and Drug Administration (FDA) for the prevention of COVID-19 in individuals ages 16\nyears and older.1 The CDC-issued EUI provide information for the use of this vaccine that are beyond the FDA-\napproved labeling.","4982":"New booster recommendation for people ages 12 years and older to receive 1 bivalent mRNA booster after\ncompletion of a monovalent primary series; it replaces all prior booster recommendations for this age group\nRecommendations for use of a bivalent Moderna booster dose in people ages 18 years and older\nRecommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 12 years and older\nUpdated guidance for observation periods following COVID-19 vaccination\nUpdated guidance on COVID-19 vaccination and multisystem inflammatory syndrome (MIS) in children (MIS-C) and in\nadults (MIS-A)\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adolescents ages 12\u201317 years\nReorganization of Janssen COVID-19 Vaccine guidance into an appendix\nUpdated guidance on COVID-19 vaccination following exposure to SARS-CoV-2\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nPrevious Updates\n\uf1aa\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nUpdated guidance on COVID-19 vaccination and myocarditis and pericarditis\nNew clinical considerations for coadministration of mRNA COVID-19 vaccines and orthopoxvirus vaccines\nNew guidance for use of Moderna COVID-19 Vaccine in children and adolescents ages 6\u201317 years\nNew guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children ages 6 months\u20134 years\nNew guidance for use of Moderna COVID-19 Vaccine in children ages 6 months\u20135 years\nReorganization of sections on COVID-19 vaccination recommendations and schedules\nAddition of new section in Special populations for infants and young children\nNew guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5\u201311 years\nUpdated guidance that the following people should receive a second COVID-19 booster dose:\nPeople ages 12 years and older who are moderately or severely immunocompromised\nPeople ages 50 years and older\nUpdated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-\ndepleting therapies\nClarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults\n(MIS-A)\nUpdated guidance for primary series vaccination after SARS-CoV-2 infection\nAdded considerations for the option to receive a second COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 vaccination after SARS-CoV-2 infection\nAdded guidance that people ages 12 years and older who are moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that people ages 18\u201349 years who are not moderately or severely immunocompromised and who\nreceived Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster\ndose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose\nFurther clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C)\nand adults (MIS-A) and myocarditis\nUpdated information on the availability of Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL\ndosage volume) and Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL dosage volume) for\nadministration of a 50 \u00b5g booster dose.","6489":"Be sure to stick\nto your treatment plans, your routine healthcare appointments, and have all your prescriptions filled. Plan for options for\nwork, childcare, and other responsibilities that may cause stress if you were to become sick. COVID-19 remains a major health concern and this can be stressful to manage. Understanding what you can do to protect\nyourself and what to do if you get sick can help minimize that stress. Take as many steps as you can to prevent COVID-19 and\nget treated quickly if you test positive for COVID-19. \uf209\nBuild Your Personal COVID-19 Plan\nMore Information\nWhat Are Monoclonal Antibodies?","6893":"The COVID-19 vaccine by Moderna can also be used under EUI for similar uses as an alternative mRNA\nCOVID-19 vaccine (see the Moderna EUI Fact Sheet for Recipients), and the same or similar\nrecommendations in this EUI also apply to the use of the COVID-19 vaccine by Moderna under EUI. What is COVID-19? Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a coronavirus called SARS-CoV-2. It\nis predominantly a respiratory illness that can affect other organs. People with SARS-CoV-2 infection have\nreported a wide range of symptoms, from no symptoms to severe illness leading to death.","9760":"New evidence suggests that an interval longer than 3 weeks between primary series doses may reduce the risk\nof myocarditis and result in greater immunogenicity and effectiveness, such that there may be greater benefits\nand fewer risks with this dosing interval; however, the benefit of delaying the second dose beyond an interval\nof 8 weeks may be limited. Several studies provide evidence that indicate greater immunogenicity and VE following a longer interval\nbetween the first and second dose of the mRNA primary series.","9972":"Has the person to be vaccinated ever had an allergic reaction to:\n* When vaccine recipients report a history of an immediate allergic reaction, providers should attempt to determine whether reactions reported following\nvaccination are consistent with immediate allergic reactions versus other types of reactions commonly observed following vaccination, such as vasovagal reaction or\npostvaccination side effects (which are not contraindications to receiving additional doses of that vaccine). \u2020 People with a known allergy to polysorbate have a contraindication to both Novavax and Janssen COVID-19 vaccines and a precaution to mRNA COVID-19 vaccines.","6278":"Learn more about mRNA and\u200b viral vector COVID-19 vaccines. MYTH: COVID-19 vaccines can alter my DNA. FACT: COVID-19 vaccines do not change or interact with your DNA in any way. Both messenger RNA (mRNA) and viral vector COVID-19 vaccines work\nby delivering instructions (genetic material) to our cells to start\nbuilding protection against the virus that causes COVID-19. 10\/30\/22, 9:34 AM Myths and Facts about COVID-19 Vaccines | CDC\nAfter the body produces an immune response, it discards all the\nvaccine ingredients just as it would discard any information that cells\nno longer need. This process is a part of normal body functioning.","9662":"People who received both 1 primary dose and 1 booster dose\nof the Janssen COVID-19 Vaccine or 1 primary dose of the Janssen COVID-19 Vaccine followed by 1\nbooster dose of an mRNA COVID-19 vaccine should receive an additional dose with the COVID-19\nvaccine by Pfizer-BioNTech (30 \u03bcg in 0.3 mL) at least 2 months after the booster dose. \u2022 Revaccination with the COVID-19 vaccine by Pfizer-BioNTech for any primary doses received before or\nduring treatment with certain therapies (indicated below).","8782":"Cloth masks should be washed at least once a day or as soon as\nthey become wet or dirty. You can either wash and dry your\nmasks by hand or use a washer and dryer. 2. Wash or sanitize your hands after removing any mask. Taking off your mask while you eat or drink\nIf you are taking off your mask to eat or drink outside of your home, you can place it somewhere safe to keep it clean, such as\nyour pocket, purse, or paper bag. After eating, put the mask back on with the same side facing out.","3607":"Rates per 100,000\nRepresent the rate of total doses distributed, the rate of total doses administered, the rate of people receiving at least\none dose, the rate of people who are fully vaccinated, and the rate of people receiving a booster dose per 100,000. The\nrate per 100,000 people is calculated for the total population and select demographic groups (such as people ages 65\nyears or older) using population data. This allows comparison between areas with different population sizes.","2330":"\u2022\n\u2022\n-\n-\n\u2022\n\u2022\n\u2022 TM\nPre-teens, Teens and Adults Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nAGE GROUP\n18 YEARS AND OLDER\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nModerna\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nJohnson & Johnson's Janssen\n\uf1aa\nPRIMARY SERIES\nADDITIONAL DOSE\nAt least 4 weeks after 1st dose\nand should be Pfizer-BioNTech\nor Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nor last booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nNovavax\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nA monovalent Novavax booster\nis available in limited situations\nMore details: Novavax booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nChildren Ages 6 Months-11 Years Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 8 weeks after 2nd dose\nUp to Date: 2 weeks after 3rd dose in primary series, since a booster is not recommended for this age group at this\ntime\nAGE GROUP\nModerna\n\uf1aa\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nIf you have completed your primary series\u2014but are not yet eligible for a booster\u2014you are also considered up to date.","7288":"This\nwill ensure that you receive the same vaccine when you return for the second dose of\nthe primary series. For more information about IISs visit:\nhttps:\/\/www.cdc.gov\/vaccines\/programs\/iis\/about.html. CAN I BE CHARGED AN ADMINISTRATION FEE FOR RECEIPT OF THESE\nNo. At this time, the provider cannot charge you for a vaccine dose and you cannot be\ncharged an out-of-pocket vaccine administration fee or any other fee if only receiving a\nCOVID-19 vaccination. However, vaccination providers may seek appropriate\nreimbursement from a program or plan that covers COVID-19 vaccine administration\nfees for the vaccine recipient (private insurance, Medicare, Medicaid, Health\nResources & Services Administration [HRSA] COVID-19 Uninsured Program for\nnon-insured recipients).","2343":"AGE GROUP\nPRIMARY SERIES PRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nChildren 5 years of age can get a\nPfizer-BioNTech booster at least\n2 months after their 3rd dose. (Children 6 months to 4 years\nare not recommended for a\nbooster.) Up to Date: Children 6 months to 4 years are up to date two weeks after completing the 3 dose of their primary\nseries. Children 5 years of age who received a Moderna primary series are up to date immediately after they have\nreceived the most recent booster recommended for them.","8714":"10\/30\/22, 9:39 AM Use Masks to Slow the Spread of COVID-19\nEspa\u00f1ol | Other Languages\nMasks\nWear a Mask to Protect Yourself and Others\nMasking is a critical public health tool and it is important to remember that any mask\nis better than no mask. Wear the most protective mask you can that fits well and that you will wear\nconsistently. Wearing a high-quality mask along with vaccination, self-testing, and physical\ndistancing, helps protect you and others by reducing the chance of spreading COVID-\n19.","6571":"Being immunocompromised can make you more likely to get very sick from COVID-19 or be sick for a\nlonger period of time. People who are immunocompromised or are taking medicines that weaken their immune system may not be protected even\nif they are up to date on their vaccines. Talk with your healthcare provider about wearing a mask in a medium COVID-19\nCommunity Level and what additional precautions may be necessary in medium or high COVID-19 Community Levels.","3301":"Rare cases of myocarditis and pericarditis have occurred most frequently, although not exclusively, in adolescent and young\nadult males within the first week after receiving the second dose or a booster dose of an mRNA COVID-19 vaccine. The reporting rates for myocarditis after mRNA COVID-19 primary series vaccination or booster vaccination exceed the\nbackground rates in several age groups in males and females with the highest rates observed in males ages 12\u201339 years; see\nthe June 23, 2022 and September 1, 2022 ACIP meetings for more information.","9937":"Extending\nthe interval between these vaccines dose to 8 weeks might\nreduce the risk. Note: There are some persons the extended interval should not\nbe considered including those who are:\n\u0083 Moderately or severely immunocompromised\n\u0083 Adults ages 65 years and older;\n\u0083 In situations in which there is increased concern about\nCOVID-19 community levels or an individual\u2019s higher risk of\nsevere disease. Additional recipient education materials\fPrevaccination Checklist\nfor COVID-19 Vaccines\nInformation for Healthcare Professionals\n2. Is the person to be vaccinated sick today? People with mild illnesses can be vaccinated. Do not\nwithhold vaccination if a person is taking antibiotics.","3754":"Also updated to indicate the COVID-19 vaccine by Moderna under\nEUI allows similar uses as an alternative mRNA COVID-19 vaccine to Pfizer-BioNTech, removing\nthe restriction of ages 18 years and older on those similar uses.","3372":"Table of Contents \uf426\nCOVID-19 vaccination and SARS-CoV-2 infection\nPeople exposed to SARS-CoV-2\nPeople with prior or current SARS-CoV-2 infection\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nPeople with known current SARS-CoV-2 infection should defer any COVID-19 vaccination, including booster vaccination, at\nleast until recovery from the acute illness (if symptoms were present) and criteria to discontinue isolation have been met. In addition, people who recently had SARS-CoV-2 infection may consider delaying a primary series dose or booster dose by 3\nmonths from symptom onset or positive test (if infection was asymptomatic).","4282":"Biologics or biologic response modifiers that treat autoimmune\u202fdiseases\nChemotherapy or other cancer treatment medications\nAntiviral medication\nAntibiotics\nStatins\nIf you regularly take over-the-counter medications, you should keep taking them before you get\nvaccinated. \uf1aa\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:30 AM Getting Your COVID-19 Vaccine | CDC\nBlood pressure medications\/antihypertensives (amlodipine, lisinopril, etc.) Diuretics\nThyroid medications\nAntidepressants\nMetformin\nDiabetic medications\nInsulin\nSteroids (prednisone, etc.) This is not a complete list. These are some examples of common medications. If you have questions about medications that you are taking, talk to your healthcare or vaccination provider.","2500":"Select a Location (all fields required)\nState County Go\f10\/30\/22, 9:39 AM COVID-19 by County | CDC\nIndividual-Level Prevention Steps You Can Take Based on Your\nCOVID-19 Community Level\nLOW, MEDIUM, AND HIGH\nAt all COVID-19 Community Levels:\nStay up to date on vaccination, including recommended booster doses. Maintain ventilation improvements. Avoid contact with people who have suspected or confirmed COVID-19. Follow recommendations for isolation if you have suspected or confirmed COVID-19. Follow the recommendations for what to do if you are exposed to someone with COVID-19. If you are at high risk of getting very sick, talk with a healthcare provider about additional\nprevention actions.","7166":"Children who\nwill turn from 11 years to 12 years of age between doses in the primary regimen may receive, for any\ndose in the primary regimen, either: (1) the Pfizer-BioNTech COVID-19 Vaccine authorized for use in\nindividuals 5 through 11 years of age; or (2) COMIRNATY (COVID-19 Vaccine, mRNA) or the Pfizer-\nBioNTech COVID-19 Vaccine authorized for use in individuals 12 years of age and older.","9550":"\u0083 A 2-dose primary series using the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 5\u201311 years (orange\ncap and label border)\fSpecial Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nPfizer-BioNTech COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group (Continuted)\nOR\n\u0083 A 3-dose primary series initiated with the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 6 months\u20134\nyears (maroon cap and label border).","8726":"Know the COVID-19 Community Level where you live\nCOVID-19 Community Levels are a tool to help communities decide what prevention steps to take based on the latest data. Masks can help protect you and others from COVID-19. Learn more about different types of masks and respirators and\nhow to get the best fit. At All COVID-19 Community Levels\nPeople may choose to mask at any time. Masks are recommended in indoor public transportation settings\nand may be required in other places by local or state authorities. \u2022\nMedium or High\nIf you are at high risk for getting very sick, wear a high-quality mask or respirator.","5125":"Find a U.S. COVID-19 testing location near you or use a self-test. If you already had COVID-19 within the past 90 days, see specific testing recommendations. \uf209\nCan I travel if ...? I am sick with or tested positive for COVID-19 and\nam recommended to isolate. Do NOT travel. Follow recommendations for isolation. I have ended isolation but still need to continue\nwearing my mask per CDC\u2019s guidance. Do not travel on public transportation such as\nairplanes, buses, and trains if you will not be able\nto wear a high-quality mask or respirator when\naround others indoors for the full duration of your\ntrip.","7982":"Google searches related to the COVID-19 vaccine during\nthis reporting period remained low relative to other topics such as Uvalde, TX, and monkeypox.e According to a Meltwater\ntrends analysis, there was a 17% decrease in news coverage and 45% decrease in social media mentions of COVID-19 vaccines.f\nRecent polling indicates fewer than a third of domestic consumers report being \u201csomewhat\u201d or \u201cvery\u201d worried about contracting\nAdditionally, sources indicate vaccine uptake plateauing,g as of May 31, 2022, COVID Data Tracker reported that 77.9% of\npeople had received at least one shot60 and 66.7% were fully vaccinated.61 Reported intention to vaccinate maintains a similarly\nconsistent cadence since approximately August 2021.c,62,63\nThe FDA64 and CDC65 strengthened recommendations and expansion of booster eligibility.","2393":"Boosters are shots that enhance or restore protection against COVID-19, which may have decreased\nover time. What is the difference between a third primary dose and a booster? \uf1aa\nPeople can stay up to date with COVID-19 vaccination by completing a primary series and receiving the most recent\nbooster dose recommended for them by CDC. The people you live or spend time with can help protect you and\nthemselves by staying up to date on their COVID-19 vaccines too.","4058":"Data show that an mRNA booster increases the immune response, which improves protection against getting a serious\nCOVID-19 infection. CDC recommends COVID-19 vaccines for everyone ages 6 months and older, and boosters for everyone 5 years and\nolder, if eligible. Learn more about COVID-19 vaccine recommendations, including recommendations for people who are moderately or\nseverely immunocompromised. Use CDC\u2019s COVID-19 Booster Tool to learn if and when you can get boosters to stay up to\ndate with your COVID-19 vaccines. Do I need a COVID-19 vaccine booster? \uf1aa\n\uf20c\nYes. COVID-19 vaccines are working well to prevent severe illness, hospitalization, and death.","8046":"On May 17, 2022, the FDA amended the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine, authorizing\na single booster dose for children ages 5-11 years at least five months after completion of a primary series with the same\nvaccine.101 The FDA committee that reviews and evaluates data concerning the safety, effectiveness, and appropriate use of\nvaccines, VRBPAC (Vaccines and Related Biological Products Advisory Committee), meet on June 14\u201315, 2022 to discuss the\nemergency use authorization of COVID-19 vaccines in this age.102 On June 17, 2022, the Advisory Committee on Immunization\nPractices (ACIP) issued interim recommendations for use of the Moderna COVID-19 vaccine in children ages 6 months to 5\nyears and the Pfizer COVID-19 vaccine\nfor use in children ages 6 months to 4\nyears.103 Some parents have expressed\nenthusiasm and relief about childhood\nvaccination.104,105,106 However, a recent\nKaiser Family Foundation (KFF) poll\nfound that only 18% of parents with\nchildren younger than 5 years will get\ntheir child vaccinated right away, while\n38% say they plan to wait and see how\nthe vaccine is working for others, 27%\nsay they will definitely not get their child\nvaccinated, and 11% say they will only do\nso if they are required.107,108\nPerceptions, Concerns, and Threats to Vaccine Confidence\n\u0083 Concerns about side effects, such as myocarditis, may negatively impact vaccine uptake.109,110\n\u0083 Some consumers believe vaccines are unnecessary because COVID-19 rarely affects this group.111,112\n\u0083 Some believe infection-induced immunity protects children better than vaccines.113,114\n\u0083 Some social media users do not think there is enough data to support vaccination against COVID-19 in children.115,116,117\n\u0083 With cases of hepatitis in children rising globally, some believe they are caused by COVID-19 vaccines.118,119,120\n\u0083 Some are concerned that immunity from vaccines decreases rapidly in adolescents.122,123\nCommonly asked questions and queries from the public\n\u0083 Should children under the age of 5 years still wear masks?i\n\u0082 Wearing a well-fitting mask or respirator consistently and correctly reduces the risk of spreading the virus that causes\nCOVID-19.","7148":"VACCINE INFORMATION FACT SHEET FOR RECIPIENTS AND CAREGIVERS\nABOUT COMIRNATY (COVID-19 VACCINE, mRNA), THE PFIZER-BIONTECH\nCOVID-19 VACCINE, AND THE PFIZER-BIONTECH COVID-19 VACCINE,\nBIVALENT (ORIGINAL AND OMICRON BA.4\/BA.5) TO PREVENT CORONAVIRUS\nDISEASE 2019 (COVID-19) FOR USE IN INDIVIDUALS 12 YEARS OF AGE AND\nOLDER\nFOR 12 YEARS OF AGE AND OLDER\nYou are being offered either COMIRNATY (COVID-19 Vaccine, mRNA), the\nPfizer-BioNTech COVID-19 Vaccine, or the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent (Original and Omicron BA.4\/BA.5), hereafter referred to as the\nPfizer-BioNTech COVID-19 Vaccine, Bivalent, to prevent Coronavirus Disease\n2019 (COVID-19) caused by SARS-CoV-2.","6662":"10\/30\/22, 9:39 AM People with Moderate to Severe Asthma | CDC\nEspa\u00f1ol | Other Languages\nPeople with Moderate to Severe Asthma\nThis information is based on what we currently know about the spread and severity of COVID-19. Risk of severe illness from COVID-19\nPeople with moderate-to-severe or uncontrolled asthma are more likely to be hospitalized from COVID-19. Take steps to\nprotect yourself. Vaccine information for COVID-19\nFollow your Asthma Action Plan\nKeep your asthma under control by following your asthma action plan. Avoid your asthma triggers. Continue current medications, including any inhalers with steroids in them (\u201csteroids\u201d is another word for\ncorticosteroids). Know how to use your inhaler.","84":"You should continue to be monitored in a medical facility for at least\nseveral hours.","5176":"More Information\nRequired Proof of COVID-19 Vaccination\nFrequently Asked Questions about Travel and COVID-19\nHealth Information for International Destinations\nDomestic Travel During COVID-19\nUS State Department Travel Site : Safety and security information by country, passport, visas, and entry\/exit\nrequirements\nUS Customs and Border Protection : Information about what you can and cannot bring back from your trip abroad\nUS Embassies : In-country contacts\nTransportation Security Administration (TSA) : Information about flying\n\uf209\n\uf209\n\uf209\n\uf209\nLast Updated Aug. 24, 2022","8290":"10\/30\/22, 9:37 AM Symptoms of COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nSymptoms of COVID-19\nPeople with COVID-19 have had a wide range of symptoms reported \u2013 ranging from mild symptoms to severe illness. Symptoms may appear 2-14 days after exposure to the virus. Anyone can have mild to severe symptoms. This list does not include all possible symptoms. Symptoms may change with new COVID-19 variants and can vary depending\non vaccination status. CDC will continue to update this list as we learn more about COVID-19.","5493":"Studies have shown that some groups of people may be affected more by post-COVID conditions. These are examples\nand not a comprehensive list of people or groups who might be more at risk than other groups for developing post-COVID\nconditions:\nSome people may be more at risk for developing post-COVID conditions (or long COVID). 10\/30\/22, 9:42 AM Long COVID or Post-COVID Conditions | CDC\nPeople who have experienced more severe COVID-19 illness, especially those who were hospitalized or needed intensive\ncare. People who had underlying health conditions prior to COVID-19. People who did not get a COVID-19 vaccine.","5258":"\u2022\nYour symptoms are not improving\nContinue to isolate until:\nYou are fever-free for 24 hours (without the use of\nfever-reducing medication). Your symptoms are improving. \u2022\nModerate illness (you experienced shortness of\nbreath or had difficulty breathing)\nYou need to isolate through day 10. Severe illness (you were hospitalized) or have a\nweakened immune system\nYou need to isolate through day 10. \u2022\f10\/30\/22, 9:41 AM Isolation and Precautions for People with COVID-19 | CDC\nRegardless of when you end isolation\nUntil at least day 11:\nAvoid being around people who are more likely to get very sick from COVID-19.","6065":"The FDA has authorized the Moderna COVID-19 Vaccine, Bivalent (Original and Omicron\nBA.4\/BA.5) and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4\/BA.5) for the\nexpress purpose of improving protection conferred by COVID-19 booster doses against the currently circulating\nOmicron variant of SARS-CoV-2, resulting in a more favorable benefit\/risk balance as compared to the use of\nthe COVID-19 vaccine by Moderna. Consequently, the benefit\/risk balance for the use of the COVID-19 vaccine\nby Moderna for booster dose use is expected to be less favorable compared to the available alternative\nbivalent booster vaccines.","18":"Ask the facility healthcare provider (or facility staff) for help if:\n\u2022 The redness or pain where you got the shot gets worse after 24 hours\n\u2022 Your side effects are worrying you\n\u2022 Your side effects do not seem to be going away after a few days\nIn the rest of your body:\n\u2022 Fever\n\u2022 Chills\n\u2022 Tiredness\n\u2022 Headache\n\u2022 Muscle pain\n\u2022 Nausea\nCOMMON SIDE EFFECTS\nHELPFUL TIPS\nREMEMBER","7521":"Examples include:\nPfizer-BioNTech COVID-19 vaccines (e.g., COMIRNATY,\u202fTozinameran)\nAstraZeneca-Oxford COVID-19 vaccines (e.g.,\u202fCovishield,\u202fVaxzevria)\nModerna\u202fCOVID-19 vaccine (e.g., Takeda,\u202fSpikevax)\nBharat Biotech International COVID-19 Vaccines (e.g., BBV152, COVAXIN)\np p\nAirlines and other aircraft operators must be able to confirm proof of vaccination and review other required information\nand should determine when translation is necessary for these purposes. If your documents are in a language other than\nEnglish, you should check with your airline or aircraft operator before travel. Does my proof of vaccination need to be in English?","7579":"This link will lead you to the relevant embassy or consulate:\nhttps:\/\/www.usembassy.gov\nTo facilitate the review of a humanitarian or emergency exception request, individuals should submit the following\ninformation to the embassy or consulate for transmission to the CDC. All information needs to be completed in full and in\nEnglish for the request to be sent to CDC.","10077":"\u0083 Persons, particularly adolescent or young adult males, might consider waiting 4 weeks after orthopoxvirus (monkeypox) vaccination (either\nJYNNEOS or ACAM2000) before receiving a Moderna, Novavax, or Pfizer-BioNtech COVID-19 vaccine because of the observed risk for myocarditis\nand\/or pericarditis after JYNNEOS. \u0083 Administer each injection in a different injection site. \u2020 See Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States at: www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html#recommendations for detailed\nguidance. \u2021 For booster vaccination, homologous or heterologous mRNA booster is recommended.","9916":"\u25cb Anaphylaxis after non-COVID-19 vaccines or injectable\ntherapies\n\u0083 All other people\nHealthcare professionals should be familiar with identifying severe\nallergic reactions, including anaphylaxis, and be competent in\ntreating these events at the time of vaccine administration. See\nManagement of Anaphylaxis at COVID-19 Vaccination Sites | CDC\nfor guidance. COVID-19 vaccines are administered by IM injection and can be\ngiven at the same clinical visit as other routinely administered\nvaccines using separate injection sites. Other routine vaccines\ncan also be administered any time before or after COVID-19\nvaccination. Orthopoxvirus vaccines (monkey pox) have additional\nconsiderations. See guidance section 8 Clinical Guidance. 1. How old is the person to be vaccinated?","851":"10\/30\/22, 9:41 AM Breastfeeding and Caring for Newborns if You Have COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nBreastfeeding and Caring for Newborns if You Have\nWe still have much to learn about the risks of COVID-19 for newborns of people with COVID-19, however we do know these\nfacts:\nAlthough the absolute risks are low, if you are pregnant or were recently pregnant, you are more likely to get very sick\nfrom COVID-19 compared to people who are not pregnant. Additionally, if you have COVID-19 during pregnancy, you are\nat increased risk of complications that can affect your pregnancy and developing baby.","8442":"10\/30\/22, 9:42 AM Travel | CDC\nEspa\u00f1ol | Other Languages\nTravel\nFind a COVID-19 vaccine or booster near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. Domestic Travel\n\uf698 International Travel\n\uf1c8 Cruise Ship Travel\n\uf4fc\n\uf1c8\nGet Started\nTravel Assessment\nA tool to help you know the requirements to board a flight to the United States. Travel Requirements for Non-U.S. Citizen, Non-U.S. Immigrants\nYou must be fully vaccinated with the primary series of an accepted COVID-19 vaccine to travel to the United States by\nplane. Only limited exceptions apply. For more information, see Requirement for Proof of COVID-19 Vaccination for Air\nPassengers.","3747":"3 The original recommended interval (3 weeks for Pfizer-BioNTech; 4 weeks for Moderna) between the first and\nsecond primary doses remains the recommended interval for: people who are moderately to severely\nimmunocompromised; adults ages 65 years and older; and others who need early protection due to increased\nconcern about community transmission or risk of severe disease.","6304":"Antibody tests\nindicate you had a previous infection and that you may have some\nlevel of protection against the virus. Learn more about the possibility of COVID-19 illness after vaccination. MYTH: Getting a COVID-19 vaccine will cause me to test positive on a viral test. \uf1aa\nFACT: None of the authorized and recommended COVID-19 vaccines can cause you to test positive on viral\ntests, which are used to see if you have a current infection.\u200b\f10\/30\/22, 9:34 AM Myths and Facts about COVID-19 Vaccines | CDC\nRelated Pages\nFrequently Asked Questions about Vaccination\n\u203a\nKey Things to Know about COVID-19 Vaccines\n\u203a\nLast Updated July 20, 2022","2764":"However, there are established ways people can manage the stress associated with a post-COVID condition. Here are some steps you can do to help manage and cope with stress:\nTake breaks from watching, reading, or listening to news stories, including social media. Hearing about the COVID-19\npandemic repeatedly can be upsetting. Take care of your body. Take deep breaths, stretch, meditate , or practice mindfulness . Try to eat healthy, well-balanced meals. Exercise, if you can. Listen to signs from your body. Get plenty of sleep. Avoid alcohol and drugs. Make time to unwind.","1179":"Although Texas still reports vaccination data in\naggregate form, Texas and CDC recently collaborated to update the format of this record submission to improve COVID-19\nreporting of Texas\u2019 data on CDC\u2019s COVID Data Tracker at the national, state, and county levels. Previously, for Texas, CDC estimated the number of people with at least one dose and the number of people who are fully\nvaccinated for the populations ages 12 years or older, 18 years or older, and 65 years or older in the metrics for Texas alone\nand when including Texas in the national level metrics on the\u202fVaccinations in the United States\u202fsite.","689":"January 13, 2022: Colorado made updates to data previously submitted to CDC that resulted in an increase of\n47,260 doses administered. January 13, 2022: North Carolina made updates to data previously submitted to CDC that resulted in an increase of\n41,000 doses administered. January 13, 2022: Hawaii made updates to data previously submitted to CDC that resulted in an increase of 318,481\ndoses administered. January 11, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n31,680 doses administered. January 6, 2022: California updated 22,696,262 records previously submitted to CDC.","4831":"Space repeat dose after the dose given in error by at least\nthe minimum interval (Table 2 and Table 3). Any COVID-19 vaccine dose\nadministered at any interval after the\nrecommended interval\nDo not repeat dose. There is no maximum interval. This deviation from CDC guidance does not require VAERS reporting. Tixagevimab\/cilgavimab (EVUSHELD\u2122)\nadministered less than 14 days after\nIn general, do not repeat vaccine dose. However, based on clinical\njudgement, a repeat dose of vaccine may be administered at an interval\nof at least 28 days after the dose of vaccine.","154":"\u2022\n\u2022\n\u2022\n\u2022\nGuidance is available to protect worker and animal health, developed collaboratively by the U.S. Department of\nAgriculture (USDA), CDC, and state animal and public health partners using a One Health approach:\nPrevent Introduction of SARS-CoV-2 on Mink Farms: Interim SARS-CoV-2 Guidance and Recommendations for Farmed\nMink and Other Mustelids\nResponse and Containment Guidelines: Interim Guidance for Animal Health and Public Health Officials Managing Farmed\nMink and other Farmed Mustelids with SARS-CoV-2\n\uf20c \uf209\n\uf20c \uf209\nResearch on animals and COVID-19\nMany studies have been done to learn more about how this virus can affect different animals, including if they are susceptible\nto infection and if they can spread infection to other animals.","3377":"Studies have shown that increased time\nbetween infection and vaccination may result in an improved immune response to vaccination. Also, a low risk of reinfection\nhas been observed in the weeks to months following infection. Individual factors such as risk of COVID-19 severe disease,\nCOVID-19 community level, or characteristics of the predominant SARS-CoV-2 strain should be taken into account when\ndetermining whether to delay getting a COVID-19 vaccination after infection. Viral testing to assess for acute SARS-CoV-2 infection or serologic testing to assess for prior infection is not recommended for\nthe purpose of vaccine decision-making.","2950":"Currently, a booster dose using any COVID-\n19 vaccine is not authorized for children in this age group. Children age 5 years: A 2-dose primary series and 1 bivalent Pfizer-BioNTech booster dose is recommended. The primary\nseries doses are separated by 3\u20138 weeks and the bivalent booster dose is administered at least 2 months after\ncompletion of the primary series (for people who have not received any booster doses), or at least 2 months after the\nlast monovalent booster dose. Currently, only the bivalent Pfizer-BioNTech booster dose is authorized for children age 5\nyears who receive a Pfizer-BioNTech primary series.","298":"This number\nincludes 152,195 recent and historic doses covering the time period from April 2, 2022 to May 2, 2022. On April 27, 2022, the daily number of vaccine doses administered for Pennsylvania was 254,383 doses. This number\nincludes 235,854 recent and historic second booster doses that were newly reported. On April 21, 2022, the District of Columbia [DC] upgraded its data collection and reporting system. The system upgrade\nmay have resulted in a higher reported count for the total number of people who were fully vaccinated in the district on\nMay 2, 2022.","5659":"What to know about NIOSH-approved respirators\nWhen worn consistently and properly, they provide the highest level of protection from particles, including the\nvirus that causes COVID-19. Additionally, they contain your respiratory droplets and particles so you do not expose\n\uf209\n\u2022\f10\/30\/22, 9:39 AM Masks and Respirators\ny, y y p y p p y p\nothers. They seal tightly to your face when fitted properly. It is important to pick a respirator that fits your face and seals well since not all fit the same. Respirators approved by NIOSH are evaluated against a specific US standard that includes a quality requirement.","6181":"CDC monitors COVID-19 vaccine effectiveness to understand how well the vaccines:\nProtect different age groups, such as children, adolescents, and adults, including adults ages 65 and older\nProtect specific groups, such as people with underlying health conditions or healthcare workers\nProtect against new variants\nLower the risk of infection, including infection without symptoms\nProtect against milder COVID-19 illness\nPrevent more serious outcomes, such as hospitalization or death\nPrevent complications from COVID-19, such as post-COVID conditions and multisystem inflammatory syndrome\n(MIS)\nPrevent spreading COVID-19 to others\nProvide long- and short-term protection\nPerform among people who have received one or more booster doses\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nAssessing How Vaccines Work in the Real World Helps Us:\nAdjust vaccine recommendations,\nas needed, such as booster doses\n\uf263\nGuide vaccine policy and vaccine\ndistribution\n\uf260\nInform development of vaccine\ntechnologies\n\uf33d\nCOVID-19 Vaccines and New Variants of the Virus\f10\/30\/22, 9:33 AM Monitoring COVID-19 Vaccine Effectiveness | CDC\nViruses are constantly changing to create new types of the virus, called variants.","2368":"transplantation or taking immunosuppressive therapy)\nModerate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined\nimmunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)\nAdvanced or untreated HIV infection (people with HIV and CD4 cell counts less than 200\/mm3, history of an AIDS-\ndefining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)\nActive treatment with high-dose corticosteroids (i.e., 20 or more mg of prednisone or equivalent per day when\nadministered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs,\ncancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and\nother biologic agents that are immunosuppressive or immunomodulatory\n\u2022\n\u2022\n\u2022\nIf you are moderately or severely immunocompromised or severely allergic to COVID-19 vaccines, you may be eligible for\npre-exposure prophylaxis with EVUSHELD .","4256":"10\/30\/22, 9:30 AM Getting Your COVID-19 Vaccine | CDC\nEspa\u00f1ol | Other Languages\nGetting Your COVID-19 Vaccine\nEveryone 6 Months and Older Should Get a COVID-19 Vaccine\nCOVID-19 vaccination has many benefits and is an important tool to help protect you from severe illness, hospitalization, and\ndeath. Getting a COVID-19 vaccine after having COVID-19\nEven if you or your child have had COVID-19, you should still get yourself or your child vaccinated. Getting a COVID-19 vaccine after having COVID-19 provides added protection against the virus that causes COVID-19.","832":"Over the ensuing months and in the context of\nupdated vaccine booster recommendations, more than 20 ACIP meetings have publicly reviewed data on vaccine\neffectiveness and have provided real-time data demonstrating COVID-19 vaccines and boosters remain highly protective\nagainst severe illness and death. Importantly, the rates of COVID-19\u2013associated hospitalizations and deaths are substantially\nhigher among unvaccinated adults than among those who have received a primary series and those who are up to date with\nrecommended COVID-19 vaccination, particularly among adults aged \u226565 years.","3726":"\u25aa Updated on February 11, 2022, to allow an additional Pfizer-BioNTech COVID-19 vaccine dose in\npersons ages 18 years and older with certain immunocompromising conditions who received\nprimary vaccination with the Janssen COVID-19 vaccine; revaccination of certain moderately or\nseverely immunocompromised persons ages 12 years and older who received certain therapies\n(i.e., hematopoietic cell transplant (HCT) or chimeric antigen receptor (CAR)-T-cell therapy) and\nreceived COVID-19 vaccine prior to or during treatment; and the ability of healthcare providers\nto administer the Pfizer-BioNTech COVID-19 vaccine outside of the FDA-authorized or FDA-\napproved labeling and CDC recommended dosing intervals based on clinical judgment when the\nbenefits of vaccination are deemed to outweigh the potential and unknown risks.","9344":"This Vaccine Information Fact Sheet for Recipients and Caregivers comprises the Fact\nSheet for the authorized Moderna COVID-19 Vaccine and the authorized Moderna\nCOVID-19 Vaccine, Bivalent for use in individuals 6 years of age and older, and also\nincludes information about the FDA-licensed vaccine, SPIKEVAX (COVID-19 Vaccine,\nmRNA) for use in individuals 12 years of age and older.1\nThe FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and the Moderna COVID-\n19 Vaccine authorized for Emergency Use Authorization (EUA) for individuals 12 years of\nage and older can be used interchangeably, when used according to their respective\ninstructions for use.2\nSPIKEVAX (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made\nby ModernaTX, Inc.","6814":"ARE OTHER CHOICES AVAILABLE FOR PREVENTING COVID-19 BESIDES THE\nPFIZER-BIONTECH COVID-19 VACCINE OR THE PFIZER-BIONTECH COVID-19\nVACCINE, BIVALENT? Other vaccines to prevent COVID-19 may be available under EUA, including bivalent\nvaccines that contain Omicron component of SARS-CoV-2. CAN MY CHILD RECEIVE THE PFIZER-BIONTECH COVID-19 VACCINE OR THE\nPFIZER-BIONTECH COVID-19 VACCINE, BIVALENT AT THE SAME TIME AS\nOTHER VACCINES? Data have not yet been submitted to FDA on administration of the Pfizer-BioNTech\nCOVID-19 Vaccine or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent at the same\ntime with other vaccines.","9909":"Use this guidance with:\n\u0083 Interim Clinical Considerations for Use of COVID-19 Vaccines\nCurrently Approved or Authorized in the United States\n\u0083 Advisory Committee on Immunization Practices on\nImmunization General Best Practice Guidelines\n\u0083 Interim COVID-19 Immunization Schedule for Ages 6 Months\nand Older\n\u0083 COVID-19 Vaccination Clinical & Professional Resources for\neach vaccine product\nConsider the following post-vaccination observation times to monitor for syncope and allergic reactions:\n\u0083 People with a history of:\n\u25cb Allergy-related contraindication to a different type of\n\u25cb Non-severe, immediate (onset within 4 hours) allergic\nreaction after a previous dose of COVID-19 vaccine.","6346":"Everyone likes to be seen on time, but it\u2019s\nimportant to remember that each patient should receive the same attention from the provider once it is their turn. The\nlist below can help you during your appointment. Printable Version: On the Day of Your Appointment | Espa\u00f1ol [PDF \u2013 372 KB]\n\uf189 \uf20c\nBring Your List of Concerns\nSince appointment time is often limited, it will help to make a list of why you are coming in for an appointment. Start\nwith your most concerning issues (sometimes called \u201cchief complaints\u201d).","7980":"Google searches related to the COVID-19 vaccine during\nthis reporting period remained low relative to other topics such as Uvalde, TX, and monkeypox.e According to a Meltwater\ntrends analysis, there was a 17% decrease in news coverage and 45% decrease in social media mentions of COVID-19 vaccines.f\nRecent polling indicates fewer than a third of domestic consumers report being \u201csomewhat\u201d or \u201cvery\u201d worried about contracting\nAdditionally, sources indicate vaccine uptake plateauing,g as of May 31, 2022, COVID Data Tracker reported that 77.9% of\npeople had received at least one shot60 and 66.7% were fully vaccinated.61 Reported intention to vaccinate maintains a similarly\nconsistent cadence since approximately August 2021.c,62,63\nThe FDA64 and CDC65 strengthened recommendations and expansion of booster eligibility.","929":"These timeframes do not apply if\nyou have a severely weakened immune system or were severely ill with COVID-19. Please refer to \u201cQuarantine and Isolation\u201d\nand consult with your health care professional about when it\u2019s safe for you to end your isolation period. Monitor your newborn for COVID-19 symptoms. If your newborn has one or more of these signs or symptoms, they may have early symptoms of COVID-19 or another illness,\nand you should contact your healthcare professional.","1052":"10\/30\/22, 9:42 AM COVID-19 Treatments and Medications | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Treatments and Medications\nThis page provides a treatment overview for the General Public. For healthcare providers: Interim Clinical Considerations for COVID-19 Treatment in Outpatients\nWhat You Need to Know\nIf you test positive for COVID-19 and are more likely to get very sick, treatments are available that can reduce your\nchances of hospitalization and death. Don\u2019t delay: Treatment must be started within days after you first develop symptoms to be effective. Other medications can help reduce symptoms and help you manage your illness.","8847":"Have your\nvaccination record card available to help you remember which vaccine you received and when. Add a Dependent in v-safe\nYou can add any dependent (family member, friend, or individual who relies on you for support) who is vaccinated in v-safe. Children under age 16 years must be added to a parent or guardian\u2019s v-safe account. You can add a dependent to your\nexisting account or create a new account if you don\u2019t have one yet. All v-safe communications will be sent to the parent\u2019s or\nguardian\u2019s smartphone.","6097":"Advisory\nCommittee on Immunization Practices meeting, November 19, 2021:\nDisanto G, Sacco R, Bernasconi, E. Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing\nWith Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis. JAMA Neurology. 2021;78(12):1529-1531. FDA. Fact Sheet for Healthcare Providers Administering Vaccine. Emergency Use Authorization of the Moderna\nCOVID-19 Vaccine to Prevent Coronavirus Disease 2019, Revised January 3, 2022\nGrunau B et al. A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute\nRespiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval. Clin Infect Dis. 2021 Nov 30:\nHaggenburg S, Hofsink Q, Lissenberg-Witte BI, et al.","7120":"Tell them that you are pregnant or were recently pregnant and are having an emergency. Seek medical care immediately if you experience any urgent maternal warning signs and symptoms (for example,\nheadache that won\u2019t go away, dizziness, fever, severe swelling of hand, face, arm or leg, trouble breathing, chest pain or\nfast-beating heart, severe nausea and throwing up, or vaginal bleeding or discharge during or after pregnancy). These\nsymptoms could indicate a potentially life-threatening complication.","4436":"Improving Ventilation and Spending Time Outdoors\nImproving ventilation (moving air into, out of, or within a room) and filtration (trapping particles on a filter to remove\nthem from the air) can help prevent virus particles from accumulating in indoor air. Improving ventilation and filtration\ncan help protect you from getting infected with and spreading the virus that causes COVID-19. Spending time outside\nwhen possible instead of inside can also help: Viral particles spread between people more readily indoors than outdoors. Actions that can improve ventilation and filtration include:\nBringing in as much outdoor air as possible\u2014for example, opening windows.","7191":"COMIRNATY (COVID-19 Vaccine, mRNA) and the Pfizer-BioNTech COVID-19\nVaccine, when prepared according to their respective instructions for use, can be used\ninterchangeably. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is made in the\nsame way as COMIRNATY and Pfizer-BioNTech COVID-19 Vaccine but it also\n3 Monovalent refers to any authorized or approved COVID-19 vaccine that contains or encodes the spike protein\nof only the Original SARS-CoV-2. contains an Omicron component to help prevent COVID-19 caused by the Omicron\nvariant of SARS-CoV-2. For more information on EUA, see the \u201cWhat is an Emergency Use Authorization\n(EUA)?\u201d section at the end of this Fact Sheet.","9186":"If you can\u2019t put on a mask (because of trouble\nbreathing, for example), cover your coughs and sneezes in some other way. Try to stay at least 6 feet\naway from other people. This will help protect the people around you. Masks should not be placed on young children under age 2 years, anyone who has trouble breathing, or\nanyone who is not able to remove the mask without help. \u2022\n\u2022\n\u2022\n\u2022\n\uf277 Cover your coughs and sneezes\nCover your mouth and nose with a tissue when you cough or sneeze.","8523":"What contact information am I required to provide to airlines and aircraft operators before I board\na flight to the United States? \uf1aa\nUnder current federal regulations, pilots must report all illnesses and deaths to CDC before arriving to a U.S. destination. According to CDC protocols, if a sick traveler has a contagious disease that is a risk to others on board the airplane, CDC\nworks with local and state health departments and international public health agencies to contact exposed passengers\nand crew.","7147":"Clin\nWoodworth KR, Olsen EO, Neelam V, et al. Birth and Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2\nInfection in Pregnancy \u2014 SET-NET, 16 Jurisdictions, March 29\u2013October 14, 2020. MMWR Morb Mortal Wkly Rep\nDeSisto CL, WallaceB, Simeone RM, et al. Risk for Stillbirth Among Women With and Without COVID-19 at Delivery\nHospitalization \u2014 United States, March 2020\u2013September 2021. MMWR Morb Mortal Wkly Rep 2021;70:1640-1645. More Information\nUrgent Maternal Warning Signs\n\uf209\n\uf209\n\uf209\nLast Updated Oct. 25, 2022","8095":"\u0082 Other symptoms of monkeypox can include:\n\u008f Fever\n\u008f Chills\n\u008f Swollen lymph nodes\n\u008f Exhaustion\n\u008f Muscle aches and backache\n\u008f Headache\n\u008f Respiratory symptoms (e.g., sore throat, nasal congestion, or cough)\n\u0082 You may experience all or only a few symptoms\n\u008f Sometimes people have flu-like symptoms before the rash. \u008f Some people get a rash first, followed by other symptoms. \u008f Others only experience a rash.138\n\u0083 Are there any travel restrictions due to monkeypox? d\n\u0082 Recommendation for travelers:139\n\u008f If you have monkeypox symptoms or had close contact with someone who\nhas monkeypox, talk to your healthcare provider.","7317":"Ongoing studies of COVID-19 are\nhelping us understand:\nHow often reinfections occur\nWho is at higher risk of reinfection\nHow soon reinfections take place after a previous infection\nThe severity (how serious the infection is) of reinfections compared with initial (the first) infections\nThe risk of transmission to others after reinfection\nWhat CDC is doing\nCDC continues to work to better understand reinfections with COVID-19 to inform public health action. CDC is using a range\nof data sources to assess how often reinfections occur, who is most at risk for reinfection, and the risk of reinfection when\nthere is community spread of Omicron or other virus variants.","768":"Most people with COVID-19 have mild symptoms, but some people become severely ill. Some people including those with minor or no symptoms may suffer from post-COVID conditions \u2014 or \u201clong COVID\u201d. Older adults and people who have certain underlying medical conditions are at increased risk of severe illness from\nCOVID-19. Hundreds of thousands of people have died from COVID-19 in the United States. Vaccines against COVID-19 are safe and effective. Vaccines teach our immune system to fight the virus that causes\nCOVID-19. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\nAbout SARS-CoV-2, the virus that causes COVID-19\nCOVID-19 is caused by a virus called SARS-CoV-2.","2761":"However, there are established ways people can manage the stress associated with a post-COVID condition. Here are some steps you can do to help manage and cope with stress:\nTake breaks from watching, reading, or listening to news stories, including social media. Hearing about the COVID-19\npandemic repeatedly can be upsetting. Take care of your body. Take deep breaths, stretch, meditate , or practice mindfulness . Try to eat healthy, well-balanced meals. Exercise, if you can. Listen to signs from your body. Get plenty of sleep. Avoid alcohol and drugs. Make time to unwind.","3169":"Primary series\nIn general, the same monovalent vaccine product should be used for all doses in the primary series. A mixed primary series composed of any combination of Moderna, Novavax, and Pfizer-BioNTechCOVID-19 vaccines is not\nauthorized. If a mixed primary series is inadvertently administered, the series is complete, and doses do not need to be\nrepeated. In the following exceptional situations, a different COVID-19 vaccine may be administered to complete a primary series at a\nminimum interval of 28 days from the last COVID-19 vaccine dose. No VAERS report is required.","8125":"\u0083 Utilize proper risk communication strategies when communicating about monkeypox, including creating tailored, effective\ncommunication with trusted messengers that explain both what is known and what is not known about the spread and\noutcomes of monkeypox infection.151\n\u0083 Create and disseminate graphics through trusted messengers that show the difference in the structure of the virus particles\nand virions for the virus that causes monkeypox and the virus that causes COVID-19.","9507":"In addition, the FDA decision is based on the totality of the\nscientific evidence available showing that the product may be effective to prevent COVID-19\nduring the COVID-19 pandemic and that the known and potential benefits of the product\noutweigh the known and potential risks of the product. All of these criteria must be met to allow\nfor the product to be used during the COVID-19 pandemic. An EUA is in effect for the duration of the COVID-19 EUA declaration justifying emergency\nuse of this product, unless terminated or revoked (after which the product may no longer be\nused).","8650":"\u2022\n\u2022\n\u2022\nInitial Development\n\uf1aa\n\uf33d New vaccines are first developed in laboratories. Scientists have been working for many years to develop\nvaccines against coronaviruses, such as those that cause severe acute respiratory syndrome (SARS) and\nMiddle East respiratory syndrome (MERS). SARS-CoV-2, the virus that causes COVID-19, is related to these\nother coronaviruses. The knowledge that was gained through past research on coronavirus vaccines\nhelped speed up the initial development of the current COVID-19 vaccines. Clinical Trials\n\uf1aa\n\uf3ba After initial laboratory development, vaccines go through three phases of clinical trials to make sure they\nare safe and effective. No trial phases have been skipped.","1230":"\u200b\nSources: 2019 U.S. Census Estimates (states, D.C., Puerto Rico) and 2020 U.S. Census Estimates (territories excluding Puerto\nRico) used for population counts (ages 5 years and older), CDC Immunizations Data Lake. Data as of 6 AM ET Wednesday\nAI\/AN, Non-\nHispanic\nAsian, Non-\nHispanic\nBlack, Non-\nHispanic\nHispanic \/\nLatino\nMultiracial,\nNon-\nHispanic\nNHOPI,\nNon-\nHispanic\nWhite, Non-\nHispanic\nMale Female\n\u2022\n\u2022\n\u2022\n\uf2ff For Healthcare and Public Health\nCOVIDVaxView: Data about Vaccination Uptake and Confidence\nCOVID 19 Information for Health Departments\f10\/30\/22, 9:34 AM COVID-19 Vaccination Data in the United States | CDC\nCOVID-19 Information for Health Departments\nLast Updated Oct. 28, 2022","2545":"Booster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 2 to 3 At least 8 weeks (2 months)\n* Guidance related to special situations when vaccinating children, such as those who have a birthday before completing the primary series or booster dose, see Special Situations for COVID-19\nVaccination of Children and Adolescents\n\u2020 Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate\nmonovalent COVID-19 vaccine may be administered at least 28 days after the first dose to complete the primary series.","4503":"Additional Resources\nCOVID-19 Community Levels\nScience Brief: SARS-CoV-2 Transmission\nScience Brief: Indicators for Monitoring COVID-19 Community Levels and Making Public Health Recommendations\nScience Brief: Community Use of Masks to Control the Spread of SARS-CoV-2\nScience Brief: COVID-19 Vaccines and Vaccination\nLast Updated Oct. 19, 2022","842":"COVID-19 vaccines were developed using science that has been around for decades. Before COVID-19 vaccines were recommended, scientists conducted clinical trials with thousands of children and adults\nand found no serious safety concerns. Hundreds of millions of people in the United States have received COVID-19 vaccines under the most intensive safety\nmonitoring program in U.S. history. Serious side effects that could cause a long-term health problem are rare following any vaccination, including COVID-19\nvaccination. The benefits of COVID-19 vaccination outweigh the known and potential risks. More information on why children and teens should get vaccinated against COVID-19.","4919":"Ability of the patient to be vaccinated in a setting where appropriate medical care is immediately available for anaphylaxis. For people\nwith a contraindication due to allergy to one type of COVID-19 vaccine who are receiving another type that has been deemed a precaution\nand for people with an immediate, non-severe allergic reaction after a previous dose of COVID-19 vaccine who are receiving vaccination\nwith a subsequent dose of that COVID-19 vaccine type, vaccination should only be undertaken in an appropriate setting under the\nsupervision of a healthcare professional experienced in the management of severe allergic reactions.","4696":"These people are recommended to receive a bivalent mRNA\nbooster dose at least 2 months following their dose of Janssen COVID-19 Vaccine and after their clinical condition has\nstabilized. Prior to booster vaccination, a conversation between the patient and their clinical team, including a hematologist or\nother specialists, may assist with decisions about using an mRNA COVID-19 vaccine as a booster and the timing of the booster\nvaccination.","8293":"Older adults and people who\nhave underlying medical conditions like heart or lung disease or diabetes are at higher risk for getting very sick from COVID-\n19. Possible symptoms include:\nFever or chills\nCough\nShortness of breath or difficulty breathing\nFatigue\nMuscle or body aches\nHeadache\nNew loss of taste or smell\nSore throat\nCongestion or runny nose\nNausea or vomiting\nDiarrhea\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nFeeling Sick?","4141":"\uf1aa\nThe COVID-19 vaccines for children have the same active ingredients as the vaccines given to adults. However, children\nreceive a smaller and more age-appropriate dose that is right for them. The smaller doses were rigorously tested and\nfound to create the needed immune response for each age group. Making it important for our child to get the vaccine\nmade for their age group. Are the COVID-19 vaccines for children the same ones that are given to adults? \uf1aa\nSafety\nAlthough COVID-19 vaccines were developed quickly, research and development on vaccines like these have been\nunderway for decades.","1200":"Beginning October 22, 2021, CDC is able to attribute non-residents of Texas to their respective state or territory of\nresidence. Texas residents who received a COVID-19 vaccination in a different state or territory are also now attributed\nto Texas\u2019 population-based metrics. Beginning November 18, the\u202fVaccination Demographics and\u202fDemographic Trends\u202fsites include vaccination demographic\ninformation from Texas. New Hampshire\u202flifted its national COVID-19 emergency response declaration in May 2021, which allows vaccine recipients to\nopt out of having their COVID-19 vaccinations included in the state\u2019s IIS. As such, data submitted by New Hampshire since May\n2021 may not be representative of all COVID-19 vaccinations occurring in the state.","9565":"Either dose may be:\n\u0083 0.20 mL (10 mcg) of the product authorized for children ages 5\u201311 years (orange cap and label border), or\n\u0083 0.30 mL (30 mcg) of the product authorized for children ages 12\u201317 years (gray cap and label border)\nOR 3-8 weeks\nOR\fSpecial Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nInterchangeability of Moderna and Pfizer-BioNTech COVID-19 vaccines\nCOVID-19 vaccine from the same manufacturer should be used for the primary series.","10110":"These people should receive an\nmRNA or Novavax COVID-19 vaccine booster dose. \u00b6 People with a known allergy to polysorbate have a contraindication to both Novavax ad Janssen COVID-19 vaccines. ** People who develop GBS within 6 weeks after receipt of Janssen COVID-19 Vaccine should not receive another dose of Janssen COVID-19 Vaccine. These people should receive a booster dose of an mRNA COVID-19 vaccine for subsequent doses.","4409":"| CDC\n\uf263 Learn About Getting Your Vaccine\nDo you need to wait to get vaccinated after getting COVID-19 or getting treatment for COVID-19? How can you prepare for vaccination? What can you expect during and after your vaccination? Getting Your COVID-19 Vaccine\n\u2022\n\u2022\n\u2022\nResources\nRelated Pages\nSafety of COVID-19 Vaccines\n\u203a\nStay Up to Date with Your Vaccines\n\u203a\nLast Updated Sept. 15, 2022","2421":"Evidence continues to grow showing that COVID-19 vaccination is safe and effective during pregnancy\n\uf209\n\uf209\n\u2022\f10\/30\/22, 9:29 AM COVID-19 Vaccines for People Who Would Like to Have a Baby | CDC\nassisted reproductive technology procedures (e.g., in vitro fertilization). A study of more than 2,000 females aged 21-45 years and their partners found that COVID-19 vaccination of either\npartner did not affect the likelihood of becoming pregnant. Like with all vaccines, scientists continue to study COVID-19 vaccines carefully and will continue to report findings as they\nbecome available.","2895":"There is currently no FDA-approved or FDA-authorized COVID-19 vaccine for children younger than age 6 months. People can stay up to date with COVID-19 vaccination by completing a primary series and receiving the most recent booster\ndose recommended for them by CDC (see Box, Table 2 and Table 3). See Appendices B (People who received COVID-19 vaccine outside the United States) and C (People who received COVID-19\nvaccine as part of a clinical trial) for recommendations for these populations. Primary series vaccination\nFor primary series vaccination, three monovalent COVID-19 vaccines (listed in alphabetical order by manufacturer), are\nrecommended: Moderna, Novavax, and Pfizer-BioNTech.","8096":"\u0082 Other symptoms of monkeypox can include:\n\u008f Fever\n\u008f Chills\n\u008f Swollen lymph nodes\n\u008f Exhaustion\n\u008f Muscle aches and backache\n\u008f Headache\n\u008f Respiratory symptoms (e.g., sore throat, nasal congestion, or cough)\n\u0082 You may experience all or only a few symptoms\n\u008f Sometimes people have flu-like symptoms before the rash. \u008f Some people get a rash first, followed by other symptoms. \u008f Others only experience a rash.138\n\u0083 Are there any travel restrictions due to monkeypox? d\n\u0082 Recommendation for travelers:139\n\u008f If you have monkeypox symptoms or had close contact with someone who\nhas monkeypox, talk to your healthcare provider.","3781":"10\/30\/22, 9:31 AM Ensuring COVID-19 Vaccine Safety in the US | CDC\nEspa\u00f1ol | Other Languages\nEnsuring COVID-19 Vaccine Safety in the US\nVaccine Safety and Monitoring\nCOVID-19 vaccines were developed using science that has been around for decades. COVID-19 vaccines are safe, and meet the Food and Drug Administration\u2019s (FDA\u2019s)\nrigorous scientific standards for safety, effectiveness, and manufacturing quality. COVID 19-vaccines are effective at preventing severe illness from COVID-19 and\nlimiting the spread of the virus that causes it. Millions of people in the United States have received COVID-19 vaccines. COVID-19 vaccines are monitored by the most intense safety monitoring efforts in\nU.S. history.","2767":"However, there are established ways people can manage the stress associated with a post-COVID condition. Here are some steps you can do to help manage and cope with stress:\nTake breaks from watching, reading, or listening to news stories, including social media. Hearing about the COVID-19\npandemic repeatedly can be upsetting. Take care of your body. Take deep breaths, stretch, meditate , or practice mindfulness . Try to eat healthy, well-balanced meals. Exercise, if you can. Listen to signs from your body. Get plenty of sleep. Avoid alcohol and drugs. Make time to unwind.","4854":"Diluent (Pfizer-BioNTech\nthat should not be mixed\nwith diluent, i.e., gray\ncap)\nVaccine is mixed with any diluent (i.e.,\nany type or volume of diluent)\nContact the manufacturer for information on the stability of the\nvaccine. If the manufacturer does not have information to support the\nstability of the vaccine, repeat the dose immediately (no minimum\ninterval). Do not administer the second dose until the person becomes eligible to receive vaccination (either by reaching the authorized age or if the\nauthorization is extended to include additional age groups), even if this results in the second dose being administered after the recommended\ninterval between doses.","667":"February 11, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n14,616 doses administered\nFebruary 9, 2022: Utah made updates to data previously submitted to CDC that resulted in an increase of 73,002\ndoses administered. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nFebruary 4, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 75,630\ndoses administered. February 4, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n32,976 doses administered.","9173":"If someone is showing any of these signs, seek\nemergency medical care immediately:\nTrouble breathing\nPersistent pain or pressure in the chest\nNew confusion\nInability to wake or stay awake\nPale, gray, or blue-colored skin, lips, or nail beds, depending on skin tone\n*This list is not all possible symptoms. Please call your medical provider for any other symptoms that are\nsevere or concerning to you. Call 911 or call ahead to your local emergency facility: Notify the operator that you are seeking care for\nsomeone who has or may have COVID-19. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\uf33f Call ahead before visiting your doctor\nCall ahead.","2372":"EVUSHELD is a medicine given every six months by your healthcare\nprovider to help prevent you from getting COVID-19. EVUSHELD may offer less protection against three strains (BA.4.6,\nBF.7, and BA.2.75.2) of the Omicron variant. It is important to use multiple prevention measures and talk to your\nhealthcare provider to find out if EVUSHELD is right for you. TM TM\nTM\nTM\nDownload: EVUSHELD EUA Fact Sheet for Patients, Parents and Caregivers\nTM \uf209\nFrequently Asked Questions\nNo, vaccines used for the primary vaccination series should be the same product or brand.","10114":"Summary Document for\nInterim Clinical Considerations\nfor Use of COVID-19 Vaccines Currently Authorized or Approved in the United States\nConsiderations for all FDA-authorized or -approved COVID-19 vaccines\nPersons with history of multisystem\ninflammatory syndrome (MIS-C and\nMIS-A) from SARS-CoV-2 infection\n\u0083 COVID-19 vaccines can be given; wait until clinical recovery and at least 90 days after an MIS-C or MIS-A diagnosis.","8683":"10\/30\/22, 9:38 AM Understanding Risk | CDC\nEspa\u00f1ol | Other Languages\nUnderstanding Risk\nCOVID-19 can affect anyone, and the disease can cause symptoms ranging from mild to very severe. We know that certain\nthings can make people more likely to get very sick with COVID-19. We also know that certain settings and activities can make\nyou more likely to get infected with the virus that causes COVID-19. Understanding Your Risk Helps You Make Decisions\nUnderstanding the risk of COVID-19 for yourself and those around you can help you make informed decisions to keep\nyou safe and healthy.","5263":"Remember to wear a high-quality mask when indoors around others at home and in public. Do not go places where you are unable to wear a mask until you are able to discontinue masking (see below). For travel guidance, see CDC\u2019s Travel webpage. Consult your doctor before ending isolation. Ending isolation without a viral test may not be an\noption for you. \u2022\n\u2022\nIf you are unsure if your symptoms are moderate or severe or if you have a weakened immune system, talk to a\nhealthcare provider for further guidance.","5895":"\u25aa Received COVID-19 vaccine dose(s) during treatment with B-cell-depleting therapies\nover a limited period\n\u25aa Received COVID-19 vaccine dose(s) prior to or during treatment involving HCT or CAR-\nT-cell therapy\nWhat are the doses and intervals of the COVID-19 vaccine by Moderna for primary and\/or additional doses? \u2022 A second primary dose of the COVID-19 vaccine by Moderna (100 \u03bcg in 0.5 mL from red-capped\nmultidose vial) should be administered intramuscularly to persons ages 12 years and older; this may be\n4\u20138 weeks after the first primary dose.","5111":"Follow all requirements of transportation operators (such as airlines, cruise lines, buses) and any requirements,\nincluding mask wearing proof of vaccination or testing at your destination\n\uf1c8\nGet Started\nTravel Assessment\nA tool to help you know the requirements to board a flight to the United States. Land Travel\nFor information about COVID-19 requirements for land travel and at ferry terminals, visit the U.S. Department of\nHomeland Security\u2019s Fact Sheet: Guidance for Travelers to Enter the U.S. at Land Ports of Entry and Ferry Terminals.","9570":"If a different manufacturer is\nadministered, follow the guidance below:\n\u0083 If a dose of the age-appropriate product from BOTH\nModerna and Pfizer-BioNTech COVID-19 is given, count\nboth doses if the recommended interval between doses\nhas been met. \u25cb If ages 6 months through 4 years, complete the series\nfollowing the Pfizer-BioNTech 3-dose schedule using\nan age-appropriate vaccine from either manufacturer. See examples. \u25cb Repeating doses is not recommended. \u0083 This guidance applies to:\n\u25cb All eligible children, including those who are\nmoderately or severely immunocompromised. \u25cb Vaccines from both manufacturers, regardless which\nvaccine was given first. Examples:\nVaccination history: 1 dose of Pfizer-BioNTech and 1 dose of Moderna COVID-19 vaccines.","5864":"2 A non-FDA authorized or approved COVID-19 vaccine that is listed for emergency use by the World Health Organization, or is included in CDC\u2019s\nTechnical Instructions for Implementing Presidential Proclamation Advancing Safe Resumption of Global Travel During the COVID-19 Pandemic and\nCDC\u2019s Order, or that is a non-placebo part of a clinical trial within or outside the United States that is a WHO-EUL COVID-19 vaccine or a vaccine that is\nnot listed for emergency use by WHO but for which a U.S. data and safety monitoring board or equivalent has independently confirmed efficacy in the\nUnited States (hereinafter \u201cnon-FDA authorized or approved COVID-19 vaccines\u201d).","3346":"Considerations for subsequent COVID-19 vaccination may include:\n\uf20c\n\uf20c\n\uf20c\nNovavax COVID-19 Vaccine\nConsiderations for COVID-19 vaccination\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nThe myocarditis or pericarditis was considered unrelated to vaccination with Moderna, Novavax, or Pfizer-BioNTech (e.g.,\ndue to SARS-CoV-2 or other viruses), especially if the myocarditis or pericarditis diagnosis occurred more than 3 weeks\nafter the most recent dose of COVID-19 vaccine\nPersonal risk of severe acute COVID-19 (e.g., age, underlying conditions)\nTiming of any immunomodulatory therapies; ACIP\u2019s general best practice guidelines for immunization can be consulted\nfor more information\nFor myocarditis associated with MIS-C or MIS-A, see COVID-19 vaccination and MIS-C and MIS-A.","4191":"However, staying up to date with your COVID-19\nvaccinations means that you are less likely to have a breakthrough infection and, if you do get sick, you are less likely to\nget severely ill or die. Staying up to date with COVID-19 vaccination also means you are less likely to spread the disease to\nothers and increases your protection against new variants of SARS-CoV-2, the virus that causes COVID-19. Why should I get vaccinated if I might get COVID-19 anyway? \uf1aa\nThere is no recommended waiting period between getting a COVID-19 vaccine and other vaccines.","6631":"It is also important for people with medical conditions and their healthcare providers to work together and manage\nthose conditions carefully and safely. Stay up to date with your COVID-19 vaccines. If you have a medical condition, the\nfollowing are actions you can take based on your medical conditions and other risk factors. Seek care when needed\nCall your healthcare provider if you have any concerns about your medical conditions or if you get sick and think that you\nmay have COVID-19. Discuss steps you can take to manage your health and risks. If you need emergency help, call 911\nright away.","7133":"Related Pages\nCOVID-19 Toolkit for Pregnant People and New Parents\n\u203a\nCOVID-19 Vaccines While Pregnant or Breastfeeding\n\u203a\nBreastfeeding and Caring for Newborns if You Have COVID-19\n\u203a\nHow to Protect Yourself and Others\n\u203a\f10\/30\/22, 9:39 AM Pregnant and Recently Pregnant People | CDC\nWhat to Do If You Are Sick\n\u203a\nRelated Research and More Information\nRelated Research\nZambrano LD, Ellington S, Strid P, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with\nLaboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status \u2014 United States, January 22\u2013October 3, 2020. MMWR\nMorb Mortal Wkly Rep 2020;69:1641\u20131647. DOI: 10.15585\/mmwr.mm6944e3.","5312":"FDA has authorized the emergency use of the Janssen COVID-19 Vaccine in individuals 18 years\nof age and older for whom other FDA-authorized or approved COVID-19 vaccines are not\naccessible or clinically appropriate, and in individuals 18 years of age and older who elect to\nreceive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19\nvaccine. WHO SHOULD NOT GET THE JANSSEN COVID-19 VACCINE? You should not get the Janssen COVID-19 Vaccine if you:\n\u2022 had a severe allergic reaction after a previous dose of this vaccine. \u2022 had a severe allergic reaction to any ingredient of this vaccine.","3219":"Procedures should be in\nplace to prevent falling injuries and manage syncopal reactions. Patients should be seated or lying down during vaccination. Vaccination providers, particularly when vaccinating adolescents, should consider observing vaccine recipients for 15 minutes\nafter vaccination. If syncope develops, patients should be observed until symptoms resolve.","5772":"You should not get the vaccine if you:\n\u2022 Had a severe allergic reaction after a previous dose of the COVID-19 vaccine by Moderna\n\u2022 Had a severe allergic reaction to any ingredient of the COVID-19 vaccine by Moderna\nWhat should I mention to the vaccination provider before getting the COVID-19 vaccine by Moderna? Tell your vaccination provider the name, number of doses, and date(s) of COVID-19 vaccine(s) you received\npreviously.","1716":"Preserve all records related to COVID-19 vaccine management for a minimum of three years, or longer as required\nby the agreement or law of the jurisdiction. Comply with CDC instructions and timelines for disposing of COVID-19 vaccine and diluent, including used doses. Find detailed information regarding COVID-19 Vaccine storage and handling requirements at CDC Vaccine Storage and\nHandling Toolkit. (https:\/\/vaers.hhs.gov\/reportevent.html )\nThe Vaccine Adverse Event Reporting System (VAERS) is a national early warning system to detect possible safety\nproblems in vaccines used in the United States. VAERS accepts and analyzes reports of adverse events (AEs) after a\nperson has received a vaccination.","2129":"Therefore, limited data are available on the\nSafety of COVID-19 vaccines in people who are breastfeeding\nEffects of vaccination on the breastfed baby, and\nEffects on milk production or excretion\nAvailable data on safety of COVID-19 vaccination while breastfeeding indicate no severe reactions after the first or second\ndose, neither in the breastfeeding person not the breastfed child. There has been no evidence to suggest that COVID-19\nvaccines are harmful to either people who have received a vaccine and are breastfeeding or to their babies. COVID-19 vaccines cannot cause COVID-19 in anyone, including pregnant people and their babies. None of the COVID-19\nvaccines contain live virus.","9294":"In addition,\nHispanic or Latino and non-Hispanic Black children are disproportionately affected by MIS-C.\nCOVID-19 vaccination reduced the likelihood of MIS-C in children ages 12 through 18 years by 91%. Data from July to\nDecember 2021 show that 95% of children ages 12 through 18 years hospitalized with MIS-C were not vaccinated. CDC is\ncollecting data on how well COVID-19 vaccination works against MIS-C in younger children. As more children under 12\nyears old get vaccinated, CDC will be able to analyze and share those data.","2892":"There is currently no FDA-approved or FDA-authorized COVID-19 vaccine for children younger than age 6 months. People can stay up to date with COVID-19 vaccination by completing a primary series and receiving the most recent booster\ndose recommended for them by CDC (see Box, Table 2 and Table 3). See Appendices B (People who received COVID-19 vaccine outside the United States) and C (People who received COVID-19\nvaccine as part of a clinical trial) for recommendations for these populations. Primary series vaccination\nFor primary series vaccination, three monovalent COVID-19 vaccines (listed in alphabetical order by manufacturer), are\nrecommended: Moderna, Novavax, and Pfizer-BioNTech.","4469":"\u2022 \uf209\n\u2022\n\uf209\n\u2022 \uf209\f10\/30\/22, 9:39 AM How to Protect Yourself and Others | CDC\nFollowing Recommendations for What to Do If You Have Been Exposed\nIf you were exposed to someone with\nCOVID-19, you may have been infected\nwith the virus. Follow CDC\u2019s\nrecommendations for what to do if you\nwere exposed. This includes wearing a\nhigh-quality mask when indoors\naround others (including inside your\nhome) for 10 days, testing, and\nmonitoring yourself for symptoms. Staying Home When You Have Suspected or Confirmed COVID-19\nIf you have COVID-19, you can spread it to others, even if you do not have symptoms.","9576":"Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nEmergency Use Instructions for Healthcare Providers:\nPfizer-BioNTech COVID-19 Vaccine for Primary and\/or Additional Doses\nThe Centers for Disease Control and Prevention (CDC) is issuing Emergency Use Instructions (EUI) to provide\ninformation about the use of the COVID-19 vaccine by Pfizer-BioNTech (Comirnaty), which is approved\n(licensed) by the Food and Drug Administration (FDA) for the prevention of COVID-19 in individuals ages 16\nyears and older.1 The CDC-issued EUI provide information for the use of this vaccine that are beyond the FDA-\napproved labeling.","4146":"All vaccine development steps were taken to ensure COVID-19 vaccine safety and effectiveness,\nAre COVID-19 vaccines safe even though the vaccines were developed rapidly? \uf1aa\f10\/30\/22, 9:18 AM Frequently Asked Questions about COVID-19 Vaccination | CDC\ny p p y ,\nincluding:\nClinical Trials \u2013 All vaccines in the United States must go through three phases of clinical trials to ensure they are\nsafe and effective. The phases overlapped to speed up the process, but all phases were completed. Authorization or Approval \u2013 Before vaccines are available to people, the U.S. Food and Drug Administration (FDA)\nreviews data from clinical trials.","2063":"\u2022\n-\n-\n-\n\u2022\n-\n-\nPeople who are Pregnant\nAlthough the overall risks are low, if you are pregnant or were recently\npregnant, you are\nMore likely to get very sick from COVID-19 compared to people who\nare not pregnant. People who get very sick from COVID-19 may\nrequire hospitalization, admission to an intensive care unit (ICU), or\nuse of a ventilator or special equipment to breathe. Severe COVID-19\nillness can also lead to death. At increased risk of complications that can affect your pregnancy and\ndeveloping baby. For example, COVID-19 during pregnancy increases\nthe risk of delivering a preterm or stillborn infant.","8673":"Some people have no side effects. Many people have reported common side effects after COVID-19\nvaccination, like pain or swelling at the injection site, a headache, chills, or fever. These reactions are\ncommon and are normal signs that your body is building protection. Reports of serious adverse events after vaccination are rare. CDC and FDA continue to closely monitor\nseveral reporting systems, like the\nVaccine Adverse Event Reporting System (VAERS),\nVaccine Safety Datalink (VSD), and\nv-safe, which help look for safety issues now that the vaccines are being given to patients in real-\nworld settings across the country.","4633":"For this model, a \u201cpremium\u201d\nfilter is based on one rated for MERV 13 filtration and \u201cregular\u201d filter is based on MERV 6 filtration. Learn more about\nHVAC filters and portable air cleaners. Visit Ventilation in Buildings (item #3 in Ventilation FAQs) to learn more about\nMERV ratings. Last Updated Feb. 9, 2022","9275":"Impact of COVID-19 in Children and Teens\nJust like adults, children and teens of all ages can:\nGet very sick from COVID-19\nHave both short- and long-term health problems\nSpread COVID-19 to others\nThere is no way to tell in advance how children or teens will be affected by COVID-19. Those with underlying medical\nconditions or who have a weakened immune system are more likely to get severely ill from COVID-19.","3693":"\u2022 CDC issuance of initial EUI for the COVID-19 vaccine by Pfizer-BioNTech on November 17, 2021\nCDC issued initial EUI for the COVID-19 vaccine by Pfizer-BioNTech1 and updated its Interim Clinical\nConsiderations on November 17, 2021, to ensure that certain people who were vaccinated outside of\nthe United States, or who received certain non-FDA authorized or approved COVID-19 vaccines\nthrough participation in a clinical trial, can get an additional primary dose or booster dose of the\nCOVID-19 vaccine by Pfizer-BioNTech.","8824":"CDC LOGO\nThe CDC and\/or ATSDR logo and other related CDC, ATSDR or Department of Health and Human Services (HHS) logos and\nmarks are U.S. government property and may not be used without express written permission from CDC, ATSDR and\/or HHS. These logos and marks are designed to signify official agency products, activities, representatives, and facilities. They should\nnever be used to promote or suggest endorsement of non-CDC, ATSDR or HHS companies, activities, products, events,\nfacilities or services. They should never be used by outside parties to misrepresent the purpose, character, statements or\npolicies of the agencies.","8017":"Identified misinformation themes that may impact vaccine confidence\n\u0083 Some consumers believe that natural immunity is superior to vaccine-induced immunity despite the health risks associated\nwith getting SARS-CoV-2.96\n\u0083 Some social media users state that the efficacy of the Pfizer vaccine is only between 1 and 12 percent at preventing illness97\nwhile leaving out the additional context that the vaccine-acquired immunity decreases with time, the vaccines are less\neffective against some variants of SARS-CoV-2, and, most importantly, the vaccine provides protection against severe illness.98\n\u0083 Some social media users believe SARS-CoV-2 is the same as influenza.99\n\u0083 Some social media users believe COVID-19 vaccines are causing a surge in the number of COVID-19 cases.100\nWays public health and partners can take action to improve vaccine confidence\n\u0083 Develop and amplify messages explaining why vaccines are still important in the COVID-19 prevention response.","328":"Due to a data processing issue on February 27, 2022, vaccination data were not updated on CDC COVID Data Tracker\nand reflect data as of February 26, 2022. CDC is actively working to address this issue and the data will be updated when\navailable. February 25, 2022: New Hampshire reviewed data and made adjustments to reporting, resulting in a decrease of\n209,146 for the number of vaccine doses administered since December 14, 2020. The adjustment is the result of updates\nto how pharmacies report data to CDC and\/or the jurisdictions.","8361":"Be compassionate and curious about the patient\u2019s mixed feelings, both the part of them that wants to trust that getting a\nvaccine is important and safe and the other part that feels hesitant. It is important to show support for the patient to\nincorporate their personal values and the health needs of their family and community as they make their decision. If a patient asks a question about vaccine safety, vaccine risks, or their health or mental health, respond within the\nboundaries of your competence, ethics, and scope of practice.","2384":"People who are moderately or severely immunocompromised\nwho have low or no protection after two doses of mRNA vaccines may have an improved immune response after a third\nprimary dose of the same vaccine. What are the benefits of a third primary dose for people who are moderately or severely\nimmunocompromised and received two doses of mRNA COVID-19 vaccine? \uf1aa\nThe safety, effectiveness, and benefit of the third primary dose in people who are moderately or severely\nimmunocompromised continues to be evaluated. So far, reactions reported after the third primary dose of an mRNA\nCOVID-19 vaccine are similar to those of the two-dose primary series.","6946":"Has the COVID-19 vaccine by Pfizer-BioNTech been used before? Yes. Millions of people have received this vaccine in the United States since it became available starting in\nmid-December 2020. Also, in clinical trials, approximately 23,000 people ages 12 years and older received\nat least 1 dose of the vaccine. There have been some studies in people who received the COVID-19 vaccine\nby Pfizer-BioNTech after completing a primary vaccination with a non-FDA authorized or approved COVID-\n19 vaccine or Janssen COVID-19 Vaccine. What are the risks of the COVID-19 vaccine by Pfizer-BioNTech?","9624":"Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the novel coronavirus, SARS-CoV-2,\nthat emerged in late 2019. It is predominantly a respiratory illness that can affect other organs. People with\nSARS-CoV-2 infection have reported a wide range of symptoms, ranging from no symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include fever or chills, cough,\nshortness of breath, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat,\ncongestion or runny nose, nausea or vomiting, and diarrhea. Who can receive the COVID-19 vaccine by Pfizer-BioNTech?","7800":"\u2022\n\u2022\n\u2022\n\u2022\n\uf6e5 When To Take an At-Home COVID-19 Test\nTest Yourself If\u2026 Timing\nYou have any COVID-19 symptoms Immediately\nYou were exposed to someone with COVID-19 At least 5 days after your exposure\nIf you test negative for COVID-19, consider testing\nagain 1 to 2 days after your first test\nYou are going to an indoor event or a gathering Immediately before the gathering, or as close to\nthe time of the event as possible\nThis is especially important before gathering with\nindividuals at risk of severe disease, older adults,\nthose who are immunocompromised, or people\nwho are not up to date on their COVID-19\nvaccines, including children who cannot get\nvaccinated yet.","7159":"It is approved as a 2-dose series for\nprevention of COVID-19 in individuals 12 years of age and older. It is also\nauthorized under EUA to provide:\n\uf0b7 a third primary series dose to individuals 12 years of age and older with\ncertain kinds of immunocompromise. 1 You may receive this Vaccine Information Fact Sheet even if your child is 11 years old.","9711":"Frequencies of local and systemic adverse reactions in the 7 days post booster\nvaccination were higher with heterologous than homologous boosters and in those aged under 70 years when\ncompared to older recipients. Frequencies of local and systemic adverse reactions were higher when the\nAstraZeneca COVID-19 vaccine was used to boost those who received primary vaccination with the Pfizer-\nBioNTech COVID-19 vaccine, when compared with the Pfizer-BioNTech COVID-19 vaccine after either primary\nvaccination (Munro et al., 2021).","9960":"Use the Interim Immunization Schedule for Ages 6 Months\nand Older to schedule doses\nPersons who received COVID-19 vaccine outside the United States\nVaccination guidance for people vaccinated outside of the United States can be found in the link Interim Clinical Considerations for\nUse of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\n4. Does the recipient have a health condition or undergoing treatment that makes them\nmoderately or severely immunocompromised? People with moderate or severe immunocompromising\nconditions or people who take immunosuppressive medications\nor therapies are at increased risk for severe COVID-19\ndisease.","1137":"Summary\nCDC uses multiple information technology systems\u202fto rapidly collect reliable data about how many doses of COVID-19\nvaccines have been distributed and how many people have been vaccinated with those doses (administration). CDC \u2014\ntogether with other federal agencies, vaccine providers, jurisdictions, state\/local public health departments, and tribal health\nfacilities across the United States \u2014 uses these data systems to inform decision-making regarding COVID-19 vaccination. The\u202fCOVID-19 Vaccination IT Overview\u202fprovides an overarching view of the vaccine IT data systems and how they integrate to\ntrack COVID-19 vaccine distribution and administration.","2758":"If you are experiencing a post-COVID\ncondition, you should engage in whatever coping strategies are best for your mental and physical health. Participate in specific long COVID research. The National Institutes of Health (NIH) is conducting a research project, called the RECOVER Initiative, to\nunderstand how people recover from a COVID-19 infection and why some people do not fully recover and develop\nlong COVID or post-COVID conditions. Learn more about Researching COVID to Enhance Recovery . \u2022\n\uf209\nWays to Cope with Stress\nExperts are still determining which types of medications or treatments can help to relieve the effects of post-COVID\nconditions.","9652":"\u2022 An additional dose with the COVID-19 vaccine by Pfizer-BioNTech (30 \u03bcg in 0.3 mL) should be\nadministered intramuscularly for persons ages 12 years and older with certain immunocompromising\nconditions at least 28 days after a primary dose with the Janssen COVID-19 Vaccine (e.g., 1 primary\ndose of the Janssen COVID-19 Vaccine followed by an additional dose with an mRNA COVID-19 vaccine\nat least 28 days after the primary dose).","785":"Just as a family has a\nfamily tree, the SARS-CoV-2 virus can be similarly mapped out. Sometimes branches of that tree have different attributes that\nchange how fast the virus spreads, or the severity of illness it causes, or the effectiveness of treatments against it. Scientists\ncall the viruses with these changes \u201cvariants\u201d. They are still SARS-CoV-2, but may act differently. Last Updated Nov 4 2021\f10\/30\/22, 9:37 AM Basics of COVID-19 | CDC\nLast Updated Nov. 4, 2021","1928":"The study will:\nEnroll pregnant people who plan to receive COVID-19 vaccination; COVID-19 vaccines will be given as part of the\nstudy\nCollect baseline maternal health information, including if they previously had COVID-19\nFollow people during pregnancy and for three months after delivery\nFollow babies through their first three months of life\nCDC: Birth Defects Study to Evaluate Pregnancy Exposures (BD-STEPS) \u2014 BD-STEPS is an ongoing study that collects\ninformation including COVID-19 vaccination information from people who have recently been pregnant to understand\n\u2022\n\u2022\n\u2022 \uf209\n\uf209\n\u2022\n\u2022\n-\n-\n-\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\n-\n-\n\u2022\f10\/30\/22, 9:32 AM COVID-19 Vaccine Monitoring Systems for Pregnant People | CDC\ninformation, including COVID-19 vaccination information, from people who have recently been pregnant to understand\nthe potential causes of birth defects and how to prevent them.","8378":"These\ninclude:\nExperienced vaccinators\nVaccinators who have not administered vaccines in the past 12 months or longer\nMedical support staff (not licensed to administer vaccines but can assist with vaccine preparation and cold chain\nmanagement)\nAdministrative support staff (can assist with cold chain management, data reporting, and distribution of required\nmaterials to vaccine recipients)\nTraining is important not only for those who will prepare and administer vaccine, but also for those responsible for other\ncritical, mandatory functions, including protecting the vaccine cold chain, inputting required data, and ensuring vaccine\nrecipients receive documentation of vaccination.","2475":"Orvieto R, Noach-Hirsh M, Segev-Zahav A, Haas J, Nahum R, Aizer A. Does mRNA SARS-CoV-2 vaccine influence patients\u2019\nperformance during IVF-ET cycle?. Reprod Biol Endocrinol. 2021;19(1):69. Published 2021 May 13. doi:10.1186\/s12958-\n14. Wesselink AK, Hatch EE, Rothman KJ, et al. A prospective cohort study of COVID-19 vaccination, SARS-CoV-2 infection, and\nfertility [published online ahead of print, 2022 Jan 20]. Am J Epidemiol. 2022;kwac011. doi:10.1093\/aje\/kwac011\n15. Edelman A, Boniface ER, Benhar E, et al. Association Between Menstrual Cycle Length and Coronavirus Disease 2019\n(COVID-19) Vaccination: A U.S. Cohort [published online ahead of print, 2022 Jan 5]. Obstet Gynecol. 16.","5642":"Do NOT wear international respirators\nIf they have exhalation valves, vents, or other openings\nIf it is hard to breathe while wearing them\nIf they are wet or dirty\nWith other masks or respirators\nAs a replacement for NIOSH-approved respiratory protection when required by your job\nst\nPoor quality KN95 respirators\nAbout 60% of KN95 respirators NIOSH evaluated during the COVID-19 pandemic in 2020 and 2021 did not meet\nthe requirements that they intended to meet. Using a poor-quality product may not provide the level of protection indicated. Learn about factors to consider when purchasing an international respirator. This webpage and a webinar provide\nreliable information to guide you.","9212":"Clean and disinfect areas that may have blood, stool, or body fluids on them. Use household cleaners and disinfectants. Clean visible dirty surfaces with household cleaners\ncontaining soap or detergent. Then, use a household disinfectant. Use a product from EPA\u2019s List N: Disinfectants for Coronavirus (COVID-19)\nBe sure to follow the instructions on the label to ensure safe and effective use of the product. Many products recommend keeping the surface wet with a disinfectant for a certain period of\ntime (look at \u201ccontact time\u201d on the product label).","7224":"In clinical trials, approximately 23,000 individuals 12 years of age and older have\nreceived at least 1 dose of Pfizer-BioNTech COVID-19 Vaccine. Millions of individuals\nhave received the Pfizer-BioNTech COVID-19 Vaccine under EUA since December 11,\n2020. In a clinical trial, approximately 300 individuals greater than 55 years of age received\none dose of a bivalent vaccine that differs from the Pfizer-BioNTech COVID-19\nVaccine, Bivalent in that it contains a different Omicron component. WHAT ARE THE BENEFITS OF THESE VACCINES? COMIRNATY (COVID-19 Vaccine, mRNA) and the Pfizer-BioNTech COVID-19 Vaccine\nhave been shown to prevent COVID-19.","9824":"The FDA has authorized the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron\fPfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nBA.4\/BA.5) and the Moderna COVID-19 Vaccine, Bivalent (Original and Omicron BA.4\/BA.5) for the express purpose of\nimproving protection conferred by COVID-19 booster doses against the currently circulating Omicron variant of SARS-CoV-\n2, resulting in a more favorable benefit\/risk balance as compared to the use of the COVID-19 vaccine by Pfizer-BioNTech.","9615":"Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nThe COVID-19 vaccine by Pfizer-BioNTech is approved by the FDA as a 2-dose primary series for active\nimmunization to prevent COVID-19 in persons ages 12 years and older. CDC is issuing these EUI to provide\ninformation about use of the COVID-19 vaccine by Pfizer-BioNTech for primary and\/or additional doses that\nextend beyond its FDA-approved labeling as described further under \u201cWho can receive the COVID-19 vaccine\nby Pfizer-BioNTech\u201d and \u201cWhat are the doses and intervals of the COVID-19 vaccine by Pfizer-BioNTech for\nprimary and\/or additional doses\u201d. What is COVID-19?","5982":"Effectiveness of a Moderna COVID-19 Vaccine (0.25 mL [50 \u03bcg of mRNA]) booster dose in individuals who\ncompleted primary vaccination with another authorized or approved COVID-19 vaccine (homologous or\nheterologous booster dose) is inferred from immunogenicity data supporting effectiveness of a Moderna\nCOVID-19 Vaccine (0.25 mL [50 \u03bcg of mRNA]) booster dose administered following completion of a Moderna\nCOVID-19 Vaccine primary series and from immunogenicity data from an independent Phase 1\/2 open-label\nclinical trial (NCT04889209) conducted in the United States that evaluated a booster dose (0.5 mL [100 \u03bcg of\nmRNA]) of the Moderna COVID-19 Vaccine.","5189":"How is CDC using my information? The information you provide will contribute to what we know about the safety of COVID-19 vaccines, which helps us get a\nmore complete picture of the risks and benefits of COVID-19 vaccination. What You Need to Know\nCDC is conducting surveys of patients (or their parents or guardians) and healthcare providers to gather\ninformation about myocarditis after COVID-19 vaccination. CDC is contacting people who meet the case definition for myocarditis following COVID-19 vaccination.","1679":"The recommendations stand as public health\nguidance for the safe use of vaccines and related biological products.","7659":"I will be in the United States for less than 3 days, but to get my exception to travel, I must attest to\nself-quarantine for 5 days and get a test 3-5 days after arriving in the United States. Do I still have\nto quarantine and get a post-travel test if I am going to be in the United States for less than 3\ndays? \uf1aa\nLast Updated July 14, 2022","4822":"Storage and handling Dose administered after improper\nstorage and handling (i.e., temperature\nexcursion)\nContact the manufacturer for information on the stability of the\nvaccine. If the manufacturer does not have data to support the stability\nof the vaccine, repeat the dose immediately (no minimum interval). Dose administered past the\nexpiration\/beyond-use date\nContact the manufacturer for information on the stability of the\nvaccine. If the manufacturer does not have data to support the stability\nof the vaccine, repeat the dose immediately (no minimum interval). Intervals Any COVID-19 dose administered prior\nto the minimum interval\nRepeat dose.","9669":"The EUI apply to the FDA-approved formulations of the COVID-19 vaccine by Pfizer-BioNTech that may be used\nfor individuals 12 years of age and older. As of December 16, 2021, there are two FDA-approved formulations\nof this vaccine that are distinguished by purple and gray caps with vials labeled either as Comirnaty or Pfizer-\nBioNTech COVID-19 Vaccine. They are also FDA-authorized under EUA. The multiple dose vials with purple caps\ncontain phosphate buffered saline that must be diluted with normal saline prior to administration. The\nmultidose vials with gray caps contain tromethamine (Tris) buffer and do not require dilution for\nadministration.","409":"On August 31, 2021, CDC updated its algorithm for assigning a race\/ethnicity category for vaccine recipients to align with\nU.S. Census Bureau race\/ethnicity classifications. As a result, approximately 4.5 million vaccine recipients where a valid\nrace was reported in conjunction with \u201cother\u201d race who were previously categorized as \u201cNon-Hispanic Multiracial\u201d are\nnow categorized into a single race\/ethnicity group. Beginning August 9, 2021, submitting entities will have the ability to update or delete previously submitted records using\nnew functionality available in CDC\u2019s Data Clearinghouse.","7111":"You should also talk to your healthcare professional if you think you are experiencing depression during or after\npregnancy. Get recommended vaccines during pregnancy. These vaccines can help protect you and your baby. Get a flu vaccine every year. Others living in your household should also get vaccinated to protect themselves and\nyou. Get the Tdap vaccine to protect your baby against whooping cough, which can have similar symptoms to COVID-19. CDC recommends all pregnant people receive a Tdap vaccine during each pregnancy. In addition, everyone who is\naround the baby should be up to date with their whooping cough vaccine.","3912":"Immunocompromised or a Weakened Immune System\nHaving a weakened immune system, also known as being\nimmunocompromised, can make you more likely to get very sick if\nyou get COVID-19. People who are immunocompromised, or who are\ntaking medicines that weaken their immune system, may not be\nprotected as well as others, even if they are up to date on their\nvaccines. EVUSHELD\u2122 is a medicine given by a healthcare provider\nevery 6 months to help prevent COVID-19 before you are exposed or\ntest positive for COVID-19. EVUSHELD\u2122 remains protective, but may\noffer less protection against certain strains of the Omicron variant.","577":"August 25, 2022: Illinois made update to data previously submitted to CDC that resulted in a new increase of 37,546\nadministered doses. August 18, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 50,115\nadministered doses. August 18, 2022: Arkansas made updates to data previously submitted to CDC that resulted in a net increase of\n11,332 administered doses. August 11, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 82,375\nadministered doses.","554":"December 14, 2020: Doses reported as administered before the beginning of the national vaccination program on\n12\/14\/2020 are not included in the figures but are included in the cumulative count of total doses administered in the\nCDC COVID Tracker\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n-\n\uf209\n-\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\uf209\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nCDC COVID Tracker. Record Management\nJurisdictions continuously receive new and updated vaccination information from partners that may require updating and\/or\ndeleting older records to maintain current data accuracy. Occasionally, an organization will delete a record with data fields\nthat cannot be updated and upload a replacement record with the correct information.","4545":"10\/30\/22, 9:41 AM If You Are Sick or Caring for Someone | CDC\nIf You Are Sick or Caring for Someone\nIf you test positive and are an older adult or someone who is at high risk of getting very sick from COVID-19, treatment\nmay be available. Contact a healthcare provider right away after a positive test to determine if you are eligible, even if\nyour symptoms are mild right now. You can also visit a Test to Treat location and, if eligible, receive a prescription\nfrom a provider. Don\u2019t delay: Treatment must be started within the first few days to be effective.","6087":"Benotmane, I., Bruel T., Planas, D., Fafi-Kremer, S., Schwarz, O., Caillard, S. A fourth dose of the mRNA-1273\nSARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients. Buchan SA, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by\nvaccine product, schedule and interval. CDC. Science Brief: SARS-CoV-2 infection-induced and vaccine-induced immunity. 2021. Das, R. Update on 50 \u00b5g Booster Dose of Moderna COVID-19 Vaccine in Individuals \u226518 Years of Age.","9648":"\u2022 A second primary dose of the COVID-19 vaccine by Pfizer-BioNTech (30 \u03bcg in 0.3 mL) may be delayed\nby 3 months from symptom onset or positive test (if infection was asymptomatic) in persons ages 12\nyears and older who recently had SARS-CoV-2 infection\fPfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\n\u2022 A primary dose, including as an additional primary dose for those with certain immunocompromising\nconditions, of the Pfizer-BioNTech vaccine (30 \u03bcg in 0.3 mL) should be administered intramuscularly to\npersons ages 12 years and older at least 28 days after primary vaccination with certain non-FDA\nauthorized or approved COVID-19 vaccines.","6652":"Ask your primary care provider if you would like to speak with a professional. Getting\nregular exercise and being physically active is also a great way to reduce stress. Accommodate dietary needs and avoid triggers\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nHave non-perishable food choices such as canned goods available that meet your needs based on your medical\ncondition (e.g., kidney diet and KCER 3-Day Emergency Diet Plan , diabetic diet).","218":"This level is called the\n\u201cthreshold of protection.\u201d When antibodies decrease below the threshold of protection, you may become more vulnerable to\nsevere illness. We do not yet know what the threshold of protection for antibodies is for the virus that causes COVID-19 or\nhow long it takes these antibodies to wane. Even after antibodies wane, your immune system may have cells that remember\nthe virus that can act quickly to protect you from severe illness if you become infected. These topics are being researched by\nscientists all over the world\f10\/30\/22, 9:37 AM Antibodies and COVID-19 | CDC\nscientists all over the world.","1325":"In the following exceptional situations, a different COVID-19 vaccine may be administered to complete a primary series at\na minimum interval of 28 days from the last COVID-19 vaccine dose:\nThe same vaccine is not available\nA previous dose is unknown\nThe person would otherwise not complete the primary series\nA person starts but is unable to complete a primary series with the same COVID-19 vaccine due to a contraindication. No VAERS report is required. For more information, see:\nTiming, spacing, and interchangeability of COVID-19 vaccines. Should the same COVID-19 vaccine product be used for all doses in the primary series?","5460":"People who experience post-COVID conditions most commonly report:\nGeneral symptoms\nTiredness or fatigue that interferes with daily life\nSymptoms that get worse after physical or mental effort (also known as \u201cpost-exertional malaise\u201d)\nFever\nRespiratory and heart symptoms\nDifficulty breathing or shortness of breath\nCough\nChest pain\nFast-beating or pounding heart (also known as heart palpitations)\nNeurological symptoms\nDifficulty thinking or concentrating (sometimes referred to as \u201cbrain fog\u201d)\nHeadache\nSleep problems\nDizziness when you stand up (lightheadedness)\nPins-and-needles feelings\nChange in smell or taste\nDepression or anxiety\nDigestive symptoms\nScience at CDC\nScientific evidence and studies behind long COVID\nScience behind Long COVID\nHow to Get Involved in Long COVID Research\nThe National Institutes of Health (NIH) is conducting a research project, called the RECOVER Initiative, to understand how people recover from a COVID-\n19 infection and why some people do not fully recover and develop long COVID or post-COVID conditions.","9993":"Additional information\ncan be found at Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination. 7. Has the person to be vaccinated ever had anaphylaxis after another vaccine (other than\nCOVID-19 vaccine) or another injectable medication? A history of anaphylaxis to any other vaccine or injectable\ntherapy (i.e., intramuscular, intravenous, or subcutaneous\nvaccines or therapies not related to a component of COVID-19\nvaccines) is a precaution to COVID-19 vaccines. This also\napplies if the non-COVID-19 vaccine or therapy has multiple\ncomponents, one or more of which is a component of a\nCOVID-19 vaccine, and it is unknown which component\nelicited the allergic reaction.","8859":"To find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. Contact Form\nHave questions about v-safe or need help? If you have questions or need assistance with v-safe, these resources can help:\nV-safe Frequently Asked Questions and Troubleshooting\nContact live v-safe support:\nAvailable Monday-Friday 8:00 AM \u2013 8:00 PM ET\n\u2022\n\u2022\n\uf209\nRelated Pages\nHow to Enroll or Access Your v-safe Account\n\u203a\nHow to Add a Dependent in v-safe\n\u203a\nHow to Complete a v-safe Check-In\n\u203a\nV-safe Print Resources\n\u203a\nV-safe Frequently Asked Questions and Troubleshooting\n\u203a\nLast Updated July 18, 2022","6778":"In a clinical trial, approximately 300 individuals greater than 55 years of age received\n1 dose of a bivalent vaccine that differs from the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent in that it contains a different Omicron component. WHAT ARE THE BENEFITS OF THESE VACCINES? The Pfizer-BioNTech COVID-19 Vaccine has been shown to prevent COVID-19. FDA\nhas authorized the Pfizer-BioNTech COVID-19 Vaccine, Bivalent to provide better\nprotection against COVID-19 caused by the Omicron variant of SARS-CoV-2. The duration of protection against COVID-19 is currently unknown. WHAT ARE THE RISKS OF THESE VACCINES? There is a remote chance that these vaccines could cause a severe allergic reaction.","5686":"If your child has a hard time breathing, gets dizzy, or has other symptoms while you are trying to get the mask to fit\nbetter or when using an ASTM F3502 mask or a respirator, choose a regular cloth or disposable mask. They should\ncontinue to follow CDC guidance to protect themselves and others. Consult your healthcare provider if these symptoms\ndo not resolve.","9556":"OR 8 weeks\nOR\nChildren who turn from age 11 years to 12 years\nRecommended: Children who started a primary series and turned from age 11 to age 12 years before completion of the\nseries should receive:\n0.20 mL (10 mcg) of the\nproduct authorized for\nchildren ages 5\u201311 years\n(orange cap and label border)\nChild turns 12\n0.30 mL (30 mcg) of the\nproduct authorized for\nchildren ages 12\u201317 years\n(gray cap and label border)\nAcceptable: If the following dosing occurs, it is NOT considered an error and the primary series is considered complete.","1292":"Can COVID-19 vaccines and other vaccines be administered at the same time? \uf1aa\nPeople who previously received COVID-19 vaccination (i.e. Moderna, Novavax, or Pfizer-BioNTech) may be given\northopoxvirus vaccine (either JYNNEOS or ACAM2000) without a minimum interval between vaccinations. People who previously received orthopoxvirus vaccination (either JYNNEOS or ACAM2000), particularly adolescent or\nyoung adult males, might consider waiting 4 weeks before receiving a COVID-19 vaccine (i.e. Moderna, Novavax, or Pfizer-\nBioNTech) because of the observed risk for myocarditis and pericarditis after receipt of ACAM2000 orthopoxvirus vaccine\nand COVID-19 vaccines (i.e. Moderna, Novavax, or Pfizer-BioNTech) and the unknown risk for myocarditis and pericarditis\nafter JYNNEOS administration.","6788":"A\nsevere allergic reaction would usually occur within a few minutes to 1 hour after getting\na dose. For this reason, your child\u2019s vaccination provider may ask your child to stay at\nthe place where your child received the vaccine for monitoring after vaccination. Signs\nof a severe allergic reaction can include:\n\uf0b7 Difficulty breathing\n\uf0b7 Swelling of the face and throat\n\uf0b7 A fast heartbeat\n\uf0b7 A bad rash all over the body\n\uf0b7 Dizziness and weakness\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the\nlining outside the heart) have occurred in some people who have received the\nPfizer-BioNTech COVID-19 Vaccine.","1091":"You can treat symptoms\nwith over-the-counter medicines,\nsuch as acetaminophen (Tylenol)\nor ibuprofen (Motrin, Advil), to help\nyou feel better. Learn more about what to do if\nyou are sick. COVID-19 vaccines available in the United States effectively protect people from getting seriously ill, being hospitalized, and\neven dying\u2014especially people who are boosted. As with vaccines for other diseases, you are protected best when you stay up\nto date. CDC recommends that everyone who is eligible stay up to date on their COVID-19 vaccines.","5108":"Non-U.S. citizen, non-U.S. immigrants: You must show proof of being fully vaccinated with the primary series of an\naccepted COVID-19 vaccine before you board your flight to the United States. Only limited exceptions apply. \uf209\nBefore You Leave the United States\nMake sure to plan ahead:\nGet up to date with your COVID-19 vaccines before you travel. Find out when you can get your booster and where to get a vaccine or booster. COVID-19 vaccines are effective at protecting people\u2014especially those who are boosted\u2014 from getting seriously ill,\nbeing hospitalized, and even dying.","8003":"Layered\nprevention strategies, such as staying up to date with vaccines, screening and testing in high-risk settings, improving\nventilation, and wearing masks, can help limit severe disease and reduce the potential for strain on the healthcare system. CDC recommends using county COVID-19 Community Levels to help determine which COVID-19 prevention measures\nto use for individuals and communities. COVID-19 Community Levels do not apply in healthcare settings like hospitals\nand nursing homes. Healthcare settings are recommended to continue to follow CDC\u2019s infection prevention and control\nrecommendations for healthcare workers.89\n\u0083 Should masks90,91 and vaccines92,93 still be utilized as personal mitigation measures when traveling?","2817":"Younger children who have myocarditis or pericarditis may have non-specific\nsymptoms such as irritability, vomiting, poor feeding, tachypnea, or lethargy. Ask about prior COVID-19 vaccination if you identify these symptoms, as well as relevant other medical, travel, and social\nhistory. For initial evaluation, consider an ECG, troponin level, and inflammatory markers such as C-reactive protein and\nerythrocyte sedimentation rate. In the setting of normal ECG, troponin, and inflammatory markers, myocarditis or\npericarditis are unlikely. For suspected cases, consider consultation with cardiology for assistance with cardiac evaluation and management.","2012":"\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nLearn more about COVID-19 vaccine safety from published research and how CDC and FDA are making sure COVID-19\nvaccines used in the United States are safe. \u2022\n\uf20c\f10\/30\/22, 9:31 AM COVID-19 Vaccine Safety in Children and Teens | CDC\ndoses given of the Pfizer-BioNTech COVID-19 vaccine between November 2021 and April 2022 . In reports of myocarditis following mRNA-based COVID-19 vaccination from December 2020 to August 2021 , the risk\nof myocarditis was highest following the second dose of the Pfizer-BioNTech vaccine in adolescent and young adult\nmales.","7807":"10\/30\/22, 9:38 AM Self-Testing At Home or Anywhere | CDC\nLearn what to do if you test positive or test negative. \uf425\nWatch Video: When To Use a Self-Test [00:04:04] | Espa\u00f1ol [00:04:53]\nWatch Video: When To Use a Self-Test \u2013 ASL [00:02:32]\n\uf357\n\uf357\nHow to Get an At-Home COVID-19 Test\nBuy tests online or in pharmacies and retail stores. Private health insurance may reimburse the cost of\npurchasing self-tests. Visit FDA\u2019s website for a list of authorized tests. Free tests may also be available through local health departments.","7420":"If you are a noncitizen nonimmigrant and are fully vaccinated, make sure your vaccine and proof of vaccination are\nacceptable to board a flight to the United States. For additional information on recommendations and requirements before and during travel to the United States and after\narriving in the United States, visit International Travel to and from the United States. \uf1c8\nGet Started\nTravel Assessment\nA tool to help you know the requirements to board a flight to the United States.","7764":"Over 350 million mRNA vaccines were given during the study period\nand CDC scientists found that rates of myocarditis were highest following the second dose of an mRNA vaccine\namong males in the following age groups:\n12\u201315 years (70.7 cases per one million doses of Pfizer-BioNTech)\n16\u201317 years (105.9 cases per one million doses of Pfizer-BioNTech)\n18\u201324 years (52.4 cases and 56.3 cases per million doses of Pfizer-BioNTech and Moderna, respectively)\nMultiple studies and reviews of data from vaccine safety monitoring systems continue to show that vaccines are safe. As\na result, the agency will refocus enhanced surveillance and safety monitoring efforts toward children and adolescents.","3351":"History of myocarditis or pericarditis prior to COVID-19 vaccination\nPeople who have a history of myocarditis or pericarditis unrelated to vaccination with Moderna, Novavax, or Pfizer-BioNTech\n(e.g., due to SARS-CoV-2 or other viruses) may receive any currently FDA-approved or FDA-authorized COVID-19 vaccine after\nthe episode of myocarditis or pericarditis has completely resolved. This includes resolution of symptoms attributed to\nmyocarditis or pericarditis, as well as no evidence of ongoing heart inflammation or sequelae as determined by the person\u2019s\nclinical team. For people who have a history of myocarditis associated with MIS-C or MIS-A, see COVID-19 vaccination and MIS-\nC and MIS-A.","4232":"Some vaccination providers and health departments may offer you access to a QR code or digital copy of your CDC\nCOVID-19 Vaccination card in addition to giving you a physical card. Contact your vaccination provider or local\nhealth department to learn if you can get a digital copy of your card. CDC does not provide the white CDC COVID-19 Vaccination card to people and does not maintain vaccination records. CDC distributes the white CDC COVID-19 Vaccination cards to vaccination providers and only a vaccination provider can\ngive you this card. How can I get a new CDC COVID-19 Vaccination card?","5880":"The below describes who can receive the COVID-19 vaccine by Moderna under EUI. The COVID-19 vaccine by\nPfizer-BioNTech can also be used under EUI for similar uses as an alternative mRNA COVID-19 vaccine (see the\nPfizer-BioNTech EUI Fact Sheet for Healthcare Providers). \u2022 Persons ages 12 years and older, particularly those at higher risk of mRNA COVID-19 vaccine-\nassociated myocarditis, may receive a second primary dose of the COVID-19 vaccine by Moderna after\na longer interval of 4\u20138 weeks following the first primary dose.","3658":"Traveling by private vehicle (if possible) can lower\nthe chances of spreading COVID-19 to others. I was exposed to a person with COVID-19 in the\npast 10 days. Follow CDC guidance, including getting tested at\nleast 5 full days after your last exposure. Do not travel on public transportation such as\nairplanes, buses, and trains if you will not be able\nto wear a high-quality mask or respirator when\naround others indoors for the full duration of your\ntrip. If you travel, wear a high-quality mask or\nrespirator the entire time you are around others\nindoors.","6112":"\"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster)\nfollowing two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre,\nrandomised, controlled, phase 2 trial.\" The Lancet (2021). National Advisory Committee on Vaccination. An Advisory Committee Statement: Guidance on booster COVID-\n19 vaccine doses in Canada. Public Health Agency of Canada; 3 Dec 2021.\nhttps:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/immunization\/national-advisory-\nvaccine-doses.pdf\nNational Collaborating Centre for Methods and Tools. Rapid Review Update 1: What is the ongoing\neffectiveness, immunogenicity, and safety of COVID-19 vaccines in persons who have had a prior, confirmed\nCOVID-19 infection?. Hamilton (ON): McMaster University; 2021. Available from: https:\/\/www.nccmt.ca\/covid-\n19\/covid-19-rapid-evidence-service\/36.","3679":"EUI Webpage Update 09\/02\/2022 Page 1 of 3\nQuestions and Answers about Emergency Use Instructions (EUI)\nBelow are answers to frequently asked questions about Emergency Use Instructions (EUI). Refer to EUI for\nPfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine for primary, additional, and\/or\nbooster doses. What are Emergency Use Instructions (EUI)? Emergency Use Instructions (EUI) allow CDC to inform healthcare providers and recipients about certain\nuses of medical products approved (licensed) by the U.S. Food and Drug Administration (FDA) that are\nneeded during public health emergencies without the FDA needing to issue an Emergency Use\nAuthorization (EUA).","935":"In addition, everyone who is eligible, including those who are pregnant, breastfeeding, trying\nto get pregnant now, or might become pregnant in the future, should get a booster shot. You should always wash your hands\nwith soap and water for 20 seconds before breastfeeding or expressing breast milk, even if you don\u2019t have COVID-19. If soap\nand water are not available, use a hand sanitizer with at least 60% alcohol. If you have COVID-19 and choose to breastfeed:\nWash your hands before breastfeeding\nWear a mask while breastfeeding and whenever you are within 6 feet of your baby.","7143":"Clin\nWoodworth KR, Olsen EO, Neelam V, et al. Birth and Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2\nInfection in Pregnancy \u2014 SET-NET, 16 Jurisdictions, March 29\u2013October 14, 2020. MMWR Morb Mortal Wkly Rep\nDeSisto CL, WallaceB, Simeone RM, et al. Risk for Stillbirth Among Women With and Without COVID-19 at Delivery\nHospitalization \u2014 United States, March 2020\u2013September 2021. MMWR Morb Mortal Wkly Rep 2021;70:1640-1645. More Information\nUrgent Maternal Warning Signs\n\uf209\n\uf209\n\uf209\nLast Updated Oct. 25, 2022","683":"January 20, 2022: Georgia made updates to data previously submitted to CDC that resulted in an increase of 139\ndoses administered. January 20, 2022: Wyoming made updates to data previously submitted to CDC that resulted in an increase of 2,761\ndoses administered. January 20, 2022: Pennsylvania made updates to data previously submitted to CDC that resulted in an increase of\n206,575 doses administered. January 19, 2022: Idaho added 20,015 records for persons aged 18 years not previously submitted to CDC. January 14, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 4,868\ndoses administered.","3584":"People Who Are Eligible to Receive a First Booster Dose\nRepresents the total number of fully vaccinated people who are eligible to receive a first booster dose of an mRNA\nCOVID-19 vaccine if it has been at least 5 months since their completed Pfizer-BioNTech or Moderna primary series or at\nleast 2 months since their completed J&J\/Janssen single-dose vaccine. Completion of a primary series does not distinguish\nif the recipient is immunocompromised and received an additional dose. This measure excludes recipients who received\nan \u201cOther\u201d primary series vaccine type.","8376":"10\/30\/22, 9:17 AM Training and Education for COVID-19 Vaccination | CDC\nVaccines & Immunizations\nVaccines & Immunizations Home\nTraining and Education\nIt\u2019s important healthcare professionals receive the training\nneeded to effectively meet the demands of their roles. Training must be ongoing as new COVID-19 vaccines become\navailable and as vaccine recommendations evolve when we\nlearn more about the vaccines and how to improve the\nvaccination process. A variety of healthcare professionals and personnel will be needed to implement COVID-19 vaccination efforts.","8458":"Follow CDC guidance, including getting tested at\nleast 5 full days after your last exposure. Do not travel on public transportation such as\nairplanes, buses, and trains if you will not be able\nto wear a high-quality mask or respirator when\naround others indoors for the full duration of your\ntrip. If you travel, wear a high-quality mask or\nrespirator the entire time you are around others\nindoors. Traveling by private vehicle (if possible) can lower\nthe chances of spreading COVID-19 to others. If Your COVID-19 Test is Positive\nThis poster is available to download and can be used as a resource for airport\ntesting sites.","6131":"Moderna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 09\/02\/22;\nSkowronski DM. 2021, MedRxiv preprint. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules\nand extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. WHO Strategic Advisory Group of Experts on Immunization (SAGE). Interim recommendations for an extended\nprimary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised\npersons;.updated 26 October 2021. Geneva: World Health Organization; 2021.\nimmunocompromised-persons. WHO Strategic Advisory Group of Experts on Immunization (SAGE). Interim recommendations for use of the\ninactivated COVID-19 vaccine, CoronaVac, developed by Sinovac Interim guidance; updated 21 October 2021. Geneva: World Health Organization; 2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-\nvaccines-SAGE_recommendation-Sinovac-CoronaVac-2021.1.","2154":"Learn more at Possible Side Effects After Getting a COVID-19 Vaccine. Although rare, some people have had severe allergic reactions after receiving a COVID-19 vaccine. Talk with your healthcare\nprovider if you have a history of allergic reaction to any other vaccine or injectable therapy (intramuscular, intravenous, or\nsubcutaneous). Key considerations you can discuss with your healthcare provider include:\nThe benefits of vaccination\nThe unknown risks of developing a severe allergic reaction\nIf you have an allergic reaction after receiving a COVID-19 vaccine during pregnancy, you can receive treatment for it.","2073":"None\nof the COVID-19 vaccines contain\nlive virus. They cannot make anyone\nsick with COVID-19, including\npeople who are pregnant or their\nbabies. Learn more about how\nvaccines work. Data on the safety of receiving an mRNA COVID-19 vaccine (Moderna or Pfizer-BioNTech), before and during pregnancy\nare reassuring. Data from vaccine safety monitoring systems have not found any safety concerns for people who received an\nmRNA COVID-19 vaccine late in pregnancy or for their babies. Scientists have not found an increased risk for miscarriage among pregnant people who received an mRNA COVID-\n19 vaccine just before or during early pregnancy (before 20 weeks of pregnancy).","1403":"Should they receive the bivalent\nmRNA booster dose? \uf1aa\nPatients who undergo HCT or CAR-T-cell therapy should be revaccinated for the monovalent primary series\nand bivalent mRNA booster dose received before or during treatment. There is no revaccination for monovalent mRNA\nbooster dose(s) received before or during treatment. After revaccination with the primary series, the patient should\nMy patient who is moderately or severely immunocompromised underwent HCT or CAR-T cell\ntherapy after receiving the primary series and 2 monovalent mRNA booster doses. Should they be\nrevaccinated? \uf1aa\f10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\ng p y p\nreceive 1 bivalent mRNA booster dose.","4307":"\u2022\n\u2022\n\u2022\n\u2022\nIf you had an immediate allergic reaction (a reaction that started within 4 hours of getting vaccinated) to a COVID-\n19 vaccine, but the reaction was not considered severe by a medical professional, you can receive another dose of\nthe same vaccine under certain conditions. Your doctor may refer you to an allergy and immunology specialist for\nmore care or advice. \u2022\f10\/30\/22, 9:30 AM Getting Your COVID-19 Vaccine | CDC\nIf you have allergies not related to vaccines\nYou should get vaccinated if you have allergies that are not related to vaccines or injectable medications such as food, pet,\nvenom, environmental, or latex allergies.","3618":"County of Residence\nCDC determines county of residence by matching the county Federal Information Processing Standard State (FIPS) code\nto the state as submitted in the raw data provided to CDC. Last Updated Aug. 17, 2022","303":"This number\nincludes 152,195 recent and historic doses covering the time period from April 2, 2022 to May 2, 2022. On April 27, 2022, the daily number of vaccine doses administered for Pennsylvania was 254,383 doses. This number\nincludes 235,854 recent and historic second booster doses that were newly reported. On April 21, 2022, the District of Columbia [DC] upgraded its data collection and reporting system. The system upgrade\nmay have resulted in a higher reported count for the total number of people who were fully vaccinated in the district on\nMay 2, 2022.","397":"The adjustments are the results of updates to how pharmacies\nreport data to CDC and\/or the jurisdictions. Due to a short network outage at CDC on August 14, 2021, some of the vaccine administration files were not ingested on\nAugust 15, 2021. Counts from these files are not reflected in the 6am counts for August 15, 2021 but will be in August 16,\n2021 counts. This affected 11 entities for a grand total of 66,326 vaccine administrations. The Federal Pharmacy Partnership for Long-Term Care (LTC) Program was a partnership between CDC and CVS,\nWalgreens, and Managed Health Care Associates, Inc.","3575":"People Receiving at Least One Dose\nRepresents the total number of people who received at least one dose of COVID-19 vaccine approved or authorized for\nuse in the United States. This metric includes everyone who has received only one dose and those who received more\nthan one dose. People Who Are Fully Vaccinated\nRepresents the total number of people who have received the second dose in a two-dose COVID-19 vaccine primary\nseries or one dose of a single-dose COVID-19 vaccine primary series approved or authorized for use in the United States.","9470":"Individuals 6 years of age and older may receive a booster dose with Moderna COVID-19\nVaccine, Bivalent. Vaccinations may not provide full immunity to COVID-19 in people who are\nimmunocompromised; therefore, you or your child should continue to maintain physical\nprecautions to help prevent COVID-19. Your close contacts should be vaccinated as appropriate. WHAT ABOUT PREGNANCY OR BREASTFEEDING? If you are, or your child is, pregnant or breastfeeding, discuss the options with your healthcare\nprovider. WILL THESE VACCINES GIVE ME OR MY CHILD COVID-19? No. These vaccines do not contain SARS-CoV-2 and cannot give you or your child COVID-19.","3973":"COVID-19 Vaccine Distribution and Tracking\nVaccine Data Reporting\nDistribution is the process of shipping vaccines to provider locations, as directed by jurisdictions, federal agencies, and\npharmacy partners who are enrolled in the CDC COVID-19 Vaccination Provider Program. Vaccine delivery to provider\nlocations is the last part of the distribution process. How are COVID-19 vaccines distributed? \uf1aa\nJurisdictions (states, territories, tribes, and local entities), federal agencies, and pharmacy partners use the Vaccine\nTracking System (VTrckS) to order vaccines from the federal government. VTrckS records information such as vaccine\nmanufacturer, provider data, orders, shipments, and inventory.","3232":"If antibody testing was done, vaccination with the primary series or a\nbooster dose should be completed as recommended regardless of the antibody test result. SARS-CoV-2 antibody tests\ncurrently authorized under an EUA have variable performance characteristics and limitations. Furthermore, serologic\ncorrelates of protection have not been established and antibody testing does not evaluate the cellular immune response. Interpretation of SARS-CoV-2 test results in vaccinated people\nPrior receipt of a COVID-19 vaccine will not affect the results of SARS-CoV-2 viral tests (nucleic acid amplification or antigen\ntests).","7903":"9 Emerging Misinformation Theme Affecting Vaccine\nConfidence\n9 Consumers have questions about the relationship\nbetween COVID-19 vaccines and monkeypox. 10 Appendix: Inputs and Sources\nThe findings and conclusions in this report are those of the author(s) and do not necessarily\nrepresent the official position of the Centers for Disease Control and Prevention (CDC).","41":"10\/30\/22, 9:31 AM Allergic Reactions after COVID-19 Vaccination | CDC\nEspa\u00f1ol | Other Languages\nAllergic Reactions after COVID-19 Vaccination\nIf You Are Having a Severe Allergic Reaction to a COVID-19\nVaccine\nSevere allergic reactions to vaccines are rare but can happen. If you get a COVID-19 vaccine and you think you might be\nhaving a severe allergic reaction after leaving the vaccination provider site, seek immediate medical care by calling 911. A severe allergic reaction can cause:\ndifficulty breathing or wheezing,\na drop in blood pressure,\nswelling of the tongue or throat, or\na generalized rash or hives, which may include mucus membranes.","3527":"10\/30\/22, 9:35 AM Data Definitions for COVID-19 Vaccinations in the United States\nEspa\u00f1ol | Other Languages\nData Definitions for COVID-19 Vaccinations in the\nUnited States\nHow CDC Estimates Vaccination Coverage\nCDC estimates the number of people receiving at least one dose, the number of people who are fully vaccinated, and the\nnumber of people with booster doses. CDC estimates are based on data that include a dose number (first, second, boosters,\nor additional dose). To protect the privacy of vaccine recipients, CDC receives data without any personally identifiable\ninformation (deidentified data). Each jurisdiction or provider uses a unique person identifier to link records within their own\nsystems.","7962":"Similarly, create communications materials showing the lack of evidence that COVID-19 vaccines are\nassociated with AIDS, hepatitis, impaired immunity, and long-term effects on fertility, pregnancy, and lactation. cAll social media posts that are used as citations in the identified misinformation sections for this report can be found online through\nthis link. COVID-19 State of Vaccine Confidence Insights Report | October 10, 2022\nContinuing and Evolving Themes Impacting Vaccine Confidence\nThe themes below have been noted in previous reports and continue to undermine vaccine confidence. The information\nhighlighted below focuses on what is new or different from previous reports.","10031":"\u0083 Individual factors such as risk of severe disease, COVID-19 community level, or characteristics of the\npredominant SARS-CoV-2 strain should be considered when determining whether to delay getting\na booster dose after infection. \u0083 NOTE: Viral testing to assess for acute SARS-CoV-2 infection or serologic testing to assess\nfor prior infection is NOT RECOMMENDED for the purpose of vaccine decision-making. Been vaccinated with\nmonkeypox vaccine in\nthe last 4 weeks?","5284":"You are being offered the Janssen COVID-19 Vaccine to prevent Coronavirus Disease 2019\n(COVID-19) caused by SARS-CoV-2 because there is currently a pandemic of COVID-19. This Fact Sheet contains information to help you understand the risks and benefits of receiving the\nJanssen COVID-19 Vaccine. The Janssen COVID-19 Vaccine may prevent you from getting COVID-19. Read this Fact Sheet for information about the Janssen COVID-19 Vaccine. Talk to the vaccination\nprovider if you have questions.","1931":"The study will:\nEnroll pregnant people who plan to receive COVID-19 vaccination; COVID-19 vaccines will be given as part of the\nstudy\nCollect baseline maternal health information, including if they previously had COVID-19\nFollow people during pregnancy and for three months after delivery\nFollow babies through their first three months of life\nCDC: Birth Defects Study to Evaluate Pregnancy Exposures (BD-STEPS) \u2014 BD-STEPS is an ongoing study that collects\ninformation including COVID-19 vaccination information from people who have recently been pregnant to understand\n\u2022\n\u2022\n\u2022 \uf209\n\uf209\n\u2022\n\u2022\n-\n-\n-\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\n-\n-\n\u2022\f10\/30\/22, 9:32 AM COVID-19 Vaccine Monitoring Systems for Pregnant People | CDC\ninformation, including COVID-19 vaccination information, from people who have recently been pregnant to understand\nthe potential causes of birth defects and how to prevent them.","6700":"Spray or pour spray products onto a cleaning cloth or paper towel instead of spraying the product directly onto the\ncleaning surface (if the product label allows). Store products safely and correctly\nStore and use chemicals out of the reach of children and pets. Label diluted cleaning solutions. Follow EPA\u2019s 6 steps for Safe and Effective Disinfectant Use . If you feel ill\nCall your healthcare provider to ask about your symptoms. If you don\u2019t have a healthcare provider, contact your nearest\ncommunity health center or health department. Remember to call 911 for medical emergencies.","251":"Serological surveillance (studies that investigate antibodies in the population) provides information about how long antibody\nprotection against COVID-19 lasts and if this protection is different among people who have antibodies from infection,\ncompared with people who have antibodies from vaccination, or both. We can also learn more about which groups of people might not produce as many antibodies or maintain them as long as\nothers\u2014for example, immunocompromised people compared with people who have healthy immune systems. This is\nimportant information for making decisions about whether or not additional vaccine doses or boosters are needed, when\nthey would be recommended, and who would need them first.","6521":"The number of deaths among people over age 65 is 97 times higher than the number of deaths among\npeople ages 18-29 years. A person\u2019s risk of severe illness from COVID-19 increases as the number of underlying medical conditions they have\nincreases. Some people are at increased risk of getting very sick or dying from COVID-19 because of where they live or work, or\nbecause they can\u2019t get health care. This includes many people from racial and ethnic minority groups and people with\ndisabilities. Studies have shown people from racial and ethnic minority groups are also dying from COVID-19 at younger ages.","3531":"10\/30\/22, 9:35 AM Data Definitions for COVID-19 Vaccinations in the United States\nEspa\u00f1ol | Other Languages\nData Definitions for COVID-19 Vaccinations in the\nUnited States\nHow CDC Estimates Vaccination Coverage\nCDC estimates the number of people receiving at least one dose, the number of people who are fully vaccinated, and the\nnumber of people with booster doses. CDC estimates are based on data that include a dose number (first, second, boosters,\nor additional dose). To protect the privacy of vaccine recipients, CDC receives data without any personally identifiable\ninformation (deidentified data). Each jurisdiction or provider uses a unique person identifier to link records within their own\nsystems.","1597":"This is not intended to prevent prioritizing particular populations for specific vaccination\nclinics\/events with the purpose of promoting health equity. 10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nProvision of Information to Vaccine Recipients (Updated 2\/9\/22 to reference Moderna\u2019s COVID-19 vaccine BLA approval)\nBefore administering COVID-19 Vaccine, providers must provide an approved FDA Emergency Use Authorization (EUA)\nFact Sheet, FDA Vaccine Information Fact Sheet, or CDC Vaccine Information Statement (VIS), as applicable, to each\nvaccine recipient, the adult caregiver accompanying the recipient, or other legal representative.","9704":"Studies of\nCOVID-19 vaccine boosting in the United Kingdom have shown that a third dose of AstraZeneca, Moderna, or\nPfizer-BioNTech COVID-19 vaccines successfully boosted immune responses in people who had been primed\nwith two doses of Pfizer-BioNTech or AstraZeneca COVID-19 vaccines approximately 3 months earlier. Levels of\nbinding (IgG) and neutralizing antibodies, including against Delta variant, were generally higher when an mRNA\nvaccine was used as either a heterologous or homologous boost, or where the AstraZeneca COVID-19 vaccine\nwas used as a heterologous boost after primary vaccination with the Pfizer-BioNTech COVID-19 vaccine\n(Munro et al., 2021).","6453":"What to do if you test positive for COVID-19\nEffective treatments are now widely available and free, and you may be eligible. Contact your healthcare provider, health department, or Community Health Center to learn about treatment\noptions. Don\u2019t delay! Treatment must be started soon after you first develop symptoms to be effective. If you don\u2019t have timely access to a healthcare provider, check if a Test to Treat location is in your community. You\ncan get tested, receive a prescription from a healthcare provider (either onsite or by telehealth), and have it filled all at\none location.","9083":"10\/30\/22, 9:43 AM Wearing Masks in Travel and Public Transportation Settings | CDC\nEspa\u00f1ol | Other Languages\nWearing Masks in Travel and Public Transportation\nSettings\nFor people aged 2 years or older\u2014\nincluding passengers and workers\u2014CDC\nrecommends properly wearing a high-\nquality mask or respirator over the nose\nand mouth in indoor areas of public\ntransportation (such as airplanes, trains,\nbuses, ferries) and transportation hubs\n(such as airports, stations, and seaports). When people properly wear a high-quality\nmask or respirator, they protect\nthemselves and those around them, and\nhelp keep travel and public transportation\nsafer for everyone. Wearing a high-quality\nmask or respirator is most beneficial in\ncrowded or poorly ventilated locations,\nsuch as airport jetways.","2434":"Researchers found no significant changes in these sperm\ncharacteristics after vaccination. However, one study found that COVID-19 infection may be associated with a decline in fertility for men for up to\n60 days after infection. Fever from any illness has been associated with a short-term decrease in sperm production in healthy men. Although fever can be a side effect of COVID-19 vaccination, there is no current evidence that fever after COVID-\nvaccination affects sperm production. Fever is also a common symptom of COVID-19 infection. Safety Monitoring\nCOVID-19 vaccines are undergoing the most intense safety monitoring in U.S. history.","7644":"All airlines or other aircraft operators will provide and collect the passenger attestation on behalf of the U.S. Government\nprior to boarding. How do air passengers provide an attestation? \uf1aa\nAs required by United States federal law, all airlines or other aircraft operators will provide and collect the passenger\nattestation on behalf of the U.S. Government prior to boarding. Please check with the airline or aircraft operator for your\nflight to learn how the airline or aircraft operator will collect your attestation. Do I have to print the attestation posted on the CDC website before coming the airport? How do\nair passengers provide an attestation?","9734":"Countries such as the United Kingdom (JCVI, 2021a-b), Canada (National Advisory Committee on Vaccination,\n2021), Germany, and France have recommended heterologous dosing, including with use of Pfizer-BioNTech\nCOVID-19 vaccine, for an additional primary series and\/or booster dose based on their reviews of available\nimmunological and safety data, as well as the epidemiology of COVID-19 and other contextual factors.","8969":"Even if you are no longer pregnant, you may still be eligible to enroll in the registry. \u2022\n\u2022\n\u2022\nV-safe and the V-safe COVID-19 Vaccine Pregnancy Registry:\nWhat\u2019s the Difference? v-safe is a smartphone-based system that uses text messaging and web surveys to provide personalized health check-ins\nafter you receive a COVID-19 vaccine. The v-safe COVID-19 Vaccine Pregnancy Registry is for v-safe participants who self-\nidentify as pregnant at the time of vaccination or shortly thereafter (within 30 days of vaccination). The registry activities are in\naddition to the v-safe after vaccination health check-ins that participants receive via text message.","4270":"\u2022\n\u2022\nIf you have multisystem inflammatory\nsyndrome\nChildren and adults who have (or have recently had)\nmultisystem inflammatory syndrome (MIS), should\nwait to get vaccinated until:\nRecovering from being sick and\nIt has been 90 days since the date of diagnosis of\nMIS-A or MIS-C.\n\u2022\n\u2022\nTalk to your doctor if you have questions about getting a COVID-19 vaccine. \uf19c Find COVID-19 Vaccines or Boosters\nTo find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-\n232-0233. Find a Vaccine or Booster\nBefore the Vaccination\nIt is not known how over-the-counter (OTC) medicines, such as ibuprofen, aspirin, or acetaminophen, might affect how well\nthe vaccine works.","7713":"\uf209\nMore Information\nACIP COVID-19 Vaccines Safety Technical Sub-Group (VaST)\nCOVID-19 Vaccine Safety Publications\f10\/30\/22, 9:31 AM Safety of COVID-19 Vaccines | CDC\nVaST Subgroup Technical Report\nv-safe After Vaccination Health Checker\nVaccine Adverse Event Reporting System (VAERS)\nLast Updated Oct. 24, 2022","6383":"Remind your provider to share any test results if the expected window for receiving the results has passed. Set Goals with Your Healthcare Provider\nYour provider may run tests that return normal results. This does not change the existence, severity, or importance of\nyour symptoms or conditions. Healthcare providers and patients are encouraged to set achievable goals through shared\ndecision-making and to approach treatment by focusing on specific symptoms or conditions. Review the Healthcare Appointment Checklist\nConsider reviewing the Healthcare Appointment Checklist for Post-COVID Conditions before your next appointment\n(Espa\u00f1ol [PDF \u2013 72 KB]). Many instructions apply to follow-up appointments.","6634":"It is also important for people with medical conditions and their healthcare providers to work together and manage\nthose conditions carefully and safely. Stay up to date with your COVID-19 vaccines. If you have a medical condition, the\nfollowing are actions you can take based on your medical conditions and other risk factors. Seek care when needed\nCall your healthcare provider if you have any concerns about your medical conditions or if you get sick and think that you\nmay have COVID-19. Discuss steps you can take to manage your health and risks. If you need emergency help, call 911\nright away.","9103":"Examples of poorly ventilated areas include:\nSmall, enclosed spaces, such as airport jetways\nPublic transportation during periods when the ventilation system is off and windows are closed (e.g., when the\nengine is turned off on an airplane)\nDuring international travel and in transportation hubs that serve international travelers\nIf you are at high risk for getting very sick from COVID-19, or if you live with or have social contact with someone at\nhigh risk\nWhen the COVID-19 Community Level in the area you are located in is high (applies to US locations only)\nWhen should I wear a mask in travel and public transportation settings?","97":"\u2022\n\u2022\n\u2022\n\u2022\nFor Pet Owners, Veterinarians, & Public Health Officials\nPet Owners\nand Others\nHandling\nAnimals\nPets and\nAnimals\nFrequently\nAsked\nQuestions\nAnimal\nTesting\nGuidance\nOne Health\nToolkit for\nHealth\nOfficials\nManaging\nCompanion\nAnimals with\n\u2022\n\u2022\n\u2022\n\u2022\nCoronaviruses are a large family of viruses. Some coronaviruses cause cold-like illnesses in people, while others cause illness\nin certain types of animals, such as cattle, camels, and bats. Some coronaviruses, such as canine and feline coronaviruses,\ninfect only animals and do not infect people. Some coronaviruses that infect animals can be spread to people and then\nspread between people, but this is rare. This is what happened with SARS-CoV-2, which likely originated in bats.","8823":"CDC LOGO\nThe CDC and\/or ATSDR logo and other related CDC, ATSDR or Department of Health and Human Services (HHS) logos and\nmarks are U.S. government property and may not be used without express written permission from CDC, ATSDR and\/or HHS. These logos and marks are designed to signify official agency products, activities, representatives, and facilities. They should\nnever be used to promote or suggest endorsement of non-CDC, ATSDR or HHS companies, activities, products, events,\nfacilities or services. They should never be used by outside parties to misrepresent the purpose, character, statements or\npolicies of the agencies.","5840":"\u2022 Revaccination of moderately or severely immunocompromised persons ages 12 years and older who\nreceived certain therapies (indicated below) and received primary dose(s) of COVID-19 vaccine prior to\nor during treatment. o\no\nReceived COVID-19 vaccine dose(s) during treatment with B-cell-depleting therapies over a\nlimited period\nReceived COVID-19 vaccine dose(s) prior to or during treatment involving hematopoietic cell\ntransplant (HCT) or chimeric antigen receptor (CAR)-T-cell therapy\nThe COVID-19 vaccine by Pfizer-BioNTech under EUI also allow similar uses as an alternative mRNA COVID-19\nvaccine to Moderna, and the same or similar recommendations in the EUI also apply to the use of the COVID-\n19 vaccine by Pfizer-BioNTech under EUI.","589":"August 4, 2022: Texas made updates to data previously submitted to CDC that resulted in a net decrease of\n1,125,795 administered doses. This contributed to a decrease in overall US figures. August 4, 2022: Wyoming made updates to data previously submitted to CDC that resulted in a net increase of 2,013\nadministered doses. July 28, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 91,864\nadministered doses.","4023":"Data availability: Data on the CDC COVID Data Tracker represent all vaccine partners including jurisdictional\npartner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management\nAgency and Health Resources and Services Administration partner sites, and federal entity facilities. These\nadditional data streams may not be available to jurisdictions and therefore may not be included in totals\npresented on jurisdictional dashboards. Data definition: CDC\u2019s COVID Data Tracker attributes dose administrations to the jurisdiction (state, territory, tribe,\nor local entity) administering those doses and attributes people receiving COVID-19 vaccine to the jurisdiction\nwhere the vaccine recipient resides.","5801":"Additional information on the common and serious side effects of the COVID-19 vaccine by Moderna can\nbe found in the package insert for Spikevax and in the EUA Fact Sheet for Recipients and Caregivers. Moderna COVID-19 Vaccine EUI Recipient Fact Sheet, ver 9\/02\/2022 Page 4 of 4\nWhat are the benefits of the COVID-19 vaccine by Moderna? The COVID-19 vaccine by Moderna has been shown in clinical studies to be effective in preventing COVID-\n19.","5066":"A new section on persons with a history of multisystem inflammatory syndrome added to considerations for\nvaccination of people with certain underlying medical conditions. Updated recommendation for timing of COVID-19 vaccine administration in persons with a history of heparin-induced\nthrombocytopenia. Updated information on vaccination of children and adolescents. The Advisory Committee on Immunization Practices\u2019 updated interim recommendation for the use of the Janssen\n(Johnson & Johnson) COVID-19 Vaccine. Clarification that COVID-19 vaccination is recommended for all people 16 years and older added to key points and\nvaccine administration. Updated information about the Janssen COVID-19 Vaccine added to background.","9548":"Children who turn from age 4 to age 5 years\nRecommended: Children who started a primary series and turned from age 4 to age 5 years between dose 1 and dose 2\nin the primary series should receive:\nof the product\nauthorized for\nchildren ages 6\n(maroon cap and\nlabel border)\nChild turns 5\nof the product\nauthorized for\nchildren ages 5\u201311\nyears (orange cap\nand label border)\nof the product\nauthorized for\nchildren ages\n(orange cap and\nlabel border)\nRecommended: Children who started a primary series and turned from age 4 to age 5 years between dose 2 and dose 3\nin the primary series should receive:\nof the product\nauthorized for\nchildren ages 6\n(maroon cap and\nlabel border)\nof the product\nauthorized for\nchildren ages 6\n(maroon cap and\nlabel border)\nChild turns 5\nof the product\nauthorized for\nchildren ages\n(orange cap and\nlabel border)\nAcceptable: If the following dosing occurs, it is NOT considered an error and the primary series is considered complete.","8586":"Each type of vaccine prompts our bodies to recognize and help protect us from\nthe virus that causes COVID-19. None of these vaccines can give you COVID-19. Vaccines do not use any live virus\f10\/30\/22, 9:34 AM Understanding How COVID-19 Vaccines Work | CDC\nmRNA vaccines (Pfizer-BioNTech or Moderna)\nTo trigger an immune response, many vaccines put a weakened or inactivated germ into our bodies. Not mRNA vaccines. Instead, mRNA vaccines use mRNA created in a laboratory to teach our cells how to make a protein\u2014or even just a piece of a\nprotein\u2014that triggers an immune response inside our bodies.","5935":"The EUI do not apply to the Moderna COVID-19 Vaccine, Bivalent (Original and Omicron BA.4\/BA.5), which is\nsupplied in a multiple-dose vial with a dark blue cap and a label with a gray border. What are the common side effects with the COVID-19 vaccine by Moderna? Adverse reactions following administration of the vaccine that have been reported in clinical trials and\/or post\nauthorization include injection site pain, fatigue, headache, muscle pain, joint pain, chills, nausea, vomiting,\naxillary swelling\/tenderness, fever, injection site swelling, injection site redness, and rash. What are possible serious side effects with the COVID-19 vaccine by Moderna?","9987":"Although they can receive the same product,\na different COVID-19 vaccine product can also be administered. Providers should consider observing these patients for 30\nminutes after vaccination\nPeople with a contraindication to one type of COVID-19 vaccine\n(e.g., mRNA) should not receive any doses of that type of vaccine\nand have a precaution to the other types of vaccine\u2020. For COVID-19 vaccine components see:\nPotential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects following\nIn patients who experience post-vaccination symptoms, determining the etiology (including allergic reaction, vasovagal reaction, or\nvaccine side effects) is important to determine whether a person can receive additional doses of the vaccine.","512":"The issue was resolved on\nApril 6, 2021, and the count of doses reporting \u201cUnknown Age\u201d now accurately reflects the totals reported to CDC. On April 2, 2021, New York State showed a higher than usual increase in doses administered. This is an accurate\nreflection of the data and is the result of a delay in records reported from New York. Since March 29, 2021, the total number of doses delivered, and total number of doses administered by dialysis centers\nparticipating in the Federal Dialysis Center Program are reflected in national totals and in jurisdictional totals.","4052":"10\/30\/22, 9:18 AM Frequently Asked Questions about COVID-19 Vaccination | CDC\nEspa\u00f1ol | Other Languages\nFrequently Asked Questions about COVID-19\nVaccination\nBelow are answers to commonly asked questions about COVID-19 vaccination. Have more questions? Visit How to Protect Yourself and Others. Boosters\nYes. Recent data suggest COVID-19 vaccine effectiveness at preventing infection or severe illness wanes over time,\nespecially for certain groups of people, such as people ages 65 years and older and people with immunocompromise. The emergence of COVID-19 variants further emphasizes the importance of vaccination, boosters, and prevention efforts\nneeded to protect against COVID-19.","2132":"Vaccines are effective at preventing COVID-19 in people who are breastfeeding. Recent reports\nhave shown that breastfeeding people who have received mRNA COVID-19 vaccines have antibodies in their breastmilk, which\ncould help protect their babies. More data are needed to determine what level of protection these antibodies might provide\nto the baby. CDC also recommends COVID-19 vaccines for children aged 6 months and older.","4084":"Use CDC\u2019s COVID-19 Booster Tool to learn if and when you can get boosters to stay up to date with your COVID-19\nvaccines. If I have received a J&J\/Janssen COVID-19 vaccine and a J&J\/Janssen COVID-19 booster, are\nadditional boosters recommended? \uf1aa\n\u2022\nGetting Your Vaccine\nAn employer may require that their workers be vaccinated. Check directly with your employer to see if they have any\nvaccination requirements or rules that apply to you. Am I required to get vaccinated for work? \uf1aa\nThe number of vaccine doses you need to complete your primary series depends on which vaccine you receive.","8181":"COVID-19 vaccine recommendations are based on three things:\n1. Your age\n2. The vaccine you first received, and\n3. The length of time since your last dose\nPeople who are moderately or severely immunocompromised have different recommendations for COVID-19 vaccines. You are still up to date if you receive all COVID-19 vaccine doses recommended for you and then become ill with COVID-19. You do not need to be immediately revaccinated or receive an additional booster. Boosters are an important part of protecting yourself from getting seriously ill or dying from\nCOVID-19. They are recommended for most people.","8240":"J&J\/Janssen Vaccine Overview\nJ&J\/Janssen\nPRIMARY SERIES\nPfizer BioNTech or Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 1 dose\nor last booster\nst\nUp to Date: Immediately after you have received the most recent booster recommended for you\nMore details: Staying up to date\n\u2022\n-\n\u2022\n-\n-\n-\nMixing COVID-19 Vaccine Products\nDo Not Mix Primary Series\nCDC does not recommend mixing products for your primary series doses. If you received Pfizer-BioNTech, Moderna, or\nNovavax for the first dose of your primary series, you should get the same product for all following primary series doses. Mixing Boosters\nThe following information applies to boosters for people ages 5 and older.","538":"On February 15, 2021, the COVID-19 Vaccine Tracker was updated to reflect the revised Pfizer-BioNTech emergency use\nauthorization (EUA) to allow the use of a sixth dose, if present in a vial, as authorized by the Food and Drug\nAdministration (FDA)external icon . Pfizer-BioNTech deliveries to a jurisdiction on or after February 15, 2021, will\nreflect this increase to six doses per vial compared to five doses; historical data will not be updated. The change to the\nPfizer-BioNTech dosage increases the number of doses delivered relative to the number of doses administered.","324":"Due to a data processing issue on February 27, 2022, vaccination data were not updated on CDC COVID Data Tracker\nand reflect data as of February 26, 2022. CDC is actively working to address this issue and the data will be updated when\navailable. February 25, 2022: New Hampshire reviewed data and made adjustments to reporting, resulting in a decrease of\n209,146 for the number of vaccine doses administered since December 14, 2020. The adjustment is the result of updates\nto how pharmacies report data to CDC and\/or the jurisdictions.","3340":"Until additional safety data are available, experts advise that people who develop myocarditis or pericarditis after a dose of\nModerna, Novavax, or Pfizer-BioNTech COVID-19 vaccine generally should not receive a subsequent dose of any COVID-19\nvaccine. If, after a risk assessment, the decision is made to administer a subsequent COVID-19 vaccine dose, the person\nshould wait until at least after their episode of myocarditis or pericarditis has resolved (i.e., resolution of symptoms, no\nevidence of ongoing heart inflammation or sequelae as determined by patient\u2019s clinical team). For information on potential use of Janssen COVID-19 Vaccine, see Appendix A.","653":"March 11, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 40,332\ndoses administered. March 11, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of 2,928\ndoses administered. March 04, 2022: Illinois made updates to data previously submitted to CDC that resulted a decrease\nof 18,988 doses administered. March 03, 2022: California made updates to data previously submitted to CDC that resulted in an increase\nof 16,930 doses administered. March 01, 2022: Michigan made updates to data previously submitted to CDC that resulted in a decrease of 13,028\ndoses administered.","862":"Caring for your newborn in the hospital if you have COVID-19\nCurrent evidence suggests that the chance of a newborn getting COVID-19 from their birth parent is low, especially when the\nparent takes steps (such as wearing a mask and washing hands) to prevent spread before and during care of the newborn. Decide if your newborn is rooming-in with you in the hospital. Talk to your healthcare provider about the risks and benefits of having your newborn stay in the same room with you.","8476":"Testing Travel Health Alert\nEnglish [JPG \u2013 1.06 MB] | Spanish [JPG \u2013 1.16 MB]\n\uf20a \uf20a\nFor Air Carriers and Airports\nInterim Guidance for Airlines and Airline Crew\nInterim Guidance for Transporting by Air People with\nCOVID-19 or Possible Exposure\nFor Ships\nMaritime Guidance\nShip Crew Well-Being During COVID-19\nWorker Safety Guidance\nResources for Transportation Industry\nSocial Media MMWR\f10\/30\/22, 9:42 AM Travel | CDC\nFacebook\nCDC Travelers\u2019 Health\nCDC GOV\nTwitter\nFollow CDC Travel\nFollow CDC GOV\nCDC\u2019s primary vehicle for scientific public health\ninformation and recommendations. See the latest\nCOVID-19 reports. Stay informed\nTravelers\u2019 Health\nGet the latest updates on COVID-19 and travel information\nrelated to this outbreak.","9525":"Children who turn from age 5 to age 6 years\nRecommended: Children who started a primary series and turned from age 5 to age 6 years before completion of the\nseries should receive:\n0.25 mL (25 mcg) of the\nproduct authorized for\nyears (dark blue cap\/\nmagenta label border)\n0.50 mL (50 mcg) of\nthe product authorized\nfor children ages 6\u201311\nyears (dark blue cap\/\npurple label border)\nChild turns 6\nAcceptable: : If the following dosing occurs, it is NOT considered an error and the primary series is considered complete.","4067":"What are the risks to getting a booster? \uf1aa\nYes, you are fully vaccinated even if you haven\u2019t gotten your booster yet. The definition of fully vaccinated does not\ninclude a COVID-19 booster. Fully vaccinated, however, is not the same as having the best protection. People are best\nprotected when they stay up to date with COVID-19 vaccinations, which includes getting a booster when eligible. Am I still considered \u201cfully vaccinated\u201d if I don\u2019t get a booster? \uf1aa\nYes. You are up to date if you have completed a COVID-19 vaccine primary series and received the most recent booster\ndose recommended for you by CDC.","194":"10\/30\/22, 9:37 AM Antibodies and COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nAntibodies and COVID-19\nAntibodies and the immune system\nDEFINITIONS\nThe immune system is a complex network of cells, tissues, and organs that\nwork together to protect the body from infection. Antibodies are proteins that your immune system makes to help fight\ninfection and protect you from getting sick in the future. \u2022\n\u2022\nWhen you are infected with a virus or bacteria, your immune system makes antibodies specifically to fight it. Your immune\nsystem can also safely learn to make antibodies through vaccination. Once you have antibodies to a particular disease, they\nprovide some protection from that disease.","1906":"10\/30\/22, 9:32 AM COVID-19 Vaccine Monitoring Systems for Pregnant People | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccine Monitoring Systems for Pregnant\nPeople\nLearn more about COVID-19 and pregnancy. Learn more about COVID-19 vaccination considerations for people who are pregnant or breastfeeding. Monitoring COVID-19 Vaccine Safety during Pregnancy\nCDC and the Food and Drug Administration (FDA) currently have five safety monitoring systems in place to capture\ninformation about vaccination during pregnancy and closely monitors that information reported to each system.","91":"10\/30\/22, 9:37 AM Animals and COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nAnimals and COVID-19\nCDC is reviewing this page to align with updated guidance. What You Need to Know\nThe risk of animals spreading SARS-CoV-2, the virus that causes COVID-19, to people is low. The virus can spread from people to animals during close contact. More studies and surveillance are needed to understand how SARS-CoV-2 is spread between people and animals. People with suspected or confirmed COVID-19 should avoid contact with animals, including pets, livestock, and\nwildlife.","5414":"The EUA is supported by a Secretary of Health and Human\nServices (HHS) declaration that circumstances exist to justify the emergency use of drugs and\nbiological products during the COVID-19 pandemic. The Janssen COVID-19 Vaccine has not undergone the same type of review as an FDA-approved\nor cleared product. FDA may issue an EUA when certain criteria are met, which includes that there\nare no adequate, approved, and available alternatives.","2779":"Everyone experiences these conditions differently and may want different types of support or even no support at all. To determine the most helpful steps you can take for others, first listen with compassion and ask questions about what they\nneed. CDC\u2019s How Right Now campaign provides helpful tools for navigating conversations about the type of support someone with\npost-COVID conditions may need. If you are feeling overwhelmed with emotions like sadness, depression, anxiety, or thoughts of hurting yourself or others:\nCall 911 if you feel like you want to harm yourself or others. Visit the Disaster Distress Helpline , call or text 1-800-985-5990.","9867":"Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination. London\n(United Kingdom): Department of Health & Social Care; 1 Sept 2021.\nimmunosuppressed-jcvi-advice\/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-\nprimary-dose-vaccination. Kamar, N., Abravanel, F., Marion O. Assessment of 4 doses of SARS-CoV-2 messenger RNA-based vaccine in\nrecipients of a solid organ transplant. Infection Diseases 2021;4(11):e2136030. Haggenburg S, Hofsink Q, Lissenberg-Witte BI, et al. Three-dose mRNA-1273 vaccination schedule: sufficient\nantibody response in majority of immunocompromised hematology patients. medRxiv. 2022a. Preprint. doi:\nHaggenburg S, Lissenberg-Witte B.I, van Binnendijk RS., et al. Quantitative analysis of mRNA-1273 COVID-19\nvaccination response in immunocompromised adult hematology patients. Blood Advances. 2022;6(5):1537-\n1546.","6003":"What is the available supporting evidence for a longer\/extended interval (8 weeks) between the first and\nsecond dose in the mRNA vaccine primary series schedule? New evidence suggests that an interval longer than 4 weeks between primary series doses may reduce the risk\nof myocarditis and result in greater immunogenicity and effectiveness, such that there may be greater benefits\nand fewer risks with this dosing interval; however, the benefit of delaying the second dose beyond an interval\nof 8 weeks may be limited.","3101":"\u2020\n\u2020\nPrevious vaccination with Janssen COVID-19 Vaccine\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nIn addition to following the recommended COVID-19 vaccination schedule, tixagevimab\/cilgavimab (EVUSHELD ), a\ncombination of two monoclonal antibodies, should be administered to people who are moderately or severely\nimmunocompromised every 6 months for pre-exposure prophylaxis to supplement vaccine protection. Per the product\nEUA , EVUSHELD is given at least 2 weeks after COVID-19 vaccine. People may initiate EVUSHELD at any time after this\ninterval, including between doses in the primary series and primary and booster doses.","5580":"Whatever product you choose, it should provide a good fit (i.e., fitting closely on the face without any gaps along the edges or\naround the nose) and be comfortable enough when worn properly (covering your nose and mouth) so that you can keep it on\nwhen you need to. Learn how to improve how well your mask protects you by visiting CDC\u2019s Improve How Your Mask Protects\nYou page. A respirator has better filtration, and if worn properly the whole time it is in use, can provide a higher level of protection than\na cloth or procedural mask.","4958":"New booster recommendation for people ages 12 years and older to receive 1 bivalent mRNA booster after\ncompletion of a monovalent primary series; it replaces all prior booster recommendations for this age group\nRecommendations for use of a bivalent Moderna booster dose in people ages 18 years and older\nRecommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 12 years and older\nUpdated guidance for observation periods following COVID-19 vaccination\nUpdated guidance on COVID-19 vaccination and multisystem inflammatory syndrome (MIS) in children (MIS-C) and in\nadults (MIS-A)\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adolescents ages 12\u201317 years\nReorganization of Janssen COVID-19 Vaccine guidance into an appendix\nUpdated guidance on COVID-19 vaccination following exposure to SARS-CoV-2\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nPrevious Updates\n\uf1aa\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nUpdated guidance on COVID-19 vaccination and myocarditis and pericarditis\nNew clinical considerations for coadministration of mRNA COVID-19 vaccines and orthopoxvirus vaccines\nNew guidance for use of Moderna COVID-19 Vaccine in children and adolescents ages 6\u201317 years\nNew guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children ages 6 months\u20134 years\nNew guidance for use of Moderna COVID-19 Vaccine in children ages 6 months\u20135 years\nReorganization of sections on COVID-19 vaccination recommendations and schedules\nAddition of new section in Special populations for infants and young children\nNew guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5\u201311 years\nUpdated guidance that the following people should receive a second COVID-19 booster dose:\nPeople ages 12 years and older who are moderately or severely immunocompromised\nPeople ages 50 years and older\nUpdated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-\ndepleting therapies\nClarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults\n(MIS-A)\nUpdated guidance for primary series vaccination after SARS-CoV-2 infection\nAdded considerations for the option to receive a second COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 vaccination after SARS-CoV-2 infection\nAdded guidance that people ages 12 years and older who are moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that people ages 18\u201349 years who are not moderately or severely immunocompromised and who\nreceived Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster\ndose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose\nFurther clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C)\nand adults (MIS-A) and myocarditis\nUpdated information on the availability of Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL\ndosage volume) and Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL dosage volume) for\nadministration of a 50 \u00b5g booster dose.","4190":"However, staying up to date with your COVID-19\nvaccinations means that you are less likely to have a breakthrough infection and, if you do get sick, you are less likely to\nget severely ill or die. Staying up to date with COVID-19 vaccination also means you are less likely to spread the disease to\nothers and increases your protection against new variants of SARS-CoV-2, the virus that causes COVID-19. Why should I get vaccinated if I might get COVID-19 anyway? \uf1aa\nThere is no recommended waiting period between getting a COVID-19 vaccine and other vaccines.","5551":"Some masks and respirators offer higher levels of protection than others, and some may be harder to tolerate or wear\nconsistently than others. It is most important to wear a well-fitting mask or respirator correctly that is comfortable for\nyou and that provides good protection. While all masks and respirators provide some level of protection, properly fitting respirators provide the highest level of\nprotection. Wearing a highly protective mask or respirator may be most important for certain higher risk situations, or by\nsome people at increased risk for severe disease.","4715":"People should seek medical attention immediately if they develop any of the following symptoms after receiving Janssen\nWeakness or tingling sensations, especially in the legs or arms, that is worsening and spreading to other parts of the\nbody\nDifficulty walking\nDifficulty with facial movements, including speaking, chewing, or swallowing\nDouble vision or inability to move eyes\nDifficulty with bladder control or bowel function\nDevelopment of GBS after receipt of Janssen COVID-19 Vaccine is a precaution for receiving subsequent dose(s) of Janssen\nCOVID-19 Vaccine. People who develop GBS within 6 weeks after receipt of Janssen COVID-19 Vaccine should not receive\nanother dose of Janssen COVID-19 Vaccine.","9258":"\uf6eb IF YOU TEST\nNegative\nContinue taking precautions through day\nWear a high-quality mask when\naround others at home and indoors\nin public\nYou can still develop COVID-19 up to 10\ndays after you have been exposed. \u2022\n\uf6ec IF YOU TEST\nPositive\nIsolate immediately\n*About negative test results\nAs noted in the Food and Drug Administration labeling for authorized over-the-counter antigen tests, negative test results do\nnot rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions,\nincluding infection control decisions. Masks are not recommended for children under ages 2 years and younger, or for people with some disabilities.","9407":"SPIKEVAX (COVID-19 Vaccine, mRNA), Moderna COVID-19 Vaccine, or Moderna COVID-\n19 Vaccine, Bivalent will be given to you or your child as an injection into the muscle. for the primary series for individuals 12 years of age and older without presenting any safety or effectiveness\nconcerns. Primary Series: SPIKEVAX (COVID-19 Vaccine, mRNA) and Moderna COVID-19 Vaccine\nare administered as a two-dose series, 1 month apart. A third primary series dose may be\nadministered at least 1 month after the second dose to individuals with certain kinds of\nimmunocompromise.","6528":"This is especially important\nif you are older or have severe health conditions or more than one health condition, including those on this list. Learn more\nabout how CDC develops COVID-19 vaccination recommendations. If you have a medical condition, learn more about Actions\nYou Can Take. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\nMedical Conditions\nCancer\nHaving cancer can make you more likely to get very sick from COVID-19. Treatments for many types of cancer can weaken\nyour body\u2019s ability to fight off disease. At this time, based on available studies, having a history of cancer may increase your\nrisk. Get more information:\nThe conditions on this list are in alphabetical order.","253":"We can also learn if antibodies to SARS-CoV-2 provide the same protection against new variants of the virus that causes\nCOVID-19. Studies show that people who have antibodies from an infection with the virus that causes COVID-19 can improve their\nlevel of protection by getting vaccinated. \uf209\nAntibody quiz\f10\/30\/22, 9:37 AM Antibodies and COVID-19 | CDC\nNow that you\u2019ve learned about antibodies and COVID-19, test your knowledge with an interactive quiz. Test Your Knowledge\nAntibodies for the virus that causes COVID-19 are expected to decrease, or wane, over time. True\nFalse\nNext \uf29e\nLast Updated Nov. 10, 2021","8528":"Be sure to give the airline your current contact information when booking your ticket so you can be notified if you are\nexposed to a sick traveler on a flight. What happens if there is a sick passenger on an international or domestic flight? \uf1aa\f10\/30\/22, 9:43 AM Travel: Frequently Asked Questions and Answers | CDC\nLand Travel\nCruise Travel\nFor more information, see the CDC webpage Protecting Travelers\u2019 Health from Airport to Community: Investigating\nContagious Diseases on Flights.","4400":"To find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n- \uf209\n- \uf209\n- \uf209\n-\nScheduling Vaccination Appointments\nTo schedule your COVID-19 vaccine appointment, visit a vaccine provider\u2019s online\nscheduling services. If you have a question about scheduling your appointment contact\nthe vaccination provider directly. To verify, reschedule, or cancel a COVID-19 vaccination appointment, contact the\nlocation that set up your appointment. You can get your vaccines at different locations. CDC cannot schedule, verify, reschedule, or cancel a vaccination appointment. Most vaccination providers schedule appointments online. \u2022\n\u2022\f10\/30\/22, 9:27 AM How Do I Find a COVID-19 Vaccine?","5913":"People who received both 1\nprimary dose and 1 booster dose of the Janssen COVID-19 Vaccine or 1 primary dose of the Janssen\nCOVID-19 Vaccine followed by 1 booster dose of an mRNA COVID-19 vaccine should receive an\nadditional dose with the COVID-19 vaccine by Moderna (100 \u03bcg in 0.5 mL from red-capped multidose\nvial) at least 2 months after the booster dose. \u2022 Revaccination with the COVID-19 vaccine by Moderna for any primary doses received before or during\ntreatment with certain therapies (indicated below) for persons ages 12 years and older.","5171":"Summary of Recent Changes\nUpdates as of April 18, 2022\nAs a result of a court order, effective immediately and as of April 18, 2022, CDC\u2019s January 29, 2021 Order requiring\nmasks on public transportation conveyances and at transportation hubs is no longer in effect. Therefore, CDC will not\nenforce the Order. CDC continues to recommend that people wear high-quality masks in indoor public transportation\nsettings at this time.","8230":"People ages 6 months through 64 years, and especially males ages 12 through 39 years, may consider getting the 2nd\nprimary Pfizer-BioNTech, Moderna, or Novavax 8 weeks after the 1st dose. A longer time between the 1st and 2nd primary doses may increase how much protection the vaccines offer, and\nfurther minimize the rare risk of myocarditis and pericarditis.","8816":"Occasionally, sites that copy and re-post CDC materials fail to check for updates, which may result in out-of-date\ninformation being offered to users. For that reason, we urge you to link directly to our resource documents rather than re-\nposting. If you do re-post, please check back periodically to see if there are revisions. Linking to CDC, ATSDR or HHS content should open up a new browser window to our site\/page. CDC content should not\nappear within the original window, framed by the existing site.","6031":"What is the available supporting evidence for delaying a second primary dose in people who recently had\nSARS-CoV-2 infection by 3 months from symptom onset or positive test (if infection was asymptomatic)? SARS-CoV-2 infection induces a robust humoral and cellular immune response (CDC, 2021). Additionally, a\nlonger interval of at least 3 or 6 months between infection and vaccination may improve immune response by\nallowing time for the response to mature and avoiding interference from the vaccine (Abu-Raddad L, 2021;\nZhong, 2021). Multiple large-scale studies have observed decreased risk of subsequent infection with\nantigenically similar variants by 80-93% for months after infection (CDC, 2021).","2755":"If you are experiencing a post-COVID\ncondition, you should engage in whatever coping strategies are best for your mental and physical health. Participate in specific long COVID research. The National Institutes of Health (NIH) is conducting a research project, called the RECOVER Initiative, to\nunderstand how people recover from a COVID-19 infection and why some people do not fully recover and develop\nlong COVID or post-COVID conditions. Learn more about Researching COVID to Enhance Recovery . \u2022\n\uf209\nWays to Cope with Stress\nExperts are still determining which types of medications or treatments can help to relieve the effects of post-COVID\nconditions.","8374":"Content developed by the American Psychological Association (Jared Skillings, PhD, ABPP; Erin Swedish, PhD; Robin McLeod, PhD; Mitch Prinstein, PhD, ABPP;\nand Stephen Gillaspy, PhD) in partnership with U.S. Centers for Disease Control and Prevention\nStep 3: Motivational interviewing\nStep 4: Respond to questions about vaccines, health, or mental health\nAdditional Resources:\nKey Things to Know about COVID-19 Vaccines\nFrequently Asked Questions about COVID-19 Vaccines\nAnswering Patients\u2019 Questions About COVID-19 Vaccine and Vaccination\nTalking with Parents About COVID-19 Vaccination\nHow to Tailor COVID-19 Information for Your Specific Audience\nHow to Address COVID-19 Misinformation\nPage last reviewed: November 3, 2021","695":"This did not result in a change\nto the number of doses administered. December 30, 2021: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 58,731\ndoses administered. December 29, 2021: South Dakota made updates to data previously submitted to CDC that resulted in an increase of\n3,074 doses administered. December 28, 2021: Updates were made to data previously submitted to CDC that resulted in a decrease of 9,436\ndoses administered. December 23, 2021: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 4,916\ndoses administered.","8986":"If you choose\nnot to give your permission for CDC to access medical records, you can still participate in the registry. \uf209\f10\/30\/22, 9:32 AM Vaccine Pregnancy Registry | CDC\nParticipation Is Voluntary\nParticipants are not paid for their participation in the registry, and not all people reporting pregnancy will be contacted to\nparticipate. Participation is completely voluntary, and you can opt out at any time. However, in general, many people feel\ngood about participating in activities to help answer critical scientific questions, which can help inform recommendations for\nthe public. Registry Data Collection and Use\nWho Is Participating in the Registry\nCDC is currently enrolling eligible participants.","1296":"Can COVID-19 vaccines and other vaccines be administered at the same time? \uf1aa\nPeople who previously received COVID-19 vaccination (i.e. Moderna, Novavax, or Pfizer-BioNTech) may be given\northopoxvirus vaccine (either JYNNEOS or ACAM2000) without a minimum interval between vaccinations. People who previously received orthopoxvirus vaccination (either JYNNEOS or ACAM2000), particularly adolescent or\nyoung adult males, might consider waiting 4 weeks before receiving a COVID-19 vaccine (i.e. Moderna, Novavax, or Pfizer-\nBioNTech) because of the observed risk for myocarditis and pericarditis after receipt of ACAM2000 orthopoxvirus vaccine\nand COVID-19 vaccines (i.e. Moderna, Novavax, or Pfizer-BioNTech) and the unknown risk for myocarditis and pericarditis\nafter JYNNEOS administration.","379":"The adjustments are the result of updates to how pharmacies report data to CDC and\/or the jurisdictions. On October 26, 2021, CDC corrected an error in the census denominators used to calculate percentage-based metrics\nfor the population \u2265 65 years of age in Puerto Rico. No other population groups were affected. The census counts for the population aged 65 years and older in Puerto Rico increased from 542,928 to 679,656\npeople. The census counts for the population aged 65 years and older in the US increased from 54,696,581 to 54,833,309\npeople. CDC will update its historical data on data.cdc.gov to reflect these corrections.","6198":"Active\nmonitoring includes reviewing data and medical records and evaluating the relationship to COVID-19 vaccination. Information about CDC\u2019s ongoing study of myocarditis after COVID-19 vaccination can be found here: Investigating Long-\nTerm Effects of Myocarditis | CDC\n\u2022\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nSeek medical care if you or your child have any of the specific or general symptoms of myocarditis or pericarditis\nespecially if it\u2019s within a week after COVID-19 vaccination. Healthcare Providers: For additional recommendations and clinical guidance, visit Clinical Considerations: Myocarditis after\nmRNA COVID-19 Vaccines. Should I Still Get Myself or My Child Vaccinated? 10\/30\/22, 9:31 AM Myocarditis and Pericarditis After mRNA COVID-19 Vaccination | CDC\nYes.","3507":"If your test result is positive, contact your state, territorial, local or tribal health department to tell them you have\nCOVID-19 and recently traveled on a cruise ship. Follow all state, territorial, local or tribal recommendations or requirements after travel. Frequently Asked Questions\n\uf209\nCDC has worked closely with the cruise industry, state, territorial, and local health authorities, and federal and seaport\npartners to provide a safer and healthier environment for cruise passengers and crew. Cruise ships have access to\nguidance and tools to manage their own COVID-19 mitigation programs.","8363":"Be compassionate and curious about the patient\u2019s mixed feelings, both the part of them that wants to trust that getting a\nvaccine is important and safe and the other part that feels hesitant. It is important to show support for the patient to\nincorporate their personal values and the health needs of their family and community as they make their decision. If a patient asks a question about vaccine safety, vaccine risks, or their health or mental health, respond within the\nboundaries of your competence, ethics, and scope of practice.","4066":"What are the risks to getting a booster? \uf1aa\nYes, you are fully vaccinated even if you haven\u2019t gotten your booster yet. The definition of fully vaccinated does not\ninclude a COVID-19 booster. Fully vaccinated, however, is not the same as having the best protection. People are best\nprotected when they stay up to date with COVID-19 vaccinations, which includes getting a booster when eligible. Am I still considered \u201cfully vaccinated\u201d if I don\u2019t get a booster? \uf1aa\nYes. You are up to date if you have completed a COVID-19 vaccine primary series and received the most recent booster\ndose recommended for you by CDC.","9092":"Along with staying up to date with their COVID-19 vaccines, avoiding crowds, and hand-washing, wearing a high-quality mask\nor respirator is one of multiple prevention steps that people can take to protect themselves and others in travel and\ntransportation settings. People should also follow any requirements and recommendations of state, tribal, local, and territorial authorities, authorities\nat international destinations, and operators of public transportation or transportation hubs. For more information about safer travel during the pandemic, see Domestic Travel During COVID-19 and International Travel.","11":"Even after your COVID-19 vaccination, when you are in a correctional facility, it\u2019s important\nto continue wearing a well-fitting mask, try to stay at least 6 feet away from others as\nmuch as possible, and wash your hands often. Side effects may make\nyou feel a little sick or\neven make it hard to\ndo daily activities, but\nthey should go away\nin a few days. vaccination rates and\nensure that staff and\nresidents stay up to date\non their COVID-19 vaccines. COVID-19 vaccines may\nnot fully protect you\nuntil a week or two after\nyour final shot. It takes\ntime for your body to\nbuild protection after\nany vaccination.","2714":"\u2022\n\u2022\n\u2022\nTrack your own health\nCaregivers should stay home and monitor their health for COVID-19 symptoms while caring for the person who is\nsick. Symptoms include fever, cough, and shortness of breath but other symptoms may be present as well. Trouble\nbreathing is a more serious warning sign that you need medical attention. Caregivers should continue to stay home after care is complete. Caregivers can leave their home 5 days after their\nlast close contact with the person who is sick (based on the time it takes to develop illness), or 5 days after the\nperson who is sick meets the criteria to end home isolation.","5262":"Remember to wear a high-quality mask when indoors around others at home and in public. Do not go places where you are unable to wear a mask until you are able to discontinue masking (see below). For travel guidance, see CDC\u2019s Travel webpage. Consult your doctor before ending isolation. Ending isolation without a viral test may not be an\noption for you. \u2022\n\u2022\nIf you are unsure if your symptoms are moderate or severe or if you have a weakened immune system, talk to a\nhealthcare provider for further guidance.","773":"It is part of the coronavirus family, which include common viruses that cause\na variety of diseases from head or chest colds to more severe (but more rare) diseases like severe acute respiratory syndrome\n(SARS) and Middle East respiratory syndrome (MERS). Like many other respiratory viruses, coronaviruses spread quickly through droplets that you project out of your mouth or\nnose when you breathe, cough, sneeze, or speak. The word corona means crown and refers to the appearance that coronaviruses get from the spike proteins sticking out of\nthem. These spike proteins are important to the biology of this virus.","1864":"National Protocol\nOutcome: Household transmission among community members confirmed with SARS-CoV-2\nPopulation: Households of community members with positive SARS-CoV-2 tests recruited from national commercial\nlaboratories\nExternal partner: Westat\n\uf209 \uf20c\nTest-negative prospective case control\n\uf1aa\nIncreasing Community Access to Testing (ICATT) program\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Anyone seeking testing at a pharmacy\nParticipating sites: 8,319 locations across the United States and its territories\nIVY\nInfluenza and Other Viruses in the Acutely Ill (IVY) network\nOutcome: Hospitalization with SARS-CoV-2\nPopulation: Hospitalized adults\nParticipating Sites: 21 large adult hospitals in 20 cities in 18 states:\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nCalifornia\nColorado\nFlorida\nGeorgia\nIowa\nMaryland\nMassachusetts\nMichigan\nMinnesota\nMissouri\nNew York\nNorth Carolina\nOhio\nOregon\nTennessee\nTexas\nUtah\nWashington\nPReventing Emerging Infections through Vaccine EffectiveNess Testing (PREVENT ) Sites\nOutcome: Symptomatic SARS-CoV-2 infections\nPopulation: Healthcare personnel\nParticipating Sites\nBaystate Medical Center, Springfield, MA\nJackson Memorial Hospital, Miami, FL\nOlive View-UCLA Medical Center, Los Angeles, CA\nThomas Jefferson University Hospital, Philadelphia, PA\nTruman Medical Centers, Kansas City, MO\nUniversity of Alabama Hospital, Birmingham, AL\nCommunity Regional Medical Center\/ UCSF, Fresno, CA\nUniversity of Chicago Medical Center, Chicago, IL\nUniversity of Iowa Hospitals and Clinics, Iowa City, IA\nUniversity of Massachusetts Memorial Medical Center, Worcester, MA\nLCMC Health Hospitals, New Orleans, LA\nUniversity of Mississippi Medical Center, Jackson, MS\nUniversity of Texas Southwestern Medical Center and Parkland Hospital, Dallas, TX\nUniversity of Washington Hospitals, Seattle, WA\nValleywise Health Medical Center, Phoenix, AZ.","7046":"Although the overall risks are low, if you are pregnant or were recently pregnant, you are more likely to get very\nsick from COVID-19 compared to people who are not pregnant. Additionally, if you have COVID-19 during\npregnancy, you are at increased risk of complications that can affect your pregnancy and developing baby. Having certain underlying medical conditions, and other factors, including age, can further increase the risk for\ngetting very sick from COVID-19 during or recently after pregnancy (for at least 42 days following end of\npregnancy).","1510":"HHS is responsible to ship, at U.S. Government (USG) expense, USG-\npurchased masks to agreed-upon distribution points designated by the provider. 2. Such masks will be distributed by the provider at locations readily accessible to the public. Subject to receiving\nadequate supply from the U.S. government:\na. Providers should have supply in every store that offers COVID-19 vaccine. b. Providers should prioritize maintaining highest inventory in stores servicing high socially vulnerable (SVI)\npopulations and stores with the highest demand. 3.","5216":"10\/30\/22, 9:41 AM Isolation and Precautions for People with COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nIsolation and Precautions for People with COVID-19\nIf you have COVID-19, you can spread the virus to others. There are precautions you can take to prevent spreading it to\nothers: isolation, masking, and avoiding contact with people who are at high risk of getting very sick. Isolation is used to\nseparate people with confirmed or suspected COVID-19 from those without COVID-19. These recommendations do not change based on COVID-19 Community Levels. If you have COVID-19, also see additional\ninformation on treatments that may be available to you.","7606":"CDC considers a country to have limited COVID-19 vaccine availability if less than 10% of the total population has been\nfully vaccinated against COVID-19 with any vaccine, as reported in official source data in Our World in Data (OWID). CDC reviews OWID country-level data on the proportion of a population that is fully vaccinated and updates the list of\ncountries with limited vaccine availability every three months. If country data are missing from OWID, CDC reviews other\nofficial sources of information to determine a countries\u2019 vaccination coverage (percent of the population fully vaccinated\nwith available COVID-19 vaccines).","7350":"On the same day, CDC issued the Order: Implementing Presidential Proclamation on\nSafe Resumption of Global Travel During the COVID-19 Pandemic to implement the President\u2019s direction. \uf209\nOn April 4, 2022, CDC issued an Amended Order to align post arrival public health requirements for excepted noncitizen\nnonimmigrants with current CDC recommendations. The Amended Order also clarifies that parents or guardians do not need\nto complete an attestation on behalf of children under 2 years of age; and formalizes other guidance described in Technical\nInstructions, announced in frequently asked questions, and in the attestation. This amendment is effective as of April 14, 2022\nat 12:01am EDT.","1888":"\uf209\nRead all MMWR COVID-19 vaccine effectiveness and safety reports. For the latest CDC data on COVID-19 vaccine effectiveness: CDC COVID Data Tracker\nFor more information on COVID-19 vaccine effectiveness: COVID-19 Vaccines are Effective. Page last reviewed: March 22, 2022","1730":"If a different product from the primary series is inadvertently administered for the additional or booster (third\ndose), VAERS reporting is required. VAERS reporting is not required for the following situations:\nIf a mixed series is given intentionally (e.g., due to hypersensitivity to a vaccine ingredient)\nMixing and matching of booster doses intentionally (as of October 21, 2021, mixing and matching of\nbooster doses is allowed)\nSerious AEs regardless of causality.","1935":"Last Updated July 15, 2022","8831":"10\/30\/22, 9:31 AM V-safe After Vaccination Health Checker | CDC\nEspa\u00f1ol | Other Languages\nV-safe After Vaccination Health Checker\nGet vaccinated. Get your smartphone. Get started with v-safe. Use your smartphone to tell CDC how you, or your dependent, feel after getting any dose of the COVID-19 vaccine. Your\nparticipation in v-safe helps us monitor the safety of COVID-19 vaccines for everyone. What is v-safe? V-safe provides personalized and confidential health check-ins via text messages and web surveys so you can quickly and\neasily share with CDC how you, or your dependent, feel after getting a COVID-19 vaccine.","3707":"1 The COVID-19 vaccine by Pfizer-BioNTech (brand name Comirnaty) was approved by FDA in August 2021 as a 2-dose\nprimary series for active immunization to prevent COVID-19 in persons aged \u2265 16 years. FDA also amended the EUA for the\nPfizer-BioNTech COVID-19 vaccine to authorize an additional primary dose in certain immunocompromised persons aged \u2265\n12 years and a homologous or heterologous booster dose in persons aged \u2265 18 years following primary vaccination with the\nPfizer-BioNTech or a different FDA-authorized COVID-19 vaccine.","4891":"Severe allergic reactions include:\nPossible anaphylaxis, a progressive life-threatening reaction that typically includes urticaria but also with other symptoms such as\nwheezing, difficulty breathing, or low blood pressure\nAny angioedema affecting the airway (i.e., tongue, uvula, or larynx)\nDiffuse rash which also involves mucosal surfaces (e.g., Stevens-Johnson Syndrome)\nNon-severe allergic reactions may include:\nUrticaria (hives) beyond the injection site\nAngioedema (visible swelling) involving lips, facial skin, or skin in other locations.","1925":"Through VSD, CDC will study:\nWeekly counts and rates of COVID-19 vaccination in pregnant people\nMiscarriage and stillbirth that occurs among people who received COVID-19 vaccine during pregnancy\nAdverse outcomes in pregnancy following COVID-19 vaccination, including:\nPregnancy complications\nBirth outcomes\nInfant outcomes for the first year of life (includes infant death, birth defects, and developmental disorders)\nCDC: Clinical Immunization Safety Assessment (CISA) Project \u2014 The CISA Project is a collaboration between CDC and\nseven medical research centers to provide expert consultation on individual cases of adverse events after vaccination\nand conduct clinical research studies about vaccine safety.","2762":"However, there are established ways people can manage the stress associated with a post-COVID condition. Here are some steps you can do to help manage and cope with stress:\nTake breaks from watching, reading, or listening to news stories, including social media. Hearing about the COVID-19\npandemic repeatedly can be upsetting. Take care of your body. Take deep breaths, stretch, meditate , or practice mindfulness . Try to eat healthy, well-balanced meals. Exercise, if you can. Listen to signs from your body. Get plenty of sleep. Avoid alcohol and drugs. Make time to unwind.","2133":"Vaccines are effective at preventing COVID-19 in people who are breastfeeding. Recent reports\nhave shown that breastfeeding people who have received mRNA COVID-19 vaccines have antibodies in their breastmilk, which\ncould help protect their babies. More data are needed to determine what level of protection these antibodies might provide\nto the baby. CDC also recommends COVID-19 vaccines for children aged 6 months and older.","3520":"CDC will continue to provide testing recommendations for cruise ship\noperators to follow and cruise ships will continue to report COVID-19 cases to CDC. Why was the cruise ship color-coding system removed? \uf1aa\nCruise travelers have the option of contacting their cruise line directly regarding outbreaks occurring on board their ship. How can travelers find out about COVID-19 outbreaks on cruise ships? \uf1aa\nMore Information\nIf you need to contact your health department: State & Territorial Health Department Websites\nGuidance for Cruise Ships on the Mitigation and Management of COVID-19\nTravel during the COVID-19 Pandemic\nInternational Travel\nFrequently Asked Questions and Answers for Travelers\nLast Updated July 18, 2022","61":"If You Had a Rash on the Arm where You Got a COVID-19 Shot\nIf you had a red, itchy, swollen, or painful rash where you got a COVID-19 shot, you should still get another shot at the\nscheduled date and time. This applies to second, additional, or booster shots. Your vaccination provider may recommend that\nyou get your next COVID-19 vaccine in the opposite arm, if possible. These rashes can start a few days to more than a week after your shot and are sometimes quite large.","2473":"Orvieto R, Noach-Hirsh M, Segev-Zahav A, Haas J, Nahum R, Aizer A. Does mRNA SARS-CoV-2 vaccine influence patients\u2019\nperformance during IVF-ET cycle?. Reprod Biol Endocrinol. 2021;19(1):69. Published 2021 May 13. doi:10.1186\/s12958-\n14. Wesselink AK, Hatch EE, Rothman KJ, et al. A prospective cohort study of COVID-19 vaccination, SARS-CoV-2 infection, and\nfertility [published online ahead of print, 2022 Jan 20]. Am J Epidemiol. 2022;kwac011. doi:10.1093\/aje\/kwac011\n15. Edelman A, Boniface ER, Benhar E, et al. Association Between Menstrual Cycle Length and Coronavirus Disease 2019\n(COVID-19) Vaccination: A U.S. Cohort [published online ahead of print, 2022 Jan 5]. Obstet Gynecol. 16.","8139":"COVID-19 State of Vaccine Confidence Insights Report | October 10, 2022\nAppendix: Inputs and Sources\nType Input Cadence Sources Tactics for Utilization\nSocial Media\nListening\n& Media\nMonitoring\nCommunication\nSurveillance Report\nDaily on\nweekdays\n\u0082Google news\n\u0082Meltwater\n\u0082CrowdTangle\n\u0082Native platform searches\n\u0082Share of voice topic analysis to identify\nthemes\n\u0082Emerging topics\nMeltwater Daily \u0082Facebook, Twitter, Instagram\n\u0082Blogs\n\u0082News media\n\u0082Online forums\n\u0082Share of voice topic analysis\n\u0082Emerging theme topics\n\u0082Identify high reach\/velocity topics\nOADC (Office of the\nAssociate Director of\nCommunication) Channel\nCOVID-19 Post metrics\nWeekly \u0082Sprout Social\n\u0082Native OADC account analytics\n\u0082Analyze # of posts, topics\n\u0082Success of messages, # of impressions,\nreach, # engagements\nOADC Channel Comment\nAnalysis\nDaily on\nweekdays\n\u0082Native platform searches \u0082Sentiment analysis\n\u0082Identify message gaps\/voids\nDirect Reports\nCDC-INFO Metrics Weekly \u0082CDC-INFO inquiry line list\n\u0082Prepared response (PR) usage report\n\u0082Cross-compare PR usage with inquiry\ntheme analysis\n\u0082Sentiment analysis\n\u0082Identify information gaps\/voids\nVTF Media Requests Weekly \u0082Media request line list \u0082Leading indicator for news coverage\n\u0082Identify information gaps\/voids\nWeb Metrics Weekly \u0082Top pages\n\u0082Google search queries\n\u0082Top FAQs\n\u0082Referring domains\n\u0082Identify information gaps\/voids,\n\u0082Identify keywords\/search terms, changes in\nweb traffic\nResearch\nPoll Review Weekly \u0082Harris Poll, PEW research, Gallup Poll,\nKFF\n\u0082New data related to vaccine\nhesitancy\n\u0082Identify socio-behavior indicators related\nto motivation and intention to vaccinate\nLiterature Review Weekly \u0082PubMed, LitCovid, ProQuest Central,\nAltmetric\n\u0082New data related to vaccine\nhesitancy\n\u0082Identify current vaccination intention\n\u0082Identify barriers to vaccination\nThird Party\nReports\nTanaq Social Listening\n+Media Monitoring Report\nWeekly \u0082Meltwater\n\u0082Sprout Social\n\u0082First Draft\n\u0082Native platform searches\n\u0082Trending topics\n\u0082Demographic and geographic\nconversation monitoring\nCrowdTangle content\ninsights report\nBiweekly \u0082Facebook \u0082Top pages (voices), groups\n\u0082General trends\/sentiment analysis\n\u0082News analysis through posts\nUniversity of Washington\nSt. Louis iHeard\nWeekly \u0082Proprietary methods \u0082Survey results\n\u0082Emerging threats and data deficits\n\u0082Vaccine narratives\nProject VCTR Weekly \u0082Proprietary methods \u0082National and regional trends in negative\nattitudes toward vaccination\n\u0082Conversations around Legislation\nVirality Project Weekly \u0082Proprietary methods \u0082Mis- and disinformation trends related to","1554":"Novavax COVID-19 Vaccination of Persons 18 Years of Age and Older\nPursuant to CDC\/ACIP recommendations and the July 21, 2022, Secretarial Directive, as of July 25, 2022, CDC COVID-\n19 Vaccination Program enrolled providers shall:\nIf they have the vaccine in stock, make immediately available and administer upon request a two-dose Novavax\nCOVID-19 Vaccine, Adjuvanted primary series for persons ages 18 years and older. When unable to fulfill a request from an age-eligible person for Novavax COVID-19 Vaccine, Adjuvanted, notify the\nrequesting person that providers having the vaccine can be located through the website\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nhttps:\/\/www.vaccines.gov\/.","6082":"References\nAbu-Raddad L, Chemaitelly H, Ayoub HH, et al. Association of Prior SARS-CoV-2 Infection With Risk of\nBreakthrough Infection Following mRNA Vaccination in Qatar. JAMA. 2021;326(19):1930-1939. Alejo J., et al. Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant\nRecipients: A Case Series. Transplantation 2021;105(21):e280-e281. Amirthalingam G, Bernal, JL, Andrews, NJ, et al. Serological responses and vaccine effectiveness for extended\nAtmar, R.L., et al. Heterologous SARS-CoV-2 Booster Vaccinations \u2013 Preliminary Report. medRxiv Preprint.","4222":"If you are\ngetting a COVID-19 booster, depending on your age and which type of COVID-19 vaccine you have already had, you may\nbe able to choose which type of COVID-19 vaccine booster to get. Learn more about which vaccine is available by age and how to stay up to date with your COVID-19 vaccination. Can I choose which COVID-19 vaccine I get? \uf1aa\nAfter Your Vaccine\nIf you have lost your CDC COVID-19 Vaccination card or don\u2019t have a copy of it, contact your vaccination provider directly\nto request a new vaccination card. They may be able to reissue a CDC COVID-19 Vaccination card.","5828":"To learn more about this program, visit www.hrsa.gov\/cicp\/\nor call 1-855-266-2427. How can I learn more? \u2022 Ask the vaccination provider. \u2022 Visit CDC at https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/index.html. \u2022 Visit FDA at https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-\nand-policy-framework\/emergency-use-authorization. \u2022 Contact your local or state public health department.","8500":"What should my\ntravel companions do? \uf1aa\nHow can I protect myself from COVID-19 when using different types of transportation? \uf1aa\f10\/30\/22, 9:43 AM Travel: Frequently Asked Questions and Answers | CDC\nAir Travel\nFor additional FAQs on the vaccine requirement before air travel to the U.S., visit Requirement for Proof of COVID-19\nVaccination for Air Passengers. Maintaining distance between yourself and others is often difficult on public transportation. People may not be able to\navoid crowding on airplanes, trains, or buses. Protect yourself from COVID-19 by staying up to date with your COVID-19 vaccines and by wearing a high-quality mask on\npublic transportation.","6603":"Get more information on physical activity and health, physical activity\nrecommendations, how to become more active, and how to create activity-friendly communities:\nPhysical Activity\nPhysical Activity Guidelines for Americans, 2nd edition\nMove Your Way\nActive People, Healthy Nation : Strategies to Increase Physical Activity\nNational Center on Health, Physical Activity and Disability \u2013 Building Healthy Inclusive Communities\nPregnancy\nPregnant and recently pregnant people (for at least 42 days following end of pregnancy) are more likely to get very sick from\nCOVID-19 compared with non-pregnant people.","6497":"10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nEspa\u00f1ol | Other Languages\nPeople with Certain Medical Conditions\nOverview\nIf you or your family member are at high risk for severe illness, wear a mask or respirator with greater protection in\npublic indoor spaces if you are in an area with a high COVID-19 Community Level. Talk with your healthcare provider\nabout wearing a mask in a medium COVID-19 Community Level. If you test positive and are an older adult or someone who is at high risk of getting very sick from COVID-19, treatment is\navailable.","4002":"Vaccination data in CDC\u2019s COVID Data Tracker are updated weekly on\nThursday between 1:30 pm and 8:00 pm ET. On federal holidays, updates will occur the following day. Data can be updated on different schedules and reflect data \u201cas of\u201d different dates or times of day. There can be a\ndelay between the time a vaccination record appears in a jurisdictional or federal system and when it is received\nby CDC. COVID Data Tracker\u2019s vaccination data typically have a lag time from vaccination data shown on a state\u2019s\nwebsite. The amount of lag time varies for each state.","28":"Espa\u00f1ol | Other Languages\nGet the facts about COVID-19 and the virus that causes it, including how it spreads and new variants. CDC is reviewing this page to align with updated guidance. Protect Your Family Members\nCDC recommends COVID-19 vaccines for everyone 6 months and older and boosters for\neveryone 5 years and older, if eligible.","10091":"Summary Document for\nInterim Clinical Considerations\nfor Use of COVID-19 Vaccines Currently Authorized or Approved in the United States\nAll currently authorized or approved COVID-19 vaccines\nContraindications\nHistory of:\n\u0083 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine\n\u0083 A known diagnosed allergy to a component of the COVID-19 vaccine\n\u0083 For the Janssen COVID-19 Vaccine, TTS following receipt of a previous Janssen COVID-19 Vaccine (or other COVID-19 vaccines not currently\nauthorized or approved in the United States that are based on adenovirus vectors, e.g., AstraZeneca)\u00a7\nPrecautions\n\u0083 History of anaphylaxis after any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies\n[excluding subcutaneous immunotherapy for allergies, i.e., \u201callergy shots\u201d])\n\u0083 History of multisystem inflammatory syndrome in children (MIS-C) or multisystem inflammatory syndrome in adults (MIS-A)\n\u0083 History of an immediate (within 4 hours of exposure) non-severe allergic reaction after a dose of one type of COVID-19 vaccine have a precaution\nto the same type of COVID-19 vaccine\n\u0083 Allergy-related contraindication to one type of COVID-19 vaccine have a precaution to the other types of COVID-19 vaccines.\u00b6\n\u0083 Moderate or severe acute illness, with or without fever\n\u0083 History of myocarditis or pericarditis after a dose of an mRNA or Novavax COVID-19 vaccine\n\u0083 For Janssen COVID-19 Vaccine, a history of Guillain-Barr\u00e9 syndrome**\nConsiderations for all FDA-authorized or -approved COVID-19 vaccines\nPersons receiving HCT and CAR-T-cell\ntherapy\n\u0083 If received doses of COVID-19 vaccine prior to or during HCT or CAR-T cell therapy, should be revaccinated for any monovalent primary series\nand bivalent booster doses received before or during treatment at least 3 months (12 weeks) after transplant or CAR-T-cell therapy.","4402":"To find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n- \uf209\n- \uf209\n- \uf209\n-\nScheduling Vaccination Appointments\nTo schedule your COVID-19 vaccine appointment, visit a vaccine provider\u2019s online\nscheduling services. If you have a question about scheduling your appointment contact\nthe vaccination provider directly. To verify, reschedule, or cancel a COVID-19 vaccination appointment, contact the\nlocation that set up your appointment. You can get your vaccines at different locations. CDC cannot schedule, verify, reschedule, or cancel a vaccination appointment. Most vaccination providers schedule appointments online. \u2022\n\u2022\f10\/30\/22, 9:27 AM How Do I Find a COVID-19 Vaccine?","9925":"Use the manufacturers' fact sheets for healthcare professionals\nand CDC clinical materials for healthcare professionals and to\nidentify the correct product based on the vaccine composition\nand recipient's age. People receiving mRNA or Novavax COVID-19 vaccines,\nespecially males ages 12\u201339 years, should be made\naware of the rare risk of myocarditis and\/or pericarditis\nfollowing receipt of these COVID-19 vaccines and the\nbenefit of COVID-19 vaccination in reducing the risk of\nsevere outcomes from COVID-19, including the possibility\nof cardiac sequelae. Counseling should include the need to\nseek care if symptoms of myocarditis or pericarditis, such as\nchest pain, shortness of breath, or tachycardia develop after\nvaccination, particularly in the week after vaccination.","1686":"COVID-19 vaccination providers are required to\nimplement all recommendations of the ACIP, adopted by the CDC Director, relevant to COVID-19 vaccination including:\nUse of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson)\nand mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on\nImmunization Practices \u2014 United States, July 2021\nUse of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory\nCommittee on Immunization Practices \u2014 United States, June 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Adolescents Aged 12\u201315 Years \u2014 United States, May 2021\nUpdated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen\n(Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among\nVaccine Recipients \u2014 United States, April 2021\nInterim Recommendation for Use of Janssen COVID-19 Vaccine \u2014 United States, February 2021\nInterim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine, United States 2020\nInterim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine, United States, December 2020\nInterim Recommendation for Use of Moderna COVID-19 Vaccine, United States, December 2020\n\uf209\n\uf20c\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nInterim Recommendation for Use of Moderna COVID 19 Vaccine, United States, December 2020\nUpdated Interim Recommendation for Allocation of COVID-19 Vaccine, United States, December 2020\nFind more information about vaccine administration and reporting requirements.","5928":"The EUI apply to the FDA-approved formulation of the COVID-19 vaccine by Moderna (supplied in a red-capped\nmultidose vial containing 5.5 or 7.5 mL of vaccine). The formulation supplied in a red-capped multidose vial is\nthe same formulation that is FDA-authorized under EUA and FDA-licensed under BLA on January 31, 2022. This\nformulation provides primary doses (100 \u03bcg in 0.5 mL) and booster doses (50 \u03bcg in 0.25 mL). FDA has\nexplained that the FDA-approved Spikevax and the EUA-authorized Moderna COVID-19 Vaccine supplied in\nred-capped multidose vials have the same formulation and can be used interchangeably without presenting\nany safety or effectiveness concerns.","9368":"This Vaccine Information Fact Sheet contains information to help you understand the risks and\nbenefits of SPIKEVAX (COVID-19 Vaccine, mRNA), Moderna COVID-19 Vaccine, and\nModerna COVID-19 Vaccine, Bivalent, which you or your child may receive because there is\ncurrently a pandemic of COVID-19. Talk to the vaccination provider if you have questions. SPIKEVAX (COVID-19 Vaccine, mRNA), Moderna COVID-19 Vaccine, and Moderna\nCOVID-19 Vaccine, Bivalent may not protect everyone. This Fact Sheet may have been updated. For the most recent Fact Sheet, please visit\nwww.modernatx.com\/covid19vaccine-eua. WHAT YOU NEED TO KNOW BEFORE YOU OR YOUR CHILD GET THIS\nVACCINE\nWHAT IS COVID-19?","1060":"Don\u2019t delay: Treatment must be\nstarted within days of when you\nfirst develop symptoms to be effective. \uf209\nPeople who are more likely to get very sick include older adults (ages 50 years or more, with risk increasing with age), people\nwho are unvaccinated, and people with certain medical conditions, such as chronic lung disease, heart disease, or a\nweakened immune system. Being vaccinated makes you much less likely to get very sick.","4885":"However, some\nof these people may be able to receive Novavax or Janssen COVID-19 vaccine after a detailed risk assessment (see footnote 5 below). An immediate allergic reaction to a vaccine or injectable therapy is defined as any hypersensitivity-related signs or symptoms such as urticaria\n(hives), angioedema (visible swelling), respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occurs within four hours following\nadministration.","1796":"COVID-19 Vaccine Disability Information and Access Line (DIAL)\nCall 888-677-1199 Monday-Friday from 9 a.m. to 8 p.m. (EST) or email\nDIAL@usaginganddisability.org to help:\nFind local vaccination locations\nMake appointments\nConnect to local services such as accessible transportation\nHome visits: If a child under your care is unable to leave the home, contact\nyour state, territorial, local , or tribal health department to request an in-home\nvaccination. \uf209\nChildren with service animals are\nallowed by law to have them\naccompany them at COVID-19\nvaccination sites. Related Pages\nCOVID-19 Parental Resources Kit\nCOVID-19: Toolkit for People with Disabilities\nCOVID-19 Vaccine Recommendations for Children and Teens\nLast Reviewed: October 12, 2022","5484":"As a result of these effects, people who have had COVID-19 may be more likely to develop\nnew health conditions such as diabetes, heart conditions, or neurological conditions compared with people who have not had\nCOVID-19. People experiencing any severe illness may develop health problems\nPICS refers to the health effects that may begin when a person is in an intensive care unit (ICU), and which may persist after a\nperson returns home. These effects can include muscle weakness, problems with thinking and judgment, and symptoms of\npost-traumatic stress disorder (PTSD). PTSD involves long-term reactions to a very stressful event.","9360":"2 FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and one presentation of the EUA-authorized Moderna\nCOVID-19 Vaccine (supplied in vials with red caps and labels with a light blue border) can be used interchangeably\nfor the primary series for individuals 12 years of age and older without presenting any safety or effectiveness\nconcerns. The Moderna COVID-19 Vaccine has received EUA from FDA to provide:\n\u2022 a two-dose primary series to individuals 6 years of age and older; and\n\u2022 a third primary series dose to individuals 6 years of age and older with certain kinds\nof immunocompromise.","7383":"NOTE: Certain categories of non-U.S. citizens, including immigrant visa applicants\/holders, refugees, parolees, and asylees,\nand those seeking to enter the United States by land or sea travel may be subject to separate COVID-19 vaccination\nrequirements. These individuals are advised to consult and become familiar with all applicable U.S. requirements for entry. For additional information on before, during, and after international travel, visit International Travel to and from the United\nStates.","9036":"CDC is working with state and local public health officials to monitor the spread of all variants. The Omicron variant continues to spread throughout communities and can infect people who have been\nvaccinated or have previously had COVID-19. Staying up to date with your COVID-19 vaccines reduces your risk of severe illness, hospitalization, and death from\nCOVID-19. \u2022\n\u2022\n\u2022\n\u2022\nVARIANT OF CONCERN\nOmicron\nOriginal Lineage: B.1.1.529\nThe Omicron variant, like other variants, is made up of a number of lineages and sublineages. These lineages are often very similar to each other; however, there may be differences between lineages that\naffect the behavior of the virus.","5632":"Respirators have markings printed on the\nproduct to indicate they are authentic, see appropriate N95 markings and KN95 markings. It is important to wear your respirator properly, so it forms a seal to your face. Gaps can let air with respiratory droplets leak\nin and out around the edges of the respirator. Gaps can be caused by choosing the wrong size or type of respirator or when a\nrespirator is worn with facial hair. For information about how to use your N95 correctly, see How to Use Your N95\nRespirator.","111":"Mink on mink farms. Wildlife, including white-tailed deer, mule deer, a black-tailed marmoset, a giant anteater, and wild mink near mink\nfarms. For information on how to protect pets and animals, visit\nWhat You Should Know about COVID-19 and Pets\nCompanion Animals with COVID-19: Toolkit for Health Officials\nReducing Risk of Spreading COVID-19 between People and Wildlife\nRisk of animals spreading SARS-CoV-2 to people\nThere is no evidence that animals play a significant role in spreading SARS-CoV-2, the virus that causes COVID-19, to people. There have been a few reports of infected mammalian animals spreading the virus to people during close contact, but this is\nrare.","7704":"Reports of adverse events to VAERS following vaccination, including deaths, do not necessarily mean that a vaccine\ncaused a health problem. CDC and FDA review reports of death following COVID-19 vaccination and update information as it\nbecomes available. Learn more about adverse events, including reports of death, after COVID-19 vaccination. \uf209\nBenefits of Vaccination Outweigh the Risks\nSerious side effects that could cause a long-term health problem are extremely rare following any vaccination, including\nCOVID-19 vaccination. The benefits of COVID-19 vaccination outweigh the known and potential risks. CDC continues to closely monitor the safety of COVID-19 vaccines.","1254":"Detailed information can be found in CDC\u2019s\nUse of COVID-19 Vaccines in the U.S. and the CDC Summary Document for Interim Clinical Considerations. To find locations that administer COVID-19 vaccinations, you can visit Vaccines.gov; text your zip code to 438829\n(GETVAX); call 1-800-232-0233; or check your state health department website. Visit How Do I Find a COVID-19 Vaccine to\nlearn more. Individuals interested in getting vaccinated at their local pharmacy should check the pharmacy\u2019s website to find out if\nCOVID-19 vaccine is available. Most pharmacy locations are now offering walk-in vaccination appointments as supply\nallows.","6588":"You may be eligible for EVUSHELD\nevery 6 months if you:\nAre moderately or severely immunocompromised and may not mount an adequate immune response to COVID-\n19 vaccination OR have a history of severe allergic reactions to COVID-19 vaccines, and\nDo not currently have COVID-19 and have not recently had close contact with someone with COVID-19, and\nAre an adult or adolescent ages 12 years and older weighing at least 88 pounds (40 kg)\nEVUSHELD contains different antibodies and is given by your healthcare provider before you are exposed or test\npositive for COVID-19. EVUSHELD may offer less protection against certain strains of the Omicron variant.","4830":"Space repeat dose after the dose given in error by at least\nthe minimum interval (Table 2 and Table 3). Any COVID-19 vaccine dose\nadministered at any interval after the\nrecommended interval\nDo not repeat dose. There is no maximum interval. This deviation from CDC guidance does not require VAERS reporting. Tixagevimab\/cilgavimab (EVUSHELD\u2122)\nadministered less than 14 days after\nIn general, do not repeat vaccine dose. However, based on clinical\njudgement, a repeat dose of vaccine may be administered at an interval\nof at least 28 days after the dose of vaccine.","1518":"Providers may direct bulk quantities of the masks to long-term care facilities for free distribution to their residents\nand communities at no cost subject to the requirements of this section. 4. USG will have the sole responsibility for any reporting of inventory throughput or other data. 5. Providers distributing USG-purchased N95 masks provided through this initiative agree to provide the masks at\nno charge, for use by individuals. Receipt of masks cannot be conditioned on purchase of other products or\nservices.","8268":"COVID-19 vaccines available abroad that are accepted in the United States as valid vaccinations\n\uf1aa\nVaccines approved or authorized by the U.S. Food and Drug Administration (FDA) currently include:\nPfizer-BioNTech\nModerna\nNovavax\nJohnson & Johnson\u2019s Janssen\nVaccines listed for emergency use by the World Health Organization (WHO) currently include those that are listed\nabove and the following:\nAstraZeneca\/Oxford vaccine\nSinopharm\nSinovac\nCOVAXIN\nCovovax\nCanSino\n\u2022\n\u2022\n\u2022\n\u2022\n\uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022\n\u2022\f10\/30\/22, 9:27 AM Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC\nHow to Complete a Primary Series\nReceive 1 dose of a single-dose accepted COVID-19 vaccine\nReceive 2 doses of a 2-dose accepted COVID-19 vaccine\nCDC does not recommend mixing different COVID-19 vaccines for the primary series, but CDC is aware that mixing\nCOVID-19 vaccines for the primary series is increasingly common in many countries outside the United States.","3119":"Moderate and severe immunocompromising conditions and treatments include but are not limited to:\nActive treatment for solid tumor and hematologic malignancies\nHematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status\n(e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\nReceipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\nReceipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of\ntransplantation or taking immunosuppressive therapy)\nModerate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined\nimmunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)\nAdvanced HIV infection (people with HIV and CD4 cell counts less than 200\/mm3, history of an AIDS-defining illness\nwithout immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection\nActive treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when\nadministered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs,\ncancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and\nother biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents)\nFactors to consider in assessing the general level of immune competence in a patient include disease severity, duration,\nclinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.","642":"April 8, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 11,575 doses\nadministered. April 8, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of 12,153\ndoses administered. April 6, 2022: Puerto Rico made updates to data previously submitted to CDC that resulted in a decrease of 32,684\ndoses administered. April 1, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 26,134 doses\nadministered.","1838":"The\ndescriptions include the evaluation\u2019s data collection platform, protocol (if available), outcome, population, and participating\nsites. Links to protocols that detail the evaluation designs are included when possible. The list of evaluations is organized by type of study. Choose a category below to see a description of those evaluation. Vaccine Effectiveness Evaluations by Design\nSelect a study design below to get more information about the evaluation\u2019s name, population, outcome, protocol and\nparticipating sites:\nThis page provides information for public health professionals and researchers.","1135":"Summary\nCDC uses multiple information technology systems\u202fto rapidly collect reliable data about how many doses of COVID-19\nvaccines have been distributed and how many people have been vaccinated with those doses (administration). CDC \u2014\ntogether with other federal agencies, vaccine providers, jurisdictions, state\/local public health departments, and tribal health\nfacilities across the United States \u2014 uses these data systems to inform decision-making regarding COVID-19 vaccination. The\u202fCOVID-19 Vaccination IT Overview\u202fprovides an overarching view of the vaccine IT data systems and how they integrate to\ntrack COVID-19 vaccine distribution and administration.","5688":"\u2022\n\u2022\n-\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:39 AM Masks and Respirators\nAlternative Masks for Special Situations\nFor more information on science behind improving how your mask protects you, see:\nEfficacy of Portable Air Cleaners and Masking for Reducing Indoor Exposure to Simulated Exhaled SARS-CoV-2 Aerosols\n\u2014 United States, 2021\nMaximizing Fit for Cloth and Medical Procedure Masks to Improve Performance and Reduce SARS-CoV-2 Transmission\nand Exposure, 2021\nClear masks or cloth masks with a clear plastic panel are an alternative type of\nmask that may be helpful when interacting with certain groups of people, such\nas:\nPeople who are deaf or hard of hearing\nYoung children or students learning to read\nStudents learning a new language\nPeople with disabilities\nPeople who need to see the proper shape of the mouth for making appropriate vowel sounds\nThe FDA cleared for marketing a transparent medical mask.","1742":"Also report any additional select AEs and\/or any revised safety reporting requirements per FDA\u2019s conditions of authorized\nuse of vaccine(s) throughout the duration of any COVID-19 vaccine\u2019s Emergency Use Authorization (EUA) or as outlined in\nthe Fact Sheet for Healthcare Providers for any approved COVID-19 Vaccine. \uf209\nCOVID-19 vaccination providers perform vital functions within the CDC COVID-19 Vaccination Program, including properly\nstoring, handling, and managing vaccine supply, as well as correctly administering vaccine to intended recipients. Thus, it\nis essential for providers to have a clear understanding of COVID-19 Vaccination Program requirements.","7674":"To view the current total number of COVID-19 vaccinations that have been administered in the United\nStates, please visit the CDC COVID Data Tracker. COVID-19 vaccines are safe and effective. COVID-19 vaccines were evaluated in tens of thousands of participants in clinical\ntrials. The vaccines met the Food and Drug Administration\u2019s (FDA\u2019s) rigorous scientific standards for safety, effectiveness, and\nmanufacturing quality needed to support emergency use authorization (EUA). Learn more about EUAs in this video. The Pfizer-BioNTech, Moderna, and Johnson & Johnson\/Janssen and Novavax COVID-19 vaccines will continue to undergo the\nmost intensive safety monitoring in US history.","4185":"Preparing for Your Vaccine\nCOVID-19 vaccination significantly lowers your risk of severe illness, hospitalization, and death if you get infected. Compared to people who are up to date with their COVID-19 vaccinations, unvaccinated people are more likely to get\nCOVID-19, much more likely to be hospitalized with COVID-19, and much more likely to die from COVID-19. Like all vaccines, COVID-19 vaccines are not 100% effective at preventing infection. Some people who are up to date with\ntheir COVID-19 vaccinations will get COVID-19 breakthrough infection.","2555":"\u00b6 An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines may be optimal for some people ages 6 months\u201364\nyears, especially for males ages 12\u201339 years, as it may reduce the small risk of myocarditis and pericarditis associated with these vaccines. A shorter interval (4 weeks for Moderna) between the\nfirst and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is\nincreased concern about COVID-19 community levels or an individual\u2019s higher risk of severe disease.","7960":"\u0082 It is not possible for the vaccines to cause XYZ because of this reason. \u0082 We looked into XYZ by reviewing DATA SOURCE A and DATA SOURCE B, and we didn\u2019t find it. \u0082 We know what could cause XYZ and it is CAUSE, not the vaccine. \u0082 There is no evidence that XYZ is true. \u0083 Encourage healthcare workers and public health officials to be transparent about possible vaccine side effects (myocarditis,\nfever, body aches, etc.).","3217":"Anaphylactic reactions have been rarely reported following receipt of COVID-19 vaccines. Administration of antihistamines\nbefore COVID-19 vaccination to prevent allergic reactions is not generally recommended. However, while antihistamines will\nnot prevent anaphylaxis, some experts advise antihistamine use as a means of preventing milder allergic reactions in patients\nwho might be at higher risk for allergic reactions. For more information on the assessment and potential management of\nanaphylaxis, see Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination. For more information on patient counseling, see Vaccine Recipient Education. Syncope (fainting) may occur in association with any injectable vaccine, especially in adolescents.","3366":"SARS-CoV-2 viral testing may be necessary to differentiate between\ncommon post-vaccination symptoms and symptoms of SARS-CoV-2 infection:\nPeople who develop signs and symptoms associated with COVID-19 (e.g., cough, shortness of breath, runny nose, sore\nthroat, loss of taste or smell) should isolate and be evaluated for SARS-CoV-2 infection as soon as possible. People who develop signs and symptoms that could be from either COVID-19 vaccination or SARS-CoV-2 infection (e.g.,\nfever, fatigue, headache, myalgia) without typical COVID-19 symptoms described above, and are clinically stable, should\nisolate and, if symptoms do not improve by two days post-vaccination, be evaluated for SARS-CoV-2 infection.","4173":"People with COVID-19 during pregnancy are more likely to\ndeliver a preterm (earlier than 37 weeks) or stillborn infant and may also be more likely to have other pregnancy\ncomplications. COVID-19 vaccination during pregnancy helps:\nPrevent severe illness and death in people who are pregnant\nProtect babies younger than 6 months old from hospitalization caused by COVID-19\nLearn more about vaccination considerations and the safety and effectiveness of COVID-19 vaccinations for people who\nare pregnant or breastfeeding. If you are pregnant and have received a COVID-19 vaccine, we encourage you to enroll in v-safe, CDC\u2019s smartphone-based\nsystem that provides personalized health check-ins after vaccination.","7867":"\uf209\nBD Veritor\nManufactured by BD\nSteps for testing \u2013 BD Veritor At-Home COVID-19 Test \uf209\nBinaxNow\nManufactured by Abbott\nHow To: A Guide for the BinaxNOW\u2122 COVID-19 Self-Test \uf209\nCarestart\nManufactured by Access Bio\nAccess Bio Carestart Antigen Home Test Kit \u2013 Instructional Video \uf209\nCelltrion DiaTrust\u2122\nManufactured by Celltrion USA\nHow to use the Celltrion DiaTrust\u2122 COVID-19 Ag Home Test \uf209\f10\/30\/22, 9:38 AM Self-Testing Videos | CDC\nCLINITEST\nManufactured by Siemens\nHow to use the CLINITEST\u00ae Rapid COVID-19 Antigen Self-Test (prefilled extraction tubes)\n\uf209\nFlowFlex\nManufactured by ACON Laboratories\nFlowFlex SARS-CoV-2 Antigen Rapid Test with Prefilled Extraction Buffer Tubes \uf209\niHealth\nManufactured by iHealth\niHealth COVID-19 Antigen Rapid Test \u2013 Self-testing accessible to everyone \uf209\nInBios SCoV-2 Ag Detect\u2122\nManufactured by InBios\nInBios SCoV-2 Ag Detect\u2122 Rapid Test \uf209\nInteliSwab\nManufactured by OraSure Technologies\nInteliSwab\u2122 COVID-19 Rapid Test Training Video (OTC) \uf209\nQuickVue\nManufactured by Quidel\nQuickVue At-Home (quickvueathome.com) \uf209\nCOVID-19 At-Home Test\nManufactured by BD Sensor\nHow to use the COVID-19 At-Home Test \uf209\f10\/30\/22, 9:38 AM Self-Testing Videos | CDC\nLast Updated Feb. 10, 2022","8457":"I have ended isolation but still need to continue\nwearing my mask per CDC\u2019s guidance. Do not travel on public transportation such as\nairplanes, buses, and trains if you will not be able\nto wear a high-quality mask or respirator when\naround others indoors for the full duration of your\ntrip. If you travel, wear a high-quality mask or\nrespirator the entire time you are around others\nindoors. Traveling by private vehicle (if possible) can lower\nthe chances of spreading COVID-19 to others. I was exposed to a person with COVID-19 in the\npast 10 days.","7174":"This Vaccine Information Fact Sheet contains information to help you understand the\nrisks and benefits of COMIRNATY (COVID-19 Vaccine, mRNA), the Pfizer-BioNTech\nCOVID-19 Vaccine, and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent, which you\nmay receive because there is currently a pandemic of COVID-19. Talk to your\nvaccination provider if you have questions. This Fact Sheet may have been updated. For the most recent Fact Sheet, please see\nwww.cvdvaccine.com. WHAT YOU NEED TO KNOW BEFORE YOU GET ANY OF THESE VACCINES\nWHAT IS COVID-19? COVID-19 disease is caused by a coronavirus called SARS-CoV-2. You can get\nCOVID-19 through contact with another person who has the virus.","5225":"This information is intended for a general audience. Healthcare professionals should see Ending Isolation and Precautions for\nPeople with COVID-19. This CDC guidance is meant to supplement\u2014not replace\u2014any federal, state, local, territorial, or tribal\nhealth and safety laws, rules, and regulations. Regardless of vaccination status, you should isolate from others when you have COVID-19. You should also isolate if you are sick and suspect that you have COVID-19 but do not yet have test results. If your results are\npositive, follow the full isolation recommendations below. If your results are negative, you can end your isolation.","8391":"Vaccine manufacturers, CDC, other federal entities, public health agencies, and professional organizations provide a\nvariety of training resources, including print materials, training modules, webinars, seminars, and videos. For healthcare\nprofessionals who will be preparing and administering vaccine, it is essential that training programs also include an\nTraining recommendations\n\uf1aa\f10\/30\/22, 9:17 AM Training and Education for COVID-19 Vaccination | CDC\nobservation component and competency assessment. The following sections describe trainings and competencies\nhealthcare professionals need based on their roles and experience to ensure the vaccine cold chain is protected and\nvaccines are administered safely to recipients.","9552":"\u0083 A 2-dose primary series using the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 5\u201311 years (orange\ncap and label border)\fSpecial Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nPfizer-BioNTech COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group (Continuted)\nOR\n\u0083 A 3-dose primary series initiated with the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 6 months\u20134\nyears (maroon cap and label border).","3364":"SARS-CoV-2 viral testing may be necessary to differentiate between\ncommon post-vaccination symptoms and symptoms of SARS-CoV-2 infection:\nPeople who develop signs and symptoms associated with COVID-19 (e.g., cough, shortness of breath, runny nose, sore\nthroat, loss of taste or smell) should isolate and be evaluated for SARS-CoV-2 infection as soon as possible. People who develop signs and symptoms that could be from either COVID-19 vaccination or SARS-CoV-2 infection (e.g.,\nfever, fatigue, headache, myalgia) without typical COVID-19 symptoms described above, and are clinically stable, should\nisolate and, if symptoms do not improve by two days post-vaccination, be evaluated for SARS-CoV-2 infection.","4498":"The closer you are to a greater number of people, the\nmore likely you are to be exposed to the virus that causes COVID-19. To avoid this possible exposure, you may want to\navoid crowded areas or keep distance between yourself and others These actions also protect people who are at high\f10\/30\/22, 9:39 AM How to Protect Yourself and Others | CDC\navoid crowded areas, or keep distance between yourself and others. These actions also protect people who are at high\nrisk for getting very sick from COVID-\n19 in settings where there are multiple\nrisks for exposure.","2883":"Additional product-specific information is available from CDC for all FDA-authorized or -approved vaccines. Moderna COVID-19 Vaccine supplied in a vial with a dark blue cap and a label with a purple border stating \u201cBOOSTER DOSES ONLY Booster dose: 0.5mL \u201d\nis FDA-authorized for use in children ages 6\u201311 years as a primary series dose. It is not authorized for the booster dose.","7126":"\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\n\u2022\n\u2022\n-\n-\n\u2022\nIf You Are Sick or Think You Were Exposed to COVID-19\nIf you have any symptoms of COVID-19, contact your healthcare professional within 24 hours, and follow steps for when you\nfeel sick. If you are diagnosed with COVID-19, learn about breastfeeding and caring for newborns when the mother has COVID-19. Current evidence suggests that breast milk is not likely to spread the virus to babies.","3997":"Because CDC removes duplicate records, data presented on the COVID Data Tracker might differ\nfrom data listed in jurisdictional Immunization Information Systems (IIS) and dashboards. CDC makes every effort to\nreconcile doses administered that are reported through more than one system. How does CDC manage data from multiple sources? \uf1aa\nEach state or territorial health department is responsible for establishing internal operations and schedules for\nreporting data. As a result, there are differences among states in the frequency of reporting. Data on doses of vaccine delivered and administered include data received by CDC as of 6:00 am ET on\nWednesday, the day of weekly reporting.","4398":"If You Are Homebound\nContact your healthcare provider or your state or local health department for information about getting a COVID-19\nvaccine. In many states, you may also dial 211 to connect to essential community services. Contact groups that are advocates for people who are homebound or that provide home health services. Call The Aging Network at 1-800-677-1116. Search for services by ZIP code with the Eldercare Locator . Contact the Disability Information and Access Line (DIAL) at 1-888-677-1199. Call the hotline for Medicare recipients at 1-800-633-4227 (TTY 1-877-486-2048).","9376":"COVID-19 is caused by a coronavirus called SARS-CoV-2. This type of coronavirus has not\nbeen seen before. You can get COVID-19 through contact with another person who has the\nvirus. It is predominantly a respiratory illness that can affect other organs. People with COVID-\n19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever or\nchills; cough; shortness of breath; fatigue; muscle or body aches; headache; new loss of taste or\nsmell; sore throat; congestion or runny nose; nausea or vomiting; diarrhea.","6539":"We will update the list as we learn more. A person with a condition that is not listed may still be at greater risk of getting very sick from COVID-19 than\nother people who do not have the condition. It is important that you talk with your healthcare provider about your\nrisk. \u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nCancer\nCOVID-19: What People with Cancer Should Know \u2013 National Cancer Institute\nChronic kidney disease\nHaving chronic kidney disease of any stage can make you more likely to get very sick from COVID-19.","4566":"Filtration: Traps particles on a filter\nto remove them from the air. Bring as much fresh air into your home as possible\nBringing fresh, outdoor air into your home helps keep virus particles from accumulating inside. If it\u2019s safe to do so, open doors and windows as much as you can to bring in fresh, outdoor air. While it\u2019s better to\nopen them widely, even having a window cracked open slightly can help. If you can, open multiple doors and windows to allow more fresh air to move inside.","4458":"There are two types of viral tests: rapid tests and laboratory tests. These tests might use samples from your nose or\nthroat, or saliva. Knowing if you are infected with the virus that causes COVID-19 allows you to take care of yourself and\ntake actions to reduce the chance that you will infect others. CDC\u2019s Viral Testing Tool is an online, mobile-friendly tool that asks a series of questions and recommends actions and\nresources based on your responses. It can help you interpret what your test result means. You can also access tests the following ways:\nOrder free self-tests at COVIDtests.gov .","2480":"Trogstad, L. Increased Occurrence of Menstrual Disturbances in 18- to 30-Year-Old Women after COVID-19 Vaccination\n17. Gonzalez DC, Nassau DE, Khodamoradi K, et al. Sperm Parameters Before and After COVID-19 mRNA Vaccination. JAMA. 18. Carlsen E, Andersson AM, Petersen JH, Skakkebaek NE. History of febrile illness and variation in semen quality. Hum\n\uf209\n\uf209\n\uf209\n\uf209\n\uf209\n\uf209\n\uf209\n\uf209\n\uf209\n\uf209\n\uf209\nLast Updated July 14, 2022","506":"The issue has since\nbeen resolved and totals for April 14, 2021 accurately reflect the total doses administered. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nOn April 6, 2021, improvements in reporting vaccine recipient race\/ethnicity data to CDC resulted in an increase in the\nnumber of people for whom race\/ethnicity data are available. These improvements will continue to allow for better\nrace\/ethnicity data reporting. Due to a data synchronization error between April 3 and 5, 2021, the daily count of doses reporting \u201cUnknown Age\u201d in\nthe COVID-19 Case Surveillance Public Use Data incorrectly appeared higher than expected.","4964":"New booster recommendation for people ages 12 years and older to receive 1 bivalent mRNA booster after\ncompletion of a monovalent primary series; it replaces all prior booster recommendations for this age group\nRecommendations for use of a bivalent Moderna booster dose in people ages 18 years and older\nRecommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 12 years and older\nUpdated guidance for observation periods following COVID-19 vaccination\nUpdated guidance on COVID-19 vaccination and multisystem inflammatory syndrome (MIS) in children (MIS-C) and in\nadults (MIS-A)\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adolescents ages 12\u201317 years\nReorganization of Janssen COVID-19 Vaccine guidance into an appendix\nUpdated guidance on COVID-19 vaccination following exposure to SARS-CoV-2\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nPrevious Updates\n\uf1aa\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nUpdated guidance on COVID-19 vaccination and myocarditis and pericarditis\nNew clinical considerations for coadministration of mRNA COVID-19 vaccines and orthopoxvirus vaccines\nNew guidance for use of Moderna COVID-19 Vaccine in children and adolescents ages 6\u201317 years\nNew guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children ages 6 months\u20134 years\nNew guidance for use of Moderna COVID-19 Vaccine in children ages 6 months\u20135 years\nReorganization of sections on COVID-19 vaccination recommendations and schedules\nAddition of new section in Special populations for infants and young children\nNew guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5\u201311 years\nUpdated guidance that the following people should receive a second COVID-19 booster dose:\nPeople ages 12 years and older who are moderately or severely immunocompromised\nPeople ages 50 years and older\nUpdated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-\ndepleting therapies\nClarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults\n(MIS-A)\nUpdated guidance for primary series vaccination after SARS-CoV-2 infection\nAdded considerations for the option to receive a second COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 vaccination after SARS-CoV-2 infection\nAdded guidance that people ages 12 years and older who are moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that people ages 18\u201349 years who are not moderately or severely immunocompromised and who\nreceived Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster\ndose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose\nFurther clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C)\nand adults (MIS-A) and myocarditis\nUpdated information on the availability of Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL\ndosage volume) and Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL dosage volume) for\nadministration of a 50 \u00b5g booster dose.","7273":"Vaccinations may not provide full\nimmunity to COVID-19 in people who are immunocompromised, and you should\ncontinue to maintain physical precautions to help prevent COVID-19. Your close\ncontacts should be vaccinated as appropriate. WHAT IF I AM PREGNANT OR BREASTFEEDING? If you are pregnant or breastfeeding, discuss your options with your healthcare\nprovider. WILL THESE VACCINES GIVE ME COVID-19? No. These vaccines do not contain SARS-CoV-2 and cannot give you COVID-19. KEEP YOUR VACCINATION CARD\nWhen you get your first COVID-19 vaccine, you will get a vaccination card. Remember\nto bring your card when you return.","4416":"10\/30\/22, 9:39 AM How to Protect Yourself and Others | CDC\nEspa\u00f1ol | Other Languages\nHow to Protect Yourself and Others\nCOVID-19 Prevention Actions\nThere are many ways your actions can help protect you, your household, and your community from severe illness from\nCOVID-19. CDC\u2019s COVID-19 Community Levels provide information about the amount of severe illness in the community\nwhere you are located to help you decide when to take action to protect yourself and others. COVID-19 County Check\nFind community levels and prevention steps by county. Data updated weekly.","9997":"Vaccine may be given, but\ncounsel patients about unknown risks of developing a severe\nallergic reaction and balance these risks against the benefits\nof vaccination. Deferral of vaccination and\/or consultation\nwith an allergist-immunologist should be considered. Providers should consider observing these patients for\n30 minutes after vaccination. Prevaccination Checklist\nfor COVID-19 Vaccines\nInformation for Healthcare Professionals\n8. Clinical Considerations:\nResponse Consideration\nHistory of myocarditis\nor pericarditis\n\u0083 Development of myocarditis or pericarditis after a dose of an mRNA (Moderna, Pfizer-BioNTech)\nor Novavax COVID-19 vaccine is a precaution to a subsequent dose of any COVID-19 vaccine and\nsubsequent doses should generally be avoided.","5243":"Do not go places where you are unable to wear a mask. For travel guidance, see CDC\u2019s Travel webpage. Do not travel. Stay home and separate from others as much as possible. Use a separate bathroom, if possible. Take steps to improve ventilation at home, if possible. Don\u2019t share personal household items, like cups, towels, and utensils. Monitor your symptoms. If you have an emergency warning sign (like trouble breathing), seek emergency medical care\nimmediately. Learn more about what to do if you have COVID-19. End isolation based on how serious your COVID-19 symptoms were.","1709":"As part of the COVID-19 Vaccination Provider Agreement, providers are required to:\nStore and handle COVID-19 vaccines under proper conditions, including maintaining cold chain conditions and chain\nof custody at all times in accordance with an EUA or vaccine package insert, manufacturer guidance, and CDC\nguidance in the Vaccine Storage and Handling Toolkit. Monitor storage unit temperatures at all times, using equipment and practices that comply with guidance in the\ntoolkit. Comply with immunization program guidance for handling temperature excursions. Monitor and comply with COVID-19 vaccine expiration dates.","6936":"Also, mention all of your medical conditions, including if you:\n\u2022 Have any allergies\n\u2022 Have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining\noutside the heart)\n\u2022 Have a fever\n\u2022 Have a bleeding disorder or are on a blood thinner\n\u2022 Are immunocompromised or are on a medicine that affects your immune system\n\u2022 Have ever fainted in association with an injection\fPfizer-BioNTech COVID-19 Vaccine EUI Recipient Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nHow is the COVID-19 vaccine by Pfizer-BioNTech given? COVID-19 vaccine by Pfizer-BioNTech is given as an injection into the muscle.","4930":"Table of Contents \uf426\nReferences and Previous Updates\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine \u2014 United States, December 2020\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Moderna COVID-19 Vaccine\n\u2014 United States, December 2020\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Janssen COVID-19 Vaccine \u2014\nUnited States, February 2021\nUpdated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson\n& Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine\nRecipients\u2014United States, April 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Adolescents Aged 12\u201315 years \u2014 United States, May 2021\nUse of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory\nCommittee on Immunization Practices \u2014 United States, June 2021\nUse of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and\nmRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization\nPractices \u2014 United States, July 2021\nUse of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged \u226516 Years: Recommendations of the Advisory Committee\non Immunization Practices \u2014 United States, September 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendations for Additional Primary and Booster\nDoses of COVID-19 Vaccines \u2014 United States, 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Children Aged 5\u201311 Years \u2014 United States, November 2021\nUse of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory\nCommittee on Immunization Practices \u2014 United States, December 2021\nThe Advisory Committee on Immunization Practices\u2019 Recommendation for Use of Moderna COVID-19 Vaccine in Adults\nAged \u226518 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-\nReferences\n\uf1aa\n\uf20c\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\n19 Vaccines \u2014 United States, February 2022\nInterim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-\nBioNTech COVID-19 Vaccines in Children Aged 6 Months\u20135 Years \u2014 United States, June 2022\nInterim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19\nVaccine in Persons Aged \u226518 years \u2014 United States, July 2022.","9290":"\uf209\nVaccination Helps Prevent Multisystem Inflammatory Syndrome\nin Children (MIS-C) Associated with COVID-19\nChildren and teens who get COVID-19 can develop serious complications, such as multisystem inflammatory syndrome in\nchildren (MIS-C). MIS-C is a condition where different body parts become inflamed, including the heart, lungs, kidneys, brain,\nskin, eyes, or gastrointestinal organs. Since the beginning of the pandemic, thousands of cases of MIS-C have been reported. Children ages 5 through 11 years are\nmost frequently affected by MIS-C, with almost half of all reported cases occurring in children in this age group.","7055":"Severe illness means that a person with COVID-19 may need:\nHospitalization\nAdmission into an intensive care unit (ICU)\nA ventilator or special equipment to help them breathe\nPeople with COVID-19 who become severely ill can die. See why pregnancy is included in the list of underlying medical\nconditions that increase a person\u2019s risk of severe illness from COVID-19.","9074":"\uf106 As of 12:01AM ET on June 12, 2022, CDC will no longer require air passengers traveling from a foreign\ncountry to the United States to show a negative COVID-19 viral test or documentation of recovery from\nCOVID-19 before they board their flight. For more information, see Rescission: Requirement for Negative\nPre-Departure COVID-19 Test Result or Documentation of Recovery from COVID-19 for all Airline or Other\nAircraft Passengers Arriving into the United States from Any Foreign Country. Learn when you should get tested for COVID-19, how you can find tests, and what your test\nresult means.","5613":"Procedure Masks\nWear procedure masks with\nA proper fit over your nose, mouth, and chin to prevent leaks\nMultiple layers of non-woven material\nA nose wire\n\u2022\n\u2022\n\u2022\nDo NOT wear procedure masks with\nGaps around the sides of the face or nose (see example)\nWet or dirty material\n\u2022\n\u2022\nWays to have better fit and extra protection with cloth and disposable masks\nWear two masks (disposable mask underneath AND cloth mask on top)\nCombine either a cloth mask or disposable mask with a fitter or brace\nKnot and tuck ear loops of a 3-ply mask where they join the edge of the\nmask\nFor disposable procedure masks, fold and tuck the unneeded\nmaterial under the edges.","7860":"10\/30\/22, 9:38 AM Self-Testing Videos | CDC\nEspa\u00f1ol | Other Languages\nSelf-Testing Videos\nManufacturer instructions for doing rapid COVID-19 tests\nManufacturer Videos\nBelow are the available instruction videos for using FDA-authorized self-tests. Visit FDA.gov for a complete list of\nauthorized tests. Learn more about Self-Testing at home or anywhere and find CDC instructional videos, including when to use a self-test\nand how to interpret results.","2907":"Monovalent mRNA vaccines are no longer authorized as a booster dose for people ages 5 years and older. A monovalent Novavax booster dose (instead of a bivalent mRNA booster dose) may be used in limited situations in people\nages 18 years and older who completed any FDA-approved or FDA-authorized monovalent primary series, have not received\nany previous booster dose(s), and are unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available)\nor unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.","4261":"People who already had COVID-19 and do not get vaccinated after their recovery are more likely to get COVID-19 again\nthan those who get vaccinated after their recovery. If you were given monoclonal antibodies or convalescent plasma while sick with COVID-19 you do not need to wait to get\nvaccinated. \u2022\n\u2022\n\u2022\nWhen you can wait\n\uf1aa\nIf you recently had COVID-19, you may consider delaying your next vaccine dose (primary dose or booster) by 3\nmonths from when:\nyour symptoms started,\nyou first received a positive test if you had no symptoms.","5621":"These masks have markings printed\non the product to indicate they are authentic. Follow manufacturer\u2019s instructions on how to wear, store, and clean or properly\ndispose of the mask. These should be worn according to the manufacturer\u2019s\ninstructions without modifications.","8574":"\u2022\n\u2022\n\u2022\n\u2022\nCOVID-19 vaccines help our bodies develop immunity to the virus that causes COVID-19 without us having to get the\nillness. Different types of vaccines work in different ways to offer protection. But with all types\nof vaccines, the body is left with a supply of \u201cmemory\u201d T-lymphocytes as well as B-\nlymphocytes that will remember how to fight that virus in the future. It typically takes a few weeks after vaccination for the body to produce T-lymphocytes\nand B-lymphocytes.","1840":"The\ndescriptions include the evaluation\u2019s data collection platform, protocol (if available), outcome, population, and participating\nsites. Links to protocols that detail the evaluation designs are included when possible. The list of evaluations is organized by type of study. Choose a category below to see a description of those evaluation. Vaccine Effectiveness Evaluations by Design\nSelect a study design below to get more information about the evaluation\u2019s name, population, outcome, protocol and\nparticipating sites:\nThis page provides information for public health professionals and researchers.","3529":"10\/30\/22, 9:35 AM Data Definitions for COVID-19 Vaccinations in the United States\nEspa\u00f1ol | Other Languages\nData Definitions for COVID-19 Vaccinations in the\nUnited States\nHow CDC Estimates Vaccination Coverage\nCDC estimates the number of people receiving at least one dose, the number of people who are fully vaccinated, and the\nnumber of people with booster doses. CDC estimates are based on data that include a dose number (first, second, boosters,\nor additional dose). To protect the privacy of vaccine recipients, CDC receives data without any personally identifiable\ninformation (deidentified data). Each jurisdiction or provider uses a unique person identifier to link records within their own\nsystems.","8068":"In addition, CDC is communicating with key medical groups and continues to provide updated reporting and\nlaboratory guidance for clinicians who may identify hepatitis of unknown cause in children.126\n\u0083 When will vaccines be available for children ages 5 years and younger?d\n\u0082 As of June 18, 2022, everyone ages 6 months and older is recommended to get a Moderna or Pfizer-BioNTech COVID-19\nIdentified misinformation themes that may impact vaccine confidence\n\u0083 Some social media users believe authorizing vaccines in children is only a ploy for pharmaceutical companies to make\n\u0083 Some social media users claim that COVID-19 cases in children are always mild.129,130,131 w\nWays public health and partners can take action to improve vaccine confidence\n\u0083 Encourage primary care providers and other medical professionals who care for children to explain the benefits of COVID-19\nvaccination to parents and guardians.","8289":"10\/30\/22, 9:37 AM Symptoms of COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nSymptoms of COVID-19\nPeople with COVID-19 have had a wide range of symptoms reported \u2013 ranging from mild symptoms to severe illness. Symptoms may appear 2-14 days after exposure to the virus. Anyone can have mild to severe symptoms. This list does not include all possible symptoms. Symptoms may change with new COVID-19 variants and can vary depending\non vaccination status. CDC will continue to update this list as we learn more about COVID-19.","5186":"How is CDC using my information? The information you provide will contribute to what we know about the safety of COVID-19 vaccines, which helps us get a\nmore complete picture of the risks and benefits of COVID-19 vaccination. What You Need to Know\nCDC is conducting surveys of patients (or their parents or guardians) and healthcare providers to gather\ninformation about myocarditis after COVID-19 vaccination. CDC is contacting people who meet the case definition for myocarditis following COVID-19 vaccination.","5353":"You should seek medical attention\nright away if you have any of the following symptoms after receiving the Janssen COVID-19\nVaccine:\n\u2022 Shortness of breath,\n\u2022 Chest pain,\n\u2022 Leg swelling,\n\u2022 Persistent abdominal pain,\n\u2022 Severe or persistent headaches or blurred vision,\n\u2022 Easy bruising or tiny blood spots under the skin beyond the site of the injection. Immune Thrombocytopenia (ITP)\nImmune Thrombocytopenia (ITP) is a disorder that can cause easy or excessive bruising and\nbleeding due to very low levels of platelets. ITP has occurred in some people who have received\nthe Janssen COVID-19 Vaccine.","5896":"\u25aa Received COVID-19 vaccine dose(s) during treatment with B-cell-depleting therapies\nover a limited period\n\u25aa Received COVID-19 vaccine dose(s) prior to or during treatment involving HCT or CAR-\nT-cell therapy\nWhat are the doses and intervals of the COVID-19 vaccine by Moderna for primary and\/or additional doses? \u2022 A second primary dose of the COVID-19 vaccine by Moderna (100 \u03bcg in 0.5 mL from red-capped\nmultidose vial) should be administered intramuscularly to persons ages 12 years and older; this may be\n4\u20138 weeks after the first primary dose.","2053":"10\/30\/22, 9:30 AM COVID-19 Vaccines While Pregnant or Breastfeeding\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccines While Pregnant or Breastfeeding\nWhat You Need to Know\nCOVID-19 vaccination is recommended for all people aged 6 months and older. This includes people who are\npregnant, breastfeeding, trying to get pregnant now, or those who might become pregnant in the future. This also\nincludes infants ages 6 months and older born to people who were vaccinated or had a COVID-19 infection before\nor during pregnancy. If you are pregnant or were recently pregnant, you are more likely to get very sick from COVID-19 compared\nto people who are not pregnant.","3209":"Unless people have a contraindication to vaccination, they should be encouraged to complete the series to optimize\nprotection against COVID-19 even if they experience local or systemic symptoms following the first dose. People receiving Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines, especially males ages 12\u201339 years, should be\nmade aware of the rare risk of myocarditis and pericarditis following receipt of these COVID-19 vaccines. Counseling should\ninclude the need to seek care if symptoms of myocarditis or pericarditis develop after vaccination, particularly in the week\nafter vaccination. See COVID-19 vaccination and myocarditis and pericarditis for additional information.","6592":"TM \uf209 TM\n\u2022\n\u2022\n\u2022\nTM\nTM\nTM\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022\n\u2022 \uf209\n\u2022 \uf209\f10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nNational Institute of Mental Health (NIMH) Depression\nMood Disorders\nOverweight and obesity\nOverweight (defined as a body mass index (BMI) is 25 kg\/m or higher, but under 30 kg\/m ), obesity (BMI is 30 kg\/m or\nhigher, but under 40 kg\/m ), or severe obesity (BMI is 40 kg\/m or higher), can make you more likely to get very sick from\nCOVID-19. The risk of severe illness from COVID-19 increases sharply with higher BMI.","2857":"These clinical considerations provide information to healthcare professionals and public health officials on use of COVID-19\nvaccines. They are informed by the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control\nand Prevention\u2019s (CDC) recommendations, the U.S. Food and Drug Administration\u2019s (FDA) approval or Emergency Use\nAuthorization (EUA) of COVID-19 vaccines, CDC\u2019s Emergency Use Instructions (EUI) for FDA-approved vaccines, the World\nHealth Organization (WHO) emergency use listing (EUL), ACIP\u2019s general best practice guidelines for immunization, and\nexpert opinion.","8660":"The clinical trials for COVID-19 vaccines have involved tens of thousands of volunteers of different ages,\nraces, and ethnicities. Clinical trials for vaccines compare outcomes (such as how many people get sick) between people who\nare vaccinated and people who are not. Results from these trials have shown that COVID-19 vaccines are\nsafe and effective, especially against severe illness, hospitalization, and death. 10\/30\/22, 9:34 AM Understanding How COVID-19 Vaccines Work | CDC\nAuthorization or Approval\n\uf1aa\n\uf2a7 Before vaccines are made available to people in real-world settings, FDA assesses the findings from\nclinical trials.","378":"The Pfizer-BioNTech COVID-19 Vaccine recommended for adults and adolescents has\nnot been recommended for use among children ages 5 through 11. November 1, 2021: Hawaii does not provide CDC with county-of-residence information. As such, CDC is suppressing\ncounty-level data for Hawaii residents, including those who received vaccines in other states or territories. From October 22 to October 31, 2021, vaccination data on residents of Hawaii receiving vaccines in other states\nwere displayed on COVID Data Tracker. On October 29, 2021, data review and reporting adjustments for Kentucky resulted in a decrease of 411,224 doses\nadministered.","2250":"10\/30\/22, 9:29 AM COVID-19 Vaccines for Long-term Care Residents | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccines for Long-term Care Residents\nCDC is reviewing this page to align with updated guidance. CDC recommends COVID-19 vaccines for residents of long-term care (LTC)\nages 6 months and older, and boosters for everyone 5 years and older, if\neligible. Many LTC settings, such as residential care, assisted living, nursing homes,\nand continuing care retirement communities provide care to older adults\nwith underlying medical conditions, often living closely together.","8307":"*This list is not all possible symptoms. Please call your medical provider for any other symptoms that are severe or\nconcerning to you. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:37 AM Symptoms of COVID-19 | CDC\n\uf277 Difference Between Flu and COVID-19\nInfluenza (Flu) and COVID-19 are both contagious respiratory illnesses, but they are caused by different\nviruses. COVID-19 is caused by infection with a coronavirus named SARS-CoV-2, and flu is caused by infection\nwith influenza viruses. You cannot tell the difference between flu and COVID-19 by symptoms alone because\nsome of the symptoms are the same. Some PCR tests can differentiate between flu and COVID-19 at the\nsame time.","4208":"\uf1aa\f10\/30\/22, 9:18 AM Frequently Asked Questions about COVID-19 Vaccination | CDC\nNo. You should wait to be vaccinated until after you\u202fcomplete your isolation period. People who have symptoms will end\nisolation at a different time than people who do not have symptoms. This also applies to people who have been\nvaccinated but get COVID-19 before getting any additional or booster doses. Additionally, you may consider delaying your\nnext vaccine (primary dose or booster) by 3 months from when your symptoms started or, if you had no symptoms, when\nyou received a positive test.","6898":"Symptoms may\nappear 2 to 14 days after exposure to the virus. Symptoms may include: fever or chills, cough, shortness of\nbreath, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or\nrunny nose, nausea or vomiting, and diarrhea. Who can receive primary and additional dose(s) of the COVID-19 vaccine by Pfizer-BioNTech under the\nEUI? People who can receive the COVID-19 vaccine by Pfizer-BioNTech under EUI are described below.","8686":"If you have risk factors, have a COVID-19 plan in place in case you get sick, and discuss that plan\nwith your healthcare provider and those close to you. Learn what extra precautions you can take to protect yourself and\nothers in settings that make you more likely to be exposed to COVID-19. \uf3c2 Risk of Getting COVID-19\n\uf266 Risk of Getting Very Sick\nInformation for Specific Groups\nOlder Adults\nPeople Who Are Immunocompromised\nPeople with Medical Conditions\nPeople with Asthma\nPregnant and Recently Pregnant People\n\uf419 Risk for COVID-19 Infection, Hospitalization, and Death\nAge Group Rate Ratios Race and Ethnicity Rate Ratios\nLast Updated Aug. 11, 2022","5663":"They filter at least 95% of particles in the air when approved by NIOSH and when you have a proper fit. If you have COVID-19, an N95 or other filtering facepiece respirator with a valve may not protect others as well as\none without a valve. To make a filtering facepiece respirator with a valve as protective as one without a valve,\nfollow the manufacturer\u2019s instructions for covering the valve.","5672":"Do NOT wear NIOSH-approved respirators\nIf it is hard to breathe while wearing them\nIf they are wet or dirty\nWith other masks or respirators\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nConsiderations for Children\nMasks\nAnyone ages 2 years or older should wear masks in indoor public spaces when the COVID-19 Community Level is high. Learn\nmore about CDC\u2019s recommendations for masking in K-12 schools and Early Care and Education (ECE) programs. Schools and\nECE programs should support anyone who chooses to wear a mask at low or medium COVID-19 Community Levels. The\nbenefits of mask-wearing are well-established. Respirators\nParents and caregivers may have questions about NIOSH-approved respirators (such as N95s) for children.","3911":"Immunocompromised or a Weakened Immune System\nHaving a weakened immune system, also known as being\nimmunocompromised, can make you more likely to get very sick if\nyou get COVID-19. People who are immunocompromised, or who are\ntaking medicines that weaken their immune system, may not be\nprotected as well as others, even if they are up to date on their\nvaccines. EVUSHELD\u2122 is a medicine given by a healthcare provider\nevery 6 months to help prevent COVID-19 before you are exposed or\ntest positive for COVID-19. EVUSHELD\u2122 remains protective, but may\noffer less protection against certain strains of the Omicron variant.","545":"From December 21, 2020 through January 13, 2021, Virginia transferred 17,550 doses and Maryland transferred 16,000\ndoses to the District of Columbia (DC) for administration to persons from the region who were vaccinated in DC. This\napproved transfer of inventory is reflected in the totals presented on the CDC COVID Data Tracker to accurately reflect\nthe inventory made available to each jurisdiction. Because of how and when (i.e., early in the vaccination program) these\ntransfers occurred, they may not be reflected in totals presented within other inventory management systems (e.g., the\nVaccine Tracking System [VTrckS]).","7382":"NOTE: Certain categories of non-U.S. citizens, including immigrant visa applicants\/holders, refugees, parolees, and asylees,\nand those seeking to enter the United States by land or sea travel may be subject to separate COVID-19 vaccination\nrequirements. These individuals are advised to consult and become familiar with all applicable U.S. requirements for entry. For additional information on before, during, and after international travel, visit International Travel to and from the United\nStates.","8719":"\u2022\n\u2022\n\u2022\nMasks and Respirators\nLearn about different types of masks and respirators\nyou can use to protect yourself and others\nYour Guide to Masks\nLearn the proper use and care of masks, including\nconsiderations for people with disabilities\nHow to Use Your N95 Respirator\nFree N95 Respirator Manufacturers\nFree Mask Locator\nFind free masks (N95 respirators) at a participating location near you. Find a Mask Near You Or call 1-800-232-0233 (TTY 1-888-720-7489)\n\uf1aa\n\uf1aa\nLast Updated Aug. 12, 2021","7620":"If crew will not be immediately\nembarking the cruise ship, then they must follow the requirements of the attestation prior to embarking the ship. Crew members of all other vessels are subject to the testing and self-quarantine requirements of the attestation as long\nas they remain in the United States, including U.S. waters.","3559":"All reported numbers may change over time as updated data are\ncontinuously reported to CDC. 10\/30\/22, 9:35 AM Data Definitions for COVID-19 Vaccinations in the United States\nadministration date, recipient ID, and date of submission. Because the method used to determine dose numbers needs to be\napplied across multiple jurisdictions with different reporting practices, CDC\u2019s dose number estimates might differ from those\nreported by jurisdictions and federal entities. People receiving doses are attributed to the jurisdiction in which they\nreside. This includes doses administered by Federal Emergency Management Agency (FEMA) partner sites, Health Resources\nand Services Administration (HRSA) partner sites, and federal entity facilities.","476":"CDC then\nmultiplies this percentage by the count for the total population receiving at least one dose in Texas. CDC repeats the\nsame calculations to estimate the \u201cfully vaccinated\u201d metrics for the three population groups. These values will also be\nincluded in the topline national totals for 12+, 18+, and 65+. On May 7, 2021, the COVID-19 Vaccine Tracker was updated to reflect the revised Moderna emergency use authorization\n(EUA) to account for the new 14 dose vial as authorized by the Food and Drug Administration (FDA) .","8264":"Accepted List Above\nWait at least 28 days after the last dose you received of that vaccine then start COVID-19 vaccination over with a\nCOVID-19 vaccine that has been approved or authorized by the FDA. If the FDA has not approved or authorized a vaccine there may be limited data available or reviewed on the safety or\neffectiveness of the COVID-19 vaccine.","1274":"An 8-week interval may be optimal for some people, especially males ages 12\u201339 years because of the small risk of\nmyocarditis and pericarditis associated with Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines. Vaccine\neffectiveness may also be increased with an interval longer than 3 or 4 weeks. For additional information on the vaccination schedule, see:\nPeople who are not moderately or severely immunocompromised\nPeople who are moderately or severely immunocompromised\nConsiderations for extended intervals for COVID-19 vaccine primary series\nIs there a maximum interval between doses 1 and 2 of a COVID-19 primary vaccination series? \uf1aa\nYes.","4725":"People who initiated vaccination outside of the United States are\nconsidered to be up to date with their COVID-19 vaccines when they have completed the recommended actions described\nbelow. Age-appropriate Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccine products can be used. For additional\nguidance on primary and booster vaccination, see guidance for people who are not moderately or severely\nimmunocompromised and guidance for people who are moderately or severely immunocompromised. Table B. People who received COVID-19 vaccine outside the United States\nTable B.1. Received a COVID-19 vaccine that is FDA-approved or FDA-authorized\nVaccination history Recommended actions\nReceived all recommended primary dose(s) Do not repeat primary series.","7309":"10\/30\/22, 9:37 AM Reinfections and COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nReinfections and COVID-19\nReinfection with the virus that causes COVID-19 means a person was infected, recovered, and then later became infected\nagain. After recovering from COVID-19, most individuals will have some protection from repeat infections. However,\nreinfections do occur after COVID-19. We are still learning more about these reinfections.","5335":"\u2022 General side effects: headache, feeling very tired, muscle aches, nausea, and fever. \u2022 Swollen lymph nodes. \u2022 Blood clots. \u2022 Unusual feeling in the skin (such as tingling or a crawling feeling) (paresthesia), decreased feeling\nor sensitivity, especially in the skin (hypoesthesia). \u2022 Persistent ringing in the ears (tinnitus). \u2022 Diarrhea, vomiting. Severe Allergic Reactions\nThere is a remote chance that the Janssen COVID-19 Vaccine could cause a severe allergic\nreaction. A severe allergic reaction would usually occur within a few minutes to one hour after\ngetting a dose of the Janssen COVID-19 Vaccine.","7228":"FDA has authorized Pfizer-BioNTech\nCOVID-19 Vaccine, Bivalent to provide better protection against COVID-19 caused by\nthe Omicron variant of SARS-CoV-2. The duration of protection against COVID-19 is currently unknown. WHAT ARE THE RISKS OF THESE VACCINES? There is a remote chance that these vaccines could cause a severe allergic reaction. A\nsevere allergic reaction would usually occur within a few minutes to 1 hour after getting\na dose. For this reason, your vaccination provider may ask you to stay at the place\nwhere you received your vaccine for monitoring after vaccination.","1654":"Reporting Suspected Fraud or Abuse\nIndividuals becoming aware of any suspected fraud or abuse or violations of provider agreement requirements are\nencouraged to report them to the Office of the Inspector General, U.S. Department of Health and Human Services at 1-\n800-HHS-TIPS or TIPS.HHS.GOV .","120":"These cases include farmed mink in Europe and the United States, white-tailed deer in Canada, pet hamsters in Hong\nKong, and a cat in Thailand. In most of these cases, the animals were known to be first infected by a person who had COVID-\n19. It\u2019s important to remember that people are much more likely to get COVID-19 from other people than from animals. There is\nno need to euthanize or otherwise harm animals infected with SARS-CoV-2. There is a possibility that the virus could infect animals, mutate, and a new strain could spread back to people and then\namong people (called spillback).","5156":"If you are not fully vaccinated and allowed to travel to the United States by air through an exception, you will be required\nto sign an attestation (legal statement) before you board your flight to the United States stating you meet the exception. Depending on the type of exception, you may also have to state you have arranged to take certain protective measures. For more information see Requirement for Proof of COVID-19 Vaccination for Air Passengers.","1386":"My patient never received a monovalent mRNA booster dose(s) and now only 1 bivalent booster\ndose is recommended for everyone ages 5 years and older. Can my patient still get the previously\nrecommended monovalent mRNA booster dose(s)? \uf1aa\nCan a child who completes a Pfizer-BioNTech primary series at ages 6 months\u20134 years get a\nbooster dose when they turn age 5 years? \uf1aa\f10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\nYes. The child should receive 1 bivalent booster dose when they turn age 5 years, and it has been at least 2 months since\ncompleting their primary series.","6846":"The Countermeasures Injury Compensation Program (CICP) is a federal program that\nmay help pay for costs of medical care and other specific expenses of certain people\fwho have been seriously injured by certain medicines or vaccines, including these\nvaccines. Generally, a claim must be submitted to the CICP within one (1) year from the\ndate of receiving the vaccine. To learn more about this program, visit\nwww.hrsa.gov\/cicp\/ or call 1-855-266-2427. WHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)? An EUA is a mechanism to facilitate the availability and use of medical products,\nincluding vaccines, during public health emergencies, such as the current COVID-19\npandemic.","9105":"Examples of poorly ventilated areas include:\nSmall, enclosed spaces, such as airport jetways\nPublic transportation during periods when the ventilation system is off and windows are closed (e.g., when the\nengine is turned off on an airplane)\nDuring international travel and in transportation hubs that serve international travelers\nIf you are at high risk for getting very sick from COVID-19, or if you live with or have social contact with someone at\nhigh risk\nWhen the COVID-19 Community Level in the area you are located in is high (applies to US locations only)\nWhen should I wear a mask in travel and public transportation settings?","8593":"This immune response, which produces antibodies, is what\nhelps protect us from getting sick from that germ in the future. About Pfizer-BioNTech and Moderna\nResearch for mRNA technology\nResearchers have been studying and working with mRNA vaccines for decades . In fact, mRNA vaccines have been studied before for flu, Zika, rabies, and cytomegalovirus (CMV). Beyond vaccines, cancer research has also used mRNA to trigger the immune system to target specific cancer cells. Protein subunit vaccines (Novavax)\nVaccines do not use any live virus. Vaccines cannot cause infection with the virus that causes COVID-19 or other viruses.","4638":"10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nEspa\u00f1ol | Other Languages\nVaccines & Immunizations\nVaccines & Immunizations Home\nInterim Clinical Considerations for Use of COVID-19\nVaccines: Appendices, References, and Previous\nUpdates\nSummary of recent changes (last updated October 19, 2022):\nGuidance for use of a monovalent Novavax COVID-19 booster dose in people ages 18 years and older in limited\nsituations\nJanssen COVID-19 Vaccine is authorized for adults ages 18 years and older for the primary series dose and 1 booster dose in\ncertain limited situations due to the risk of thrombosis with thrombocytopenia syndrome (TTS) following receipt of the\nvaccine:\nWhen there is a contraindication to mRNA (i.e., Moderna or Pfizer-BioNTech) and Novavax COVID-19 vaccines (e.g.,\nsevere allergic reaction after a previous dose or to a component of an mRNA COVID-19 vaccine) (see Table 4)\nWhen a person would otherwise remain unvaccinated for COVID-19 due to limited access to other COVID-19 vaccines\nWhen a person wants to receive Janssen COVID-19 Vaccine despite the safety concerns identified\nCOVID-19 vaccine recipients should be informed that Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines are\nrecommended over Janssen COVID-19 Vaccine.","4044":"How often are COVID-19 vaccination data updated? \uf1aa\n\u2022\n\u2022\n\u2022\nUsers can download daily cumulative data from CDC\u2019s COVID Data Tracker vaccination pages manually or\nprogrammatically. Users can also download historical COVID-19 vaccination data manually or programmatically. Where can I download COVID-19 data? \uf1aa\f10\/30\/22, 9:35 AM Frequently Asked Questions about COVID-19 Vaccination Data | CDC\nVaccination Information\nCOVID-19 vaccination is recommended for children of certain ages and all adults, including those who are pregnant. Learn more about staying up to date with COVID-19 vaccination. Who is eligible for a COVID-19 vaccine?","6253":"10\/30\/22, 9:34 AM Myths and Facts about COVID-19 Vaccines | CDC\nRecently, the number of deaths reported to VAERS following COVID-\n19 vaccination has been misinterpreted and misreported as if this\nnumber means deaths that were proven to be caused by vaccination. Reports of adverse events to VAERS following vaccination, including\ndeaths, do not necessarily mean that a vaccine caused a health\nproblem. Learn more about VAERS. MYTH: The mRNA vaccine is not considered a vaccine. FACT: mRNA vaccines, such as Pfizer-BioNTech and Moderna, work differently than other types of vaccines,\nbut they still trigger an immune response inside your body.","5348":"In people who developed these blood clots and\nlow levels of platelets, symptoms began approximately one to two weeks after vaccination. Blood\nclots with low levels of platelets following the Janssen COVID-19 Vaccine have been reported in\nmales and females, across a wide age range of individuals 18 years and older; reporting has been\nhighest in females ages 30 through 49 years (about 8 cases for every 1,000,000 vaccine doses\nadministered), and about 1 out of every 7 cases has been fatal.","221":"I have COVID-19 antibodies. What does it mean? A positive antibody test result can help identify someone who has had COVID-19 in the past or has been vaccinated against\nCOVID-19. Antibody tests are not used if you have symptoms of COVID-19 or for diagnosing a current case of COVID-19. This is\nbecause it takes most people with a healthy immune system 1 to 3 weeks after getting COVID-19 to develop antibodies. A viral\ntest is recommended to identify a current infection with the virus that causes COVID-19. More information about the role and\nuses of antibody testing is available.","8805":"Second, the\nU.S. government work designation does not apply to works of state and local governments; works of state and local\ngovernments may be protected by copyright. Third, copyright laws also differ internationally. While U.S. federal copyright\nlaws may not protect U.S. government works outside the United States, the work may still be protected under the copyright\nlaws of other countries when used in these jurisdictions. Copyright-protected materials featured on the CDC and ATSDR\nwebsites should include a copyright statement. However, if in doubt, please write to the contact point for that site.","124":"More studies and surveillance are needed to track variants and mutations and to understand\nhow SARS-CoV-2 spreads between people and animals. Mink and SARS-CoV-2\nIn the United States, respiratory disease and increases in mink deaths have been seen on most affected mink farms. However, some infected mink might also appear healthy. Infected workers likely introduced SARS-CoV-2 to mink on the farms,\nand the virus then began to spread among the mink. Once the virus is introduced on a farm, spread can occur between mink,\nas well as from mink to other animals on the farm (dogs, cats).","8176":"COVID-19 vaccine recommendations are based on three things:\n1. Your age\n2. The vaccine you first received, and\n3. The length of time since your last dose\nPeople who are moderately or severely immunocompromised have different recommendations for COVID-19 vaccines. You are still up to date if you receive all COVID-19 vaccine doses recommended for you and then become ill with COVID-19. You do not need to be immediately revaccinated or receive an additional booster. Boosters are an important part of protecting yourself from getting seriously ill or dying from\nCOVID-19. They are recommended for most people.","2998":"The monovalent Novavax booster dose is administered at least 6 months after completion of any primary series and cannot be used in people\nwho previously received any booster dose(s). People ages 18 years and older who received the Janssen COVID-19 Vaccine primary series dose are recommended to receive\n1 bivalent mRNA booster dose (i.e., Moderna or Pfizer-BioNTech) at least 2 months after completion of the primary series\ndose (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose. See Appendix A for additional information on Janssen COVID-19 Vaccine.","10094":"Summary Document for\nInterim Clinical Considerations\nfor Use of COVID-19 Vaccines Currently Authorized or Approved in the United States\nAll currently authorized or approved COVID-19 vaccines\nContraindications\nHistory of:\n\u0083 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine\n\u0083 A known diagnosed allergy to a component of the COVID-19 vaccine\n\u0083 For the Janssen COVID-19 Vaccine, TTS following receipt of a previous Janssen COVID-19 Vaccine (or other COVID-19 vaccines not currently\nauthorized or approved in the United States that are based on adenovirus vectors, e.g., AstraZeneca)\u00a7\nPrecautions\n\u0083 History of anaphylaxis after any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies\n[excluding subcutaneous immunotherapy for allergies, i.e., \u201callergy shots\u201d])\n\u0083 History of multisystem inflammatory syndrome in children (MIS-C) or multisystem inflammatory syndrome in adults (MIS-A)\n\u0083 History of an immediate (within 4 hours of exposure) non-severe allergic reaction after a dose of one type of COVID-19 vaccine have a precaution\nto the same type of COVID-19 vaccine\n\u0083 Allergy-related contraindication to one type of COVID-19 vaccine have a precaution to the other types of COVID-19 vaccines.\u00b6\n\u0083 Moderate or severe acute illness, with or without fever\n\u0083 History of myocarditis or pericarditis after a dose of an mRNA or Novavax COVID-19 vaccine\n\u0083 For Janssen COVID-19 Vaccine, a history of Guillain-Barr\u00e9 syndrome**\nConsiderations for all FDA-authorized or -approved COVID-19 vaccines\nPersons receiving HCT and CAR-T-cell\ntherapy\n\u0083 If received doses of COVID-19 vaccine prior to or during HCT or CAR-T cell therapy, should be revaccinated for any monovalent primary series\nand bivalent booster doses received before or during treatment at least 3 months (12 weeks) after transplant or CAR-T-cell therapy.","8647":"People get this protection from a vaccine, without ever having to risk the\npotentially serious consequences of getting sick with COVID-19. Any side effects from getting the vaccine are normal\nsigns the body is building protection. How viral vector COVID-19 vaccines work\n\uf1aa\n\u2022\n\u2022\n\u2022\nDeveloping COVID-19 Vaccines\nWhile COVID-19 vaccines were developed rapidly, all steps have been taken to ensure their safety and effectiveness. Bringing\na new vaccine to the public involves many steps including:\nvaccine development,\nclinical trials,\nU.S. Food and Drug Administration (FDA) authorization or approval. As vaccines are distributed outside of clinical trials, monitoring systems are used to make sure that COVID-19 vaccines are\nsafe.","5786":"Has the COVID-19 vaccine by Moderna been used before? Yes. Millions of people have received this vaccine in the United States since it became available starting\nDecember 18, 2020. Also, in clinical trials, approximately 15,400 people 18 ages years and older received at\nleast 1 dose of the vaccine and approximately 2,500 people ages 12\u201317 years received a primary series of\nthe vaccine. There have been some studies in people who received the COVID-19 vaccine by Moderna after\ncompleting a primary vaccination with a non-FDA authorized or approved COVID-19 vaccine or Janssen\nCOVID-19 Vaccine. What are the risks of the COVID-19 vaccine by Moderna?","8394":"Trainings, Webinars, and Reference Materials\n\uf17f Training Programs and Reference\nMaterials\n\uf53e COVID-19 Vaccination Provider\nTraining\n\uf519 Strategies for Sharps Disposal\nContainer Use During Supply\nShortages\n\uf4b0 Training Modules For COVID-19\nVaccination\n\uf4e6 COVID-19 Vaccine Webinar Series\n\uf69e Safe and Proper Sharps Disposal\nDuring the COVID-19 Mass Vaccination\nCampaign\nTraining Required by Professional Qualification\nFind the training and core competencies you will need by clicking on your professional qualification below:\nHealthcare professionals who have administered vaccine in the last 12 months\nHealthcare professionals or retired (past 5 years) physicians, nurses, or practical nurses who are licensed\/previously\nlicensed to administer COVID-19 vaccine but have not done so in the last 12 months\nVaccination support workers (not licensed to administer vaccine) qualified to prepare, store, handle, or transport vaccine\nAdministration support staff qualified to store, handle, or transport vaccine\nCOVID-19 Vaccine Training Routine Vaccine Administration Routine Vaccine Storage and Handling\nCDC Training Module(s) for the\nvaccine product(s) in your facility\nIf needed: You Call the Shots: Vaccine\nAdministration\nOr other vaccine administration\ntraining offered by a worksite, state or\nlocal health department, medical\nprofessional organization, or\nmedical\/nursing school within the last\n12 months.","8984":"Requesting Permission to Contact Your Healthcare Provider\nParticipants will also be asked if they would be willing to provide permission for Pregnancy Registry staff to review their\nmedical records for additional details about their pregnancies. Personal information and responses given to the registry are\nconfidential and will be protected to the full extent allowed by law. Having information on details, like medications or clinical\nlaboratory results, provides a complete picture of your pregnancy. Your healthcare provider(s) can help provide this\ninformation, which is important as we try to understand more about COVID-19 vaccination during pregnancy.","1148":"Vaccine Administration Management System (VAMS) is a web-based application available to support planning and\nexecution for temporary, mobile, or satellite COVID-19 vaccination clinics. VAMS connects with IISs and sends data\nto IISs through the COVID-19 Data Clearing House. COVID-19 Data Clearing House is a cloud-hosted data repository that receives, deduplicates, and deidentifies\nCOVID-19 vaccination data, which are then used to populate the Immunization (IZ) Data Lake. Immunization Data Lake (IZ Data Lake)\u202fis a cloud-hosted data repository to receive, store, manage, and analyze\ndeidentified COVID-19 vaccination data.","8116":"If given between 4\u201314 days after the date of exposure, vaccination may reduce the symptoms of disease, but\nmay not prevent the disease.141\fCOVID-19 State of Vaccine Confidence Insights Report | October 10, 2022\n\u0082 Monkeypox PrEP should be offered to people with the highest potential for exposure to monkeypox such as:142\n\u008f Gay, bisexual, and other men who have sex with men, transgender or nonbinary people who in the past 6 months have\nhad\n\u00bb A new diagnosis of one or more nationally reportable sexually transmitted diseases (i.e., acute HIV, chancroid,\nchlamydia, gonorrhea, or syphilis)\n\u00bb More than one sex partner\n\u008f People who have had any of the following in the past 6 months:\n\u00bb Sex at a commercial sex venue\n\u00bb Sex in association with a large public event in a geographic area where monkeypox transmission is occurring\n\u008f Sexual partners of people with the above risks\n\u008f People who anticipate experiencing the above risks\nIdentified misinformation themes that may impact vaccine confidence\n\u0083 Some social media users believe COVID-19 vaccines weaken the body\u2019s immune system, making vaccinated individuals more\nsusceptible to monkeypox.143,144\n\u0083 Some social media users believe monkeypox is caused by COVID-19 vaccines.145,146\n\u0083 Some social media users believe monkeypox is being used to scare people now that COVID-19 is not seen as a threat.147,148\n\u0083 Some social media users believe pharmaceutical companies are attempting to create a monkeypox pandemic to increase\nWays public health and partners can take action to improve vaccine confidence\n\u0083 Encourage local health departments, public health experts, and healthcare workers to explain the absence of association\nbetween COVID-19 vaccines and monkeypox.","9111":"Some people using public transport or working in transportation settings (or someone they live or have social\ncontact with) might have a weakened immune system or be at increased risk for severe illness. Some might not be able to get COVID-19 vaccines, including children younger than 6 months old. Some of these people may have no alternative to public transportation. People from countries or US communities with different levels of COVID-19 or circulating variants mix in travel and\npublic transportation settings.","8160":"As with other vaccine-preventable diseases, you are protected best from COVID-19 when you stay up\nto date with the recommended vaccinations, including recommended boosters. Four COVID-19 vaccines are approved or authorized in the United States:\nPfizer-BioNTech\nModerna\nNovavax\nJohnson & Johnson\u2019s Janssen (J&J\/Janssen) (However, CDC recommends that the J&J\/Janssen COVID-19 vaccine only be\nconsidered in certain situations, due to safety concerns.) Updated (Bivalent) Boosters\nThe updated (bivalent) boosters are called \u201cbivalent\u201d because they protect against both the original virus that causes COVID-\n19 and the Omicron variant BA.4 and BA.5. Previous boosters are called \u201cmonovalent\u201d because they were designed to protect against the original virus that causes\nCOVID-19.","5487":"For people who\nexperience PICS following a COVID-19 diagnosis, it is difficult to determine whether these health problems are caused by a\nsevere illness, the virus itself, or a combination of both. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\nSome people with post-COVID conditions have symptoms that are not explained by tests. Some people experience new health conditions after COVID-19 illness. People experiencing any severe illness, hospitalization, or treatment may develop problems such as post-intensive care\nsyndrome, or PICS. \uf209\nPeople More Likely to Develop Long COVID\nResearchers are working to understand which people or groups of people are more likely to have post-COVID conditions, and\nwhy.","6987":"The Countermeasures Injury Compensation Program (CICP) is a federal program that may help pay for costs\nof medical care and other specific expenses of certain people who have been seriously injured by certain\nmedicines or vaccines, including this vaccine. Generally, a claim must be submitted to the CICP within one\n(1) year from the date of receiving the vaccine. To learn more about this program, visit www.hrsa.gov\/cicp\/\nor call 1-855-266-2427. How can I learn more? \u2022 Ask the vaccination provider. \u2022 Visit CDC at https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/index.html. \u2022 Visit FDA at https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-\nand-policy-framework\/emergency-use-authorization. \u2022 Contact your local or state public health department.","9512":"In addition, the FDA decision is based on the totality of the\nscientific evidence available showing that the product may be effective to prevent COVID-19\nduring the COVID-19 pandemic and that the known and potential benefits of the product\noutweigh the known and potential risks of the product. All of these criteria must be met to allow\nfor the product to be used during the COVID-19 pandemic. An EUA is in effect for the duration of the COVID-19 EUA declaration justifying emergency\nuse of this product, unless terminated or revoked (after which the product may no longer be\nused).","5992":"Neutralizing antibody titers, as measured by a pseudovirus neutralization assay using a\nlentivirus expressing the SARS-CoV-2 Spike protein with D614G mutation, were assessed on Day 1 prior to\nadministration of the booster dose and on Day 15 after the booster dose. A booster response to the Moderna\nCOVID-19 Vaccine (0.5 mL [100 \u03bcg of mRNA]) was demonstrated regardless of primary vaccination. Recent studies indicate that additional doses in people who are moderately or severely immunocompromised\nare safe and can increase antibody response.","2547":"Booster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 2 to 3 At least 8 weeks (2 months)\n* Guidance related to special situations when vaccinating children, such as those who have a birthday before completing the primary series or booster dose, see Special Situations for COVID-19\nVaccination of Children and Adolescents\n\u2020 Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate\nmonovalent COVID-19 vaccine may be administered at least 28 days after the first dose to complete the primary series.","197":"Even if you do get sick, having antibodies can protect you from getting severely ill\nbecause your body has some experience in fighting that disease. How long this protection lasts can be different for each\ndisease, each person, or influenced by other factors. Antibodies are just one part of your immune response. Antibodies and COVID-19\nAntibodies to SARS-CoV-2, the virus that causes COVID-19, can be detected in the blood of people who have recovered from\nCOVID-19 or people who have been vaccinated against COVID-19.","3344":"Considerations for subsequent COVID-19 vaccination may include:\n\uf20c\n\uf20c\n\uf20c\nNovavax COVID-19 Vaccine\nConsiderations for COVID-19 vaccination\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nThe myocarditis or pericarditis was considered unrelated to vaccination with Moderna, Novavax, or Pfizer-BioNTech (e.g.,\ndue to SARS-CoV-2 or other viruses), especially if the myocarditis or pericarditis diagnosis occurred more than 3 weeks\nafter the most recent dose of COVID-19 vaccine\nPersonal risk of severe acute COVID-19 (e.g., age, underlying conditions)\nTiming of any immunomodulatory therapies; ACIP\u2019s general best practice guidelines for immunization can be consulted\nfor more information\nFor myocarditis associated with MIS-C or MIS-A, see COVID-19 vaccination and MIS-C and MIS-A.","1218":"Graphic: COVID-19 Updated (Bivalent) Booster\nAdministrations in the United States \u2013 October 26, 2022\nFile Details: 1 MB, JPG\nView Image\f10\/30\/22, 9:34 AM COVID-19 Vaccination Data in the United States | CDC\nCOVID-19 Updated (Bivalent) Booster Administrations in the United States \u2013\nPercent and number of people receiving COVID-19 updated (bivalent) boosters by age\nPercent and number of people receiving COVID-19 updated (bivalent) boosters by race\/ethnicity*\nAI\/AN: American Indian\/Alaska Native\nNHOPI: Native Hawaiian and Other Pacific Islanders\n*Among 87% of people with a known Race\/Ethnicity\nPercent and number of people receiving COVID-19 updated (bivalent) boosters by sex**\n**Among 99% of people with known Sex\nImportant considerations\nUpdated (bivalent) booster counts include the number of people administered a vaccine dose with a Covid-19 vaccine\ncode (CVX code) 229 (Moderna ages 6+) or 300 (Pfizer ages 12+) on or after September 1, 2022 or a CVX code 301 (Pfizer\nages 5+) on or after October 12, 2022.","1933":"The study will:\nEnroll pregnant people who plan to receive COVID-19 vaccination; COVID-19 vaccines will be given as part of the\nstudy\nCollect baseline maternal health information, including if they previously had COVID-19\nFollow people during pregnancy and for three months after delivery\nFollow babies through their first three months of life\nCDC: Birth Defects Study to Evaluate Pregnancy Exposures (BD-STEPS) \u2014 BD-STEPS is an ongoing study that collects\ninformation including COVID-19 vaccination information from people who have recently been pregnant to understand\n\u2022\n\u2022\n\u2022 \uf209\n\uf209\n\u2022\n\u2022\n-\n-\n-\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\n-\n-\n\u2022\f10\/30\/22, 9:32 AM COVID-19 Vaccine Monitoring Systems for Pregnant People | CDC\ninformation, including COVID-19 vaccination information, from people who have recently been pregnant to understand\nthe potential causes of birth defects and how to prevent them.","3100":"\u2020\n\u2020\nPrevious vaccination with Janssen COVID-19 Vaccine\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nIn addition to following the recommended COVID-19 vaccination schedule, tixagevimab\/cilgavimab (EVUSHELD ), a\ncombination of two monoclonal antibodies, should be administered to people who are moderately or severely\nimmunocompromised every 6 months for pre-exposure prophylaxis to supplement vaccine protection. Per the product\nEUA , EVUSHELD is given at least 2 weeks after COVID-19 vaccine. People may initiate EVUSHELD at any time after this\ninterval, including between doses in the primary series and primary and booster doses.","7972":"Although current\ncases are a fraction of the peak daily\nnew infection during the Omicron wave\n(daily cases exceeded 800,000),52 CDC\nCOVID-19 Community Levels for more\nthan 55% of the population were in a\n\u2018medium\u2019 or \u2018high\u2019 designation.53\nOnline discussions of current vaccine efficacy against dominant variants may be due to reports of waning COVID-19 vaccine-\nacquired immunity,54,55 breakthrough infection and death,56 and research supporting such claims.57 Despite increasing numbers\nof cases58 and domestic COVID-19-attributed deaths surpassing 1 million individuals,d general consumer awareness and\nconcern regarding SARS-CoV-2 is at the lowest point since July 2021.","999":"You can order free self-test kits at COVIDtests.gov or purchase tests online, in pharmacies, and retail stores. You can also visit FDA\u2019s website to see a list of authorized tests. As noted in the labeling for authorized over-the-counter antigen tests: Negative results should be treated as presumptive\n(meaning that they are preliminary results). Negative results do not rule out SARS-CoV-2 infection and should not be\nused as the sole basis for treatment or patient management decisions, including infection control decisions. Please see\nFDA guidance on the use of at-home COVID-19 antigen tests.","12":"Even after your COVID-19 vaccination, when you are in a correctional facility, it\u2019s important\nto continue wearing a well-fitting mask, try to stay at least 6 feet away from others as\nmuch as possible, and wash your hands often. Side effects may make\nyou feel a little sick or\neven make it hard to\ndo daily activities, but\nthey should go away\nin a few days. vaccination rates and\nensure that staff and\nresidents stay up to date\non their COVID-19 vaccines. COVID-19 vaccines may\nnot fully protect you\nuntil a week or two after\nyour final shot. It takes\ntime for your body to\nbuild protection after\nany vaccination.","7763":"Over 350 million mRNA vaccines were given during the study period\nand CDC scientists found that rates of myocarditis were highest following the second dose of an mRNA vaccine\namong males in the following age groups:\n12\u201315 years (70.7 cases per one million doses of Pfizer-BioNTech)\n16\u201317 years (105.9 cases per one million doses of Pfizer-BioNTech)\n18\u201324 years (52.4 cases and 56.3 cases per million doses of Pfizer-BioNTech and Moderna, respectively)\nMultiple studies and reviews of data from vaccine safety monitoring systems continue to show that vaccines are safe. As\na result, the agency will refocus enhanced surveillance and safety monitoring efforts toward children and adolescents.","1252":"This includes 8 million doses administered onsite to long-\nterm care facilities in the early days of the COVID-19 vaccination program. A total of 21 retail pharmacy partners are participating in the program, with more than 41,000 locations nationwide. This includes long-term care pharmacies. How the Federal Retail Pharmacy Program Works\f10\/30\/22, 9:22 AM COVID-19 Vaccination Federal Retail Pharmacy Partnership Program | CDC\nParticipating Retail Pharmacies\n\uf42d\nConnecting with Federal Pharmacy Partners\n\uf18c\nCOVID-19 Vaccine Eligibility and Availability\nEveryone 6 months of age and older is eligible to get a COVID-19 vaccination.","3783":"10\/30\/22, 9:31 AM Ensuring COVID-19 Vaccine Safety in the US | CDC\nEspa\u00f1ol | Other Languages\nEnsuring COVID-19 Vaccine Safety in the US\nVaccine Safety and Monitoring\nCOVID-19 vaccines were developed using science that has been around for decades. COVID-19 vaccines are safe, and meet the Food and Drug Administration\u2019s (FDA\u2019s)\nrigorous scientific standards for safety, effectiveness, and manufacturing quality. COVID 19-vaccines are effective at preventing severe illness from COVID-19 and\nlimiting the spread of the virus that causes it. Millions of people in the United States have received COVID-19 vaccines. COVID-19 vaccines are monitored by the most intense safety monitoring efforts in\nU.S. history.","9884":"Rapid Review Update 1: What is the ongoing\neffectiveness, immunogenicity, and safety of COVID-19 vaccines in persons who have had a prior, confirmed\nCOVID-19 infection?. Hamilton (ON): McMaster University; 2021. Available from: https:\/\/www.nccmt.ca\/covid-\n19\/covid-19-rapid-evidence-service\/36. Parry H, Bruton R, Stephens C, et al. Extended interval BNT162b2 vaccination enhances peak antibody\nPatamatamkul S, Thammawat S, Buranrat B. Induction of robust neutralizing antibodies against the COVID-19\nDelta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster following a primary vaccination series with\nCoronaVac. medRxiv 2021.09.25.21264099; doi: https:\/\/doi.org\/10.1101\/2021.09.25.21264099. Payne RP, Longet S, Austin JA, et al. 2021. Immunogenicity of standard and extended dosing intervals of\nBNT162b2 mRNA vaccine. Cell.","5839":"\u2022 Delaying the second primary dose in persons ages 12 years and older who recently had SARS-CoV-2\ninfection, by 3 months from symptom onset or positive test (if infection was asymptomatic)\n\u2022 Primary dose(s), including for those with certain immunocompromising conditions or those with\nincomplete primary series, for persons ages 12 years and older who received primary vaccination with\ncertain non-FDA authorized or approved COVID-19 vaccines2. \u2022 An additional dose in persons ages 18 years and older with certain immunocompromising conditions\nwho received primary vaccination with the Janssen (Johnson & Johnson) COVID-19 Vaccine.","7400":"Categories of noncitizen nonimmigrants that meet the criteria for an exception under the Proclamation and CDC\u2019s Amended\nOrder include:\nPersons on diplomatic or official foreign government travel\nChildren under 18 years of age\nPersons with documented medical contraindications to receiving a COVID-19 vaccine\nParticipants in certain COVID-19 vaccine trials\nPersons issued a humanitarian or emergency exception\nPersons with valid visas [excluding B-1 (business) or B-2 (tourism) visas] who are citizens of a foreign country with limited\nCOVID-19 vaccine availability (See list for updates effective June 28, 2022)\nMembers of the U.S. Armed Forces or their spouses or children (under 18 years of age)\nSea crew members traveling with to a C-1 and D nonimmigrant visa\nPersons whose entry would be in the national interest, as determined by the Secretary of State, Secretary of\nTransportation, or Secretary of Homeland Security (or their designees)\nIf you travel by air to the United States under one of these exceptions, you will be required to attest that you are excepted\nfrom the requirement to present Proof of Being Fully Vaccinated Against COVID-19 based on one of the exceptions listed\nabove.","2815":"Younger children who have myocarditis or pericarditis may have non-specific\nsymptoms such as irritability, vomiting, poor feeding, tachypnea, or lethargy. Ask about prior COVID-19 vaccination if you identify these symptoms, as well as relevant other medical, travel, and social\nhistory. For initial evaluation, consider an ECG, troponin level, and inflammatory markers such as C-reactive protein and\nerythrocyte sedimentation rate. In the setting of normal ECG, troponin, and inflammatory markers, myocarditis or\npericarditis are unlikely. For suspected cases, consider consultation with cardiology for assistance with cardiac evaluation and management.","6113":"\"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster)\nfollowing two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre,\nrandomised, controlled, phase 2 trial.\" The Lancet (2021). National Advisory Committee on Vaccination. An Advisory Committee Statement: Guidance on booster COVID-\n19 vaccine doses in Canada. Public Health Agency of Canada; 3 Dec 2021.\nhttps:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/immunization\/national-advisory-\nvaccine-doses.pdf\nNational Collaborating Centre for Methods and Tools. Rapid Review Update 1: What is the ongoing\neffectiveness, immunogenicity, and safety of COVID-19 vaccines in persons who have had a prior, confirmed\nCOVID-19 infection?. Hamilton (ON): McMaster University; 2021. Available from: https:\/\/www.nccmt.ca\/covid-\n19\/covid-19-rapid-evidence-service\/36.","7380":"The Presidential Proclamation and CDC\u2019s Amended Order have no effect on several non-U.S. citizens, including:\nNon-U.S. citizens eligible for asylum;\nNon-U.S. citizens eligible for withholding of removal;\nNon-U.S. citizens eligible for protection under the regulations issued pursuant to the legislation implementing the\nConvention Against Torture and Other Cruel, Inhuman or Degrading Treatment or Punishment;\nNon-U.S. citizens admitted to the United States as refugees ;\nPersons\u202fwith\u202fa\u202fvisa 92 or 93 (Follow-to-Join) status; and\nNon-U.S. citizens granted parole into the United States.","6774":"WHAT ARE THE INGREDIENTS IN THESE VACCINES? The Pfizer-BioNTech COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent include the following ingredients: mRNA, lipids (((4-\nand cholesterol), tromethamine, tromethamine hydrochloride, sucrose, and sodium\nchloride. HAVE THESE VACCINES BEEN USED BEFORE? In a clinical trial, approximately 3,100 individuals 5 through 11 years of age have\nreceived at least 1 dose of the Pfizer-BioNTech COVID-19 Vaccine. Millions of\nindividuals have received the Pfizer-BioNTech COVID-19 Vaccine under EUA since\nDecember 11, 2020.","3190":"Orthopoxvirus vaccination:\n\uf20c \uf20c\nVaccination after SARS-CoV-2 Infection\nInterchangeability of COVID-19 vaccine products\n\uf20c\nCoadministration of COVID-19 vaccines with other vaccines\n\uf20c\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nPeople who previously received COVID-19 vaccination (i.e. Moderna, Novavax, or Pfizer-BioNTech) may be given\northopoxvirus vaccine (either JYNNEOS or ACAM2000) without a minimum interval between vaccinations. People who previously received orthopoxvirus vaccination (either JYNNEOS or ACAM2000), particularly adolescent or\nyoung adult males, might consider waiting 4 weeks before receiving a COVID-19 vaccine (i.e. Moderna, Novavax, or\nPfizer-BioNTech) because of the observed risk for myocarditis and pericarditis after receipt of ACAM2000 orthopoxvirus\nvaccine and COVID-19 vaccines (i.e.","3030":"For example, people who become\nmoderately or severely immunocompromised after completing a 2-dose mRNA primary series do not need additional primary\ndoses; however, they should follow the schedule for people who are moderately or severely immunocompromised for the\nbooster dose. Moderna COVID-19 Vaccine\nChildren ages 6 months\u20134 years: A 3-dose primary series is recommended. The first and second doses are separated by\n4 weeks and the second and third doses are separated by at least 4 weeks. Currently, a booster dose using any COVID-19\nvaccine is not authorized for children in this age group.","2226":"10\/30\/22, 9:33 AM COVID-19 Vaccines Work | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccines Work\nCDC is reviewing this page to align with updated guidance. All currently approved or authorized COVID-19 vaccines are safe and effective and reduce your risk of severe illness. Vaccination can reduce the spread of disease, which helps protect those who get vaccinated and the people around them. COVID-19 Vaccines Protect Against COVID-19 Infections and Hospitalizations\nVaccines reduce the risk of COVID-19, including the risk of severe illness and death among people who are fully vaccinated.","6614":"Get more information:\n\uf209\n\u2022 \uf209\n\u2022\n\u2022\n\u2022 \uf209\n\u2022\n\u2022 \uf209\n\u2022 \u00ae \uf209\n\u2022 SM\n\u2022 \uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nGet more information:\nSmoking & Tobacco Use\nTips From Former Smokers\nHealth Benefits of Quitting Smoking\nSolid organ or blood stem cell transplant\nHaving had a solid organ or blood stem cell transplant, which includes bone marrow transplants, can make you more likely to\nget very sick from COVID-19. Get more information:\nTransplant Safety\nCOVID-19 Resources for Transplant Community\nStroke or cerebrovascular disease\nHaving cerebrovascular disease, such as having a stroke which affects blood flow to the brain, can make you more likely to get\nvery sick from COVID-19.","7029":"For this reason,\neveryone who receives a COVID-19 vaccine is monitored by their vaccination provider for at least 15 minutes. After leaving a vaccination provider site, if you think you or your child might be having a severe allergic reaction, seek\nimmediate medical care by calling 911. Learn more about what you can do if you have an allergic reaction. Reporting Side Effects and Adverse Events\nUse v-safe or the Vaccine Adverse Event Reporting System (VAERS) to report your side effects:\nV-safe, a smartphone-based tool, provides quick and confidential health check-ins via text messages and web surveys.","939":"In addition, everyone who is eligible, including those who are pregnant, breastfeeding, trying\nto get pregnant now, or might become pregnant in the future, should get a booster shot. You should always wash your hands\nwith soap and water for 20 seconds before breastfeeding or expressing breast milk, even if you don\u2019t have COVID-19. If soap\nand water are not available, use a hand sanitizer with at least 60% alcohol. If you have COVID-19 and choose to breastfeed:\nWash your hands before breastfeeding\nWear a mask while breastfeeding and whenever you are within 6 feet of your baby.","1411":"Below are three scenarios and the recommended action:\nIf your patient received the primary series before or during treatment: Revaccinate the patient with the primary series\nand administer 1 bivalent mRNA booster dose at least 2 months after repeating the primary series. If your patient received the primary series and 1 or 2 (or more) monovalent booster doses before or during\ntreatment: Revaccinate the patient with the primary series. Do not revaccinate for the monovalent mRNA booster dose(s). The patient is recommended to receive 1 bivalent mRNA booster dose at least 2 months after repeating the primary\nseries.","6837":"This will ensure that your child receives the same vaccine when your child\nreturns for the second dose of the primary series. For more information about IISs visit:\nhttps:\/\/www.cdc.gov\/vaccines\/programs\/iis\/about.html. CAN I BE CHARGED AN ADMINISTRATION FEE FOR RECEIPT OF THESE\nNo. At this time, the provider cannot charge you for a vaccine dose and you cannot be\ncharged an out-of-pocket vaccine administration fee or any other fee if only receiving a\nCOVID-19 vaccination.","1785":"10\/30\/22, 9:29 AM COVID-19 Vaccination for Children and Teens with Disabilities | Human Development and Disability | NCBDDD | CDC\nThe benefits of COVID-19 vaccination outweigh the known and potential risks\nCOVID-19 vaccines have been shown to be safe and effective at protecting against COVID-19 and preventing severe\nillness if infected. In clinical trials, about 20% of children and teens who participated had an underlying medical condition. Some children and teens with a weakened immune system should get an additional dose of vaccine as part of their\nprimary COVID-19 vaccination series.","1919":"The v-safe COVID-19 Vaccine Pregnancy Registry is a registry to collect additional\nhealth information from v-safe participants who report being pregnant at the time of vaccination or a positive pregnancy\ntest after vaccination. This information helps CDC monitor the safety of COVID-19 vaccines in people who are pregnant. CDC: Vaccine Safety Datalink (VSD) \u2014 VSD is a network of nine integrated healthcare organizations across the United\nStates that monitor and evaluate the safety of vaccines. The system is also used to help determine whether possible side\neffects identified using VAERS are actually related to vaccination.","5518":"For example, some\nstudies look for the presence of post-COVID conditions based on self-reported symptoms, while others collect symptoms and\nconditions recorded in medical records. Some studies focus only on people who have been hospitalized, while others include\npeople who were not hospitalized. The estimates for how many people experience post-COVID conditions can be quite\ndifferent depending on who was included in the study, as well as how and when the study collected information.","2131":"Therefore, limited data are available on the\nSafety of COVID-19 vaccines in people who are breastfeeding\nEffects of vaccination on the breastfed baby, and\nEffects on milk production or excretion\nAvailable data on safety of COVID-19 vaccination while breastfeeding indicate no severe reactions after the first or second\ndose, neither in the breastfeeding person not the breastfed child. There has been no evidence to suggest that COVID-19\nvaccines are harmful to either people who have received a vaccine and are breastfeeding or to their babies. COVID-19 vaccines cannot cause COVID-19 in anyone, including pregnant people and their babies. None of the COVID-19\nvaccines contain live virus.","3243":"History of a known diagnosed allergy to a component of the COVID-19 vaccine Contraindication Do not vaccinate with a\nCOVID-19 vaccine that\ncontains that component. History of anaphylaxis after any vaccine other than COVID-19 vaccine or after any injectable therapy (i.e.,\nintramuscular, intravenous, or subcutaneous vaccines or therapies [excluding subcutaneous\nimmunotherapy for allergies, i.e., \u201callergy shots\u201d])\nPrecaution The benefit of vaccination\noutweighs the risks for\nmost people. People with a history of a non-severe, immediate (onset less than 4 hours) allergic reaction after a dose of\none type of COVID-19 vaccine have a precaution to the same type of COVID-19 vaccine.","8975":"What to Expect If You Participate in the Registry\nPhone Call Health Check-ins\nAbt Associates , the registry staff contracted by CDC, will contact people by phone to invite them to participate in the\nregistry. People who choose to enroll in the registry will receive calls from Abt Associates several times throughout their pregnancy for\nadditional health check-ins. During these check-ins, they will be asked questions about their pregnancy and medical history. After delivery, participants might be contacted for more information when their babies are about three months old.","285":"This total includes\nrecent dose administrations and historic dose administrations from May 1 to June 30, 2022, that had not been reported\nto CDC by Indiana. Effective July 14, 2022, New Hampshire will only report year of birth instead of full birthdate for vaccine recipients to\nCDC. This will result in numbers and rates for some age groups being under- or over-estimated. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n-\n\u2022\n-\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nOn June 15, 2022, the daily number of vaccine doses administered for Indiana was 238,242 doses.","1199":"Beginning October 22, 2021, CDC is able to attribute non-residents of Texas to their respective state or territory of\nresidence. Texas residents who received a COVID-19 vaccination in a different state or territory are also now attributed\nto Texas\u2019 population-based metrics. Beginning November 18, the\u202fVaccination Demographics and\u202fDemographic Trends\u202fsites include vaccination demographic\ninformation from Texas. New Hampshire\u202flifted its national COVID-19 emergency response declaration in May 2021, which allows vaccine recipients to\nopt out of having their COVID-19 vaccinations included in the state\u2019s IIS. As such, data submitted by New Hampshire since May\n2021 may not be representative of all COVID-19 vaccinations occurring in the state.","1999":"New studies\nhave shown the rare risk of myocarditis and pericarditis associated with mRNA COVID-19 vaccination (Pfizer-BioNTech and\nModerna)\u2014mostly among males between the ages of 12 and 39 years\u2014may be further reduced with a longer time between\nthe first and second dose. In children ages 5 through 11 years, there were 20 confirmed reports of myocarditis out of approximately 18.1 million\ndoses given of the Pfizer-BioNTech COVID-19 vaccine between November 2021 and April 2022\nWhat You Need to Know\nCDC recommends COVID-19 vaccines for everyone ages 6 months and older, and COVID-19 boosters for everyone\nages 5 years and older, if eligible.","772":"It is part of the coronavirus family, which include common viruses that cause\na variety of diseases from head or chest colds to more severe (but more rare) diseases like severe acute respiratory syndrome\n(SARS) and Middle East respiratory syndrome (MERS). Like many other respiratory viruses, coronaviruses spread quickly through droplets that you project out of your mouth or\nnose when you breathe, cough, sneeze, or speak. The word corona means crown and refers to the appearance that coronaviruses get from the spike proteins sticking out of\nthem. These spike proteins are important to the biology of this virus.","6237":"Getting sick with COVID-19 can cause severe illness or death, and we can\u2019t reliably predict who will have mild or\nsevere illness. If you get sick, you can spread COVID-19 to others. You can also continue to have long-term health issues\nafter COVID-19 infection. Learn about why you should get vaccinated even if you already had COVID-19. 10\/30\/22, 9:34 AM Myths and Facts about COVID-19 Vaccines | CDC\nMYTH: COVID-19 vaccines cause variants. FACT: COVID-19 vaccines do not create or cause variants of the virus that causes COVID-19. Instead, COVID-19\nvaccines can help prevent new variants from emerging.","6199":"Active\nmonitoring includes reviewing data and medical records and evaluating the relationship to COVID-19 vaccination. Information about CDC\u2019s ongoing study of myocarditis after COVID-19 vaccination can be found here: Investigating Long-\nTerm Effects of Myocarditis | CDC\n\u2022\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nSeek medical care if you or your child have any of the specific or general symptoms of myocarditis or pericarditis\nespecially if it\u2019s within a week after COVID-19 vaccination. Healthcare Providers: For additional recommendations and clinical guidance, visit Clinical Considerations: Myocarditis after\nmRNA COVID-19 Vaccines. Should I Still Get Myself or My Child Vaccinated? 10\/30\/22, 9:31 AM Myocarditis and Pericarditis After mRNA COVID-19 Vaccination | CDC\nYes.","8882":"Action Steps:\nEmpower vaccine recipients to share their personal stories and reasons\nfor vaccination within their circles of influence. Work with health departments and national partners to engage\ncommunities around vaccine confidence and service delivery strategies,\nincluding adaptation of vaccination provider sites to meet community\nneeds. Collaborate with trusted messengers\u2014such as faith-based and community\nleaders\u2014to tailor and share culturally relevant messages and materials\nwith diverse communities.","8745":"Wear a mask or respirator that provides them with greater protection when the COVID-19 Community Level is high\nChildren\nChildren ages 2 years and older can wear masks or respirators to protect themselves and others from COVID-19. Choose a high-quality and comfortable mask or respirator that your child can wear properly. A poorly fitting or uncomfortable\nmask or respirator might be worn incorrectly or removed often, and that would reduce its intended benefits. Choose a size that fits over the child\u2019s nose and under the chin but does not impair vision. Follow the user instructions for the mask or respirator.","8234":"Anyone wanting protection due to high levels of community transmission, people ages 65 years and older, or people\nwho are more likely to get very sick from COVID-19, should get the second dose of:\nPfizer-BioNTech COVID-19 vaccine 3 weeks (or 21 days) after the first dose. Moderna COVID-19 vaccine 4 weeks (or 28 days) after the first dose. Novavax COVID-19 vaccine 3 weeks (or 21 days) after the first dose. Staying up to date: If you have completed your primary series, but are not yet eligible for a booster, you are also considered\nup to date.","9306":"10\/30\/22, 9:34 AM Why Children and Teens Should Get Vaccinated Against COVID-19 | CDC\nRead the science about immunity from COVID-19 infection and vaccination. Related Pages\n6 Things to Know About COVID-19 Vaccination for Children\n\u203a\nFrequently Asked Questions about COVID-19 Vaccination for Children and Teens\n\u203a\nGetting Children and Teens Vaccinated Against COVID-19\n\u203a\nCOVID-19 Vaccine Recommendations for Children and Teens\n\u203a\nLast Updated July 21, 2022","7885":"\u0083 Clarify the benefits of COVID-19 vaccines, including boosters, in preventing severe disease. \u0083 Work with community members and trusted messengers to create and disseminate messages that explain that some side\neffects are normal and expected. If a vaccinated individual gets COVID-19, vaccination will increase the chances that it is a\nmild case. \u0083 Develop and amplify messages explaining why vaccines are still important in the COVID-19 prevention response. \u0083 Disseminate messages about community-level risk and corresponding COVID-19 mitigation measures. \u0083 Encourage local health departments, public health experts, and healthcare workers to explain the absence of association\nbetween COVID-19 vaccines and monkeypox.","3851":"\uf1aa\n\uf20c\nCOVID-19 vaccination providers are required to report information on vaccine supply, vaccine administration, and vaccine\nadverse events. Reporting this information is critical to help stop the COVID-19 pandemic. Vaccine supply\nAll COVID-19 vaccination providers must report COVID-19 vaccine inventory daily in the COVID Locating Health Provider\nPortal. In some jurisdictions, providers may report vaccine inventory to the jurisdiction\u2019s IIS for the jurisdiction to upload\ninto the portal. If you have questions about the inventory reporting process for your jurisdiction, please contact your\njurisdiction\u2019s immunization program. Learn more at Vaccines.gov. Vaccine administration data\nWhat are the reporting requirements for the CDC COVID-19 Vaccination Program?","8259":"To find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. \uf263 Learn About Getting Your Vaccine\nDo you need to wait to get vaccinated after getting COVID-19 or getting treatment for COVID-19? How can you prepare for vaccination? What can you expect during and after your vaccination? Getting Your COVID-19 Vaccine\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nIf You Receive a Vaccine That is Not in the U.S.","8806":"Second, the\nU.S. government work designation does not apply to works of state and local governments; works of state and local\ngovernments may be protected by copyright. Third, copyright laws also differ internationally. While U.S. federal copyright\nlaws may not protect U.S. government works outside the United States, the work may still be protected under the copyright\nlaws of other countries when used in these jurisdictions. Copyright-protected materials featured on the CDC and ATSDR\nwebsites should include a copyright statement. However, if in doubt, please write to the contact point for that site.","6593":"TM \uf209 TM\n\u2022\n\u2022\n\u2022\nTM\nTM\nTM\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022\n\u2022 \uf209\n\u2022 \uf209\f10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nNational Institute of Mental Health (NIMH) Depression\nMood Disorders\nOverweight and obesity\nOverweight (defined as a body mass index (BMI) is 25 kg\/m or higher, but under 30 kg\/m ), obesity (BMI is 30 kg\/m or\nhigher, but under 40 kg\/m ), or severe obesity (BMI is 40 kg\/m or higher), can make you more likely to get very sick from\nCOVID-19. The risk of severe illness from COVID-19 increases sharply with higher BMI.","1732":"Serious AEs per FDA are defined as:\nDeath\nA life-threatening AE\nInpatient hospitalization or prolongation of existing hospitalization\nA persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions\nA congenital anomaly\/birth defect\nRequirements for Reporting to VAERS (Updated 9\/13\/2022)\n\uf1aa\n\uf209\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nAn important medical event that based on appropriate medical judgement may jeopardize the individual and\nmay require medical or surgical intervention to prevent one of the outcomes listed above\nCases of myocarditis after a Pfizer-BioNTech, Moderna, or Novavax vaccine\nCases of pericarditis after a Pfizer-BioNTech, Moderna, or Novavax vaccine\nCases of Multisystem Inflammatory Syndrome in children and adults\nCases of COVID-19 that result in hospitalization or death\nHealthcare providers are encouraged to report to VAERS any additional clinically significant AEs following vaccination,\neven if unsure whether vaccination caused the event.","3567":"In some limited circumstances, people might\nreceive vaccinations outside the jurisdiction (state, territory, tribe, or local entity) where they live. When the vaccine\nmanufacturer is not reported, the recipient is considered fully vaccinated with two doses. COVID-19 Vaccinations Data Definitions\nTotal Doses Distributed\nThe total number of vaccine doses that have been distributed to vaccine provider locations. For states, Washington DC, the U.S. Virgin Islands, and Puerto Rico, total counts of COVID-19 vaccine doses include doses\ndistributed since December 14, 2020.","9496":"The Countermeasures Injury Compensation Program (CICP) is a federal program that may help\npay for costs of medical care and other specific expenses of certain people who have been\nseriously injured by certain medicines or vaccines, including these vaccines. Generally, a claim\nmust be submitted to the CICP within one (1) year from the date of receiving the vaccine. To\flearn more about this program, visit www.hrsa.gov\/cicp\/ or call 1-855-266-2427. WHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)? An EUA is a mechanism to facilitate the availability and use of medical products, including\nvaccines, during public health emergencies, such as the current COVID-19 pandemic.","1320":"Some experts suggest delaying the repeat dose for 8 weeks after the invalid dose\nbased on the potential for increased reactogenicity and the rare risk of myocarditis and pericarditis associated with\nModerna, Novavax, and Pfizer-BioNTech vaccines, especially in males ages 12-39 years. See Considerations for\nextended intervals for COVID-19 vaccine primary series. If a person moves from a younger age group to an older age group during the primary series or between the primary\nseries and booster dose, they should receive the vaccine dosage for the older age group for all subsequent doses.","2147":"Which COVID-19 vaccine should pregnant people receive? \uf1aa\nChildren, teens, and adults, including pregnant people, may get a COVID-19 vaccine and other vaccines, including a flu\nvaccine, at the same time. Can pregnant people get a COVID-19 vaccine at the same time as other vaccines? \uf1aa\nIF YOU ARE PREGNANT AND HAVE QUESTIONS ABOUT COVID-19 VACCINE\nIf you would like to speak to someone about COVID-19 vaccination during pregnancy, you can contact MotherToBaby\nwhose experts are available to answer questions in English or Spanish by phone or chat. This service is free and\nconfidential.","90":"\uf209\nRelated Pages\nInformation about COVID-19 Vaccines for People with Allergies\n\u203a\nPossible Side Effects\n\u203a\nEnsuring the Safety of COVID-19 Vaccines\n\u203a\f10\/30\/22, 9:31 AM Allergic Reactions after COVID-19 Vaccination | CDC\n\uf2ff For Healthcare Professionals\nInterim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19\nVaccination Sites\nInterim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United\nStates\nCOVID-19 Clinical Resources\n\u2022\n\u2022\n\u2022\nMore Information\nResearch\nAllergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine \u2014 United\nAllergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine \u2014 United States,\nMore Information\nVaccine Adverse Event Reporting System (VAERS)\nCOVID-19 Vaccine Safety Publications\n\uf209\nLast Updated July 20, 2022","7378":"The Presidential Proclamation and CDC\u2019s Amended Order have no effect on several non-U.S. citizens, including:\nNon-U.S. citizens eligible for asylum;\nNon-U.S. citizens eligible for withholding of removal;\nNon-U.S. citizens eligible for protection under the regulations issued pursuant to the legislation implementing the\nConvention Against Torture and Other Cruel, Inhuman or Degrading Treatment or Punishment;\nNon-U.S. citizens admitted to the United States as refugees ;\nPersons\u202fwith\u202fa\u202fvisa 92 or 93 (Follow-to-Join) status; and\nNon-U.S. citizens granted parole into the United States.","5718":"If you are 12 years and older and you are receiving vaccination for uses provided under EUI, you have a\nchoice of receiving the COVID-19 vaccine by either Moderna or Pfizer-BioNTech (see the Pfizer-BioNTech\nEUI Fact Sheet for Recipients and Caregivers). What are Emergency Use Instructions (EUI)? EUI are issued by CDC to provide information about emergency use of FDA-approved (licensed) medical\nproducts that may not be included in or differ in some way from the information provided in the FDA-\napproved labeling (package insert). EUI consist of fact sheets for healthcare providers and recipients.","6733":"Children who will turn from 11 years\nto 12 years of age between doses in the primary regimen may receive, for any dose in the primary series,\neither: (1) the Pfizer-BioNTech COVID-19 Vaccine authorized for use in individuals 5 through 11 years of\nage; or (2) COMIRNATY (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine\nauthorized for use in individuals 12 years of age and older.","7435":"10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nAll forms of proof of COVID-19 vaccination must have\nPersonal identifiers (full name plus at least one other identifier such as date of birth or passport number) that match the\npersonal identifiers on the passenger\u2019s passport or other travel documents\nName of official source issuing the record (e.g., public health agency, government agency, or other authorized vaccine\nprovider)\nVaccine manufacturer and date(s) of vaccination\nHow the 14 days are calculated:\nYour last dose must have been given a full 14 days before the day you board your flight to the United States.","7320":"CDC has worked closely with public health jurisdictions and the\nCouncil of State and Territorial Epidemiologists (CSTE) to help states to count repeat infections in the same individuals over\ntime. An updated national surveillance case definition of COVID-19 was introduced on September 1, 2021, and includes criteria for\ncounting new infections (reinfections) after previous probable or confirmed infections. CDC is working with multiple public\nhealth jurisdictions that are identifying reinfections to collect and analyze the data.","9613":"Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nThe COVID-19 vaccine by Pfizer-BioNTech is approved by the FDA as a 2-dose primary series for active\nimmunization to prevent COVID-19 in persons ages 12 years and older. CDC is issuing these EUI to provide\ninformation about use of the COVID-19 vaccine by Pfizer-BioNTech for primary and\/or additional doses that\nextend beyond its FDA-approved labeling as described further under \u201cWho can receive the COVID-19 vaccine\nby Pfizer-BioNTech\u201d and \u201cWhat are the doses and intervals of the COVID-19 vaccine by Pfizer-BioNTech for\nprimary and\/or additional doses\u201d. What is COVID-19?","9131":"\uf209\n[PDF - 439 KB]\n\uf20c\nMasks Are Recommended\nCDC recommends properly wearing a high-quality mask or respirator over the nose and\nmouth in indoor areas of public transportation and transportation hubs. Airplane:\nEnglish\nSpanish\nTrain:\nEnglish\nSpanish\nBus:\nEnglish\nSpanish\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\f10\/30\/22, 9:43 AM Wearing Masks in Travel and Public Transportation Settings | CDC\n8.5 W x 11 H [PDF \u2013 304 KB, 1 Page]\n\uf20c\n\uf20c\nLast Updated Sept. 8, 2022","425":"Demographic Trends of People Receiving COVID-19 Vaccinations in the United States previously showed \u201cdate\nadministered\u201d erroneously. This has been replaced with \u201cdate reported to CDC\u201d as of June 24, 2021. On June 14, 2021: During a system upgrade, CDC identified vaccine administration records from files that were\npreviously received but not fully processed. Completion of processing on June 14, 2021 has resulted in a net increase of\n339,047 vaccine administration counts. By jurisdiction, the net increases are: CT (+39), DC (+4,528), FL (+132,008), GU\ncounts for the following jurisdictions will decrease: NJ (-20,609).","6904":"\u2022 People ages 12 years and older who recently had SARS-CoV-2 infection may receive a second\nprimary dose after a deferral period of 3 months from symptom onset or positive test (if infection\nwas asymptomatic)\fPfizer-BioNTech COVID-19 Vaccine EUI Recipient Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\n\u2022 People ages 12 years and older who received an incomplete primary dose series (only the first\ndose of a 2-dose primary series) with certain non-FDA authorized or approved COVID-19 vaccines\nat least 28 days ago should receive a primary dose of the COVID-19 vaccine by Pfizer-BioNTech to\ncomplete the series.","537":"On February 15, 2021, the COVID-19 Vaccine Tracker was updated to reflect the revised Pfizer-BioNTech emergency use\nauthorization (EUA) to allow the use of a sixth dose, if present in a vial, as authorized by the Food and Drug\nAdministration (FDA)external icon . Pfizer-BioNTech deliveries to a jurisdiction on or after February 15, 2021, will\nreflect this increase to six doses per vial compared to five doses; historical data will not be updated. The change to the\nPfizer-BioNTech dosage increases the number of doses delivered relative to the number of doses administered.","3027":"The COVID-19 vaccination schedule for people who are moderately or severely immunocompromised is detailed below and\nsummarized in Table 3; see also COVID-19 vaccination and EVUSHELD\u2122. Table of Contents \uf426\nCOVID-19 vaccination guidance for people who are moderately\nor severely immunocompromised\nView the COVID-19 Vaccination Schedule for People who are Moderately or Severely Immunocompromised \uf20a\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nPeople who are or who become moderately or severely immunocompromised should follow the COVID-19 vaccination\nschedule according to their age and immune status at the time of eligibility for that dose.","3748":"3 The original recommended interval (3 weeks for Pfizer-BioNTech; 4 weeks for Moderna) between the first and\nsecond primary doses remains the recommended interval for: people who are moderately to severely\nimmunocompromised; adults ages 65 years and older; and others who need early protection due to increased\nconcern about community transmission or risk of severe disease.","1677":"Where CDC becomes aware of a provider engaging in any of the following, CDC will consider taking any and\nall appropriate measures, including the possibility of rescinding the CDC provider agreement:\nAdministering COVID-19 Vaccine at any out-of-pocket cost to the recipient\nDenying anyone vaccination, or differentially reducing appointment access, based on the vaccine recipient\u2019s\ncoverage status or network status\nCharging an office visit or other fee if COVID-19 vaccination is the sole medical service provided\nRequiring additional medical services to receive COVID-19 vaccination\nSeeking any reimbursement, including through balance billing, from the vaccine recipient\nACIP Recommendations (9\/7\/2021)\nThe Advisory Committee on Immunization Practices (ACIP) comprises 15 medical and public health experts who develop\nevidence-based recommendations for use of vaccines in the United States.","4992":"Added considerations for an 8-week interval between the first and second doses of a primary mRNA vaccine schedule\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nUpdated guidance for moderately or severely immunocompromised people\nClarification of existing recommendation to receive a 3-dose mRNA vaccine primary series followed by a booster\ndose for a total of 4 doses\nNew guidance to shorten the interval between completion of the mRNA vaccine primary series and the booster\ndose to at least 3 months (instead of 5 months)\nNew guidance for those who received the Janssen COVID-19 Vaccine primary series to receive an additional dose\nand a booster dose, for a total of 3 doses to be up to date\nUpdated guidance that it is no longer necessary to delay COVID-19 vaccination following receipt of monoclonal\nantibodies or convalescent plasma\nUpdated guidance on receiving a booster dose if vaccinated outside the United States\nUpdated contraindication and precaution section to include history of myocarditis or pericarditis after an mRNA\nCOVID-19 vaccine as a precaution\nReorganized and condensed multiple sections\nUpdated guidance for use of Pfizer-BioNTech COVID-19 Vaccine as a booster in people ages 12\u201317 years\nUpdated guidance for administration of a COVID-19 vaccine booster dose at least 5 months after completion of an\nmRNA vaccine (Pfizer-BioNTech or Moderna) primary series\nUpdated guidance for use of an additional primary dose for moderately or severely immunocompromised people ages\n5\u201311 years who received a Pfizer-BioNTech vaccine primary series\nUpdated recommendations for people who received COVID-19 vaccines outside the United States that are not FDA-\nauthorized or approved\nUpdated information about a second formulation of Pfizer-BioNTech COVID-19 Vaccine that is authorized for use in\npersons ages 12 years and older\nUpdated information on vaccinating people during quarantine after a known SARS-CoV-2 exposure or during COVID-\nUpdate to alert providers of possible false positive Rapid Plasma Reagin (RPR; non-treponemal) test results in some\npeople after COVID-19 vaccines\nUpdated information on vaccine administration errors and deviations\nUpdated guidance on use of Janssen (Johnson & Johnson) COVID-19 Vaccine\nUpdated recommendations for receipt of a COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 booster doses in recipients of mRNA COVID-19 vaccines\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nRecommendations and clinical guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children aged 5-11 years\nincluding updated section on Vaccination of children and adolescents\nUpdated guidance on COVID-19 vaccine dosing and schedule\nUpdated guidance for myocarditis and pericarditis after mRNA COVID-19 vaccination in new section on Considerations\nfor mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna\nNew guidance for people who received passive antibody products in section on COVID-19 vaccination and SARS-CoV-2\ninfection\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial in the United States\nUpdated guidance on Considerations for COVID-19 vaccination in moderately and severely immunocompromised\npeople\nUpdated guidance in section on Contraindications and precautions\nUpdated Table in Appendix A: Vaccine administration errors and deviations\nUpdated Appendix B: Triage of people with a history of allergies or allergic reactions\nUpdated Appendix C: Ingredients included in COVID-19 vaccines\nUpdated Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects\nfollowing COVID-19 vaccination\nUpdated guidance in section on Considerations for use of a COVID-19 booster dose.","7985":"Google searches related to the COVID-19 vaccine during\nthis reporting period remained low relative to other topics such as Uvalde, TX, and monkeypox.e According to a Meltwater\ntrends analysis, there was a 17% decrease in news coverage and 45% decrease in social media mentions of COVID-19 vaccines.f\nRecent polling indicates fewer than a third of domestic consumers report being \u201csomewhat\u201d or \u201cvery\u201d worried about contracting\nAdditionally, sources indicate vaccine uptake plateauing,g as of May 31, 2022, COVID Data Tracker reported that 77.9% of\npeople had received at least one shot60 and 66.7% were fully vaccinated.61 Reported intention to vaccinate maintains a similarly\nconsistent cadence since approximately August 2021.c,62,63\nThe FDA64 and CDC65 strengthened recommendations and expansion of booster eligibility.","1786":"10\/30\/22, 9:29 AM COVID-19 Vaccination for Children and Teens with Disabilities | Human Development and Disability | NCBDDD | CDC\nThe benefits of COVID-19 vaccination outweigh the known and potential risks\nCOVID-19 vaccines have been shown to be safe and effective at protecting against COVID-19 and preventing severe\nillness if infected. In clinical trials, about 20% of children and teens who participated had an underlying medical condition. Some children and teens with a weakened immune system should get an additional dose of vaccine as part of their\nprimary COVID-19 vaccination series.","6728":"Children\nwho will turn from 4 years to 5 years of age between any doses in the primary series, and who initiated a\n3-dose primary series with the Pfizer-BioNTech COVID-19 Vaccine authorized for use in individuals\n6 months through 4 years of age, may receive the Pfizer-BioNTech COVID-19 Vaccine authorized for use\nin individuals 5 through 11 years of age for doses 2 and\/or 3. 4 You may receive this Fact Sheet even if your child is 12 years old.","7670":"To view the current total number of COVID-19 vaccinations that have been administered in the United\nStates, please visit the CDC COVID Data Tracker. COVID-19 vaccines are safe and effective. COVID-19 vaccines were evaluated in tens of thousands of participants in clinical\ntrials. The vaccines met the Food and Drug Administration\u2019s (FDA\u2019s) rigorous scientific standards for safety, effectiveness, and\nmanufacturing quality needed to support emergency use authorization (EUA). Learn more about EUAs in this video. The Pfizer-BioNTech, Moderna, and Johnson & Johnson\/Janssen and Novavax COVID-19 vaccines will continue to undergo the\nmost intensive safety monitoring in US history.","2122":"Keeping\nyourself as healthy as possible during pregnancy is important for the health of your baby. When during pregnancy should a person get a COVID-19 vaccine? \uf1aa\f10\/30\/22, 9:30 AM COVID-19 Vaccines While Pregnant or Breastfeeding\nPeople who are Breastfeeding\nCDC recommends that people who are breastfeeding get vaccinated and stay up to date with their COVID-19 vaccines,\nincluding getting a COVID-19 booster shot when it\u2019s time to get one. Clinical trials for the COVID-19 vaccines currently used in the United States did not include people who were breastfeeding.","1141":"Vaccine Distribution Data Systems\nVaccine Tracking System (VTrckS) is CDC\u2019s vaccine order management system where jurisdictions (states,\nterritories, tribes, and local entities), federal agencies, and pharmacy partners order vaccines from the federal\ngovernment. VTrckS Provider Order Portal (VPOP) is CDC\u2019s platform where federal entity providers report their on-hand\nCOVID-19 vaccine inventory each day. Immunization Data Lake (IZ Data Lake) is a cloud-hosted data repository to receive, store, manage, and analyze\ndeidentified COVID-19 vaccination data. \u2022\n\u2022 \uf209\n\u2022\nVaccine Administration Data Systems\nImmunization Information Systems (IISs)\u202fMost IISs create\u202fa centralized\u202fdata repository for storing\nvaccination\u202finformation specific to that jurisdiction.","5364":"Guillain Barr\u00e9 Syndrome\nGuillain Barr\u00e9 syndrome (a neurological disorder in which the body\u2019s immune system damages\nnerve cells, causing muscle weakness and sometimes paralysis) has occurred in some people who\nhave received the Janssen COVID-19 Vaccine. In most of these people, symptoms began within\n42 days following receipt of the Janssen COVID-19 Vaccine. The chance of having this occur is\nvery low. You should seek medical attention right away if you develop any of the following\nsymptoms after receiving the Janssen COVID-19 Vaccine:\n\u2022 Weakness or tingling sensations, especially in the legs or arms, that\u2019s worsening and spreading\nto other parts of the body. \u2022 Difficulty walking.","350":"CDC is actively working to address this issue and the data will be updated\nwhen available. December 30, 2021: CDC updated 349 incorrect census county-level population denominators. This update does not\nimpact the overall number of people who have received at least one dose of a COVID-19 vaccine or the overall number of\npeople who are fully vaccinated. The update does impact the percentage of populations within 189 counties who have\nreceived at least one dose or who are fully vaccinated.","10090":"Summary Document for\nInterim Clinical Considerations\nfor Use of COVID-19 Vaccines Currently Authorized or Approved in the United States\nAll currently authorized or approved COVID-19 vaccines\nContraindications\nHistory of:\n\u0083 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine\n\u0083 A known diagnosed allergy to a component of the COVID-19 vaccine\n\u0083 For the Janssen COVID-19 Vaccine, TTS following receipt of a previous Janssen COVID-19 Vaccine (or other COVID-19 vaccines not currently\nauthorized or approved in the United States that are based on adenovirus vectors, e.g., AstraZeneca)\u00a7\nPrecautions\n\u0083 History of anaphylaxis after any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies\n[excluding subcutaneous immunotherapy for allergies, i.e., \u201callergy shots\u201d])\n\u0083 History of multisystem inflammatory syndrome in children (MIS-C) or multisystem inflammatory syndrome in adults (MIS-A)\n\u0083 History of an immediate (within 4 hours of exposure) non-severe allergic reaction after a dose of one type of COVID-19 vaccine have a precaution\nto the same type of COVID-19 vaccine\n\u0083 Allergy-related contraindication to one type of COVID-19 vaccine have a precaution to the other types of COVID-19 vaccines.\u00b6\n\u0083 Moderate or severe acute illness, with or without fever\n\u0083 History of myocarditis or pericarditis after a dose of an mRNA or Novavax COVID-19 vaccine\n\u0083 For Janssen COVID-19 Vaccine, a history of Guillain-Barr\u00e9 syndrome**\nConsiderations for all FDA-authorized or -approved COVID-19 vaccines\nPersons receiving HCT and CAR-T-cell\ntherapy\n\u0083 If received doses of COVID-19 vaccine prior to or during HCT or CAR-T cell therapy, should be revaccinated for any monovalent primary series\nand bivalent booster doses received before or during treatment at least 3 months (12 weeks) after transplant or CAR-T-cell therapy.","6156":"\u2022\n\u2022\nCDC uses the following platforms and methods to collect and\nanalyze surveillance data on COVID-19 cases, hospitalizations,\nand deaths by vaccination status:\nCase surveillance\nCDC collaborates with more than 30 state and local health departments that routinely link case surveillance, immunization\nregistry, and vital registration data to monitor rates of COVID-19 cases and deaths by vaccination status, including receipt of\nbooster doses. These rates are published monthly on COVID Data Tracker. Data from the participating health departments represent more than 70% of the U.S. population and all regions of the\ncountry. The volume of this data allows CDC to analyze rare outcomes over time, like COVID-19-associated deaths.","3550":"Previously, CDC had capped estimates of vaccination coverage at 99.9%. CDC changed the cap to 95% on December 9, 2021,\nto account for differences in the accuracy of vaccination coverage estimates between different jurisdictions. CDC encourages people to bring their CDC COVID-19 Vaccination record card with them to their appointment for another\nCOVID-19 vaccine dose because having the card will help ensure the doses are linked.","8428":"Core Competencies Based on Role:\nRelevant information contained in the EUA Fact Sheet(s) for Healthcare Providers for the vaccine product(s) in\nyour facility\nStorage and handling requirements\nTransport guidance\nVaccination documentation and reporting requirements\nRequired and additional information for vaccine recipients\nCOVID-19 Vaccine Administration Competencies Assessment Form\nAdministration support staff qualified to store, handle, or transport\nvaccine\n\uf209\n\uf20c\nAdditional Resources:\nCOVID-19 Vaccination Clinical & Professional Resources\nInterim Guidance for Immunization Services During the Pandemic\nPatient Safety Checklist for Vaccination Clinics Held at Satellite Temporary or Off-Site Locations \uf20c\f10\/30\/22, 9:17 AM Training and Education for COVID-19 Vaccination | CDC\nPatient Safety Checklist for Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations\nNational Forum on COVID-19 Vaccine: Resources Page\nVaccine Confidence Training (American College of Obstetricians and Gynecologists)\n\uf20c\n\uf209\nPage last reviewed: April 14, 2022","755":"10\/30\/22, 9:37 AM Basics of COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nBasics of COVID-19\nCDC is reviewing this page to align with updated guidance. COVID-19 (coronavirus disease 2019) is a disease caused by a virus named SARS-CoV-2 and was discovered in December 2019\nin Wuhan, China. It is very contagious and has quickly spread around the world. COVID-19 most often causes respiratory symptoms that can feel much like a cold, a flu, or pneumonia. COVID-19 may attack\nmore than your lungs and respiratory system. Other parts of your body may also be affected by the disease.","3345":"Considerations for subsequent COVID-19 vaccination may include:\n\uf20c\n\uf20c\n\uf20c\nNovavax COVID-19 Vaccine\nConsiderations for COVID-19 vaccination\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nThe myocarditis or pericarditis was considered unrelated to vaccination with Moderna, Novavax, or Pfizer-BioNTech (e.g.,\ndue to SARS-CoV-2 or other viruses), especially if the myocarditis or pericarditis diagnosis occurred more than 3 weeks\nafter the most recent dose of COVID-19 vaccine\nPersonal risk of severe acute COVID-19 (e.g., age, underlying conditions)\nTiming of any immunomodulatory therapies; ACIP\u2019s general best practice guidelines for immunization can be consulted\nfor more information\nFor myocarditis associated with MIS-C or MIS-A, see COVID-19 vaccination and MIS-C and MIS-A.","6139":"WHO Strategic Advisory Group of Experts on Immunization (SAGE). Interim recommendations for use of the\ninactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm; updated 28\nOctober 2021. Geneva: World Health Organization; 2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-\n2019-nCoV-vaccines-SAGE-recommendation-BIBP. Zhong D, Xiao S, Debes AK, Egbert ER, Caturegli P, Colantuoni E, et al. Durability of Antibody Levels After\nVaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. JAMA. 2021 Dec","3130":"Vaccinators should not deny COVID-19 vaccination to a person due to lack of documentation. Revaccination is defined as repeating 1 or more dose(s) of vaccine. COVID-19 revaccination should be with Moderna, Novavax,\nor Pfizer-BioNTech COVID-19 vaccine (Table 3) regardless of vaccine administered for initial vaccination. Recipients of HCT or\nCAR-T-cell therapy should undergo revaccination for the monovalent primary series and bivalent booster doses received prior\nto or during treatment. There is no revaccination for monovalent booster doses received prior to or during treatment. After\nrevaccination with the primary series, the patient should receive 1 bivalent booster dose.","4792":"To file an electronic report, please see the VAERS website . Determine how the error occurred and implement strategies to prevent it from happening again. A discussion on\nstrategies to prevent errors can be found in the \u201cVaccine Administration\u201d chapter of Epidemiology and Prevention of\nVaccine-Preventable Diseases (Pink Book). Additional resources can be found on CDC\u2019s vaccine administration web page,\nincluding a job aid for preventing errors. Follow the revaccination guidance in the table below, using an age-appropriate COVID-19 vaccine product. Then continue\nwith the recommended schedule of subsequent dose(s) unless otherwise noted (see footnotes to this Appendix).","9020":"Anyone can submit a report to VAERS ,\nincluding patients, parents or caregivers, healthcare providers, and vaccine manufacturers. There are two ways to report an adverse event to VAERS: report online or report using a writable pdf form . If you need\nfurther assistance with reporting to VAERS, please email info@VAERS.org or call 1-800-822-7967. For healthcare providers \u2013 Under Emergency Use Authorization, FDA requires healthcare professionals to report to VAERS\ncertain adverse events that occur after COVID-19 vaccination. CDC also encourages reporting of any medically important\nadverse event even if it isn\u2019t clear if the vaccine caused the health problem.","9631":"\u2022 Persons ages 12 years and older who recently had SARS-CoV-2 infection may receive the second\nprimary dose after a deferral period of 3 months from symptom onset or positive test (if infection was\nasymptomatic)\n\u2022 Persons ages 12 years and older who received an incomplete primary series (e.g., only the first dose of\n2-dose primary series) with certain non-FDA authorized or approved COVID-19 vaccines should receive\na primary dose of the COVID-19 vaccine by Pfizer-BioNTech.","2754":"If you are experiencing a post-COVID\ncondition, you should engage in whatever coping strategies are best for your mental and physical health. Participate in specific long COVID research. The National Institutes of Health (NIH) is conducting a research project, called the RECOVER Initiative, to\nunderstand how people recover from a COVID-19 infection and why some people do not fully recover and develop\nlong COVID or post-COVID conditions. Learn more about Researching COVID to Enhance Recovery . \u2022\n\uf209\nWays to Cope with Stress\nExperts are still determining which types of medications or treatments can help to relieve the effects of post-COVID\nconditions.","9353":"Children who will turn from 11 years to 12 years of age between doses in the primary series may receive, for any\ndose in the primary series, either: (1) the Moderna COVID-19 Vaccine authorized for use in individuals 6 years\nthrough 11 years of age; or (2) Moderna COVID-19 Vaccine authorized for use in individuals 12 years of age and\nolder; or (3) SPIKEVAX (COVID-19 Vaccine, mRNA).","17":"Ask the facility healthcare provider (or facility staff) for help if:\n\u2022 The redness or pain where you got the shot gets worse after 24 hours\n\u2022 Your side effects are worrying you\n\u2022 Your side effects do not seem to be going away after a few days\nIn the rest of your body:\n\u2022 Fever\n\u2022 Chills\n\u2022 Tiredness\n\u2022 Headache\n\u2022 Muscle pain\n\u2022 Nausea\nCOMMON SIDE EFFECTS\nHELPFUL TIPS\nREMEMBER","2656":"Call 911 or call ahead to your local emergency facility: Notify the operator that you are seeking care for someone who\nhas or may have COVID-19. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\nProtect yourself\nLimit contact\nCOVID-19 spreads between people who\nare in close contact (within about 6 feet)\nthrough respiratory droplets, created\nwhen someone talks, coughs or sneezes. Staying away from others helps stop the\nspread of COVID-19. The caregiver, when possible, should not\nbe someone who is at higher risk for\nsevere illness from COVID-19. The person who is sick should isolate\nThe sick person should separate\nthemselves from others in the home. Learn when and how to isolate.","6930":"Talk to your healthcare provider about if and when you should receive a primary, additional, and\/or a\nbooster dose. See CDC\u2019s Interim Clinical Considerations for additional information on moderately and\nseverely immunocompromised persons recommended for an additional primary dose and populations\neligible for a booster dose. Who should NOT get the COVID-19 vaccine by Pfizer-BioNTech?","6870":"Pfizer-BioNTech COVID-19 Vaccine EUI Recipient Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nEmergency Use Instructions (EUI) Fact Sheet for Recipients and Caregivers:\nPfizer-BioNTech COVID-19 Vaccine for Primary and\/or Additional Doses\nThis Fact Sheet describes Emergency Use Instructions (EUI) that have been issued by the Centers for\nDisease Control and Prevention (CDC) to provide information about the primary and additional doses of the\nCOVID-19 vaccine by Pfizer-BioNTech that go beyond its FDA-approved labeling.","5375":"V-safe is a new voluntary smartphone-based\ntool that uses text messaging and web surveys to check in with people who have been vaccinated\nto identify potential side effects after COVID-19 vaccination. V-safe asks questions that help CDC\nmonitor the safety of COVID-19 vaccines. V-safe also provides live telephone follow-up by CDC\nif participants report a significant health impact following COVID-19 vaccination. For more\ninformation on how to sign up, visit: www.cdc.gov\/vsafe. WHAT IF I DECIDE NOT TO GET THE JANSSEN COVID-19 VACCINE? Under the EUA, there is an option to accept or refuse receiving the vaccine.","7568":"What\ndocumentation do I need to show? \uf1aa\f10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\ncompleted the series)\nPersonal identifiers in the clinical trial documentation (full name plus at least one other identifier such as date of birth\nor passport number) that match with your passport or other travel documentation. CDC may grant a humanitarian or emergency exception in very limited circumstances only when an individual must travel\nto the United States to preserve health (e.g., emergency medical evacuations, life-saving medical treatment) or safety\n(e.g., violence) and is unable to become fully vaccinated before travel.","956":"If you do not develop symptoms, get tested at least 5 days after you last had close contact with someone with\nCOVID-19. Self-tests are one of several options for testing for the virus that causes COVID-19 and may be more\nconvenient than laboratory-based tests and point-of-care tests. Ask your healthcare provider or your local\nhealth department if you need help interpreting your test results. Any caregiver feeding the baby should wear a mask when caring for the baby for the entire time you are in isolation and\nduring their own quarantine period after you complete isolation.","4967":"New booster recommendation for people ages 12 years and older to receive 1 bivalent mRNA booster after\ncompletion of a monovalent primary series; it replaces all prior booster recommendations for this age group\nRecommendations for use of a bivalent Moderna booster dose in people ages 18 years and older\nRecommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 12 years and older\nUpdated guidance for observation periods following COVID-19 vaccination\nUpdated guidance on COVID-19 vaccination and multisystem inflammatory syndrome (MIS) in children (MIS-C) and in\nadults (MIS-A)\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adolescents ages 12\u201317 years\nReorganization of Janssen COVID-19 Vaccine guidance into an appendix\nUpdated guidance on COVID-19 vaccination following exposure to SARS-CoV-2\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nPrevious Updates\n\uf1aa\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nUpdated guidance on COVID-19 vaccination and myocarditis and pericarditis\nNew clinical considerations for coadministration of mRNA COVID-19 vaccines and orthopoxvirus vaccines\nNew guidance for use of Moderna COVID-19 Vaccine in children and adolescents ages 6\u201317 years\nNew guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children ages 6 months\u20134 years\nNew guidance for use of Moderna COVID-19 Vaccine in children ages 6 months\u20135 years\nReorganization of sections on COVID-19 vaccination recommendations and schedules\nAddition of new section in Special populations for infants and young children\nNew guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5\u201311 years\nUpdated guidance that the following people should receive a second COVID-19 booster dose:\nPeople ages 12 years and older who are moderately or severely immunocompromised\nPeople ages 50 years and older\nUpdated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-\ndepleting therapies\nClarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults\n(MIS-A)\nUpdated guidance for primary series vaccination after SARS-CoV-2 infection\nAdded considerations for the option to receive a second COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 vaccination after SARS-CoV-2 infection\nAdded guidance that people ages 12 years and older who are moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that people ages 18\u201349 years who are not moderately or severely immunocompromised and who\nreceived Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster\ndose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose\nFurther clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C)\nand adults (MIS-A) and myocarditis\nUpdated information on the availability of Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL\ndosage volume) and Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL dosage volume) for\nadministration of a 50 \u00b5g booster dose.","310":"CDC and DC are actively working to validate this increase, and if needed, data corrections will occur in a\ntimely manner. Vaccination data submitted by Texas on April 20, 2022 are currently under review by CDC and state officials due to the\nuse of a new reporting process and are not reflected on COVID-19 Data Tracker. The data will be updated when\navailable. April 15, 2022: New Hampshire reviewed data and made adjustments to the vaccination records they have reported to\nCDC, resulting in a decrease of 62,163 vaccine doses administered since December 14, 2020.","1150":"\u2022\n\u2022\n\u2022\n\u2022\nCOVID-19 Vaccination Data Sources\f10\/30\/22, 9:35 AM COVID-19 Vaccination Data Systems and Data Sources\nFederal Agency Data\nOn CDC COVID Data Tracker (CDT), data are individually displayed at the national level and included as part of national\ntotals for each metric for the following agencies (except Department of State, DoS):\nBureau of Prisons (BoP)\nDepartment of Defense (DoD)\nIndian Health Services (IHS)\nVeterans Health Administration (VHA)\nFederal agency data\u202fare\u202falso included as part of jurisdiction, state, or territory aggregate metrics. To avoid duplicate\ncounts, the agency data\u202fshould not be combined with other data.","9295":"In addition,\nHispanic or Latino and non-Hispanic Black children are disproportionately affected by MIS-C.\nCOVID-19 vaccination reduced the likelihood of MIS-C in children ages 12 through 18 years by 91%. Data from July to\nDecember 2021 show that 95% of children ages 12 through 18 years hospitalized with MIS-C were not vaccinated. CDC is\ncollecting data on how well COVID-19 vaccination works against MIS-C in younger children. As more children under 12\nyears old get vaccinated, CDC will be able to analyze and share those data.","1049":"Learn more\nResources\nProfessional Resources on Testing: Healthcare Workers | Health Departments | Labs\n\uf2ff\nDon\u2019t Delay: Test Soon and Treat Early [1 page, 361 KB]\nHow to Collect an Anterior Nasal Swab Specimen for COVID-19 Testing [2 pages, 372 KB]\nHow to Collect a Nasal Mid-Turbinate Swab Specimen for COVID-19 Testing [2 pages, 4 MB]\nUsing Your Self-Test [1 page, 295 KB]\nUsing Your Self-Test (Customizable File) [1 page, 279 KB]\nPrint Resources\n\uf1aa\n\u2022 \uf20c\n\u2022 \uf20c\n\u2022 \uf20c\n\u2022 \uf20c\n\u2022 \uf20c\n\u2022 \uf20c\nLast Updated Sept. 28, 2022","2185":"Dagan N, Barda N, Biron-Shental T, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat Med. 13. Theiler RN, Wick M, Mehta R, et al. Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy. Am J\n14. Morgan JA, Biggio JR, Martin JK, et al. Maternal Outcomes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-\nCoV-2) Infection in Vaccinated Compared With Unvaccinated Pregnant Patients. Obstetrics & Gynecology: January 2022 \u2013\nVolume 139 \u2013 Issue 1 \u2013 p 107-109. DOI: https:\/\/doi.org\/10.1097\/AOG.0000000000004621\n15. Stock SJ, Carruthers J, Calvert C, et al. SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in\nScotland. Nat Med(2022).","165":"CDC leads the One Health Federal Interagency COVID-19 Coordination (OH-FICC) Group, which brings together public\nhealth, animal health, and environmental health representatives from more than 20 federal agencies to collaborate and\nexchange information on the One Health aspects of COVID-19. For example, the group researches and develops\nguidance on the connection between people and pets, wildlife, zoo animals, and livestock; animal diagnostics and\ntesting; and environmental health issues relevant to COVID-19. CDC leads the regular State-Federal One Health Update Call to bring local, state, tribal, and territorial partners together\nwith OH-FICC members.","7614":"\uf1aa\nYou will need to show\nYour C-1 and D visa; AND\nAn official letter from your employer (paper or digital) indicating your entry to or transit through the United States is\nrequired for the purpose of operating a vessel or return travel after disembarking the vessel consistent with your visa\nand official letter. What documentation do I need if I am a sea crew member traveling with a C-1 and D\nnonimmigrant visa?","5160":"\uf3c0 ALL Travelers\nRECOMMENDED\nG t t t d ith i l t t 3 5 d ft i l\f10\/30\/22, 9:43 AM International Travel to and from the United States | CDC\nGet tested with a viral test 3-5 days after arrival. Find a U.S. COVID-19 testing location near you or use a self-test. If you already had COVID-19 within the past 90 days, see specific testing recommendations. Monitor yourself for COVID-19 symptoms. Follow additional guidance if you know you were exposed to a person with COVID-19. Follow all state, tribal, local and territorial recommendations or requirements after arrival.","5795":"Common side effects\nreported were mostly mild, but some people had side effects that affected their ability to do daily\nactivities. Cases of myocarditis and pericarditis have rarely been reported in some people. Cases have occurred\npredominantly in adolescents and young adult males within the first week after the second dose of vaccine. There is evidence from multiple sources that suggest a higher risk for myocarditis following Moderna\ncompared to Pfizer-BioNTech vaccination; however, it is not possible to directly compare the risk in people\nages 12\u201317 years.","9200":"Use hand sanitizer if soap and water are not available. Use an alcohol-based hand sanitizer with at least\n60% alcohol, covering all surfaces of your hands and rubbing them together until they feel dry. Soap and water are the best option, especially if hands are visibly dirty. Avoid touching your eyes, nose, and mouth with unwashed hands. Handwashing Tips\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\uf262 Avoid sharing personal household items\nDo not share dishes, drinking glasses, cups, eating utensils, towels, or bedding with other people in your\nhome. Wash these items thoroughly after using them with soap and water or put in the dishwasher.","7219":"Pfizer-BioNTech COVID-19 Vaccine for individuals 12 years of age and older contains\n1 of the following sets of additional ingredients; ask the vaccination provider which\nversion is being administered:\n\uf0b7 potassium chloride, monobasic potassium phosphate, sodium chloride, dibasic\nsodium phosphate dihydrate, and sucrose\nOR\n\uf0b7 tromethamine, tromethamine hydrochloride, and sucrose\nPfizer-BioNTech COVID-19 Vaccine, Bivalent for individuals 12 years of age and older\ncontains the following additional ingredients:\n\uf0b7 tromethamine, tromethamine hydrochloride, and sucrose\nCOMIRNATY (COVID-19 Vaccine, mRNA) contains 1 of the following sets of additional\ningredients; ask the vaccination provider which version is being administered:\n\uf0b7 potassium chloride, monobasic potassium phosphate, sodium chloride, dibasic\nsodium phosphate dihydrate, and sucrose\nOR\n\uf0b7 tromethamine, tromethamine hydrochloride, and sucrose\nHAVE THESE VACCINES BEEN USED BEFORE?","5695":"These transparent medical masks should be reserved for use\nby healthcare workers and patients who require them.","4492":"They can also block droplets and\nparticles you breathe, cough, or\nsneeze out so you do not spread them\nto others. Respirators (for example,\nN95) provide higher protection than\nmasks. When wearing a mask or respirator\n(for example, N95), it is most important to choose one that you can wear correctly, that fits closely to your face over your\nmouth and nose, that provides good protection, and that is comfortable for you. Increasing Space and Distance\nSmall particles that people breathe out can contain virus particles.","4639":"10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nEspa\u00f1ol | Other Languages\nVaccines & Immunizations\nVaccines & Immunizations Home\nInterim Clinical Considerations for Use of COVID-19\nVaccines: Appendices, References, and Previous\nUpdates\nSummary of recent changes (last updated October 19, 2022):\nGuidance for use of a monovalent Novavax COVID-19 booster dose in people ages 18 years and older in limited\nsituations\nJanssen COVID-19 Vaccine is authorized for adults ages 18 years and older for the primary series dose and 1 booster dose in\ncertain limited situations due to the risk of thrombosis with thrombocytopenia syndrome (TTS) following receipt of the\nvaccine:\nWhen there is a contraindication to mRNA (i.e., Moderna or Pfizer-BioNTech) and Novavax COVID-19 vaccines (e.g.,\nsevere allergic reaction after a previous dose or to a component of an mRNA COVID-19 vaccine) (see Table 4)\nWhen a person would otherwise remain unvaccinated for COVID-19 due to limited access to other COVID-19 vaccines\nWhen a person wants to receive Janssen COVID-19 Vaccine despite the safety concerns identified\nCOVID-19 vaccine recipients should be informed that Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines are\nrecommended over Janssen COVID-19 Vaccine.","7310":"10\/30\/22, 9:37 AM Reinfections and COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nReinfections and COVID-19\nReinfection with the virus that causes COVID-19 means a person was infected, recovered, and then later became infected\nagain. After recovering from COVID-19, most individuals will have some protection from repeat infections. However,\nreinfections do occur after COVID-19. We are still learning more about these reinfections.","8614":"The vaccine also contains another ingredient called an adjuvant that helps the immune system respond to that spike protein\nin the future. Once the immune system knows how to respond to the spike protein, the immune system will be able to\nrespond quickly to the actual virus spike protein and protect you against COVID-19. About Novavax\nResearch for protein subunit technology\nProtein subunit vaccines have been used for years. More than 30 years ago, a hepatitis B vaccine became the first protein subunit vaccine to be approved for use in\npeople in the United States.","7538":"\uf1aa\f10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nCertain categories of persons traveling to the United States for reasons related to official foreign government travel or\nbecause they have been invited by the United Nations are eligible for an exception under the Proclamation and CDC\u2019s\nAmended Order.","6781":"In a clinical trial, approximately 300 individuals greater than 55 years of age received\n1 dose of a bivalent vaccine that differs from the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent in that it contains a different Omicron component. WHAT ARE THE BENEFITS OF THESE VACCINES? The Pfizer-BioNTech COVID-19 Vaccine has been shown to prevent COVID-19. FDA\nhas authorized the Pfizer-BioNTech COVID-19 Vaccine, Bivalent to provide better\nprotection against COVID-19 caused by the Omicron variant of SARS-CoV-2. The duration of protection against COVID-19 is currently unknown. WHAT ARE THE RISKS OF THESE VACCINES? There is a remote chance that these vaccines could cause a severe allergic reaction.","9253":"For travel guidance, see CDC\u2019s Travel\nwebpage. Take extra precautions if you will be around people who\nare more likely to get very sick from COVID-19. More about how to protect yourself and others\n\u2022\n\uf426\ncough\nshortness of breath\nother COVID-19 symptoms\nIf you develop symptoms\nisolate immediately\nget tested\nstay home until you know the result\nIf your test result is positive, follow the isolation\nrecommendations. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\uf3c0 GET TESTED\nGet tested at least 5 full days after your last exposure\nTest even if you don\u2019t develop symptoms. If you already had COVID-19 within the past 90 days, see specific testing recommendations.","8248":"Children under age 5 years are not recommended\nto receive a booster at this time. Children age 5 years old are only currently recommended to receive the updated (bivalent) Pfizer-BioNTech booster, and\nthey can get this booster whether they received the Pfizer-BioNTech or Moderna primary series. Children age 5 years old can no longer get an original (monovalent) mRNA (Pfizer-BioNTech or Moderna) booster. Children age 5 years old\n\uf1aa\nPeople ages 6 years and older can get a different product for their updated (bivalent) booster than they received for their\nprimary series or last booster.","4881":"Among people without a\ncontraindication or precaution,\na history of:\nAny allergy not listed as a\ncontraindication or\nprecaution\nActions:\nDo not vaccinate\nConsider referral to allergist-\nimmunologist\nConsider alternate vaccine type if\nage appropriate\nActions:\nRisk assessment\nShould consider a 30-minute observation\nperiod\nConsider referral to allergist-immunologist\nActions:\nProceed with vaccination\nShould consider a 15-\nminute observation\nperiod per General Best\nPractice Guidelines\nCOVID-19 vaccine-specific FDA fact sheets and U.S. COVID-19 Vaccine Product Information can be consulted for a full list of ingredients. People with a contraindication to one of the mRNA COVID-19 vaccines should not receive doses of either of the mRNA vaccines.","1726":"If a different product from the primary series is inadvertently administered for the additional or booster (third\ndose), VAERS reporting is required. VAERS reporting is not required for the following situations:\nIf a mixed series is given intentionally (e.g., due to hypersensitivity to a vaccine ingredient)\nMixing and matching of booster doses intentionally (as of October 21, 2021, mixing and matching of\nbooster doses is allowed)\nSerious AEs regardless of causality.","3482":"Follow additional guidance if you know you were exposed to a person with COVID-19. \uf2a5 Plan ahead\nBe up to date with your COVID-19 vaccines before travel. Check if your cruise line requires proof of vaccination or pre-embarkation testing, or has any other\nrequirements to board. If traveling by air before or after cruise travel, check if your airline or destination (see here for U.S.\nrequirement) requires any testing, vaccination, or other documents. Consider getting travel insurance. Consider buying additional insurance that covers health care and\nemergency evacuation, especially if you will be traveling to remote areas.","3979":"\uf1aa\nData on COVID-19 vaccine doses administered in the United States and territories are recorded by vaccination providers\nand reported to CDC through multiple sources, including:\nState, local, and territorial Immunization Information Systems (IISs)\nVaccine Administration Management System (VAMS), which supports vaccination clinics in jurisdictions, federal\nagencies, and multi-state healthcare organizations\nDirect data submissions to the COVID-19 Data Clearing House\nHow are vaccine administration data reported to CDC? \uf1aa\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Frequently Asked Questions about COVID-19 Vaccination Data | CDC\nData Variations\nThe COVID-19 Vaccination IT Overview provides an overarching view of the vaccine IT data systems and how they\nintegrate to track COVID-19 vaccine distribution and administration.","5403":"However, vaccination providers may seek appropriate reimbursement from a program\nor plan that covers COVID-19 vaccine administration fees for the vaccine recipient (private\ninsurance, Medicare, Medicaid, HRSA COVID-19 Uninsured Program for non-insured\nrecipients). WHERE CAN I REPORT CASES OF SUSPECTED FRAUD? Individuals becoming aware of any potential violations of the CDC COVID-19 Vaccination\nProgram requirements are encouraged to report them to the Office of the Inspector General, U.S.\nDepartment of Health and Human Services, at 1-800-HHS-TIPS or TIPS.HHS.GOV. WHAT IS THE COUNTERMEASURE INJURY COMPENSATION PROGRAM?","3053":"Children age 5 years: A 3-dose primary series and 1 bivalent Pfizer-BioNTech booster dose is recommended. For the\nprimary series, the first and second doses are separated by 3 weeks and the second and third doses are separated by at\nleast 4 weeks. The bivalent booster dose is administered at least 2 months after completion of the primary series (for\npeople who have not received any booster doses), or at least 2 months after the last monovalent booster dose. Currently, only the bivalent Pfizer-BioNTech booster dose is authorized for children age 5 years who receive a Pfizer-\nBioNTech primary series.","4158":"FDA has determined COVID-19 vaccines meet FDA\u2019s standards and has granted\nthose vaccines Emergency Use Authorizations (EUAs) or full FDA approval. Tracking Safety Using Vaccine Monitoring Systems \u2013 Like every other vaccine approved for use in the United States,\nCOVID-19 vaccines continue to be monitored for safety and effectiveness. Hundreds of millions of people in the\nUnited States have safely received COVID-19 vaccines. CDC and FDA continue to provide updated information on\nthe safety of U.S. authorized or approved COVID-19 vaccines using data from several monitoring systems. Learn more about developing COVID-19 vaccines. \u2022\n\u2022\n\uf209\n\u2022\nVaccine ingredients vary by manufacturer.","7415":"As required by United\nStates federal law, all airlines or other aircraft operators will provide and collect the passenger attestation on behalf of the\nU S Government\np g p g\nTechnical Instructions for Implementing Presidential Proclamation Advancing Safe Resumption of Global Travel During\nthe COVID-19 Pandemic and CDC\u2019s Associated Amended Order\nAircraft Operators\/Airlines\/Crew FAQs Requirement for Proof of COVID-19 Vaccination for Non-U.S. citizen Air\nPassengers who Are Nonimmigrants Traveling to the United States\n\uf20c\f10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nU.S. Government.","5603":"Wear cloth masks with\nA proper fit over your nose, mouth, and chin to prevent leaks\nMultiple layers of tightly woven, breathable fabric\nNose wire\nFabric that blocks light when held up to bright light source\n\u2022\n\u2022\n\u2022\n\u2022\nDo NOT wear cloth masks with\nGaps around the sides of the face or nose\nExhalation valves, vents, or other openings (see example)\nSingle-layer fabric or those made of thin fabric that don\u2019t block light\nWet or dirty material\n\u2022\n\u2022\n\u2022\n\u2022\nDisposable procedure masks are widely available. They are sometimes referred to as surgical masks or medical procedure\nmasks.","9417":"FDA has authorized Moderna COVID-19 Vaccine, Bivalent to provide\nbetter protection against COVID-19 caused by the Omicron variant of SARS-CoV-2. The duration of protection against COVID-19 is currently unknown. WHAT ARE THE RISKS OF THESE VACCINES? There is a remote chance that these vaccines could cause a severe allergic reaction. A severe\nallergic reaction would usually occur within a few minutes to one hour after getting a dose. For\nthis reason, the vaccination provider may ask you or your child to stay at the place where you or\nyour child received the vaccine for monitoring after vaccination.","8708":"Wash your hands often with soap and water. Use hand sanitizer if soap and water aren\u2019t available. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:37 AM Understanding Variants | CDC\nLast Updated Aug. 6, 2021","7826":"Contact them as soon as possible if:\nYour symptoms get worse. You are more likely to get very sick because you are an older adult or have an underlying\nmedical condition Possible treatment may be available for you\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\f10\/30\/22, 9:38 AM Self-Testing At Home or Anywhere | CDC\nmedical condition. Possible treatment may be available for you. You have questions about your isolation. -\n\uf6eb IF YOUR TEST IS\nNegative\nThe test did not detect the virus, but doesn\u2019t rule out an infection. Some self-tests are designed to be used in a series (also known as serial testing). Consider\nrepeating the test 24 to 48 hours later.","6563":"Get more information:\nHeart Disease\nAmerican Heart Association: COVID-19\nNHLBI Information & Resources on COVID-19\nHIV infection\nHaving HIV (Human Immunodeficiency Virus) can make you more likely to get very sick from COVID-19. Get more information:\n\u2022\n\u2022 \uf209\n\u2022\n\u2022 \uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022 \uf209\n\u2022\n\u2022\n\u2022\n\u2022 \uf209\n\u2022 \uf209\f10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nHIV Infection\nInterim Guidance for COVID-19 and Persons with HIV\nImmunocompromised condition or weakened immune system\nSome people are immunocompromised or have a weakened immune system because of a medical condition or a treatment\nfor a condition.","3414":"Administration of subsequent COVID-19 vaccine doses: Onset of MIS 90 days or more after most recent\nCOVID-19 vaccine dose\nAdministration of subsequent COVID-19 vaccine dose(s) should be considered for those who meet the two criteria listed\nbelow:\n1. Clinical recovery has been achieved, including return to baseline cardiac function; and\n2. It has been at least 90 days after the diagnosis of MIS-C\/A\nFor people who had MIS-C\/A but do not meet both criteria above, see Consultation for decisions about COVID-19 vaccination.","7696":"Myocarditis\nand pericarditis after COVID-19 vaccination are rare. Learn more about COVID-19 vaccines and adverse events, including\nmyocarditis and pericarditis. Guillain-Barr\u00e9 Syndrome (GBS)\nGuillain-Barr\u00e9 Syndrome (GBS) is a rare disorder where the body\u2019s immune system damages nerve cells, causing muscle\nweakness and sometimes paralysis. GBS after COVID-19 vaccination is rare. Learn more about COVID-19 vaccines and adverse\nevents, including GBS. Reports of Death Are Rare\nReports of death after COVID-19 vaccination are rare. FDA requires healthcare providers to report any death after COVID-19\nvaccination to the Vaccine Adverse Event Reporting System (VAERS) , even if it\u2019s unclear whether the vaccine was the\ncause.","3110":"Moderate and severe immunocompromising conditions and treatments include but are not limited to:\nActive treatment for solid tumor and hematologic malignancies\nHematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status\n(e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\nReceipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\nReceipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of\ntransplantation or taking immunosuppressive therapy)\nModerate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined\nimmunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)\nAdvanced HIV infection (people with HIV and CD4 cell counts less than 200\/mm3, history of an AIDS-defining illness\nwithout immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection\nActive treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when\nadministered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs,\ncancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and\nother biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents)\nFactors to consider in assessing the general level of immune competence in a patient include disease severity, duration,\nclinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.","4547":"10\/30\/22, 9:41 AM If You Are Sick or Caring for Someone | CDC\nIf You Are Sick or Caring for Someone\nIf you test positive and are an older adult or someone who is at high risk of getting very sick from COVID-19, treatment\nmay be available. Contact a healthcare provider right away after a positive test to determine if you are eligible, even if\nyour symptoms are mild right now. You can also visit a Test to Treat location and, if eligible, receive a prescription\nfrom a provider. Don\u2019t delay: Treatment must be started within the first few days to be effective.","5989":"In this study, adults who had completed primary vaccination with a\nModerna COVID-19 Vaccine 2-dose series (N=151), a Janssen COVID-19 Vaccine single dose (N=156), or a\nPfizer-BioNTech COVID-19 Vaccine 2-dose series (N=151) at least 12 weeks (range 12 to 20 weeks) prior to\nenrollment and who reported no history of SARS-CoV-2 infection were randomized 1:1:1 to receive a booster\ndose of one of three vaccines: Moderna COVID-19 Vaccine, Janssen COVID-19 Vaccine, or Pfizer-BioNTech\nCOVID-19 Vaccine.","1093":"You can treat symptoms\nwith over-the-counter medicines,\nsuch as acetaminophen (Tylenol)\nor ibuprofen (Motrin, Advil), to help\nyou feel better. Learn more about what to do if\nyou are sick. COVID-19 vaccines available in the United States effectively protect people from getting seriously ill, being hospitalized, and\neven dying\u2014especially people who are boosted. As with vaccines for other diseases, you are protected best when you stay up\nto date. CDC recommends that everyone who is eligible stay up to date on their COVID-19 vaccines.","5117":"\uf209\n\uf209\f10\/30\/22, 9:43 AM International Travel to and from the United States | CDC\nincluding mask wearing, proof of vaccination, or testing at your destination . Requirements in other countries may differ from U.S. requirements. If you do not follow your destination\u2019s\nrequirements, you may be denied entry and required to return to the United States. If you have a weakened immune system or are at increased risk for severe disease, take multiple prevention steps to\nprovide additional layers of protection from COVID-19 even if you are up to date with your COVID-19 vaccines.","390":"On October 24, 2021, CDC identified and corrected a processing error for percent of fully vaccinated people in 50+ years\nof age with a booster dose. This error resulted in a higher percentage of people reported with a booster dose in the age\ngroup of 50+ for October 22 and 23, 2021. On October 22, 2021: County-level graphics include Texas vaccination data. Texas and CDC collaborated to update how\nTexas submits aggregate vaccination data to enhance the information provided on CDC COVID Data Tracker.","4128":"Since there\nis no way to tell in advance how children, who are not moderately or severely immunocompromised, or those who may\nbe immunocompromised. A child can be immunocompromised and still healthy, will be affected by COVID-19 it\u2019s\nimportant to get them vaccinated as soon as possible to protect them against severe illness. To find your child a COVID-19\nvaccine or booster near you:\u202fSearch\u202fvaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. Should parents and caregivers wait for updated or additional vaccines, if a child is low risk for\ninfection?","6604":"Get more information:\nPregnant and Recently Pregnant People\nToolkit for Pregnant People and New Parents\nInvestigating the Impact of COVID-19 during Pregnancy\nSickle cell disease or thalassemia\nHaving hemoglobin blood disorders like sickle cell disease or thalassemia (inherited red blood cell disorders) can make you\nmore likely to get very sick from COVID-19. Get more information:\nSickle Cell Disease\nThalassemia\nSmoking, current or former\nBeing a current or former cigarette smoker can make you more likely to get very sick from COVID-19. If you currently smoke,\nquit. If you used to smoke, don\u2019t start again. If you\u2019ve never smoked, don\u2019t start.","6118":"\"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster)\nfollowing two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre,\nrandomised, controlled, phase 2 trial.\" The Lancet (2021). National Advisory Committee on Vaccination. An Advisory Committee Statement: Guidance on booster COVID-\n19 vaccine doses in Canada. Public Health Agency of Canada; 3 Dec 2021.\nhttps:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/immunization\/national-advisory-\nvaccine-doses.pdf\nNational Collaborating Centre for Methods and Tools. Rapid Review Update 1: What is the ongoing\neffectiveness, immunogenicity, and safety of COVID-19 vaccines in persons who have had a prior, confirmed\nCOVID-19 infection?. Hamilton (ON): McMaster University; 2021. Available from: https:\/\/www.nccmt.ca\/covid-\n19\/covid-19-rapid-evidence-service\/36.","2875":"COVID-19 vaccine products currently approved or authorized in the United States*\nModerna\nAge indication Vaccine composition Vaccine vial cap color Label border color Dilution required Dose Injection volume\nPrimary series vaccination\n6 months\u20135 years Monovalent Dark blue Magenta No 25 \u00b5g 0.25 mL\n6\u201311 years\u2020 Monovalent Dark blue Purple No 50 \u00b5g 0.5 mL\n12 years and older Monovalent Red Light blue No 100 \u00b5g 0.5 mL\nBooster vaccination\n6\u201311 years Bivalent Dark blue Gray No 25 \u00b5g 0.25 mL\n12 years and older Bivalent Dark blue Gray No 50 \u00b5g 0.5 mL\nNovavax\nAge indication Vaccine composition Vaccine vial cap color Label border color Dilution required Dose Injection volume\nPrimary series vaccination\n12 years and older Monovalent Royal blue No color No 5 \u00b5g rS and\n50 \u00b5g of Matrix-M\u2122 adjuvant\nBooster vaccination\n18 years and older Monovalent Royal blue No color No 5 \u00b5g rS and\n50 \u00b5g of Matrix-M\u2122 adjuvant\nPfizer-BioNTech\nAge indication Vaccine composition Vaccine vial cap color Label border color Dilution required Dose Injection volume\nPrimary series vaccination\n6 months\u20134 years\u2021 Monovalent Maroon Maroon Yes 3 \u00b5g 0.2 mL\n5\u201311 years Monovalent Orange Orange Yes 10 \u00b5g 0.2 mL\n12 years and older Monovalent Gray Gray No 30 \u00b5g 0.3 mL\nBooster vaccination\n5\u201311 years Bivalent Orange Orange Yes 10 \u00b5g 0.2 mL\n12 years and older Bivalent Gray Gray No 30 \u00b5g 0.3 mL\nJanssen\nAge indication Vaccine composition Vaccine vial cap color Label border color Dilution required Dose Injection volume\nPrimary series vaccination\n18 years and older Monovalent Blue No color No 5\u00d71010 viral particles 0.5 mL\nBooster vaccination\n18 years and older Monovalent Blue No color No 5\u00d71010 viral particles 0.5 mL\nAbbreviations: rS = recombinant spike protein\n*Illustrations of the different vaccine vial cap and label border colors are available for Moderna and Pfizer-BioNTech COVID-19 vaccines.","4481":"Contact your healthcare provider,\nhealth department, or\nCommunity Health Center to\nlearn about treatment options. Don\u2019t delay! Treatment must be\nstarted within a few days after\nyou first develop symptoms to be\neffective. If you don\u2019t have timely access to\na healthcare provider, check if a\nTest to Treat location is in\nyour community. You can get\ntested, receive a prescription\nfrom a healthcare provider (either\nonsite or by telehealth), and have it filled all at one location. \u2022\n\uf209\n\u2022\n\u2022\n\uf209\nAvoiding Contact with People Who Have Suspected or Confirmed COVID-19\nAvoiding contact with people who have COVID-19, whether or not they feel sick, can reduce your risk of catching the virus\nfrom them.","3430":"Acetaminophen can be offered as an option for pregnant people experiencing fever (fever has been associated with adverse\npregnancy outcomes) or other post-vaccination symptoms. 1. SPIKEVAX is the proprietary name for the product licensed under the BLA. The Moderna COVID-19 Vaccine has been\navailable since December 18, 2020 under an EUA. The Moderna COVID-19 Vaccine authorized for use in individuals 12\nyears of age and older (supplied in multiple-dose vials with red caps and labels with light blue borders) has the same\nformulation as SPIKEVAX.","7396":"Categories of noncitizen nonimmigrants that meet the criteria for an exception under the Proclamation and CDC\u2019s Amended\nOrder include:\nPersons on diplomatic or official foreign government travel\nChildren under 18 years of age\nPersons with documented medical contraindications to receiving a COVID-19 vaccine\nParticipants in certain COVID-19 vaccine trials\nPersons issued a humanitarian or emergency exception\nPersons with valid visas [excluding B-1 (business) or B-2 (tourism) visas] who are citizens of a foreign country with limited\nCOVID-19 vaccine availability (See list for updates effective June 28, 2022)\nMembers of the U.S. Armed Forces or their spouses or children (under 18 years of age)\nSea crew members traveling with to a C-1 and D nonimmigrant visa\nPersons whose entry would be in the national interest, as determined by the Secretary of State, Secretary of\nTransportation, or Secretary of Homeland Security (or their designees)\nIf you travel by air to the United States under one of these exceptions, you will be required to attest that you are excepted\nfrom the requirement to present Proof of Being Fully Vaccinated Against COVID-19 based on one of the exceptions listed\nabove.","4382":"Conventional water treatment methods that use filtration and disinfection, such as those in\nmost municipal drinking water systems, should remove or kill the virus that causes COVID-19.\u200b\f10\/30\/22, 9:37 AM How Coronavirus Spreads | CDC\nNatural Bodies of Water (Lakes, Oceans, Rivers)\nThere are no scientific reports of the virus that causes COVID-19 spreading to people through the water in lakes, oceans,\nrivers, or other natural bodies of water. Wastewater\nGenetic material from the virus that causes COVID-19 has been found in untreated wastewater (also referred to as \u201csewage\u201d).","8002":"Layered\nprevention strategies, such as staying up to date with vaccines, screening and testing in high-risk settings, improving\nventilation, and wearing masks, can help limit severe disease and reduce the potential for strain on the healthcare system. CDC recommends using county COVID-19 Community Levels to help determine which COVID-19 prevention measures\nto use for individuals and communities. COVID-19 Community Levels do not apply in healthcare settings like hospitals\nand nursing homes. Healthcare settings are recommended to continue to follow CDC\u2019s infection prevention and control\nrecommendations for healthcare workers.89\n\u0083 Should masks90,91 and vaccines92,93 still be utilized as personal mitigation measures when traveling?","8632":"At the end of the process, our bodies have learned how to help protect against future infection with the virus that\ncauses COVID-19. The benefit is that people get this protection from a vaccine, without ever having to risk the\npotentially serious consequences of getting sick with COVID-19. Many side effects from getting the vaccine are\nnormal signs the body is building protection. How protein subunit COVID-19 vaccines work\n\uf1aa\n\u2022\n\u2022\n\u2022\nFACTSHEET\nHow Protein Subunit COVID-19 Vaccines Work\nPDF infographic explaining how Protein Subunit COVID-19 vaccines work.","9862":"Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination. London\n(United Kingdom): Department of Health & Social Care; 1 Sept 2021.\nimmunosuppressed-jcvi-advice\/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-\nprimary-dose-vaccination. Kamar, N., Abravanel, F., Marion O. Assessment of 4 doses of SARS-CoV-2 messenger RNA-based vaccine in\nrecipients of a solid organ transplant. Infection Diseases 2021;4(11):e2136030. Haggenburg S, Hofsink Q, Lissenberg-Witte BI, et al. Three-dose mRNA-1273 vaccination schedule: sufficient\nantibody response in majority of immunocompromised hematology patients. medRxiv. 2022a. Preprint. doi:\nHaggenburg S, Lissenberg-Witte B.I, van Binnendijk RS., et al. Quantitative analysis of mRNA-1273 COVID-19\nvaccination response in immunocompromised adult hematology patients. Blood Advances. 2022;6(5):1537-\n1546.","5110":"Follow all requirements of transportation operators (such as airlines, cruise lines, buses) and any requirements,\nincluding mask wearing proof of vaccination or testing at your destination\n\uf1c8\nGet Started\nTravel Assessment\nA tool to help you know the requirements to board a flight to the United States. Land Travel\nFor information about COVID-19 requirements for land travel and at ferry terminals, visit the U.S. Department of\nHomeland Security\u2019s Fact Sheet: Guidance for Travelers to Enter the U.S. at Land Ports of Entry and Ferry Terminals.","8461":"Follow CDC guidance, including getting tested at\nleast 5 full days after your last exposure. Do not travel on public transportation such as\nairplanes, buses, and trains if you will not be able\nto wear a high-quality mask or respirator when\naround others indoors for the full duration of your\ntrip. If you travel, wear a high-quality mask or\nrespirator the entire time you are around others\nindoors. Traveling by private vehicle (if possible) can lower\nthe chances of spreading COVID-19 to others. If Your COVID-19 Test is Positive\nThis poster is available to download and can be used as a resource for airport\ntesting sites.","7661":"I will be in the United States for less than 3 days, but to get my exception to travel, I must attest to\nself-quarantine for 5 days and get a test 3-5 days after arriving in the United States. Do I still have\nto quarantine and get a post-travel test if I am going to be in the United States for less than 3\ndays? \uf1aa\nLast Updated July 14, 2022","4463":"Free tests are also available through local health departments. If you have Medicare Part B, including those enrolled in a Medicare Advantage plan, Medicare will cover up to 8\nfree self-tests each calendar month from participating pharmacies and providers. Private health insurance may\nalso reimburse the cost of purchasing self-tests. Visit FDA\u2019s website for a list of authorized tests. Call your healthcare provider, visit a community testing site , or call your local health department for more\noptions.","3250":"Precaution\nManagement of post-COVID-19-vaccination symptoms\nTable of Contents \uf426\nVaccination and SARS-CoV-2 laboratory testing\n\uf209\n\uf209\nTable of Contents \uf426\nContraindications and precautions\n*\n*\n\u2020\n*\n* *\n*\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nMedical condition or history Guidance Recommended action(s)\nPeople with an allergy-related contraindication to one type of COVID-19 vaccine have a precaution to\nthe other types of COVID-19 vaccines. Special situation: People with a known allergy to polysorbate have a contraindication to both Novavax and\nJanssen COVID-19 vaccines. Precaution\nModerate or severe acute illness, with or without fever Precaution Defer vaccination until the\nillness has improved. History of MIS-C or MIS-A Precaution See COVID-19 vaccination\nand MIS-C and MIS-A.","561":"October 26, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of\n221,933 administered doses. October 20, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of\n205,853 administered doses. October 13, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of\n191,076 administered doses. October 13, 2022: New Jersey made updates to data previously submitted to CDC that resulted in a net increase of\n118,479 administered doses.","9485":"The vaccination provider may include your or your child\u2019s vaccination information in your\nstate\/local jurisdiction\u2019s Immunization Information System (IIS) or other designated system. This will ensure that you or your child receive the same vaccine when you return for the second\ndose of the primary series. For more information about IISs, visit:\nhttps:\/\/www.cdc.gov\/vaccines\/programs\/iis\/about.html. CAN I BE CHARGED AN ADMINISTRATION FEE FOR RECEIPT OF THESE\nNo. At this time, the provider cannot charge you for a vaccine dose and you cannot be charged\nan out-of-pocket vaccine administration fee or any other fee if only receiving a COVID-19\nvaccination.","1870":"National Protocol\nOutcome: Household transmission among community members confirmed with SARS-CoV-2\nPopulation: Households of community members with positive SARS-CoV-2 tests recruited from national commercial\nlaboratories\nExternal partner: Westat\n\uf209 \uf20c\nTest-negative prospective case control\n\uf1aa\nIncreasing Community Access to Testing (ICATT) program\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Anyone seeking testing at a pharmacy\nParticipating sites: 8,319 locations across the United States and its territories\nIVY\nInfluenza and Other Viruses in the Acutely Ill (IVY) network\nOutcome: Hospitalization with SARS-CoV-2\nPopulation: Hospitalized adults\nParticipating Sites: 21 large adult hospitals in 20 cities in 18 states:\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nCalifornia\nColorado\nFlorida\nGeorgia\nIowa\nMaryland\nMassachusetts\nMichigan\nMinnesota\nMissouri\nNew York\nNorth Carolina\nOhio\nOregon\nTennessee\nTexas\nUtah\nWashington\nPReventing Emerging Infections through Vaccine EffectiveNess Testing (PREVENT ) Sites\nOutcome: Symptomatic SARS-CoV-2 infections\nPopulation: Healthcare personnel\nParticipating Sites\nBaystate Medical Center, Springfield, MA\nJackson Memorial Hospital, Miami, FL\nOlive View-UCLA Medical Center, Los Angeles, CA\nThomas Jefferson University Hospital, Philadelphia, PA\nTruman Medical Centers, Kansas City, MO\nUniversity of Alabama Hospital, Birmingham, AL\nCommunity Regional Medical Center\/ UCSF, Fresno, CA\nUniversity of Chicago Medical Center, Chicago, IL\nUniversity of Iowa Hospitals and Clinics, Iowa City, IA\nUniversity of Massachusetts Memorial Medical Center, Worcester, MA\nLCMC Health Hospitals, New Orleans, LA\nUniversity of Mississippi Medical Center, Jackson, MS\nUniversity of Texas Southwestern Medical Center and Parkland Hospital, Dallas, TX\nUniversity of Washington Hospitals, Seattle, WA\nValleywise Health Medical Center, Phoenix, AZ.","5269":"\u2022\n\u2022\n\u2022\n\u2022\nAfter you have ended isolation, when you are feeling better (no fever without the use of fever-reducing medications and\nsymptoms improving),\nWear your mask through day 10. OR\nIf you have access to antigen tests, you should consider using them. With two sequential negative tests 48 hours apart,\nyou may remove your mask sooner than day 10. Note: If your antigen test results are positive, you may still be infectious. You should continue wearing a mask and wait at\nleast 48 hours before taking another test. Continue taking antigen tests at least 48 hours apart until you have two sequential\nnegative results.","9433":"You should seek medical attention right away if you or your child have any of\nthe following symptoms after receiving the vaccine:\n\u2022 Chest pain\n\u2022 Shortness of breath\n\u2022 Feelings of having a fast-beating, fluttering, or pounding heart\nSide effects that have been reported in clinical trials with these vaccines include:\n\u2022 Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm\nof the injection, swelling (hardness), and redness\n\u2022 General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea and\nvomiting, fever, and rash\nSide effects that have been reported during post-authorization use include:\n\u2022 Severe allergic reactions\n\u2022 Myocarditis (inflammation of the heart muscle)\n\u2022 Pericarditis (inflammation of the lining outside the heart)\n\u2022 Fainting in association with injection of the vaccine\nThese may not be all the possible side effects of these vaccines.","6216":"10\/30\/22, 9:34 AM Myths and Facts about COVID-19 Vaccines | CDC\nEspa\u00f1ol | Other Languages\nMyths and Facts about COVID-19 Vaccines\nAccurate vaccine information is critical and can help stop common myths and rumors. It can be difficult to know which\nsources of information you can trust. Learn more about finding credible vaccine information. Bust Common Myths and Learn the Facts\nBelow are myths and facts about COVID-19 vaccination. Have more questions? Visit FAQs about Vaccination. MYTH: The ingredients in COVID-19 vaccines are dangerous. FACT: Nearly all the ingredients in COVID-19 vaccines are also ingredients in many foods \u2013 fats, sugars, and\nsalts.","5544":"10\/30\/22, 9:39 AM Masks and Respirators\nEspa\u00f1ol | Other Languages\nTypes of Masks and Respirators\nSummary of Recent Changes\nKey Messages:\nMasking is a critical public health tool for preventing spread of COVID-19, and it is important to remember that any mask\nis better than no mask. To protect yourself and others from COVID-19, CDC continues to recommend that you wear the most protective mask\nyou can that fits well and that you will wear consistently. Masks and respirators are effective at reducing transmission of SARS-CoV-2, the virus that causes COVID-19, when worn\nconsistently and correctly.","8769":"They should do this by\nconsidering the person\u2019s ability to:\nWear a mask correctly (proper mask size and fit)\nAvoid frequent touching of the mask and face\nLimit sucking, drooling, or having excess saliva on the mask\nRemove the mask without assistance\nPeople who are deaf or hard of hearing\nThese individuals may consider:\nWearing a clear mask or a cloth mask with a clear panel\nIf a clear mask is not available, using written communication, closed\ncaptioning, or decreasing background noise to make communication\npossible while wearing a mask that blocks lips\nTravelers\nWearing a high-quality\nmask while you travel\ncan help protect you\nand others. Learn about the latest\nrecommendation for\nwearing masks during\ntravel.","3273":"Information on how to submit a report to VAERS is available at https:\/\/vaers.hhs.gov or by calling 1-800-822-\n7967. In addition, CDC has developed a new voluntary, smartphone-based tool, v-safe. This tool uses text messaging and web\nsurveys to provide near real-time health check-ins after patients receive COVID-19 vaccination. Reports to v-safe indicating a\nmedically significant health impact, including pregnancy, are followed up by the CDC\/v-safe call center to collect additional\ninformation to complete a VAERS report, if appropriate.","5572":"Choosing a Mask or Respirator for Different Situations\nMasks and respirators (i.e., specialized filtering masks such as \u201cN95s\u201d) can provide different levels of protection depending on\nthe type of mask and how they are used. Loosely woven cloth products provide the least protection, layered finely woven\nproducts offer more protection, well-fitting disposable surgical masks and KN95s offer even more protection, and well-fitting\nNIOSH-approved respirators (including N95s) offer the highest level of protection.","2939":"The primary series doses are separated by 4\u20138 weeks and the bivalent mRNA booster dose is\nadministered at least 2 months after completion of the primary series\nView the COVID-19 Vaccination Schedule for People who are NOT Moderately or Severely Immunocompromised \uf20a\nSchedule: ages 6 months through 11 years\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nadministered at least 2 months after completion of the primary series. Pfizer-BioNTech COVID-19 Vaccine\nChildren ages 6 months\u20134 years: A 3-dose primary series is recommended. The first and second doses are separated by\n3\u20138 weeks and the second and third doses are separated by at least 8 weeks.","6643":"Do not delay getting care for your medical condition because of COVID-19. Emergency departments, urgent care, clinics,\nand your healthcare provider have infection prevention plans to help protect you from getting COVID-19 if you need\ncare. Continue medications and preventive care\nContinue your medicines and do not change your treatment plan without talking to your healthcare provider. Have at least a 30-day supply of prescription and non-prescription medicines. Talk to a healthcare provider, insurer, or\npharmacist about getting an extra supply (i.e., more than 30 days) of prescription medicines, if possible, to reduce your\ntrips to the pharmacy.","2452":"American Society of Reproductive Medicine (ASRM), American College of Obstetricians and Gynecologists (ACOG) and the\nS i t f M t l F t l M di i (SMFM) I J i t St t t M di l E t C ti t A t th t COVID\f10\/30\/22, 9:29 AM COVID-19 Vaccines for People Who Would Like to Have a Baby | CDC\nSociety for Maternal-Fetal Medicine (SMFM) Issue Joint Statement: Medical Experts Continue to Assert that COVID\nVaccines Do Not Impact Fertility. February 5, 2021. Available at: https:\/\/www.asrm.org\/news-and-publications\/news-and-\nresearch\/press-releases-and-bulletins\/asrm-smfm-acog-issue-joint-statement-medical-experts-continue-to-assert-that-\ncovid-vaccines-do-not-impact-fertility\/ . 2. American Academy of Pediatrics (AAP).","196":"Even if you do get sick, having antibodies can protect you from getting severely ill\nbecause your body has some experience in fighting that disease. How long this protection lasts can be different for each\ndisease, each person, or influenced by other factors. Antibodies are just one part of your immune response. Antibodies and COVID-19\nAntibodies to SARS-CoV-2, the virus that causes COVID-19, can be detected in the blood of people who have recovered from\nCOVID-19 or people who have been vaccinated against COVID-19.","6441":"Even if you receive EVUSHELD , you should continue to take the necessary\nsteps to protect yourself and others, including undergoing testing and seeking medical attention if you develop\nsymptoms of COVID-19, as well as starting treatment for COVID-19 as appropriate. Your healthcare provider will determine if you are eligible for EVUSHELD . Talk to your healthcare provider about\nwhether EVUSHELD is the best option for you.","4953":"New booster recommendation for people ages 12 years and older to receive 1 bivalent mRNA booster after\ncompletion of a monovalent primary series; it replaces all prior booster recommendations for this age group\nRecommendations for use of a bivalent Moderna booster dose in people ages 18 years and older\nRecommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 12 years and older\nUpdated guidance for observation periods following COVID-19 vaccination\nUpdated guidance on COVID-19 vaccination and multisystem inflammatory syndrome (MIS) in children (MIS-C) and in\nadults (MIS-A)\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adolescents ages 12\u201317 years\nReorganization of Janssen COVID-19 Vaccine guidance into an appendix\nUpdated guidance on COVID-19 vaccination following exposure to SARS-CoV-2\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nPrevious Updates\n\uf1aa\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nUpdated guidance on COVID-19 vaccination and myocarditis and pericarditis\nNew clinical considerations for coadministration of mRNA COVID-19 vaccines and orthopoxvirus vaccines\nNew guidance for use of Moderna COVID-19 Vaccine in children and adolescents ages 6\u201317 years\nNew guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children ages 6 months\u20134 years\nNew guidance for use of Moderna COVID-19 Vaccine in children ages 6 months\u20135 years\nReorganization of sections on COVID-19 vaccination recommendations and schedules\nAddition of new section in Special populations for infants and young children\nNew guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5\u201311 years\nUpdated guidance that the following people should receive a second COVID-19 booster dose:\nPeople ages 12 years and older who are moderately or severely immunocompromised\nPeople ages 50 years and older\nUpdated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-\ndepleting therapies\nClarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults\n(MIS-A)\nUpdated guidance for primary series vaccination after SARS-CoV-2 infection\nAdded considerations for the option to receive a second COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 vaccination after SARS-CoV-2 infection\nAdded guidance that people ages 12 years and older who are moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that people ages 18\u201349 years who are not moderately or severely immunocompromised and who\nreceived Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster\ndose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose\nFurther clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C)\nand adults (MIS-A) and myocarditis\nUpdated information on the availability of Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL\ndosage volume) and Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL dosage volume) for\nadministration of a 50 \u00b5g booster dose.","752":"July 23, 2021: The number of doses administered by a national pharmacy provider decreased by 14,187 for the\nFederal Long-Term Care program. July 20, 2021: A federal entity made updates to data previously submitted to CDC that resulted in a decrease of\n159,648 doses administered. July 14, 2021: Utah made updates to data previously submitted to CDC that resulted in an increase of 6,028 doses\nadministered. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nLast Updated Oct. 28, 2022","6917":"People who already received a\nbooster dose with an authorized COVID-19 vaccine after receiving the Janssen COVID-19\nVaccine primary dose should receive an additional dose with the COVID-19 vaccine by\nPfizer-BioNTech at least 2 months after the booster dose. People ages 12 years and older with a moderately or severely immunocompromising\ncondition who received primary dose(s) of COVID-19 vaccine prior to or during certain\ntherapies (indicated below) should be revaccinated with the COVID-19 vaccine by Pfizer-\nBioNTech, regardless of which vaccine was received initially.","6805":"Please include \u201cPfizer-BioNTech COVID-19\nVaccine EUA\u201d or \u201cPfizer-BioNTech COVID-19 Vaccine, Bivalent EUA\u201d in the first line of\nbox #18 of the report form. In addition, you can report side effects to Pfizer Inc. at the contact information provided\nbelow. Website Fax number Telephone number\nYou may also be given an option to enroll in v-safe. V-safe is a voluntary\nsmartphone-based tool that uses text messaging and web surveys to check in with\npeople who have been vaccinated to identify potential side effects after COVID-19\nvaccination. V-safe asks questions that help CDC monitor the safety of COVID-19\nvaccines.","4145":"All vaccine development steps were taken to ensure COVID-19 vaccine safety and effectiveness,\nAre COVID-19 vaccines safe even though the vaccines were developed rapidly? \uf1aa\f10\/30\/22, 9:18 AM Frequently Asked Questions about COVID-19 Vaccination | CDC\ny p p y ,\nincluding:\nClinical Trials \u2013 All vaccines in the United States must go through three phases of clinical trials to ensure they are\nsafe and effective. The phases overlapped to speed up the process, but all phases were completed. Authorization or Approval \u2013 Before vaccines are available to people, the U.S. Food and Drug Administration (FDA)\nreviews data from clinical trials.","2721":"\u2022\n\u2022\n\u2022\nTrack your own health\nCaregivers should stay home and monitor their health for COVID-19 symptoms while caring for the person who is\nsick. Symptoms include fever, cough, and shortness of breath but other symptoms may be present as well. Trouble\nbreathing is a more serious warning sign that you need medical attention. Caregivers should continue to stay home after care is complete. Caregivers can leave their home 5 days after their\nlast close contact with the person who is sick (based on the time it takes to develop illness), or 5 days after the\nperson who is sick meets the criteria to end home isolation.","2419":"Recent studies have found no differences in pregnancy success rates among women who had antibodies from COVID-19\nvaccines or from a recent COVID-19 infection, and women who had no antibodies, including for patients undergoing\ni t d d ti t h l d ( i it f tili ti )\nCDC and Medical Professionals Recommend COVID-19\nVaccination for People Who Want to Have Children\nProfessional medical organizations serving people of reproductive age, including adolescents, emphasize that there is\nno evidence that COVID-19 vaccination causes problems with fertility.","5209":"How to Report Health Problems after Vaccination\nYou or your healthcare professional can report any adverse events or health problems after COVID-19 vaccination to VAERS\nby filling out an online form or a PDF form . FDA requires healthcare professionals to report certain adverse events that occur after administering COVID-19 vaccine,\nbut anyone can submit a report to VAERS, including you. Reports to VAERS are important to understanding the safety of COVID-19 vaccines as more people receive them over time. If\nyou need further assistance with reporting to VAERS, please email info@VAERS.org or call 1-800-822-7967.","1038":"Science at CDC\nScientific evidence and studies behind specific COVID-19 guidance and recommendations\nMMWR: Minimizing the impact of COVID-19 on Individual persons, Communities, and Health Care Systems\f10\/30\/22, 9:37 AM COVID-19 Testing: What You Need to Know | CDC\n\uf277 Difference Between Flu and COVID-19\nInfluenza (Flu) and COVID-19 are both contagious respiratory illnesses, but they are caused by different\nviruses. COVID-19 is caused by infection with a coronavirus named SARS-CoV-2, and flu is caused by infection\nwith influenza viruses. You cannot tell the difference between flu and COVID-19 by symptoms alone because\nsome of the symptoms are the same.","7743":"CDC\nscientists have conducted detailed reviews of TTS cases and made the information available to healthcare providers\nand the public:\nUS Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S\nCase Series of Thrombosis with Thrombocytopenia Syndrome following COVID-19 vaccination\u2014United States,\nUpdates on Thrombosis with Thrombocytopenia Syndrome (TTS) [1.3 MB, 39 Pages]\nGuillain-Barr\u00e9 Syndrome (GBS) in people who have received the J&J\/Janssen COVID-19 vaccine is rare. GBS is a rare\ndisorder where the body\u2019s immune system damages nerve cells, causing muscle weakness and sometimes\nparalysis. GBS has largely been reported in men ages 50 years and older.","5053":"Updated considerations for people who are pregnant, lactating, trying to get pregnant now, or might become\npregnant in the future. Updated considerations for COVID-19 vaccination in people with a history of Guillain-Barr\u00e9 syndrome. Updated information on vaccine administration errors and deviations in Appendix A (Table). Updated considerations regarding mRNA vaccine dosing intervals. Updated considerations for immunocompromised people. New section on considerations for use of mRNA COVID-19 vaccines in people with a history of myocarditis or\npericarditis added to considerations for vaccination of people with certain underlying medical conditions.","2924":"Bivalent vaccine (\u201cupdated vaccine\u201d): The vaccine product is based on the original (ancestral) strain of SARS-CoV-2\nand the Omicron BA.4 and BA.5 (BA.4\/BA.5) variants of SARS-CoV-2. Table of Contents \uf426\nCOVID-19 vaccination guidance for people who are not\nmoderately or severely immunocompromised\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nThe COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised is detailed below\nand summarized in Table 2. Moderna COVID-19 Vaccine\nChildren ages 6 months\u20134 years: A 2-dose primary series separated by 4\u20138 weeks is recommended. Currently, a booster\ndose using any COVID-19 vaccine is not authorized for children in this age group.","9413":"In clinical trials, approximately 30,000 individuals 12\nyears of age and older, 4,000 individuals 6 years through 11 years of age, and 5,000 individuals 6\nmonths through 5 years of age have received at least 1 dose of Moderna COVID-19 Vaccine. In a clinical trial, approximately 400 individuals 18 years of age and older received 1 dose of a\nbivalent vaccine that differs from the Moderna COVID-19 Vaccine, Bivalent in that it contains a\ndifferent Omicron component. WHAT ARE THE BENEFITS OF THESE VACCINES? SPIKEVAX (COVID-19 Vaccine, mRNA) and Moderna COVID-19 Vaccine have been shown\nto prevent COVID-19.","4388":"10\/30\/22, 9:27 AM How Do I Find a COVID-19 Vaccine? | CDC\nEspa\u00f1ol | Other Languages\nHow Do I Find a COVID-19 Vaccine or Booster? Find COVID-19 Vaccines or Boosters Near You\nThere are several other ways you can look for vaccine providers near you in the United States. Ask your doctor, pharmacist, or community health center, or visit their website. Contact your state health department. Check your local pharmacy\u2019s website to see if vaccination appointments are available. Some pharmacies may offer\nvaccines to those who walk-in without making an appointment ahead of time.","10015":"History of multisystem\ninflammatory\nsyndrome; either MIS-C\n(children) or MIS-A\n(adults)\n\u0083 Persons with a history of multisystem inflammatory syndrome; either MIS-C (children) or MIS-A\n(adults) is a precaution to receipt of COVID-19 vaccine. \u0083 Considerations when conducting a risk assessment for potential COVID-19 vaccination\n\u0083 Healthcare providers and health departments may also request a consultation from the Clinical\nImmunization Safety Assessment Project\nHistory of an immune-\nmediated syndrome\ncharacterized by\nthrombosis and\nthrombocytopenia,\nsuch as heparin-induced\nthrombocytopenia (HIT)\n\u0083 Janssen COVID-19 vaccine is not recommended for persons with a history of an episode of an\nimmune-mediated syndrome characterized by thrombosis and thrombocytopenia, such as\nspontaneous or classic HIT. \u0083 These persons should receive an mRNA (ie.","4164":"To learn more about the ingredients in authorized or approved COVID-19 vaccines, see\nPfizer-BioNTech COVID-19 Vaccine Overview and Safety\nModerna COVID-19 Vaccine Overview and Safety\nJohnson & Johnson\u2019s Janssen COVID-19 Vaccine Overview and Safety\nNovavax COVID-19 Vaccine Overview and Safety\nIngredients Included in COVID-19 Vaccines\nWhat are the ingredients in COVID-19 vaccines? \uf1aa\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nYes, COVID-19 vaccination is recommended for people who are pregnant, breastfeeding, or trying to get pregnant now, as\nwell as people who might become pregnant in the future.","6664":"10\/30\/22, 9:39 AM People with Moderate to Severe Asthma | CDC\nEspa\u00f1ol | Other Languages\nPeople with Moderate to Severe Asthma\nThis information is based on what we currently know about the spread and severity of COVID-19. Risk of severe illness from COVID-19\nPeople with moderate-to-severe or uncontrolled asthma are more likely to be hospitalized from COVID-19. Take steps to\nprotect yourself. Vaccine information for COVID-19\nFollow your Asthma Action Plan\nKeep your asthma under control by following your asthma action plan. Avoid your asthma triggers. Continue current medications, including any inhalers with steroids in them (\u201csteroids\u201d is another word for\ncorticosteroids). Know how to use your inhaler.","8012":"Wear a mask with the best fit, protection, and comfort for you.95\n\u0082 Mask use recommendations are available here.","5339":"\u2022 General side effects: headache, feeling very tired, muscle aches, nausea, and fever. \u2022 Swollen lymph nodes. \u2022 Blood clots. \u2022 Unusual feeling in the skin (such as tingling or a crawling feeling) (paresthesia), decreased feeling\nor sensitivity, especially in the skin (hypoesthesia). \u2022 Persistent ringing in the ears (tinnitus). \u2022 Diarrhea, vomiting. Severe Allergic Reactions\nThere is a remote chance that the Janssen COVID-19 Vaccine could cause a severe allergic\nreaction. A severe allergic reaction would usually occur within a few minutes to one hour after\ngetting a dose of the Janssen COVID-19 Vaccine.","8284":"People can update their records with vaccines they received while outside of the United States by:\nContacting the\u202fimmunization information system (IIS)\u202fin their state. Contacting their healthcare provider or local or state immunization program through their\u202fstate\u2019s health\ndepartment. \u2022\n\u2022\nLearn more about\u202fCOVID-19 vaccination cards. For Healthcare Workers: Learn more about the recommendations for people vaccinated outside of the United States. \uf2ff For Healthcare and Public Health\nUse of COVID-19 Vaccines in the United States: Interim Clinical Considerations\nLast Updated Oct. 14, 2022","8165":"As with other vaccine-preventable diseases, you are protected best from COVID-19 when you stay up\nto date with the recommended vaccinations, including recommended boosters. Four COVID-19 vaccines are approved or authorized in the United States:\nPfizer-BioNTech\nModerna\nNovavax\nJohnson & Johnson\u2019s Janssen (J&J\/Janssen) (However, CDC recommends that the J&J\/Janssen COVID-19 vaccine only be\nconsidered in certain situations, due to safety concerns.) Updated (Bivalent) Boosters\nThe updated (bivalent) boosters are called \u201cbivalent\u201d because they protect against both the original virus that causes COVID-\n19 and the Omicron variant BA.4 and BA.5. Previous boosters are called \u201cmonovalent\u201d because they were designed to protect against the original virus that causes\nCOVID-19.","4465":"Free tests are also available through local health departments. If you have Medicare Part B, including those enrolled in a Medicare Advantage plan, Medicare will cover up to 8\nfree self-tests each calendar month from participating pharmacies and providers. Private health insurance may\nalso reimburse the cost of purchasing self-tests. Visit FDA\u2019s website for a list of authorized tests. Call your healthcare provider, visit a community testing site , or call your local health department for more\noptions.","5853":"In 2013, the Pandemic and All-Hazards Preparedness Reauthorization Act included a new provision that\nallowed for the issuance of EUI to permit CDC to inform healthcare providers and recipients about certain uses\nof FDA-approved or cleared medical products. Specifically, EUI inform healthcare providers and recipients\nabout such products\u2019 approved, licensed, or cleared conditions of use. The CDC Director has statutory (legal)\nauthority to create, issue, and disseminate EUI before or during an emergency. 1 Spikevax is the proprietary name for the product licensed under the Biologics License Application (BLA).","7401":"Categories of noncitizen nonimmigrants that meet the criteria for an exception under the Proclamation and CDC\u2019s Amended\nOrder include:\nPersons on diplomatic or official foreign government travel\nChildren under 18 years of age\nPersons with documented medical contraindications to receiving a COVID-19 vaccine\nParticipants in certain COVID-19 vaccine trials\nPersons issued a humanitarian or emergency exception\nPersons with valid visas [excluding B-1 (business) or B-2 (tourism) visas] who are citizens of a foreign country with limited\nCOVID-19 vaccine availability (See list for updates effective June 28, 2022)\nMembers of the U.S. Armed Forces or their spouses or children (under 18 years of age)\nSea crew members traveling with to a C-1 and D nonimmigrant visa\nPersons whose entry would be in the national interest, as determined by the Secretary of State, Secretary of\nTransportation, or Secretary of Homeland Security (or their designees)\nIf you travel by air to the United States under one of these exceptions, you will be required to attest that you are excepted\nfrom the requirement to present Proof of Being Fully Vaccinated Against COVID-19 based on one of the exceptions listed\nabove.","8090":"However, monkeypox can spread to anyone through close, personal, often skin-to-skin contact. Anyone who has been in close contact with someone who has monkeypox is at risk.137\n\u0083 How do I know if I have monkeypox?d\n\u0082 People with monkeypox can get a rash that may be located on or near the genitals (penis, testicles, labia, and vagina) or\nanus (butthole) and could be on other areas like the hands, feet, chest, face, or mouth. \u008f The rash will go through several stages, including scabs, before healing. \u008f The rash can initially look like pimples or blisters and may be painful or itchy.","10137":"Summary Document for\nInterim Clinical Considerations\nfor Use of COVID-19 Vaccines Currently Authorized or Approved in the United States\nConsiderations for Janssen COVID-19 Vaccine\nPersons with a history of thrombosis\nwith thrombocytopenia syndrome\n(TTS)\n\u0083 It is contraindicated to administer Janssen COVID-19 Vaccine to persons with a history of TTS following receipt of the Janssen COVID-19 Vaccine or\nany other adenovirus vector-based COVID-19 vaccines (e.g., AstraZeneca\u2019s COVID-19 Vaccine). \u0083 These persons should receive a dose of an mRNA COVID-19 vaccine as a booster dose at least 2 months (8 weeks) following their dose of the\nJanssen COVID-19 Vaccine and after their clinical condition has stabilized.","8808":"The following requirements must be followed to utilize CDC\u2019s public domain content:\n1) Attribution to the agency that developed the material must be provided in your use of the materials. Such attribution\nshould clearly state the materials were developed by CDC ATSDR and\/or HHS (e.g., \u201cSource: CDC\u201d; \u201cMaterials developed by\nCDC\u201d);\n2) You must utilize a disclaimer which clearly indicates that your use of the material, including any links to the materials on the\nCDC, ATSDR or HHS websites, does not imply endorsement by CDC, ATSDR, HHS or the United States Government of you,\nyour company, product, facility, service or enterprise.","9473":"Individuals 6 years of age and older may receive a booster dose with Moderna COVID-19\nVaccine, Bivalent. Vaccinations may not provide full immunity to COVID-19 in people who are\nimmunocompromised; therefore, you or your child should continue to maintain physical\nprecautions to help prevent COVID-19. Your close contacts should be vaccinated as appropriate. WHAT ABOUT PREGNANCY OR BREASTFEEDING? If you are, or your child is, pregnant or breastfeeding, discuss the options with your healthcare\nprovider. WILL THESE VACCINES GIVE ME OR MY CHILD COVID-19? No. These vaccines do not contain SARS-CoV-2 and cannot give you or your child COVID-19.","8236":"Anyone wanting protection due to high levels of community transmission, people ages 65 years and older, or people\nwho are more likely to get very sick from COVID-19, should get the second dose of:\nPfizer-BioNTech COVID-19 vaccine 3 weeks (or 21 days) after the first dose. Moderna COVID-19 vaccine 4 weeks (or 28 days) after the first dose. Novavax COVID-19 vaccine 3 weeks (or 21 days) after the first dose. Staying up to date: If you have completed your primary series, but are not yet eligible for a booster, you are also considered\nup to date.","2260":"COVID-19 vaccines are safe and effective\u2014especially against becoming seriously ill\u2014and very important for older adults. Older adults and people with these conditions are more likely to get very sick from COVID-19. You can\u2019t get COVID-19 from COVID-19 vaccines. Learn more about COVID-19 vaccine recommendations specifically for\npeople who are moderately or severely immunocompromised. COVID-19 vaccines can help keep you from getting seriously ill even if you do get COVID-19. Use\u202fCDC\u2019s COVID-19 booster tool\u202fto learn if and when you can get boosters to stay up to date with your COVID-19\nvaccines.","3646":"10\/30\/22, 9:42 AM Domestic Travel During COVID-19 | CDC\nCOVID-19 County Check\nFind community levels and prevention steps by county. Data updated weekly. Select a Location (all fields required)\nState County Go\nView CDC\u2019s full list of individual and community recommendations for each level. \uf3c0 Testing\nRECOMMENDED\nConsider getting tested with a viral test as close to the time of departure as possible (no more than 3\ndays) before travel. Make sure you know your test results before travel. Don\u2019t travel if your test result is positive. Find a COVID-19 testing location near you or use a self-test.","2276":"Residents who receive a COVID-19 vaccine (or their medical proxy) will also receive a fact sheet before vaccination. The\nfact sheet explains the risks and benefits of COVID-19 vaccination. Some COVID-19 vaccination providers may require written, email, or verbal consent from recipients before getting\nvaccinated. This is at the provider\u2019s discretion; written consent is not required by federal law for COVID-19 vaccination in\nthe United States (U.S.). Residents (or their medical proxies) will receive a\u202fvaccination card\u202for printout that tells them which COVID-19 vaccine\nthey received and the date they received it. This should also be recorded in their medical chart.","3573":"For the Republic of Palau, the Federated States of Micronesia, the Republic of the Marshall Islands, Guam, American\nSamoa, and the Commonwealth of the Northern Marianas Islands, total counts of COVID-19 vaccine doses include doses\nmarked as shipped since December 13, 2020. Total Doses Administered\nThe total number of vaccine doses that have been given to people in the United States since December 14, 2020. This is\nthe date when the first dose was administered to a person in the United States under the Emergency Use Authorization\nnot within a clinical trial.","7014":"The most commonly reported side effects were:\nFever\nHeadache\nFatigue (tiredness)\nPain at the injection site\nHelpful tips to relieve side effects\nAdults\nTo relieve pain or swelling on the arm where you got the shot:\nApply a clean, cool, wet washcloth over the area. Use or keep moving your arm. Also, if possible, get some rest. To reduce discomfort from fever:\nDrink plenty of fluids,\nDress in comfortable clothes,\nTalk to your doctor about taking over-the-counter (OTC) medicine, such as ibuprofen, acetaminophen, aspirin (only for\npeople ages 18 years or older), or antihistamines.","8347":"If the patient asks a question about COVID-19 vaccine safety, vaccine risks, or their health or mental health, see potential\nresponses in Step 4. Motivational interviewing is an evidence-based and culturally sensitive way to speak with unvaccinated patients about\ngetting vaccinated. The goal of motivational interviewing is to help people manage mixed feelings and move toward\nhealthy behavior change that is consistent with their values and needs.","4226":"If you cannot contact your vaccination provider directly or your vaccination provider cannot reissue a CDC COVID-\n19 Vaccination card, contact your state health department\u2019s immunization information system (IIS). Your state\u2019s IIS\ncannot issue you a vaccination card, but they can provide a digital or paper copy of your full vaccination record,\nincluding your COVID-19 vaccinations. If you need another COVID-19 vaccine dose and are unable to get a copy of your vaccination card or vaccination\nrecord, talk to a vaccination provider to learn about your possible options.","9138":"10\/30\/22, 9:41 AM What to Do If You Are Sick | CDC\nEspa\u00f1ol | Other Languages\nWhat to Do If You Are Sick\nIf you test positive and are an older adult or someone who is at high risk of getting very sick from COVID-19, treatment is\navailable. Contact a healthcare provider right away after a positive test to determine if you are eligible, even if your\nsymptoms are mild right now. You can also visit a Test to Treat location and, if eligible, receive a prescription from a\nprovider. Don\u2019t delay: Treatment must be started within the first few days to be effective.","6766":"Booster Dose:\nThe Pfizer-BioNTech COVID-19 Vaccine, Bivalent is administered as a single booster\ndose at least 2 months after:\n\uf0b7 completion of primary vaccination with any authorized or approved monovalent\nCOVID-19 vaccine; or\n\uf0b7 receipt of the most recent booster dose with any authorized or approved\nmonovalent COVID-19 vaccine. The vaccine may not protect everyone. WHO SHOULD NOT GET THE PFIZER-BIONTECH COVID-19 VACCINE OR THE\nPFIZER-BIONTECH COVID-19 VACCINE, BIVALENT? Your child should not get any of these vaccines if your child:\n\uf0b7 had a severe allergic reaction after a previous dose of the Pfizer-BioNTech\nCOVID-19 Vaccine. \uf0b7 had a severe allergic reaction to any ingredient in these vaccines.","9678":"Adverse reactions following administration of the vaccine that have been reported in clinical trials and\/or post\nauthorization include injection site pain, fatigue, headache, muscle pain, chills, joint pain, fever, injection site\nswelling, injection site redness, nausea, malaise, lymphadenopathy, decreased appetite, rash, pain in\nextremity, diarrhea, and vomiting. Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nWhat are possible serious side effects with the COVID-19 vaccine by Pfizer-BioNTech? Severe allergic reactions, including anaphylaxis, and other hypersensitivity reactions (e.g., rash, pruritus,\nurticaria, angioedema), syncope, myocarditis and pericarditis have been reported following administration of\nthe vaccine outside of clinical trials.","2530":"Immunization Schedule for Children 6 Months through 17 Years of Age*\nType\nRecipient\nAge\nProduct\u2020\nFor Most People\nThose Who ARE Moderately or\nSeverely Immunocompromised\nDoses Interval Between Doses\u2021 Doses Interval Between Doses\nmRNA\nvaccine\nthrough\nMONOVALENT Moderna:\nBlue vial cap with\nmagenta-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 4\u20138 weeks\u00b6\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nthrough\nMONOVALENT Moderna:\nBlue vial cap with\npurple-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 4\u20138 weeks\u00b6\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Moderna:\nBlue vial cap with\ngray-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nthrough\nMONOVALENT Moderna:\nRed vial cap with\nblue-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 4\u20138 weeks\u00b6\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Moderna:\nBlue vial cap with\ngray-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nthrough\nMONOVALENT Pfizer-BioNTech:\nMaroon vial cap with\nmaroon-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 3\u20138 weeks\u00b6 Dose 1 to 2 At least 3 weeks\nDoses 2 and 3 At least 8 weeks (2 months) Dose 2 to 3 At least 8 weeks (2 months)\nthrough\nMONOVALENT Pfizer-BioNTech:\nOrange vial cap with\norange-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 3\u20138 weeks\u00b6\nDose 1 to 2 At least 3 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Pfizer-BioNTech:\nOrange vial cap with\norange-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nthrough\nMONOVALENT Pfizer-BioNTech:\nGray vial cap with\ngray-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 3-8 weeks\u00b6\nDose 1 to 2 At least 3 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Pfizer-BioNTech:\nGray vial cap with\ngray-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nProtein\nsubunit\nvaccine\nand older\nMONOVALENT Novavax\nPrimary series: Monovalent\nDose 1 to 2 At least 3\u20138 weeks\u00b6 Dose 1 to 2 At least 3 weeks\nmRNA (Moderna, Pfizer-\nBioNTech) should be used for the\nbooster dose.","6532":"This is especially important\nif you are older or have severe health conditions or more than one health condition, including those on this list. Learn more\nabout how CDC develops COVID-19 vaccination recommendations. If you have a medical condition, learn more about Actions\nYou Can Take. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\nMedical Conditions\nCancer\nHaving cancer can make you more likely to get very sick from COVID-19. Treatments for many types of cancer can weaken\nyour body\u2019s ability to fight off disease. At this time, based on available studies, having a history of cancer may increase your\nrisk. Get more information:\nThe conditions on this list are in alphabetical order.","3054":"Children age 5 years: A 3-dose primary series and 1 bivalent Pfizer-BioNTech booster dose is recommended. For the\nprimary series, the first and second doses are separated by 3 weeks and the second and third doses are separated by at\nleast 4 weeks. The bivalent booster dose is administered at least 2 months after completion of the primary series (for\npeople who have not received any booster doses), or at least 2 months after the last monovalent booster dose. Currently, only the bivalent Pfizer-BioNTech booster dose is authorized for children age 5 years who receive a Pfizer-\nBioNTech primary series.","3829":"\uf1aa\nYes, all providers participating in the program are required to sign a COVID-19 Vaccination Provider Agreement. As a VFC\nprovider, you will have already implemented or be familiar with many of the requirements of the program, including\nordering vaccine and reporting to your jurisdiction\u2019s immunization information system (IIS). You may also have already\ncompleted some of the training recommended to become a COVID-19 vaccination provider. I am already a Vaccines for Children (VFC) provider; do I also have to sign a COVID-19 Vaccination\nProvider Agreement? \uf1aa\nCDC offers a variety of training resources for preparing and administering COVID-19 vaccines.","8365":"If you feel competent and aware of how to answer the patient\u2019s question, respond with empathy and provide scientific\ninformation as needed. Refer the patient to resources on the CDC website, which are listed below. If the patient\u2019s question is outside of your competence or awareness, recommend that they speak with their medical or\nmental health provider or a knowledgeable expert, as needed.","250":"Serological surveillance (studies that investigate antibodies in the population) provides information about how long antibody\nprotection against COVID-19 lasts and if this protection is different among people who have antibodies from infection,\ncompared with people who have antibodies from vaccination, or both. We can also learn more about which groups of people might not produce as many antibodies or maintain them as long as\nothers\u2014for example, immunocompromised people compared with people who have healthy immune systems. This is\nimportant information for making decisions about whether or not additional vaccine doses or boosters are needed, when\nthey would be recommended, and who would need them first.","9722":"In a pilot prospective cohort study of healthcare workers (HCWs) from\nLebanon, 50 HCWs who received a 2-dose primary series of Sinopharm BIBP COVID-19 vaccine and a single\nbooster dose of Pfizer-BioNTech COVID-19 vaccine had significantly higher anti-S-IgG titers compared to 50\nhomologous vaccinees (2 primary series doses and 1 booster dose of Pfizer-BioNTech COVID-19 vaccine)\n(Moghnieh, 2021). A longitudinal study of 41 Thai HCWs who received a 2-dose primary series of Sinovac\n(CoronaVac) COVID-19 vaccine demonstrated booster antibody responses following either AstraZeneca or\nPfizer-BioNTech COVID-19 vaccines, including against the Delta variant (Patamatamkul, 2021). Local and\nsystemic reactogenicity was reported to be mild to moderate across studies.","3673":"Find a COVID-19 testing location near you or use a self-test. If you already had COVID-19 within the past 90 days, see specific testing recommendations. Monitor yourself for COVID-19 symptoms. Follow additional guidance if you know you were exposed to a person with COVID-19. Follow all state, tribal, local, and territorial recommendations or requirements after travel. If you are going to be around someone who is at higher risk of getting very sick with COVID-19, consider\nadditional precautions. \uf209\nIf Your Test is Positive or You Develop COVID-19 Symptoms\nIsolate yourself to protect others from getting infected.","7471":"Isolation means to separate sick people with a contagious disease from people who are not sick. What is the difference between quarantine and isolation? \uf1aa\nChildren ages 2 through 17 years (minors) who are noncitizen nonimmigrants do not have to quarantine after arrival in\nthe United States; however, the attestation requires that they get a COVID-19 viral test 3-5 days after arrival. If a child, like\nany other traveler, tests positive for COVID-19 or develops COVID-19 symptoms, they should isolate for a full 5 calendar\ndays.","9185":"Many medical visits for routine care are being postponed or done by phone or telemedicine. If you have a medical appointment that cannot be postponed, call your doctor\u2019s office, and tell them you\nhave or may have COVID-19. This will help the office protect themselves and other patients. \u2022\n\u2022\n\uf309 If you are sick, wear a well-fitting mask\nYou should wear a mask if you must be around other people or animals, including pets (even at home). Wear a mask with the best fit, protection, and comfort for you. You don\u2019t need to wear the mask if you are alone.","6186":"10\/30\/22, 9:31 AM Myocarditis and Pericarditis After mRNA COVID-19 Vaccination | CDC\nEspa\u00f1ol | Other Languages\nMyocarditis and Pericarditis After mRNA COVID-19\nVaccination\nMyocarditis is inflammation of the heart muscle. Pericarditis is inflammation of the outer lining of the heart. In both cases, the body\u2019s immune system causes inflammation in response to an infection or some other trigger. Learn\nmore about myocarditis and pericarditis. Both myocarditis and pericarditis have the following symptoms:\nChest pain\nShortness of breath\nFeelings of having a fast-beating, fluttering, or pounding heart\nMyocarditis and pericarditis have rarely been reported.","8592":"This immune response, which produces antibodies, is what\nhelps protect us from getting sick from that germ in the future. About Pfizer-BioNTech and Moderna\nResearch for mRNA technology\nResearchers have been studying and working with mRNA vaccines for decades . In fact, mRNA vaccines have been studied before for flu, Zika, rabies, and cytomegalovirus (CMV). Beyond vaccines, cancer research has also used mRNA to trigger the immune system to target specific cancer cells. Protein subunit vaccines (Novavax)\nVaccines do not use any live virus. Vaccines cannot cause infection with the virus that causes COVID-19 or other viruses.","3436":"The FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and the emergency use authorized\nModerna COVID-19 Vaccine for people ages 12 years and older (supplied in multiple-dose vials with red caps and labels\nwith light blue borders) have the same formulation and can be used interchangeably to provide primary series doses\nto individuals 12 years of age and older without presenting any safety or effectiveness concerns. 2. COMIRNATY is the proprietary name for the product licensed under the BLA. The Pfizer-BioNTech COVID-19 Vaccine has\nbeen available since December 10, 2020 under an EUA.","5295":"This Fact Sheet may have been updated. For the most recent Fact Sheet, please visit\nwww.janssencovid19vaccine.com. WHAT YOU NEED TO KNOW BEFORE YOU GET THIS VACCINE\nWHAT IS COVID-19? COVID-19 is caused by a coronavirus called SARS-CoV-2. This type of coronavirus has not been\nseen before. You can get COVID-19 through contact with another person who has the virus. It is\npredominantly a respiratory illness that can affect other organs. People with COVID-19 have had\na wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms\nmay appear 2 to 14 days after exposure to the virus.","3519":"CDC will continue to provide testing recommendations for cruise ship\noperators to follow and cruise ships will continue to report COVID-19 cases to CDC. Why was the cruise ship color-coding system removed? \uf1aa\nCruise travelers have the option of contacting their cruise line directly regarding outbreaks occurring on board their ship. How can travelers find out about COVID-19 outbreaks on cruise ships? \uf1aa\nMore Information\nIf you need to contact your health department: State & Territorial Health Department Websites\nGuidance for Cruise Ships on the Mitigation and Management of COVID-19\nTravel during the COVID-19 Pandemic\nInternational Travel\nFrequently Asked Questions and Answers for Travelers\nLast Updated July 18, 2022","8990":"If you choose\nnot to give your permission for CDC to access medical records, you can still participate in the registry. \uf209\f10\/30\/22, 9:32 AM Vaccine Pregnancy Registry | CDC\nParticipation Is Voluntary\nParticipants are not paid for their participation in the registry, and not all people reporting pregnancy will be contacted to\nparticipate. Participation is completely voluntary, and you can opt out at any time. However, in general, many people feel\ngood about participating in activities to help answer critical scientific questions, which can help inform recommendations for\nthe public. Registry Data Collection and Use\nWho Is Participating in the Registry\nCDC is currently enrolling eligible participants.","1025":"Isolate and take precautions including wearing a high-quality mask to protect others from getting\ninfected. Tell people you had recent contact with that they may have been exposed. Monitor your symptoms. If you have any emergency warning signs, seek emergency care immediately. Consider contacting a healthcare provider, community health center , or pharmacy to learn about\ntreatment options that may be available to you. Treatment must be started within several days after you\nfirst develop symptoms to be effective. You are more likely to get very sick if you are an older adult or have an underlying medical\ncondition.","1737":"Serious AEs per FDA are defined as:\nDeath\nA life-threatening AE\nInpatient hospitalization or prolongation of existing hospitalization\nA persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions\nA congenital anomaly\/birth defect\nRequirements for Reporting to VAERS (Updated 9\/13\/2022)\n\uf1aa\n\uf209\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nAn important medical event that based on appropriate medical judgement may jeopardize the individual and\nmay require medical or surgical intervention to prevent one of the outcomes listed above\nCases of myocarditis after a Pfizer-BioNTech, Moderna, or Novavax vaccine\nCases of pericarditis after a Pfizer-BioNTech, Moderna, or Novavax vaccine\nCases of Multisystem Inflammatory Syndrome in children and adults\nCases of COVID-19 that result in hospitalization or death\nHealthcare providers are encouraged to report to VAERS any additional clinically significant AEs following vaccination,\neven if unsure whether vaccination caused the event.","4392":"10\/30\/22, 9:27 AM How Do I Find a COVID-19 Vaccine? | CDC\nEspa\u00f1ol | Other Languages\nHow Do I Find a COVID-19 Vaccine or Booster? Find COVID-19 Vaccines or Boosters Near You\nThere are several other ways you can look for vaccine providers near you in the United States. Ask your doctor, pharmacist, or community health center, or visit their website. Contact your state health department. Check your local pharmacy\u2019s website to see if vaccination appointments are available. Some pharmacies may offer\nvaccines to those who walk-in without making an appointment ahead of time.","2425":"Limited, Temporary Impact of COVID-19 Vaccines on Menstrual\nCycles\nResults from recent research studies show that people who menstruate may observe small, temporary changes in\nmenstruation after COVID-19 vaccination, including:\nLonger-lasting menstrual periods\nShorter intervals between periods\nHeavier bleeding than usual\nDespite these temporary changes in menstruation, there is no evidence that COVID-19 vaccines cause fertility problems. Research Studies of Fertility in Healthy Men\nCurrently, no evidence shows that any vaccines, including COVID-19 vaccines, cause male fertility problems. A recent\nsmall study of 45 healthy men who received an mRNA COVID-19 vaccine looked at sperm characteristics, like\nquantity and movement, before and after vaccination.","5016":"Added considerations for an 8-week interval between the first and second doses of a primary mRNA vaccine schedule\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nUpdated guidance for moderately or severely immunocompromised people\nClarification of existing recommendation to receive a 3-dose mRNA vaccine primary series followed by a booster\ndose for a total of 4 doses\nNew guidance to shorten the interval between completion of the mRNA vaccine primary series and the booster\ndose to at least 3 months (instead of 5 months)\nNew guidance for those who received the Janssen COVID-19 Vaccine primary series to receive an additional dose\nand a booster dose, for a total of 3 doses to be up to date\nUpdated guidance that it is no longer necessary to delay COVID-19 vaccination following receipt of monoclonal\nantibodies or convalescent plasma\nUpdated guidance on receiving a booster dose if vaccinated outside the United States\nUpdated contraindication and precaution section to include history of myocarditis or pericarditis after an mRNA\nCOVID-19 vaccine as a precaution\nReorganized and condensed multiple sections\nUpdated guidance for use of Pfizer-BioNTech COVID-19 Vaccine as a booster in people ages 12\u201317 years\nUpdated guidance for administration of a COVID-19 vaccine booster dose at least 5 months after completion of an\nmRNA vaccine (Pfizer-BioNTech or Moderna) primary series\nUpdated guidance for use of an additional primary dose for moderately or severely immunocompromised people ages\n5\u201311 years who received a Pfizer-BioNTech vaccine primary series\nUpdated recommendations for people who received COVID-19 vaccines outside the United States that are not FDA-\nauthorized or approved\nUpdated information about a second formulation of Pfizer-BioNTech COVID-19 Vaccine that is authorized for use in\npersons ages 12 years and older\nUpdated information on vaccinating people during quarantine after a known SARS-CoV-2 exposure or during COVID-\nUpdate to alert providers of possible false positive Rapid Plasma Reagin (RPR; non-treponemal) test results in some\npeople after COVID-19 vaccines\nUpdated information on vaccine administration errors and deviations\nUpdated guidance on use of Janssen (Johnson & Johnson) COVID-19 Vaccine\nUpdated recommendations for receipt of a COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 booster doses in recipients of mRNA COVID-19 vaccines\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nRecommendations and clinical guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children aged 5-11 years\nincluding updated section on Vaccination of children and adolescents\nUpdated guidance on COVID-19 vaccine dosing and schedule\nUpdated guidance for myocarditis and pericarditis after mRNA COVID-19 vaccination in new section on Considerations\nfor mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna\nNew guidance for people who received passive antibody products in section on COVID-19 vaccination and SARS-CoV-2\ninfection\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial in the United States\nUpdated guidance on Considerations for COVID-19 vaccination in moderately and severely immunocompromised\npeople\nUpdated guidance in section on Contraindications and precautions\nUpdated Table in Appendix A: Vaccine administration errors and deviations\nUpdated Appendix B: Triage of people with a history of allergies or allergic reactions\nUpdated Appendix C: Ingredients included in COVID-19 vaccines\nUpdated Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects\nfollowing COVID-19 vaccination\nUpdated guidance in section on Considerations for use of a COVID-19 booster dose.","8639":"Next, our cells display the spike protein on their surface. Our immune system recognizes that the spike protein does\nnot belong there. This triggers our immune system to produce antibodies and activate other immune cells to fight\noff what it is an infection. This response is similar to what your body does if you get sick with COVID-19, but is\ntemporary. At the end of the immune building process, our bodies have learned how to help protect against future infection\nwith the virus that causes COVID-19.","3350":"History of myocarditis or pericarditis prior to COVID-19 vaccination\nPeople who have a history of myocarditis or pericarditis unrelated to vaccination with Moderna, Novavax, or Pfizer-BioNTech\n(e.g., due to SARS-CoV-2 or other viruses) may receive any currently FDA-approved or FDA-authorized COVID-19 vaccine after\nthe episode of myocarditis or pericarditis has completely resolved. This includes resolution of symptoms attributed to\nmyocarditis or pericarditis, as well as no evidence of ongoing heart inflammation or sequelae as determined by the person\u2019s\nclinical team. For people who have a history of myocarditis associated with MIS-C or MIS-A, see COVID-19 vaccination and MIS-\nC and MIS-A.","6165":"The data is updated monthly. National Healthcare Safety Network\nInfections in long-term care facility residents by vaccination status are reported through a network of approximately 15,000\nmedical facilities called the National Healthcare Safety Network (NHSN). An analysis of this data was published in CDC\u2019s\nMMWR. Related Pages\nVaccine Breakthrough Infections: The Possibility of Getting COVID-19 after Getting Vaccinated\n\u203a\nCOVID-19 Vaccine Breakthrough Case Investigation and Reporting\n\u203a\nCases and Deaths by Vaccination Status\n\u203a\nHospitalizations by Vaccination Status\n\u203a\nCDC\u2019s MMWR: Published analyses of case surveillance data by vaccination status for periods of Delta variant and\nOmicron variant\n\u203a\nLast Updated June 23, 2022","1834":"10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nVaccines & Immunizations\nVaccines & Immunizations\nCOVID-19 Vaccine Effectiveness Research\nClinical trials are conducted to determine vaccine efficacy before the U.S Food and Drug Administration (FDA) determines\nwhether to approve a vaccine. CDC and other partners assess COVID-19 vaccine effectiveness under real-world conditions\nafter the FDA approves a vaccine. This helps us understand if vaccines are performing as expected outside the more\ncontrolled setting of a clinical trial, which tests a vaccine before approval. Below you\u2019ll find descriptions of current and planned vaccine effectiveness evaluations CDC is conducting with partners.","5779":"Also, mention all of your medical conditions, including if you:\n\u2022 Have any allergies\n\u2022 Have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining\noutside the heart)\n\u2022 Have a fever\n\u2022 Have a bleeding disorder or are on a blood thinner\n\u2022 Are immunocompromised or are on a medicine that affects your immune system\n\u2022 Have ever fainted in association with an injection\fModerna COVID-19 Vaccine EUI Recipient Fact Sheet, ver 9\/02\/2022 Page 3 of 4\nHow is the COVID-19 vaccine by Moderna given? COVID-19 vaccine by Moderna is given as an injection into the muscle.","2565":"Immunization Schedule for Persons 18 Years of Age\nType\nRecipient\nAge\nProduct*\nFor Most People\nThose Who ARE Moderately or\nSeverely Immunocompromised\nDoses\nInterval Between\nDoses\u2020\nDoses\nInterval Between\nDoses\nmRNA\nvaccine\nand older\nMONOVALENT Moderna\nRed vial cap with a\nblue-bordered label\nPrimary series: Monovalent\nAt least 4\u20138\nweeks\u2021\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Moderna\nBlue cap with\ngray-bordered label\nBooster dose\u00a7: Bivalent\nAt least 8 weeks\nAt least 8 weeks\nand older\nMONOVALENT Pfizer-BioNTech\nGray vial cap with\ngray-bordered label\nPrimary series: Monovalent\nAt least 3-8\nweeks\u2021\nDose 1 to 2 At least 3 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Pfizer-BioNTech:\nGray vial cap with\ngray-bordered label\nBooster dose\u00a7: Bivalent\nAt least 8 weeks\nAt least 8 weeks\nProtein\nsubunit\nvaccine\nand older\nMONOVALENT Novavax\nPrimary series: Monovalent\nAt least 3\u20138\nweeks\u2021\nDose 1 to 2 At least 3 weeks\nModerna or Pfizer-BioNTech\nbivalent COVID-19 vaccine should\nbe used for the booster dose.","6066":"The FDA has authorized the Moderna COVID-19 Vaccine, Bivalent (Original and Omicron\nBA.4\/BA.5) and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4\/BA.5) for the\nexpress purpose of improving protection conferred by COVID-19 booster doses against the currently circulating\nOmicron variant of SARS-CoV-2, resulting in a more favorable benefit\/risk balance as compared to the use of\nthe COVID-19 vaccine by Moderna. Consequently, the benefit\/risk balance for the use of the COVID-19 vaccine\nby Moderna for booster dose use is expected to be less favorable compared to the available alternative\nbivalent booster vaccines.","9598":"See the Moderna EUI Fact Sheet for Healthcare Providers. Refer to CDC\u2019s Interim Clinical Considerations for specific recommendations on use of the COVID-19 vaccine by\nPfizer-BioNTech allowed under the EUI. For additional information about the COVID-19 vaccine by Pfizer-\nBioNTech COVID-19, refer to the Comirnaty package insert or the Full Emergency Use Authorization (EUA)\nPrescribing Information (FDA, 2022). What are EUI and why is CDC issuing EUI for the COVID-19 vaccine by Pfizer-BioNTech?","2665":"Caregivers should quarantine\nKeep a separate bedroom and bathroom for a person who is sick\n\u2022\n\u2022\n-\n-\n\u2022\f10\/30\/22, 9:41 AM COVID19 - Caring for someone at home | CDC\nCaregivers and anyone who has been in close contact with someone who has COVID-19 should stay home, except in\nlimited circumstances. Learn when and how to quarantine. When it's safe for a person who has been sick to be around others\nDeciding when it is safe to be around others is different for different situations. Find out when someone who is sick can\nsafely end home isolation.","1269":"Novavax COVID-19 vaccine for booster vaccination and Janssen COVID-19 Vaccine for primary series and booster\nvaccination should only be used in very limited situations. For more information, see COVID-19 vaccines. Is there a preferred COVID-19 vaccine? \uf1aa\nNo. You should administer the second dose as close as possible to the recommended interval after the first dose. However, if the second dose is administered after this interval, there is no need to restart the series.","9825":"The FDA has authorized the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron\fPfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nBA.4\/BA.5) and the Moderna COVID-19 Vaccine, Bivalent (Original and Omicron BA.4\/BA.5) for the express purpose of\nimproving protection conferred by COVID-19 booster doses against the currently circulating Omicron variant of SARS-CoV-\n2, resulting in a more favorable benefit\/risk balance as compared to the use of the COVID-19 vaccine by Pfizer-BioNTech.","1682":"COVID-19 vaccination providers are required to\nimplement all recommendations of the ACIP, adopted by the CDC Director, relevant to COVID-19 vaccination including:\nUse of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson)\nand mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on\nImmunization Practices \u2014 United States, July 2021\nUse of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory\nCommittee on Immunization Practices \u2014 United States, June 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Adolescents Aged 12\u201315 Years \u2014 United States, May 2021\nUpdated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen\n(Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among\nVaccine Recipients \u2014 United States, April 2021\nInterim Recommendation for Use of Janssen COVID-19 Vaccine \u2014 United States, February 2021\nInterim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine, United States 2020\nInterim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine, United States, December 2020\nInterim Recommendation for Use of Moderna COVID-19 Vaccine, United States, December 2020\n\uf209\n\uf20c\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nInterim Recommendation for Use of Moderna COVID 19 Vaccine, United States, December 2020\nUpdated Interim Recommendation for Allocation of COVID-19 Vaccine, United States, December 2020\nFind more information about vaccine administration and reporting requirements.","7234":"Signs of a severe\nallergic reaction can include:\n\uf0b7 Difficulty breathing\n\uf0b7 Swelling of your face and throat\n\uf0b7 A fast heartbeat\n\uf0b7 A bad rash all over your body\n\uf0b7 Dizziness and weakness\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the\nlining outside the heart) have occurred in some people who have received\nCOMIRNATY (COVID-19 Vaccine, mRNA) or Pfizer-BioNTech COVID-19 Vaccine,\nmore commonly in adolescent males and adult males under 40 years of age than\namong females and older males. In most of these people, symptoms began within a\nfew days following receipt of the second dose of vaccine. The chance of having this\noccur is very low.","520":"Since that date, first doses have been slightly overcounted and second doses have been slightly\nundercounted. As of March 12, 2021, to calculate national population estimates, CDC uses, as a denominator, a combination of:\nThe 2019 National Census Population Estimates from the US Census Bureau Annual Estimates of the Resident\nPopulation for the United States (including the District of Columbia [DC]) and Puerto Rico and the 2018 CIA\nWorld Factbook population estimates for US territories and freely associated states (American Samoa, the\nFederated States of Micronesia, Guam, the Commonwealth of Northern Mariana Islands, Republic of Palau, the\nRepublic of the Marshall Islands, and US Virgin Islands).","2975":"COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised\nAge\ngroup\nNumber of\nprimary doses\nNumber of\nbivalent booster\ndoses\nRecommended\nbivalent booster\ndose*\nInterval between 1st and\n2nd primary dose\nInterval between 2nd\nand 3rd primary dose\nInterval between primary\nseries and booster dose\nModerna primary series\nyears\n2 NA NA 4\u20138 weeks NA NA\nyears\nPfizer-BioNTech\n4\u20138 weeks NA At least 2 months\nSchedule: ages 12 years and older\n\u2020 \u2021\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nAge\ngroup\nNumber of\nprimary doses\nNumber of\nbivalent booster\ndoses\nRecommended\nbivalent booster\ndose*\nInterval between 1st and\n2nd primary dose\nInterval between 2nd\nand 3rd primary dose\nInterval between primary\nseries and booster dose\nand older\nPfizer-BioNTech\n4\u20138 weeks NA At least 2 months\nNovavax primary series\nand older\nPfizer-BioNTech\n3\u20138 weeks NA At least 2 months\nPfizer-BioNTech primary series\nyears\n3 NA NA 3\u20138 weeks At least 8 weeks NA\nyears\nPfizer-BioNTech\n3\u20138 weeks NA At least 2 months\nand older\nPfizer-BioNTech\n3\u20138 weeks NA At least 2 months\nAbbreviation: NA = not authorized\nA monovalent Novavax booster dose (instead of a bivalent mRNA booster dose) may be used in limited situations in people ages 18 years and older who\ncompleted a primary series using any COVID-19 vaccine, have not received any previous booster dose(s), and are unable to receive an mRNA vaccine (i.e.,\nmRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.","583":"August 11, 2022: New Jersey made updates to data previously submitted to CDC that resulted in a net increase of\n37,096 administered doses. August 11, 2022: California made updates to data previously submitted to CDC that resulted in a net increase of\n202,640 administered doses. August 4, 2022: Idaho made updates to data previously submitted to CDC that resulted in a net decrease of 42,051\nadministered doses. This contributed to a decrease in overall US figures. August 4, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 77,754\nadministered doses.","2940":"The primary series doses are separated by 4\u20138 weeks and the bivalent mRNA booster dose is\nadministered at least 2 months after completion of the primary series\nView the COVID-19 Vaccination Schedule for People who are NOT Moderately or Severely Immunocompromised \uf20a\nSchedule: ages 6 months through 11 years\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nadministered at least 2 months after completion of the primary series. Pfizer-BioNTech COVID-19 Vaccine\nChildren ages 6 months\u20134 years: A 3-dose primary series is recommended. The first and second doses are separated by\n3\u20138 weeks and the second and third doses are separated by at least 8 weeks.","254":"We can also learn if antibodies to SARS-CoV-2 provide the same protection against new variants of the virus that causes\nCOVID-19. Studies show that people who have antibodies from an infection with the virus that causes COVID-19 can improve their\nlevel of protection by getting vaccinated. \uf209\nAntibody quiz\f10\/30\/22, 9:37 AM Antibodies and COVID-19 | CDC\nNow that you\u2019ve learned about antibodies and COVID-19, test your knowledge with an interactive quiz. Test Your Knowledge\nAntibodies for the virus that causes COVID-19 are expected to decrease, or wane, over time. True\nFalse\nNext \uf29e\nLast Updated Nov. 10, 2021","213":"When someone who is fully vaccinated gets COVID-19, it is called a vaccine breakthrough infection. No vaccine\nis 100% effective, so some breakthrough infections are expected. The risk of infection, severe illness, hospitalization, and\ndeath are all much lower for vaccinated people compared to people who are unvaccinated. When reinfections or\nbreakthrough infections happen, having antibodies plays an important role in helping prevent severe illness, hospitalization,\nand death. For many diseases, including COVID-19, antibodies are expected to decrease or \u201cwane\u201d over time. After a long enough period\nof time, your level of antibodies can decrease below a level that provides effective protection.","5259":"\u2022\nYour symptoms are not improving\nContinue to isolate until:\nYou are fever-free for 24 hours (without the use of\nfever-reducing medication). Your symptoms are improving. \u2022\nModerate illness (you experienced shortness of\nbreath or had difficulty breathing)\nYou need to isolate through day 10. Severe illness (you were hospitalized) or have a\nweakened immune system\nYou need to isolate through day 10. \u2022\f10\/30\/22, 9:41 AM Isolation and Precautions for People with COVID-19 | CDC\nRegardless of when you end isolation\nUntil at least day 11:\nAvoid being around people who are more likely to get very sick from COVID-19.","2373":"EVUSHELD is a medicine given every six months by your healthcare\nprovider to help prevent you from getting COVID-19. EVUSHELD may offer less protection against three strains (BA.4.6,\nBF.7, and BA.2.75.2) of the Omicron variant. It is important to use multiple prevention measures and talk to your\nhealthcare provider to find out if EVUSHELD is right for you. TM TM\nTM\nTM\nDownload: EVUSHELD EUA Fact Sheet for Patients, Parents and Caregivers\nTM \uf209\nFrequently Asked Questions\nNo, vaccines used for the primary vaccination series should be the same product or brand.","6672":"Do not stop any medications or change your asthma treatment plan without talking to your healthcare provider. Talk to your healthcare provider, insurer, and pharmacist about creating an emergency supply of prescription\nmedications, such as asthma inhalers. Make sure that you have 30 days of non-prescription medications and supplies on\nhand in case you need to stay home for a long time. Be careful around cleaning agents and disinfectants\nCDC is reviewing this page to align with updated guidance.","1953":"Participants can enroll in v-safe after any dose of vaccine, and parents and\nguardians can enroll on behalf of their children. V-safe COVID-19 Vaccine Pregnancy Registry \u2014 A registry to collect health information from people enrolled in v-safe\nwho receive COVID-19 vaccines shortly before or during pregnancy. This voluntary program helps CDC monitor the\nsafety of COVID-19 vaccines in people who are pregnant.","6124":"Parry H, Bruton R, Stephens C, et al. Extended interval BNT162b2 vaccination enhances peak antibody\nPayne RP, Longet S, Austin JA, et al. 2021. Immunogenicity of standard and extended dosing intervals of\nBNT162b2 mRNA vaccine. Cell. doi: 10.1016\/j.cell.2021.10.011\nPulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with\nemergence of the Omicron variant in South Africa. 2022. https:\/\/doi.org\/10.1101\/2021.11.11.21266068\nSchietzel S, Anderegg M, Limacher A, et al. Humoral and cellular immune responses on SARS-CoV-2 vaccines in\npatients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients. Infections. 2022;8:e002036. doi:10.1136\/rmdopen-2021-002036.","9297":"Children and Teens Can Experience Ongoing Health Problems\nAfter getting COVID-19, children and teens can also experience a wide range of new, returning, or ongoing health problems. These include physical and mental health complications that may occur four or more weeks after initial infection. These\ncomplications can appear after mild or severe COVID-19, or after MIS-C. Symptoms Post COVID-19 Vaccination Symptoms Post COVID-19 Infection\nCough\nMuscle and joint pain\nHeadache\nTrouble falling or staying asleep\nTrouble concentrating\nLimitations in physical activity\nFeeling distressed about symptoms\nMental health challenges\nDecreased school or daycare attendance\nMissed opportunities for participation in sports,\nplaydates, or other activities\nLearn more about post-COVID conditions.","3264":"Vaccination providers\nare required by FDA and the provider agreement for the CDC COVID-19 Vaccination Program to report the following that\noccur after COVID-19 vaccination under BLA or EUA:\nVaccine administration errors whether or not associated with an adverse event\nSerious adverse events , irrespective of attribution to vaccination\nCases of Multisystem Inflammatory Syndrome (MIS) in adults and children\nCases of myocarditis after a Pfizer-BioNTech, Moderna, or Novavax vaccine\nCases of pericarditis after a Pfizer-BioNTech, Moderna, or Novavax vaccine\nCases of COVID-19 that result in hospitalization or death\nReporting is encouraged for any other clinically significant adverse event, even if it is uncertain whether the vaccine caused\nthe event.","2431":"Researchers found no significant changes in these sperm\ncharacteristics after vaccination. However, one study found that COVID-19 infection may be associated with a decline in fertility for men for up to\n60 days after infection. Fever from any illness has been associated with a short-term decrease in sperm production in healthy men. Although fever can be a side effect of COVID-19 vaccination, there is no current evidence that fever after COVID-\nvaccination affects sperm production. Fever is also a common symptom of COVID-19 infection. Safety Monitoring\nCOVID-19 vaccines are undergoing the most intense safety monitoring in U.S. history.","1375":"\uf1aa\nThe bivalent booster dose is administered at least 2 months after the last monovalent mRNA booster dose. My patient already received a monovalent mRNA booster dose(s). What is the interval between a\npreviously received monovalent mRNA booster dose and the bivalent booster dose? \uf1aa\nYes. Everyone ages 5 years and older who completed a primary series is recommended to receive 1 bivalent booster\ndose regardless of previous booster dose history. For people who previously received 1 or more monovalent booster\ndoses, the bivalent booster dose should be administered at least 2 months after the last monovalent booster dose.","5845":"\u2022 Revaccination of moderately or severely immunocompromised persons ages 12 years and older who\nreceived certain therapies (indicated below) and received primary dose(s) of COVID-19 vaccine prior to\nor during treatment. o\no\nReceived COVID-19 vaccine dose(s) during treatment with B-cell-depleting therapies over a\nlimited period\nReceived COVID-19 vaccine dose(s) prior to or during treatment involving hematopoietic cell\ntransplant (HCT) or chimeric antigen receptor (CAR)-T-cell therapy\nThe COVID-19 vaccine by Pfizer-BioNTech under EUI also allow similar uses as an alternative mRNA COVID-19\nvaccine to Moderna, and the same or similar recommendations in the EUI also apply to the use of the COVID-\n19 vaccine by Pfizer-BioNTech under EUI.","1127":"CDC Privacy Policy\n\uf374 Find a vaccine near you\n\uf33f Call 1-800-232-0233\n\uf2ba Text your zip code to 438829\nGet Email Updates\nTo receive email updates about this page, enter your\nemail address:\n\uf14a\nEmail Address\nWhat's this? Submit\n\uf1e5 Add CDC web content on your site\nPut CDC syndicated pages on your website for free. Just add a small piece of web code to your page and the\ncontent will automatically update whenever CDC updates this page. Content Syndication\nLast Reviewed: May 13, 2022","6052":"The option to be revaccinated for people who received vaccination during\ntherapy would allow the opportunity to develop a more sufficient immune response. Risk\u2010Benefit of the COVID-19 vaccine by Moderna as Primary or Additional, Vaccination for Individuals\nDescribed in the EUI\nThe duration of vaccine-induced protection from primary vaccination with COVID-19 vaccines is unknown. Efficacy data from clinical studies of 2-dose primary series supported benefit of the COVID-19 vaccine by\nModerna in preventing severe COVID-19 and supported its FDA approval.","2091":"Other studies have shown that by reducing the\nrisk of severe illness in pregnant people, COVID-19 vaccination might also help prevent stillbirths. Vaccination during pregnancy builds antibodies that can help protect the baby. Much like people who are not pregnant,\nwhen people who are pregnant receive an mRNA COVID-19 vaccine, their bodies build antibodies against COVID-19. Antibodies made after pregnant people received an mRNA COVID-19 vaccine have been found in their baby\u2019s umbilical\ncord blood.","5633":"The information on this page is about N95 respirators but also applies to international respirators, like KN95\nrespirators. \uf20a\f10\/30\/22, 9:39 AM Masks and Respirators\nMost publicly available respirators are disposable and should be discarded when they are dirty, damaged, or difficult to\nbreathe through. More information on these two types of respirators is provided below. Respirators that Meet International Standards\nSome respirators are designed and tested to meet international standards. The most widely available respirators that meet\nKP100, P2, P3, PFF2, PFF3, R95, and Special. What to know about international respirators\nThey are designed to standards that do not often have a quality requirement.","6908":"\u2022 People ages 12 years and older who recently had SARS-CoV-2 infection may receive a second\nprimary dose after a deferral period of 3 months from symptom onset or positive test (if infection\nwas asymptomatic)\fPfizer-BioNTech COVID-19 Vaccine EUI Recipient Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\n\u2022 People ages 12 years and older who received an incomplete primary dose series (only the first\ndose of a 2-dose primary series) with certain non-FDA authorized or approved COVID-19 vaccines\nat least 28 days ago should receive a primary dose of the COVID-19 vaccine by Pfizer-BioNTech to\ncomplete the series.","3312":"In age groups where product comparisons can be made (i.e., 18\u201339 years), some evidence suggests that the risk of\nmyocarditis and pericarditis may be higher following vaccination with Moderna COVID-19 Vaccine relative to Pfizer-BioNTech\nCOVID-19 Vaccine; however, findings are not consistent in all U.S. monitoring systems. In post-authorization surveillance , cases of myocarditis and pericarditis among children ages 5\u201311 years after Pfizer-\nBioNTech COVID-19 vaccination have been rarely reported, primarily in males and after dose 2; the reporting rate of\nmyocarditis in VAERS following dose 2 of Pfizer-BioNTech marginally exceeded the background incidence rate for male\nchildren in this age group.","3977":"With one exception, distribution and delivery of COVID-19\nvaccines and other routine vaccines are accomplished through a federal delivery system. Pfizer-BioNTech distributes and\ndelivers doses of its COVID-19 vaccine through its own delivery system. How are vaccine distribution data reported to CDC?","6289":"FACT: Because none of the authorized COVID-19 vaccines in the United States contain the live virus that causes\nCOVID-19, the vaccine cannot make you sick with COVID-19. COVID-19 vaccines teach our immune systems how to recognize and\nfight the virus that causes COVID-19. Sometimes this process can\ncause symptoms, such as fever. These symptoms are normal and are\nsigns that the body is building protection against the virus that causes\nCOVID-19. Learn more about how COVID-19 vaccines work.","3700":"\u2022 CDC issuance of initial EUI for the COVID-19 vaccine by Moderna on February 11, 2022\nThe FDA approvedl the COVID-19 vaccine by Moderna (brand name Spikevax) on January 31, 2022, as a\ntwo-dose primary series for active immunization to prevent COVID-19 in persons ages 18 years and\nolder., CDC subsequently issued EUI for the Moderna COVID-19 vaccine to allow primary, additional,\nand\/or booster doses in persons ages 18 years and older, including those vaccinated with certain non-\nFDA authorized or approved COVID-19 vaccines and certain individuals with immunocompromising\nconditions, similar to the uses that go beyond or differ from the FDA-approved labeling as described in\nthe EUI for the Pfizer-BioNTech COVID-19 vaccine.","5868":"Moderna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 09\/02\/22;\nThe COVID-19 vaccine by Moderna was approved by the FDA on January 31, 2022 as a 2-dose primary series\nfor active immunization to prevent COVID-19 in persons ages 18 years and older. CDC is issuing these EUI to\nprovide information about use of the COVID-19 vaccine by Moderna for primary and\/or additional booster that\nextend beyond its FDA-approved labeling as described further under \u201cWho can receive the COVID-19 vaccine\nby Moderna\u201d and \u201cWhat are the doses and intervals of the COVID-19 vaccine by Moderna for primary and\/or\nadditional doses\u201d. What is COVID-19?","4962":"New booster recommendation for people ages 12 years and older to receive 1 bivalent mRNA booster after\ncompletion of a monovalent primary series; it replaces all prior booster recommendations for this age group\nRecommendations for use of a bivalent Moderna booster dose in people ages 18 years and older\nRecommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 12 years and older\nUpdated guidance for observation periods following COVID-19 vaccination\nUpdated guidance on COVID-19 vaccination and multisystem inflammatory syndrome (MIS) in children (MIS-C) and in\nadults (MIS-A)\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adolescents ages 12\u201317 years\nReorganization of Janssen COVID-19 Vaccine guidance into an appendix\nUpdated guidance on COVID-19 vaccination following exposure to SARS-CoV-2\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nPrevious Updates\n\uf1aa\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nUpdated guidance on COVID-19 vaccination and myocarditis and pericarditis\nNew clinical considerations for coadministration of mRNA COVID-19 vaccines and orthopoxvirus vaccines\nNew guidance for use of Moderna COVID-19 Vaccine in children and adolescents ages 6\u201317 years\nNew guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children ages 6 months\u20134 years\nNew guidance for use of Moderna COVID-19 Vaccine in children ages 6 months\u20135 years\nReorganization of sections on COVID-19 vaccination recommendations and schedules\nAddition of new section in Special populations for infants and young children\nNew guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5\u201311 years\nUpdated guidance that the following people should receive a second COVID-19 booster dose:\nPeople ages 12 years and older who are moderately or severely immunocompromised\nPeople ages 50 years and older\nUpdated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-\ndepleting therapies\nClarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults\n(MIS-A)\nUpdated guidance for primary series vaccination after SARS-CoV-2 infection\nAdded considerations for the option to receive a second COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 vaccination after SARS-CoV-2 infection\nAdded guidance that people ages 12 years and older who are moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that people ages 18\u201349 years who are not moderately or severely immunocompromised and who\nreceived Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster\ndose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose\nFurther clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C)\nand adults (MIS-A) and myocarditis\nUpdated information on the availability of Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL\ndosage volume) and Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL dosage volume) for\nadministration of a 50 \u00b5g booster dose.","9740":"In this study, adults who had\ncompleted primary vaccination with a Moderna COVID-19 Vaccine 2-dose series (N=151), a Janssen COVID-19\nVaccine single-dose (N=156), or a Pfizer-BioNTech COVID-19 vaccine 2-dose series (N=151) at least 12 weeks\nprior to enrollment and who reported no history of SARS-CoV-2 infection were randomized 1:1:1 to receive a\nbooster dose of one of three vaccines: Moderna COVID-19 Vaccine, Janssen COVID-19 Vaccine, or Pfizer-\nBioNTech COVID-19 Vaccine.","3741":"\u25aa Updated on June 24, 2022, to allow the use of Moderna COVID-19 vaccine for ages 12 years and\nolder for: a longer interval of 4\u20138 weeks between the first and second primary dose of Moderna\nCOVID-19; primary dose(s), including for those with certain immunocompromising conditions or\n2 FDA amended the EUA for the Pfizer-BioNTech COVID-19 vaccine on December 9, 20201 to expand the eligible population\nfor homologous booster doses to persons aged \u2265 16 years.","4647":"10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nEspa\u00f1ol | Other Languages\nVaccines & Immunizations\nVaccines & Immunizations Home\nInterim Clinical Considerations for Use of COVID-19\nVaccines: Appendices, References, and Previous\nUpdates\nSummary of recent changes (last updated October 19, 2022):\nGuidance for use of a monovalent Novavax COVID-19 booster dose in people ages 18 years and older in limited\nsituations\nJanssen COVID-19 Vaccine is authorized for adults ages 18 years and older for the primary series dose and 1 booster dose in\ncertain limited situations due to the risk of thrombosis with thrombocytopenia syndrome (TTS) following receipt of the\nvaccine:\nWhen there is a contraindication to mRNA (i.e., Moderna or Pfizer-BioNTech) and Novavax COVID-19 vaccines (e.g.,\nsevere allergic reaction after a previous dose or to a component of an mRNA COVID-19 vaccine) (see Table 4)\nWhen a person would otherwise remain unvaccinated for COVID-19 due to limited access to other COVID-19 vaccines\nWhen a person wants to receive Janssen COVID-19 Vaccine despite the safety concerns identified\nCOVID-19 vaccine recipients should be informed that Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines are\nrecommended over Janssen COVID-19 Vaccine.","4326":"Make sure your vaccination provider updates your vaccination card\n(or gives you one if this is your first dose). Stay up to date with the recommended COVID-19 vaccines and\nboosters. You may experience side effects after getting a COVID-19 vaccine. Adverse effects (serious safety problems) and severe allergic\nreactions are rare. To report any side effects, you can sign up for v-safe. V-safe is a\nsmartphone-based tool that provides quick and confidential health check-ins via text messages and web surveys so you\ncan quickly and easily share with CDC how you or your dependent feel after getting a COVID-19 vaccine.","9340":"This Vaccine Information Fact Sheet for Recipients and Caregivers comprises the Fact\nSheet for the authorized Moderna COVID-19 Vaccine and the authorized Moderna\nCOVID-19 Vaccine, Bivalent for use in individuals 6 years of age and older, and also\nincludes information about the FDA-licensed vaccine, SPIKEVAX (COVID-19 Vaccine,\nmRNA) for use in individuals 12 years of age and older.1\nThe FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and the Moderna COVID-\n19 Vaccine authorized for Emergency Use Authorization (EUA) for individuals 12 years of\nage and older can be used interchangeably, when used according to their respective\ninstructions for use.2\nSPIKEVAX (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made\nby ModernaTX, Inc.","1721":"Anyone can report an adverse event to VAERS. Healthcare professionals are required\nto report certain adverse events and vaccine manufacturers are required to report all adverse events that come to their\nattention. The reporting requirements for COVID-19 vaccines are the same for those authorized under emergency use (EUA) or\napproved under a Biologics License Application (BLA). Healthcare providers who administer COVID-19 vaccines are\nrequired to report the following to VAERS:\nVaccine administration errors, whether or not associated with an adverse event (AE)\nIf the incorrect mRNA COVID-19 vaccine product was inadvertently administered for a second dose in a 2-dose\nseries, VAERS reporting is required.","2113":"If you have symptoms or health problems that concern you at any\ntime following COVID-19 vaccination, please contact your healthcare provider. *Abt Associates has been contract by CDC to contact participants of CDC\u2019s v-safe COVID-19 Vaccines Pregnancy\nRegistry. \uf209\nCommon Questions about Vaccination during Pregnancy\nScientific studies to date have shown no safety concerns for babies born to people who were vaccinated against COVID-\n19 during pregnancy. Based on how these vaccines work in the body, experts believe they are unlikely to pose a\nrisk for long-term health effects.","132":"One wild mink and a small number of escaped farm mink\ntrapped near affected farms in Utah and Oregon were found to be infected with SARS-CoV-2. Although there is no evidence that mink are playing a significant role in the spread of SARS-CoV-2 to people, there is a\npossibility of mink spreading SARS-CoV-2 to people and other animals on mink farms. Mink-to-human spread of SARS-CoV-2\nhas been reported in the Netherlands, Denmark, and Poland, and data suggest it might have occurred in the United States. People can spread SARS-CoV-2 to animals, especially during close contact.","8346":"If the patient asks a question about COVID-19 vaccine safety, vaccine risks, or their health or mental health, see potential\nresponses in Step 4. Motivational interviewing is an evidence-based and culturally sensitive way to speak with unvaccinated patients about\ngetting vaccinated. The goal of motivational interviewing is to help people manage mixed feelings and move toward\nhealthy behavior change that is consistent with their values and needs.","5830":"Moderna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 09\/02\/22;\nEmergency Use Instructions for Healthcare Providers:\nModerna COVID-19 Vaccine for Primary and\/or Additional Doses\nThe Centers for Disease Control and Prevention (CDC) is issuing Emergency Use Instructions (EUI) to provide\ninformation about the use of the COVID-19 vaccine by Moderna (Spikevax), which is approved (licensed) by the\nFood and Drug Administration (FDA) for the prevention of COVID-19 in individuals ages 18 years and older.1\nThe CDC-issued EUI provide information for the use of this vaccine that are beyond the FDA-approved labeling.","1646":"The following are not included in the above prohibition:\nCommunications regarding receipt of a second dose, or potential booster dose(s), of COVID-19 vaccine\nCommunications to vaccine recipient for public health purposes\nCommunications to vaccine recipients involving pharmacy or clinical services of the provider, personalized to the\nvaccine recipient\u2019s medical needs, even if those services are not directly related to COVID-19 vaccination\nAvailability of other vaccines (e.g., shingles, pneumococcal conjugate, seasonal influenza, routine childhood vaccines)\nClinical emails\nDisease screening services\nCommunications about the availability of programs to manage particular health conditions (e.g., asthma, diabetes,\nheart disease)\nIn addition, de-identified, aggregate datasets can be used by providers and shared with other partners for public health,\npopulation health, and health equity purposes.","7223":"In clinical trials, approximately 23,000 individuals 12 years of age and older have\nreceived at least 1 dose of Pfizer-BioNTech COVID-19 Vaccine. Millions of individuals\nhave received the Pfizer-BioNTech COVID-19 Vaccine under EUA since December 11,\n2020. In a clinical trial, approximately 300 individuals greater than 55 years of age received\none dose of a bivalent vaccine that differs from the Pfizer-BioNTech COVID-19\nVaccine, Bivalent in that it contains a different Omicron component. WHAT ARE THE BENEFITS OF THESE VACCINES? COMIRNATY (COVID-19 Vaccine, mRNA) and the Pfizer-BioNTech COVID-19 Vaccine\nhave been shown to prevent COVID-19.","3363":"SARS-CoV-2 viral testing may be necessary to differentiate between\ncommon post-vaccination symptoms and symptoms of SARS-CoV-2 infection:\nPeople who develop signs and symptoms associated with COVID-19 (e.g., cough, shortness of breath, runny nose, sore\nthroat, loss of taste or smell) should isolate and be evaluated for SARS-CoV-2 infection as soon as possible. People who develop signs and symptoms that could be from either COVID-19 vaccination or SARS-CoV-2 infection (e.g.,\nfever, fatigue, headache, myalgia) without typical COVID-19 symptoms described above, and are clinically stable, should\nisolate and, if symptoms do not improve by two days post-vaccination, be evaluated for SARS-CoV-2 infection.","7265":"ARE OTHER CHOICES AVAILABLE FOR PREVENTING COVID-19 BESIDES\nCOMIRNATY (COVID-19 VACCINE, mRNA), THE PFIZER-BIONTECH COVID-19\nVACCINE, OR THE PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT? For primary vaccination, another choice for preventing COVID-19 is SPIKEVAX\n(COVID-19 Vaccine, mRNA), an FDA-approved COVID-19 vaccine. Other vaccines to\nprevent COVID-19 may be available under EUA, including bivalent vaccines that\ncontain an Omicron component of SARS-CoV-2. CAN I RECEIVE COMIRNATY (COVID-19 VACCINE, mRNA), PFIZER-BIONTECH\nCOVID-19 VACCINE, OR THE PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT\nAT THE SAME TIME AS OTHER VACCINES?","7090":"Know when to wear a well-fitted mask to help protect yourself and others. Avoid crowds and poorly ventilated indoor spaces. Test to prevent spread to others\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:39 AM Pregnant and Recently Pregnant People | CDC\nTest to prevent spread to others. Stay 6 feet apart from others who don\u2019t live with you. Wash your hands often with soap and water. Use hand sanitizer if soap and\nwater aren\u2019t available. \u2022\n\u2022\n\u2022\nStaying Healthy During and After Your Pregnancy\nKeep all of your healthcare appointments during and after pregnancy. Visit with your healthcare provider for all\nrecommended appointments.","4212":"\uf1aa\f10\/30\/22, 9:18 AM Frequently Asked Questions about COVID-19 Vaccination | CDC\nNo. You should wait to be vaccinated until after you\u202fcomplete your isolation period. People who have symptoms will end\nisolation at a different time than people who do not have symptoms. This also applies to people who have been\nvaccinated but get COVID-19 before getting any additional or booster doses. Additionally, you may consider delaying your\nnext vaccine (primary dose or booster) by 3 months from when your symptoms started or, if you had no symptoms, when\nyou received a positive test.","9261":"Other prevention actions (such\nas improving ventilation) should be used to avoid transmission during these 10 days. Last Updated Aug. 24, 2022","5763":"\u25aa Received COVID-19 vaccine dose(s) during treatment with B-cell-depleting\ntherapies over a limited period: the suggested interval to start revaccination is\nabout 6 months after completion of the B-cell-depleting therapy\n\u25aa Received COVID-19 vaccine dose(s) prior to or during treatment with\nhematopoietic cell transplant (HCT) or chimeric antigen receptor (CAR)-T-cell\ntherapy: revaccination at least 3 months after treatment\nThe COVID-19 vaccine by Pfizer-BioNTech can also be used under EUI for similar uses in persons ages 12\nyears and older as an alternative mRNA COVID-19 vaccine (see the Pfizer-BioNTech EUI Fact Sheet for\nRecipients).","10078":"\u0083 Persons, particularly adolescent or young adult males, might consider waiting 4 weeks after orthopoxvirus (monkeypox) vaccination (either\nJYNNEOS or ACAM2000) before receiving a Moderna, Novavax, or Pfizer-BioNtech COVID-19 vaccine because of the observed risk for myocarditis\nand\/or pericarditis after JYNNEOS. \u0083 Administer each injection in a different injection site. \u2020 See Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States at: www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html#recommendations for detailed\nguidance. \u2021 For booster vaccination, homologous or heterologous mRNA booster is recommended.","4358":"10\/30\/22, 9:33 AM How CDC Monitors Vaccine Effectiveness | CDC\nEspa\u00f1ol | Other Languages\nHow CDC Monitors Vaccine Effectiveness\nSurveillance data allow us to monitor rates of COVID-19 cases, hospitalizations, and deaths by vaccination status. To understand how well COVID-19 vaccines are working in real-world conditions over time, CDC uses a multi-layered\napproach, which includes ongoing analyses of surveillance data and studies of vaccine effectiveness. Analyses of surveillance data can provide signals of\npotential changes in vaccine effectiveness. \uf41a\nThese signals can then be further studied through more\nrobust, controlled vaccine effectiveness studies\nconducted by CDC and partners.","6309":"10\/30\/22, 9:42 AM Patient Tips: Healthcare Provider Appointments for Post-COVID Conditions | CDC\nEspa\u00f1ol | Other Languages\nPatient Tips: Healthcare Provider Appointments for\nPost-COVID Conditions\nBefore Your Appointment\nWhat You Need to Know\nPreparing for an appointment can make all the difference in getting the proper evaluation, diagnosis, and\ntreatment. To help get the most out of appointments for post-COVID conditions, download the Healthcare Appointment\nChecklist (Espa\u00f1ol [PDF \u2013 72 KB]). Try to arrive early or log on a few minutes ahead of the appointment and ensure paperwork is completed on your\nappointment day. After visiting your healthcare provider, review your notes to prepare for your next appointment.","8940":"VAERS is one of several systems CDC and the U.S. Food and Drug Administration (FDA) use to help ensure vaccines\nused in the United States, including COVID-19 vaccines, are closely monitored for safety. VAERS gives vaccine safety experts valuable information so they can assess possible vaccine safety concerns,\nincluding for the new COVID-19 vaccines. VAERS is especially useful for detecting unusual or unexpected patterns of health problems (also called \u201cadverse\nevents\u201d) that might indicate a possible safety problem with a vaccine. If a health problem is reported to VAERS, that doesn\u2019t mean that the vaccine caused the problem.","7766":"Over 350 million mRNA vaccines were given during the study period\nand CDC scientists found that rates of myocarditis were highest following the second dose of an mRNA vaccine\namong males in the following age groups:\n12\u201315 years (70.7 cases per one million doses of Pfizer-BioNTech)\n16\u201317 years (105.9 cases per one million doses of Pfizer-BioNTech)\n18\u201324 years (52.4 cases and 56.3 cases per million doses of Pfizer-BioNTech and Moderna, respectively)\nMultiple studies and reviews of data from vaccine safety monitoring systems continue to show that vaccines are safe. As\na result, the agency will refocus enhanced surveillance and safety monitoring efforts toward children and adolescents.","5535":"Better understand how many people are affected by post-COVID conditions, and how often people who are infected with\nCOVID-19 develop post-COVID conditions afterwards. Better understand risk factors, including which groups might be more at risk, and if different groups experience different\nsymptoms. Help understand how post-COVID conditions limit or restrict people\u2019s daily activity. Help identify groups that have been more affected by post-COVID conditions, lack access to care and treatment for post-\nCOVID conditions, or experience stigma. Better understand the role vaccination plays in preventing post-COVID conditions.","2690":"Masks should not be placed on young children under age 2, anyone who has trouble breathing, or is not able to\nremove the covering without help. Caregiver\nPut on a mask and ask the sick person to put on a mask before entering the room. \u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:41 AM COVID19 - Caring for someone at home | CDC\np p g\nWear gloves when you touch or have contact with the sick person\u2019s blood, stool, or body fluids, such as saliva,\nmucus, vomit, and urine. Throw out gloves into a lined trash can and wash your hands right away.","1645":"The following are not included in the above prohibition:\nCommunications regarding receipt of a second dose, or potential booster dose(s), of COVID-19 vaccine\nCommunications to vaccine recipient for public health purposes\nCommunications to vaccine recipients involving pharmacy or clinical services of the provider, personalized to the\nvaccine recipient\u2019s medical needs, even if those services are not directly related to COVID-19 vaccination\nAvailability of other vaccines (e.g., shingles, pneumococcal conjugate, seasonal influenza, routine childhood vaccines)\nClinical emails\nDisease screening services\nCommunications about the availability of programs to manage particular health conditions (e.g., asthma, diabetes,\nheart disease)\nIn addition, de-identified, aggregate datasets can be used by providers and shared with other partners for public health,\npopulation health, and health equity purposes.","9743":"Neutralizing antibody titers, as measured by a pseudovirus neutralization assay\nusing a lentivirus expressing the SARS-CoV-2 Spike protein with D614G mutation, were assessed prior to\nadministration of the booster dose (Day 1) and after the booster dose (Day 15). A booster response to the\nPfizer-BioNTech COVID-19 Vaccine was demonstrated regardless of which COVID-19 vaccine was used for\nprimary vaccination. An overall review of adverse reactions reported following the Pfizer-BioNTech COVID-19\nvaccine heterologous booster dose did not identify any new safety concerns as compared to adverse reactions\nreported following the Pfizer-BioNTech COVID-19 vaccine primary vaccination or homologous booster dose\n(FDA, 2022).","8076":"\u0083 Develop communications materials detailing the benefits of vaccination compared to infection-induced immunity. \u0083 Clarify the absence of an association between hepatitis and COVID-19 vaccines. COVID-19 State of Vaccine Confidence Insights Report | October 10, 2022\nEmerging Misinformation Theme Affecting Vaccine Confidence\nConsumers have questions about the relationship between COVID-19 vaccines and\nmonkeypox.","9444":"Please include either \u201cSPIKEVAX (COVID-19 Vaccine,\nmRNA)\u201d, \u201cModerna COVID-19 Vaccine EUA,\u201d or \u201cModerna COVID-19 Vaccine, Bivalent\nEUA\u201d, as appropriate, in the first line of box #18 of the report form. In addition, you can report side effects to ModernaTX, Inc. at 1-866-MODERNA (1-866-663-\n3762). You may also be given an option to enroll in v-safe. V-safe is a voluntary smartphone-based tool\nthat uses text messaging and web surveys to check in with people who have been vaccinated to\nidentify potential side effects after COVID-19 vaccination. V-safe asks questions that help CDC\nmonitor the safety of COVID-19 vaccines.","3452":"10\/30\/22, 9:43 AM Cruise Ship Travel During COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nCruise Ship Travel During COVID-19\nWhat You Need to Know\nCheck if you are up to date with your COVID-19 vaccines before cruise ship travel. If you have a medical condition or are taking medication that weakens your immune system, you might NOT be fully\nprotected even if you are up to date with your COVID-19 vaccines. Talk to your healthcare provider about your risk\nbefore travel. Even after vaccination, you may need to continue taking precautions. The virus that causes COVID-19 spreads easily between people in close quarters on board ships.","7472":"Isolation means to separate sick people with a contagious disease from people who are not sick. What is the difference between quarantine and isolation? \uf1aa\nChildren ages 2 through 17 years (minors) who are noncitizen nonimmigrants do not have to quarantine after arrival in\nthe United States; however, the attestation requires that they get a COVID-19 viral test 3-5 days after arrival. If a child, like\nany other traveler, tests positive for COVID-19 or develops COVID-19 symptoms, they should isolate for a full 5 calendar\ndays.","2859":"The following COVID-19 vaccines, categorized into three vaccine types, are currently approved under a Biologics License\nApplication (BLA) or authorized under an EUA by FDA (Table 1):\nmRNA vaccines\nModerna COVID-19 Vaccine\/SPIKEVAX (1) and Moderna COVID-19 Vaccine, Bivalent\nPfizer-BioNTech COVID-19 Vaccine\/COMIRNATY (2) and Pfizer-BioNTech COVID-19 Vaccine, Bivalent\nProtein subunit vaccine\nNovavax COVID-19 Vaccine, Adjuvanted\nAdenovirus vector vaccine\nJanssen (Johnson & Johnson) COVID-19 Vaccine\nNone of the currently FDA-approved or FDA-authorized COVID-19 vaccines are live-virus vaccines. Overview of COVID-19 vaccination\n\uf209\n\uf209\n\uf209\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nJanssen COVID-19 Vaccine is authorized for adults ages 18 years and older in certain limited situations due to safety\nconsiderations (see Appendix A).","5970":"Frequencies of local and\nsystemic adverse reactions in the 7 days post booster vaccination were higher with heterologous than\nhomologous boosters and in those aged under 70 years when compared to older recipients. Among all mRNA\nvaccines, the 100 microgram COVID-19 vaccine by Moderna was the most reactogenic (Munro et al., 2021). WHO\u2019s Strategic Advisory Group of Experts (SAGE) on Immunization has noted that although data are currently\nlimited on the safety, immunogenicity, and effectiveness of heterologous versus homologous additional doses,\nevolving evidence suggests that use of a heterologous vaccine for an additional dose may be more\nimmunogenic than a homologous series.","5802":"Receiving the second primary dose of the COVID-19 vaccine by Moderna 4\u20138 weeks after the first dose\nmay reduce the risk of myocarditis and result in greater immune response and better protection against\nCOVID-19. Primary, additional, and\/or booster doses of the COVID-19 vaccine by Moderna as described\nunder EUI may help to increase immune response in people, which could improve protection against\nCOVID-19. Similarly, for individuals who received the Janssen Vaccine for primary vaccination, an additional\nprimary or second booster dose of the COVID-19 vaccine by Moderna could improve protection against\nCOVID-19. The COVID-19 vaccine by Moderna may not protect everyone.","6040":"Delaying vaccination for 3\nmonths after infection may therefore help to maximize protection with minimal risk to the individual. However, robustness and duration of protection is variable (National Collaborating Center for Methods and\nTools, 2021). The circulating variant, as well as individual-level factors such as age and comorbidities, can\nimpact level of protection. For example, overall risk of reinfection increased during the Omicron wave, and\nprotection from infection or vaccination, was less robust than against previous variants (Pulliam et al., 2022).","7184":"It is predominantly a\nrespiratory illness that can affect other organs. People with COVID-19 have had a wide\nrange of symptoms reported, ranging from mild symptoms to severe illness leading to\ndeath. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may\ninclude: fever or chills; cough; shortness of breath; fatigue; muscle or body aches;\nheadache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or\nvomiting; diarrhea. HOW ARE COMIRNATY (COVID-19 VACCINE, mRNA), THE PFIZER-BIONTECH\nCOVID-19 VACCINE, AND THE PFIZER-BIONTECH COVID-19 VACCINE,\nBIVALENT RELATED?","6744":"This Fact Sheet contains information to help you understand the risks and benefits of\nthe Pfizer-BioNTech COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent, which your child may receive because there is currently a pandemic of\nCOVID-19. Talk to your child\u2019s vaccination provider if you have questions. This Fact Sheet may have been updated. For the most recent Fact Sheet, please see\nwww.cvdvaccine.com. WHAT YOU NEED TO KNOW BEFORE YOUR CHILD GETS ANY OF THESE\nVACCINES\nWHAT IS COVID-19? COVID-19 disease is caused by a coronavirus called SARS-CoV-2. You can get\nCOVID-19 through contact with another person who has the virus.","4375":"These changes occur over\ntime and can lead to the emergence of variants that may have new characteristics, including different ways\nof spreading. Learn more about what you can do to protect yourself and others. COVID-19 and Animals\nCOVID-19 can spread from people to animals in some situations. Pet cats and dogs can sometimes become infected by\npeople with COVID-19. Learn what you should do if you have pets. COVID-19 County Check\nFind community levels and prevention steps by county. Data updated weekly.","499":"On April 19, 2021, the population metrics for 65+ Texas residents dropped from the metrics reported on April 18, 2021. This was due to a schedule delay in updating the calculation used to infer the 65+ population metrics. The issue was\nresolved on April 19, 2021 and metrics accurately reflect the total doses administered. This did not affect any other\nstates, but did affect the total US estimates for 65+. On April 13, 2021, the total doses administered data posted to Tracker inadvertently included 221,081 duplicate doses\naffecting Vermont (6,605), Georgia (102,711), Illinois (64,886), West Virginia (60), and Maine (46,819).","9638":"\u2022 For certain moderately or severely immunocompromised persons:\no Ages 12 years and older who received primary vaccination with certain non-FDA authorized or\napproved COVID-19 vaccines should receive an additional primary dose of the COVID-19\nvaccine by Pfizer-BioNTech. o Ages 18 years and older who received primary vaccination with the Janssen COVID-19 Vaccine\nshould receive an additional dose with the COVID-19 vaccine by Pfizer-BioNTech. o Ages 12 years and older who received certain therapies (indicated below) and received\nprimary dose(s) of COVID-19 vaccine prior to or during treatment should be revaccinated with\nthe COVID-19 vaccine by Pfizer-BioNTech for any doses received before or during treatment.","2730":"10\/30\/22, 9:42 AM Caring for People with Post-COVID Conditions | CDC\nEspa\u00f1ol | Other Languages\nCaring for People with Post-COVID Conditions\nHaving a post-COVID condition or supporting someone with a post-COVID condition can be challenging. It can be difficult to\ncare for yourself or loved ones, especially when there are few or no immediate answers or solutions. However, there are ways\nto help relieve some of the additional burdens of experiencing or caring for someone with a new and unknown condition. If you care for someone, remember to take steps to protect yourself and others from COVID-19. This information is intended for a general audience.","3441":"The two approved formulations of COMIRNATY and the two FDA-\nauthorized formulations of the Pfizer-BioNTech COVID-19 Vaccine for people ages 12 years and older are the same\nformulations, and vials of the BLA-compliant vaccine may bear the name \u201cPfizer-BioNTech COVID-19 Vaccine.\u201d The FDA-\napproved COMIRNATY (COVID-19 Vaccine, mRNA) and the emergency use authorized formulations of Pfizer-BioNTech\nCOVID-19 Vaccine for people ages 12 years and older (gray cap\/label vials ), when prepared according to their\nrespective instructions for use, can be used interchangeably without presenting any safety or effectiveness concerns. 3.","330":"On January 25, 2022, Idaho began providing vaccine data for recipients younger than 18 years of age to CDC. This\nresulted in an increase of 177,996 doses administered. On January 20, 2022, data review and reporting adjustments resulted in a decrease of 12,298 vaccine doses\nadministered in Hawaii since December 14, 2020. On January 19, 2022, CDC changed the address algorithm for the Bureau of Prisons (BOP) and Department of Defense\n(DOD) to better align vaccine administration counts with the residential county of the recipient instead of the county\nwhere vaccine was administered.","2709":"Clean other surfaces in your home when they are visibly dirty or as needed. Clean them more frequently if people\nin your household are more likely to get very sick from COVID-19. Disinfect if certain conditions apply. Clean surfaces using a product suitable for each surface, following instructions on the product label. When Someone Is Sick\nIf someone in your home is sick or someone who has COVID-19 has been in your home in the last 24 hours, clean and\ndisinfect your home. Disinfecting removes germs and reduces their spread. Immediately after disinfecting, wash your\nhands with soap and water for 20 seconds.","1508":"Mask Distribution Initiative (January 20, 2022)\nAs a subcomponent of the CDC COVID-19 Vaccination Program, designated enrolled providers are authorized to\nreceive from the Department of Health and Human Services Strategic National Stockpile (SNS) N95 masks (also\nknown as respirators) that are approved by the National Institute for Occupational Safety and Health (NIOSH) for free\ndistribution to people in the United States. 1. Designated providers will provide shipping and other necessary information to the SNS to receive shipments of\nthe masks, in addition to the name, title, and contact information for the individual who will coordinate the\nprovider\u2019s participation in this initiative.","4712":"The highest risk has\nbeen observed in people ages 40\u201364 years, with symptoms of GBS beginning within 42 days after Janssen COVID-19\nvaccination; most GBS reports have been in males.","2057":"Additionally, if you have COVID-19 during pregnancy, you are at increased\nrisk of complications that can affect your pregnancy and developing baby. Getting a COVID-19 vaccine can help protect you and your baby from serious health problems from COVID-\n19. People who are pregnant should stay up to date with their COVID-19 vaccines, including getting a COVID-19\nbooster shot when it\u2019s time to get one. Evidence continues to build showing that:\nCOVID-19 vaccination during pregnancy is safe and effective. COVID-19 vaccines are not associated with fertility problems in women or men.","7413":"An authorized person may\nattest on behalf of any passenger who is unable sign their own attestation (e.g., because they are too young, or because of\nphysical or mental impairment). Children under 2 years of age do not need to complete an attestation.","9443":"Serious and unexpected side\neffects may occur. The possible side effects of these vaccines are still being studied. WHAT SHOULD I DO ABOUT SIDE EFFECTS? If you or your child experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital. Call the vaccination provider or your or your child\u2019s healthcare provider if you or your child\nhave any side effects that bother you or do not go away. Report vaccine side effects to FDA\/CDC Vaccine Adverse Event Reporting System\n(VAERS). The VAERS toll-free number is 1-800-822-7967 or report online to\nhttps:\/\/vaers.hhs.gov\/reportevent.html.","7226":"FDA has authorized Pfizer-BioNTech\nCOVID-19 Vaccine, Bivalent to provide better protection against COVID-19 caused by\nthe Omicron variant of SARS-CoV-2. The duration of protection against COVID-19 is currently unknown. WHAT ARE THE RISKS OF THESE VACCINES? There is a remote chance that these vaccines could cause a severe allergic reaction. A\nsevere allergic reaction would usually occur within a few minutes to 1 hour after getting\na dose. For this reason, your vaccination provider may ask you to stay at the place\nwhere you received your vaccine for monitoring after vaccination.","4057":"Data show that an mRNA booster increases the immune response, which improves protection against getting a serious\nCOVID-19 infection. CDC recommends COVID-19 vaccines for everyone ages 6 months and older, and boosters for everyone 5 years and\nolder, if eligible. Learn more about COVID-19 vaccine recommendations, including recommendations for people who are moderately or\nseverely immunocompromised. Use CDC\u2019s COVID-19 Booster Tool to learn if and when you can get boosters to stay up to\ndate with your COVID-19 vaccines. Do I need a COVID-19 vaccine booster? \uf1aa\n\uf20c\nYes. COVID-19 vaccines are working well to prevent severe illness, hospitalization, and death.","2100":"Recent data show that completing a two-dose primary mRNA COVID-19 vaccine series during pregnancy can help\nprotect babies younger than age 6 months from hospitalization due to COVID-19. In these reports, the majority of\nbabies hospitalized with COVID-19 were born to pregnant people who were not vaccinated during pregnancy. Another study found that receiving a booster dose with an mRNA COVID-19 vaccine during pregnancy significantly\nincreased the levels of antibodies found in umbilical cord blood. This means that getting a COVID-19 booster during\npregnancy can help further protect babies against COVID-19. No safety concerns were found in animal studies.","5728":"The COVID-19\nvaccine by Pfizer-BioNTech can also be used under EUI for similar uses as an alternative mRNA COVID-19\nvaccine (see the Pfizer-BioNTech EUI Fact Sheet for Recipients), and the same or similar recommendations\nin this EUI also apply to the use of the COVID-19 vaccine by Pfizer-BioNTech under EUI. What is COVID-19? Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a coronavirus called SARS-CoV-2. It\nis predominantly a respiratory illness that can also affect other organs. People with SARS-CoV-2 infection\nhave reported a wide range of symptoms, from no symptoms to severe illness leading to death.","4147":"All vaccine development steps were taken to ensure COVID-19 vaccine safety and effectiveness,\nAre COVID-19 vaccines safe even though the vaccines were developed rapidly? \uf1aa\f10\/30\/22, 9:18 AM Frequently Asked Questions about COVID-19 Vaccination | CDC\ny p p y ,\nincluding:\nClinical Trials \u2013 All vaccines in the United States must go through three phases of clinical trials to ensure they are\nsafe and effective. The phases overlapped to speed up the process, but all phases were completed. Authorization or Approval \u2013 Before vaccines are available to people, the U.S. Food and Drug Administration (FDA)\nreviews data from clinical trials.","1393":"What is the guidance for a use of the monovalent Novavax COVID-19 vaccine for a booster dose? \uf1aa\nPeople who are Moderately or Severely Immunocompromised\nYes. For COVID-19 vaccination guidance for people who are moderately or severely immunocompromised people, please\nrefer to:\nGuidance for COVID-19 vaccination for people who are moderately or severely immunocompromised\nCOVID-19 Vaccines for Moderately or Severely Immunocompromised People\nAre there special considerations for vaccinating people who are moderately or severely\nimmunocompromised? \uf1aa\nPeople can self-attest to their moderately or severely immunocompromised status and should be vaccinated according to\nthe schedule for people who are moderately or severely immunocompromised.","8299":"If you are experiencing any of these symptoms, consider the following options:\nGet tested for COVID-19\nIf you have already tested positive for COVID-19, learn more about CDC\u2019s isolation guidance\n\u2022\n\u2022\nWhen to Seek Emergency Medical Attention\nLook for emergency warning signs* for COVID 19:\nTrouble breathing\nPersistent pain or pressure in the chest\nNew confusion\nInability to wake or stay awake\nPale, gray, or blue-colored skin, lips, or nail beds, depending on skin tone\nIf someone is showing any of these signs, call 911 or call ahead to your local emergency facility. Notify the operator that\nyou are seeking care for someone who has or may have COVID-19.","9688":"Do not administer the COVID-19 vaccine by Pfizer-BioNTech to persons with known history of a severe allergic\nreaction (e.g., anaphylaxis) to a previous dose or any component of the vaccine (see Contraindications, and\nWarnings and Precautions sections in the Comirnaty package insert or Full EUA Prescribing Information as well\nas CDC\u2019s Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the\nUnited States for additional considerations). What information should be provided to persons receiving a primary or additional dose of the COVID-19\nvaccine by Pfizer-BioNTech as described in the EUI? \u2022 Provide the EUI Fact Sheet for Recipients and Caregivers.","1976":"Tribal nations\nIndian Health Service (IHS) Vaccine Safety Monitoring Systems\nPassive Surveillance\nVaccine Adverse Event Reporting System (VAERS)\nVAERS functionality permits analysis of adverse events (AE) in IHS system of care\nIHS Safety Tracking & Response System\nFederal and participating tribal sites\nWorker-related AEs and vaccine administration errors\nActive Surveillance\nIHS Sentinel Survey\nBiweekly survey of AEs, including vaccine administration errors\n58 federal and tribal sites representing IHS Areas\nSupports reporting to VAERS\n\u2022 \uf209\n\u2022\n\u2022\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022\n-\n\u2022\n-\n-\n\u2022\n-\n-\n-\nRelated Pages\f10\/30\/22, 9:32 AM COVID-19 Vaccine Reporting Systems | CDC\ng\nAllergic Reactions after Getting a COVID-19 Vaccine\u200b\n\u203a\nSafety of COVID-19 Vaccines\n\u203a\nDeveloping COVID-19 Vaccines\n\u203a\nMore Information\nCDC\u2019s Vaccine Safety Information\nEnsuring the Safety of Vaccines in the United States\u200b\nACIP Work Groups\nCOVID-19 Vaccine Safety Publications\nLast Updated July 19, 2022","3408":"Evaluation of people who develop MIS-C or MIS-A after COVID-19 vaccination\nIn the rare instance a person develops MIS-C, MIS-A, or a similar clinical illness after receipt of COVID-19 vaccine, referral to a\nspecialist in infectious diseases, rheumatology, and\/or cardiology should be considered. Assessment should include testing for current or prior SARS-CoV-2 infection, in addition to other potential etiologies as\nclinically indicated. Obtaining a serum sample before any intravenous immune globulin (IVIG) is administered is highly\nrecommended so that the sample can be tested for SARS-CoV-2 anti-nucleocapsid antibody, which may require a reference\nlaboratory. Treatment should not be delayed until test results are available.","8143":"10\/30\/22, 9:27 AM Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC\nEspa\u00f1ol | Other Languages\nStay Up to Date with COVID-19 Vaccines Including\nBoosters\nRecommendations for Novavax booster doses were recently updated. Read more. What You Need to Know\nUpdated (bivalent) boosters became available September 2, 2022. CDC recommends everyone stay up to date with COVID-19 vaccines for their age group:\nChildren and teens ages 6 months\u201317 years\nAdults ages 18 years and older\nGetting a COVID-19 vaccine after you recover from COVID-19 infection provides added protection against COVID-\n19.","7085":"To reach MotherToBaby:\nChat live or send an email MotherToBaby\n\u2022\n\u2022 \uf209\nReducing Your Risk of Getting COVID-19\nIt is especially important for people who are or were recently pregnant, and those who live\nor visit with them, to take steps to protect themselves and others from getting COVID-19. Limit in-person interactions with people who might have been exposed to COVID-19,\nincluding people within your household, as much as possible. If you or someone in your\nhousehold is sick with COVID-19, follow guidance for isolation. Important Ways to Slow the Spread of COVID-19\nGet vaccinated and stay up to date on your COVID-19 vaccines. Find a\nvaccine.","4644":"10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nEspa\u00f1ol | Other Languages\nVaccines & Immunizations\nVaccines & Immunizations Home\nInterim Clinical Considerations for Use of COVID-19\nVaccines: Appendices, References, and Previous\nUpdates\nSummary of recent changes (last updated October 19, 2022):\nGuidance for use of a monovalent Novavax COVID-19 booster dose in people ages 18 years and older in limited\nsituations\nJanssen COVID-19 Vaccine is authorized for adults ages 18 years and older for the primary series dose and 1 booster dose in\ncertain limited situations due to the risk of thrombosis with thrombocytopenia syndrome (TTS) following receipt of the\nvaccine:\nWhen there is a contraindication to mRNA (i.e., Moderna or Pfizer-BioNTech) and Novavax COVID-19 vaccines (e.g.,\nsevere allergic reaction after a previous dose or to a component of an mRNA COVID-19 vaccine) (see Table 4)\nWhen a person would otherwise remain unvaccinated for COVID-19 due to limited access to other COVID-19 vaccines\nWhen a person wants to receive Janssen COVID-19 Vaccine despite the safety concerns identified\nCOVID-19 vaccine recipients should be informed that Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines are\nrecommended over Janssen COVID-19 Vaccine.","8468":"COVID-19 Vaccines Are Free\nTravel Health Alerts\nCDC\u2019s public health messaging system offers up-to-date messages to travelers\nat specific airports, seaports, and land borders where most international\ntravelers enter or leave the United States. This is the latest information posted by CDC, in partnership with US Customs\nand Border Protection (CBP), the Transportation Security Administration (TSA)\nand other port-of-entry partners.","5172":"Summary of Recent Changes\nUpdates as of April 18, 2022\nAs a result of a court order, effective immediately and as of April 18, 2022, CDC\u2019s January 29, 2021 Order requiring\nmasks on public transportation conveyances and at transportation hubs is no longer in effect. Therefore, CDC will not\nenforce the Order. CDC continues to recommend that people wear high-quality masks in indoor public transportation\nsettings at this time.","9583":"The CDC-issued EUI provide information on the following uses of the COVID-19 vaccine by\nPfizer-BioNTech for:\n\u2022 A longer interval of 3\u20138 weeks between the first and second primary dose of Pfizer-BioNTech COVID-\n19 vaccine for persons ages 12 years and older, particularly for individuals at higher risk of mRNA\nCOVID-19 vaccine-associated myocarditis.","5806":"Receiving the second primary dose of the COVID-19 vaccine by Moderna 4\u20138 weeks after the first dose\nmay reduce the risk of myocarditis and result in greater immune response and better protection against\nCOVID-19. Primary, additional, and\/or booster doses of the COVID-19 vaccine by Moderna as described\nunder EUI may help to increase immune response in people, which could improve protection against\nCOVID-19. Similarly, for individuals who received the Janssen Vaccine for primary vaccination, an additional\nprimary or second booster dose of the COVID-19 vaccine by Moderna could improve protection against\nCOVID-19. The COVID-19 vaccine by Moderna may not protect everyone.","1627":"It shall be cause for immediate termination from the CDC COVID-19 Vaccination Program and\ncriminal or civil prosecution for violation of 18 U.S.C. \u00a7 1001 or other relevant federal statutes. Prioritization for receipt of COVID-19 vaccine in the early months of the CDC COVID-19 Vaccination Program was\nnecessary given limited supplies of vaccine. Supplies of COVID-19 vaccine doses are rapidly increasing. Effective May\n1, 2021, in conformance with the Secretary\u2019s March 17, 2021 directive to transition beyond priority groups, all\npersons qualified under the terms of the applicable COVID-19 vaccine Emergency Use Authorization are eligible to be\nvaccinated.","7804":"\u2022\n\u2022\n\u2022\n\u2022\n\uf6e5 When To Take an At-Home COVID-19 Test\nTest Yourself If\u2026 Timing\nYou have any COVID-19 symptoms Immediately\nYou were exposed to someone with COVID-19 At least 5 days after your exposure\nIf you test negative for COVID-19, consider testing\nagain 1 to 2 days after your first test\nYou are going to an indoor event or a gathering Immediately before the gathering, or as close to\nthe time of the event as possible\nThis is especially important before gathering with\nindividuals at risk of severe disease, older adults,\nthose who are immunocompromised, or people\nwho are not up to date on their COVID-19\nvaccines, including children who cannot get\nvaccinated yet.","3975":"COVID-19 Vaccine Distribution and Tracking\nVaccine Data Reporting\nDistribution is the process of shipping vaccines to provider locations, as directed by jurisdictions, federal agencies, and\npharmacy partners who are enrolled in the CDC COVID-19 Vaccination Provider Program. Vaccine delivery to provider\nlocations is the last part of the distribution process. How are COVID-19 vaccines distributed? \uf1aa\nJurisdictions (states, territories, tribes, and local entities), federal agencies, and pharmacy partners use the Vaccine\nTracking System (VTrckS) to order vaccines from the federal government. VTrckS records information such as vaccine\nmanufacturer, provider data, orders, shipments, and inventory.","3671":"Find a COVID-19 testing location near you or use a self-test. If you already had COVID-19 within the past 90 days, see specific testing recommendations. Monitor yourself for COVID-19 symptoms. Follow additional guidance if you know you were exposed to a person with COVID-19. Follow all state, tribal, local, and territorial recommendations or requirements after travel. If you are going to be around someone who is at higher risk of getting very sick with COVID-19, consider\nadditional precautions. \uf209\nIf Your Test is Positive or You Develop COVID-19 Symptoms\nIsolate yourself to protect others from getting infected.","2156":"Learn more at Possible Side Effects After Getting a COVID-19 Vaccine. Although rare, some people have had severe allergic reactions after receiving a COVID-19 vaccine. Talk with your healthcare\nprovider if you have a history of allergic reaction to any other vaccine or injectable therapy (intramuscular, intravenous, or\nsubcutaneous). Key considerations you can discuss with your healthcare provider include:\nThe benefits of vaccination\nThe unknown risks of developing a severe allergic reaction\nIf you have an allergic reaction after receiving a COVID-19 vaccine during pregnancy, you can receive treatment for it.","2253":"These\nmedical conditions and living situations can make residents more likely to\nbe infected by the virus that causes COVID-19 and to become seriously ill\nfrom COVID-19. Children and adolescents with intellectual and developmental disabilities living in any type of shared setting, including\nintermediate care facilities and group homes, are also considered LTC residents. This means they are also more likely to be\ninfected or become seriously ill from COVID-19. If you live in a LTC setting, you can help protect yourself and the people around you by getting a COVID-19 vaccine as soon as\npossible.","5188":"How is CDC using my information? The information you provide will contribute to what we know about the safety of COVID-19 vaccines, which helps us get a\nmore complete picture of the risks and benefits of COVID-19 vaccination. What You Need to Know\nCDC is conducting surveys of patients (or their parents or guardians) and healthcare providers to gather\ninformation about myocarditis after COVID-19 vaccination. CDC is contacting people who meet the case definition for myocarditis following COVID-19 vaccination.","1753":"Requirements for Quality Assurance Monitoring (Updated 10\/18\/2021)\n\uf1aa\nAll organizations and providers\nparticipating in the CDC COVID-19\nVaccination Program:\nmust administer COVID-19 Vaccine at\nno out-of-pocket cost to the recipient\nmay not deny anyone vaccination based on the vaccine recipient\u2019s coverage status or network status\nmay not charge an office visit or other fee if COVID-19 vaccination is the sole medical service provided\nmay not require additional medical services to receive COVID-19 vaccination\nmay seek appropriate reimbursement from a program or plan that covers COVID-19 Vaccine administration fees for the\nvaccine recipient, such as:\nvaccine recipient\u2019s private insurance company\nMedicare or Medicaid reimbursement\nmay not seek any reimbursement, including through balance billing, from the vaccine recipient\nRequirements for COVID-19 Vaccination Program Providers\nCOVID-19 Vaccine is Provided at 100% No Cost to Recipients\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nIndividuals aware of any potential violations of these requirements are encouraged to report them to the Office of the\nInspector General, U.S. Department of Health and Human Services, by calling 1-800-HHS-TIPS or the website TIPS.HHS.GOV\n.","5028":"New section added on Overview of COVID-19 vaccines recommendations. Updated guidance in section on COVID-19 vaccine dosage and schedule. Updated guidance in section on People vaccinated for prevention of COVID-19 outside the United States. Updated guidance in section on COVID-19 vaccination and SARS-CoV-2 infection for People with prior or current SARS-\nCoV-2 infection; People with a history of multisystem inflammatory syndrome in children (MIS-C) or adults (MIS-A);\nPeople who received passive antibody products; and Vaccinated people who subsequently develop COVID-19. New guidance on Considerations for COVID-19 revaccination in the section on Considerations for COVID-19\nvaccination in moderately and severely immunocompromised people.","7986":"This did not positively impact\nGoogle searches, which showed a decreasing interest in booster information, from a recent peak at the end of March 2022.66,67\nPerceptions, Concerns, and Threats to Vaccine Confidence\n\u0083 Competing national events,68 continued rollback of mitigation measures,69 and consistently decreasing coverage from social\nmedia, news media, and political sources70,71,72 may lessen the frequency and impact of COVID-19-specific information for\nconsumers.","9912":"\u25cb Anaphylaxis after non-COVID-19 vaccines or injectable\ntherapies\n\u0083 All other people\nHealthcare professionals should be familiar with identifying severe\nallergic reactions, including anaphylaxis, and be competent in\ntreating these events at the time of vaccine administration. See\nManagement of Anaphylaxis at COVID-19 Vaccination Sites | CDC\nfor guidance. COVID-19 vaccines are administered by IM injection and can be\ngiven at the same clinical visit as other routinely administered\nvaccines using separate injection sites. Other routine vaccines\ncan also be administered any time before or after COVID-19\nvaccination. Orthopoxvirus vaccines (monkey pox) have additional\nconsiderations. See guidance section 8 Clinical Guidance. 1. How old is the person to be vaccinated?","4412":"10\/30\/22, 9:39 AM How to Protect Yourself and Others | CDC\nEspa\u00f1ol | Other Languages\nHow to Protect Yourself and Others\nCOVID-19 Prevention Actions\nThere are many ways your actions can help protect you, your household, and your community from severe illness from\nCOVID-19. CDC\u2019s COVID-19 Community Levels provide information about the amount of severe illness in the community\nwhere you are located to help you decide when to take action to protect yourself and others. COVID-19 County Check\nFind community levels and prevention steps by county. Data updated weekly.","6211":"10\/30\/22, 9:34 AM Myths and Facts about COVID-19 Vaccines | CDC\nEspa\u00f1ol | Other Languages\nMyths and Facts about COVID-19 Vaccines\nAccurate vaccine information is critical and can help stop common myths and rumors. It can be difficult to know which\nsources of information you can trust. Learn more about finding credible vaccine information. Bust Common Myths and Learn the Facts\nBelow are myths and facts about COVID-19 vaccination. Have more questions? Visit FAQs about Vaccination. MYTH: The ingredients in COVID-19 vaccines are dangerous. FACT: Nearly all the ingredients in COVID-19 vaccines are also ingredients in many foods \u2013 fats, sugars, and\nsalts.","3630":"If traveling to an area with high or medium COVID-19 Community Levels, and you are, live with, or are visiting\nsomeone who is at higher risk of getting very sick, learn how to protect yourself and them. Make sure you understand and follow all state, tribal, local, and territorial travel restrictions, including proper mask\nwearing, proof of vaccination, or testing requirements. For up-to-date information and travel guidance, check the state, tribal, local and territorial health\ndepartment\u2019s website where you are, along your route, and where you are going. If traveling by air, check if your airline requires any testing, vaccination, or other documents.","9305":"\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nChildren and Teens Who Have Already Had COVID-19 Should Still\nGet Vaccinated\nOngoing study of data show evidence that people can get added protection by getting vaccinated after having been infected\nwith the virus that causes COVID-19. Even if a child has had COVID-19, they should still get vaccinated. For children who have\nbeen infected with COVID-19, their next dose can be delayed 3 months from when symptoms started or, if they did not have\nsymptoms, when they received a positive test. This possible delay can happen with a primary dose or a booster dose.","9853":"Fact Sheet for Healthcare Providers Administering Vaccine. Emergency Use Authorization of the Pfizer-\nBioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019, Revised January 3, 2022\nGruber, W. BNT162b2 [COMIRNATY\u00ae (COVID-19 Vaccine, mRNA)] Booster (Third) Dose. Advisory Committee\non Immunization Practices meeting, September 22, 2021:\nGrunau B et al. A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute\nRespiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval. Clin Infect Dis. 2021 Nov 30:\nJoint Committee on Vaccination and Immunisation (JCVI). JCVI statement regarding a COVID-19 booster\nvaccine programme for winter 2021 to 2022. London (United Kingdom): Department of Health & Social Care;\nprogramme-for-winter-2021-to-2022.","9279":"Some examples of\nconditions that can make children more likely to get severe COVID-19 include:\nAsthma or chronic lung disease\nDiabetes\nObesity\nSickle cell disease\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:34 AM Why Children and Teens Should Get Vaccinated Against COVID-19 | CDC\nHowever, those without underlying medical conditions can also experience severe illness and be hospitalized. In fact,\napproximately 1 in 3 children younger than 18 years old hospitalized with COVID-19 have no underlying conditions. Read the data about risk factors for severe COVID-19 in children published in Pediatrics, childhood COVID-19-related\nhospitalizations published in MMWR, and weekly summaries of COVID-19 hospitalization data through COVID-NET.","5789":"Limited data are available on use of the COVID-19 vaccine by Moderna as an additional primary dose in\npeople who completed their primary vaccination with a non-FDA authorized or approved COVID-19\nvaccine, or as an additional dose for individuals who received Janssen COVID-19 Vaccine for primary\nvaccination. Side effects of the COVID-19 vaccine by Moderna include injection site pain, tenderness and\nswelling of the lymph nodes in the same arm of the injection, swelling (hardness), and redness; fatigue;\nheadache; muscle pain; joint pain; chills; nausea and vomiting; fever; and rash.","4933":"Table of Contents \uf426\nReferences and Previous Updates\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine \u2014 United States, December 2020\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Moderna COVID-19 Vaccine\n\u2014 United States, December 2020\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Janssen COVID-19 Vaccine \u2014\nUnited States, February 2021\nUpdated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson\n& Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine\nRecipients\u2014United States, April 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Adolescents Aged 12\u201315 years \u2014 United States, May 2021\nUse of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory\nCommittee on Immunization Practices \u2014 United States, June 2021\nUse of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and\nmRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization\nPractices \u2014 United States, July 2021\nUse of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged \u226516 Years: Recommendations of the Advisory Committee\non Immunization Practices \u2014 United States, September 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendations for Additional Primary and Booster\nDoses of COVID-19 Vaccines \u2014 United States, 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Children Aged 5\u201311 Years \u2014 United States, November 2021\nUse of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory\nCommittee on Immunization Practices \u2014 United States, December 2021\nThe Advisory Committee on Immunization Practices\u2019 Recommendation for Use of Moderna COVID-19 Vaccine in Adults\nAged \u226518 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-\nReferences\n\uf1aa\n\uf20c\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\n19 Vaccines \u2014 United States, February 2022\nInterim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-\nBioNTech COVID-19 Vaccines in Children Aged 6 Months\u20135 Years \u2014 United States, June 2022\nInterim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19\nVaccine in Persons Aged \u226518 years \u2014 United States, July 2022.","6710":"For more information on coping with a disaster or traumatic event, visit\n\u2022\n\u2022\f10\/30\/22, 9:39 AM People with Moderate to Severe Asthma | CDC\np g ,\nStress and Coping | COVID-19 | CDC\nCoping with a Disaster or Traumatic Event | CDC Emergency Preparedness & Response\nPatient resources\nEXHALE Guide for People With Asthma, Their Families, and Their Caregivers [1.5 MB, 8 pages]\nAllergy and Asthma Network\nAsthma and Allergy Foundation of America\nNational Environmental Education Foundation\nAdditional resources for schools and childcare programs\nFor information on administering asthma medication in schools, K-12 Schools and Childcare Programs\n-\n-\n\u2022 \uf20c\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022\nLast Updated Apr. 7, 2022","3900":"10\/30\/22, 9:38 AM Factors That Affect Your Risk of Getting Very Sick from COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nFactors That Affect Your Risk of Getting Very Sick from\nVaccination, past infection, or timely access to testing and treatment can help protect you from getting very sick if you get\nCOVID-19. However, some people are more likely than others to get very sick if they get COVID-19. This includes people who\nare older, are immunocompromised, have certain disabilities, or have underlying health conditions. Understanding your\nCOVID-19 risk and the risks that might affect others can help you make decisions to protect yourself and others.","9962":"COVID-19 vaccines may be administered to people\nwith underlying medical conditions, such as HIV infection\nor other immunocompromising conditions, or who take\nimmunosuppressive medications or therapies, and who have no\ncontraindications to vaccination. People can self-report if they\nare moderately or severely immunocompromised. Vaccinators\nshould not deny COVID-19 vaccination to a person due to lack of\ndocumentation of immune status. Use the Interim Immunization Schedule for Ages 6 Months\nand Older to schedule doses\fPrevaccination Checklist\nfor COVID-19 Vaccines\nInformation for Healthcare Professionals\n5. Has the person to be vaccinated received a hematopoietic cell transplant (HCT) or CAR-T-cell\ntherapy since receiving COVID-19 vaccine?","3723":"\u25aa Updated on February 11, 2022, to allow an additional Pfizer-BioNTech COVID-19 vaccine dose in\npersons ages 18 years and older with certain immunocompromising conditions who received\nprimary vaccination with the Janssen COVID-19 vaccine; revaccination of certain moderately or\nseverely immunocompromised persons ages 12 years and older who received certain therapies\n(i.e., hematopoietic cell transplant (HCT) or chimeric antigen receptor (CAR)-T-cell therapy) and\nreceived COVID-19 vaccine prior to or during treatment; and the ability of healthcare providers\nto administer the Pfizer-BioNTech COVID-19 vaccine outside of the FDA-authorized or FDA-\napproved labeling and CDC recommended dosing intervals based on clinical judgment when the\nbenefits of vaccination are deemed to outweigh the potential and unknown risks.","1496":"At this time, all COVID-19 vaccine in the United States has been purchased by the federal government for administration\nexclusively by enrolled providers through the CDC COVID-19 Vaccination Program. How to Enroll as a COVID-19\nVaccination Provider\n\uf2a1\nFAQs for Private & Public Healthcare\nProviders About Implementing the\nCDC COVID-19 Vaccination Program\nin Provider Practices\n\uf2a1\nVaccines for Children Program vs.\nCDC COVID-19 Vaccination Program\n\uf2a1\nFAQs for Federal Retail Pharmacy\nProgram Participants\n\uf2a1\nCOVID-19 vaccination providers participating in the CDC COVID-19 Vaccination Program are required to sign a CDC\nCOVID-19 Vaccination Program Provider Agreement.","5367":"\u2022 Difficulty with facial movements, including speaking, chewing, or swallowing. \u2022 Double vision or inability to move eyes. \u2022 Difficulty with bladder control or bowel function. These may not be all the possible side effects of the Janssen COVID-19 Vaccine. Serious and\nunexpected effects may occur. The Janssen COVID-19 Vaccine is still being studied in clinical\ntrials. WHAT SHOULD I DO ABOUT SIDE EFFECTS? If you experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital. Call the vaccination provider or your healthcare provider if you have any side effects that bother\nyou or do not go away.","6705":"Cleaning and Disinfecting Your Home\n\u2022\n-\n-\n-\n-\n-\n\u2022\n-\n\uf209\n\u2022\n-\n-\n\u2022\n-\n-\n-\n-\n-\n-\n-\n\u2022\n-\n-\n- \uf209\n\uf209\nTake steps to help yourself cope with stress and anxiety\nIt is natural for some people to feel concerned or stressed as more cases of COVID-19 are discovered and our\ncommunities act to combat the spread of disease. Strong emotions can trigger an asthma attack.","1240":"Additionally, COVID-19 vaccine is free of charge for everyone. Increasing the number of places where people can get\nvaccinated for COVID-19 will help ensure more people are protected, ultimately helping us end this pandemic. The FRPP is designed to use the strength and expertise of pharmacy partners to help rapidly and conveniently vaccinate the\nAmerican public. Through the program, certain participating retail pharmacies nationwide receive COVID-19 vaccine supply\ndirectly from the federal government, and then provide vaccinations to eligible individuals at no cost.","988":"A single, negative antigen test result does not rule out infection. To best detect\ninfection, a negative antigen test should be repeated at least 48 hours apart (known as serial testing). Sometimes a\nfollow-up NAAT may be recommended to confirm an antigen test result. *Self-tests, or at-home tests, are usually antigen tests that can be taken anywhere without having to go to a specific testing\nsite. Follow FDA and manufacturer\u2019s instructions, including for the number of times you may need to test. Multiple negative\ntest results increase the confidence that you are not infected with the virus that causes COVID-19.","1868":"National Protocol\nOutcome: Household transmission among community members confirmed with SARS-CoV-2\nPopulation: Households of community members with positive SARS-CoV-2 tests recruited from national commercial\nlaboratories\nExternal partner: Westat\n\uf209 \uf20c\nTest-negative prospective case control\n\uf1aa\nIncreasing Community Access to Testing (ICATT) program\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Anyone seeking testing at a pharmacy\nParticipating sites: 8,319 locations across the United States and its territories\nIVY\nInfluenza and Other Viruses in the Acutely Ill (IVY) network\nOutcome: Hospitalization with SARS-CoV-2\nPopulation: Hospitalized adults\nParticipating Sites: 21 large adult hospitals in 20 cities in 18 states:\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nCalifornia\nColorado\nFlorida\nGeorgia\nIowa\nMaryland\nMassachusetts\nMichigan\nMinnesota\nMissouri\nNew York\nNorth Carolina\nOhio\nOregon\nTennessee\nTexas\nUtah\nWashington\nPReventing Emerging Infections through Vaccine EffectiveNess Testing (PREVENT ) Sites\nOutcome: Symptomatic SARS-CoV-2 infections\nPopulation: Healthcare personnel\nParticipating Sites\nBaystate Medical Center, Springfield, MA\nJackson Memorial Hospital, Miami, FL\nOlive View-UCLA Medical Center, Los Angeles, CA\nThomas Jefferson University Hospital, Philadelphia, PA\nTruman Medical Centers, Kansas City, MO\nUniversity of Alabama Hospital, Birmingham, AL\nCommunity Regional Medical Center\/ UCSF, Fresno, CA\nUniversity of Chicago Medical Center, Chicago, IL\nUniversity of Iowa Hospitals and Clinics, Iowa City, IA\nUniversity of Massachusetts Memorial Medical Center, Worcester, MA\nLCMC Health Hospitals, New Orleans, LA\nUniversity of Mississippi Medical Center, Jackson, MS\nUniversity of Texas Southwestern Medical Center and Parkland Hospital, Dallas, TX\nUniversity of Washington Hospitals, Seattle, WA\nValleywise Health Medical Center, Phoenix, AZ.","6964":"The COVID-19 vaccine by Pfizer-BioNTech has been shown in clinical studies to be effective in preventing\nCOVID-19. Receiving the second primary dose of the COVID-19 vaccine by Pfizer-BioNTech 3\u20138 weeks after\nthe first dose may reduce the risk of myocarditis and result in greater immune response and better\nprotection against COVID-19. Primary, additional, and\/or booster doses of the COVID-19 vaccine by Pfizer-\nBioNTech as described under EUI may help to increase immune response in people, which could improve\nprotection against COVID-19.","2278":"Residents who receive a COVID-19 vaccine (or their medical proxy) will also receive a fact sheet before vaccination. The\nfact sheet explains the risks and benefits of COVID-19 vaccination. Some COVID-19 vaccination providers may require written, email, or verbal consent from recipients before getting\nvaccinated. This is at the provider\u2019s discretion; written consent is not required by federal law for COVID-19 vaccination in\nthe United States (U.S.). Residents (or their medical proxies) will receive a\u202fvaccination card\u202for printout that tells them which COVID-19 vaccine\nthey received and the date they received it. This should also be recorded in their medical chart.","7318":"Ongoing studies of COVID-19 are\nhelping us understand:\nHow often reinfections occur\nWho is at higher risk of reinfection\nHow soon reinfections take place after a previous infection\nThe severity (how serious the infection is) of reinfections compared with initial (the first) infections\nThe risk of transmission to others after reinfection\nWhat CDC is doing\nCDC continues to work to better understand reinfections with COVID-19 to inform public health action. CDC is using a range\nof data sources to assess how often reinfections occur, who is most at risk for reinfection, and the risk of reinfection when\nthere is community spread of Omicron or other virus variants.","5182":"10\/30\/22, 9:31 AM Investigating Long-Term Effects of Myocarditis | CDC\nEspa\u00f1ol | Other Languages\nInvestigating Long-Term Effects of Myocarditis\nHow CDC Is Investigating Myocarditis Health Effects after COVID-19 Vaccination\nParticipating in the Survey\nHow did CDC get my contact information? CDC got your contact information from the Vaccine Adverse Event Reporting System (VAERS ), a secure system that\ncontains information needed to check in with patients to see how they are recovering after they experience a serious event\nfollowing vaccination. The U.S. Food and Drug Administration (FDA) requires healthcare professionals to report to VAERS certain serious adverse\nevents and hospitalizations that occur after COVID-19 vaccination.","7841":"Related Questions\nPositive results from self-tests are highly reliable. Negative results from self-tests do not rule out SARS-CoV-2 infection. A negative self-test result may not be reliable,\nespecially if you have symptoms associated with COVID-19. Invalid results from self-tests mean the test did not work properly, and a new test is needed to get an accurate result. Should I trust the results of a self-test? \uf1aa\nCDC strongly encourages everyone who uses a self-test to report any positive results to their healthcare provider.","6666":"10\/30\/22, 9:39 AM People with Moderate to Severe Asthma | CDC\nEspa\u00f1ol | Other Languages\nPeople with Moderate to Severe Asthma\nThis information is based on what we currently know about the spread and severity of COVID-19. Risk of severe illness from COVID-19\nPeople with moderate-to-severe or uncontrolled asthma are more likely to be hospitalized from COVID-19. Take steps to\nprotect yourself. Vaccine information for COVID-19\nFollow your Asthma Action Plan\nKeep your asthma under control by following your asthma action plan. Avoid your asthma triggers. Continue current medications, including any inhalers with steroids in them (\u201csteroids\u201d is another word for\ncorticosteroids). Know how to use your inhaler.","1752":"Requirements for Quality Assurance Monitoring (Updated 10\/18\/2021)\n\uf1aa\nAll organizations and providers\nparticipating in the CDC COVID-19\nVaccination Program:\nmust administer COVID-19 Vaccine at\nno out-of-pocket cost to the recipient\nmay not deny anyone vaccination based on the vaccine recipient\u2019s coverage status or network status\nmay not charge an office visit or other fee if COVID-19 vaccination is the sole medical service provided\nmay not require additional medical services to receive COVID-19 vaccination\nmay seek appropriate reimbursement from a program or plan that covers COVID-19 Vaccine administration fees for the\nvaccine recipient, such as:\nvaccine recipient\u2019s private insurance company\nMedicare or Medicaid reimbursement\nmay not seek any reimbursement, including through balance billing, from the vaccine recipient\nRequirements for COVID-19 Vaccination Program Providers\nCOVID-19 Vaccine is Provided at 100% No Cost to Recipients\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nIndividuals aware of any potential violations of these requirements are encouraged to report them to the Office of the\nInspector General, U.S. Department of Health and Human Services, by calling 1-800-HHS-TIPS or the website TIPS.HHS.GOV\n.","5297":"This Fact Sheet may have been updated. For the most recent Fact Sheet, please visit\nwww.janssencovid19vaccine.com. WHAT YOU NEED TO KNOW BEFORE YOU GET THIS VACCINE\nWHAT IS COVID-19? COVID-19 is caused by a coronavirus called SARS-CoV-2. This type of coronavirus has not been\nseen before. You can get COVID-19 through contact with another person who has the virus. It is\npredominantly a respiratory illness that can affect other organs. People with COVID-19 have had\na wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms\nmay appear 2 to 14 days after exposure to the virus.","1744":"Training, site\nvisits, and other oversight measures are important for maintaining or improving providers\u2019 adherence to these\nrequirements. Site visits are a key opportunity for quality assurance monitoring and training (as necessary) enrolled\nproviders. The goals of site visits are to:\nAssess COVID-19 vaccination provider adherence to program requirements and recommendations. Identify and address areas where providers are doing well and areas needing additional follow-up. Identify and address educational needs of COVID-19 vaccination providers to help them meet program\nrequirements. Ensure that vaccine recipients are receiving properly managed and viable vaccine.","8408":"Core Competencies:\nRelevant information contained in the EUA Fact Sheet(s) for Healthcare Providers for the vaccine product(s) in\nyour facility\nClinical considerations\nStorage and handling requirements\nPreparation requirements\nAdministration requirements\nAnaphylaxis guidance\nVaccination documentation and reporting requirements\nRequired and additional information for vaccine recipients\nCOVID-19 Vaccine Administration Competencies Assessment Form\nHealthcare professionals or retired (past 5 years) physicians, nurses, or\npractical nurses who are licensed\/previously licensed to administer\nCOVID-19 vaccine but have not done so in the last 12 months\n\uf209\n\uf20c\nCOVID-19 Vaccine Training Routine Vaccine Administration Routine Vaccine Storage and Handling\nVaccination support workers (not licensed to administer vaccine) qualified\nto prepare, store, handle, or transport vaccine\f10\/30\/22, 9:17 AM Training and Education for COVID-19 Vaccination | CDC\nCOVID-19 Vaccine Training Routine Vaccine Administration Routine Vaccine Storage and Handling\nCDC Training Module(s) for the\nvaccine product(s) in your facility\nIf needed: You Call the Shots: Vaccine\nAdministration\nOr other vaccine administration\ntraining offered by a worksite, state or\nlocal health department, medical\nprofessional organization, or\nmedical\/nursing school within the last\n12 months.","6074":"Reporting Adverse Event or Medication Errors\nThe vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event\nReporting System (VAERS):\n\u2022 vaccine administration errors whether or not associated with an adverse event,\n\u2022 serious adverse events (irrespective of attribution to vaccination),\n\u2022 cases of myocarditis\n\u2022 cases of pericarditis\n\u2022 cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and\n\u2022 cases of COVID-19 that result in hospitalization or death. Complete and submit reports to VAERS online at https:\/\/vaers.hhs.gov\/reportevent.html. Moderna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 09\/02\/22;\nFor further assistance with reporting to VAERS call 1-800-822-7967.","1871":"National Protocol\nOutcome: Household transmission among community members confirmed with SARS-CoV-2\nPopulation: Households of community members with positive SARS-CoV-2 tests recruited from national commercial\nlaboratories\nExternal partner: Westat\n\uf209 \uf20c\nTest-negative prospective case control\n\uf1aa\nIncreasing Community Access to Testing (ICATT) program\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Anyone seeking testing at a pharmacy\nParticipating sites: 8,319 locations across the United States and its territories\nIVY\nInfluenza and Other Viruses in the Acutely Ill (IVY) network\nOutcome: Hospitalization with SARS-CoV-2\nPopulation: Hospitalized adults\nParticipating Sites: 21 large adult hospitals in 20 cities in 18 states:\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nCalifornia\nColorado\nFlorida\nGeorgia\nIowa\nMaryland\nMassachusetts\nMichigan\nMinnesota\nMissouri\nNew York\nNorth Carolina\nOhio\nOregon\nTennessee\nTexas\nUtah\nWashington\nPReventing Emerging Infections through Vaccine EffectiveNess Testing (PREVENT ) Sites\nOutcome: Symptomatic SARS-CoV-2 infections\nPopulation: Healthcare personnel\nParticipating Sites\nBaystate Medical Center, Springfield, MA\nJackson Memorial Hospital, Miami, FL\nOlive View-UCLA Medical Center, Los Angeles, CA\nThomas Jefferson University Hospital, Philadelphia, PA\nTruman Medical Centers, Kansas City, MO\nUniversity of Alabama Hospital, Birmingham, AL\nCommunity Regional Medical Center\/ UCSF, Fresno, CA\nUniversity of Chicago Medical Center, Chicago, IL\nUniversity of Iowa Hospitals and Clinics, Iowa City, IA\nUniversity of Massachusetts Memorial Medical Center, Worcester, MA\nLCMC Health Hospitals, New Orleans, LA\nUniversity of Mississippi Medical Center, Jackson, MS\nUniversity of Texas Southwestern Medical Center and Parkland Hospital, Dallas, TX\nUniversity of Washington Hospitals, Seattle, WA\nValleywise Health Medical Center, Phoenix, AZ.","7810":"If you\u2019re not able to obtain a self-test when you need it, you might also visit a community testing site, or\ncall your local health department for more options. \u2022\n\uf209\n\u2022\n\u2022\nFDA-Authorized Tests\n\uf6e0 How to Use an At-Home COVID-19 Test\nRead the complete manufacturer\u2019s instructions for use before using the test. To use an at-home test, you will collect a nasal specimen and then test that specimen. If you do not follow the manufacturer\u2019s instructions, your test result may be incorrect. Wash your hands before and after you collect a nasal specimen for your test.","7236":"Signs of a severe\nallergic reaction can include:\n\uf0b7 Difficulty breathing\n\uf0b7 Swelling of your face and throat\n\uf0b7 A fast heartbeat\n\uf0b7 A bad rash all over your body\n\uf0b7 Dizziness and weakness\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the\nlining outside the heart) have occurred in some people who have received\nCOMIRNATY (COVID-19 Vaccine, mRNA) or Pfizer-BioNTech COVID-19 Vaccine,\nmore commonly in adolescent males and adult males under 40 years of age than\namong females and older males. In most of these people, symptoms began within a\nfew days following receipt of the second dose of vaccine. The chance of having this\noccur is very low.","3157":"Such testing outside of the context of research studies is not recommended\nat this time. Doses administered up to 4 days before the minimum interval, known as the 4-day grace period, are considered valid. This\napplies to primary series and booster doses. If a dose is administered prior to the 4-day grace period, see Appendix D. Doses\nadministered at any time after the recommended interval are valid. People should receive the recommended age-appropriate vaccine product and dosage based on their age on the day of\nvaccination.","475":"CDC then\nmultiplies this percentage by the count for the total population receiving at least one dose in Texas. CDC repeats the\nsame calculations to estimate the \u201cfully vaccinated\u201d metrics for the three population groups. These values will also be\nincluded in the topline national totals for 12+, 18+, and 65+. On May 7, 2021, the COVID-19 Vaccine Tracker was updated to reflect the revised Moderna emergency use authorization\n(EUA) to account for the new 14 dose vial as authorized by the Food and Drug Administration (FDA) .","4843":"Children ages 5\u201317 years who receive a mixed mRNA COVID-19 vaccine\nprimary series can follow the Pfizer-BioNTech COVID-19 Vaccine\nschedule and receive a booster dose. Diluent (Pfizer-BioNTech\nformulation only [orange\ncap and maroon cap])\nONLY diluent administered (i.e., sterile\n0.9% sodium chloride)\nAdminister the authorized dose immediately (no minimum interval). No diluent, resulting in higher than\nauthorized dose\nDo not repeat dose. Inform the recipient of the potential for local and\nsystemic adverse events. Incorrect diluent type (e.g., sterile water,\nbacteriostatic 0.9% sodium chloride)\nContact the manufacturer for information on the stability of the\nvaccine.","10099":"There is no\nrevaccination for monovalent booster doses. Persons who are moderately or\nseverely immunocompromised\n\u0083 See the Interim COVID-19 Immunization Schedule for Ages 6 Months or Older at https:\/\/www.cdc.gov\/vaccines\/covid-19\/downloads\/COVID-19-\nPersons receiving\nimmunosuppressive therapies\n\u0083 Whenever possible, COVID-19 vaccines should be administered at least 2 weeks before initiation or resumption of immunosuppressive therapies\n\u0083 Current infection\n\u0083 History of previous infection\n\u0083 Exposed to an infected person\nCOVID-19 vaccination is recommended for everyone ages 6 months and older, regardless of a history of symptomatic or asymptomatic SARS-CoV-2\ninfection. \u0083 Defer vaccination until person has recovered from acute illness and criteria have been met for them to discontinue isolation.","7106":"You should also talk to your healthcare professional if you think you are experiencing depression during or after\npregnancy. Get recommended vaccines during pregnancy. These vaccines can help protect you and your baby. Get a flu vaccine every year. Others living in your household should also get vaccinated to protect themselves and\nyou. Get the Tdap vaccine to protect your baby against whooping cough, which can have similar symptoms to COVID-19. CDC recommends all pregnant people receive a Tdap vaccine during each pregnancy. In addition, everyone who is\naround the baby should be up to date with their whooping cough vaccine.","8651":"\u2022\n\u2022\n\u2022\nInitial Development\n\uf1aa\n\uf33d New vaccines are first developed in laboratories. Scientists have been working for many years to develop\nvaccines against coronaviruses, such as those that cause severe acute respiratory syndrome (SARS) and\nMiddle East respiratory syndrome (MERS). SARS-CoV-2, the virus that causes COVID-19, is related to these\nother coronaviruses. The knowledge that was gained through past research on coronavirus vaccines\nhelped speed up the initial development of the current COVID-19 vaccines. Clinical Trials\n\uf1aa\n\uf3ba After initial laboratory development, vaccines go through three phases of clinical trials to make sure they\nare safe and effective. No trial phases have been skipped.","9561":"Either dose may be:\n\u0083 0.20 mL (10 mcg) of the product authorized for children ages 5\u201311 years (orange cap and label border), or\n\u0083 0.30 mL (30 mcg) of the product authorized for children ages 12\u201317 years (gray cap and label border)\nOR 3-8 weeks\nOR\fSpecial Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nInterchangeability of Moderna and Pfizer-BioNTech COVID-19 vaccines\nCOVID-19 vaccine from the same manufacturer should be used for the primary series.","14":"Ask the facility healthcare provider (or facility staff) for help if:\n\u2022 The redness or pain where you got the shot gets worse after 24 hours\n\u2022 Your side effects are worrying you\n\u2022 Your side effects do not seem to be going away after a few days\nIn the rest of your body:\n\u2022 Fever\n\u2022 Chills\n\u2022 Tiredness\n\u2022 Headache\n\u2022 Muscle pain\n\u2022 Nausea\nCOMMON SIDE EFFECTS\nHELPFUL TIPS\nREMEMBER","10003":"Considerations for subsequent COVID-19\nvaccination may include:\n\u25cb The myocarditis or pericarditis was considered unrelated to vaccination with Moderna, Novavax,\nor Pfizer-BioNTech (e.g., due to SARS-CoV-2 or other viruses), especially if the myocarditis or\npericarditis diagnosis occurred more than 3 weeks after the most recent dose of COVID-19 vaccine\n\u25cb Personal risk of severe acute COVID-19 (e.g., age, underlying conditions)\n\u25cb Timing of any immunomodulatory therapies;\nConsult ACIP\u2019s General Best Practice Guidelines for Immunization\n\u0083 For information on potential use of Janssen COVID-19 Vaccine in this situation, see Appendix A\n\u0083 Persons who have a history of myocarditis or pericarditis unrelated to mRNA (Moderna, Pfizer-Bio-\nNTech) or Novavax COVID-19 vaccination may receive any currently FDA-approved or -authorized\nCOVID-19 vaccine after the episode of myocarditis or pericarditis has resolved.","4713":"The highest risk has\nbeen observed in people ages 40\u201364 years, with symptoms of GBS beginning within 42 days after Janssen COVID-19\nvaccination; most GBS reports have been in males.","9135":"\uf209\n[PDF - 439 KB]\n\uf20c\nMasks Are Recommended\nCDC recommends properly wearing a high-quality mask or respirator over the nose and\nmouth in indoor areas of public transportation and transportation hubs. Airplane:\nEnglish\nSpanish\nTrain:\nEnglish\nSpanish\nBus:\nEnglish\nSpanish\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\n\uf20c\f10\/30\/22, 9:43 AM Wearing Masks in Travel and Public Transportation Settings | CDC\n8.5 W x 11 H [PDF \u2013 304 KB, 1 Page]\n\uf20c\n\uf20c\nLast Updated Sept. 8, 2022","6202":"CDC continues to recommend that everyone ages 6 months and older get vaccinated for COVID-19. The known risks of\nCOVID-19 illness and its related, possibly severe complications, such as long-term health problems, hospitalization, and even\ndeath, far outweigh the potential risks of having a rare adverse reaction to vaccination, including the possible risk of\nmyocarditis or pericarditis. If you have already gotten the first dose of Pfizer-BioNTech or Moderna vaccine, or if your child has already gotten the first\ndose of the Pfizer-BioNTech vaccine, it\u2019s important to get the second dose unless a vaccination provider or your doctor tells\nyou not to get it.","1":"cdc.gov\/coronavirus\nWhat to Expect after Getting a COVID-19 Vaccine\nThe COVID-19 shot may cause side effects in some people. Side effects should go away in a few days. On the arm where you got the shot:\n\u2022 Pain\n\u2022 Redness\n\u2022 Swelling\nIf you are sore where you got the shot:\n\u2022 Apply a clean, cool, wet washcloth over the area\n\u2022 Use or move your arm gently\nIf you have a fever:\n\u2022 Drink a lot of water\n\u2022 Get plenty of rest\n\u2022 Dress lightly\nIf you have pain, headache, or fever, ask a healthcare provider (or facility\nstaff) if you can have medicine.","3083":"COVID-19 vaccination schedule for people who are moderately or severely immunocompromised\nAge\ngroup\nNumber of\nprimary doses\nNumber of\nbivalent booster\ndoses\nRecommended\nbivalent booster\ndose*\nInterval between 1st\nand 2nd primary dose\nInterval between 2nd\nand 3rd primary dose\nInterval between primary\nseries and booster dose\nModerna primary series\nyears\n3 NA NA 4 weeks At least 4 weeks NA\n5 years 3 1 Pfizer-BioNTech 4 weeks At least 4 weeks At least 2 months\nyears\nPfizer-BioNTech\n4 weeks At least 4 weeks At least 2 months\nand older\nPfizer-BioNTech\n4 weeks At least 4 weeks At least 2 months\nNovavax primary series\nand older\nPfizer-BioNTech\n3 weeks NA At least 2 months\nPfizer-BioNTech primary series\nyears\n3 NA NA 3 weeks At least 8 weeks NA\n5 years 3 1 Pfizer-BioNTech 3 weeks At least 4 weeks At least 2 months\nyears\nPfizer-BioNTech\n3 weeks At least 4 weeks At least 2 months\nand older\nPfizer-BioNTech\n3 weeks At least 4 weeks At least 2 months\nAbbreviation: NA = not authorized\n*A monovalent Novavax booster dose (instead of a bivalent mRNA booster dose) may be used in limited situations in people ages 18 years and older who\ncompleted a primary series using any COVID-19 vaccine, have not received any previous booster dose(s), and are unable to receive an mRNA vaccine (i.e.,\nmRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.","6048":"What is the available supporting evidence for revaccination of people who received COVID-19 vaccine during\nB-cell-depleting therapy administered over a limited period? Moderna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 09\/02\/22;\nStudies of people on B-cell-depleting therapies indicate patients do not achieve adequate seroconversion or\nhave a decreased odds ratio of seroconversion if they were vaccinated during therapy (Haggenberg, 2022a;\nHaggenberg, 2022b).The timing of vaccination relative to therapy influences vaccine immunogenicity;\nvaccination at least 6 months after therapy has demonstrated improved seroconversion (Kornek, 2022;\nSchietzel, 2022, Disanto, 2021).","297":"Due to a data processing issue on May 9, 2022, vaccination data were not updated for two dashboards on Vaccination\nDemographic Trends \u2013 \u201cBooster Vaccination Trends by Age, Sex, and Race\/Ethnicity among Fully Vaccinated People Ages\n12 Years and Older\u201d and \u201cVaccination Trends by Age and Sex\u201d \u2013 which reflect data as of May 8, 2022. CDC is actively\nworking to address this issue and the data will be updated when available. On May 3, 2022, the daily number of vaccine doses administered for South Carolina was 152,237 doses.","5040":"Updated Table in Appendix A: Vaccine administration errors and deviations. New section on Considerations for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose after completion of a\nPfizer-BioNTech primary vaccine series. Updated information in the section on COVID-19 vaccination and SARS-CoV-2 infection. Updated information in the section on Vaccinating people with a known COVID-19 exposure or during COVID-19\noutbreaks. New section on Vaccinating people receiving medical care unrelated to COVID-19. New section on Vaccinating people undergoing SARS-CoV-2 screening.","9900":"doi:10.1136\/rmdopen-2021-002036. WHO Strategic Advisory Group of Experts on Immunization (SAGE). Interim recommendations for an extended\nprimary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised\npersons;.updated 26 October 2021. Geneva: World Health Organization; 2021.\nimmunocompromised-persons. Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nWHO Strategic Advisory Group of Experts on Immunization (SAGE). Interim recommendations for use of the\ninactivated COVID-19 vaccine, CoronaVac, developed by Sinovac Interim guidance; updated 21 October 2021. Geneva: World Health Organization; 2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-\nvaccines-SAGE_recommendation-Sinovac-CoronaVac-2021.1. WHO Strategic Advisory Group of Experts on Immunization (SAGE).","2397":"When are people who have weakened immune systems considered up to date with their COVID-\n\uf1aa\nPeople can stay up to date with COVID-19 vaccination by completing a primary series and receiving the most recent\nbooster dose recommended for them by CDC. The people you live or spend time with can help protect you and\nthemselves by staying up to date on their COVID-19 vaccines too. When are people who have weakened immune systems considered up to date with their COVID-\n\uf1aa\nYou are up to date if you receive all COVID-19 vaccine doses recommended for you, even if you become ill with COVID-19.","5370":"Report vaccine side effects to FDA\/CDC Vaccine Adverse Event Reporting System (VAERS). The VAERS toll-free number is 1-800-822-7967 or report online to\nhttps:\/\/vaers.hhs.gov\/reportevent.html. Please include \u201cJanssen COVID-19 Vaccine EUA\u201d in the\nfirst line of box #18 of the report form. In addition, you can report side effects to Janssen Biotech, Inc. at the contact information provided\nbelow. e-mail Fax number Telephone numbers\nJNJvaccineAE@its.jnj.com 215-293-9955 US Toll Free: 1-800-565-4008\nYou may also be given an option to enroll in v-safe.","5274":"This may mean you need to continue wearing a mask and testing beyond day 10. As noted in the Food and Drug Administration labeling for authorized over-the-counter antigen tests, negative test results\ndo not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management\ndecisions, including infection control decisions. \uf309 Removing Your Mask\n\u2022\n\u2022\nAfter you have ended isolation, if your COVID-19 symptoms recur or worsen, restart your isolation at day 0. Talk to a\nhealthcare provider if you have questions about your symptoms or when to end isolation. Last Updated Aug. 11, 2022","4788":"Table of Contents \uf426\nA vaccine administration error is any preventable event that may cause or lead to inappropriate use of vaccine or patient\nharm. For all vaccine administration errors:\nInform the recipient of the vaccine administration error. Consult with the state immunization program and\/or immunization information system (IIS) to determine how the dose\nshould be entered into the IIS, both as an administered dose and to account for inventory. Report the error to the Vaccine Adverse Event Reporting System (VAERS), unless otherwise indicated in the table. Providers are required to report all COVID-19 vaccine administration errors\u2014even those not associated with an adverse\nevent\u2014to VAERS.","3495":"Follow recommendations for protecting yourself and others. If you have symptoms of COVID-19, stay in your cabin and notify the onboard medical center immediately. It\u2019s important to report your symptoms, even if they are mild, to protect others on board including\npassengers at increased risk for severe illness and crew. \uf309 Masks\nFollow any ship-specific mask protocols. Follow CDC\u2019s recommendations for wearing masks in travel and public transportation settings. If You Develop Symptoms or Use a Self-Test on Board with a Positive Result\nIsolate yourself in your cabin immediately. Call your ship\u2019s medical center.","4114":"CDC continues to review evidence and updates guidance as new information becomes available. How long does protection from a COVID-19 vaccine last? \uf1aa\nResults from recent research studies show that people who menstruate may observe small, temporary changes in\nmenstruation after COVID-19 vaccination, including:\nLonger duration of menstrual periods\nShorter intervals between periods\nHeavier bleeding than usual\nDespite these temporary changes in menstruation there is no evidence that COVID-19 vaccines cause fertility problems\nDo COVID-19 vaccines affect your menstrual cycle (period)?","5517":"For example, some\nstudies look for the presence of post-COVID conditions based on self-reported symptoms, while others collect symptoms and\nconditions recorded in medical records. Some studies focus only on people who have been hospitalized, while others include\npeople who were not hospitalized. The estimates for how many people experience post-COVID conditions can be quite\ndifferent depending on who was included in the study, as well as how and when the study collected information.","2752":"Understanding other people\u2019s experiences with post-COVID conditions and reflecting on how these experiences\nmay be similar or different than your own can help confirm you are not alone. Contribute to ongoing scientific research. Participating in research studies can build a larger understanding of new and unknown illnesses. Information\nabout enrolling in clinical trials related to COVID-19 can be found at CombatCovid.hhs.gov , and includes\nopportunities for persons with and without COVID-19. \u2022\n\u2022\n\uf209\f10\/30\/22, 9:42 AM Caring for People with Post-COVID Conditions | CDC\nPeople experiencing post-COVID conditions may find different strategies to be helpful.","975":"\u2022\n\u2022\n\u2022\n\u2022\n\uf6e0 COVID-19 Tests or Treatment\nCommunity-Based Testing Locations Treatment Locator\nTypes of Tests\nViral tests look for a current infection with SARS-CoV-2, the virus that causes COVID-19, by testing specimens from your nose\nor mouth. There are two main types of viral tests: nucleic acid amplification tests (NAATs) and antigen tests. In certain\ncircumstances, one test type may be recommended over the other. All tests should be performed following FDA\u2019s\nrequirements. NAATs, such as PCR-based tests, are most often performed in a laboratory. They are typically the most reliable tests for\npeople with or without symptoms.","5903":"\u2022 A second primary dose of the COVID-19 vaccine by Moderna (100 \u03bcg in 0.5 mL from red-capped\nmultidose vial) may be delayed by 3 months from symptom onset or positive test (if infection was\nasymptomatic) in persons ages 12 years and older who recently had SARS-CoV-2 infection\fModerna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 09\/02\/22;\n\u2022 A primary dose, including as an additional primary dose for those with certain immunocompromising\nconditions, of the COVID-19 vaccine by Moderna (100 \u03bcg in 0.5 mL from red-capped multidose vial)\nshould be administered intramuscularly to persons ages 12 years and older at least 28 days after\nprimary vaccination with certain non-FDA authorized or approved COVID-19 vaccines.","457":"On May 16, 2021, the total number of administered doses for the US and New Hampshire were incorrectly reported. This\nwas due to an error in data processing. The data for May 16, 2021 have been updated and now correctly report the total\nadministered doses of 272,925,411 for the US, and 1,211,530 for New Hampshire. On May 13, 2021, the number of persons aged <18 years, who had received at least 1 dose of vaccine was incorrectly\nreported as 3,687,617 on the Vaccinations Demographics page. This was due to inclusion of those ages 18 years in the\n<18 years group.","837":"Protection provided by the current vaccines\nagainst symptomatic infection and transmission is less than that against severe disease and diminishes over time, especially\nagainst the currently circulating variants. For this reason, it is important to stay up to date, especially as new vaccines become\navailable. Read more about risk factors for severe COVID-19 in children published in Pediatrics, childhood COVID-19-related\nhospitalizations published in MMWR, and weekly summaries of COVID-19 hospitalization data through COVID-NET. \uf209\nCOVID-19 Vaccines Are Safe for Children and Adults\nWhile COVID-19 vaccines were developed quickly, all steps have been taken to ensure their safety and effectiveness.","6191":"When reported, the cases have especially been in adolescents and\nyoung adult males within several days after mRNA COVID-19 vaccination (Pfizer-BioNTech or Moderna). More often after the second dose\nUsually within a week of vaccination\nMost patients with myocarditis or pericarditis who received care responded well to medicine and rest and felt better\nquickly. Patients can usually return to their normal daily activities after their symptoms improve. Those who have been diagnosed with myocarditis should consult with their cardiologist (heart doctor) about return to\nexercise or sports. CDC and its partners are actively monitoring reports of myocarditis and pericarditis after COVID-19 vaccination.","4483":"If possible, avoid being around a person who has COVID-19 until they can safely end home isolation. Sometimes it may not be practical for you to stay away from a person who has COVID-19 or you may want to help take\ncare of them. In those situations, use as many prevention strategies as you can, such as practicing hand hygiene,\nconsistently and correctly wearing a high-quality mask, improving ventilation, and keeping your distance, when possible,\nfrom the person who is sick or who tested positive.","1466":"\uf1aa\nPeople who previously received SARS-CoV-2 antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent\nplasma) as part of COVID-19 treatment, post-exposure prophylaxis, or pre-exposure prophylaxis can be vaccinated at any\ntime; COVID-19 vaccination does not need to be delayed following receipt of monoclonal antibodies or convalescent\nplasma. However, people who are moderately or severely immunocompromised and received a COVID-19 vaccination should wait\nat least two weeks before receiving tixagevimab\/cilgavimab (EVUSHELD\u2122) for pre-exposure prophylaxis per the\nproduct EUA . For more information, see COVID-19 vaccination and EVUSHELD\u2122 and CDC\u2019s EVUSHELD\u2122 guidance. If my patient received a SARS-CoV-2 antibody product (anti-SARS-CoV-2 monoclonal antibodies or\nconvalescent plasma) can they be vaccinated?","6910":"\u2022 For people who are moderately or severely immunocompromised:\no\no\no\nPeople ages 12 years and older who are moderately or severely immunocompromised and\nreceived their primary vaccination with certain non-FDA authorized or approved COVID-19\nvaccines at least 28 days ago should receive an additional (third) primary dose of the\nCOVID-19 vaccine by Pfizer-BioNTech. People ages 18 years and older with a moderately or severely immunocompromising\ncondition who received a primary dose of the Janssen COVID-19 Vaccine should receive an\nadditional dose with the COVID-19 vaccine by Pfizer-BioNTech at least 28 days after\nreceiving the Janssen COVID-19 Vaccine primary dose.","4672":"GBS within 6 weeks after receipt of Janssen COVID-19 Vaccine Not\nrecommended\nDo not vaccinate with Janssen COVID-19 Vaccine. These people\nshould receive a booster dose using a bivalent mRNA COVID-19\nvaccine. History of GBS Precaution See FAQs and GBS section (below) for additional information. Abbreviations: TTS = thrombosis with thrombocytopenia syndrome; HIT = heparin-induced thrombocytopenia; GBS = Guillain-Barr\u00e9 syndrome\nPost-vaccination symptoms\nIn clinical trials of Janssen COVID-19 Vaccine, pain at the injection site was the most frequently reported local reaction among\nvaccine recipients; erythema and swelling were reported less frequently. Fatigue and headache were the most commonly\nreported systemic reactions.","9371":"COVID-19 is caused by a coronavirus called SARS-CoV-2. This type of coronavirus has not\nbeen seen before. You can get COVID-19 through contact with another person who has the\nvirus. It is predominantly a respiratory illness that can affect other organs. People with COVID-\n19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever or\nchills; cough; shortness of breath; fatigue; muscle or body aches; headache; new loss of taste or\nsmell; sore throat; congestion or runny nose; nausea or vomiting; diarrhea.","471":"The percentage of total doses that were\nadministered to people in each age group (ages 12 years and older, ages 18 years and older, and ages 65 years and\nolder) is the same as both the percentage of people who received at least one dose and the percentage of fully\nvaccinated people within each age group. CDC estimates the \u201cat least one dose\u201d metric for these populations of Texas by\nfirst obtaining the percentage of the three population groups who have received \u2018at least one dose\u2019 from Texas.","4991":"Added considerations for an 8-week interval between the first and second doses of a primary mRNA vaccine schedule\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nUpdated guidance for moderately or severely immunocompromised people\nClarification of existing recommendation to receive a 3-dose mRNA vaccine primary series followed by a booster\ndose for a total of 4 doses\nNew guidance to shorten the interval between completion of the mRNA vaccine primary series and the booster\ndose to at least 3 months (instead of 5 months)\nNew guidance for those who received the Janssen COVID-19 Vaccine primary series to receive an additional dose\nand a booster dose, for a total of 3 doses to be up to date\nUpdated guidance that it is no longer necessary to delay COVID-19 vaccination following receipt of monoclonal\nantibodies or convalescent plasma\nUpdated guidance on receiving a booster dose if vaccinated outside the United States\nUpdated contraindication and precaution section to include history of myocarditis or pericarditis after an mRNA\nCOVID-19 vaccine as a precaution\nReorganized and condensed multiple sections\nUpdated guidance for use of Pfizer-BioNTech COVID-19 Vaccine as a booster in people ages 12\u201317 years\nUpdated guidance for administration of a COVID-19 vaccine booster dose at least 5 months after completion of an\nmRNA vaccine (Pfizer-BioNTech or Moderna) primary series\nUpdated guidance for use of an additional primary dose for moderately or severely immunocompromised people ages\n5\u201311 years who received a Pfizer-BioNTech vaccine primary series\nUpdated recommendations for people who received COVID-19 vaccines outside the United States that are not FDA-\nauthorized or approved\nUpdated information about a second formulation of Pfizer-BioNTech COVID-19 Vaccine that is authorized for use in\npersons ages 12 years and older\nUpdated information on vaccinating people during quarantine after a known SARS-CoV-2 exposure or during COVID-\nUpdate to alert providers of possible false positive Rapid Plasma Reagin (RPR; non-treponemal) test results in some\npeople after COVID-19 vaccines\nUpdated information on vaccine administration errors and deviations\nUpdated guidance on use of Janssen (Johnson & Johnson) COVID-19 Vaccine\nUpdated recommendations for receipt of a COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 booster doses in recipients of mRNA COVID-19 vaccines\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nRecommendations and clinical guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children aged 5-11 years\nincluding updated section on Vaccination of children and adolescents\nUpdated guidance on COVID-19 vaccine dosing and schedule\nUpdated guidance for myocarditis and pericarditis after mRNA COVID-19 vaccination in new section on Considerations\nfor mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna\nNew guidance for people who received passive antibody products in section on COVID-19 vaccination and SARS-CoV-2\ninfection\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial in the United States\nUpdated guidance on Considerations for COVID-19 vaccination in moderately and severely immunocompromised\npeople\nUpdated guidance in section on Contraindications and precautions\nUpdated Table in Appendix A: Vaccine administration errors and deviations\nUpdated Appendix B: Triage of people with a history of allergies or allergic reactions\nUpdated Appendix C: Ingredients included in COVID-19 vaccines\nUpdated Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects\nfollowing COVID-19 vaccination\nUpdated guidance in section on Considerations for use of a COVID-19 booster dose.","5726":"The COVID-19\nvaccine by Pfizer-BioNTech can also be used under EUI for similar uses as an alternative mRNA COVID-19\nvaccine (see the Pfizer-BioNTech EUI Fact Sheet for Recipients), and the same or similar recommendations\nin this EUI also apply to the use of the COVID-19 vaccine by Pfizer-BioNTech under EUI. What is COVID-19? Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a coronavirus called SARS-CoV-2. It\nis predominantly a respiratory illness that can also affect other organs. People with SARS-CoV-2 infection\nhave reported a wide range of symptoms, from no symptoms to severe illness leading to death.","10140":"Summary Document for\nInterim Clinical Considerations\nfor Use of COVID-19 Vaccines Currently Authorized or Approved in the United States\nConsiderations for Janssen COVID-19 Vaccine\nPersons with a history of thrombosis\nwith thrombocytopenia syndrome\n(TTS)\n\u0083 It is contraindicated to administer Janssen COVID-19 Vaccine to persons with a history of TTS following receipt of the Janssen COVID-19 Vaccine or\nany other adenovirus vector-based COVID-19 vaccines (e.g., AstraZeneca\u2019s COVID-19 Vaccine). \u0083 These persons should receive a dose of an mRNA COVID-19 vaccine as a booster dose at least 2 months (8 weeks) following their dose of the\nJanssen COVID-19 Vaccine and after their clinical condition has stabilized.","1843":"For information for the general public,\nplease see Monitoring Vaccine Effectiveness\nProspective Cohort\n\uf1aa\nHEROES\nArizona Healthcare, Emergency Response, and Other Essential Workers Surveillance (AZ Heroes) Study\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Healthcare providers\/first responders\/essential and other frontline workers\nParticipating Sites\nUniversity of Arizona, Tucson, AZ\nMel and Enid Zuckerman College of Public Health, Tucson, AZ\n\uf20c\nRECOVER\nResearch on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER)\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Healthcare providers\/first responders\/essential and other frontline workers\nParticipating Sites\nBaylor Scott and White Health, Temple, TX\n\uf209\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nKaiser Permanente Northwest, Portland, OR\nSt. Luke\u2019s Hospital, Duluth, MN\nUniversity of Arizona, Tucson, AZ\nUniversity of Miami, Miami, FL\nUniversity of Utah, Salt Lake City, UT\nPROTECT\nPediatric Research Observing Trends and Exposures in COVID-19 Timelines\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Children aged <18 years\nParticipating Sites\nBaylor Scott and White Health, Temple, TX\nUniversity of Arizona, Tucson, AZ\nUniversity of Miami, Miami, FL\nUniversity of Utah, Salt Lake City, UT\nCASCADIA\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Children aged <18 years and adults aged <50 years\nParticipating Sites\nKaiser Permanente Northwest, Portland, OR\nUniversity of Washington, Seattle, WA\nHousehold Transmission Studies\n\uf1aa\nHEROES-RECOVER Household Transmission Study\nResearch on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER) SARS-CoV-2 Household\nTransmission Study\nOutcome: Transmission in households of healthcare, first responder, and essential and other frontline workers with\nPopulation: Households of infected healthcare providers\/first responders\/essential and other frontline workers\nParticipating Sites\nBaylor Scott and White Health, Temple, TX\nKaiser Permanente Northwest, Portland, OR\nSt. Luke\u2019s Hospital, St. Louis, MO\nUniversity of Arizona, Tucson, AZ\nUniversity of Miami, Miami, FL\nUniversity of Utah, Salt Lake City, UT\n\uf20c\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nUniversity of Utah, Salt Lake City, UT\nRVTN (Respiratory Virus Transmission Network)\nRVTN \u2013 Sentinel\nSentinel Protocol\nOutcome: Household transmission among community members confirmed with SARS-CoV-2\nPopulation: Households of community members with positive SARS-CoV-2 tests recruited from sentinel testing sites\nParticipating Sites\nUniversity of Arizona, Tucson, AZ\nStanford University, Stanford, CA\nUniversity of Colorado, Denver, CO\nColumbia University, New York City, NY\nUniversity of North Carolina, Chapel Hill, NC\nVanderbilt University Medical Center, Nashville, TN\nMarshfield Clinic Research Institute, Marshfield, WI\n\uf20c\nRVTN \u2013 National\nNational Approach (also known as \u201cTrack COVID at Home \u201d).","1970":"FDA Biologics Effectiveness and Safety System (BEST) \u2014 A system of electronic health record, administrative, and\nclaims-based data for active surveillance and research. Members of the military\nDepartment of Defense (DOD) VAERS data \u2014 Spontaneous adverse event reporting to VAERS for the DOD population. DOD Vaccine Adverse Event Clinical System (VAECS) \u2014 A system for case tracking and evaluation of adverse events\nfollowing immunization in DOD and DOD-affiliated populations. DOD Electronic Health Record and Defense Medical Surveillance System \u2014 Large, linked electronic health records\n(AHLTA\/MHS GENESIS) and administrative data systems for near real-time safety monitoring and research.","4616":"How can I decrease the level of virus particles during and after a guest visits my home? Select the options below to see how particle levels change as you adjust ventilation settings. (To create additional scenarios, including to adjust the length of the visit and size of the home, see the expanded model from the National\nInstitute of Standards and Technology.)","6018":"\u2022 In a large test-negative design study to evaluate VE among adults aged \u226518 years in British Columbia\nand Quebec, Canada, two-dose mRNA VE against infection and hospitalization was significantly higher\nwith a longer dosing interval (7\u20138 weeks vs. 3\u20134 weeks) (Skowronski, 2021). VE appeared to plateau at\nthe 7\u20138 week interval. \u2022 A test-negative case control study among adults aged 50\u201389 years in England demonstrated that\nPfizer-BioNTech VE was higher with longer (>6 weeks) intervals compared to short (3\u20134 weeks)\nintervals for all age groups (Amirthalingam, 2021).","5963":"Studies of COVID-19\nvaccine boosting in the United Kingdom have shown that a third dose of AstraZeneca, Moderna, or Pfizer-\nBioNTech COVID-19 vaccines successfully boosted immune responses in people who had been primed with\ntwo doses of Pfizer-BioNTech or AstraZeneca COVID-19 vaccines approximately 3 months earlier. Levels of\nbinding (IgG) and neutralizing antibodies, including against Delta variant, were generally higher when an mRNA\nvaccine was used as either a heterologous or homologous boost (Munro et al., 2021)).","9440":"Serious and unexpected side\neffects may occur. The possible side effects of these vaccines are still being studied. WHAT SHOULD I DO ABOUT SIDE EFFECTS? If you or your child experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital. Call the vaccination provider or your or your child\u2019s healthcare provider if you or your child\nhave any side effects that bother you or do not go away. Report vaccine side effects to FDA\/CDC Vaccine Adverse Event Reporting System\n(VAERS). The VAERS toll-free number is 1-800-822-7967 or report online to\nhttps:\/\/vaers.hhs.gov\/reportevent.html.","8302":"If you are experiencing any of these symptoms, consider the following options:\nGet tested for COVID-19\nIf you have already tested positive for COVID-19, learn more about CDC\u2019s isolation guidance\n\u2022\n\u2022\nWhen to Seek Emergency Medical Attention\nLook for emergency warning signs* for COVID 19:\nTrouble breathing\nPersistent pain or pressure in the chest\nNew confusion\nInability to wake or stay awake\nPale, gray, or blue-colored skin, lips, or nail beds, depending on skin tone\nIf someone is showing any of these signs, call 911 or call ahead to your local emergency facility. Notify the operator that\nyou are seeking care for someone who has or may have COVID-19.","8106":"\u0082 Two vaccines may be used for the prevention of monkeypox disease:\n\u008f JYNNEOS vaccine is approved for the prevention of monkeypox disease. \u008f ACAM2000 vaccine was made available for use against monkeypox under an Expanded Access Investigational New Drug\n\u0082 CDC recommends that the monkeypox vaccine be given within 4 days from the date of exposure in order to prevent onset\nof the disease.","9883":"Rapid Review Update 1: What is the ongoing\neffectiveness, immunogenicity, and safety of COVID-19 vaccines in persons who have had a prior, confirmed\nCOVID-19 infection?. Hamilton (ON): McMaster University; 2021. Available from: https:\/\/www.nccmt.ca\/covid-\n19\/covid-19-rapid-evidence-service\/36. Parry H, Bruton R, Stephens C, et al. Extended interval BNT162b2 vaccination enhances peak antibody\nPatamatamkul S, Thammawat S, Buranrat B. Induction of robust neutralizing antibodies against the COVID-19\nDelta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster following a primary vaccination series with\nCoronaVac. medRxiv 2021.09.25.21264099; doi: https:\/\/doi.org\/10.1101\/2021.09.25.21264099. Payne RP, Longet S, Austin JA, et al. 2021. Immunogenicity of standard and extended dosing intervals of\nBNT162b2 mRNA vaccine. Cell.","5523":"Estimates of\nthe proportion of people who had COVID-19 that go on to experience post-COVID conditions can vary:\nStudies are in progress to better understand post-COVID conditions and how many people experience them. 10\/30\/22, 9:42 AM Long COVID or Post-COVID Conditions | CDC\n13.3% at one month or longer after infection\n2.5% at three months or longer, based on self-reporting\nMore than 30% at 6 months among patients who were hospitalized\nScientists are also learning more about how new variants could potentially affect post-COVID symptoms.","9126":"Support wearing of masks or respirators on conveyances and in transportation hubs for everyone aged 2 years or\nolder, including employees. If an employer allows voluntary use of filtering facepiece respirators, the employer must follow 29 CFR\n1910.134(c)(2) requirements for voluntary respirator use. Improve ventilation. Keep conveyance ventilation systems on when passengers and workers are on board, including during\nembarkation and disembarkation processes. Open windows on conveyances where feasible. Reduce crowding where feasible. Promote hand hygiene, such as making hand sanitizer dispensers available and ensuring they are kept filled and\nworking.","687":"January 20, 2022: Georgia made updates to data previously submitted to CDC that resulted in an increase of 139\ndoses administered. January 20, 2022: Wyoming made updates to data previously submitted to CDC that resulted in an increase of 2,761\ndoses administered. January 20, 2022: Pennsylvania made updates to data previously submitted to CDC that resulted in an increase of\n206,575 doses administered. January 19, 2022: Idaho added 20,015 records for persons aged 18 years not previously submitted to CDC. January 14, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 4,868\ndoses administered.","4206":"You may consider delaying your vaccine by 3 months from when your symptoms started or, if you had no symptoms,\nwhen you received a positive test. People who already had COVID-19 and do not get vaccinated after their recovery are more likely to get COVID-19\nagain than those who get vaccinated after their recovery. Learn more about the benefits of getting a COVID-19 vaccine. If I already had COVID-19 and recovered, do I still need to get a COVID-19 vaccine? \uf1aa\nCan I get vaccinated against COVID-19 while I am currently sick with COVID-19?","5401":"WHERE WILL MY VACCINATION INFORMATION BE RECORDED? The vaccination provider may include your vaccination information in your state\/local\njurisdiction\u2019s Immunization Information System (IIS) or other designated system. For more\ninformation about IISs visit: https:\/\/www.cdc.gov\/vaccines\/programs\/iis\/about.html. CAN I BE CHARGED AN ADMINISTRATION FEE FOR RECEIPT OF THE COVID-19\nVACCINE? No. At this time, the provider cannot charge you for a vaccine dose and you cannot be charged an\nout-of-pocket vaccine administration fee or any other fee if only receiving a COVID-19\nvaccination.","4670":"Medical condition or history Guidance Recommended action(s)\nTTS following receipt of a previous Janssen COVID-19 Vaccine (or other\nCOVID-19 vaccines not currently authorized in the United States that\nare based on adenovirus vectors, e.g., AstraZeneca)\nContraindication Do not vaccinate with Janssen COVID-19 Vaccine. See\nThrombosis with thrombocytopenia syndrome (TTS) section\n(below) for information on booster vaccination with a bivalent\nmRNA COVID-19 vaccine. History of an episode of an immune-mediated syndrome characterized\nby thrombosis and thrombocytopenia, such as spontaneous or classic\nHIT\nNot\nrecommended\nDo not vaccinate with Janssen COVID-19 Vaccine. These people\nshould receive an mRNA or Novavax COVID-19 vaccine.","6293":"Other Myths and Facts\nCOVID-19 vaccination is recommended for people who are pregnant, trying to get pregnant now, or might become\npregnant in the future, as well as their partners. Learn more about COVID-19 vaccines and people who would like to have a baby. MYTH: COVID-19 vaccines will affect my fertility. \uf1aa\nFACT: Currently no evidence shows that any vaccines, including COVID-19 vaccines, cause fertility\nproblems (problems trying to get pregnant) in women or men.","9358":"2 FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and one presentation of the EUA-authorized Moderna\nCOVID-19 Vaccine (supplied in vials with red caps and labels with a light blue border) can be used interchangeably\nfor the primary series for individuals 12 years of age and older without presenting any safety or effectiveness\nconcerns. The Moderna COVID-19 Vaccine has received EUA from FDA to provide:\n\u2022 a two-dose primary series to individuals 6 years of age and older; and\n\u2022 a third primary series dose to individuals 6 years of age and older with certain kinds\nof immunocompromise.","1875":"National Protocol\nOutcome: Household transmission among community members confirmed with SARS-CoV-2\nPopulation: Households of community members with positive SARS-CoV-2 tests recruited from national commercial\nlaboratories\nExternal partner: Westat\n\uf209 \uf20c\nTest-negative prospective case control\n\uf1aa\nIncreasing Community Access to Testing (ICATT) program\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Anyone seeking testing at a pharmacy\nParticipating sites: 8,319 locations across the United States and its territories\nIVY\nInfluenza and Other Viruses in the Acutely Ill (IVY) network\nOutcome: Hospitalization with SARS-CoV-2\nPopulation: Hospitalized adults\nParticipating Sites: 21 large adult hospitals in 20 cities in 18 states:\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nCalifornia\nColorado\nFlorida\nGeorgia\nIowa\nMaryland\nMassachusetts\nMichigan\nMinnesota\nMissouri\nNew York\nNorth Carolina\nOhio\nOregon\nTennessee\nTexas\nUtah\nWashington\nPReventing Emerging Infections through Vaccine EffectiveNess Testing (PREVENT ) Sites\nOutcome: Symptomatic SARS-CoV-2 infections\nPopulation: Healthcare personnel\nParticipating Sites\nBaystate Medical Center, Springfield, MA\nJackson Memorial Hospital, Miami, FL\nOlive View-UCLA Medical Center, Los Angeles, CA\nThomas Jefferson University Hospital, Philadelphia, PA\nTruman Medical Centers, Kansas City, MO\nUniversity of Alabama Hospital, Birmingham, AL\nCommunity Regional Medical Center\/ UCSF, Fresno, CA\nUniversity of Chicago Medical Center, Chicago, IL\nUniversity of Iowa Hospitals and Clinics, Iowa City, IA\nUniversity of Massachusetts Memorial Medical Center, Worcester, MA\nLCMC Health Hospitals, New Orleans, LA\nUniversity of Mississippi Medical Center, Jackson, MS\nUniversity of Texas Southwestern Medical Center and Parkland Hospital, Dallas, TX\nUniversity of Washington Hospitals, Seattle, WA\nValleywise Health Medical Center, Phoenix, AZ.","845":"COVID-19 vaccines were developed using science that has been around for decades. Before COVID-19 vaccines were recommended, scientists conducted clinical trials with thousands of children and adults\nand found no serious safety concerns. Hundreds of millions of people in the United States have received COVID-19 vaccines under the most intensive safety\nmonitoring program in U.S. history. Serious side effects that could cause a long-term health problem are rare following any vaccination, including COVID-19\nvaccination. The benefits of COVID-19 vaccination outweigh the known and potential risks. More information on why children and teens should get vaccinated against COVID-19.","3895":"COVID-19 vaccination providers are\nresponsible for checking this web page regularly for any updates and are required to comply with these updates. How can I make sure I am complying with all components of the provider agreement? \uf1aa\nCDC has a variety of educational materials and resources for you and your patients. Visit Vaccine Recipient Education for\ninformation on communicating with patients about COVID-19 vaccines and educational materials for patients. My patients have a lot of questions. What resources can I refer them to? \uf1aa\nPage last reviewed: April 11, 2022","6379":"Some people with post-COVID conditions find it helpful to include:\nwhether symptoms have improved\nwhich treatments have improved symptoms\nany side effects\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\n-\f10\/30\/22, 9:42 AM Patient Tips: Healthcare Provider Appointments for Post-COVID Conditions | CDC\nany other new symptoms or changes\nMake a note to give your healthcare provider feedback about how recommended interventions have worked for you. Write down any issues you did not have time to talk about at the last appointment. Keep track of medications, vitamins, herbs, supplements, and over-the-counter drugs you take, using a current\nmedications and supplements list.","5714":"If you are 12 years and older and you are receiving vaccination for uses provided under EUI, you have a\nchoice of receiving the COVID-19 vaccine by either Moderna or Pfizer-BioNTech (see the Pfizer-BioNTech\nEUI Fact Sheet for Recipients and Caregivers). What are Emergency Use Instructions (EUI)? EUI are issued by CDC to provide information about emergency use of FDA-approved (licensed) medical\nproducts that may not be included in or differ in some way from the information provided in the FDA-\napproved labeling (package insert). EUI consist of fact sheets for healthcare providers and recipients.","6757":"WHAT SHOULD YOU MENTION TO YOUR CHILD\u2019S VACCINATION PROVIDER\nBEFORE YOUR CHILD GETS ANY OF THESE VACCINES? Tell the vaccination provider about all of your child\u2019s medical conditions,\nincluding if your child:\n\uf0b7 has any allergies\n\uf0b7 has had myocarditis (inflammation of the heart muscle) or pericarditis\n(inflammation of the lining outside the heart)\n\uf0b7 has a fever\n\uf0b7 has a bleeding disorder or is on a blood thinner\n5 Monovalent refers to any authorized or approved COVID-19 vaccine that contains or encodes the spike protein\nof only the Original SARS-CoV-2.","5":"cdc.gov\/coronavirus\nWhat to Expect after Getting a COVID-19 Vaccine\nThe COVID-19 shot may cause side effects in some people. Side effects should go away in a few days. On the arm where you got the shot:\n\u2022 Pain\n\u2022 Redness\n\u2022 Swelling\nIf you are sore where you got the shot:\n\u2022 Apply a clean, cool, wet washcloth over the area\n\u2022 Use or move your arm gently\nIf you have a fever:\n\u2022 Drink a lot of water\n\u2022 Get plenty of rest\n\u2022 Dress lightly\nIf you have pain, headache, or fever, ask a healthcare provider (or facility\nstaff) if you can have medicine.","9492":"However, vaccination providers may seek appropriate reimbursement from a\nprogram or plan that covers COVID-19 vaccine administration fees for the vaccine recipient\n(private insurance, Medicare, Medicaid, HRSA COVID-19 Uninsured Program for non-insured\nrecipients). WHERE CAN I REPORT CASES OF SUSPECTED FRAUD? Individuals becoming aware of any potential violations of the CDC COVID-19 Vaccination\nProgram requirements are encouraged to report them to the Office of the Inspector General, U.S.\nDepartment of Health and Human Services, at 1-800-HHS-TIPS or TIPS.HHS.GOV. WHAT IS THE COUNTERMEASURES INJURY COMPENSATION PROGRAM?","1528":"In addition, providers will post notice visible to the public at the site of any\nmask distribution under this initiative utilizing uniform signage that will be provided electronically by HHS, which,\nat a minimum, will address:\na. The masks have been provided by the U.S. Department of Health and Human Services for free distribution. b. The masks are provided for personal use only. c. And, the public notice will include a QR code and\/or weblink that can be used by recipients of the masks to\nobtain user instructions.","9392":"Tell the vaccination provider about all of your or your child\u2019s medical conditions, including if\nyou or your child:\n\u2022 have any allergies\n\u2022 have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of\nthe lining outside the heart)\n\u2022 have a fever\n\u2022 have a bleeding disorder or are on a blood thinner\n\u2022 are immunocompromised or are on a medicine that affects your or your child\u2019s immune\nsystem\n\u2022 are pregnant or plan to become pregnant\n\u2022 are breastfeeding\n\u2022 have received another COVID-19 vaccine\n\u2022 have ever fainted in association with an injection\nWHO SHOULD NOT GET SPIKEVAX (COVID-19 VACCINE, mRNA), MODERNA\nCOVID-19 VACCINE, OR MODERNA COVID-19 VACCINE, BIVALENT?","1248":"This includes 8 million doses administered onsite to long-\nterm care facilities in the early days of the COVID-19 vaccination program. A total of 21 retail pharmacy partners are participating in the program, with more than 41,000 locations nationwide. This includes long-term care pharmacies. How the Federal Retail Pharmacy Program Works\f10\/30\/22, 9:22 AM COVID-19 Vaccination Federal Retail Pharmacy Partnership Program | CDC\nParticipating Retail Pharmacies\n\uf42d\nConnecting with Federal Pharmacy Partners\n\uf18c\nCOVID-19 Vaccine Eligibility and Availability\nEveryone 6 months of age and older is eligible to get a COVID-19 vaccination.","6689":"Follow your Asthma Action Plan. Call 911 for medical emergencies. The person cleaning and disinfecting should:\nChoose disinfectants that are less likely to cause an asthma attack, using the U.S. Environmental Protection Agency\n(EPA)\u2019s list of approved products , such as:\nProducts with hydrogen peroxide (no stronger than 3%) or ethanol (ethyl alcohol). Ensure that products with\nhydrogen peroxide do not contain other chemicals that can trigger asthma attacks such as peroxyacetic acid\nor peracetic acid. Limit use of chemicals that can trigger asthma attacks, such as bleach (sodium hypochlorite) or quaternary\nammonium compounds (for example, benzalkonium chloride), and do not use them in enclosed spaces.","7509":"If you have received both doses of an accepted 2-dose vaccine series,\nregardless of how long it has been between doses, you are considered fully vaccinated. This means if you received a\nsingle dose of an accepted 2-dose series and then a booster dose of an accepted vaccine, you would be considered fully\nvaccinated under CDC\u2019s Amended Order because you have received two total doses. The second dose does not have to\nbe the same vaccine as the first, but both doses must be one of the accepted vaccines for you to be considered fully\nvaccinated.","8297":"If you are experiencing any of these symptoms, consider the following options:\nGet tested for COVID-19\nIf you have already tested positive for COVID-19, learn more about CDC\u2019s isolation guidance\n\u2022\n\u2022\nWhen to Seek Emergency Medical Attention\nLook for emergency warning signs* for COVID 19:\nTrouble breathing\nPersistent pain or pressure in the chest\nNew confusion\nInability to wake or stay awake\nPale, gray, or blue-colored skin, lips, or nail beds, depending on skin tone\nIf someone is showing any of these signs, call 911 or call ahead to your local emergency facility. Notify the operator that\nyou are seeking care for someone who has or may have COVID-19.","677":"January 27, 2022: California made updates to data previously submitted to CDC that resulted in a decrease of\n1,593,072 doses administered for California and a decrease of 800,606 doses administered at the National level\n(national level decrease factors in new administrations reported by other jurisdictions). January 21, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 29,394\ndoses administered. January 21, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n34,238 doses administered.","2085":"CDC will continue to follow\npeople vaccinated during all trimesters of pregnancy to better understand any effects of the vaccine on pregnancies\nand babies. Data show that receiving an mRNA COVID-19 vaccine during pregnancy reduces the risk of severe illness and other\nhealth effects from COVID-19 for people who are pregnant. Recent studies compared people who were pregnant and\nreceived an mRNA COVID-19 vaccine with pregnant people who did not. Scientists found that COVID-19 vaccination was\neffective at reducing the risk of getting very sick from COVID-19. One study that looked at people who were\nhospitalized during pregnancy found that most were not vaccinated.","4300":"If you have allergies related to vaccines\n\u2022\n\u2022 \uf209\nTalk to your doctor if you:\nhave had a severe allergic reaction to a previous dose to learn if you should get a different type of COVID-19\nvaccine,\nare allergic to polyethylene glycol (PEG) and you should not get Pfizer-BioNTech or Moderna COVID-19 vaccine,\nare allergic to polysorbate and you should not get Novavax or J&J\/Janssen COVID-19 vaccine\nif you are allergic to other types of vaccines or injectable medications for other diseases.","2948":"Currently, a booster dose using any COVID-\n19 vaccine is not authorized for children in this age group. Children age 5 years: A 2-dose primary series and 1 bivalent Pfizer-BioNTech booster dose is recommended. The primary\nseries doses are separated by 3\u20138 weeks and the bivalent booster dose is administered at least 2 months after\ncompletion of the primary series (for people who have not received any booster doses), or at least 2 months after the\nlast monovalent booster dose. Currently, only the bivalent Pfizer-BioNTech booster dose is authorized for children age 5\nyears who receive a Pfizer-BioNTech primary series.","5255":"\u2022\nYour symptoms are not improving\nContinue to isolate until:\nYou are fever-free for 24 hours (without the use of\nfever-reducing medication). Your symptoms are improving. \u2022\nModerate illness (you experienced shortness of\nbreath or had difficulty breathing)\nYou need to isolate through day 10. Severe illness (you were hospitalized) or have a\nweakened immune system\nYou need to isolate through day 10. \u2022\f10\/30\/22, 9:41 AM Isolation and Precautions for People with COVID-19 | CDC\nRegardless of when you end isolation\nUntil at least day 11:\nAvoid being around people who are more likely to get very sick from COVID-19.","6140":"WHO Strategic Advisory Group of Experts on Immunization (SAGE). Interim recommendations for use of the\ninactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm; updated 28\nOctober 2021. Geneva: World Health Organization; 2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-\n2019-nCoV-vaccines-SAGE-recommendation-BIBP. Zhong D, Xiao S, Debes AK, Egbert ER, Caturegli P, Colantuoni E, et al. Durability of Antibody Levels After\nVaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. JAMA. 2021 Dec","4064":"However, public health\nexperts are seeing reduced protection over time against mild and moderate disease, especially among certain\npopulations. If we need a booster, are the vaccines working? \uf1aa\n\uf20c\nYes. COVID-19 boosters are the same ingredients (formulation) as the current COVID-19 vaccines. Do boosters use the same ingredients as existing vaccines? \uf1aa\f10\/30\/22, 9:18 AM Frequently Asked Questions about COVID-19 Vaccination | CDC\nAdults and children may have some side effects from a COVID-19 vaccine, including pain, redness or swelling at the\ninjection site, tiredness, headache, muscle pain, chills, fever, and nausea. Serious side effects are rare, but may occur.","6226":"This process is a part of normal\nbody functioning. COVID-19 vaccines do NOT contain ingredients like preservatives, tissues (like aborted fetal cells), antibiotics, food\nproteins, medicines, latex, or metals. 10\/30\/22, 9:34 AM Myths and Facts about COVID-19 Vaccines | CDC\nLearn more about what ingredients are and are not in Pfizer-BioNTech, Moderna, Novavax, or Johnson &\nJohnson\/Janssen COVID-19 vaccines. MYTH: The natural immunity I get from being sick with COVID-19 is better than the immunity I\nget from COVID-19 vaccination. FACT: Getting a COVID-19 vaccination is a safer and more dependable way to build immunity to COVID-19 than\ngetting sick with COVID-19.","5987":"In this study, adults who had completed primary vaccination with a\nModerna COVID-19 Vaccine 2-dose series (N=151), a Janssen COVID-19 Vaccine single dose (N=156), or a\nPfizer-BioNTech COVID-19 Vaccine 2-dose series (N=151) at least 12 weeks (range 12 to 20 weeks) prior to\nenrollment and who reported no history of SARS-CoV-2 infection were randomized 1:1:1 to receive a booster\ndose of one of three vaccines: Moderna COVID-19 Vaccine, Janssen COVID-19 Vaccine, or Pfizer-BioNTech\nCOVID-19 Vaccine.","5412":"The Countermeasures Injury Compensation Program (CICP) is a federal program that may help\npay for costs of medical care and other specific expenses for certain people who have been\nseriously injured by certain medicines or vaccines, including this vaccine. Generally, a claim must\nbe submitted to the CICP within one (1) year from the date of receiving the vaccine. To learn more\nabout this program, visit www.hrsa.gov\/cicp or call 1-855-266-2427. WHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)? The United States FDA has made the Janssen COVID-19 Vaccine available under an emergency\naccess mechanism called an EUA.","6894":"The COVID-19 vaccine by Moderna can also be used under EUI for similar uses as an alternative mRNA\nCOVID-19 vaccine (see the Moderna EUI Fact Sheet for Recipients), and the same or similar\nrecommendations in this EUI also apply to the use of the COVID-19 vaccine by Moderna under EUI. What is COVID-19? Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a coronavirus called SARS-CoV-2. It\nis predominantly a respiratory illness that can affect other organs. People with SARS-CoV-2 infection have\nreported a wide range of symptoms, from no symptoms to severe illness leading to death.","2198":"Nir O, Schwartz A, Toussia-Cohen S, et al. Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies\namong parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy. Am J Obstet Gynecol 2022;\n20. Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort\nstudy. Am J Obstet Gynecol. Published online March 25, 2021. DOI: https:\/\/doi.org\/10.1016\/j.ajog.2021.03.023\n21. Shook LL, Atyeo CG, Yonker LM, et al. Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination\nor Natural Infection. JAMA. Published online February 07, 2022. DOI: https:\/\/doi.org\/10.1001\/jama.2022.1206\n22. Halasa NB, Olson SM, Staat MA, et al.","8654":"\u2022\n\u2022\n\u2022\nInitial Development\n\uf1aa\n\uf33d New vaccines are first developed in laboratories. Scientists have been working for many years to develop\nvaccines against coronaviruses, such as those that cause severe acute respiratory syndrome (SARS) and\nMiddle East respiratory syndrome (MERS). SARS-CoV-2, the virus that causes COVID-19, is related to these\nother coronaviruses. The knowledge that was gained through past research on coronavirus vaccines\nhelped speed up the initial development of the current COVID-19 vaccines. Clinical Trials\n\uf1aa\n\uf3ba After initial laboratory development, vaccines go through three phases of clinical trials to make sure they\nare safe and effective. No trial phases have been skipped.","6826":"Vaccinations may not provide full\nimmunity to COVID-19 in people who are immunocompromised, and you should\ncontinue to have your child maintain physical precautions to help prevent COVID-19. In addition, your child\u2019s close contacts should be vaccinated as appropriate. WHAT ABOUT PREGNANCY OR BREASTFEEDING? If your child is pregnant or breastfeeding, discuss the options with your healthcare\nprovider. WILL THESE VACCINES GIVE MY CHILD COVID-19? No. These vaccines do not contain SARS-CoV-2 and cannot give your child COVID-19. KEEP YOUR CHILD\u2019S VACCINATION CARD\nWhen your child gets the first COVID-19 vaccine, you will get a vaccination card.","8065":"Further\nlaboratory tests are being conducted to look more closely at the virus genome and other potential pathogens, such as\niCDC-INFO\fCOVID-19 State of Vaccine Confidence Insights Report | October 10, 2022\nSARS-CoV-2.","6454":"What to do if you test positive for COVID-19\nEffective treatments are now widely available and free, and you may be eligible. Contact your healthcare provider, health department, or Community Health Center to learn about treatment\noptions. Don\u2019t delay! Treatment must be started soon after you first develop symptoms to be effective. If you don\u2019t have timely access to a healthcare provider, check if a Test to Treat location is in your community. You\ncan get tested, receive a prescription from a healthcare provider (either onsite or by telehealth), and have it filled all at\none location.","4875":"\u00a7\n\u00b6\n\u00a7\n*\n\u2020\n\u2021\n\u00a7\n\u00b6\n\uf209 \uf209\n#\nTable of Contents \uf426\nCONTRAINDICATION TO COVID-19\nVACCINATION PRECAUTION TO COVID-19 VACCINATION\nNO CONTRAINDICATION OR\nPRECAUTION TO COVID-19\nVACCINATION\nAppendix E. Triage of people with a history of allergies or allergic reactions\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nCONTRAINDICATION TO COVID-19\nVACCINATION PRECAUTION TO COVID-19 VACCINATION\nNO CONTRAINDICATION OR\nPRECAUTION TO COVID-19\nVACCINATION\nHistory of the following:\nSevere allergic reaction (e.g.,\nanaphylaxis) after a previous\ndose or to a component of a\nKnown (diagnosed) allergy to a\ncomponent of a COVID-19\nvaccine\nAmong people without a contraindication, a history\nof:\nAnaphylaxis after non-COVID-19 vaccines or\ninjectable therapies\nNon-severe, immediate (onset within 4 hours)\nallergic reaction after a previous dose of\nNote: People with an allergy-related\ncontraindication to one type of COVID-19 vaccine\nhave a precaution to the other types of COVID-19\nvaccines.","2336":"\u2022\n\u2022\n-\n-\n\u2022\n\u2022\n\u2022 TM\nPre-teens, Teens and Adults Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nAGE GROUP\n18 YEARS AND OLDER\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nModerna\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nJohnson & Johnson's Janssen\n\uf1aa\nPRIMARY SERIES\nADDITIONAL DOSE\nAt least 4 weeks after 1st dose\nand should be Pfizer-BioNTech\nor Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nor last booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nNovavax\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nA monovalent Novavax booster\nis available in limited situations\nMore details: Novavax booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nChildren Ages 6 Months-11 Years Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 8 weeks after 2nd dose\nUp to Date: 2 weeks after 3rd dose in primary series, since a booster is not recommended for this age group at this\ntime\nAGE GROUP\nModerna\n\uf1aa\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nIf you have completed your primary series\u2014but are not yet eligible for a booster\u2014you are also considered up to date.","8203":"Up to Date: Immediately after you have received the most recent booster recommended for you\nMore details: Staying up to date\f10\/30\/22, 9:27 AM Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC\nAGE GROUP\nPfizer-BioNTech Vaccine Overview\nPfizer-BioNTech\nPRIMARY SERIES\nPfizer-BioNTech\nPRIMARY SERIES\n3\u20138 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech or Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nor last booster\nUp to Date: Immediately after you have received the most recent booster recommended for you\nMore details: Staying up to date\nAGE GROUP\nAGE GROUP\nModerna\n\uf1aa\nModerna\nPRIMARY SERIES\nModerna\nPRIMARY SERIES\n4\u20138 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech\nUPDATED (BIVALENT) BOOSTER\nChildren 5 years of age can get a\nPfizer-BioNTech booster at least\n2 months after their 2nd dose.","1309":"\uf1aa\nVaccine Dosage and Formulation\f10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\nCDC recommends that people should receive the age-appropriate vaccine dosage based on their age on the day of\nvaccination. If a person moves from a younger age group to an older age group during the primary series or between the\nprimary series and receipt of the booster dose, they should receive the vaccine dosage for the older age group for all\nsubsequent doses. However, Food and Drug Administration (FDA) authorization allows for different dosing for certain age transitions.","3309":"In age groups where product comparisons can be made (i.e., 18\u201339 years), some evidence suggests that the risk of\nmyocarditis and pericarditis may be higher following vaccination with Moderna COVID-19 Vaccine relative to Pfizer-BioNTech\nCOVID-19 Vaccine; however, findings are not consistent in all U.S. monitoring systems. In post-authorization surveillance , cases of myocarditis and pericarditis among children ages 5\u201311 years after Pfizer-\nBioNTech COVID-19 vaccination have been rarely reported, primarily in males and after dose 2; the reporting rate of\nmyocarditis in VAERS following dose 2 of Pfizer-BioNTech marginally exceeded the background incidence rate for male\nchildren in this age group.","5513":"Living with a post-COVID condition can be hard, especially when there are no immediate answers or solutions. Talk to your doctor if you think you or your child has long COVID or a post-COVID condition. Learn more: Tips for\nTalking to Your Healthcare Provider about Post-COVID Conditions\n\uf3b7\nData for Long COVID\nCDC is using multiple approaches to estimate how many people experience post-COVID conditions. Each approach can\nprovide a piece of the puzzle to give us a better picture of who is experiencing post-COVID conditions.","2491":"Learn more about the factors that can\naffect your risk of getting very sick from COVID-19 to better understand how COVID-19 could affect you and others around\nyou. Know Your COVID-19 Community Level\nTake action to protect yourself and others from COVID-19 based on the COVID-19 Community Level in your area. What You Need to Know\nCOVID-19 Community Levels help individuals and communities decide which prevention actions to take based on\nthe latest information. Each level helps convey how much COVID-19 is impacting your community using data on hospitalizations and\ncases. Using these data, communities are classified as low, medium, or high.","6767":"Booster Dose:\nThe Pfizer-BioNTech COVID-19 Vaccine, Bivalent is administered as a single booster\ndose at least 2 months after:\n\uf0b7 completion of primary vaccination with any authorized or approved monovalent\nCOVID-19 vaccine; or\n\uf0b7 receipt of the most recent booster dose with any authorized or approved\nmonovalent COVID-19 vaccine. The vaccine may not protect everyone. WHO SHOULD NOT GET THE PFIZER-BIONTECH COVID-19 VACCINE OR THE\nPFIZER-BIONTECH COVID-19 VACCINE, BIVALENT? Your child should not get any of these vaccines if your child:\n\uf0b7 had a severe allergic reaction after a previous dose of the Pfizer-BioNTech\nCOVID-19 Vaccine. \uf0b7 had a severe allergic reaction to any ingredient in these vaccines.","3664":"Traveling by private vehicle (if possible) can lower\nthe chances of spreading COVID-19 to others. 10\/30\/22, 9:42 AM Domestic Travel During COVID-19 | CDC\nDuring Travel\nProtect Yourself and Others\nAfter Travel\n\uf48e RECOMMENDED\nFollow CDC\u2019s recommendations for wearing masks in travel and public transportation settings. Follow recommendations for protecting yourself and others. Follow all \u202fstate, tribal, local, and territorial health recommendations and requirements at your\ndestination. \uf3c0 ALL Travelers\nRECOMMENDED\nGet tested with a viral test if your travel involved situations with greater risk of exposure such as being in\ncrowded places while not wearing a high-quality mask or respirator.","8492":"Do not travel on public\ntransportation such as airplanes, buses, and trains if you will not be able to wear a high-quality mask or respirator when\naround others indoors for the full duration of your trip. Find out when you can travel and steps to take to protect others\nduring you trip. If you had COVID-19 in the past 90 days, see specific testing recommendations before you travel. Follow other travel recommendations and requirements for domestic and international travel. Can I travel if I recently had COVID-19? \uf1aa\nIf you test positive during your trip, do not travel and follow recommendations for isolation.","4708":"People with a history of an episode of an immune-mediated syndrome characterized by thrombosis and thrombocytopenia,\nsuch as spontaneous or classic HIT, should not receive Janssen COVID-19 Vaccine. These people should receive a currently\nFDA-approved or FDA-authorized mRNA (i.e., Moderna or Pfizer-BioNTech) or Novavax COVID-19 vaccine. Available evidence does not indicate that other thromboembolic conditions (e.g., inherited or acquired thrombophilia,\npregnancy, hormonal contraception use) increase the risk of TTS. Guillain-Barr\u00e9 syndrome (GBS)\nVaccine safety monitoring suggests an elevated risk of GBS after Janssen COVID-19 vaccination with proportionally more\nGBS cases observed after Janssen COVID-19 vaccination compared with mRNA COVID-19 vaccination.","5956":"\u2022 Provide a CDC COVID-19 Vaccination Record Card to the recipient or their caregiver with the lot number\nand date of administration recorded for the primary, additional, or booster dose of the COVID-19 vaccine\nby Moderna. \u2022 Provide the v-safe information sheet to vaccine recipients\/caregivers and encourage vaccine recipients\nto participate in v-safe. V-safe is a voluntary smartphone-based tool that uses text messaging and web\nsurveys to check in with people who have been vaccinated to identify potential side effects after COVID-\n19 vaccination. V-safe asks questions that help CDC monitor the safety of COVID-19 vaccines. For more\ninformation, visit: www.cdc.gov\/vsafe.","8489":"Do not travel on public\ntransportation such as airplanes, buses, and trains if you will not be able to wear a high-quality mask or respirator when\naround others indoors for the full duration of your trip. Find out when you can travel and steps to take to protect others\nduring you trip. If you had COVID-19 in the past 90 days, see specific testing recommendations before you travel. Follow other travel recommendations and requirements for domestic and international travel. Can I travel if I recently had COVID-19? \uf1aa\nIf you test positive during your trip, do not travel and follow recommendations for isolation.","5738":"\u2022 People ages 12 years and older, especially those at higher risk of myocarditis associated with mRNA\nCOVID-19 vaccines, may receive the second primary dose of the COVID-19 vaccine by Moderna 4\u20138\nweeks after the first primary dose. The second dose should not be received earlier than 4 weeks\nafter the first dose.","786":"Just as a family has a\nfamily tree, the SARS-CoV-2 virus can be similarly mapped out. Sometimes branches of that tree have different attributes that\nchange how fast the virus spreads, or the severity of illness it causes, or the effectiveness of treatments against it. Scientists\ncall the viruses with these changes \u201cvariants\u201d. They are still SARS-CoV-2, but may act differently. Last Updated Nov 4 2021\f10\/30\/22, 9:37 AM Basics of COVID-19 | CDC\nLast Updated Nov. 4, 2021","7506":"If you have received both doses of an accepted 2-dose vaccine series,\nregardless of how long it has been between doses, you are considered fully vaccinated. This means if you received a\nsingle dose of an accepted 2-dose series and then a booster dose of an accepted vaccine, you would be considered fully\nvaccinated under CDC\u2019s Amended Order because you have received two total doses. The second dose does not have to\nbe the same vaccine as the first, but both doses must be one of the accepted vaccines for you to be considered fully\nvaccinated.","1533":"U.S. Government Property\nMasks provided through this initiative are U.S. government property and remain U.S. government property until\nreceived by the individual who intends to wear the mask. Any sale, diversion, or other distribution of these masks for\npayment, whether direct or indirect, is prohibited and may be subject to civil or criminal prosecution. Provider may terminate its participation in the Mask Distribution Initiative by notifying the SNS without impacting\nparticipation in the CDC COVID-19 Vaccination Program. Any remaining inventory of USG-purchased N95 masks will\nbe distributed in conformance with Agreement.","1947":"If an unexpected\nadverse event is seen, experts quickly study it further to assess whether it is a true safety concern. Experts then decide whether changes are needed in U.S. vaccine recommendations or clinical guidance. This monitoring is critical to help ensure that the benefits continue to outweigh the risks for people who receive\nvaccines. FDA\u2019s COVID-19 Vaccines website includes important recommendations for ongoing safety evaluation after any\nCOVID-19 vaccine is made available under EUA . CDC has expanded safety surveillance through new systems and additional information sources, as well as by scaling up\nexisting safety monitoring systems.","8414":"Core Competencies:\nRelevant information contained in the EUA Fact Sheet(s) for Healthcare Providers for the vaccine product(s) in\nyour facility\nClinical considerations\nStorage and handling requirements\nPreparation requirements\nAdministration requirements\nAnaphylaxis guidance\nVaccination documentation and reporting requirements\nRequired and additional information for vaccine recipients\nCOVID-19 Vaccine Administration Competencies Assessment Form\nHealthcare professionals or retired (past 5 years) physicians, nurses, or\npractical nurses who are licensed\/previously licensed to administer\nCOVID-19 vaccine but have not done so in the last 12 months\n\uf209\n\uf20c\nCOVID-19 Vaccine Training Routine Vaccine Administration Routine Vaccine Storage and Handling\nVaccination support workers (not licensed to administer vaccine) qualified\nto prepare, store, handle, or transport vaccine\f10\/30\/22, 9:17 AM Training and Education for COVID-19 Vaccination | CDC\nCOVID-19 Vaccine Training Routine Vaccine Administration Routine Vaccine Storage and Handling\nCDC Training Module(s) for the\nvaccine product(s) in your facility\nIf needed: You Call the Shots: Vaccine\nAdministration\nOr other vaccine administration\ntraining offered by a worksite, state or\nlocal health department, medical\nprofessional organization, or\nmedical\/nursing school within the last\n12 months.","7497":"\uf1aa\nCDC recommends that people stay up to date on their COVID-19 vaccines by getting booster shots when eligible. However, CDC\u2019s Amended Order is keeping the requirement to only have to show proof of being fully vaccinated with a\nprimary series of an accepted COVID-19 vaccine at this time to board a flight to the United States. While booster doses for COVID-19 vaccines approved or authorized by the Food and Drug Administration are widely\navailable for those eligible in the United States, many other countries do not offer booster doses because of limits on\navailable vaccines.","1377":"My patient previously received a monovalent mRNA booster dose(s). Can they get a bivalent\nbooster dose? \uf1aa\nThe current recommendation is for everyone who is eligible to receive 1 bivalent booster dose: this includes people who\nreceived the primary series but did not receive the previously recommended monovalent mRNA booster dose(s) and\npeople who received 1 or 2 monovalent mRNA booster doses. Because the guidance has changed, not everyone will\nreceive the same number of booster doses. However, once a person receives 1 bivalent booster dose, no additional\nbooster doses are currently recommended.","4328":"\u2022\n\u2022\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nWatch Video: Use v-safe to tell CDC how you\u2019re feeling after COVID-19 vaccination [00:00:34]\nYour CDC COVID-19 Vaccination Card\nBring your card to your appointment whenever you get a primary\nseries dose or booster so that your provider can fill in information\nabout your shot. If your vaccine card is full, your vaccine provider can give you another\ncard. If you did not receive a CDC COVID-19 vaccination card at your first\nappointment, contact the vaccination provider site where you got\nyour first shot to find out how you can get a vaccination card.","9848":"Benotmane, I., Bruel T., Planas, D., Fafi-Kremer, S., Schwarz, O., Caillard, S. A fourth dose of the mRNA-1273\nSARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients. Buchan SA, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by\nvaccine product, schedule and interval. Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nCDC. Science Brief: SARS-CoV-2 infection-induced and vaccine-induced immunity. 2021. Disanto G, Sacco R, Bernasconi, E. Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing\nWith Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis. JAMA Neurology. 2021;78(12):1529-1531. FDA.","241":"Antibody tests are not currently\nrecommended by FDA for routine, widespread use in making individual medical decisions while this information is being\ngathered and evaluated. If you have questions about whether an antibody test is right for you, talk with your healthcare\nprovider or your state or local health department. Not all antibody tests identify the same antibodies. Some antibody tests are more or less sensitive to specific sections of the\nantibody protein than others. This means that different antibody tests might not have the same results, even when they are\nboth testing for antibodies to SARS-CoV-2.","8588":"This immune response, which produces antibodies, is what\nhelps protect us from getting sick from that germ in the future. About Pfizer-BioNTech and Moderna\nResearch for mRNA technology\nResearchers have been studying and working with mRNA vaccines for decades . In fact, mRNA vaccines have been studied before for flu, Zika, rabies, and cytomegalovirus (CMV). Beyond vaccines, cancer research has also used mRNA to trigger the immune system to target specific cancer cells. Protein subunit vaccines (Novavax)\nVaccines do not use any live virus. Vaccines cannot cause infection with the virus that causes COVID-19 or other viruses.","4006":"Vaccination data in CDC\u2019s COVID Data Tracker are updated weekly on\nThursday between 1:30 pm and 8:00 pm ET. On federal holidays, updates will occur the following day. Data can be updated on different schedules and reflect data \u201cas of\u201d different dates or times of day. There can be a\ndelay between the time a vaccination record appears in a jurisdictional or federal system and when it is received\nby CDC. COVID Data Tracker\u2019s vaccination data typically have a lag time from vaccination data shown on a state\u2019s\nwebsite. The amount of lag time varies for each state.","8852":"Creating an account to add a dependent does not require that you enter your own vaccination information or complete\nhealth check-ins for yourself. What Happens After I Enroll? During the first week after each vaccination, v-safe will send you a text message each day to ask how you are feeling. After\nthat, you will receive occasional health check-ins. Depending on your answers, someone from CDC may call to get more\ninformation. You can opt out at any time. Your personal information in v-safe is protected so it\u2019s safe and private*.","8691":"10\/30\/22, 9:37 AM Understanding Variants | CDC\nUnderstanding Variants\nThe virus that causes COVID-19 is constantly changing, and new variants of the virus are expected to occur. Sometimes\nnew variants emerge and disappear. Other times, new variants persist. Numerous variants of the virus that causes\nCOVID-19 are being tracked in the United States and globally during this pandemic. How Variants Work\nIf you think about a virus like a tree growing and branching out; each branch on the tree is slightly different than the\nothers. By comparing the branches, scientists can label them according to the differences.","9038":"Visit CDC\u2019s COVID Data Tracker for the most current data on circulating\nvariants. Omicron spreads more easily than earlier variants, including the Delta variant. Anyone with Omicron infection, regardless of vaccination status or whether or not they have symptoms, can\nspread the virus to others. Data suggest that Omicron can cause reinfection, even in people who have\nrecovered from COVID-19. Symptoms are similar to previous variants\nCOVID-19 vaccination status, other health conditions, age, and history of prior infection can affect the presence\nand severity of symptoms.","9023":"Learn more about selected adverse events reported to VAERS. Updates on COVID 19 and Pregnancy (ACIP meeting slides)\nMonitoring the safety of COVID-19 vaccines in pregnancy in the U.S.\n\u2022 \uf20c\n\u2022 \uf209\n\uf209\n\uf209 \uf209\n\uf209\nRelated Pages\nCOVID-19 Vaccine Safety and Monitoring\n\u203a\nCOVID-19 Vaccines While Pregnant or Breastfeeding\n\u203a\nBenefits of Getting a COVID-19 Vaccine\n\u203a\nMyths and Facts about COVID-19 Vaccines\n\u203a\nCOVID Data Tracker: COVID-19 Vaccination Among Pregnant People\n\u203a\nLast Updated July 18, 2022","3778":"10\/30\/22, 9:31 AM Ensuring COVID-19 Vaccine Safety in the US | CDC\nEspa\u00f1ol | Other Languages\nEnsuring COVID-19 Vaccine Safety in the US\nVaccine Safety and Monitoring\nCOVID-19 vaccines were developed using science that has been around for decades. COVID-19 vaccines are safe, and meet the Food and Drug Administration\u2019s (FDA\u2019s)\nrigorous scientific standards for safety, effectiveness, and manufacturing quality. COVID 19-vaccines are effective at preventing severe illness from COVID-19 and\nlimiting the spread of the virus that causes it. Millions of people in the United States have received COVID-19 vaccines. COVID-19 vaccines are monitored by the most intense safety monitoring efforts in\nU.S. history.","934":"Fever (a temperature of 100.4 or higher is considered an emergency)\nLethargy (being overly tired or inactive)\nRunny nose\nCough\nVomiting\nDiarrhea\n-\n\u2022\n\u2022\n-\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\n-\n\u2022\n-\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:41 AM Breastfeeding and Caring for Newborns if You Have COVID-19 | CDC\nPoor feeding\nIncreased work of breathing or shallow breathing\nSee CDC\u2019s webpage on Evaluation and Management Considerations for Neonates At Risk for COVID-19 for more information. Breastfeeding and COVID-19\nCurrent evidence suggests that breast milk is not likely to spread the virus to babies. COVID-19 vaccination is recommended for people who are pregnant, breastfeeding, trying to get pregnant now, or might\nbecome pregnant in the future.","5224":"This information is intended for a general audience. Healthcare professionals should see Ending Isolation and Precautions for\nPeople with COVID-19. This CDC guidance is meant to supplement\u2014not replace\u2014any federal, state, local, territorial, or tribal\nhealth and safety laws, rules, and regulations. Regardless of vaccination status, you should isolate from others when you have COVID-19. You should also isolate if you are sick and suspect that you have COVID-19 but do not yet have test results. If your results are\npositive, follow the full isolation recommendations below. If your results are negative, you can end your isolation.","4466":"\u2022 \uf209\n\u2022\n\uf209\n\u2022 \uf209\f10\/30\/22, 9:39 AM How to Protect Yourself and Others | CDC\nFollowing Recommendations for What to Do If You Have Been Exposed\nIf you were exposed to someone with\nCOVID-19, you may have been infected\nwith the virus. Follow CDC\u2019s\nrecommendations for what to do if you\nwere exposed. This includes wearing a\nhigh-quality mask when indoors\naround others (including inside your\nhome) for 10 days, testing, and\nmonitoring yourself for symptoms. Staying Home When You Have Suspected or Confirmed COVID-19\nIf you have COVID-19, you can spread it to others, even if you do not have symptoms.","5910":"People who received both 1\nprimary dose and 1 booster dose of the Janssen COVID-19 Vaccine or 1 primary dose of the Janssen\nCOVID-19 Vaccine followed by 1 booster dose of an mRNA COVID-19 vaccine should receive an\nadditional dose with the COVID-19 vaccine by Moderna (100 \u03bcg in 0.5 mL from red-capped multidose\nvial) at least 2 months after the booster dose. \u2022 Revaccination with the COVID-19 vaccine by Moderna for any primary doses received before or during\ntreatment with certain therapies (indicated below) for persons ages 12 years and older.","5161":"\uf3c0 ALL Travelers\nRECOMMENDED\nG t t t d ith i l t t 3 5 d ft i l\f10\/30\/22, 9:43 AM International Travel to and from the United States | CDC\nGet tested with a viral test 3-5 days after arrival. Find a U.S. COVID-19 testing location near you or use a self-test. If you already had COVID-19 within the past 90 days, see specific testing recommendations. Monitor yourself for COVID-19 symptoms. Follow additional guidance if you know you were exposed to a person with COVID-19. Follow all state, tribal, local and territorial recommendations or requirements after arrival.","8596":"They do not affect or interact with our DNA. These vaccines do not enter the nucleus of the cell where our DNA (genetic material) is located, so it cannot\nchange or influence our genes. \u2022\n\u2022\n\u2022\n\uf426\n\uf209\n\u2022\n\u2022 \uf209\nFirst, mRNA COVID-19 vaccines are given in the upper arm muscle or upper thigh, depending on the age of who is\ngetting vaccinated. After vaccination, the mRNA will enter the muscle cells. Once inside, they use the cells\u2019 machinery to produce a\nharmless piece of what is called the spike protein. The spike protein is found on the surface of the virus that causes\nCOVID-19.","7663":"10\/30\/22, 9:31 AM Safety of COVID-19 Vaccines | CDC\nEspa\u00f1ol | Other Languages\nSafety of COVID-19 Vaccines\nWhat You Need to Know\nCOVID-19 vaccines are safe and effective. Millions of people in the United States have received COVID-19 vaccines under the most intense safety monitoring\nin US history. CDC recommends COVID-19 vaccines for everyone 6 months and older and boosters for everyone 5 years and\nolder, if eligible. \u2022\n\u2022\n\u2022\nHundreds of Millions of People Have Safely Received a COVID-19\nVaccine\nMore than 632 million doses of COVID-19 vaccine have been given in the United States from December 14, 2020, through\nOctober 19, 2022.","1162":"The data used for these calculations are from the\u202fCensus Bureau Annual Estimates of the Resident Population for the\nUnited States (50 states and Washington D.C.) and Puerto Rico, 2019 . CDC uses\u202f2020 U.S. Census International Data Base \u202festimates for American Samoa, Federated States of Micronesia,\nGuam, Republic of the Marshall Islands, Republic of Palau, Republic of the Marshall Islands, and U.S. Virgin Islands. CDC\/ATSDR & Surgo Ventures\nSocial Vulnerability Index (SVI) scores, which range from 0 to 1, are from\u202fCDC\/ATSDR\u2019s Geospatial Research, Analysis, and\nService Program. COVID-19 Community Vulnerability Index (CCVI) scores, which also range from 0 to 1, are from\u202fSurgo\nVentures.","9075":"\uf106 As of 12:01AM ET on June 12, 2022, CDC will no longer require air passengers traveling from a foreign\ncountry to the United States to show a negative COVID-19 viral test or documentation of recovery from\nCOVID-19 before they board their flight. For more information, see Rescission: Requirement for Negative\nPre-Departure COVID-19 Test Result or Documentation of Recovery from COVID-19 for all Airline or Other\nAircraft Passengers Arriving into the United States from Any Foreign Country. Learn when you should get tested for COVID-19, how you can find tests, and what your test\nresult means.","6640":"Do not delay getting care for your medical condition because of COVID-19. Emergency departments, urgent care, clinics,\nand your healthcare provider have infection prevention plans to help protect you from getting COVID-19 if you need\ncare. Continue medications and preventive care\nContinue your medicines and do not change your treatment plan without talking to your healthcare provider. Have at least a 30-day supply of prescription and non-prescription medicines. Talk to a healthcare provider, insurer, or\npharmacist about getting an extra supply (i.e., more than 30 days) of prescription medicines, if possible, to reduce your\ntrips to the pharmacy.","2396":"When are people who have weakened immune systems considered up to date with their COVID-\n\uf1aa\nPeople can stay up to date with COVID-19 vaccination by completing a primary series and receiving the most recent\nbooster dose recommended for them by CDC. The people you live or spend time with can help protect you and\nthemselves by staying up to date on their COVID-19 vaccines too. When are people who have weakened immune systems considered up to date with their COVID-\n\uf1aa\nYou are up to date if you receive all COVID-19 vaccine doses recommended for you, even if you become ill with COVID-19.","5145":"\uf209\n\uf195 Contact Information \u2013 ALL Travelers\nREQUIRED\nAll air passengers to the United States are required to provide contact information to airlines before boarding\nflights to the United States. This strengthens a travel process already in place to rapidly identify and contact people in the U.S. who\nmay have been exposed to a communicable disease, such as COVID-19. Access to travelers\u2019 contact information will allow U.S. federal, state, territorial and local health\ndepartments, and agencies to share appropriate health and public health information necessary to help\nkeep the public safe.","3222":"Procedures should be in\nplace to prevent falling injuries and manage syncopal reactions. Patients should be seated or lying down during vaccination. Vaccination providers, particularly when vaccinating adolescents, should consider observing vaccine recipients for 15 minutes\nafter vaccination. If syncope develops, patients should be observed until symptoms resolve.","5257":"\u2022\nYour symptoms are not improving\nContinue to isolate until:\nYou are fever-free for 24 hours (without the use of\nfever-reducing medication). Your symptoms are improving. \u2022\nModerate illness (you experienced shortness of\nbreath or had difficulty breathing)\nYou need to isolate through day 10. Severe illness (you were hospitalized) or have a\nweakened immune system\nYou need to isolate through day 10. \u2022\f10\/30\/22, 9:41 AM Isolation and Precautions for People with COVID-19 | CDC\nRegardless of when you end isolation\nUntil at least day 11:\nAvoid being around people who are more likely to get very sick from COVID-19.","2688":"Masks should not be placed on young children under age 2, anyone who has trouble breathing, or is not able to\nremove the covering without help. Caregiver\nPut on a mask and ask the sick person to put on a mask before entering the room. \u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:41 AM COVID19 - Caring for someone at home | CDC\np p g\nWear gloves when you touch or have contact with the sick person\u2019s blood, stool, or body fluids, such as saliva,\nmucus, vomit, and urine. Throw out gloves into a lined trash can and wash your hands right away.","9034":"CDC is working with state and local public health officials to monitor the spread of all variants. The Omicron variant continues to spread throughout communities and can infect people who have been\nvaccinated or have previously had COVID-19. Staying up to date with your COVID-19 vaccines reduces your risk of severe illness, hospitalization, and death from\nCOVID-19. \u2022\n\u2022\n\u2022\n\u2022\nVARIANT OF CONCERN\nOmicron\nOriginal Lineage: B.1.1.529\nThe Omicron variant, like other variants, is made up of a number of lineages and sublineages. These lineages are often very similar to each other; however, there may be differences between lineages that\naffect the behavior of the virus.","4676":"GBS within 6 weeks after receipt of Janssen COVID-19 Vaccine Not\nrecommended\nDo not vaccinate with Janssen COVID-19 Vaccine. These people\nshould receive a booster dose using a bivalent mRNA COVID-19\nvaccine. History of GBS Precaution See FAQs and GBS section (below) for additional information. Abbreviations: TTS = thrombosis with thrombocytopenia syndrome; HIT = heparin-induced thrombocytopenia; GBS = Guillain-Barr\u00e9 syndrome\nPost-vaccination symptoms\nIn clinical trials of Janssen COVID-19 Vaccine, pain at the injection site was the most frequently reported local reaction among\nvaccine recipients; erythema and swelling were reported less frequently. Fatigue and headache were the most commonly\nreported systemic reactions.","4381":"Conventional water treatment methods that use filtration and disinfection, such as those in\nmost municipal drinking water systems, should remove or kill the virus that causes COVID-19.\u200b\f10\/30\/22, 9:37 AM How Coronavirus Spreads | CDC\nNatural Bodies of Water (Lakes, Oceans, Rivers)\nThere are no scientific reports of the virus that causes COVID-19 spreading to people through the water in lakes, oceans,\nrivers, or other natural bodies of water. Wastewater\nGenetic material from the virus that causes COVID-19 has been found in untreated wastewater (also referred to as \u201csewage\u201d).","7182":"It is predominantly a\nrespiratory illness that can affect other organs. People with COVID-19 have had a wide\nrange of symptoms reported, ranging from mild symptoms to severe illness leading to\ndeath. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may\ninclude: fever or chills; cough; shortness of breath; fatigue; muscle or body aches;\nheadache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or\nvomiting; diarrhea. HOW ARE COMIRNATY (COVID-19 VACCINE, mRNA), THE PFIZER-BIONTECH\nCOVID-19 VACCINE, AND THE PFIZER-BIONTECH COVID-19 VACCINE,\nBIVALENT RELATED?","623":"May 12, 2022: California made updates to data previously submitted to CDC that resulted in an increase of 25,505\ntotal doses administered, a net decrease of 646,951 people with at least one dose, and a net increase of 472,028\npeople with a first booster dose. May 11, 2022: Alaska made updates to data previously submitted to CDC that resulted in an increase of 3,118 doses\nadministered. May 10, 2022: Wyoming made updates to data previously submitted to CDC that resulted in a decrease of 12,716\ndoses administered.","8399":"If needed: You Call the Shots: Vaccine\nStorage and Handling\nOr other vaccine storage and handling\ntraining offered by a worksite, state or\nlocal health department, medical\nprofessional organization, or\nmedical\/nursing school within the last\n12 months.","5079":"Updated information and recommendations for vaccination of pregnant or lactating people. Updated recommendations for vaccination of children and adolescents. Updated information related to axillary lymphadenopathy added to patient counseling for mRNA COVID-19 vaccines. Updated information on the Janssen COVID-19 Vaccine added to patient counseling. Updated recommendations related to contraindications (polysorbate allergy) and precautions (most people with a\nprecaution can and should be administered vaccine) for COVID-19 vaccines. Recommended pause in the use of Janssen (Johnson & Johnson) COVID-19 Vaccine. Recommendations for clinicians related to occurrence of cerebral venous sinus thrombosis (CVST) with\nthrombocytopenia after receipt of Janssen COVID-19 Vaccine.","6348":"Everyone likes to be seen on time, but it\u2019s\nimportant to remember that each patient should receive the same attention from the provider once it is their turn. The\nlist below can help you during your appointment. Printable Version: On the Day of Your Appointment | Espa\u00f1ol [PDF \u2013 372 KB]\n\uf189 \uf20c\nBring Your List of Concerns\nSince appointment time is often limited, it will help to make a list of why you are coming in for an appointment. Start\nwith your most concerning issues (sometimes called \u201cchief complaints\u201d).","2297":"Related Pages\nMyths and Facts about COVID-19 Vaccines\n\u203a\nFrequently Asked Questions about COVID-19 Vaccination\n\u203a\nCOVID-19 Vaccine Boosters\n\u203a\nInformation about Medicare and COVID-19 Vaccine\n\u203a \uf209\n\uf2ff For Healthcare Workers\nPost-Vaccination Considerations for Residents\nLast Updated July 14, 2022","5409":"The Countermeasures Injury Compensation Program (CICP) is a federal program that may help\npay for costs of medical care and other specific expenses for certain people who have been\nseriously injured by certain medicines or vaccines, including this vaccine. Generally, a claim must\nbe submitted to the CICP within one (1) year from the date of receiving the vaccine. To learn more\nabout this program, visit www.hrsa.gov\/cicp or call 1-855-266-2427. WHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)? The United States FDA has made the Janssen COVID-19 Vaccine available under an emergency\naccess mechanism called an EUA.","9650":"\u2022 A second primary dose of the COVID-19 vaccine by Pfizer-BioNTech (30 \u03bcg in 0.3 mL) may be delayed\nby 3 months from symptom onset or positive test (if infection was asymptomatic) in persons ages 12\nyears and older who recently had SARS-CoV-2 infection\fPfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\n\u2022 A primary dose, including as an additional primary dose for those with certain immunocompromising\nconditions, of the Pfizer-BioNTech vaccine (30 \u03bcg in 0.3 mL) should be administered intramuscularly to\npersons ages 12 years and older at least 28 days after primary vaccination with certain non-FDA\nauthorized or approved COVID-19 vaccines.","3131":"Vaccinators should not deny COVID-19 vaccination to a person due to lack of documentation. Revaccination is defined as repeating 1 or more dose(s) of vaccine. COVID-19 revaccination should be with Moderna, Novavax,\nor Pfizer-BioNTech COVID-19 vaccine (Table 3) regardless of vaccine administered for initial vaccination. Recipients of HCT or\nCAR-T-cell therapy should undergo revaccination for the monovalent primary series and bivalent booster doses received prior\nto or during treatment. There is no revaccination for monovalent booster doses received prior to or during treatment. After\nrevaccination with the primary series, the patient should receive 1 bivalent booster dose.","3223":"Additionally, providers should consider observing people with the following medical histories for 30 minutes after COVID-19\nvaccination to monitor for allergic reactions:\nAllergy-related contraindication to a different type of COVID-19 vaccine\nTable of Contents \uf426\nPatient counseling\nPre-vaccination counseling\nPost-vaccination observation period\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nAllergy-related contraindication to a different type of COVID-19 vaccine\nNon-severe, immediate (onset within 4 hours) allergic reaction after a previous dose of COVID-19 vaccine\nAnaphylaxis after non-COVID-19 vaccines or injectable therapies\nSee also Contraindications and precautions.","4590":"\uf209\nTurn on the exhaust fan in your bathroom and kitchen\f10\/30\/22, 9:40 AM Improving Ventilation in Your Home | CDC\nExhaust fans above your stovetop and in your bathroom that vent outdoors can help move air outside. Although some\nstove exhaust fans don\u2019t send the air to the outside, they can still improve air flow and keep virus particles from being\nconcentrated in one place. Keep the exhaust fan turned on over your stovetop and in your bathroom if you have visitors in your home.","6358":"Be prepared to discuss your activity levels, what activities make your illness worse, and any medications that seem to\nimprove or worsen the symptoms. Answer the provider\u2019s questions. Explain how you feel. Be straightforward, and don\u2019t be embarrassed to talk about\nanything. Let your provider know if there have been any changes to your prescribed medications and supplements. Know Your Next Steps\nMake sure you understand the next steps. Bring pencil and paper to write down instructions or use your hand-held\ndevice for notes. Repeat back what the provider has told you to check for understanding.","63":"These rashes are also\nknown as \u201cCOVID arm.\u201d Tell your vaccination provider that you experienced a rash or \u201cCOVID arm\u201d after your shot. Your\nvaccination provider may recommend that you get your next COVID-19 vaccine in the opposite arm if possible. If the rash is itchy, you can take an antihistamine. If it is painful, you can take a pain medication like acetaminophen or a non-\nsteroidal anti-inflammatory drug (NSAID). Safeguards Are in Place\nEveryone who gets a COVID-19 vaccine should be monitored on site for at least 15 minutes after vaccination.","8796":"10\/30\/22, 9:25 AM Use of Agency Materials | Other | CDC\nUsing CDC.gov\nUse of Agency Materials\nMost of the information on the CDC and ATSDR websites is not subject to copyright, is in the public domain, and may be freely\nused or reproduced without obtaining copyright permission. There are, however, a few exceptions. A federal government website may have a mix of public domain and copyright-\nprotected materials. First, some resources, as well as images, on the CDC and ATSDR websites are restricted in their use\nbecause they were developed by government contractors or grantees, or have been licensed by a third party.","505":"The issue has since\nbeen resolved and totals for April 14, 2021 accurately reflect the total doses administered. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nOn April 6, 2021, improvements in reporting vaccine recipient race\/ethnicity data to CDC resulted in an increase in the\nnumber of people for whom race\/ethnicity data are available. These improvements will continue to allow for better\nrace\/ethnicity data reporting. Due to a data synchronization error between April 3 and 5, 2021, the daily count of doses reporting \u201cUnknown Age\u201d in\nthe COVID-19 Case Surveillance Public Use Data incorrectly appeared higher than expected.","6194":"When reported, the cases have especially been in adolescents and\nyoung adult males within several days after mRNA COVID-19 vaccination (Pfizer-BioNTech or Moderna). More often after the second dose\nUsually within a week of vaccination\nMost patients with myocarditis or pericarditis who received care responded well to medicine and rest and felt better\nquickly. Patients can usually return to their normal daily activities after their symptoms improve. Those who have been diagnosed with myocarditis should consult with their cardiologist (heart doctor) about return to\nexercise or sports. CDC and its partners are actively monitoring reports of myocarditis and pericarditis after COVID-19 vaccination.","320":"The adjustment is the result of updates\nto how pharmacies report data to CDC and\/or the jurisdictions. March 10, 2022: CDC has removed count-based options from the map views on Vaccinations in the US. This information\nis still available for download and continues to appear on the map when hovering over a specific jurisdiction when the\nrelevant rate or percentage-based metric is selected. Beginning March 9, 2022, CDC attributes vaccine recipients to their jurisdiction of residence for the \u201cPeople Receiving\nDose 1\u201d metric on Vaccination Trends. Previously, this metric attributed recipients to the jurisdiction where vaccine was\nadministered.","4609":"10\/30\/22, 9:41 AM Interactive Home Ventilation Tool | CDC\nEspa\u00f1ol | Other Languages\nInteractive Home Ventilation Tool\nSmall particles that people breathe out can contain virus particles, including the virus that causes COVID-19. If a guest visits\nyour home, improving ventilation (air flow) can help prevent virus particles from accumulating in the air. Good ventilation,\nalong with other preventive actions, like staying 6 feet apart and correctly wearing masks, can help prevent you from getting\nand spreading COVID-19. \uf5bd We need your feedback! Help us improve this tool by taking a quick survey after using the tool below.","5018":"Added considerations for an 8-week interval between the first and second doses of a primary mRNA vaccine schedule\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nUpdated guidance for moderately or severely immunocompromised people\nClarification of existing recommendation to receive a 3-dose mRNA vaccine primary series followed by a booster\ndose for a total of 4 doses\nNew guidance to shorten the interval between completion of the mRNA vaccine primary series and the booster\ndose to at least 3 months (instead of 5 months)\nNew guidance for those who received the Janssen COVID-19 Vaccine primary series to receive an additional dose\nand a booster dose, for a total of 3 doses to be up to date\nUpdated guidance that it is no longer necessary to delay COVID-19 vaccination following receipt of monoclonal\nantibodies or convalescent plasma\nUpdated guidance on receiving a booster dose if vaccinated outside the United States\nUpdated contraindication and precaution section to include history of myocarditis or pericarditis after an mRNA\nCOVID-19 vaccine as a precaution\nReorganized and condensed multiple sections\nUpdated guidance for use of Pfizer-BioNTech COVID-19 Vaccine as a booster in people ages 12\u201317 years\nUpdated guidance for administration of a COVID-19 vaccine booster dose at least 5 months after completion of an\nmRNA vaccine (Pfizer-BioNTech or Moderna) primary series\nUpdated guidance for use of an additional primary dose for moderately or severely immunocompromised people ages\n5\u201311 years who received a Pfizer-BioNTech vaccine primary series\nUpdated recommendations for people who received COVID-19 vaccines outside the United States that are not FDA-\nauthorized or approved\nUpdated information about a second formulation of Pfizer-BioNTech COVID-19 Vaccine that is authorized for use in\npersons ages 12 years and older\nUpdated information on vaccinating people during quarantine after a known SARS-CoV-2 exposure or during COVID-\nUpdate to alert providers of possible false positive Rapid Plasma Reagin (RPR; non-treponemal) test results in some\npeople after COVID-19 vaccines\nUpdated information on vaccine administration errors and deviations\nUpdated guidance on use of Janssen (Johnson & Johnson) COVID-19 Vaccine\nUpdated recommendations for receipt of a COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 booster doses in recipients of mRNA COVID-19 vaccines\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nRecommendations and clinical guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children aged 5-11 years\nincluding updated section on Vaccination of children and adolescents\nUpdated guidance on COVID-19 vaccine dosing and schedule\nUpdated guidance for myocarditis and pericarditis after mRNA COVID-19 vaccination in new section on Considerations\nfor mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna\nNew guidance for people who received passive antibody products in section on COVID-19 vaccination and SARS-CoV-2\ninfection\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial in the United States\nUpdated guidance on Considerations for COVID-19 vaccination in moderately and severely immunocompromised\npeople\nUpdated guidance in section on Contraindications and precautions\nUpdated Table in Appendix A: Vaccine administration errors and deviations\nUpdated Appendix B: Triage of people with a history of allergies or allergic reactions\nUpdated Appendix C: Ingredients included in COVID-19 vaccines\nUpdated Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects\nfollowing COVID-19 vaccination\nUpdated guidance in section on Considerations for use of a COVID-19 booster dose.","3534":"However, CDC cannot use the unique person identifier to identify individual people by name. There are challenges in linking records when someone receives vaccine doses in different jurisdictions or from different\nproviders. That person could receive different unique person identifiers for different doses. CDC may not be able to link\nmultiple unique person identifiers for different jurisdictions or providers to a single person, and subsequent doses may\nappear to be a first dose when reported. Thus, CDC\u2019s data may over-estimate first doses and under-estimate subsequent\ndoses. Another issue that poses challenges to estimating doses administered is that different jurisdictions and providers use\ndifferent reporting practices.","78":"Reports of adverse events that are\nunexpected, appear to happen more often than expected, or have unusual patterns are followed up with specific studies. Learn more about how CDC and federal partners are monitoring the safety of COVID-19 vaccines in the United States,\nincluding reports of selected adverse events after COVID-19 vaccination. \u2022\n\u2022\n-\n-\n-\n-\nVaccination providers should have appropriate personnel, medications, and equipment\u2014such as epinephrine,\nantihistamines, blood pressure monitor, and timing devices to check your pulse\u2014at all COVID-19 vaccination provider\nsites. If you experience a severe allergic reaction after getting a COVID-19 vaccine, vaccination providers can provide care\nrapidly and call for emergency medical services.","802":"Getting sick with COVID-19 can cause severe illness or death, even in children, and we can\u2019t reliably predict who will\nhave mild or severe illness. You may have long-term health issues after having COVID-19. Even people who do not have symptoms when they\nare first infected can have these ongoing health problems, also known as long COVID or post-COVID conditions. These complications can appear after mild or severe COVID-19, or after multisystem inflammatory syndrome in\nchildren (MIS-C).","6762":"\uf0b7 is immunocompromised or is on a medicine that affects your child\u2019s immune\nsystem\n\uf0b7 is pregnant\n\uf0b7 is breastfeeding\n\uf0b7 has received another COVID-19 vaccine\n\uf0b7 has ever fainted in association with an injection\nHOW ARE THESE VACCINES GIVEN? The Pfizer-BioNTech COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent will be given to your child as an injection into the muscle. Primary Series: The Pfizer-BioNTech COVID-19 Vaccine is given for the primary series. The vaccine is administered as a 2-dose series, 3 weeks apart. A third primary series\ndose may be administered at least 28 days after the second dose to individuals with\ncertain kinds of immunocompromise.","6347":"Everyone likes to be seen on time, but it\u2019s\nimportant to remember that each patient should receive the same attention from the provider once it is their turn. The\nlist below can help you during your appointment. Printable Version: On the Day of Your Appointment | Espa\u00f1ol [PDF \u2013 372 KB]\n\uf189 \uf20c\nBring Your List of Concerns\nSince appointment time is often limited, it will help to make a list of why you are coming in for an appointment. Start\nwith your most concerning issues (sometimes called \u201cchief complaints\u201d).","6258":"10\/30\/22, 9:34 AM Myths and Facts about COVID-19 Vaccines | CDC\nRecently, the number of deaths reported to VAERS following COVID-\n19 vaccination has been misinterpreted and misreported as if this\nnumber means deaths that were proven to be caused by vaccination. Reports of adverse events to VAERS following vaccination, including\ndeaths, do not necessarily mean that a vaccine caused a health\nproblem. Learn more about VAERS. MYTH: The mRNA vaccine is not considered a vaccine. FACT: mRNA vaccines, such as Pfizer-BioNTech and Moderna, work differently than other types of vaccines,\nbut they still trigger an immune response inside your body.","2756":"If you are experiencing a post-COVID\ncondition, you should engage in whatever coping strategies are best for your mental and physical health. Participate in specific long COVID research. The National Institutes of Health (NIH) is conducting a research project, called the RECOVER Initiative, to\nunderstand how people recover from a COVID-19 infection and why some people do not fully recover and develop\nlong COVID or post-COVID conditions. Learn more about Researching COVID to Enhance Recovery . \u2022\n\uf209\nWays to Cope with Stress\nExperts are still determining which types of medications or treatments can help to relieve the effects of post-COVID\nconditions.","2026":"\uf20c\n\u2022 \uf209\n\u2022\nLearn more about myocarditis and pericarditis after COVID-19 vaccination and the association between myocarditis and\nhaving COVID-19. If your child gets a COVID-19 vaccine and you think they might be having a severe allergic reaction after leaving the\nvaccination provider site, seek immediate medical care by calling 911. People Cannot Get COVID-19 from Any COVID-19 Vaccine\nmRNA vaccines, such as the Pfizer-BioNTech and Moderna vaccines, do not use the live virus that causes COVID-19 and do not\ninteract with DNA in any way. Instead, mRNA vaccines teach the body how to fight the virus that causes COVID-19.","9892":"doi: 10.1016\/j.cell.2021.10.011\nPulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with\nemergence of the Omicron variant in South Africa. 2022. https:\/\/doi.org\/10.1101\/2021.11.11.21266068\nPerez, J. Efficacy and safety of BNT162b2 booster \u2013 C4591031 2 month interim analysis. Advisory Committee\non Immunization Practices meeting, November 19, 2021:\nSkowronski DM. 2021, MedRxiv preprint. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules\nand extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. Schietzel S, Anderegg M, Limacher A, et al. Humoral and cellular immune responses on SARS-CoV-2 vaccines in\npatients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients. Infections. 2022;8:e002036.","915":"The mask helps\nprevent you from spreading the virus to others. Others in your household, and caregivers who have COVID-19, should isolate and avoid caring for the newborn as much\nas possible. If they have to care for the newborn, they should follow hand washing and mask recommendations above. You most likely won\u2019t pass the virus to your newborn or any other close contacts after your isolation period has ended.","6114":"\"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster)\nfollowing two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre,\nrandomised, controlled, phase 2 trial.\" The Lancet (2021). National Advisory Committee on Vaccination. An Advisory Committee Statement: Guidance on booster COVID-\n19 vaccine doses in Canada. Public Health Agency of Canada; 3 Dec 2021.\nhttps:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/immunization\/national-advisory-\nvaccine-doses.pdf\nNational Collaborating Centre for Methods and Tools. Rapid Review Update 1: What is the ongoing\neffectiveness, immunogenicity, and safety of COVID-19 vaccines in persons who have had a prior, confirmed\nCOVID-19 infection?. Hamilton (ON): McMaster University; 2021. Available from: https:\/\/www.nccmt.ca\/covid-\n19\/covid-19-rapid-evidence-service\/36.","5226":"This information is intended for a general audience. Healthcare professionals should see Ending Isolation and Precautions for\nPeople with COVID-19. This CDC guidance is meant to supplement\u2014not replace\u2014any federal, state, local, territorial, or tribal\nhealth and safety laws, rules, and regulations. Regardless of vaccination status, you should isolate from others when you have COVID-19. You should also isolate if you are sick and suspect that you have COVID-19 but do not yet have test results. If your results are\npositive, follow the full isolation recommendations below. If your results are negative, you can end your isolation.","3952":"10\/30\/22, 9:40 AM Find Free Masks (N95 Respirators) | CDC\nEspa\u00f1ol | Other Languages\nFind Free Masks (N95 Respirators)\nThis tool shows a list of pharmacies that provide free masks (N95 respirators). It does not show their current inventory. Please\ncheck with the location for availability. Need help finding free masks in the U.S.? Call 1-800-232-0233 (TTY 1-888-720-7489)\nFind Free Masks\nPowered by VaccineFinder\nSearch for Free Masks\nZip Code\n5-digit Zip Code\nRelated Pages\nFree N95 Respirator Manufacturers\n\u203a\nHow to Use Your N95 Respirator\n\u203a\nUse and Care of Masks\n\u203a\nLast Updated Mar. 16, 2022","2266":"Staying up to date\u202fmeans getting all recommended COVID-19 vaccines including boosters when eligible. If your loved one is not able to ask questions or otherwise communicate with the LTC staff, here\u2019s what to know about\nconsent for getting a COVID-19 vaccine:\nResidents and their families can ask a LTC provider about the current COVID-19 vaccination rate among their staff and\nresidents. Nursing homes are required by the Centers for Medicare and Medicaid Services (CMS) to monitor weekly COVID-19\nvaccination data for residents and healthcare personnel through CDC\u2019s National Healthcare Safety Network.","4516":"Put on the N95\n\uf1b0\f10\/30\/22, 9:40 AM How to Use Your N95 Respirator | CDC\nHold the N95 in your hand with the nose piece bar (or\nfoam) at your fingertips. If yours does not have a nose\npiece, use the text written on it to be sure the top end is\nat your fingertips. Place the N95 under your chin with the nose piece bar at\nthe top. Pull the top strap over your head, placing it near the\ncrown. Then, pull the bottom strap over and place it at\nthe back of your neck, below your ears. Do not\ncrisscross the straps.","7110":"You should also talk to your healthcare professional if you think you are experiencing depression during or after\npregnancy. Get recommended vaccines during pregnancy. These vaccines can help protect you and your baby. Get a flu vaccine every year. Others living in your household should also get vaccinated to protect themselves and\nyou. Get the Tdap vaccine to protect your baby against whooping cough, which can have similar symptoms to COVID-19. CDC recommends all pregnant people receive a Tdap vaccine during each pregnancy. In addition, everyone who is\naround the baby should be up to date with their whooping cough vaccine.","6545":"Chronic lung diseases can include:\nAsthma, if it\u2019s moderate to severe\nBronchiectasis (thickening of the lungs\u2019 airways)\nBronchopulmonary dysplasia (chronic lung disease affecting newborns)\nChronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis\nHaving damaged or scarred lung tissue known as interstitial lung disease (including idiopathic pulmonary fibrosis)\nPulmonary embolism (blood clot in the lungs)\nPulmonary hypertension (high blood pressure in the lungs)\nGet more information:\nCOPD\nAsthma\nPeople with Moderate to Severe Asthma\nAmerican Lung Association: Controlling Chronic Lung Diseases Amid COVID-19\nCystic fibrosis\nHaving cystic fibrosis, with or without lung or other solid organ transplant (like kidney, liver, intestines, heart, and pancreas)\ncan make you more likely to get very sick from COVID-19.","2315":"\u2022\n\u2022\n-\n-\n\u2022\n\u2022\n\u2022 TM\nPre-teens, Teens and Adults Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nAGE GROUP\n18 YEARS AND OLDER\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nModerna\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nJohnson & Johnson's Janssen\n\uf1aa\nPRIMARY SERIES\nADDITIONAL DOSE\nAt least 4 weeks after 1st dose\nand should be Pfizer-BioNTech\nor Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nor last booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nNovavax\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nA monovalent Novavax booster\nis available in limited situations\nMore details: Novavax booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nChildren Ages 6 Months-11 Years Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 8 weeks after 2nd dose\nUp to Date: 2 weeks after 3rd dose in primary series, since a booster is not recommended for this age group at this\ntime\nAGE GROUP\nModerna\n\uf1aa\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nIf you have completed your primary series\u2014but are not yet eligible for a booster\u2014you are also considered up to date.","8917":"By offering COVID-19\nvaccines in a setting where patients are comfortable with trusted and trained vaccinators, it might be possible to\nincrease vaccination rates for this high-risk population and ensure patients receive a complete vaccination series. Patients on dialysis are often medically frail, and it might be challenging and impractical for them to seek out venues\nseparate from the dialysis clinic to receive COVID-19 vaccines. Currently, dialysis providers are reporting low COVID-19 vaccination coverage among their patients because of\nchallenges with getting vaccines. Why is it important to vaccinate dialysis healthcare personnel?","6313":"10\/30\/22, 9:42 AM Patient Tips: Healthcare Provider Appointments for Post-COVID Conditions | CDC\nEspa\u00f1ol | Other Languages\nPatient Tips: Healthcare Provider Appointments for\nPost-COVID Conditions\nBefore Your Appointment\nWhat You Need to Know\nPreparing for an appointment can make all the difference in getting the proper evaluation, diagnosis, and\ntreatment. To help get the most out of appointments for post-COVID conditions, download the Healthcare Appointment\nChecklist (Espa\u00f1ol [PDF \u2013 72 KB]). Try to arrive early or log on a few minutes ahead of the appointment and ensure paperwork is completed on your\nappointment day. After visiting your healthcare provider, review your notes to prepare for your next appointment.","8331":"Share your story with ISDcomm@cdc.gov and you could\nsee it on our COVID-19 Vaccine Community Features page. 10\/30\/22, 9:17 AM Talking to Recipients about COVID-19 Vaccination | CDC\nAdditional Resources\nInteractive COVID-19 Vaccine Conversations Module for\nHealthcare Professionals\nHow to Talk About COVID-19 Vaccines with Friends and\nFamily\nMyths and Facts about COVID-19 Vaccines\nHow COVID-19 Vaccines Were Developed\nSafety of COVID-19 Vaccines\nHow Schools Can Support COVID-19 Vaccines\nAbout mRNA COVID-19 Vaccines\nVaccine Confidence Training (American College of\nObstetricians and Gynecologists) \uf209\nPage last reviewed: April 14, 2022","2636":"*Note: Older adults and people of any age with serious underlying medical conditions are at higher risk for developing more\nsevere illness from COVID-19. People at higher risk of severe illness should call their doctor as soon as symptoms start. CDC is reviewing this page to align with updated guidance. Provide support\nHelp cover basic needs\nHelp the person who is sick\nfollow their doctor\u2019s instructions\nfor care and medicine. For most people, symptoms\nlast a few days, and people\nusually feel better after a\nweek. See if over-the-counter\nmedicines for fever help the\nperson feel better. Make sure the person who is\nsick drinks a lot of fluids and\nrests.","1026":"Possible treatment may be available for you. \u2022\n\u2022\n\u2022\n\u2022 \uf209\n-\n\uf6ec If Your COVID-19 Test is\nNegative\nA negative COVID-19 test means the test did not detect the virus, but this doesn\u2019t rule out that you could have\nan infection. If you used an antigen test, see FDA instructions on repeat testing . If you have symptoms:\nYou may have COVID-19, but tested before the virus was detectable, or you may have another\nillness. Take general public health precautions to prevent spreading an illness to others. Contact a healthcare provider if you have any questions about your test result or if your symptoms\nworsen.","1586":"9\/1\/22 Update (Revises 2\/11\/22 Update to add reference to bivalent COVID-19 vaccine booster doses):\nThird primary dose\/booster dose COVID-19 vaccination of persons in the United States who received COVID-19\nvaccination outside of the United States or as part of a clinical trial\nAll providers are required to offer third primary doses or bivalent booster doses of the Pfizer-BioNTech or Moderna\nCOVID-19 vaccine to qualifying persons who received particular non-FDA authorized\/approved COVID-19 vaccines\noutside of the United States or as part of certain COVID-19 clinical trials as described in the Emergency Use\nInstructions issued by CDC on November 17, 2021, and February 11, 2022: Pfizer EUI , Moderna EUI , and\nInterim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States\n(https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html).","8174":"COVID-19 vaccine recommendations are based on three things:\n1. Your age\n2. The vaccine you first received, and\n3. The length of time since your last dose\nPeople who are moderately or severely immunocompromised have different recommendations for COVID-19 vaccines. You are still up to date if you receive all COVID-19 vaccine doses recommended for you and then become ill with COVID-19. You do not need to be immediately revaccinated or receive an additional booster. Boosters are an important part of protecting yourself from getting seriously ill or dying from\nCOVID-19. They are recommended for most people.","9232":"10\/30\/22, 9:41 AM What to Do If You Were Exposed to COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nWhat to Do If You Were Exposed to COVID-19\nAbout Being Exposed to COVID-19\nIf you have tested positive or are showing symptoms of COVID-19, isolate immediately. \uf283 Isolation and Exposure Calculator\nA tool to help you determine if you need to isolate or take other steps to prevent spreading COVID-19.","7853":"\uf1aa\f10\/30\/22, 9:38 AM Self-Testing At Home or Anywhere | CDC\nPrint Resources\nDon't Delay: Test Soon and Treat Early\n[PDF - 361 KB, 1 page]\n\uf20c\f10\/30\/22, 9:38 AM Self-Testing At Home or Anywhere | CDC\nHow to Collect An Anterior Nasal Swab Specimen for COVID-19 Testing\n[PDF - 372 KB, 2 pages]\n\uf20c\nHow to Collect a Nasal Mid-Turbinate Swab Specimen for COVID-19 Testing\n[PDF - 4 MB, 2 pages]\n\uf20c\f10\/30\/22, 9:38 AM Self-Testing At Home or Anywhere | CDC\nUsing Your Self-Test\n[PDF - 295 KB, 1 page]\n\uf20c\f10\/30\/22, 9:38 AM Self-Testing At Home or Anywhere | CDC\nUsing Your Self-Test - customizable\n[PDF - 279 KB, 1 Page]\n\uf20c\f10\/30\/22, 9:38 AM Self-Testing At Home or Anywhere | CDC\nHelpful Links\nFDA-Authorized At-Home Tests\nSymptoms of COVID-19\nUnderlying Medical Conditions\nTalking to Close Contacts\nQuarantine and Isolation\n\uf209\nLast Updated Sept. 6, 2022","9296":"Children and Teens Can Experience Ongoing Health Problems\nAfter getting COVID-19, children and teens can also experience a wide range of new, returning, or ongoing health problems. These include physical and mental health complications that may occur four or more weeks after initial infection. These\ncomplications can appear after mild or severe COVID-19, or after MIS-C. Symptoms Post COVID-19 Vaccination Symptoms Post COVID-19 Infection\nCough\nMuscle and joint pain\nHeadache\nTrouble falling or staying asleep\nTrouble concentrating\nLimitations in physical activity\nFeeling distressed about symptoms\nMental health challenges\nDecreased school or daycare attendance\nMissed opportunities for participation in sports,\nplaydates, or other activities\nLearn more about post-COVID conditions.","293":"Due to a data processing issue on May 9, 2022, vaccination data were not updated for two dashboards on Vaccination\nDemographic Trends \u2013 \u201cBooster Vaccination Trends by Age, Sex, and Race\/Ethnicity among Fully Vaccinated People Ages\n12 Years and Older\u201d and \u201cVaccination Trends by Age and Sex\u201d \u2013 which reflect data as of May 8, 2022. CDC is actively\nworking to address this issue and the data will be updated when available. On May 3, 2022, the daily number of vaccine doses administered for South Carolina was 152,237 doses.","1561":"6\/23\/22 Update (replaces 6\/18\/22 update; and revised to be a consolidated update that addresses all\nprimary series pediatric COVID-19 vaccination; 6\/23\/22 update also adds availability of age-appropriate\nModerna COVID-19 Vaccine for 6 years through 17 years of age):\nCOVID-19 Vaccination of Children 6 Months through 17 Years of Age\nPursuant to CDC\/ACIP recommendations and Secretarial Directives:\nAll authorized providers in the CDC COVID-19 Vaccination Program shall make immediately available and administer\nupon request \u2013\na two-dose series using the age-appropriate Moderna COVID-19 Vaccine product for children ages 6 months\nthrough 17 years\na three-dose series using the age-appropriate Pfizer-BioNTech COVID-19 Vaccine product for children ages 6\nmonths through 4 years\na two-dose series using the age-appropriate Pfizer-BioNTech COVID-19 Vaccine product for children ages 5 years\nthrough 17 years\n6\/23\/22 Update (replaces 6\/18\/22, 1\/6\/22, 9\/14\/21 and 10\/7\/21 updates; additional eligible group noted\nin bold italics; Updated on 10\/12\/22 to remove reference to the purple cap Pfizer-BioNTech vials which\nare no longer available):\nThird Dose for Recipients of Pfizer-BioNTech or Moderna COVID-19 Vaccine Who Are Immunocompromised\nPursuant to CDC\/ACIP recommendations and Secretarial Directives, a third primary dose of an mRNA COVID-19\nvaccine should be administered using the same mRNA COVID-19 vaccine as was administered for the 2-dose primary\nseries to persons who are moderately to severely immunocompromised at least 28 days after completing the two-\ndose primary series:\nPfizer-BioNTech COVID-19 Vaccine \u2013\nOrange cap to children 5 through 11 years of age\nGray cap to people 12 years and older\nModerna COVID-19 Vaccine \u2013\nDark blue cap\/magenta border to children 6 months through 5 years of age\nDark blue cap\/purple border to children 6 years through 11 years of age\nRed cap\/light blue border to people 12 years and older\nCOVID-19 Vaccination Under the CDC Interim Clinical Considerations and Emergency Use Instructions\nProviders may also administer COVID-19 vaccines as described in CDC guidance as updated from time to time:\nInterim Clinical Considerations for Use of COVID-19 Vaccines in the United States\nEmergency Use Instructions (see vaccine Fact Sheets)\n5\/23\/22 Update (revision of 5\/19\/22 update to add reference to the May 23, 2022, Secretarial Directive;\n9\/1\/22 revision noted in bold italics to clarify that booster doses available to this age group are\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\n9\/1\/22 revision noted in bold italics to clarify that booster doses available to this age group are\nmonovalent):\nCOVID-19 Vaccine Booster Doses for Children 5 through 11 Years of Age\nPursuant to CDC\/ACIP recommendations and the May 23, 2022, Secretarial Directive on Pediatric and Second COVID-\n19 Vaccine Booster Doses, all providers in the CDC COVID-19 Vaccination Program shall make immediately available\nand administer a single monovalent booster dose of Pfizer-BioNTech COVID-19 vaccine to individuals seeking such a\ndose as follows:\nChildren ages 5 through 11 years should receive a single monovalent Pfizer-BioNTech COVID-19 vaccine booster\ndose at least 5 months after completion of a Pfizer-BioNTech COVID-19 vaccine primary series.","2128":"Therefore, limited data are available on the\nSafety of COVID-19 vaccines in people who are breastfeeding\nEffects of vaccination on the breastfed baby, and\nEffects on milk production or excretion\nAvailable data on safety of COVID-19 vaccination while breastfeeding indicate no severe reactions after the first or second\ndose, neither in the breastfeeding person not the breastfed child. There has been no evidence to suggest that COVID-19\nvaccines are harmful to either people who have received a vaccine and are breastfeeding or to their babies. COVID-19 vaccines cannot cause COVID-19 in anyone, including pregnant people and their babies. None of the COVID-19\nvaccines contain live virus.","10034":"\u0083 If an orthopoxvirus vaccine is recommended for prophylaxis in the setting of an orthopoxvirus (e.g.,\nmonkeypox) outbreak, orthopoxvirus vaccination should not be delayed because of recent receipt\nof a Moderna, Novavax, or Pfizer-BioNTech COVID-19 vaccine; no minimum interval between\nCOVID-19 vaccination with these vaccines and orthopoxvirus vaccination is necessary.","3268":"Vaccination providers\nare required by FDA and the provider agreement for the CDC COVID-19 Vaccination Program to report the following that\noccur after COVID-19 vaccination under BLA or EUA:\nVaccine administration errors whether or not associated with an adverse event\nSerious adverse events , irrespective of attribution to vaccination\nCases of Multisystem Inflammatory Syndrome (MIS) in adults and children\nCases of myocarditis after a Pfizer-BioNTech, Moderna, or Novavax vaccine\nCases of pericarditis after a Pfizer-BioNTech, Moderna, or Novavax vaccine\nCases of COVID-19 that result in hospitalization or death\nReporting is encouraged for any other clinically significant adverse event, even if it is uncertain whether the vaccine caused\nthe event.","3548":"As people receiving doses are attributed to the jurisdiction in which they reside, the reporting\nmethod might change between doses if they move to a different jurisdiction. Also, CDC may lack information about a person\u2019s\nresidence. These issues can cause CDC\u2019s dose number estimates to differ from those reported by jurisdictions and federal\nentities. CDC has capped estimates of vaccination coverage shown on COVID Data Tracker at 95%. This cap helps address potential\nover-estimates of vaccination coverage due to first, second, and booster doses that were not linked. Other reasons for\noverestimates include census denominator data not including part-time residents or potential data reporting errors.","3391":"There are\nlimited data on the safety of COVID-19 vaccines in people who have had MIS-C or MIS-A (MIS C\/A). The risk of recurrence of a\ndysregulated immune response following reinfection with SARS-CoV-2 or an MIS-like illness following COVID-19 vaccination is\nunknown. People with a history of MIS-C or MIS-A\nExperts consider the benefits of COVID-19 vaccination for people with a history of MIS-C\/A (i.e., a reduced risk of severe\ndisease including potential recurrence of MIS-C after reinfection) to outweigh a theoretical risk of an MIS-like illness or the risk\nof myocarditis following COVID-19 vaccination for those who meet the following two criteria:\n1.","9588":"\u2022 Delaying the second primary dose in persons ages 12 years and older who recently had SARS-CoV-2\ninfection, by 3 months from symptom onset or positive test (if infection was asymptomatic)\n\u2022 Primary dose(s), including for those with certain immunocompromising conditions or those with\nincomplete primary series, for persons ages 12 years and older who received primary or booster\nvaccination with certain non-FDA authorized or approved COVID-19 vaccines2. \u2022 An additional dose in persons ages 18 years and older with certain immunocompromising conditions\nwho received primary vaccination with the Janssen COVID-19 Vaccine.","887":"Once your isolation period has ended you should still wear a mask until day 10. After 10 days, you should still wash your\nhands before caring for your newborn, but you don\u2019t need to take the other precautions. These timeframes do not apply if\nyou have a severely weakened immune system or were severely ill with COVID-19. Please refer to \u201cQuarantine and Isolation\u201d\nand consult with your health care professional about when it is safe for you to end your isolation period.","5241":"Do not go places where you are unable to wear a mask. For travel guidance, see CDC\u2019s Travel webpage. Do not travel. Stay home and separate from others as much as possible. Use a separate bathroom, if possible. Take steps to improve ventilation at home, if possible. Don\u2019t share personal household items, like cups, towels, and utensils. Monitor your symptoms. If you have an emergency warning sign (like trouble breathing), seek emergency medical care\nimmediately. Learn more about what to do if you have COVID-19. End isolation based on how serious your COVID-19 symptoms were.","9951":"Has the person to be vaccinated ever received a dose of COVID-19 vaccine? COVID-19 vaccination is recommended for everyone 6\nmonths of age and older. For the primary series, Moderna,\nNovavax, and Pfizer-BioNTech COVID-19 vaccines are\nrecommended; only monovalent vaccines are approved or\nauthorized for primary series doses. The same vaccine product\nshould be used for all primary series doses. Moderna and Pfizer-BioNTech are recommended for booster\ndoses. People ages 5 years and older are recommended to\nreceive 1 bivalent mRNA booster dose after completion\nof any monovalent primary series or previously received\nmonovalent booster dose(s). Use an age-appropratie\nproduct.","1809":"The goal is to continue to protect people who are disproportionately affected by COVID-19\u2014especially residents in LTC\nsettings. It is important to build confidence in COVID-19 vaccines while increasing protection for LTC residents. Many LTC providers have already identified strategies and partnerships to obtain and administer COVID-19 vaccines for\nresidents and staff. These include the following:\nWorking with established LTC partners and retail pharmacy partners\nCoordinating with state and local health departments\nEnsuring COVID-19 vaccine equity for LTC staff and residents\nAdditional strategies can be found in the LTC Pharmacy Partnerships section of the CDC COVID-19 Vaccination Planning and\nPartnerships page.","3039":"Children age 5 years: A 3-dose primary series and 1 bivalent Pfizer-BioNTech booster dose is recommended. The first\nand second doses are separated by 4 weeks and the second and third doses are separated by at least 4 weeks. The\nbivalent booster dose is administered at least 2 months after completion of the primary series.Currently, only the\nbivalent Pfizer-BioNTech booster dose is authorized for children age 5 years who receive a Moderna primary series. Children ages 6\u201311 years: A 3-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is\nrecommended.","5416":"The EUA is supported by a Secretary of Health and Human\nServices (HHS) declaration that circumstances exist to justify the emergency use of drugs and\nbiological products during the COVID-19 pandemic. The Janssen COVID-19 Vaccine has not undergone the same type of review as an FDA-approved\nor cleared product. FDA may issue an EUA when certain criteria are met, which includes that there\nare no adequate, approved, and available alternatives.","7626":"Mariners who are not embarking the ship the day they arrive in the United States must self-quarantine in\nshoreside accommodations (i.e., a hotel room) for 5 days or until they board the ship. Mariners who will board the ship before the 5-day self-quarantine period is completed must self-quarantine\nin their hotel until boarding the ship. Once onboard, these mariners must follow one of the self-quarantine\noptions outlined above for the remainder of their quarantine period. Testing Requirements\nMariners must get tested with a viral test 3-5 days after arrival in the U.S. if they remain in the United States, including\nU.S. waters, at that time.","9449":"Please include either \u201cSPIKEVAX (COVID-19 Vaccine,\nmRNA)\u201d, \u201cModerna COVID-19 Vaccine EUA,\u201d or \u201cModerna COVID-19 Vaccine, Bivalent\nEUA\u201d, as appropriate, in the first line of box #18 of the report form. In addition, you can report side effects to ModernaTX, Inc. at 1-866-MODERNA (1-866-663-\n3762). You may also be given an option to enroll in v-safe. V-safe is a voluntary smartphone-based tool\nthat uses text messaging and web surveys to check in with people who have been vaccinated to\nidentify potential side effects after COVID-19 vaccination. V-safe asks questions that help CDC\nmonitor the safety of COVID-19 vaccines.","9932":"Use the manufacturers' fact sheets for healthcare professionals\nand CDC clinical materials for healthcare professionals and to\nidentify the correct product based on the vaccine composition\nand recipient's age. People receiving mRNA or Novavax COVID-19 vaccines,\nespecially males ages 12\u201339 years, should be made\naware of the rare risk of myocarditis and\/or pericarditis\nfollowing receipt of these COVID-19 vaccines and the\nbenefit of COVID-19 vaccination in reducing the risk of\nsevere outcomes from COVID-19, including the possibility\nof cardiac sequelae. Counseling should include the need to\nseek care if symptoms of myocarditis or pericarditis, such as\nchest pain, shortness of breath, or tachycardia develop after\nvaccination, particularly in the week after vaccination.","4097":"If you receive your second dose of a COVID-19 vaccine at any time after the recommended date, you do not have to\nrestart the vaccine series. This guidance might be updated as more information becomes available. Learn more about staying up to date with your COVID-19 vaccines. If I didn\u2019t get my second dose of a 2-dose COVID-19 vaccine within the recommended time, do I\nneed to start over? \uf1aa\nYour provider cannot give you a dose of vaccine that does not follow its specific vaccine product guidelines and\nrequirements.","6584":"You may be eligible for EVUSHELD\nevery 6 months if you:\nAre moderately or severely immunocompromised and may not mount an adequate immune response to COVID-\n19 vaccination OR have a history of severe allergic reactions to COVID-19 vaccines, and\nDo not currently have COVID-19 and have not recently had close contact with someone with COVID-19, and\nAre an adult or adolescent ages 12 years and older weighing at least 88 pounds (40 kg)\nEVUSHELD contains different antibodies and is given by your healthcare provider before you are exposed or test\npositive for COVID-19. EVUSHELD may offer less protection against certain strains of the Omicron variant.","7574":"Individuals who fit the exception criteria described\nin the Presidential Proclamation and CDC\u2019s Amended Order may contact the U.S. embassy or consulate in or nearest\nthe country from which they are departing for the United States. The embassy will then transmit the information to the\nCDC for consideration. Please review the procedures for applying for a humanitarian or emergency exception as listed on the webpage of the\nembassy or consulate where you will apply.","290":"This total includes\nrecent and historic dose administrations from September 2021\u2014 April 2022 that had not previously been reported to\nCDC by Indiana. On May 26, 2022, the daily number of vaccine doses administered for Indiana was 70,721 doses. This total includes\nrecent dose administrations and historic dose administrations from August 1 to August 31, 2021 that had not been\nreported to CDC by Indiana.","9347":"It is approved as a two-dose series for prevention of COVID-19 in\nindividuals 18 years of age and older. It is also authorized under EUA to provide:\n\u2022 a two-dose primary series to individuals 12 years through 17 years of age; and\n\u2022 a third primary series dose to individuals 12 years of age and older who have been\ndetermined to have certain kinds of immunocompromise. 1 You may receive this Fact Sheet even if your child is 5 years old.","1992":"CDC and U.S. Food and Drug\nAdministration (FDA) continue to monitor vaccines, keep people informed of findings, and use data to make COVID-19\nvaccination recommendations. Serious Health Events after COVID-19 Vaccination Are Rare\nSerious reactions after COVID-19 vaccination in children and teens are rare. When they are reported, serious reactions most\nfrequently occur within a few days after vaccination. Rare cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer lining of the heart)\nhave been reported after children and teens ages 5 years and older got the Pfizer-BioNTech COVID-19 vaccine.","6937":"Also, mention all of your medical conditions, including if you:\n\u2022 Have any allergies\n\u2022 Have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining\noutside the heart)\n\u2022 Have a fever\n\u2022 Have a bleeding disorder or are on a blood thinner\n\u2022 Are immunocompromised or are on a medicine that affects your immune system\n\u2022 Have ever fainted in association with an injection\fPfizer-BioNTech COVID-19 Vaccine EUI Recipient Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nHow is the COVID-19 vaccine by Pfizer-BioNTech given? COVID-19 vaccine by Pfizer-BioNTech is given as an injection into the muscle.","3734":"Additionally, clarification was added to the\nEUI for Moderna COVID-19 vaccine that a new booster-only formulation of the Moderna COVID-\n19 vaccine for persons ages 18 years and older (dark blue-capped multi-dose vials [50 \u03bcg in 0.5\nmL] EUA-authorized on March 29, 2022) may be used to administer booster dose(s) as\nrecommended in CDC\u2019s Interim Clinical Considerations.","5419":"In addition, the FDA decision is based on\nthe totality of scientific evidence available showing that the product may be effective to prevent\nCOVID-19 during the COVID-19 pandemic and that the known and potential benefits of the\nproduct outweigh the known and potential risks of the product. All of these criteria must be met to\nallow for the product to be used during the COVID-19 pandemic. The EUA for the Janssen COVID-19 Vaccine is in effect for the duration of the COVID-19\ndeclaration justifying emergency use of these products, unless terminated or revoked (after which\nthe products may no longer be used).","2516":"\u2022\n\u2022\nScience at CDC\nScientific evidence and studies behind specific COVID-19 guidance and recommendations\nScience Brief: Community Levels and Making Public Health Recommendations\nCommunity-Level Prevention Strategies\nLOW, MEDIUM, AND HIGH\nAt all COVID-19 Community Levels:\nPromote equitable access to vaccination, testing, masks and respirators, treatment and\nprevention medications, community outreach, and support services. Ensure access to testing, including through point-of-care and at-home tests for all people. Maintain ventilation improvements. Provide communications and messaging to encourage isolation among people who test\npositive. \u2022\n\u2022\n\u2022\n\u2022\nMEDIUM AND HIGH\nWhen the COVID-19 Community Level is Medium or High:\f10\/30\/22, 9:39 AM COVID-19 by County | CDC\nImplement screening testing in high-risk settings where screening testing is recommended.","5764":"\u25aa Received COVID-19 vaccine dose(s) during treatment with B-cell-depleting\ntherapies over a limited period: the suggested interval to start revaccination is\nabout 6 months after completion of the B-cell-depleting therapy\n\u25aa Received COVID-19 vaccine dose(s) prior to or during treatment with\nhematopoietic cell transplant (HCT) or chimeric antigen receptor (CAR)-T-cell\ntherapy: revaccination at least 3 months after treatment\nThe COVID-19 vaccine by Pfizer-BioNTech can also be used under EUI for similar uses in persons ages 12\nyears and older as an alternative mRNA COVID-19 vaccine (see the Pfizer-BioNTech EUI Fact Sheet for\nRecipients).","8038":"On May 17, 2022, the FDA amended the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine, authorizing\na single booster dose for children ages 5-11 years at least five months after completion of a primary series with the same\nvaccine.101 The FDA committee that reviews and evaluates data concerning the safety, effectiveness, and appropriate use of\nvaccines, VRBPAC (Vaccines and Related Biological Products Advisory Committee), meet on June 14\u201315, 2022 to discuss the\nemergency use authorization of COVID-19 vaccines in this age.102 On June 17, 2022, the Advisory Committee on Immunization\nPractices (ACIP) issued interim recommendations for use of the Moderna COVID-19 vaccine in children ages 6 months to 5\nyears and the Pfizer COVID-19 vaccine\nfor use in children ages 6 months to 4\nyears.103 Some parents have expressed\nenthusiasm and relief about childhood\nvaccination.104,105,106 However, a recent\nKaiser Family Foundation (KFF) poll\nfound that only 18% of parents with\nchildren younger than 5 years will get\ntheir child vaccinated right away, while\n38% say they plan to wait and see how\nthe vaccine is working for others, 27%\nsay they will definitely not get their child\nvaccinated, and 11% say they will only do\nso if they are required.107,108\nPerceptions, Concerns, and Threats to Vaccine Confidence\n\u0083 Concerns about side effects, such as myocarditis, may negatively impact vaccine uptake.109,110\n\u0083 Some consumers believe vaccines are unnecessary because COVID-19 rarely affects this group.111,112\n\u0083 Some believe infection-induced immunity protects children better than vaccines.113,114\n\u0083 Some social media users do not think there is enough data to support vaccination against COVID-19 in children.115,116,117\n\u0083 With cases of hepatitis in children rising globally, some believe they are caused by COVID-19 vaccines.118,119,120\n\u0083 Some are concerned that immunity from vaccines decreases rapidly in adolescents.122,123\nCommonly asked questions and queries from the public\n\u0083 Should children under the age of 5 years still wear masks?i\n\u0082 Wearing a well-fitting mask or respirator consistently and correctly reduces the risk of spreading the virus that causes\nCOVID-19.","3080":"COVID-19 vaccination schedule for people who are moderately or severely immunocompromised\nAge\ngroup\nNumber of\nprimary doses\nNumber of\nbivalent booster\ndoses\nRecommended\nbivalent booster\ndose*\nInterval between 1st\nand 2nd primary dose\nInterval between 2nd\nand 3rd primary dose\nInterval between primary\nseries and booster dose\nModerna primary series\nyears\n3 NA NA 4 weeks At least 4 weeks NA\n5 years 3 1 Pfizer-BioNTech 4 weeks At least 4 weeks At least 2 months\nyears\nPfizer-BioNTech\n4 weeks At least 4 weeks At least 2 months\nand older\nPfizer-BioNTech\n4 weeks At least 4 weeks At least 2 months\nNovavax primary series\nand older\nPfizer-BioNTech\n3 weeks NA At least 2 months\nPfizer-BioNTech primary series\nyears\n3 NA NA 3 weeks At least 8 weeks NA\n5 years 3 1 Pfizer-BioNTech 3 weeks At least 4 weeks At least 2 months\nyears\nPfizer-BioNTech\n3 weeks At least 4 weeks At least 2 months\nand older\nPfizer-BioNTech\n3 weeks At least 4 weeks At least 2 months\nAbbreviation: NA = not authorized\n*A monovalent Novavax booster dose (instead of a bivalent mRNA booster dose) may be used in limited situations in people ages 18 years and older who\ncompleted a primary series using any COVID-19 vaccine, have not received any previous booster dose(s), and are unable to receive an mRNA vaccine (i.e.,\nmRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.","7000":"10\/30\/22, 9:30 AM Possible Side Effects After Getting a COVID-19 Vaccine | CDC\nEspa\u00f1ol | Other Languages\nPossible Side Effects After Getting a COVID-19 Vaccine\nCommon Side Effects\nSide effects after a COVID-19 vaccination tend to be mild, temporary, and like those experienced after routine vaccinations. They can vary across different age groups. What You Need to Know\nSide effects after getting a COVID-19 vaccine can vary from person to person. Some people experience a little discomfort and can continue to go about their day. Others have side effects that\naffect their ability to do daily activities. Side effects generally go away in a few days.","5846":"See the Pfizer-BioNTech COVID-19 EUI Fact Sheet for Healthcare\nProviders. Refer to CDC\u2019s Interim Clinical Considerations for specific recommendations on use of the COVID-19 vaccine by\nModerna allowed under the EUI. For additional information about the COVID-19 vaccine by Moderna COVID-\n19, refer to the Spikevax package insert or the Full Emergency Use Authorization (EUA) Prescribing Information\n(FDA, 2022). What are EUI and why is CDC issuing EUI for the COVID-19 vaccine by Moderna?","5954":"\u2022 Provide a CDC COVID-19 Vaccination Record Card to the recipient or their caregiver with the lot number\nand date of administration recorded for the primary, additional, or booster dose of the COVID-19 vaccine\nby Moderna. \u2022 Provide the v-safe information sheet to vaccine recipients\/caregivers and encourage vaccine recipients\nto participate in v-safe. V-safe is a voluntary smartphone-based tool that uses text messaging and web\nsurveys to check in with people who have been vaccinated to identify potential side effects after COVID-\n19 vaccination. V-safe asks questions that help CDC monitor the safety of COVID-19 vaccines. For more\ninformation, visit: www.cdc.gov\/vsafe.","2616":"The vaccine is made of mRNA\nwrapped in a coating that makes\ndelivery easy and keeps the body\nfrom damaging it. How does the\nvaccine work? The mRNA in the vaccine teaches\nyour cells how to make copies\nof the spike protein. If you are\nexposed to the real virus later,\nyour body will recognize it and\nknow how to fight it off. After the mRNA delivers the\ninstructions, your cells break\nit down and get rid of it. Antibody\nWhen your body\nresponds to the\nvaccine, it can\nsometimes cause a\nmild fever, headache,\nor chills. This is\ncompletely normal\nand a sign that the\nvaccine is working. GETTING VACCINATED?","4767":"COVID-19 vaccines that are listed for emergency use by WHO , but are not approved or authorized by FDA, have not been evaluated for\nefficacy or safety by CDC or ACIP. Special situation: Do not administer a second bivalent mRNA booster dose if the person previously received a bivalent\nModerna or Pfizer-BioNTech booster dose containing the original SARS-CoV-2 strain and Omicron BA.1 variant.","3200":"Moderna, Novavax, or Pfizer-BioNTech) and the unknown risk for myocarditis and\npericarditis after JYNNEOS administration. For best practices for administering multiple injections, see ACIP\u2019s general best practices and Epidemiology and Prevention of\nVaccine-Preventable Diseases (Pink Book). The vaccine-specific EUA or EUI Fact Sheet for Recipients and Caregivers should be provided to all vaccine recipients, parents\nor guardians, and caregivers (when relevant) before vaccination with any currently FDA-approved or FDA-authorized COVID-\n19 vaccine. Providers should counsel COVID-19 vaccine recipients, parents, or guardians about common local (e.g.,\npain\/tenderness, swelling, erythema at the injection site) and systemic (e.g., fever, fatigue\/malaise, headache, chills, myalgia,\narthralgia) post-vaccination reactions.","6651":"Ask your primary care provider if you would like to speak with a professional. Getting\nregular exercise and being physically active is also a great way to reduce stress. Accommodate dietary needs and avoid triggers\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nHave non-perishable food choices such as canned goods available that meet your needs based on your medical\ncondition (e.g., kidney diet and KCER 3-Day Emergency Diet Plan , diabetic diet).","5119":"Talk to your healthcare provider about your risk before travel and consider delaying travel to areas with high\nCOVID-19 levels. Even if you are up to date, you should know what precautions to take. If you will be visiting someone who is at higher risk of getting very sick from COVID-19, learn how to protect them. During Travel\n\uf209\n\uf3c0 Testing\nRECOMMENDED\nConsider getting tested with a viral test as close to the time of departure as possible (no more than 3\ndays) before travel. Make sure you know your test results before travel. Don\u2019t travel if your test result is positive.","7899":"To report a\nrumor, go to: www.cdc.gov\/\nreport-rumors and start the\nsubject line with: \"Rumors:\"\nand in the question box, give\nas much information about the\nrumor as you can, including a\ndescription of the rumor, where\nyou heard it, and how many\ntimes you have heard it. 3 Major Theme Impacting Vaccine Confidence,\n4 Consumers continue to express their concerns about\nactual and potential COVID-19 vaccine side effects. 5 Continuing and Evolving Themes Impacting Vaccine\nConfidence\n5 Concern about COVID-19 despite rising cases and 1\nmillion dead Americans. 7 Parents continue to express concern and hesitation\nregarding COVID-19 vaccination in children.","2340":"AGE GROUP\nPRIMARY SERIES PRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nChildren 5 years of age can get a\nPfizer-BioNTech booster at least\n2 months after their 3rd dose. (Children 6 months to 4 years\nare not recommended for a\nbooster.) Up to Date: Children 6 months to 4 years are up to date two weeks after completing the 3 dose of their primary\nseries. Children 5 years of age who received a Moderna primary series are up to date immediately after they have\nreceived the most recent booster recommended for them.","9004":"How CDC Is Using Data from the Registry\nIn April 2021, CDC released the first U.S. data on the safety of mRNA COVID-19 vaccines administered during pregnancy\nbased on analyses of data from three vaccine safety-related databases, including the v-safe COVID-19 Pregnancy Registry. The\nanalyses did not identify any safety concerns for pregnant people who were vaccinated or for their babies. Additional follow-\nup is needed, particularly among those vaccinated in the first or second trimesters of pregnancy; however, these preliminary\nfindings continue to indicate COVID-19 vaccines are safe and effective.","4554":"10\/30\/22, 9:40 AM Improving Ventilation in Your Home | CDC\nEspa\u00f1ol | Other Languages\nImproving Ventilation in Your Home\nVentilate your home by getting fresh air into your home, filtering the air that is there, and improving air flow. Improving\nventilation can help you reduce virus particles in your home and keep COVID-19 from spreading. You may or may not know if\nsomeone in your home or if a visitor to your home has COVID-19 or other respiratory viruses. Good ventilation, along with\nother preventive actions, can help prevent you and others from getting and spreading COVID-19 and other respiratory\nviruses.","8256":"People ages 6 years and older can no longer get an original (monovalent) mRNA (Pfizer-\nPeople ages 6 years and older\n\uf1aa\f10\/30\/22, 9:27 AM Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC\nVaccination Received Outside the United States\nSpecific recommendations for people vaccinated outside the United States depend on whether:\nThe vaccine(s) received are accepted in the United States as valid vaccinations\nThe primary series was completed and, if eligible, a booster dose was received\nThese recommendations apply only to people who are not moderately or severely immunocompromised. BioNTech or Moderna) booster.","8198":"AGE GROUP\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPfizer-BioNTech\nPRIMARY SERIES\nPfizer-BioNTech\nPRIMARY SERIES\n3\u20138 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech\nPRIMARY SERIES\nAt least 8 weeks after 2nd dose\nUp to Date: 2 weeks after 3rd dose, since a booster is not recommended for this age group at this time\nMore details: Staying up to date\nPfizer-BioNTech\nPRIMARY SERIES\nPfizer-BioNTech\nPRIMARY SERIES\n3\u20138 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nor last booster, children age 5\nyears can only get a Pfizer-\nBioNTech booster, and children\nages 6\u201311 years can get a Pfizer-\nBioNTech or Moderna booster.","9735":"Countries such as the United Kingdom (JCVI, 2021a-b), Canada (National Advisory Committee on Vaccination,\n2021), Germany, and France have recommended heterologous dosing, including with use of Pfizer-BioNTech\nCOVID-19 vaccine, for an additional primary series and\/or booster dose based on their reviews of available\nimmunological and safety data, as well as the epidemiology of COVID-19 and other contextual factors.","3886":"My facility does not stock vaccines. Are there other ways I can contribute? \uf1aa\nVisit the Vaccine Adverse Event Reporting System (VAERS ) for information about all reporting requirements or to\nsubmit a report. COVID-19 vaccination providers are required to report vaccine administration errors to VAERS, even if the error is not\nassociated with an adverse event. They are also required to report certain adverse events after COVID-19 vaccination\n(and other adverse events if later revised by CDC). How do I report a vaccine administration error or adverse event?","1089":"You can treat symptoms\nwith over-the-counter medicines,\nsuch as acetaminophen (Tylenol)\nor ibuprofen (Motrin, Advil), to help\nyou feel better. Learn more about what to do if\nyou are sick. COVID-19 vaccines available in the United States effectively protect people from getting seriously ill, being hospitalized, and\neven dying\u2014especially people who are boosted. As with vaccines for other diseases, you are protected best when you stay up\nto date. CDC recommends that everyone who is eligible stay up to date on their COVID-19 vaccines.","4246":"Should I wear a mask if I have a weak immune system? \uf1aa\nThe white CDC COVID-19 vaccination cards are only issued to people vaccinated in the United States. However, there are\nseveral ways you can update your records with vaccines you received while outside the United States. Learn more about\nCOVID-19 Vaccines for People Who Were Vaccinated Abroad. I was vaccinated in another country. How do I transfer my proof of vaccination from that country\nto get a proof of vaccination card in the United States? \uf1aa\nIt depends on a number of factors.","4789":"Table of Contents \uf426\nA vaccine administration error is any preventable event that may cause or lead to inappropriate use of vaccine or patient\nharm. For all vaccine administration errors:\nInform the recipient of the vaccine administration error. Consult with the state immunization program and\/or immunization information system (IIS) to determine how the dose\nshould be entered into the IIS, both as an administered dose and to account for inventory. Report the error to the Vaccine Adverse Event Reporting System (VAERS), unless otherwise indicated in the table. Providers are required to report all COVID-19 vaccine administration errors\u2014even those not associated with an adverse\nevent\u2014to VAERS.","3276":"*\u2020\n*\n\u2020 \uf209\nTable of Contents \uf426\nReporting of vaccine adverse events\n\uf209\n\uf209\nTable of Contents \uf426\nSafety considerations for mRNA COVID-19 vaccines: Moderna\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nIn clinical trials of Moderna and Pfizer-BioNTech COVID-19 vaccines, types of post-vaccination reactions were generally similar. Pain at the injection site, sometimes severe, was the most frequent local reaction. Fatigue, headache, and myalgia were the\nmost common systemic symptoms. Most systemic symptoms were mild to moderate in severity, occurred within 1\u20132 days of\nvaccination, and resolved within 1\u20132 days of onset.","4310":"People with a history of allergies to medications taken by mouth or a family history\nof severe allergic reactions can also get vaccinated. If you have had an immediate allergic reaction\u2014even if it was not severe\u2014to a vaccine or injectable therapy for\nanother disease, you should discuss this with your doctor to determine which COVID-19 vaccine is best for you. \u2022\nAt the Vaccination Site\nYou should receive a paper or electronic version of a fact sheet that tells you more about the COVID-19 vaccine you or\nyour child received.","7470":"Isolation means to separate sick people with a contagious disease from people who are not sick. What is the difference between quarantine and isolation? \uf1aa\nChildren ages 2 through 17 years (minors) who are noncitizen nonimmigrants do not have to quarantine after arrival in\nthe United States; however, the attestation requires that they get a COVID-19 viral test 3-5 days after arrival. If a child, like\nany other traveler, tests positive for COVID-19 or develops COVID-19 symptoms, they should isolate for a full 5 calendar\ndays.","4285":"If you are taking medications that suppress the immune system, you should talk to your healthcare provider about what\nis currently known about COVID-19 vaccine effectiveness. Ask about the best timing for you to get your vaccine. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nGet a COVID-19 vaccine with your routine medical procedures and screenings\nYou can combine most procedures, screenings, and vaccinations at the same appointment when you get your COVID-19\nvaccination. Talk to your healthcare provider if you have questions. Children, teens, and adults may get a COVID-19 vaccine and other vaccines, including a flu vaccine, at the same time.","5886":"\u2022 Persons ages 12 years and older who recently had SARS-CoV-2 infection may receive the second\nprimary dose after a deferral period of 3 months from symptom onset or positive test (if infection was\nasymptomatic)\n\u2022 Persons ages 12 years and older who received an incomplete primary series (e.g., only the first dose of\n2-dose primary series) with certain non-FDA authorized or approved COVID-19 vaccines should receive\na primary dose of the COVID-19 vaccine by Moderna.","9861":"Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination. London\n(United Kingdom): Department of Health & Social Care; 1 Sept 2021.\nimmunosuppressed-jcvi-advice\/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-\nprimary-dose-vaccination. Kamar, N., Abravanel, F., Marion O. Assessment of 4 doses of SARS-CoV-2 messenger RNA-based vaccine in\nrecipients of a solid organ transplant. Infection Diseases 2021;4(11):e2136030. Haggenburg S, Hofsink Q, Lissenberg-Witte BI, et al. Three-dose mRNA-1273 vaccination schedule: sufficient\nantibody response in majority of immunocompromised hematology patients. medRxiv. 2022a. Preprint. doi:\nHaggenburg S, Lissenberg-Witte B.I, van Binnendijk RS., et al. Quantitative analysis of mRNA-1273 COVID-19\nvaccination response in immunocompromised adult hematology patients. Blood Advances. 2022;6(5):1537-\n1546.","58":"If You Had a Non-severe Allergic Reaction to a COVID-19 Vaccine\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:31 AM Allergic Reactions after COVID-19 Vaccination | CDC\nIf you had an immediate allergic reaction (a reaction that started within 4 hours of getting vaccinated) to a COVID-19 vaccine,\nbut the reaction was not considered severe by a medical professional, you likely can receive another dose of the same vaccine\nunder certain conditions. Your doctor may refer you to an allergy and immunology specialist for additional care or advice.","1247":"The program relies on collaborations between public health agencies (CDC, state, local, and territorial health departments) to\nencourage individuals to go to pharmacies and get vaccinated. Community outreach remains critical to educating people about the importance of vaccination and where vaccines are\navailable nearby. For more information, see 12 COVID-19 Vaccination Strategies for Your Community. Federal Retail Pharmacy Program Highlights\nAs of October 18, 2022, more than 276.4 million doses of COVID-19 vaccine have been administered and reported by\nFederal Retail Pharmacy Program participants in the US.","6046":"What is the available supporting evidence for revaccination of people who received COVID-19 vaccine during\nB-cell-depleting therapy administered over a limited period? Moderna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 09\/02\/22;\nStudies of people on B-cell-depleting therapies indicate patients do not achieve adequate seroconversion or\nhave a decreased odds ratio of seroconversion if they were vaccinated during therapy (Haggenberg, 2022a;\nHaggenberg, 2022b).The timing of vaccination relative to therapy influences vaccine immunogenicity;\nvaccination at least 6 months after therapy has demonstrated improved seroconversion (Kornek, 2022;\nSchietzel, 2022, Disanto, 2021).","6410":"Examples of medical conditions or treatments that may result in moderate to severe immunocompromise include but are not\nlimited to:\nActive treatment for solid tumor and hematologic malignancies\nHematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status\n(e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\nReceipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\nReceipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of\ntransplantation or taking immunosuppressive therapy)\nModerate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined\nimmunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)\nAdvanced or untreated HIV infection (people with HIV and CD4 cell counts less than 200\/mm3, history of an AIDS-\ndefining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)\nActive treatment with high-dose corticosteroids (i.e., 20 or more mg of prednisone or equivalent per day when\nadministered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs,\ncancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and\nother biologic agents that are immunosuppressive or immunomodulatory\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nHow to Protect Yourself\f10\/30\/22, 9:38 AM People Who Are Immunocompromised | CDC\nYou are up to date with your COVID-19 vaccines when you have received all doses in the primary series and all boosters\nrecommended for you, when eligible.","4040":"As a result, instead of daily, the following COVID Data Tracker\ntabs will be refreshed weekly on Thursday by 8:00 PM ET: Vaccinations in the United States, Vaccinations by\nCounty, Vaccination Trends, Vaccination Demographics, Vaccination Demographic Trends, Vaccination\nEquity, Vaccinations and Case Trends, Vaccinations and Other Outcomes . Weekly updates might be delayed due to delays in reporting. Data on doses of vaccine distributed and administered include data received by CDC as of 6:00 am ET on\nWednesday, the day of weekly reporting. There will be no updates on federal holidays. Data will be updated the following day.","1010":"Reinfections can occur within 90 days, which can make it hard to know if a positive test indicates a new infection. Consider consulting a healthcare provider if you have any questions or concerns about your individual circumstances. Interpreting Your Results\f10\/30\/22, 9:37 AM COVID-19 Testing: What You Need to Know | CDC\nInterpreting Your Results\nTesting for Antibodies\nAntibody or serology tests look for antibodies in your blood that fight the virus that causes COVID-19. Antibodies are proteins\ncreated by your immune system after you have been infected or have been vaccinated against an infection.","261":"This section serves as an\narchive of footnotes for historical COVID-19 vaccine data updates. Reported changes to COVID-19 vaccine data can occur for\nthe following reasons:\nUpdates to COVID-19 vaccine policy and guidance\/recommendations\nData changes outside scheduled Record Management events\nChanges in reporting methods\nAdjustments made due to errors (such as syncing errors)\nVaccination Data Updates:\nOn October 20, 2022, the daily number of vaccine doses administered for Indiana was 69,965 doses. This total includes\nrecent dose administrations and historic dose administrations from August 1 to September 30, 2022 that had not been\nreported to CDC by Indiana.","2820":"Younger children who have myocarditis or pericarditis may have non-specific\nsymptoms such as irritability, vomiting, poor feeding, tachypnea, or lethargy. Ask about prior COVID-19 vaccination if you identify these symptoms, as well as relevant other medical, travel, and social\nhistory. For initial evaluation, consider an ECG, troponin level, and inflammatory markers such as C-reactive protein and\nerythrocyte sedimentation rate. In the setting of normal ECG, troponin, and inflammatory markers, myocarditis or\npericarditis are unlikely. For suspected cases, consider consultation with cardiology for assistance with cardiac evaluation and management.","3631":"Prepare to be flexible during your trip as restrictions and policies may change during your travel. If you have a weakened immune system or are at increased risk for severe disease, take multiple prevention steps to\nprovide additional layers of protection from COVID-19 even if you are up to date with your COVID-19 vaccines. Talk to your healthcare provider about your risk before travel and consider delaying travel to areas with high\nCOVID-19 Community levels. Even if you are up to date, you should know what precautions to take.","9114":"Some people using public transport or working in transportation settings (or someone they live or have social\ncontact with) might have a weakened immune system or be at increased risk for severe illness. Some might not be able to get COVID-19 vaccines, including children younger than 6 months old. Some of these people may have no alternative to public transportation. People from countries or US communities with different levels of COVID-19 or circulating variants mix in travel and\npublic transportation settings.","7186":"COMIRNATY (COVID-19 Vaccine, mRNA) and the Pfizer-BioNTech COVID-19\nVaccine, when prepared according to their respective instructions for use, can be used\ninterchangeably. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is made in the\nsame way as COMIRNATY and Pfizer-BioNTech COVID-19 Vaccine but it also\n3 Monovalent refers to any authorized or approved COVID-19 vaccine that contains or encodes the spike protein\nof only the Original SARS-CoV-2. contains an Omicron component to help prevent COVID-19 caused by the Omicron\nvariant of SARS-CoV-2. For more information on EUA, see the \u201cWhat is an Emergency Use Authorization\n(EUA)?\u201d section at the end of this Fact Sheet.","4243":"10\/30\/22, 9:18 AM Frequently Asked Questions about COVID-19 Vaccination | CDC\nIf you have a condition or are taking medications that weaken your immune system, your immune response to COVID-19\nvaccination may not be as strong as in people who are not immunocompromised. Check your county\u2019s COVID-19\nCommunity Level for recommendations on whether you should wear a mask and additional actions you can take to\nprotect yourself from COVID-19. You may choose to wear a mask at any time based on your own level of comfort and\npersonal risk. Learn more about COVID-19 vaccinations for people who are moderately or severely immunocompromised.","31":"Some people in your family may need to take more\nsteps to be better protected from COVID-19, including\nAnyone not up to date with their COVID-19 vaccines\nPeople with weakened immune systems or underlying medical conditions\n\u2022\n\u2022\nProtect Yourself & Others\nHow It Spreads\nVariants of the Virus\nStress & Coping\nAnimals & COVID-19\nBasics of COVID-19\n\uf1aa\n\uf1aa\n\uf1aa\n\uf1aa\n\uf1aa\n\uf1aa\nLast Updated Jan. 24, 2022","5373":"Report vaccine side effects to FDA\/CDC Vaccine Adverse Event Reporting System (VAERS). The VAERS toll-free number is 1-800-822-7967 or report online to\nhttps:\/\/vaers.hhs.gov\/reportevent.html. Please include \u201cJanssen COVID-19 Vaccine EUA\u201d in the\nfirst line of box #18 of the report form. In addition, you can report side effects to Janssen Biotech, Inc. at the contact information provided\nbelow. e-mail Fax number Telephone numbers\nJNJvaccineAE@its.jnj.com 215-293-9955 US Toll Free: 1-800-565-4008\nYou may also be given an option to enroll in v-safe.","2677":"\u2022\nWhen to wear a mask or gloves\nIn general, people do not need to wear masks when outdoors. If you are sick and need to be around others, or are caring for someone who has COVID-19, wear a mask. If the COVID-19 Community Level where you live is\nLow\nWear a mask based on your personal preference, informed by your personal level of risk. Medium\nIf you are at risk for severe illness, talk to your healthcare provider about wearing masks indoors in public.","1107":"People have been seriously harmed and even died after taking products\nnot approved for use to treat or prevent COVID-19, even products approved or prescribed for other uses. Talk to a\nhealthcare provider about taking medications to treat COVID-19. For Healthcare Professionals\f10\/30\/22, 9:42 AM COVID-19 Treatments and Medications | CDC\n\uf2ff General Treatment Resources\nCOVID-19 Treatment Guidelines: What\u2019s New\nCoronavirus (COVID-19) Drugs\nTherapeutic Management of Nonhospitalized Adults With COVID-19\nCOVID-19 Therapeutics Locator\nOral Antiviral Treatment Resources\nPaxlovid Eligibility and Effectiveness Information Sheet\nWhat are Oral Antivirals? FDA Updates on Paxlovid for Health Care Providers\nPaxlovid Patient Eligibility Screening Checklist Tool for Prescribers\nMonoclonal Antibody Treatment Resources\nAnti-SARS-CoV-2 Monoclonal Antibodies\nWhat Are Monoclonal Antibodies?","2797":"There will be times where you may not be able to support a person exactly as they need, and it\u2019s\nok to acknowledge that. Just be direct in saying what you can and can\u2019t do. For example:\n\u201cI understand that you need help getting groceries because you are not feeling up to grocery\nshopping. I don\u2019t have a car, but I can recommend the delivery service I use.\u201d\n\u2022\n\u2022\n\u2022\nEmployers can support employees experiencing post-COVID conditions by offering flexible leave and work schedule policies,\nand by providing access to employee assistance programs.","6611":"Get more information:\n\uf209\n\u2022 \uf209\n\u2022\n\u2022\n\u2022 \uf209\n\u2022\n\u2022 \uf209\n\u2022 \u00ae \uf209\n\u2022 SM\n\u2022 \uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nGet more information:\nSmoking & Tobacco Use\nTips From Former Smokers\nHealth Benefits of Quitting Smoking\nSolid organ or blood stem cell transplant\nHaving had a solid organ or blood stem cell transplant, which includes bone marrow transplants, can make you more likely to\nget very sick from COVID-19. Get more information:\nTransplant Safety\nCOVID-19 Resources for Transplant Community\nStroke or cerebrovascular disease\nHaving cerebrovascular disease, such as having a stroke which affects blood flow to the brain, can make you more likely to get\nvery sick from COVID-19.","2028":"Then, the\nbody gets rid of the mRNA within a few days after vaccination. There Is No Evidence That COVID-19 Vaccination Causes Problems\nBecoming Pregnant\nThere is no evidence that vaccine ingredients, including mRNA, or antibodies made following COVID-19 vaccination would\ncause any problems with becoming pregnant now or in the future. Learn more about COVID-19 vaccines for people who\nwould like to have a baby someday. Research on COVID-19 Vaccine Safety in Children\nLearn more about\u202fhow mRNA vaccines, like the Pfizer-BioNTech and Moderna vaccines, work.","517":"Due to a delay in data syncing on March 13, 2021, 4,575,496 new doses administered were initially reported, which\nincluded records that were reported after 6:00 AM ET (the regular cutoff time for daily reporting). The site has since been\nupdated to reflect the totals reported as of March 13 at 6:00 AM ET. Totals for March 14, 2021reflect the number of\ndoses reported through the regular daily reporting period. Dose counts for the state of Connecticut were updated March 13, 2021to correct for data transmission errors that began\non February 20, 2021.","7879":"State of Vaccine Confidence\nInsights Report\nDate Range: May 3 \u2013 May 31, 2022\nSummary\nMajor themes identified from social media, news, and other sources that may impact\nvaccine confidence:\nConsumers continue to express their concerns about actual and potential COVID-19 vaccine\nside effects. Continuing and evolving themes that may impact vaccine confidence:\n\u0083 Consumers continue to express their lack of concern about COVID-19 despite rising cases\nand over 1 million dead Americans. \u0083 Parents continue to express concern and hesitation regarding COVID-19 vaccination for\nchildren. Emerging Misinformation Theme Affecting Vaccine Confidence:\n\u0083 Consumers have questions about the relationship between COVID-19 vaccines and\nmonkeypox. Ways public health and partners can take action.","6220":"Exact vaccine ingredients vary by\nmanufacturer. Pfizer-BioNTech and\nModerna COVID-19 vaccines also\ncontain messenger RNA (mRNA) and\nthe Johnson & Johnson\/Janssen\nCOVID-19 vaccine contains a\nharmless version of a virus unrelated\nto the virus that causes COVID-19. The Novavax COVID-19 vaccine\nincludes harmless pieces (proteins) of\nthe virus that causes COVID-19; they\nare pieces of what is often called the\n\u201cspike protein.\u201d These give\ninstructions to cells in your body to\ncreate an immune response. This\nresponse helps protect you from\ngetting sick with COVID-19 in the\nfuture. After the body produces an\nimmune response, it discards all the\nvaccine ingredients just as it would discard any information that cells no longer need.","5033":"New section added on Overview of COVID-19 vaccines recommendations. Updated guidance in section on COVID-19 vaccine dosage and schedule. Updated guidance in section on People vaccinated for prevention of COVID-19 outside the United States. Updated guidance in section on COVID-19 vaccination and SARS-CoV-2 infection for People with prior or current SARS-\nCoV-2 infection; People with a history of multisystem inflammatory syndrome in children (MIS-C) or adults (MIS-A);\nPeople who received passive antibody products; and Vaccinated people who subsequently develop COVID-19. New guidance on Considerations for COVID-19 revaccination in the section on Considerations for COVID-19\nvaccination in moderately and severely immunocompromised people.","1042":"Science at CDC\nScientific evidence and studies behind specific COVID-19 guidance and recommendations\nMMWR: Minimizing the impact of COVID-19 on Individual persons, Communities, and Health Care Systems\f10\/30\/22, 9:37 AM COVID-19 Testing: What You Need to Know | CDC\n\uf277 Difference Between Flu and COVID-19\nInfluenza (Flu) and COVID-19 are both contagious respiratory illnesses, but they are caused by different\nviruses. COVID-19 is caused by infection with a coronavirus named SARS-CoV-2, and flu is caused by infection\nwith influenza viruses. You cannot tell the difference between flu and COVID-19 by symptoms alone because\nsome of the symptoms are the same.","567":"October 13, 2022: California made updates to data previously submitted to CDC that resulted in a net increase of\n3,409 administered doses. October 6, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of\n212,852 administered doses. September 29, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of\n234,224 administered doses. August 31, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 38,447\nadministered doses.","1434":"None of the currently authorized SARS-CoV-2 antibody tests have been\nvalidated to evaluate specific immunity or protection from SARS-CoV-2 infection. For assistance with patient counseling and education related to COVID-19 testing and vaccination, please see:\nCOVID-19 Testing: What you Need to Know [CDC]\nUsing Antibody Tests for COVID-19: Information for Patients and Consumers [CDC]\nAntibody (Serology) Testing for COVID-19: Information for Patients and Consumers [FDA]\nFor more detailed information, please see: Interim Guidelines for COVID-19 Antibody Testing. My patient is asking for an antibody test to decide whether to get vaccinated (or revaccinated).","4440":"Improving Ventilation and Spending Time Outdoors\nImproving ventilation (moving air into, out of, or within a room) and filtration (trapping particles on a filter to remove\nthem from the air) can help prevent virus particles from accumulating in indoor air. Improving ventilation and filtration\ncan help protect you from getting infected with and spreading the virus that causes COVID-19. Spending time outside\nwhen possible instead of inside can also help: Viral particles spread between people more readily indoors than outdoors. Actions that can improve ventilation and filtration include:\nBringing in as much outdoor air as possible\u2014for example, opening windows.","1715":"Preserve all records related to COVID-19 vaccine management for a minimum of three years, or longer as required\nby the agreement or law of the jurisdiction. Comply with CDC instructions and timelines for disposing of COVID-19 vaccine and diluent, including used doses. Find detailed information regarding COVID-19 Vaccine storage and handling requirements at CDC Vaccine Storage and\nHandling Toolkit. (https:\/\/vaers.hhs.gov\/reportevent.html )\nThe Vaccine Adverse Event Reporting System (VAERS) is a national early warning system to detect possible safety\nproblems in vaccines used in the United States. VAERS accepts and analyzes reports of adverse events (AEs) after a\nperson has received a vaccination.","3093":"People who are moderately or severely immunocompromised ages 18 years and older who received the Janssen COVID-19\nVaccine primary series dose are recommended to receive a second (additional) dose using a monovalent mRNA vaccine and 1\nbivalent mRNA booster dose (i.e., Moderna or Pfizer-BioNTech). The primary series dose and the additional dose are\nseparated by at least 4 weeks. The bivalent mRNA booster dose is administered at least 2 months after the additional dose\n(for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose. See Appendix A for additional information on Janssen COVID-19 Vaccine.","34":"Some people in your family may need to take more\nsteps to be better protected from COVID-19, including\nAnyone not up to date with their COVID-19 vaccines\nPeople with weakened immune systems or underlying medical conditions\n\u2022\n\u2022\nProtect Yourself & Others\nHow It Spreads\nVariants of the Virus\nStress & Coping\nAnimals & COVID-19\nBasics of COVID-19\n\uf1aa\n\uf1aa\n\uf1aa\n\uf1aa\n\uf1aa\n\uf1aa\nLast Updated Jan. 24, 2022","248":"Serological surveillance (studies that investigate antibodies in the population) provides information about how long antibody\nprotection against COVID-19 lasts and if this protection is different among people who have antibodies from infection,\ncompared with people who have antibodies from vaccination, or both. We can also learn more about which groups of people might not produce as many antibodies or maintain them as long as\nothers\u2014for example, immunocompromised people compared with people who have healthy immune systems. This is\nimportant information for making decisions about whether or not additional vaccine doses or boosters are needed, when\nthey would be recommended, and who would need them first.","7421":"If you are a noncitizen nonimmigrant and are fully vaccinated, make sure your vaccine and proof of vaccination are\nacceptable to board a flight to the United States. For additional information on recommendations and requirements before and during travel to the United States and after\narriving in the United States, visit International Travel to and from the United States. \uf1c8\nGet Started\nTravel Assessment\nA tool to help you know the requirements to board a flight to the United States.","9432":"You should seek medical attention right away if you or your child have any of\nthe following symptoms after receiving the vaccine:\n\u2022 Chest pain\n\u2022 Shortness of breath\n\u2022 Feelings of having a fast-beating, fluttering, or pounding heart\nSide effects that have been reported in clinical trials with these vaccines include:\n\u2022 Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm\nof the injection, swelling (hardness), and redness\n\u2022 General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea and\nvomiting, fever, and rash\nSide effects that have been reported during post-authorization use include:\n\u2022 Severe allergic reactions\n\u2022 Myocarditis (inflammation of the heart muscle)\n\u2022 Pericarditis (inflammation of the lining outside the heart)\n\u2022 Fainting in association with injection of the vaccine\nThese may not be all the possible side effects of these vaccines.","8438":"\u2022\f10\/30\/22, 9:37 AM Transmission | CDC\nWear a well-fitting mask or respirator when the COVID-19 Community Level is high. If you are sick and need to be around others, or are caring for someone who has COVID-19, wear a mask. If you are at high risk of getting very sick, wear a well-fitting mask or respirator when the COVID-19 Community Level\nis medium or high. \u2022\n\u2022\n\u2022\nHave questions about getting or spreading COVID-19 after being vaccinated? Learn more about COVID-19 vaccine myths and facts. Last Updated July 12, 2021","1826":"COVID-19 vaccines may be administered along with and on the same day as other vaccines, such as the flu vaccine. Administer each injection in a different injection site. For more information, see Interim Clinical Considerations for Use of\nCOVID-19 Vaccines. Additional Resources\nLong-term Care Administrators and Managers: Options for Coordinating Access to COVID-19 Vaccines\nHow Jurisdictions Can Ensure COVID-19 Vaccine Access for Staff and Residents in Long-term Care Settings\nFAQs About Medical Consent & Additional Dose of mRNA COVID-19 Vaccine for Long-term Care Residents\nCOVID-19 Vaccines for Long-term Care Residents\nAbout mRNA Vaccines: Background Information for Healthcare Providers\nPage last reviewed: July 5, 2022","1912":"CDC and FDA: Vaccine Adverse Event Reporting System (VAERS) \u2014 VAERS is a national system to which healthcare\nprofessionals, vaccine manufacturers, and the public can report possible side effects or health problems that happen\nafter vaccination. Scientists investigate reports of events that are unexpected, appear to happen more often than\nexpected, or have unusual patterns. The VAERS reporting form has a question to identify pregnant people (question\n8). CDC clinicians review all pregnancy reports related to COVID-19 vaccinations. CDC: v-safe COVID-19 Vaccine Pregnancy Registry \u2014 V-safe is a smartphone-based, after-vaccination health checker for\npeople who receive COVID-19 vaccines.","4339":"Contact your vaccination provider or\nlocal health department to learn if a digital copy of your card is available to you. If you were vaccinated abroad there are ways you can update your U.S. vaccination record. To report suspicious activity involving fake CDC COVID-19 vaccination cards, please visit Fraud Alert: COVID-19 Scams\nor call 1-800-HHS-TIPS. \u2022\n\u2022\n\u2022 \uf209\nWhat if you lose your card? \uf1aa\nContact your vaccination provider directly to request a vaccination card or to get a copy of your vaccination\nrecord. If you cannot contact your vaccination provider site directly, contact your state health department\u2019s\nimmunization information system (IIS).","7981":"Google searches related to the COVID-19 vaccine during\nthis reporting period remained low relative to other topics such as Uvalde, TX, and monkeypox.e According to a Meltwater\ntrends analysis, there was a 17% decrease in news coverage and 45% decrease in social media mentions of COVID-19 vaccines.f\nRecent polling indicates fewer than a third of domestic consumers report being \u201csomewhat\u201d or \u201cvery\u201d worried about contracting\nAdditionally, sources indicate vaccine uptake plateauing,g as of May 31, 2022, COVID Data Tracker reported that 77.9% of\npeople had received at least one shot60 and 66.7% were fully vaccinated.61 Reported intention to vaccinate maintains a similarly\nconsistent cadence since approximately August 2021.c,62,63\nThe FDA64 and CDC65 strengthened recommendations and expansion of booster eligibility.","5766":"Talk to your healthcare provider about if and when you should receive a primary, additional and\/or a\nbooster dose. See CDC\u2019s Interim Clinical Considerations for additional information on moderately and\nseverely immunocompromised persons recommended for an additional primary dose and populations\neligible for a booster dose. Who should NOT get the COVID-19 vaccine by Moderna?","8059":"K-12 schools or ECE programs may\nchoose to implement universal indoor mask use to meet the needs of the families they serve, which could include people at\nrisk for getting very sick with COVID-19.124\n\u0083 Is the COVID-19 vaccine the cause of recent hepatitis cases in children?d\n\u0082 There is no evidence that COVID-19 vaccine causes hepatitis.125 CDC continues to examine possible causes, including testing\nfor and ruling out some of the viruses that commonly cause hepatitis (hepatitis A, B, C, D, and E). Adenovirus has been\ndetected in nearly half of the children and continues to be investigated as a candidate for the underlying cause.","163":"CDC leads the One Health Federal Interagency COVID-19 Coordination (OH-FICC) Group, which brings together public\nhealth, animal health, and environmental health representatives from more than 20 federal agencies to collaborate and\nexchange information on the One Health aspects of COVID-19. For example, the group researches and develops\nguidance on the connection between people and pets, wildlife, zoo animals, and livestock; animal diagnostics and\ntesting; and environmental health issues relevant to COVID-19. CDC leads the regular State-Federal One Health Update Call to bring local, state, tribal, and territorial partners together\nwith OH-FICC members.","2967":"Pfizer-BioNTech COVID-19 Vaccine\nPeople ages 12 years and older: A 2-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-\nBioNTech) is recommended. The primary series doses are separated by 3\u20138 weeks and the bivalent mRNA booster dose\nis administered at least 2 months after completion of the primary series (for people who have not received any booster\ndoses), or at least 2 months after the last monovalent booster dose.","8971":"Even if you are no longer pregnant, you may still be eligible to enroll in the registry. \u2022\n\u2022\n\u2022\nV-safe and the V-safe COVID-19 Vaccine Pregnancy Registry:\nWhat\u2019s the Difference? v-safe is a smartphone-based system that uses text messaging and web surveys to provide personalized health check-ins\nafter you receive a COVID-19 vaccine. The v-safe COVID-19 Vaccine Pregnancy Registry is for v-safe participants who self-\nidentify as pregnant at the time of vaccination or shortly thereafter (within 30 days of vaccination). The registry activities are in\naddition to the v-safe after vaccination health check-ins that participants receive via text message.","10014":"History of multisystem\ninflammatory\nsyndrome; either MIS-C\n(children) or MIS-A\n(adults)\n\u0083 Persons with a history of multisystem inflammatory syndrome; either MIS-C (children) or MIS-A\n(adults) is a precaution to receipt of COVID-19 vaccine. \u0083 Considerations when conducting a risk assessment for potential COVID-19 vaccination\n\u0083 Healthcare providers and health departments may also request a consultation from the Clinical\nImmunization Safety Assessment Project\nHistory of an immune-\nmediated syndrome\ncharacterized by\nthrombosis and\nthrombocytopenia,\nsuch as heparin-induced\nthrombocytopenia (HIT)\n\u0083 Janssen COVID-19 vaccine is not recommended for persons with a history of an episode of an\nimmune-mediated syndrome characterized by thrombosis and thrombocytopenia, such as\nspontaneous or classic HIT. \u0083 These persons should receive an mRNA (ie.","8453":"I have ended isolation but still need to continue\nwearing my mask per CDC\u2019s guidance. Do not travel on public transportation such as\nairplanes, buses, and trains if you will not be able\nto wear a high-quality mask or respirator when\naround others indoors for the full duration of your\ntrip. If you travel, wear a high-quality mask or\nrespirator the entire time you are around others\nindoors. Traveling by private vehicle (if possible) can lower\nthe chances of spreading COVID-19 to others. I was exposed to a person with COVID-19 in the\npast 10 days.","4810":"Appendix D. Vaccine administration errors and deviations\nThe FDA-issued Fact Sheet for Healthcare Providers Administering Vaccines should be referenced for detailed\ninformation on storage and handling, dosing and schedule, dose preparation, and administration of COVID-19 vaccines. The information provided below on managing vaccine administration errors should not be interpreted as a\nrecommendation or promotion of unauthorized use of the vaccines. \uf209\n\uf209\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nType Administration error\/deviation Interim recommendation\nmuscle)\nIncorrect route (e.g., subcutaneous) Do not repeat dose. Inform the recipient of the potential for local and systemic adverse\nevents.","8601":"After the protein piece is made, our cells break down the mRNA and remove it, leaving the body as waste. Next, our cells display the spike protein piece on their surface. Our immune system recognizes that the protein does\nnot belong there. This triggers our immune system to produce antibodies and activate other immune cells to fight\noff what it thinks is an infection. This is what your body might do if you got sick with COVID-19. At the end of the process, our bodies have learned how to help protect against future infection with the virus that\ncauses COVID-19.","8911":"This creates a\nhigh-risk environment for other dialysis patients and healthcare personnel and underscores the importance of\nvaccination to protect everyone in these clinics. Why vaccinate patients while they are at the dialysis clinic? Dialysis patients can be easily reached for COVID-19 vaccination at dialysis clinics, which have extensive operational,\nlogistical, and IT infrastructure to serve as capable vaccine providers. Many dialysis patients are accustomed to receiving routine vaccinations at the dialysis clinic.","2078":"None\nof the COVID-19 vaccines contain\nlive virus. They cannot make anyone\nsick with COVID-19, including\npeople who are pregnant or their\nbabies. Learn more about how\nvaccines work. Data on the safety of receiving an mRNA COVID-19 vaccine (Moderna or Pfizer-BioNTech), before and during pregnancy\nare reassuring. Data from vaccine safety monitoring systems have not found any safety concerns for people who received an\nmRNA COVID-19 vaccine late in pregnancy or for their babies. Scientists have not found an increased risk for miscarriage among pregnant people who received an mRNA COVID-\n19 vaccine just before or during early pregnancy (before 20 weeks of pregnancy).","965":"10\/30\/22, 9:37 AM COVID-19 Testing: What You Need to Know | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Testing: What You Need to Know\nWhen you get tested:\nMake sure to test at the right time\nChoose the right type of test for your circumstance\nFollow test directions as recommended by FDA\nIf you do not, your results may be less likely to correctly indicate whether you have COVID-19 or not. \u2022\n\u2022\n\u2022\nWhen to Get Tested for COVID-19\nKey times to get tested:\nIf you have symptoms, test immediately. If you were exposed to COVID-19 and do not have symptoms, wait at\nleast 5 full days after your exposure before testing.","5327":"In clinical trials, more than 61,000\nindividuals 18 years of age and older have received the Janssen COVID-19 Vaccine. Millions of\nindividuals have received the vaccine under EUA since February 27, 2021. WHAT ARE THE BENEFITS OF THE JANSSEN COVID-19 VACCINE? The Janssen COVID-19 Vaccine has been shown to prevent COVID-19. The duration of protection\nagainst COVID-19 is currently unknown. WHAT ARE THE RISKS OF THE JANSSEN COVID-19 VACCINE? Side effects that have been reported with the Janssen COVID-19 Vaccine include:\n\u2022 Injection site reactions: pain, redness of the skin and swelling.","1514":"HHS is responsible to ship, at U.S. Government (USG) expense, USG-\npurchased masks to agreed-upon distribution points designated by the provider. 2. Such masks will be distributed by the provider at locations readily accessible to the public. Subject to receiving\nadequate supply from the U.S. government:\na. Providers should have supply in every store that offers COVID-19 vaccine. b. Providers should prioritize maintaining highest inventory in stores servicing high socially vulnerable (SVI)\npopulations and stores with the highest demand. 3.","7113":"You should also talk to your healthcare professional if you think you are experiencing depression during or after\npregnancy. Get recommended vaccines during pregnancy. These vaccines can help protect you and your baby. Get a flu vaccine every year. Others living in your household should also get vaccinated to protect themselves and\nyou. Get the Tdap vaccine to protect your baby against whooping cough, which can have similar symptoms to COVID-19. CDC recommends all pregnant people receive a Tdap vaccine during each pregnancy. In addition, everyone who is\naround the baby should be up to date with their whooping cough vaccine.","2477":"Orvieto R, Noach-Hirsh M, Segev-Zahav A, Haas J, Nahum R, Aizer A. Does mRNA SARS-CoV-2 vaccine influence patients\u2019\nperformance during IVF-ET cycle?. Reprod Biol Endocrinol. 2021;19(1):69. Published 2021 May 13. doi:10.1186\/s12958-\n14. Wesselink AK, Hatch EE, Rothman KJ, et al. A prospective cohort study of COVID-19 vaccination, SARS-CoV-2 infection, and\nfertility [published online ahead of print, 2022 Jan 20]. Am J Epidemiol. 2022;kwac011. doi:10.1093\/aje\/kwac011\n15. Edelman A, Boniface ER, Benhar E, et al. Association Between Menstrual Cycle Length and Coronavirus Disease 2019\n(COVID-19) Vaccination: A U.S. Cohort [published online ahead of print, 2022 Jan 5]. Obstet Gynecol. 16.","4265":"Getting COVID-19 again soon after just having had COVID-19 can happen but is not common in the weeks to months\nafter you had it. Reasons to get a vaccine sooner rather than later include:\nyour own personal risk of having severe health concerns,\nyour local COVID-19 community level, and\nthe most common COVID-19 variant currently causing illness\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nWhen you should wait\n\uf1aa\f10\/30\/22, 9:30 AM Getting Your COVID-19 Vaccine | CDC\nIf you have COVID-19 People who have COVID-19 and are in isolation,\nshould wait to get vaccinated until:\nSymptoms are gone (if you had symptoms) and\nYour isolation guidelines have been met.","6508":"Staying up to date with COVID-19 vaccines, getting doses of EVUSHELD if eligible, and following preventive\nmeasures for COVID-19 are important. This is especially important if you are older or have severe health\nconditions or more than one health condition, including those on the list below. Approved and authorized COVID-19 vaccines (primary series and booster) are safe and effective. Some people who are immunocompromised, or people with weakened immune systems, may be eligible for an\nadditional primary dose of COVID-19 vaccine.","7037":"It\ndoes this so you can quickly and easily share with CDC how you or your child feel after getting a COVID-19 vaccine. Vaccine Adverse Event Reporting System can be used by you or your healthcare provider to report a side effect,\nadverse event, or reaction from COVID-19 vaccine. \u2022\n\u2022 \uf209\n\uf263 Stay Up to Date with COVID-19 Vaccines and Boosters\nWhen do you need to schedule your next shot? Do you or your child need to get a booster? Can you get a different vaccine product after your 1st dose?","6230":"COVID-19 vaccination causes a more predictable immune response than infection with the virus that causes COVID-19. Getting a COVID-19 vaccine gives most people a high level of protection against COVID-19 and can provide added\nprotection for people who already had COVID-19. One study showed that, for people who already had COVID-19, those\nwho do not get vaccinated after their recovery are more than 2 times as likely to get COVID-19 again than those who get\nfully vaccinated after their recovery. All COVID-19 vaccines currently available in the United States are effective at preventing COVID-19.","399":"The adjustments are the results of updates to how pharmacies\nreport data to CDC and\/or the jurisdictions. Due to a short network outage at CDC on August 14, 2021, some of the vaccine administration files were not ingested on\nAugust 15, 2021. Counts from these files are not reflected in the 6am counts for August 15, 2021 but will be in August 16,\n2021 counts. This affected 11 entities for a grand total of 66,326 vaccine administrations. The Federal Pharmacy Partnership for Long-Term Care (LTC) Program was a partnership between CDC and CVS,\nWalgreens, and Managed Health Care Associates, Inc.","8321":"10\/30\/22, 9:17 AM Talking to Recipients about COVID-19 Vaccination | CDC\nVaccines & Immunizations\nVaccines & Immunizations\nVaccines & Immunizations Home\nVaccine Recipient Education\nQuick References for COVID-19 Vaccine Recipients Who Want More Information\nMany people have questions about the coronavirus disease 2019 (COVID-19) vaccines. As vaccine recipients\u2019 most-trusted\nsource of information on vaccines, you play a critical role in helping vaccine recipients understand the importance of\nvaccination and that COVID-19 vaccines are safe and effective. The following resources will help you share clear and accurate information about COVID-19 vaccines, raise awareness\nabout the benefits of vaccination, and address common questions and concerns about what to expect when getting\nvaccinated.","7091":"Know when to wear a well-fitted mask to help protect yourself and others. Avoid crowds and poorly ventilated indoor spaces. Test to prevent spread to others\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:39 AM Pregnant and Recently Pregnant People | CDC\nTest to prevent spread to others. Stay 6 feet apart from others who don\u2019t live with you. Wash your hands often with soap and water. Use hand sanitizer if soap and\nwater aren\u2019t available. \u2022\n\u2022\n\u2022\nStaying Healthy During and After Your Pregnancy\nKeep all of your healthcare appointments during and after pregnancy. Visit with your healthcare provider for all\nrecommended appointments.","8759":"Safety precautions\nIf your child has a medical condition, such as a heart or lung problem, ask their healthcare provider before they use\nmethods to improve mask fit or use an ASTM F3502 mask or a respirator. If your child has a hard time breathing, gets dizzy, or has other symptoms while you are trying to get the mask to fit\nbetter or when using an ASTM F3502 mask or a respirator, choose a cloth or disposable mask. They should continue to\nprotect themselves and others. Consult your healthcare provider if these symptoms do not resolve.","30":"Some people in your family may need to take more\nsteps to be better protected from COVID-19, including\nAnyone not up to date with their COVID-19 vaccines\nPeople with weakened immune systems or underlying medical conditions\n\u2022\n\u2022\nProtect Yourself & Others\nHow It Spreads\nVariants of the Virus\nStress & Coping\nAnimals & COVID-19\nBasics of COVID-19\n\uf1aa\n\uf1aa\n\uf1aa\n\uf1aa\n\uf1aa\n\uf1aa\nLast Updated Jan. 24, 2022","3506":"Cruise ships may have their own requirements for testing, isolation, quarantine, mask wearing, and dining for people\nwith COVID-19 or their close contacts. If you have questions about a cruise ship\u2019s specific policies, please contact them\ndirectly. If you disembark the ship before completing your isolation or quarantine period, you should follow CDC\u2019s guidance, or\nlocal guidance if you disembark in another country. 10\/30\/22, 9:43 AM Cruise Ship Travel During COVID-19 | CDC\nGet tested for current infection with a COVID-19 viral test 3\u20135 days after your trip or if you develop symptoms. Isolate if you develop symptoms or your test result is positive.","8380":"These\ninclude:\nExperienced vaccinators\nVaccinators who have not administered vaccines in the past 12 months or longer\nMedical support staff (not licensed to administer vaccines but can assist with vaccine preparation and cold chain\nmanagement)\nAdministrative support staff (can assist with cold chain management, data reporting, and distribution of required\nmaterials to vaccine recipients)\nTraining is important not only for those who will prepare and administer vaccine, but also for those responsible for other\ncritical, mandatory functions, including protecting the vaccine cold chain, inputting required data, and ensuring vaccine\nrecipients receive documentation of vaccination.","5730":"The COVID-19\nvaccine by Pfizer-BioNTech can also be used under EUI for similar uses as an alternative mRNA COVID-19\nvaccine (see the Pfizer-BioNTech EUI Fact Sheet for Recipients), and the same or similar recommendations\nin this EUI also apply to the use of the COVID-19 vaccine by Pfizer-BioNTech under EUI. What is COVID-19? Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a coronavirus called SARS-CoV-2. It\nis predominantly a respiratory illness that can also affect other organs. People with SARS-CoV-2 infection\nhave reported a wide range of symptoms, from no symptoms to severe illness leading to death.","5011":"Added considerations for an 8-week interval between the first and second doses of a primary mRNA vaccine schedule\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nUpdated guidance for moderately or severely immunocompromised people\nClarification of existing recommendation to receive a 3-dose mRNA vaccine primary series followed by a booster\ndose for a total of 4 doses\nNew guidance to shorten the interval between completion of the mRNA vaccine primary series and the booster\ndose to at least 3 months (instead of 5 months)\nNew guidance for those who received the Janssen COVID-19 Vaccine primary series to receive an additional dose\nand a booster dose, for a total of 3 doses to be up to date\nUpdated guidance that it is no longer necessary to delay COVID-19 vaccination following receipt of monoclonal\nantibodies or convalescent plasma\nUpdated guidance on receiving a booster dose if vaccinated outside the United States\nUpdated contraindication and precaution section to include history of myocarditis or pericarditis after an mRNA\nCOVID-19 vaccine as a precaution\nReorganized and condensed multiple sections\nUpdated guidance for use of Pfizer-BioNTech COVID-19 Vaccine as a booster in people ages 12\u201317 years\nUpdated guidance for administration of a COVID-19 vaccine booster dose at least 5 months after completion of an\nmRNA vaccine (Pfizer-BioNTech or Moderna) primary series\nUpdated guidance for use of an additional primary dose for moderately or severely immunocompromised people ages\n5\u201311 years who received a Pfizer-BioNTech vaccine primary series\nUpdated recommendations for people who received COVID-19 vaccines outside the United States that are not FDA-\nauthorized or approved\nUpdated information about a second formulation of Pfizer-BioNTech COVID-19 Vaccine that is authorized for use in\npersons ages 12 years and older\nUpdated information on vaccinating people during quarantine after a known SARS-CoV-2 exposure or during COVID-\nUpdate to alert providers of possible false positive Rapid Plasma Reagin (RPR; non-treponemal) test results in some\npeople after COVID-19 vaccines\nUpdated information on vaccine administration errors and deviations\nUpdated guidance on use of Janssen (Johnson & Johnson) COVID-19 Vaccine\nUpdated recommendations for receipt of a COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 booster doses in recipients of mRNA COVID-19 vaccines\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nRecommendations and clinical guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children aged 5-11 years\nincluding updated section on Vaccination of children and adolescents\nUpdated guidance on COVID-19 vaccine dosing and schedule\nUpdated guidance for myocarditis and pericarditis after mRNA COVID-19 vaccination in new section on Considerations\nfor mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna\nNew guidance for people who received passive antibody products in section on COVID-19 vaccination and SARS-CoV-2\ninfection\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial in the United States\nUpdated guidance on Considerations for COVID-19 vaccination in moderately and severely immunocompromised\npeople\nUpdated guidance in section on Contraindications and precautions\nUpdated Table in Appendix A: Vaccine administration errors and deviations\nUpdated Appendix B: Triage of people with a history of allergies or allergic reactions\nUpdated Appendix C: Ingredients included in COVID-19 vaccines\nUpdated Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects\nfollowing COVID-19 vaccination\nUpdated guidance in section on Considerations for use of a COVID-19 booster dose.","2029":"Then, the\nbody gets rid of the mRNA within a few days after vaccination. There Is No Evidence That COVID-19 Vaccination Causes Problems\nBecoming Pregnant\nThere is no evidence that vaccine ingredients, including mRNA, or antibodies made following COVID-19 vaccination would\ncause any problems with becoming pregnant now or in the future. Learn more about COVID-19 vaccines for people who\nwould like to have a baby someday. Research on COVID-19 Vaccine Safety in Children\nLearn more about\u202fhow mRNA vaccines, like the Pfizer-BioNTech and Moderna vaccines, work.","10066":"\u0083 Inform vaccine recipients mRNA or Novavax COVID-19 vaccines are recommended over Janssen COVID-19 Vaccine. \u0083 Counsel vaccine recipients, parents, or guardians about expected reactions post-vaccination (e.g., pain and swelling at the injection site, fever,\nfatigue, headaches). \u0083 Inform mRNA and Novavax vaccine recipients especially males ages 12-39 years, of the rare risk of myocarditis and pericarditis following receipt of\nthese COVID-19 vaccines and the benefit of COVID-19 vaccination in reducing the risk of severe outcomes from COVID-19.\u2020 Counseling should also\ninclude the need to seek care if symptoms of myocarditis or pericarditis occur after vaccination, particularly in the week following vaccination.","5540":"Collaborate with professional medical groups to develop and offer clinical guidance and other educational materials for\nhealthcare providers, patients, and the public. \u2022\n\u2022\n\u2022\nCDC and other federal agencies, as well as academic institutions and research organizations, are working to learn more\nabout the short- and long-term health effects associated with COVID-19 , who gets them and why. \uf209\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nRelated Pages\nFor Healthcare Professionals\nCaring for People with Post-COVID Conditions\n\u203a\nPreparing for Appointments for Post-COVID Conditions\n\u203a\nResearching COVID to Enhance Recovery\n\u203a \uf209\nGuidance on \u201cLong COVID\u201d as a Disability Under the ADA\n\u203a \uf209\nPost-COVID Conditions: Healthcare Providers\n\u203a\nLast Updated Sept. 1, 2022","9197":"Throw away used tissues in a lined trash can\n\u2022\f10\/30\/22, 9:41 AM What to Do If You Are Sick | CDC\nThrow away used tissues in a lined trash can. Immediately wash your hands with soap and water for at least 20 seconds. If soap and water are not\navailable, clean your hands with an alcohol-based hand sanitizer that contains at least 60% alcohol. \u2022\n\u2022\n\uf304 Clean your hands often\nWash your hands often with soap and water for at least 20 seconds. This is especially important after\nblowing your nose, coughing, or sneezing; going to the bathroom; and before eating or preparing food.","6690":"Follow additional precautions for cleaning and disinfecting places where people with asthma might be, to reduce\nexposure to asthma triggers. Use products safely and correctly:\nAlways read and follow the directions on the product label to ensure you are using it safely and effectively. Wear skin protection such as gloves and consider eye protection to protect yourself against splashes. Make sure there is enough air flow (ventilation). Use only the amount recommended on the label. Use water at room temperature for dilution (unless stated otherwise on the label). Do NOT mix chemical products. Label diluted cleaning solutions.","6512":"\u2022\n\u2022\n\u2022 TM\n\u2022\n\u2022\f10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nBased on the current evidence, a person with any of the conditions listed below is more likely to get very sick from COVID-19. This means that a person with one or more of these conditions who gets very sick from COVID-19 (has severe illness from\nCOVID-19) is more likely to:\nBe hospitalized\nNeed intensive care\nRequire a ventilator to help them breathe\nDie\nIn addition:\nOlder adults are at highest risk of getting very sick from COVID-19. More than 81% of COVID-19 deaths occur in people\nover age 65.","4934":"Table of Contents \uf426\nReferences and Previous Updates\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine \u2014 United States, December 2020\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Moderna COVID-19 Vaccine\n\u2014 United States, December 2020\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Janssen COVID-19 Vaccine \u2014\nUnited States, February 2021\nUpdated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson\n& Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine\nRecipients\u2014United States, April 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Adolescents Aged 12\u201315 years \u2014 United States, May 2021\nUse of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory\nCommittee on Immunization Practices \u2014 United States, June 2021\nUse of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and\nmRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization\nPractices \u2014 United States, July 2021\nUse of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged \u226516 Years: Recommendations of the Advisory Committee\non Immunization Practices \u2014 United States, September 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendations for Additional Primary and Booster\nDoses of COVID-19 Vaccines \u2014 United States, 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Children Aged 5\u201311 Years \u2014 United States, November 2021\nUse of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory\nCommittee on Immunization Practices \u2014 United States, December 2021\nThe Advisory Committee on Immunization Practices\u2019 Recommendation for Use of Moderna COVID-19 Vaccine in Adults\nAged \u226518 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-\nReferences\n\uf1aa\n\uf20c\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\n19 Vaccines \u2014 United States, February 2022\nInterim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-\nBioNTech COVID-19 Vaccines in Children Aged 6 Months\u20135 Years \u2014 United States, June 2022\nInterim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19\nVaccine in Persons Aged \u226518 years \u2014 United States, July 2022.","5746":"\u2022 For people who are moderately or severely immunocompromised:\no\no\no\nPeople ages 12 years and older who are moderately or severely immunocompromised and\nreceived their primary vaccination with certain non-FDA authorized or approved COVID-19\nvaccines at least 28 days ago should receive an additional (third) primary dose of the\nCOVID-19 vaccine by Moderna. People ages 18 years and older with a moderately or severely immunocompromising\ncondition who received a primary dose of the Janssen COVID-19 Vaccine should receive an\nadditional dose with the COVID-19 vaccine by Moderna at least 28 days after receiving the\nJanssen COVID-19 Vaccine primary dose.","2503":"Select a Location (all fields required)\nState County Go\f10\/30\/22, 9:39 AM COVID-19 by County | CDC\nIndividual-Level Prevention Steps You Can Take Based on Your\nCOVID-19 Community Level\nLOW, MEDIUM, AND HIGH\nAt all COVID-19 Community Levels:\nStay up to date on vaccination, including recommended booster doses. Maintain ventilation improvements. Avoid contact with people who have suspected or confirmed COVID-19. Follow recommendations for isolation if you have suspected or confirmed COVID-19. Follow the recommendations for what to do if you are exposed to someone with COVID-19. If you are at high risk of getting very sick, talk with a healthcare provider about additional\nprevention actions.","6974":"Additionally, the FDA issued an Emergency Use Authorization of\nthe COVID-19 vaccine by Pfizer-BioNTech as an additional primary or a booster dose, determining, among\nother things, that the known and potential benefits of vaccination outweigh the known and potential risks\nof the vaccine. Based on available information, the use of the COVID-19 vaccine by Pfizer-BioNTech as\ndescribed in this Fact Sheet could help improve or restore protection that may not have been sufficient or\nmay have decreased over time after the primary vaccination. What alternative choices are available for primary and\/or additional doses other than the COVID-19\nvaccine by Pfizer-BioNTech?","1907":"10\/30\/22, 9:32 AM COVID-19 Vaccine Monitoring Systems for Pregnant People | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccine Monitoring Systems for Pregnant\nPeople\nLearn more about COVID-19 and pregnancy. Learn more about COVID-19 vaccination considerations for people who are pregnant or breastfeeding. Monitoring COVID-19 Vaccine Safety during Pregnancy\nCDC and the Food and Drug Administration (FDA) currently have five safety monitoring systems in place to capture\ninformation about vaccination during pregnancy and closely monitors that information reported to each system.","2536":"Immunization Schedule for Children 6 Months through 17 Years of Age*\nType\nRecipient\nAge\nProduct\u2020\nFor Most People\nThose Who ARE Moderately or\nSeverely Immunocompromised\nDoses Interval Between Doses\u2021 Doses Interval Between Doses\nmRNA\nvaccine\nthrough\nMONOVALENT Moderna:\nBlue vial cap with\nmagenta-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 4\u20138 weeks\u00b6\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nthrough\nMONOVALENT Moderna:\nBlue vial cap with\npurple-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 4\u20138 weeks\u00b6\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Moderna:\nBlue vial cap with\ngray-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nthrough\nMONOVALENT Moderna:\nRed vial cap with\nblue-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 4\u20138 weeks\u00b6\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Moderna:\nBlue vial cap with\ngray-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nthrough\nMONOVALENT Pfizer-BioNTech:\nMaroon vial cap with\nmaroon-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 3\u20138 weeks\u00b6 Dose 1 to 2 At least 3 weeks\nDoses 2 and 3 At least 8 weeks (2 months) Dose 2 to 3 At least 8 weeks (2 months)\nthrough\nMONOVALENT Pfizer-BioNTech:\nOrange vial cap with\norange-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 3\u20138 weeks\u00b6\nDose 1 to 2 At least 3 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Pfizer-BioNTech:\nOrange vial cap with\norange-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nthrough\nMONOVALENT Pfizer-BioNTech:\nGray vial cap with\ngray-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 3-8 weeks\u00b6\nDose 1 to 2 At least 3 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Pfizer-BioNTech:\nGray vial cap with\ngray-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nProtein\nsubunit\nvaccine\nand older\nMONOVALENT Novavax\nPrimary series: Monovalent\nDose 1 to 2 At least 3\u20138 weeks\u00b6 Dose 1 to 2 At least 3 weeks\nmRNA (Moderna, Pfizer-\nBioNTech) should be used for the\nbooster dose.","2917":"Terminology for COVID-19 vaccine use\nPrimary series: Initial vaccination which can range from a single dose to a 3-dose series depending on the vaccine\nproduct and a person\u2019s age and immune status. The same vaccine product should be used for all doses of the\nprimary series. Additional dose: A dose of vaccine administered after the primary series to people who may be less likely to mount a\nprotective immune response after initial vaccination. People who are moderately or severely immunocompromised\nand who received Janssen COVID-19 Vaccine for their primary series are recommended to receive an additional dose\nusing an mRNA vaccine.","6534":"They are not in order of risk. CDC completed a review for each medical condition on this list. This was done to ensure that these conditions met\ncriteria for inclusion on this list. CDC conducts ongoing reviews of additional underlying conditions. If other\nmedical conditions have enough evidence, they might be added to the list. Because we are learning more about COVID-19 every day, this list does not include all medical conditions that\nplace a person at higher risk of severe illness from COVID-19. Rare medical conditions, including many conditions\nthat mostly affect children, may not be included on the list below.","8194":"However, certain factors, such as personal risk of severe\ndisease, or risk of disease in a loved one or close contact, local COVID-19 Community Level, and the most common COVID-19\nvariant currently causing illness, could be reasons to get a vaccine sooner rather than later. Children and teens ages 6 months\u201317 years\nFor Healthcare Workers: Learn more about COVID 19 vaccine schedules. \uf2ff\nCOVID-19 vaccine dosage is based on age on the day of vaccination, not on size or weight. Children get a smaller dose of\nCOVID-19 vaccine than teens and adults based on their age group.","3214":"Anaphylactic reactions have been rarely reported following receipt of COVID-19 vaccines. Administration of antihistamines\nbefore COVID-19 vaccination to prevent allergic reactions is not generally recommended. However, while antihistamines will\nnot prevent anaphylaxis, some experts advise antihistamine use as a means of preventing milder allergic reactions in patients\nwho might be at higher risk for allergic reactions. For more information on the assessment and potential management of\nanaphylaxis, see Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination. For more information on patient counseling, see Vaccine Recipient Education. Syncope (fainting) may occur in association with any injectable vaccine, especially in adolescents.","1712":"Preserve all records related to COVID-19 vaccine management for a minimum of three years, or longer as required\nby the agreement or law of the jurisdiction. Comply with CDC instructions and timelines for disposing of COVID-19 vaccine and diluent, including used doses. Find detailed information regarding COVID-19 Vaccine storage and handling requirements at CDC Vaccine Storage and\nHandling Toolkit. (https:\/\/vaers.hhs.gov\/reportevent.html )\nThe Vaccine Adverse Event Reporting System (VAERS) is a national early warning system to detect possible safety\nproblems in vaccines used in the United States. VAERS accepts and analyzes reports of adverse events (AEs) after a\nperson has received a vaccination.","6244":"New variants of a virus happen because the virus that causes COVID-19 constantly changes through a natural ongoing\nprocess of mutation (change). As the virus spreads, it has more opportunities to change. High vaccination coverage in a\npopulation reduces the spread of the virus and helps prevent new variants from emerging. CDC recommends COVID-19\nvaccines for everyone ages 6 months and older, and boosters for everyone 5 years and older, if eligible. Learn more about variants. MYTH: All events reported to the Vaccine Adverse Event Reporting System (VAERS) are caused\nby vaccination.","9310":"Healthcare Appointment Checklist for Post-COVID\nConditions | COVID-19 |\nAccessible link: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/long-term-effects\/post-COVID-appointment\/index.html\nThis checklist is designed to help patients and caregivers get the most out of appointments with healthcare providers for post-COVID conditions. Before the Appointment\n\nAsk the new provider\u2019s office if they\nneed paperwork signed so your medical\nrecords can be sent to\nthem directly. Keep a journal or a list for a week\nor two to document your activities,\nsymptoms, their severity, and anything\nthat made you feel better or worse. Prepare a brief report that summarizes\nyour experience and symptoms and\ndescribes your best and worst days. Make a list of your current\nmedications\/supplements.","435":"On June 10, 2021, a data synchronization error resulted in a number of records missing the 6 AM ET cutoff for inclusion\nthe same day on CDT. Records were instead being included on CDT the following day. The issue has been resolved and\ndata are correctly synchronized as of June 17, 2021. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\n-\n\u2022\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nOn June 6, 2021, the total number of administered doses for New Mexico was incorrectly reported as 1,903,485 due to a\ndata processing error, which has been amended. The correct total for NM on June 6, 2021, was 2,175,419 administered\ndoses.","9515":"Special Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nSpecial Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nModerna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group\nCDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage based on their age on\nthe day of vaccination. \u0083 If a person moves from a younger age group to an older age group during the primary series or between the primary series and receipt\nof the booster dose(s), they should receive the vaccine product and dosage for the older age group for all subsequent doses.","9323":"Make a list of questions to ask your\nhealthcare provider. Identify which\nones are a priority for you (in case\ntime is limited). Make a plan for remembering your\nconversation with your healthcare\nprovider \u2014 e.g., taking notes or\nbringing a friend. If needed, arrange transportation to\nyour appointment. During the Appointment\n\nTell your provider the most important\nsymptoms or issues you\u2019d like\nto discuss. Answer the provider\u2019s questions. Share your medication\/supplement list. Discuss your level of activity. Ask your own questions, starting with\nyour priorities and issues. Make sure you understand the\nnext steps, such as tests, follow-up,\nreferrals, and future appointments. Ask for an appointment summary.","2468":"N Engl J Med. 2021;384(24):2273-2282. 10. Razzaghi H, Meghani M, Pingali C, et al. COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy \u2014\nEight Integrated Health Care Organizations, United States, December 14, 2020\u2013May 8, 2021. MMWR Morb Mortal Wkly\nRep 2021;70:895\u2013899. DOI: http:\/\/dx.doi.org\/10.15585\/mmwr.mm7024e2 . 11. Aharon D, Lederman M, Ghofranian A, et al. In Vitro Fertilization and Early Pregnancy Outcomes After Coronavirus\nDisease 2019 (COVID-19) Vaccination [published online ahead of print, 2022 Jan 25]. Obstet Gynecol. 12. Morris RS. SARS-CoV-2 spike protein seropositivity from vaccination or infection does not cause sterility. F S Rep.\n13.","5014":"Added considerations for an 8-week interval between the first and second doses of a primary mRNA vaccine schedule\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nUpdated guidance for moderately or severely immunocompromised people\nClarification of existing recommendation to receive a 3-dose mRNA vaccine primary series followed by a booster\ndose for a total of 4 doses\nNew guidance to shorten the interval between completion of the mRNA vaccine primary series and the booster\ndose to at least 3 months (instead of 5 months)\nNew guidance for those who received the Janssen COVID-19 Vaccine primary series to receive an additional dose\nand a booster dose, for a total of 3 doses to be up to date\nUpdated guidance that it is no longer necessary to delay COVID-19 vaccination following receipt of monoclonal\nantibodies or convalescent plasma\nUpdated guidance on receiving a booster dose if vaccinated outside the United States\nUpdated contraindication and precaution section to include history of myocarditis or pericarditis after an mRNA\nCOVID-19 vaccine as a precaution\nReorganized and condensed multiple sections\nUpdated guidance for use of Pfizer-BioNTech COVID-19 Vaccine as a booster in people ages 12\u201317 years\nUpdated guidance for administration of a COVID-19 vaccine booster dose at least 5 months after completion of an\nmRNA vaccine (Pfizer-BioNTech or Moderna) primary series\nUpdated guidance for use of an additional primary dose for moderately or severely immunocompromised people ages\n5\u201311 years who received a Pfizer-BioNTech vaccine primary series\nUpdated recommendations for people who received COVID-19 vaccines outside the United States that are not FDA-\nauthorized or approved\nUpdated information about a second formulation of Pfizer-BioNTech COVID-19 Vaccine that is authorized for use in\npersons ages 12 years and older\nUpdated information on vaccinating people during quarantine after a known SARS-CoV-2 exposure or during COVID-\nUpdate to alert providers of possible false positive Rapid Plasma Reagin (RPR; non-treponemal) test results in some\npeople after COVID-19 vaccines\nUpdated information on vaccine administration errors and deviations\nUpdated guidance on use of Janssen (Johnson & Johnson) COVID-19 Vaccine\nUpdated recommendations for receipt of a COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 booster doses in recipients of mRNA COVID-19 vaccines\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nRecommendations and clinical guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children aged 5-11 years\nincluding updated section on Vaccination of children and adolescents\nUpdated guidance on COVID-19 vaccine dosing and schedule\nUpdated guidance for myocarditis and pericarditis after mRNA COVID-19 vaccination in new section on Considerations\nfor mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna\nNew guidance for people who received passive antibody products in section on COVID-19 vaccination and SARS-CoV-2\ninfection\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial in the United States\nUpdated guidance on Considerations for COVID-19 vaccination in moderately and severely immunocompromised\npeople\nUpdated guidance in section on Contraindications and precautions\nUpdated Table in Appendix A: Vaccine administration errors and deviations\nUpdated Appendix B: Triage of people with a history of allergies or allergic reactions\nUpdated Appendix C: Ingredients included in COVID-19 vaccines\nUpdated Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects\nfollowing COVID-19 vaccination\nUpdated guidance in section on Considerations for use of a COVID-19 booster dose.","9696":"\u2022 Provide a CDC COVID-19 Vaccination Record Card to the recipient or their caregiver with the lot number\nand date of administration recorded for the primary, additional, or booster dose of the COVID-19 vaccine\nby Pfizer-BioNTech. \u2022 Provide the v-safe information sheet to vaccine recipients\/caregivers and encourage vaccine recipients\nto participate in v-safe. V-safe is a voluntary smartphone-based tool that uses text messaging and web\nsurveys to check in with people who have been vaccinated to identify potential side effects after COVID-\n19 vaccination. V-safe asks questions that help CDC monitor the safety of COVID-19 vaccines. For more\ninformation, visit: www.cdc.gov\/vsafe.","8585":"Each type of vaccine prompts our bodies to recognize and help protect us from\nthe virus that causes COVID-19. None of these vaccines can give you COVID-19. Vaccines do not use any live virus\f10\/30\/22, 9:34 AM Understanding How COVID-19 Vaccines Work | CDC\nmRNA vaccines (Pfizer-BioNTech or Moderna)\nTo trigger an immune response, many vaccines put a weakened or inactivated germ into our bodies. Not mRNA vaccines. Instead, mRNA vaccines use mRNA created in a laboratory to teach our cells how to make a protein\u2014or even just a piece of a\nprotein\u2014that triggers an immune response inside our bodies.","7008":"\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nChildren and teens ages 6 months\u201317 years\n\uf1aa\nAGE GROUP\nCommon side effects can include:\nPain on the leg or arm where the shot was given\nSwollen lymph nodes\nIrritability or crying\nSleepiness\nLoss of appetite\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nAGE GROUP\nSide effects are more common after the second dose\nand can include:\nPain, swelling, and redness on the arm where the\nshot was given\nTiredness\nHeadache\nMuscle or joint pain\nChills\nSwollen lymph nodes\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nAdults 18 years and older\n\uf1aa\f10\/30\/22, 9:30 AM Possible Side Effects After Getting a COVID-19 Vaccine | CDC\nAfter a second shot or booster\nReactions reported after getting a booster shot are similar to those after the two-dose or single-dose primary shots. Most side\neffects were mild to moderate.","1046":"Learn more\nResources\nProfessional Resources on Testing: Healthcare Workers | Health Departments | Labs\n\uf2ff\nDon\u2019t Delay: Test Soon and Treat Early [1 page, 361 KB]\nHow to Collect an Anterior Nasal Swab Specimen for COVID-19 Testing [2 pages, 372 KB]\nHow to Collect a Nasal Mid-Turbinate Swab Specimen for COVID-19 Testing [2 pages, 4 MB]\nUsing Your Self-Test [1 page, 295 KB]\nUsing Your Self-Test (Customizable File) [1 page, 279 KB]\nPrint Resources\n\uf1aa\n\u2022 \uf20c\n\u2022 \uf20c\n\u2022 \uf20c\n\u2022 \uf20c\n\u2022 \uf20c\n\u2022 \uf20c\nLast Updated Sept. 28, 2022","8772":"\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:40 AM Use and Care of Masks | CDC\nHow to Care for Your Mask\nCorrect and consistent care for your mask helps to provide the best protection\nHow to take off your mask\n1. For reusable cloth masks\nIf your cloth mask is wet or dirty, put it in a sealed plastic bag\nuntil you can wash it. This will keep it from getting moldy. If your cloth mask is dry and clean, you can store it in a\nbreathable bag (like a paper or mesh fabric bag) to keep it clean\nbetween uses in the same day.","5707":"Moderna COVID-19 Vaccine EUI Recipient Fact Sheet, ver 9\/02\/2022\nEmergency Use Instructions (EUI) Fact Sheet for Recipients and Caregivers:\nModerna COVID-19 Vaccine for Primary and\/or Additional Doses\nThis Fact Sheet describes Emergency Use Instructions (EUI) that have been issued by the Centers for\nDisease Control and Prevention (CDC) to provide information about the primary and additional doses of the\nCOVID-19 vaccine by Moderna that go beyond its FDA-approved labeling.","9379":"HOW ARE SPIKEVAX (COVID-19 VACCINE, mRNA), MODERNA COVID-19\nVACCINE, AND MODERNA COVID-19 VACCINE, BIVALENT RELATED? SPIKEVAX (COVID-19 Vaccine, mRNA) and Moderna COVID-19 Vaccine can be used\ninterchangeably.4 Moderna COVID-19 Vaccine, Bivalent is made in the same way as\n3 Monovalent refers to any authorized or approved COVID-19 vaccine that contains or encodes the spike protein of\nonly the Original SARS-CoV-2.","6506":"What You Need To Know\nA person with any of the medical conditions listed below is more likely to get very sick with COVID-19. If you have\none of these conditions, talk with your healthcare provider about how best to protect yourself from severe illness\nfrom COVID-19. The list below does not include all possible conditions that put you at higher risk of severe illness from COVID-19. If\nyou have questions about a condition not included on this list, talk to your healthcare provider about how best to\nmanage your condition and protect yourself from COVID-19.","7733":"CDC scientists have conducted detailed reviews of cases of anaphylaxis and made the information available to\nhealthcare providers and the public:\nAllergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine\nReports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US\u2014December 14, 2020-January 18,\nAllergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine\u2014 United\nThe benefits of COVID-19 vaccination continue to outweigh any potential risks.","10051":"Summary Document for\nInterim Clinical Considerations\nfor Use of COVID-19 Vaccines Currently Authorized or Approved in the United States\nCOVID-19 vaccine products currently approved or authorized in the United States\nPfizer-BioNTech\n* Booster doses are only indicated for recipients 18 years and age and older in limited situations, see: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html\nAge indication Vaccine\ncomposition\nVaccine vial\ncap color\nLabel border\ncolor\nDilution\nrequired\nPrimary series Booster doses\nDose Injection volume Dose Injection volume\n6 months\u20134 years Monovalent Maroon Maroon Yes 3 \u00b5g 0.2 mL NA NA\n5\u201311 years Monovalent Orange Orange Yes 10 \u00b5g 0.2 mL NA NA\n5\u201311 years Bivalent Orange Orange Yes NA NA 10 \u00b5g 0.2 mL\n12 years and older Monovalent Gray Gray No 30 \u00b5g 0.3 mL NA NA\n12 years and older Bivalent Gray Gray No NA NA 30 \u00b5g 0.3 mL\nModerna\nAge indication Vaccine\ncomposition\nVaccine vial\ncap color\nLabel border\ncolor\nDilution\nrequired\nPrimary series Booster doses\nDose Injection volume Dose Injection volume\n6 months\u20135 years Monovalent Dark blue Magenta No 25 \u00b5g 0.25 mL NA NA\n6-11 years Monovalent Dark blue Purple No 50 \u00b5g 0.5 mL NA NA\n6-11 years Bivalent Dark blue Gray No NA NA 25 \u00b5g 0.25 mL\n12 years and older Monovalent Red Light blue No 100 \u00b5g 0.5 mL NA NA\n12 years and older Bivalent Dark blue Gray No NA NA 50 \u00b5g 0.5 mL\nJanssen\nAge indication Vaccine\ncomposition\nVaccine vial\ncap color\nLabel border\ncolor\nDilution\nrequired\nPrimary series Booster doses\nDose Injection volume Dose Injection volume\n18 years and older Monovalent Blue No Color No\nparticles\nparticles\nNovavax\nAge indication Vaccine\ncomposition\nVaccine vial\ncap color\nLabel border\ncolor\nDilution\nrequired\nPrimary series Booster doses*\nDose Injection volume Dose Injection volume\n12 years and older Monovalent Royal blue No Color No\n5 \u00b5g rS and 50 \u00b5g of\nMatrix-M\u2122 adjuvant\n5 \u00b5g rS and 50 \u00b5g of\nMatrix-M\u2122 adjuvant\nJanssen COVID-19 Vaccine is authorized for adults ages 18 years and older in certain limited situations due to safety considerations.","1124":"Older Adults and People with\nDisabilities\nChildren and Adolescents\nHomebound Persons\nDialysis Patients\nHealthcare Personnel\nTeachers, School Staff, and Child Care\nWorkers\nPregnant or Breastfeeding Patients\nPeople with Certain Underlying\nMedical Conditions\nPatients Vaccinated Outside the US\nPatients Receiving Antiviral Therapy\nResources\nHealth\nDepartments\n\uf426\nYou and Your\nFamily\n\uf426\nCOVID-19 Vaccine Effectiveness and Safety\nMMWR COVID-19 Vaccine Reports\nEquity in Vaccination\nCDC\u2019s program, Partnering for Vaccine Equity, aims to\nreduce disparities in disproportionately affected\ncommunities by supporting a wide variety of partners\nworking to increase vaccine confidence and access\namong racial and ethnic minority groups. Equity in Vaccination\nGet Vaccinated\nFind COVID-19 vaccines and boosters near you. Message & data rates may apply.","1647":"The following are not included in the above prohibition:\nCommunications regarding receipt of a second dose, or potential booster dose(s), of COVID-19 vaccine\nCommunications to vaccine recipient for public health purposes\nCommunications to vaccine recipients involving pharmacy or clinical services of the provider, personalized to the\nvaccine recipient\u2019s medical needs, even if those services are not directly related to COVID-19 vaccination\nAvailability of other vaccines (e.g., shingles, pneumococcal conjugate, seasonal influenza, routine childhood vaccines)\nClinical emails\nDisease screening services\nCommunications about the availability of programs to manage particular health conditions (e.g., asthma, diabetes,\nheart disease)\nIn addition, de-identified, aggregate datasets can be used by providers and shared with other partners for public health,\npopulation health, and health equity purposes.","4597":"Pointing fans toward people can blow contaminated air directly at them. Use ceiling fans to help improve air flow in the home whether or not windows are open. \u2022\n\u2022\n\u2022\nLimit the number of visitors in your home and the time spent inside\nThe more people inside your home, and the longer they stay, the more virus particles can accumulate. Limit the number of visitors in your home to reduce the accumulation of virus particles in the air.","5344":"For this reason, your vaccination provider may\nask you to stay at the place where you received your vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include:\n\u2022 Difficulty breathing,\n\u2022 Swelling of your face and throat,\n\u2022 A fast heartbeat,\n\u2022 A bad rash all over your body,\n\u2022 Dizziness and weakness. Blood Clots with Low Levels of Platelets\nBlood clots involving blood vessels in the brain, lungs, abdomen, and legs along with low levels\nof platelets (blood cells that help your body stop bleeding), have occurred in some people who\fhave received the Janssen COVID-19 Vaccine.","9474":"Individuals 6 years of age and older may receive a booster dose with Moderna COVID-19\nVaccine, Bivalent. Vaccinations may not provide full immunity to COVID-19 in people who are\nimmunocompromised; therefore, you or your child should continue to maintain physical\nprecautions to help prevent COVID-19. Your close contacts should be vaccinated as appropriate. WHAT ABOUT PREGNANCY OR BREASTFEEDING? If you are, or your child is, pregnant or breastfeeding, discuss the options with your healthcare\nprovider. WILL THESE VACCINES GIVE ME OR MY CHILD COVID-19? No. These vaccines do not contain SARS-CoV-2 and cannot give you or your child COVID-19.","2644":"Help them with grocery\nshopping, filling prescriptions,\nand getting other items they\nmay need. Consider having the\nitems delivered through a\ndelivery service, if possible. Take care of their pet(s), and limit contact between the person who is sick and their pet(s) when possible. Make sure the person who is sick drinks a lot of fluids and rests\n\u2022\n-\n\u2022\n\u2022\n\u2022\n\u2022\nWatch for warning signs\nHave their doctor\u2019s phone number on hand. Use CDC\u2019s self-checker tool to help you make decisions about seeking appropriate medical care. \u2022\n\u2022\f10\/30\/22, 9:41 AM COVID19 - Caring for someone at home | CDC\nCall their doctor if the person keeps getting sicker.","8517":"\uf1aa\nAir passengers are required to provide the following contact information, to the extent that it exists, within 72 hours\nbefore their flight\u2019s departure: full name (as it appears on their passport), address while in the United States, primary\ncontact phone number, secondary or emergency contact phone number, and email address. Passengers must also:\nAcknowledge that the obligation to provide complete and accurate information is a U.S. government requirement and\nthat failure to provide complete and accurate information may result in criminal penalties. Confirm the information they provided is complete and accurate.","8762":"Safety precautions\nIf your child has a medical condition, such as a heart or lung problem, ask their healthcare provider before they use\nmethods to improve mask fit or use an ASTM F3502 mask or a respirator. If your child has a hard time breathing, gets dizzy, or has other symptoms while you are trying to get the mask to fit\nbetter or when using an ASTM F3502 mask or a respirator, choose a cloth or disposable mask. They should continue to\nprotect themselves and others. Consult your healthcare provider if these symptoms do not resolve.","5379":"V-safe is a new voluntary smartphone-based\ntool that uses text messaging and web surveys to check in with people who have been vaccinated\nto identify potential side effects after COVID-19 vaccination. V-safe asks questions that help CDC\nmonitor the safety of COVID-19 vaccines. V-safe also provides live telephone follow-up by CDC\nif participants report a significant health impact following COVID-19 vaccination. For more\ninformation on how to sign up, visit: www.cdc.gov\/vsafe. WHAT IF I DECIDE NOT TO GET THE JANSSEN COVID-19 VACCINE? Under the EUA, there is an option to accept or refuse receiving the vaccine.","8711":"10\/30\/22, 9:39 AM Use Masks to Slow the Spread of COVID-19\nEspa\u00f1ol | Other Languages\nMasks\nWear a Mask to Protect Yourself and Others\nMasking is a critical public health tool and it is important to remember that any mask\nis better than no mask. Wear the most protective mask you can that fits well and that you will wear\nconsistently. Wearing a high-quality mask along with vaccination, self-testing, and physical\ndistancing, helps protect you and others by reducing the chance of spreading COVID-\n19.","398":"The adjustments are the results of updates to how pharmacies\nreport data to CDC and\/or the jurisdictions. Due to a short network outage at CDC on August 14, 2021, some of the vaccine administration files were not ingested on\nAugust 15, 2021. Counts from these files are not reflected in the 6am counts for August 15, 2021 but will be in August 16,\n2021 counts. This affected 11 entities for a grand total of 66,326 vaccine administrations. The Federal Pharmacy Partnership for Long-Term Care (LTC) Program was a partnership between CDC and CVS,\nWalgreens, and Managed Health Care Associates, Inc.","4678":"Most systemic symptoms were mild to moderate in severity and resolved within 1\u20132 days. Overall, symptoms were more frequent in people ages 18\u201359 years compared to people ages 60 years and older. Thrombosis with thrombocytopenia syndrome (TTS)\nTTS is a rare syndrome that includes acute venous or arterial thrombosis and new onset thrombocytopenia in patients with\nno recent known exposure to heparin. Although the condition is rare, currently available evidence supports a causal\nrelationship between Janssen COVID-19 Vaccine and TTS.","8167":"They also provide some protection against Omicron, but not as much as the updated (bivalent) boosters. The virus that causes COVID-19 has changed over time. The different versions of the virus that have developed over time are\ncalled variants. Learn more about variants of the COVID-19 virus. Two COVID-19 vaccine manufacturers, Pfizer and Moderna, have developed updated (bivalent) COVID-19 boosters. When Are You Up to Date? You are up to date with your COVID-19 vaccines if you have completed a COVID-19 vaccine primary series and received the\nmost recent booster dose recommended for you by CDC.","2168":"Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N\nEngl J Med2021; 384:2273-2282. DOI: https:\/\/doi.org\/10.1056\/NEJMoa2104983 . \uf209\f10\/30\/22, 9:30 AM COVID-19 Vaccines While Pregnant or Breastfeeding\ng J ; p g J\n2. Zauche LH, Wallace B, Smoots AN, et al. Receipt of mRNA COVID-19 vaccines and risk of spontaneous abortions. New\nEngl J MedPublished online September 8, 2021; DOI: https:\/\/doi.org\/10.1056\/NEJMc2113891\n3. Kharbanda EO, Haapata J, DeSilva M, et al. Spontaneous Abortion Following COVID-19 Vaccination During\nPregnancy. JAMA. Published online September 8, 2021. DOI: https:\/\/doi.org\/10.1001\/jama.2021.15494\n4. Lipkind HS, Vazquez-Benitez G, DeSilva M, et al.","4258":"People who already had COVID-19 and do not get vaccinated after their recovery are more likely to get COVID-19 again\nthan those who get vaccinated after their recovery. If you were given monoclonal antibodies or convalescent plasma while sick with COVID-19 you do not need to wait to get\nvaccinated. \u2022\n\u2022\n\u2022\nWhen you can wait\n\uf1aa\nIf you recently had COVID-19, you may consider delaying your next vaccine dose (primary dose or booster) by 3\nmonths from when:\nyour symptoms started,\nyou first received a positive test if you had no symptoms.","2247":"10\/30\/22, 9:29 AM COVID-19 Vaccines for Long-term Care Residents | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccines for Long-term Care Residents\nCDC is reviewing this page to align with updated guidance. CDC recommends COVID-19 vaccines for residents of long-term care (LTC)\nages 6 months and older, and boosters for everyone 5 years and older, if\neligible. Many LTC settings, such as residential care, assisted living, nursing homes,\nand continuing care retirement communities provide care to older adults\nwith underlying medical conditions, often living closely together.","5127":"Find a U.S. COVID-19 testing location near you or use a self-test. If you already had COVID-19 within the past 90 days, see specific testing recommendations. \uf209\nCan I travel if ...? I am sick with or tested positive for COVID-19 and\nam recommended to isolate. Do NOT travel. Follow recommendations for isolation. I have ended isolation but still need to continue\nwearing my mask per CDC\u2019s guidance. Do not travel on public transportation such as\nairplanes, buses, and trains if you will not be able\nto wear a high-quality mask or respirator when\naround others indoors for the full duration of your\ntrip.","5236":"Do not go places where you are unable to wear a mask. For travel guidance, see CDC\u2019s Travel webpage. Do not travel. Stay home and separate from others as much as possible. Use a separate bathroom, if possible. Take steps to improve ventilation at home, if possible. Don\u2019t share personal household items, like cups, towels, and utensils. Monitor your symptoms. If you have an emergency warning sign (like trouble breathing), seek emergency medical care\nimmediately. Learn more about what to do if you have COVID-19. End isolation based on how serious your COVID-19 symptoms were.","1526":"In addition, providers will post notice visible to the public at the site of any\nmask distribution under this initiative utilizing uniform signage that will be provided electronically by HHS, which,\nat a minimum, will address:\na. The masks have been provided by the U.S. Department of Health and Human Services for free distribution. b. The masks are provided for personal use only. c. And, the public notice will include a QR code and\/or weblink that can be used by recipients of the masks to\nobtain user instructions.","668":"February 11, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n14,616 doses administered\nFebruary 9, 2022: Utah made updates to data previously submitted to CDC that resulted in an increase of 73,002\ndoses administered. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nFebruary 4, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 75,630\ndoses administered. February 4, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n32,976 doses administered.","3580":"The number of people fully vaccinated with Johnson & Johnson\u2019s Janssen (J&J\/Janssen) vaccine does not equal the\ntotal number of J&J\/Janssen vaccine doses administered because some people were reported to have received one\nor more mRNA vaccines (i.e., Pfizer-BioNTech, Moderna) prior to receiving the single-dose J&J\/ Janssen vaccine. For reporting on CDC COVID Data Tracker, CDC counts people as being \u201cfully vaccinated\u201d if they received one dose\nof a single-dose vaccine or two doses on different days (regardless of time interval) of either an mRNA or a protein-\nbased series.","8722":"10\/30\/22, 9:40 AM Use and Care of Masks | CDC\nEspa\u00f1ol | Other Languages\nUse and Care of Masks\nWear a mask with the best fit, protection, and comfort for you\nWhen to Wear a Mask or Respirator\nLayered prevention strategies \u2014 like staying up to date on vaccines and wearing masks \u2014 can help prevent severe illness and\nreduce the potential for strain on the healthcare system. Wear a mask with the best fit, protection, and comfort for you.","1688":"COVID-19 vaccination providers are required to\nimplement all recommendations of the ACIP, adopted by the CDC Director, relevant to COVID-19 vaccination including:\nUse of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson)\nand mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on\nImmunization Practices \u2014 United States, July 2021\nUse of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory\nCommittee on Immunization Practices \u2014 United States, June 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Adolescents Aged 12\u201315 Years \u2014 United States, May 2021\nUpdated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen\n(Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among\nVaccine Recipients \u2014 United States, April 2021\nInterim Recommendation for Use of Janssen COVID-19 Vaccine \u2014 United States, February 2021\nInterim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine, United States 2020\nInterim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine, United States, December 2020\nInterim Recommendation for Use of Moderna COVID-19 Vaccine, United States, December 2020\n\uf209\n\uf20c\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nInterim Recommendation for Use of Moderna COVID 19 Vaccine, United States, December 2020\nUpdated Interim Recommendation for Allocation of COVID-19 Vaccine, United States, December 2020\nFind more information about vaccine administration and reporting requirements.","748":"August 25, 2021: A federal entity made updates to data previously submitted to CDC that resulted in an increase of\n3,818 doses administered. August 17, 2021: Rhode Island made updates to data previously submitted to CDC that resulted in an increase of\n1,386 doses administered. August 12, 2021: Vermont made updates to data previously submitted to CDC that resulted in a decrease of 23,325\ndoses administered. August 4, 2021: Colorado made updates to data previously submitted to CDC that resulted in an increase of 11,379\ndoses administered.","6036":"What is the available supporting evidence for delaying a second primary dose in people who recently had\nSARS-CoV-2 infection by 3 months from symptom onset or positive test (if infection was asymptomatic)? SARS-CoV-2 infection induces a robust humoral and cellular immune response (CDC, 2021). Additionally, a\nlonger interval of at least 3 or 6 months between infection and vaccination may improve immune response by\nallowing time for the response to mature and avoiding interference from the vaccine (Abu-Raddad L, 2021;\nZhong, 2021). Multiple large-scale studies have observed decreased risk of subsequent infection with\nantigenically similar variants by 80-93% for months after infection (CDC, 2021).","6083":"References\nAbu-Raddad L, Chemaitelly H, Ayoub HH, et al. Association of Prior SARS-CoV-2 Infection With Risk of\nBreakthrough Infection Following mRNA Vaccination in Qatar. JAMA. 2021;326(19):1930-1939. Alejo J., et al. Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant\nRecipients: A Case Series. Transplantation 2021;105(21):e280-e281. Amirthalingam G, Bernal, JL, Andrews, NJ, et al. Serological responses and vaccine effectiveness for extended\nAtmar, R.L., et al. Heterologous SARS-CoV-2 Booster Vaccinations \u2013 Preliminary Report. medRxiv Preprint.","1924":"Through VSD, CDC will study:\nWeekly counts and rates of COVID-19 vaccination in pregnant people\nMiscarriage and stillbirth that occurs among people who received COVID-19 vaccine during pregnancy\nAdverse outcomes in pregnancy following COVID-19 vaccination, including:\nPregnancy complications\nBirth outcomes\nInfant outcomes for the first year of life (includes infant death, birth defects, and developmental disorders)\nCDC: Clinical Immunization Safety Assessment (CISA) Project \u2014 The CISA Project is a collaboration between CDC and\nseven medical research centers to provide expert consultation on individual cases of adverse events after vaccination\nand conduct clinical research studies about vaccine safety.","2359":"People Who Were Vaccinated Outside of the United States\nPeople who are moderately or severely immunocompromised and who received COVID-19 vaccines not available in the\nUnited States should either complete or restart the recommended COVID-19 vaccine series, including a booster, in the United\nStates. For more information, talk to your healthcare provider, or see the COVID-19 Interim Clinical Considerations.","7019":"It is not recommended to take these medicines before vaccination to try to prevent side effects as it is not known\nhow OTC medicines might affect how well the vaccine works. Children\nAsk your child\u2019s healthcare provider for advice on using a non-aspirin pain reliever and learn about other steps you can take\nat home to comfort your child after vaccination.","1381":"My patient previously received a monovalent mRNA booster dose(s). Can they get a bivalent\nbooster dose? \uf1aa\nThe current recommendation is for everyone who is eligible to receive 1 bivalent booster dose: this includes people who\nreceived the primary series but did not receive the previously recommended monovalent mRNA booster dose(s) and\npeople who received 1 or 2 monovalent mRNA booster doses. Because the guidance has changed, not everyone will\nreceive the same number of booster doses. However, once a person receives 1 bivalent booster dose, no additional\nbooster doses are currently recommended.","8740":"Select a Location (all fields required)\nState County Go\nIt is important to wear a mask or respirator when you are sick or caring for someone who is sick with COVID 19 When caring\f10\/30\/22, 9:40 AM Use and Care of Masks | CDC\nIt is important to wear a mask or respirator when you are sick or caring for someone who is sick with COVID-19. When caring\nfor someone who is sick with COVID-19, a respirator will provide you the best level of protection.","1750":"Requirements for Quality Assurance Monitoring (Updated 10\/18\/2021)\n\uf1aa\nAll organizations and providers\nparticipating in the CDC COVID-19\nVaccination Program:\nmust administer COVID-19 Vaccine at\nno out-of-pocket cost to the recipient\nmay not deny anyone vaccination based on the vaccine recipient\u2019s coverage status or network status\nmay not charge an office visit or other fee if COVID-19 vaccination is the sole medical service provided\nmay not require additional medical services to receive COVID-19 vaccination\nmay seek appropriate reimbursement from a program or plan that covers COVID-19 Vaccine administration fees for the\nvaccine recipient, such as:\nvaccine recipient\u2019s private insurance company\nMedicare or Medicaid reimbursement\nmay not seek any reimbursement, including through balance billing, from the vaccine recipient\nRequirements for COVID-19 Vaccination Program Providers\nCOVID-19 Vaccine is Provided at 100% No Cost to Recipients\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nIndividuals aware of any potential violations of these requirements are encouraged to report them to the Office of the\nInspector General, U.S. Department of Health and Human Services, by calling 1-800-HHS-TIPS or the website TIPS.HHS.GOV\n.","735":"October 5, 2021: North Carolina made updates to data previously submitted to CDC that resulted in an increase of\n16,009 doses administered. September 29, 2021: Florida made updates to 3,001,563 records previously submitted to CDC that resulted in no net\nchange in number of doses administered. September 25, 2021: Iowa made updated to data previously submitted to CDC that resulted in an increase of 4,928\ndoses administered. September 24, 2021: Virginia made updates to 9,172,838 records previously submitted to CDC that resulted in no\nnet change in number of doses administered.","5426":"Manufactured by:\nJanssen Biotech, Inc.\na Janssen Pharmaceutical Company of Johnson & Johnson\nHorsham, PA 19044, USA\n\u00a9 2021 Janssen Pharmaceutical Companies\nFor more information, call US Toll Free: 1-800-565-4008, US Toll: (908) 455-9922 or go to www.janssencovid19vaccine.com\n. Scan to capture that this Fact Sheet was provided to vaccine\nrecipient for the electronic medical records\/immunization\ninformation systems.","1603":"In lieu of CDC developing a separate COVID-19 Vaccine Information Statement (VIS) at this time for the licensed Pfizer\nvaccine, FDA has issued a combination COVID-19 Vaccine Information Fact Sheet for Recipients and Caregivers to\naddress both the FDA authorized (EUA) Pfizer-BioNTech COVID-19 Vaccine and the FDA Biologics License Application (BLA)\napproved (licensed) Pfizer-BioNTech COMIRNATY COVID-19 Vaccine. The vaccines have identical formulations. When\nadministering the Pfizer-BioNTech COVID-19 vaccine under either the EUA or under BLA approval, providers must give\neach vaccine recipient, adult caregiver accompanying the recipient, or other legal representative, a copy of the age-\nappropriate Pfizer-BioNTech COVID-19 Vaccine Information Fact Sheet.","9870":"Kornek B, Leutmezer F, Rommer PS, et al. B Cell Depletion and SARS-CoV-2 Vaccine Responses in\nNeuroimmunologic Patients. Annals of Neurology. 2022;91:342-352. Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) \u2013 5 October 2021. Geneva: World\nHealth Organization; 2021. Kaslow DC. Policy question: Is a 3rd dose needed for older persons who have\nreceived 2 doses of inactivated COVID-19 vaccines? https:\/\/www.who.int\/news-\nroom\/events\/detail\/2021\/10\/04\/default-calendar\/sage_meeting_october_2021. Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nMoghnieh R, Mekdashi R, El-Hassan S, et al.","450":"On May 27, 2021, the New Hampshire \u2018at least one dose\u2019 values posted to Tracker appeared lower than that reported the\nday prior (May 26, 2021). This correction is accurate and is due to New Hampshire and CDC collaboratively correcting\ndata transmission errors. On May 25, 2021, the 7,836,063 administered doses reported for Long-Term Care Facilities (LTCF), were fewer by 4,105\nrecords compared to the 7,840,168 reported on May 24, 2021. This was due to an error in data processing that has now\nbeen corrected. The data for May 26, 2021 accurately reflect total LTCF doses.","4167":"People with COVID-19 during pregnancy are more likely to\ndeliver a preterm (earlier than 37 weeks) or stillborn infant and may also be more likely to have other pregnancy\ncomplications. COVID-19 vaccination during pregnancy helps:\nPrevent severe illness and death in people who are pregnant\nProtect babies younger than 6 months old from hospitalization caused by COVID-19\nLearn more about vaccination considerations and the safety and effectiveness of COVID-19 vaccinations for people who\nare pregnant or breastfeeding. If you are pregnant and have received a COVID-19 vaccine, we encourage you to enroll in v-safe, CDC\u2019s smartphone-based\nsystem that provides personalized health check-ins after vaccination.","1324":"However, FDA allows the formulation for either age group to be administered for certain age transitions. See Moderna\nCOVID-19 Vaccine for Children who Transition from a Younger to Older Age Group , Pfizer-BioNTech for Children who\nTransition from a Younger to Older Age Group , and the product-specific EUA for more information. What should be done if the incorrect vaccine formulation is administered based on a patient\u2019s\nage? \uf1aa\n\uf20c\n\uf20c \uf209\nIn general, all doses of the primary series should be with the same product.","4961":"New booster recommendation for people ages 12 years and older to receive 1 bivalent mRNA booster after\ncompletion of a monovalent primary series; it replaces all prior booster recommendations for this age group\nRecommendations for use of a bivalent Moderna booster dose in people ages 18 years and older\nRecommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 12 years and older\nUpdated guidance for observation periods following COVID-19 vaccination\nUpdated guidance on COVID-19 vaccination and multisystem inflammatory syndrome (MIS) in children (MIS-C) and in\nadults (MIS-A)\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adolescents ages 12\u201317 years\nReorganization of Janssen COVID-19 Vaccine guidance into an appendix\nUpdated guidance on COVID-19 vaccination following exposure to SARS-CoV-2\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nPrevious Updates\n\uf1aa\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nUpdated guidance on COVID-19 vaccination and myocarditis and pericarditis\nNew clinical considerations for coadministration of mRNA COVID-19 vaccines and orthopoxvirus vaccines\nNew guidance for use of Moderna COVID-19 Vaccine in children and adolescents ages 6\u201317 years\nNew guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children ages 6 months\u20134 years\nNew guidance for use of Moderna COVID-19 Vaccine in children ages 6 months\u20135 years\nReorganization of sections on COVID-19 vaccination recommendations and schedules\nAddition of new section in Special populations for infants and young children\nNew guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5\u201311 years\nUpdated guidance that the following people should receive a second COVID-19 booster dose:\nPeople ages 12 years and older who are moderately or severely immunocompromised\nPeople ages 50 years and older\nUpdated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-\ndepleting therapies\nClarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults\n(MIS-A)\nUpdated guidance for primary series vaccination after SARS-CoV-2 infection\nAdded considerations for the option to receive a second COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 vaccination after SARS-CoV-2 infection\nAdded guidance that people ages 12 years and older who are moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that people ages 18\u201349 years who are not moderately or severely immunocompromised and who\nreceived Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster\ndose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose\nFurther clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C)\nand adults (MIS-A) and myocarditis\nUpdated information on the availability of Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL\ndosage volume) and Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL dosage volume) for\nadministration of a 50 \u00b5g booster dose.","6177":"CDC monitors COVID-19 vaccine effectiveness to understand how well the vaccines:\nProtect different age groups, such as children, adolescents, and adults, including adults ages 65 and older\nProtect specific groups, such as people with underlying health conditions or healthcare workers\nProtect against new variants\nLower the risk of infection, including infection without symptoms\nProtect against milder COVID-19 illness\nPrevent more serious outcomes, such as hospitalization or death\nPrevent complications from COVID-19, such as post-COVID conditions and multisystem inflammatory syndrome\n(MIS)\nPrevent spreading COVID-19 to others\nProvide long- and short-term protection\nPerform among people who have received one or more booster doses\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nAssessing How Vaccines Work in the Real World Helps Us:\nAdjust vaccine recommendations,\nas needed, such as booster doses\n\uf263\nGuide vaccine policy and vaccine\ndistribution\n\uf260\nInform development of vaccine\ntechnologies\n\uf33d\nCOVID-19 Vaccines and New Variants of the Virus\f10\/30\/22, 9:33 AM Monitoring COVID-19 Vaccine Effectiveness | CDC\nViruses are constantly changing to create new types of the virus, called variants.","8049":"On May 17, 2022, the FDA amended the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine, authorizing\na single booster dose for children ages 5-11 years at least five months after completion of a primary series with the same\nvaccine.101 The FDA committee that reviews and evaluates data concerning the safety, effectiveness, and appropriate use of\nvaccines, VRBPAC (Vaccines and Related Biological Products Advisory Committee), meet on June 14\u201315, 2022 to discuss the\nemergency use authorization of COVID-19 vaccines in this age.102 On June 17, 2022, the Advisory Committee on Immunization\nPractices (ACIP) issued interim recommendations for use of the Moderna COVID-19 vaccine in children ages 6 months to 5\nyears and the Pfizer COVID-19 vaccine\nfor use in children ages 6 months to 4\nyears.103 Some parents have expressed\nenthusiasm and relief about childhood\nvaccination.104,105,106 However, a recent\nKaiser Family Foundation (KFF) poll\nfound that only 18% of parents with\nchildren younger than 5 years will get\ntheir child vaccinated right away, while\n38% say they plan to wait and see how\nthe vaccine is working for others, 27%\nsay they will definitely not get their child\nvaccinated, and 11% say they will only do\nso if they are required.107,108\nPerceptions, Concerns, and Threats to Vaccine Confidence\n\u0083 Concerns about side effects, such as myocarditis, may negatively impact vaccine uptake.109,110\n\u0083 Some consumers believe vaccines are unnecessary because COVID-19 rarely affects this group.111,112\n\u0083 Some believe infection-induced immunity protects children better than vaccines.113,114\n\u0083 Some social media users do not think there is enough data to support vaccination against COVID-19 in children.115,116,117\n\u0083 With cases of hepatitis in children rising globally, some believe they are caused by COVID-19 vaccines.118,119,120\n\u0083 Some are concerned that immunity from vaccines decreases rapidly in adolescents.122,123\nCommonly asked questions and queries from the public\n\u0083 Should children under the age of 5 years still wear masks?i\n\u0082 Wearing a well-fitting mask or respirator consistently and correctly reduces the risk of spreading the virus that causes\nCOVID-19.","4422":"Select a Location (all fields required)\nState County Go\nPrevention Actions to Use at All COVID-19 Community Levels\nIn addition to basic health and hygiene practices, like handwashing, CDC recommends some prevention actions at all COVID-\n19 Community Levels, which include:\nStaying Up to Date with COVID-19 Vaccines\nImproving Ventilation\nGetting Tested for COVID-19 If Needed\nFollowing Recommendations for What to Do If You\nHave Been Exposed\n\u2022\n\u2022\n\u2022\n\u2022\nStaying Home If You Have Suspected or Confirmed\nSeeking Treatment If You Have COVID-19 and Are at\nHigh Risk of Getting Very Sick\nAvoiding Contact with People Who Have Suspected or\n\u2022\n\u2022\n\u2022\nStaying Up to Date with COVID-19 Vaccines\nCOVID-19 vaccines help your body develop protection from the virus that causes COVID-19.","6049":"What is the available supporting evidence for revaccination of people who received COVID-19 vaccine during\nB-cell-depleting therapy administered over a limited period? Moderna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 09\/02\/22;\nStudies of people on B-cell-depleting therapies indicate patients do not achieve adequate seroconversion or\nhave a decreased odds ratio of seroconversion if they were vaccinated during therapy (Haggenberg, 2022a;\nHaggenberg, 2022b).The timing of vaccination relative to therapy influences vaccine immunogenicity;\nvaccination at least 6 months after therapy has demonstrated improved seroconversion (Kornek, 2022;\nSchietzel, 2022, Disanto, 2021).","8799":"10\/30\/22, 9:25 AM Use of Agency Materials | Other | CDC\nUsing CDC.gov\nUse of Agency Materials\nMost of the information on the CDC and ATSDR websites is not subject to copyright, is in the public domain, and may be freely\nused or reproduced without obtaining copyright permission. There are, however, a few exceptions. A federal government website may have a mix of public domain and copyright-\nprotected materials. First, some resources, as well as images, on the CDC and ATSDR websites are restricted in their use\nbecause they were developed by government contractors or grantees, or have been licensed by a third party.","7652":"\uf1aa\nNoncitizen nonimmigrants that plan to take a connecting flight in the United States to another country may continue on\ntheir itinerary; however, they are still required to complete and sign the attestation in case their travel plans are changed\nor delayed. If they take their connecting flight and leave the United States, they are no longer subject to the requirements\nof the attestation. I am taking a connecting flight through the United States but the attestation says I have to attest\nto self-quarantine for 5 days and get a viral COVID-19 test 3-5 days after arrival.","1578":"6\/23\/22 Update (replaces 6\/18\/22 update; and revised to be a consolidated update that addresses all\nprimary series pediatric COVID-19 vaccination; 6\/23\/22 update also adds availability of age-appropriate\nModerna COVID-19 Vaccine for 6 years through 17 years of age):\nCOVID-19 Vaccination of Children 6 Months through 17 Years of Age\nPursuant to CDC\/ACIP recommendations and Secretarial Directives:\nAll authorized providers in the CDC COVID-19 Vaccination Program shall make immediately available and administer\nupon request \u2013\na two-dose series using the age-appropriate Moderna COVID-19 Vaccine product for children ages 6 months\nthrough 17 years\na three-dose series using the age-appropriate Pfizer-BioNTech COVID-19 Vaccine product for children ages 6\nmonths through 4 years\na two-dose series using the age-appropriate Pfizer-BioNTech COVID-19 Vaccine product for children ages 5 years\nthrough 17 years\n6\/23\/22 Update (replaces 6\/18\/22, 1\/6\/22, 9\/14\/21 and 10\/7\/21 updates; additional eligible group noted\nin bold italics; Updated on 10\/12\/22 to remove reference to the purple cap Pfizer-BioNTech vials which\nare no longer available):\nThird Dose for Recipients of Pfizer-BioNTech or Moderna COVID-19 Vaccine Who Are Immunocompromised\nPursuant to CDC\/ACIP recommendations and Secretarial Directives, a third primary dose of an mRNA COVID-19\nvaccine should be administered using the same mRNA COVID-19 vaccine as was administered for the 2-dose primary\nseries to persons who are moderately to severely immunocompromised at least 28 days after completing the two-\ndose primary series:\nPfizer-BioNTech COVID-19 Vaccine \u2013\nOrange cap to children 5 through 11 years of age\nGray cap to people 12 years and older\nModerna COVID-19 Vaccine \u2013\nDark blue cap\/magenta border to children 6 months through 5 years of age\nDark blue cap\/purple border to children 6 years through 11 years of age\nRed cap\/light blue border to people 12 years and older\nCOVID-19 Vaccination Under the CDC Interim Clinical Considerations and Emergency Use Instructions\nProviders may also administer COVID-19 vaccines as described in CDC guidance as updated from time to time:\nInterim Clinical Considerations for Use of COVID-19 Vaccines in the United States\nEmergency Use Instructions (see vaccine Fact Sheets)\n5\/23\/22 Update (revision of 5\/19\/22 update to add reference to the May 23, 2022, Secretarial Directive;\n9\/1\/22 revision noted in bold italics to clarify that booster doses available to this age group are\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\n9\/1\/22 revision noted in bold italics to clarify that booster doses available to this age group are\nmonovalent):\nCOVID-19 Vaccine Booster Doses for Children 5 through 11 Years of Age\nPursuant to CDC\/ACIP recommendations and the May 23, 2022, Secretarial Directive on Pediatric and Second COVID-\n19 Vaccine Booster Doses, all providers in the CDC COVID-19 Vaccination Program shall make immediately available\nand administer a single monovalent booster dose of Pfizer-BioNTech COVID-19 vaccine to individuals seeking such a\ndose as follows:\nChildren ages 5 through 11 years should receive a single monovalent Pfizer-BioNTech COVID-19 vaccine booster\ndose at least 5 months after completion of a Pfizer-BioNTech COVID-19 vaccine primary series.","3820":"COVID-19 vaccination providers cannot\ncharge vaccine recipients for the vaccine (which is provided free to enrolled providers by the U.S. government) or for any\nadministration fees, copays, or coinsurance. COVID-19 vaccination providers cannot deny vaccination to anyone who\ndoes not have health coverage, is underinsured, or is out of network. COVID-19 vaccination providers cannot charge recipients for an office visit or any other fee if the only service provided is\na COVID-19 vaccination. Additional healthcare services can be provided at the same time and billed as appropriate. However, providers cannot require additional services for a person to receive a COVID-19 vaccine.","2459":"About the COVID-19 Vaccine: Frequently Asked Questions. Available at:\ncovid-19-vaccine-frequently-asked-questions\/ . 3. American College of Obstetricians and Gynecologists (ACOG). COVID-19 Vaccination Considerations for Obstetric\u2013\nGynecologic Care. https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-\nvaccination-considerations-for-obstetric-gynecologic-care . 4. American Society for Reproductive Medicine (ASRM) Patient Management and Clinical Recommendations During the\nCoronavirus (COVID-19) Pandemic: UPDATE No. 16 \u2013 Reproductive Facts Regarding COVID-19 Vaccination. Available at:\nhttps:\/\/www.asrm.org\/covid-update-16 . 5. Joint Statement Regarding COVID-19 Vaccine in Men Desiring Fertility. Society for Male Reproduction and Urology (SMRU)\nand Society for the Study of Male Reproduction (SSMR). January 9, 2021. Available at https:\/\/www.asrm.org\/news-and-\nfor-male-reproduction-and-urology-smru-and-the-society-for-the-study-of-male-reproduction-ssmr\/ . 6. Vaccines and Related Biological Products Advisory Committee Meeting. FDA Briefing Document.","16":"Ask the facility healthcare provider (or facility staff) for help if:\n\u2022 The redness or pain where you got the shot gets worse after 24 hours\n\u2022 Your side effects are worrying you\n\u2022 Your side effects do not seem to be going away after a few days\nIn the rest of your body:\n\u2022 Fever\n\u2022 Chills\n\u2022 Tiredness\n\u2022 Headache\n\u2022 Muscle pain\n\u2022 Nausea\nCOMMON SIDE EFFECTS\nHELPFUL TIPS\nREMEMBER","4279":"You may be able to take these types of medications to reduce fever or pain after you get your vaccine to\nrelieve any pain or discomfort resulting from possible side effects. If you do not regularly take over-the-counter medications, you should not take them before you get a COVID-19\nvaccination. Taking one of the following medications regularly is not, on its own, a reason to avoid getting your COVID-19 vaccination:\nOver-the-counter medications (non-prescription)\nNon-steroidal anti-inflammatory drugs (NSAIDs) (naproxen, ibuprofen, aspirin, etc.) Acetaminophen (Tylenol, etc.)","6017":"\u2022 In a large test-negative design study to evaluate VE among adults aged \u226518 years in British Columbia\nand Quebec, Canada, two-dose mRNA VE against infection and hospitalization was significantly higher\nwith a longer dosing interval (7\u20138 weeks vs. 3\u20134 weeks) (Skowronski, 2021). VE appeared to plateau at\nthe 7\u20138 week interval. \u2022 A test-negative case control study among adults aged 50\u201389 years in England demonstrated that\nPfizer-BioNTech VE was higher with longer (>6 weeks) intervals compared to short (3\u20134 weeks)\nintervals for all age groups (Amirthalingam, 2021).","1329":"In the following exceptional situations, a different COVID-19 vaccine may be administered to complete a primary series at\na minimum interval of 28 days from the last COVID-19 vaccine dose:\nThe same vaccine is not available\nA previous dose is unknown\nThe person would otherwise not complete the primary series\nA person starts but is unable to complete a primary series with the same COVID-19 vaccine due to a contraindication. No VAERS report is required. For more information, see:\nTiming, spacing, and interchangeability of COVID-19 vaccines. Should the same COVID-19 vaccine product be used for all doses in the primary series?","8419":"Core Competencies:\nRelevant information contained in the EUA Fact Sheet(s) for Healthcare Providers for the vaccine product(s) in\nyour facility\nPreparation requirements\nStorage and handling requirements\nTransport guidance\nVaccination documentation and reporting requirements\nRequired and additional information for vaccine recipients\nCOVID-19 Vaccine Administration Competencies Assessment Form\n\uf209\n\uf20c\nCOVID-19 Vaccine Training Routine Vaccine Administration Routine Vaccine Storage and Handling\nCDC Training Module(s) for the\nvaccine product(s) in your facility\nn\/a Recommended if storing and handling\nvaccine: You Call the Shots: Vaccine\nStorage and Handling\nOr other vaccine storage and handling\ntraining offered by a worksite, state or\nlocal health department, medical\nprofessional organization, or\nmedical\/nursing school within the last\n12 months.","6057":"Effectiveness of an additional\nprimary dose of the COVID-19 vaccine by Moderna is inferred from immunogenicity data in\nimmunocompromised adults who received a third 0.5 mL (100 \u03bcg of mRNA) primary dose. Rates of local or\nsystemic adverse events with 50 \u03bcg booster dose were comparable to those observed after Dose 2 of the\nprimary series (Miller, 2021; Das, 2021). Available data on the safety or efficacy of a Moderna COVID-19 vaccine dose after receipt of a non-FDA\nauthorized or approved COVID-19 vaccine are limited.","2390":"Boosters are shots that enhance or restore protection against COVID-19, which may have decreased\nover time. What is the difference between a third primary dose and a booster? \uf1aa\nPeople can stay up to date with COVID-19 vaccination by completing a primary series and receiving the most recent\nbooster dose recommended for them by CDC. The people you live or spend time with can help protect you and\nthemselves by staying up to date on their COVID-19 vaccines too.","3173":"The same vaccine is not available\nA previous dose is unknown\nThe person would otherwise not complete the primary series\nA person starts but is unable to complete a primary series with the same COVID-19 vaccine due to a contraindication. Children ages 6 months\u20134 years who receive different mRNA products for the first 2 doses of an mRNA COVID-19 vaccine\nseries should follow a 3-dose schedule . A third dose of either mRNA vaccine should be administered at least 8 weeks after\nthe second dose to complete the 3-dose primary series.","3299":"Overall, symptoms were more frequent in people ages 12\u201364 years\ncompared to people ages 65 years and older and more frequent after dose 2 than dose 1 of the primary series. Among adults\nages 18 years and older who received the Novavax booster dose, symptoms were more frequently reported after the booster\ndose than dose 2 of the primary series. See also COVID-19 vaccination and myocarditis and pericarditis. A rare risk for myocarditis and pericarditis has been observed following receipt of mRNA COVID-19 vaccines (i.e., Moderna or\nPfizer-BioNTech) and Novavax COVID-19 Vaccine.","6866":"Pfizer-BioNTech COVID-19 Vaccine EUI Recipient Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nEmergency Use Instructions (EUI) Fact Sheet for Recipients and Caregivers:\nPfizer-BioNTech COVID-19 Vaccine for Primary and\/or Additional Doses\nThis Fact Sheet describes Emergency Use Instructions (EUI) that have been issued by the Centers for\nDisease Control and Prevention (CDC) to provide information about the primary and additional doses of the\nCOVID-19 vaccine by Pfizer-BioNTech that go beyond its FDA-approved labeling.","2495":"For each level, CDC recommends actions you can take to help you protect yourself and others from severe impacts\nof COVID-19. \u2022\n\u2022\n\u2022\n\u2022\nFor Healthcare Facilities: Prevention actions in healthcare facilities, such as hospitals, rehabilitation centers, and\nnursing homes, are not linked to COVID-19 Community Levels. \uf313\nPeople may choose to wear a mask at any time. Masks are recommended in indoor public transportation settings and\nmay be required in other places by local or state authorities. COVID-19 County Check\nFind community levels and prevention steps by county. Data updated weekly.","572":"August 25, 2022: Illinois made update to data previously submitted to CDC that resulted in a new increase of 37,546\nadministered doses. August 18, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 50,115\nadministered doses. August 18, 2022: Arkansas made updates to data previously submitted to CDC that resulted in a net increase of\n11,332 administered doses. August 11, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 82,375\nadministered doses.","2141":"People Who Would Like to Have a Baby\nCDC recommends that people who are trying to get pregnant now or might become pregnant in the future, as well as their\npartners, get vaccinated and stay up to date with their COVID-19 vaccines, including getting a COVID-19 booster shot when it\u2019s\ntime to get one. COVID-19 vaccines are not associated with fertility problems in women or men. Vaccine Side Effects\nYou can choose to get either an mRNA COVID-19 vaccine (Moderna or Pfizer-BioNTech) or Novavax COVID-19 vaccine. The\nJ&J\/Janssen COVID-19 vaccine is authorized for use only in certain limited situations.","974":"\u2022\n\u2022\n\u2022\n\u2022\n\uf6e0 COVID-19 Tests or Treatment\nCommunity-Based Testing Locations Treatment Locator\nTypes of Tests\nViral tests look for a current infection with SARS-CoV-2, the virus that causes COVID-19, by testing specimens from your nose\nor mouth. There are two main types of viral tests: nucleic acid amplification tests (NAATs) and antigen tests. In certain\ncircumstances, one test type may be recommended over the other. All tests should be performed following FDA\u2019s\nrequirements. NAATs, such as PCR-based tests, are most often performed in a laboratory. They are typically the most reliable tests for\npeople with or without symptoms.","6978":"Currently, the Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine are the only FDA-\napproved COVID-19 vaccines for which EUI provide information about primary and\/or additional doses\fPfizer-BioNTech COVID-19 Vaccine EUI Recipient Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nfollowing the COVID-19 vaccine that you received. If vaccinated outside of the United States or through a\nclinical trial and the COVID-19 vaccine you initially received for primary vaccination is not authorized or\napproved in the United States, then the vaccine you initially received may not be available to you.","8371":"Content developed by the American Psychological Association (Jared Skillings, PhD, ABPP; Erin Swedish, PhD; Robin McLeod, PhD; Mitch Prinstein, PhD, ABPP;\nand Stephen Gillaspy, PhD) in partnership with U.S. Centers for Disease Control and Prevention\nStep 3: Motivational interviewing\nStep 4: Respond to questions about vaccines, health, or mental health\nAdditional Resources:\nKey Things to Know about COVID-19 Vaccines\nFrequently Asked Questions about COVID-19 Vaccines\nAnswering Patients\u2019 Questions About COVID-19 Vaccine and Vaccination\nTalking with Parents About COVID-19 Vaccination\nHow to Tailor COVID-19 Information for Your Specific Audience\nHow to Address COVID-19 Misinformation\nPage last reviewed: November 3, 2021","1190":"Additionally, Texas was\nomitted from several demographic and county-level graphics pages. Further, prior to October 22, 2021, all records reported\nby Texas were assumed to be for residents of Texas. Beginning September 28, 2021, age-based metrics for Texas are directly reported rather than estimated for the\npopulations ages 12 years or older, 18 years or older, and 65 years or older on the\u202fVaccinations in the United States site. Beginning September 28, 2021, the national counts for booster dose data on the\u202fVaccinations in the United States site\ninclude Texas. Beginning October 22, 2021, county-level graphics on\u202fVaccinations by County,\u202fVaccination Equity, and Vaccinations and\nOther Outcomes include Texas.","7128":"Related Pages\nCOVID-19 Toolkit for Pregnant People and New Parents\n\u203a\nCOVID-19 Vaccines While Pregnant or Breastfeeding\n\u203a\nBreastfeeding and Caring for Newborns if You Have COVID-19\n\u203a\nHow to Protect Yourself and Others\n\u203a\f10\/30\/22, 9:39 AM Pregnant and Recently Pregnant People | CDC\nWhat to Do If You Are Sick\n\u203a\nRelated Research and More Information\nRelated Research\nZambrano LD, Ellington S, Strid P, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with\nLaboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status \u2014 United States, January 22\u2013October 3, 2020. MMWR\nMorb Mortal Wkly Rep 2020;69:1641\u20131647. DOI: 10.15585\/mmwr.mm6944e3.","8607":"The benefit is that people get this protection from a vaccine, without ever having to risk the\npotentially serious consequences of getting sick with COVID-19. Any side effects from getting the vaccine are normal\nsigns the body is building protection. How mRNA COVID-19 vaccines work\n\uf1aa\n\u2022\n\u2022\n\u2022\n\u2022\nFACTSHEET\nHow mRNA COVID-19 Vaccines Work\nPDF infographic explaining how mRNA COVID-19 vaccines work. English [128 KB, 1 page]\nOther Languages\n\u2022 \uf20c\n\u2022\f10\/30\/22, 9:34 AM Understanding How COVID-19 Vaccines Work | CDC\nProtein subunit vaccines contain pieces (proteins) of the virus that causes COVID-19. These virus pieces are the spike protein.","215":"This level is called the\n\u201cthreshold of protection.\u201d When antibodies decrease below the threshold of protection, you may become more vulnerable to\nsevere illness. We do not yet know what the threshold of protection for antibodies is for the virus that causes COVID-19 or\nhow long it takes these antibodies to wane. Even after antibodies wane, your immune system may have cells that remember\nthe virus that can act quickly to protect you from severe illness if you become infected. These topics are being researched by\nscientists all over the world\f10\/30\/22, 9:37 AM Antibodies and COVID-19 | CDC\nscientists all over the world.","9952":"Has the person to be vaccinated ever received a dose of COVID-19 vaccine? COVID-19 vaccination is recommended for everyone 6\nmonths of age and older. For the primary series, Moderna,\nNovavax, and Pfizer-BioNTech COVID-19 vaccines are\nrecommended; only monovalent vaccines are approved or\nauthorized for primary series doses. The same vaccine product\nshould be used for all primary series doses. Moderna and Pfizer-BioNTech are recommended for booster\ndoses. People ages 5 years and older are recommended to\nreceive 1 bivalent mRNA booster dose after completion\nof any monovalent primary series or previously received\nmonovalent booster dose(s). Use an age-appropratie\nproduct.","9084":"10\/30\/22, 9:43 AM Wearing Masks in Travel and Public Transportation Settings | CDC\nEspa\u00f1ol | Other Languages\nWearing Masks in Travel and Public Transportation\nSettings\nFor people aged 2 years or older\u2014\nincluding passengers and workers\u2014CDC\nrecommends properly wearing a high-\nquality mask or respirator over the nose\nand mouth in indoor areas of public\ntransportation (such as airplanes, trains,\nbuses, ferries) and transportation hubs\n(such as airports, stations, and seaports). When people properly wear a high-quality\nmask or respirator, they protect\nthemselves and those around them, and\nhelp keep travel and public transportation\nsafer for everyone. Wearing a high-quality\nmask or respirator is most beneficial in\ncrowded or poorly ventilated locations,\nsuch as airport jetways.","6123":"Parry H, Bruton R, Stephens C, et al. Extended interval BNT162b2 vaccination enhances peak antibody\nPayne RP, Longet S, Austin JA, et al. 2021. Immunogenicity of standard and extended dosing intervals of\nBNT162b2 mRNA vaccine. Cell. doi: 10.1016\/j.cell.2021.10.011\nPulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with\nemergence of the Omicron variant in South Africa. 2022. https:\/\/doi.org\/10.1101\/2021.11.11.21266068\nSchietzel S, Anderegg M, Limacher A, et al. Humoral and cellular immune responses on SARS-CoV-2 vaccines in\npatients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients. Infections. 2022;8:e002036. doi:10.1136\/rmdopen-2021-002036.","2792":"After taking time to compassionately listen to their responses, directly ask what they need or what\nyou can do to help. Learn more about CDC\u2019s tips on how to start these types of meaningful conversations. \u2022\n\u2022\n\u2022\n\uf1b0 Determine how you can help with what they need\nAfter you have listened and worked to understand what support looks like for the person, determine your\nrole in that support. Some people may want someone to listen to their experiences more frequently. Others may need more physical support (help with household chores, running errands).","9837":"Reporting Adverse Event or Medication Errors\nThe vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event\nReporting System (VAERS):\n\u2022 vaccine administration errors whether or not associated with an adverse event,\n\u2022 serious adverse events (irrespective of attribution to vaccination),\n\u2022 cases of myocarditis\n\u2022 cases of pericarditis\n\u2022 cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and\n\u2022 cases of COVID-19 that result in hospitalization or death. Complete and submit reports to VAERS online at https:\/\/vaers.hhs.gov\/reportevent.html. For further assistance with reporting to VAERS call 1-800-822-7967. References\nAbu-Raddad L, Chemaitelly H, Ayoub HH, et al.","6174":"CDC monitors COVID-19 vaccine effectiveness to understand how well the vaccines:\nProtect different age groups, such as children, adolescents, and adults, including adults ages 65 and older\nProtect specific groups, such as people with underlying health conditions or healthcare workers\nProtect against new variants\nLower the risk of infection, including infection without symptoms\nProtect against milder COVID-19 illness\nPrevent more serious outcomes, such as hospitalization or death\nPrevent complications from COVID-19, such as post-COVID conditions and multisystem inflammatory syndrome\n(MIS)\nPrevent spreading COVID-19 to others\nProvide long- and short-term protection\nPerform among people who have received one or more booster doses\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nAssessing How Vaccines Work in the Real World Helps Us:\nAdjust vaccine recommendations,\nas needed, such as booster doses\n\uf263\nGuide vaccine policy and vaccine\ndistribution\n\uf260\nInform development of vaccine\ntechnologies\n\uf33d\nCOVID-19 Vaccines and New Variants of the Virus\f10\/30\/22, 9:33 AM Monitoring COVID-19 Vaccine Effectiveness | CDC\nViruses are constantly changing to create new types of the virus, called variants.","9015":"Although the Pregnancy Registry does not look at COVID-19 vaccination and\nbreastfeeding, other researchers across the nation are working to better understand COVID-19 vaccination and\nbreastfeeding. Pregnancy Registry-Related Publications\nPreliminary Findings of mRNA COVID-19 Vaccine Safety in Pregnant Persons\nReceipt of mRNA COVID-19 Vaccines and Risk of Spontaneous Abortion\nCOVID-19 vaccine safety in pregnancy: Updates from the v-safe COVID-19 vaccine pregnancy registry (ACIP\nmeeting slides)\nUpdates on COVID-19 and Pregnancy (ACIP meeting slides)\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf20c\n\u2022 \uf20c\f10\/30\/22, 9:32 AM Vaccine Pregnancy Registry | CDC\nHow to Report Adverse Events\nVAERS collects reports of possible adverse events that happen after vaccination.","1014":"They can help\nprotect you from infection, or severe illness if you do get infected, for a period of time afterward. How long this protection\nlasts is different for each disease and each person. Antibody tests should not be used to diagnose a current infection with the virus that causes COVID-19. An antibody test may\nnot show if you have a current infection, because it can take 1 to 3 weeks after the infection for your body to make antibodies. \uf6ec If Your COVID-19 Test is\nPositive\nAny positive COVID-19 test means the virus was detected and you have an infection.","9072":"\uf106 As of 12:01AM ET on June 12, 2022, CDC will no longer require air passengers traveling from a foreign\ncountry to the United States to show a negative COVID-19 viral test or documentation of recovery from\nCOVID-19 before they board their flight. For more information, see Rescission: Requirement for Negative\nPre-Departure COVID-19 Test Result or Documentation of Recovery from COVID-19 for all Airline or Other\nAircraft Passengers Arriving into the United States from Any Foreign Country. Learn when you should get tested for COVID-19, how you can find tests, and what your test\nresult means.","4355":"\u2022\n\u2022\n\uf2ff For Healthcare Workers\nHealthcare professionals registered in Vaccine Administration Management System (VAMS) can access\nvaccination certificates in VAMS. \uf263 Stay Up to Date with COVID-19 Vaccines and Boosters\nWhen do you need to schedule your next shot? Do you or your child need to get a booster? Can you get a different vaccine product after your 1st dose? Stay Up to Date\n\u2022\n\u2022\n\u2022\nLast Updated Sept. 22, 2022\f10\/30\/22, 9:30 AM Getting Your COVID-19 Vaccine | CDC","6109":"Kamar, N., Abravanel, F., Marion O. Assessment of 4 doses of SARS-CoV-2 messenger RNA-based vaccine in\nrecipients of a solid organ transplant. Infection Diseases 2021;4(11):e2136030. Kornek B, Leutmezer F, Rommer PS, et al. B Cell Depletion and SARS-CoV-2 Vaccine Responses in\nNeuroimmunologic Patients. Annals of Neurology. 2022;91:342-352. Miller, Jacqueline. Safety and Immunogenicity of a 50 \u00b5g Booster Dose of Moderna COVID-19 Vaccine. Advisory Committee on Immunization Practices meeting, October 21, 2021:\nMunro, Alasdair PS, et al.","406":"On August 31, 2021, CDC updated its algorithm for assigning a race\/ethnicity category for vaccine recipients to align with\nU.S. Census Bureau race\/ethnicity classifications. As a result, approximately 4.5 million vaccine recipients where a valid\nrace was reported in conjunction with \u201cother\u201d race who were previously categorized as \u201cNon-Hispanic Multiracial\u201d are\nnow categorized into a single race\/ethnicity group. Beginning August 9, 2021, submitting entities will have the ability to update or delete previously submitted records using\nnew functionality available in CDC\u2019s Data Clearinghouse.","9331":"If\nneeded, ask the provider to write down\nor print out any instructions, medication\nnames, or diagnoses. After the Appointment\n\nMake appointments for follow up. Record future appointments,\nincluding tests, in your calendar. If\nothers will go with you or drive you to\nfuture appointments, make sure the\nappointments are on their calendars too. Follow your provider\u2019s instructions to\nthe best of your ability. Contact your provider\u2019s office with any\nquestions or clarifications. Continue to record symptoms and\nkeep your journal, so you can refer\nto updates or changes during your\nnext appointment. Update and keep track of medications\nand supplements. For more information on post-COVID conditions, please visit\nhttps:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/long-term-effects.html.","8429":"Core Competencies Based on Role:\nRelevant information contained in the EUA Fact Sheet(s) for Healthcare Providers for the vaccine product(s) in\nyour facility\nStorage and handling requirements\nTransport guidance\nVaccination documentation and reporting requirements\nRequired and additional information for vaccine recipients\nCOVID-19 Vaccine Administration Competencies Assessment Form\nAdministration support staff qualified to store, handle, or transport\nvaccine\n\uf209\n\uf20c\nAdditional Resources:\nCOVID-19 Vaccination Clinical & Professional Resources\nInterim Guidance for Immunization Services During the Pandemic\nPatient Safety Checklist for Vaccination Clinics Held at Satellite Temporary or Off-Site Locations \uf20c\f10\/30\/22, 9:17 AM Training and Education for COVID-19 Vaccination | CDC\nPatient Safety Checklist for Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations\nNational Forum on COVID-19 Vaccine: Resources Page\nVaccine Confidence Training (American College of Obstetricians and Gynecologists)\n\uf20c\n\uf209\nPage last reviewed: April 14, 2022","9627":"The below describes who can receive the COVID-19 vaccine by Pfizer-BioNTech under EUI. The COVID-19\nvaccine by Moderna can also be used under EUI for similar uses as an alternative mRNA COVID-19 vaccine (see\nthe Moderna EUI Fact Sheet for Healthcare Providers). \u2022 Persons ages 12 years and older, particularly those at higher risk of mRNA COVID-19 vaccine-\nassociated myocarditis, may receive a second primary dose of the COVID-19 vaccine by Pfizer-\nBioNTech after a longer interval of 3\u20138 weeks following the first primary dose.","4569":"Do not open windows and doors if doing so is unsafe for you or others (for example, young children or pets in\nyour home, risk of falling, people in the home with asthma or other respiratory conditions, poor air quality). If opening windows or doors is unsafe, consider other approaches for reducing virus particles in the air, such as\nusing air filtration and bathroom and stove exhaust fans. Use fans to move virus particles in the air from inside your home to outside. Don\u2019t leave fans unattended with\nyoung children.","984":"These tests detect viral genetic material, which may stay in your body for up to 90\ndays after you test positive Therefore you should not use a NAAT if you have tested positive in the last 90 days\n\u2022\f10\/30\/22, 9:37 AM COVID-19 Testing: What You Need to Know | CDC\ndays after you test positive. Therefore, you should not use a NAAT if you have tested positive in the last 90 days. Antigen tests* are rapid tests which produce results in 15-30 minutes. They are less reliable than NAATs, especially for\npeople who do not have symptoms.","7730":"CDC scientists have conducted detailed reviews of cases of anaphylaxis and made the information available to\nhealthcare providers and the public:\nAllergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine\nReports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US\u2014December 14, 2020-January 18,\nAllergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine\u2014 United\nThe benefits of COVID-19 vaccination continue to outweigh any potential risks.","1460":"Special Populations and Situations\nIn accordance with general best practices, preterm infants (infants born before 37 weeks\u2019 gestation), regardless of birth\nweight, should receive COVID-19 vaccination at their chronological age and according to the same schedule and guidance\nas for full-term infants and children. What is the guidance for vaccinating preterm infants? \uf1aa\nInfants of mothers who were vaccinated and\/or had COVID-19 or SARS-CoV-2 infection before or during pregnancy\nshould be vaccinated according to the recommended schedule. What is the guidance for vaccinating infants of mothers who received COVID-19 vaccine and\/or\nhad COVID-19 or SARS-CoV-2 infection before or during pregnancy?","601":"July 7, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 64,066\nadministered doses. June 30, 2022: A federal entity made updates to data previously submitted to CDC that resulted in a net increase of\n732,308 administered doses. June 30, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 27,319\nadministered doses. June 23, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 21,371\nadministered doses.","6450":"Monitor your health for COVID-19 symptoms and get tested at least 5 days after you had close contact with someone\nwith COVID-19, even if you don\u2019t develop symptoms. Wear a high quality mask for 10 full days any time you are around others inside your home or in public. Do not go to\nplaces where you are unable to wear a mask. What to do if you have COVID-19 symptoms\nStay home. Get tested right away. Use a self-test at home or find a testing location near you.","3841":"What training is available to learn how to prepare and administer COVID-19 vaccines? \uf1aa\nEach COVID-19 vaccine has its own storage and handling requirements. As a COVID-19 vaccination provider, you are\nrequired to ensure vaccines are maintained within proper temperature ranges by using a digital data logger (DDL) to\nmonitor vaccine storage unit temperatures and recording temperatures daily. Additional details are available on CDC\u2019s\nweb pages for each vaccine (U.S. COVID-19 Vaccine Product Information) and in the Vaccine Storage and Handling Toolkit\n, COVID-19 Vaccine Addendum. What are the storage and handling requirements for COVID-19 vaccines?","246":"Serological surveillance (studies that investigate antibodies in the population) provides information about how long antibody\nprotection against COVID-19 lasts and if this protection is different among people who have antibodies from infection,\ncompared with people who have antibodies from vaccination, or both. We can also learn more about which groups of people might not produce as many antibodies or maintain them as long as\nothers\u2014for example, immunocompromised people compared with people who have healthy immune systems. This is\nimportant information for making decisions about whether or not additional vaccine doses or boosters are needed, when\nthey would be recommended, and who would need them first.","3178":"People who received Janssen COVID-19 Vaccine after a dose of another COVID-19 vaccine should be considered to have\nreceived a valid, single-dose Janssen primary series. Booster vaccination\nFor booster vaccination, bivalent mRNA vaccines are recommended. Any homologous or heterologous bivalent mRNA vaccine\ncan be used if a booster dose is FDA-authorized for use in that age group. COVID-19 vaccines may be administered without regard to timing of other vaccines. This includes simultaneous\nadministration of COVID-19 vaccine and other vaccines on the same day. However, there are additional considerations if\nadministering an orthopoxvirus vaccine (see below).","8221":"Novavax Vaccine Overview\nNovavax\n\uf1aa\nNovavax\nPRIMARY SERIES\nNovavax\nPRIMARY SERIES\n3-8 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech or Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd\nprimary series dose\nUp to Date: Immediately after you have received the most recent booster recommended for you\nMore details: Staying up to date\nAGE GROUP\n18 YEARS AND OLDER\nPfizer-BioNTech Vaccine Overview\nPfizer-BioNTech\n\uf1aa\nPfizer-BioNTech\nPRIMARY SERIES\nPfizer-BioNTech\nPRIMARY SERIES\n3\u20138 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech or Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd\nprimary series dose or last\nbooster\nUp to Date: Immediately after you have received the most recent booster recommended for you\nMore details: Staying up to date\f10\/30\/22, 9:27 AM Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC\nAGE GROUP\n18 YEARS AND OLDER\nModerna Vaccine Overview\nModerna\n\uf1aa\nModerna\nPRIMARY SERIES\nModerna\nPRIMARY SERIES\n4\u20138 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech or Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd\nprimary series dose or last\nbooster\nUp to Date: Immediately after you have received the most recent booster recommended for you\nMore details: Staying up to date\nNovavax\n\uf1aa\nAGE GROUP\n18 YEARS AND OLDER\nNovavax is not authorized as a booster dose at this time.","9582":"Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nEmergency Use Instructions for Healthcare Providers:\nPfizer-BioNTech COVID-19 Vaccine for Primary and\/or Additional Doses\nThe Centers for Disease Control and Prevention (CDC) is issuing Emergency Use Instructions (EUI) to provide\ninformation about the use of the COVID-19 vaccine by Pfizer-BioNTech (Comirnaty), which is approved\n(licensed) by the Food and Drug Administration (FDA) for the prevention of COVID-19 in individuals ages 16\nyears and older.1 The CDC-issued EUI provide information for the use of this vaccine that are beyond the FDA-\napproved labeling.","3570":"For the Republic of Palau, the Federated States of Micronesia, the Republic of the Marshall Islands, Guam, American\nSamoa, and the Commonwealth of the Northern Marianas Islands, total counts of COVID-19 vaccine doses include doses\nmarked as shipped since December 13, 2020. Total Doses Administered\nThe total number of vaccine doses that have been given to people in the United States since December 14, 2020. This is\nthe date when the first dose was administered to a person in the United States under the Emergency Use Authorization\nnot within a clinical trial.","4591":"\uf209\nTurn on the exhaust fan in your bathroom and kitchen\f10\/30\/22, 9:40 AM Improving Ventilation in Your Home | CDC\nExhaust fans above your stovetop and in your bathroom that vent outdoors can help move air outside. Although some\nstove exhaust fans don\u2019t send the air to the outside, they can still improve air flow and keep virus particles from being\nconcentrated in one place. Keep the exhaust fan turned on over your stovetop and in your bathroom if you have visitors in your home.","7042":"10\/30\/22, 9:39 AM Pregnant and Recently Pregnant People | CDC\nEspa\u00f1ol | Other Languages\nPregnant and Recently Pregnant People\nAt Increased Risk for Severe Illness from COVID-19\nWhat You Need to Know\nTo maximize protection from variants and prevent possibly spreading the virus to others, wear a mask indoors in\npublic in areas with a high COVID-19 Community Level. People who are pregnant or have other conditions that\ncould put them at higher risk for severe illness should speak with their healthcare provider about wearing a mask\nin public indoor spaces at the medium COVID-19 Community Level.","1680":"COVID-19 vaccination providers are required to\nimplement all recommendations of the ACIP, adopted by the CDC Director, relevant to COVID-19 vaccination including:\nUse of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson)\nand mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on\nImmunization Practices \u2014 United States, July 2021\nUse of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory\nCommittee on Immunization Practices \u2014 United States, June 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Adolescents Aged 12\u201315 Years \u2014 United States, May 2021\nUpdated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen\n(Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among\nVaccine Recipients \u2014 United States, April 2021\nInterim Recommendation for Use of Janssen COVID-19 Vaccine \u2014 United States, February 2021\nInterim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine, United States 2020\nInterim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine, United States, December 2020\nInterim Recommendation for Use of Moderna COVID-19 Vaccine, United States, December 2020\n\uf209\n\uf20c\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nInterim Recommendation for Use of Moderna COVID 19 Vaccine, United States, December 2020\nUpdated Interim Recommendation for Allocation of COVID-19 Vaccine, United States, December 2020\nFind more information about vaccine administration and reporting requirements.","8674":"Some people have no side effects. Many people have reported common side effects after COVID-19\nvaccination, like pain or swelling at the injection site, a headache, chills, or fever. These reactions are\ncommon and are normal signs that your body is building protection. Reports of serious adverse events after vaccination are rare. CDC and FDA continue to closely monitor\nseveral reporting systems, like the\nVaccine Adverse Event Reporting System (VAERS),\nVaccine Safety Datalink (VSD), and\nv-safe, which help look for safety issues now that the vaccines are being given to patients in real-\nworld settings across the country.","1607":"Similarly, in lieu of a separate COVID-19 VIS for the licensed Moderna vaccine, FDA has issued a combination Moderna\nCOVID-19 Vaccine Fact Sheet for Recipients and Caregivers to address both the FDA authorized (EUA) Moderna COVID-\n19 Vaccine and the FDA BLA approved (licensed) Moderna SPIKEVAX COVID-19 Vaccine. The vaccines have identical\nformulations. When administering the Moderna COVID-19 vaccine under either the EUA or under BLA approval,\nproviders must give each vaccine recipient, adult caregiver accompanying the recipient, or other legal representative, a\ncopy of the combined Moderna COVID-19 Vaccine Information Fact Sheet. [Additions to CDC COVID-19 Vaccination Program Provider Agreements, Paragraph 1.]","5408":"The Countermeasures Injury Compensation Program (CICP) is a federal program that may help\npay for costs of medical care and other specific expenses for certain people who have been\nseriously injured by certain medicines or vaccines, including this vaccine. Generally, a claim must\nbe submitted to the CICP within one (1) year from the date of receiving the vaccine. To learn more\nabout this program, visit www.hrsa.gov\/cicp or call 1-855-266-2427. WHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)? The United States FDA has made the Janssen COVID-19 Vaccine available under an emergency\naccess mechanism called an EUA.","8196":"AGE GROUP\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPfizer-BioNTech\nPRIMARY SERIES\nPfizer-BioNTech\nPRIMARY SERIES\n3\u20138 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech\nPRIMARY SERIES\nAt least 8 weeks after 2nd dose\nUp to Date: 2 weeks after 3rd dose, since a booster is not recommended for this age group at this time\nMore details: Staying up to date\nPfizer-BioNTech\nPRIMARY SERIES\nPfizer-BioNTech\nPRIMARY SERIES\n3\u20138 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nor last booster, children age 5\nyears can only get a Pfizer-\nBioNTech booster, and children\nages 6\u201311 years can get a Pfizer-\nBioNTech or Moderna booster.","9503":"An EUA\nis supported by a Secretary of Health and Human Services (HHS) declaration that circumstances\nexist to justify the emergency use of drugs and biological products during the COVID-19\npandemic. A product authorized for emergency use has not undergone the same type of review\nby FDA as an FDA approved product. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate,\napproved, and available alternatives.","5797":"Common side effects\nreported were mostly mild, but some people had side effects that affected their ability to do daily\nactivities. Cases of myocarditis and pericarditis have rarely been reported in some people. Cases have occurred\npredominantly in adolescents and young adult males within the first week after the second dose of vaccine. There is evidence from multiple sources that suggest a higher risk for myocarditis following Moderna\ncompared to Pfizer-BioNTech vaccination; however, it is not possible to directly compare the risk in people\nages 12\u201317 years.","9333":"If\nneeded, ask the provider to write down\nor print out any instructions, medication\nnames, or diagnoses. After the Appointment\n\nMake appointments for follow up. Record future appointments,\nincluding tests, in your calendar. If\nothers will go with you or drive you to\nfuture appointments, make sure the\nappointments are on their calendars too. Follow your provider\u2019s instructions to\nthe best of your ability. Contact your provider\u2019s office with any\nquestions or clarifications. Continue to record symptoms and\nkeep your journal, so you can refer\nto updates or changes during your\nnext appointment. Update and keep track of medications\nand supplements. For more information on post-COVID conditions, please visit\nhttps:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/long-term-effects.html.","7134":"Allotey, J., et al., Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in\npregnancy: living systematic review and meta-analysis. BMJ, 2020. 370: p. m3320. doi: 10.1136\/bmj.m3320\nGalang RR, Newton SM, Woodworth KR, et al. Risk factors for illness severity among pregnant women with confirmed\nSARS-CoV-2 infection \u2013 Surveillance for Emerging Threats to Mothers and Babies Network, 22 state, local, and territorial\nKo JY, DeSisto CL, Simeone RM, et al. Adverse pregnancy outcomes, maternal complications, and severe illness among\nU.S. delivery hospitalizations with and without a COVID-19 diagnosis [published online ahead of print, 2021 May 12].","8536":"People with an increased risk of severe illness, regardless of vaccination status, including\nOlder adults and adults of any age with serious chronic medical conditions such as heart disease, chronic lung\ndisease, and diabetes. Children with underlying medical conditions. Can traveling on a cruise increase my risk of getting COVID-19? \uf1aa\nLast Updated Sept. 8, 2022","7966":"Similarly, create communications materials showing the lack of evidence that COVID-19 vaccines are\nassociated with AIDS, hepatitis, impaired immunity, and long-term effects on fertility, pregnancy, and lactation. cAll social media posts that are used as citations in the identified misinformation sections for this report can be found online through\nthis link. COVID-19 State of Vaccine Confidence Insights Report | October 10, 2022\nContinuing and Evolving Themes Impacting Vaccine Confidence\nThe themes below have been noted in previous reports and continue to undermine vaccine confidence. The information\nhighlighted below focuses on what is new or different from previous reports.","8136":"COVID-19 State of Vaccine Confidence Insights Report | October 10, 2022\nAppendix: Inputs and Sources\nType Input Cadence Sources Tactics for Utilization\nSocial Media\nListening\n& Media\nMonitoring\nCommunication\nSurveillance Report\nDaily on\nweekdays\n\u0082Google news\n\u0082Meltwater\n\u0082CrowdTangle\n\u0082Native platform searches\n\u0082Share of voice topic analysis to identify\nthemes\n\u0082Emerging topics\nMeltwater Daily \u0082Facebook, Twitter, Instagram\n\u0082Blogs\n\u0082News media\n\u0082Online forums\n\u0082Share of voice topic analysis\n\u0082Emerging theme topics\n\u0082Identify high reach\/velocity topics\nOADC (Office of the\nAssociate Director of\nCommunication) Channel\nCOVID-19 Post metrics\nWeekly \u0082Sprout Social\n\u0082Native OADC account analytics\n\u0082Analyze # of posts, topics\n\u0082Success of messages, # of impressions,\nreach, # engagements\nOADC Channel Comment\nAnalysis\nDaily on\nweekdays\n\u0082Native platform searches \u0082Sentiment analysis\n\u0082Identify message gaps\/voids\nDirect Reports\nCDC-INFO Metrics Weekly \u0082CDC-INFO inquiry line list\n\u0082Prepared response (PR) usage report\n\u0082Cross-compare PR usage with inquiry\ntheme analysis\n\u0082Sentiment analysis\n\u0082Identify information gaps\/voids\nVTF Media Requests Weekly \u0082Media request line list \u0082Leading indicator for news coverage\n\u0082Identify information gaps\/voids\nWeb Metrics Weekly \u0082Top pages\n\u0082Google search queries\n\u0082Top FAQs\n\u0082Referring domains\n\u0082Identify information gaps\/voids,\n\u0082Identify keywords\/search terms, changes in\nweb traffic\nResearch\nPoll Review Weekly \u0082Harris Poll, PEW research, Gallup Poll,\nKFF\n\u0082New data related to vaccine\nhesitancy\n\u0082Identify socio-behavior indicators related\nto motivation and intention to vaccinate\nLiterature Review Weekly \u0082PubMed, LitCovid, ProQuest Central,\nAltmetric\n\u0082New data related to vaccine\nhesitancy\n\u0082Identify current vaccination intention\n\u0082Identify barriers to vaccination\nThird Party\nReports\nTanaq Social Listening\n+Media Monitoring Report\nWeekly \u0082Meltwater\n\u0082Sprout Social\n\u0082First Draft\n\u0082Native platform searches\n\u0082Trending topics\n\u0082Demographic and geographic\nconversation monitoring\nCrowdTangle content\ninsights report\nBiweekly \u0082Facebook \u0082Top pages (voices), groups\n\u0082General trends\/sentiment analysis\n\u0082News analysis through posts\nUniversity of Washington\nSt. Louis iHeard\nWeekly \u0082Proprietary methods \u0082Survey results\n\u0082Emerging threats and data deficits\n\u0082Vaccine narratives\nProject VCTR Weekly \u0082Proprietary methods \u0082National and regional trends in negative\nattitudes toward vaccination\n\u0082Conversations around Legislation\nVirality Project Weekly \u0082Proprietary methods \u0082Mis- and disinformation trends related to","8182":"COVID-19 vaccine recommendations are based on three things:\n1. Your age\n2. The vaccine you first received, and\n3. The length of time since your last dose\nPeople who are moderately or severely immunocompromised have different recommendations for COVID-19 vaccines. You are still up to date if you receive all COVID-19 vaccine doses recommended for you and then become ill with COVID-19. You do not need to be immediately revaccinated or receive an additional booster. Boosters are an important part of protecting yourself from getting seriously ill or dying from\nCOVID-19. They are recommended for most people.","8480":"Stay informed with Emergency Partners Information\nConnection (EPIC) Newsletters\nStay informed about ways to keep yourself and your loved\nones safe when a public health emergency happens. Sign\nup for EPIC newsletters and announcements. Last Updated Sept. 8, 2022","7651":"\uf1aa\nNoncitizen nonimmigrants that plan to take a connecting flight in the United States to another country may continue on\ntheir itinerary; however, they are still required to complete and sign the attestation in case their travel plans are changed\nor delayed. If they take their connecting flight and leave the United States, they are no longer subject to the requirements\nof the attestation. I am taking a connecting flight through the United States but the attestation says I have to attest\nto self-quarantine for 5 days and get a viral COVID-19 test 3-5 days after arrival.","4456":"There are two types of viral tests: rapid tests and laboratory tests. These tests might use samples from your nose or\nthroat, or saliva. Knowing if you are infected with the virus that causes COVID-19 allows you to take care of yourself and\ntake actions to reduce the chance that you will infect others. CDC\u2019s Viral Testing Tool is an online, mobile-friendly tool that asks a series of questions and recommends actions and\nresources based on your responses. It can help you interpret what your test result means. You can also access tests the following ways:\nOrder free self-tests at COVIDtests.gov .","10073":"In exceptional situations when the previous product cannot be determined\/not available or if a person is unable to complete a series with the same\nCOVID-19 vaccine due to a contraindication any age-appropriate mRNA COVID-19 vaccine may be used (administer at a minimum interval of 28 days). \u0083 For booster vaccination, any homologous or heterologous age-appropriate mRNA vaccine can be used. Recommendations vary\nbased on age and primary series product. (https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us. html#timing-spacing-interchangeability).\u2021\nCoadministration with other vaccines\n\u0083 COVID-19 vaccines may be administered on the same day as other vaccines.","2072":"None\nof the COVID-19 vaccines contain\nlive virus. They cannot make anyone\nsick with COVID-19, including\npeople who are pregnant or their\nbabies. Learn more about how\nvaccines work. Data on the safety of receiving an mRNA COVID-19 vaccine (Moderna or Pfizer-BioNTech), before and during pregnancy\nare reassuring. Data from vaccine safety monitoring systems have not found any safety concerns for people who received an\nmRNA COVID-19 vaccine late in pregnancy or for their babies. Scientists have not found an increased risk for miscarriage among pregnant people who received an mRNA COVID-\n19 vaccine just before or during early pregnancy (before 20 weeks of pregnancy).","559":"As part of ongoing efforts to improve\ndata quality and maintain accurate COVID-19 vaccination information, CDC has been working with states to remove duplicate\nor incorrect vaccination records and to add replacement records. These collaborative updates help to ensure CDC is publicly\nproviding the best, most up-to-date data. This option became available for select entities on July 14, 2021 and was expanded\nto all entities starting August 9, 2021. Historical update and delete events for reporting entities and their impacts on vaccine\ndata are reported below.","4123":"Since there\nis no way to tell in advance how children, who are not moderately or severely immunocompromised, or those who may\nbe immunocompromised. A child can be immunocompromised and still healthy, will be affected by COVID-19 it\u2019s\nimportant to get them vaccinated as soon as possible to protect them against severe illness. To find your child a COVID-19\nvaccine or booster near you:\u202fSearch\u202fvaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. Should parents and caregivers wait for updated or additional vaccines, if a child is low risk for\ninfection?","3651":"If you already had COVID-19 within the past 90 days, see specific testing recommendations. \uf209\nCan I travel if ...? I am sick with or tested positive for COVID-19 and\nam recommended to isolate. Do NOT travel. Follow recommendations for isolation. I have ended isolation but still need to continue\nwearing my mask per CDC\u2019s guidance. Do not travel on public transportation such as\nairplanes, buses, and trains if you will not be able\nto wear a high-quality mask or respirator when\naround others indoors for the full duration of your\ntrip. If you travel, wear a high-quality mask or\nrespirator the entire time you are around others\nindoors.","2000":"New studies\nhave shown the rare risk of myocarditis and pericarditis associated with mRNA COVID-19 vaccination (Pfizer-BioNTech and\nModerna)\u2014mostly among males between the ages of 12 and 39 years\u2014may be further reduced with a longer time between\nthe first and second dose. In children ages 5 through 11 years, there were 20 confirmed reports of myocarditis out of approximately 18.1 million\ndoses given of the Pfizer-BioNTech COVID-19 vaccine between November 2021 and April 2022\nWhat You Need to Know\nCDC recommends COVID-19 vaccines for everyone ages 6 months and older, and COVID-19 boosters for everyone\nages 5 years and older, if eligible.","5658":"What to know about NIOSH-approved respirators\nWhen worn consistently and properly, they provide the highest level of protection from particles, including the\nvirus that causes COVID-19. Additionally, they contain your respiratory droplets and particles so you do not expose\n\uf209\n\u2022\f10\/30\/22, 9:39 AM Masks and Respirators\ny, y y p y p p y p\nothers. They seal tightly to your face when fitted properly. It is important to pick a respirator that fits your face and seals well since not all fit the same. Respirators approved by NIOSH are evaluated against a specific US standard that includes a quality requirement.","2140":"People Who Would Like to Have a Baby\nCDC recommends that people who are trying to get pregnant now or might become pregnant in the future, as well as their\npartners, get vaccinated and stay up to date with their COVID-19 vaccines, including getting a COVID-19 booster shot when it\u2019s\ntime to get one. COVID-19 vaccines are not associated with fertility problems in women or men. Vaccine Side Effects\nYou can choose to get either an mRNA COVID-19 vaccine (Moderna or Pfizer-BioNTech) or Novavax COVID-19 vaccine. The\nJ&J\/Janssen COVID-19 vaccine is authorized for use only in certain limited situations.","1452":"Monovalent mRNA (Moderna or Pfizer-BioNTech) and\nNovavax vaccines are recommended for the primary series and a bivalent mRNA vaccine (Moderna or Pfizer-BioNTech) is\nrecommended for the booster dose for all vaccine-eligible populations including people who are pregnant or lactating. Those who are considering receipt of the Janssen COVID-19 Vaccine should see Appendix A: Guidance for use of Janssen\nCOVID-19 Vaccine. Can pregnant or breastfeeding people be vaccinated? \uf1aa\f10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\nFor more information, see COVID-19 Vaccines While Pregnant or Breastfeeding.","6573":"Being immunocompromised can make you more likely to get very sick from COVID-19 or be sick for a\nlonger period of time. People who are immunocompromised or are taking medicines that weaken their immune system may not be protected even\nif they are up to date on their vaccines. Talk with your healthcare provider about wearing a mask in a medium COVID-19\nCommunity Level and what additional precautions may be necessary in medium or high COVID-19 Community Levels.","5943":"Moderna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 09\/02\/22;\nAnaphylaxis and other severe allergic reactions, myocarditis, pericarditis, and syncope have been reported\nfollowing administration of the vaccine outside of clinical trials. The observed risk of myocarditis and\npericarditis is highest in males 18 through 24 years of age. Some observational analyses of postmarketing data\nsuggest that there may be an increased risk of myocarditis and pericarditis in males under 40 years of age\nfollowing the second dose of the COVID-19 vaccine by Moderna relative to other authorized or approved\nmRNA COVID-19 vaccines.","5116":"\uf209\n\uf209\f10\/30\/22, 9:43 AM International Travel to and from the United States | CDC\nincluding mask wearing, proof of vaccination, or testing at your destination . Requirements in other countries may differ from U.S. requirements. If you do not follow your destination\u2019s\nrequirements, you may be denied entry and required to return to the United States. If you have a weakened immune system or are at increased risk for severe disease, take multiple prevention steps to\nprovide additional layers of protection from COVID-19 even if you are up to date with your COVID-19 vaccines.","3314":"In age groups where product comparisons can be made (i.e., 18\u201339 years), some evidence suggests that the risk of\nmyocarditis and pericarditis may be higher following vaccination with Moderna COVID-19 Vaccine relative to Pfizer-BioNTech\nCOVID-19 Vaccine; however, findings are not consistent in all U.S. monitoring systems. In post-authorization surveillance , cases of myocarditis and pericarditis among children ages 5\u201311 years after Pfizer-\nBioNTech COVID-19 vaccination have been rarely reported, primarily in males and after dose 2; the reporting rate of\nmyocarditis in VAERS following dose 2 of Pfizer-BioNTech marginally exceeded the background incidence rate for male\nchildren in this age group.","6272":"10\/30\/22, 9:34 AM Myths and Facts about COVID-19 Vaccines | CDC\nVaccines work by stimulating your immune system to produce antibodies, exactly like it would if you were exposed to the\ndisease. After getting vaccinated, you develop immunity to that disease, without having to get the disease first. Learn more about the ingredients in the COVID-19 vaccinations authorized for use in the United States. MYTH: Receiving a COVID-19 vaccine can make you magnetic. FACT: Receiving a COVID-19 vaccine will not make you magnetic, including at the site of vaccination which is\nusually your arm. vaccines\ndo not\ncontain\ningredient\ns that can\nproduce\nan\nelectroma\ngnetic field\nat the site\nof your\ninjection.","9889":"doi: 10.1016\/j.cell.2021.10.011\nPulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with\nemergence of the Omicron variant in South Africa. 2022. https:\/\/doi.org\/10.1101\/2021.11.11.21266068\nPerez, J. Efficacy and safety of BNT162b2 booster \u2013 C4591031 2 month interim analysis. Advisory Committee\non Immunization Practices meeting, November 19, 2021:\nSkowronski DM. 2021, MedRxiv preprint. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules\nand extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. Schietzel S, Anderegg M, Limacher A, et al. Humoral and cellular immune responses on SARS-CoV-2 vaccines in\npatients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients. Infections. 2022;8:e002036.","597":"Scheduled Vaccination Data Updates\n\uf1aa\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nJuly 21, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 97,219\nadministered doses. July 14, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 63,386\nadministered doses. July 14, 2022: New Jersey made updates to data previously submitted to CDC that resulted in a net increase of\n40,945 administered doses. July 14, 2022: California made updates to data previously submitted to CDC that resulted in a net increase of 240,980\nadministered doses.","214":"This level is called the\n\u201cthreshold of protection.\u201d When antibodies decrease below the threshold of protection, you may become more vulnerable to\nsevere illness. We do not yet know what the threshold of protection for antibodies is for the virus that causes COVID-19 or\nhow long it takes these antibodies to wane. Even after antibodies wane, your immune system may have cells that remember\nthe virus that can act quickly to protect you from severe illness if you become infected. These topics are being researched by\nscientists all over the world\f10\/30\/22, 9:37 AM Antibodies and COVID-19 | CDC\nscientists all over the world.","9826":"Consequently, the benefit\/risk balance for the use of the COVID-19 vaccine by Pfizer-BioNTech for booster dose use is\nexpected to be less favorable compared to the available alternative bivalent booster vaccines. Accordingly, these EUI are\nbeing revised to no longer provide for the use of the monovalent COVID-19 vaccine by Pfizer-BioNTech for certain booster\ndose uses. Refer to the CDC\u2019s Interim Clinical Considerations for Use of COVID-19 Vaccines for additional information. Available Alternatives\nCurrently, the Pfizer-BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine are the only FDA-approved\nvaccines for which EUI provide for primary, additional, and\/or booster dose administration.","7686":"An adverse event can be caused by the vaccine or can be caused by a\ncoincidental event not related to the vaccine, such as an unrelated fever, that happened following vaccination. \uf209\f10\/30\/22, 9:31 AM Safety of COVID-19 Vaccines | CDC\nTo date, the systems in place to monitor the safety of these vaccines have found four serious types of adverse events\nfollowing COVID-19 vaccination, with evidence that suggests, although rare, a link to certain types of COVID-19 vaccinations\nthat were administered.","8270":"COVID-19 vaccines available abroad that are accepted in the United States as valid vaccinations\n\uf1aa\nVaccines approved or authorized by the U.S. Food and Drug Administration (FDA) currently include:\nPfizer-BioNTech\nModerna\nNovavax\nJohnson & Johnson\u2019s Janssen\nVaccines listed for emergency use by the World Health Organization (WHO) currently include those that are listed\nabove and the following:\nAstraZeneca\/Oxford vaccine\nSinopharm\nSinovac\nCOVAXIN\nCovovax\nCanSino\n\u2022\n\u2022\n\u2022\n\u2022\n\uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022\n\u2022\f10\/30\/22, 9:27 AM Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC\nHow to Complete a Primary Series\nReceive 1 dose of a single-dose accepted COVID-19 vaccine\nReceive 2 doses of a 2-dose accepted COVID-19 vaccine\nCDC does not recommend mixing different COVID-19 vaccines for the primary series, but CDC is aware that mixing\nCOVID-19 vaccines for the primary series is increasingly common in many countries outside the United States.","2631":"10\/30\/22, 9:41 AM COVID19 - Caring for someone at home | CDC\nEspa\u00f1ol | Other Languages\nCaring for Someone Sick at Home\nAdvice for caregivers in non-healthcare settings\nIf you are caring for someone with COVID-19 at home or in a non-healthcare setting, follow this advice to protect yourself and\nothers. Learn what to do when someone has symptoms of COVID-19 or when someone has been diagnosed with the virus. This information also should be followed when caring for people who have tested positive but are not showing symptoms.","7569":"What\ndocumentation do I need to show? \uf1aa\f10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\ncompleted the series)\nPersonal identifiers in the clinical trial documentation (full name plus at least one other identifier such as date of birth\nor passport number) that match with your passport or other travel documentation. CDC may grant a humanitarian or emergency exception in very limited circumstances only when an individual must travel\nto the United States to preserve health (e.g., emergency medical evacuations, life-saving medical treatment) or safety\n(e.g., violence) and is unable to become fully vaccinated before travel.","3949":"10\/30\/22, 9:40 AM Find Free Masks (N95 Respirators) | CDC\nEspa\u00f1ol | Other Languages\nFind Free Masks (N95 Respirators)\nThis tool shows a list of pharmacies that provide free masks (N95 respirators). It does not show their current inventory. Please\ncheck with the location for availability. Need help finding free masks in the U.S.? Call 1-800-232-0233 (TTY 1-888-720-7489)\nFind Free Masks\nPowered by VaccineFinder\nSearch for Free Masks\nZip Code\n5-digit Zip Code\nRelated Pages\nFree N95 Respirator Manufacturers\n\u203a\nHow to Use Your N95 Respirator\n\u203a\nUse and Care of Masks\n\u203a\nLast Updated Mar. 16, 2022","6323":"For example, write\ndown a list of the symptoms you think started after your COVID-19 infection:\nthe date of onset of original COVID-19 illness and\/or positive COVID-19 test, if known\nwhen your post-COVID condition symptoms started\na list of prior treatments and diagnostic tests related to your post-COVID symptoms (blood work, x-rays, etc.) what makes your symptoms worse\n\u2022\n\u2022\n-\n-\n-\n-\f10\/30\/22, 9:42 AM Patient Tips: Healthcare Provider Appointments for Post-COVID Conditions | CDC\ny y p\nhow the symptoms affect your activities, including challenges that effect daily living, working, attending school, etc. how often symptoms occur\nhow you have been feeling\ntry to describe examples of your best and worst days.","819":"For anyone who has been infected with COVID-19, their next dose can be delayed 3 months from when symptoms started or,\nif they did not have symptoms, when they received a positive test. This possible delay can happen with a primary dose or a\nbooster dose. Read more about immunity from COVID-19 infection and vaccination. \uf549 About Variants\nMany viruses are constantly changing, including the virus that causes COVID-19. These changes occur over\ntime and can lead to the emergence of variants that may have new characteristics, including different ways\nof spreading.","4928":"Table of Contents \uf426\nReferences and Previous Updates\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine \u2014 United States, December 2020\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Moderna COVID-19 Vaccine\n\u2014 United States, December 2020\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Janssen COVID-19 Vaccine \u2014\nUnited States, February 2021\nUpdated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson\n& Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine\nRecipients\u2014United States, April 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Adolescents Aged 12\u201315 years \u2014 United States, May 2021\nUse of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory\nCommittee on Immunization Practices \u2014 United States, June 2021\nUse of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and\nmRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization\nPractices \u2014 United States, July 2021\nUse of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged \u226516 Years: Recommendations of the Advisory Committee\non Immunization Practices \u2014 United States, September 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendations for Additional Primary and Booster\nDoses of COVID-19 Vaccines \u2014 United States, 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Children Aged 5\u201311 Years \u2014 United States, November 2021\nUse of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory\nCommittee on Immunization Practices \u2014 United States, December 2021\nThe Advisory Committee on Immunization Practices\u2019 Recommendation for Use of Moderna COVID-19 Vaccine in Adults\nAged \u226518 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-\nReferences\n\uf1aa\n\uf20c\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\n19 Vaccines \u2014 United States, February 2022\nInterim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-\nBioNTech COVID-19 Vaccines in Children Aged 6 Months\u20135 Years \u2014 United States, June 2022\nInterim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19\nVaccine in Persons Aged \u226518 years \u2014 United States, July 2022.","7816":"If you\u2019re not able to obtain a self-test when you need it, you might also visit a community testing site, or\ncall your local health department for more options. \u2022\n\uf209\n\u2022\n\u2022\nFDA-Authorized Tests\n\uf6e0 How to Use an At-Home COVID-19 Test\nRead the complete manufacturer\u2019s instructions for use before using the test. To use an at-home test, you will collect a nasal specimen and then test that specimen. If you do not follow the manufacturer\u2019s instructions, your test result may be incorrect. Wash your hands before and after you collect a nasal specimen for your test.","3040":"The first and second doses are separated by 4 weeks and the second and third doses are separated by at\nleast 4 weeks. The bivalent mRNA booster dose is administered at least 2 months after completion of the primary series. Pfizer-BioNTech COVID-19 Vaccine\nChildren ages 6 months\u20134 years: A 3-dose primary series is recommended. The first and second doses are separated by\n3 weeks and the second and third doses are separated by at least 8 weeks. Currently, a booster dose using any COVID-19\nvaccine is not authorized for children in this age group.","2590":"These situations are 1. an mRNA vaccine is contraindicated, or not available or 2. the recipient is unwilling to receive an mRNA vaccine and would otherwise not receive a booster\ndose. Administer the booster dose at least 6 months after the last primary series dose.","6029":"\u2022 The lower reported rates of myocarditis\/pericarditis among persons receiving their second vaccine\ndose at extended intervals (\u22658 weeks) was observed across schedules of mRNA vaccine primary series\n(i.e., Pfizer-Pfizer, Moderna-Moderna, Pfizer-Moderna) (Buchan, preprint). Countries such as Australia, Canada, Denmark, Finland, France, Germany, Norway, Taiwan, and the United\nKingdom have recommended extended mRNA vaccine primary series dosing for all persons or specific sub-\ngroups, based on their reviews of available immunological, safety, and effectiveness data, as well as the\nepidemiology of COVID-19, operational considerations, and other contextual factors.","4777":"At this time, only the Medicago COVID-19 Vaccine in people ages 18 years and older\nmeet these criteria. Moderately or severely immunocompromised clinical trial participants should receive a third primary dose of an mRNA\nvaccine 28 days after receiving the second vaccine dose of a primary series as detailed in guidance for people who are\nmoderately or severely immunocompromised, unless they have received or plan to receive a third primary dose through a\nclinical trial. For information on booster doses, see guidance for people who are not moderately or severely immunocompromised and\nguidance for people who are moderately or severely immunocompromised.","3848":"\uf1aa\n\uf20c\nCOVID-19 vaccination providers are required to report information on vaccine supply, vaccine administration, and vaccine\nadverse events. Reporting this information is critical to help stop the COVID-19 pandemic. Vaccine supply\nAll COVID-19 vaccination providers must report COVID-19 vaccine inventory daily in the COVID Locating Health Provider\nPortal. In some jurisdictions, providers may report vaccine inventory to the jurisdiction\u2019s IIS for the jurisdiction to upload\ninto the portal. If you have questions about the inventory reporting process for your jurisdiction, please contact your\njurisdiction\u2019s immunization program. Learn more at Vaccines.gov. Vaccine administration data\nWhat are the reporting requirements for the CDC COVID-19 Vaccination Program?","6030":"What is the available supporting evidence for delaying a second primary dose in people who recently had\nSARS-CoV-2 infection by 3 months from symptom onset or positive test (if infection was asymptomatic)? SARS-CoV-2 infection induces a robust humoral and cellular immune response (CDC, 2021). Additionally, a\nlonger interval of at least 3 or 6 months between infection and vaccination may improve immune response by\nallowing time for the response to mature and avoiding interference from the vaccine (Abu-Raddad L, 2021;\nZhong, 2021). Multiple large-scale studies have observed decreased risk of subsequent infection with\nantigenically similar variants by 80-93% for months after infection (CDC, 2021).","1083":"Ask a healthcare provider if\nmedications to treat COVID-19 are right for you. If you don\u2019t have a healthcare provider, visit a Test to Treat location or\ncontact your local community health center or health department. If you are hospitalized, your healthcare provider might use other types of treatments, depending on how sick you are. These\ncould include medications to treat the virus, reduce an overactive immune response, or treat COVID-19 complications. \uf209\f10\/30\/22, 9:42 AM COVID-19 Treatments and Medications | CDC\nManaging COVID-19 symptoms\nMost people with COVID-19 have\nmild illness and can recover at\nhome.","2263":"Staying up to date\u202fmeans getting all recommended COVID-19 vaccines including boosters when eligible. If your loved one is not able to ask questions or otherwise communicate with the LTC staff, here\u2019s what to know about\nconsent for getting a COVID-19 vaccine:\nResidents and their families can ask a LTC provider about the current COVID-19 vaccination rate among their staff and\nresidents. Nursing homes are required by the Centers for Medicare and Medicaid Services (CMS) to monitor weekly COVID-19\nvaccination data for residents and healthcare personnel through CDC\u2019s National Healthcare Safety Network.","9377":"COVID-19 is caused by a coronavirus called SARS-CoV-2. This type of coronavirus has not\nbeen seen before. You can get COVID-19 through contact with another person who has the\nvirus. It is predominantly a respiratory illness that can affect other organs. People with COVID-\n19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever or\nchills; cough; shortness of breath; fatigue; muscle or body aches; headache; new loss of taste or\nsmell; sore throat; congestion or runny nose; nausea or vomiting; diarrhea.","8685":"If you have risk factors, have a COVID-19 plan in place in case you get sick, and discuss that plan\nwith your healthcare provider and those close to you. Learn what extra precautions you can take to protect yourself and\nothers in settings that make you more likely to be exposed to COVID-19. \uf3c2 Risk of Getting COVID-19\n\uf266 Risk of Getting Very Sick\nInformation for Specific Groups\nOlder Adults\nPeople Who Are Immunocompromised\nPeople with Medical Conditions\nPeople with Asthma\nPregnant and Recently Pregnant People\n\uf419 Risk for COVID-19 Infection, Hospitalization, and Death\nAge Group Rate Ratios Race and Ethnicity Rate Ratios\nLast Updated Aug. 11, 2022","779":"The spike protein is the part of the virus that attaches to\na human cell to infect it, allowing it to replicate inside of the cell and spread to other cells. Some antibodies can protect you\nfrom SARS-CoV-2 by targeting these spike proteins. Because of the importance of this specific part of the virus, scientists who\nsequence the virus for research constantly monitor mutations causing changes to the spike protein through a process called\ngenomic surveillance. As genetic changes to the virus happen over time, the SARS-CoV-2 virus begins to form genetic lineages.","6660":"Know the triggers for your condition and avoid when possible (e.g., avoid asthma triggers by having another member of\nyour household clean and disinfect your house for you or avoid possible sickle cell disease triggers to prevent pain\ncrises). \u2022\n\uf209\n\u2022\nAdditional Resources\nDon\u2019t Delay: Test Soon and Treat Early\nFile Details: 361 KB, 1 page\nView PDF in English\nView PDF in Spanish\n\uf20c\n\uf20c\nLast Updated Oct. 19, 2022","9922":"Clinical considerations based on the age of the recipient include:\nCOVID-19 vaccines products (monovalent and bivalent)\nhave different age indications. \u0083 Janssen COVID-19 Vaccine can be administered to persons\n18 years of age and older in certain limited situations due to\nsafety considerations. \u0083 Novavax COVID-19 Vaccine can be administrated to persons 12\nyears of age and older. \u0083 Moderna COVID-19 Vaccine can be administered to persons\nages 6 months of age and older. \u0083 Pfizer-BioNTech COVID-19 vaccine can be administered to\npersons 6 months of age and older.","2951":"Currently, a booster dose using any COVID-\n19 vaccine is not authorized for children in this age group. Children age 5 years: A 2-dose primary series and 1 bivalent Pfizer-BioNTech booster dose is recommended. The primary\nseries doses are separated by 3\u20138 weeks and the bivalent booster dose is administered at least 2 months after\ncompletion of the primary series (for people who have not received any booster doses), or at least 2 months after the\nlast monovalent booster dose. Currently, only the bivalent Pfizer-BioNTech booster dose is authorized for children age 5\nyears who receive a Pfizer-BioNTech primary series.","9703":"What is the available supporting evidence for use of the COVID-19 vaccine by Pfizer-BioNTech for additional\nprimary doses in people who received a primary vaccination with non-FDA authorized or approved COVID-\nCDC has not systematically evaluated the safety, immunogenicity, and efficacy of an additional dose of the\nCOVID-19 vaccine by Pfizer-BioNTech following receipt of primary vaccination with a non-FDA authorized or\napproved COVID-19 vaccine. Most evidence is with use of a booster dose after primary vaccination.","4442":"Increasing air filtration in your heating, ventilation, and air conditioning (HVAC) system, such as by changing filters\nfrequently and using filters that are properly fitted and provide higher filtration. Using portable high-efficiency particulate air (HEPA) cleaners. Turning on exhaust fans and using other fans to improve air flow. Turning your thermostat to the \u201cON\u201d position instead of \u201cAUTO\u201d to ensure your HVAC system provides continuous\nairflow and filtration. CDC\u2019s interactive ventilation tools can help you see how much you can improve ventilation in your home or school.","7638":"\uf1aa\nrd\nYou will need to show an official U.S. Government letter (paper or digital) documenting approval of the exception. What documentation is needed to show my entry to the United States is in the U.S. national\ninterest? \uf1aa\nAttestations\nWhat is an attestation? \uf1aa\f10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nAn attestation is a statement, writing, entry, or other representation subject to 18 U.S.C. \u00a7 1001 that confirms that the\ninformation provided is true. Willfully providing false or misleading information may lead to criminal fines and\nimprisonment.","4139":"\uf1aa\nThe COVID-19 vaccines for children have the same active ingredients as the vaccines given to adults. However, children\nreceive a smaller and more age-appropriate dose that is right for them. The smaller doses were rigorously tested and\nfound to create the needed immune response for each age group. Making it important for our child to get the vaccine\nmade for their age group. Are the COVID-19 vaccines for children the same ones that are given to adults? \uf1aa\nSafety\nAlthough COVID-19 vaccines were developed quickly, research and development on vaccines like these have been\nunderway for decades.","3090":"The monovalent\nNovavax booster dose is administered at least 6 months after completion of any primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent\nbooster dose. The monovalent Novavax booster dose is administered at least 6 months after completion of any primary series and cannot be used in people\nwho previously received any booster dose(s).","6310":"10\/30\/22, 9:42 AM Patient Tips: Healthcare Provider Appointments for Post-COVID Conditions | CDC\nEspa\u00f1ol | Other Languages\nPatient Tips: Healthcare Provider Appointments for\nPost-COVID Conditions\nBefore Your Appointment\nWhat You Need to Know\nPreparing for an appointment can make all the difference in getting the proper evaluation, diagnosis, and\ntreatment. To help get the most out of appointments for post-COVID conditions, download the Healthcare Appointment\nChecklist (Espa\u00f1ol [PDF \u2013 72 KB]). Try to arrive early or log on a few minutes ahead of the appointment and ensure paperwork is completed on your\nappointment day. After visiting your healthcare provider, review your notes to prepare for your next appointment.","5625":"Wear masks that meet a standard with\nA proper fit over your nose and mouth to prevent leaks\nMultiple layers of non-woven material\nA nose wire\nDo NOT wear masks that meet a standard\nIf it is hard to breathe while wearing them\nIf they are wet or dirty\nWith other masks or respirators\nAs a replacement for NIOSH-approved respiratory protection when required\nby your job\n\u2022 \uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nRespirators\nWhen choosing a respirator, look at how well it fits and read the manufacturer instructions. These instructions should include\ninformation on how to wear, store, and clean or properly dispose of the respirator.","428":"Demographic Trends of People Receiving COVID-19 Vaccinations in the United States previously showed \u201cdate\nadministered\u201d erroneously. This has been replaced with \u201cdate reported to CDC\u201d as of June 24, 2021. On June 14, 2021: During a system upgrade, CDC identified vaccine administration records from files that were\npreviously received but not fully processed. Completion of processing on June 14, 2021 has resulted in a net increase of\n339,047 vaccine administration counts. By jurisdiction, the net increases are: CT (+39), DC (+4,528), FL (+132,008), GU\ncounts for the following jurisdictions will decrease: NJ (-20,609).","8695":"These small differences, or\nvariants, have been studied and identified since the beginning of the pandemic. Some variations allow the virus to spread more easily or make it resistant to treatments or vaccines. Those variants must\nbe monitored more carefully. How Variants Change\nAs the virus spreads, it has new opportunities to change and may become more difficult to stop. These changes can be\nmonitored by comparing differences in physical traits (such as resistance to treatment) or changes in genetic code\n(mutations) from one variant to another.","3107":"Providers should consult CDC\u2019s\nEVUSHELD guidance and current treatment guidelines for more information on the use of EVUSHELD as pre-\nexposure prophylaxis. Such use of monoclonal antibodies, however, is not a substitute for COVID-19 vaccination.","2991":"The monovalent\nNovavax booster dose is administered at least 6 months after completion of any primary series. An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines may be optimal for\nsome people ages 6 months\u201364 years, especially for males ages 12\u201339 years, as it may reduce the small risk of myocarditis and pericarditis associated with\nthese vaccines.","4449":"\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:39 AM How to Protect Yourself and Others | CDC\nMoving indoor activities outdoors\nYou are less likely to be infected with COVID-19 during outdoor activities because virus particles do not build up in the air\noutdoors as much as they do indoors. As the COVID-19 Community Level rises, consider increasing the number of group\nactivities you move outside. Financial support may be available to certain entities, like schools, to make ventilation improvements. \uf209\nGetting Tested for COVID-19 If Needed\nGet tested if you have COVID-19 symptoms. A viral test tells you if you are infected with the virus that causes COVID-19.","708":"December 23, 2021: West Virginia made updates to data previously submitted to CDC that resulted in a decrease of\n651,436 doses administered. December 22, 2021: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n25,151 doses administered. December 21, 2021: Pennsylvania made updates to data previously submitted to CDC that resulted in a decrease of\n101,475 doses administered. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nDecember 17, 2021: New Mexico updated 2,213 records, previously submitted to CDC. This did not result in change\nto number of doses administered.","9752":"Recent studies indicate that additional doses in people who are moderately or severely immunocompromised\nare safe and can increase antibody response. Small studies in solid organ transplant recipients in Toulouse,\nStrasbourg, and Baltimore demonstrate immunogenicity of a 4th mRNA dose when administered 1\u20132 months\nafter the 3rd dose (Kamar et al., 2021; Benotmane et al., preprint; Alejo et al., 2021).","7259":"V-safe also provides second-dose reminders if needed and live telephone\nfollow-up by CDC if participants report a significant health impact following COVID-19\nvaccination. For more information on how to sign up, visit: www.cdc.gov\/vsafe. WHAT IF I DECIDE NOT TO GET COMIRNATY (COVID-19 VACCINE, mRNA), THE\nPFIZER-BIONTECH COVID-19 VACCINE, OR THE PFIZER-BIONTECH COVID-19\nVACCINE, BIVALENT? Under the EUA, it is your choice to receive or not receive any of these vaccines. Should\nyou decide not to receive any of these vaccines, it will not change your standard\nmedical care.","4112":"Can I ask my healthcare provider for a dose of COVID-19 vaccine that does not follow vaccination\nguidelines, sometimes called \u201coff-label\u201d use? \uf1aa\n\uf209\nScientists are monitoring how long COVID-19 vaccine protection lasts. COVID-19 vaccines work well to prevent severe\nillness, hospitalization, and death. However, public health experts are seeing decreases in the protection COVID-19\nvaccines provide over time, especially for certain groups of people. Due to this, CDC recommends COVID-19 vaccines for\neveryone ages 6 months and older, and boosters for everyone 5 years and older, if eligible. Learn more about COVID-19\nbooster recommendations, including recommendations for people who are moderately or severely\nimmunocompromised.","7640":"\uf1aa\nrd\nYou will need to show an official U.S. Government letter (paper or digital) documenting approval of the exception. What documentation is needed to show my entry to the United States is in the U.S. national\ninterest? \uf1aa\nAttestations\nWhat is an attestation? \uf1aa\f10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nAn attestation is a statement, writing, entry, or other representation subject to 18 U.S.C. \u00a7 1001 that confirms that the\ninformation provided is true. Willfully providing false or misleading information may lead to criminal fines and\nimprisonment.","484":"Moderna\ndeliveries to a jurisdiction on or after May 7, 2021, will reflect this combination of fourteen dose and ten dose vials;\nhistorical data will not be updated. The change to the Moderna dosage increases the number of doses delivered relative\nto the number of doses administered. On May 7, 2021, the New Hampshire \u201ctotal doses administered\u201d value posted to Tracker was lower than that reported on\nthe two prior days (May 5 and 6, 2021). This downward correction is accurate and is due to New Hampshire and CDC\ncollaboratively correcting data transmission errors. Updates will be provided as available.","130":"More studies and surveillance are needed to track variants and mutations and to understand\nhow SARS-CoV-2 spreads between people and animals. Mink and SARS-CoV-2\nIn the United States, respiratory disease and increases in mink deaths have been seen on most affected mink farms. However, some infected mink might also appear healthy. Infected workers likely introduced SARS-CoV-2 to mink on the farms,\nand the virus then began to spread among the mink. Once the virus is introduced on a farm, spread can occur between mink,\nas well as from mink to other animals on the farm (dogs, cats).","8412":"Core Competencies:\nRelevant information contained in the EUA Fact Sheet(s) for Healthcare Providers for the vaccine product(s) in\nyour facility\nClinical considerations\nStorage and handling requirements\nPreparation requirements\nAdministration requirements\nAnaphylaxis guidance\nVaccination documentation and reporting requirements\nRequired and additional information for vaccine recipients\nCOVID-19 Vaccine Administration Competencies Assessment Form\nHealthcare professionals or retired (past 5 years) physicians, nurses, or\npractical nurses who are licensed\/previously licensed to administer\nCOVID-19 vaccine but have not done so in the last 12 months\n\uf209\n\uf20c\nCOVID-19 Vaccine Training Routine Vaccine Administration Routine Vaccine Storage and Handling\nVaccination support workers (not licensed to administer vaccine) qualified\nto prepare, store, handle, or transport vaccine\f10\/30\/22, 9:17 AM Training and Education for COVID-19 Vaccination | CDC\nCOVID-19 Vaccine Training Routine Vaccine Administration Routine Vaccine Storage and Handling\nCDC Training Module(s) for the\nvaccine product(s) in your facility\nIf needed: You Call the Shots: Vaccine\nAdministration\nOr other vaccine administration\ntraining offered by a worksite, state or\nlocal health department, medical\nprofessional organization, or\nmedical\/nursing school within the last\n12 months.","4704":"Clinicians should consult guidance from the American Society of Hematology for information on the diagnosis and\ntreatment of suspected cases of TTS and report any occurrence of TTS to VAERS\n\uf209\n\uf209\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\ntreatment of suspected cases of TTS, and report any occurrence of TTS to VAERS . People with a history of thrombosis or risk factors for thrombosis\nAlthough the mechanism of TTS associated with the Janssen COVID-19 Vaccine is unclear, it appears to be similar to another\nrare immune-mediated syndrome, spontaneous heparin-induced thrombocytopenia (HIT).","6227":"COVID-19 vaccination causes a more predictable immune response than infection with the virus that causes COVID-19. Getting a COVID-19 vaccine gives most people a high level of protection against COVID-19 and can provide added\nprotection for people who already had COVID-19. One study showed that, for people who already had COVID-19, those\nwho do not get vaccinated after their recovery are more than 2 times as likely to get COVID-19 again than those who get\nfully vaccinated after their recovery. All COVID-19 vaccines currently available in the United States are effective at preventing COVID-19.","5680":"Follow the user instructions for the mask or respirator. These instructions may show how to make sure the product fits\nproperly. Some types of masks and respirators may feel different if your child is used to wearing a regular cloth or disposable\nprocedure masks. Safety precautions\nIf your child has a medical condition, such as a heart or lung problem, ask their healthcare provider before they use\nmethods to improve mask fit or use an ASTM F3502 mask or a respirator.","201":"Getting a vaccine is safer than getting COVID-19, and\nvaccination against COVID-19 is recommended for everyone 5 years of age and older. If someone has already had COVID-19,\nvaccination against COVID-19 increases their body\u2019s antibody response, which improves their protection. It is important to remember that some people with antibodies to SARS-CoV-2 may become infected after vaccination (vaccine\nbreakthrough infection) or after recovering from a past infection (reinfected). Based on what we know right now, risk of\nreinfection is low for at least the first 6 months following an infection with the virus that causes COVID-19 diagnosed by a\nlaboratory test.","2312":"\u2022\n\u2022\n-\n-\n\u2022\n\u2022\n\u2022 TM\nPre-teens, Teens and Adults Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nAGE GROUP\n18 YEARS AND OLDER\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nModerna\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nJohnson & Johnson's Janssen\n\uf1aa\nPRIMARY SERIES\nADDITIONAL DOSE\nAt least 4 weeks after 1st dose\nand should be Pfizer-BioNTech\nor Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nor last booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nNovavax\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nA monovalent Novavax booster\nis available in limited situations\nMore details: Novavax booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nChildren Ages 6 Months-11 Years Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 8 weeks after 2nd dose\nUp to Date: 2 weeks after 3rd dose in primary series, since a booster is not recommended for this age group at this\ntime\nAGE GROUP\nModerna\n\uf1aa\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nIf you have completed your primary series\u2014but are not yet eligible for a booster\u2014you are also considered up to date.","3542":"As people receiving doses are attributed to the jurisdiction in which they reside, the reporting\nmethod might change between doses if they move to a different jurisdiction. Also, CDC may lack information about a person\u2019s\nresidence. These issues can cause CDC\u2019s dose number estimates to differ from those reported by jurisdictions and federal\nentities. CDC has capped estimates of vaccination coverage shown on COVID Data Tracker at 95%. This cap helps address potential\nover-estimates of vaccination coverage due to first, second, and booster doses that were not linked. Other reasons for\noverestimates include census denominator data not including part-time residents or potential data reporting errors.","5619":"(For instructions, see the following\nUse masks that attach behind the neck and head with either elastic\nbands or ties (instead of ear loops)\n\u2022\n\u2022\n\u2022\n-\n\uf209\n\u2022\f10\/30\/22, 9:39 AM Masks and Respirators\nSome masks are designed and tested to ensure they perform at a consistent level. These masks are labeled to tell you what\nstandard they meet. These masks are labeled:\nMasks that Meet a Standard\nMEETS ASTM F3502\nMEETS WORKPLACE PERFORMANCE\nMEETS WORKPLACE PERFORMANCE PLUS\nThese are new standards. Lists of masks that meet these standards and more\ninformation on their availability can be found on the NIOSH Personal Protective\nEquipment Information (PPE-Info) webpage.","5784":"Has the COVID-19 vaccine by Moderna been used before? Yes. Millions of people have received this vaccine in the United States since it became available starting\nDecember 18, 2020. Also, in clinical trials, approximately 15,400 people 18 ages years and older received at\nleast 1 dose of the vaccine and approximately 2,500 people ages 12\u201317 years received a primary series of\nthe vaccine. There have been some studies in people who received the COVID-19 vaccine by Moderna after\ncompleting a primary vaccination with a non-FDA authorized or approved COVID-19 vaccine or Janssen\nCOVID-19 Vaccine. What are the risks of the COVID-19 vaccine by Moderna?","9664":"See Table 3 COVID-19 vaccination schedule for moderately or severely immunocompromised people in CDC\u2019s\nInterim Clinical Considerations for the latest dosing recommendations. On a case-by-case basis, providers of\nmoderately or severely immunocompromised patients who are ages 12 years and older may administer the\nCOVID-19 vaccine by Pfizer-BioNTech outside of the FDA-authorized or FDA-approved labeling and CDC\nrecommended dosing intervals based on clinical judgment when the benefits of vaccination are deemed to\noutweigh the potential and unknown risks for the recipient. What are the formulations of the COVID-19 vaccine by Pfizer-BioNTech that these EUI apply to?","5765":"Talk to your healthcare provider about if and when you should receive a primary, additional and\/or a\nbooster dose. See CDC\u2019s Interim Clinical Considerations for additional information on moderately and\nseverely immunocompromised persons recommended for an additional primary dose and populations\neligible for a booster dose. Who should NOT get the COVID-19 vaccine by Moderna?","7619":"\uf1aa\f10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nThe requirements for testing and quarantine post-arrival by air conveyance apply to sea crew\/mariners entering the\nUnited States as Covered Individuals who are:\nnot fully vaccinated against COVID-19, and\nwithout documentation of having recovered from COVID-19 in the past 90 days. Sea crew members boarding cruise ships that are participating in CDC\u2019s COVID-19 Program for Cruise Ships must follow\napplicable guidance for testing and quarantine during and after embarking the cruise ship.","4273":"\u2022\n\u2022\nIf you have multisystem inflammatory\nsyndrome\nChildren and adults who have (or have recently had)\nmultisystem inflammatory syndrome (MIS), should\nwait to get vaccinated until:\nRecovering from being sick and\nIt has been 90 days since the date of diagnosis of\nMIS-A or MIS-C.\n\u2022\n\u2022\nTalk to your doctor if you have questions about getting a COVID-19 vaccine. \uf19c Find COVID-19 Vaccines or Boosters\nTo find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-\n232-0233. Find a Vaccine or Booster\nBefore the Vaccination\nIt is not known how over-the-counter (OTC) medicines, such as ibuprofen, aspirin, or acetaminophen, might affect how well\nthe vaccine works.","7734":"CDC scientists have conducted detailed reviews of cases of anaphylaxis and made the information available to\nhealthcare providers and the public:\nAllergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine\nReports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US\u2014December 14, 2020-January 18,\nAllergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine\u2014 United\nThe benefits of COVID-19 vaccination continue to outweigh any potential risks.","1257":"Detailed information can be found in CDC\u2019s\nUse of COVID-19 Vaccines in the U.S. and the CDC Summary Document for Interim Clinical Considerations. To find locations that administer COVID-19 vaccinations, you can visit Vaccines.gov; text your zip code to 438829\n(GETVAX); call 1-800-232-0233; or check your state health department website. Visit How Do I Find a COVID-19 Vaccine to\nlearn more. Individuals interested in getting vaccinated at their local pharmacy should check the pharmacy\u2019s website to find out if\nCOVID-19 vaccine is available. Most pharmacy locations are now offering walk-in vaccination appointments as supply\nallows.","6821":"If you are considering having your child receive the\nPfizer-BioNTech COVID-19 Vaccine or the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent with other vaccines, discuss the options with your child\u2019s healthcare provider. WHAT IF MY CHILD IS IMMUNOCOMPROMISED? If your child is immunocompromised, you may be given the option to have your child\nreceive a third primary series dose of the Pfizer-BioNTech COVID-19 Vaccine. Individuals 5 through 11 years of age may receive a booster dose with the\nPfizer-BioNTech COVID-19 Vaccine, Bivalent.","9911":"Use this guidance with:\n\u0083 Interim Clinical Considerations for Use of COVID-19 Vaccines\nCurrently Approved or Authorized in the United States\n\u0083 Advisory Committee on Immunization Practices on\nImmunization General Best Practice Guidelines\n\u0083 Interim COVID-19 Immunization Schedule for Ages 6 Months\nand Older\n\u0083 COVID-19 Vaccination Clinical & Professional Resources for\neach vaccine product\nConsider the following post-vaccination observation times to monitor for syncope and allergic reactions:\n\u0083 People with a history of:\n\u25cb Allergy-related contraindication to a different type of\n\u25cb Non-severe, immediate (onset within 4 hours) allergic\nreaction after a previous dose of COVID-19 vaccine.","9315":"Healthcare Appointment Checklist for Post-COVID\nConditions | COVID-19 |\nAccessible link: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/long-term-effects\/post-COVID-appointment\/index.html\nThis checklist is designed to help patients and caregivers get the most out of appointments with healthcare providers for post-COVID conditions. Before the Appointment\n\nAsk the new provider\u2019s office if they\nneed paperwork signed so your medical\nrecords can be sent to\nthem directly. Keep a journal or a list for a week\nor two to document your activities,\nsymptoms, their severity, and anything\nthat made you feel better or worse. Prepare a brief report that summarizes\nyour experience and symptoms and\ndescribes your best and worst days. Make a list of your current\nmedications\/supplements.","3672":"Find a COVID-19 testing location near you or use a self-test. If you already had COVID-19 within the past 90 days, see specific testing recommendations. Monitor yourself for COVID-19 symptoms. Follow additional guidance if you know you were exposed to a person with COVID-19. Follow all state, tribal, local, and territorial recommendations or requirements after travel. If you are going to be around someone who is at higher risk of getting very sick with COVID-19, consider\nadditional precautions. \uf209\nIf Your Test is Positive or You Develop COVID-19 Symptoms\nIsolate yourself to protect others from getting infected.","5662":"What to know about NIOSH-approved respirators\nWhen worn consistently and properly, they provide the highest level of protection from particles, including the\nvirus that causes COVID-19. Additionally, they contain your respiratory droplets and particles so you do not expose\n\uf209\n\u2022\f10\/30\/22, 9:39 AM Masks and Respirators\ny, y y p y p p y p\nothers. They seal tightly to your face when fitted properly. It is important to pick a respirator that fits your face and seals well since not all fit the same. Respirators approved by NIOSH are evaluated against a specific US standard that includes a quality requirement.","8269":"COVID-19 vaccines available abroad that are accepted in the United States as valid vaccinations\n\uf1aa\nVaccines approved or authorized by the U.S. Food and Drug Administration (FDA) currently include:\nPfizer-BioNTech\nModerna\nNovavax\nJohnson & Johnson\u2019s Janssen\nVaccines listed for emergency use by the World Health Organization (WHO) currently include those that are listed\nabove and the following:\nAstraZeneca\/Oxford vaccine\nSinopharm\nSinovac\nCOVAXIN\nCovovax\nCanSino\n\u2022\n\u2022\n\u2022\n\u2022\n\uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022\n\u2022\f10\/30\/22, 9:27 AM Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC\nHow to Complete a Primary Series\nReceive 1 dose of a single-dose accepted COVID-19 vaccine\nReceive 2 doses of a 2-dose accepted COVID-19 vaccine\nCDC does not recommend mixing different COVID-19 vaccines for the primary series, but CDC is aware that mixing\nCOVID-19 vaccines for the primary series is increasingly common in many countries outside the United States.","3045":"The first and second doses are separated by 4 weeks and the second and third doses are separated by at\nleast 4 weeks. The bivalent mRNA booster dose is administered at least 2 months after completion of the primary series. Pfizer-BioNTech COVID-19 Vaccine\nChildren ages 6 months\u20134 years: A 3-dose primary series is recommended. The first and second doses are separated by\n3 weeks and the second and third doses are separated by at least 8 weeks. Currently, a booster dose using any COVID-19\nvaccine is not authorized for children in this age group.","8933":"10\/30\/22, 9:32 AM Vaccine Adverse Event Reporting System (VAERS) | CDC\nEspa\u00f1ol | Other Languages\nVaccine Adverse Event Reporting System (VAERS)\nHow Reports Come into VAERS\nThere are two ways to report an adverse event to VAERS: report online or report using a writable pdf form. If you need\nfurther assistance with reporting to VAERS, please email info@VAERS.org or call 1-800-822-7967. For healthcare providers \u2013 Under Emergency Use Authorization, FDA requires healthcare professionals to report to VAERS\ncertain adverse events that occur after COVID-19 vaccination. CDC also encourages reporting of any medically important\nadverse event even if it isn\u2019t clear if the vaccine caused the health problem.","5378":"V-safe is a new voluntary smartphone-based\ntool that uses text messaging and web surveys to check in with people who have been vaccinated\nto identify potential side effects after COVID-19 vaccination. V-safe asks questions that help CDC\nmonitor the safety of COVID-19 vaccines. V-safe also provides live telephone follow-up by CDC\nif participants report a significant health impact following COVID-19 vaccination. For more\ninformation on how to sign up, visit: www.cdc.gov\/vsafe. WHAT IF I DECIDE NOT TO GET THE JANSSEN COVID-19 VACCINE? Under the EUA, there is an option to accept or refuse receiving the vaccine.","2357":"Examples of medical conditions or treatments that may result in moderate to severe immunocompromise include but are not\nlimited to:\nActive treatment for solid tumor and hematologic malignancies\nHematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status\n(e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\nReceipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\nReceipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of\ntransplantation or taking immunosuppressive therapy)\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nTalk to your healthcare provider about COVID-19 and your medical condition.","4445":"Increasing air filtration in your heating, ventilation, and air conditioning (HVAC) system, such as by changing filters\nfrequently and using filters that are properly fitted and provide higher filtration. Using portable high-efficiency particulate air (HEPA) cleaners. Turning on exhaust fans and using other fans to improve air flow. Turning your thermostat to the \u201cON\u201d position instead of \u201cAUTO\u201d to ensure your HVAC system provides continuous\nairflow and filtration. CDC\u2019s interactive ventilation tools can help you see how much you can improve ventilation in your home or school.","6859":"In addition, the FDA decision is based\non the totality of the scientific evidence available showing that the product may be\neffective to prevent COVID-19 during the COVID-19 pandemic and that the known and\npotential benefits of the product outweigh the known and potential risks of the product. All of these criteria must be met to allow for the product to be used during the\nCOVID-19 pandemic. An EUA is in effect for the duration of the COVID-19 EUA declaration justifying\nemergency use of this product, unless terminated or revoked (after which the product\nmay no longer be used).","6777":"WHAT ARE THE INGREDIENTS IN THESE VACCINES? The Pfizer-BioNTech COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent include the following ingredients: mRNA, lipids (((4-\nand cholesterol), tromethamine, tromethamine hydrochloride, sucrose, and sodium\nchloride. HAVE THESE VACCINES BEEN USED BEFORE? In a clinical trial, approximately 3,100 individuals 5 through 11 years of age have\nreceived at least 1 dose of the Pfizer-BioNTech COVID-19 Vaccine. Millions of\nindividuals have received the Pfizer-BioNTech COVID-19 Vaccine under EUA since\nDecember 11, 2020.","8206":"(Children 6 months to 4 years\nare not recommended for a\nbooster.) Up to Date: Children 6 months to 4 years of age are up to date two weeks after completing the 2nd dose of their\nprimary series. Children 5 years of age who received a Moderna primary series are up to date immediately after they\nhave received the most recent booster recommended for them.","9590":"\u2022 Revaccination of moderately or severely immunocompromised persons ages 12 years and older who\nreceived certain therapies (indicated below) and received primary dose(s) of COVID-19 vaccine prior to\nor during treatment. o\no\nReceived COVID-19 vaccine dose(s) during treatment with B-cell-depleting therapies over a\nlimited period\nReceived COVID-19 vaccine dose(s) prior to or during treatment involving hematopoietic cell\ntransplant (HCT) or chimeric antigen receptor (CAR)-T-cell therapy\nThe COVID-19 vaccine by Moderna under EUI also allow similar uses as an alternative mRNA COVID-19 vaccine\nto Pfizer-BioNTech, and the same or similar recommendations in the EUI also apply to the use of the COVID-19\nvaccine by Moderna under EUI.","8483":"10\/30\/22, 9:43 AM Travel: Frequently Asked Questions and Answers | CDC\nEspa\u00f1ol | Other Languages\nTravel: Frequently Asked Questions and Answers\nGeneral\nCheck CDC\u2019s Domestic Travel or International Travel pages for the latest recommendations for travelers. Travel is any trip that involves leaving your community. Transportation within your community for errands and work\ntransit is not considered travel. What is travel? \uf1aa\nYes, you can travel once you have ended isolation. However, you should wear a high-quality mask or respirator the entire\ntime you are around others indoors until it\u2019s safe for you to remove your mask around others.","8568":"10\/30\/22, 9:34 AM Understanding How COVID-19 Vaccines Work | CDC\nEspa\u00f1ol | Other Languages\nUnderstanding How COVID-19 Vaccines Work\nHow COVID-19 Vaccines Work\nWhat You Need to Know\nCOVID-19 vaccines help our bodies develop immunity to the virus that causes COVID-19 without us having to get the\nillness. Different types of vaccines work in different ways to offer protection. None of the COVID-19 vaccines can give you COVID-19. Bringing new vaccines to the public involves various steps, all which must be followed before they are made\navailable for use.","2663":"Caregivers should quarantine\nKeep a separate bedroom and bathroom for a person who is sick\n\u2022\n\u2022\n-\n-\n\u2022\f10\/30\/22, 9:41 AM COVID19 - Caring for someone at home | CDC\nCaregivers and anyone who has been in close contact with someone who has COVID-19 should stay home, except in\nlimited circumstances. Learn when and how to quarantine. When it's safe for a person who has been sick to be around others\nDeciding when it is safe to be around others is different for different situations. Find out when someone who is sick can\nsafely end home isolation.","10075":"In exceptional situations when the previous product cannot be determined\/not available or if a person is unable to complete a series with the same\nCOVID-19 vaccine due to a contraindication any age-appropriate mRNA COVID-19 vaccine may be used (administer at a minimum interval of 28 days). \u0083 For booster vaccination, any homologous or heterologous age-appropriate mRNA vaccine can be used. Recommendations vary\nbased on age and primary series product. (https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us. html#timing-spacing-interchangeability).\u2021\nCoadministration with other vaccines\n\u0083 COVID-19 vaccines may be administered on the same day as other vaccines.","116":"These cases include farmed mink in Europe and the United States, white-tailed deer in Canada, pet hamsters in Hong\nKong, and a cat in Thailand. In most of these cases, the animals were known to be first infected by a person who had COVID-\n19. It\u2019s important to remember that people are much more likely to get COVID-19 from other people than from animals. There is\nno need to euthanize or otherwise harm animals infected with SARS-CoV-2. There is a possibility that the virus could infect animals, mutate, and a new strain could spread back to people and then\namong people (called spillback).","3762":"What are the risks and benefits of receiving COVID-19 vaccines by Pfizer-BioNTech and Moderna as\nprimary, additional, and\/or booster vaccination? The duration of vaccine-induced protection from primary vaccination with COVID-19 vaccines is\nunknown. Efficacy data from clinical studies of 2-dose primary series supported benefit of the COVID-19\nvaccines by Pfizer-BioNTech and Moderna in preventing severe COVID-19 and supported their FDA\napproval. Data on the safety or efficacy of additional primary or booster doses of FDA-approved COVID-\n19 vaccines (Pfizer-BioNTech or Moderna) after receipt of a non-FDA authorized or approved COVID-19\nvaccine are limited.","7036":"It\ndoes this so you can quickly and easily share with CDC how you or your child feel after getting a COVID-19 vaccine. Vaccine Adverse Event Reporting System can be used by you or your healthcare provider to report a side effect,\nadverse event, or reaction from COVID-19 vaccine. \u2022\n\u2022 \uf209\n\uf263 Stay Up to Date with COVID-19 Vaccines and Boosters\nWhen do you need to schedule your next shot? Do you or your child need to get a booster? Can you get a different vaccine product after your 1st dose?","5483":"As a result of these effects, people who have had COVID-19 may be more likely to develop\nnew health conditions such as diabetes, heart conditions, or neurological conditions compared with people who have not had\nCOVID-19. People experiencing any severe illness may develop health problems\nPICS refers to the health effects that may begin when a person is in an intensive care unit (ICU), and which may persist after a\nperson returns home. These effects can include muscle weakness, problems with thinking and judgment, and symptoms of\npost-traumatic stress disorder (PTSD). PTSD involves long-term reactions to a very stressful event.","7636":"Non-cruise ship operators and mariners have several options to fulfill this requirement:\nCrew can visit a shoreside testing facility (e.g., testing at a pharmacy or healthcare facility)\nOperators can contract a 3 party to preform testing onboard\nOperators can provide crew with COVID-19 self-tests (sometimes referred to as home tests or at-home tests) or\nask that crew embark the vessel with their own self-test. CDC recommends that if self-tests are used, they should be conducted under supervision of tele-medicine\npersonnel. How should sea crew members fulfill the requirements of the attestation?","5446":"Most people with COVID-19 get better within a few days to a few weeks after\ninfection, so at least four weeks after infection is the start of when post-COVID conditions could first be identified. Anyone\nwho was infected can experience post-COVID conditions. Most people with post-COVID conditions experienced symptoms\ndays after first learning they had COVID-19, but some people who later experienced post-COVID conditions did not know\nwhen they got infected. There is no test to diagnose post-COVID conditions, and people may have a wide variety of symptoms that could come from\nother health problems.","6637":"It is also important for people with medical conditions and their healthcare providers to work together and manage\nthose conditions carefully and safely. Stay up to date with your COVID-19 vaccines. If you have a medical condition, the\nfollowing are actions you can take based on your medical conditions and other risk factors. Seek care when needed\nCall your healthcare provider if you have any concerns about your medical conditions or if you get sick and think that you\nmay have COVID-19. Discuss steps you can take to manage your health and risks. If you need emergency help, call 911\nright away.","8162":"As with other vaccine-preventable diseases, you are protected best from COVID-19 when you stay up\nto date with the recommended vaccinations, including recommended boosters. Four COVID-19 vaccines are approved or authorized in the United States:\nPfizer-BioNTech\nModerna\nNovavax\nJohnson & Johnson\u2019s Janssen (J&J\/Janssen) (However, CDC recommends that the J&J\/Janssen COVID-19 vaccine only be\nconsidered in certain situations, due to safety concerns.) Updated (Bivalent) Boosters\nThe updated (bivalent) boosters are called \u201cbivalent\u201d because they protect against both the original virus that causes COVID-\n19 and the Omicron variant BA.4 and BA.5. Previous boosters are called \u201cmonovalent\u201d because they were designed to protect against the original virus that causes\nCOVID-19.","56":"If You Had a Non-severe Allergic Reaction to a COVID-19 Vaccine\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:31 AM Allergic Reactions after COVID-19 Vaccination | CDC\nIf you had an immediate allergic reaction (a reaction that started within 4 hours of getting vaccinated) to a COVID-19 vaccine,\nbut the reaction was not considered severe by a medical professional, you likely can receive another dose of the same vaccine\nunder certain conditions. Your doctor may refer you to an allergy and immunology specialist for additional care or advice.","5041":"Updated Table in Appendix A: Vaccine administration errors and deviations. New section on Considerations for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose after completion of a\nPfizer-BioNTech primary vaccine series. Updated information in the section on COVID-19 vaccination and SARS-CoV-2 infection. Updated information in the section on Vaccinating people with a known COVID-19 exposure or during COVID-19\noutbreaks. New section on Vaccinating people receiving medical care unrelated to COVID-19. New section on Vaccinating people undergoing SARS-CoV-2 screening.","7856":"\uf1aa\f10\/30\/22, 9:38 AM Self-Testing At Home or Anywhere | CDC\nPrint Resources\nDon't Delay: Test Soon and Treat Early\n[PDF - 361 KB, 1 page]\n\uf20c\f10\/30\/22, 9:38 AM Self-Testing At Home or Anywhere | CDC\nHow to Collect An Anterior Nasal Swab Specimen for COVID-19 Testing\n[PDF - 372 KB, 2 pages]\n\uf20c\nHow to Collect a Nasal Mid-Turbinate Swab Specimen for COVID-19 Testing\n[PDF - 4 MB, 2 pages]\n\uf20c\f10\/30\/22, 9:38 AM Self-Testing At Home or Anywhere | CDC\nUsing Your Self-Test\n[PDF - 295 KB, 1 page]\n\uf20c\f10\/30\/22, 9:38 AM Self-Testing At Home or Anywhere | CDC\nUsing Your Self-Test - customizable\n[PDF - 279 KB, 1 Page]\n\uf20c\f10\/30\/22, 9:38 AM Self-Testing At Home or Anywhere | CDC\nHelpful Links\nFDA-Authorized At-Home Tests\nSymptoms of COVID-19\nUnderlying Medical Conditions\nTalking to Close Contacts\nQuarantine and Isolation\n\uf209\nLast Updated Sept. 6, 2022","3018":"\u2020 \u2021\n*\n\u2020\n\u2021\nPrevious vaccination with Janssen COVID-19 Vaccine\nConsiderations for extended intervals for COVID-19 vaccine primary series\ndoses\n\uf20c\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nCOVID-19 vaccines are FDA-approved or FDA-authorized for a 3-week (i.e., Novavax and Pfizer-BioNTech) and 4-week (i.e.,\nModerna) interval between the first and second primary series doses. These intervals continue to be recommended for\npeople who are moderately or severely immunocompromised, adults ages 65 years and older, and in situations when the\nfullest possible protection needs to be achieved sooner (e.g., increased concern about COVID-19 community levels or an\nindividual\u2019s higher risk for severe disease).","4228":"If you cannot contact your vaccination provider directly or your vaccination provider cannot reissue a CDC COVID-\n19 Vaccination card, contact your state health department\u2019s immunization information system (IIS). Your state\u2019s IIS\ncannot issue you a vaccination card, but they can provide a digital or paper copy of your full vaccination record,\nincluding your COVID-19 vaccinations. If you need another COVID-19 vaccine dose and are unable to get a copy of your vaccination card or vaccination\nrecord, talk to a vaccination provider to learn about your possible options.","6452":"Monitor your health for COVID-19 symptoms and get tested at least 5 days after you had close contact with someone\nwith COVID-19, even if you don\u2019t develop symptoms. Wear a high quality mask for 10 full days any time you are around others inside your home or in public. Do not go to\nplaces where you are unable to wear a mask. What to do if you have COVID-19 symptoms\nStay home. Get tested right away. Use a self-test at home or find a testing location near you.","8421":"Core Competencies:\nRelevant information contained in the EUA Fact Sheet(s) for Healthcare Providers for the vaccine product(s) in\nyour facility\nPreparation requirements\nStorage and handling requirements\nTransport guidance\nVaccination documentation and reporting requirements\nRequired and additional information for vaccine recipients\nCOVID-19 Vaccine Administration Competencies Assessment Form\n\uf209\n\uf20c\nCOVID-19 Vaccine Training Routine Vaccine Administration Routine Vaccine Storage and Handling\nCDC Training Module(s) for the\nvaccine product(s) in your facility\nn\/a Recommended if storing and handling\nvaccine: You Call the Shots: Vaccine\nStorage and Handling\nOr other vaccine storage and handling\ntraining offered by a worksite, state or\nlocal health department, medical\nprofessional organization, or\nmedical\/nursing school within the last\n12 months.","7200":"The Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent, or COMIRNATY (COVID-19 Vaccine, mRNA) will be given to you as an\ninjection into the muscle. Primary Series: The Pfizer-BioNTech COVID-19 Vaccine and COMIRNATY (COVID-19\nVaccine, mRNA) are given for the primary series. The vaccine is administered as a\n2-dose series, 3 weeks apart. A third primary series dose may be administered at least\n4 weeks after the second dose to individuals with certain kinds of immunocompromise.","4025":"Data availability: Data on the CDC COVID Data Tracker represent all vaccine partners including jurisdictional\npartner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management\nAgency and Health Resources and Services Administration partner sites, and federal entity facilities. These\nadditional data streams may not be available to jurisdictions and therefore may not be included in totals\npresented on jurisdictional dashboards. Data definition: CDC\u2019s COVID Data Tracker attributes dose administrations to the jurisdiction (state, territory, tribe,\nor local entity) administering those doses and attributes people receiving COVID-19 vaccine to the jurisdiction\nwhere the vaccine recipient resides.","6448":"Monitor your health for COVID-19 symptoms and get tested at least 5 days after you had close contact with someone\nwith COVID-19, even if you don\u2019t develop symptoms. Wear a high quality mask for 10 full days any time you are around others inside your home or in public. Do not go to\nplaces where you are unable to wear a mask. What to do if you have COVID-19 symptoms\nStay home. Get tested right away. Use a self-test at home or find a testing location near you.","5519":"For example, some\nstudies look for the presence of post-COVID conditions based on self-reported symptoms, while others collect symptoms and\nconditions recorded in medical records. Some studies focus only on people who have been hospitalized, while others include\npeople who were not hospitalized. The estimates for how many people experience post-COVID conditions can be quite\ndifferent depending on who was included in the study, as well as how and when the study collected information.","3445":"For intervals of 3 months or less, 28 days (4 weeks) is a \u201cmonth.\u201d For intervals of 4 months or longer, a month is a\n\u201ccalendar month.\u201d For age group ranges (e.g., 6 months\u20134 years, 5\u201311 years), a dash (\u2013) should be read as \u201cthrough\u201d and\nthe upper range includes that year through the last day before the birth date. 4. The Society of Breast Imaging has developed Recommendations for the Management of Axillary Adenopathy in Patients\nwith Recent COVID-19 Vaccination which includes considerations for patients and healthcare professionals in\nscheduling screening exams in relation to the administration of a COVID-19 vaccine.","4795":"To file an electronic report, please see the VAERS website . Determine how the error occurred and implement strategies to prevent it from happening again. A discussion on\nstrategies to prevent errors can be found in the \u201cVaccine Administration\u201d chapter of Epidemiology and Prevention of\nVaccine-Preventable Diseases (Pink Book). Additional resources can be found on CDC\u2019s vaccine administration web page,\nincluding a job aid for preventing errors. Follow the revaccination guidance in the table below, using an age-appropriate COVID-19 vaccine product. Then continue\nwith the recommended schedule of subsequent dose(s) unless otherwise noted (see footnotes to this Appendix).","4283":"Biologics or biologic response modifiers that treat autoimmune\u202fdiseases\nChemotherapy or other cancer treatment medications\nAntiviral medication\nAntibiotics\nStatins\nIf you regularly take over-the-counter medications, you should keep taking them before you get\nvaccinated. \uf1aa\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:30 AM Getting Your COVID-19 Vaccine | CDC\nBlood pressure medications\/antihypertensives (amlodipine, lisinopril, etc.) Diuretics\nThyroid medications\nAntidepressants\nMetformin\nDiabetic medications\nInsulin\nSteroids (prednisone, etc.) This is not a complete list. These are some examples of common medications. If you have questions about medications that you are taking, talk to your healthcare or vaccination provider.","3868":"Vaccine adverse events\nHealthcare providers are required under Emergency Use Authorization (EUA) to report to the Vaccine Adverse Event\nReporting System (VAERS) the following adverse events (AEs) after COVID-19 vaccination (and other adverse events if\nlater revised by CDC):\nVaccine administration errors, whether associated with an AE or not\nCases of COVID-19 that result in hospitalization or death\nSerious AEs regardless of causality, defined by the U.S. Food and Drug Administration (FDA) as:\nDeath\nLife-threatening AE\nInpatient hospitalization or prolongation of existing hospitalization\nPersistent or significant incapacity or substantial disruption of the ability to conduct normal life functions\nCongenital anomaly\/birth defect\nAn important medical event that, based on appropriate medical judgement, may jeopardize the individual and\nmay require medical or surgical intervention to prevent one of the outcomes listed above.","4975":"New booster recommendation for people ages 12 years and older to receive 1 bivalent mRNA booster after\ncompletion of a monovalent primary series; it replaces all prior booster recommendations for this age group\nRecommendations for use of a bivalent Moderna booster dose in people ages 18 years and older\nRecommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 12 years and older\nUpdated guidance for observation periods following COVID-19 vaccination\nUpdated guidance on COVID-19 vaccination and multisystem inflammatory syndrome (MIS) in children (MIS-C) and in\nadults (MIS-A)\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adolescents ages 12\u201317 years\nReorganization of Janssen COVID-19 Vaccine guidance into an appendix\nUpdated guidance on COVID-19 vaccination following exposure to SARS-CoV-2\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nPrevious Updates\n\uf1aa\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nUpdated guidance on COVID-19 vaccination and myocarditis and pericarditis\nNew clinical considerations for coadministration of mRNA COVID-19 vaccines and orthopoxvirus vaccines\nNew guidance for use of Moderna COVID-19 Vaccine in children and adolescents ages 6\u201317 years\nNew guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children ages 6 months\u20134 years\nNew guidance for use of Moderna COVID-19 Vaccine in children ages 6 months\u20135 years\nReorganization of sections on COVID-19 vaccination recommendations and schedules\nAddition of new section in Special populations for infants and young children\nNew guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5\u201311 years\nUpdated guidance that the following people should receive a second COVID-19 booster dose:\nPeople ages 12 years and older who are moderately or severely immunocompromised\nPeople ages 50 years and older\nUpdated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-\ndepleting therapies\nClarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults\n(MIS-A)\nUpdated guidance for primary series vaccination after SARS-CoV-2 infection\nAdded considerations for the option to receive a second COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 vaccination after SARS-CoV-2 infection\nAdded guidance that people ages 12 years and older who are moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that people ages 18\u201349 years who are not moderately or severely immunocompromised and who\nreceived Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster\ndose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose\nFurther clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C)\nand adults (MIS-A) and myocarditis\nUpdated information on the availability of Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL\ndosage volume) and Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL dosage volume) for\nadministration of a 50 \u00b5g booster dose.","3407":"Evaluation of people who develop MIS-C or MIS-A after COVID-19 vaccination\nIn the rare instance a person develops MIS-C, MIS-A, or a similar clinical illness after receipt of COVID-19 vaccine, referral to a\nspecialist in infectious diseases, rheumatology, and\/or cardiology should be considered. Assessment should include testing for current or prior SARS-CoV-2 infection, in addition to other potential etiologies as\nclinically indicated. Obtaining a serum sample before any intravenous immune globulin (IVIG) is administered is highly\nrecommended so that the sample can be tested for SARS-CoV-2 anti-nucleocapsid antibody, which may require a reference\nlaboratory. Treatment should not be delayed until test results are available.","2361":"People Who Were Vaccinated Outside of the United States\nPeople who are moderately or severely immunocompromised and who received COVID-19 vaccines not available in the\nUnited States should either complete or restart the recommended COVID-19 vaccine series, including a booster, in the United\nStates. For more information, talk to your healthcare provider, or see the COVID-19 Interim Clinical Considerations.","7917":"Although some side effects from COVID-19 vaccines are normal and expected,1 concern about adverse events and long-term\neffects from the vaccine keep many from seeking COVID-19 vaccination.2,3 On May 5, 2022, the FDA limited the authorized\nuse of the Janssen COVID-19 Vaccine to individuals ages 18 years and older for whom other authorized or approved COVID-19\nvaccines are not accessible or clinically appropriate, and to individuals ages 18 years and older who elect to receive the Janssen\nCOVID-19 vaccine because they would otherwise not receive a COVID-19 vaccine.4 This decision spurred online conversations\ndiscussing the perceived lack of effectiveness of all COVID-19 vaccines, further discouraging vaccine uptake.5,6,7\nPerceptions, Concerns, and Threats to Vaccine Confidence\n\u0083 Hepatitis.","1103":"Additionally, you should\nundergo testing and seek medical attention if you develop symptoms of COVID-19, and start treatment for COVID-19 as\nappropriate. Talk to your healthcare provider to determine if EVUSHELD is right for you. \uf19c Treatment Locator\nClick the button below or call 1-800-232-0233 (TTY 1-888-720-7489) to find a location that offers testing and\ntreatment or a pharmacy where you can fill your prescription. View Locations\nTo find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. TM \uf209\nTM\nTM TM\nTM\nTM\nThe right medications for COVID-19 can help.","8781":"Cloth masks should be washed at least once a day or as soon as\nthey become wet or dirty. You can either wash and dry your\nmasks by hand or use a washer and dryer. 2. Wash or sanitize your hands after removing any mask. Taking off your mask while you eat or drink\nIf you are taking off your mask to eat or drink outside of your home, you can place it somewhere safe to keep it clean, such as\nyour pocket, purse, or paper bag. After eating, put the mask back on with the same side facing out.","4852":"Diluent (Pfizer-BioNTech\nthat should not be mixed\nwith diluent, i.e., gray\ncap)\nVaccine is mixed with any diluent (i.e.,\nany type or volume of diluent)\nContact the manufacturer for information on the stability of the\nvaccine. If the manufacturer does not have information to support the\nstability of the vaccine, repeat the dose immediately (no minimum\ninterval). Do not administer the second dose until the person becomes eligible to receive vaccination (either by reaching the authorized age or if the\nauthorization is extended to include additional age groups), even if this results in the second dose being administered after the recommended\ninterval between doses.","4414":"10\/30\/22, 9:39 AM How to Protect Yourself and Others | CDC\nEspa\u00f1ol | Other Languages\nHow to Protect Yourself and Others\nCOVID-19 Prevention Actions\nThere are many ways your actions can help protect you, your household, and your community from severe illness from\nCOVID-19. CDC\u2019s COVID-19 Community Levels provide information about the amount of severe illness in the community\nwhere you are located to help you decide when to take action to protect yourself and others. COVID-19 County Check\nFind community levels and prevention steps by county. Data updated weekly.","4018":"Vaccination data reported on the CDC COVID Data Tracker might differ from data reported by jurisdictions for a\nnumber of reasons. For example:\nData quality: CDC receives administration data across multiple jurisdictions with different reporting practices. To\nreduce potential duplication across systems, CDC reconciles these data prior to reporting. Data completeness: Jurisdictions may have more complete and updated data for certain data elements (e.g.,\ncounty of residence) that allow them to characterize their population more fully than the CDC. Thus, vaccination\ncoverage reported on the CDC COVID Data Tracker may appear artificially low due to systematic missing data\nreported to CDC.","1577":"6\/23\/22 Update (replaces 6\/18\/22 update; and revised to be a consolidated update that addresses all\nprimary series pediatric COVID-19 vaccination; 6\/23\/22 update also adds availability of age-appropriate\nModerna COVID-19 Vaccine for 6 years through 17 years of age):\nCOVID-19 Vaccination of Children 6 Months through 17 Years of Age\nPursuant to CDC\/ACIP recommendations and Secretarial Directives:\nAll authorized providers in the CDC COVID-19 Vaccination Program shall make immediately available and administer\nupon request \u2013\na two-dose series using the age-appropriate Moderna COVID-19 Vaccine product for children ages 6 months\nthrough 17 years\na three-dose series using the age-appropriate Pfizer-BioNTech COVID-19 Vaccine product for children ages 6\nmonths through 4 years\na two-dose series using the age-appropriate Pfizer-BioNTech COVID-19 Vaccine product for children ages 5 years\nthrough 17 years\n6\/23\/22 Update (replaces 6\/18\/22, 1\/6\/22, 9\/14\/21 and 10\/7\/21 updates; additional eligible group noted\nin bold italics; Updated on 10\/12\/22 to remove reference to the purple cap Pfizer-BioNTech vials which\nare no longer available):\nThird Dose for Recipients of Pfizer-BioNTech or Moderna COVID-19 Vaccine Who Are Immunocompromised\nPursuant to CDC\/ACIP recommendations and Secretarial Directives, a third primary dose of an mRNA COVID-19\nvaccine should be administered using the same mRNA COVID-19 vaccine as was administered for the 2-dose primary\nseries to persons who are moderately to severely immunocompromised at least 28 days after completing the two-\ndose primary series:\nPfizer-BioNTech COVID-19 Vaccine \u2013\nOrange cap to children 5 through 11 years of age\nGray cap to people 12 years and older\nModerna COVID-19 Vaccine \u2013\nDark blue cap\/magenta border to children 6 months through 5 years of age\nDark blue cap\/purple border to children 6 years through 11 years of age\nRed cap\/light blue border to people 12 years and older\nCOVID-19 Vaccination Under the CDC Interim Clinical Considerations and Emergency Use Instructions\nProviders may also administer COVID-19 vaccines as described in CDC guidance as updated from time to time:\nInterim Clinical Considerations for Use of COVID-19 Vaccines in the United States\nEmergency Use Instructions (see vaccine Fact Sheets)\n5\/23\/22 Update (revision of 5\/19\/22 update to add reference to the May 23, 2022, Secretarial Directive;\n9\/1\/22 revision noted in bold italics to clarify that booster doses available to this age group are\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\n9\/1\/22 revision noted in bold italics to clarify that booster doses available to this age group are\nmonovalent):\nCOVID-19 Vaccine Booster Doses for Children 5 through 11 Years of Age\nPursuant to CDC\/ACIP recommendations and the May 23, 2022, Secretarial Directive on Pediatric and Second COVID-\n19 Vaccine Booster Doses, all providers in the CDC COVID-19 Vaccination Program shall make immediately available\nand administer a single monovalent booster dose of Pfizer-BioNTech COVID-19 vaccine to individuals seeking such a\ndose as follows:\nChildren ages 5 through 11 years should receive a single monovalent Pfizer-BioNTech COVID-19 vaccine booster\ndose at least 5 months after completion of a Pfizer-BioNTech COVID-19 vaccine primary series.","1863":"National Protocol\nOutcome: Household transmission among community members confirmed with SARS-CoV-2\nPopulation: Households of community members with positive SARS-CoV-2 tests recruited from national commercial\nlaboratories\nExternal partner: Westat\n\uf209 \uf20c\nTest-negative prospective case control\n\uf1aa\nIncreasing Community Access to Testing (ICATT) program\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Anyone seeking testing at a pharmacy\nParticipating sites: 8,319 locations across the United States and its territories\nIVY\nInfluenza and Other Viruses in the Acutely Ill (IVY) network\nOutcome: Hospitalization with SARS-CoV-2\nPopulation: Hospitalized adults\nParticipating Sites: 21 large adult hospitals in 20 cities in 18 states:\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nCalifornia\nColorado\nFlorida\nGeorgia\nIowa\nMaryland\nMassachusetts\nMichigan\nMinnesota\nMissouri\nNew York\nNorth Carolina\nOhio\nOregon\nTennessee\nTexas\nUtah\nWashington\nPReventing Emerging Infections through Vaccine EffectiveNess Testing (PREVENT ) Sites\nOutcome: Symptomatic SARS-CoV-2 infections\nPopulation: Healthcare personnel\nParticipating Sites\nBaystate Medical Center, Springfield, MA\nJackson Memorial Hospital, Miami, FL\nOlive View-UCLA Medical Center, Los Angeles, CA\nThomas Jefferson University Hospital, Philadelphia, PA\nTruman Medical Centers, Kansas City, MO\nUniversity of Alabama Hospital, Birmingham, AL\nCommunity Regional Medical Center\/ UCSF, Fresno, CA\nUniversity of Chicago Medical Center, Chicago, IL\nUniversity of Iowa Hospitals and Clinics, Iowa City, IA\nUniversity of Massachusetts Memorial Medical Center, Worcester, MA\nLCMC Health Hospitals, New Orleans, LA\nUniversity of Mississippi Medical Center, Jackson, MS\nUniversity of Texas Southwestern Medical Center and Parkland Hospital, Dallas, TX\nUniversity of Washington Hospitals, Seattle, WA\nValleywise Health Medical Center, Phoenix, AZ.","7793":"10\/30\/22, 9:38 AM Self-Testing At Home or Anywhere | CDC\nEspa\u00f1ol | Other Languages\nSelf-Testing At Home or Anywhere\nFor doing rapid COVID-19 tests anywhere\nCDC is reviewing this page to align with updated guidance. \uf6df What is a Self-Test or At-Home Test? Self-tests for COVID-19 give rapid results and can be taken anywhere, regardless of your vaccination status or\nwhether or not you have symptoms. They detect current infection and are sometimes also called \u201chome tests,\u201d \u201cat-home tests,\u201d or \u201cover-the-\ncounter (OTC) tests.\u201d\nThey give your result in a few minutes and are different from laboratory-based tests that may take days\nto return your result.","1879":"Emerging Infection Program Sites\n\uf209 \uf20c\nFLU-VE Network\nUS Influenza Vaccine Effectiveness Network Protocol for Influenza and Other Respiratory Viruses (including COVID-\nOutcome: Symptomatic infection with SARS-CoV-2\nPopulation: Outpatient adults and children \u22656 months of age\nParticipating Sites\nGroup Health Cooperative, Seattle, WA\nMarshfield Clinic Research Institute, Marshfield, WI\nUniversity of Michigan, Ann Arbor, MI\nHenry Ford Health Systems, Detroit, MI\n\uf20c\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nUniversity of Pittsburgh Medical Center, Pittsburgh, PA\nScott & White Healthcare, Temple, TX\nVISION\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections, emergency department\/urgent care visits with\nPopulation: Individuals of all ages who have an emergency department or urgent care visit or hospitalization within\nthe facility network\nParticipating Sites\nBaylor Scott and White Health (Texas)\nColumbia University (New York)\nHealthPartners (Minnesota and Wisconsin)\nIntermountain Healthcare (Utah)\nKaiser Permanente Northern California (California)\nKaiser Permanente Northwest (Oregon and Washington)\nRegenstrief Institute (Indiana)\nUniversity of Colorado (Colorado)\nOvercoming COVID-19 to track and characterize development of complications in children and young adults exposed\nOutcome: Hospitalization with SARS-CoV-2\nPopulation: Hospitalized children and adolescents aged 18 years and younger\nParticipating Sites: Sites can be found here .","3946":"CDC established the COVID-19 Response Health Equity Strategy: Accelerating Progress Towards Reducing COVID-19\nDisparities and Achieving Health Equity [86KB, 5 pages] and provides additional resources to advance the vision of all\npeople having the opportunity to attain the highest level of health possible. \uf20c\n\uf20c\nLast Updated Oct. 19, 2022","617":"June 2, 2022: California made updates to data previously submitted to CDC that resulted in a net increase of 37,678\nadministration records. May 25, 2022: North Dakota made updates to data previously submitted to CDC that resulted in a increase of 64\ndoses administered. May 20, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 139,447\ndoses administered. May 13, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 31,945 doses\nadministered.","4518":"Put on the N95\n\uf1b0\f10\/30\/22, 9:40 AM How to Use Your N95 Respirator | CDC\nHold the N95 in your hand with the nose piece bar (or\nfoam) at your fingertips. If yours does not have a nose\npiece, use the text written on it to be sure the top end is\nat your fingertips. Place the N95 under your chin with the nose piece bar at\nthe top. Pull the top strap over your head, placing it near the\ncrown. Then, pull the bottom strap over and place it at\nthe back of your neck, below your ears. Do not\ncrisscross the straps.","5058":"New information on the occurrence of myocarditis or pericarditis following vaccination with mRNA COVID-19 vaccines\nadded to patient counseling. Information on cases of myocarditis and pericarditis occurring after mRNA COVID-19 vaccination, particularly in\nadolescents and young adults. Information on the efficacy of the Pfizer-BioNTech COVID-19 Vaccine in adolescents aged 12\u201315 years in patient\ncounseling section. Updated data on local and systemic symptoms following vaccination with mRNA COVID-19 vaccines in patient\ncounseling section.","4844":"Children ages 5\u201317 years who receive a mixed mRNA COVID-19 vaccine\nprimary series can follow the Pfizer-BioNTech COVID-19 Vaccine\nschedule and receive a booster dose. Diluent (Pfizer-BioNTech\nformulation only [orange\ncap and maroon cap])\nONLY diluent administered (i.e., sterile\n0.9% sodium chloride)\nAdminister the authorized dose immediately (no minimum interval). No diluent, resulting in higher than\nauthorized dose\nDo not repeat dose. Inform the recipient of the potential for local and\nsystemic adverse events. Incorrect diluent type (e.g., sterile water,\nbacteriostatic 0.9% sodium chloride)\nContact the manufacturer for information on the stability of the\nvaccine.","9192":"Throw away used tissues in a lined trash can\n\u2022\f10\/30\/22, 9:41 AM What to Do If You Are Sick | CDC\nThrow away used tissues in a lined trash can. Immediately wash your hands with soap and water for at least 20 seconds. If soap and water are not\navailable, clean your hands with an alcohol-based hand sanitizer that contains at least 60% alcohol. \u2022\n\u2022\n\uf304 Clean your hands often\nWash your hands often with soap and water for at least 20 seconds. This is especially important after\nblowing your nose, coughing, or sneezing; going to the bathroom; and before eating or preparing food.","5624":"Wear masks that meet a standard with\nA proper fit over your nose and mouth to prevent leaks\nMultiple layers of non-woven material\nA nose wire\nDo NOT wear masks that meet a standard\nIf it is hard to breathe while wearing them\nIf they are wet or dirty\nWith other masks or respirators\nAs a replacement for NIOSH-approved respiratory protection when required\nby your job\n\u2022 \uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nRespirators\nWhen choosing a respirator, look at how well it fits and read the manufacturer instructions. These instructions should include\ninformation on how to wear, store, and clean or properly dispose of the respirator.","539":"On February 15, 2021, the COVID-19 Vaccine Tracker was updated to reflect the revised Pfizer-BioNTech emergency use\nauthorization (EUA) to allow the use of a sixth dose, if present in a vial, as authorized by the Food and Drug\nAdministration (FDA)external icon . Pfizer-BioNTech deliveries to a jurisdiction on or after February 15, 2021, will\nreflect this increase to six doses per vial compared to five doses; historical data will not be updated. The change to the\nPfizer-BioNTech dosage increases the number of doses delivered relative to the number of doses administered.","9475":"Individuals 6 years of age and older may receive a booster dose with Moderna COVID-19\nVaccine, Bivalent. Vaccinations may not provide full immunity to COVID-19 in people who are\nimmunocompromised; therefore, you or your child should continue to maintain physical\nprecautions to help prevent COVID-19. Your close contacts should be vaccinated as appropriate. WHAT ABOUT PREGNANCY OR BREASTFEEDING? If you are, or your child is, pregnant or breastfeeding, discuss the options with your healthcare\nprovider. WILL THESE VACCINES GIVE ME OR MY CHILD COVID-19? No. These vaccines do not contain SARS-CoV-2 and cannot give you or your child COVID-19.","5135":"If you travel, wear a high-quality mask or\nrespirator the entire time you are around others\nindoors. Traveling by private vehicle (if possible) can lower\nthe chances of spreading COVID-19 to others. I was exposed to a person with COVID-19 in the\npast 10 days. Follow CDC guidance, including getting tested at\nleast 5 full days after your last exposure. Do not travel on public transportation such as\nairplanes, buses, and trains if you will not be able\nto wear a high-quality mask or respirator when\naround others indoors for the full duration of your\ntrip.","9049":"Omicron causes less severe illness and death in general, according to data\nHowever, a surge in cases may lead to increases in hospitalizations and deaths. Vaccines help prevent severe illness, hospitalizations, and death\nBreakthrough infections in people who are vaccinated are expected. The emergence of the Omicron variant\nfurther emphasizes the importance of vaccination and boosters. Antiviral treatments are effective\f10\/30\/22, 9:36 AM Variants of the Virus | CDC\nVariants Are Expected\nViruses constantly change through mutation and sometimes these mutations result in a new variant of the virus. Some\nvariations allow the virus to spread more easily or make it resistant to treatments or vaccines.","5909":"People who received both 1\nprimary dose and 1 booster dose of the Janssen COVID-19 Vaccine or 1 primary dose of the Janssen\nCOVID-19 Vaccine followed by 1 booster dose of an mRNA COVID-19 vaccine should receive an\nadditional dose with the COVID-19 vaccine by Moderna (100 \u03bcg in 0.5 mL from red-capped multidose\nvial) at least 2 months after the booster dose. \u2022 Revaccination with the COVID-19 vaccine by Moderna for any primary doses received before or during\ntreatment with certain therapies (indicated below) for persons ages 12 years and older.","2498":"For each level, CDC recommends actions you can take to help you protect yourself and others from severe impacts\nof COVID-19. \u2022\n\u2022\n\u2022\n\u2022\nFor Healthcare Facilities: Prevention actions in healthcare facilities, such as hospitals, rehabilitation centers, and\nnursing homes, are not linked to COVID-19 Community Levels. \uf313\nPeople may choose to wear a mask at any time. Masks are recommended in indoor public transportation settings and\nmay be required in other places by local or state authorities. COVID-19 County Check\nFind community levels and prevention steps by county. Data updated weekly.","1118":"Vaccination Clinic Guidance\nOperational Guidance School-Located Vaccination\nClinics\nRetail Pharmacies\nLong-term Care Settings Private and Public Healthcare\nProvider Clinics\nMobile Vaccination\nHospitals, Emergency Curbside\/Drive-Through\f10\/30\/22, 9:20 AM COVID-19 Vaccination Clinical and Professional Resources | CDC\nDepartments, and Urgent Clinics\nSpecific Populations\nInformation about COVID-19 vaccination for specific populations, including\nguidance for healthcare professionals and information for patients.","1560":"Novavax COVID-19 Vaccination of Persons 18 Years of Age and Older\nPursuant to CDC\/ACIP recommendations and the July 21, 2022, Secretarial Directive, as of July 25, 2022, CDC COVID-\n19 Vaccination Program enrolled providers shall:\nIf they have the vaccine in stock, make immediately available and administer upon request a two-dose Novavax\nCOVID-19 Vaccine, Adjuvanted primary series for persons ages 18 years and older. When unable to fulfill a request from an age-eligible person for Novavax COVID-19 Vaccine, Adjuvanted, notify the\nrequesting person that providers having the vaccine can be located through the website\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nhttps:\/\/www.vaccines.gov\/.","5465":"People who experience post-COVID conditions most commonly report:\nGeneral symptoms\nTiredness or fatigue that interferes with daily life\nSymptoms that get worse after physical or mental effort (also known as \u201cpost-exertional malaise\u201d)\nFever\nRespiratory and heart symptoms\nDifficulty breathing or shortness of breath\nCough\nChest pain\nFast-beating or pounding heart (also known as heart palpitations)\nNeurological symptoms\nDifficulty thinking or concentrating (sometimes referred to as \u201cbrain fog\u201d)\nHeadache\nSleep problems\nDizziness when you stand up (lightheadedness)\nPins-and-needles feelings\nChange in smell or taste\nDepression or anxiety\nDigestive symptoms\nScience at CDC\nScientific evidence and studies behind long COVID\nScience behind Long COVID\nHow to Get Involved in Long COVID Research\nThe National Institutes of Health (NIH) is conducting a research project, called the RECOVER Initiative, to understand how people recover from a COVID-\n19 infection and why some people do not fully recover and develop long COVID or post-COVID conditions.","2269":"CMS\nposts updated information about individual nursing homes, including resident and staff vaccination rates, on the\nCMS COVID-19 Nursing Home Data . Resident and staff vaccination data from assisted living and other LTC settings may be monitored by your state. \u2022\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:29 AM COVID-19 Vaccines for Long-term Care Residents | CDC\nConsent or assent for a COVID-19 vaccine will be given by LTC residents (or people appointed to make medical decisions\non their behalf called a medical proxy) and documented in their charts per the provider\u2019s standard practice.","3289":"Febrile seizures can occur in infants and young children ages 6 months\u20135 years with any condition that causes a fever (most\ncommon with high fevers), including COVID-19 . Febrile seizures are uncommon after vaccination and were rare in mRNA\nCOVID-19 vaccine clinical trials for infants and young children. In rare instances, administration of certain combination\nvaccines or more than one vaccine at the same clinic visit has been associated with an increased risk of febrile seizures in\ninfants and young children. The impact of coadministration of COVID-19 and routine vaccines on the risk of febrile seizures\nhas not been specifically studied.","9612":"Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nThe COVID-19 vaccine by Pfizer-BioNTech is approved by the FDA as a 2-dose primary series for active\nimmunization to prevent COVID-19 in persons ages 12 years and older. CDC is issuing these EUI to provide\ninformation about use of the COVID-19 vaccine by Pfizer-BioNTech for primary and\/or additional doses that\nextend beyond its FDA-approved labeling as described further under \u201cWho can receive the COVID-19 vaccine\nby Pfizer-BioNTech\u201d and \u201cWhat are the doses and intervals of the COVID-19 vaccine by Pfizer-BioNTech for\nprimary and\/or additional doses\u201d. What is COVID-19?","7089":"To reach MotherToBaby:\nChat live or send an email MotherToBaby\n\u2022\n\u2022 \uf209\nReducing Your Risk of Getting COVID-19\nIt is especially important for people who are or were recently pregnant, and those who live\nor visit with them, to take steps to protect themselves and others from getting COVID-19. Limit in-person interactions with people who might have been exposed to COVID-19,\nincluding people within your household, as much as possible. If you or someone in your\nhousehold is sick with COVID-19, follow guidance for isolation. Important Ways to Slow the Spread of COVID-19\nGet vaccinated and stay up to date on your COVID-19 vaccines. Find a\nvaccine.","8036":"On May 17, 2022, the FDA amended the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine, authorizing\na single booster dose for children ages 5-11 years at least five months after completion of a primary series with the same\nvaccine.101 The FDA committee that reviews and evaluates data concerning the safety, effectiveness, and appropriate use of\nvaccines, VRBPAC (Vaccines and Related Biological Products Advisory Committee), meet on June 14\u201315, 2022 to discuss the\nemergency use authorization of COVID-19 vaccines in this age.102 On June 17, 2022, the Advisory Committee on Immunization\nPractices (ACIP) issued interim recommendations for use of the Moderna COVID-19 vaccine in children ages 6 months to 5\nyears and the Pfizer COVID-19 vaccine\nfor use in children ages 6 months to 4\nyears.103 Some parents have expressed\nenthusiasm and relief about childhood\nvaccination.104,105,106 However, a recent\nKaiser Family Foundation (KFF) poll\nfound that only 18% of parents with\nchildren younger than 5 years will get\ntheir child vaccinated right away, while\n38% say they plan to wait and see how\nthe vaccine is working for others, 27%\nsay they will definitely not get their child\nvaccinated, and 11% say they will only do\nso if they are required.107,108\nPerceptions, Concerns, and Threats to Vaccine Confidence\n\u0083 Concerns about side effects, such as myocarditis, may negatively impact vaccine uptake.109,110\n\u0083 Some consumers believe vaccines are unnecessary because COVID-19 rarely affects this group.111,112\n\u0083 Some believe infection-induced immunity protects children better than vaccines.113,114\n\u0083 Some social media users do not think there is enough data to support vaccination against COVID-19 in children.115,116,117\n\u0083 With cases of hepatitis in children rising globally, some believe they are caused by COVID-19 vaccines.118,119,120\n\u0083 Some are concerned that immunity from vaccines decreases rapidly in adolescents.122,123\nCommonly asked questions and queries from the public\n\u0083 Should children under the age of 5 years still wear masks?i\n\u0082 Wearing a well-fitting mask or respirator consistently and correctly reduces the risk of spreading the virus that causes\nCOVID-19.","2182":"Dagan N, Barda N, Biron-Shental T, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat Med. 13. Theiler RN, Wick M, Mehta R, et al. Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy. Am J\n14. Morgan JA, Biggio JR, Martin JK, et al. Maternal Outcomes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-\nCoV-2) Infection in Vaccinated Compared With Unvaccinated Pregnant Patients. Obstetrics & Gynecology: January 2022 \u2013\nVolume 139 \u2013 Issue 1 \u2013 p 107-109. DOI: https:\/\/doi.org\/10.1097\/AOG.0000000000004621\n15. Stock SJ, Carruthers J, Calvert C, et al. SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in\nScotland. Nat Med(2022).","4443":"Increasing air filtration in your heating, ventilation, and air conditioning (HVAC) system, such as by changing filters\nfrequently and using filters that are properly fitted and provide higher filtration. Using portable high-efficiency particulate air (HEPA) cleaners. Turning on exhaust fans and using other fans to improve air flow. Turning your thermostat to the \u201cON\u201d position instead of \u201cAUTO\u201d to ensure your HVAC system provides continuous\nairflow and filtration. CDC\u2019s interactive ventilation tools can help you see how much you can improve ventilation in your home or school.","2432":"Researchers found no significant changes in these sperm\ncharacteristics after vaccination. However, one study found that COVID-19 infection may be associated with a decline in fertility for men for up to\n60 days after infection. Fever from any illness has been associated with a short-term decrease in sperm production in healthy men. Although fever can be a side effect of COVID-19 vaccination, there is no current evidence that fever after COVID-\nvaccination affects sperm production. Fever is also a common symptom of COVID-19 infection. Safety Monitoring\nCOVID-19 vaccines are undergoing the most intense safety monitoring in U.S. history.","6405":"Examples of medical conditions or treatments that may result in moderate to severe immunocompromise include but are not\nlimited to:\nActive treatment for solid tumor and hematologic malignancies\nHematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status\n(e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\nReceipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\nReceipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of\ntransplantation or taking immunosuppressive therapy)\nModerate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined\nimmunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)\nAdvanced or untreated HIV infection (people with HIV and CD4 cell counts less than 200\/mm3, history of an AIDS-\ndefining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)\nActive treatment with high-dose corticosteroids (i.e., 20 or more mg of prednisone or equivalent per day when\nadministered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs,\ncancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and\nother biologic agents that are immunosuppressive or immunomodulatory\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nHow to Protect Yourself\f10\/30\/22, 9:38 AM People Who Are Immunocompromised | CDC\nYou are up to date with your COVID-19 vaccines when you have received all doses in the primary series and all boosters\nrecommended for you, when eligible.","8889":"10\/30\/22, 9:21 AM Vaccinating Dialysis Patients and Healthcare Personnel | CDC\nVaccines & Immunizations\nVaccines & Immunizations\nVaccinating Dialysis Patients and Healthcare Personnel\nTake action to protect patients at high-risk in your jurisdiction\nCOVID-19 vaccines are effective at protecting people from getting sick. By allocating vaccines for outpatient dialysis patients\nand the healthcare personnel who care for them in your jurisdiction, you can protect patients who are at high risk,\ndisproportionately affected by COVID-19, or might suffer severe consequences if infected. How can jurisdictions support COVID-19 vaccination efforts for\ndialysis patients and healthcare personnel? Make sure you are aware of the dialysis clinics located in your jurisdiction.","8893":"Reach out to dialysis clinics where you do not have an established contact. Some of your local dialysis centers might be\noperated by corporate chains. For these centers, jurisdictions can opt to coordinate with national or regional corporate\nleaders to reach their respective clinic sites. Work collaboratively with dialysis clinics to understand their needs, priorities, and barriers to vaccination among patients\nand healthcare personnel. Make sure each dialysis clinic in your jurisdiction is enrolled as a COVID-19 vaccination provider.","4213":"People who have had a known COVID-19 exposure should not seek vaccination until their\u202fquarantine period\u202fhas ended to\navoid potentially exposing healthcare personnel and others during the vaccination visit. This recommendation to wait\nalso applies to people with a known COVID-19 exposure who have received their first dose and need additional or\nbooster doses. Learn more about how to stay up to date with your COVID-19 vaccines. Yes, depending on your age, for your primary series you can choose which type of COVID-19 vaccine to get.","5594":"Gaps can be caused by choosing the wrong size or type of mask and when a mask is worn with facial hair. It is important to check that it fits snugly over your nose, mouth, and chin. Check for gaps by cupping your hands around the outside edges of the mask. Make sure no air is flowing from the area near your eyes or from the sides of the mask.","8583":"Each type of vaccine prompts our bodies to recognize and help protect us from\nthe virus that causes COVID-19. None of these vaccines can give you COVID-19. Vaccines do not use any live virus\f10\/30\/22, 9:34 AM Understanding How COVID-19 Vaccines Work | CDC\nmRNA vaccines (Pfizer-BioNTech or Moderna)\nTo trigger an immune response, many vaccines put a weakened or inactivated germ into our bodies. Not mRNA vaccines. Instead, mRNA vaccines use mRNA created in a laboratory to teach our cells how to make a protein\u2014or even just a piece of a\nprotein\u2014that triggers an immune response inside our bodies.","5574":"Choosing a Mask or Respirator for Different Situations\nMasks and respirators (i.e., specialized filtering masks such as \u201cN95s\u201d) can provide different levels of protection depending on\nthe type of mask and how they are used. Loosely woven cloth products provide the least protection, layered finely woven\nproducts offer more protection, well-fitting disposable surgical masks and KN95s offer even more protection, and well-fitting\nNIOSH-approved respirators (including N95s) offer the highest level of protection.","4073":"Does the definition of \u201cup to date\u201d include boosters? \uf1aa\nPeople (except those who are moderately or severely immunocompromised) who first received a J&J\/Janssen COVID-19\nvaccine and got it again for their booster may also receive a booster of an mRNA COVID-19 vaccine (Pfizer-BioNTech or\nModerna). Get the mRNA booster at least 4 months after the most recent J&J\/Janssen booster. One CDC study found that adults who received the J&J\/Janssen COVID-19 vaccine as both their primary and\nbooster had lower levels of protection against COVID-19-associated emergency department and urgent care visits\nduring Omicron compared to adults who received an mRNA COVID-19 booster.","3415":"Administration of subsequent COVID-19 vaccine doses: Onset of MIS 90 days or more after most recent\nCOVID-19 vaccine dose\nAdministration of subsequent COVID-19 vaccine dose(s) should be considered for those who meet the two criteria listed\nbelow:\n1. Clinical recovery has been achieved, including return to baseline cardiac function; and\n2. It has been at least 90 days after the diagnosis of MIS-C\/A\nFor people who had MIS-C\/A but do not meet both criteria above, see Consultation for decisions about COVID-19 vaccination.","1331":"\uf1aa\f10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\nPeople who are not moderately or severely immunocompromised\nPeople who are moderately or severely immunocompromised\nNo, the bivalent mRNA vaccines (i.e., Moderna and Pfizer-BioNTech) are not currently authorized to be used for the\nprimary series; they may only be used for the booster dose. If a bivalent Pfizer-BioNTech vaccine is administered for a primary series dose: Do not repeat the dose. The primary and\nbooster dosages are the same; the bivalent dose can be counted as a primary series dose.","39":"10\/30\/22, 9:31 AM Allergic Reactions after COVID-19 Vaccination | CDC\nEspa\u00f1ol | Other Languages\nAllergic Reactions after COVID-19 Vaccination\nIf You Are Having a Severe Allergic Reaction to a COVID-19\nVaccine\nSevere allergic reactions to vaccines are rare but can happen. If you get a COVID-19 vaccine and you think you might be\nhaving a severe allergic reaction after leaving the vaccination provider site, seek immediate medical care by calling 911. A severe allergic reaction can cause:\ndifficulty breathing or wheezing,\na drop in blood pressure,\nswelling of the tongue or throat, or\na generalized rash or hives, which may include mucus membranes.","1144":"Vaccine Distribution Data Systems\nVaccine Tracking System (VTrckS) is CDC\u2019s vaccine order management system where jurisdictions (states,\nterritories, tribes, and local entities), federal agencies, and pharmacy partners order vaccines from the federal\ngovernment. VTrckS Provider Order Portal (VPOP) is CDC\u2019s platform where federal entity providers report their on-hand\nCOVID-19 vaccine inventory each day. Immunization Data Lake (IZ Data Lake) is a cloud-hosted data repository to receive, store, manage, and analyze\ndeidentified COVID-19 vaccination data. \u2022\n\u2022 \uf209\n\u2022\nVaccine Administration Data Systems\nImmunization Information Systems (IISs)\u202fMost IISs create\u202fa centralized\u202fdata repository for storing\nvaccination\u202finformation specific to that jurisdiction.","598":"July 7, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 64,066\nadministered doses. June 30, 2022: A federal entity made updates to data previously submitted to CDC that resulted in a net increase of\n732,308 administered doses. June 30, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 27,319\nadministered doses. June 23, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 21,371\nadministered doses.","7112":"You should also talk to your healthcare professional if you think you are experiencing depression during or after\npregnancy. Get recommended vaccines during pregnancy. These vaccines can help protect you and your baby. Get a flu vaccine every year. Others living in your household should also get vaccinated to protect themselves and\nyou. Get the Tdap vaccine to protect your baby against whooping cough, which can have similar symptoms to COVID-19. CDC recommends all pregnant people receive a Tdap vaccine during each pregnancy. In addition, everyone who is\naround the baby should be up to date with their whooping cough vaccine.","3909":"Immunocompromised or a Weakened Immune System\nHaving a weakened immune system, also known as being\nimmunocompromised, can make you more likely to get very sick if\nyou get COVID-19. People who are immunocompromised, or who are\ntaking medicines that weaken their immune system, may not be\nprotected as well as others, even if they are up to date on their\nvaccines. EVUSHELD\u2122 is a medicine given by a healthcare provider\nevery 6 months to help prevent COVID-19 before you are exposed or\ntest positive for COVID-19. EVUSHELD\u2122 remains protective, but may\noffer less protection against certain strains of the Omicron variant.","2443":"Fever in pregnancy may be treated with\nacetaminophen as needed, in moderation, and in consultation with a healthcare provider. It is not recommended you take\nthese medicines before vaccination to try to prevent side effects. Learn about other ways to relieve side effects. \u2022 \uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\uf209\n- \uf209\n\u2022 \uf209 18\nLearn more about getting your COVID-19 vaccine. References\n1.","2061":"\u2022\n-\n-\n-\n\u2022\n-\n-\nPeople who are Pregnant\nAlthough the overall risks are low, if you are pregnant or were recently\npregnant, you are\nMore likely to get very sick from COVID-19 compared to people who\nare not pregnant. People who get very sick from COVID-19 may\nrequire hospitalization, admission to an intensive care unit (ICU), or\nuse of a ventilator or special equipment to breathe. Severe COVID-19\nillness can also lead to death. At increased risk of complications that can affect your pregnancy and\ndeveloping baby. For example, COVID-19 during pregnancy increases\nthe risk of delivering a preterm or stillborn infant.","8664":"Initially, they determined that COVID-19 vaccines met FDA\u2019s safety and effectiveness\nstandards and granted those vaccines Emergency Use Authorizations (EUAs) . The EUAs allowed the\nvaccines to be quickly distributed for use while maintaining the same high safety standards required for\nall vaccines. Learn more in this video about EUAs. FDA has granted full approval for some COVID-19 vaccines. Before granting approval, FDA reviewed\nevidence that built on the data and information submitted to support the EUA.","5729":"The COVID-19\nvaccine by Pfizer-BioNTech can also be used under EUI for similar uses as an alternative mRNA COVID-19\nvaccine (see the Pfizer-BioNTech EUI Fact Sheet for Recipients), and the same or similar recommendations\nin this EUI also apply to the use of the COVID-19 vaccine by Pfizer-BioNTech under EUI. What is COVID-19? Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a coronavirus called SARS-CoV-2. It\nis predominantly a respiratory illness that can also affect other organs. People with SARS-CoV-2 infection\nhave reported a wide range of symptoms, from no symptoms to severe illness leading to death.","7515":"I have recovered from COVID-19 and have received one dose of an accepted COVID-19 vaccine\ndose, and therefore am considered fully vaccinated in my country, but not under CDC\u2019s Amended\nOrder. Would I be considered fully vaccinated under CDC\u2019s Amended Order if I got a booster dose\nof an accepted COVID-19 vaccine? \uf1aa\nAre different formulations of vaccines considered acceptable proof of vaccination? \uf1aa\f10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nYes, different formulations of COVID-19 vaccines authorized for emergency use or approved by the U.S. Food and Drug\nAdministration\u202for listed for emergency use by WHO are accepted.","6336":"If your healthcare provider\u2019s office policy allows it, consider bringing them to your\nappointment with you. What to Expect\nThe provider you meet with could be a doctor, nurse, nurse practitioner, physician assistant, or other type of healthcare\nprofessional. It may take more than one appointment to evaluate potential post-COVID symptoms and determine an accurate\ndiagnosis to better manage and treat your symptoms. Your provider may ask questions about your medical history, current\nsymptoms, and quality of life. Depending on your symptoms, they may run tests to determine a diagnosis and plan for\ntreatment. -\n-\n-\n-\n\u2022\n\u2022\nHealthcare providers are still learning about post-COVID conditions.","9847":"Benotmane, I., Bruel T., Planas, D., Fafi-Kremer, S., Schwarz, O., Caillard, S. A fourth dose of the mRNA-1273\nSARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients. Buchan SA, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by\nvaccine product, schedule and interval. Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nCDC. Science Brief: SARS-CoV-2 infection-induced and vaccine-induced immunity. 2021. Disanto G, Sacco R, Bernasconi, E. Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing\nWith Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis. JAMA Neurology. 2021;78(12):1529-1531. FDA.","8519":"\uf1aa\nAir passengers are required to provide the following contact information, to the extent that it exists, within 72 hours\nbefore their flight\u2019s departure: full name (as it appears on their passport), address while in the United States, primary\ncontact phone number, secondary or emergency contact phone number, and email address. Passengers must also:\nAcknowledge that the obligation to provide complete and accurate information is a U.S. government requirement and\nthat failure to provide complete and accurate information may result in criminal penalties. Confirm the information they provided is complete and accurate.","5929":"The EUI apply to the FDA-approved formulation of the COVID-19 vaccine by Moderna (supplied in a red-capped\nmultidose vial containing 5.5 or 7.5 mL of vaccine). The formulation supplied in a red-capped multidose vial is\nthe same formulation that is FDA-authorized under EUA and FDA-licensed under BLA on January 31, 2022. This\nformulation provides primary doses (100 \u03bcg in 0.5 mL) and booster doses (50 \u03bcg in 0.25 mL). FDA has\nexplained that the FDA-approved Spikevax and the EUA-authorized Moderna COVID-19 Vaccine supplied in\nred-capped multidose vials have the same formulation and can be used interchangeably without presenting\nany safety or effectiveness concerns.","7170":"2 When prepared according to their respective instructions for use, the FDA-approved COMIRNATY\n(COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine for individuals\n12 years of age and older can be used interchangeably without presenting any safety or effectiveness\nconcerns. The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to\nprovide:\n\uf0b7 a 2-dose primary series to individuals 12 years of age and older; and\n\uf0b7 a third primary series dose to individuals 12 years of age and older with\ncertain kinds of immunocompromise.","1960":"CDC Vaccine Safety Datalink (VSD)\u2014 A network of nine integrated healthcare organizations across the United States that\nconducts active surveillance and research using electronic health records; the system is also used to help determine\nwhether possible side effects identified using VAERS are actually related to vaccination. CDC Clinical Immunization Safety Assessment (CISA) Project\u2014 A collaboration between CDC and seven medical research\ncenters to provide expert consultation on individual cases, assist with vaccine safety surveillance, and conduct clinical\nresearch studies about vaccine safety. FDA and the Centers for Medicare and Medicaid Services \u2014 A claims-based system for active surveillance and\nresearch.","387":"On October 24, 2021, CDC identified and corrected a processing error for percent of fully vaccinated people in 50+ years\nof age with a booster dose. This error resulted in a higher percentage of people reported with a booster dose in the age\ngroup of 50+ for October 22 and 23, 2021. On October 22, 2021: County-level graphics include Texas vaccination data. Texas and CDC collaborated to update how\nTexas submits aggregate vaccination data to enhance the information provided on CDC COVID Data Tracker.","4460":"Free tests are also available through local health departments. If you have Medicare Part B, including those enrolled in a Medicare Advantage plan, Medicare will cover up to 8\nfree self-tests each calendar month from participating pharmacies and providers. Private health insurance may\nalso reimburse the cost of purchasing self-tests. Visit FDA\u2019s website for a list of authorized tests. Call your healthcare provider, visit a community testing site , or call your local health department for more\noptions.","8985":"If you choose\nnot to give your permission for CDC to access medical records, you can still participate in the registry. \uf209\f10\/30\/22, 9:32 AM Vaccine Pregnancy Registry | CDC\nParticipation Is Voluntary\nParticipants are not paid for their participation in the registry, and not all people reporting pregnancy will be contacted to\nparticipate. Participation is completely voluntary, and you can opt out at any time. However, in general, many people feel\ngood about participating in activities to help answer critical scientific questions, which can help inform recommendations for\nthe public. Registry Data Collection and Use\nWho Is Participating in the Registry\nCDC is currently enrolling eligible participants.","5645":"Do NOT wear international respirators\nIf they have exhalation valves, vents, or other openings\nIf it is hard to breathe while wearing them\nIf they are wet or dirty\nWith other masks or respirators\nAs a replacement for NIOSH-approved respiratory protection when required by your job\nst\nPoor quality KN95 respirators\nAbout 60% of KN95 respirators NIOSH evaluated during the COVID-19 pandemic in 2020 and 2021 did not meet\nthe requirements that they intended to meet. Using a poor-quality product may not provide the level of protection indicated. Learn about factors to consider when purchasing an international respirator. This webpage and a webinar provide\nreliable information to guide you.","9414":"In clinical trials, approximately 30,000 individuals 12\nyears of age and older, 4,000 individuals 6 years through 11 years of age, and 5,000 individuals 6\nmonths through 5 years of age have received at least 1 dose of Moderna COVID-19 Vaccine. In a clinical trial, approximately 400 individuals 18 years of age and older received 1 dose of a\nbivalent vaccine that differs from the Moderna COVID-19 Vaccine, Bivalent in that it contains a\ndifferent Omicron component. WHAT ARE THE BENEFITS OF THESE VACCINES? SPIKEVAX (COVID-19 Vaccine, mRNA) and Moderna COVID-19 Vaccine have been shown\nto prevent COVID-19.","3313":"In age groups where product comparisons can be made (i.e., 18\u201339 years), some evidence suggests that the risk of\nmyocarditis and pericarditis may be higher following vaccination with Moderna COVID-19 Vaccine relative to Pfizer-BioNTech\nCOVID-19 Vaccine; however, findings are not consistent in all U.S. monitoring systems. In post-authorization surveillance , cases of myocarditis and pericarditis among children ages 5\u201311 years after Pfizer-\nBioNTech COVID-19 vaccination have been rarely reported, primarily in males and after dose 2; the reporting rate of\nmyocarditis in VAERS following dose 2 of Pfizer-BioNTech marginally exceeded the background incidence rate for male\nchildren in this age group.","824":"Additionally, their immune response to COVID-19 vaccination may not be\nas strong as in people who are not immunocompromised. People who are moderately or severely immunocompromised have\nspecific recommendations for COVID-19 vaccines, including boosters. COVID-19 vaccines were first authorized for emergency use in the U.S. in December 2020. Studies following the use of the\nvaccines showed approximately 90% protection against symptomatic infection, severe illness, and death. By July 2021, we saw\ndecreased vaccine effectiveness against infection as new variants emerged, and CDC put forward recommendations to\ncontinue masking, even for people who had received a primary series.","9282":"Some examples of\nconditions that can make children more likely to get severe COVID-19 include:\nAsthma or chronic lung disease\nDiabetes\nObesity\nSickle cell disease\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:34 AM Why Children and Teens Should Get Vaccinated Against COVID-19 | CDC\nHowever, those without underlying medical conditions can also experience severe illness and be hospitalized. In fact,\napproximately 1 in 3 children younger than 18 years old hospitalized with COVID-19 have no underlying conditions. Read the data about risk factors for severe COVID-19 in children published in Pediatrics, childhood COVID-19-related\nhospitalizations published in MMWR, and weekly summaries of COVID-19 hospitalization data through COVID-NET.","6023":"A longer interval between the first and second dose of mRNA vaccines may improve safety, especially for\nyoung men. \u2022 In an unpublished (preprint) retrospective population-based cohort using Canada\u2019s provincial vaccine\nregistry and passive vaccine safety surveillance between December 2020 and September 2021,\nreported rates of myocarditis\/pericarditis among all persons were greater with shorter intervals (3\u20134\nweeks) between dose 1 and dose 2 compared to extended intervals (\u22658 weeks) for both Moderna\n(Buchan, preprint).","9984":"Although they can receive the same product,\na different COVID-19 vaccine product can also be administered. Providers should consider observing these patients for 30\nminutes after vaccination\nPeople with a contraindication to one type of COVID-19 vaccine\n(e.g., mRNA) should not receive any doses of that type of vaccine\nand have a precaution to the other types of vaccine\u2020. For COVID-19 vaccine components see:\nPotential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects following\nIn patients who experience post-vaccination symptoms, determining the etiology (including allergic reaction, vasovagal reaction, or\nvaccine side effects) is important to determine whether a person can receive additional doses of the vaccine.","669":"February 11, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n14,616 doses administered\nFebruary 9, 2022: Utah made updates to data previously submitted to CDC that resulted in an increase of 73,002\ndoses administered. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nFebruary 4, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 75,630\ndoses administered. February 4, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n32,976 doses administered.","8019":"Identified misinformation themes that may impact vaccine confidence\n\u0083 Some consumers believe that natural immunity is superior to vaccine-induced immunity despite the health risks associated\nwith getting SARS-CoV-2.96\n\u0083 Some social media users state that the efficacy of the Pfizer vaccine is only between 1 and 12 percent at preventing illness97\nwhile leaving out the additional context that the vaccine-acquired immunity decreases with time, the vaccines are less\neffective against some variants of SARS-CoV-2, and, most importantly, the vaccine provides protection against severe illness.98\n\u0083 Some social media users believe SARS-CoV-2 is the same as influenza.99\n\u0083 Some social media users believe COVID-19 vaccines are causing a surge in the number of COVID-19 cases.100\nWays public health and partners can take action to improve vaccine confidence\n\u0083 Develop and amplify messages explaining why vaccines are still important in the COVID-19 prevention response.","5614":"Procedure Masks\nWear procedure masks with\nA proper fit over your nose, mouth, and chin to prevent leaks\nMultiple layers of non-woven material\nA nose wire\n\u2022\n\u2022\n\u2022\nDo NOT wear procedure masks with\nGaps around the sides of the face or nose (see example)\nWet or dirty material\n\u2022\n\u2022\nWays to have better fit and extra protection with cloth and disposable masks\nWear two masks (disposable mask underneath AND cloth mask on top)\nCombine either a cloth mask or disposable mask with a fitter or brace\nKnot and tuck ear loops of a 3-ply mask where they join the edge of the\nmask\nFor disposable procedure masks, fold and tuck the unneeded\nmaterial under the edges.","3263":"For information on contraindications and precautions to Janssen COVID-19 vaccination, see Appendix A.\nHealthcare professionals and health departments may request a consultation from the Clinical Immunization Safety\nAssessment COVIDvax project for a complex COVID-19 vaccine safety question not readily addressed by CDC guidance. Adverse events that occur in a recipient following COVID-19 vaccination should be reported to VAERS.","715":"December 16, 2021: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 22,422\ndoses administered. December 9, 2021: Illinois made updates to data previously submitted to CDC that resulted in an increase of 53,344\ndoses administered. December 2, 2021: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 46,380\ndoses administered. November 23, 2021: Pennsylvania made updates to data previously submitted to CDC that resulted in a decrease of\n1,151,719 doses administered. November 18, 2021: Illinois made updates to data previously submitted to CDC that resulted in a decrease of\n214,250 doses administered.","1672":"Where CDC becomes aware of a provider engaging in any of the following, CDC will consider taking any and\nall appropriate measures, including the possibility of rescinding the CDC provider agreement:\nAdministering COVID-19 Vaccine at any out-of-pocket cost to the recipient\nDenying anyone vaccination, or differentially reducing appointment access, based on the vaccine recipient\u2019s\ncoverage status or network status\nCharging an office visit or other fee if COVID-19 vaccination is the sole medical service provided\nRequiring additional medical services to receive COVID-19 vaccination\nSeeking any reimbursement, including through balance billing, from the vaccine recipient\nACIP Recommendations (9\/7\/2021)\nThe Advisory Committee on Immunization Practices (ACIP) comprises 15 medical and public health experts who develop\nevidence-based recommendations for use of vaccines in the United States.","671":"February 3, 2022: Alaska made updates to data previously submitted to CDC that resulted in a decrease of 3,945\ndoses administered. January 28, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n26,796 doses administered. January 28, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 14,973\ndoses administered.","2098":"Recent data show that completing a two-dose primary mRNA COVID-19 vaccine series during pregnancy can help\nprotect babies younger than age 6 months from hospitalization due to COVID-19. In these reports, the majority of\nbabies hospitalized with COVID-19 were born to pregnant people who were not vaccinated during pregnancy. Another study found that receiving a booster dose with an mRNA COVID-19 vaccine during pregnancy significantly\nincreased the levels of antibodies found in umbilical cord blood. This means that getting a COVID-19 booster during\npregnancy can help further protect babies against COVID-19. No safety concerns were found in animal studies.","4857":"In addition to the minimum age, some experts suggest delaying the second dose for 8 weeks after the invalid dose\nbased on the potential for increased reactogenicity and the rare risk of myocarditis and pericarditis from mRNA COVID-19 vaccine. If the administration error resulted in a higher-than-authorized vaccine dose, in general a subsequent dose may still be administered at the\nrecommended interval.","5240":"Do not go places where you are unable to wear a mask. For travel guidance, see CDC\u2019s Travel webpage. Do not travel. Stay home and separate from others as much as possible. Use a separate bathroom, if possible. Take steps to improve ventilation at home, if possible. Don\u2019t share personal household items, like cups, towels, and utensils. Monitor your symptoms. If you have an emergency warning sign (like trouble breathing), seek emergency medical care\nimmediately. Learn more about what to do if you have COVID-19. End isolation based on how serious your COVID-19 symptoms were.","9594":"\u2022 Revaccination of moderately or severely immunocompromised persons ages 12 years and older who\nreceived certain therapies (indicated below) and received primary dose(s) of COVID-19 vaccine prior to\nor during treatment. o\no\nReceived COVID-19 vaccine dose(s) during treatment with B-cell-depleting therapies over a\nlimited period\nReceived COVID-19 vaccine dose(s) prior to or during treatment involving hematopoietic cell\ntransplant (HCT) or chimeric antigen receptor (CAR)-T-cell therapy\nThe COVID-19 vaccine by Moderna under EUI also allow similar uses as an alternative mRNA COVID-19 vaccine\nto Pfizer-BioNTech, and the same or similar recommendations in the EUI also apply to the use of the COVID-19\nvaccine by Moderna under EUI.","4195":"However, staying up to date with your COVID-19\nvaccinations means that you are less likely to have a breakthrough infection and, if you do get sick, you are less likely to\nget severely ill or die. Staying up to date with COVID-19 vaccination also means you are less likely to spread the disease to\nothers and increases your protection against new variants of SARS-CoV-2, the virus that causes COVID-19. Why should I get vaccinated if I might get COVID-19 anyway? \uf1aa\nThere is no recommended waiting period between getting a COVID-19 vaccine and other vaccines.","4028":"Additionally, CDC estimates the number of people receiving at least one dose,\nthe number of people who are fully vaccinated, and the number of people with a booster dose. CDC estimates are\nbased on data reported by jurisdictions that includes a dose number (first, second, booster or additional dose). This may differ from how jurisdictions attribute their doses. Population definition: CDC includes all age groups in the Total Population calculations to provide a better measure\nof community immunity.","2763":"However, there are established ways people can manage the stress associated with a post-COVID condition. Here are some steps you can do to help manage and cope with stress:\nTake breaks from watching, reading, or listening to news stories, including social media. Hearing about the COVID-19\npandemic repeatedly can be upsetting. Take care of your body. Take deep breaths, stretch, meditate , or practice mindfulness . Try to eat healthy, well-balanced meals. Exercise, if you can. Listen to signs from your body. Get plenty of sleep. Avoid alcohol and drugs. Make time to unwind.","4669":"Medical condition or history Guidance Recommended action(s)\nTTS following receipt of a previous Janssen COVID-19 Vaccine (or other\nCOVID-19 vaccines not currently authorized in the United States that\nare based on adenovirus vectors, e.g., AstraZeneca)\nContraindication Do not vaccinate with Janssen COVID-19 Vaccine. See\nThrombosis with thrombocytopenia syndrome (TTS) section\n(below) for information on booster vaccination with a bivalent\nmRNA COVID-19 vaccine. History of an episode of an immune-mediated syndrome characterized\nby thrombosis and thrombocytopenia, such as spontaneous or classic\nHIT\nNot\nrecommended\nDo not vaccinate with Janssen COVID-19 Vaccine. These people\nshould receive an mRNA or Novavax COVID-19 vaccine.","6389":"10\/30\/22, 9:38 AM People Who Are Immunocompromised | CDC\nEspa\u00f1ol | Other Languages\nPeople Who Are Immunocompromised\nKnow how to protect yourself and what to do if you get sick\nSome people who are immunocompromised (have a weakened immune system) are more likely to get sick with COVID-19 or\nbe sick for a longer period. People can be immunocompromised either due to a medical condition or from receipt of\nimmunosuppressive medications or treatments. Talk to your healthcare provider if you have another medical condition or are on medication that may not be reflected above.","707":"December 23, 2021: West Virginia made updates to data previously submitted to CDC that resulted in a decrease of\n651,436 doses administered. December 22, 2021: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n25,151 doses administered. December 21, 2021: Pennsylvania made updates to data previously submitted to CDC that resulted in a decrease of\n101,475 doses administered. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nDecember 17, 2021: New Mexico updated 2,213 records, previously submitted to CDC. This did not result in change\nto number of doses administered.","418":"On June 30, 2021, data review and reporting adjustments resulted in an increase in the number of vaccine doses\nadministered for North Carolina of 621,198 doses since December 2020. The adjustment is the result of updates to how\npharmacies report data to CDC and\/or the jurisdictions. On June 25, 2021, data review and reporting adjustments resulted in a decrease in the number of vaccine doses\nadministered for New Jersey of 331,640 doses and a smaller-than-usual increase for New Hampshire of 6,449 doses. The\nadjustments are the result of updates to how pharmacies report data to CDC and\/or the jurisdictions.","5147":"\uf3c0 Testing \u2013 ALL Travelers\nRECOMMENDED\nConsider getting tested with a viral test as close to the time of departure as possible (no more than 3\ndays) before travel. If you already had COVID-19 within the past 90 days, see specific testing recommendations. Make sure you know your test results before travel. Don\u2019t travel if your test result is positive. Non-U.S. Citizen, Non-U.S. Immigrants\nProof of Vaccination\nREQUIRED\nAir Travel: All non-U.S. citizen, non-U.S. immigrants traveling to the United States by air are required to show proof of\nbeing fully vaccinated against COVID-19. Only limited exceptions apply. Learn more about this requirement and accepted\nvaccines.","4194":"However, staying up to date with your COVID-19\nvaccinations means that you are less likely to have a breakthrough infection and, if you do get sick, you are less likely to\nget severely ill or die. Staying up to date with COVID-19 vaccination also means you are less likely to spread the disease to\nothers and increases your protection against new variants of SARS-CoV-2, the virus that causes COVID-19. Why should I get vaccinated if I might get COVID-19 anyway? \uf1aa\nThere is no recommended waiting period between getting a COVID-19 vaccine and other vaccines.","2195":"DOI: https:\/\/doi.org\/10.1038\/s41591-021-01666-2\n16. Sekkarie A, Woodruff R, Whitaker M, et al. Characteristics and treatment of hospitalized pregnant women with\nCoronavirus Disease 2019, COVID-19 [published online ahead of print, 2022 Aug 12]. Am J Obstet Gynecol MFM. 17. Prasad, S., Kalafat, E., Blakeway, H. et al. Systematic review and meta-analysis of the effectiveness and perinatal\n18. Yang YJ, Murphy EA, Singh S, et al. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination,\nHistory of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With\nMaternal and Umbilical Cord Antibody Levels at Delivery. Obstetrics & Gynecology: 2021. 19.","6720":"This Fact Sheet for Recipients and Caregivers comprises the Fact Sheet for the\nauthorized Pfizer-BioNTech COVID-19 Vaccine3,4 and the Pfizer-BioNTech\nCOVID-19 Vaccine, Bivalent for use in individuals 5 through 11 years of age. The Pfizer-BioNTech COVID-19 Vaccine has received Emergency Use\nAuthorization (EUA) from the U.S. Food and Drug Administration (FDA) to\nprovide:\n\uf0b7 a 2-dose primary series to individuals 5 through 11 years of age. \uf0b7 a third primary series dose to individuals 5 through 11 years of age with\ncertain kinds of immunocompromise. 1 The Pfizer-BioNTech COVID-19 Vaccine, a monovalent vaccine, encodes the spike protein of only the\nOriginal SARS-CoV-2.","9530":"Either dose may be:\n\u0083 0.25 mL (25 mcg) of the product authorized for children ages 6 months\u20135 years (dark blue cap\/magenta label border), or\n\u0083 0.50 mL (50 mcg) of the product authorized for children ages 6\u201311 years (dark blue cap\/purple label border)\nOR\nOR\fSpecial Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nModerna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group (continued)\nChildren who turn from age 11 years to 12 years\nRecommended: Children who started a primary series and turned from age 11 to age 12 years before completion of the\nseries should receive:\nof the product\nauthorized for\nchildren ages\n6\u201311 years (dark\nblue cap\/purple\nlabel border)\nof the product\nauthorized for children\nages 12 years and\nolder (red cap\/light\nblue label border)\nChild turns 12\nAcceptable: If the following dosing occurs, it is NOT considered an error and the primary series is considered complete.","2009":"\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nLearn more about COVID-19 vaccine safety from published research and how CDC and FDA are making sure COVID-19\nvaccines used in the United States are safe. \u2022\n\uf20c\f10\/30\/22, 9:31 AM COVID-19 Vaccine Safety in Children and Teens | CDC\ndoses given of the Pfizer-BioNTech COVID-19 vaccine between November 2021 and April 2022 . In reports of myocarditis following mRNA-based COVID-19 vaccination from December 2020 to August 2021 , the risk\nof myocarditis was highest following the second dose of the Pfizer-BioNTech vaccine in adolescent and young adult\nmales.","2833":"There has not been a similar reporting pattern\nobserved after receipt of the Janssen COVID-19 Vaccine (Johnson & Johnson). CDC continues to recommend COVID-19 vaccination for everyone 6 months of age and older. The Advisory Committee on\nImmunization Practices (ACIP) and CDC have determined that the benefits (such as prevention of COVID-19 cases and its\nsevere outcomes) outweigh the risks of myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines. \uf209\f10\/30\/22, 9:16 AM Clinical Considerations: Myocarditis after mRNA COVID-19 Vaccines | CDC\nFor follow-up of patients with myocarditis, consult the guidance from the American Heart Association and American\nCollege of Cardiology .","4762":"*\nPeople ages 5 years and older who received a COVID-19 vaccine that is FDA-authorized, FDA-approved, or listed for emergency use by WHO\nshould receive 1 bivalent mRNA booster dose. A monovalent Novavax booster dose (instead of a bivalent mRNA booster dose) may be used in limited situations in people ages 18 years and\nolder who have not received any previous booster dose(s). The Novavax booster dose is administered at least 6 months after the last primary\nseries dose.","98":"\u2022\n\u2022\n\u2022\n\u2022\nFor Pet Owners, Veterinarians, & Public Health Officials\nPet Owners\nand Others\nHandling\nAnimals\nPets and\nAnimals\nFrequently\nAsked\nQuestions\nAnimal\nTesting\nGuidance\nOne Health\nToolkit for\nHealth\nOfficials\nManaging\nCompanion\nAnimals with\n\u2022\n\u2022\n\u2022\n\u2022\nCoronaviruses are a large family of viruses. Some coronaviruses cause cold-like illnesses in people, while others cause illness\nin certain types of animals, such as cattle, camels, and bats. Some coronaviruses, such as canine and feline coronaviruses,\ninfect only animals and do not infect people. Some coronaviruses that infect animals can be spread to people and then\nspread between people, but this is rare. This is what happened with SARS-CoV-2, which likely originated in bats.","8334":"10\/30\/22, 9:18 AM Talking with Patients about COVID-19 Vaccination | CDC\nVaccines & Immunizations\nVaccines & Immunizations\nVaccines & Immunizations Home\nTalking with Patients about COVID-19 Vaccination\nAn Introduction to Motivational Interviewing for Healthcare Professionals\nAs a trusted source of health information and healing, your approach to a conversation with patients and families who are\nhesitant about receiving COVID-19 vaccines can influence their willingness to consider vaccination. Here are four steps to apply motivational interviewing rapidly (1\u20135 minutes) during a patient visit. Be compassionate, show empathy, and be genuinely curious about the reasons why the patient feels the way they do.","8932":"10\/30\/22, 9:32 AM Vaccine Adverse Event Reporting System (VAERS) | CDC\nEspa\u00f1ol | Other Languages\nVaccine Adverse Event Reporting System (VAERS)\nHow Reports Come into VAERS\nThere are two ways to report an adverse event to VAERS: report online or report using a writable pdf form. If you need\nfurther assistance with reporting to VAERS, please email info@VAERS.org or call 1-800-822-7967. For healthcare providers \u2013 Under Emergency Use Authorization, FDA requires healthcare professionals to report to VAERS\ncertain adverse events that occur after COVID-19 vaccination. CDC also encourages reporting of any medically important\nadverse event even if it isn\u2019t clear if the vaccine caused the health problem.","3378":"Studies have shown that increased time\nbetween infection and vaccination may result in an improved immune response to vaccination. Also, a low risk of reinfection\nhas been observed in the weeks to months following infection. Individual factors such as risk of COVID-19 severe disease,\nCOVID-19 community level, or characteristics of the predominant SARS-CoV-2 strain should be taken into account when\ndetermining whether to delay getting a COVID-19 vaccination after infection. Viral testing to assess for acute SARS-CoV-2 infection or serologic testing to assess for prior infection is not recommended for\nthe purpose of vaccine decision-making.","660":"February 18, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 20,754\ndoses administered. February 18, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n12,473 doses administered. February 17, 2022: A federal entity made updates to data previously submitted to CDC that resulted in an increase of\n4,251 doses administered. February 11, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 58,355\ndoses administered.","2694":"Practice everyday preventive actions to keep from getting sick: wash your hands often; avoid touching your\neyes, nose, and mouth; and frequently clean and disinfect surfaces. \u2022\n-\nClean your hands often\nWash hands: Wash your hands often with soap and water for at least 20 seconds. Tell everyone in the home to do\nthe same, especially after being near the person who is sick. Hand sanitizer: If soap and water are not readily available, use a hand sanitizer that contains at least 60% alcohol. Cover all surfaces of your hands and rub them together until they feel dry.","494":"On April 19, 2021, the population metrics for 65+ Texas residents dropped from the metrics reported on April 18, 2021. This was due to a schedule delay in updating the calculation used to infer the 65+ population metrics. The issue was\nresolved on April 19, 2021 and metrics accurately reflect the total doses administered. This did not affect any other\nstates, but did affect the total US estimates for 65+. On April 13, 2021, the total doses administered data posted to Tracker inadvertently included 221,081 duplicate doses\naffecting Vermont (6,605), Georgia (102,711), Illinois (64,886), West Virginia (60), and Maine (46,819).","9872":"Kornek B, Leutmezer F, Rommer PS, et al. B Cell Depletion and SARS-CoV-2 Vaccine Responses in\nNeuroimmunologic Patients. Annals of Neurology. 2022;91:342-352. Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) \u2013 5 October 2021. Geneva: World\nHealth Organization; 2021. Kaslow DC. Policy question: Is a 3rd dose needed for older persons who have\nreceived 2 doses of inactivated COVID-19 vaccines? https:\/\/www.who.int\/news-\nroom\/events\/detail\/2021\/10\/04\/default-calendar\/sage_meeting_october_2021. Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nMoghnieh R, Mekdashi R, El-Hassan S, et al.","4152":"FDA has determined COVID-19 vaccines meet FDA\u2019s standards and has granted\nthose vaccines Emergency Use Authorizations (EUAs) or full FDA approval. Tracking Safety Using Vaccine Monitoring Systems \u2013 Like every other vaccine approved for use in the United States,\nCOVID-19 vaccines continue to be monitored for safety and effectiveness. Hundreds of millions of people in the\nUnited States have safely received COVID-19 vaccines. CDC and FDA continue to provide updated information on\nthe safety of U.S. authorized or approved COVID-19 vaccines using data from several monitoring systems. Learn more about developing COVID-19 vaccines. \u2022\n\u2022\n\uf209\n\u2022\nVaccine ingredients vary by manufacturer.","5512":"Living with Long COVID\nHowever, people experiencing post-COVID conditions can seek care from a healthcare provider to come up with a personal\nmedical management plan that can help improve their symptoms and quality of life. Review these tips to help prepare for a\nhealthcare provider appointment for post-COVID conditions. In addition, there are many support groups being organized that\ncan help patients and their caregivers. Although post-COVID conditions appear to be less common in children and adolescents than in adults, long-term effects after\nCOVID-19 do occur in children and adolescents.","7462":"While CDC\u2019s Order does not apply to Ukrainians who are approved under the Uniting for Ukraine program, the U.S.\nDepartment of Homeland Security (DHS) has identified health requirements as a component of the program, which\ninclude receiving measles, polio, and at least one dose of COVID-19 vaccine. For more information about the health\nrequirements of the program, how to apply to the program, and the processes to receive travel authorization to come to\nthe United States please visit DHS\u2019 website for the Uniting for Ukraine program . For information not found on DHS\u2019\nwebsite, please contact the USCIS Contact Center .","2375":"EVUSHELD is a medicine given every six months by your healthcare\nprovider to help prevent you from getting COVID-19. EVUSHELD may offer less protection against three strains (BA.4.6,\nBF.7, and BA.2.75.2) of the Omicron variant. It is important to use multiple prevention measures and talk to your\nhealthcare provider to find out if EVUSHELD is right for you. TM TM\nTM\nTM\nDownload: EVUSHELD EUA Fact Sheet for Patients, Parents and Caregivers\nTM \uf209\nFrequently Asked Questions\nNo, vaccines used for the primary vaccination series should be the same product or brand.","8306":"*This list is not all possible symptoms. Please call your medical provider for any other symptoms that are severe or\nconcerning to you. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:37 AM Symptoms of COVID-19 | CDC\n\uf277 Difference Between Flu and COVID-19\nInfluenza (Flu) and COVID-19 are both contagious respiratory illnesses, but they are caused by different\nviruses. COVID-19 is caused by infection with a coronavirus named SARS-CoV-2, and flu is caused by infection\nwith influenza viruses. You cannot tell the difference between flu and COVID-19 by symptoms alone because\nsome of the symptoms are the same. Some PCR tests can differentiate between flu and COVID-19 at the\nsame time.","7603":"CDC considers a country to have limited COVID-19 vaccine availability if less than 10% of the total population has been\nfully vaccinated against COVID-19 with any vaccine, as reported in official source data in Our World in Data (OWID). CDC reviews OWID country-level data on the proportion of a population that is fully vaccinated and updates the list of\ncountries with limited vaccine availability every three months. If country data are missing from OWID, CDC reviews other\nofficial sources of information to determine a countries\u2019 vaccination coverage (percent of the population fully vaccinated\nwith available COVID-19 vaccines).","7152":"This Vaccine Information Fact Sheet for Recipients and Caregivers comprises the\nFact Sheet for the authorized Pfizer-BioNTech COVID-19 Vaccine and the\nPfizer-BioNTech COVID-19 Vaccine, Bivalent, and also includes information\nabout the U.S. Food and Drug Administration (FDA)-licensed vaccine,\nCOMIRNATY (COVID-19 Vaccine, mRNA) for use in individuals 12 years of age\nand older1. The FDA-approved COMIRNATY (COVID-19 Vaccine, mRNA) and the\nPfizer-BioNTech COVID-19 Vaccine authorized under Emergency Use\nAuthorization (EUA) for individuals 12 years of age and older, when prepared\naccording to their respective instructions for use, can be used interchangeably.2\nCOMIRNATY (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19\nvaccine made by Pfizer for BioNTech.","7650":"\uf1aa\nNoncitizen nonimmigrants that plan to take a connecting flight in the United States to another country may continue on\ntheir itinerary; however, they are still required to complete and sign the attestation in case their travel plans are changed\nor delayed. If they take their connecting flight and leave the United States, they are no longer subject to the requirements\nof the attestation. I am taking a connecting flight through the United States but the attestation says I have to attest\nto self-quarantine for 5 days and get a viral COVID-19 test 3-5 days after arrival.","412":"Use of this new functionality may result in fluctuations across\nmetrics on the CDC COVID Data Tracker as historical data are updated or deleted. The functionality will also allow for\nmore accurate reporting and improved data quality. On July 1, 2021, data review and reporting adjustments resulted in a larger-than-usual increase in the number of vaccine\ndoses administered for Arizona and Puerto Rico of 258,590 and 465,704 doses respectively. The adjustment is the result\nof CDC and the jurisdictions actively working to correct data transmission errors.","1003":"About Self-Tests\n\u2022\n\u2022 \uf209\n\u2022 \uf209\n\u2022\nChoosing a COVID-19 Test\nI am in a circumstance where I should get tested and:\n\uf6e2 I have not had COVID-19 or I have not had a positive test within the past 90 days. You may choose NAAT or antigen tests. If you use an antigen test and your result is negative, multiple tests may be necessary. \uf6e8 I tested positive for COVID-19 in the last 90 days. My first positive test result was within:\n30 days or less\nI have symptoms\nUse antigen tests. If negative, multiple tests may be\nnecessary.","1153":"\u2022\n\u2022\n\u2022\n\u2022\nCOVID-19 Vaccination Data Sources\f10\/30\/22, 9:35 AM COVID-19 Vaccination Data Systems and Data Sources\nFederal Agency Data\nOn CDC COVID Data Tracker (CDT), data are individually displayed at the national level and included as part of national\ntotals for each metric for the following agencies (except Department of State, DoS):\nBureau of Prisons (BoP)\nDepartment of Defense (DoD)\nIndian Health Services (IHS)\nVeterans Health Administration (VHA)\nFederal agency data\u202fare\u202falso included as part of jurisdiction, state, or territory aggregate metrics. To avoid duplicate\ncounts, the agency data\u202fshould not be combined with other data.","4842":"Children ages 5\u201317 years who receive a mixed mRNA COVID-19 vaccine\nprimary series can follow the Pfizer-BioNTech COVID-19 Vaccine\nschedule and receive a booster dose. Diluent (Pfizer-BioNTech\nformulation only [orange\ncap and maroon cap])\nONLY diluent administered (i.e., sterile\n0.9% sodium chloride)\nAdminister the authorized dose immediately (no minimum interval). No diluent, resulting in higher than\nauthorized dose\nDo not repeat dose. Inform the recipient of the potential for local and\nsystemic adverse events. Incorrect diluent type (e.g., sterile water,\nbacteriostatic 0.9% sodium chloride)\nContact the manufacturer for information on the stability of the\nvaccine.","4679":"Most systemic symptoms were mild to moderate in severity and resolved within 1\u20132 days. Overall, symptoms were more frequent in people ages 18\u201359 years compared to people ages 60 years and older. Thrombosis with thrombocytopenia syndrome (TTS)\nTTS is a rare syndrome that includes acute venous or arterial thrombosis and new onset thrombocytopenia in patients with\nno recent known exposure to heparin. Although the condition is rare, currently available evidence supports a causal\nrelationship between Janssen COVID-19 Vaccine and TTS.","8657":"The clinical trials for COVID-19 vaccines have involved tens of thousands of volunteers of different ages,\nraces, and ethnicities. Clinical trials for vaccines compare outcomes (such as how many people get sick) between people who\nare vaccinated and people who are not. Results from these trials have shown that COVID-19 vaccines are\nsafe and effective, especially against severe illness, hospitalization, and death. 10\/30\/22, 9:34 AM Understanding How COVID-19 Vaccines Work | CDC\nAuthorization or Approval\n\uf1aa\n\uf2a7 Before vaccines are made available to people in real-world settings, FDA assesses the findings from\nclinical trials.","6254":"10\/30\/22, 9:34 AM Myths and Facts about COVID-19 Vaccines | CDC\nRecently, the number of deaths reported to VAERS following COVID-\n19 vaccination has been misinterpreted and misreported as if this\nnumber means deaths that were proven to be caused by vaccination. Reports of adverse events to VAERS following vaccination, including\ndeaths, do not necessarily mean that a vaccine caused a health\nproblem. Learn more about VAERS. MYTH: The mRNA vaccine is not considered a vaccine. FACT: mRNA vaccines, such as Pfizer-BioNTech and Moderna, work differently than other types of vaccines,\nbut they still trigger an immune response inside your body.","727":"October 22, 2021: A federal retail pharmacy partner made updates to data previously submitted to CDC that\nresulted in a decrease of 563 records. October 21, 2021: South Dakota made updates to data previously submitted to CDC that resulted in a decrease of\n11,366 records. October 20, 2021: North Carolina made updates to 7,727,520 records previously submitted to CDC that resulted in\nno net change in number of records. October 8, 2021: Michigan made updates to 9,632,251 records previously submitted to CDC that resulted in no net\nchange in number of doses administered.","1321":"However, FDA allows the formulation for either age group to be administered for certain age transitions. See Moderna\nCOVID-19 Vaccine for Children who Transition from a Younger to Older Age Group , Pfizer-BioNTech for Children who\nTransition from a Younger to Older Age Group , and the product-specific EUA for more information. What should be done if the incorrect vaccine formulation is administered based on a patient\u2019s\nage? \uf1aa\n\uf20c\n\uf20c \uf209\nIn general, all doses of the primary series should be with the same product.","7003":"Even if you don\u2019t experience any side effects, your body is building protection against the virus that causes COVID-\n19. Adverse events (serious health problems) are rare but can cause long-term health problems. They usually happen\nwithin six weeks of getting a vaccine.","3907":"Immunocompromised or a Weakened Immune System\nHaving a weakened immune system, also known as being\nimmunocompromised, can make you more likely to get very sick if\nyou get COVID-19. People who are immunocompromised, or who are\ntaking medicines that weaken their immune system, may not be\nprotected as well as others, even if they are up to date on their\nvaccines. EVUSHELD\u2122 is a medicine given by a healthcare provider\nevery 6 months to help prevent COVID-19 before you are exposed or\ntest positive for COVID-19. EVUSHELD\u2122 remains protective, but may\noffer less protection against certain strains of the Omicron variant.","2354":"Examples of medical conditions or treatments that may result in moderate to severe immunocompromise include but are not\nlimited to:\nActive treatment for solid tumor and hematologic malignancies\nHematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status\n(e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\nReceipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\nReceipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of\ntransplantation or taking immunosuppressive therapy)\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nTalk to your healthcare provider about COVID-19 and your medical condition.","291":"Due to a data processing issue on May 9, 2022, vaccination data were not updated for two dashboards on Vaccination\nDemographic Trends \u2013 \u201cBooster Vaccination Trends by Age, Sex, and Race\/Ethnicity among Fully Vaccinated People Ages\n12 Years and Older\u201d and \u201cVaccination Trends by Age and Sex\u201d \u2013 which reflect data as of May 8, 2022. CDC is actively\nworking to address this issue and the data will be updated when available. On May 3, 2022, the daily number of vaccine doses administered for South Carolina was 152,237 doses.","9188":"If you can\u2019t put on a mask (because of trouble\nbreathing, for example), cover your coughs and sneezes in some other way. Try to stay at least 6 feet\naway from other people. This will help protect the people around you. Masks should not be placed on young children under age 2 years, anyone who has trouble breathing, or\nanyone who is not able to remove the mask without help. \u2022\n\u2022\n\u2022\n\u2022\n\uf277 Cover your coughs and sneezes\nCover your mouth and nose with a tissue when you cough or sneeze.","1938":"10\/30\/22, 9:32 AM COVID-19 Vaccine Reporting Systems | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccine Reporting Systems\nHundreds of millions of people in the United States have safely received COVID-19 vaccinations. These vaccines have\nundergone the most intensive safety monitoring in U.S. history that includes both established and new safety monitoring\nsystems. We know COVID-19 vaccines are safe and effective because of our monitoring systems. Vaccine Safety Monitoring\nAfter a vaccine is authorized or approved for use, vaccine safety surveillance systems monitor adverse events and watch\nfor potential safety problems. This continued monitoring can identify adverse events that may not have been seen in clinical trials.","2203":"Nir O, Schwartz A, Toussia-Cohen S, et al. Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies\namong parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy. Am J Obstet Gynecol 2022;\n20. Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort\nstudy. Am J Obstet Gynecol. Published online March 25, 2021. DOI: https:\/\/doi.org\/10.1016\/j.ajog.2021.03.023\n21. Shook LL, Atyeo CG, Yonker LM, et al. Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination\nor Natural Infection. JAMA. Published online February 07, 2022. DOI: https:\/\/doi.org\/10.1001\/jama.2022.1206\n22. Halasa NB, Olson SM, Staat MA, et al.","5599":"If the mask has a good fit, you will feel warm air come through the front of the mask and may be able to see the mask\nmaterial move in and out with each breath. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nCloth Masks\f10\/30\/22, 9:39 AM Masks and Respirators\nCloth Masks can be made from a variety of fabrics and many types of cloth masks are available.","2517":"\u2022\n\u2022\nScience at CDC\nScientific evidence and studies behind specific COVID-19 guidance and recommendations\nScience Brief: Community Levels and Making Public Health Recommendations\nCommunity-Level Prevention Strategies\nLOW, MEDIUM, AND HIGH\nAt all COVID-19 Community Levels:\nPromote equitable access to vaccination, testing, masks and respirators, treatment and\nprevention medications, community outreach, and support services. Ensure access to testing, including through point-of-care and at-home tests for all people. Maintain ventilation improvements. Provide communications and messaging to encourage isolation among people who test\npositive. \u2022\n\u2022\n\u2022\n\u2022\nMEDIUM AND HIGH\nWhen the COVID-19 Community Level is Medium or High:\f10\/30\/22, 9:39 AM COVID-19 by County | CDC\nImplement screening testing in high-risk settings where screening testing is recommended.","7329":"CDC is publishing several analyses that use\ndatasets from various sources, including cohort studies (which follow the same people over time):\nEffectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19\u2013Associated Hospitalization Among Adults with\nPrevious SARS-CoV-2 Infection \u2014 United States, June 2021\u2013February 2022\nCOVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis \u2014 California and\nNew York, May\u2013November 2021\nLaboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19\u2013Like Illness with Infection-Induced or mRNA\nVaccine-Induced SARS-CoV-2 Immunity \u2014 Nine States, January\u2013September 2021\nReinfection with SARS-CoV-2 among previously infected healthcare personnel and first responders\nSuspected SARS-CoV-2 Reinfections: Incidence, Predictors, and Healthcare Use among Patients at 238 U.S. Healthcare\nFacilities, June 1, 2020- February 28, 2021.","7701":"Reports of adverse events to VAERS following vaccination, including deaths, do not necessarily mean that a vaccine\ncaused a health problem. CDC and FDA review reports of death following COVID-19 vaccination and update information as it\nbecomes available. Learn more about adverse events, including reports of death, after COVID-19 vaccination. \uf209\nBenefits of Vaccination Outweigh the Risks\nSerious side effects that could cause a long-term health problem are extremely rare following any vaccination, including\nCOVID-19 vaccination. The benefits of COVID-19 vaccination outweigh the known and potential risks. CDC continues to closely monitor the safety of COVID-19 vaccines.","6092":"Advisory\nCommittee on Immunization Practices meeting, November 19, 2021:\nDisanto G, Sacco R, Bernasconi, E. Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing\nWith Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis. JAMA Neurology. 2021;78(12):1529-1531. FDA. Fact Sheet for Healthcare Providers Administering Vaccine. Emergency Use Authorization of the Moderna\nCOVID-19 Vaccine to Prevent Coronavirus Disease 2019, Revised January 3, 2022\nGrunau B et al. A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute\nRespiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval. Clin Infect Dis. 2021 Nov 30:\nHaggenburg S, Hofsink Q, Lissenberg-Witte BI, et al.","2245":"COVID-19 vaccines used in the United States\ncontinue to protect against severe disease, hospitalization, and death from known circulating variants. They may not be as\neffective in preventing infection from these variants. CDC will continue to monitor vaccine effectiveness to see what impact, if\nany, variants have on how well COVID-19 vaccines work in real-world conditions. For More Information\nThe latest CDC data on COVID-19 vaccine effectiveness are summarized on the CDC COVID Data Tracker. Information on CDC\u2019s Monitoring COVID-19 Vaccine Effectiveness\nLast Updated June 28, 2022","4019":"Vaccination data reported on the CDC COVID Data Tracker might differ from data reported by jurisdictions for a\nnumber of reasons. For example:\nData quality: CDC receives administration data across multiple jurisdictions with different reporting practices. To\nreduce potential duplication across systems, CDC reconciles these data prior to reporting. Data completeness: Jurisdictions may have more complete and updated data for certain data elements (e.g.,\ncounty of residence) that allow them to characterize their population more fully than the CDC. Thus, vaccination\ncoverage reported on the CDC COVID Data Tracker may appear artificially low due to systematic missing data\nreported to CDC.","4979":"New booster recommendation for people ages 12 years and older to receive 1 bivalent mRNA booster after\ncompletion of a monovalent primary series; it replaces all prior booster recommendations for this age group\nRecommendations for use of a bivalent Moderna booster dose in people ages 18 years and older\nRecommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 12 years and older\nUpdated guidance for observation periods following COVID-19 vaccination\nUpdated guidance on COVID-19 vaccination and multisystem inflammatory syndrome (MIS) in children (MIS-C) and in\nadults (MIS-A)\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adolescents ages 12\u201317 years\nReorganization of Janssen COVID-19 Vaccine guidance into an appendix\nUpdated guidance on COVID-19 vaccination following exposure to SARS-CoV-2\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nPrevious Updates\n\uf1aa\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nUpdated guidance on COVID-19 vaccination and myocarditis and pericarditis\nNew clinical considerations for coadministration of mRNA COVID-19 vaccines and orthopoxvirus vaccines\nNew guidance for use of Moderna COVID-19 Vaccine in children and adolescents ages 6\u201317 years\nNew guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children ages 6 months\u20134 years\nNew guidance for use of Moderna COVID-19 Vaccine in children ages 6 months\u20135 years\nReorganization of sections on COVID-19 vaccination recommendations and schedules\nAddition of new section in Special populations for infants and young children\nNew guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5\u201311 years\nUpdated guidance that the following people should receive a second COVID-19 booster dose:\nPeople ages 12 years and older who are moderately or severely immunocompromised\nPeople ages 50 years and older\nUpdated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-\ndepleting therapies\nClarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults\n(MIS-A)\nUpdated guidance for primary series vaccination after SARS-CoV-2 infection\nAdded considerations for the option to receive a second COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 vaccination after SARS-CoV-2 infection\nAdded guidance that people ages 12 years and older who are moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that people ages 18\u201349 years who are not moderately or severely immunocompromised and who\nreceived Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster\ndose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose\nFurther clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C)\nand adults (MIS-A) and myocarditis\nUpdated information on the availability of Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL\ndosage volume) and Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL dosage volume) for\nadministration of a 50 \u00b5g booster dose.","7331":"Duration of Viral Nucleic Acid Shedding and Early Reinfection With Severe Respiratory Syndrome Coronavirus 2 in\nHealthcare Workers and First Responders\nReduced Risk of Reinfection with SARS CoV 2 After COVID 19 Vaccination Kentucky May June 2021\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\uf549 About Variants\nViruses are constantly changing, including the virus that causes COVID-19. These changes can lead to\nthe emergence of variants (new strains of the virus) that can increase the risk of reinfection.","5482":"As a result of these effects, people who have had COVID-19 may be more likely to develop\nnew health conditions such as diabetes, heart conditions, or neurological conditions compared with people who have not had\nCOVID-19. People experiencing any severe illness may develop health problems\nPICS refers to the health effects that may begin when a person is in an intensive care unit (ICU), and which may persist after a\nperson returns home. These effects can include muscle weakness, problems with thinking and judgment, and symptoms of\npost-traumatic stress disorder (PTSD). PTSD involves long-term reactions to a very stressful event.","6620":"Get more information:\nStroke\nCOVID19 Stroke Podcast Series for Patients and Caregivers\nSubstance use disorders\nHaving a substance use disorder (such as alcohol, opioid, or cocaine use disorder) can make you more likely to get very sick\nfrom COVID-19. Get more information:\nHow to Recognize a Substance Use Disorder\nDrug Overdose\nTuberculosis\nHaving tuberculosis (TB) can make you more likely to get very sick from COVID-19. Get more information:\nBasic TB Facts\nPublic Health Emergencies\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022 \uf209\n\u2022\n\u2022 \uf209\n\u2022 \uf209\n\u2022\n\u2022\n\u2022\nAdditional Information on Children and Teens\nCurrent evidence suggests that children with medical complexity, with genetic, neurologic, or metabolic conditions, or with\ncongenital heart disease can be at increased risk for getting very sick from COVID-19.","2689":"Masks should not be placed on young children under age 2, anyone who has trouble breathing, or is not able to\nremove the covering without help. Caregiver\nPut on a mask and ask the sick person to put on a mask before entering the room. \u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:41 AM COVID19 - Caring for someone at home | CDC\np p g\nWear gloves when you touch or have contact with the sick person\u2019s blood, stool, or body fluids, such as saliva,\nmucus, vomit, and urine. Throw out gloves into a lined trash can and wash your hands right away.","9469":"Data have not yet been submitted to FDA on administration of SPIKEVAX (COVID-19\nVaccine, mRNA), Moderna COVID-19 Vaccine, or Moderna COVID-19 Vaccine, Bivalent at\nthe same time as other vaccines. If you are considering receiving or having your child receive\nSPIKEVAX (COVID-19 Vaccine, mRNA), Moderna COVID-19 Vaccine, or Moderna COVID-\n19 Vaccine, Bivalent with other vaccines, discuss your options with your or your child\u2019s\nhealthcare provider. WHAT IF I AM, OR MY CHILD IS, IMMUNOCOMPROMISED? If you are, or your child is, immunocompromised, you or your child may receive a third primary\nseries dose of Moderna COVID-19 Vaccine or SPIKEVAX (COVID-19 Vaccine, mRNA).","6982":"It is your choice to receive or not receive the COVID-19 vaccine by Pfizer-BioNTech as a primary and\/or\nadditional dose. Should you decide not to receive it, it will not change your standard medical care. Will I get a vaccination card? When you are administered a primary, additional, or a booster dose of the COVID-19 vaccine by Pfizer-\nBioNTech, you will get a vaccination card to document when you received the shot. You should keep your\nvaccination card. What is the Countermeasures Injury Compensation Program?","2303":"10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccines for People Who Are Moderately or\nSeverely Immunocompromised\nWhat You Need to Know\nIf you are moderately or severely immunocompromised (have a weakened immune system), you are at increased\nrisk of severe COVID-19 illness and death. Additionally, your immune response to COVID-19 vaccination may not\nbe as strong as in people who are not immunocompromised. As with vaccines for other diseases, you are protected best when you stay up to date with your COVID-19 vaccines\nas described below.","5230":"Isolation & Exposure\nFor Healthcare Professionals: Ending Isolation and Precautions for People with COVID-19\n\uf3b7\n\uf285 When to Isolate\n\uf6eb IF YOU TEST\nNegative\nYou can end your isolation\n\uf6ec IF YOU TEST\nPositive\nFollow the full isolation\nrecommendations below\nIf you had no symptoms If you had symptoms\f10\/30\/22, 9:41 AM Isolation and Precautions for People with COVID-19 | CDC\nIf you test positive for COVID-19, stay home for at least 5 days and isolate from others in your home. You are likely most infectious during these first 5 days. Wear a high-quality mask if you must be around others at home and in public.","7230":"FDA has authorized Pfizer-BioNTech\nCOVID-19 Vaccine, Bivalent to provide better protection against COVID-19 caused by\nthe Omicron variant of SARS-CoV-2. The duration of protection against COVID-19 is currently unknown. WHAT ARE THE RISKS OF THESE VACCINES? There is a remote chance that these vaccines could cause a severe allergic reaction. A\nsevere allergic reaction would usually occur within a few minutes to 1 hour after getting\na dose. For this reason, your vaccination provider may ask you to stay at the place\nwhere you received your vaccine for monitoring after vaccination.","795":"COVID-19 vaccines can offer added protection to people who had COVID-19, including protection against being\nhospitalized from a new infection, especially as variants continue to emerge. As with vaccines for other diseases, people are protected best when they stay up to date with the recommended\nnumber of doses and boosters, when eligible. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\nA Safer, More Reliable Way to Build Protection\nGetting a COVID-19 vaccine is a safer, more reliable way to build protection than getting sick with COVID-19. COVID-19\nvaccination helps protect you by creating an antibody response without you having to experience potentially severe\nillness or post-COVID conditions.","8267":"COVID-19 vaccines available abroad that are accepted in the United States as valid vaccinations\n\uf1aa\nVaccines approved or authorized by the U.S. Food and Drug Administration (FDA) currently include:\nPfizer-BioNTech\nModerna\nNovavax\nJohnson & Johnson\u2019s Janssen\nVaccines listed for emergency use by the World Health Organization (WHO) currently include those that are listed\nabove and the following:\nAstraZeneca\/Oxford vaccine\nSinopharm\nSinovac\nCOVAXIN\nCovovax\nCanSino\n\u2022\n\u2022\n\u2022\n\u2022\n\uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022\n\u2022\f10\/30\/22, 9:27 AM Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC\nHow to Complete a Primary Series\nReceive 1 dose of a single-dose accepted COVID-19 vaccine\nReceive 2 doses of a 2-dose accepted COVID-19 vaccine\nCDC does not recommend mixing different COVID-19 vaccines for the primary series, but CDC is aware that mixing\nCOVID-19 vaccines for the primary series is increasingly common in many countries outside the United States.","9158":"Be sure to get care if you have trouble\nbreathing, or have any other emergency warning signs, or if you think it is an emergency. Do not travel and avoid public transportation, ride-sharing, or taxis if possible. \u2022\n\u2022\n\u2022\n\u2022\n\uf283 Isolation and Exposure Calculator\nA tool to help you determine if you need to isolate or take other steps to prevent spreading COVID-19. Isolation & Exposure\n\uf3c0 Separate yourself from other people\nAs much as possible, stay in a specific room and away from other people and pets in your home. If possible,\nyou should use a separate bathroom.","9123":"What are other ways I can reduce risk in travel and transportation settings? \uf1aa\nDoes CDC recommend masks on school buses? \uf1aa\f10\/30\/22, 9:43 AM Wearing Masks in Travel and Public Transportation Settings | CDC\nK-12 schools and early education settings should follow guidance for schools according to the COVID-19 Community\nLevel in their area with respect to mask wearing on buses or vans. Does CDC recommend masks on school buses? \uf1aa\nOperators of Conveyances and Transportation Hubs\nOperators of conveyances and transportation hubs can take steps to help keep travel and public transportation safer for\neveryone.","1180":"Although Texas still reports vaccination data in\naggregate form, Texas and CDC recently collaborated to update the format of this record submission to improve COVID-19\nreporting of Texas\u2019 data on CDC\u2019s COVID Data Tracker at the national, state, and county levels. Previously, for Texas, CDC estimated the number of people with at least one dose and the number of people who are fully\nvaccinated for the populations ages 12 years or older, 18 years or older, and 65 years or older in the metrics for Texas alone\nand when including Texas in the national level metrics on the\u202fVaccinations in the United States\u202fsite.","2080":"Data from American, European, and Canadian studies showed that vaccination with an mRNA COVID-19 vaccine\nduring pregnancy was not associated with an increased risk for pregnancy complications, including preterm birth,\nstillbirth, bacterial infection of the placenta, and excessive maternal blood loss after birth. A Chicago study has shown that vaccination of pregnant people with a COVID-19 vaccine prior to and during the\nfirst trimester was not associated with an increased risk of birth defects detectable on prenatal ultrasound. The monitoring of the effect of COVID-19 vaccination during pregnancy is ongoing.","6636":"It is also important for people with medical conditions and their healthcare providers to work together and manage\nthose conditions carefully and safely. Stay up to date with your COVID-19 vaccines. If you have a medical condition, the\nfollowing are actions you can take based on your medical conditions and other risk factors. Seek care when needed\nCall your healthcare provider if you have any concerns about your medical conditions or if you get sick and think that you\nmay have COVID-19. Discuss steps you can take to manage your health and risks. If you need emergency help, call 911\nright away.","5247":"If you had symptoms and:\nIf you had symptoms and had:\nDay 0 is the day you were tested (not the day you\nreceived your positive test result)\nDay 1 is the first full day following the day you were\ntested\nIf you develop symptoms within 10 days of when you\nwere tested, the clock restarts at day 0 on the day of\nsymptom onset\n\u2022\n\u2022\n\u2022\nDay 0 of isolation is the day of symptom onset,\nregardless of when you tested positive\nDay 1 is the first full day after the day your symptoms\nstarted\n\u2022\n\u2022\n\uf31a Isolation\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\uf318 Ending Isolation\nYour symptoms are improving\nYou may end isolation after day 5 if:\nYou are fever-free for 24 hours (without the use of\nfever-reducing medication).","8177":"COVID-19 vaccine recommendations are based on three things:\n1. Your age\n2. The vaccine you first received, and\n3. The length of time since your last dose\nPeople who are moderately or severely immunocompromised have different recommendations for COVID-19 vaccines. You are still up to date if you receive all COVID-19 vaccine doses recommended for you and then become ill with COVID-19. You do not need to be immediately revaccinated or receive an additional booster. Boosters are an important part of protecting yourself from getting seriously ill or dying from\nCOVID-19. They are recommended for most people.","8760":"Safety precautions\nIf your child has a medical condition, such as a heart or lung problem, ask their healthcare provider before they use\nmethods to improve mask fit or use an ASTM F3502 mask or a respirator. If your child has a hard time breathing, gets dizzy, or has other symptoms while you are trying to get the mask to fit\nbetter or when using an ASTM F3502 mask or a respirator, choose a cloth or disposable mask. They should continue to\nprotect themselves and others. Consult your healthcare provider if these symptoms do not resolve.","2428":"Limited, Temporary Impact of COVID-19 Vaccines on Menstrual\nCycles\nResults from recent research studies show that people who menstruate may observe small, temporary changes in\nmenstruation after COVID-19 vaccination, including:\nLonger-lasting menstrual periods\nShorter intervals between periods\nHeavier bleeding than usual\nDespite these temporary changes in menstruation, there is no evidence that COVID-19 vaccines cause fertility problems. Research Studies of Fertility in Healthy Men\nCurrently, no evidence shows that any vaccines, including COVID-19 vaccines, cause male fertility problems. A recent\nsmall study of 45 healthy men who received an mRNA COVID-19 vaccine looked at sperm characteristics, like\nquantity and movement, before and after vaccination.","5248":"If you had symptoms and:\nIf you had symptoms and had:\nDay 0 is the day you were tested (not the day you\nreceived your positive test result)\nDay 1 is the first full day following the day you were\ntested\nIf you develop symptoms within 10 days of when you\nwere tested, the clock restarts at day 0 on the day of\nsymptom onset\n\u2022\n\u2022\n\u2022\nDay 0 of isolation is the day of symptom onset,\nregardless of when you tested positive\nDay 1 is the first full day after the day your symptoms\nstarted\n\u2022\n\u2022\n\uf31a Isolation\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\uf318 Ending Isolation\nYour symptoms are improving\nYou may end isolation after day 5 if:\nYou are fever-free for 24 hours (without the use of\nfever-reducing medication).","9436":"You should seek medical attention right away if you or your child have any of\nthe following symptoms after receiving the vaccine:\n\u2022 Chest pain\n\u2022 Shortness of breath\n\u2022 Feelings of having a fast-beating, fluttering, or pounding heart\nSide effects that have been reported in clinical trials with these vaccines include:\n\u2022 Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm\nof the injection, swelling (hardness), and redness\n\u2022 General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea and\nvomiting, fever, and rash\nSide effects that have been reported during post-authorization use include:\n\u2022 Severe allergic reactions\n\u2022 Myocarditis (inflammation of the heart muscle)\n\u2022 Pericarditis (inflammation of the lining outside the heart)\n\u2022 Fainting in association with injection of the vaccine\nThese may not be all the possible side effects of these vaccines.","7167":"2 When prepared according to their respective instructions for use, the FDA-approved COMIRNATY\n(COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine for individuals\n12 years of age and older can be used interchangeably without presenting any safety or effectiveness\nconcerns. The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to\nprovide:\n\uf0b7 a 2-dose primary series to individuals 12 years of age and older; and\n\uf0b7 a third primary series dose to individuals 12 years of age and older with\ncertain kinds of immunocompromise.","4016":"This is due to several factors, including the time it takes\nfor doses delivered to be administered, the time it takes for administered doses to be reported to CDC, and how\njurisdictions and federal pharmacy partners manage available vaccine stock to meet local demands. What are the reporting limitations and variations in COVID-19 vaccine data? \uf1aa\n\u2022\n\u2022\n\u2022\n\u2022\nWhy do data vary between the CDC COVID Data Tracker and state health department websites? \uf1aa\f10\/30\/22, 9:35 AM Frequently Asked Questions about COVID-19 Vaccination Data | CDC\nCDC Publicly Available Data\nFor the most complete and up-to-date data for any particular county or state, visit the relevant health department\nwebsite.","4333":"You\ncan also contact your state health department to get a copy of your\nvaccination record. Keep your CDC COVID-19 vaccination card for proof of vaccination. Consider taking a picture of your card after each of\nyour COVID-19 vaccination appointments as a backup copy. \u2022\n\u2022\n\u2022\f10\/30\/22, 9:30 AM Getting Your COVID-19 Vaccine | CDC\nSome vaccination providers and health departments may offer you access to a QR code or digital copy of your COVID-19\nvaccination card in addition to giving you a physical CDC COVID-19 vaccination card.","6151":"This information can provide signals of potential changes in vaccine effectiveness that can be further studied through more\nrobust, controlled vaccine effectiveness studies, which are ongoing at CDC. \uf294 CDC analyzes surveillance data by vaccination status to\nBetter understand patterns of COVID-19 among people who are vaccinated and unvaccinated. Identify signals of potential changes in vaccine effectiveness, which can be confirmed through more\nrobust studies.","3266":"Vaccination providers\nare required by FDA and the provider agreement for the CDC COVID-19 Vaccination Program to report the following that\noccur after COVID-19 vaccination under BLA or EUA:\nVaccine administration errors whether or not associated with an adverse event\nSerious adverse events , irrespective of attribution to vaccination\nCases of Multisystem Inflammatory Syndrome (MIS) in adults and children\nCases of myocarditis after a Pfizer-BioNTech, Moderna, or Novavax vaccine\nCases of pericarditis after a Pfizer-BioNTech, Moderna, or Novavax vaccine\nCases of COVID-19 that result in hospitalization or death\nReporting is encouraged for any other clinically significant adverse event, even if it is uncertain whether the vaccine caused\nthe event.","8171":"They also provide some protection against Omicron, but not as much as the updated (bivalent) boosters. The virus that causes COVID-19 has changed over time. The different versions of the virus that have developed over time are\ncalled variants. Learn more about variants of the COVID-19 virus. Two COVID-19 vaccine manufacturers, Pfizer and Moderna, have developed updated (bivalent) COVID-19 boosters. When Are You Up to Date? You are up to date with your COVID-19 vaccines if you have completed a COVID-19 vaccine primary series and received the\nmost recent booster dose recommended for you by CDC.","147":"Finding these mutations in mink on the Michigan farm is not unexpected because they have been seen before in mink\nfrom farms in the Netherlands and Denmark, and also in people linked to mink farms worldwide. To confirm the spread of SARS-CoV-2 from mink to people, public health officials would need more information on the\nepidemiology and genetics of the virus in mink, mink farm workers, and the communities around mink farms. These results highlight the importance of routinely studying the genetic material of SARS-CoV-2 in susceptible animal\npopulations like mink, as well as in people.","3188":"Orthopoxvirus vaccination:\n\uf20c \uf20c\nVaccination after SARS-CoV-2 Infection\nInterchangeability of COVID-19 vaccine products\n\uf20c\nCoadministration of COVID-19 vaccines with other vaccines\n\uf20c\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nPeople who previously received COVID-19 vaccination (i.e. Moderna, Novavax, or Pfizer-BioNTech) may be given\northopoxvirus vaccine (either JYNNEOS or ACAM2000) without a minimum interval between vaccinations. People who previously received orthopoxvirus vaccination (either JYNNEOS or ACAM2000), particularly adolescent or\nyoung adult males, might consider waiting 4 weeks before receiving a COVID-19 vaccine (i.e. Moderna, Novavax, or\nPfizer-BioNTech) because of the observed risk for myocarditis and pericarditis after receipt of ACAM2000 orthopoxvirus\nvaccine and COVID-19 vaccines (i.e.","827":"Additionally, their immune response to COVID-19 vaccination may not be\nas strong as in people who are not immunocompromised. People who are moderately or severely immunocompromised have\nspecific recommendations for COVID-19 vaccines, including boosters. COVID-19 vaccines were first authorized for emergency use in the U.S. in December 2020. Studies following the use of the\nvaccines showed approximately 90% protection against symptomatic infection, severe illness, and death. By July 2021, we saw\ndecreased vaccine effectiveness against infection as new variants emerged, and CDC put forward recommendations to\ncontinue masking, even for people who had received a primary series.","6427":"Know how to get tested as soon as possible if you develop symptoms. Order free at-home tests to have when you need them. If you need more tests, check with your health\ninsurance, Medicaid, or Medicare plan to learn what tests are available . To find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. EVUSHELD is authorized by the U.S. Food and Drug Administration (FDA) as pre-exposure prophylaxis to prevent\nCOVID-19. It is a medicine containing antibodies and is given before you are exposed to or test positive for COVID-19.","5964":"Studies of COVID-19\nvaccine boosting in the United Kingdom have shown that a third dose of AstraZeneca, Moderna, or Pfizer-\nBioNTech COVID-19 vaccines successfully boosted immune responses in people who had been primed with\ntwo doses of Pfizer-BioNTech or AstraZeneca COVID-19 vaccines approximately 3 months earlier. Levels of\nbinding (IgG) and neutralizing antibodies, including against Delta variant, were generally higher when an mRNA\nvaccine was used as either a heterologous or homologous boost (Munro et al., 2021)).","4347":"Vaccination providers must report COVID-19 vaccinations to their IIS\nand related systems. Your state\u2019s IIS cannot issue you a vaccination card, but they can provide a digital or\npaper copy of your vaccination record. If you need another COVID-19 vaccine dose and are unable to get a copy of your vaccination card or\nvaccination record, talk to a vaccination provider. If you have additional questions about vaccination records, please contact your state health department. Your local\nor state health department can also provide more information about the laws or regulations in your area.","5866":"Moderna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 09\/02\/22;\nThe COVID-19 vaccine by Moderna was approved by the FDA on January 31, 2022 as a 2-dose primary series\nfor active immunization to prevent COVID-19 in persons ages 18 years and older. CDC is issuing these EUI to\nprovide information about use of the COVID-19 vaccine by Moderna for primary and\/or additional booster that\nextend beyond its FDA-approved labeling as described further under \u201cWho can receive the COVID-19 vaccine\nby Moderna\u201d and \u201cWhat are the doses and intervals of the COVID-19 vaccine by Moderna for primary and\/or\nadditional doses\u201d. What is COVID-19?","1427":"My patient is moderately or severely immunocompromised and receiving EVUSHELD\u2122. Should\nthey also get COVID-19 vaccines? \uf1aa\n\uf209\nYes. In addition to following the recommended COVID-19 vaccination schedule, EVUSHELD\u2122 should be administered to\npeople who are moderately or severely immunocompromised every 6 months to supplement vaccine protection. Administration of EVUSHELD\u2122 should be deferred for at least 2 weeks after COVID-19 vaccination per the EVUSHELD EUA\n\u2122. COVID-19 vaccines can be administered any time after receipt of EVUSHELD\u2122. For more information, see COVID-19 vaccination and EVUSHELD\u2122 and CDC\u2019s EVUSHELD\u2122 guidance.","9816":"Additionally, the real world data from the Ministry of Health of Israel that included over 6,300 individuals aged\n12\u201315 years and over 4.1 million individuals aged 16 years and older who received a booster dose of the\nCOVID-19 vaccine by Pfizer-BioNTech at least 5 months after primary vaccination revealed no new safety\nconcerns. Available data on the safety or efficacy of a Pfizer-BioNTech COVID-19 vaccine dose after receipt of a non-FDA\nauthorized or approved COVID-19 vaccine are limited.","8785":"Be sure to wash or\nsanitize your hands again after taking off your mask and after putting your mask back on. When to throw away or change your mask\nDisposable masks should be thrown away after they\u2019re worn once. If you use respirators, check the manufacturer\u2019s instructions to learn how long they can be worn before they should be\nthrown away. Disposable masks and respirators\u202fthat become wet or dirty should be thrown away in the trash right away. Do not\ncontinue to wear a wet or dirty mask. Replace it with a dry, clean mask.","1849":"For information for the general public,\nplease see Monitoring Vaccine Effectiveness\nProspective Cohort\n\uf1aa\nHEROES\nArizona Healthcare, Emergency Response, and Other Essential Workers Surveillance (AZ Heroes) Study\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Healthcare providers\/first responders\/essential and other frontline workers\nParticipating Sites\nUniversity of Arizona, Tucson, AZ\nMel and Enid Zuckerman College of Public Health, Tucson, AZ\n\uf20c\nRECOVER\nResearch on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER)\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Healthcare providers\/first responders\/essential and other frontline workers\nParticipating Sites\nBaylor Scott and White Health, Temple, TX\n\uf209\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nKaiser Permanente Northwest, Portland, OR\nSt. Luke\u2019s Hospital, Duluth, MN\nUniversity of Arizona, Tucson, AZ\nUniversity of Miami, Miami, FL\nUniversity of Utah, Salt Lake City, UT\nPROTECT\nPediatric Research Observing Trends and Exposures in COVID-19 Timelines\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Children aged <18 years\nParticipating Sites\nBaylor Scott and White Health, Temple, TX\nUniversity of Arizona, Tucson, AZ\nUniversity of Miami, Miami, FL\nUniversity of Utah, Salt Lake City, UT\nCASCADIA\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Children aged <18 years and adults aged <50 years\nParticipating Sites\nKaiser Permanente Northwest, Portland, OR\nUniversity of Washington, Seattle, WA\nHousehold Transmission Studies\n\uf1aa\nHEROES-RECOVER Household Transmission Study\nResearch on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER) SARS-CoV-2 Household\nTransmission Study\nOutcome: Transmission in households of healthcare, first responder, and essential and other frontline workers with\nPopulation: Households of infected healthcare providers\/first responders\/essential and other frontline workers\nParticipating Sites\nBaylor Scott and White Health, Temple, TX\nKaiser Permanente Northwest, Portland, OR\nSt. Luke\u2019s Hospital, St. Louis, MO\nUniversity of Arizona, Tucson, AZ\nUniversity of Miami, Miami, FL\nUniversity of Utah, Salt Lake City, UT\n\uf20c\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nUniversity of Utah, Salt Lake City, UT\nRVTN (Respiratory Virus Transmission Network)\nRVTN \u2013 Sentinel\nSentinel Protocol\nOutcome: Household transmission among community members confirmed with SARS-CoV-2\nPopulation: Households of community members with positive SARS-CoV-2 tests recruited from sentinel testing sites\nParticipating Sites\nUniversity of Arizona, Tucson, AZ\nStanford University, Stanford, CA\nUniversity of Colorado, Denver, CO\nColumbia University, New York City, NY\nUniversity of North Carolina, Chapel Hill, NC\nVanderbilt University Medical Center, Nashville, TN\nMarshfield Clinic Research Institute, Marshfield, WI\n\uf20c\nRVTN \u2013 National\nNational Approach (also known as \u201cTrack COVID at Home \u201d).","7160":"It is approved as a 2-dose series for\nprevention of COVID-19 in individuals 12 years of age and older. It is also\nauthorized under EUA to provide:\n\uf0b7 a third primary series dose to individuals 12 years of age and older with\ncertain kinds of immunocompromise. 1 You may receive this Vaccine Information Fact Sheet even if your child is 11 years old.","6339":"If your healthcare provider\u2019s office policy allows it, consider bringing them to your\nappointment with you. What to Expect\nThe provider you meet with could be a doctor, nurse, nurse practitioner, physician assistant, or other type of healthcare\nprofessional. It may take more than one appointment to evaluate potential post-COVID symptoms and determine an accurate\ndiagnosis to better manage and treat your symptoms. Your provider may ask questions about your medical history, current\nsymptoms, and quality of life. Depending on your symptoms, they may run tests to determine a diagnosis and plan for\ntreatment. -\n-\n-\n-\n\u2022\n\u2022\nHealthcare providers are still learning about post-COVID conditions.","8841":"Sign up during the waiting period after you get any dose of COVID-19 vaccine or at any time\nafter vaccination\nAdd a dependent and complete health check-ins on their behalf\nEnter and report how you, or your dependent, feel after first, second, additional, and booster doses\nAvailable in multiple languages including English, Spanish, Chinese, Korean, and Vietnamese\n\u2022\n\u2022\n\u2022\n\u2022\nPlease note:\nV-safe is not an official record of being vaccinated against COVID-19\nV-safe does not give medical advice\nV-safe cannot schedule COVID-19 vaccination appointments\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:31 AM V-safe After Vaccination Health Checker | CDC\nEnroll in v-safe\nYou can enroll in v-safe after any dose of COVID-19 vaccine by using your smartphone and going to vsafe.cdc.gov.","7303":"A product authorized for\nemergency use has not undergone the same type of review by FDA as an\nFDA-approved product. FDA may issue an EUA when certain criteria are met, which includes that there are no\nadequate, approved, and available alternatives. In addition, the FDA decision is based\non the totality of the scientific evidence available showing that the product may be\neffective to prevent COVID-19 during the COVID-19 pandemic and that the known and\npotential benefits of the product outweigh the known and potential risks of the product.","7591":"Flight itinerary, including any connecting flights\nAirline\nFlight #\nDeparture airport and date of departure\nArrival airport and date of arrival\nAny COVID-19 vaccines received to date, if applicable:\nName of vaccine product (or products if a combination)\nDate of first dose\nDate of second dose (if a two-dose series) PDF or photograph of vaccination record\nPurpose of travel to the US and a brief explanation of why urgent travel is needed\nJustification for humanitarian or emergency exception to providing proof of being fully vaccinated (e.g., vaccine\navailability, passenger ineligible for vaccine at location, insufficient time to become fully vaccinated)\nDocumentation to support justification (e.g., medical records, orders for emergency evacuation)\nInformation regarding any other solutions that were sought prior to application (e.g., assistance in obtaining\nvaccination, etc.)","7813":"If you\u2019re not able to obtain a self-test when you need it, you might also visit a community testing site, or\ncall your local health department for more options. \u2022\n\uf209\n\u2022\n\u2022\nFDA-Authorized Tests\n\uf6e0 How to Use an At-Home COVID-19 Test\nRead the complete manufacturer\u2019s instructions for use before using the test. To use an at-home test, you will collect a nasal specimen and then test that specimen. If you do not follow the manufacturer\u2019s instructions, your test result may be incorrect. Wash your hands before and after you collect a nasal specimen for your test.","2720":"\u2022\n\u2022\n\u2022\nTrack your own health\nCaregivers should stay home and monitor their health for COVID-19 symptoms while caring for the person who is\nsick. Symptoms include fever, cough, and shortness of breath but other symptoms may be present as well. Trouble\nbreathing is a more serious warning sign that you need medical attention. Caregivers should continue to stay home after care is complete. Caregivers can leave their home 5 days after their\nlast close contact with the person who is sick (based on the time it takes to develop illness), or 5 days after the\nperson who is sick meets the criteria to end home isolation.","10126":"\u0083 If after a risk assessment the decision is made to receive a subsequent COVID-19 vaccine dose, the person should wait until after their episode has\nresolved. \u0083 For information on potential use of Janssen COVID-19 Vaccine in this situation, see Appendix A at www.cdc.gov\/vaccines\/covid-19\/clinical-\nconsiderations\/interim-considerations-us-appendix. html#appendix-a\n\u0083 Persons who have a history of myocarditis or pericarditis unrelated to mRNA or Novavax COVID-19 vaccination may receive any age-appropriate\nCOVID-19 vaccine after the episode of myocarditis or pericarditis has resolved.","4886":"However, some\nof these people may be able to receive Novavax or Janssen COVID-19 vaccine after a detailed risk assessment (see footnote 5 below). An immediate allergic reaction to a vaccine or injectable therapy is defined as any hypersensitivity-related signs or symptoms such as urticaria\n(hives), angioedema (visible swelling), respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occurs within four hours following\nadministration.","6527":"This is especially important\nif you are older or have severe health conditions or more than one health condition, including those on this list. Learn more\nabout how CDC develops COVID-19 vaccination recommendations. If you have a medical condition, learn more about Actions\nYou Can Take. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\nMedical Conditions\nCancer\nHaving cancer can make you more likely to get very sick from COVID-19. Treatments for many types of cancer can weaken\nyour body\u2019s ability to fight off disease. At this time, based on available studies, having a history of cancer may increase your\nrisk. Get more information:\nThe conditions on this list are in alphabetical order.","9453":"V-safe also provides second-dose reminders if needed\nand live telephone follow-up by CDC if participants report a significant health impact following\nCOVID-19 vaccination. For more information on how to sign up, visit: www.cdc.gov\/vsafe. WHAT IF I DECIDE NOT TO GET OR NOT TO HAVE MY CHILD GET SPIKEVAX\n(COVID-19 VACCINE, mRNA), MODERNA COVID-19 VACCINE, OR MODERNA\nCOVID-19 VACCINE, BIVALENT? Under the EUA, there is an option to accept or refuse receiving the vaccine. Should you decide\nnot to receive, or for your child not to receive, any of these vaccines, it will not change the\nstandard medical care.","10103":"\u0083 People who recently had SARS-CoV-2 infection may consider delaying their next COVID-19 dose by 3 months from symptom onset or positive test\n(if infection was asymptomatic). \u0083 Viral testing to assess for acute SARS-CoV-2 infection or serologic testing to assess for prior infection is not recommended for the purpose of\nvaccine decision-making. \u0083 Additional information at: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html#infection\n\u0083 COVID-19 vaccination is not recommended for post-exposure prophylaxis. \u00a7 Additionally, people with a history of an episode of immune-mediated syndrome characterized by thrombosis and thrombocytopenia, such as spontaneous or classic HIT, should not receive Janssen COVID-19 Vaccine.","3824":"If a vaccine recipient has health coverage, providers may seek appropriate reimbursement from the recipient\u2019s plan or\nprogram (e.g., private health insurance, Medicare, Medicaid ) for a vaccine administration fee. However, providers\ncannot bill the recipient for the balance not covered by the recipient\u2019s plan or program. For further information on\nreimbursement requirements, please see the CDC COVID-19 Vaccination Program Provider Requirements and Support\nwebpage. Can I charge patients a fee for administering COVID-19 vaccines?","8690":"10\/30\/22, 9:37 AM Understanding Variants | CDC\nUnderstanding Variants\nThe virus that causes COVID-19 is constantly changing, and new variants of the virus are expected to occur. Sometimes\nnew variants emerge and disappear. Other times, new variants persist. Numerous variants of the virus that causes\nCOVID-19 are being tracked in the United States and globally during this pandemic. How Variants Work\nIf you think about a virus like a tree growing and branching out; each branch on the tree is slightly different than the\nothers. By comparing the branches, scientists can label them according to the differences.","26":"Espa\u00f1ol | Other Languages\nGet the facts about COVID-19 and the virus that causes it, including how it spreads and new variants. CDC is reviewing this page to align with updated guidance. Protect Your Family Members\nCDC recommends COVID-19 vaccines for everyone 6 months and older and boosters for\neveryone 5 years and older, if eligible.","8742":"Considerations for specific groups of people\nPeople at higher risk for severe illness\nSome people are more likely to become very sick with COVID-19\nPeople who are older\nPeople with certain medical conditions\nPregnant and recently pregnant people\nPeople at increased risk, and those who live with or visit them, should\nTalk to their healthcare provider about whether they and the people\naround them should wear a mask or respirator when the COVID-19\nCommunity Level is medium.","6850":"The Countermeasures Injury Compensation Program (CICP) is a federal program that\nmay help pay for costs of medical care and other specific expenses of certain people\fwho have been seriously injured by certain medicines or vaccines, including these\nvaccines. Generally, a claim must be submitted to the CICP within one (1) year from the\ndate of receiving the vaccine. To learn more about this program, visit\nwww.hrsa.gov\/cicp\/ or call 1-855-266-2427. WHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)? An EUA is a mechanism to facilitate the availability and use of medical products,\nincluding vaccines, during public health emergencies, such as the current COVID-19\npandemic.","8957":"VAERS reports often lack\ncontextual information, such as total vaccinations given or information on unvaccinated groups for comparison. Most reports\nto VAERS are voluntary, which means they may be subject to biases. Data from VAERS reports should always be interpreted\nwith these limitations in mind. Learn more about how VAERS helps to monitor vaccine safety. Learn More about VAERS\nVIDEO\nVAERS and Vaccine Safety: How It Works\nVideo Length: 00:02:04\nWatch Video\nVIDEO\nVaccine Safety Monitoring Information for Healthcare Providers\nVideo Length: 00:04:44\nWatch Video\n\uf2ff For Providers and Jurisdictions\n10 Things Healthcare Providers Need to Know About VAERS\nCOVID-19 Clinical Resources\n\u2022\n\u2022\nLast Updated Aug. 25, 2021","3255":"History of myocarditis or pericarditis after a dose of an mRNA or Novavax COVID-19 vaccine Precaution A subsequent dose of any\nCOVID-19 vaccine should\ngenerally be avoided. See COVID-19 vaccination\nand myocarditis and\npericarditis for additional\nconsiderations. Abbreviations: MIS-C = multisystem inflammatory syndrome in children; MIS-A = multisystem inflammatory syndrome in adults\nSee Appendix E for definitions of allergic reactions, and risk assessment and triage of people with a history of allergies or allergic reactions. See FDA EUA fact sheets and U.S. COVID-19 Vaccine Product Information for full list of vaccine ingredients.","5062":"Clarification in contraindications and precautions and Appendix B of guidance for people with a history of an\nimmediate allergic reaction to a vaccine or injectable therapy that contains a component also contained in a COVID-19\nvaccine. Updated list of ingredients in COVID-19 vaccines (i.e., lack of metals) in Appendix C.\nCorrection of footnote numbering. Updated information for authorized age groups to include vaccination of adolescents aged 12\u201315 years with Pfizer-\nBioNTech COVID-19 Vaccine. 10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nUpdated information on coadministration of COVID-19 vaccines with other vaccines.","9943":"While there is no evidence acute illness reduces vaccine\nefficacy or increases adverse reactions, as a precaution, delay\nvaccinating patients with moderate or severe illness until\nthe illness has improved. Defer vaccination of people with current SARS-CoV-2\ninfection. For those with\n\u0083 Symptoms: defer vaccination until recovery from the acute\nillness and isolation has been discontinued. \u0083 Asymptomatic infection: defer vaccination until isolation has\nbeen discontinued. This recommendation applies regardless of whether the SARS-\nCoV-2 infection occurred before the recipient received an initial\ndose or between doses. Viral or serological testing to assess\nfor current or prior infection solely for the purpose of vaccine-\ndecision making is not recommended. 3.","5331":"In clinical trials, more than 61,000\nindividuals 18 years of age and older have received the Janssen COVID-19 Vaccine. Millions of\nindividuals have received the vaccine under EUA since February 27, 2021. WHAT ARE THE BENEFITS OF THE JANSSEN COVID-19 VACCINE? The Janssen COVID-19 Vaccine has been shown to prevent COVID-19. The duration of protection\nagainst COVID-19 is currently unknown. WHAT ARE THE RISKS OF THE JANSSEN COVID-19 VACCINE? Side effects that have been reported with the Janssen COVID-19 Vaccine include:\n\u2022 Injection site reactions: pain, redness of the skin and swelling.","7015":"The most commonly reported side effects were:\nFever\nHeadache\nFatigue (tiredness)\nPain at the injection site\nHelpful tips to relieve side effects\nAdults\nTo relieve pain or swelling on the arm where you got the shot:\nApply a clean, cool, wet washcloth over the area. Use or keep moving your arm. Also, if possible, get some rest. To reduce discomfort from fever:\nDrink plenty of fluids,\nDress in comfortable clothes,\nTalk to your doctor about taking over-the-counter (OTC) medicine, such as ibuprofen, acetaminophen, aspirin (only for\npeople ages 18 years or older), or antihistamines.","4851":"Diluent (Pfizer-BioNTech\nthat should not be mixed\nwith diluent, i.e., gray\ncap)\nVaccine is mixed with any diluent (i.e.,\nany type or volume of diluent)\nContact the manufacturer for information on the stability of the\nvaccine. If the manufacturer does not have information to support the\nstability of the vaccine, repeat the dose immediately (no minimum\ninterval). Do not administer the second dose until the person becomes eligible to receive vaccination (either by reaching the authorized age or if the\nauthorization is extended to include additional age groups), even if this results in the second dose being administered after the recommended\ninterval between doses.","5587":"A mask or respirator will be less effective if it fits poorly or if you wear it improperly or take it off\nfrequently. Individuals may consider the situation and other factors when choosing a mask or respirator that offers greater\nprotection. When caring for someone who is sick with COVID-19. If you are at increased risk for severe illness, for example, people who are immunocompromised, older adults, and\npeople with certain underlying medical conditions. When working at a job where you interact with large numbers of the public, especially when not everyone is consistently\nwearing a mask.","5762":"\u25aa Received COVID-19 vaccine dose(s) during treatment with B-cell-depleting\ntherapies over a limited period: the suggested interval to start revaccination is\nabout 6 months after completion of the B-cell-depleting therapy\n\u25aa Received COVID-19 vaccine dose(s) prior to or during treatment with\nhematopoietic cell transplant (HCT) or chimeric antigen receptor (CAR)-T-cell\ntherapy: revaccination at least 3 months after treatment\nThe COVID-19 vaccine by Pfizer-BioNTech can also be used under EUI for similar uses in persons ages 12\nyears and older as an alternative mRNA COVID-19 vaccine (see the Pfizer-BioNTech EUI Fact Sheet for\nRecipients).","1575":"6\/23\/22 Update (replaces 6\/18\/22 update; and revised to be a consolidated update that addresses all\nprimary series pediatric COVID-19 vaccination; 6\/23\/22 update also adds availability of age-appropriate\nModerna COVID-19 Vaccine for 6 years through 17 years of age):\nCOVID-19 Vaccination of Children 6 Months through 17 Years of Age\nPursuant to CDC\/ACIP recommendations and Secretarial Directives:\nAll authorized providers in the CDC COVID-19 Vaccination Program shall make immediately available and administer\nupon request \u2013\na two-dose series using the age-appropriate Moderna COVID-19 Vaccine product for children ages 6 months\nthrough 17 years\na three-dose series using the age-appropriate Pfizer-BioNTech COVID-19 Vaccine product for children ages 6\nmonths through 4 years\na two-dose series using the age-appropriate Pfizer-BioNTech COVID-19 Vaccine product for children ages 5 years\nthrough 17 years\n6\/23\/22 Update (replaces 6\/18\/22, 1\/6\/22, 9\/14\/21 and 10\/7\/21 updates; additional eligible group noted\nin bold italics; Updated on 10\/12\/22 to remove reference to the purple cap Pfizer-BioNTech vials which\nare no longer available):\nThird Dose for Recipients of Pfizer-BioNTech or Moderna COVID-19 Vaccine Who Are Immunocompromised\nPursuant to CDC\/ACIP recommendations and Secretarial Directives, a third primary dose of an mRNA COVID-19\nvaccine should be administered using the same mRNA COVID-19 vaccine as was administered for the 2-dose primary\nseries to persons who are moderately to severely immunocompromised at least 28 days after completing the two-\ndose primary series:\nPfizer-BioNTech COVID-19 Vaccine \u2013\nOrange cap to children 5 through 11 years of age\nGray cap to people 12 years and older\nModerna COVID-19 Vaccine \u2013\nDark blue cap\/magenta border to children 6 months through 5 years of age\nDark blue cap\/purple border to children 6 years through 11 years of age\nRed cap\/light blue border to people 12 years and older\nCOVID-19 Vaccination Under the CDC Interim Clinical Considerations and Emergency Use Instructions\nProviders may also administer COVID-19 vaccines as described in CDC guidance as updated from time to time:\nInterim Clinical Considerations for Use of COVID-19 Vaccines in the United States\nEmergency Use Instructions (see vaccine Fact Sheets)\n5\/23\/22 Update (revision of 5\/19\/22 update to add reference to the May 23, 2022, Secretarial Directive;\n9\/1\/22 revision noted in bold italics to clarify that booster doses available to this age group are\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\n9\/1\/22 revision noted in bold italics to clarify that booster doses available to this age group are\nmonovalent):\nCOVID-19 Vaccine Booster Doses for Children 5 through 11 Years of Age\nPursuant to CDC\/ACIP recommendations and the May 23, 2022, Secretarial Directive on Pediatric and Second COVID-\n19 Vaccine Booster Doses, all providers in the CDC COVID-19 Vaccination Program shall make immediately available\nand administer a single monovalent booster dose of Pfizer-BioNTech COVID-19 vaccine to individuals seeking such a\ndose as follows:\nChildren ages 5 through 11 years should receive a single monovalent Pfizer-BioNTech COVID-19 vaccine booster\ndose at least 5 months after completion of a Pfizer-BioNTech COVID-19 vaccine primary series.","2617":"The vaccine is made of mRNA\nwrapped in a coating that makes\ndelivery easy and keeps the body\nfrom damaging it. How does the\nvaccine work? The mRNA in the vaccine teaches\nyour cells how to make copies\nof the spike protein. If you are\nexposed to the real virus later,\nyour body will recognize it and\nknow how to fight it off. After the mRNA delivers the\ninstructions, your cells break\nit down and get rid of it. Antibody\nWhen your body\nresponds to the\nvaccine, it can\nsometimes cause a\nmild fever, headache,\nor chills. This is\ncompletely normal\nand a sign that the\nvaccine is working. GETTING VACCINATED?","9705":"Studies of\nCOVID-19 vaccine boosting in the United Kingdom have shown that a third dose of AstraZeneca, Moderna, or\nPfizer-BioNTech COVID-19 vaccines successfully boosted immune responses in people who had been primed\nwith two doses of Pfizer-BioNTech or AstraZeneca COVID-19 vaccines approximately 3 months earlier. Levels of\nbinding (IgG) and neutralizing antibodies, including against Delta variant, were generally higher when an mRNA\nvaccine was used as either a heterologous or homologous boost, or where the AstraZeneca COVID-19 vaccine\nwas used as a heterologous boost after primary vaccination with the Pfizer-BioNTech COVID-19 vaccine\n(Munro et al., 2021).","8351":"\uf209\nHow to Apply Motivational Interviewing During a Patient Visit\nStep 1: Embrace an attitude of empathy and collaboration\nStep 2: Ask permission to discuss vaccines\f10\/30\/22, 9:18 AM Talking with Patients about COVID-19 Vaccination | CDC\nAsk the patient a scaled question. For example, \u201cOn a scale of 1 to 10, how likely are you to get a COVID-19 vaccine?\u201d (1 =\nnever; 10 = already have an appointment to get vaccinated). Then explore both sides of whatever number is given. Example: Let\u2019s assume someone says 4. This is where curiosity comes in. You can say, \u201cOkay, why 4?","9976":"Has the person to be vaccinated ever had an allergic reaction to:\n* When vaccine recipients report a history of an immediate allergic reaction, providers should attempt to determine whether reactions reported following\nvaccination are consistent with immediate allergic reactions versus other types of reactions commonly observed following vaccination, such as vasovagal reaction or\npostvaccination side effects (which are not contraindications to receiving additional doses of that vaccine). \u2020 People with a known allergy to polysorbate have a contraindication to both Novavax and Janssen COVID-19 vaccines and a precaution to mRNA COVID-19 vaccines.","2864":"The following COVID-19 vaccines, categorized into three vaccine types, are currently approved under a Biologics License\nApplication (BLA) or authorized under an EUA by FDA (Table 1):\nmRNA vaccines\nModerna COVID-19 Vaccine\/SPIKEVAX (1) and Moderna COVID-19 Vaccine, Bivalent\nPfizer-BioNTech COVID-19 Vaccine\/COMIRNATY (2) and Pfizer-BioNTech COVID-19 Vaccine, Bivalent\nProtein subunit vaccine\nNovavax COVID-19 Vaccine, Adjuvanted\nAdenovirus vector vaccine\nJanssen (Johnson & Johnson) COVID-19 Vaccine\nNone of the currently FDA-approved or FDA-authorized COVID-19 vaccines are live-virus vaccines. Overview of COVID-19 vaccination\n\uf209\n\uf209\n\uf209\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nJanssen COVID-19 Vaccine is authorized for adults ages 18 years and older in certain limited situations due to safety\nconsiderations (see Appendix A).","2058":"Additionally, if you have COVID-19 during pregnancy, you are at increased\nrisk of complications that can affect your pregnancy and developing baby. Getting a COVID-19 vaccine can help protect you and your baby from serious health problems from COVID-\n19. People who are pregnant should stay up to date with their COVID-19 vaccines, including getting a COVID-19\nbooster shot when it\u2019s time to get one. Evidence continues to build showing that:\nCOVID-19 vaccination during pregnancy is safe and effective. COVID-19 vaccines are not associated with fertility problems in women or men.","9586":"\u2022 Delaying the second primary dose in persons ages 12 years and older who recently had SARS-CoV-2\ninfection, by 3 months from symptom onset or positive test (if infection was asymptomatic)\n\u2022 Primary dose(s), including for those with certain immunocompromising conditions or those with\nincomplete primary series, for persons ages 12 years and older who received primary or booster\nvaccination with certain non-FDA authorized or approved COVID-19 vaccines2. \u2022 An additional dose in persons ages 18 years and older with certain immunocompromising conditions\nwho received primary vaccination with the Janssen COVID-19 Vaccine.","1021":"Isolate and take precautions including wearing a high-quality mask to protect others from getting\ninfected. Tell people you had recent contact with that they may have been exposed. Monitor your symptoms. If you have any emergency warning signs, seek emergency care immediately. Consider contacting a healthcare provider, community health center , or pharmacy to learn about\ntreatment options that may be available to you. Treatment must be started within several days after you\nfirst develop symptoms to be effective. You are more likely to get very sick if you are an older adult or have an underlying medical\ncondition.","3091":"The monovalent\nNovavax booster dose is administered at least 6 months after completion of any primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent\nbooster dose. The monovalent Novavax booster dose is administered at least 6 months after completion of any primary series and cannot be used in people\nwho previously received any booster dose(s).","1428":"My patient is moderately or severely immunocompromised and receiving EVUSHELD\u2122. Should\nthey also get COVID-19 vaccines? \uf1aa\n\uf209\nYes. In addition to following the recommended COVID-19 vaccination schedule, EVUSHELD\u2122 should be administered to\npeople who are moderately or severely immunocompromised every 6 months to supplement vaccine protection. Administration of EVUSHELD\u2122 should be deferred for at least 2 weeks after COVID-19 vaccination per the EVUSHELD EUA\n\u2122. COVID-19 vaccines can be administered any time after receipt of EVUSHELD\u2122. For more information, see COVID-19 vaccination and EVUSHELD\u2122 and CDC\u2019s EVUSHELD\u2122 guidance.","3161":"If a person moves from a younger age group to an older age group during the primary series or between the\nprimary series and the booster dose, they should receive the vaccine product and dosage for the older age group for all\nsubsequent doses.","9834":"Reporting Adverse Event or Medication Errors\nThe vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event\nReporting System (VAERS):\n\u2022 vaccine administration errors whether or not associated with an adverse event,\n\u2022 serious adverse events (irrespective of attribution to vaccination),\n\u2022 cases of myocarditis\n\u2022 cases of pericarditis\n\u2022 cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and\n\u2022 cases of COVID-19 that result in hospitalization or death. Complete and submit reports to VAERS online at https:\/\/vaers.hhs.gov\/reportevent.html. For further assistance with reporting to VAERS call 1-800-822-7967. References\nAbu-Raddad L, Chemaitelly H, Ayoub HH, et al.","1158":"When the denominator data are not available for federal entities, these metrics are displayed\nas \u201cN\/A\u201d or entered as \u201c0.\u201d\nJurisdictions and Other Reporting Partners\nNational and jurisdictional metrics reported on CDT include vaccination data distribution to and administered in the following\nlocations:\nJurisdiction (state, territory, tribe, or local entity) partner clinics\nRetail pharmacies\nFederal partners and programs such as\nFederal Pharmacy Partnership for Long-term Care (LTC) Program\nDialysis centers participating in the Federal Dialysis Center Program\nFederal Emergency Management Agency (FEMA)\nHealth Resources and Services Administration (HRSA)\n\u2022\n-\n-\n-\n-\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\n-\n-\nPopulation Data Sources\nCensus\nCDC calculates rate and percentage measures for vaccination among the entire population and among select demographic\ngroups (such as people ages 65 years or older).","2654":"Call 911 or call ahead to your local emergency facility: Notify the operator that you are seeking care for someone who\nhas or may have COVID-19. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\nProtect yourself\nLimit contact\nCOVID-19 spreads between people who\nare in close contact (within about 6 feet)\nthrough respiratory droplets, created\nwhen someone talks, coughs or sneezes. Staying away from others helps stop the\nspread of COVID-19. The caregiver, when possible, should not\nbe someone who is at higher risk for\nsevere illness from COVID-19. The person who is sick should isolate\nThe sick person should separate\nthemselves from others in the home. Learn when and how to isolate.","3416":"Administration of subsequent COVID-19 vaccine doses: Onset of MIS 90 days or more after most recent\nCOVID-19 vaccine dose\nAdministration of subsequent COVID-19 vaccine dose(s) should be considered for those who meet the two criteria listed\nbelow:\n1. Clinical recovery has been achieved, including return to baseline cardiac function; and\n2. It has been at least 90 days after the diagnosis of MIS-C\/A\nFor people who had MIS-C\/A but do not meet both criteria above, see Consultation for decisions about COVID-19 vaccination.","6424":"When indoors with others, try to improve ventilation as much as possible. Wash your hands often with soap and water or use a hand sanitizer that contains at least 60% alcohol. It\u2019s important to be prepared and know what to do if you get sick with COVID-19. Don\u2019t delay seeking medical care. Be\nprepared by understanding the following steps:\nWhat you can do now\nKnow the symptoms of COVID-19. Learn how to check your COVID-19 Community Level. Knowing your community levels will help you decide when to add\nlayers of protection, like wearing a mask.","1590":"9\/1\/22 Update (Revises 2\/11\/22 Update to add reference to bivalent COVID-19 vaccine booster doses):\nThird primary dose\/booster dose COVID-19 vaccination of persons in the United States who received COVID-19\nvaccination outside of the United States or as part of a clinical trial\nAll providers are required to offer third primary doses or bivalent booster doses of the Pfizer-BioNTech or Moderna\nCOVID-19 vaccine to qualifying persons who received particular non-FDA authorized\/approved COVID-19 vaccines\noutside of the United States or as part of certain COVID-19 clinical trials as described in the Emergency Use\nInstructions issued by CDC on November 17, 2021, and February 11, 2022: Pfizer EUI , Moderna EUI , and\nInterim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States\n(https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html).","2052":"10\/30\/22, 9:30 AM COVID-19 Vaccines While Pregnant or Breastfeeding\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccines While Pregnant or Breastfeeding\nWhat You Need to Know\nCOVID-19 vaccination is recommended for all people aged 6 months and older. This includes people who are\npregnant, breastfeeding, trying to get pregnant now, or those who might become pregnant in the future. This also\nincludes infants ages 6 months and older born to people who were vaccinated or had a COVID-19 infection before\nor during pregnancy. If you are pregnant or were recently pregnant, you are more likely to get very sick from COVID-19 compared\nto people who are not pregnant.","9795":"However, robustness and duration of protection is variable (National Collaborating Center for Methods and\nTools, 2021). The circulating variant, as well as individual-level factors such as age and comorbidities, can\nimpact level of protection. For example, overall risk of reinfection increased during the Omicron wave, and\nprotection from infection or vaccination, was less robust than against previous variants (Pulliam et al., 2022). Additionally, some populations (e.g., older adults, immunocompromised) may have decreased levels of\nprotection following infection, necessitating an interval that balances the benefits and risks of delaying\nvaccination after infection at a population level.","747":"August 25, 2021: A federal entity made updates to data previously submitted to CDC that resulted in an increase of\n3,818 doses administered. August 17, 2021: Rhode Island made updates to data previously submitted to CDC that resulted in an increase of\n1,386 doses administered. August 12, 2021: Vermont made updates to data previously submitted to CDC that resulted in a decrease of 23,325\ndoses administered. August 4, 2021: Colorado made updates to data previously submitted to CDC that resulted in an increase of 11,379\ndoses administered.","2994":"A shorter interval (3 weeks for Novavax and Pfizer-BioNTech; 4 weeks for Moderna) between the first and second doses remains the\nrecommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is\nincreased concern about COVID-19 community levels or an individual\u2019s higher risk of severe disease. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent\nbooster dose.","444":"May 2021: New Hampshire lifted its national COVID-19 emergency response declaration in May 2021, which allows\nvaccine recipients to opt out of having their COVID-19 vaccinations included in the state\u2019s Immunization Information\nSystem registry. As such, data submitted by New Hampshire since May 2021 may not be representative of all COVID-19\nvaccination occurring in the state. On May 27, 2021, the total doses administered data posted to COVID Data Tracker for Vermont showed a decrease in\ndoses administered. This is an accurate reflection of the data and is the result of ongoing efforts to improve the data\nquality of records reported from Vermont.","4635":"For this model, a \u201cpremium\u201d\nfilter is based on one rated for MERV 13 filtration and \u201cregular\u201d filter is based on MERV 6 filtration. Learn more about\nHVAC filters and portable air cleaners. Visit Ventilation in Buildings (item #3 in Ventilation FAQs) to learn more about\nMERV ratings. Last Updated Feb. 9, 2022","3598":"\u2022\n\u2022\f10\/30\/22, 9:35 AM Data Definitions for COVID-19 Vaccinations in the United States\nLearn more about CDC\u2019s recommendations for a COVID-19 vaccine booster dose. On September 30, 2021, this language was changed to reflect the recommendation for a booster dose. People who\nreceived an additional dose since August 13, 2021, are included in this count. People Who Received a Second Booster Dose\nRepresents the total number of fully vaccinated people who received two subsequent doses of COVID-19 vaccine\nbeginning August 13, 2021, which includes people who received two booster doses and moderately or severely\nimmunocompromised people who received one additional dose and one booster dose.","1115":"10\/30\/22, 9:20 AM COVID-19 Vaccination Clinical and Professional Resources | CDC\nEspa\u00f1ol | Other Languages\nVaccines & Immunizations\nVaccines & Immunizations Home\nCOVID-19 Vaccination Clinical & Professional Resources\nClinical Resources for Each COVID-19 Vaccine\nProduct Information by U.S. Vaccine\nWhat's New\nImmunization Schedule for 6\nMonths of Age and Older\nEquity in Childhood COVID-19\nVaccination\n6 Things to Know About the\nCOVID-19 Vaccine for Children\nResources to Promote COVID-\n19 Vaccine for Children and\nTeens\n\uf20c\nInterim Clinical\nConsiderations\nProvider\nRequirements and\nSupport\nTalking with\nVaccine Recipients\nand Reporting\nSystems\n\uf32c Enroll as a COVID-19 Vaccine\nProvider\nLearn More and Enroll\n\uf12c COVID-19 VACCINE CHATBOT\nUse SmartFind chat tool to find answers to\ncommon COVID-19 vaccination questions.","2972":"Use of the monovalent Novavax booster dose in limited situations\nPeople ages 18 years and older who completed primary vaccination using any COVID-19 vaccine and have not received\nany previous booster dose(s) may receive a monovalent Novavax booster dose at least 6 months after completion of the\nprimary series if they are unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available) or\nunwilling to receive an mRNA vaccine and would otherwise not receive a booster dose. Table 2.","8123":"\u0083 Utilize proper risk communication strategies when communicating about monkeypox, including creating tailored, effective\ncommunication with trusted messengers that explain both what is known and what is not known about the spread and\noutcomes of monkeypox infection.151\n\u0083 Create and disseminate graphics through trusted messengers that show the difference in the structure of the virus particles\nand virions for the virus that causes monkeypox and the virus that causes COVID-19.","7082":"Learn more\nabout what you can do\u202fwhen you have been fully vaccinated when you are up to date with your COVID-19 vaccines. If you are pregnant and have questions about COVID-19 vaccine\nIf you would like to speak to someone about COVID-19 vaccination during pregnancy, you can contact MotherToBaby. MotherToBaby experts are available to answer questions in English or Spanish by phone or chat. The free and\nconfidential service is available Monday\u2013Friday 8am\u20135pm (local time).","6193":"When reported, the cases have especially been in adolescents and\nyoung adult males within several days after mRNA COVID-19 vaccination (Pfizer-BioNTech or Moderna). More often after the second dose\nUsually within a week of vaccination\nMost patients with myocarditis or pericarditis who received care responded well to medicine and rest and felt better\nquickly. Patients can usually return to their normal daily activities after their symptoms improve. Those who have been diagnosed with myocarditis should consult with their cardiologist (heart doctor) about return to\nexercise or sports. CDC and its partners are actively monitoring reports of myocarditis and pericarditis after COVID-19 vaccination.","5719":"If you are 12 years and older and you are receiving vaccination for uses provided under EUI, you have a\nchoice of receiving the COVID-19 vaccine by either Moderna or Pfizer-BioNTech (see the Pfizer-BioNTech\nEUI Fact Sheet for Recipients and Caregivers). What are Emergency Use Instructions (EUI)? EUI are issued by CDC to provide information about emergency use of FDA-approved (licensed) medical\nproducts that may not be included in or differ in some way from the information provided in the FDA-\napproved labeling (package insert). EUI consist of fact sheets for healthcare providers and recipients.","4096":"\uf1aa\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:18 AM Frequently Asked Questions about COVID-19 Vaccination | CDC\n2 doses of Novavax vaccine 3-8* weeks apart for people ages 12 years and older. 1 dose of Johnson & Johnson\u2019s Janssen (J&J\/Janssen) vaccine for people ages 18 and older. *Talk to your healthcare or vaccine provider about the timing for the second dose in your primary series. You\nshould not get the second dose early. People who are moderately or severely immunocompromised may have a different immune response following COVID-\n19 vaccination. Please see specific COVID-19 vaccination guidance for people who are moderately or severely\nimmunocompromised. \u2022\n\u2022\nNo.","8069":"In addition, CDC is communicating with key medical groups and continues to provide updated reporting and\nlaboratory guidance for clinicians who may identify hepatitis of unknown cause in children.126\n\u0083 When will vaccines be available for children ages 5 years and younger?d\n\u0082 As of June 18, 2022, everyone ages 6 months and older is recommended to get a Moderna or Pfizer-BioNTech COVID-19\nIdentified misinformation themes that may impact vaccine confidence\n\u0083 Some social media users believe authorizing vaccines in children is only a ploy for pharmaceutical companies to make\n\u0083 Some social media users claim that COVID-19 cases in children are always mild.129,130,131 w\nWays public health and partners can take action to improve vaccine confidence\n\u0083 Encourage primary care providers and other medical professionals who care for children to explain the benefits of COVID-19\nvaccination to parents and guardians.","7751":"Based on a recent analysis of data from the Vaccine Safety Datalink, the rate of GBS within the first 21 days\nfollowing J&J\/Janssen COVID-19 vaccination was found to be 21 times higher than after Pfizer-BioNTech or Moderna\n(mRNA COVID-19 vaccines). After the first 42 days, the rate of GBS was 11 times higher following J&J\/Janssen COVID-\n19 vaccination. The analysis found no increased risk of GBS after Pfizer-BioNTech or Moderna (mRNA COVID-19\nvaccines). CDC and FDA will continue to monitor for and evaluate reports of GBS occurring after COVID-19\nvaccination and will share more information as it becomes available.","3166":"Considerations for timing of COVID-19 vaccination in relation to\nimmunosuppressive therapies\n\uf209\nTable of Contents \uf426\nTiming, spacing, interchangeability, and coadministration of\n4-Day grace period\nTransitioning from a younger to older age group\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nHowever, FDA authorization allows for dosing options for certain situations where a child ages from a younger to older age\ngroup for Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine . Refer to Table 1 for information about\nage-specific vaccine products and dosages. For information on the timing of COVID-19 vaccination (primary series and booster doses) after SARS-CoV-2 infection, see\nCOVID-19 vaccination and SARS-CoV-2 infection.","5060":"Clarification in contraindications and precautions and Appendix B of guidance for people with a history of an\nimmediate allergic reaction to a vaccine or injectable therapy that contains a component also contained in a COVID-19\nvaccine. Updated list of ingredients in COVID-19 vaccines (i.e., lack of metals) in Appendix C.\nCorrection of footnote numbering. Updated information for authorized age groups to include vaccination of adolescents aged 12\u201315 years with Pfizer-\nBioNTech COVID-19 Vaccine. 10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nUpdated information on coadministration of COVID-19 vaccines with other vaccines.","8615":"The vaccine also contains another ingredient called an adjuvant that helps the immune system respond to that spike protein\nin the future. Once the immune system knows how to respond to the spike protein, the immune system will be able to\nrespond quickly to the actual virus spike protein and protect you against COVID-19. About Novavax\nResearch for protein subunit technology\nProtein subunit vaccines have been used for years. More than 30 years ago, a hepatitis B vaccine became the first protein subunit vaccine to be approved for use in\npeople in the United States.","8914":"This creates a\nhigh-risk environment for other dialysis patients and healthcare personnel and underscores the importance of\nvaccination to protect everyone in these clinics. Why vaccinate patients while they are at the dialysis clinic? Dialysis patients can be easily reached for COVID-19 vaccination at dialysis clinics, which have extensive operational,\nlogistical, and IT infrastructure to serve as capable vaccine providers. Many dialysis patients are accustomed to receiving routine vaccinations at the dialysis clinic.","2568":"Immunization Schedule for Persons 18 Years of Age\nType\nRecipient\nAge\nProduct*\nFor Most People\nThose Who ARE Moderately or\nSeverely Immunocompromised\nDoses\nInterval Between\nDoses\u2020\nDoses\nInterval Between\nDoses\nmRNA\nvaccine\nand older\nMONOVALENT Moderna\nRed vial cap with a\nblue-bordered label\nPrimary series: Monovalent\nAt least 4\u20138\nweeks\u2021\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Moderna\nBlue cap with\ngray-bordered label\nBooster dose\u00a7: Bivalent\nAt least 8 weeks\nAt least 8 weeks\nand older\nMONOVALENT Pfizer-BioNTech\nGray vial cap with\ngray-bordered label\nPrimary series: Monovalent\nAt least 3-8\nweeks\u2021\nDose 1 to 2 At least 3 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Pfizer-BioNTech:\nGray vial cap with\ngray-bordered label\nBooster dose\u00a7: Bivalent\nAt least 8 weeks\nAt least 8 weeks\nProtein\nsubunit\nvaccine\nand older\nMONOVALENT Novavax\nPrimary series: Monovalent\nAt least 3\u20138\nweeks\u2021\nDose 1 to 2 At least 3 weeks\nModerna or Pfizer-BioNTech\nbivalent COVID-19 vaccine should\nbe used for the booster dose.","8373":"Content developed by the American Psychological Association (Jared Skillings, PhD, ABPP; Erin Swedish, PhD; Robin McLeod, PhD; Mitch Prinstein, PhD, ABPP;\nand Stephen Gillaspy, PhD) in partnership with U.S. Centers for Disease Control and Prevention\nStep 3: Motivational interviewing\nStep 4: Respond to questions about vaccines, health, or mental health\nAdditional Resources:\nKey Things to Know about COVID-19 Vaccines\nFrequently Asked Questions about COVID-19 Vaccines\nAnswering Patients\u2019 Questions About COVID-19 Vaccine and Vaccination\nTalking with Parents About COVID-19 Vaccination\nHow to Tailor COVID-19 Information for Your Specific Audience\nHow to Address COVID-19 Misinformation\nPage last reviewed: November 3, 2021","6061":"Effectiveness of an additional\nprimary dose of the COVID-19 vaccine by Moderna is inferred from immunogenicity data in\nimmunocompromised adults who received a third 0.5 mL (100 \u03bcg of mRNA) primary dose. Rates of local or\nsystemic adverse events with 50 \u03bcg booster dose were comparable to those observed after Dose 2 of the\nprimary series (Miller, 2021; Das, 2021). Available data on the safety or efficacy of a Moderna COVID-19 vaccine dose after receipt of a non-FDA\nauthorized or approved COVID-19 vaccine are limited.","2064":"Getting a COVID-19 vaccine can protect you and others around you from getting very sick from COVID-19, and keeping you as\nhealthy as possible during pregnancy is important for the health of your baby. CDC recommends COVID-19 vaccines for everyone aged 6 months and older, including people who are pregnant,\nbreastfeeding, trying to get pregnant now, or those who might become pregnant in the future. This recommendation includes\ngetting boosters when it is time to get one.","9329":"If\nneeded, ask the provider to write down\nor print out any instructions, medication\nnames, or diagnoses. After the Appointment\n\nMake appointments for follow up. Record future appointments,\nincluding tests, in your calendar. If\nothers will go with you or drive you to\nfuture appointments, make sure the\nappointments are on their calendars too. Follow your provider\u2019s instructions to\nthe best of your ability. Contact your provider\u2019s office with any\nquestions or clarifications. Continue to record symptoms and\nkeep your journal, so you can refer\nto updates or changes during your\nnext appointment. Update and keep track of medications\nand supplements. For more information on post-COVID conditions, please visit\nhttps:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/long-term-effects.html.","5799":"Additional information on the common and serious side effects of the COVID-19 vaccine by Moderna can\nbe found in the package insert for Spikevax and in the EUA Fact Sheet for Recipients and Caregivers. Moderna COVID-19 Vaccine EUI Recipient Fact Sheet, ver 9\/02\/2022 Page 4 of 4\nWhat are the benefits of the COVID-19 vaccine by Moderna? The COVID-19 vaccine by Moderna has been shown in clinical studies to be effective in preventing COVID-\n19.","4920":"Ability of the patient to be vaccinated in a setting where appropriate medical care is immediately available for anaphylaxis. For people\nwith a contraindication due to allergy to one type of COVID-19 vaccine who are receiving another type that has been deemed a precaution\nand for people with an immediate, non-severe allergic reaction after a previous dose of COVID-19 vaccine who are receiving vaccination\nwith a subsequent dose of that COVID-19 vaccine type, vaccination should only be undertaken in an appropriate setting under the\nsupervision of a healthcare professional experienced in the management of severe allergic reactions.","1355":"Can a monovalent mRNA vaccine (i.e., Moderna or Pfizer-BioNTech) be used for the booster dose? \uf1aa\nBooster Doses\nEveryone ages 5 years and older is recommended to receive 1 bivalent mRNA booster dose if they have completed a\nprimary series with any FDA-approved or FDA-authorized COVID-19 vaccine:\nChildren age 5 years are recommended to receive the Pfizer-BioNTech bivalent booster dose. Who should receive a booster dose? \uf1aa\f10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\nChildren age 5 years are recommended to receive the Pfizer BioNTech bivalent booster dose.","6864":"Manufactured for\nBioNTech Manufacturing GmbH\nAn der Goldgrube 12\n55131 Mainz, Germany\nManufactured by\nPfizer Inc., New York, NY 10017\nScan to capture that this Fact Sheet was provided to vaccine\nrecipient for the electronic medical records\/immunization\ninformation systems.","9354":"Children who will turn from 11 years to 12 years of age between doses in the primary series may receive, for any\ndose in the primary series, either: (1) the Moderna COVID-19 Vaccine authorized for use in individuals 6 years\nthrough 11 years of age; or (2) Moderna COVID-19 Vaccine authorized for use in individuals 12 years of age and\nolder; or (3) SPIKEVAX (COVID-19 Vaccine, mRNA).","2528":"Immunization Schedule for Children 6 Months through 17 Years of Age*\nType\nRecipient\nAge\nProduct\u2020\nFor Most People\nThose Who ARE Moderately or\nSeverely Immunocompromised\nDoses Interval Between Doses\u2021 Doses Interval Between Doses\nmRNA\nvaccine\nthrough\nMONOVALENT Moderna:\nBlue vial cap with\nmagenta-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 4\u20138 weeks\u00b6\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nthrough\nMONOVALENT Moderna:\nBlue vial cap with\npurple-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 4\u20138 weeks\u00b6\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Moderna:\nBlue vial cap with\ngray-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nthrough\nMONOVALENT Moderna:\nRed vial cap with\nblue-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 4\u20138 weeks\u00b6\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Moderna:\nBlue vial cap with\ngray-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nthrough\nMONOVALENT Pfizer-BioNTech:\nMaroon vial cap with\nmaroon-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 3\u20138 weeks\u00b6 Dose 1 to 2 At least 3 weeks\nDoses 2 and 3 At least 8 weeks (2 months) Dose 2 to 3 At least 8 weeks (2 months)\nthrough\nMONOVALENT Pfizer-BioNTech:\nOrange vial cap with\norange-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 3\u20138 weeks\u00b6\nDose 1 to 2 At least 3 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Pfizer-BioNTech:\nOrange vial cap with\norange-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nthrough\nMONOVALENT Pfizer-BioNTech:\nGray vial cap with\ngray-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 3-8 weeks\u00b6\nDose 1 to 2 At least 3 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Pfizer-BioNTech:\nGray vial cap with\ngray-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nProtein\nsubunit\nvaccine\nand older\nMONOVALENT Novavax\nPrimary series: Monovalent\nDose 1 to 2 At least 3\u20138 weeks\u00b6 Dose 1 to 2 At least 3 weeks\nmRNA (Moderna, Pfizer-\nBioNTech) should be used for the\nbooster dose.","3856":"\uf1aa\f10\/30\/22, 9:17 AM FAQs About Implementing COVID-19 Vaccination Program in Provider Practices | CDC\nCOVID-19 vaccination providers, after administering a dose of COVID-19 vaccine, must record all information marked by\nan asterisk below (if it is not already recorded in the vaccine recipient\u2019s record) and report the following required vaccine\nadministration data, or other data elements if revised by CDC, to the appropriate entity noted in the agreement:\n1. Administered at location\/facility name\/ID\n2. Administered at location type\n3. Administration address (including company)*\n4. Recipient name and ID*\n5. Recipient date of birth*\n6. Recipient sex*\n7. Recipient race\n8. Recipient ethnicity\n9. Recipient address*\n10. Administration date*\n11. CVX (product)*\n12.","4034":"Jurisdictions may use more targeted population counts for the denominators in their rate\ncalculations (for example, people over age 18), which would result in values different than those reported on the\nCDC COVID Data Tracker\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nData will be updated weekly on Thursday after review and verification, usually between 1:30 pm and 8:00 pm ET. Note: Beginning June 13, 2022, instead of daily, jurisdictions and other partners report vaccine administration and\ndelivery data to CDC weekly on Wednesdays by 6:00 AM ET.","7129":"Related Pages\nCOVID-19 Toolkit for Pregnant People and New Parents\n\u203a\nCOVID-19 Vaccines While Pregnant or Breastfeeding\n\u203a\nBreastfeeding and Caring for Newborns if You Have COVID-19\n\u203a\nHow to Protect Yourself and Others\n\u203a\f10\/30\/22, 9:39 AM Pregnant and Recently Pregnant People | CDC\nWhat to Do If You Are Sick\n\u203a\nRelated Research and More Information\nRelated Research\nZambrano LD, Ellington S, Strid P, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with\nLaboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status \u2014 United States, January 22\u2013October 3, 2020. MMWR\nMorb Mortal Wkly Rep 2020;69:1641\u20131647. DOI: 10.15585\/mmwr.mm6944e3.","2534":"Immunization Schedule for Children 6 Months through 17 Years of Age*\nType\nRecipient\nAge\nProduct\u2020\nFor Most People\nThose Who ARE Moderately or\nSeverely Immunocompromised\nDoses Interval Between Doses\u2021 Doses Interval Between Doses\nmRNA\nvaccine\nthrough\nMONOVALENT Moderna:\nBlue vial cap with\nmagenta-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 4\u20138 weeks\u00b6\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nthrough\nMONOVALENT Moderna:\nBlue vial cap with\npurple-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 4\u20138 weeks\u00b6\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Moderna:\nBlue vial cap with\ngray-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nthrough\nMONOVALENT Moderna:\nRed vial cap with\nblue-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 4\u20138 weeks\u00b6\nDose 1 to 2 At least 4 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Moderna:\nBlue vial cap with\ngray-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nthrough\nMONOVALENT Pfizer-BioNTech:\nMaroon vial cap with\nmaroon-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 3\u20138 weeks\u00b6 Dose 1 to 2 At least 3 weeks\nDoses 2 and 3 At least 8 weeks (2 months) Dose 2 to 3 At least 8 weeks (2 months)\nthrough\nMONOVALENT Pfizer-BioNTech:\nOrange vial cap with\norange-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 3\u20138 weeks\u00b6\nDose 1 to 2 At least 3 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Pfizer-BioNTech:\nOrange vial cap with\norange-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nthrough\nMONOVALENT Pfizer-BioNTech:\nGray vial cap with\ngray-bordered label\nPrimary series: Monovalent\nDose 1 to 2 At least 3-8 weeks\u00b6\nDose 1 to 2 At least 3 weeks\nDose 2 to 3 At least 4 weeks\nBIVALENT Pfizer-BioNTech:\nGray vial cap with\ngray-bordered label\nBooster dose: Bivalent\nDose 2 to 3 At least 8 weeks (2 months) Dose 3 to 4 At least 8 weeks (2 months)\nProtein\nsubunit\nvaccine\nand older\nMONOVALENT Novavax\nPrimary series: Monovalent\nDose 1 to 2 At least 3\u20138 weeks\u00b6 Dose 1 to 2 At least 3 weeks\nmRNA (Moderna, Pfizer-\nBioNTech) should be used for the\nbooster dose.","9066":"CDC established multiple ways to connect and share viral genomic sequence\ndata being produced by CDC, public health laboratories, and commercial diagnostic laboratories within publicly accessible\ndatabases. Learn More About Tracking Variants\nSome, but not all, monoclonal antibody treatments remain effective against Omicron. Public health agencies\nwork with healthcare providers to ensure that effective treatments are used appropriately to treat patients. We Have the Tools to Fight Variants\nThe following pages cover more detailed information about specific key prevention actions which can help fight variants. Vaccines Masks Testing Ventilation\n\u2022\n\u2022\n\u2022\n\u2022\n\uf3c4 Definitions &\nClassifications\n\uf3c0 Tracking &\nSurveillance\n\uf251 US & Global\nVariant Data\nLast Updated Aug. 11, 2021","8208":"(Children 6 months to 4 years\nare not recommended for a\nbooster.) Up to Date: Children 6 months to 4 years of age are up to date two weeks after completing the 2nd dose of their\nprimary series. Children 5 years of age who received a Moderna primary series are up to date immediately after they\nhave received the most recent booster recommended for them.","4125":"Since there\nis no way to tell in advance how children, who are not moderately or severely immunocompromised, or those who may\nbe immunocompromised. A child can be immunocompromised and still healthy, will be affected by COVID-19 it\u2019s\nimportant to get them vaccinated as soon as possible to protect them against severe illness. To find your child a COVID-19\nvaccine or booster near you:\u202fSearch\u202fvaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. Should parents and caregivers wait for updated or additional vaccines, if a child is low risk for\ninfection?","6748":"It is predominantly a\nrespiratory illness that can affect other organs. People with COVID-19 have had a wide\nrange of symptoms reported, ranging from mild symptoms to severe illness leading to\ndeath. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may\ninclude: fever or chills; cough; shortness of breath; fatigue; muscle or body aches;\nheadache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or\nvomiting; diarrhea. For more information on EUA, see the \u201cWhat is an Emergency Use Authorization\n(EUA)?\u201d section at the end of this Fact Sheet.","670":"February 3, 2022: Alaska made updates to data previously submitted to CDC that resulted in a decrease of 3,945\ndoses administered. January 28, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n26,796 doses administered. January 28, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 14,973\ndoses administered.","655":"March 11, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 40,332\ndoses administered. March 11, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of 2,928\ndoses administered. March 04, 2022: Illinois made updates to data previously submitted to CDC that resulted a decrease\nof 18,988 doses administered. March 03, 2022: California made updates to data previously submitted to CDC that resulted in an increase\nof 16,930 doses administered. March 01, 2022: Michigan made updates to data previously submitted to CDC that resulted in a decrease of 13,028\ndoses administered.","8109":"If given between 4\u201314 days after the date of exposure, vaccination may reduce the symptoms of disease, but\nmay not prevent the disease.141\fCOVID-19 State of Vaccine Confidence Insights Report | October 10, 2022\n\u0082 Monkeypox PrEP should be offered to people with the highest potential for exposure to monkeypox such as:142\n\u008f Gay, bisexual, and other men who have sex with men, transgender or nonbinary people who in the past 6 months have\nhad\n\u00bb A new diagnosis of one or more nationally reportable sexually transmitted diseases (i.e., acute HIV, chancroid,\nchlamydia, gonorrhea, or syphilis)\n\u00bb More than one sex partner\n\u008f People who have had any of the following in the past 6 months:\n\u00bb Sex at a commercial sex venue\n\u00bb Sex in association with a large public event in a geographic area where monkeypox transmission is occurring\n\u008f Sexual partners of people with the above risks\n\u008f People who anticipate experiencing the above risks\nIdentified misinformation themes that may impact vaccine confidence\n\u0083 Some social media users believe COVID-19 vaccines weaken the body\u2019s immune system, making vaccinated individuals more\nsusceptible to monkeypox.143,144\n\u0083 Some social media users believe monkeypox is caused by COVID-19 vaccines.145,146\n\u0083 Some social media users believe monkeypox is being used to scare people now that COVID-19 is not seen as a threat.147,148\n\u0083 Some social media users believe pharmaceutical companies are attempting to create a monkeypox pandemic to increase\nWays public health and partners can take action to improve vaccine confidence\n\u0083 Encourage local health departments, public health experts, and healthcare workers to explain the absence of association\nbetween COVID-19 vaccines and monkeypox.","343":"Massachusetts does not provide data directly to CDC. From January 27, 2021 to January 18, 2022, vaccination data\nwas provided from other entities on residents of the affected counties who were vaccinated in other state\/counties. This data was displayed on the CDC COVID Data Tracker, but without complete reporting, it creates artificially low\nnumbers for these counties which is why this data will no longer be displayed. Due to a data processing issue on January 7, 2022, vaccination delivery data were not updated on CDC COVID Data\nTracker and reflect data as of January 6, 2022.","5733":"Symptoms\nmay appear 2 to 14 days after exposure to the virus. Symptoms may include: fever or chills, cough,\nshortness of breath, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat,\ncongestion or runny nose, nausea or vomiting, and diarrhea. Who can receive primary and additional dose(s) of the COVID-19 vaccine by Moderna under the EUI? People who can receive the COVID-19 vaccine by Moderna under EUI are described below.","1336":"\uf1aa\f10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\nPeople who are not moderately or severely immunocompromised\nPeople who are moderately or severely immunocompromised\nNo, the bivalent mRNA vaccines (i.e., Moderna and Pfizer-BioNTech) are not currently authorized to be used for the\nprimary series; they may only be used for the booster dose. If a bivalent Pfizer-BioNTech vaccine is administered for a primary series dose: Do not repeat the dose. The primary and\nbooster dosages are the same; the bivalent dose can be counted as a primary series dose.","3171":"Primary series\nIn general, the same monovalent vaccine product should be used for all doses in the primary series. A mixed primary series composed of any combination of Moderna, Novavax, and Pfizer-BioNTechCOVID-19 vaccines is not\nauthorized. If a mixed primary series is inadvertently administered, the series is complete, and doses do not need to be\nrepeated. In the following exceptional situations, a different COVID-19 vaccine may be administered to complete a primary series at a\nminimum interval of 28 days from the last COVID-19 vaccine dose. No VAERS report is required.","2879":"COVID-19 vaccine products currently approved or authorized in the United States*\nModerna\nAge indication Vaccine composition Vaccine vial cap color Label border color Dilution required Dose Injection volume\nPrimary series vaccination\n6 months\u20135 years Monovalent Dark blue Magenta No 25 \u00b5g 0.25 mL\n6\u201311 years\u2020 Monovalent Dark blue Purple No 50 \u00b5g 0.5 mL\n12 years and older Monovalent Red Light blue No 100 \u00b5g 0.5 mL\nBooster vaccination\n6\u201311 years Bivalent Dark blue Gray No 25 \u00b5g 0.25 mL\n12 years and older Bivalent Dark blue Gray No 50 \u00b5g 0.5 mL\nNovavax\nAge indication Vaccine composition Vaccine vial cap color Label border color Dilution required Dose Injection volume\nPrimary series vaccination\n12 years and older Monovalent Royal blue No color No 5 \u00b5g rS and\n50 \u00b5g of Matrix-M\u2122 adjuvant\nBooster vaccination\n18 years and older Monovalent Royal blue No color No 5 \u00b5g rS and\n50 \u00b5g of Matrix-M\u2122 adjuvant\nPfizer-BioNTech\nAge indication Vaccine composition Vaccine vial cap color Label border color Dilution required Dose Injection volume\nPrimary series vaccination\n6 months\u20134 years\u2021 Monovalent Maroon Maroon Yes 3 \u00b5g 0.2 mL\n5\u201311 years Monovalent Orange Orange Yes 10 \u00b5g 0.2 mL\n12 years and older Monovalent Gray Gray No 30 \u00b5g 0.3 mL\nBooster vaccination\n5\u201311 years Bivalent Orange Orange Yes 10 \u00b5g 0.2 mL\n12 years and older Bivalent Gray Gray No 30 \u00b5g 0.3 mL\nJanssen\nAge indication Vaccine composition Vaccine vial cap color Label border color Dilution required Dose Injection volume\nPrimary series vaccination\n18 years and older Monovalent Blue No color No 5\u00d71010 viral particles 0.5 mL\nBooster vaccination\n18 years and older Monovalent Blue No color No 5\u00d71010 viral particles 0.5 mL\nAbbreviations: rS = recombinant spike protein\n*Illustrations of the different vaccine vial cap and label border colors are available for Moderna and Pfizer-BioNTech COVID-19 vaccines.","5745":"\u2022 People ages 12 years and older who recently had SARS-CoV-2 infection may receive a second\nprimary dose after a deferral period of 3 months from symptom onset or positive test (if infection\nwas asymptomatic)\n\u2022 People ages 12 years and older who received an incomplete primary dose series (only the first dose\nof a 2-dose primary series) with certain non-FDA authorized or approved COVID-19 vaccines at\fModerna COVID-19 Vaccine EUI Recipient Fact Sheet, ver 9\/02\/2022 Page 2 of 4\nleast 28 days ago should receive a primary dose of the COVID-19 vaccine by Moderna to complete\nthe series.","8582":"Each type of vaccine prompts our bodies to recognize and help protect us from\nthe virus that causes COVID-19. None of these vaccines can give you COVID-19. Vaccines do not use any live virus\f10\/30\/22, 9:34 AM Understanding How COVID-19 Vaccines Work | CDC\nmRNA vaccines (Pfizer-BioNTech or Moderna)\nTo trigger an immune response, many vaccines put a weakened or inactivated germ into our bodies. Not mRNA vaccines. Instead, mRNA vaccines use mRNA created in a laboratory to teach our cells how to make a protein\u2014or even just a piece of a\nprotein\u2014that triggers an immune response inside our bodies.","3179":"People who received Janssen COVID-19 Vaccine after a dose of another COVID-19 vaccine should be considered to have\nreceived a valid, single-dose Janssen primary series. Booster vaccination\nFor booster vaccination, bivalent mRNA vaccines are recommended. Any homologous or heterologous bivalent mRNA vaccine\ncan be used if a booster dose is FDA-authorized for use in that age group. COVID-19 vaccines may be administered without regard to timing of other vaccines. This includes simultaneous\nadministration of COVID-19 vaccine and other vaccines on the same day. However, there are additional considerations if\nadministering an orthopoxvirus vaccine (see below).","395":"\u2022\n-\n\u2022\n\u2022\n\u2022\n-\n\u2022\n\u2022\n\u2022\n-\n\u2022\n\u2022\n\u2022\n\u2022\n-\n\u2022\n\u2022\n-\n-\n-\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nOn September 29, 2021: CDC identified and corrected a processing error after reporting adjustments were made for\nTexas. This error resulted in a higher count for the total number of people who were fully vaccinated in the state. On September 28, 2021, reporting adjustments for Texas resulted in a decrease of 91,119 doses. On September 23, 2021, data review and reporting adjustments resulted in a decrease in the number of vaccine doses\nadministered for Washington State of 473,191 doses.","5458":"People with post-COVID conditions may experience health\nproblems from different types and combinations of symptoms happening over different lengths of time. Most patients\u2019\nsymptoms slowly improve with time. However, for some people, post-COVID conditions can last weeks, months, or longer\nafter COVID-19 illness and can sometimes result in disability.","2051":"10\/30\/22, 9:30 AM COVID-19 Vaccines While Pregnant or Breastfeeding\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccines While Pregnant or Breastfeeding\nWhat You Need to Know\nCOVID-19 vaccination is recommended for all people aged 6 months and older. This includes people who are\npregnant, breastfeeding, trying to get pregnant now, or those who might become pregnant in the future. This also\nincludes infants ages 6 months and older born to people who were vaccinated or had a COVID-19 infection before\nor during pregnancy. If you are pregnant or were recently pregnant, you are more likely to get very sick from COVID-19 compared\nto people who are not pregnant.","236":"The science of antibodies is called \u201cserology.\u201d Antibody tests, also called \u201cserology tests,\u201d identify antibodies in blood samples. While other parts of the immune system also contribute to protection, it is easiest to test for antibodies. As of August 2021, more than 80 antibody tests have been granted FDA emergency use authorization (EUA) to detect\nantibodies to SARS-CoV-2. Scientists are using these antibody tests to learn more about the level of antibodies needed to\nprotect people from COVID-19 (threshold of protection) and how long this protection lasts.","2456":"About the COVID-19 Vaccine: Frequently Asked Questions. Available at:\ncovid-19-vaccine-frequently-asked-questions\/ . 3. American College of Obstetricians and Gynecologists (ACOG). COVID-19 Vaccination Considerations for Obstetric\u2013\nGynecologic Care. https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-\nvaccination-considerations-for-obstetric-gynecologic-care . 4. American Society for Reproductive Medicine (ASRM) Patient Management and Clinical Recommendations During the\nCoronavirus (COVID-19) Pandemic: UPDATE No. 16 \u2013 Reproductive Facts Regarding COVID-19 Vaccination. Available at:\nhttps:\/\/www.asrm.org\/covid-update-16 . 5. Joint Statement Regarding COVID-19 Vaccine in Men Desiring Fertility. Society for Male Reproduction and Urology (SMRU)\nand Society for the Study of Male Reproduction (SSMR). January 9, 2021. Available at https:\/\/www.asrm.org\/news-and-\nfor-male-reproduction-and-urology-smru-and-the-society-for-the-study-of-male-reproduction-ssmr\/ . 6. Vaccines and Related Biological Products Advisory Committee Meeting. FDA Briefing Document.","7566":"You will need to show official documentation (e.g., clinical trial letter, participant card, or modified vaccination card) of\nclinical trial participation that includes the following information:\nDocumentation you participated in a phase 3 trial of with a qualifying COVID-19 vaccine candidate\nDocumentation you received the full series of an active (non-placebo) qualifying COVID-19 vaccine candidate or an EUL\nvaccine, with the name of the vaccine product and the date(s) received (showing it has been at least 2 weeks since you\ncompleted the series)\nHow do I know if the vaccine trial I participated in is on the approved list for an exception?","1401":"Vaccinators and clinic administrators\nshould not deny COVID-19 vaccination to a person because of a lack of documentation. How do I verify if a person is moderately or severely immunocompromised? \uf1aa\nYes. Everyone ages 5 years and older who completed a primary series is recommended to receive 1 bivalent mRNA\nbooster dose regardless of previous booster dose history; this includes people who are moderately or severely\nimmunocompromised. The bivalent mRNA booster dose should be administered at least 2 months after the last\nmonovalent booster dose. My patient is moderately or severely immunocompromised and received the primary series and\nthe previously recommended monovalent mRNA booster dose(s).","1349":"\uf1aa\n\uf209\nNo, the monovalent mRNA vaccines (i.e., Moderna or Pfizer-BioNTech) are no longer authorized for use as a booster dose;\nthey can only be used for the primary series. A bivalent mRNA vaccine is recommended for the booster dose. If a patient accidently received a monovalent mRNA vaccine for the booster dose, the dose generally does not need to be\nrepeated. However, providers may administer 1 bivalent booster dose as a repeat dose based on clinical judgment and\npatient preference. The repeat dose should be administered at least 2 months after the monovalent booster dose. For more information, see vaccine administration errors and deviations.","6241":"Getting sick with COVID-19 can cause severe illness or death, and we can\u2019t reliably predict who will have mild or\nsevere illness. If you get sick, you can spread COVID-19 to others. You can also continue to have long-term health issues\nafter COVID-19 infection. Learn about why you should get vaccinated even if you already had COVID-19. 10\/30\/22, 9:34 AM Myths and Facts about COVID-19 Vaccines | CDC\nMYTH: COVID-19 vaccines cause variants. FACT: COVID-19 vaccines do not create or cause variants of the virus that causes COVID-19. Instead, COVID-19\nvaccines can help prevent new variants from emerging.","7608":"How does CDC determine whether a country is designated as having limited vaccine availability? \uf1aa\n\uf209\nYou will need to show a U.S. military identification document, such as a military ID or Common Access Card (CAC) or a\nDEERS ID Card, or other proof of status as a member or spouse or child (under 18 years of age) of a member of the U.S.\nArmed Forces. What documentation do I need if I am a member of the U.S. Armed Forces or a spouse or child\n(under 18 years of age) of someone who is a member of the U.S. Armed Forces?","4030":"Additionally, CDC estimates the number of people receiving at least one dose,\nthe number of people who are fully vaccinated, and the number of people with a booster dose. CDC estimates are\nbased on data reported by jurisdictions that includes a dose number (first, second, booster or additional dose). This may differ from how jurisdictions attribute their doses. Population definition: CDC includes all age groups in the Total Population calculations to provide a better measure\nof community immunity.","1820":"As with other infectious diseases, people are protected best from COVID-19 when\nthey stay up to date with recommended vaccine doses. Efforts to maximize the proportion of people in the United States who\nare fully vaccinated against COVID-19 remain critical to reducing the spread. Staying up to date means getting all recommended COVID-19 vaccine doses, including a booster shot, when eligible. People who are moderately or severely immunocompromised have specific COVID-19 vaccine recommendations, which\ninclude an additional third dose to complete their primary series, as well as a booster shot for those eligible.","3064":"Moderna COVID-19 Vaccine\nPeople ages 12 years and older: A 3-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-\nBioNTech) is recommended. For the primary series, the first and second doses are separated by 4 weeks and the second\nand third doses are separated by at least 4 weeks. The bivalent mRNA booster dose is administered at least 2 months\nafter completion of the primary series (for people who have not received any booster doses), or at least 2 months after\nthe last monovalent booster dose.","1867":"National Protocol\nOutcome: Household transmission among community members confirmed with SARS-CoV-2\nPopulation: Households of community members with positive SARS-CoV-2 tests recruited from national commercial\nlaboratories\nExternal partner: Westat\n\uf209 \uf20c\nTest-negative prospective case control\n\uf1aa\nIncreasing Community Access to Testing (ICATT) program\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Anyone seeking testing at a pharmacy\nParticipating sites: 8,319 locations across the United States and its territories\nIVY\nInfluenza and Other Viruses in the Acutely Ill (IVY) network\nOutcome: Hospitalization with SARS-CoV-2\nPopulation: Hospitalized adults\nParticipating Sites: 21 large adult hospitals in 20 cities in 18 states:\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nCalifornia\nColorado\nFlorida\nGeorgia\nIowa\nMaryland\nMassachusetts\nMichigan\nMinnesota\nMissouri\nNew York\nNorth Carolina\nOhio\nOregon\nTennessee\nTexas\nUtah\nWashington\nPReventing Emerging Infections through Vaccine EffectiveNess Testing (PREVENT ) Sites\nOutcome: Symptomatic SARS-CoV-2 infections\nPopulation: Healthcare personnel\nParticipating Sites\nBaystate Medical Center, Springfield, MA\nJackson Memorial Hospital, Miami, FL\nOlive View-UCLA Medical Center, Los Angeles, CA\nThomas Jefferson University Hospital, Philadelphia, PA\nTruman Medical Centers, Kansas City, MO\nUniversity of Alabama Hospital, Birmingham, AL\nCommunity Regional Medical Center\/ UCSF, Fresno, CA\nUniversity of Chicago Medical Center, Chicago, IL\nUniversity of Iowa Hospitals and Clinics, Iowa City, IA\nUniversity of Massachusetts Memorial Medical Center, Worcester, MA\nLCMC Health Hospitals, New Orleans, LA\nUniversity of Mississippi Medical Center, Jackson, MS\nUniversity of Texas Southwestern Medical Center and Parkland Hospital, Dallas, TX\nUniversity of Washington Hospitals, Seattle, WA\nValleywise Health Medical Center, Phoenix, AZ.","1815":"LTC providers are encouraged to consider the option that works best for their residents and staff when coordinating access to\nCOVID-19 vaccines, either in the local community or on-site. Additional details on these options are available on the pages\nlinked below. \uf141 Information About Who Is Eligible for a COVID-19 Vaccine Booster Shot\n\uf209\n\uf1aa Information for Long-term Care\nAdministrators and Managers\n\uf1aa Information for Jurisdictions (State and Local\nImmunization Programs)\f10\/30\/22, 9:22 AM COVID-19 Vaccine Access in Long-term Care Settings | CDC\nAdditional Information: COVID-19 Vaccination Recommendations\nCOVID-19 vaccines available in the United States are highly effective at preventing serious outcomes of COVID-19 including\nsevere disease, hospitalization, and death.","629":"May 6, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 25,958 doses\nadministered. May 6, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of 9,143\ndoses administered. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nApril 29, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 7,617 doses\nadministered. April 22, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of 4,711\ndoses administered.","169":"CDC, USDA, state public health and animal health officials, and academic partners are working in some states to conduct\nactive surveillance (proactive testing) of SARS-CoV-2 in pets, including cats, dogs, and other small mammals, that had\ncontact with a person with COVID-19. CDC deployed One Health teams to multiple states to support state and local departments of health and agriculture,\nfederal partners, and others in conducting on-farm investigations into SARS-CoV-2 in people, mink, and other animals\n(domestic and wildlife).","7146":"Clin\nWoodworth KR, Olsen EO, Neelam V, et al. Birth and Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2\nInfection in Pregnancy \u2014 SET-NET, 16 Jurisdictions, March 29\u2013October 14, 2020. MMWR Morb Mortal Wkly Rep\nDeSisto CL, WallaceB, Simeone RM, et al. Risk for Stillbirth Among Women With and Without COVID-19 at Delivery\nHospitalization \u2014 United States, March 2020\u2013September 2021. MMWR Morb Mortal Wkly Rep 2021;70:1640-1645. More Information\nUrgent Maternal Warning Signs\n\uf209\n\uf209\n\uf209\nLast Updated Oct. 25, 2022","680":"January 27, 2022: California made updates to data previously submitted to CDC that resulted in a decrease of\n1,593,072 doses administered for California and a decrease of 800,606 doses administered at the National level\n(national level decrease factors in new administrations reported by other jurisdictions). January 21, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 29,394\ndoses administered. January 21, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n34,238 doses administered.","1880":"Emerging Infection Program Sites\n\uf209 \uf20c\nFLU-VE Network\nUS Influenza Vaccine Effectiveness Network Protocol for Influenza and Other Respiratory Viruses (including COVID-\nOutcome: Symptomatic infection with SARS-CoV-2\nPopulation: Outpatient adults and children \u22656 months of age\nParticipating Sites\nGroup Health Cooperative, Seattle, WA\nMarshfield Clinic Research Institute, Marshfield, WI\nUniversity of Michigan, Ann Arbor, MI\nHenry Ford Health Systems, Detroit, MI\n\uf20c\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nUniversity of Pittsburgh Medical Center, Pittsburgh, PA\nScott & White Healthcare, Temple, TX\nVISION\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections, emergency department\/urgent care visits with\nPopulation: Individuals of all ages who have an emergency department or urgent care visit or hospitalization within\nthe facility network\nParticipating Sites\nBaylor Scott and White Health (Texas)\nColumbia University (New York)\nHealthPartners (Minnesota and Wisconsin)\nIntermountain Healthcare (Utah)\nKaiser Permanente Northern California (California)\nKaiser Permanente Northwest (Oregon and Washington)\nRegenstrief Institute (Indiana)\nUniversity of Colorado (Colorado)\nOvercoming COVID-19 to track and characterize development of complications in children and young adults exposed\nOutcome: Hospitalization with SARS-CoV-2\nPopulation: Hospitalized children and adolescents aged 18 years and younger\nParticipating Sites: Sites can be found here .","3980":"\uf1aa\nData on COVID-19 vaccine doses administered in the United States and territories are recorded by vaccination providers\nand reported to CDC through multiple sources, including:\nState, local, and territorial Immunization Information Systems (IISs)\nVaccine Administration Management System (VAMS), which supports vaccination clinics in jurisdictions, federal\nagencies, and multi-state healthcare organizations\nDirect data submissions to the COVID-19 Data Clearing House\nHow are vaccine administration data reported to CDC? \uf1aa\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Frequently Asked Questions about COVID-19 Vaccination Data | CDC\nData Variations\nThe COVID-19 Vaccination IT Overview provides an overarching view of the vaccine IT data systems and how they\nintegrate to track COVID-19 vaccine distribution and administration.","6062":"However, based on available information, it appears\nreasonable to anticipate that known and potential risks of an additional primary dose of the COVID-19 vaccine\nby Moderna may be outweighed by its likely benefit to enhance or restore protection by the primary\nvaccination, which might have waned over time, especially in people with immunocompromising conditions or\ntaking immunosuppressive medications. In addition, these EUI are being revised to no longer provide for certain booster dose uses of the COVID-19\nvaccine by Moderna.","5333":"\u2022 General side effects: headache, feeling very tired, muscle aches, nausea, and fever. \u2022 Swollen lymph nodes. \u2022 Blood clots. \u2022 Unusual feeling in the skin (such as tingling or a crawling feeling) (paresthesia), decreased feeling\nor sensitivity, especially in the skin (hypoesthesia). \u2022 Persistent ringing in the ears (tinnitus). \u2022 Diarrhea, vomiting. Severe Allergic Reactions\nThere is a remote chance that the Janssen COVID-19 Vaccine could cause a severe allergic\nreaction. A severe allergic reaction would usually occur within a few minutes to one hour after\ngetting a dose of the Janssen COVID-19 Vaccine.","507":"The issue has since\nbeen resolved and totals for April 14, 2021 accurately reflect the total doses administered. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nOn April 6, 2021, improvements in reporting vaccine recipient race\/ethnicity data to CDC resulted in an increase in the\nnumber of people for whom race\/ethnicity data are available. These improvements will continue to allow for better\nrace\/ethnicity data reporting. Due to a data synchronization error between April 3 and 5, 2021, the daily count of doses reporting \u201cUnknown Age\u201d in\nthe COVID-19 Case Surveillance Public Use Data incorrectly appeared higher than expected.","1720":"Anyone can report an adverse event to VAERS. Healthcare professionals are required\nto report certain adverse events and vaccine manufacturers are required to report all adverse events that come to their\nattention. The reporting requirements for COVID-19 vaccines are the same for those authorized under emergency use (EUA) or\napproved under a Biologics License Application (BLA). Healthcare providers who administer COVID-19 vaccines are\nrequired to report the following to VAERS:\nVaccine administration errors, whether or not associated with an adverse event (AE)\nIf the incorrect mRNA COVID-19 vaccine product was inadvertently administered for a second dose in a 2-dose\nseries, VAERS reporting is required.","9341":"This Vaccine Information Fact Sheet for Recipients and Caregivers comprises the Fact\nSheet for the authorized Moderna COVID-19 Vaccine and the authorized Moderna\nCOVID-19 Vaccine, Bivalent for use in individuals 6 years of age and older, and also\nincludes information about the FDA-licensed vaccine, SPIKEVAX (COVID-19 Vaccine,\nmRNA) for use in individuals 12 years of age and older.1\nThe FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and the Moderna COVID-\n19 Vaccine authorized for Emergency Use Authorization (EUA) for individuals 12 years of\nage and older can be used interchangeably, when used according to their respective\ninstructions for use.2\nSPIKEVAX (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made\nby ModernaTX, Inc.","9383":"HOW ARE SPIKEVAX (COVID-19 VACCINE, mRNA), MODERNA COVID-19\nVACCINE, AND MODERNA COVID-19 VACCINE, BIVALENT RELATED? SPIKEVAX (COVID-19 Vaccine, mRNA) and Moderna COVID-19 Vaccine can be used\ninterchangeably.4 Moderna COVID-19 Vaccine, Bivalent is made in the same way as\n3 Monovalent refers to any authorized or approved COVID-19 vaccine that contains or encodes the spike protein of\nonly the Original SARS-CoV-2.","4855":"In addition to the minimum age, some experts suggest delaying the second dose for 8 weeks after the invalid dose\nbased on the potential for increased reactogenicity and the rare risk of myocarditis and pericarditis from mRNA COVID-19 vaccine. If the administration error resulted in a higher-than-authorized vaccine dose, in general a subsequent dose may still be administered at the\nrecommended interval.","9350":"It is approved as a two-dose series for prevention of COVID-19 in\nindividuals 18 years of age and older. It is also authorized under EUA to provide:\n\u2022 a two-dose primary series to individuals 12 years through 17 years of age; and\n\u2022 a third primary series dose to individuals 12 years of age and older who have been\ndetermined to have certain kinds of immunocompromise. 1 You may receive this Fact Sheet even if your child is 5 years old.","2584":"A shorter interval (4 weeks for Moderna) between the\nfirst and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is\nincreased concern about COVID-19 community levels or an individual\u2019s higher risk of severe disease. \u00a7 A single Novavax booster dose (instead of a bivalent mRNA booster dose) may be given to persons 18 years of age or older who have not received a previous booster dose in limited\nsituations.","1245":"The program relies on collaborations between public health agencies (CDC, state, local, and territorial health departments) to\nencourage individuals to go to pharmacies and get vaccinated. Community outreach remains critical to educating people about the importance of vaccination and where vaccines are\navailable nearby. For more information, see 12 COVID-19 Vaccination Strategies for Your Community. Federal Retail Pharmacy Program Highlights\nAs of October 18, 2022, more than 276.4 million doses of COVID-19 vaccine have been administered and reported by\nFederal Retail Pharmacy Program participants in the US.","2645":"For medical emergencies, call 911 and tell the dispatcher that the\nperson has or might have COVID-19. \u2022\nWhen to seek emergency medical attention\nLook for emergency warning signs* for COVID-19. If someone is showing any of these signs, seek emergency medical\ncare immediately:\nTrouble breathing\nPersistent pain or pressure in the chest\nNew confusion\nInability to wake or stay awake\nPale, gray, or blue-colored skin, lips, or nail beds, depending on skin tone\n*This list is not all possible symptoms. Please call your medical provider for any other symptoms that are severe or\nconcerning to you.","452":"On May 27, 2021, the New Hampshire \u2018at least one dose\u2019 values posted to Tracker appeared lower than that reported the\nday prior (May 26, 2021). This correction is accurate and is due to New Hampshire and CDC collaboratively correcting\ndata transmission errors. On May 25, 2021, the 7,836,063 administered doses reported for Long-Term Care Facilities (LTCF), were fewer by 4,105\nrecords compared to the 7,840,168 reported on May 24, 2021. This was due to an error in data processing that has now\nbeen corrected. The data for May 26, 2021 accurately reflect total LTCF doses.","4741":"*\nReceived a bivalent mRNA booster dose after completion of the primary\nseries\nDo not repeat if booster dose contained the original SARS-CoV-2 strain\nand Omicron BA.4\/BA.5 variants\nFor other bivalent mRNA vaccines, see Special situation (after table\nfootnotes). Table B.2. Received a COVID-19 vaccine listed for emergency use by WHO but not approved or authorized by FDA\nVaccination history Recommended actions\nReceived all recommended primary doses for that vaccine Do not repeat primary series. Administer a bivalent mRNA booster dose if eligible. *\nReceived partial primary series for that vaccine Complete the primary series with Moderna, Novavax, or Pfizer-\nBioNTech vaccine dose(s) as close to the recommended time as\npossible.","3354":"History of myocarditis or pericarditis prior to COVID-19 vaccination\nPeople who have a history of myocarditis or pericarditis unrelated to vaccination with Moderna, Novavax, or Pfizer-BioNTech\n(e.g., due to SARS-CoV-2 or other viruses) may receive any currently FDA-approved or FDA-authorized COVID-19 vaccine after\nthe episode of myocarditis or pericarditis has completely resolved. This includes resolution of symptoms attributed to\nmyocarditis or pericarditis, as well as no evidence of ongoing heart inflammation or sequelae as determined by the person\u2019s\nclinical team. For people who have a history of myocarditis associated with MIS-C or MIS-A, see COVID-19 vaccination and MIS-\nC and MIS-A.","1943":"If an unexpected\nadverse event is seen, experts quickly study it further to assess whether it is a true safety concern. Experts then decide whether changes are needed in U.S. vaccine recommendations or clinical guidance. This monitoring is critical to help ensure that the benefits continue to outweigh the risks for people who receive\nvaccines. FDA\u2019s COVID-19 Vaccines website includes important recommendations for ongoing safety evaluation after any\nCOVID-19 vaccine is made available under EUA . CDC has expanded safety surveillance through new systems and additional information sources, as well as by scaling up\nexisting safety monitoring systems.","5771":"You should not get the vaccine if you:\n\u2022 Had a severe allergic reaction after a previous dose of the COVID-19 vaccine by Moderna\n\u2022 Had a severe allergic reaction to any ingredient of the COVID-19 vaccine by Moderna\nWhat should I mention to the vaccination provider before getting the COVID-19 vaccine by Moderna? Tell your vaccination provider the name, number of doses, and date(s) of COVID-19 vaccine(s) you received\npreviously.","7428":"Accepted COVID-19 Vaccines\nVaccines Approved or Authorized by\nthe U.S. Food and Drug\nAdministration\nVaccines Listed for Emergency Use\n(EUL) by the World Health\nOrganization\nCertain Clinical Trial Vaccines\nwhich Have Confirmed\nEfficacy\nSingle\ndose\nJanssen\/J&J Janssen\/J&J\nConvidecia (CanSinoBIO)\ndose\nseries\nComirnaty (Pfizer-BioNTech)\nSpikevax (Moderna)\nNovavax\nComirnaty (Pfizer-BioNTech)\nSpikevax (Moderna)\nVaxzevria (AstraZeneca)\nCovaxin\nCovishield\nBIBP\/Sinopharm\nCoronaVac (Sinovac)\nNuvaxovid (Novavax)\nCovovax\nMedicago\n\uf209\nAcceptable Proof of COVID-19 Vaccination\nDocumentation\nType Examples\nVerifiable\nrecords (digital\nor paper)\nVaccination certificate with QR code , digital pass via Smartphone application with QR code (e.g.,\nUnited Kingdom National Health Service COVID Pass, European Union Digital COVID Certificate)\nNon-verifiable\npaper records\nPrintout of COVID-19 vaccination record or a COVID-19 vaccination certificate issued at national or\nsubnational level or by an authorized vaccine provider (e.g., the CDC vaccination card)\nNon-verifiable\ndigital records\nDigital photos of vaccination card or record, downloaded vaccine record or vaccination certificate from\nofficial source (e.g., public health agency, government agency, or other authorized vaccine provider), or\na mobile phone application without QR code\n1.","9938":"Extending\nthe interval between these vaccines dose to 8 weeks might\nreduce the risk. Note: There are some persons the extended interval should not\nbe considered including those who are:\n\u0083 Moderately or severely immunocompromised\n\u0083 Adults ages 65 years and older;\n\u0083 In situations in which there is increased concern about\nCOVID-19 community levels or an individual\u2019s higher risk of\nsevere disease. Additional recipient education materials\fPrevaccination Checklist\nfor COVID-19 Vaccines\nInformation for Healthcare Professionals\n2. Is the person to be vaccinated sick today? People with mild illnesses can be vaccinated. Do not\nwithhold vaccination if a person is taking antibiotics.","6671":"Do not stop any medications or change your asthma treatment plan without talking to your healthcare provider. Talk to your healthcare provider, insurer, and pharmacist about creating an emergency supply of prescription\nmedications, such as asthma inhalers. Make sure that you have 30 days of non-prescription medications and supplies on\nhand in case you need to stay home for a long time. Be careful around cleaning agents and disinfectants\nCDC is reviewing this page to align with updated guidance.","4572":"Do not open windows and doors if doing so is unsafe for you or others (for example, young children or pets in\nyour home, risk of falling, people in the home with asthma or other respiratory conditions, poor air quality). If opening windows or doors is unsafe, consider other approaches for reducing virus particles in the air, such as\nusing air filtration and bathroom and stove exhaust fans. Use fans to move virus particles in the air from inside your home to outside. Don\u2019t leave fans unattended with\nyoung children.","4269":"Getting COVID-19 again soon after just having had COVID-19 can happen but is not common in the weeks to months\nafter you had it. Reasons to get a vaccine sooner rather than later include:\nyour own personal risk of having severe health concerns,\nyour local COVID-19 community level, and\nthe most common COVID-19 variant currently causing illness\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nWhen you should wait\n\uf1aa\f10\/30\/22, 9:30 AM Getting Your COVID-19 Vaccine | CDC\nIf you have COVID-19 People who have COVID-19 and are in isolation,\nshould wait to get vaccinated until:\nSymptoms are gone (if you had symptoms) and\nYour isolation guidelines have been met.","5611":"Procedure Masks\nWear procedure masks with\nA proper fit over your nose, mouth, and chin to prevent leaks\nMultiple layers of non-woven material\nA nose wire\n\u2022\n\u2022\n\u2022\nDo NOT wear procedure masks with\nGaps around the sides of the face or nose (see example)\nWet or dirty material\n\u2022\n\u2022\nWays to have better fit and extra protection with cloth and disposable masks\nWear two masks (disposable mask underneath AND cloth mask on top)\nCombine either a cloth mask or disposable mask with a fitter or brace\nKnot and tuck ear loops of a 3-ply mask where they join the edge of the\nmask\nFor disposable procedure masks, fold and tuck the unneeded\nmaterial under the edges.","8094":"\u0082 Other symptoms of monkeypox can include:\n\u008f Fever\n\u008f Chills\n\u008f Swollen lymph nodes\n\u008f Exhaustion\n\u008f Muscle aches and backache\n\u008f Headache\n\u008f Respiratory symptoms (e.g., sore throat, nasal congestion, or cough)\n\u0082 You may experience all or only a few symptoms\n\u008f Sometimes people have flu-like symptoms before the rash. \u008f Some people get a rash first, followed by other symptoms. \u008f Others only experience a rash.138\n\u0083 Are there any travel restrictions due to monkeypox? d\n\u0082 Recommendation for travelers:139\n\u008f If you have monkeypox symptoms or had close contact with someone who\nhas monkeypox, talk to your healthcare provider.","4254":"10\/30\/22, 9:30 AM Getting Your COVID-19 Vaccine | CDC\nEspa\u00f1ol | Other Languages\nGetting Your COVID-19 Vaccine\nEveryone 6 Months and Older Should Get a COVID-19 Vaccine\nCOVID-19 vaccination has many benefits and is an important tool to help protect you from severe illness, hospitalization, and\ndeath. Getting a COVID-19 vaccine after having COVID-19\nEven if you or your child have had COVID-19, you should still get yourself or your child vaccinated. Getting a COVID-19 vaccine after having COVID-19 provides added protection against the virus that causes COVID-19.","2778":"Everyone experiences these conditions differently and may want different types of support or even no support at all. To determine the most helpful steps you can take for others, first listen with compassion and ask questions about what they\nneed. CDC\u2019s How Right Now campaign provides helpful tools for navigating conversations about the type of support someone with\npost-COVID conditions may need. If you are feeling overwhelmed with emotions like sadness, depression, anxiety, or thoughts of hurting yourself or others:\nCall 911 if you feel like you want to harm yourself or others. Visit the Disaster Distress Helpline , call or text 1-800-985-5990.","9796":"However, robustness and duration of protection is variable (National Collaborating Center for Methods and\nTools, 2021). The circulating variant, as well as individual-level factors such as age and comorbidities, can\nimpact level of protection. For example, overall risk of reinfection increased during the Omicron wave, and\nprotection from infection or vaccination, was less robust than against previous variants (Pulliam et al., 2022). Additionally, some populations (e.g., older adults, immunocompromised) may have decreased levels of\nprotection following infection, necessitating an interval that balances the benefits and risks of delaying\nvaccination after infection at a population level.","161":"Studies on animals do not show whether animals can spread\ninfection to people. Based on these studies, we know that invertebrates, birds, reptiles, and amphibians are not susceptible to infection with\nSARS-CoV-2. What CDC is doing\nSince the beginning of the pandemic, CDC has been leading efforts to improve our understanding of how SARS-CoV-2 affects\nanimals and how the virus might spread between people and animals. CDC has also worked to improve coordination of\nfederal, state, and other One Health partners.","5991":"Neutralizing antibody titers, as measured by a pseudovirus neutralization assay using a\nlentivirus expressing the SARS-CoV-2 Spike protein with D614G mutation, were assessed on Day 1 prior to\nadministration of the booster dose and on Day 15 after the booster dose. A booster response to the Moderna\nCOVID-19 Vaccine (0.5 mL [100 \u03bcg of mRNA]) was demonstrated regardless of primary vaccination. Recent studies indicate that additional doses in people who are moderately or severely immunocompromised\nare safe and can increase antibody response.","3151":"On a case-by-case basis, providers caring for moderately or severely immunocompromised patients may administer\nModerna, Novavax, and Pfizer-BioNTech COVID-19 vaccines outside of the FDA and CDC dosing intervals when, based on their\nclinical judgment, the benefits of vaccination are deemed to outweigh the potential and unknown risks for the recipient. However, providers should not routinely administer doses of COVID-19 vaccine beyond those recommended in this guidance. The utility of serologic testing , cellular immune testing, or B-cell quantification to assess immune response to vaccination\nand guide clinical care has not been established.","1480":"Which COVID-19 vaccines are recommended for people with a history of Bell\u2019s palsy? \uf1aa\nGBS is a neurological disorder in which the body\u2019s immune system damages nerve cells, causing muscle weakness and\nsometimes paralysis. For people with a history of GBS, as for the general population, mRNA (i.e., Moderna or Pfizer-\nBioNTech) and Novavax COVID-19 vaccines are recommended for the primary series, and an age-appropriate mRNA\nWhich COVID-19 vaccines are recommended for people with a history of Guillain-Barre syndrome\n(GBS)? \uf1aa\f10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\nvaccine is recommended for the booster dose.","3318":"No cases of myocarditis or pericarditis were reported in children in the pre-authorization clinical\ntrials of Pfizer-BioNTech (ages 6 months\u20134 years) or Moderna (ages 6 months\u20135 years) vaccines. To date, post-authorization\nsurveillance has not detected an increased risk for myocarditis and pericarditis following mRNA COVID-19 vaccination in\nchildren ages 6 months\u20134 years (i.e., Pfizer-BioNTech) and ages 6 months\u20135 years (i.e., Moderna). Cases of myocarditis and pericarditis were identified in clinical trials of Novavax COVID-19 Vaccine and have also been\nreported during post-authorization use outside the United States. These findings suggest that an increased risk for these\nconditions may be present after receiving Novavax COVID-19 vaccine.","5950":"Do not administer the COVID-19 vaccine by Moderna to persons with known history of a severe allergic reaction\n(e.g., anaphylaxis) to a previous dose or any component of the vaccine (see Contraindications, and Warnings\nand Precautions sections in the Spikevax package insert or Full EUA Prescribing Information as well as CDC\u2019s\nInterim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United\nStates for additional considerations). What information should be provided to persons receiving a primary or additional dose of the COVID-19\nvaccine by Moderna as described in the EUI? \u2022 Provide the EUI Fact Sheet for Recipients and Caregivers.","4907":"PEG and polysorbate are structurally related, and cross-reactive hypersensitivity between these compounds may occur. People with a known allergy to polysorbate have a contraindication to both Novavax and Janssen COVID-19 vaccines and a precaution to\nmRNA COVID-19 vaccines (i.e., Moderna or Pfizer-BioNTech). ll h ll l d d f h h\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nIn all other cases, an allergy-related contraindication to one type of COVID-19 vaccine is a precaution to the others. For people with these precautions, referral to an allergist-immunologist should be considered.","473":"The percentage of total doses that were\nadministered to people in each age group (ages 12 years and older, ages 18 years and older, and ages 65 years and\nolder) is the same as both the percentage of people who received at least one dose and the percentage of fully\nvaccinated people within each age group. CDC estimates the \u201cat least one dose\u201d metric for these populations of Texas by\nfirst obtaining the percentage of the three population groups who have received \u2018at least one dose\u2019 from Texas.","547":"From December 21, 2020 through January 13, 2021, Virginia transferred 17,550 doses and Maryland transferred 16,000\ndoses to the District of Columbia (DC) for administration to persons from the region who were vaccinated in DC. This\napproved transfer of inventory is reflected in the totals presented on the CDC COVID Data Tracker to accurately reflect\nthe inventory made available to each jurisdiction. Because of how and when (i.e., early in the vaccination program) these\ntransfers occurred, they may not be reflected in totals presented within other inventory management systems (e.g., the\nVaccine Tracking System [VTrckS]).","9804":"Risk\u2010Benefit of the COVID-19 vaccine by Pfizer-BioNTech as Primary or Additional Vaccination for Individuals\nDescribed in the EUI\nThe duration of vaccine-induced protection from primary vaccination with COVID-19 vaccines is unknown. Efficacy data from clinical studies of 2-dose primary series supported benefit of the COVID-19 vaccine by\nPfizer-BioNTech in preventing severe COVID-19 and supported its FDA approval. Effectiveness of an additional\nprimary dose of the COVID-19 vaccine by Pfizer-BioNTech is inferred from immunogenicity data in\nimmunocompromised adults who received a single additional primary dose.","643":"March 25, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 22,574\ndoses administered. March 25, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of 3,715\ndoses administered. March 18, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 32,506\ndoses administered. March 16, 2022: Puerto Rico made updates to data previously submitted to CDC that resulted in an increase of 1,173\ndoses administered.","5485":"For people who\nexperience PICS following a COVID-19 diagnosis, it is difficult to determine whether these health problems are caused by a\nsevere illness, the virus itself, or a combination of both. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\nSome people with post-COVID conditions have symptoms that are not explained by tests. Some people experience new health conditions after COVID-19 illness. People experiencing any severe illness, hospitalization, or treatment may develop problems such as post-intensive care\nsyndrome, or PICS. \uf209\nPeople More Likely to Develop Long COVID\nResearchers are working to understand which people or groups of people are more likely to have post-COVID conditions, and\nwhy.","3993":"\uf1aa\nCDC is tracking the number of manufactured vaccine doses that are not administered (wastage). A small amount of\nvaccine will go unused in any vaccination program. This information is not currently available on the COVID Data Tracker. Does CDC report COVID-19 vaccine wastage? \uf1aa\nData on COVID-19 vaccine doses administered in the United States are collected by the following vaccination providers:\npublic health jurisdictions, federal entities, healthcare providers, long-term care facilities, employers, retail pharmacies,\nand other businesses. These providers report COVID-19 vaccination data to CDC through multiple sources using various\nreporting methods.","6658":"Know the triggers for your condition and avoid when possible (e.g., avoid asthma triggers by having another member of\nyour household clean and disinfect your house for you or avoid possible sickle cell disease triggers to prevent pain\ncrises). \u2022\n\uf209\n\u2022\nAdditional Resources\nDon\u2019t Delay: Test Soon and Treat Early\nFile Details: 361 KB, 1 page\nView PDF in English\nView PDF in Spanish\n\uf20c\n\uf20c\nLast Updated Oct. 19, 2022","2006":"Through continued safety monitoring, COVID-19 vaccination has been found to be safe for children and teens. Millions of children and teens ages 5 through 17 years have already received at least one dose of a COVID-19\nvaccine. The known risks and possible severe complications of COVID-19 outweigh the potential risks of having a rare,\nadverse reaction to vaccination. Use CDC\u2019s COVID-19 booster tool to learn if and when your child or teen can get boosters to stay up to date with\ntheir COVID-19 vaccines.","4094":"\uf1aa\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:18 AM Frequently Asked Questions about COVID-19 Vaccination | CDC\n2 doses of Novavax vaccine 3-8* weeks apart for people ages 12 years and older. 1 dose of Johnson & Johnson\u2019s Janssen (J&J\/Janssen) vaccine for people ages 18 and older. *Talk to your healthcare or vaccine provider about the timing for the second dose in your primary series. You\nshould not get the second dose early. People who are moderately or severely immunocompromised may have a different immune response following COVID-\n19 vaccination. Please see specific COVID-19 vaccination guidance for people who are moderately or severely\nimmunocompromised. \u2022\n\u2022\nNo.","5902":"\u2022 A second primary dose of the COVID-19 vaccine by Moderna (100 \u03bcg in 0.5 mL from red-capped\nmultidose vial) may be delayed by 3 months from symptom onset or positive test (if infection was\nasymptomatic) in persons ages 12 years and older who recently had SARS-CoV-2 infection\fModerna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 09\/02\/22;\n\u2022 A primary dose, including as an additional primary dose for those with certain immunocompromising\nconditions, of the COVID-19 vaccine by Moderna (100 \u03bcg in 0.5 mL from red-capped multidose vial)\nshould be administered intramuscularly to persons ages 12 years and older at least 28 days after\nprimary vaccination with certain non-FDA authorized or approved COVID-19 vaccines.","4987":"New booster recommendation for people ages 12 years and older to receive 1 bivalent mRNA booster after\ncompletion of a monovalent primary series; it replaces all prior booster recommendations for this age group\nRecommendations for use of a bivalent Moderna booster dose in people ages 18 years and older\nRecommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 12 years and older\nUpdated guidance for observation periods following COVID-19 vaccination\nUpdated guidance on COVID-19 vaccination and multisystem inflammatory syndrome (MIS) in children (MIS-C) and in\nadults (MIS-A)\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adolescents ages 12\u201317 years\nReorganization of Janssen COVID-19 Vaccine guidance into an appendix\nUpdated guidance on COVID-19 vaccination following exposure to SARS-CoV-2\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nPrevious Updates\n\uf1aa\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nUpdated guidance on COVID-19 vaccination and myocarditis and pericarditis\nNew clinical considerations for coadministration of mRNA COVID-19 vaccines and orthopoxvirus vaccines\nNew guidance for use of Moderna COVID-19 Vaccine in children and adolescents ages 6\u201317 years\nNew guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children ages 6 months\u20134 years\nNew guidance for use of Moderna COVID-19 Vaccine in children ages 6 months\u20135 years\nReorganization of sections on COVID-19 vaccination recommendations and schedules\nAddition of new section in Special populations for infants and young children\nNew guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5\u201311 years\nUpdated guidance that the following people should receive a second COVID-19 booster dose:\nPeople ages 12 years and older who are moderately or severely immunocompromised\nPeople ages 50 years and older\nUpdated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-\ndepleting therapies\nClarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults\n(MIS-A)\nUpdated guidance for primary series vaccination after SARS-CoV-2 infection\nAdded considerations for the option to receive a second COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 vaccination after SARS-CoV-2 infection\nAdded guidance that people ages 12 years and older who are moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that people ages 18\u201349 years who are not moderately or severely immunocompromised and who\nreceived Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster\ndose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose\nFurther clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C)\nand adults (MIS-A) and myocarditis\nUpdated information on the availability of Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL\ndosage volume) and Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL dosage volume) for\nadministration of a 50 \u00b5g booster dose.","5289":"You are being offered the Janssen COVID-19 Vaccine to prevent Coronavirus Disease 2019\n(COVID-19) caused by SARS-CoV-2 because there is currently a pandemic of COVID-19. This Fact Sheet contains information to help you understand the risks and benefits of receiving the\nJanssen COVID-19 Vaccine. The Janssen COVID-19 Vaccine may prevent you from getting COVID-19. Read this Fact Sheet for information about the Janssen COVID-19 Vaccine. Talk to the vaccination\nprovider if you have questions.","6504":"What You Need To Know\nA person with any of the medical conditions listed below is more likely to get very sick with COVID-19. If you have\none of these conditions, talk with your healthcare provider about how best to protect yourself from severe illness\nfrom COVID-19. The list below does not include all possible conditions that put you at higher risk of severe illness from COVID-19. If\nyou have questions about a condition not included on this list, talk to your healthcare provider about how best to\nmanage your condition and protect yourself from COVID-19.","7136":"Allotey, J., et al., Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in\npregnancy: living systematic review and meta-analysis. BMJ, 2020. 370: p. m3320. doi: 10.1136\/bmj.m3320\nGalang RR, Newton SM, Woodworth KR, et al. Risk factors for illness severity among pregnant women with confirmed\nSARS-CoV-2 infection \u2013 Surveillance for Emerging Threats to Mothers and Babies Network, 22 state, local, and territorial\nKo JY, DeSisto CL, Simeone RM, et al. Adverse pregnancy outcomes, maternal complications, and severe illness among\nU.S. delivery hospitalizations with and without a COVID-19 diagnosis [published online ahead of print, 2021 May 12].","5139":"If you travel, wear a high-quality mask or\nrespirator the entire time you are around others\nindoors. Traveling by private vehicle (if possible) can lower\nthe chances of spreading COVID-19 to others. 10\/30\/22, 9:43 AM International Travel to and from the United States | CDC\nProtect Yourself and Others\nBefore You Travel to the United States\nAfter Arrival in the United States\n\uf48e RECOMMENDED\nFollow CDC\u2019s recommendations for wearing masks in travel and public transportation settings. Follow recommendations for protecting yourself and others. Follow all\u202frecommendations and requirements at your destination .","2484":"Trogstad, L. Increased Occurrence of Menstrual Disturbances in 18- to 30-Year-Old Women after COVID-19 Vaccination\n17. Gonzalez DC, Nassau DE, Khodamoradi K, et al. Sperm Parameters Before and After COVID-19 mRNA Vaccination. JAMA. 18. Carlsen E, Andersson AM, Petersen JH, Skakkebaek NE. History of febrile illness and variation in semen quality. Hum\n\uf209\n\uf209\n\uf209\n\uf209\n\uf209\n\uf209\n\uf209\n\uf209\n\uf209\n\uf209\n\uf209\nLast Updated July 14, 2022","3252":"Precaution\nManagement of post-COVID-19-vaccination symptoms\nTable of Contents \uf426\nVaccination and SARS-CoV-2 laboratory testing\n\uf209\n\uf209\nTable of Contents \uf426\nContraindications and precautions\n*\n*\n\u2020\n*\n* *\n*\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nMedical condition or history Guidance Recommended action(s)\nPeople with an allergy-related contraindication to one type of COVID-19 vaccine have a precaution to\nthe other types of COVID-19 vaccines. Special situation: People with a known allergy to polysorbate have a contraindication to both Novavax and\nJanssen COVID-19 vaccines. Precaution\nModerate or severe acute illness, with or without fever Precaution Defer vaccination until the\nillness has improved. History of MIS-C or MIS-A Precaution See COVID-19 vaccination\nand MIS-C and MIS-A.","7902":"9 Emerging Misinformation Theme Affecting Vaccine\nConfidence\n9 Consumers have questions about the relationship\nbetween COVID-19 vaccines and monkeypox. 10 Appendix: Inputs and Sources\nThe findings and conclusions in this report are those of the author(s) and do not necessarily\nrepresent the official position of the Centers for Disease Control and Prevention (CDC).","8212":"More details: Staying up to date\nModerna\nPRIMARY SERIES\nModerna\nPRIMARY SERIES\n4\u20138 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech or Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd\nprimary series dose\f10\/30\/22, 9:27 AM Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC\nAdults ages 18 years and older\nModerna Vaccine Overview\nUp to Date: Immediately after you have received the most recent booster recommended for you\nMore details: Staying up to date\nAGE GROUP\nNovavax is not authorized as a booster dose at this time.","3540":"However, CDC cannot use the unique person identifier to identify individual people by name. There are challenges in linking records when someone receives vaccine doses in different jurisdictions or from different\nproviders. That person could receive different unique person identifiers for different doses. CDC may not be able to link\nmultiple unique person identifiers for different jurisdictions or providers to a single person, and subsequent doses may\nappear to be a first dose when reported. Thus, CDC\u2019s data may over-estimate first doses and under-estimate subsequent\ndoses. Another issue that poses challenges to estimating doses administered is that different jurisdictions and providers use\ndifferent reporting practices.","1058":"The Treatment Locator (hhs.gov) can help you find a location that offers testing and treatment or a pharmacy\nwhere you can fill your prescription. \u2022\n\u2022\n\u2022\n\u2022 \uf209\nIf you test positive and are more\nlikely to get very sick from COVID-\n19, treatments are available\nthat can reduce your chances of\nbeing hospitalized or dying from\nthe disease. Medications to treat\nCOVID-19 must be prescribed by a\nhealthcare provider and started as\nsoon as possible after diagnosis to\nbe effective. Contact a healthcare\nprovider right away to determine if\nyou are eligible for treatment, even\nif your symptoms are mild right\nnow.","3533":"10\/30\/22, 9:35 AM Data Definitions for COVID-19 Vaccinations in the United States\nEspa\u00f1ol | Other Languages\nData Definitions for COVID-19 Vaccinations in the\nUnited States\nHow CDC Estimates Vaccination Coverage\nCDC estimates the number of people receiving at least one dose, the number of people who are fully vaccinated, and the\nnumber of people with booster doses. CDC estimates are based on data that include a dose number (first, second, boosters,\nor additional dose). To protect the privacy of vaccine recipients, CDC receives data without any personally identifiable\ninformation (deidentified data). Each jurisdiction or provider uses a unique person identifier to link records within their own\nsystems.","9303":"\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nChildren and Teens Who Have Already Had COVID-19 Should Still\nGet Vaccinated\nOngoing study of data show evidence that people can get added protection by getting vaccinated after having been infected\nwith the virus that causes COVID-19. Even if a child has had COVID-19, they should still get vaccinated. For children who have\nbeen infected with COVID-19, their next dose can be delayed 3 months from when symptoms started or, if they did not have\nsymptoms, when they received a positive test. This possible delay can happen with a primary dose or a booster dose.","4607":"10\/30\/22, 9:41 AM Interactive Home Ventilation Tool | CDC\nEspa\u00f1ol | Other Languages\nInteractive Home Ventilation Tool\nSmall particles that people breathe out can contain virus particles, including the virus that causes COVID-19. If a guest visits\nyour home, improving ventilation (air flow) can help prevent virus particles from accumulating in the air. Good ventilation,\nalong with other preventive actions, like staying 6 feet apart and correctly wearing masks, can help prevent you from getting\nand spreading COVID-19. \uf5bd We need your feedback! Help us improve this tool by taking a quick survey after using the tool below.","3379":"Studies have shown that increased time\nbetween infection and vaccination may result in an improved immune response to vaccination. Also, a low risk of reinfection\nhas been observed in the weeks to months following infection. Individual factors such as risk of COVID-19 severe disease,\nCOVID-19 community level, or characteristics of the predominant SARS-CoV-2 strain should be taken into account when\ndetermining whether to delay getting a COVID-19 vaccination after infection. Viral testing to assess for acute SARS-CoV-2 infection or serologic testing to assess for prior infection is not recommended for\nthe purpose of vaccine decision-making.","556":"As part of ongoing efforts to improve\ndata quality and maintain accurate COVID-19 vaccination information, CDC has been working with states to remove duplicate\nor incorrect vaccination records and to add replacement records. These collaborative updates help to ensure CDC is publicly\nproviding the best, most up-to-date data. This option became available for select entities on July 14, 2021 and was expanded\nto all entities starting August 9, 2021. Historical update and delete events for reporting entities and their impacts on vaccine\ndata are reported below.","8253":"People ages 6 years and older can no longer get an original (monovalent) mRNA (Pfizer-\nPeople ages 6 years and older\n\uf1aa\f10\/30\/22, 9:27 AM Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC\nVaccination Received Outside the United States\nSpecific recommendations for people vaccinated outside the United States depend on whether:\nThe vaccine(s) received are accepted in the United States as valid vaccinations\nThe primary series was completed and, if eligible, a booster dose was received\nThese recommendations apply only to people who are not moderately or severely immunocompromised. BioNTech or Moderna) booster.","10059":"\u0083 Inform vaccine recipients mRNA or Novavax COVID-19 vaccines are recommended over Janssen COVID-19 Vaccine. \u0083 Counsel vaccine recipients, parents, or guardians about expected reactions post-vaccination (e.g., pain and swelling at the injection site, fever,\nfatigue, headaches). \u0083 Inform mRNA and Novavax vaccine recipients especially males ages 12-39 years, of the rare risk of myocarditis and pericarditis following receipt of\nthese COVID-19 vaccines and the benefit of COVID-19 vaccination in reducing the risk of severe outcomes from COVID-19.\u2020 Counseling should also\ninclude the need to seek care if symptoms of myocarditis or pericarditis occur after vaccination, particularly in the week following vaccination.","2296":"Related Pages\nMyths and Facts about COVID-19 Vaccines\n\u203a\nFrequently Asked Questions about COVID-19 Vaccination\n\u203a\nCOVID-19 Vaccine Boosters\n\u203a\nInformation about Medicare and COVID-19 Vaccine\n\u203a \uf209\n\uf2ff For Healthcare Workers\nPost-Vaccination Considerations for Residents\nLast Updated July 14, 2022","4568":"Filtration: Traps particles on a filter\nto remove them from the air. Bring as much fresh air into your home as possible\nBringing fresh, outdoor air into your home helps keep virus particles from accumulating inside. If it\u2019s safe to do so, open doors and windows as much as you can to bring in fresh, outdoor air. While it\u2019s better to\nopen them widely, even having a window cracked open slightly can help. If you can, open multiple doors and windows to allow more fresh air to move inside.","713":"December 16, 2021: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 22,422\ndoses administered. December 9, 2021: Illinois made updates to data previously submitted to CDC that resulted in an increase of 53,344\ndoses administered. December 2, 2021: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 46,380\ndoses administered. November 23, 2021: Pennsylvania made updates to data previously submitted to CDC that resulted in a decrease of\n1,151,719 doses administered. November 18, 2021: Illinois made updates to data previously submitted to CDC that resulted in a decrease of\n214,250 doses administered.","3068":"Novavax COVID-19 Vaccine\nPeople ages 12 years and older: A 2-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-\nBioNTech) is recommended. The primary series doses are separated by 3 weeks and the bivalent mRNA booster dose is\nadministered at least 2 months after completion of the primary series. Pfizer-BioNTech COVID-19 Vaccine\nSchedule: ages 6 months through 11 years\nSchedule: ages 12 years and older\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nPeople ages 12 years and older: A 3-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-\nBioNTech) is recommended.","4505":"10\/30\/22, 9:40 AM How to Use Your N95 Respirator | CDC\nHow to Use Your N95 Respirator\nWear Your N95 Properly So It Is Effective\nN95s must form a seal to the face to work properly. This is especially important for people at increased risk for\nsevere disease. Wearing an N95 can make it harder to breathe. If you have heart or lung problems, talk to your\ndoctor before using an N95. Some N95s may contain latex in the straps. If you have natural rubber latex allergies, see the manufacturers\u2019\nwebsite for information about your specific model.","3561":"All reported numbers may change over time as updated data are\ncontinuously reported to CDC. 10\/30\/22, 9:35 AM Data Definitions for COVID-19 Vaccinations in the United States\nadministration date, recipient ID, and date of submission. Because the method used to determine dose numbers needs to be\napplied across multiple jurisdictions with different reporting practices, CDC\u2019s dose number estimates might differ from those\nreported by jurisdictions and federal entities. People receiving doses are attributed to the jurisdiction in which they\nreside. This includes doses administered by Federal Emergency Management Agency (FEMA) partner sites, Health Resources\nand Services Administration (HRSA) partner sites, and federal entity facilities.","4673":"GBS within 6 weeks after receipt of Janssen COVID-19 Vaccine Not\nrecommended\nDo not vaccinate with Janssen COVID-19 Vaccine. These people\nshould receive a booster dose using a bivalent mRNA COVID-19\nvaccine. History of GBS Precaution See FAQs and GBS section (below) for additional information. Abbreviations: TTS = thrombosis with thrombocytopenia syndrome; HIT = heparin-induced thrombocytopenia; GBS = Guillain-Barr\u00e9 syndrome\nPost-vaccination symptoms\nIn clinical trials of Janssen COVID-19 Vaccine, pain at the injection site was the most frequently reported local reaction among\nvaccine recipients; erythema and swelling were reported less frequently. Fatigue and headache were the most commonly\nreported systemic reactions.","2139":"People Who Would Like to Have a Baby\nCDC recommends that people who are trying to get pregnant now or might become pregnant in the future, as well as their\npartners, get vaccinated and stay up to date with their COVID-19 vaccines, including getting a COVID-19 booster shot when it\u2019s\ntime to get one. COVID-19 vaccines are not associated with fertility problems in women or men. Vaccine Side Effects\nYou can choose to get either an mRNA COVID-19 vaccine (Moderna or Pfizer-BioNTech) or Novavax COVID-19 vaccine. The\nJ&J\/Janssen COVID-19 vaccine is authorized for use only in certain limited situations.","9660":"People who received both 1 primary dose and 1 booster dose\nof the Janssen COVID-19 Vaccine or 1 primary dose of the Janssen COVID-19 Vaccine followed by 1\nbooster dose of an mRNA COVID-19 vaccine should receive an additional dose with the COVID-19\nvaccine by Pfizer-BioNTech (30 \u03bcg in 0.3 mL) at least 2 months after the booster dose. \u2022 Revaccination with the COVID-19 vaccine by Pfizer-BioNTech for any primary doses received before or\nduring treatment with certain therapies (indicated below).","5123":"Talk to your healthcare provider about your risk before travel and consider delaying travel to areas with high\nCOVID-19 levels. Even if you are up to date, you should know what precautions to take. If you will be visiting someone who is at higher risk of getting very sick from COVID-19, learn how to protect them. During Travel\n\uf209\n\uf3c0 Testing\nRECOMMENDED\nConsider getting tested with a viral test as close to the time of departure as possible (no more than 3\ndays) before travel. Make sure you know your test results before travel. Don\u2019t travel if your test result is positive.","2862":"The following COVID-19 vaccines, categorized into three vaccine types, are currently approved under a Biologics License\nApplication (BLA) or authorized under an EUA by FDA (Table 1):\nmRNA vaccines\nModerna COVID-19 Vaccine\/SPIKEVAX (1) and Moderna COVID-19 Vaccine, Bivalent\nPfizer-BioNTech COVID-19 Vaccine\/COMIRNATY (2) and Pfizer-BioNTech COVID-19 Vaccine, Bivalent\nProtein subunit vaccine\nNovavax COVID-19 Vaccine, Adjuvanted\nAdenovirus vector vaccine\nJanssen (Johnson & Johnson) COVID-19 Vaccine\nNone of the currently FDA-approved or FDA-authorized COVID-19 vaccines are live-virus vaccines. Overview of COVID-19 vaccination\n\uf209\n\uf209\n\uf209\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nJanssen COVID-19 Vaccine is authorized for adults ages 18 years and older in certain limited situations due to safety\nconsiderations (see Appendix A).","6141":"WHO Strategic Advisory Group of Experts on Immunization (SAGE). Interim recommendations for use of the\ninactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm; updated 28\nOctober 2021. Geneva: World Health Organization; 2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-\n2019-nCoV-vaccines-SAGE-recommendation-BIBP. Zhong D, Xiao S, Debes AK, Egbert ER, Caturegli P, Colantuoni E, et al. Durability of Antibody Levels After\nVaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. JAMA. 2021 Dec","6633":"It is also important for people with medical conditions and their healthcare providers to work together and manage\nthose conditions carefully and safely. Stay up to date with your COVID-19 vaccines. If you have a medical condition, the\nfollowing are actions you can take based on your medical conditions and other risk factors. Seek care when needed\nCall your healthcare provider if you have any concerns about your medical conditions or if you get sick and think that you\nmay have COVID-19. Discuss steps you can take to manage your health and risks. If you need emergency help, call 911\nright away.","4068":"What are the risks to getting a booster? \uf1aa\nYes, you are fully vaccinated even if you haven\u2019t gotten your booster yet. The definition of fully vaccinated does not\ninclude a COVID-19 booster. Fully vaccinated, however, is not the same as having the best protection. People are best\nprotected when they stay up to date with COVID-19 vaccinations, which includes getting a booster when eligible. Am I still considered \u201cfully vaccinated\u201d if I don\u2019t get a booster? \uf1aa\nYes. You are up to date if you have completed a COVID-19 vaccine primary series and received the most recent booster\ndose recommended for you by CDC.","7527":"\uf1aa\nExceptions\nCategories of noncitizen, nonimmigrants that meet the criteria for an exception under the proclamation and CDC\u2019s\nAmended Order include:\nPersons on diplomatic or official foreign government travel\nChildren under 18 years of age\nPersons with documented medical contraindications to receiving a COVID-19 vaccine\nParticipants in certain COVID-19 vaccine trials\nPersons issued a humanitarian or emergency exception\nPersons with valid visas [excluding B-1 (business) or B-2 (tourism) visas] who are citizens of a foreign country with\nlimited COVID-19 vaccine availability (See list effective as of April 14, 2022)\nMembers of the U.S. Armed Forces or their spouses or children (under 18 years of age)\nSea crew members traveling pursuant to a C-1 and D nonimmigrant visa\nPersons whose entry would be in the national interest, as determined by the Secretary of State, Secretary of\nTransportation, or Secretary of Homeland Security (or their designees)\nIf you are a noncitizen, nonimmigrant who does not fall under any of these exceptions, you must show proof of being\nfully vaccinated before boarding a flight to the United States.","9839":"Reporting Adverse Event or Medication Errors\nThe vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event\nReporting System (VAERS):\n\u2022 vaccine administration errors whether or not associated with an adverse event,\n\u2022 serious adverse events (irrespective of attribution to vaccination),\n\u2022 cases of myocarditis\n\u2022 cases of pericarditis\n\u2022 cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and\n\u2022 cases of COVID-19 that result in hospitalization or death. Complete and submit reports to VAERS online at https:\/\/vaers.hhs.gov\/reportevent.html. For further assistance with reporting to VAERS call 1-800-822-7967. References\nAbu-Raddad L, Chemaitelly H, Ayoub HH, et al.","1632":"It shall be cause for immediate termination from the CDC COVID-19 Vaccination Program and\ncriminal or civil prosecution for violation of 18 U.S.C. \u00a7 1001 or other relevant federal statutes. Prioritization for receipt of COVID-19 vaccine in the early months of the CDC COVID-19 Vaccination Program was\nnecessary given limited supplies of vaccine. Supplies of COVID-19 vaccine doses are rapidly increasing. Effective May\n1, 2021, in conformance with the Secretary\u2019s March 17, 2021 directive to transition beyond priority groups, all\npersons qualified under the terms of the applicable COVID-19 vaccine Emergency Use Authorization are eligible to be\nvaccinated.","8503":"What should my\ntravel companions do? \uf1aa\nHow can I protect myself from COVID-19 when using different types of transportation? \uf1aa\f10\/30\/22, 9:43 AM Travel: Frequently Asked Questions and Answers | CDC\nAir Travel\nFor additional FAQs on the vaccine requirement before air travel to the U.S., visit Requirement for Proof of COVID-19\nVaccination for Air Passengers. Maintaining distance between yourself and others is often difficult on public transportation. People may not be able to\navoid crowding on airplanes, trains, or buses. Protect yourself from COVID-19 by staying up to date with your COVID-19 vaccines and by wearing a high-quality mask on\npublic transportation.","181":"Related Pages\nReducing the Risk of SARS-CoV-2 Spreading between People and Wildlife\n\u203a\nWhat You Should Know about COVID-19 and Pets\n\u203a\nMore Information\nInformation on Bringing an Animal into the United States\nWorld Organisation for Animal Health: COVID-19 Events in\nAnimals\nUSDA: Confirmed cases of SARS-CoV-2 in Animals in the\nUnited States\nUSDA: Coronavirus Disease 2019\nFDA: Coronavirus Disease 2019\n\uf209\n\uf209\n\uf209\n\uf209\nMedia Announcements\nConfirmation of COVID-19 in a Canada Lynx at a Pennsylvania Zoo\nConfirmation of COVID-19 in Hyenas at a Colorado Zoo\nConfirmation of COVID-19 in a Coatimundi at an Illinois Zoo\nConfirmation of COVID-19 in a Binturong and a Fishing Cat at an Illinois Zoo\nConfirmation of COVID-19 in Ferret in Florida\nConfirmation of COVID-19 in Deer in Ohio\nTexas A&M Research Uncovers First Known COVID-19 UK Variant In Animals\nConfirmation of COVID-19 in a Snow Leopard at a Kentucky Zoo\u200b\nUSDA Confirms SARS-CoV-2 in Mink in Utah\nConfirmation of COVID-19 in Pet Dog in New York\nConfirmation of COVID-19 in Two Pet Cats in New York\nUSDA Statement on the Confirmation of COVID-19 Infection in a Tiger in New York\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022\n\u2022 \uf209\nLast Updated July 5, 2022","7221":"In clinical trials, approximately 23,000 individuals 12 years of age and older have\nreceived at least 1 dose of Pfizer-BioNTech COVID-19 Vaccine. Millions of individuals\nhave received the Pfizer-BioNTech COVID-19 Vaccine under EUA since December 11,\n2020. In a clinical trial, approximately 300 individuals greater than 55 years of age received\none dose of a bivalent vaccine that differs from the Pfizer-BioNTech COVID-19\nVaccine, Bivalent in that it contains a different Omicron component. WHAT ARE THE BENEFITS OF THESE VACCINES? COMIRNATY (COVID-19 Vaccine, mRNA) and the Pfizer-BioNTech COVID-19 Vaccine\nhave been shown to prevent COVID-19.","9832":"Reporting Adverse Event or Medication Errors\nThe vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event\nReporting System (VAERS):\n\u2022 vaccine administration errors whether or not associated with an adverse event,\n\u2022 serious adverse events (irrespective of attribution to vaccination),\n\u2022 cases of myocarditis\n\u2022 cases of pericarditis\n\u2022 cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and\n\u2022 cases of COVID-19 that result in hospitalization or death. Complete and submit reports to VAERS online at https:\/\/vaers.hhs.gov\/reportevent.html. For further assistance with reporting to VAERS call 1-800-822-7967. References\nAbu-Raddad L, Chemaitelly H, Ayoub HH, et al.","6154":"\u2022\n\u2022\nCDC uses the following platforms and methods to collect and\nanalyze surveillance data on COVID-19 cases, hospitalizations,\nand deaths by vaccination status:\nCase surveillance\nCDC collaborates with more than 30 state and local health departments that routinely link case surveillance, immunization\nregistry, and vital registration data to monitor rates of COVID-19 cases and deaths by vaccination status, including receipt of\nbooster doses. These rates are published monthly on COVID Data Tracker. Data from the participating health departments represent more than 70% of the U.S. population and all regions of the\ncountry. The volume of this data allows CDC to analyze rare outcomes over time, like COVID-19-associated deaths.","7618":"\uf1aa\f10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nThe requirements for testing and quarantine post-arrival by air conveyance apply to sea crew\/mariners entering the\nUnited States as Covered Individuals who are:\nnot fully vaccinated against COVID-19, and\nwithout documentation of having recovered from COVID-19 in the past 90 days. Sea crew members boarding cruise ships that are participating in CDC\u2019s COVID-19 Program for Cruise Ships must follow\napplicable guidance for testing and quarantine during and after embarking the cruise ship.","3220":"Procedures should be in\nplace to prevent falling injuries and manage syncopal reactions. Patients should be seated or lying down during vaccination. Vaccination providers, particularly when vaccinating adolescents, should consider observing vaccine recipients for 15 minutes\nafter vaccination. If syncope develops, patients should be observed until symptoms resolve.","3656":"Traveling by private vehicle (if possible) can lower\nthe chances of spreading COVID-19 to others. I was exposed to a person with COVID-19 in the\npast 10 days. Follow CDC guidance, including getting tested at\nleast 5 full days after your last exposure. Do not travel on public transportation such as\nairplanes, buses, and trains if you will not be able\nto wear a high-quality mask or respirator when\naround others indoors for the full duration of your\ntrip. If you travel, wear a high-quality mask or\nrespirator the entire time you are around others\nindoors.","7931":"Although COVID-19 vaccine-related myocarditis is much\nlower for children than teens,13 personal anecdotes14 and reports of\nhospitalization15 following myocarditis continue to negatively impact\nvaccine confidence.16,17,18 CDC and its partners are actively monitoring\nreports of myocarditis and pericarditis after COVID-19 vaccination and CDC\ngives regular public updates about the risks of myocarditis and pericarditis\nafter mRNA vaccination, predominantly in adolescents and young adult\nmales within several days after COVID-19 vaccination.19\n\u0083 One CDC study found that \u201cthe incidence of cardiac outcomes after\nmRNA COVID-19 vaccination was highest for males aged 12\u201317 years after the second vaccine dose; however, within this\ndemographic group, the risk for cardiac outcomes was 1.8\u20135.6 times as high after SARS-CoV-2 infection than after the second\nvaccine dose.\u201d20 Another study \u201cfound that the risk for cardiac complications was significantly higher after SARS-CoV-2\ninfection than after mRNA COVID-19 vaccination for both males and females in all age groups.\u201d21\n\u0083 Vaccine-acquired Immune Deficiency Syndrome and HIV.","3557":"How CDC Attributes Doses\nCDC determines the number of people receiving at least one dose, the number of people who are fully vaccinated, and the\nnumber of people with booster doses based on information reported to CDC on dose number, dose manufacturer,\nadministration date recipient ID and date of submission Because the method used to determine dose numbers needs to be\nCDC reports COVID-19 vaccination data online on COVID Data Tracker and in vaccination datasets. Sharing timely and\naccurate information with the public is one of CDC\u2019s core activities. Timely and accurate reporting from jurisdictions\nprovides the reliable data that can be reported by CDC.","7690":"They are:\nAnaphylaxis\nAnaphylaxis is a severe type of allergic reaction with symptoms such as hives, difficulty breathing, low blood pressure, or\nsignificant swelling of the tongue or lips. Anaphylaxis after COVID-19 vaccination is rare. Learn more about COVID-19 vaccines\nand allergic reactions, including anaphylaxis. Thrombosis with Thrombocytopenia Syndrome (TTS)\nThrombosis with thrombocytopenia syndrome (TTS) is a rare but serious adverse event that causes blood clots or issues with\nclotting. TTS after COVID-19 vaccination is rare. Learn more about COVID-19 vaccines and adverse events, including TTS. Myocarditis and Pericarditis\nMyocarditis is inflammation of the heart muscle, and pericarditis is inflammation of the outer lining of the heart.","4665":"Guidance for use of Janssen COVID-19 Vaccine\n\uf209\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nContraindications and precautions\nTable A. Contraindications and precautions to Janssen COVID-19 vaccination\nContraindications and precautions to Janssen COVID-19 vaccination are summarized in Table A; see Contraindications and\nprecautions to COVID-19 vaccination for additional information (e.g., people with a history of allergic reactions).","3883":"My facility does not stock vaccines. Are there other ways I can contribute? \uf1aa\nVisit the Vaccine Adverse Event Reporting System (VAERS ) for information about all reporting requirements or to\nsubmit a report. COVID-19 vaccination providers are required to report vaccine administration errors to VAERS, even if the error is not\nassociated with an adverse event. They are also required to report certain adverse events after COVID-19 vaccination\n(and other adverse events if later revised by CDC). How do I report a vaccine administration error or adverse event?","6209":"If you have concerns about COVID-19 vaccination, talk with your healthcare provider or your child\u2019s doctor, nurse, or clinic. If you have any health problems after vaccination, report them to\u202fVAERS . \uf209\nLast Updated Sept. 27, 2022","5081":"Updated information and recommendations for vaccination of pregnant or lactating people. Updated recommendations for vaccination of children and adolescents. Updated information related to axillary lymphadenopathy added to patient counseling for mRNA COVID-19 vaccines. Updated information on the Janssen COVID-19 Vaccine added to patient counseling. Updated recommendations related to contraindications (polysorbate allergy) and precautions (most people with a\nprecaution can and should be administered vaccine) for COVID-19 vaccines. Recommended pause in the use of Janssen (Johnson & Johnson) COVID-19 Vaccine. Recommendations for clinicians related to occurrence of cerebral venous sinus thrombosis (CVST) with\nthrombocytopenia after receipt of Janssen COVID-19 Vaccine.","3113":"Moderate and severe immunocompromising conditions and treatments include but are not limited to:\nActive treatment for solid tumor and hematologic malignancies\nHematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status\n(e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\nReceipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\nReceipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of\ntransplantation or taking immunosuppressive therapy)\nModerate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined\nimmunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)\nAdvanced HIV infection (people with HIV and CD4 cell counts less than 200\/mm3, history of an AIDS-defining illness\nwithout immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection\nActive treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when\nadministered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs,\ncancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and\nother biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents)\nFactors to consider in assessing the general level of immune competence in a patient include disease severity, duration,\nclinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.","6985":"It is your choice to receive or not receive the COVID-19 vaccine by Pfizer-BioNTech as a primary and\/or\nadditional dose. Should you decide not to receive it, it will not change your standard medical care. Will I get a vaccination card? When you are administered a primary, additional, or a booster dose of the COVID-19 vaccine by Pfizer-\nBioNTech, you will get a vaccination card to document when you received the shot. You should keep your\nvaccination card. What is the Countermeasures Injury Compensation Program?","6754":"WHAT SHOULD YOU MENTION TO YOUR CHILD\u2019S VACCINATION PROVIDER\nBEFORE YOUR CHILD GETS ANY OF THESE VACCINES? Tell the vaccination provider about all of your child\u2019s medical conditions,\nincluding if your child:\n\uf0b7 has any allergies\n\uf0b7 has had myocarditis (inflammation of the heart muscle) or pericarditis\n(inflammation of the lining outside the heart)\n\uf0b7 has a fever\n\uf0b7 has a bleeding disorder or is on a blood thinner\n5 Monovalent refers to any authorized or approved COVID-19 vaccine that contains or encodes the spike protein\nof only the Original SARS-CoV-2.","710":"December 16, 2021: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 22,422\ndoses administered. December 9, 2021: Illinois made updates to data previously submitted to CDC that resulted in an increase of 53,344\ndoses administered. December 2, 2021: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 46,380\ndoses administered. November 23, 2021: Pennsylvania made updates to data previously submitted to CDC that resulted in a decrease of\n1,151,719 doses administered. November 18, 2021: Illinois made updates to data previously submitted to CDC that resulted in a decrease of\n214,250 doses administered.","8758":"Safety precautions\nIf your child has a medical condition, such as a heart or lung problem, ask their healthcare provider before they use\nmethods to improve mask fit or use an ASTM F3502 mask or a respirator. If your child has a hard time breathing, gets dizzy, or has other symptoms while you are trying to get the mask to fit\nbetter or when using an ASTM F3502 mask or a respirator, choose a cloth or disposable mask. They should continue to\nprotect themselves and others. Consult your healthcare provider if these symptoms do not resolve.","5529":"We are still learning\nto what extent certain groups are at higher risk, and if different groups of people tend to experience different types of post-\nCOVID conditions. These studies, including for example CDC\u2019s INSPIRE and NIH\u2019s RECOVER , will help us better understand\npost-COVID conditions and how healthcare providers can treat or support patients with these longer-term effects. CDC will\ncontinue to share information with healthcare providers to help them evaluate and manage these conditions. CDC is working to:\nBetter identify the most frequent symptoms and diagnoses experienced by patients with post-COVID conditions.","2901":"Bivalent mRNA vaccines are not authorized or approved at this time\nfor primary series doses. The same vaccine product should be used for all doses of the primary series (see Interchangeability\nof COVID-19 vaccine products). Booster vaccination\nFor booster vaccination, an mRNA vaccine (i.e., Moderna or Pfizer-BioNTech) is recommended. Recommendations vary based\non age and primary series product. People ages 5 years and older are recommended to receive 1 bivalent mRNA booster dose\nafter completion of any FDA-approved or FDA-authorized monovalent primary series or previously received monovalent\nbooster dose(s). This new booster recommendation replaces all prior booster recommendations for this age\ngroup.","5454":"This can make it difficult for healthcare providers to recognize post-COVID conditions. Your healthcare\nprovider considers a diagnosis of post-COVID conditions based on your health history, including if you had a diagnosis of\f10\/30\/22, 9:42 AM Long COVID or Post-COVID Conditions | CDC\nCOVID-19 either by a positive test or by symptoms or exposure, as well as doing a health examination. Symptoms\nPeople with post-COVID conditions can have a wide range of symptoms that can last more than four weeks or even months\nafter infection. Sometimes the symptoms can even go away or come back again. Post-COVID conditions may not affect everyone the same way.","2107":"You can receive a COVID-19 vaccine, including a booster shot, without any additional\ndocumentation from your healthcare provider. -\n-\n-\n\u2022\nCDC\u2019s v-safe After Vaccination Health Checker is a voluntary smartphone-based tool that provides quick and confidential\nhealth check-ins via text messages and web surveys so you can quickly and easily share with CDC how you or your\ndependent feel after getting a COVID-19 vaccine. If you enroll in v-safe and report that you are pregnant at the time of vaccination or after vaccination, CDC\u2019s v-safe COVID-\n19 Vaccine Pregnancy Registry staff* may contact you.","8055":"Because mask use is not recommended for children ages younger than 2 years and may be\ndifficult for very young children or for some children with disabilities who cannot safely wear a mask, ECE programs and\nK-12 schools may need to consider other prevention strategies\u2014such as improving ventilation and avoiding crowding\u2014\nwhen the COVID-19 Community Level is medium or high or in response to an outbreak.","5418":"In addition, the FDA decision is based on\nthe totality of scientific evidence available showing that the product may be effective to prevent\nCOVID-19 during the COVID-19 pandemic and that the known and potential benefits of the\nproduct outweigh the known and potential risks of the product. All of these criteria must be met to\nallow for the product to be used during the COVID-19 pandemic. The EUA for the Janssen COVID-19 Vaccine is in effect for the duration of the COVID-19\ndeclaration justifying emergency use of these products, unless terminated or revoked (after which\nthe products may no longer be used).","89":"\uf209\nRelated Pages\nInformation about COVID-19 Vaccines for People with Allergies\n\u203a\nPossible Side Effects\n\u203a\nEnsuring the Safety of COVID-19 Vaccines\n\u203a\f10\/30\/22, 9:31 AM Allergic Reactions after COVID-19 Vaccination | CDC\n\uf2ff For Healthcare Professionals\nInterim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19\nVaccination Sites\nInterim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United\nStates\nCOVID-19 Clinical Resources\n\u2022\n\u2022\n\u2022\nMore Information\nResearch\nAllergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine \u2014 United\nAllergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine \u2014 United States,\nMore Information\nVaccine Adverse Event Reporting System (VAERS)\nCOVID-19 Vaccine Safety Publications\n\uf209\nLast Updated July 20, 2022","5876":"Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the novel coronavirus, SARS-CoV-2,\nthat emerged in late 2019. It is predominantly a respiratory illness that can affect other organs. People with\nSARS-CoV-2 infection have reported a wide range of symptoms, ranging from no symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include fever or chills, cough,\nshortness of breath, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat,\ncongestion or runny nose, nausea or vomiting, and diarrhea. Who can receive the COVID-19 vaccine by Moderna?","4000":"Because CDC removes duplicate records, data presented on the COVID Data Tracker might differ\nfrom data listed in jurisdictional Immunization Information Systems (IIS) and dashboards. CDC makes every effort to\nreconcile doses administered that are reported through more than one system. How does CDC manage data from multiple sources? \uf1aa\nEach state or territorial health department is responsible for establishing internal operations and schedules for\nreporting data. As a result, there are differences among states in the frequency of reporting. Data on doses of vaccine delivered and administered include data received by CDC as of 6:00 am ET on\nWednesday, the day of weekly reporting.","4348":"CDC does not provide the white CDC COVID-19 vaccination card to people and does not maintain vaccination\nrecords. Only a vaccination provider can give you this card. \u2022\n\u2022\n\u2022\nWhat is the difference between a vaccine record and a COVID-19 vaccination card? \uf1aa\nA vaccine record (sometimes called immunization record) provides a history of all the vaccines you received. This record may be required for certain jobs, travel abroad, or a school registration. A COVID-19 vaccination card is only for COVID-19 vaccination and is given to you when you get your COVID-19\nvaccine.","8578":"Therefore, it is possible that a person could be infected with the\nvirus that causes COVID-19 just before or just after vaccination and then get sick\nbecause the vaccine did not have enough time to provide protection. Sometimes after vaccination, the process of building immunity can cause symptoms,\nsuch as fever. These symptoms are normal signs the body is building immunity. Types of Vaccines: mRNA, Viral Vector, and Protein Subunit\nFacts about COVID-19 Vaccines\nCurrently, there are three main types of COVID-19 vaccines that are approved or authorized for use in the United States:\nmRNA, viral vector, and protein subunit.","8529":"Be sure to give the airline your current contact information when booking your ticket so you can be notified if you are\nexposed to a sick traveler on a flight. What happens if there is a sick passenger on an international or domestic flight? \uf1aa\f10\/30\/22, 9:43 AM Travel: Frequently Asked Questions and Answers | CDC\nLand Travel\nCruise Travel\nFor more information, see the CDC webpage Protecting Travelers\u2019 Health from Airport to Community: Investigating\nContagious Diseases on Flights.","5270":"\u2022\n\u2022\n\u2022\n\u2022\nAfter you have ended isolation, when you are feeling better (no fever without the use of fever-reducing medications and\nsymptoms improving),\nWear your mask through day 10. OR\nIf you have access to antigen tests, you should consider using them. With two sequential negative tests 48 hours apart,\nyou may remove your mask sooner than day 10. Note: If your antigen test results are positive, you may still be infectious. You should continue wearing a mask and wait at\nleast 48 hours before taking another test. Continue taking antigen tests at least 48 hours apart until you have two sequential\nnegative results.","3006":"An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19\nvaccines may be optimal for some people as it may reduce the small risk of myocarditis and pericarditis associated with these\nCOVID-19 vaccines. While absolute risk remains small, an elevated risk for myocarditis and pericarditis has been observed among mRNA COVID-\n19 vaccine recipients, particularly in males ages 12\u201339 years (see COVID-19 vaccination and myocarditis and pericarditis). Cases of myocarditis and pericarditis were identified in clinical trials of Novavax COVID-19 Vaccine and through passive\nsurveillance during post-authorization use outside the United States.","3823":"If a vaccine recipient has health coverage, providers may seek appropriate reimbursement from the recipient\u2019s plan or\nprogram (e.g., private health insurance, Medicare, Medicaid ) for a vaccine administration fee. However, providers\ncannot bill the recipient for the balance not covered by the recipient\u2019s plan or program. For further information on\nreimbursement requirements, please see the CDC COVID-19 Vaccination Program Provider Requirements and Support\nwebpage. Can I charge patients a fee for administering COVID-19 vaccines?","2200":"Nir O, Schwartz A, Toussia-Cohen S, et al. Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies\namong parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy. Am J Obstet Gynecol 2022;\n20. Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort\nstudy. Am J Obstet Gynecol. Published online March 25, 2021. DOI: https:\/\/doi.org\/10.1016\/j.ajog.2021.03.023\n21. Shook LL, Atyeo CG, Yonker LM, et al. Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination\nor Natural Infection. JAMA. Published online February 07, 2022. DOI: https:\/\/doi.org\/10.1001\/jama.2022.1206\n22. Halasa NB, Olson SM, Staat MA, et al.","4862":"If the\ndosing is in accordance with the FDA EUA, it is not considered an error and VAERS reporting is not indicated. Some experts suggest delaying the repeat dose for 8 weeks after the invalid dose based on the potential for increased reactogenicity and the\nrare risk of myocarditis and pericarditis from mRNA (i.e., Moderna or Pfizer-BioNTech) and Novavax COVID-19 vaccines, particularly in groups at\nincreased risk for myocarditis and pericarditis (e.g., males ages 12\u201339 years). Individual risk for COVID-19 and the likelihood for an adverse\nevent following vaccination should be taken into consideration when recommending a longer interval.","8134":"COVID-19 State of Vaccine Confidence Insights Report | October 10, 2022\nAppendix: Inputs and Sources\nType Input Cadence Sources Tactics for Utilization\nSocial Media\nListening\n& Media\nMonitoring\nCommunication\nSurveillance Report\nDaily on\nweekdays\n\u0082Google news\n\u0082Meltwater\n\u0082CrowdTangle\n\u0082Native platform searches\n\u0082Share of voice topic analysis to identify\nthemes\n\u0082Emerging topics\nMeltwater Daily \u0082Facebook, Twitter, Instagram\n\u0082Blogs\n\u0082News media\n\u0082Online forums\n\u0082Share of voice topic analysis\n\u0082Emerging theme topics\n\u0082Identify high reach\/velocity topics\nOADC (Office of the\nAssociate Director of\nCommunication) Channel\nCOVID-19 Post metrics\nWeekly \u0082Sprout Social\n\u0082Native OADC account analytics\n\u0082Analyze # of posts, topics\n\u0082Success of messages, # of impressions,\nreach, # engagements\nOADC Channel Comment\nAnalysis\nDaily on\nweekdays\n\u0082Native platform searches \u0082Sentiment analysis\n\u0082Identify message gaps\/voids\nDirect Reports\nCDC-INFO Metrics Weekly \u0082CDC-INFO inquiry line list\n\u0082Prepared response (PR) usage report\n\u0082Cross-compare PR usage with inquiry\ntheme analysis\n\u0082Sentiment analysis\n\u0082Identify information gaps\/voids\nVTF Media Requests Weekly \u0082Media request line list \u0082Leading indicator for news coverage\n\u0082Identify information gaps\/voids\nWeb Metrics Weekly \u0082Top pages\n\u0082Google search queries\n\u0082Top FAQs\n\u0082Referring domains\n\u0082Identify information gaps\/voids,\n\u0082Identify keywords\/search terms, changes in\nweb traffic\nResearch\nPoll Review Weekly \u0082Harris Poll, PEW research, Gallup Poll,\nKFF\n\u0082New data related to vaccine\nhesitancy\n\u0082Identify socio-behavior indicators related\nto motivation and intention to vaccinate\nLiterature Review Weekly \u0082PubMed, LitCovid, ProQuest Central,\nAltmetric\n\u0082New data related to vaccine\nhesitancy\n\u0082Identify current vaccination intention\n\u0082Identify barriers to vaccination\nThird Party\nReports\nTanaq Social Listening\n+Media Monitoring Report\nWeekly \u0082Meltwater\n\u0082Sprout Social\n\u0082First Draft\n\u0082Native platform searches\n\u0082Trending topics\n\u0082Demographic and geographic\nconversation monitoring\nCrowdTangle content\ninsights report\nBiweekly \u0082Facebook \u0082Top pages (voices), groups\n\u0082General trends\/sentiment analysis\n\u0082News analysis through posts\nUniversity of Washington\nSt. Louis iHeard\nWeekly \u0082Proprietary methods \u0082Survey results\n\u0082Emerging threats and data deficits\n\u0082Vaccine narratives\nProject VCTR Weekly \u0082Proprietary methods \u0082National and regional trends in negative\nattitudes toward vaccination\n\u0082Conversations around Legislation\nVirality Project Weekly \u0082Proprietary methods \u0082Mis- and disinformation trends related to","804":"Getting sick with COVID-19 can cause severe illness or death, even in children, and we can\u2019t reliably predict who will\nhave mild or severe illness. You may have long-term health issues after having COVID-19. Even people who do not have symptoms when they\nare first infected can have these ongoing health problems, also known as long COVID or post-COVID conditions. These complications can appear after mild or severe COVID-19, or after multisystem inflammatory syndrome in\nchildren (MIS-C).","7512":"I have recovered from COVID-19 and have received one dose of an accepted COVID-19 vaccine\ndose, and therefore am considered fully vaccinated in my country, but not under CDC\u2019s Amended\nOrder. Would I be considered fully vaccinated under CDC\u2019s Amended Order if I got a booster dose\nof an accepted COVID-19 vaccine? \uf1aa\nAre different formulations of vaccines considered acceptable proof of vaccination? \uf1aa\f10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nYes, different formulations of COVID-19 vaccines authorized for emergency use or approved by the U.S. Food and Drug\nAdministration\u202for listed for emergency use by WHO are accepted.","1195":"Beginning October 22, 2021, CDC is able to attribute non-residents of Texas to their respective state or territory of\nresidence. Texas residents who received a COVID-19 vaccination in a different state or territory are also now attributed\nto Texas\u2019 population-based metrics. Beginning November 18, the\u202fVaccination Demographics and\u202fDemographic Trends\u202fsites include vaccination demographic\ninformation from Texas. New Hampshire\u202flifted its national COVID-19 emergency response declaration in May 2021, which allows vaccine recipients to\nopt out of having their COVID-19 vaccinations included in the state\u2019s IIS. As such, data submitted by New Hampshire since May\n2021 may not be representative of all COVID-19 vaccinations occurring in the state.","4322":"Make sure your vaccination provider updates your vaccination card\n(or gives you one if this is your first dose). Stay up to date with the recommended COVID-19 vaccines and\nboosters. You may experience side effects after getting a COVID-19 vaccine. Adverse effects (serious safety problems) and severe allergic\nreactions are rare. To report any side effects, you can sign up for v-safe. V-safe is a\nsmartphone-based tool that provides quick and confidential health check-ins via text messages and web surveys so you\ncan quickly and easily share with CDC how you or your dependent feel after getting a COVID-19 vaccine.","8533":"For information about COVID-19 requirements for land travel, visit the U.S. Department of Homeland Security\u2019s Fact\nSheet: Guidance for Travelers to Enter the U.S. at Land Ports of Entry and Ferry Terminals . What are the requirements for international land travel? \uf1aa\n\uf209\nYes. The chance of getting COVID-19 on cruise ships is high because the virus spreads easily between people in close\nquarters on board ships. For this reason, CDC recommends the following groups of people avoid traveling on cruise\nships, including river cruises, worldwide:\nPeople who are not up to date with their COVID-19 vaccines.","4108":"Can I ask my healthcare provider for a dose of COVID-19 vaccine that does not follow vaccination\nguidelines, sometimes called \u201coff-label\u201d use? \uf1aa\n\uf209\nScientists are monitoring how long COVID-19 vaccine protection lasts. COVID-19 vaccines work well to prevent severe\nillness, hospitalization, and death. However, public health experts are seeing decreases in the protection COVID-19\nvaccines provide over time, especially for certain groups of people. Due to this, CDC recommends COVID-19 vaccines for\neveryone ages 6 months and older, and boosters for everyone 5 years and older, if eligible. Learn more about COVID-19\nbooster recommendations, including recommendations for people who are moderately or severely\nimmunocompromised.","2120":"Keeping\nyourself as healthy as possible during pregnancy is important for the health of your baby. When during pregnancy should a person get a COVID-19 vaccine? \uf1aa\f10\/30\/22, 9:30 AM COVID-19 Vaccines While Pregnant or Breastfeeding\nPeople who are Breastfeeding\nCDC recommends that people who are breastfeeding get vaccinated and stay up to date with their COVID-19 vaccines,\nincluding getting a COVID-19 booster shot when it\u2019s time to get one. Clinical trials for the COVID-19 vaccines currently used in the United States did not include people who were breastfeeding.","2489":"Learn more about the factors that can\naffect your risk of getting very sick from COVID-19 to better understand how COVID-19 could affect you and others around\nyou. Know Your COVID-19 Community Level\nTake action to protect yourself and others from COVID-19 based on the COVID-19 Community Level in your area. What You Need to Know\nCOVID-19 Community Levels help individuals and communities decide which prevention actions to take based on\nthe latest information. Each level helps convey how much COVID-19 is impacting your community using data on hospitalizations and\ncases. Using these data, communities are classified as low, medium, or high.","3187":"Extensive experience with non-COVID 19 vaccines has demonstrated that immunogenicity and adverse event profiles are\ngenerally similar when vaccines are administered simultaneously as when they are administered alone. Studies that\ncompared coadministration of COVID-19 vaccines and seasonal influenza vaccines with separate administration of these\nvaccines found similar levels of immunogenicity and similar or slightly higher reactogenicity; no specific safety concerns were\nidentified. In accordance with general best practices, routine administration of all age-appropriate doses of vaccines simultaneously is\nrecommended for children, adolescents, and adults for whom no specific contraindications exist at the time of the healthcare\nvisit.","8786":"Be sure to wash or\nsanitize your hands again after taking off your mask and after putting your mask back on. When to throw away or change your mask\nDisposable masks should be thrown away after they\u2019re worn once. If you use respirators, check the manufacturer\u2019s instructions to learn how long they can be worn before they should be\nthrown away. Disposable masks and respirators\u202fthat become wet or dirty should be thrown away in the trash right away. Do not\ncontinue to wear a wet or dirty mask. Replace it with a dry, clean mask.","6830":"Remember to bring the card when your child returns. ADDITIONAL INFORMATION\nIf you have questions, visit the website or call the telephone number provided below. To access the most recent Fact Sheets, please scan the QR code provided below. Global website Telephone number\nwww.cvdvaccine.com\nHOW CAN I LEARN MORE? \uf0b7 Ask the vaccination provider. \uf0b7 Visit CDC at https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/index.html. \uf0b7 Visit FDA at https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-\nlegal-regulatory-and-policy-framework\/emergency-use-authorization. \uf0b7 Contact your local or state public health department. WHERE WILL MY CHILD\u2019S VACCINATION INFORMATION BE RECORDED? The vaccination provider may include your child\u2019s vaccination information in your\nstate\/local jurisdiction\u2019s Immunization Information System (IIS) or other designated\nsystem.","4581":"Follow the manufacturer\u2019s\ninstructions to replace the filter\nyourself or ask a professional for\nhelp. Make sure the filter is installed\nproperly (see figure). Change your filter every three\nmonths or according to the\nmanufacturer\u2019s instructions. Ideally, have the ventilation\nsystem inspected and adjusted by\na professional every year to make\nsure it is operating efficiently. \uf21b\n\u2022\n\u2022 \uf209\n\u2022\n\u2022\n\u2022\nConsider using a portable air cleaner\nUsing a portable high-efficiency particulate air (HEPA) cleaner can provide filtration if you don\u2019t have an HVAC system or\ncan improve filtration if you do have an HVAC system.","7843":"Healthcare providers can ensure that those who have tested positive for COVID-19 receive the most appropriate medical\ncare, including specific treatments if necessary. In most jurisdictions, healthcare providers who\u202fdiagnose COVID-19 are required to report those cases to public health. The US Government\u202fdoes not want to construct any barriers that would deter the use of self-tests. COVID-19\nsurveillance\u202fcontinues to be based on results from laboratory testing. The primary role of case reporting is to allow public\nhealth agencies to take actions to mitigate disease spread. The public health community, including CDC, is confident that\nsituational awareness remains strong without receiving self-test results.","2290":"Safe, Easy, Free, and Nearby COVID-19 Vaccination\nThe federal government is providing the vaccine free of charge to all people living in the U.S., regardless of their\nimmigration or health insurance status. COVID-19 Vaccines Are Free\n\u2022\n\u2022\n\u2022\nTo find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. 10\/30\/22, 9:29 AM COVID-19 Vaccines for Long-term Care Residents | CDC\nLearn more about how the federal government, LTC providers, and jurisdictions are ensuring access to COVID-19 vaccines in\nLTC settings. Learn more about possible side effects and what to expect after getting your COVID-19 vaccine.","7365":"10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nA person who has received only one dose of an accepted 2-dose series and has recovered from COVID-19 does not meet\nthis definition, and therefore is NOT considered fully vaccinated for travel to the United States. *CDC has not recommended the use of mix-and-match COVID-19 vaccine primary series. However, such strategies are\nincreasingly common in many countries outside of the United States. Therefore, for the purpose of interpreting\nvaccination records for travel to the United States, CDC will accept combinations of accepted COVID-19 vaccines.","7782":"FDA requires healthcare providers to report any death after\nCOVID-19 vaccination to VAERS even if it\u2019s unclear whether the vaccine was the cause Reports of adverse events to\n\u2022\n-\n\u2022\n\uf209\n\u2022\n\uf209\n\u2022 \uf20c\n-\n-\n\uf209\n-\n-\n-\n-\f10\/30\/22, 9:32 AM Selected Adverse Events Reported after COVID-19 Vaccination | CDC\nCOVID-19 vaccination to VAERS, even if it s unclear whether the vaccine was the cause. Reports of adverse events to\nVAERS following vaccination, including deaths, do not necessarily mean that a vaccine caused a health problem. More than 632 million doses of COVID-19 vaccines were administered in the United States from December 14, 2020,\nthrough October 19, 2022.","6993":"The Countermeasures Injury Compensation Program (CICP) is a federal program that may help pay for costs\nof medical care and other specific expenses of certain people who have been seriously injured by certain\nmedicines or vaccines, including this vaccine. Generally, a claim must be submitted to the CICP within one\n(1) year from the date of receiving the vaccine. To learn more about this program, visit www.hrsa.gov\/cicp\/\nor call 1-855-266-2427. How can I learn more? \u2022 Ask the vaccination provider. \u2022 Visit CDC at https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/index.html. \u2022 Visit FDA at https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-\nand-policy-framework\/emergency-use-authorization. \u2022 Contact your local or state public health department.","4368":"10\/30\/22, 9:37 AM How Coronavirus Spreads | CDC\nEspa\u00f1ol | Other Languages\nHow COVID-19 Spreads\nCOVID-19 spreads when an infected person breathes out droplets and very small particles that contain the virus. These\ndroplets and particles can be breathed in by other people or land on their eyes, noses, or mouth. In some circumstances, they\nmay contaminate surfaces they touch. Anyone infected with COVID-19 can spread it, even if they do NOT have symptoms. \uf549 About Variants\nMany viruses are constantly changing, including the virus that causes COVID-19.","4394":"If You Are Homebound\nContact your healthcare provider or your state or local health department for information about getting a COVID-19\nvaccine. In many states, you may also dial 211 to connect to essential community services. Contact groups that are advocates for people who are homebound or that provide home health services. Call The Aging Network at 1-800-677-1116. Search for services by ZIP code with the Eldercare Locator . Contact the Disability Information and Access Line (DIAL) at 1-888-677-1199. Call the hotline for Medicare recipients at 1-800-633-4227 (TTY 1-877-486-2048).","1050":"10\/30\/22, 9:42 AM COVID-19 Treatments and Medications | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Treatments and Medications\nThis page provides a treatment overview for the General Public. For healthcare providers: Interim Clinical Considerations for COVID-19 Treatment in Outpatients\nWhat You Need to Know\nIf you test positive for COVID-19 and are more likely to get very sick, treatments are available that can reduce your\nchances of hospitalization and death. Don\u2019t delay: Treatment must be started within days after you first develop symptoms to be effective. Other medications can help reduce symptoms and help you manage your illness.","7557":"The name of the COVID-\n19 vaccine product and the medical condition must both be listed. Medical contraindications to COVID-19 vaccination include immediate or severe allergic reaction (e.g.,\nanaphylaxis) after a previous dose or component of a COVID-19 vaccine or known allergy to a component of a\nCOVID-19 vaccine. Must have sufficient personally identifiable information (full name plus at least one other identifier such as date of\nbirth or passport number) to confirm that the letter matches with your passport or other travel information.","5004":"Added considerations for an 8-week interval between the first and second doses of a primary mRNA vaccine schedule\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nUpdated guidance for moderately or severely immunocompromised people\nClarification of existing recommendation to receive a 3-dose mRNA vaccine primary series followed by a booster\ndose for a total of 4 doses\nNew guidance to shorten the interval between completion of the mRNA vaccine primary series and the booster\ndose to at least 3 months (instead of 5 months)\nNew guidance for those who received the Janssen COVID-19 Vaccine primary series to receive an additional dose\nand a booster dose, for a total of 3 doses to be up to date\nUpdated guidance that it is no longer necessary to delay COVID-19 vaccination following receipt of monoclonal\nantibodies or convalescent plasma\nUpdated guidance on receiving a booster dose if vaccinated outside the United States\nUpdated contraindication and precaution section to include history of myocarditis or pericarditis after an mRNA\nCOVID-19 vaccine as a precaution\nReorganized and condensed multiple sections\nUpdated guidance for use of Pfizer-BioNTech COVID-19 Vaccine as a booster in people ages 12\u201317 years\nUpdated guidance for administration of a COVID-19 vaccine booster dose at least 5 months after completion of an\nmRNA vaccine (Pfizer-BioNTech or Moderna) primary series\nUpdated guidance for use of an additional primary dose for moderately or severely immunocompromised people ages\n5\u201311 years who received a Pfizer-BioNTech vaccine primary series\nUpdated recommendations for people who received COVID-19 vaccines outside the United States that are not FDA-\nauthorized or approved\nUpdated information about a second formulation of Pfizer-BioNTech COVID-19 Vaccine that is authorized for use in\npersons ages 12 years and older\nUpdated information on vaccinating people during quarantine after a known SARS-CoV-2 exposure or during COVID-\nUpdate to alert providers of possible false positive Rapid Plasma Reagin (RPR; non-treponemal) test results in some\npeople after COVID-19 vaccines\nUpdated information on vaccine administration errors and deviations\nUpdated guidance on use of Janssen (Johnson & Johnson) COVID-19 Vaccine\nUpdated recommendations for receipt of a COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 booster doses in recipients of mRNA COVID-19 vaccines\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nRecommendations and clinical guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children aged 5-11 years\nincluding updated section on Vaccination of children and adolescents\nUpdated guidance on COVID-19 vaccine dosing and schedule\nUpdated guidance for myocarditis and pericarditis after mRNA COVID-19 vaccination in new section on Considerations\nfor mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna\nNew guidance for people who received passive antibody products in section on COVID-19 vaccination and SARS-CoV-2\ninfection\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial in the United States\nUpdated guidance on Considerations for COVID-19 vaccination in moderately and severely immunocompromised\npeople\nUpdated guidance in section on Contraindications and precautions\nUpdated Table in Appendix A: Vaccine administration errors and deviations\nUpdated Appendix B: Triage of people with a history of allergies or allergic reactions\nUpdated Appendix C: Ingredients included in COVID-19 vaccines\nUpdated Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects\nfollowing COVID-19 vaccination\nUpdated guidance in section on Considerations for use of a COVID-19 booster dose.","4935":"Table of Contents \uf426\nReferences and Previous Updates\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine \u2014 United States, December 2020\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Moderna COVID-19 Vaccine\n\u2014 United States, December 2020\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Janssen COVID-19 Vaccine \u2014\nUnited States, February 2021\nUpdated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson\n& Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine\nRecipients\u2014United States, April 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Adolescents Aged 12\u201315 years \u2014 United States, May 2021\nUse of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory\nCommittee on Immunization Practices \u2014 United States, June 2021\nUse of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and\nmRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization\nPractices \u2014 United States, July 2021\nUse of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged \u226516 Years: Recommendations of the Advisory Committee\non Immunization Practices \u2014 United States, September 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendations for Additional Primary and Booster\nDoses of COVID-19 Vaccines \u2014 United States, 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Children Aged 5\u201311 Years \u2014 United States, November 2021\nUse of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory\nCommittee on Immunization Practices \u2014 United States, December 2021\nThe Advisory Committee on Immunization Practices\u2019 Recommendation for Use of Moderna COVID-19 Vaccine in Adults\nAged \u226518 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-\nReferences\n\uf1aa\n\uf20c\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\n19 Vaccines \u2014 United States, February 2022\nInterim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-\nBioNTech COVID-19 Vaccines in Children Aged 6 Months\u20135 Years \u2014 United States, June 2022\nInterim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19\nVaccine in Persons Aged \u226518 years \u2014 United States, July 2022.","2952":"Currently, a booster dose using any COVID-\n19 vaccine is not authorized for children in this age group. Children age 5 years: A 2-dose primary series and 1 bivalent Pfizer-BioNTech booster dose is recommended. The primary\nseries doses are separated by 3\u20138 weeks and the bivalent booster dose is administered at least 2 months after\ncompletion of the primary series (for people who have not received any booster doses), or at least 2 months after the\nlast monovalent booster dose. Currently, only the bivalent Pfizer-BioNTech booster dose is authorized for children age 5\nyears who receive a Pfizer-BioNTech primary series.","6889":"The COVID-19 vaccine by Moderna can also be used under EUI for similar uses as an alternative mRNA\nCOVID-19 vaccine (see the Moderna EUI Fact Sheet for Recipients), and the same or similar\nrecommendations in this EUI also apply to the use of the COVID-19 vaccine by Moderna under EUI. What is COVID-19? Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a coronavirus called SARS-CoV-2. It\nis predominantly a respiratory illness that can affect other organs. People with SARS-CoV-2 infection have\nreported a wide range of symptoms, from no symptoms to severe illness leading to death.","4924":"Table of Contents \uf426\nReferences and Previous Updates\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine \u2014 United States, December 2020\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Moderna COVID-19 Vaccine\n\u2014 United States, December 2020\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Janssen COVID-19 Vaccine \u2014\nUnited States, February 2021\nUpdated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson\n& Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine\nRecipients\u2014United States, April 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Adolescents Aged 12\u201315 years \u2014 United States, May 2021\nUse of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory\nCommittee on Immunization Practices \u2014 United States, June 2021\nUse of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and\nmRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization\nPractices \u2014 United States, July 2021\nUse of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged \u226516 Years: Recommendations of the Advisory Committee\non Immunization Practices \u2014 United States, September 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendations for Additional Primary and Booster\nDoses of COVID-19 Vaccines \u2014 United States, 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Children Aged 5\u201311 Years \u2014 United States, November 2021\nUse of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory\nCommittee on Immunization Practices \u2014 United States, December 2021\nThe Advisory Committee on Immunization Practices\u2019 Recommendation for Use of Moderna COVID-19 Vaccine in Adults\nAged \u226518 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-\nReferences\n\uf1aa\n\uf20c\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\n19 Vaccines \u2014 United States, February 2022\nInterim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-\nBioNTech COVID-19 Vaccines in Children Aged 6 Months\u20135 Years \u2014 United States, June 2022\nInterim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19\nVaccine in Persons Aged \u226518 years \u2014 United States, July 2022.","2339":"\u2022\n\u2022\n-\n-\n\u2022\n\u2022\n\u2022 TM\nPre-teens, Teens and Adults Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nAGE GROUP\n18 YEARS AND OLDER\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nModerna\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nor last booster\nUp to Date: Immediately after the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nJohnson & Johnson's Janssen\n\uf1aa\nPRIMARY SERIES\nADDITIONAL DOSE\nAt least 4 weeks after 1st dose\nand should be Pfizer-BioNTech\nor Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nor last booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nAGE GROUP\n18 YEARS AND OLDER\nAGE GROUP\nNovavax\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\nA monovalent Novavax booster\nis available in limited situations\nMore details: Novavax booster\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd dose\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nChildren Ages 6 Months-11 Years Who Are Moderately or Severely\nImmunocompromised\nAGE GROUP\nAGE GROUP\nPfizer-BioNTech\n\uf1aa\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 3rd dose\nUp to Date: Immediately after you have received the most recent booster recommended for you [ 1 ]\nPRIMARY SERIES\nPRIMARY SERIES\n3 weeks after 1st dose\nPRIMARY SERIES\nAt least 8 weeks after 2nd dose\nUp to Date: 2 weeks after 3rd dose in primary series, since a booster is not recommended for this age group at this\ntime\nAGE GROUP\nModerna\n\uf1aa\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nIf you have completed your primary series\u2014but are not yet eligible for a booster\u2014you are also considered up to date.","8694":"10\/30\/22, 9:37 AM Understanding Variants | CDC\nUnderstanding Variants\nThe virus that causes COVID-19 is constantly changing, and new variants of the virus are expected to occur. Sometimes\nnew variants emerge and disappear. Other times, new variants persist. Numerous variants of the virus that causes\nCOVID-19 are being tracked in the United States and globally during this pandemic. How Variants Work\nIf you think about a virus like a tree growing and branching out; each branch on the tree is slightly different than the\nothers. By comparing the branches, scientists can label them according to the differences.","3152":"On a case-by-case basis, providers caring for moderately or severely immunocompromised patients may administer\nModerna, Novavax, and Pfizer-BioNTech COVID-19 vaccines outside of the FDA and CDC dosing intervals when, based on their\nclinical judgment, the benefits of vaccination are deemed to outweigh the potential and unknown risks for the recipient. However, providers should not routinely administer doses of COVID-19 vaccine beyond those recommended in this guidance. The utility of serologic testing , cellular immune testing, or B-cell quantification to assess immune response to vaccination\nand guide clinical care has not been established.","6493":"Monoclonal Antibody Therapy for COVID-19: What Is It and\nHow Does It Work? [00:01:04]\nIsolation and Exposure Calculator\nCOVID-19 Test to Treat Locator\nCOVID-19 Therapeutics Locator\nFind a COVID-19 Vaccine\nDon\u2019t Delay: Test Soon and Treat Early [1 page, 262 KB]\n| Additional Languages\n\uf209\n\uf209\n\uf209\n\uf209\n\uf20c\nLast Updated Oct. 19, 2022","4330":"\u2022\n\u2022\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nWatch Video: Use v-safe to tell CDC how you\u2019re feeling after COVID-19 vaccination [00:00:34]\nYour CDC COVID-19 Vaccination Card\nBring your card to your appointment whenever you get a primary\nseries dose or booster so that your provider can fill in information\nabout your shot. If your vaccine card is full, your vaccine provider can give you another\ncard. If you did not receive a CDC COVID-19 vaccination card at your first\nappointment, contact the vaccination provider site where you got\nyour first shot to find out how you can get a vaccination card.","3852":"\uf1aa\f10\/30\/22, 9:17 AM FAQs About Implementing COVID-19 Vaccination Program in Provider Practices | CDC\nCOVID-19 vaccination providers, after administering a dose of COVID-19 vaccine, must record all information marked by\nan asterisk below (if it is not already recorded in the vaccine recipient\u2019s record) and report the following required vaccine\nadministration data, or other data elements if revised by CDC, to the appropriate entity noted in the agreement:\n1. Administered at location\/facility name\/ID\n2. Administered at location type\n3. Administration address (including company)*\n4. Recipient name and ID*\n5. Recipient date of birth*\n6. Recipient sex*\n7. Recipient race\n8. Recipient ethnicity\n9. Recipient address*\n10. Administration date*\n11. CVX (product)*\n12.","422":"On June 30, 2021, data review and reporting adjustments resulted in an increase in the number of vaccine doses\nadministered for North Carolina of 621,198 doses since December 2020. The adjustment is the result of updates to how\npharmacies report data to CDC and\/or the jurisdictions. On June 25, 2021, data review and reporting adjustments resulted in a decrease in the number of vaccine doses\nadministered for New Jersey of 331,640 doses and a smaller-than-usual increase for New Hampshire of 6,449 doses. The\nadjustments are the result of updates to how pharmacies report data to CDC and\/or the jurisdictions.","876":"Talk to your healthcare provider about how you can protect your newborn, such as using a physical barrier (for example,\nplacing the newborn in an incubator) while in the hospital. You most likely will not pass the virus to your newborn or any other close contacts after your isolation period has ended. If you had symptoms, your isolation period ends after:\n5 days since symptoms first appeared, and\n24 hours with no fever, without fever-reducing medicine, and\nOther symptoms of COVID-19 are improving. If you never had symptoms, your isolation period ends after\n5 days have passed since you tested positive for COVID-19.","5137":"If you travel, wear a high-quality mask or\nrespirator the entire time you are around others\nindoors. Traveling by private vehicle (if possible) can lower\nthe chances of spreading COVID-19 to others. 10\/30\/22, 9:43 AM International Travel to and from the United States | CDC\nProtect Yourself and Others\nBefore You Travel to the United States\nAfter Arrival in the United States\n\uf48e RECOMMENDED\nFollow CDC\u2019s recommendations for wearing masks in travel and public transportation settings. Follow recommendations for protecting yourself and others. Follow all\u202frecommendations and requirements at your destination .","2802":"If you are a caregiver, remember that maintaining healthy behaviors and seeking additional support is an important part of\nhelping other people. Support Groups\nBody Politic\nSurvivor Corps\n\uf209\n\uf209\f10\/30\/22, 9:42 AM Caring for People with Post-COVID Conditions | CDC\nLong COVID Alliance\nLong COVID Kids\n\uf209\n\uf209\nAdditional Resources\nPost-COVID Conditions\nPatient Tips: Healthcare Provider Appointments for Post-COVID Conditions\nMental Health and Coping During COVID-19\nCoping with a Disaster or Traumatic Event\nHow Right Now | Finding What Helps\nGuidance for Direct Service Providers | COVID-19\nCaring for Yourself When Caring for Another\nConnect With Patients and Families | SCCM\nRECOVER (recovercovid.org)\nCombat COVID: Information about Clinical Trials\n\uf209\n\uf209\n\uf209\nLast Updated Sept. 1, 2022","7815":"If you\u2019re not able to obtain a self-test when you need it, you might also visit a community testing site, or\ncall your local health department for more options. \u2022\n\uf209\n\u2022\n\u2022\nFDA-Authorized Tests\n\uf6e0 How to Use an At-Home COVID-19 Test\nRead the complete manufacturer\u2019s instructions for use before using the test. To use an at-home test, you will collect a nasal specimen and then test that specimen. If you do not follow the manufacturer\u2019s instructions, your test result may be incorrect. Wash your hands before and after you collect a nasal specimen for your test.","5190":"\u2022\n\u2022\nCDC is contacting people who meet the case definition for myocarditis following COVID-19 vaccination and have been\nreported to the Vaccine Adverse Event Reporting System (VAERS). To meet the case definition, people must have had:\nSymptoms such as chest pain, shortness of breath, and feelings of having a fast-beating, fluttering, or pounding\nheart and\nMedical tests to support the diagnosis of myocarditis and rule out other causes. CDC will contact people with myocarditis reported to VAERS after at least 90 days have passed since myocarditis\nsymptoms began and will publish data as it becomes available.","8579":"Therefore, it is possible that a person could be infected with the\nvirus that causes COVID-19 just before or just after vaccination and then get sick\nbecause the vaccine did not have enough time to provide protection. Sometimes after vaccination, the process of building immunity can cause symptoms,\nsuch as fever. These symptoms are normal signs the body is building immunity. Types of Vaccines: mRNA, Viral Vector, and Protein Subunit\nFacts about COVID-19 Vaccines\nCurrently, there are three main types of COVID-19 vaccines that are approved or authorized for use in the United States:\nmRNA, viral vector, and protein subunit.","9481":"KEEP THE VACCINATION CARD\nWhen you, or your child, receive the first COVID-19 vaccine, you will get a vaccination card. Remember to bring the card when you return. ADDITIONAL INFORMATION\nIf you have questions, visit the website or call the telephone number provided below. To access the most recent Fact Sheets, please scan the QR code provided below. Moderna COVID-19 Vaccine website Telephone number\nHOW CAN I LEARN MORE? \u2022 Ask the vaccination provider\n\u2022 Visit CDC at https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/index.html\n\u2022 Visit FDA at https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-\nregulatory-and-policy-framework\/emergency-use-authorization\n\u2022 Contact your state or local public health department\nWHERE WILL VACCINATION INFORMATION BE RECORDED?","8811":"The following requirements must be followed to utilize CDC\u2019s public domain content:\n1) Attribution to the agency that developed the material must be provided in your use of the materials. Such attribution\nshould clearly state the materials were developed by CDC ATSDR and\/or HHS (e.g., \u201cSource: CDC\u201d; \u201cMaterials developed by\nCDC\u201d);\n2) You must utilize a disclaimer which clearly indicates that your use of the material, including any links to the materials on the\nCDC, ATSDR or HHS websites, does not imply endorsement by CDC, ATSDR, HHS or the United States Government of you,\nyour company, product, facility, service or enterprise.","3227":"Additionally, providers should consider observing people with the following medical histories for 30 minutes after COVID-19\nvaccination to monitor for allergic reactions:\nAllergy-related contraindication to a different type of COVID-19 vaccine\nTable of Contents \uf426\nPatient counseling\nPre-vaccination counseling\nPost-vaccination observation period\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nAllergy-related contraindication to a different type of COVID-19 vaccine\nNon-severe, immediate (onset within 4 hours) allergic reaction after a previous dose of COVID-19 vaccine\nAnaphylaxis after non-COVID-19 vaccines or injectable therapies\nSee also Contraindications and precautions.","1013":"They can help\nprotect you from infection, or severe illness if you do get infected, for a period of time afterward. How long this protection\nlasts is different for each disease and each person. Antibody tests should not be used to diagnose a current infection with the virus that causes COVID-19. An antibody test may\nnot show if you have a current infection, because it can take 1 to 3 weeks after the infection for your body to make antibodies. \uf6ec If Your COVID-19 Test is\nPositive\nAny positive COVID-19 test means the virus was detected and you have an infection.","4613":"10\/30\/22, 9:41 AM Interactive Home Ventilation Tool | CDC\nEspa\u00f1ol | Other Languages\nInteractive Home Ventilation Tool\nSmall particles that people breathe out can contain virus particles, including the virus that causes COVID-19. If a guest visits\nyour home, improving ventilation (air flow) can help prevent virus particles from accumulating in the air. Good ventilation,\nalong with other preventive actions, like staying 6 feet apart and correctly wearing masks, can help prevent you from getting\nand spreading COVID-19. \uf5bd We need your feedback! Help us improve this tool by taking a quick survey after using the tool below.","6486":"Be sure to stick\nto your treatment plans, your routine healthcare appointments, and have all your prescriptions filled. Plan for options for\nwork, childcare, and other responsibilities that may cause stress if you were to become sick. COVID-19 remains a major health concern and this can be stressful to manage. Understanding what you can do to protect\nyourself and what to do if you get sick can help minimize that stress. Take as many steps as you can to prevent COVID-19 and\nget treated quickly if you test positive for COVID-19. \uf209\nBuild Your Personal COVID-19 Plan\nMore Information\nWhat Are Monoclonal Antibodies?","8320":"10\/30\/22, 9:17 AM Talking to Recipients about COVID-19 Vaccination | CDC\nVaccines & Immunizations\nVaccines & Immunizations\nVaccines & Immunizations Home\nVaccine Recipient Education\nQuick References for COVID-19 Vaccine Recipients Who Want More Information\nMany people have questions about the coronavirus disease 2019 (COVID-19) vaccines. As vaccine recipients\u2019 most-trusted\nsource of information on vaccines, you play a critical role in helping vaccine recipients understand the importance of\nvaccination and that COVID-19 vaccines are safe and effective. The following resources will help you share clear and accurate information about COVID-19 vaccines, raise awareness\nabout the benefits of vaccination, and address common questions and concerns about what to expect when getting\nvaccinated.","8309":"If one of these tests is not available, many testing locations provide flu and COVID-19 tests\nseparately. Talk to a healthcare provider about getting tested for both flu and COVID-19 if you have\nsymptoms. Learn more\nResources\nPrint Resources\n\uf1aa\n\uf20c\nVideos\n\uf1aa\nSymptoms of COVID-19\nVideo Length: 00:00:21\nWatch Video\nASL Symptoms of Coronavirus\nVideo Length: 00:09:25\nWatch Video\nMore Information\nUnderstanding Your Risk\nHealthcare Workers: Information on COVID-19\nLast Updated Oct. 26, 2022\f10\/30\/22, 9:37 AM Symptoms of COVID-19 | CDC","7077":"If you have questions about getting vaccinated, talking with your healthcare professional\nmight help, but is not required. Getting vaccinated prevents severe illness, hospitalizations, and death. People who have not received a COVID-19 vaccine\nshould get vaccinated as soon as possible and continue masking. To maximize protection from variants and prevent possibly\nspreading the virus to others, people who are up to date with their COVID-19 vaccines should wear a mask indoors in public in\nareas with a high COVID-19 Community Level. With the emergence of variants, this is more urgent than ever.","3478":"Follow additional guidance if you know you were exposed to a person with COVID-19. \uf2a5 Plan ahead\nBe up to date with your COVID-19 vaccines before travel. Check if your cruise line requires proof of vaccination or pre-embarkation testing, or has any other\nrequirements to board. If traveling by air before or after cruise travel, check if your airline or destination (see here for U.S.\nrequirement) requires any testing, vaccination, or other documents. Consider getting travel insurance. Consider buying additional insurance that covers health care and\nemergency evacuation, especially if you will be traveling to remote areas.","6119":"\"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster)\nfollowing two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre,\nrandomised, controlled, phase 2 trial.\" The Lancet (2021). National Advisory Committee on Vaccination. An Advisory Committee Statement: Guidance on booster COVID-\n19 vaccine doses in Canada. Public Health Agency of Canada; 3 Dec 2021.\nhttps:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/immunization\/national-advisory-\nvaccine-doses.pdf\nNational Collaborating Centre for Methods and Tools. Rapid Review Update 1: What is the ongoing\neffectiveness, immunogenicity, and safety of COVID-19 vaccines in persons who have had a prior, confirmed\nCOVID-19 infection?. Hamilton (ON): McMaster University; 2021. Available from: https:\/\/www.nccmt.ca\/covid-\n19\/covid-19-rapid-evidence-service\/36.","8818":"Occasionally, sites that copy and re-post CDC materials fail to check for updates, which may result in out-of-date\ninformation being offered to users. For that reason, we urge you to link directly to our resource documents rather than re-\nposting. If you do re-post, please check back periodically to see if there are revisions. Linking to CDC, ATSDR or HHS content should open up a new browser window to our site\/page. CDC content should not\nappear within the original window, framed by the existing site.","3389":"Those who received antibody products due to\na recent SARS-CoV-2 infection should follow the guidance in the section above. Special situation: administration of tixagevimab\/cilgavimab (EVUSHELD\u2122) for pre-exposure prophylaxis should be deferred for\nat least two weeks after receipt of a dose of COVID-19 vaccine, per the product EUA . See COVID-19 vaccination and\nEVUSHELD\u2122 for more information on the timing of EVUSHELD\u2122 administration. MIS-C is a rare but severe condition in children and adolescents infected with SARS-CoV-2. MIS-A, a similar condition in adults,\nis even rarer and less well characterized. Both include a dysregulated immune response to SARS-CoV-2 infection.","9352":"Children who will turn from 5 years to 6 years of\nage between doses in the primary series may receive, for any dose, either: (1) the Moderna COVID-19 Vaccine\nauthorized for use in individuals 6 months through 5 years of age; or (2) Moderna COVID-19 Vaccine authorized\nfor use in individuals 6 years through 11 years of age.","8991":"As of May 2, 2022, the registry has enrolled 23,779 pregnant people in the\nUnited States. Why CDC Is Collecting Registry Information\nIf you participate in the registry, the information you and other participants provide will be evaluated and used to educate the\npublic about COVID-19 vaccines and pregnancy. In addition, this information will be used by CDC and the Food and Drug\nAdministration (FDA) to guide recommendations on COVID-19 vaccination during pregnancy.","2490":"Learn more about the factors that can\naffect your risk of getting very sick from COVID-19 to better understand how COVID-19 could affect you and others around\nyou. Know Your COVID-19 Community Level\nTake action to protect yourself and others from COVID-19 based on the COVID-19 Community Level in your area. What You Need to Know\nCOVID-19 Community Levels help individuals and communities decide which prevention actions to take based on\nthe latest information. Each level helps convey how much COVID-19 is impacting your community using data on hospitalizations and\ncases. Using these data, communities are classified as low, medium, or high.","5220":"10\/30\/22, 9:41 AM Isolation and Precautions for People with COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nIsolation and Precautions for People with COVID-19\nIf you have COVID-19, you can spread the virus to others. There are precautions you can take to prevent spreading it to\nothers: isolation, masking, and avoiding contact with people who are at high risk of getting very sick. Isolation is used to\nseparate people with confirmed or suspected COVID-19 from those without COVID-19. These recommendations do not change based on COVID-19 Community Levels. If you have COVID-19, also see additional\ninformation on treatments that may be available to you.","3501":"Cruise ships may have their own requirements for testing, isolation, quarantine, mask wearing, and dining for people\nwith COVID-19 or their close contacts. If you have questions about a cruise ship\u2019s specific policies, please contact them\ndirectly. If you disembark the ship before completing your isolation or quarantine period, you should follow CDC\u2019s guidance, or\nlocal guidance if you disembark in another country. 10\/30\/22, 9:43 AM Cruise Ship Travel During COVID-19 | CDC\nGet tested for current infection with a COVID-19 viral test 3\u20135 days after your trip or if you develop symptoms. Isolate if you develop symptoms or your test result is positive.","8247":"J&J\/Janssen Vaccine Overview\nJ&J\/Janssen\nPRIMARY SERIES\nPfizer BioNTech or Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 1 dose\nor last booster\nst\nUp to Date: Immediately after you have received the most recent booster recommended for you\nMore details: Staying up to date\n\u2022\n-\n\u2022\n-\n-\n-\nMixing COVID-19 Vaccine Products\nDo Not Mix Primary Series\nCDC does not recommend mixing products for your primary series doses. If you received Pfizer-BioNTech, Moderna, or\nNovavax for the first dose of your primary series, you should get the same product for all following primary series doses. Mixing Boosters\nThe following information applies to boosters for people ages 5 and older.","4159":"FDA has determined COVID-19 vaccines meet FDA\u2019s standards and has granted\nthose vaccines Emergency Use Authorizations (EUAs) or full FDA approval. Tracking Safety Using Vaccine Monitoring Systems \u2013 Like every other vaccine approved for use in the United States,\nCOVID-19 vaccines continue to be monitored for safety and effectiveness. Hundreds of millions of people in the\nUnited States have safely received COVID-19 vaccines. CDC and FDA continue to provide updated information on\nthe safety of U.S. authorized or approved COVID-19 vaccines using data from several monitoring systems. Learn more about developing COVID-19 vaccines. \u2022\n\u2022\n\uf209\n\u2022\nVaccine ingredients vary by manufacturer.","3899":"10\/30\/22, 9:38 AM Factors That Affect Your Risk of Getting Very Sick from COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nFactors That Affect Your Risk of Getting Very Sick from\nVaccination, past infection, or timely access to testing and treatment can help protect you from getting very sick if you get\nCOVID-19. However, some people are more likely than others to get very sick if they get COVID-19. This includes people who\nare older, are immunocompromised, have certain disabilities, or have underlying health conditions. Understanding your\nCOVID-19 risk and the risks that might affect others can help you make decisions to protect yourself and others.","5812":"What are the Risks and Benefits of the COVID-19 vaccine by Moderna? The FDA approved the COVID-19 vaccine by Moderna to prevent COVID-19 based on safety and efficacy\ndata available from clinical trials. Additionally, the FDA issued an Emergency Use Authorization of the\nCOVID-19 vaccine by Moderna as an additional primary or a booster dose, determining, among other\nthings, that the known and potential benefits of vaccination outweigh the known and potential risks of the\nvaccine.","2355":"Examples of medical conditions or treatments that may result in moderate to severe immunocompromise include but are not\nlimited to:\nActive treatment for solid tumor and hematologic malignancies\nHematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status\n(e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\nReceipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\nReceipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of\ntransplantation or taking immunosuppressive therapy)\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\nTalk to your healthcare provider about COVID-19 and your medical condition.","7078":"Learn more\nabout what you can do\u202fwhen you have been fully vaccinated when you are up to date with your COVID-19 vaccines. If you are pregnant and have questions about COVID-19 vaccine\nIf you would like to speak to someone about COVID-19 vaccination during pregnancy, you can contact MotherToBaby. MotherToBaby experts are available to answer questions in English or Spanish by phone or chat. The free and\nconfidential service is available Monday\u2013Friday 8am\u20135pm (local time).","2056":"Additionally, if you have COVID-19 during pregnancy, you are at increased\nrisk of complications that can affect your pregnancy and developing baby. Getting a COVID-19 vaccine can help protect you and your baby from serious health problems from COVID-\n19. People who are pregnant should stay up to date with their COVID-19 vaccines, including getting a COVID-19\nbooster shot when it\u2019s time to get one. Evidence continues to build showing that:\nCOVID-19 vaccination during pregnancy is safe and effective. COVID-19 vaccines are not associated with fertility problems in women or men.","10028":"An mRNA or Novavax COVID-19 vaccine is recommended. \u0083 Persons who develop GBS within 6 weeks of Janssen COVID-19 vaccination should only receive an\nmRNA COVID-19 vaccine. Prevaccination Checklist\nfor COVID-19 Vaccines\nInformation for Healthcare Professionals\nResponse Consideration\nHistory of prior\nCOVID-19 disease in\nthe last 3 months\n\u0083 COVID-19 vaccination is recommended for everyone ages 6 months and older, regardless of a\nhistory of symptomatic or asymptomatic SARS-CoV-2 infection. People who recently had COVID-19\ndisease or SARS-CoV-2 infection (within the last 3 months) may consider delaying their primary\nseries or booster dose dose by 3 months from symptom onset or positive test (if infection\nwas asymptomatic).","963":"10\/30\/22, 9:37 AM COVID-19 Testing: What You Need to Know | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Testing: What You Need to Know\nWhen you get tested:\nMake sure to test at the right time\nChoose the right type of test for your circumstance\nFollow test directions as recommended by FDA\nIf you do not, your results may be less likely to correctly indicate whether you have COVID-19 or not. \u2022\n\u2022\n\u2022\nWhen to Get Tested for COVID-19\nKey times to get tested:\nIf you have symptoms, test immediately. If you were exposed to COVID-19 and do not have symptoms, wait at\nleast 5 full days after your exposure before testing.","2236":"For the best\nprotection, everyone 6 months and older is recommended to stay up to date with their COVID-19 vaccines, which includes\ngetting boosters if eligible. Vaccine Breakthrough Infections\nCOVID-19 vaccines are effective at preventing severe disease, hospitalization, and death. However, since vaccines are not\n100% effective at preventing infection, some people who are up to date with the recommended vaccines\u202fwill still get COVID-\n19. This is called a\u202fbreakthrough infection. When people who are vaccinated develop symptoms of COVID-19, they tend to\nexperience less severe symptoms than people who are unvaccinated.","627":"May 6, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 25,958 doses\nadministered. May 6, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of 9,143\ndoses administered. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nApril 29, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 7,617 doses\nadministered. April 22, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of 4,711\ndoses administered.","2003":"New studies\nhave shown the rare risk of myocarditis and pericarditis associated with mRNA COVID-19 vaccination (Pfizer-BioNTech and\nModerna)\u2014mostly among males between the ages of 12 and 39 years\u2014may be further reduced with a longer time between\nthe first and second dose. In children ages 5 through 11 years, there were 20 confirmed reports of myocarditis out of approximately 18.1 million\ndoses given of the Pfizer-BioNTech COVID-19 vaccine between November 2021 and April 2022\nWhat You Need to Know\nCDC recommends COVID-19 vaccines for everyone ages 6 months and older, and COVID-19 boosters for everyone\nages 5 years and older, if eligible.","6208":"If you have concerns about COVID-19 vaccination, talk with your healthcare provider or your child\u2019s doctor, nurse, or clinic. If you have any health problems after vaccination, report them to\u202fVAERS . \uf209\nLast Updated Sept. 27, 2022","1313":"For\nmore information see:\nModerna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group\nPfizer-BioNTech for Children who Transition from a Younger to Older Age Group\nInterim COVID-19 Immunization Schedule for 6 Months of Age and Older\nWhat should I do for a child who is moving from a younger age group with a lower dose\nformulation to an older age group with a higher dose formulation? \uf1aa\n\uf20c\n\uf20c\n\uf20c\nIf the incorrect formulation is administered\nResulting in a higher-than-authorized dose: Do not repeat dose. Resulting in a lower-than-authorized dose: Repeat the dose immediately (no minimum interval) with the age-\nappropriate dose and formulation.","3226":"Additionally, providers should consider observing people with the following medical histories for 30 minutes after COVID-19\nvaccination to monitor for allergic reactions:\nAllergy-related contraindication to a different type of COVID-19 vaccine\nTable of Contents \uf426\nPatient counseling\nPre-vaccination counseling\nPost-vaccination observation period\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nAllergy-related contraindication to a different type of COVID-19 vaccine\nNon-severe, immediate (onset within 4 hours) allergic reaction after a previous dose of COVID-19 vaccine\nAnaphylaxis after non-COVID-19 vaccines or injectable therapies\nSee also Contraindications and precautions.","6167":"The data is updated monthly. National Healthcare Safety Network\nInfections in long-term care facility residents by vaccination status are reported through a network of approximately 15,000\nmedical facilities called the National Healthcare Safety Network (NHSN). An analysis of this data was published in CDC\u2019s\nMMWR. Related Pages\nVaccine Breakthrough Infections: The Possibility of Getting COVID-19 after Getting Vaccinated\n\u203a\nCOVID-19 Vaccine Breakthrough Case Investigation and Reporting\n\u203a\nCases and Deaths by Vaccination Status\n\u203a\nHospitalizations by Vaccination Status\n\u203a\nCDC\u2019s MMWR: Published analyses of case surveillance data by vaccination status for periods of Delta variant and\nOmicron variant\n\u203a\nLast Updated June 23, 2022","7436":"You are considered fully vaccinated on the 14th day after the vaccination series was completed. For example, if your last\ndose was any time on October 1st, then October 15th would be the first day that you meet the 14-day requirement. Frequently Asked Questions\nWhat are you looking for? Enter a word or phrase to locate questions and answers that match. Overview\nThe requirements outlined in the Presidential Proclamation and CDC\u2019s Amended Order apply to anybody who is\nconsidered a noncitizen nonimmigrant and is traveling to the United States by air.","3524":"CDC will continue to provide testing recommendations for cruise ship\noperators to follow and cruise ships will continue to report COVID-19 cases to CDC. Why was the cruise ship color-coding system removed? \uf1aa\nCruise travelers have the option of contacting their cruise line directly regarding outbreaks occurring on board their ship. How can travelers find out about COVID-19 outbreaks on cruise ships? \uf1aa\nMore Information\nIf you need to contact your health department: State & Territorial Health Department Websites\nGuidance for Cruise Ships on the Mitigation and Management of COVID-19\nTravel during the COVID-19 Pandemic\nInternational Travel\nFrequently Asked Questions and Answers for Travelers\nLast Updated July 18, 2022","2557":"\u00b6 An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines may be optimal for some people ages 6 months\u201364\nyears, especially for males ages 12\u201339 years, as it may reduce the small risk of myocarditis and pericarditis associated with these vaccines. A shorter interval (4 weeks for Moderna) between the\nfirst and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is\nincreased concern about COVID-19 community levels or an individual\u2019s higher risk of severe disease.","9593":"\u2022 Revaccination of moderately or severely immunocompromised persons ages 12 years and older who\nreceived certain therapies (indicated below) and received primary dose(s) of COVID-19 vaccine prior to\nor during treatment. o\no\nReceived COVID-19 vaccine dose(s) during treatment with B-cell-depleting therapies over a\nlimited period\nReceived COVID-19 vaccine dose(s) prior to or during treatment involving hematopoietic cell\ntransplant (HCT) or chimeric antigen receptor (CAR)-T-cell therapy\nThe COVID-19 vaccine by Moderna under EUI also allow similar uses as an alternative mRNA COVID-19 vaccine\nto Pfizer-BioNTech, and the same or similar recommendations in the EUI also apply to the use of the COVID-19\nvaccine by Moderna under EUI.","5155":"If you are not fully vaccinated and allowed to travel to the United States by air through an exception, you will be required\nto sign an attestation (legal statement) before you board your flight to the United States stating you meet the exception. Depending on the type of exception, you may also have to state you have arranged to take certain protective measures. For more information see Requirement for Proof of COVID-19 Vaccination for Air Passengers.","6456":"What to do if you test positive for COVID-19\nEffective treatments are now widely available and free, and you may be eligible. Contact your healthcare provider, health department, or Community Health Center to learn about treatment\noptions. Don\u2019t delay! Treatment must be started soon after you first develop symptoms to be effective. If you don\u2019t have timely access to a healthcare provider, check if a Test to Treat location is in your community. You\ncan get tested, receive a prescription from a healthcare provider (either onsite or by telehealth), and have it filled all at\none location.","9246":"After Being Exposed to COVID-19\n\uf285 START PRECAUTIONS\nImmediately\nWear a mask as soon as you find out you were exposed\nStart counting from Day 1\nDay 0 is the day of your last exposure to someone with COVID-19\nDay 1 is the first full day after your last exposure\n\u2022\n\u2022\n\uf309 CONTINUE PRECAUTIONS\n10 Full Days\nYou can still develop COVID-19 up to 10 days after you have been exposed\nTake Precautions Watch for symptoms\nfever (100.4\u00b0F or greater)\ncough\n\u2022\f10\/30\/22, 9:41 AM What to Do If You Were Exposed to COVID-19 | CDC\nWear a high-quality mask or respirator (e.g., N95) any\ntime you are around others inside your home or indoors\nin public\nDo not go places where you are unable to wear a\nmask.","113":"Mink on mink farms. Wildlife, including white-tailed deer, mule deer, a black-tailed marmoset, a giant anteater, and wild mink near mink\nfarms. For information on how to protect pets and animals, visit\nWhat You Should Know about COVID-19 and Pets\nCompanion Animals with COVID-19: Toolkit for Health Officials\nReducing Risk of Spreading COVID-19 between People and Wildlife\nRisk of animals spreading SARS-CoV-2 to people\nThere is no evidence that animals play a significant role in spreading SARS-CoV-2, the virus that causes COVID-19, to people. There have been a few reports of infected mammalian animals spreading the virus to people during close contact, but this is\nrare.","8358":"And why not a lower\nnumber?\u201d Let them answer, and ask a follow-up question like, \u201cWhat would help you move to a 5 or 6?\u201d\nThe goal is to help the patient become more open to moving toward higher numbers\u2014in other words, getting vaccinated. You want them to talk about this out loud because talking actually changes how they process their choices and can\ndevelop forward momentum. People hesitant about vaccines usually have more practice explaining why they haven\u2019t gotten vaccinated, so it\u2019s good to\nreverse that. Ask them to express their vaccination benefits out loud.","5560":"Masking is a critical public health\nAdded information to present similar content for masks and respirators\nClarified that people can choose respirators such as N95s and KN95s, including removing concerns related to supply\nshortages for N95s\nClarified that \u201csurgical N95s\u201d are a specific type of respirator that should be prioritized for healthcare settings\nClarified that some types of masks and respirators provide more protection to the wearer than others\nView Previous Updates\nUpdates as of January 28, 2022\n\uf1aa\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nFor information about how to use your N95 correctly, see How to Use Your N95 Respirator.","1044":"Some PCR tests can differentiate between flu and COVID-19 at the\nsame time. If one of these tests is not available, many testing locations provide flu and COVID-19 tests\nseparately. Talk to a healthcare provider about getting tested for both flu and COVID-19 if you have\nsymptoms.","7544":"You will need to show that you are traveling under one of the visa categories (listed above); or travel with an official letter,\nsuch as letter from the U.S. government or foreign government. If you have been invited by the United Nations, you will\nneed a letter of invitation from the United Nations or other documentation showing the purpose of such travel. You will also be required to complete the attestation, attesting to arranging to self-quarantine for 5 days after arrival in\nthe United States except when you must attend official diplomatic or foreign government events or duties.","3769":"However, based on available information, the known and potential risks of primary,\nadditional, and\/or booster doses of the COVID-19 vaccines by Pfizer-BioNTech or Moderna might be\noutweighed by their likely benefit to enhance or restore protection by the primary vaccination, which\nmight have waned over time. Refer to the EUI Fact Sheets for Healthcare Providers for Pfizer-BioNTech\nand Moderna and Interim Clinical Considerations for Use of COVID-19 Vaccines for additional\ninformation.","3606":"Rates per 100,000\nRepresent the rate of total doses distributed, the rate of total doses administered, the rate of people receiving at least\none dose, the rate of people who are fully vaccinated, and the rate of people receiving a booster dose per 100,000. The\nrate per 100,000 people is calculated for the total population and select demographic groups (such as people ages 65\nyears or older) using population data. This allows comparison between areas with different population sizes.","3247":"Precaution\nManagement of post-COVID-19-vaccination symptoms\nTable of Contents \uf426\nVaccination and SARS-CoV-2 laboratory testing\n\uf209\n\uf209\nTable of Contents \uf426\nContraindications and precautions\n*\n*\n\u2020\n*\n* *\n*\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nMedical condition or history Guidance Recommended action(s)\nPeople with an allergy-related contraindication to one type of COVID-19 vaccine have a precaution to\nthe other types of COVID-19 vaccines. Special situation: People with a known allergy to polysorbate have a contraindication to both Novavax and\nJanssen COVID-19 vaccines. Precaution\nModerate or severe acute illness, with or without fever Precaution Defer vaccination until the\nillness has improved. History of MIS-C or MIS-A Precaution See COVID-19 vaccination\nand MIS-C and MIS-A.","5575":"Choosing a Mask or Respirator for Different Situations\nMasks and respirators (i.e., specialized filtering masks such as \u201cN95s\u201d) can provide different levels of protection depending on\nthe type of mask and how they are used. Loosely woven cloth products provide the least protection, layered finely woven\nproducts offer more protection, well-fitting disposable surgical masks and KN95s offer even more protection, and well-fitting\nNIOSH-approved respirators (including N95s) offer the highest level of protection.","3465":"\uf106 As of July 18, 2022, CDC\u2019s COVID-19 Program for Cruise Ships is no longer in effect. CDC will continue to\npublish guidance to help cruise ships continue to provide a safer and healthier environment for passengers,\ncrew and communities going forward. For more information, please see the Frequently Asked Questions\n(FAQs). Before Cruise Travel\nDo not travel or board a cruise ship if\u2026\nYou are sick with COVID-19. You tested positive for COVID-19 less than 10 days ago (day 0 is the day your symptoms started or the day your\npositive test sample was taken if you had no symptoms).","3349":"Considerations for subsequent COVID-19 vaccination may include:\n\uf20c\n\uf20c\n\uf20c\nNovavax COVID-19 Vaccine\nConsiderations for COVID-19 vaccination\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nThe myocarditis or pericarditis was considered unrelated to vaccination with Moderna, Novavax, or Pfizer-BioNTech (e.g.,\ndue to SARS-CoV-2 or other viruses), especially if the myocarditis or pericarditis diagnosis occurred more than 3 weeks\nafter the most recent dose of COVID-19 vaccine\nPersonal risk of severe acute COVID-19 (e.g., age, underlying conditions)\nTiming of any immunomodulatory therapies; ACIP\u2019s general best practice guidelines for immunization can be consulted\nfor more information\nFor myocarditis associated with MIS-C or MIS-A, see COVID-19 vaccination and MIS-C and MIS-A.","8938":"Learn more about\u202fselected adverse events\u202freported to VAERS. How VAERS Reports Are Reviewed\nVaccine safety experts review all reports of serious adverse events submitted to VAERS. A serious adverse event after\nvaccination is something that causes:\nPermanent disability\nHospitalization or an extended hospital stay (if vaccinated while in the hospital)\nLife-threatening illness\nBirth defects (congenital anomalies)\nDeath\nImportant Things To Know About VAERS\nVAERS is an early warning system used to monitor adverse events that happen after vaccination. VAERS is the\nfrontline system of a comprehensive vaccine safety monitoring program in the United States.","625":"May 12, 2022: California made updates to data previously submitted to CDC that resulted in an increase of 25,505\ntotal doses administered, a net decrease of 646,951 people with at least one dose, and a net increase of 472,028\npeople with a first booster dose. May 11, 2022: Alaska made updates to data previously submitted to CDC that resulted in an increase of 3,118 doses\nadministered. May 10, 2022: Wyoming made updates to data previously submitted to CDC that resulted in a decrease of 12,716\ndoses administered.","3988":"CDC uses the Immunization (IZ) Data Lake to receive, store, manage, and analyze COVID-19 vaccine distribution and\nadministration data from all sources. Data in the IZ Data Lake are deidentified, meaning they do not identify specific\npeople who have been vaccinated. CDC data scientists make every effort to ensure the data in the IZ Data Lake are\ncorrect (validated) and that the system does not double-count doses or vaccination records. (deduplication). CDC reports\nCOVID-19 vaccination data online on COVID Data Tracker and in vaccination datasets. How does CDC report vaccine distribution and administration data?","1454":"Monovalent mRNA (Moderna or Pfizer-BioNTech) and\nNovavax vaccines are recommended for the primary series and a bivalent mRNA vaccine (Moderna or Pfizer-BioNTech) is\nrecommended for the booster dose for all vaccine-eligible populations including people who are pregnant or lactating. Those who are considering receipt of the Janssen COVID-19 Vaccine should see Appendix A: Guidance for use of Janssen\nCOVID-19 Vaccine. Can pregnant or breastfeeding people be vaccinated? \uf1aa\f10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\nFor more information, see COVID-19 Vaccines While Pregnant or Breastfeeding.","5546":"10\/30\/22, 9:39 AM Masks and Respirators\nEspa\u00f1ol | Other Languages\nTypes of Masks and Respirators\nSummary of Recent Changes\nKey Messages:\nMasking is a critical public health tool for preventing spread of COVID-19, and it is important to remember that any mask\nis better than no mask. To protect yourself and others from COVID-19, CDC continues to recommend that you wear the most protective mask\nyou can that fits well and that you will wear consistently. Masks and respirators are effective at reducing transmission of SARS-CoV-2, the virus that causes COVID-19, when worn\nconsistently and correctly.","9193":"Throw away used tissues in a lined trash can\n\u2022\f10\/30\/22, 9:41 AM What to Do If You Are Sick | CDC\nThrow away used tissues in a lined trash can. Immediately wash your hands with soap and water for at least 20 seconds. If soap and water are not\navailable, clean your hands with an alcohol-based hand sanitizer that contains at least 60% alcohol. \u2022\n\u2022\n\uf304 Clean your hands often\nWash your hands often with soap and water for at least 20 seconds. This is especially important after\nblowing your nose, coughing, or sneezing; going to the bathroom; and before eating or preparing food.","8943":"VAERS is one of several systems CDC and the U.S. Food and Drug Administration (FDA) use to help ensure vaccines\nused in the United States, including COVID-19 vaccines, are closely monitored for safety. VAERS gives vaccine safety experts valuable information so they can assess possible vaccine safety concerns,\nincluding for the new COVID-19 vaccines. VAERS is especially useful for detecting unusual or unexpected patterns of health problems (also called \u201cadverse\nevents\u201d) that might indicate a possible safety problem with a vaccine. If a health problem is reported to VAERS, that doesn\u2019t mean that the vaccine caused the problem.","874":"If you are in isolation for COVID-19 and are sharing a room with your newborn, take the following steps to reduce the chance\nof spreading the virus to your newborn:\nWash your hands with soap and water for at least 20 seconds before holding or caring for your newborn. If soap and\nwater are not available, use a hand sanitizer with at least 60% alcohol. Wear a well-fitting mask whenever you are within 6 feet of your newborn. Keep your newborn more than 6 feet away from you as much as possible.","4983":"New booster recommendation for people ages 12 years and older to receive 1 bivalent mRNA booster after\ncompletion of a monovalent primary series; it replaces all prior booster recommendations for this age group\nRecommendations for use of a bivalent Moderna booster dose in people ages 18 years and older\nRecommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 12 years and older\nUpdated guidance for observation periods following COVID-19 vaccination\nUpdated guidance on COVID-19 vaccination and multisystem inflammatory syndrome (MIS) in children (MIS-C) and in\nadults (MIS-A)\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adolescents ages 12\u201317 years\nReorganization of Janssen COVID-19 Vaccine guidance into an appendix\nUpdated guidance on COVID-19 vaccination following exposure to SARS-CoV-2\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nPrevious Updates\n\uf1aa\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nUpdated guidance on COVID-19 vaccination and myocarditis and pericarditis\nNew clinical considerations for coadministration of mRNA COVID-19 vaccines and orthopoxvirus vaccines\nNew guidance for use of Moderna COVID-19 Vaccine in children and adolescents ages 6\u201317 years\nNew guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children ages 6 months\u20134 years\nNew guidance for use of Moderna COVID-19 Vaccine in children ages 6 months\u20135 years\nReorganization of sections on COVID-19 vaccination recommendations and schedules\nAddition of new section in Special populations for infants and young children\nNew guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5\u201311 years\nUpdated guidance that the following people should receive a second COVID-19 booster dose:\nPeople ages 12 years and older who are moderately or severely immunocompromised\nPeople ages 50 years and older\nUpdated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-\ndepleting therapies\nClarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults\n(MIS-A)\nUpdated guidance for primary series vaccination after SARS-CoV-2 infection\nAdded considerations for the option to receive a second COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 vaccination after SARS-CoV-2 infection\nAdded guidance that people ages 12 years and older who are moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that people ages 18\u201349 years who are not moderately or severely immunocompromised and who\nreceived Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster\ndose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose\nFurther clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C)\nand adults (MIS-A) and myocarditis\nUpdated information on the availability of Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL\ndosage volume) and Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL dosage volume) for\nadministration of a 50 \u00b5g booster dose.","371":"On November 14, 2021, a temporary network outage at CDC occurring Friday, November 12, 2021 resulted in vaccine\nadministration files from 13 partner entities not being properly processed and resulted in 281,912 records being\nomitted. The omitted 281,912 records are included in the data for Sunday, November 14, 2021. On November 5, 2021, population estimates for all territories and protectorates (excluding Puerto Rico) have been\nupdated using the 2020 US Census International Data Base. On November 2, 2021, CDC recommended use of the Pfizer-BioNTech Vaccine for children ages 5 through 11 for the\npediatric population ages 5 to 11.","1734":"Serious AEs per FDA are defined as:\nDeath\nA life-threatening AE\nInpatient hospitalization or prolongation of existing hospitalization\nA persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions\nA congenital anomaly\/birth defect\nRequirements for Reporting to VAERS (Updated 9\/13\/2022)\n\uf1aa\n\uf209\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nAn important medical event that based on appropriate medical judgement may jeopardize the individual and\nmay require medical or surgical intervention to prevent one of the outcomes listed above\nCases of myocarditis after a Pfizer-BioNTech, Moderna, or Novavax vaccine\nCases of pericarditis after a Pfizer-BioNTech, Moderna, or Novavax vaccine\nCases of Multisystem Inflammatory Syndrome in children and adults\nCases of COVID-19 that result in hospitalization or death\nHealthcare providers are encouraged to report to VAERS any additional clinically significant AEs following vaccination,\neven if unsure whether vaccination caused the event.","8422":"Core Competencies Based on Role:\nRelevant information contained in the EUA Fact Sheet(s) for Healthcare Providers for the vaccine product(s) in\nyour facility\nStorage and handling requirements\nTransport guidance\nVaccination documentation and reporting requirements\nRequired and additional information for vaccine recipients\nCOVID-19 Vaccine Administration Competencies Assessment Form\nAdministration support staff qualified to store, handle, or transport\nvaccine\n\uf209\n\uf20c\nAdditional Resources:\nCOVID-19 Vaccination Clinical & Professional Resources\nInterim Guidance for Immunization Services During the Pandemic\nPatient Safety Checklist for Vaccination Clinics Held at Satellite Temporary or Off-Site Locations \uf20c\f10\/30\/22, 9:17 AM Training and Education for COVID-19 Vaccination | CDC\nPatient Safety Checklist for Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations\nNational Forum on COVID-19 Vaccine: Resources Page\nVaccine Confidence Training (American College of Obstetricians and Gynecologists)\n\uf20c\n\uf209\nPage last reviewed: April 14, 2022","3419":"Administration of subsequent COVID-19 vaccine doses: Onset of MIS fewer than 90 days after most recent\nCOVID-19 vaccine dose\nSubsequent COVID-19 vaccine dose(s) should be deferred at this time until additional data are available. However, on a case-\nby-case basis, a provider may offer subsequent dose(s) if the two criteria above are met and there is strong evidence that the\nMIS-C\/A was a complication of a recent SARS-CoV-2 infection.","2905":"Monovalent mRNA vaccines are no longer authorized as a booster dose for people ages 5 years and older. A monovalent Novavax booster dose (instead of a bivalent mRNA booster dose) may be used in limited situations in people\nages 18 years and older who completed any FDA-approved or FDA-authorized monovalent primary series, have not received\nany previous booster dose(s), and are unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available)\nor unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.","3797":"10 Things\nHealthcare Providers Need to Know about VAERS\nCOVID-19 Vaccine Safety Monitoring Systems for Pregnant People\nLearn how CDC is monitoring the safety of COVID-19 vaccination in people who are pregnant. \u2022\n\u2022\n\u2022\f10\/30\/22, 9:31 AM Ensuring COVID-19 Vaccine Safety in the US | CDC\nPfizer-BioNTech\nNovavax\nModerna\nJohnson & Johnson\u2019s Janssen\nDifferent Vaccines\nInformation about Specific\nVaccines\n\uf1aa\n\uf1aa\n\uf1aa\n\uf1aa\n\uf1aa\n\uf270 COVID-19 Vaccine Safety\nPublications\nRead the latest safety-related research on\nthe COVID-19 vaccines. \uf18b Safety Monitoring Systems\nInformation Sheet\nLearn more about the systems that monitor\nthe safety of COVID-19 vaccines.","1359":"Can a monovalent mRNA vaccine (i.e., Moderna or Pfizer-BioNTech) be used for the booster dose? \uf1aa\nBooster Doses\nEveryone ages 5 years and older is recommended to receive 1 bivalent mRNA booster dose if they have completed a\nprimary series with any FDA-approved or FDA-authorized COVID-19 vaccine:\nChildren age 5 years are recommended to receive the Pfizer-BioNTech bivalent booster dose. Who should receive a booster dose? \uf1aa\f10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\nChildren age 5 years are recommended to receive the Pfizer BioNTech bivalent booster dose.","2308":"CDC recommends everyone ages 5 years and older get an updated COVID-19 booster to help restore\nprotection that has decreased since your last vaccine. One updated booster dose is recommended for all\npeople ages 5 years and older, regardless of whether or not they are immunocompromised. CDC recommends that people with moderate or severe immunocompromise get an extra primary series dose\nif receiving the Moderna or Pfizer-BioNTech series. Use CDC\u2019s COVID-19 booster tool to learn if and when you can get boosters to stay up to date with your COVID-19\nvaccines.","9128":"Support wearing of masks or respirators on conveyances and in transportation hubs for everyone aged 2 years or\nolder, including employees. If an employer allows voluntary use of filtering facepiece respirators, the employer must follow 29 CFR\n1910.134(c)(2) requirements for voluntary respirator use. Improve ventilation. Keep conveyance ventilation systems on when passengers and workers are on board, including during\nembarkation and disembarkation processes. Open windows on conveyances where feasible. Reduce crowding where feasible. Promote hand hygiene, such as making hand sanitizer dispensers available and ensuring they are kept filled and\nworking.","970":"If you test too\nearly, you may be more likely to get an inaccurate result. If you are in certain high-risk settings, you may need to test as part of\na screening testing program. Consider testing before contact with someone at high risk for severe\nCOVID-19, especially if you are in an area with a medium or high COVID-19 Community Level. For guidance on using tests to determine which mitigations are recommended as you recover from COVID-19, go to Isolation\nand Precautions for People with COVID-19.","2045":"COVID-19 vaccine safety in children aged 5\u201311 Years \u2014 United States, November 3\u2013December 19, 2021\nEvaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age\nAdverse events among children ages 5\u201311 years after COVID-19 vaccination: Updates from v-safe and the Vaccine\nAdverse Event Reporting System (VAERS)\nThe Advisory Committee on Immunization Practices\u2019 interim recommendation for use of Pfizer-BioNTech COVID-19\nvaccine in children aged 5\u201311 years \u2014 United States, November 2021\nChildren ages 5 through 11 years\n\uf1aa\n\u2022\n\u2022 \uf209\n\u2022\n\uf20c\n\u2022\nSafety monitoring of COVID-19 vaccine booster doses among persons aged 12\u201317 years \u2014 United States, December\nChildren ages 12 through 17 years\n\uf1aa\n\u2022\f10\/30\/22, 9:31 AM COVID-19 Vaccine Safety in Children and Teens | CDC\nSafety monitoring in the Vaccine Adverse Event Reporting System (VAERS)\nMyocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021\nCOVID-19 vaccine safety in adolescents aged 12\u201317 years \u2014 United States, December 14, 2020\u2013July 16, 2021\nUse of Pfizer-BioNTech COVID-19 vaccine in persons aged \u226516 years: Recommendations of the Advisory Committee\non Immunization Practices \u2014 United States, September 2021\nUse of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: Update from the Advisory\nCommittee on Immunization Practices \u2014 United States, June 2021\nThe Advisory Committee on Immunization Practices\u2019 interim recommendation for use of Pfizer-BioNTech COVID-19\nvaccine in adolescents aged 12\u201315 Years \u2014 United States, May 2021\n\u2022 \uf209\n\u2022\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\nFor a complete list of research, visit Vaccine Safety Publications.","9244":"After Being Exposed to COVID-19\n\uf285 START PRECAUTIONS\nImmediately\nWear a mask as soon as you find out you were exposed\nStart counting from Day 1\nDay 0 is the day of your last exposure to someone with COVID-19\nDay 1 is the first full day after your last exposure\n\u2022\n\u2022\n\uf309 CONTINUE PRECAUTIONS\n10 Full Days\nYou can still develop COVID-19 up to 10 days after you have been exposed\nTake Precautions Watch for symptoms\nfever (100.4\u00b0F or greater)\ncough\n\u2022\f10\/30\/22, 9:41 AM What to Do If You Were Exposed to COVID-19 | CDC\nWear a high-quality mask or respirator (e.g., N95) any\ntime you are around others inside your home or indoors\nin public\nDo not go places where you are unable to wear a\nmask.","3079":"Use of the monovalent Novavax booster dose in limited situations\nPeople ages 18 years and older who completed primary vaccination using any COVID-19 vaccine and have not received\nany previous booster dose(s) may receive a monovalent Novavax booster dose at least 6 months after completion of the\nprimary series if they are unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available) or\nunwilling to receive an mRNA vaccine and would otherwise not receive a booster dose. Table 3.","3705":"1 The COVID-19 vaccine by Pfizer-BioNTech (brand name Comirnaty) was approved by FDA in August 2021 as a 2-dose\nprimary series for active immunization to prevent COVID-19 in persons aged \u2265 16 years. FDA also amended the EUA for the\nPfizer-BioNTech COVID-19 vaccine to authorize an additional primary dose in certain immunocompromised persons aged \u2265\n12 years and a homologous or heterologous booster dose in persons aged \u2265 18 years following primary vaccination with the\nPfizer-BioNTech or a different FDA-authorized COVID-19 vaccine.","8043":"On May 17, 2022, the FDA amended the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine, authorizing\na single booster dose for children ages 5-11 years at least five months after completion of a primary series with the same\nvaccine.101 The FDA committee that reviews and evaluates data concerning the safety, effectiveness, and appropriate use of\nvaccines, VRBPAC (Vaccines and Related Biological Products Advisory Committee), meet on June 14\u201315, 2022 to discuss the\nemergency use authorization of COVID-19 vaccines in this age.102 On June 17, 2022, the Advisory Committee on Immunization\nPractices (ACIP) issued interim recommendations for use of the Moderna COVID-19 vaccine in children ages 6 months to 5\nyears and the Pfizer COVID-19 vaccine\nfor use in children ages 6 months to 4\nyears.103 Some parents have expressed\nenthusiasm and relief about childhood\nvaccination.104,105,106 However, a recent\nKaiser Family Foundation (KFF) poll\nfound that only 18% of parents with\nchildren younger than 5 years will get\ntheir child vaccinated right away, while\n38% say they plan to wait and see how\nthe vaccine is working for others, 27%\nsay they will definitely not get their child\nvaccinated, and 11% say they will only do\nso if they are required.107,108\nPerceptions, Concerns, and Threats to Vaccine Confidence\n\u0083 Concerns about side effects, such as myocarditis, may negatively impact vaccine uptake.109,110\n\u0083 Some consumers believe vaccines are unnecessary because COVID-19 rarely affects this group.111,112\n\u0083 Some believe infection-induced immunity protects children better than vaccines.113,114\n\u0083 Some social media users do not think there is enough data to support vaccination against COVID-19 in children.115,116,117\n\u0083 With cases of hepatitis in children rising globally, some believe they are caused by COVID-19 vaccines.118,119,120\n\u0083 Some are concerned that immunity from vaccines decreases rapidly in adolescents.122,123\nCommonly asked questions and queries from the public\n\u0083 Should children under the age of 5 years still wear masks?i\n\u0082 Wearing a well-fitting mask or respirator consistently and correctly reduces the risk of spreading the virus that causes\nCOVID-19.","5813":"What are the Risks and Benefits of the COVID-19 vaccine by Moderna? The FDA approved the COVID-19 vaccine by Moderna to prevent COVID-19 based on safety and efficacy\ndata available from clinical trials. Additionally, the FDA issued an Emergency Use Authorization of the\nCOVID-19 vaccine by Moderna as an additional primary or a booster dose, determining, among other\nthings, that the known and potential benefits of vaccination outweigh the known and potential risks of the\nvaccine.","9974":"Has the person to be vaccinated ever had an allergic reaction to:\n* When vaccine recipients report a history of an immediate allergic reaction, providers should attempt to determine whether reactions reported following\nvaccination are consistent with immediate allergic reactions versus other types of reactions commonly observed following vaccination, such as vasovagal reaction or\npostvaccination side effects (which are not contraindications to receiving additional doses of that vaccine). \u2020 People with a known allergy to polysorbate have a contraindication to both Novavax and Janssen COVID-19 vaccines and a precaution to mRNA COVID-19 vaccines.","3277":"*\u2020\n*\n\u2020 \uf209\nTable of Contents \uf426\nReporting of vaccine adverse events\n\uf209\n\uf209\nTable of Contents \uf426\nSafety considerations for mRNA COVID-19 vaccines: Moderna\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nIn clinical trials of Moderna and Pfizer-BioNTech COVID-19 vaccines, types of post-vaccination reactions were generally similar. Pain at the injection site, sometimes severe, was the most frequent local reaction. Fatigue, headache, and myalgia were the\nmost common systemic symptoms. Most systemic symptoms were mild to moderate in severity, occurred within 1\u20132 days of\nvaccination, and resolved within 1\u20132 days of onset.","2597":"\u00b6 For guidance on use of Janssen vaccine and retrospective record review, scheduling and administration see Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendix A\nCDC Resources\nCDC COVID-19 vaccine clinical training and materials\nCDC Interim Clinical Considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States\nCDC Vaccine administration clinical materials\nCDC Vaccine Storage and Handling Toolkit\fInterim COVID-19 Immunization Schedule\nfor Persons 6 Months of Age and Older\n\u0083 Administer the correct vaccine product based on the recipient\u2019s\nage and vaccine composition. \u0083 COVID-19 vaccines may be administered on the same day as\nother routinely recommended vaccines, including influenza\nvaccine. Table 3.","2728":"\u2022\n-\n\u2022\n\u2022\n\u2022\n\u2022\n-\nMore Information\nUnderstanding Risk\f10\/30\/22, 9:41 AM COVID19 - Caring for someone at home | CDC\nHealthcare Professionals: Information on When to End Home Isolation\nTreatments Your Healthcare Provider Might Recommend for Severe Illness\nCOVID-19 Testing Overview\nLast Updated Jan. 19, 2022","1277":"Doses administered up to 4 days before the minimum interval, known as the 4-day grace period, are considered\nvalid. This applies to primary series and booster doses of vaccine. Do not use the grace period to schedule doses. Does the 4-day grace period apply to COVID-19 vaccine? \uf1aa\f10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\nIf a dose is administered earlier than the grace period, see Appendix D for guidance on corrective actions. It is considered\na vaccine administration error; you are required to report COVID-19 vaccine administration errors to the Vaccine Adverse\nEvent Reporting System (VAERS) .","849":"\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nAfter vaccination, continue to follow all current prevention measures recommended by CDC and based on latest COVID-\n19 Community Level data. Learn more about protecting your family from COVID-19. Related Pages\nFacts about COVID-19 Vaccines\n\u203a\nFrequently Asked Questions about COVID-19\nVaccination\n\u203a\nCOVID-19 Vaccines for People Who Would Like to Have\na Baby\n\u203a\nHow Do I Find a COVID-19 Vaccine? \u203a\nLast Updated Aug. 17, 2022","157":"Studies on animals do not show whether animals can spread\ninfection to people. Based on these studies, we know that invertebrates, birds, reptiles, and amphibians are not susceptible to infection with\nSARS-CoV-2. What CDC is doing\nSince the beginning of the pandemic, CDC has been leading efforts to improve our understanding of how SARS-CoV-2 affects\nanimals and how the virus might spread between people and animals. CDC has also worked to improve coordination of\nfederal, state, and other One Health partners.","8280":"Otherwise, stay up to date by getting the booster\nrecommended for you as soon as a booster is recommended for you based on your age and the appropriate time has\npassed since completing the primary series. \u2022\n\u2022\n\u2022\nProof of vaccination card in the United States\n\uf1aa\nThe white CDC COVID-19 vaccination cards are issued only to people vaccinated in the United States. CDC\nrecommends that people vaccinated outside of the United States keep their documentation of being vaccinated in\nanother country as proof of vaccination. CDC does\u202fnot\u202fkeep vaccination records nor determine how vaccination\nrecords are used.","1950":"Expanded Safety Monitoring Systems\nThe following systems and information sources add an additional layer of safety monitoring, giving CDC and FDA the ability to\nevaluate COVID-19 vaccine safety in real time and make sure COVID-19 vaccines are as safe as possible:\nCDC v-safe\u2014 A smartphone-based, after-vaccination health checker for people who receive COVID-19 vaccines. V-\nsafe uses text messaging and web surveys from CDC to check in with vaccine recipients following COVID-19\nvaccination. V-safe also provides second vaccine dose reminders if needed, and telephone follow-ups to anyone who\nreports medically-attended adverse events.","1633":"CDC COVID-19 Vaccination Program providers are required to make available and administer COVID-19\nvaccine to all such persons. This requirement is not intended to prevent prioritizing particular populations for\nspecific vaccination clinics\/events with the purpose of promoting health equity. \uf209\n\uf209\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nNote that transfer of COVID-19 Vaccine through the CDC authorized redistribution process from one enrolled provider to\nanother enrolled provider for authorized vaccination is not considered to be diversion of COVID-19 vaccine.","1893":"10\/30\/22, 9:33 AM COVID-19 Vaccine Effectiveness | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccines are Effective\nCDC is reviewing this page to align with updated guidance. COVID-19 vaccines are safe and effective. COVID-19 vaccination helps protect adults and children ages 6 months and older\nfrom getting severely ill with COVID-19 and helps protect those around them. Some people who are vaccinated against COVID-19 will still get sick and have a\nvaccine breakthrough infection because no vaccine is 100% effective.","9634":"\u2022 For certain moderately or severely immunocompromised persons:\no Ages 12 years and older who received primary vaccination with certain non-FDA authorized or\napproved COVID-19 vaccines should receive an additional primary dose of the COVID-19\nvaccine by Pfizer-BioNTech. o Ages 18 years and older who received primary vaccination with the Janssen COVID-19 Vaccine\nshould receive an additional dose with the COVID-19 vaccine by Pfizer-BioNTech. o Ages 12 years and older who received certain therapies (indicated below) and received\nprimary dose(s) of COVID-19 vaccine prior to or during treatment should be revaccinated with\nthe COVID-19 vaccine by Pfizer-BioNTech for any doses received before or during treatment.","972":"If you test too\nearly, you may be more likely to get an inaccurate result. If you are in certain high-risk settings, you may need to test as part of\na screening testing program. Consider testing before contact with someone at high risk for severe\nCOVID-19, especially if you are in an area with a medium or high COVID-19 Community Level. For guidance on using tests to determine which mitigations are recommended as you recover from COVID-19, go to Isolation\nand Precautions for People with COVID-19.","2381":"People who are moderately or severely immunocompromised\nwho have low or no protection after two doses of mRNA vaccines may have an improved immune response after a third\nprimary dose of the same vaccine. What are the benefits of a third primary dose for people who are moderately or severely\nimmunocompromised and received two doses of mRNA COVID-19 vaccine? \uf1aa\nThe safety, effectiveness, and benefit of the third primary dose in people who are moderately or severely\nimmunocompromised continues to be evaluated. So far, reactions reported after the third primary dose of an mRNA\nCOVID-19 vaccine are similar to those of the two-dose primary series.","7123":"\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\n\u2022\n\u2022\n-\n-\n\u2022\nIf You Are Sick or Think You Were Exposed to COVID-19\nIf you have any symptoms of COVID-19, contact your healthcare professional within 24 hours, and follow steps for when you\nfeel sick. If you are diagnosed with COVID-19, learn about breastfeeding and caring for newborns when the mother has COVID-19. Current evidence suggests that breast milk is not likely to spread the virus to babies.","5031":"New section added on Overview of COVID-19 vaccines recommendations. Updated guidance in section on COVID-19 vaccine dosage and schedule. Updated guidance in section on People vaccinated for prevention of COVID-19 outside the United States. Updated guidance in section on COVID-19 vaccination and SARS-CoV-2 infection for People with prior or current SARS-\nCoV-2 infection; People with a history of multisystem inflammatory syndrome in children (MIS-C) or adults (MIS-A);\nPeople who received passive antibody products; and Vaccinated people who subsequently develop COVID-19. New guidance on Considerations for COVID-19 revaccination in the section on Considerations for COVID-19\nvaccination in moderately and severely immunocompromised people.","761":"10\/30\/22, 9:37 AM Basics of COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nBasics of COVID-19\nCDC is reviewing this page to align with updated guidance. COVID-19 (coronavirus disease 2019) is a disease caused by a virus named SARS-CoV-2 and was discovered in December 2019\nin Wuhan, China. It is very contagious and has quickly spread around the world. COVID-19 most often causes respiratory symptoms that can feel much like a cold, a flu, or pneumonia. COVID-19 may attack\nmore than your lungs and respiratory system. Other parts of your body may also be affected by the disease.","10119":"\u0083 For persons who have had MIS-C or MIS-A from SARS-CoV-2 infection who have not yet received COVID-19 vaccine or who developed MIS-C or\nMIS-A after COVID-19 vaccination, a conversation between the vaccine recipient, guardian, and clinical team or specialist to discuss benefits and\nrisks of receiving a COVID-19 vaccine is encouraged. \u0083 Clinical recovery, including return to normal cardiac function, is an important factor when considering COVID-19 vaccination. Additional\ninformation at: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html#covid19-vaccination-misc-misa\nPersons who received passive antibody\ntherapy (convalescent plasma\/\nmonoclonal antibodies)\n\u0083 COVID-19 vaccination can be given at any interval following receipt of passive antibody therapy.","6832":"Remember to bring the card when your child returns. ADDITIONAL INFORMATION\nIf you have questions, visit the website or call the telephone number provided below. To access the most recent Fact Sheets, please scan the QR code provided below. Global website Telephone number\nwww.cvdvaccine.com\nHOW CAN I LEARN MORE? \uf0b7 Ask the vaccination provider. \uf0b7 Visit CDC at https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/index.html. \uf0b7 Visit FDA at https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-\nlegal-regulatory-and-policy-framework\/emergency-use-authorization. \uf0b7 Contact your local or state public health department. WHERE WILL MY CHILD\u2019S VACCINATION INFORMATION BE RECORDED? The vaccination provider may include your child\u2019s vaccination information in your\nstate\/local jurisdiction\u2019s Immunization Information System (IIS) or other designated\nsystem.","6494":"10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nEspa\u00f1ol | Other Languages\nPeople with Certain Medical Conditions\nOverview\nIf you or your family member are at high risk for severe illness, wear a mask or respirator with greater protection in\npublic indoor spaces if you are in an area with a high COVID-19 Community Level. Talk with your healthcare provider\nabout wearing a mask in a medium COVID-19 Community Level. If you test positive and are an older adult or someone who is at high risk of getting very sick from COVID-19, treatment is\navailable.","4387":"There is no information to date that anyone has become sick with COVID-19 because of direct exposure to treated or\nuntreated wastewater. Wastewater treatment plants use chemical and other disinfection processes to remove and degrade\nmany viruses and bacteria. The virus that causes COVID-19 is inactivated by the disinfection methods used in\nwastewater treatment. More Information\nASL Video Series: How does COVID-19 Spread? Last Updated Aug. 11, 2022","3674":"Learn what to do and when it is safe to be around others. Summary of Recent Changes\nUpdates as of April 18, 2022\nAs a result of a court order, effective immediately and as of April 18, 2022, CDC\u2019s January 29, 2021, Order requiring masks\non public transportation conveyances and at transportation hubs is no longer in effect. Therefore, CDC will not enforce\nthe Order. CDC continues to recommend that people wear high-quality masks in indoor public transportation settings at\nthis time. More Information\nFrequently Asked Questions about Travel and COVID-19\nInternational Travel\nLast Updated Aug. 24, 2022","821":"COVID-19 Vaccines Are Effective\nCDC recommends everyone ages 6 months and older stay up to date with their vaccines, which includes everyone 5 years and\nolder getting boosters if eligible, for the best protection against COVID-19. COVID 19-vaccines are effective at protecting people from getting seriously ill, being hospitalized, and even dying. 10\/30\/22, 9:34 AM Benefits of Getting A COVID-19 Vaccine | CDC\nPeople who have certain medical conditions or who are taking medications that weaken their immune system are at\nincreased risk of severe COVID-19 illness and death.","1175":"Reporting Conditions\nJurisdictions currently collect demographic data and report it to CDC. Not all states and territories report to CDC demographic\ndata on vaccine recipients; the laws in each state or territory dictate whether the state can collect or report demographic\ndata. Jurisdictional Reporting Conditions\nTexas\u202fhas historically provided COVID-19 vaccination administration data to CDC in aggregate format, which impacted CDC\u2019s\nability to report metrics requiring information at the individual dose level.","341":"The change produced no net change for vaccination records at the national level and\nminimal impact at the jurisdiction level. The greatest impact was at the county level. Residential counties located near DOD facilities will see increases in vaccine administration counts, and counties\nwhere DOD facilities are located will see decreases in vaccine administration counts. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n-\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nBeginning January 19, 2022:CDC is not displaying county-level data for residents of Barnstable, Dukes, and Nantucket\ncounties in Massachusetts because of the small populations in these counties. This includes residents who received\nvaccines in other states or counties.","7487":"No, the requirements of the Presidential Proclamation and CDC\u2019s Amended Order apply to air travel into the United\nStates For information about COVID-19 requirements for land travel and ferry terminals, visit the U.S. Department of\nHomeland Security\u2019s Fact Sheet: Guidance for Travelers to Enter the U.S. at Land Ports of Entry and Ferry Terminals. Do the requirements of this Amended Order apply to land border crossings or to persons arriving\nat seaports? \uf1aa\n\uf209\nYes, at this time all noncitizen nonimmigrant air passengers traveling to the United States, regardless of antibody status,\nare required to provide proof of COVID-19 vaccination.","4211":"\uf1aa\f10\/30\/22, 9:18 AM Frequently Asked Questions about COVID-19 Vaccination | CDC\nNo. You should wait to be vaccinated until after you\u202fcomplete your isolation period. People who have symptoms will end\nisolation at a different time than people who do not have symptoms. This also applies to people who have been\nvaccinated but get COVID-19 before getting any additional or booster doses. Additionally, you may consider delaying your\nnext vaccine (primary dose or booster) by 3 months from when your symptoms started or, if you had no symptoms, when\nyou received a positive test.","4012":"This is due to several factors, including the time it takes\nfor doses delivered to be administered, the time it takes for administered doses to be reported to CDC, and how\njurisdictions and federal pharmacy partners manage available vaccine stock to meet local demands. What are the reporting limitations and variations in COVID-19 vaccine data? \uf1aa\n\u2022\n\u2022\n\u2022\n\u2022\nWhy do data vary between the CDC COVID Data Tracker and state health department websites? \uf1aa\f10\/30\/22, 9:35 AM Frequently Asked Questions about COVID-19 Vaccination Data | CDC\nCDC Publicly Available Data\nFor the most complete and up-to-date data for any particular county or state, visit the relevant health department\nwebsite.","2160":"Related Pages\nAllergic Reactions\n\u203a\nFor Healthcare and Public Health\nConsiderations for the Use of COVID-19 Vaccines Currently Available in the U.S.\nCOVID-19 Vaccination among Pregnant People\nManagement of Anaphylaxis after COVID-19 Vaccination\nACOG Vaccine Confidence Training\nACOG Recommendations for Vaccinating Pregnant People\nACOG Practice Advisory: COVID-19 Vaccination Considerations for Obstetric-Gynecologic Care\nACOG video about COVID-19 vaccines for people who are pregnant\nCOVID-19 Clinical and Professional Resources\nClinic Poster: Protect yourself and your baby from COVID-19\nClinic Poster: Protect yourself and your baby from COVID-19 (Espa\u00f1ol)\n\u2022\n\u2022\n\u2022\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n- \uf209\n\u2022\n\u2022\n\u2022 \uf20c\nMore Information\nMother to Baby: Information for people who are pregnant of breastfeeding \uf209\nReferences\n1. Shimabukuro TT, Kim SY, Myers TR, et al.","3360":"History of other heart disease\nPeople who have a history of other heart disease, including congenital heart disease and Kawasaki disease, may receive any\ncurrently FDA-approved or FDA-authorized COVID-19 vaccine. Recent exposure to SARS-CoV-2 is not a contraindication or precaution to COVID-19 vaccination. People with a known or\npotential SARS-CoV-2 exposure can receive vaccine if they do not have symptoms consistent with SARS-CoV-2 infection;\nhowever, people should follow CDC\u2019s post-exposure guidance. COVID-19 vaccines are not recommended for post-exposure prophylaxis. People should be informed that vaccination is to\nhelp prevent severe COVID-19 following future exposures.","8295":"If you are experiencing any of these symptoms, consider the following options:\nGet tested for COVID-19\nIf you have already tested positive for COVID-19, learn more about CDC\u2019s isolation guidance\n\u2022\n\u2022\nWhen to Seek Emergency Medical Attention\nLook for emergency warning signs* for COVID 19:\nTrouble breathing\nPersistent pain or pressure in the chest\nNew confusion\nInability to wake or stay awake\nPale, gray, or blue-colored skin, lips, or nail beds, depending on skin tone\nIf someone is showing any of these signs, call 911 or call ahead to your local emergency facility. Notify the operator that\nyou are seeking care for someone who has or may have COVID-19.","7997":"\u0082 COVID-19 vaccines are effective at protecting you from severe outcomes and death from the virus that causes COVID-19,\neven if you have had COVID-19 in the past.86 Vaccination is an important tool to help us get back to normal.87\n\u0083 Should masks still be worn in indoor public places?88\n\u0082 When making decisions about community-level and individual-level prevention strategies, health officials, stakeholders\nand individuals might consider using the CDC\u2019s COVID-19 Community Levels approaches within their local context.","6182":"So far, research shows that the COVID-19\nvaccines used in the United States continue to protect against severe disease, hospitalization, and death from known\ncirculating variants. They may not be as effective in preventing infection from these variants. CDC will continue to monitor\nvaccine effectiveness to see what impact, if any, variants have on how well COVID-19 vaccines work in real-world conditions. How CDC Monitors COVID-19 Vaccine Effectiveness\nCDC uses multiple strategies to monitor how well COVID-19 vaccines are working in real-world conditions. Last Updated June 23, 2022","1703":"CDC has issued interim guidance for healthcare personnel in a variety of clinical and alternative\nsettings for the safe administration of vaccines during the COVID-19 pandemic. COVID-19 vaccination providers are\nrequired to implement this guidance on safe vaccination practices, including COVID-19 safety measures (e.g., social\ndistancing, mask wearing, hand hygiene), when providing COVID-19 vaccine.","5654":"\u2022\n-\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nNIOSH-Approved Respirators\nNIOSH approves many types of filtering facepiece respirators. The most widely\nand R100) offer the same or better protection as an N95 respirator. Lists of\nrespirators that are NIOSH-approved can be found on the NIOSH-Approved\nParticulate Filtering Facepiece Respirators webpage. CDC recommends that specially labeled \u201csurgical\u201d N95 respirators \u2014 a special\nsubtype of N95 respirators that provide additional protection against hazards\npresent during medical procedures, such as blood splatter \u2014 should be prioritized\nfor use by healthcare personnel. Employers who want to distribute N95 respirators to employees shall follow an\nOccupational Safety and Health (OSHA) respiratory protection program .","823":"COVID-19 Vaccines Are Effective\nCDC recommends everyone ages 6 months and older stay up to date with their vaccines, which includes everyone 5 years and\nolder getting boosters if eligible, for the best protection against COVID-19. COVID 19-vaccines are effective at protecting people from getting seriously ill, being hospitalized, and even dying. 10\/30\/22, 9:34 AM Benefits of Getting A COVID-19 Vaccine | CDC\nPeople who have certain medical conditions or who are taking medications that weaken their immune system are at\nincreased risk of severe COVID-19 illness and death.","8757":"These instructions may show how to make sure the product fits\nproperly. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:40 AM Use and Care of Masks | CDC\nSome types of masks and respirators may feel different if your child is used to wearing cloth or disposable procedure\nmasks. Parents and caregivers may have questions about NIOSH-approved respirators (such as N95s), and international respirators\n(such as KN95s and KF94s) for children. Although respirators may be available in smaller sizes, they are typically designed to\nbe used by adults in workplaces, and therefore may not have been tested for broad use in children.","2683":"If you live with or will gather with someone at risk for severe illness, wear a mask when indoors with them. High\nIf you are 2 or older, wear a well-fitting mask indoors in public, regardless of vaccination status or individual\nrisk (including in K-12 schools and other community settings). If you are at risk for severe illness, wear a mask or respirator that provides you with greater protection. If you are going to an indoor event or a gathering, test yourself immediately before or as close to the time of the event as\npossible.","21":"10\/30\/22, 9:34 AM About COVID-19 Vaccines | CDC\nEspa\u00f1ol | Other Languages\nAbout COVID-19 Vaccines\nCOVID-19 vaccines are safe and effective. CDC recommends COVID-19 vaccines for everyone 6 months and older and boosters\nfor everyone 5 years and older, if eligible. Learn about the different vaccines available. To find a COVID-19 vaccine near you: Search vaccines.gov, text your zip\ncode to 438829, or call 1-800-232-0233 to find COVID-19 vaccine locations near you. Benefits of Getting Vaccinated\nFrequently Asked Questions\n\u2022\n\u2022\n\u2022\n\u2022\nGetting a COVID-19 vaccine is fast, easy, and free. Learn how to find a COVID-19 vaccine near you, and get your vaccine\ntoday!","52":"If You Have Had an Immediate Allergic Reaction to Other\nVaccines or Injectables\nIf you have had an immediate allergic reaction (a reaction that started within 4 hours) to any vaccine other than a COVID-19\nvaccine or any injectable therapy, you may still be able to get a COVID-19 vaccine. However, your doctor may refer you to an\nallergy and immunology specialist for additional care or advice.","490":"On April 19, 2021, the population metrics for 65+ Texas residents dropped from the metrics reported on April 18, 2021. This was due to a schedule delay in updating the calculation used to infer the 65+ population metrics. The issue was\nresolved on April 19, 2021 and metrics accurately reflect the total doses administered. This did not affect any other\nstates, but did affect the total US estimates for 65+. On April 13, 2021, the total doses administered data posted to Tracker inadvertently included 221,081 duplicate doses\naffecting Vermont (6,605), Georgia (102,711), Illinois (64,886), West Virginia (60), and Maine (46,819).","6531":"This is especially important\nif you are older or have severe health conditions or more than one health condition, including those on this list. Learn more\nabout how CDC develops COVID-19 vaccination recommendations. If you have a medical condition, learn more about Actions\nYou Can Take. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\nMedical Conditions\nCancer\nHaving cancer can make you more likely to get very sick from COVID-19. Treatments for many types of cancer can weaken\nyour body\u2019s ability to fight off disease. At this time, based on available studies, having a history of cancer may increase your\nrisk. Get more information:\nThe conditions on this list are in alphabetical order.","1267":"10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\nEspa\u00f1ol | Other Languages\nVaccines & Immunizations\nVaccines & Immunizations Home\nFAQs for the Interim Clinical Considerations for COVID-\nThis page has answers to commonly asked questions about the Interim Clinical Considerations for COVID-19 Vaccination. For information about COVID-19 vaccine storage, preparation, and administration, visit the COVID-19 Vaccine FAQs for\nHealthcare Professionals. Vaccination Schedule and Use\nYes. For primary series vaccination, Moderna, Pfizer-BioNTech, and Novavax COVID-19 vaccines are recommended. For\nbooster vaccination, Moderna and Pfizer-BioNTech are recommended.","3889":"\uf1aa\n\uf209\nYou are required to provide patients with a COVID-19 vaccination record card, included in the ancillary supply kits for\nCOVID-19 vaccines, and an EUA Fact Sheet for Recipients and Caregivers for the vaccine product administered. Vaccination providers should also provide vaccine recipients with information about participating in v-safe, CDC\u2019s\nsmartphone-based after-vaccination health checker that uses text messaging and web surveys to provide personalized\nhealth check-ins. What information am I required to provide to patients? \uf1aa\nAs we learn more about COVID-19 vaccines and how to best implement the CDC COVID-19 Vaccination Program, CDC\nposts updates and amendments to the COVID-19 Provider Agreement on its website.","8156":"\u2022\n\u2022\n-\n-\n\u2022\n\u2022\n\u2022\n\u2022\n\uf3ba Updated Boosters Are Recommended for Some People\nCDC recommends that people ages 5 years and older receive one updated (bivalent) booster if it has been at\nleast 2 months since their last COVID-19 vaccine dose, whether that was:\nTheir final primary series dose, or\nAn original (monovalent) booster\nPeople who have gotten more than one original (monovalent) booster are also recommended to get an\nupdated (bivalent) booster. \u2022\n\u2022\f10\/30\/22, 9:27 AM Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC\nAbout COVID-19 Vaccines\nCOVID-19 vaccines available in the United States are effective at protecting people from getting seriously ill, being\nhospitalized, and dying.","6296":"10\/30\/22, 9:34 AM Myths and Facts about COVID-19 Vaccines | CDC\nMany things can affect menstrual cycles, including stress, changes in\nyour schedule, problems with sleep, and changes in diet or exercise. Infections may also affect menstrual cycles. MYTH: Being near someone who received a COVID-19 vaccine will affect my menstrual cycle. \uf1aa\nFACT: Your menstrual cycle cannot be affected by being near someone who received a COVID-19 vaccine. If your body develops an immune response to vaccination, which is\nthe goal, you may test positive on some antibody tests.","1628":"It shall be cause for immediate termination from the CDC COVID-19 Vaccination Program and\ncriminal or civil prosecution for violation of 18 U.S.C. \u00a7 1001 or other relevant federal statutes. Prioritization for receipt of COVID-19 vaccine in the early months of the CDC COVID-19 Vaccination Program was\nnecessary given limited supplies of vaccine. Supplies of COVID-19 vaccine doses are rapidly increasing. Effective May\n1, 2021, in conformance with the Secretary\u2019s March 17, 2021 directive to transition beyond priority groups, all\npersons qualified under the terms of the applicable COVID-19 vaccine Emergency Use Authorization are eligible to be\nvaccinated.","7728":"\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022 \uf209\n\u2022\nCDC is providing timely updates on the following adverse events of interest:\nAnaphylaxis after COVID-19 vaccination is rare and has occurred at a rate of approximately 5 cases per one million\nvaccine doses administered. Anaphylaxis, a severe type of allergic reaction, can occur after any kind of vaccination. If it happens, healthcare providers can effectively and immediately treat the reaction. Learn more about COVID-19\nvaccines and allergic reactions, including anaphylaxis.","7955":"\u0083 Work with community members and trusted messengers to create and disseminate messages that explain that some side\neffects are normal and expected. If a vaccinated individual gets COVID-19, vaccination will increase the chances that it is a\nmild case. \u0083 Disseminate messages debunking circulating misinformation when the misinformation persists or it has a high potential to\nimpact vaccination uptake in your community. Craft messages that use these evidence-based messaging strategies such as:\n\u0082 For XYZ to occur, these are the plausible biological mechanisms that would be required, and this is why that is not likely.","2179":"Magnus MC, Gjessing HK, Eide HN, et al. Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage. New\n8. Fell DB, Dhinsa T, Alton GD, et al. Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum\nOutcomes. JAMA. 2022;327(15):1478-1487. DOI: https:\/\/doi.org\/10.1001\/jama.2022.4255\n9. Badell ML, Dude CM, Rasmussen SA, Jamieson DJ. Covid-19 vaccination in pregnancy. BMJ. 2022;378:e069741. Published\n10. Ruderman RS, Mormol J, Trawick E, et al. Association of COVID-19 Vaccination During Early Pregnancy With Risk of\nCongenital Fetal Anomalies. JAMAPediatr. 2022;176(7):717-719. doi:10.1001\/jamapediatrics.2022.0164\n11. Goldshtein I, Nevo D, Steinberg DM, et al. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2\nInfection in Pregnant Women.Published online July 12, 2021. DOI: https:\/\/doi.org\/10.1001\/jama.2021.11035\n12.","1747":"Training, site\nvisits, and other oversight measures are important for maintaining or improving providers\u2019 adherence to these\nrequirements. Site visits are a key opportunity for quality assurance monitoring and training (as necessary) enrolled\nproviders. The goals of site visits are to:\nAssess COVID-19 vaccination provider adherence to program requirements and recommendations. Identify and address areas where providers are doing well and areas needing additional follow-up. Identify and address educational needs of COVID-19 vaccination providers to help them meet program\nrequirements. Ensure that vaccine recipients are receiving properly managed and viable vaccine.","3108":"Providers should consult CDC\u2019s\nEVUSHELD guidance and current treatment guidelines for more information on the use of EVUSHELD as pre-\nexposure prophylaxis. Such use of monoclonal antibodies, however, is not a substitute for COVID-19 vaccination.","8053":"At a high COVID-19 Community Level, universal indoor masking in schools and ECE programs is recommended,\nas it is in the community at-large. Schools with students at risk for getting very sick with COVID-19 must make reasonable\nmodifications or accommodations when necessary to ensure that all students, including those with disabilities, are able\nto access in-person learning.","7323":"CDC has worked closely with public health jurisdictions and the\nCouncil of State and Territorial Epidemiologists (CSTE) to help states to count repeat infections in the same individuals over\ntime. An updated national surveillance case definition of COVID-19 was introduced on September 1, 2021, and includes criteria for\ncounting new infections (reinfections) after previous probable or confirmed infections. CDC is working with multiple public\nhealth jurisdictions that are identifying reinfections to collect and analyze the data.","3876":"Even if you are not\nparticipating in the CDC COVID-19 Vaccination Program, you play an important role in helping to educate and encourage\nyour patients and others to get vaccinated. A provider\u2019s recommendation has been shown to be an important factor in\nvaccine acceptance. CDC has many resources to assist you with educating your patients, staff, families, and communities. Check your patients\u2019 vaccination status at routine appointments and, if they are unvaccinated, provide guidance on where\nthey can get vaccinated. For example, you can use Vaccines.gov to locate vaccination sites or consider partnering with a\nCOVID-19 vaccination provider to whom you can refer patients.","4468":"\u2022 \uf209\n\u2022\n\uf209\n\u2022 \uf209\f10\/30\/22, 9:39 AM How to Protect Yourself and Others | CDC\nFollowing Recommendations for What to Do If You Have Been Exposed\nIf you were exposed to someone with\nCOVID-19, you may have been infected\nwith the virus. Follow CDC\u2019s\nrecommendations for what to do if you\nwere exposed. This includes wearing a\nhigh-quality mask when indoors\naround others (including inside your\nhome) for 10 days, testing, and\nmonitoring yourself for symptoms. Staying Home When You Have Suspected or Confirmed COVID-19\nIf you have COVID-19, you can spread it to others, even if you do not have symptoms.","880":"Talk to your healthcare provider about how you can protect your newborn, such as using a physical barrier (for example,\nplacing the newborn in an incubator) while in the hospital. You most likely will not pass the virus to your newborn or any other close contacts after your isolation period has ended. If you had symptoms, your isolation period ends after:\n5 days since symptoms first appeared, and\n24 hours with no fever, without fever-reducing medicine, and\nOther symptoms of COVID-19 are improving. If you never had symptoms, your isolation period ends after\n5 days have passed since you tested positive for COVID-19.","6091":"Advisory\nCommittee on Immunization Practices meeting, November 19, 2021:\nDisanto G, Sacco R, Bernasconi, E. Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing\nWith Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis. JAMA Neurology. 2021;78(12):1529-1531. FDA. Fact Sheet for Healthcare Providers Administering Vaccine. Emergency Use Authorization of the Moderna\nCOVID-19 Vaccine to Prevent Coronavirus Disease 2019, Revised January 3, 2022\nGrunau B et al. A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute\nRespiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval. Clin Infect Dis. 2021 Nov 30:\nHaggenburg S, Hofsink Q, Lissenberg-Witte BI, et al.","8718":"\u2022\n\u2022\n\u2022\nMasks and Respirators\nLearn about different types of masks and respirators\nyou can use to protect yourself and others\nYour Guide to Masks\nLearn the proper use and care of masks, including\nconsiderations for people with disabilities\nHow to Use Your N95 Respirator\nFree N95 Respirator Manufacturers\nFree Mask Locator\nFind free masks (N95 respirators) at a participating location near you. Find a Mask Near You Or call 1-800-232-0233 (TTY 1-888-720-7489)\n\uf1aa\n\uf1aa\nLast Updated Aug. 12, 2021","3102":"\u2020\n\u2020\nPrevious vaccination with Janssen COVID-19 Vaccine\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nIn addition to following the recommended COVID-19 vaccination schedule, tixagevimab\/cilgavimab (EVUSHELD ), a\ncombination of two monoclonal antibodies, should be administered to people who are moderately or severely\nimmunocompromised every 6 months for pre-exposure prophylaxis to supplement vaccine protection. Per the product\nEUA , EVUSHELD is given at least 2 weeks after COVID-19 vaccine. People may initiate EVUSHELD at any time after this\ninterval, including between doses in the primary series and primary and booster doses.","3825":"\uf1aa\n\uf209\f10\/30\/22, 9:17 AM FAQs About Implementing COVID-19 Vaccination Program in Provider Practices | CDC\nIf you are a private provider, you are not required to provide vaccination to anyone who is not currently a patient. However, CDC strongly encourages, when possible, that providers make vaccine available to others in their local\ncommunities, including patients\u2019 family members. Pharmacies, public health clinics and any clinics held in communities\nare required to offer vaccination to anyone who is eligible. Does the program require that I provide vaccine to anyone, even if they are not currently a\npatient?","9744":"Neutralizing antibody titers, as measured by a pseudovirus neutralization assay\nusing a lentivirus expressing the SARS-CoV-2 Spike protein with D614G mutation, were assessed prior to\nadministration of the booster dose (Day 1) and after the booster dose (Day 15). A booster response to the\nPfizer-BioNTech COVID-19 Vaccine was demonstrated regardless of which COVID-19 vaccine was used for\nprimary vaccination. An overall review of adverse reactions reported following the Pfizer-BioNTech COVID-19\nvaccine heterologous booster dose did not identify any new safety concerns as compared to adverse reactions\nreported following the Pfizer-BioNTech COVID-19 vaccine primary vaccination or homologous booster dose\n(FDA, 2022).","3681":"EUI Webpage Update 09\/02\/2022 Page 1 of 3\nQuestions and Answers about Emergency Use Instructions (EUI)\nBelow are answers to frequently asked questions about Emergency Use Instructions (EUI). Refer to EUI for\nPfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine for primary, additional, and\/or\nbooster doses. What are Emergency Use Instructions (EUI)? Emergency Use Instructions (EUI) allow CDC to inform healthcare providers and recipients about certain\nuses of medical products approved (licensed) by the U.S. Food and Drug Administration (FDA) that are\nneeded during public health emergencies without the FDA needing to issue an Emergency Use\nAuthorization (EUA).","1957":"Existing Safety Monitoring Systems\nAs people get vaccinated, CDC, FDA, and other federal partners will use the following existing, robust systems and data\nsources to conduct ongoing safety monitoring:\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022 \uf209\n\uf209\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:32 AM COVID-19 Vaccine Reporting Systems | CDC\nGeneral public\nCDC & FDA Vaccine Adverse Event Reporting System (VAERS) \u2014 The national system that accepts reports from\nhealthcare professionals, vaccine manufacturers, and the public of adverse events that happen after vaccination; reports\nof adverse events that are unexpected, appear to happen more often than expected, or have unusual patterns are\nfurther assessed.","7684":"An adverse event can be caused by the vaccine or can be caused by a\ncoincidental event not related to the vaccine, such as an unrelated fever, that happened following vaccination. \uf209\f10\/30\/22, 9:31 AM Safety of COVID-19 Vaccines | CDC\nTo date, the systems in place to monitor the safety of these vaccines have found four serious types of adverse events\nfollowing COVID-19 vaccination, with evidence that suggests, although rare, a link to certain types of COVID-19 vaccinations\nthat were administered.","9868":"Kornek B, Leutmezer F, Rommer PS, et al. B Cell Depletion and SARS-CoV-2 Vaccine Responses in\nNeuroimmunologic Patients. Annals of Neurology. 2022;91:342-352. Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) \u2013 5 October 2021. Geneva: World\nHealth Organization; 2021. Kaslow DC. Policy question: Is a 3rd dose needed for older persons who have\nreceived 2 doses of inactivated COVID-19 vaccines? https:\/\/www.who.int\/news-\nroom\/events\/detail\/2021\/10\/04\/default-calendar\/sage_meeting_october_2021. Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nMoghnieh R, Mekdashi R, El-Hassan S, et al.","7989":"This did not positively impact\nGoogle searches, which showed a decreasing interest in booster information, from a recent peak at the end of March 2022.66,67\nPerceptions, Concerns, and Threats to Vaccine Confidence\n\u0083 Competing national events,68 continued rollback of mitigation measures,69 and consistently decreasing coverage from social\nmedia, news media, and political sources70,71,72 may lessen the frequency and impact of COVID-19-specific information for\nconsumers.","8939":"Learn more about\u202fselected adverse events\u202freported to VAERS. How VAERS Reports Are Reviewed\nVaccine safety experts review all reports of serious adverse events submitted to VAERS. A serious adverse event after\nvaccination is something that causes:\nPermanent disability\nHospitalization or an extended hospital stay (if vaccinated while in the hospital)\nLife-threatening illness\nBirth defects (congenital anomalies)\nDeath\nImportant Things To Know About VAERS\nVAERS is an early warning system used to monitor adverse events that happen after vaccination. VAERS is the\nfrontline system of a comprehensive vaccine safety monitoring program in the United States.","474":"CDC then\nmultiplies this percentage by the count for the total population receiving at least one dose in Texas. CDC repeats the\nsame calculations to estimate the \u201cfully vaccinated\u201d metrics for the three population groups. These values will also be\nincluded in the topline national totals for 12+, 18+, and 65+. On May 7, 2021, the COVID-19 Vaccine Tracker was updated to reflect the revised Moderna emergency use authorization\n(EUA) to account for the new 14 dose vial as authorized by the Food and Drug Administration (FDA) .","4847":"If the manufacturer does not have information to support the\nstability of the vaccine, repeat the dose immediately (no minimum\ninterval). Vaccine is mixed with too little diluent Do not repeat dose. Inform the recipient of the potential for local and\nsystemic adverse events\n\u2020\u2021\n\u2021\u00a7\n\u00a7\n\u00b6\n\u00a7\n\u00b6\n\u00a7\n# \u00a7\n\u00a7\n\u2020\n\u00b6\n\u00a7\n\u2020\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nType Administration error\/deviation Interim recommendation\nsystemic adverse events. Vaccine is mixed with too much diluent Repeat dose immediately (no minimum interval). Single-use vial of diluent is used to mix\nmultiple vials of vaccine\nDo not repeat dose. Inform patient of the potential for bacterial\ninfection.","3792":"If any vaccine safety issues\u2014also called adverse events\u2014 are reported, CDC scientists can quickly\nstudy them and determine if there is a safety concern with a particular vaccine. Here are some of the tools that CDC uses to keep close tabs on the safety of COVID-19 vaccines:\nv-safe\nV-safe provides quick and confidential health check-ins via text messages and web surveys so you can quickly\nand easily share with CDC how you or your dependent feel after getting a COVID-19 vaccine. Vaccine Adverse Event Reporting System (VAERS)\nVAERS is the national system that collects reports of adverse events that happen after vaccination.","8369":"Content developed by the American Psychological Association (Jared Skillings, PhD, ABPP; Erin Swedish, PhD; Robin McLeod, PhD; Mitch Prinstein, PhD, ABPP;\nand Stephen Gillaspy, PhD) in partnership with U.S. Centers for Disease Control and Prevention\nStep 3: Motivational interviewing\nStep 4: Respond to questions about vaccines, health, or mental health\nAdditional Resources:\nKey Things to Know about COVID-19 Vaccines\nFrequently Asked Questions about COVID-19 Vaccines\nAnswering Patients\u2019 Questions About COVID-19 Vaccine and Vaccination\nTalking with Parents About COVID-19 Vaccination\nHow to Tailor COVID-19 Information for Your Specific Audience\nHow to Address COVID-19 Misinformation\nPage last reviewed: November 3, 2021","906":"People who have come into close contact with someone with COVID-19 should be tested to check for infection:\nIf you develop symptoms, get tested immediately and isolate until you receive your test results. If you test\npositive, follow isolation recommendations. If you do not develop symptoms, get tested at least 5 days after you last had close contact with someone with\nCOVID-19. Self-tests are one of several options for testing for the virus that causes COVID-19 and may be more\nconvenient than laboratory-based tests and point-of-care tests. Ask your healthcare provider or your local\nhealth department if you need help interpreting your test results.","6200":"Active\nmonitoring includes reviewing data and medical records and evaluating the relationship to COVID-19 vaccination. Information about CDC\u2019s ongoing study of myocarditis after COVID-19 vaccination can be found here: Investigating Long-\nTerm Effects of Myocarditis | CDC\n\u2022\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nSeek medical care if you or your child have any of the specific or general symptoms of myocarditis or pericarditis\nespecially if it\u2019s within a week after COVID-19 vaccination. Healthcare Providers: For additional recommendations and clinical guidance, visit Clinical Considerations: Myocarditis after\nmRNA COVID-19 Vaccines. Should I Still Get Myself or My Child Vaccinated? 10\/30\/22, 9:31 AM Myocarditis and Pericarditis After mRNA COVID-19 Vaccination | CDC\nYes.","8080":"On May 18, 2022, a U.S. resident tested positive for monkeypox after returning to the United States from Canada.132 As of\nSeptember 14, 2022, the CDC reports 24,846 confirmed cases of monkeypox with cases in every state.133 Monkeypox virus is a\ncompletely different virus than the viruses that cause COVID-19 or measles.134\nPerceptions, Concerns, and Threats to Vaccine Confidence\n\u0083 Some consumers believe there is a link between COVID-19 vaccines and monkeypox.135,136\nCommonly asked questions and queries from the public\n\u0083 Who is at risk for monkeypox?d\n\u0082 Data suggest that gay, bisexual, and other men who have sex with men make up the majority of cases in the 2022\nmonkeypox outbreak.","8946":"It warns\nvaccine safety experts of potential problems that they may need to assess, and it alerts them to take further\naction, as needed. Hundreds of millions of people in the United States have received at least one dose of COVID-19 vaccine. The\nmajority of reports to VAERS after COVID-19 vaccination have been non-serious adverse events. CDC provides timely updates on selected adverse events reported after COVID-19 vaccination.","7905":"Centers for Disease Control & Prevention,\nCOVID-19 Response, Vaccine Task Force\nVaccine Confidence & Demand Team, Insights Unit\fCOVID-19 State of Vaccine Confidence Insights Report | October 10, 2022\nAims and Methods\nBy rapidly reviewing and analyzing numerous sources and inputs (see Appendix), the COVID-19 State of Vaccine Confidence\nInsights Report emphasizes major themes influencing COVID-19 vaccine hesitancy and uptake. These are characterized by the\nlevel and type of threat to vaccine confidence, degree of spread, and directionality.","1588":"9\/1\/22 Update (Revises 2\/11\/22 Update to add reference to bivalent COVID-19 vaccine booster doses):\nThird primary dose\/booster dose COVID-19 vaccination of persons in the United States who received COVID-19\nvaccination outside of the United States or as part of a clinical trial\nAll providers are required to offer third primary doses or bivalent booster doses of the Pfizer-BioNTech or Moderna\nCOVID-19 vaccine to qualifying persons who received particular non-FDA authorized\/approved COVID-19 vaccines\noutside of the United States or as part of certain COVID-19 clinical trials as described in the Emergency Use\nInstructions issued by CDC on November 17, 2021, and February 11, 2022: Pfizer EUI , Moderna EUI , and\nInterim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States\n(https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html).","6306":"Antibody tests\nindicate you had a previous infection and that you may have some\nlevel of protection against the virus. Learn more about the possibility of COVID-19 illness after vaccination. MYTH: Getting a COVID-19 vaccine will cause me to test positive on a viral test. \uf1aa\nFACT: None of the authorized and recommended COVID-19 vaccines can cause you to test positive on viral\ntests, which are used to see if you have a current infection.\u200b\f10\/30\/22, 9:34 AM Myths and Facts about COVID-19 Vaccines | CDC\nRelated Pages\nFrequently Asked Questions about Vaccination\n\u203a\nKey Things to Know about COVID-19 Vaccines\n\u203a\nLast Updated July 20, 2022","812":"Immunity from infection decreases over time. Importantly, there is still no antibody test available that can reliably determine if a person is protected from further\ninfection. Protection from COVID-19\n\uf1aa\n\u2022\n\u2022\nChildren, Teens, or Adults Who Have Already Had COVID-19\nShould Still Get Vaccinated\nData from ongoing studies show evidence that people can get added protection by getting vaccinated after having been\ninfected with the virus that causes COVID-19. Even if you have had COVID-19, you should still get vaccinated.","9665":"See Table 3 COVID-19 vaccination schedule for moderately or severely immunocompromised people in CDC\u2019s\nInterim Clinical Considerations for the latest dosing recommendations. On a case-by-case basis, providers of\nmoderately or severely immunocompromised patients who are ages 12 years and older may administer the\nCOVID-19 vaccine by Pfizer-BioNTech outside of the FDA-authorized or FDA-approved labeling and CDC\nrecommended dosing intervals based on clinical judgment when the benefits of vaccination are deemed to\noutweigh the potential and unknown risks for the recipient. What are the formulations of the COVID-19 vaccine by Pfizer-BioNTech that these EUI apply to?","7812":"If you\u2019re not able to obtain a self-test when you need it, you might also visit a community testing site, or\ncall your local health department for more options. \u2022\n\uf209\n\u2022\n\u2022\nFDA-Authorized Tests\n\uf6e0 How to Use an At-Home COVID-19 Test\nRead the complete manufacturer\u2019s instructions for use before using the test. To use an at-home test, you will collect a nasal specimen and then test that specimen. If you do not follow the manufacturer\u2019s instructions, your test result may be incorrect. Wash your hands before and after you collect a nasal specimen for your test.","7247":"Serious and\nunexpected side effects may occur. The possible side effects of these vaccines are still\nbeing studied. WHAT SHOULD I DO ABOUT SIDE EFFECTS? If you experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital. Call the vaccination provider or your healthcare provider if you have any side effects\nthat bother you or do not go away. Report vaccine side effects to FDA\/CDC Vaccine Adverse Event Reporting System\n(VAERS). The VAERS toll-free number is 1-800-822-7967 or report online to\nhttps:\/\/vaers.hhs.gov\/reportevent.html.","4332":"You\ncan also contact your state health department to get a copy of your\nvaccination record. Keep your CDC COVID-19 vaccination card for proof of vaccination. Consider taking a picture of your card after each of\nyour COVID-19 vaccination appointments as a backup copy. \u2022\n\u2022\n\u2022\f10\/30\/22, 9:30 AM Getting Your COVID-19 Vaccine | CDC\nSome vaccination providers and health departments may offer you access to a QR code or digital copy of your COVID-19\nvaccination card in addition to giving you a physical CDC COVID-19 vaccination card.","6802":"Serious and\nunexpected side effects may occur. The possible side effects of these vaccines are still\nbeing studied. WHAT SHOULD I DO ABOUT SIDE EFFECTS? If your child experiences a severe allergic reaction, call 9-1-1, or go to the nearest\nhospital. Call the vaccination provider or your child\u2019s healthcare provider if your child has any\nside effects that bother your child or do not go away. Report vaccine side effects to FDA\/CDC Vaccine Adverse Event Reporting System\n(VAERS). The VAERS toll-free number is 1-800-822-7967 or report online to\nhttps:\/\/vaers.hhs.gov\/reportevent.html.","7756":"Based on a recent analysis of data from the Vaccine Safety Datalink, the rate of GBS within the first 21 days\nfollowing J&J\/Janssen COVID-19 vaccination was found to be 21 times higher than after Pfizer-BioNTech or Moderna\n(mRNA COVID-19 vaccines). After the first 42 days, the rate of GBS was 11 times higher following J&J\/Janssen COVID-\n19 vaccination. The analysis found no increased risk of GBS after Pfizer-BioNTech or Moderna (mRNA COVID-19\nvaccines). CDC and FDA will continue to monitor for and evaluate reports of GBS occurring after COVID-19\nvaccination and will share more information as it becomes available.","212":"When someone who is fully vaccinated gets COVID-19, it is called a vaccine breakthrough infection. No vaccine\nis 100% effective, so some breakthrough infections are expected. The risk of infection, severe illness, hospitalization, and\ndeath are all much lower for vaccinated people compared to people who are unvaccinated. When reinfections or\nbreakthrough infections happen, having antibodies plays an important role in helping prevent severe illness, hospitalization,\nand death. For many diseases, including COVID-19, antibodies are expected to decrease or \u201cwane\u201d over time. After a long enough period\nof time, your level of antibodies can decrease below a level that provides effective protection.","8216":"Novavax Vaccine Overview\nNovavax\n\uf1aa\nNovavax\nPRIMARY SERIES\nNovavax\nPRIMARY SERIES\n3-8 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech or Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd\nprimary series dose\nUp to Date: Immediately after you have received the most recent booster recommended for you\nMore details: Staying up to date\nAGE GROUP\n18 YEARS AND OLDER\nPfizer-BioNTech Vaccine Overview\nPfizer-BioNTech\n\uf1aa\nPfizer-BioNTech\nPRIMARY SERIES\nPfizer-BioNTech\nPRIMARY SERIES\n3\u20138 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech or Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd\nprimary series dose or last\nbooster\nUp to Date: Immediately after you have received the most recent booster recommended for you\nMore details: Staying up to date\f10\/30\/22, 9:27 AM Stay Up to Date with COVID-19 Vaccines Including Boosters | CDC\nAGE GROUP\n18 YEARS AND OLDER\nModerna Vaccine Overview\nModerna\n\uf1aa\nModerna\nPRIMARY SERIES\nModerna\nPRIMARY SERIES\n4\u20138 weeks after 1st dose\nMore details: Getting your 2nd dose\nPfizer-BioNTech or Moderna\nUPDATED (BIVALENT) BOOSTER\nAt least 2 months after 2nd\nprimary series dose or last\nbooster\nUp to Date: Immediately after you have received the most recent booster recommended for you\nMore details: Staying up to date\nNovavax\n\uf1aa\nAGE GROUP\n18 YEARS AND OLDER\nNovavax is not authorized as a booster dose at this time.","404":"The program offered on-site COVID-19 vaccination services for\nresidents of nursing homes and assisted living facilities. The federal Pharmacy Partnership for LTC Program was in effect\nafter vaccines became available to April 23, 2021, and related COVID-19 Data Tracker pages were removed on October 7,\n2021. Historical data, previously available for download, that reflects the Pharmacy Partnership for LTC Program have\nbeen archived and are available on cdc.gov.\u200b All vaccine doses administered to residents and staff of nursing homes and\nassisted living facilities continue to be represented in their appropriate jurisdiction totals.","6496":"10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nEspa\u00f1ol | Other Languages\nPeople with Certain Medical Conditions\nOverview\nIf you or your family member are at high risk for severe illness, wear a mask or respirator with greater protection in\npublic indoor spaces if you are in an area with a high COVID-19 Community Level. Talk with your healthcare provider\nabout wearing a mask in a medium COVID-19 Community Level. If you test positive and are an older adult or someone who is at high risk of getting very sick from COVID-19, treatment is\navailable.","2388":"Fatigue and pain at the injection site were the most\ncommonly reported side effects\u2014and overall, most symptoms were mild and temporary. As with the two-dose primary series, serious side effects are rare, but may occur. What are the risks of vaccinating people who are moderately or severely immunocompromised\nwith a third primary dose? \uf1aa\f10\/30\/22, 9:28 AM COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised | CDC\np y y\nFor people who are immunocompromised, the third primary dose is the final dose of the primary series of an mRNA\nCOVID-19 vaccine.","273":"September 29, 2022, New Hampshire reviewed data and made adjustments to reporting, resulting in a decrease of\n175,025 for the number of vaccine doses administered since December 14, 2020. The adjustment is the result of updates\nto how pharmacies report data to CDC and\/or the jurisdictions. Vaccination data submitted by Texas on August 31, 2022 are currently under review by CDC and are not reflected on\nCOVID-19 Data Tracker. The data will be updated when available. On July 28, 2022, CDC corrected an error in the Census denominator used to calculate percentage-based metrics for the\nU.S. population aged 18 years and older.","1250":"This includes 8 million doses administered onsite to long-\nterm care facilities in the early days of the COVID-19 vaccination program. A total of 21 retail pharmacy partners are participating in the program, with more than 41,000 locations nationwide. This includes long-term care pharmacies. How the Federal Retail Pharmacy Program Works\f10\/30\/22, 9:22 AM COVID-19 Vaccination Federal Retail Pharmacy Partnership Program | CDC\nParticipating Retail Pharmacies\n\uf42d\nConnecting with Federal Pharmacy Partners\n\uf18c\nCOVID-19 Vaccine Eligibility and Availability\nEveryone 6 months of age and older is eligible to get a COVID-19 vaccination.","5038":"Updated Table in Appendix A: Vaccine administration errors and deviations. New section on Considerations for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose after completion of a\nPfizer-BioNTech primary vaccine series. Updated information in the section on COVID-19 vaccination and SARS-CoV-2 infection. Updated information in the section on Vaccinating people with a known COVID-19 exposure or during COVID-19\noutbreaks. New section on Vaccinating people receiving medical care unrelated to COVID-19. New section on Vaccinating people undergoing SARS-CoV-2 screening.","7153":"This Vaccine Information Fact Sheet for Recipients and Caregivers comprises the\nFact Sheet for the authorized Pfizer-BioNTech COVID-19 Vaccine and the\nPfizer-BioNTech COVID-19 Vaccine, Bivalent, and also includes information\nabout the U.S. Food and Drug Administration (FDA)-licensed vaccine,\nCOMIRNATY (COVID-19 Vaccine, mRNA) for use in individuals 12 years of age\nand older1. The FDA-approved COMIRNATY (COVID-19 Vaccine, mRNA) and the\nPfizer-BioNTech COVID-19 Vaccine authorized under Emergency Use\nAuthorization (EUA) for individuals 12 years of age and older, when prepared\naccording to their respective instructions for use, can be used interchangeably.2\nCOMIRNATY (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19\nvaccine made by Pfizer for BioNTech.","4526":"Make sure the straps lay flat and\nare not twisted. Place your fingertips from both hands at the top of the\nnose piece. Press down on both sides of the nose piece\nto mold it to the shape of your nose. Keep Your N95 Snug\n\uf1b1\nYour N95 must form a seal to your face to work properly. Your breath must pass through the N95 and not around its\nedges. Jewelry, glasses, and facial hair can cause gaps between your face and the edge of the mask. The N95 works better\nif you are clean shaven.","7540":"These categories are\nAny noncitizen seeking entry into or transiting the United States under one of the following nonimmigrant visa\nclassifications: A-1, A-2, C-2, C-3 (as a foreign government official or immediate family member of an official), E-1 (as an\nemployee of TECRO or TECO or the employee\u2019s immediate family members), G-1, G-2, G-3, G-4, NATO-1 through NATO-\n4, or NATO-6 (or seeking to enter as a nonimmigrant in one of those NATO classifications)\nAny noncitizen whose travel falls within the scope of Section 11 of the United Nations Headquarters Agreement or\nother travel pursuant to U.S. legal obligation (as evidenced by a letter of invitation from the United Nations or other\ndocumentation showing the purpose of such travel).","7440":"You are considered fully vaccinated on the 14th day after the vaccination series was completed. For example, if your last\ndose was any time on October 1st, then October 15th would be the first day that you meet the 14-day requirement. Frequently Asked Questions\nWhat are you looking for? Enter a word or phrase to locate questions and answers that match. Overview\nThe requirements outlined in the Presidential Proclamation and CDC\u2019s Amended Order apply to anybody who is\nconsidered a noncitizen nonimmigrant and is traveling to the United States by air.","9738":"The heterologous booster dose of Pfizer-BioNTech COVID-19 vaccine in individuals who completed primary\nvaccination with Janssen COVID-19 Vaccine is supported by the immunogenicity data from a Phase 1\/2 open-\nlabel clinical study (NCT04889209) by the National Institutes of Health conducted in the United States that\nevaluated heterologous booster regimens of FDA-authorized COVID-19 vaccines.","3521":"CDC will continue to provide testing recommendations for cruise ship\noperators to follow and cruise ships will continue to report COVID-19 cases to CDC. Why was the cruise ship color-coding system removed? \uf1aa\nCruise travelers have the option of contacting their cruise line directly regarding outbreaks occurring on board their ship. How can travelers find out about COVID-19 outbreaks on cruise ships? \uf1aa\nMore Information\nIf you need to contact your health department: State & Territorial Health Department Websites\nGuidance for Cruise Ships on the Mitigation and Management of COVID-19\nTravel during the COVID-19 Pandemic\nInternational Travel\nFrequently Asked Questions and Answers for Travelers\nLast Updated July 18, 2022","1683":"COVID-19 vaccination providers are required to\nimplement all recommendations of the ACIP, adopted by the CDC Director, relevant to COVID-19 vaccination including:\nUse of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson)\nand mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on\nImmunization Practices \u2014 United States, July 2021\nUse of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory\nCommittee on Immunization Practices \u2014 United States, June 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Adolescents Aged 12\u201315 Years \u2014 United States, May 2021\nUpdated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen\n(Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among\nVaccine Recipients \u2014 United States, April 2021\nInterim Recommendation for Use of Janssen COVID-19 Vaccine \u2014 United States, February 2021\nInterim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine, United States 2020\nInterim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine, United States, December 2020\nInterim Recommendation for Use of Moderna COVID-19 Vaccine, United States, December 2020\n\uf209\n\uf20c\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nInterim Recommendation for Use of Moderna COVID 19 Vaccine, United States, December 2020\nUpdated Interim Recommendation for Allocation of COVID-19 Vaccine, United States, December 2020\nFind more information about vaccine administration and reporting requirements.","7452":"Who must meet the requirements in the Presidential Proclamation and CDC\u2019s Amended Order to\nboard a plane to the United States? \uf1aa\n\uf209\n\uf209\nNo, U.S. citizens, U.S. nationals, U.S. lawful permanent residents, and immigrants, are not Covered Individuals; therefore\nthe Presidential Proclamation and CDC\u2019s Amended Order Implementing the Presidential Proclamation do not apply. See\nImmigrants and Other Non affected Persons\nDo the Presidential Proclamation and CDC\u2019s Amended Order apply to U.S. citizens, lawful\npermanent residents, or immigrants? \uf1aa\f10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC\nImmigrants and Other Non-affected Persons.","9518":"Special Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nSpecial Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nModerna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group\nCDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage based on their age on\nthe day of vaccination. \u0083 If a person moves from a younger age group to an older age group during the primary series or between the primary series and receipt\nof the booster dose(s), they should receive the vaccine product and dosage for the older age group for all subsequent doses.","5736":"\u2022 People ages 12 years and older, especially those at higher risk of myocarditis associated with mRNA\nCOVID-19 vaccines, may receive the second primary dose of the COVID-19 vaccine by Moderna 4\u20138\nweeks after the first primary dose. The second dose should not be received earlier than 4 weeks\nafter the first dose.","1317":"For\nmore information see:\nModerna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group\nPfizer-BioNTech for Children who Transition from a Younger to Older Age Group\nInterim COVID-19 Immunization Schedule for 6 Months of Age and Older\nWhat should I do for a child who is moving from a younger age group with a lower dose\nformulation to an older age group with a higher dose formulation? \uf1aa\n\uf20c\n\uf20c\n\uf20c\nIf the incorrect formulation is administered\nResulting in a higher-than-authorized dose: Do not repeat dose. Resulting in a lower-than-authorized dose: Repeat the dose immediately (no minimum interval) with the age-\nappropriate dose and formulation.","4399":"To find COVID-19 vaccine locations near you: Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n- \uf209\n- \uf209\n- \uf209\n-\nScheduling Vaccination Appointments\nTo schedule your COVID-19 vaccine appointment, visit a vaccine provider\u2019s online\nscheduling services. If you have a question about scheduling your appointment contact\nthe vaccination provider directly. To verify, reschedule, or cancel a COVID-19 vaccination appointment, contact the\nlocation that set up your appointment. You can get your vaccines at different locations. CDC cannot schedule, verify, reschedule, or cancel a vaccination appointment. Most vaccination providers schedule appointments online. \u2022\n\u2022\f10\/30\/22, 9:27 AM How Do I Find a COVID-19 Vaccine?","185":"Related Pages\nReducing the Risk of SARS-CoV-2 Spreading between People and Wildlife\n\u203a\nWhat You Should Know about COVID-19 and Pets\n\u203a\nMore Information\nInformation on Bringing an Animal into the United States\nWorld Organisation for Animal Health: COVID-19 Events in\nAnimals\nUSDA: Confirmed cases of SARS-CoV-2 in Animals in the\nUnited States\nUSDA: Coronavirus Disease 2019\nFDA: Coronavirus Disease 2019\n\uf209\n\uf209\n\uf209\n\uf209\nMedia Announcements\nConfirmation of COVID-19 in a Canada Lynx at a Pennsylvania Zoo\nConfirmation of COVID-19 in Hyenas at a Colorado Zoo\nConfirmation of COVID-19 in a Coatimundi at an Illinois Zoo\nConfirmation of COVID-19 in a Binturong and a Fishing Cat at an Illinois Zoo\nConfirmation of COVID-19 in Ferret in Florida\nConfirmation of COVID-19 in Deer in Ohio\nTexas A&M Research Uncovers First Known COVID-19 UK Variant In Animals\nConfirmation of COVID-19 in a Snow Leopard at a Kentucky Zoo\u200b\nUSDA Confirms SARS-CoV-2 in Mink in Utah\nConfirmation of COVID-19 in Pet Dog in New York\nConfirmation of COVID-19 in Two Pet Cats in New York\nUSDA Statement on the Confirmation of COVID-19 Infection in a Tiger in New York\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022\n\u2022 \uf209\nLast Updated July 5, 2022","2216":"Muyldermans J, De Weerdt L, De Brabandere L, Maertens K, Tommelein E. The Effects of COVID-19 Vaccination on\nLactating Women: A Systematic Review of the Literature. Front Immunol. 2022;13:852928. Published 2022 Apr 8. 26. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. COVID-19\nVaccines. [Updated 2022 Sep 19]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK565969\/\n27. Perl SH, Uzan-Yulzari A, Klainer H, et al. SARS-CoV-2\u2013Specific Antibodies in Breast Milk After COVID-19 Vaccination of\nBreastfeeding Women. 2021;325(19):2013\u20132014. DOI: https:\/\/doi.org\/10.1001\/jama.2021.5782\n28. Kelly JC, Carter EB, Raghuraman N, et al. Anti\u2013severe acute respiratory syndrome coronavirus 2 antibodies induced in\nbreast milk after Pfizer-BioNTech\/BNT162b2 vaccination.","10054":"For guidance on respective record\nreview, scheduling and administration of Janssen vaccine see Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendix A\fSummary Document for\nInterim Clinical Considerations\nfor Use of COVID-19 Vaccines Currently Authorized or Approved in the United States\nAll currently authorized or approved COVID-19 vaccines\nCOVID-19 vaccination schedule\n\u0083 See the Interim COVID-19 Immunization Schedule for Ages 6 Months or Older at https:\/\/www.cdc.gov\/vaccines\/covid-19\/downloads\/COVID-19-\nPre-vaccination counseling\nPrior to vaccination:\n\u0083 Provide the vaccine-specific Fact Sheet for Recipients and Caregivers Pfizer-BioNTech (https:\/\/www.fda.gov\/media\/144413\/download), Moderna\n(https:\/\/www.fda.gov\/media\/144637\/download), Janssen (https:\/\/www.fda.gov\/media\/146304\/download), Novavax (www.novavaxcovidvaccine.com)\n\u0083 Screen for contraindications and precautions. CDC's Prevaccination Screening Form and Guidance document can be found at www.cdc.gov\/\nvaccines\/covid-19\/info-by-product\/index.html.","9250":"For travel guidance, see CDC\u2019s Travel\nwebpage. Take extra precautions if you will be around people who\nare more likely to get very sick from COVID-19. More about how to protect yourself and others\n\u2022\n\uf426\ncough\nshortness of breath\nother COVID-19 symptoms\nIf you develop symptoms\nisolate immediately\nget tested\nstay home until you know the result\nIf your test result is positive, follow the isolation\nrecommendations. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\uf3c0 GET TESTED\nGet tested at least 5 full days after your last exposure\nTest even if you don\u2019t develop symptoms. If you already had COVID-19 within the past 90 days, see specific testing recommendations.","6741":"This Fact Sheet contains information to help you understand the risks and benefits of\nthe Pfizer-BioNTech COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent, which your child may receive because there is currently a pandemic of\nCOVID-19. Talk to your child\u2019s vaccination provider if you have questions. This Fact Sheet may have been updated. For the most recent Fact Sheet, please see\nwww.cvdvaccine.com. WHAT YOU NEED TO KNOW BEFORE YOUR CHILD GETS ANY OF THESE\nVACCINES\nWHAT IS COVID-19? COVID-19 disease is caused by a coronavirus called SARS-CoV-2. You can get\nCOVID-19 through contact with another person who has the virus.","4909":"Healthcare professionals and health\ndepartments may also request a consultation from the Clinical Immunization Safety Assessment COVIDvax project. In patients with these\nprecautions, vaccination should only be undertaken in an appropriate setting under the supervision of a healthcare professional experienced in\nthe management of severe allergic reactions.","6067":"The FDA has authorized the Moderna COVID-19 Vaccine, Bivalent (Original and Omicron\nBA.4\/BA.5) and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4\/BA.5) for the\nexpress purpose of improving protection conferred by COVID-19 booster doses against the currently circulating\nOmicron variant of SARS-CoV-2, resulting in a more favorable benefit\/risk balance as compared to the use of\nthe COVID-19 vaccine by Moderna. Consequently, the benefit\/risk balance for the use of the COVID-19 vaccine\nby Moderna for booster dose use is expected to be less favorable compared to the available alternative\nbivalent booster vaccines.","2414":"In addition, a recent report using the v-safe COVID-19 vaccine pregnancy safety monitoring\nsystem data showed that 4,800 people had a positive pregnancy test after receiving the first dose of an mRNA COVID-19\nvaccine. Another report using data from eight U.S. healthcare systems documented more than 1,000 people who\ncompleted COVID-19 vaccination (with any COVID-19 vaccine) before becoming pregnant. Learn more: COVID-19 Vaccines While Pregnant or Breastfeeding. No Evidence that COVID-19 Vaccines Affect Fertility\nThere is currently no evidence that vaccine ingredients or antibodies made following COVID-19 vaccination would cause any\nproblems with becoming pregnant now or in the future.","6579":"Get more information:\nTypes of Primary Immune Deficiency Diseases\nJeffrey Modell Foundation\nImmune Deficiency Foundation\nPrimary Immunodeficiency (PI)\nMental health conditions\nHaving mood disorders, including depression, and schizophrenia spectrum disorders can make you more likely to get very\nsick from COVID-19. Get more information:\nNational Institute of Mental Health (NIMH) Shareable Resources on Coping with COVID-19\nNational Institute of Mental Health (NIMH) Depression\n\u2022\n\u2022 \uf209\nAfter completing the primary vaccination series, some people who are moderately or severely immunocompromised\nshould get an additional primary dose and a booster. Because the immune response following COVID-19 vaccination may\ndiffer in people who are moderately or severely immunocompromised, specific guidance has been developed.","2173":"Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-\nGestational-Age at Birth \u2014 Eight Integrated Health Care Organizations, United States, December 15, 2020\u2013July 22, 2021. MMWR Morb Mortal Wkly Rep 2022;71:26\u201330. DOI: https:\/\/dx.doi.org\/10.15585\/mmwr.mm7101e1\n5. Moro PL, Olson CK, Clark E, et al. Post-authorization surveillance of adverse events following COVID-19 vaccines in\npregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 \u2013 October 2021. Vaccine. 6. Sadarangani M, Soe P, Shulha HP, et al. Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety\n(CANVAS) network cohort study [published online ahead of print, 2022 Aug 11]. Lancet Infect Dis. 2022;S1473-\n7.","9217":"You may also need to wear personal protective equipment, such as gloves, depending on the\ndirections on the product label. Immediately after disinfecting, wash your hands with soap and water for 20 seconds. \u2022\n\u2022\n\u2022\n\u2022\n- \u2022 \uf209\n\u2022\n\u2022\n\u2022\nTake steps to improve ventilation at home\nImprove ventilation (air flow) at home to help prevent from spreading COVID-19 to other people in your\nhousehold. Clear out COVID-19 virus particles in the air by opening windows, using air filters, and turning on fans in\nyour home. Use this interactive tool to learn how to improve air flow in your home.","5321":"\u2022 had a blood clot along with a low level of platelets (blood cells that help your body stop\nbleeding) following Janssen COVID-19 Vaccine or following AstraZeneca\u2019s COVID-19\nvaccine (not authorized or approved in the United States). WHAT ARE THE INGREDIENTS IN THE JANSSEN COVID-19 VACCINE? The Janssen COVID-19 Vaccine includes the following ingredients: recombinant,\nreplication-incompetent adenovirus type 26 expressing the SARS-CoV-2 spike protein, citric acid\nmonohydrate, trisodium citrate dihydrate, ethanol, 2-hydroxypropyl-\u03b2-cyclodextrin (HBCD),\npolysorbate-80, sodium chloride. HOW IS THE JANSSEN COVID -19 VACCINE GIVEN? The Janssen COVID-19 Vaccine will be given to you as an injection into the muscle.","7277":"Vaccinations may not provide full\nimmunity to COVID-19 in people who are immunocompromised, and you should\ncontinue to maintain physical precautions to help prevent COVID-19. Your close\ncontacts should be vaccinated as appropriate. WHAT IF I AM PREGNANT OR BREASTFEEDING? If you are pregnant or breastfeeding, discuss your options with your healthcare\nprovider. WILL THESE VACCINES GIVE ME COVID-19? No. These vaccines do not contain SARS-CoV-2 and cannot give you COVID-19. KEEP YOUR VACCINATION CARD\nWhen you get your first COVID-19 vaccine, you will get a vaccination card. Remember\nto bring your card when you return.","7976":"Google searches related to the COVID-19 vaccine during\nthis reporting period remained low relative to other topics such as Uvalde, TX, and monkeypox.e According to a Meltwater\ntrends analysis, there was a 17% decrease in news coverage and 45% decrease in social media mentions of COVID-19 vaccines.f\nRecent polling indicates fewer than a third of domestic consumers report being \u201csomewhat\u201d or \u201cvery\u201d worried about contracting\nAdditionally, sources indicate vaccine uptake plateauing,g as of May 31, 2022, COVID Data Tracker reported that 77.9% of\npeople had received at least one shot60 and 66.7% were fully vaccinated.61 Reported intention to vaccinate maintains a similarly\nconsistent cadence since approximately August 2021.c,62,63\nThe FDA64 and CDC65 strengthened recommendations and expansion of booster eligibility.","5999":"Small studies in solid organ transplant recipients in Toulouse,\nStrasbourg, and Baltimore demonstrate immunogenicity of a 4th mRNA dose when administered 1\u20132 months\nafter the 3rd dose (Kamar et al., 2021; Benotmane et al., preprint; Alejo et al., 2021). Multiple studies,\nincluding COV-BOOST and the NIH mix-and-match study demonstrated safety and immunogenicity of a booster\ndose in the general population when administered at intervals as short as 3 months following a 2-dose primary\nseries (Munro et al., 2021; Atmar et al., preprint). Finally, multiple countries have implemented booster doses\nat least 3 months after primary vaccination in the general population (e.g., UK, Germany, Netherlands).","9959":"Use the Interim Immunization Schedule for Ages 6 Months\nand Older to schedule doses\nPersons who received COVID-19 vaccine outside the United States\nVaccination guidance for people vaccinated outside of the United States can be found in the link Interim Clinical Considerations for\nUse of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\n4. Does the recipient have a health condition or undergoing treatment that makes them\nmoderately or severely immunocompromised? People with moderate or severe immunocompromising\nconditions or people who take immunosuppressive medications\nor therapies are at increased risk for severe COVID-19\ndisease.","3097":"People who are moderately or severely immunocompromised ages 18 years and older who received the Janssen COVID-19\nVaccine primary series dose are recommended to receive a second (additional) dose using a monovalent mRNA vaccine and 1\nbivalent mRNA booster dose (i.e., Moderna or Pfizer-BioNTech). The primary series dose and the additional dose are\nseparated by at least 4 weeks. The bivalent mRNA booster dose is administered at least 2 months after the additional dose\n(for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose. See Appendix A for additional information on Janssen COVID-19 Vaccine.","6835":"Remember to bring the card when your child returns. ADDITIONAL INFORMATION\nIf you have questions, visit the website or call the telephone number provided below. To access the most recent Fact Sheets, please scan the QR code provided below. Global website Telephone number\nwww.cvdvaccine.com\nHOW CAN I LEARN MORE? \uf0b7 Ask the vaccination provider. \uf0b7 Visit CDC at https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/index.html. \uf0b7 Visit FDA at https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-\nlegal-regulatory-and-policy-framework\/emergency-use-authorization. \uf0b7 Contact your local or state public health department. WHERE WILL MY CHILD\u2019S VACCINATION INFORMATION BE RECORDED? The vaccination provider may include your child\u2019s vaccination information in your\nstate\/local jurisdiction\u2019s Immunization Information System (IIS) or other designated\nsystem.","9641":"\u25aa Received COVID-19 vaccine dose(s) during treatment with B-cell-depleting therapies\nover a limited period\n\u25aa Received COVID-19 vaccine dose(s) prior to or during treatment involving HCT or CAR-\nT-cell therapy\nWhat are the doses and intervals of the COVID-19 vaccine by Pfizer-BioNTech for primary and\/or additional\ndoses? \u2022 A second primary dose of the COVID-19 vaccine by Pfizer-BioNTech (30 \u03bcg in 0.3 mL) should be\nadministered intramuscularly to persons ages 12 years and older; this may be 3\u20138 weeks after the first\nprimary dose. The approved interval is 3 weeks after the first dose, but an 8-week interval may be\noptimal for some people.","6740":"This Fact Sheet contains information to help you understand the risks and benefits of\nthe Pfizer-BioNTech COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent, which your child may receive because there is currently a pandemic of\nCOVID-19. Talk to your child\u2019s vaccination provider if you have questions. This Fact Sheet may have been updated. For the most recent Fact Sheet, please see\nwww.cvdvaccine.com. WHAT YOU NEED TO KNOW BEFORE YOUR CHILD GETS ANY OF THESE\nVACCINES\nWHAT IS COVID-19? COVID-19 disease is caused by a coronavirus called SARS-CoV-2. You can get\nCOVID-19 through contact with another person who has the virus.","8522":"What contact information am I required to provide to airlines and aircraft operators before I board\na flight to the United States? \uf1aa\nUnder current federal regulations, pilots must report all illnesses and deaths to CDC before arriving to a U.S. destination. According to CDC protocols, if a sick traveler has a contagious disease that is a risk to others on board the airplane, CDC\nworks with local and state health departments and international public health agencies to contact exposed passengers\nand crew.","5858":"The Moderna COVID-19 Vaccine has been\navailable since December 18, 2020, pursuant to Emergency Use Authorization (EUA). The approved formulation of Spikevax and the FDA-authorized\nModerna COVID-19 Vaccine for \u2265 12 years are the same formulation. Because of these features, and because Spikevax may be commonly referred to as\nthe \u201cModerna COVID-19 Vaccine,\u201d these EUI refer to this vaccine as the COVID-19 vaccine by Moderna.","1759":"All COVID-19 vaccination providers must report COVID-19 vaccine inventory weekly into Vaccines.gov. In some jurisdictions, providers may report vaccine inventory to the jurisdiction\u2019s IIS for the jurisdiction to upload into\nVaccines.gov. If you have questions about the process for your jurisdiction, please contact your jurisdiction\u2019s immunization\nprogram.","6944":"Has the COVID-19 vaccine by Pfizer-BioNTech been used before? Yes. Millions of people have received this vaccine in the United States since it became available starting in\nmid-December 2020. Also, in clinical trials, approximately 23,000 people ages 12 years and older received\nat least 1 dose of the vaccine. There have been some studies in people who received the COVID-19 vaccine\nby Pfizer-BioNTech after completing a primary vaccination with a non-FDA authorized or approved COVID-\n19 vaccine or Janssen COVID-19 Vaccine. What are the risks of the COVID-19 vaccine by Pfizer-BioNTech?","3213":"Anaphylactic reactions have been rarely reported following receipt of COVID-19 vaccines. Administration of antihistamines\nbefore COVID-19 vaccination to prevent allergic reactions is not generally recommended. However, while antihistamines will\nnot prevent anaphylaxis, some experts advise antihistamine use as a means of preventing milder allergic reactions in patients\nwho might be at higher risk for allergic reactions. For more information on the assessment and potential management of\nanaphylaxis, see Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination. For more information on patient counseling, see Vaccine Recipient Education. Syncope (fainting) may occur in association with any injectable vaccine, especially in adolescents.","3020":"\u2020 \u2021\n*\n\u2020\n\u2021\nPrevious vaccination with Janssen COVID-19 Vaccine\nConsiderations for extended intervals for COVID-19 vaccine primary series\ndoses\n\uf20c\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nCOVID-19 vaccines are FDA-approved or FDA-authorized for a 3-week (i.e., Novavax and Pfizer-BioNTech) and 4-week (i.e.,\nModerna) interval between the first and second primary series doses. These intervals continue to be recommended for\npeople who are moderately or severely immunocompromised, adults ages 65 years and older, and in situations when the\nfullest possible protection needs to be achieved sooner (e.g., increased concern about COVID-19 community levels or an\nindividual\u2019s higher risk for severe disease).","9067":"CDC established multiple ways to connect and share viral genomic sequence\ndata being produced by CDC, public health laboratories, and commercial diagnostic laboratories within publicly accessible\ndatabases. Learn More About Tracking Variants\nSome, but not all, monoclonal antibody treatments remain effective against Omicron. Public health agencies\nwork with healthcare providers to ensure that effective treatments are used appropriately to treat patients. We Have the Tools to Fight Variants\nThe following pages cover more detailed information about specific key prevention actions which can help fight variants. Vaccines Masks Testing Ventilation\n\u2022\n\u2022\n\u2022\n\u2022\n\uf3c4 Definitions &\nClassifications\n\uf3c0 Tracking &\nSurveillance\n\uf251 US & Global\nVariant Data\nLast Updated Aug. 11, 2021","2773":"If you feel able to, try to do some activities you enjoy. Connect with others. Talk with people you trust about your concerns and how you are feeling. For information, explore CDC\u2019s recommendations on how to cope with a disaster or traumatic event. If any of these steps require changes to your routine, diet, activity level, or medication, talk to your healthcare provider. \u2022\n\u2022\n- \uf209 \uf209\n-\n-\n-\n-\n\u2022\n\u2022\nSupport People with Post-COVID Conditions\nExperiencing post-COVID conditions can be confusing and frustrating, and a person who feels sick long-term may feel\nisolated.","6522":"People in racial and ethnic minority groups are often younger when they develop chronic medical conditions and\nmay be more likely to have more than one medical condition. People with disabilities are more likely than those without disabilities to have chronic health conditions, live in\nshared group (also called \u201ccongregate\u201d) settings, and face more barriers in accessing health care. Studies have\nshown that some people with certain disabilities are more likely to get COVID-19 and have worse outcomes. Staying up to date with COVID-19 vaccines and taking COVID-19 prevention actions are important.","288":"This total includes\nrecent and historic dose administrations from September 2021\u2014 April 2022 that had not previously been reported to\nCDC by Indiana. On May 26, 2022, the daily number of vaccine doses administered for Indiana was 70,721 doses. This total includes\nrecent dose administrations and historic dose administrations from August 1 to August 31, 2021 that had not been\nreported to CDC by Indiana.","3454":"10\/30\/22, 9:43 AM Cruise Ship Travel During COVID-19 | CDC\nEspa\u00f1ol | Other Languages\nCruise Ship Travel During COVID-19\nWhat You Need to Know\nCheck if you are up to date with your COVID-19 vaccines before cruise ship travel. If you have a medical condition or are taking medication that weakens your immune system, you might NOT be fully\nprotected even if you are up to date with your COVID-19 vaccines. Talk to your healthcare provider about your risk\nbefore travel. Even after vaccination, you may need to continue taking precautions. The virus that causes COVID-19 spreads easily between people in close quarters on board ships.","6843":"However, vaccination providers may seek appropriate\nreimbursement from a program or plan that covers COVID-19 vaccine administration\nfees for the vaccine recipient (private insurance, Medicare, Medicaid, Health\nResources & Services Administration [HRSA] COVID-19 Uninsured Program for\nnon-insured recipients). WHERE CAN I REPORT CASES OF SUSPECTED FRAUD? Individuals becoming aware of any potential violations of the CDC COVID-19\nVaccination Program requirements are encouraged to report them to the Office of the\nInspector General, U.S. Department of Health and Human Services, at\n1-800-HHS-TIPS or https:\/\/TIPS.HHS.GOV. WHAT IS THE COUNTERMEASURES INJURY COMPENSATION PROGRAM?","4577":"\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nFilter the air in your home\nIf your home has a central heating,\f10\/30\/22, 9:40 AM Improving Ventilation in Your Home | CDC\nView Larger\nventilation, and air conditioning\nsystem (HVAC, a system with air ducts\nthat go throughout the home) that has\na filter, do the following to help trap\nvirus particles:\nIn homes where the HVAC fan\noperation can be controlled by a\nthermostat, set the fan to the \u201con\u201d\nposition instead of \u201cauto\u201d when\nyou have visitors. This allows the\nfan to run continuously, even if\nheating or air conditioning is not\non. Use pleated filters . Pleated\nfilters are more efficient than\nordinary furnace filters and can\nbe found in hardware stores.","1611":"Diversion of COVID-19 Vaccines Prohibited (updated 06\/11\/2021)\nAt this time, all COVID-19 vaccine in the United States has been purchased by the United States Government for\nadministration exclusively through the CDC COVID-19 Vaccination Program. The vaccine and all related ancillary supplies,\nincluding the COVID-19 Vaccination Cards, remains U.S. government property until vaccine is administered to the\nrecipient. Inherent in the reference to COVID-19 vaccine remaining property of the United States Government, all USG-\nfurnished ancillary materials, including COVID-19 Vaccination Record Cards, have remained property of the United States\nGovernment for exclusive use in the CDC COVID-19 Vaccination Program since the program\u2019s inception.","6905":"\u2022 People ages 12 years and older who recently had SARS-CoV-2 infection may receive a second\nprimary dose after a deferral period of 3 months from symptom onset or positive test (if infection\nwas asymptomatic)\fPfizer-BioNTech COVID-19 Vaccine EUI Recipient Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\n\u2022 People ages 12 years and older who received an incomplete primary dose series (only the first\ndose of a 2-dose primary series) with certain non-FDA authorized or approved COVID-19 vaccines\nat least 28 days ago should receive a primary dose of the COVID-19 vaccine by Pfizer-BioNTech to\ncomplete the series.","3767":"However, based on available information, the known and potential risks of primary,\nadditional, and\/or booster doses of the COVID-19 vaccines by Pfizer-BioNTech or Moderna might be\noutweighed by their likely benefit to enhance or restore protection by the primary vaccination, which\nmight have waned over time. Refer to the EUI Fact Sheets for Healthcare Providers for Pfizer-BioNTech\nand Moderna and Interim Clinical Considerations for Use of COVID-19 Vaccines for additional\ninformation.","8169":"They also provide some protection against Omicron, but not as much as the updated (bivalent) boosters. The virus that causes COVID-19 has changed over time. The different versions of the virus that have developed over time are\ncalled variants. Learn more about variants of the COVID-19 virus. Two COVID-19 vaccine manufacturers, Pfizer and Moderna, have developed updated (bivalent) COVID-19 boosters. When Are You Up to Date? You are up to date with your COVID-19 vaccines if you have completed a COVID-19 vaccine primary series and received the\nmost recent booster dose recommended for you by CDC.","994":"You can order free self-test kits at COVIDtests.gov or purchase tests online, in pharmacies, and retail stores. You can also visit FDA\u2019s website to see a list of authorized tests. As noted in the labeling for authorized over-the-counter antigen tests: Negative results should be treated as presumptive\n(meaning that they are preliminary results). Negative results do not rule out SARS-CoV-2 infection and should not be\nused as the sole basis for treatment or patient management decisions, including infection control decisions. Please see\nFDA guidance on the use of at-home COVID-19 antigen tests.","5977":"Countries such as the United Kingdom (JCVI, 2021a-b), Canada (National Advisory Committee on Vaccination,\n2021), Germany, and France have recommended heterologous dosing, including with use of the Moderna\nCOVID-19 vaccine, for an additional primary series and\/or booster dose based on their reviews of available\nimmunological and safety data, as well as the epidemiology of COVID-19 and other contextual factors.","9967":"COVID-19 vaccines may be administered to people\nwith underlying medical conditions, such as HIV infection\nor other immunocompromising conditions, or who take\nimmunosuppressive medications or therapies, and who have no\ncontraindications to vaccination. People can self-report if they\nare moderately or severely immunocompromised. Vaccinators\nshould not deny COVID-19 vaccination to a person due to lack of\ndocumentation of immune status. Use the Interim Immunization Schedule for Ages 6 Months\nand Older to schedule doses\fPrevaccination Checklist\nfor COVID-19 Vaccines\nInformation for Healthcare Professionals\n5. Has the person to be vaccinated received a hematopoietic cell transplant (HCT) or CAR-T-cell\ntherapy since receiving COVID-19 vaccine?","5009":"Added considerations for an 8-week interval between the first and second doses of a primary mRNA vaccine schedule\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nUpdated guidance for moderately or severely immunocompromised people\nClarification of existing recommendation to receive a 3-dose mRNA vaccine primary series followed by a booster\ndose for a total of 4 doses\nNew guidance to shorten the interval between completion of the mRNA vaccine primary series and the booster\ndose to at least 3 months (instead of 5 months)\nNew guidance for those who received the Janssen COVID-19 Vaccine primary series to receive an additional dose\nand a booster dose, for a total of 3 doses to be up to date\nUpdated guidance that it is no longer necessary to delay COVID-19 vaccination following receipt of monoclonal\nantibodies or convalescent plasma\nUpdated guidance on receiving a booster dose if vaccinated outside the United States\nUpdated contraindication and precaution section to include history of myocarditis or pericarditis after an mRNA\nCOVID-19 vaccine as a precaution\nReorganized and condensed multiple sections\nUpdated guidance for use of Pfizer-BioNTech COVID-19 Vaccine as a booster in people ages 12\u201317 years\nUpdated guidance for administration of a COVID-19 vaccine booster dose at least 5 months after completion of an\nmRNA vaccine (Pfizer-BioNTech or Moderna) primary series\nUpdated guidance for use of an additional primary dose for moderately or severely immunocompromised people ages\n5\u201311 years who received a Pfizer-BioNTech vaccine primary series\nUpdated recommendations for people who received COVID-19 vaccines outside the United States that are not FDA-\nauthorized or approved\nUpdated information about a second formulation of Pfizer-BioNTech COVID-19 Vaccine that is authorized for use in\npersons ages 12 years and older\nUpdated information on vaccinating people during quarantine after a known SARS-CoV-2 exposure or during COVID-\nUpdate to alert providers of possible false positive Rapid Plasma Reagin (RPR; non-treponemal) test results in some\npeople after COVID-19 vaccines\nUpdated information on vaccine administration errors and deviations\nUpdated guidance on use of Janssen (Johnson & Johnson) COVID-19 Vaccine\nUpdated recommendations for receipt of a COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 booster doses in recipients of mRNA COVID-19 vaccines\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nRecommendations and clinical guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children aged 5-11 years\nincluding updated section on Vaccination of children and adolescents\nUpdated guidance on COVID-19 vaccine dosing and schedule\nUpdated guidance for myocarditis and pericarditis after mRNA COVID-19 vaccination in new section on Considerations\nfor mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna\nNew guidance for people who received passive antibody products in section on COVID-19 vaccination and SARS-CoV-2\ninfection\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial in the United States\nUpdated guidance on Considerations for COVID-19 vaccination in moderately and severely immunocompromised\npeople\nUpdated guidance in section on Contraindications and precautions\nUpdated Table in Appendix A: Vaccine administration errors and deviations\nUpdated Appendix B: Triage of people with a history of allergies or allergic reactions\nUpdated Appendix C: Ingredients included in COVID-19 vaccines\nUpdated Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects\nfollowing COVID-19 vaccination\nUpdated guidance in section on Considerations for use of a COVID-19 booster dose.","7745":"CDC\nscientists have conducted detailed reviews of TTS cases and made the information available to healthcare providers\nand the public:\nUS Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S\nCase Series of Thrombosis with Thrombocytopenia Syndrome following COVID-19 vaccination\u2014United States,\nUpdates on Thrombosis with Thrombocytopenia Syndrome (TTS) [1.3 MB, 39 Pages]\nGuillain-Barr\u00e9 Syndrome (GBS) in people who have received the J&J\/Janssen COVID-19 vaccine is rare. GBS is a rare\ndisorder where the body\u2019s immune system damages nerve cells, causing muscle weakness and sometimes\nparalysis. GBS has largely been reported in men ages 50 years and older.","3574":"People Receiving at Least One Dose\nRepresents the total number of people who received at least one dose of COVID-19 vaccine approved or authorized for\nuse in the United States. This metric includes everyone who has received only one dose and those who received more\nthan one dose. People Who Are Fully Vaccinated\nRepresents the total number of people who have received the second dose in a two-dose COVID-19 vaccine primary\nseries or one dose of a single-dose COVID-19 vaccine primary series approved or authorized for use in the United States.","4779":"At this time, only the Medicago COVID-19 Vaccine in people ages 18 years and older\nmeet these criteria. Moderately or severely immunocompromised clinical trial participants should receive a third primary dose of an mRNA\nvaccine 28 days after receiving the second vaccine dose of a primary series as detailed in guidance for people who are\nmoderately or severely immunocompromised, unless they have received or plan to receive a third primary dose through a\nclinical trial. For information on booster doses, see guidance for people who are not moderately or severely immunocompromised and\nguidance for people who are moderately or severely immunocompromised.","8960":"VAERS reports often lack\ncontextual information, such as total vaccinations given or information on unvaccinated groups for comparison. Most reports\nto VAERS are voluntary, which means they may be subject to biases. Data from VAERS reports should always be interpreted\nwith these limitations in mind. Learn more about how VAERS helps to monitor vaccine safety. Learn More about VAERS\nVIDEO\nVAERS and Vaccine Safety: How It Works\nVideo Length: 00:02:04\nWatch Video\nVIDEO\nVaccine Safety Monitoring Information for Healthcare Providers\nVideo Length: 00:04:44\nWatch Video\n\uf2ff For Providers and Jurisdictions\n10 Things Healthcare Providers Need to Know About VAERS\nCOVID-19 Clinical Resources\n\u2022\n\u2022\nLast Updated Aug. 25, 2021","8521":"\uf1aa\nAir passengers are required to provide the following contact information, to the extent that it exists, within 72 hours\nbefore their flight\u2019s departure: full name (as it appears on their passport), address while in the United States, primary\ncontact phone number, secondary or emergency contact phone number, and email address. Passengers must also:\nAcknowledge that the obligation to provide complete and accurate information is a U.S. government requirement and\nthat failure to provide complete and accurate information may result in criminal penalties. Confirm the information they provided is complete and accurate.","1587":"9\/1\/22 Update (Revises 2\/11\/22 Update to add reference to bivalent COVID-19 vaccine booster doses):\nThird primary dose\/booster dose COVID-19 vaccination of persons in the United States who received COVID-19\nvaccination outside of the United States or as part of a clinical trial\nAll providers are required to offer third primary doses or bivalent booster doses of the Pfizer-BioNTech or Moderna\nCOVID-19 vaccine to qualifying persons who received particular non-FDA authorized\/approved COVID-19 vaccines\noutside of the United States or as part of certain COVID-19 clinical trials as described in the Emergency Use\nInstructions issued by CDC on November 17, 2021, and February 11, 2022: Pfizer EUI , Moderna EUI , and\nInterim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States\n(https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html).","7669":"To view the current total number of COVID-19 vaccinations that have been administered in the United\nStates, please visit the CDC COVID Data Tracker. COVID-19 vaccines are safe and effective. COVID-19 vaccines were evaluated in tens of thousands of participants in clinical\ntrials. The vaccines met the Food and Drug Administration\u2019s (FDA\u2019s) rigorous scientific standards for safety, effectiveness, and\nmanufacturing quality needed to support emergency use authorization (EUA). Learn more about EUAs in this video. The Pfizer-BioNTech, Moderna, and Johnson & Johnson\/Janssen and Novavax COVID-19 vaccines will continue to undergo the\nmost intensive safety monitoring in US history.","7703":"Reports of adverse events to VAERS following vaccination, including deaths, do not necessarily mean that a vaccine\ncaused a health problem. CDC and FDA review reports of death following COVID-19 vaccination and update information as it\nbecomes available. Learn more about adverse events, including reports of death, after COVID-19 vaccination. \uf209\nBenefits of Vaccination Outweigh the Risks\nSerious side effects that could cause a long-term health problem are extremely rare following any vaccination, including\nCOVID-19 vaccination. The benefits of COVID-19 vaccination outweigh the known and potential risks. CDC continues to closely monitor the safety of COVID-19 vaccines.","384":"The adjustments are the result of updates to how pharmacies report data to CDC and\/or the jurisdictions. On October 26, 2021, CDC corrected an error in the census denominators used to calculate percentage-based metrics\nfor the population \u2265 65 years of age in Puerto Rico. No other population groups were affected. The census counts for the population aged 65 years and older in Puerto Rico increased from 542,928 to 679,656\npeople. The census counts for the population aged 65 years and older in the US increased from 54,696,581 to 54,833,309\npeople. CDC will update its historical data on data.cdc.gov to reflect these corrections.","3601":"This measure does not consider\neligibility based on age, whether the vaccine recipient is immunocompromised, or how much time has passed since first\nbooster dose. People who are fully vaccinated are those who received the second dose in a two-dose COVID-19 vaccine\nprimary series or one dose of a single-dose COVID-19 vaccine primary series. Learn more about CDC\u2019s recommendations for a COVID-19 vaccine booster dose.","4290":"If you are taking medications that suppress the immune system, you should talk to your healthcare provider about what\nis currently known about COVID-19 vaccine effectiveness. Ask about the best timing for you to get your vaccine. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nGet a COVID-19 vaccine with your routine medical procedures and screenings\nYou can combine most procedures, screenings, and vaccinations at the same appointment when you get your COVID-19\nvaccination. Talk to your healthcare provider if you have questions. Children, teens, and adults may get a COVID-19 vaccine and other vaccines, including a flu vaccine, at the same time.","1570":"6\/23\/22 Update (replaces 6\/18\/22 update; and revised to be a consolidated update that addresses all\nprimary series pediatric COVID-19 vaccination; 6\/23\/22 update also adds availability of age-appropriate\nModerna COVID-19 Vaccine for 6 years through 17 years of age):\nCOVID-19 Vaccination of Children 6 Months through 17 Years of Age\nPursuant to CDC\/ACIP recommendations and Secretarial Directives:\nAll authorized providers in the CDC COVID-19 Vaccination Program shall make immediately available and administer\nupon request \u2013\na two-dose series using the age-appropriate Moderna COVID-19 Vaccine product for children ages 6 months\nthrough 17 years\na three-dose series using the age-appropriate Pfizer-BioNTech COVID-19 Vaccine product for children ages 6\nmonths through 4 years\na two-dose series using the age-appropriate Pfizer-BioNTech COVID-19 Vaccine product for children ages 5 years\nthrough 17 years\n6\/23\/22 Update (replaces 6\/18\/22, 1\/6\/22, 9\/14\/21 and 10\/7\/21 updates; additional eligible group noted\nin bold italics; Updated on 10\/12\/22 to remove reference to the purple cap Pfizer-BioNTech vials which\nare no longer available):\nThird Dose for Recipients of Pfizer-BioNTech or Moderna COVID-19 Vaccine Who Are Immunocompromised\nPursuant to CDC\/ACIP recommendations and Secretarial Directives, a third primary dose of an mRNA COVID-19\nvaccine should be administered using the same mRNA COVID-19 vaccine as was administered for the 2-dose primary\nseries to persons who are moderately to severely immunocompromised at least 28 days after completing the two-\ndose primary series:\nPfizer-BioNTech COVID-19 Vaccine \u2013\nOrange cap to children 5 through 11 years of age\nGray cap to people 12 years and older\nModerna COVID-19 Vaccine \u2013\nDark blue cap\/magenta border to children 6 months through 5 years of age\nDark blue cap\/purple border to children 6 years through 11 years of age\nRed cap\/light blue border to people 12 years and older\nCOVID-19 Vaccination Under the CDC Interim Clinical Considerations and Emergency Use Instructions\nProviders may also administer COVID-19 vaccines as described in CDC guidance as updated from time to time:\nInterim Clinical Considerations for Use of COVID-19 Vaccines in the United States\nEmergency Use Instructions (see vaccine Fact Sheets)\n5\/23\/22 Update (revision of 5\/19\/22 update to add reference to the May 23, 2022, Secretarial Directive;\n9\/1\/22 revision noted in bold italics to clarify that booster doses available to this age group are\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\n9\/1\/22 revision noted in bold italics to clarify that booster doses available to this age group are\nmonovalent):\nCOVID-19 Vaccine Booster Doses for Children 5 through 11 Years of Age\nPursuant to CDC\/ACIP recommendations and the May 23, 2022, Secretarial Directive on Pediatric and Second COVID-\n19 Vaccine Booster Doses, all providers in the CDC COVID-19 Vaccination Program shall make immediately available\nand administer a single monovalent booster dose of Pfizer-BioNTech COVID-19 vaccine to individuals seeking such a\ndose as follows:\nChildren ages 5 through 11 years should receive a single monovalent Pfizer-BioNTech COVID-19 vaccine booster\ndose at least 5 months after completion of a Pfizer-BioNTech COVID-19 vaccine primary series.","8086":"However, monkeypox can spread to anyone through close, personal, often skin-to-skin contact. Anyone who has been in close contact with someone who has monkeypox is at risk.137\n\u0083 How do I know if I have monkeypox?d\n\u0082 People with monkeypox can get a rash that may be located on or near the genitals (penis, testicles, labia, and vagina) or\nanus (butthole) and could be on other areas like the hands, feet, chest, face, or mouth. \u008f The rash will go through several stages, including scabs, before healing. \u008f The rash can initially look like pimples or blisters and may be painful or itchy.","10062":"\u0083 Inform vaccine recipients mRNA or Novavax COVID-19 vaccines are recommended over Janssen COVID-19 Vaccine. \u0083 Counsel vaccine recipients, parents, or guardians about expected reactions post-vaccination (e.g., pain and swelling at the injection site, fever,\nfatigue, headaches). \u0083 Inform mRNA and Novavax vaccine recipients especially males ages 12-39 years, of the rare risk of myocarditis and pericarditis following receipt of\nthese COVID-19 vaccines and the benefit of COVID-19 vaccination in reducing the risk of severe outcomes from COVID-19.\u2020 Counseling should also\ninclude the need to seek care if symptoms of myocarditis or pericarditis occur after vaccination, particularly in the week following vaccination.","7916":"Although some side effects from COVID-19 vaccines are normal and expected,1 concern about adverse events and long-term\neffects from the vaccine keep many from seeking COVID-19 vaccination.2,3 On May 5, 2022, the FDA limited the authorized\nuse of the Janssen COVID-19 Vaccine to individuals ages 18 years and older for whom other authorized or approved COVID-19\nvaccines are not accessible or clinically appropriate, and to individuals ages 18 years and older who elect to receive the Janssen\nCOVID-19 vaccine because they would otherwise not receive a COVID-19 vaccine.4 This decision spurred online conversations\ndiscussing the perceived lack of effectiveness of all COVID-19 vaccines, further discouraging vaccine uptake.5,6,7\nPerceptions, Concerns, and Threats to Vaccine Confidence\n\u0083 Hepatitis.","4418":"Select a Location (all fields required)\nState County Go\nPrevention Actions to Use at All COVID-19 Community Levels\nIn addition to basic health and hygiene practices, like handwashing, CDC recommends some prevention actions at all COVID-\n19 Community Levels, which include:\nStaying Up to Date with COVID-19 Vaccines\nImproving Ventilation\nGetting Tested for COVID-19 If Needed\nFollowing Recommendations for What to Do If You\nHave Been Exposed\n\u2022\n\u2022\n\u2022\n\u2022\nStaying Home If You Have Suspected or Confirmed\nSeeking Treatment If You Have COVID-19 and Are at\nHigh Risk of Getting Very Sick\nAvoiding Contact with People Who Have Suspected or\n\u2022\n\u2022\n\u2022\nStaying Up to Date with COVID-19 Vaccines\nCOVID-19 vaccines help your body develop protection from the virus that causes COVID-19.","7210":"Booster Dose: Pfizer-BioNTech COVID-19 Vaccine, Bivalent is administered as a single\nbooster dose at least 2 months after:\n\uf0b7 completion of primary vaccination with any authorized or approved monovalent\nCOVID-19 vaccine; or\n\uf0b7 receipt of the most recent booster dose with any authorized or approved\nmonovalent COVID-19 vaccine\nThe vaccine may not protect everyone. WHO SHOULD NOT GET COMIRNATY (COVID-19 VACCINE, mRNA), THE\nPFIZER-BIONTECH COVID-19 VACCINE, OR THE PFIZER-BIONTECH COVID-19\nVACCINE, BIVALENT?","716":"November 10, 2021: North Dakota made updates to data previously submitted to CDC that resulted in an increase of\n3,433 doses administered. November 9, 2021: Ohio made updates to data previously submitted to CDC that resulted in a decrease of 99 doses\nadministered. November 4, 2021: Minnesota made updates to data previously submitted to CDC that resulted in an increase of\n136,589 doses administered. November 3, 2021: Maryland made updates to data previously submitted to CDC that resulted in a decrease of 5,975\ndoses administered.","2108":"You can receive a COVID-19 vaccine, including a booster shot, without any additional\ndocumentation from your healthcare provider. -\n-\n-\n\u2022\nCDC\u2019s v-safe After Vaccination Health Checker is a voluntary smartphone-based tool that provides quick and confidential\nhealth check-ins via text messages and web surveys so you can quickly and easily share with CDC how you or your\ndependent feel after getting a COVID-19 vaccine. If you enroll in v-safe and report that you are pregnant at the time of vaccination or after vaccination, CDC\u2019s v-safe COVID-\n19 Vaccine Pregnancy Registry staff* may contact you.","5162":"\uf3c0 ALL Travelers\nRECOMMENDED\nG t t t d ith i l t t 3 5 d ft i l\f10\/30\/22, 9:43 AM International Travel to and from the United States | CDC\nGet tested with a viral test 3-5 days after arrival. Find a U.S. COVID-19 testing location near you or use a self-test. If you already had COVID-19 within the past 90 days, see specific testing recommendations. Monitor yourself for COVID-19 symptoms. Follow additional guidance if you know you were exposed to a person with COVID-19. Follow all state, tribal, local and territorial recommendations or requirements after arrival.","1396":"What is the guidance for a use of the monovalent Novavax COVID-19 vaccine for a booster dose? \uf1aa\nPeople who are Moderately or Severely Immunocompromised\nYes. For COVID-19 vaccination guidance for people who are moderately or severely immunocompromised people, please\nrefer to:\nGuidance for COVID-19 vaccination for people who are moderately or severely immunocompromised\nCOVID-19 Vaccines for Moderately or Severely Immunocompromised People\nAre there special considerations for vaccinating people who are moderately or severely\nimmunocompromised? \uf1aa\nPeople can self-attest to their moderately or severely immunocompromised status and should be vaccinated according to\nthe schedule for people who are moderately or severely immunocompromised.","4749":"Space from the last WHO-EUL vaccine dose by at least 28\ndays. Administer a bivalent mRNA booster dose if eligible. *\nReceived a monovalent booster dose after completion of primary series Administer a bivalent mRNA booster dose if eligible. *\nTable B.3. Received a heterologous primary series or booster dose composed of doses of a COVID-19 vaccine listed for\nemergency use by WHO, at least one of which is not FDA-approved or FDA-authorized\nVaccination history Recommended actions\nReceived a complete primary series Do not repeat primary series. Administer a bivalent mRNA booster dose if eligible.","4593":"Keep the exhaust fans turned on for an hour after your visitors leave to help remove virus particles that might still\nbe in the air. [PNG - 225 KB]\nWith good ventilation, the concentration of virus particles in the air will be lower and they will leave your home\nfaster than with poor ventilation. \uf20a\n\u2022\n\u2022\nUse fans to improve air flow\nPlace a fan as close as possible to an open window blowing outside. This helps get rid of virus particles in your\nhome by blowing air outside. Even without an open window, fans can improve air flow. Point fans away from people.","9616":"Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nThe COVID-19 vaccine by Pfizer-BioNTech is approved by the FDA as a 2-dose primary series for active\nimmunization to prevent COVID-19 in persons ages 12 years and older. CDC is issuing these EUI to provide\ninformation about use of the COVID-19 vaccine by Pfizer-BioNTech for primary and\/or additional doses that\nextend beyond its FDA-approved labeling as described further under \u201cWho can receive the COVID-19 vaccine\nby Pfizer-BioNTech\u201d and \u201cWhat are the doses and intervals of the COVID-19 vaccine by Pfizer-BioNTech for\nprimary and\/or additional doses\u201d. What is COVID-19?","1718":"Preserve all records related to COVID-19 vaccine management for a minimum of three years, or longer as required\nby the agreement or law of the jurisdiction. Comply with CDC instructions and timelines for disposing of COVID-19 vaccine and diluent, including used doses. Find detailed information regarding COVID-19 Vaccine storage and handling requirements at CDC Vaccine Storage and\nHandling Toolkit. (https:\/\/vaers.hhs.gov\/reportevent.html )\nThe Vaccine Adverse Event Reporting System (VAERS) is a national early warning system to detect possible safety\nproblems in vaccines used in the United States. VAERS accepts and analyzes reports of adverse events (AEs) after a\nperson has received a vaccination.","8098":"\u0082 Other symptoms of monkeypox can include:\n\u008f Fever\n\u008f Chills\n\u008f Swollen lymph nodes\n\u008f Exhaustion\n\u008f Muscle aches and backache\n\u008f Headache\n\u008f Respiratory symptoms (e.g., sore throat, nasal congestion, or cough)\n\u0082 You may experience all or only a few symptoms\n\u008f Sometimes people have flu-like symptoms before the rash. \u008f Some people get a rash first, followed by other symptoms. \u008f Others only experience a rash.138\n\u0083 Are there any travel restrictions due to monkeypox? d\n\u0082 Recommendation for travelers:139\n\u008f If you have monkeypox symptoms or had close contact with someone who\nhas monkeypox, talk to your healthcare provider.","7402":"Based on the category of the exception, you may further be required to attest that:\n1. You will be tested with a COVID-19 viral test 3\u20135 days after arrival in the United States, unless you have documentation of\nhaving recovered from COVID-19 in the past 90 days;\n2. You will self-quarantine for a full 5 days, even if the test result to the post-arrival viral test is negative, unless you have\ndocumentation of having recovered from COVID-19 in the past 90 days; and\n3. You will self-isolate if the result of the post-arrival test is positive or if you develop COVID-19 symptoms.","2244":"COVID-19 vaccines used in the United States\ncontinue to protect against severe disease, hospitalization, and death from known circulating variants. They may not be as\neffective in preventing infection from these variants. CDC will continue to monitor vaccine effectiveness to see what impact, if\nany, variants have on how well COVID-19 vaccines work in real-world conditions. For More Information\nThe latest CDC data on COVID-19 vaccine effectiveness are summarized on the CDC COVID Data Tracker. Information on CDC\u2019s Monitoring COVID-19 Vaccine Effectiveness\nLast Updated June 28, 2022","5203":"CDC and FDA will use this information to guide recommendations on the safe use of COVID-19 vaccines. For you and others who experienced myocarditis after receiving an mRNA vaccine, scientists will be looking at health effects\nsuch as:\nChanges in your health, physical ability, or quality of life\nHow your heart recovers from myocarditis\nWhy is CDC contacting my healthcare provider? Having information on medications you take and your test results can provide a more complete picture of your health\nfollowing myocarditis. Your healthcare provider can provide this information, which is important as we try to understand\nmore about myocarditis after COVID-19 vaccination.","7888":"\u0083 Clarify the benefits of COVID-19 vaccines, including boosters, in preventing severe disease. \u0083 Work with community members and trusted messengers to create and disseminate messages that explain that some side\neffects are normal and expected. If a vaccinated individual gets COVID-19, vaccination will increase the chances that it is a\nmild case. \u0083 Develop and amplify messages explaining why vaccines are still important in the COVID-19 prevention response. \u0083 Disseminate messages about community-level risk and corresponding COVID-19 mitigation measures. \u0083 Encourage local health departments, public health experts, and healthcare workers to explain the absence of association\nbetween COVID-19 vaccines and monkeypox.","10146":"Current guidance can be found at:\nPost-vaccination observation periods\n15 minutes: Vaccination providers, particularly when vaccinating adolescents, should consider observing vaccine recipients for 15 minutes after\nvaccination because of the risk of syncope.","8499":"What should my\ntravel companions do? \uf1aa\nHow can I protect myself from COVID-19 when using different types of transportation? \uf1aa\f10\/30\/22, 9:43 AM Travel: Frequently Asked Questions and Answers | CDC\nAir Travel\nFor additional FAQs on the vaccine requirement before air travel to the U.S., visit Requirement for Proof of COVID-19\nVaccination for Air Passengers. Maintaining distance between yourself and others is often difficult on public transportation. People may not be able to\navoid crowding on airplanes, trains, or buses. Protect yourself from COVID-19 by staying up to date with your COVID-19 vaccines and by wearing a high-quality mask on\npublic transportation.","8890":"10\/30\/22, 9:21 AM Vaccinating Dialysis Patients and Healthcare Personnel | CDC\nVaccines & Immunizations\nVaccines & Immunizations\nVaccinating Dialysis Patients and Healthcare Personnel\nTake action to protect patients at high-risk in your jurisdiction\nCOVID-19 vaccines are effective at protecting people from getting sick. By allocating vaccines for outpatient dialysis patients\nand the healthcare personnel who care for them in your jurisdiction, you can protect patients who are at high risk,\ndisproportionately affected by COVID-19, or might suffer severe consequences if infected. How can jurisdictions support COVID-19 vaccination efforts for\ndialysis patients and healthcare personnel? Make sure you are aware of the dialysis clinics located in your jurisdiction.","5796":"Common side effects\nreported were mostly mild, but some people had side effects that affected their ability to do daily\nactivities. Cases of myocarditis and pericarditis have rarely been reported in some people. Cases have occurred\npredominantly in adolescents and young adult males within the first week after the second dose of vaccine. There is evidence from multiple sources that suggest a higher risk for myocarditis following Moderna\ncompared to Pfizer-BioNTech vaccination; however, it is not possible to directly compare the risk in people\nages 12\u201317 years.","3225":"Additionally, providers should consider observing people with the following medical histories for 30 minutes after COVID-19\nvaccination to monitor for allergic reactions:\nAllergy-related contraindication to a different type of COVID-19 vaccine\nTable of Contents \uf426\nPatient counseling\nPre-vaccination counseling\nPost-vaccination observation period\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nAllergy-related contraindication to a different type of COVID-19 vaccine\nNon-severe, immediate (onset within 4 hours) allergic reaction after a previous dose of COVID-19 vaccine\nAnaphylaxis after non-COVID-19 vaccines or injectable therapies\nSee also Contraindications and precautions.","2436":"Researchers found no significant changes in these sperm\ncharacteristics after vaccination. However, one study found that COVID-19 infection may be associated with a decline in fertility for men for up to\n60 days after infection. Fever from any illness has been associated with a short-term decrease in sperm production in healthy men. Although fever can be a side effect of COVID-19 vaccination, there is no current evidence that fever after COVID-\nvaccination affects sperm production. Fever is also a common symptom of COVID-19 infection. Safety Monitoring\nCOVID-19 vaccines are undergoing the most intense safety monitoring in U.S. history.","6149":"This information can provide signals of potential changes in vaccine effectiveness that can be further studied through more\nrobust, controlled vaccine effectiveness studies, which are ongoing at CDC. \uf294 CDC analyzes surveillance data by vaccination status to\nBetter understand patterns of COVID-19 among people who are vaccinated and unvaccinated. Identify signals of potential changes in vaccine effectiveness, which can be confirmed through more\nrobust studies.","1081":"They include:\n\u2022 \uf209\n\u2022 \uf209\n\uf209\nTreatment Who When How\nNirmatrelvir with Ritonavi\n(Paxlovid)\nAntiviral\n\uf209\nAdults; children ages 12\nyears and older\nStart as soon as possible;\nmust begin within 5 days\nof when symptoms start\nTaken at home by mouth\n(orally)\nRemdesivir (Veklury)\nAntiviral\n\uf209 Adults and children Start as soon as possible;\nmust begin within 7 days\nof when symptoms start\nIntravenous (IV) infusions\nat a healthcare facility for\n3 consecutive days\nBebtelovimab\nMonoclonal antibody\n\uf209 Adults; children ages 12\nyears and older\nStart as soon as possible;\nmust begin within 7 days\nof when symptoms start\nSingle IV injection\nMolnupiravir (Lagevrio)\nAntiviral\n\uf209 Adults Start as soon as possible;\nmust begin within 5 days\nof when symptoms start\nTaken at home by mouth\n(orally)\nSome treatments might have side effects or interact with other medications you are taking.","5863":"2 A non-FDA authorized or approved COVID-19 vaccine that is listed for emergency use by the World Health Organization, or is included in CDC\u2019s\nTechnical Instructions for Implementing Presidential Proclamation Advancing Safe Resumption of Global Travel During the COVID-19 Pandemic and\nCDC\u2019s Order, or that is a non-placebo part of a clinical trial within or outside the United States that is a WHO-EUL COVID-19 vaccine or a vaccine that is\nnot listed for emergency use by WHO but for which a U.S. data and safety monitoring board or equivalent has independently confirmed efficacy in the\nUnited States (hereinafter \u201cnon-FDA authorized or approved COVID-19 vaccines\u201d).","7279":"Vaccinations may not provide full\nimmunity to COVID-19 in people who are immunocompromised, and you should\ncontinue to maintain physical precautions to help prevent COVID-19. Your close\ncontacts should be vaccinated as appropriate. WHAT IF I AM PREGNANT OR BREASTFEEDING? If you are pregnant or breastfeeding, discuss your options with your healthcare\nprovider. WILL THESE VACCINES GIVE ME COVID-19? No. These vaccines do not contain SARS-CoV-2 and cannot give you COVID-19. KEEP YOUR VACCINATION CARD\nWhen you get your first COVID-19 vaccine, you will get a vaccination card. Remember\nto bring your card when you return.","1323":"However, FDA allows the formulation for either age group to be administered for certain age transitions. See Moderna\nCOVID-19 Vaccine for Children who Transition from a Younger to Older Age Group , Pfizer-BioNTech for Children who\nTransition from a Younger to Older Age Group , and the product-specific EUA for more information. What should be done if the incorrect vaccine formulation is administered based on a patient\u2019s\nage? \uf1aa\n\uf20c\n\uf20c \uf209\nIn general, all doses of the primary series should be with the same product.","5904":"\u2022 A second primary dose of the COVID-19 vaccine by Moderna (100 \u03bcg in 0.5 mL from red-capped\nmultidose vial) may be delayed by 3 months from symptom onset or positive test (if infection was\nasymptomatic) in persons ages 12 years and older who recently had SARS-CoV-2 infection\fModerna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 09\/02\/22;\n\u2022 A primary dose, including as an additional primary dose for those with certain immunocompromising\nconditions, of the COVID-19 vaccine by Moderna (100 \u03bcg in 0.5 mL from red-capped multidose vial)\nshould be administered intramuscularly to persons ages 12 years and older at least 28 days after\nprimary vaccination with certain non-FDA authorized or approved COVID-19 vaccines.","9055":"As the virus spreads, it may\nchange and may become harder to stop. Regardless of the variant, a surge in cases can impact healthcare resources\nEven if a variant causes less severe disease in general, an increase in the total number of cases could cause an increase in\nhospitalizations, put more strain on healthcare resources, and potentially lead to more deaths. Monitoring Variants\nCDC uses viral genomic surveillance to quickly identify and track COVID-19 variants, and acts upon these findings to best\nprotect the public\u2019s health. Some variants spread more easily and quickly than others, which may lead to more cases of\nCOVID-19.","5782":"Has the COVID-19 vaccine by Moderna been used before? Yes. Millions of people have received this vaccine in the United States since it became available starting\nDecember 18, 2020. Also, in clinical trials, approximately 15,400 people 18 ages years and older received at\nleast 1 dose of the vaccine and approximately 2,500 people ages 12\u201317 years received a primary series of\nthe vaccine. There have been some studies in people who received the COVID-19 vaccine by Moderna after\ncompleting a primary vaccination with a non-FDA authorized or approved COVID-19 vaccine or Janssen\nCOVID-19 Vaccine. What are the risks of the COVID-19 vaccine by Moderna?","6408":"Examples of medical conditions or treatments that may result in moderate to severe immunocompromise include but are not\nlimited to:\nActive treatment for solid tumor and hematologic malignancies\nHematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status\n(e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\nReceipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\nReceipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of\ntransplantation or taking immunosuppressive therapy)\nModerate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined\nimmunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)\nAdvanced or untreated HIV infection (people with HIV and CD4 cell counts less than 200\/mm3, history of an AIDS-\ndefining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)\nActive treatment with high-dose corticosteroids (i.e., 20 or more mg of prednisone or equivalent per day when\nadministered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs,\ncancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and\nother biologic agents that are immunosuppressive or immunomodulatory\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nHow to Protect Yourself\f10\/30\/22, 9:38 AM People Who Are Immunocompromised | CDC\nYou are up to date with your COVID-19 vaccines when you have received all doses in the primary series and all boosters\nrecommended for you, when eligible.","6989":"The Countermeasures Injury Compensation Program (CICP) is a federal program that may help pay for costs\nof medical care and other specific expenses of certain people who have been seriously injured by certain\nmedicines or vaccines, including this vaccine. Generally, a claim must be submitted to the CICP within one\n(1) year from the date of receiving the vaccine. To learn more about this program, visit www.hrsa.gov\/cicp\/\nor call 1-855-266-2427. How can I learn more? \u2022 Ask the vaccination provider. \u2022 Visit CDC at https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/index.html. \u2022 Visit FDA at https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-\nand-policy-framework\/emergency-use-authorization. \u2022 Contact your local or state public health department.","6711":"For more information on coping with a disaster or traumatic event, visit\n\u2022\n\u2022\f10\/30\/22, 9:39 AM People with Moderate to Severe Asthma | CDC\np g ,\nStress and Coping | COVID-19 | CDC\nCoping with a Disaster or Traumatic Event | CDC Emergency Preparedness & Response\nPatient resources\nEXHALE Guide for People With Asthma, Their Families, and Their Caregivers [1.5 MB, 8 pages]\nAllergy and Asthma Network\nAsthma and Allergy Foundation of America\nNational Environmental Education Foundation\nAdditional resources for schools and childcare programs\nFor information on administering asthma medication in schools, K-12 Schools and Childcare Programs\n-\n-\n\u2022 \uf20c\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022\nLast Updated Apr. 7, 2022","9175":"If someone is showing any of these signs, seek\nemergency medical care immediately:\nTrouble breathing\nPersistent pain or pressure in the chest\nNew confusion\nInability to wake or stay awake\nPale, gray, or blue-colored skin, lips, or nail beds, depending on skin tone\n*This list is not all possible symptoms. Please call your medical provider for any other symptoms that are\nsevere or concerning to you. Call 911 or call ahead to your local emergency facility: Notify the operator that you are seeking care for\nsomeone who has or may have COVID-19. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\uf33f Call ahead before visiting your doctor\nCall ahead.","6170":"10\/30\/22, 9:33 AM Monitoring COVID-19 Vaccine Effectiveness | CDC\nEspa\u00f1ol | Other Languages\nMonitoring COVID-19 Vaccine Effectiveness\nWhy CDC Tracks How Well the Vaccines Are Working\nCDC is reviewing this page to align with updated guidance. CDC continuously monitors vaccine effectiveness to understand how COVID-19 vaccines protect people in real-world\nconditions. Vaccine effectiveness is a measure of how well vaccination protects people against infection, symptomatic illness,\nhospitalization, and death.","5420":"In addition, the FDA decision is based on\nthe totality of scientific evidence available showing that the product may be effective to prevent\nCOVID-19 during the COVID-19 pandemic and that the known and potential benefits of the\nproduct outweigh the known and potential risks of the product. All of these criteria must be met to\nallow for the product to be used during the COVID-19 pandemic. The EUA for the Janssen COVID-19 Vaccine is in effect for the duration of the COVID-19\ndeclaration justifying emergency use of these products, unless terminated or revoked (after which\nthe products may no longer be used).","7911":"High risk Moderate risk Low risk Positive sentiment\n\u0083 May lead to vaccine\nrefusals and decreased\nuptake\n\u0083 Wide reach, pervasive\n\u0083 Potential to trigger\nhesitancy to vaccination\n\u0083 Moderate reach, modest\ndissemination\n\u0083 Concerning, but low risk\nto vaccine confidence\n\u0083 Limited reach, limited\ndissemination\n\u0083 Could increase vaccine\nconfidence, intent, or\nmotivation\n\u0083 Variable reach and\ndissemination\nHow has this theme\/idea changed over time (since last report or over the course of multiple reports)?","10013":"History of multisystem\ninflammatory\nsyndrome; either MIS-C\n(children) or MIS-A\n(adults)\n\u0083 Persons with a history of multisystem inflammatory syndrome; either MIS-C (children) or MIS-A\n(adults) is a precaution to receipt of COVID-19 vaccine. \u0083 Considerations when conducting a risk assessment for potential COVID-19 vaccination\n\u0083 Healthcare providers and health departments may also request a consultation from the Clinical\nImmunization Safety Assessment Project\nHistory of an immune-\nmediated syndrome\ncharacterized by\nthrombosis and\nthrombocytopenia,\nsuch as heparin-induced\nthrombocytopenia (HIT)\n\u0083 Janssen COVID-19 vaccine is not recommended for persons with a history of an episode of an\nimmune-mediated syndrome characterized by thrombosis and thrombocytopenia, such as\nspontaneous or classic HIT. \u0083 These persons should receive an mRNA (ie.","3815":"COVID-19 vaccination providers cannot\ncharge vaccine recipients for the vaccine (which is provided free to enrolled providers by the U.S. government) or for any\nadministration fees, copays, or coinsurance. COVID-19 vaccination providers cannot deny vaccination to anyone who\ndoes not have health coverage, is underinsured, or is out of network. COVID-19 vaccination providers cannot charge recipients for an office visit or any other fee if the only service provided is\na COVID-19 vaccination. Additional healthcare services can be provided at the same time and billed as appropriate. However, providers cannot require additional services for a person to receive a COVID-19 vaccine.","4942":"Pfizer-BioNTech COVID-19 Vaccine Fact Sheet for Healthcare Providers (fda.gov)\nModerna COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers (fda.gov)\nNovavax COVID-19 Vaccine, Adjuvanted | FDA\nJanssen COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers (fda.gov)\nEmergency Use Instructions for Healthcare Providers: Pfizer-BioNTech COVID-19 Vaccine for Primary, Additional,\nand\/or Booster Doses (cdc.gov)\nEmergency Use Instructions for Healthcare Providers: Moderna COVID-19 Vaccine for Primary, Additional, and\/or\nBooster Doses (cdc.gov)\nACIP General Best Practice Guidelines for Immunization\nInterim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination\n\uf209\n\uf209\n\uf209\n\uf209\n\uf20c\n\uf20c\nNew COVID-19 booster recommendations for people ages 5 years and older to receive 1 bivalent mRNA booster after\ncompletion of a monovalent primary series or previously received monovalent booster dose(s); these\nrecommendations replace all prior booster recommendations for this age group\nRecommendations for use of a bivalent Moderna booster dose in people ages 6\u201317 years\nRecommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 5\u201311 years\nReorganization and consolidation of the Interim Clinical Considerations to enhance usability.","1229":"\u200b\nSources: 2019 U.S. Census Estimates (states, D.C., Puerto Rico) and 2020 U.S. Census Estimates (territories excluding Puerto\nRico) used for population counts (ages 5 years and older), CDC Immunizations Data Lake. Data as of 6 AM ET Wednesday\nAI\/AN, Non-\nHispanic\nAsian, Non-\nHispanic\nBlack, Non-\nHispanic\nHispanic \/\nLatino\nMultiracial,\nNon-\nHispanic\nNHOPI,\nNon-\nHispanic\nWhite, Non-\nHispanic\nMale Female\n\u2022\n\u2022\n\u2022\n\uf2ff For Healthcare and Public Health\nCOVIDVaxView: Data about Vaccination Uptake and Confidence\nCOVID 19 Information for Health Departments\f10\/30\/22, 9:34 AM COVID-19 Vaccination Data in the United States | CDC\nCOVID-19 Information for Health Departments\nLast Updated Oct. 28, 2022","3284":"Overall, symptoms tended to be more frequent and severe following the\nsecond dose of vaccine and among adolescents and younger adults compared with older adults. Among children ages 6 months\u20134 years (i.e., Pfizer-BioNTech) or 6 months\u20135 years (i.e., Moderna), pain\/tenderness at the\ninjection site was the most frequent local reaction. The most common systemic symptom in older children was fatigue; in\nyounger children (ages 6\u201323 months), irritability\/crying and drowsiness\/sleepiness were most common. Most systemic\nsymptoms were mild to moderate in severity, typically began 1\u20132 days after vaccination, and resolved after 1\u20132 days.","1658":"COVID-19 Vaccine Administration Fees (updated 4\/8\/2022)\nAll organizations and providers participating in the CDC COVID-19 Vaccination Program:\n\uf209\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nmust administer COVID-19 Vaccine at no out-of-pocket cost to the recipient\nmay not deny anyone vaccination based on the vaccine recipient\u2019s coverage status or network status\nmay not charge an office visit or other fee if COVID-19 vaccination is the sole medical service provided\nmay not require additional medical services to receive COVID-19 vaccination\nmay seek appropriate reimbursement from a program or plan that covers COVID-19 Vaccine administration fees for\nthe vaccine recipient, such as:\nvaccine recipient\u2019s private insurance company\nMedicare or Medicaid reimbursement\nHRSA COVID-19 Coverage Assistance Fund for underinsured vaccine recipients (unavailable as of 11:59 ET on\nApril 5, 2022, due to lack of supplemental funding)\nHRSA COVID-19 Uninsured Program for non-insured vaccine recipients (unavailable as of 11:59 ET on April 5,\n2022, due to lack of supplemental funding)\nmay not seek any reimbursement, including through balance billing, from the vaccine recipient\nFor additional information on filing claims for reimbursement of COVID-19 vaccine administration fees, go to:\nCMS Guidance \u2013 https:\/\/www.cms.gov\/covidvax-provider\nCDC Statement on Exhaustion of Funding for the Uninsured Program and Coverage Assistance Fund\nDue to the lack of supplemental funding from Congress, HRSA stopped accepting claims for reimbursement of costs\nassociated with administering COVID-19 vaccines to uninsured and underinsured individuals as of 11:59 PM ET on April 5,\n2022.","4801":"It is acceptable to administer the repeat dose at an interval earlier than 8 weeks if\nthe interval is not sooner than the minimal interval noted in this table. The recommendations in the table below apply to all FDA-approved or FDA-authorized COVID-19 vaccines and all doses (i.e.,\nprimary series and booster dose), unless otherwise stated. Table D. Interim recommendations for COVID-19 vaccine administration errors and deviations\nType Administration error\/deviation Interim recommendation\nSite\/route Incorrect site (i.e., site other than the\ndeltoid muscle or vastus lateralis\nmuscle)\nDo not repeat dose.","1300":"For more information, see Interim Clinical Considerations for Use of JYNNEOS and ACAM2000 Vaccines during the 2022\nU.S. Monkeypox Outbreak and Coadministration of COVID-19 vaccines with other vaccines. Can COVID-19 vaccines be administered at the same time as an orthopoxvirus (monkeypox)\nvaccine? \uf1aa\nYes. COVID-19 vaccination is recommended for everyone ages 6 months and older, including people with underlying\nmedical conditions. COVID-19 vaccines are especially important for people with underlying medical conditions associated\nwith higher risk for severe COVID-19. Can I vaccinate patients with underlying medical conditions? \uf1aa\nAs with other vaccines, you can vaccinate patients with a mild illness.","568":"October 13, 2022: California made updates to data previously submitted to CDC that resulted in a net increase of\n3,409 administered doses. October 6, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of\n212,852 administered doses. September 29, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of\n234,224 administered doses. August 31, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 38,447\nadministered doses.","8930":"10\/30\/22, 9:32 AM Vaccine Adverse Event Reporting System (VAERS) | CDC\nEspa\u00f1ol | Other Languages\nVaccine Adverse Event Reporting System (VAERS)\nHow Reports Come into VAERS\nThere are two ways to report an adverse event to VAERS: report online or report using a writable pdf form. If you need\nfurther assistance with reporting to VAERS, please email info@VAERS.org or call 1-800-822-7967. For healthcare providers \u2013 Under Emergency Use Authorization, FDA requires healthcare professionals to report to VAERS\ncertain adverse events that occur after COVID-19 vaccination. CDC also encourages reporting of any medically important\nadverse event even if it isn\u2019t clear if the vaccine caused the health problem.","2878":"COVID-19 vaccine products currently approved or authorized in the United States*\nModerna\nAge indication Vaccine composition Vaccine vial cap color Label border color Dilution required Dose Injection volume\nPrimary series vaccination\n6 months\u20135 years Monovalent Dark blue Magenta No 25 \u00b5g 0.25 mL\n6\u201311 years\u2020 Monovalent Dark blue Purple No 50 \u00b5g 0.5 mL\n12 years and older Monovalent Red Light blue No 100 \u00b5g 0.5 mL\nBooster vaccination\n6\u201311 years Bivalent Dark blue Gray No 25 \u00b5g 0.25 mL\n12 years and older Bivalent Dark blue Gray No 50 \u00b5g 0.5 mL\nNovavax\nAge indication Vaccine composition Vaccine vial cap color Label border color Dilution required Dose Injection volume\nPrimary series vaccination\n12 years and older Monovalent Royal blue No color No 5 \u00b5g rS and\n50 \u00b5g of Matrix-M\u2122 adjuvant\nBooster vaccination\n18 years and older Monovalent Royal blue No color No 5 \u00b5g rS and\n50 \u00b5g of Matrix-M\u2122 adjuvant\nPfizer-BioNTech\nAge indication Vaccine composition Vaccine vial cap color Label border color Dilution required Dose Injection volume\nPrimary series vaccination\n6 months\u20134 years\u2021 Monovalent Maroon Maroon Yes 3 \u00b5g 0.2 mL\n5\u201311 years Monovalent Orange Orange Yes 10 \u00b5g 0.2 mL\n12 years and older Monovalent Gray Gray No 30 \u00b5g 0.3 mL\nBooster vaccination\n5\u201311 years Bivalent Orange Orange Yes 10 \u00b5g 0.2 mL\n12 years and older Bivalent Gray Gray No 30 \u00b5g 0.3 mL\nJanssen\nAge indication Vaccine composition Vaccine vial cap color Label border color Dilution required Dose Injection volume\nPrimary series vaccination\n18 years and older Monovalent Blue No color No 5\u00d71010 viral particles 0.5 mL\nBooster vaccination\n18 years and older Monovalent Blue No color No 5\u00d71010 viral particles 0.5 mL\nAbbreviations: rS = recombinant spike protein\n*Illustrations of the different vaccine vial cap and label border colors are available for Moderna and Pfizer-BioNTech COVID-19 vaccines.","1213":"In the snapshot below, CDC provides administration data on the\npercentage and number of people with an updated (bivalent) booster dose by age, sex, and racial and ethnic groups in the\nUnited States. Following these releases, over several weeks, COVID Data Tracker will add bivalent booster data to all vaccination sites,\nincluding the addition of demographic data trends (planned for release in early November 2022). Once these data go live on\nCOVID Data Tracker, the snapshot will be retired.","3834":"Visit Training and\nEducation for COVID-19 Vaccination for training information and core competencies for healthcare professionals. At a\nminimum, CDC recommends all providers complete the training module for the vaccine(s) they will be administering. The\ntraining modules can be found at COVID-19 Vaccine Training Modules. Additional vaccine preparation and administration\nresources can be found on CDC\u2019s web pages for each vaccine product at U.S. COVID-19 Vaccine Product Information. Your\nstate, local, or jurisdictional immunization program may also have training requirements. Providers who are enrolled in the VFC program may already have completed some of the training recommended to\nbecome a COVID-19 vaccination provider.","5889":"\u2022 For certain moderately or severely immunocompromised persons:\no\no\no\nAges 12 years and older who received primary vaccination with certain non-FDA authorized or\napproved COVID-19 vaccines should receive an additional primary dose of the COVID-19\nvaccine by Moderna. Ages 18 years and older who received primary vaccination with the Janssen COVID-19 Vaccine\nshould receive an additional dose with the COVID-19 vaccine by Moderna. Ages 12 years and older who received certain therapies (indicated below) and received\nprimary dose(s) of COVID-19 vaccine prior to or during treatment should be revaccinated with\nthe COVID-19 vaccine by Moderna for any doses received before or during treatment.","5933":"The EUI apply to the FDA-approved formulation of the COVID-19 vaccine by Moderna (supplied in a red-capped\nmultidose vial containing 5.5 or 7.5 mL of vaccine). The formulation supplied in a red-capped multidose vial is\nthe same formulation that is FDA-authorized under EUA and FDA-licensed under BLA on January 31, 2022. This\nformulation provides primary doses (100 \u03bcg in 0.5 mL) and booster doses (50 \u03bcg in 0.25 mL). FDA has\nexplained that the FDA-approved Spikevax and the EUA-authorized Moderna COVID-19 Vaccine supplied in\nred-capped multidose vials have the same formulation and can be used interchangeably without presenting\nany safety or effectiveness concerns.","10079":"\u0083 Persons, particularly adolescent or young adult males, might consider waiting 4 weeks after orthopoxvirus (monkeypox) vaccination (either\nJYNNEOS or ACAM2000) before receiving a Moderna, Novavax, or Pfizer-BioNtech COVID-19 vaccine because of the observed risk for myocarditis\nand\/or pericarditis after JYNNEOS. \u0083 Administer each injection in a different injection site. \u2020 See Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States at: www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html#recommendations for detailed\nguidance. \u2021 For booster vaccination, homologous or heterologous mRNA booster is recommended.","6000":"Small studies in solid organ transplant recipients in Toulouse,\nStrasbourg, and Baltimore demonstrate immunogenicity of a 4th mRNA dose when administered 1\u20132 months\nafter the 3rd dose (Kamar et al., 2021; Benotmane et al., preprint; Alejo et al., 2021). Multiple studies,\nincluding COV-BOOST and the NIH mix-and-match study demonstrated safety and immunogenicity of a booster\ndose in the general population when administered at intervals as short as 3 months following a 2-dose primary\nseries (Munro et al., 2021; Atmar et al., preprint). Finally, multiple countries have implemented booster doses\nat least 3 months after primary vaccination in the general population (e.g., UK, Germany, Netherlands).","9622":"Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the novel coronavirus, SARS-CoV-2,\nthat emerged in late 2019. It is predominantly a respiratory illness that can affect other organs. People with\nSARS-CoV-2 infection have reported a wide range of symptoms, ranging from no symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include fever or chills, cough,\nshortness of breath, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat,\ncongestion or runny nose, nausea or vomiting, and diarrhea. Who can receive the COVID-19 vaccine by Pfizer-BioNTech?","3381":"People who previously received antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part\nof COVID-19 treatment, post-exposure prophylaxis, or pre-exposure prophylaxis can be vaccinated at any time; COVID-19\nvaccination does not need to be delayed following receipt of monoclonal antibodies or convalescent plasma. Although some\nreduction in vaccine-induced antibody titers was observed in people who previously received antibody products, the\nclinical significance of this reduction is unknown, and the balance of benefits vs. risks favors proceeding with vaccination even\nconsidering the possibility of diminished vaccine effectiveness in this situation.","503":"The issue has since\nbeen resolved and totals for April 14, 2021 accurately reflect the total doses administered. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:35 AM Archive of COVID-19 Vaccination Data Updates | CDC\nOn April 6, 2021, improvements in reporting vaccine recipient race\/ethnicity data to CDC resulted in an increase in the\nnumber of people for whom race\/ethnicity data are available. These improvements will continue to allow for better\nrace\/ethnicity data reporting. Due to a data synchronization error between April 3 and 5, 2021, the daily count of doses reporting \u201cUnknown Age\u201d in\nthe COVID-19 Case Surveillance Public Use Data incorrectly appeared higher than expected.","3154":"On a case-by-case basis, providers caring for moderately or severely immunocompromised patients may administer\nModerna, Novavax, and Pfizer-BioNTech COVID-19 vaccines outside of the FDA and CDC dosing intervals when, based on their\nclinical judgment, the benefits of vaccination are deemed to outweigh the potential and unknown risks for the recipient. However, providers should not routinely administer doses of COVID-19 vaccine beyond those recommended in this guidance. The utility of serologic testing , cellular immune testing, or B-cell quantification to assess immune response to vaccination\nand guide clinical care has not been established.","8978":"What to Expect If You Participate in the Registry\nPhone Call Health Check-ins\nAbt Associates , the registry staff contracted by CDC, will contact people by phone to invite them to participate in the\nregistry. People who choose to enroll in the registry will receive calls from Abt Associates several times throughout their pregnancy for\nadditional health check-ins. During these check-ins, they will be asked questions about their pregnancy and medical history. After delivery, participants might be contacted for more information when their babies are about three months old.","1291":"Can COVID-19 vaccines and other vaccines be administered at the same time? \uf1aa\nPeople who previously received COVID-19 vaccination (i.e. Moderna, Novavax, or Pfizer-BioNTech) may be given\northopoxvirus vaccine (either JYNNEOS or ACAM2000) without a minimum interval between vaccinations. People who previously received orthopoxvirus vaccination (either JYNNEOS or ACAM2000), particularly adolescent or\nyoung adult males, might consider waiting 4 weeks before receiving a COVID-19 vaccine (i.e. Moderna, Novavax, or Pfizer-\nBioNTech) because of the observed risk for myocarditis and pericarditis after receipt of ACAM2000 orthopoxvirus vaccine\nand COVID-19 vaccines (i.e. Moderna, Novavax, or Pfizer-BioNTech) and the unknown risk for myocarditis and pericarditis\nafter JYNNEOS administration.","1915":"The v-safe COVID-19 Vaccine Pregnancy Registry is a registry to collect additional\nhealth information from v-safe participants who report being pregnant at the time of vaccination or a positive pregnancy\ntest after vaccination. This information helps CDC monitor the safety of COVID-19 vaccines in people who are pregnant. CDC: Vaccine Safety Datalink (VSD) \u2014 VSD is a network of nine integrated healthcare organizations across the United\nStates that monitor and evaluate the safety of vaccines. The system is also used to help determine whether possible side\neffects identified using VAERS are actually related to vaccination.","9776":"\u2022 In an unpublished (preprint) retrospective population-based cohort using Canada\u2019s provincial vaccine\nregistry and passive vaccine safety surveillance between December 2020 and September 2021,\nreported rates of myocarditis\/pericarditis among all persons were greater with shorter intervals (3\u20134\nweeks) between dose 1 and dose 2 compared to extended intervals (\u22658 weeks) for both Moderna\n(Buchan, preprint). \u2022 The lower reported rates of myocarditis\/pericarditis among persons receiving their second vaccine\ndose at extended intervals (\u22658 weeks) was observed across schedules of mRNA vaccine primary series\n(i.e., Pfizer-Pfizer, Moderna-Moderna, Pfizer-Moderna) (Buchan, preprint).","902":"People who have come into close contact with someone with COVID-19 should be tested to check for infection:\nIf you develop symptoms, get tested immediately and isolate until you receive your test results. If you test\npositive, follow isolation recommendations. If you do not develop symptoms, get tested at least 5 days after you last had close contact with someone with\nCOVID-19. Self-tests are one of several options for testing for the virus that causes COVID-19 and may be more\nconvenient than laboratory-based tests and point-of-care tests. Ask your healthcare provider or your local\nhealth department if you need help interpreting your test results.","9797":"Vaccination continues to be recommended regardless of the option for delaying vaccination after infection. Numerous immunologic studies and a growing number of epidemiologic studies have shown that vaccinating\npreviously infected individuals significantly enhances their immune response and effectively reduces the risk of\nsubsequent infection, including in the setting of increased circulation of more infectious variants (CDC, 2021). What is the available supporting evidence for revaccination of people who received COVID-19 vaccine during\nB-cell-depleting therapy administered over a limited period?","1447":"Current infection: Defer vaccination of people with known current SARS-CoV-2 infection until the person has recovered\nfrom acute illness (if the person has symptoms) and until criteria have been met for them to discontinue isolation. Laboratory testing is not recommended for the purpose of vaccine decision-making. For more information, see COVID-19 vaccination and SARS-CoV-2 infection. Can people with prior or current SARS-CoV-2 infection receive a COVID-19 vaccine? \uf1aa\nConsiderations Involving Pregnancy, Lactation, and Fertility\nYes. CDC recommends COVID-19 vaccination for all people who are pregnant, breastfeeding, recently pregnant, trying to\nget pregnant now, or who might become pregnant in the future.","4484":"If possible, avoid being around a person who has COVID-19 until they can safely end home isolation. Sometimes it may not be practical for you to stay away from a person who has COVID-19 or you may want to help take\ncare of them. In those situations, use as many prevention strategies as you can, such as practicing hand hygiene,\nconsistently and correctly wearing a high-quality mask, improving ventilation, and keeping your distance, when possible,\nfrom the person who is sick or who tested positive.","7687":"They are:\nAnaphylaxis\nAnaphylaxis is a severe type of allergic reaction with symptoms such as hives, difficulty breathing, low blood pressure, or\nsignificant swelling of the tongue or lips. Anaphylaxis after COVID-19 vaccination is rare. Learn more about COVID-19 vaccines\nand allergic reactions, including anaphylaxis. Thrombosis with Thrombocytopenia Syndrome (TTS)\nThrombosis with thrombocytopenia syndrome (TTS) is a rare but serious adverse event that causes blood clots or issues with\nclotting. TTS after COVID-19 vaccination is rare. Learn more about COVID-19 vaccines and adverse events, including TTS. Myocarditis and Pericarditis\nMyocarditis is inflammation of the heart muscle, and pericarditis is inflammation of the outer lining of the heart.","0":"cdc.gov\/coronavirus\nWhat to Expect after Getting a COVID-19 Vaccine\nThe COVID-19 shot may cause side effects in some people. Side effects should go away in a few days. On the arm where you got the shot:\n\u2022 Pain\n\u2022 Redness\n\u2022 Swelling\nIf you are sore where you got the shot:\n\u2022 Apply a clean, cool, wet washcloth over the area\n\u2022 Use or move your arm gently\nIf you have a fever:\n\u2022 Drink a lot of water\n\u2022 Get plenty of rest\n\u2022 Dress lightly\nIf you have pain, headache, or fever, ask a healthcare provider (or facility\nstaff) if you can have medicine.","4318":"Each approved and authorized COVID-19 vaccine has its own fact sheet that contains information to\nhelp you understand the risks and benefits of that vaccine. There is no charge for your COVID-19 vaccine. Your COVID-19 vaccine is free. COVID-19 vaccines are paid for with\ntaxpayer dollars and are given free of charge to all people living in the United States, regardless of health insurance or\nimmigration status. If anyone asks you to pay for a COVID-19 vaccine, it\u2019s a scam . After Getting a COVID-19 Vaccine\nStay on site to be monitored for at least 15 minutes.","8249":"Children under age 5 years are not recommended\nto receive a booster at this time. Children age 5 years old are only currently recommended to receive the updated (bivalent) Pfizer-BioNTech booster, and\nthey can get this booster whether they received the Pfizer-BioNTech or Moderna primary series. Children age 5 years old can no longer get an original (monovalent) mRNA (Pfizer-BioNTech or Moderna) booster. Children age 5 years old\n\uf1aa\nPeople ages 6 years and older can get a different product for their updated (bivalent) booster than they received for their\nprimary series or last booster.","7781":"FDA requires healthcare providers to report any death after\nCOVID-19 vaccination to VAERS even if it\u2019s unclear whether the vaccine was the cause Reports of adverse events to\n\u2022\n-\n\u2022\n\uf209\n\u2022\n\uf209\n\u2022 \uf20c\n-\n-\n\uf209\n-\n-\n-\n-\f10\/30\/22, 9:32 AM Selected Adverse Events Reported after COVID-19 Vaccination | CDC\nCOVID-19 vaccination to VAERS, even if it s unclear whether the vaccine was the cause. Reports of adverse events to\nVAERS following vaccination, including deaths, do not necessarily mean that a vaccine caused a health problem. More than 632 million doses of COVID-19 vaccines were administered in the United States from December 14, 2020,\nthrough October 19, 2022.","2234":"For the best\nprotection, everyone 6 months and older is recommended to stay up to date with their COVID-19 vaccines, which includes\ngetting boosters if eligible. Vaccine Breakthrough Infections\nCOVID-19 vaccines are effective at preventing severe disease, hospitalization, and death. However, since vaccines are not\n100% effective at preventing infection, some people who are up to date with the recommended vaccines\u202fwill still get COVID-\n19. This is called a\u202fbreakthrough infection. When people who are vaccinated develop symptoms of COVID-19, they tend to\nexperience less severe symptoms than people who are unvaccinated.","1653":"Communications with COVID-19 vaccine recipients involving the store component of any pharmacy or other provider\nparticipating in the CDC COVID-19 Vaccination Program are considered prohibited commercial marketing. For example,\ntext, e-mail, mail, or other communications to COVID-19 vaccine recipients about products on sale in the store are\nprohibited as commercial marketing. COVID-19 vaccination registration information and vaccine administration data collected in the course of participation in\nthe CDC COVID-19 Vaccination Program cannot be sold, for direct or indirect remuneration, even with permission of the\nvaccine recipient.","5316":"FDA has authorized the emergency use of the Janssen COVID-19 Vaccine in individuals 18 years\nof age and older for whom other FDA-authorized or approved COVID-19 vaccines are not\naccessible or clinically appropriate, and in individuals 18 years of age and older who elect to\nreceive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19\nvaccine. WHO SHOULD NOT GET THE JANSSEN COVID-19 VACCINE? You should not get the Janssen COVID-19 Vaccine if you:\n\u2022 had a severe allergic reaction after a previous dose of this vaccine. \u2022 had a severe allergic reaction to any ingredient of this vaccine.","1354":"\uf1aa\n\uf209\nNo, the monovalent mRNA vaccines (i.e., Moderna or Pfizer-BioNTech) are no longer authorized for use as a booster dose;\nthey can only be used for the primary series. A bivalent mRNA vaccine is recommended for the booster dose. If a patient accidently received a monovalent mRNA vaccine for the booster dose, the dose generally does not need to be\nrepeated. However, providers may administer 1 bivalent booster dose as a repeat dose based on clinical judgment and\npatient preference. The repeat dose should be administered at least 2 months after the monovalent booster dose. For more information, see vaccine administration errors and deviations.","1078":"They include:\n\u2022 \uf209\n\u2022 \uf209\n\uf209\nTreatment Who When How\nNirmatrelvir with Ritonavi\n(Paxlovid)\nAntiviral\n\uf209\nAdults; children ages 12\nyears and older\nStart as soon as possible;\nmust begin within 5 days\nof when symptoms start\nTaken at home by mouth\n(orally)\nRemdesivir (Veklury)\nAntiviral\n\uf209 Adults and children Start as soon as possible;\nmust begin within 7 days\nof when symptoms start\nIntravenous (IV) infusions\nat a healthcare facility for\n3 consecutive days\nBebtelovimab\nMonoclonal antibody\n\uf209 Adults; children ages 12\nyears and older\nStart as soon as possible;\nmust begin within 7 days\nof when symptoms start\nSingle IV injection\nMolnupiravir (Lagevrio)\nAntiviral\n\uf209 Adults Start as soon as possible;\nmust begin within 5 days\nof when symptoms start\nTaken at home by mouth\n(orally)\nSome treatments might have side effects or interact with other medications you are taking.","6105":"Three-dose mRNA-1273 vaccination schedule: sufficient\nantibody response in majority of immunocompromised hematology patients. medRxiv. 2022a. Preprint. doi:\nHaggenburg S, Lissenberg-Witte B.I, van Binnendijk RS., et al. Quantitative analysis of mRNA-1273 COVID-19\nvaccination response in immunocompromised adult hematology patients. Blood Advances. 2022;6(5):1537-\n1546. Moderna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 09\/02\/22;\nJoint Committee on Vaccination and Immunisation (JCVI). JCVI statement regarding a COVID-19 booster\nvaccine programme for winter 2021 to 2022. London (United Kingdom): Department of Health & Social Care;\nprogramme-for-winter-2021-to-2022. Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination. London\n(United Kingdom): Department of Health & Social Care; 1 Sept 2021.\nimmunosuppressed-jcvi-advice\/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-\nprimary-dose-vaccination.","7797":"\u2022\n\u2022\n\u2022\n\u2022\n\uf6e5 When To Take an At-Home COVID-19 Test\nTest Yourself If\u2026 Timing\nYou have any COVID-19 symptoms Immediately\nYou were exposed to someone with COVID-19 At least 5 days after your exposure\nIf you test negative for COVID-19, consider testing\nagain 1 to 2 days after your first test\nYou are going to an indoor event or a gathering Immediately before the gathering, or as close to\nthe time of the event as possible\nThis is especially important before gathering with\nindividuals at risk of severe disease, older adults,\nthose who are immunocompromised, or people\nwho are not up to date on their COVID-19\nvaccines, including children who cannot get\nvaccinated yet.","4055":"Data show that an mRNA booster increases the immune response, which improves protection against getting a serious\nCOVID-19 infection. CDC recommends COVID-19 vaccines for everyone ages 6 months and older, and boosters for everyone 5 years and\nolder, if eligible. Learn more about COVID-19 vaccine recommendations, including recommendations for people who are moderately or\nseverely immunocompromised. Use CDC\u2019s COVID-19 Booster Tool to learn if and when you can get boosters to stay up to\ndate with your COVID-19 vaccines. Do I need a COVID-19 vaccine booster? \uf1aa\n\uf20c\nYes. COVID-19 vaccines are working well to prevent severe illness, hospitalization, and death.","5985":"Effectiveness of a Moderna COVID-19 Vaccine (0.25 mL [50 \u03bcg of mRNA]) booster dose in individuals who\ncompleted primary vaccination with another authorized or approved COVID-19 vaccine (homologous or\nheterologous booster dose) is inferred from immunogenicity data supporting effectiveness of a Moderna\nCOVID-19 Vaccine (0.25 mL [50 \u03bcg of mRNA]) booster dose administered following completion of a Moderna\nCOVID-19 Vaccine primary series and from immunogenicity data from an independent Phase 1\/2 open-label\nclinical trial (NCT04889209) conducted in the United States that evaluated a booster dose (0.5 mL [100 \u03bcg of\nmRNA]) of the Moderna COVID-19 Vaccine.","3616":"County of Residence\nCDC determines county of residence by matching the county Federal Information Processing Standard State (FIPS) code\nto the state as submitted in the raw data provided to CDC. Last Updated Aug. 17, 2022","909":"Caregivers should wear a mask when they are within 6 feet of your newborn for the entire time you are in isolation, and\nduring their own quarantine after you complete your isolation. If a healthy caregiver is not available, you can care for your newborn if you are well enough. Wash your hands with soap and water for at least 20 seconds before touching for your newborn. If soap and water are\nnot available, use a hand sanitizer with at least 60% alcohol. Wear a mask when within 6 feet of your newborn and other people during your entire isolation period.","2019":"Reporting rates were around 70 cases per million doses in males ages 12 through 15 years and 105 cases per million\ndoses in males ages 16 through 17 years. Febrile seizures were rare in COVID-19 vaccine clinical trials for young children and occurred at similar rates for both Pfizer\nand Moderna COVID-19 vaccines. Learn more about febrile seizures and vaccines. A severe allergic reaction,\u202flike anaphylaxis, may happen\u202fafter any vaccination, including COVID-19 vaccination, but this is\nrare. If your child\u202fexperiences a severe allergic reaction\u202fafter getting a COVID-19 vaccine, vaccine providers can rapidly provide\ncare and call for emergency medical services, if needed.","5495":"Studies have shown that some groups of people may be affected more by post-COVID conditions. These are examples\nand not a comprehensive list of people or groups who might be more at risk than other groups for developing post-COVID\nconditions:\nSome people may be more at risk for developing post-COVID conditions (or long COVID). 10\/30\/22, 9:42 AM Long COVID or Post-COVID Conditions | CDC\nPeople who have experienced more severe COVID-19 illness, especially those who were hospitalized or needed intensive\ncare. People who had underlying health conditions prior to COVID-19. People who did not get a COVID-19 vaccine.","5261":"Remember to wear a high-quality mask when indoors around others at home and in public. Do not go places where you are unable to wear a mask until you are able to discontinue masking (see below). For travel guidance, see CDC\u2019s Travel webpage. Consult your doctor before ending isolation. Ending isolation without a viral test may not be an\noption for you. \u2022\n\u2022\nIf you are unsure if your symptoms are moderate or severe or if you have a weakened immune system, talk to a\nhealthcare provider for further guidance.","2973":"Use of the monovalent Novavax booster dose in limited situations\nPeople ages 18 years and older who completed primary vaccination using any COVID-19 vaccine and have not received\nany previous booster dose(s) may receive a monovalent Novavax booster dose at least 6 months after completion of the\nprimary series if they are unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available) or\nunwilling to receive an mRNA vaccine and would otherwise not receive a booster dose. Table 2.","4001":"Vaccination data in CDC\u2019s COVID Data Tracker are updated weekly on\nThursday between 1:30 pm and 8:00 pm ET. On federal holidays, updates will occur the following day. Data can be updated on different schedules and reflect data \u201cas of\u201d different dates or times of day. There can be a\ndelay between the time a vaccination record appears in a jurisdictional or federal system and when it is received\nby CDC. COVID Data Tracker\u2019s vaccination data typically have a lag time from vaccination data shown on a state\u2019s\nwebsite. The amount of lag time varies for each state.","4531":"Gaps can also occur if your N95 is too big, too small, or it was not put on correctly. To check for gaps, gently place your hands on the N95,\ncovering as much of it as possible, then breathe out. If\nyou feel air leaking out from the edges of the N95, or if\nIf you cannot get a tight seal, try a different size or style.","5997":"Small studies in solid organ transplant recipients in Toulouse,\nStrasbourg, and Baltimore demonstrate immunogenicity of a 4th mRNA dose when administered 1\u20132 months\nafter the 3rd dose (Kamar et al., 2021; Benotmane et al., preprint; Alejo et al., 2021). Multiple studies,\nincluding COV-BOOST and the NIH mix-and-match study demonstrated safety and immunogenicity of a booster\ndose in the general population when administered at intervals as short as 3 months following a 2-dose primary\nseries (Munro et al., 2021; Atmar et al., preprint). Finally, multiple countries have implemented booster doses\nat least 3 months after primary vaccination in the general population (e.g., UK, Germany, Netherlands).","6341":"CDC continues to work to determine how common\nthese long-term effects are, who is most likely to get them, how long the symptoms typically last, and whether symptoms\neventually resolve. During Your Appointment\nOn the day of your appointment, try to arrive a little early or, for telemedicine appointments, call in or log on a few\nminutes ahead of the appointment. If your provider is running late, you can use the time to make sure your paperwork or\nforms have been filled out and the front desk has your correct information.","119":"These cases include farmed mink in Europe and the United States, white-tailed deer in Canada, pet hamsters in Hong\nKong, and a cat in Thailand. In most of these cases, the animals were known to be first infected by a person who had COVID-\n19. It\u2019s important to remember that people are much more likely to get COVID-19 from other people than from animals. There is\nno need to euthanize or otherwise harm animals infected with SARS-CoV-2. There is a possibility that the virus could infect animals, mutate, and a new strain could spread back to people and then\namong people (called spillback).","2144":"Which COVID-19 vaccine should pregnant people receive? \uf1aa\nChildren, teens, and adults, including pregnant people, may get a COVID-19 vaccine and other vaccines, including a flu\nvaccine, at the same time. Can pregnant people get a COVID-19 vaccine at the same time as other vaccines? \uf1aa\nIF YOU ARE PREGNANT AND HAVE QUESTIONS ABOUT COVID-19 VACCINE\nIf you would like to speak to someone about COVID-19 vaccination during pregnancy, you can contact MotherToBaby\nwhose experts are available to answer questions in English or Spanish by phone or chat. This service is free and\nconfidential.","8897":"Work with dialysis clinic leaders to establish the number of doses needed to vaccinate patients and healthcare personnel\nand determine a timeline for allocating these doses. Why is it important to vaccinate dialysis patients? The median age of patients on dialysis is 62 years. Due to age and health status, dialysis patients are at high risk for\nserious illness and death related to COVID-19; people on dialysis who get COVID-19 have a 50% hospitalization rate and a\n20%\u201330% mortality rate. Vaccinating this population addresses a health equity issue.","1858":"For information for the general public,\nplease see Monitoring Vaccine Effectiveness\nProspective Cohort\n\uf1aa\nHEROES\nArizona Healthcare, Emergency Response, and Other Essential Workers Surveillance (AZ Heroes) Study\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Healthcare providers\/first responders\/essential and other frontline workers\nParticipating Sites\nUniversity of Arizona, Tucson, AZ\nMel and Enid Zuckerman College of Public Health, Tucson, AZ\n\uf20c\nRECOVER\nResearch on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER)\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Healthcare providers\/first responders\/essential and other frontline workers\nParticipating Sites\nBaylor Scott and White Health, Temple, TX\n\uf209\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nKaiser Permanente Northwest, Portland, OR\nSt. Luke\u2019s Hospital, Duluth, MN\nUniversity of Arizona, Tucson, AZ\nUniversity of Miami, Miami, FL\nUniversity of Utah, Salt Lake City, UT\nPROTECT\nPediatric Research Observing Trends and Exposures in COVID-19 Timelines\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Children aged <18 years\nParticipating Sites\nBaylor Scott and White Health, Temple, TX\nUniversity of Arizona, Tucson, AZ\nUniversity of Miami, Miami, FL\nUniversity of Utah, Salt Lake City, UT\nCASCADIA\nOutcome: Symptomatic and asymptomatic SARS-CoV-2 infections\nPopulation: Children aged <18 years and adults aged <50 years\nParticipating Sites\nKaiser Permanente Northwest, Portland, OR\nUniversity of Washington, Seattle, WA\nHousehold Transmission Studies\n\uf1aa\nHEROES-RECOVER Household Transmission Study\nResearch on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER) SARS-CoV-2 Household\nTransmission Study\nOutcome: Transmission in households of healthcare, first responder, and essential and other frontline workers with\nPopulation: Households of infected healthcare providers\/first responders\/essential and other frontline workers\nParticipating Sites\nBaylor Scott and White Health, Temple, TX\nKaiser Permanente Northwest, Portland, OR\nSt. Luke\u2019s Hospital, St. Louis, MO\nUniversity of Arizona, Tucson, AZ\nUniversity of Miami, Miami, FL\nUniversity of Utah, Salt Lake City, UT\n\uf20c\f10\/30\/22, 9:20 AM COVID-19 Vaccine Effectiveness Research | CDC\nUniversity of Utah, Salt Lake City, UT\nRVTN (Respiratory Virus Transmission Network)\nRVTN \u2013 Sentinel\nSentinel Protocol\nOutcome: Household transmission among community members confirmed with SARS-CoV-2\nPopulation: Households of community members with positive SARS-CoV-2 tests recruited from sentinel testing sites\nParticipating Sites\nUniversity of Arizona, Tucson, AZ\nStanford University, Stanford, CA\nUniversity of Colorado, Denver, CO\nColumbia University, New York City, NY\nUniversity of North Carolina, Chapel Hill, NC\nVanderbilt University Medical Center, Nashville, TN\nMarshfield Clinic Research Institute, Marshfield, WI\n\uf20c\nRVTN \u2013 National\nNational Approach (also known as \u201cTrack COVID at Home \u201d).","8510":"Everyone aged 2 years or older, regardless of vaccination status, should wear a high-quality mask\nor respirator in indoor areas of public transportation (such as airplanes, trains, buses, ferries) and transportation hubs\n(such as airports, stations, and seaports), especially in locations that are crowded or poorly ventilated such as airport\njetways. All travelers should take steps to protect themselves and others. CDC does not reimburse or help travelers get reimbursements for travel expenses as a result of canceled or delayed\ntravel because of vaccination requirements for air passengers flying to the United States or other issues related to COVID-\n19.","7425":"Accepted COVID-19 Vaccines\nVaccines Approved or Authorized by\nthe U.S. Food and Drug\nAdministration\nVaccines Listed for Emergency Use\n(EUL) by the World Health\nOrganization\nCertain Clinical Trial Vaccines\nwhich Have Confirmed\nEfficacy\nSingle\ndose\nJanssen\/J&J Janssen\/J&J\nConvidecia (CanSinoBIO)\ndose\nseries\nComirnaty (Pfizer-BioNTech)\nSpikevax (Moderna)\nNovavax\nComirnaty (Pfizer-BioNTech)\nSpikevax (Moderna)\nVaxzevria (AstraZeneca)\nCovaxin\nCovishield\nBIBP\/Sinopharm\nCoronaVac (Sinovac)\nNuvaxovid (Novavax)\nCovovax\nMedicago\n\uf209\nAcceptable Proof of COVID-19 Vaccination\nDocumentation\nType Examples\nVerifiable\nrecords (digital\nor paper)\nVaccination certificate with QR code , digital pass via Smartphone application with QR code (e.g.,\nUnited Kingdom National Health Service COVID Pass, European Union Digital COVID Certificate)\nNon-verifiable\npaper records\nPrintout of COVID-19 vaccination record or a COVID-19 vaccination certificate issued at national or\nsubnational level or by an authorized vaccine provider (e.g., the CDC vaccination card)\nNon-verifiable\ndigital records\nDigital photos of vaccination card or record, downloaded vaccine record or vaccination certificate from\nofficial source (e.g., public health agency, government agency, or other authorized vaccine provider), or\na mobile phone application without QR code\n1.","8313":"If one of these tests is not available, many testing locations provide flu and COVID-19 tests\nseparately. Talk to a healthcare provider about getting tested for both flu and COVID-19 if you have\nsymptoms. Learn more\nResources\nPrint Resources\n\uf1aa\n\uf20c\nVideos\n\uf1aa\nSymptoms of COVID-19\nVideo Length: 00:00:21\nWatch Video\nASL Symptoms of Coronavirus\nVideo Length: 00:09:25\nWatch Video\nMore Information\nUnderstanding Your Risk\nHealthcare Workers: Information on COVID-19\nLast Updated Oct. 26, 2022\f10\/30\/22, 9:37 AM Symptoms of COVID-19 | CDC","6896":"Symptoms may\nappear 2 to 14 days after exposure to the virus. Symptoms may include: fever or chills, cough, shortness of\nbreath, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or\nrunny nose, nausea or vomiting, and diarrhea. Who can receive primary and additional dose(s) of the COVID-19 vaccine by Pfizer-BioNTech under the\nEUI? People who can receive the COVID-19 vaccine by Pfizer-BioNTech under EUI are described below.","9466":"Data have not yet been submitted to FDA on administration of SPIKEVAX (COVID-19\nVaccine, mRNA), Moderna COVID-19 Vaccine, or Moderna COVID-19 Vaccine, Bivalent at\nthe same time as other vaccines. If you are considering receiving or having your child receive\nSPIKEVAX (COVID-19 Vaccine, mRNA), Moderna COVID-19 Vaccine, or Moderna COVID-\n19 Vaccine, Bivalent with other vaccines, discuss your options with your or your child\u2019s\nhealthcare provider. WHAT IF I AM, OR MY CHILD IS, IMMUNOCOMPROMISED? If you are, or your child is, immunocompromised, you or your child may receive a third primary\nseries dose of Moderna COVID-19 Vaccine or SPIKEVAX (COVID-19 Vaccine, mRNA).","1438":"What do antibody tests tell us about immunity, and should these tests influence the decision to\nvaccinate or revaccinate? \uf1aa\n\uf209\n\uf209\nVaccination and SARS-CoV-2 Infection\nCDC recommends COVID-19 vaccination for all people ages 6 months and older, including people with a history of SARS-\nCoV-2 infection. Prior infection: Offer vaccination regardless of history of prior symptomatic or asymptomatic SARS-CoV-2 infection,\nincluding to people with prolonged post-COVID-19 symptoms and people who experienced SARS-CoV-2 infection\n(symptomatic or asymptomatic) after vaccination. People who recently had SARS-CoV-2 infection may consider delaying\ntheir primary or booster COVID-19 vaccine dose by 3 months from symptom onset or positive test (if infection was\nasymptomatic).","3999":"Because CDC removes duplicate records, data presented on the COVID Data Tracker might differ\nfrom data listed in jurisdictional Immunization Information Systems (IIS) and dashboards. CDC makes every effort to\nreconcile doses administered that are reported through more than one system. How does CDC manage data from multiple sources? \uf1aa\nEach state or territorial health department is responsible for establishing internal operations and schedules for\nreporting data. As a result, there are differences among states in the frequency of reporting. Data on doses of vaccine delivered and administered include data received by CDC as of 6:00 am ET on\nWednesday, the day of weekly reporting.","4605":"Gather in larger rooms or areas where people can be spaced apart and keep visits short\n\u2022\f10\/30\/22, 9:40 AM Improving Ventilation in Your Home | CDC\nGather in larger rooms or areas where people can be spaced apart and keep visits short. Follow additional recommendations for preventing the spread of COVID-19. \u2022\n\u2022\nRelated Pages\nVentilation in Buildings\n\u203a\nVentilation in Schools and Childcare Programs\n\u203a\nLast Updated June 29, 2022","2395":"When are people who have weakened immune systems considered up to date with their COVID-\n\uf1aa\nPeople can stay up to date with COVID-19 vaccination by completing a primary series and receiving the most recent\nbooster dose recommended for them by CDC. The people you live or spend time with can help protect you and\nthemselves by staying up to date on their COVID-19 vaccines too. When are people who have weakened immune systems considered up to date with their COVID-\n\uf1aa\nYou are up to date if you receive all COVID-19 vaccine doses recommended for you, even if you become ill with COVID-19.","9068":"CDC established multiple ways to connect and share viral genomic sequence\ndata being produced by CDC, public health laboratories, and commercial diagnostic laboratories within publicly accessible\ndatabases. Learn More About Tracking Variants\nSome, but not all, monoclonal antibody treatments remain effective against Omicron. Public health agencies\nwork with healthcare providers to ensure that effective treatments are used appropriately to treat patients. We Have the Tools to Fight Variants\nThe following pages cover more detailed information about specific key prevention actions which can help fight variants. Vaccines Masks Testing Ventilation\n\u2022\n\u2022\n\u2022\n\u2022\n\uf3c4 Definitions &\nClassifications\n\uf3c0 Tracking &\nSurveillance\n\uf251 US & Global\nVariant Data\nLast Updated Aug. 11, 2021","9110":"\uf1aa\nIf you are sick, tested positive, or were exposed to COVID-19, see Can I Travel If. Using public transportation and being in transportation hubs can involve spending long periods of time in areas that\nmay be crowded or poorly ventilated, increasing chance for exposure to COVID-19. People on public transportation may not have the option to avoid being around people who are not wearing masks by\ndisembarking or relocating to another area, such as on an airplane during flight, or on a bus or train while it is in\nmotion.","6399":"Stay up to date on COVID-19 vaccinations\nCOVID-19 vaccines are effective at protecting people\u2014especially those who are up to date\u2014 from getting seriously ill, being\nhospitalized, and even dying. As with vaccines for other diseases, you are protected best when you stay up to date with your\nCOVID-19 vaccines. The people you live or spend time with can help protect you and themselves by staying up to date on their\nCOVID-19 vaccines too.","9721":"In a pilot prospective cohort study of healthcare workers (HCWs) from\nLebanon, 50 HCWs who received a 2-dose primary series of Sinopharm BIBP COVID-19 vaccine and a single\nbooster dose of Pfizer-BioNTech COVID-19 vaccine had significantly higher anti-S-IgG titers compared to 50\nhomologous vaccinees (2 primary series doses and 1 booster dose of Pfizer-BioNTech COVID-19 vaccine)\n(Moghnieh, 2021). A longitudinal study of 41 Thai HCWs who received a 2-dose primary series of Sinovac\n(CoronaVac) COVID-19 vaccine demonstrated booster antibody responses following either AstraZeneca or\nPfizer-BioNTech COVID-19 vaccines, including against the Delta variant (Patamatamkul, 2021). Local and\nsystemic reactogenicity was reported to be mild to moderate across studies.","7919":"Although some side effects from COVID-19 vaccines are normal and expected,1 concern about adverse events and long-term\neffects from the vaccine keep many from seeking COVID-19 vaccination.2,3 On May 5, 2022, the FDA limited the authorized\nuse of the Janssen COVID-19 Vaccine to individuals ages 18 years and older for whom other authorized or approved COVID-19\nvaccines are not accessible or clinically appropriate, and to individuals ages 18 years and older who elect to receive the Janssen\nCOVID-19 vaccine because they would otherwise not receive a COVID-19 vaccine.4 This decision spurred online conversations\ndiscussing the perceived lack of effectiveness of all COVID-19 vaccines, further discouraging vaccine uptake.5,6,7\nPerceptions, Concerns, and Threats to Vaccine Confidence\n\u0083 Hepatitis.","3556":"How CDC Attributes Doses\nCDC determines the number of people receiving at least one dose, the number of people who are fully vaccinated, and the\nnumber of people with booster doses based on information reported to CDC on dose number, dose manufacturer,\nadministration date recipient ID and date of submission Because the method used to determine dose numbers needs to be\nCDC reports COVID-19 vaccination data online on COVID Data Tracker and in vaccination datasets. Sharing timely and\naccurate information with the public is one of CDC\u2019s core activities. Timely and accurate reporting from jurisdictions\nprovides the reliable data that can be reported by CDC.","7475":"Isolation means to separate sick people with a contagious disease from people who are not sick. What is the difference between quarantine and isolation? \uf1aa\nChildren ages 2 through 17 years (minors) who are noncitizen nonimmigrants do not have to quarantine after arrival in\nthe United States; however, the attestation requires that they get a COVID-19 viral test 3-5 days after arrival. If a child, like\nany other traveler, tests positive for COVID-19 or develops COVID-19 symptoms, they should isolate for a full 5 calendar\ndays.","9516":"Special Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nSpecial Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nModerna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group\nCDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage based on their age on\nthe day of vaccination. \u0083 If a person moves from a younger age group to an older age group during the primary series or between the primary series and receipt\nof the booster dose(s), they should receive the vaccine product and dosage for the older age group for all subsequent doses.","566":"October 13, 2022: California made updates to data previously submitted to CDC that resulted in a net increase of\n3,409 administered doses. October 6, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of\n212,852 administered doses. September 29, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of\n234,224 administered doses. August 31, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 38,447\nadministered doses.","1390":"The monovalent Novavax COVID-19 vaccine is authorized for a booster dose in limited situations. People ages 18 years\nand older who completed primary vaccination using any COVID-19 vaccine and have not received any previous booster\ndose(s) (including any previous mRNA monovalent or bivalent booster dose[s]) may receive a monovalent Novavax\nbooster dose at least 6 months after completion of the primary series if they are unable to receive an mRNA vaccine (i.e.,\nmRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive\na booster dose.","4999":"Added considerations for an 8-week interval between the first and second doses of a primary mRNA vaccine schedule\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nUpdated guidance for moderately or severely immunocompromised people\nClarification of existing recommendation to receive a 3-dose mRNA vaccine primary series followed by a booster\ndose for a total of 4 doses\nNew guidance to shorten the interval between completion of the mRNA vaccine primary series and the booster\ndose to at least 3 months (instead of 5 months)\nNew guidance for those who received the Janssen COVID-19 Vaccine primary series to receive an additional dose\nand a booster dose, for a total of 3 doses to be up to date\nUpdated guidance that it is no longer necessary to delay COVID-19 vaccination following receipt of monoclonal\nantibodies or convalescent plasma\nUpdated guidance on receiving a booster dose if vaccinated outside the United States\nUpdated contraindication and precaution section to include history of myocarditis or pericarditis after an mRNA\nCOVID-19 vaccine as a precaution\nReorganized and condensed multiple sections\nUpdated guidance for use of Pfizer-BioNTech COVID-19 Vaccine as a booster in people ages 12\u201317 years\nUpdated guidance for administration of a COVID-19 vaccine booster dose at least 5 months after completion of an\nmRNA vaccine (Pfizer-BioNTech or Moderna) primary series\nUpdated guidance for use of an additional primary dose for moderately or severely immunocompromised people ages\n5\u201311 years who received a Pfizer-BioNTech vaccine primary series\nUpdated recommendations for people who received COVID-19 vaccines outside the United States that are not FDA-\nauthorized or approved\nUpdated information about a second formulation of Pfizer-BioNTech COVID-19 Vaccine that is authorized for use in\npersons ages 12 years and older\nUpdated information on vaccinating people during quarantine after a known SARS-CoV-2 exposure or during COVID-\nUpdate to alert providers of possible false positive Rapid Plasma Reagin (RPR; non-treponemal) test results in some\npeople after COVID-19 vaccines\nUpdated information on vaccine administration errors and deviations\nUpdated guidance on use of Janssen (Johnson & Johnson) COVID-19 Vaccine\nUpdated recommendations for receipt of a COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 booster doses in recipients of mRNA COVID-19 vaccines\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nRecommendations and clinical guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children aged 5-11 years\nincluding updated section on Vaccination of children and adolescents\nUpdated guidance on COVID-19 vaccine dosing and schedule\nUpdated guidance for myocarditis and pericarditis after mRNA COVID-19 vaccination in new section on Considerations\nfor mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna\nNew guidance for people who received passive antibody products in section on COVID-19 vaccination and SARS-CoV-2\ninfection\nUpdated guidance in section on People who received COVID-19 vaccine outside the United States\nUpdated guidance in section on People who received COVID-19 as part of a clinical trial in the United States\nUpdated guidance on Considerations for COVID-19 vaccination in moderately and severely immunocompromised\npeople\nUpdated guidance in section on Contraindications and precautions\nUpdated Table in Appendix A: Vaccine administration errors and deviations\nUpdated Appendix B: Triage of people with a history of allergies or allergic reactions\nUpdated Appendix C: Ingredients included in COVID-19 vaccines\nUpdated Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects\nfollowing COVID-19 vaccination\nUpdated guidance in section on Considerations for use of a COVID-19 booster dose.","9682":"Adverse reactions following administration of the vaccine that have been reported in clinical trials and\/or post\nauthorization include injection site pain, fatigue, headache, muscle pain, chills, joint pain, fever, injection site\nswelling, injection site redness, nausea, malaise, lymphadenopathy, decreased appetite, rash, pain in\nextremity, diarrhea, and vomiting. Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nWhat are possible serious side effects with the COVID-19 vaccine by Pfizer-BioNTech? Severe allergic reactions, including anaphylaxis, and other hypersensitivity reactions (e.g., rash, pruritus,\nurticaria, angioedema), syncope, myocarditis and pericarditis have been reported following administration of\nthe vaccine outside of clinical trials.","5793":"Common side effects\nreported were mostly mild, but some people had side effects that affected their ability to do daily\nactivities. Cases of myocarditis and pericarditis have rarely been reported in some people. Cases have occurred\npredominantly in adolescents and young adult males within the first week after the second dose of vaccine. There is evidence from multiple sources that suggest a higher risk for myocarditis following Moderna\ncompared to Pfizer-BioNTech vaccination; however, it is not possible to directly compare the risk in people\nages 12\u201317 years.","3484":"Make sure you have a plan to get\ncare overseas, in case you need it. \uf3c0 Pre-embarkation Testing\nIf your cruise line does not have a testing requirement, get tested for current infection with a viral\ntest (no more than 3 days) before boarding a cruise ship, regardless of your vaccination status. Get your test\nresults before you board your cruise. If you recovered from COVID-19 in the past 90 days, testing is not generally recommended unless you\nhave symptoms. People can continue to test positive for up to 90 days after diagnosis and not be\ninfectious to others.","7314":"Ongoing studies of COVID-19 are\nhelping us understand:\nHow often reinfections occur\nWho is at higher risk of reinfection\nHow soon reinfections take place after a previous infection\nThe severity (how serious the infection is) of reinfections compared with initial (the first) infections\nThe risk of transmission to others after reinfection\nWhat CDC is doing\nCDC continues to work to better understand reinfections with COVID-19 to inform public health action. CDC is using a range\nof data sources to assess how often reinfections occur, who is most at risk for reinfection, and the risk of reinfection when\nthere is community spread of Omicron or other virus variants.","7840":"Related Questions\nPositive results from self-tests are highly reliable. Negative results from self-tests do not rule out SARS-CoV-2 infection. A negative self-test result may not be reliable,\nespecially if you have symptoms associated with COVID-19. Invalid results from self-tests mean the test did not work properly, and a new test is needed to get an accurate result. Should I trust the results of a self-test? \uf1aa\nCDC strongly encourages everyone who uses a self-test to report any positive results to their healthcare provider.","1068":"Still, some vaccinated people,\nespecially those ages 65 years or older or who have other risk factors for severe disease, may benefit from treatment if they\f10\/30\/22, 9:42 AM COVID-19 Treatments and Medications | CDC\nget COVID-19. A healthcare provider will help decide which treatment, if any, is right for you. Check with your healthcare\nprovider or pharmacist if you are taking other medications to make sure the COVID-19 treatments can be safely taken at the\nsame time. Types of Treatments\nThe FDA has authorized certain\nantiviral medications and\nmonoclonal antibodies to treat\nmild to moderate COVID-19 in\npeople who are more likely to get\nvery sick.","1343":"After\nthe dose has been repeated, continue with the recommended vaccination schedule (i.e., complete the primary series with\na monovalent Moderna vaccine, then administer a bivalent booster dose at least 2 months after completion of the\nprimary series). Both situations are considered vaccine administration errors and should be reported to Vaccine Adverse Event Reporting\nSystem (VAERS) . For more information, see\nPeople who are not moderately or severely immunocompromised\nPeople who are moderately or severely immunocompromised\nVaccine administration errors and deviations\nCan the bivalent mRNA vaccines (i.e., Moderna and Pfizer-BioNTech) be used for the primary\nseries?","635":"April 22, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 13,434 doses\nadministered. April 15, 2022: Maryland made updates to data previously submitted to CDC that resulted in a decrease of 50,176\ndoses administered. April 15, 2022: Illinois made updates to data previously submitted to CDC that resulted in a decrease of 18,471 doses\nadministered. April 8, 2022: Maryland reported some records that were noted to be duplicates. CDC and Maryland are working to\nremove these duplicates in a timely manner.","1363":"People ages 6 years and older are recommended to receive either the Moderna or the Pfizer-BioNTech bivalent\nbooster dose. The booster dose is administered at least 2 months after the last primary dose. For people who previously received 1 or\nmore monovalent booster doses, the bivalent booster dose should be administered at least 2 months after the last\nmonovalent booster dose. Novavax monovalent COVID-19 Vaccine may be used as a booster dose in limited situations for people ages 18 years and\nolder.","535":"On February 15, 2021, the COVID-19 Vaccine Tracker was updated to reflect the revised Pfizer-BioNTech emergency use\nauthorization (EUA) to allow the use of a sixth dose, if present in a vial, as authorized by the Food and Drug\nAdministration (FDA)external icon . Pfizer-BioNTech deliveries to a jurisdiction on or after February 15, 2021, will\nreflect this increase to six doses per vial compared to five doses; historical data will not be updated. The change to the\nPfizer-BioNTech dosage increases the number of doses delivered relative to the number of doses administered.","4013":"This is due to several factors, including the time it takes\nfor doses delivered to be administered, the time it takes for administered doses to be reported to CDC, and how\njurisdictions and federal pharmacy partners manage available vaccine stock to meet local demands. What are the reporting limitations and variations in COVID-19 vaccine data? \uf1aa\n\u2022\n\u2022\n\u2022\n\u2022\nWhy do data vary between the CDC COVID Data Tracker and state health department websites? \uf1aa\f10\/30\/22, 9:35 AM Frequently Asked Questions about COVID-19 Vaccination Data | CDC\nCDC Publicly Available Data\nFor the most complete and up-to-date data for any particular county or state, visit the relevant health department\nwebsite.","5362":"Guillain Barr\u00e9 Syndrome\nGuillain Barr\u00e9 syndrome (a neurological disorder in which the body\u2019s immune system damages\nnerve cells, causing muscle weakness and sometimes paralysis) has occurred in some people who\nhave received the Janssen COVID-19 Vaccine. In most of these people, symptoms began within\n42 days following receipt of the Janssen COVID-19 Vaccine. The chance of having this occur is\nvery low. You should seek medical attention right away if you develop any of the following\nsymptoms after receiving the Janssen COVID-19 Vaccine:\n\u2022 Weakness or tingling sensations, especially in the legs or arms, that\u2019s worsening and spreading\nto other parts of the body. \u2022 Difficulty walking.","1986":"10\/30\/22, 9:31 AM COVID-19 Vaccine Safety in Children and Teens | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 Vaccine Safety in Children and Teens\nClinical Trials and Ongoing Safety Monitoring Show That COVID-\n19 Vaccination Is Safe for Children and Teens\nBefore authorizing or approving COVID-19 vaccines, scientists conducted clinical trials with thousands of children and teens to\nestablish their safety and effectiveness. Learn more about how COVID-19 vaccines were developed and approved. COVID-19 vaccines are being monitored under the most comprehensive and intense vaccine safety monitoring program in\nU.S. history. CDC monitors all COVID-19 vaccines after they are authorized or approved for use.","4457":"There are two types of viral tests: rapid tests and laboratory tests. These tests might use samples from your nose or\nthroat, or saliva. Knowing if you are infected with the virus that causes COVID-19 allows you to take care of yourself and\ntake actions to reduce the chance that you will infect others. CDC\u2019s Viral Testing Tool is an online, mobile-friendly tool that asks a series of questions and recommends actions and\nresources based on your responses. It can help you interpret what your test result means. You can also access tests the following ways:\nOrder free self-tests at COVIDtests.gov .","9488":"The vaccination provider may include your or your child\u2019s vaccination information in your\nstate\/local jurisdiction\u2019s Immunization Information System (IIS) or other designated system. This will ensure that you or your child receive the same vaccine when you return for the second\ndose of the primary series. For more information about IISs, visit:\nhttps:\/\/www.cdc.gov\/vaccines\/programs\/iis\/about.html. CAN I BE CHARGED AN ADMINISTRATION FEE FOR RECEIPT OF THESE\nNo. At this time, the provider cannot charge you for a vaccine dose and you cannot be charged\nan out-of-pocket vaccine administration fee or any other fee if only receiving a COVID-19\nvaccination.","8633":"English [953 KB, 1 page]\n\u2022 \uf20c\n\uf426\n\uf209\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:34 AM Understanding How COVID-19 Vaccines Work | CDC\nViral vector COVID-19 vaccines are given in a muscle in the upper arm. The vector virus in the vaccine is not the virus\nthat causes COVID-19, but a different, harmless virus. It enters the muscle cells and uses the cells\u2019 machinery to\nproduce a harmless piece of what is called a spike protein. The spike protein is found on the surface of the virus that\ncauses COVID-19. After the spike protein piece is made, our cells break down the vector virus and remove it.","7422":"Accepted COVID-19 Vaccines\nVaccines Approved or Authorized by\nthe U.S. Food and Drug\nAdministration\nVaccines Listed for Emergency Use\n(EUL) by the World Health\nOrganization\nCertain Clinical Trial Vaccines\nwhich Have Confirmed\nEfficacy\nSingle\ndose\nJanssen\/J&J Janssen\/J&J\nConvidecia (CanSinoBIO)\ndose\nseries\nComirnaty (Pfizer-BioNTech)\nSpikevax (Moderna)\nNovavax\nComirnaty (Pfizer-BioNTech)\nSpikevax (Moderna)\nVaxzevria (AstraZeneca)\nCovaxin\nCovishield\nBIBP\/Sinopharm\nCoronaVac (Sinovac)\nNuvaxovid (Novavax)\nCovovax\nMedicago\n\uf209\nAcceptable Proof of COVID-19 Vaccination\nDocumentation\nType Examples\nVerifiable\nrecords (digital\nor paper)\nVaccination certificate with QR code , digital pass via Smartphone application with QR code (e.g.,\nUnited Kingdom National Health Service COVID Pass, European Union Digital COVID Certificate)\nNon-verifiable\npaper records\nPrintout of COVID-19 vaccination record or a COVID-19 vaccination certificate issued at national or\nsubnational level or by an authorized vaccine provider (e.g., the CDC vaccination card)\nNon-verifiable\ndigital records\nDigital photos of vaccination card or record, downloaded vaccine record or vaccination certificate from\nofficial source (e.g., public health agency, government agency, or other authorized vaccine provider), or\na mobile phone application without QR code\n1.","2119":"CDC continues to monitor, analyze, and disseminate information from people vaccinated\nduring all trimesters of pregnancy to better understand effects on pregnancy and babies. What are the long-term effects on the baby when a person gets a COVID-19 vaccine during\npregnancy? \uf1aa\nCDC and professional medical organizations, including the American College of Obstetricians and Gynecologists and the\nSociety for Maternal-Fetal Medicine, recommend COVID-19 vaccination at any point in pregnancy, as well as booster\ndoses when it is time to get one. COVID-19 vaccination can protect you from getting very sick from COVID-19.","3684":"The CDC Director has legal authority to create, issue, and disseminate EUI before or\nduring an emergency for FDA-approved medical products. EUI inform healthcare providers and recipients\nabout such products\u2019 approved, licensed, or cleared conditions of use under circumstances that go\nbeyond the scope of the approved labeling (package insert). What EUI did CDC issue and why? CDC issued EUI for use of the COVID-19 vaccine by Pfizer-BioNTech and COVID-19 vaccine by Moderna\nfor primary, additional, and\/or booster doses in certain individuals. The EUI are necessary because\nthese uses extend beyond their FDA-approved labeling.","6935":"Also, mention all of your medical conditions, including if you:\n\u2022 Have any allergies\n\u2022 Have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining\noutside the heart)\n\u2022 Have a fever\n\u2022 Have a bleeding disorder or are on a blood thinner\n\u2022 Are immunocompromised or are on a medicine that affects your immune system\n\u2022 Have ever fainted in association with an injection\fPfizer-BioNTech COVID-19 Vaccine EUI Recipient Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nHow is the COVID-19 vaccine by Pfizer-BioNTech given? COVID-19 vaccine by Pfizer-BioNTech is given as an injection into the muscle.","8620":"Another example of other protein subunit vaccines used today include whooping cough vaccines. Viral vector vaccines (Johnson & Johnson\u2019s Janssen)\nViral vector COVID-19 vaccines use a modified version of a different virus (a vector virus) to deliver important instructions to\nour cells. About Johnson & Johnson's Janssen\nResearch for viral vector technology\nFor decades, hundreds of scientific studies of viral vector vaccines have been done and published around the world. Some vaccines recently used for Ebola outbreaks have used viral vector technology. Several studies have focused on viral vector vaccines against other diseases such as Zika, flu, and HIV.","5194":"People may get a letter in the mail or receive a phone call from CDC asking questions about their myocarditis and\nmedical history. Personal information and responses will be kept private to the extent allowable under the law. When the patient is\na minor, a parent or legal guardian will be invited to participate on their behalf. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\uf209\n\uf209\f10\/30\/22, 9:31 AM Investigating Long-Term Effects of Myocarditis | CDC\nPersonal details that could identify you will be kept private and information about your case will be combined with\ninformation from other participants. This means your name and any identifying information will not be included in any\nreports.","3037":"Children age 5 years: A 3-dose primary series and 1 bivalent Pfizer-BioNTech booster dose is recommended. The first\nand second doses are separated by 4 weeks and the second and third doses are separated by at least 4 weeks. The\nbivalent booster dose is administered at least 2 months after completion of the primary series.Currently, only the\nbivalent Pfizer-BioNTech booster dose is authorized for children age 5 years who receive a Moderna primary series. Children ages 6\u201311 years: A 3-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is\nrecommended.","1185":"Although Texas still reports vaccination data in\naggregate form, Texas and CDC recently collaborated to update the format of this record submission to improve COVID-19\nreporting of Texas\u2019 data on CDC\u2019s COVID Data Tracker at the national, state, and county levels. Previously, for Texas, CDC estimated the number of people with at least one dose and the number of people who are fully\nvaccinated for the populations ages 12 years or older, 18 years or older, and 65 years or older in the metrics for Texas alone\nand when including Texas in the national level metrics on the\u202fVaccinations in the United States\u202fsite.","4126":"Since there\nis no way to tell in advance how children, who are not moderately or severely immunocompromised, or those who may\nbe immunocompromised. A child can be immunocompromised and still healthy, will be affected by COVID-19 it\u2019s\nimportant to get them vaccinated as soon as possible to protect them against severe illness. To find your child a COVID-19\nvaccine or booster near you:\u202fSearch\u202fvaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233. Should parents and caregivers wait for updated or additional vaccines, if a child is low risk for\ninfection?","1817":"LTC providers are encouraged to consider the option that works best for their residents and staff when coordinating access to\nCOVID-19 vaccines, either in the local community or on-site. Additional details on these options are available on the pages\nlinked below. \uf141 Information About Who Is Eligible for a COVID-19 Vaccine Booster Shot\n\uf209\n\uf1aa Information for Long-term Care\nAdministrators and Managers\n\uf1aa Information for Jurisdictions (State and Local\nImmunization Programs)\f10\/30\/22, 9:22 AM COVID-19 Vaccine Access in Long-term Care Settings | CDC\nAdditional Information: COVID-19 Vaccination Recommendations\nCOVID-19 vaccines available in the United States are highly effective at preventing serious outcomes of COVID-19 including\nsevere disease, hospitalization, and death.","6906":"\u2022 People ages 12 years and older who recently had SARS-CoV-2 infection may receive a second\nprimary dose after a deferral period of 3 months from symptom onset or positive test (if infection\nwas asymptomatic)\fPfizer-BioNTech COVID-19 Vaccine EUI Recipient Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\n\u2022 People ages 12 years and older who received an incomplete primary dose series (only the first\ndose of a 2-dose primary series) with certain non-FDA authorized or approved COVID-19 vaccines\nat least 28 days ago should receive a primary dose of the COVID-19 vaccine by Pfizer-BioNTech to\ncomplete the series.","8129":"COVID-19 State of Vaccine Confidence Insights Report | October 10, 2022\nAppendix: Inputs and Sources\nType Input Cadence Sources Tactics for Utilization\nSocial Media\nListening\n& Media\nMonitoring\nCommunication\nSurveillance Report\nDaily on\nweekdays\n\u0082Google news\n\u0082Meltwater\n\u0082CrowdTangle\n\u0082Native platform searches\n\u0082Share of voice topic analysis to identify\nthemes\n\u0082Emerging topics\nMeltwater Daily \u0082Facebook, Twitter, Instagram\n\u0082Blogs\n\u0082News media\n\u0082Online forums\n\u0082Share of voice topic analysis\n\u0082Emerging theme topics\n\u0082Identify high reach\/velocity topics\nOADC (Office of the\nAssociate Director of\nCommunication) Channel\nCOVID-19 Post metrics\nWeekly \u0082Sprout Social\n\u0082Native OADC account analytics\n\u0082Analyze # of posts, topics\n\u0082Success of messages, # of impressions,\nreach, # engagements\nOADC Channel Comment\nAnalysis\nDaily on\nweekdays\n\u0082Native platform searches \u0082Sentiment analysis\n\u0082Identify message gaps\/voids\nDirect Reports\nCDC-INFO Metrics Weekly \u0082CDC-INFO inquiry line list\n\u0082Prepared response (PR) usage report\n\u0082Cross-compare PR usage with inquiry\ntheme analysis\n\u0082Sentiment analysis\n\u0082Identify information gaps\/voids\nVTF Media Requests Weekly \u0082Media request line list \u0082Leading indicator for news coverage\n\u0082Identify information gaps\/voids\nWeb Metrics Weekly \u0082Top pages\n\u0082Google search queries\n\u0082Top FAQs\n\u0082Referring domains\n\u0082Identify information gaps\/voids,\n\u0082Identify keywords\/search terms, changes in\nweb traffic\nResearch\nPoll Review Weekly \u0082Harris Poll, PEW research, Gallup Poll,\nKFF\n\u0082New data related to vaccine\nhesitancy\n\u0082Identify socio-behavior indicators related\nto motivation and intention to vaccinate\nLiterature Review Weekly \u0082PubMed, LitCovid, ProQuest Central,\nAltmetric\n\u0082New data related to vaccine\nhesitancy\n\u0082Identify current vaccination intention\n\u0082Identify barriers to vaccination\nThird Party\nReports\nTanaq Social Listening\n+Media Monitoring Report\nWeekly \u0082Meltwater\n\u0082Sprout Social\n\u0082First Draft\n\u0082Native platform searches\n\u0082Trending topics\n\u0082Demographic and geographic\nconversation monitoring\nCrowdTangle content\ninsights report\nBiweekly \u0082Facebook \u0082Top pages (voices), groups\n\u0082General trends\/sentiment analysis\n\u0082News analysis through posts\nUniversity of Washington\nSt. Louis iHeard\nWeekly \u0082Proprietary methods \u0082Survey results\n\u0082Emerging threats and data deficits\n\u0082Vaccine narratives\nProject VCTR Weekly \u0082Proprietary methods \u0082National and regional trends in negative\nattitudes toward vaccination\n\u0082Conversations around Legislation\nVirality Project Weekly \u0082Proprietary methods \u0082Mis- and disinformation trends related to","4770":"COVID-19 vaccines that are listed for emergency use by WHO , but are not approved or authorized by FDA, have not been evaluated for\nefficacy or safety by CDC or ACIP. Special situation: Do not administer a second bivalent mRNA booster dose if the person previously received a bivalent\nModerna or Pfizer-BioNTech booster dose containing the original SARS-CoV-2 strain and Omicron BA.1 variant.","6016":"\u2022 In a large test-negative design study to evaluate VE among adults aged \u226518 years in British Columbia\nand Quebec, Canada, two-dose mRNA VE against infection and hospitalization was significantly higher\nwith a longer dosing interval (7\u20138 weeks vs. 3\u20134 weeks) (Skowronski, 2021). VE appeared to plateau at\nthe 7\u20138 week interval. \u2022 A test-negative case control study among adults aged 50\u201389 years in England demonstrated that\nPfizer-BioNTech VE was higher with longer (>6 weeks) intervals compared to short (3\u20134 weeks)\nintervals for all age groups (Amirthalingam, 2021).","5888":"\u2022 For certain moderately or severely immunocompromised persons:\no\no\no\nAges 12 years and older who received primary vaccination with certain non-FDA authorized or\napproved COVID-19 vaccines should receive an additional primary dose of the COVID-19\nvaccine by Moderna. Ages 18 years and older who received primary vaccination with the Janssen COVID-19 Vaccine\nshould receive an additional dose with the COVID-19 vaccine by Moderna. Ages 12 years and older who received certain therapies (indicated below) and received\nprimary dose(s) of COVID-19 vaccine prior to or during treatment should be revaccinated with\nthe COVID-19 vaccine by Moderna for any doses received before or during treatment.","5959":"What is the available supporting evidence for use of the COVID-19 vaccine by Moderna for additional\nprimary doses in people who received a primary vaccination with non-FDA authorized or approved COVID-\nCDC has not systematically evaluated the safety, immunogenicity, and efficacy of an additional dose of the\nCOVID-19 vaccine by Moderna following receipt of primary vaccination with a non-FDA authorized or approved\nCOVID-19 vaccine. Most evidence is with use of a booster dose after primary vaccination.","2836":"It is important to rule out other potential causes of myocarditis and pericarditis. Consider consultation with infectious\ndisease and\/or rheumatology to assist in this evaluation. Where available, evaluate for potential causes of myocarditis and pericarditis, particularly acute COVID-19 infection\n(such as PCR testing), current or prior SARS-CoV-2 infection (such as, detection of SARS-CoV-2 antibodies), and other\nviral causes (such as, enterovirus PCR and comprehensive respiratory viral pathogen testing).","453":"On May 27, 2021, the New Hampshire \u2018at least one dose\u2019 values posted to Tracker appeared lower than that reported the\nday prior (May 26, 2021). This correction is accurate and is due to New Hampshire and CDC collaboratively correcting\ndata transmission errors. On May 25, 2021, the 7,836,063 administered doses reported for Long-Term Care Facilities (LTCF), were fewer by 4,105\nrecords compared to the 7,840,168 reported on May 24, 2021. This was due to an error in data processing that has now\nbeen corrected. The data for May 26, 2021 accurately reflect total LTCF doses.","8535":"For information about COVID-19 requirements for land travel, visit the U.S. Department of Homeland Security\u2019s Fact\nSheet: Guidance for Travelers to Enter the U.S. at Land Ports of Entry and Ferry Terminals . What are the requirements for international land travel? \uf1aa\n\uf209\nYes. The chance of getting COVID-19 on cruise ships is high because the virus spreads easily between people in close\nquarters on board ships. For this reason, CDC recommends the following groups of people avoid traveling on cruise\nships, including river cruises, worldwide:\nPeople who are not up to date with their COVID-19 vaccines.","462":"On May 16, 2021, the total number of administered doses for the US and New Hampshire were incorrectly reported. This\nwas due to an error in data processing. The data for May 16, 2021 have been updated and now correctly report the total\nadministered doses of 272,925,411 for the US, and 1,211,530 for New Hampshire. On May 13, 2021, the number of persons aged <18 years, who had received at least 1 dose of vaccine was incorrectly\nreported as 3,687,617 on the Vaccinations Demographics page. This was due to inclusion of those ages 18 years in the\n<18 years group.","4439":"Improving Ventilation and Spending Time Outdoors\nImproving ventilation (moving air into, out of, or within a room) and filtration (trapping particles on a filter to remove\nthem from the air) can help prevent virus particles from accumulating in indoor air. Improving ventilation and filtration\ncan help protect you from getting infected with and spreading the virus that causes COVID-19. Spending time outside\nwhen possible instead of inside can also help: Viral particles spread between people more readily indoors than outdoors. Actions that can improve ventilation and filtration include:\nBringing in as much outdoor air as possible\u2014for example, opening windows.","4107":"Can I ask my healthcare provider for a dose of COVID-19 vaccine that does not follow vaccination\nguidelines, sometimes called \u201coff-label\u201d use? \uf1aa\n\uf209\nScientists are monitoring how long COVID-19 vaccine protection lasts. COVID-19 vaccines work well to prevent severe\nillness, hospitalization, and death. However, public health experts are seeing decreases in the protection COVID-19\nvaccines provide over time, especially for certain groups of people. Due to this, CDC recommends COVID-19 vaccines for\neveryone ages 6 months and older, and boosters for everyone 5 years and older, if eligible. Learn more about COVID-19\nbooster recommendations, including recommendations for people who are moderately or severely\nimmunocompromised.","9272":"\u2022\n\u2022\n\u2022\nHelp Protect Your Child\nCOVID-19 vaccination is an important tool to help protect everyone 6 months and older from COVID-19 and its complications. Getting children and teens vaccinated against COVID-19 can help keep them from getting really sick if they do get COVID-19. Vaccinating children can also help relieve the strain on families by providing greater confidence in children participating in\nchildcare, school, and other activities. After vaccination, continue to follow all current prevention measures recommended by CDC and based on latest COVID-\n19 Community Level data. Learn more about\u202fprotecting your family from COVID-19.","1391":"The monovalent Novavax COVID-19 vaccine is authorized for a booster dose in limited situations. People ages 18 years\nand older who completed primary vaccination using any COVID-19 vaccine and have not received any previous booster\ndose(s) (including any previous mRNA monovalent or bivalent booster dose[s]) may receive a monovalent Novavax\nbooster dose at least 6 months after completion of the primary series if they are unable to receive an mRNA vaccine (i.e.,\nmRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive\na booster dose.","9351":"Children who will turn from 5 years to 6 years of\nage between doses in the primary series may receive, for any dose, either: (1) the Moderna COVID-19 Vaccine\nauthorized for use in individuals 6 months through 5 years of age; or (2) Moderna COVID-19 Vaccine authorized\nfor use in individuals 6 years through 11 years of age.","9501":"The Countermeasures Injury Compensation Program (CICP) is a federal program that may help\npay for costs of medical care and other specific expenses of certain people who have been\nseriously injured by certain medicines or vaccines, including these vaccines. Generally, a claim\nmust be submitted to the CICP within one (1) year from the date of receiving the vaccine. To\flearn more about this program, visit www.hrsa.gov\/cicp\/ or call 1-855-266-2427. WHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)? An EUA is a mechanism to facilitate the availability and use of medical products, including\nvaccines, during public health emergencies, such as the current COVID-19 pandemic.","8665":"This included:\npreclinical and clinical trial data and information,\nas well as details of the manufacturing process,\nvaccine testing results to ensure vaccine quality, and\ninspections of the sites where the vaccine is made. These vaccines were found to meet the high standards for safety, effectiveness, and manufacturing\nquality FDA requires of an approved product. Learn more about the process for FDA approval . \uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\uf209\nTracking Safety Using Vaccine Monitoring Systems\n\uf1aa\n\uf128 Hundreds of millions of people in the United States have received COVID-19 vaccines under the most\nintense safety monitoring in U.S. history. Several monitoring systems continue to track outcomes from COVID-19 vaccines to ensure their safety.","5644":"Do NOT wear international respirators\nIf they have exhalation valves, vents, or other openings\nIf it is hard to breathe while wearing them\nIf they are wet or dirty\nWith other masks or respirators\nAs a replacement for NIOSH-approved respiratory protection when required by your job\nst\nPoor quality KN95 respirators\nAbout 60% of KN95 respirators NIOSH evaluated during the COVID-19 pandemic in 2020 and 2021 did not meet\nthe requirements that they intended to meet. Using a poor-quality product may not provide the level of protection indicated. Learn about factors to consider when purchasing an international respirator. This webpage and a webinar provide\nreliable information to guide you.","6407":"Examples of medical conditions or treatments that may result in moderate to severe immunocompromise include but are not\nlimited to:\nActive treatment for solid tumor and hematologic malignancies\nHematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status\n(e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\nReceipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\nReceipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of\ntransplantation or taking immunosuppressive therapy)\nModerate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined\nimmunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)\nAdvanced or untreated HIV infection (people with HIV and CD4 cell counts less than 200\/mm3, history of an AIDS-\ndefining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)\nActive treatment with high-dose corticosteroids (i.e., 20 or more mg of prednisone or equivalent per day when\nadministered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs,\ncancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and\nother biologic agents that are immunosuppressive or immunomodulatory\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nHow to Protect Yourself\f10\/30\/22, 9:38 AM People Who Are Immunocompromised | CDC\nYou are up to date with your COVID-19 vaccines when you have received all doses in the primary series and all boosters\nrecommended for you, when eligible.","488":"On May 6, 2021, 2,406,932 new doses administered were initially reported on the Vaccination Trends Daily Count metric\nin error. The site has since been updated, and the Daily Count metrics now accurately reflect the total doses\nadministered for May 6, 2021. On May 6, 2021, the total doses administered data posted to Tracker for New Hampshire was the same as those\nreported the day before (May 5, 2021). New Hampshire and CDC are actively working to reconcile counts at this time. Updates will be provided as available.","9409":"Booster Dose: Moderna COVID-19 Vaccine, Bivalent is administered as a single booster dose at\nleast 2 months after:\n\u2022 completion of primary vaccination with any authorized or approved monovalent COVID-\n19 vaccine; or\n\u2022 receipt of the most recent booster dose with any authorized or approved monovalent\nCOVID-19 vaccine. HAVE THESE VACCINES BEEN USED BEFORE? Millions of individuals 18 years of age and older have received the Moderna COVID-19 Vaccine\nunder EUA since December 18, 2020.","4259":"People who already had COVID-19 and do not get vaccinated after their recovery are more likely to get COVID-19 again\nthan those who get vaccinated after their recovery. If you were given monoclonal antibodies or convalescent plasma while sick with COVID-19 you do not need to wait to get\nvaccinated. \u2022\n\u2022\n\u2022\nWhen you can wait\n\uf1aa\nIf you recently had COVID-19, you may consider delaying your next vaccine dose (primary dose or booster) by 3\nmonths from when:\nyour symptoms started,\nyou first received a positive test if you had no symptoms.","256":"We can also learn if antibodies to SARS-CoV-2 provide the same protection against new variants of the virus that causes\nCOVID-19. Studies show that people who have antibodies from an infection with the virus that causes COVID-19 can improve their\nlevel of protection by getting vaccinated. \uf209\nAntibody quiz\f10\/30\/22, 9:37 AM Antibodies and COVID-19 | CDC\nNow that you\u2019ve learned about antibodies and COVID-19, test your knowledge with an interactive quiz. Test Your Knowledge\nAntibodies for the virus that causes COVID-19 are expected to decrease, or wane, over time. True\nFalse\nNext \uf29e\nLast Updated Nov. 10, 2021","4989":"New booster recommendation for people ages 12 years and older to receive 1 bivalent mRNA booster after\ncompletion of a monovalent primary series; it replaces all prior booster recommendations for this age group\nRecommendations for use of a bivalent Moderna booster dose in people ages 18 years and older\nRecommendations for use of a bivalent Pfizer-BioNTech booster dose in people ages 12 years and older\nUpdated guidance for observation periods following COVID-19 vaccination\nUpdated guidance on COVID-19 vaccination and multisystem inflammatory syndrome (MIS) in children (MIS-C) and in\nadults (MIS-A)\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adolescents ages 12\u201317 years\nReorganization of Janssen COVID-19 Vaccine guidance into an appendix\nUpdated guidance on COVID-19 vaccination following exposure to SARS-CoV-2\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nPrevious Updates\n\uf1aa\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nGuidance for primary series vaccination using Novavax COVID-19 Vaccine in adults ages 18 years and older\nUpdated guidance on COVID-19 vaccination and myocarditis and pericarditis\nNew clinical considerations for coadministration of mRNA COVID-19 vaccines and orthopoxvirus vaccines\nNew guidance for use of Moderna COVID-19 Vaccine in children and adolescents ages 6\u201317 years\nNew guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children ages 6 months\u20134 years\nNew guidance for use of Moderna COVID-19 Vaccine in children ages 6 months\u20135 years\nReorganization of sections on COVID-19 vaccination recommendations and schedules\nAddition of new section in Special populations for infants and young children\nNew guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5\u201311 years\nUpdated guidance that the following people should receive a second COVID-19 booster dose:\nPeople ages 12 years and older who are moderately or severely immunocompromised\nPeople ages 50 years and older\nUpdated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-\ndepleting therapies\nClarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults\n(MIS-A)\nUpdated guidance for primary series vaccination after SARS-CoV-2 infection\nAdded considerations for the option to receive a second COVID-19 vaccine booster dose\nUpdated guidance for COVID-19 vaccination after SARS-CoV-2 infection\nAdded guidance that people ages 12 years and older who are moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that adults ages 50 years and older who are not moderately or severely immunocompromised may\nchoose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster\ndose\nAdded guidance that people ages 18\u201349 years who are not moderately or severely immunocompromised and who\nreceived Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster\ndose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose\nFurther clarification of safety issues including those related to multisystem inflammatory syndrome in children (MIS-C)\nand adults (MIS-A) and myocarditis\nUpdated information on the availability of Moderna COVID-19 Vaccine supplied in a vial with a red cap (0.25 mL\ndosage volume) and Moderna COVID-19 Vaccine supplied in a vial with a blue cap (0.5 mL dosage volume) for\nadministration of a 50 \u00b5g booster dose.","1524":"Provider shall not be required to engage in any fit testing, medical evaluations, or training, regardless of\nwhether individuals obtain masks for employment or other purposes. 6. Absent willful misconduct by provider, provider shall have no responsibility for individual usage of masks or other\nconduct. Providers are not responsible for monitoring or enforcing those that choose to take masks nor confirm\nthat they are for personal versus business or other usage. 7. Providers will post a web link to a USG and\/or manufacturer URL, provided by HHS, on their websites to\ninstructions for proper fit and use.","6623":"Like adults, children with obesity,\ndiabetes, asthma or chronic lung disease, sickle cell disease, or who are immunocompromised can also be at increased risk\nPeople of all ages, including children, can get very sick from COVID-19. Children with underlying medical conditions are at\nincreased risk for getting very sick compared to children without underlying medical conditions. 10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nfor getting very sick from COVID-19. Check out COVID-19 Vaccines for Children and Teens for more information on vaccination\ninformation for children.","6447":"Monitor your health for COVID-19 symptoms and get tested at least 5 days after you had close contact with someone\nwith COVID-19, even if you don\u2019t develop symptoms. Wear a high quality mask for 10 full days any time you are around others inside your home or in public. Do not go to\nplaces where you are unable to wear a mask. What to do if you have COVID-19 symptoms\nStay home. Get tested right away. Use a self-test at home or find a testing location near you.","5980":"Countries such as the United Kingdom (JCVI, 2021a-b), Canada (National Advisory Committee on Vaccination,\n2021), Germany, and France have recommended heterologous dosing, including with use of the Moderna\nCOVID-19 vaccine, for an additional primary series and\/or booster dose based on their reviews of available\nimmunological and safety data, as well as the epidemiology of COVID-19 and other contextual factors.","9338":"This Vaccine Information Fact Sheet for Recipients and Caregivers comprises the Fact\nSheet for the authorized Moderna COVID-19 Vaccine and the authorized Moderna\nCOVID-19 Vaccine, Bivalent for use in individuals 6 years of age and older, and also\nincludes information about the FDA-licensed vaccine, SPIKEVAX (COVID-19 Vaccine,\nmRNA) for use in individuals 12 years of age and older.1\nThe FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and the Moderna COVID-\n19 Vaccine authorized for Emergency Use Authorization (EUA) for individuals 12 years of\nage and older can be used interchangeably, when used according to their respective\ninstructions for use.2\nSPIKEVAX (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made\nby ModernaTX, Inc.","3709":"1 The COVID-19 vaccine by Pfizer-BioNTech (brand name Comirnaty) was approved by FDA in August 2021 as a 2-dose\nprimary series for active immunization to prevent COVID-19 in persons aged \u2265 16 years. FDA also amended the EUA for the\nPfizer-BioNTech COVID-19 vaccine to authorize an additional primary dose in certain immunocompromised persons aged \u2265\n12 years and a homologous or heterologous booster dose in persons aged \u2265 18 years following primary vaccination with the\nPfizer-BioNTech or a different FDA-authorized COVID-19 vaccine.","1824":"As with other infectious diseases, people are protected best from COVID-19 when\nthey stay up to date with recommended vaccine doses. Efforts to maximize the proportion of people in the United States who\nare fully vaccinated against COVID-19 remain critical to reducing the spread. Staying up to date means getting all recommended COVID-19 vaccine doses, including a booster shot, when eligible. People who are moderately or severely immunocompromised have specific COVID-19 vaccine recommendations, which\ninclude an additional third dose to complete their primary series, as well as a booster shot for those eligible.","1651":"Communications with COVID-19 vaccine recipients involving the store component of any pharmacy or other provider\nparticipating in the CDC COVID-19 Vaccination Program are considered prohibited commercial marketing. For example,\ntext, e-mail, mail, or other communications to COVID-19 vaccine recipients about products on sale in the store are\nprohibited as commercial marketing. COVID-19 vaccination registration information and vaccine administration data collected in the course of participation in\nthe CDC COVID-19 Vaccination Program cannot be sold, for direct or indirect remuneration, even with permission of the\nvaccine recipient.","5752":"\u2022 For people who are moderately or severely immunocompromised:\no\no\no\nPeople ages 12 years and older who are moderately or severely immunocompromised and\nreceived their primary vaccination with certain non-FDA authorized or approved COVID-19\nvaccines at least 28 days ago should receive an additional (third) primary dose of the\nCOVID-19 vaccine by Moderna. People ages 18 years and older with a moderately or severely immunocompromising\ncondition who received a primary dose of the Janssen COVID-19 Vaccine should receive an\nadditional dose with the COVID-19 vaccine by Moderna at least 28 days after receiving the\nJanssen COVID-19 Vaccine primary dose.","6045":"Additionally, some populations (e.g., older adults, immunocompromised) may have decreased levels of\nprotection following infection, necessitating an interval that balances the benefits and risks of delaying\nvaccination after infection at a population level. Vaccination continues to be recommended regardless of the option for delaying vaccination after infection. Numerous immunologic studies and a growing number of epidemiologic studies have shown that vaccinating\npreviously infected individuals significantly enhances their immune response and effectively reduces the risk of\nsubsequent infection, including in the setting of increased circulation of more infectious variants (CDC, 2021).","1687":"COVID-19 vaccination providers are required to\nimplement all recommendations of the ACIP, adopted by the CDC Director, relevant to COVID-19 vaccination including:\nUse of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson)\nand mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on\nImmunization Practices \u2014 United States, July 2021\nUse of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory\nCommittee on Immunization Practices \u2014 United States, June 2021\nThe Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19\nVaccine in Adolescents Aged 12\u201315 Years \u2014 United States, May 2021\nUpdated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen\n(Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among\nVaccine Recipients \u2014 United States, April 2021\nInterim Recommendation for Use of Janssen COVID-19 Vaccine \u2014 United States, February 2021\nInterim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine, United States 2020\nInterim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine, United States, December 2020\nInterim Recommendation for Use of Moderna COVID-19 Vaccine, United States, December 2020\n\uf209\n\uf20c\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\nInterim Recommendation for Use of Moderna COVID 19 Vaccine, United States, December 2020\nUpdated Interim Recommendation for Allocation of COVID-19 Vaccine, United States, December 2020\nFind more information about vaccine administration and reporting requirements.","1897":"COVID-19 Vaccines Work\nHow and Why CDC Monitors Vaccine Effectiveness\n\u2022\n\u2022\n\u2022\nVaccine Effectiveness\nVaccine effectiveness is a measure of how well vaccination protects people against outcomes such as infection, symptomatic\nillness, hospitalization, and death. Vaccine effectiveness is typically measured through observational studies specifically\ndesigned to estimate individual protection from vaccination under \u201creal-world\u201d conditions. Data on Vaccine Effectiveness and Vaccine Breakthrough\nInfections\nAs part of CDC\u2019s ongoing efforts to understand how well COVID-19 vaccines are working, CDC is monitoring vaccine\neffectiveness and rates of breakthrough infections, hospitalizations, and deaths.","3922":"Underlying Health Conditions\nCertain underlying health conditions you have (for example, obesity\nor chronic obstructive pulmonary disorder) may affect your risk of\nbecoming very sick if you get COVID-19. Often, the more health conditions you have, the higher your risk. Certain conditions increase your risk more than others. For example,\nsevere heart disease increases your risk more than high blood\npressure. Learn more about how different underlying health conditions affect the chances of getting very sick or dying from\nCOVID-19. Vaccination\nCOVID-19 vaccines are safe and effective.","2264":"Staying up to date\u202fmeans getting all recommended COVID-19 vaccines including boosters when eligible. If your loved one is not able to ask questions or otherwise communicate with the LTC staff, here\u2019s what to know about\nconsent for getting a COVID-19 vaccine:\nResidents and their families can ask a LTC provider about the current COVID-19 vaccination rate among their staff and\nresidents. Nursing homes are required by the Centers for Medicare and Medicaid Services (CMS) to monitor weekly COVID-19\nvaccination data for residents and healthcare personnel through CDC\u2019s National Healthcare Safety Network.","9736":"Countries such as the United Kingdom (JCVI, 2021a-b), Canada (National Advisory Committee on Vaccination,\n2021), Germany, and France have recommended heterologous dosing, including with use of Pfizer-BioNTech\nCOVID-19 vaccine, for an additional primary series and\/or booster dose based on their reviews of available\nimmunological and safety data, as well as the epidemiology of COVID-19 and other contextual factors.","1120":"Older Adults and People with\nDisabilities\nChildren and Adolescents\nHomebound Persons\nDialysis Patients\nHealthcare Personnel\nTeachers, School Staff, and Child Care\nWorkers\nPregnant or Breastfeeding Patients\nPeople with Certain Underlying\nMedical Conditions\nPatients Vaccinated Outside the US\nPatients Receiving Antiviral Therapy\nResources\nHealth\nDepartments\n\uf426\nYou and Your\nFamily\n\uf426\nCOVID-19 Vaccine Effectiveness and Safety\nMMWR COVID-19 Vaccine Reports\nEquity in Vaccination\nCDC\u2019s program, Partnering for Vaccine Equity, aims to\nreduce disparities in disproportionately affected\ncommunities by supporting a wide variety of partners\nworking to increase vaccine confidence and access\namong racial and ethnic minority groups. Equity in Vaccination\nGet Vaccinated\nFind COVID-19 vaccines and boosters near you. Message & data rates may apply.","1996":"CDC and U.S. Food and Drug\nAdministration (FDA) continue to monitor vaccines, keep people informed of findings, and use data to make COVID-19\nvaccination recommendations. Serious Health Events after COVID-19 Vaccination Are Rare\nSerious reactions after COVID-19 vaccination in children and teens are rare. When they are reported, serious reactions most\nfrequently occur within a few days after vaccination. Rare cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer lining of the heart)\nhave been reported after children and teens ages 5 years and older got the Pfizer-BioNTech COVID-19 vaccine.","7768":"Over 350 million mRNA vaccines were given during the study period\nand CDC scientists found that rates of myocarditis were highest following the second dose of an mRNA vaccine\namong males in the following age groups:\n12\u201315 years (70.7 cases per one million doses of Pfizer-BioNTech)\n16\u201317 years (105.9 cases per one million doses of Pfizer-BioNTech)\n18\u201324 years (52.4 cases and 56.3 cases per million doses of Pfizer-BioNTech and Moderna, respectively)\nMultiple studies and reviews of data from vaccine safety monitoring systems continue to show that vaccines are safe. As\na result, the agency will refocus enhanced surveillance and safety monitoring efforts toward children and adolescents.","2834":"It is important to rule out other potential causes of myocarditis and pericarditis. Consider consultation with infectious\ndisease and\/or rheumatology to assist in this evaluation. Where available, evaluate for potential causes of myocarditis and pericarditis, particularly acute COVID-19 infection\n(such as PCR testing), current or prior SARS-CoV-2 infection (such as, detection of SARS-CoV-2 antibodies), and other\nviral causes (such as, enterovirus PCR and comprehensive respiratory viral pathogen testing).","3497":"Follow recommendations for protecting yourself and others. If you have symptoms of COVID-19, stay in your cabin and notify the onboard medical center immediately. It\u2019s important to report your symptoms, even if they are mild, to protect others on board including\npassengers at increased risk for severe illness and crew. \uf309 Masks\nFollow any ship-specific mask protocols. Follow CDC\u2019s recommendations for wearing masks in travel and public transportation settings. If You Develop Symptoms or Use a Self-Test on Board with a Positive Result\nIsolate yourself in your cabin immediately. Call your ship\u2019s medical center.","7069":"For example, COVID-19 during pregnancy\nincreases the risk of delivering a preterm (earlier than 37 weeks) or stillborn infant. People with COVID-19 during pregnancy\nmay also be more likely to have other pregnancy complications. See the latest data on birth and infant outcomes among pregnant women with COVID-19. COVID-19 Vaccines and Pregnancy\nCOVID-19 vaccination is recommended for everyone aged 6 months and older, including\u202fpeople who are pregnant,\nbreastfeeding,\u202ftrying to get pregnant now, or might become pregnant in the future. This recommendation includes getting\nboosters when it is time to get one.","2559":"Interim COVID-19 Immunization Schedule\nfor Persons 6 Months of Age and Older\nTable 2.","5861":"2 A non-FDA authorized or approved COVID-19 vaccine that is listed for emergency use by the World Health Organization, or is included in CDC\u2019s\nTechnical Instructions for Implementing Presidential Proclamation Advancing Safe Resumption of Global Travel During the COVID-19 Pandemic and\nCDC\u2019s Order, or that is a non-placebo part of a clinical trial within or outside the United States that is a WHO-EUL COVID-19 vaccine or a vaccine that is\nnot listed for emergency use by WHO but for which a U.S. data and safety monitoring board or equivalent has independently confirmed efficacy in the\nUnited States (hereinafter \u201cnon-FDA authorized or approved COVID-19 vaccines\u201d).","2412":"In addition, a recent report using the v-safe COVID-19 vaccine pregnancy safety monitoring\nsystem data showed that 4,800 people had a positive pregnancy test after receiving the first dose of an mRNA COVID-19\nvaccine. Another report using data from eight U.S. healthcare systems documented more than 1,000 people who\ncompleted COVID-19 vaccination (with any COVID-19 vaccine) before becoming pregnant. Learn more: COVID-19 Vaccines While Pregnant or Breastfeeding. No Evidence that COVID-19 Vaccines Affect Fertility\nThere is currently no evidence that vaccine ingredients or antibodies made following COVID-19 vaccination would cause any\nproblems with becoming pregnant now or in the future.","4905":"PEG and polysorbate are structurally related, and cross-reactive hypersensitivity between these compounds may occur. People with a known allergy to polysorbate have a contraindication to both Novavax and Janssen COVID-19 vaccines and a precaution to\nmRNA COVID-19 vaccines (i.e., Moderna or Pfizer-BioNTech). ll h ll l d d f h h\f10\/30\/22, 9:16 AM Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates | CDC\nIn all other cases, an allergy-related contraindication to one type of COVID-19 vaccine is a precaution to the others. For people with these precautions, referral to an allergist-immunologist should be considered.","6696":"Follow additional precautions for cleaning and disinfecting places where people with asthma might be, to reduce\nexposure to asthma triggers. Use products safely and correctly:\nAlways read and follow the directions on the product label to ensure you are using it safely and effectively. Wear skin protection such as gloves and consider eye protection to protect yourself against splashes. Make sure there is enough air flow (ventilation). Use only the amount recommended on the label. Use water at room temperature for dilution (unless stated otherwise on the label). Do NOT mix chemical products. Label diluted cleaning solutions.","6897":"Symptoms may\nappear 2 to 14 days after exposure to the virus. Symptoms may include: fever or chills, cough, shortness of\nbreath, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or\nrunny nose, nausea or vomiting, and diarrhea. Who can receive primary and additional dose(s) of the COVID-19 vaccine by Pfizer-BioNTech under the\nEUI? People who can receive the COVID-19 vaccine by Pfizer-BioNTech under EUI are described below.","4289":"If you are taking medications that suppress the immune system, you should talk to your healthcare provider about what\nis currently known about COVID-19 vaccine effectiveness. Ask about the best timing for you to get your vaccine. \u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nGet a COVID-19 vaccine with your routine medical procedures and screenings\nYou can combine most procedures, screenings, and vaccinations at the same appointment when you get your COVID-19\nvaccination. Talk to your healthcare provider if you have questions. Children, teens, and adults may get a COVID-19 vaccine and other vaccines, including a flu vaccine, at the same time.","9808":"Risk\u2010Benefit of the COVID-19 vaccine by Pfizer-BioNTech as Primary or Additional Vaccination for Individuals\nDescribed in the EUI\nThe duration of vaccine-induced protection from primary vaccination with COVID-19 vaccines is unknown. Efficacy data from clinical studies of 2-dose primary series supported benefit of the COVID-19 vaccine by\nPfizer-BioNTech in preventing severe COVID-19 and supported its FDA approval. Effectiveness of an additional\nprimary dose of the COVID-19 vaccine by Pfizer-BioNTech is inferred from immunogenicity data in\nimmunocompromised adults who received a single additional primary dose.","3286":"Febrile seizures can occur in infants and young children ages 6 months\u20135 years with any condition that causes a fever (most\ncommon with high fevers), including COVID-19 . Febrile seizures are uncommon after vaccination and were rare in mRNA\nCOVID-19 vaccine clinical trials for infants and young children. In rare instances, administration of certain combination\nvaccines or more than one vaccine at the same clinic visit has been associated with an increased risk of febrile seizures in\ninfants and young children. The impact of coadministration of COVID-19 and routine vaccines on the risk of febrile seizures\nhas not been specifically studied.","8318":"10\/30\/22, 9:17 AM Talking to Recipients about COVID-19 Vaccination | CDC\nVaccines & Immunizations\nVaccines & Immunizations\nVaccines & Immunizations Home\nVaccine Recipient Education\nQuick References for COVID-19 Vaccine Recipients Who Want More Information\nMany people have questions about the coronavirus disease 2019 (COVID-19) vaccines. As vaccine recipients\u2019 most-trusted\nsource of information on vaccines, you play a critical role in helping vaccine recipients understand the importance of\nvaccination and that COVID-19 vaccines are safe and effective. The following resources will help you share clear and accurate information about COVID-19 vaccines, raise awareness\nabout the benefits of vaccination, and address common questions and concerns about what to expect when getting\nvaccinated.","2784":"Visit the National Domestic Violence Hotline or call 1-800-799-7233 and TTY 1-800-787-3224. Visit the National Suicide Prevention Lifeline or call 1-800-273-8255\n\u2022\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\uf1ae Listen with compassion\nThe unknown and long-term nature of a post-COVID condition can create stress. Taking steps to\nunderstand the person\u2019s experiences might make them feel less isolated\f10\/30\/22, 9:42 AM Caring for People with Post-COVID Conditions | CDC\nunderstand the person s experiences might make them feel less isolated. What to do:\nWhen listening, give feedback that acknowledges and validates what they are going through.","8768":"They should do this by\nconsidering the person\u2019s ability to:\nWear a mask correctly (proper mask size and fit)\nAvoid frequent touching of the mask and face\nLimit sucking, drooling, or having excess saliva on the mask\nRemove the mask without assistance\nPeople who are deaf or hard of hearing\nThese individuals may consider:\nWearing a clear mask or a cloth mask with a clear panel\nIf a clear mask is not available, using written communication, closed\ncaptioning, or decreasing background noise to make communication\npossible while wearing a mask that blocks lips\nTravelers\nWearing a high-quality\nmask while you travel\ncan help protect you\nand others. Learn about the latest\nrecommendation for\nwearing masks during\ntravel.","7149":"VACCINE INFORMATION FACT SHEET FOR RECIPIENTS AND CAREGIVERS\nABOUT COMIRNATY (COVID-19 VACCINE, mRNA), THE PFIZER-BIONTECH\nCOVID-19 VACCINE, AND THE PFIZER-BIONTECH COVID-19 VACCINE,\nBIVALENT (ORIGINAL AND OMICRON BA.4\/BA.5) TO PREVENT CORONAVIRUS\nDISEASE 2019 (COVID-19) FOR USE IN INDIVIDUALS 12 YEARS OF AGE AND\nOLDER\nFOR 12 YEARS OF AGE AND OLDER\nYou are being offered either COMIRNATY (COVID-19 Vaccine, mRNA), the\nPfizer-BioNTech COVID-19 Vaccine, or the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent (Original and Omicron BA.4\/BA.5), hereafter referred to as the\nPfizer-BioNTech COVID-19 Vaccine, Bivalent, to prevent Coronavirus Disease\n2019 (COVID-19) caused by SARS-CoV-2.","4504":"10\/30\/22, 9:40 AM How to Use Your N95 Respirator | CDC\nHow to Use Your N95 Respirator\nWear Your N95 Properly So It Is Effective\nN95s must form a seal to the face to work properly. This is especially important for people at increased risk for\nsevere disease. Wearing an N95 can make it harder to breathe. If you have heart or lung problems, talk to your\ndoctor before using an N95. Some N95s may contain latex in the straps. If you have natural rubber latex allergies, see the manufacturers\u2019\nwebsite for information about your specific model.","1128":"CDC Privacy Policy\n\uf374 Find a vaccine near you\n\uf33f Call 1-800-232-0233\n\uf2ba Text your zip code to 438829\nGet Email Updates\nTo receive email updates about this page, enter your\nemail address:\n\uf14a\nEmail Address\nWhat's this? Submit\n\uf1e5 Add CDC web content on your site\nPut CDC syndicated pages on your website for free. Just add a small piece of web code to your page and the\ncontent will automatically update whenever CDC updates this page. Content Syndication\nLast Reviewed: May 13, 2022","9919":"Clinical considerations based on the age of the recipient include:\nCOVID-19 vaccines products (monovalent and bivalent)\nhave different age indications. \u0083 Janssen COVID-19 Vaccine can be administered to persons\n18 years of age and older in certain limited situations due to\nsafety considerations. \u0083 Novavax COVID-19 Vaccine can be administrated to persons 12\nyears of age and older. \u0083 Moderna COVID-19 Vaccine can be administered to persons\nages 6 months of age and older. \u0083 Pfizer-BioNTech COVID-19 vaccine can be administered to\npersons 6 months of age and older.","3628":"If traveling to an area with high or medium COVID-19 Community Levels, and you are, live with, or are visiting\nsomeone who is at higher risk of getting very sick, learn how to protect yourself and them. Make sure you understand and follow all state, tribal, local, and territorial travel restrictions, including proper mask\nwearing, proof of vaccination, or testing requirements. For up-to-date information and travel guidance, check the state, tribal, local and territorial health\ndepartment\u2019s website where you are, along your route, and where you are going. If traveling by air, check if your airline requires any testing, vaccination, or other documents.","6701":"Spray or pour spray products onto a cleaning cloth or paper towel instead of spraying the product directly onto the\ncleaning surface (if the product label allows). Store products safely and correctly\nStore and use chemicals out of the reach of children and pets. Label diluted cleaning solutions. Follow EPA\u2019s 6 steps for Safe and Effective Disinfectant Use . If you feel ill\nCall your healthcare provider to ask about your symptoms. If you don\u2019t have a healthcare provider, contact your nearest\ncommunity health center or health department. Remember to call 911 for medical emergencies.","355":"December 10, 2021: North Carolina identified an issue on December 10, 2021 at the federal level with linking data across\ndifferent vaccine sites (i.e., retail pharmacy, local health department, doctor\u2019s office). This resulted in an undercount of \u201cfully vaccinated people with a booster dose\u201d in North Carolina. This issue is being\nevaluated for resolution. On November 18, 2021, CDC updated the demographic data to use the date of vaccine administration instead of the\ndate when the vaccination was reported to CDC. Beginning November 18, 2021,vaccination demographic data now include Texas.","9544":"Children who turn from age 4 to age 5 years\nRecommended: Children who started a primary series and turned from age 4 to age 5 years between dose 1 and dose 2\nin the primary series should receive:\nof the product\nauthorized for\nchildren ages 6\n(maroon cap and\nlabel border)\nChild turns 5\nof the product\nauthorized for\nchildren ages 5\u201311\nyears (orange cap\nand label border)\nof the product\nauthorized for\nchildren ages\n(orange cap and\nlabel border)\nRecommended: Children who started a primary series and turned from age 4 to age 5 years between dose 2 and dose 3\nin the primary series should receive:\nof the product\nauthorized for\nchildren ages 6\n(maroon cap and\nlabel border)\nof the product\nauthorized for\nchildren ages 6\n(maroon cap and\nlabel border)\nChild turns 5\nof the product\nauthorized for\nchildren ages\n(orange cap and\nlabel border)\nAcceptable: If the following dosing occurs, it is NOT considered an error and the primary series is considered complete.","2791":"After taking time to compassionately listen to their responses, directly ask what they need or what\nyou can do to help. Learn more about CDC\u2019s tips on how to start these types of meaningful conversations. \u2022\n\u2022\n\u2022\n\uf1b0 Determine how you can help with what they need\nAfter you have listened and worked to understand what support looks like for the person, determine your\nrole in that support. Some people may want someone to listen to their experiences more frequently. Others may need more physical support (help with household chores, running errands).","9788":"Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022; originally CDC-issued 11\/17\/2021;\nSARS-CoV-2 infection induces a robust humoral and cellular immune response (CDC, 2021). Additionally, a\nlonger interval of at least 3 or 6 months between infection and vaccination may improve immune response by\nallowing time for the response to mature and avoiding interference from the vaccine (Abu-Raddad L, 2021;\nZhong, 2021). Multiple large-scale studies have observed decreased risk of subsequent infection with\nantigenically similar variants by 80-93% for months after infection (CDC, 2021). Delaying vaccination for 3\nmonths after infection may therefore help to maximize protection with minimal risk to the individual.","8550":"If multiple factors below indicate higher transmission risk, you should consider adding more prevention\nactions. Factors that lower or increase risk of transmission\nLength of time: How long were you with the infected person? Longer exposure time increases the risk of transmission (for example, contact longer than 15 minutes is more likely to result\nin transmission than two minutes of contact). Shorter exposure time\nLower Risk\nMedium exposure time\nModerate Risk\nLonger exposure time\nHigher Risk\nCough or heavy breathing: Was the infected person coughing, singing, shouting, or breathing\nheavily? Activities like coughing, singing, shouting, or breathing heavily due to exertion increase the risk of transmission.","7469":"Does CDC\u2019s Order requiring proof of COVID-19 vaccination apply to Ukrainians who are approved\nunder the Uniting for Ukraine program? \uf1aa\n\uf209\n\uf209\n\uf209\nYes, the Amended Order applies to any noncitizen nonimmigrant on a flight to the United States from a foreign country,\nregardless of whether the United States is the final destination or a connection to another country. If I am a noncitizen nonimmigrant connecting through the U.S. to another country, do I still have to\nshow proof of being fully vaccinated? \uf1aa\nQuarantine means to separate and restrict the movement of people who were exposed to a contagious disease to see if\nthey become sick.","9901":"Interim recommendations for use of the\ninactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm; updated 28\nOctober 2021. Geneva: World Health Organization; 2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-\n2019-nCoV-vaccines-SAGE-recommendation-BIBP. Zhong D, Xiao S, Debes AK, Egbert ER, Caturegli P, Colantuoni E, et al. Durability of Antibody Levels After\nVaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. JAMA. 2021 Dec","1978":"Tribal nations\nIndian Health Service (IHS) Vaccine Safety Monitoring Systems\nPassive Surveillance\nVaccine Adverse Event Reporting System (VAERS)\nVAERS functionality permits analysis of adverse events (AE) in IHS system of care\nIHS Safety Tracking & Response System\nFederal and participating tribal sites\nWorker-related AEs and vaccine administration errors\nActive Surveillance\nIHS Sentinel Survey\nBiweekly survey of AEs, including vaccine administration errors\n58 federal and tribal sites representing IHS Areas\nSupports reporting to VAERS\n\u2022 \uf209\n\u2022\n\u2022\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022\n-\n\u2022\n-\n-\n\u2022\n-\n-\n-\nRelated Pages\f10\/30\/22, 9:32 AM COVID-19 Vaccine Reporting Systems | CDC\ng\nAllergic Reactions after Getting a COVID-19 Vaccine\u200b\n\u203a\nSafety of COVID-19 Vaccines\n\u203a\nDeveloping COVID-19 Vaccines\n\u203a\nMore Information\nCDC\u2019s Vaccine Safety Information\nEnsuring the Safety of Vaccines in the United States\u200b\nACIP Work Groups\nCOVID-19 Vaccine Safety Publications\nLast Updated July 19, 2022","7975":"Google searches related to the COVID-19 vaccine during\nthis reporting period remained low relative to other topics such as Uvalde, TX, and monkeypox.e According to a Meltwater\ntrends analysis, there was a 17% decrease in news coverage and 45% decrease in social media mentions of COVID-19 vaccines.f\nRecent polling indicates fewer than a third of domestic consumers report being \u201csomewhat\u201d or \u201cvery\u201d worried about contracting\nAdditionally, sources indicate vaccine uptake plateauing,g as of May 31, 2022, COVID Data Tracker reported that 77.9% of\npeople had received at least one shot60 and 66.7% were fully vaccinated.61 Reported intention to vaccinate maintains a similarly\nconsistent cadence since approximately August 2021.c,62,63\nThe FDA64 and CDC65 strengthened recommendations and expansion of booster eligibility.","581":"August 11, 2022: New Jersey made updates to data previously submitted to CDC that resulted in a net increase of\n37,096 administered doses. August 11, 2022: California made updates to data previously submitted to CDC that resulted in a net increase of\n202,640 administered doses. August 4, 2022: Idaho made updates to data previously submitted to CDC that resulted in a net decrease of 42,051\nadministered doses. This contributed to a decrease in overall US figures. August 4, 2022: Illinois made updates to data previously submitted to CDC that resulted in a net increase of 77,754\nadministered doses.","1289":"Doses administered at any time after the recommended interval are valid. For more information, see timing, spacing, interchangeability, and coadministration of COVID-19 vaccines. \uf209\nIn accordance with general best practices for immunizations, routine administration of all age-appropriate doses of\nvaccines simultaneously is recommended for children, adolescents, and adults for whom no specific contraindications\nexist at the time of the healthcare visit. This includes simultaneous administration of COVID-19 vaccine and other\nvaccines. However, there are additional considerations for Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines if\nadministering an orthopoxvirus (monkeypox) vaccine. For more information, see Coadministration of COVID-19 vaccines with other vaccines.","9591":"\u2022 Revaccination of moderately or severely immunocompromised persons ages 12 years and older who\nreceived certain therapies (indicated below) and received primary dose(s) of COVID-19 vaccine prior to\nor during treatment. o\no\nReceived COVID-19 vaccine dose(s) during treatment with B-cell-depleting therapies over a\nlimited period\nReceived COVID-19 vaccine dose(s) prior to or during treatment involving hematopoietic cell\ntransplant (HCT) or chimeric antigen receptor (CAR)-T-cell therapy\nThe COVID-19 vaccine by Moderna under EUI also allow similar uses as an alternative mRNA COVID-19 vaccine\nto Pfizer-BioNTech, and the same or similar recommendations in the EUI also apply to the use of the COVID-19\nvaccine by Moderna under EUI.","9108":"\uf1aa\nIf you are sick, tested positive, or were exposed to COVID-19, see Can I Travel If. Using public transportation and being in transportation hubs can involve spending long periods of time in areas that\nmay be crowded or poorly ventilated, increasing chance for exposure to COVID-19. People on public transportation may not have the option to avoid being around people who are not wearing masks by\ndisembarking or relocating to another area, such as on an airplane during flight, or on a bus or train while it is in\nmotion.","6809":"V-safe also provides second-dose reminders if needed and live telephone\nfollow-up by CDC if participants report a significant health impact following COVID-19\nvaccination. For more information on how to sign up, visit: www.cdc.gov\/vsafe. WHAT IF I DECIDE NOT TO HAVE MY CHILD GET THE PFIZER-BIONTECH\nCOVID-19 VACCINE OR THE PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT? Under the EUA, there is an option to accept or refuse receiving any of these vaccines. Should you decide for your child not to receive any of these vaccines, it will not change\nyour child\u2019s standard medical care.","3164":"Considerations for timing of COVID-19 vaccination in relation to\nimmunosuppressive therapies\n\uf209\nTable of Contents \uf426\nTiming, spacing, interchangeability, and coadministration of\n4-Day grace period\nTransitioning from a younger to older age group\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nHowever, FDA authorization allows for dosing options for certain situations where a child ages from a younger to older age\ngroup for Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine . Refer to Table 1 for information about\nage-specific vaccine products and dosages. For information on the timing of COVID-19 vaccination (primary series and booster doses) after SARS-CoV-2 infection, see\nCOVID-19 vaccination and SARS-CoV-2 infection.","8549":"If multiple factors below indicate higher transmission risk, you should consider adding more prevention\nactions. Factors that lower or increase risk of transmission\nLength of time: How long were you with the infected person? Longer exposure time increases the risk of transmission (for example, contact longer than 15 minutes is more likely to result\nin transmission than two minutes of contact). Shorter exposure time\nLower Risk\nMedium exposure time\nModerate Risk\nLonger exposure time\nHigher Risk\nCough or heavy breathing: Was the infected person coughing, singing, shouting, or breathing\nheavily? Activities like coughing, singing, shouting, or breathing heavily due to exertion increase the risk of transmission.","6818":"If you are considering having your child receive the\nPfizer-BioNTech COVID-19 Vaccine or the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent with other vaccines, discuss the options with your child\u2019s healthcare provider. WHAT IF MY CHILD IS IMMUNOCOMPROMISED? If your child is immunocompromised, you may be given the option to have your child\nreceive a third primary series dose of the Pfizer-BioNTech COVID-19 Vaccine. Individuals 5 through 11 years of age may receive a booster dose with the\nPfizer-BioNTech COVID-19 Vaccine, Bivalent.","5097":"Fully vaccinated people who meet criteria will no longer\nbe required to quarantine following an exposure to someone with COVID-19. Additional considerations for patients\nand residents in healthcare settings are provided. Additional information and updated recommendations for testing for TB infection. TB testing can be done before or at\nthe same time as mRNA COVID-19 vaccination, or otherwise delayed for \u22654 weeks after the completion of mRNA\nCOVID-19 vaccination. Last Reviewed: October 19, 2022","9528":"Either dose may be:\n\u0083 0.25 mL (25 mcg) of the product authorized for children ages 6 months\u20135 years (dark blue cap\/magenta label border), or\n\u0083 0.50 mL (50 mcg) of the product authorized for children ages 6\u201311 years (dark blue cap\/purple label border)\nOR\nOR\fSpecial Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nModerna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group (continued)\nChildren who turn from age 11 years to 12 years\nRecommended: Children who started a primary series and turned from age 11 to age 12 years before completion of the\nseries should receive:\nof the product\nauthorized for\nchildren ages\n6\u201311 years (dark\nblue cap\/purple\nlabel border)\nof the product\nauthorized for children\nages 12 years and\nolder (red cap\/light\nblue label border)\nChild turns 12\nAcceptable: If the following dosing occurs, it is NOT considered an error and the primary series is considered complete.","6477":"Oral antivirals can be taken at home and must be given within 5 days after\nthe first symptoms of COVID-19 appear. Monoclonal antibodies\n\uf209\n\uf209\f10\/30\/22, 9:38 AM People Who Are Immunocompromised | CDC\nMonoclonal antibodies can block the virus that causes COVID-19 from entering cells in your body, which can limit the\namount of the virus within your body. These must be prescribed and administered by a healthcare provider within 7 days\nafter first symptoms of COVID-19 appear. Make a COVID-19 plan now so you\u2019re prepared. Consider the ways you will protect yourself and how to be prepared if you get\nsick with COVID-19.","5564":"10\/30\/22, 9:39 AM Masks and Respirators\ntool for preventing spread of COVID-19, and it is important to remember that any mask is better than no mask. This page\npresents options in order of least to most protective. To protect yourself and others from COVID-19, CDC continues to\nrecommend that you wear the most protective mask you can that fits well and that you will wear consistently. Types of Masks and Respirators\nMasks are made to contain droplets and particles you breathe, cough, or sneeze out.","5785":"Has the COVID-19 vaccine by Moderna been used before? Yes. Millions of people have received this vaccine in the United States since it became available starting\nDecember 18, 2020. Also, in clinical trials, approximately 15,400 people 18 ages years and older received at\nleast 1 dose of the vaccine and approximately 2,500 people ages 12\u201317 years received a primary series of\nthe vaccine. There have been some studies in people who received the COVID-19 vaccine by Moderna after\ncompleting a primary vaccination with a non-FDA authorized or approved COVID-19 vaccine or Janssen\nCOVID-19 Vaccine. What are the risks of the COVID-19 vaccine by Moderna?","1571":"6\/23\/22 Update (replaces 6\/18\/22 update; and revised to be a consolidated update that addresses all\nprimary series pediatric COVID-19 vaccination; 6\/23\/22 update also adds availability of age-appropriate\nModerna COVID-19 Vaccine for 6 years through 17 years of age):\nCOVID-19 Vaccination of Children 6 Months through 17 Years of Age\nPursuant to CDC\/ACIP recommendations and Secretarial Directives:\nAll authorized providers in the CDC COVID-19 Vaccination Program shall make immediately available and administer\nupon request \u2013\na two-dose series using the age-appropriate Moderna COVID-19 Vaccine product for children ages 6 months\nthrough 17 years\na three-dose series using the age-appropriate Pfizer-BioNTech COVID-19 Vaccine product for children ages 6\nmonths through 4 years\na two-dose series using the age-appropriate Pfizer-BioNTech COVID-19 Vaccine product for children ages 5 years\nthrough 17 years\n6\/23\/22 Update (replaces 6\/18\/22, 1\/6\/22, 9\/14\/21 and 10\/7\/21 updates; additional eligible group noted\nin bold italics; Updated on 10\/12\/22 to remove reference to the purple cap Pfizer-BioNTech vials which\nare no longer available):\nThird Dose for Recipients of Pfizer-BioNTech or Moderna COVID-19 Vaccine Who Are Immunocompromised\nPursuant to CDC\/ACIP recommendations and Secretarial Directives, a third primary dose of an mRNA COVID-19\nvaccine should be administered using the same mRNA COVID-19 vaccine as was administered for the 2-dose primary\nseries to persons who are moderately to severely immunocompromised at least 28 days after completing the two-\ndose primary series:\nPfizer-BioNTech COVID-19 Vaccine \u2013\nOrange cap to children 5 through 11 years of age\nGray cap to people 12 years and older\nModerna COVID-19 Vaccine \u2013\nDark blue cap\/magenta border to children 6 months through 5 years of age\nDark blue cap\/purple border to children 6 years through 11 years of age\nRed cap\/light blue border to people 12 years and older\nCOVID-19 Vaccination Under the CDC Interim Clinical Considerations and Emergency Use Instructions\nProviders may also administer COVID-19 vaccines as described in CDC guidance as updated from time to time:\nInterim Clinical Considerations for Use of COVID-19 Vaccines in the United States\nEmergency Use Instructions (see vaccine Fact Sheets)\n5\/23\/22 Update (revision of 5\/19\/22 update to add reference to the May 23, 2022, Secretarial Directive;\n9\/1\/22 revision noted in bold italics to clarify that booster doses available to this age group are\f10\/30\/22, 9:16 AM COVID-19 Vaccination Provider Requirements and Support | CDC\n9\/1\/22 revision noted in bold italics to clarify that booster doses available to this age group are\nmonovalent):\nCOVID-19 Vaccine Booster Doses for Children 5 through 11 Years of Age\nPursuant to CDC\/ACIP recommendations and the May 23, 2022, Secretarial Directive on Pediatric and Second COVID-\n19 Vaccine Booster Doses, all providers in the CDC COVID-19 Vaccination Program shall make immediately available\nand administer a single monovalent booster dose of Pfizer-BioNTech COVID-19 vaccine to individuals seeking such a\ndose as follows:\nChildren ages 5 through 11 years should receive a single monovalent Pfizer-BioNTech COVID-19 vaccine booster\ndose at least 5 months after completion of a Pfizer-BioNTech COVID-19 vaccine primary series.","3715":"\u25aa Updated the eligible age of booster use of COVID-19 vaccine by Pfizer-BioNTech to 12 years and\nolder, booster dose interval to 5 months, vaccine use for those with incomplete primary dose\nseries of non-FDA-authorized or approved COVID-19 vaccines, and included the new FDA-\napproved formulation of the vaccine for persons ages 12 years and older (gray-capped multi-\ndose vials) on January 7, 2022.","1063":"Don\u2019t delay: Treatment must be\nstarted within days of when you\nfirst develop symptoms to be effective. \uf209\nPeople who are more likely to get very sick include older adults (ages 50 years or more, with risk increasing with age), people\nwho are unvaccinated, and people with certain medical conditions, such as chronic lung disease, heart disease, or a\nweakened immune system. Being vaccinated makes you much less likely to get very sick.","178":"Related Pages\nReducing the Risk of SARS-CoV-2 Spreading between People and Wildlife\n\u203a\nWhat You Should Know about COVID-19 and Pets\n\u203a\nMore Information\nInformation on Bringing an Animal into the United States\nWorld Organisation for Animal Health: COVID-19 Events in\nAnimals\nUSDA: Confirmed cases of SARS-CoV-2 in Animals in the\nUnited States\nUSDA: Coronavirus Disease 2019\nFDA: Coronavirus Disease 2019\n\uf209\n\uf209\n\uf209\n\uf209\nMedia Announcements\nConfirmation of COVID-19 in a Canada Lynx at a Pennsylvania Zoo\nConfirmation of COVID-19 in Hyenas at a Colorado Zoo\nConfirmation of COVID-19 in a Coatimundi at an Illinois Zoo\nConfirmation of COVID-19 in a Binturong and a Fishing Cat at an Illinois Zoo\nConfirmation of COVID-19 in Ferret in Florida\nConfirmation of COVID-19 in Deer in Ohio\nTexas A&M Research Uncovers First Known COVID-19 UK Variant In Animals\nConfirmation of COVID-19 in a Snow Leopard at a Kentucky Zoo\u200b\nUSDA Confirms SARS-CoV-2 in Mink in Utah\nConfirmation of COVID-19 in Pet Dog in New York\nConfirmation of COVID-19 in Two Pet Cats in New York\nUSDA Statement on the Confirmation of COVID-19 Infection in a Tiger in New York\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022 \uf209\n\u2022\n\u2022 \uf209\nLast Updated July 5, 2022","1927":"The study will:\nEnroll pregnant people who plan to receive COVID-19 vaccination; COVID-19 vaccines will be given as part of the\nstudy\nCollect baseline maternal health information, including if they previously had COVID-19\nFollow people during pregnancy and for three months after delivery\nFollow babies through their first three months of life\nCDC: Birth Defects Study to Evaluate Pregnancy Exposures (BD-STEPS) \u2014 BD-STEPS is an ongoing study that collects\ninformation including COVID-19 vaccination information from people who have recently been pregnant to understand\n\u2022\n\u2022\n\u2022 \uf209\n\uf209\n\u2022\n\u2022\n-\n-\n-\n\u2022\n\u2022\n\u2022\n\u2022\n-\n-\n-\n-\n\u2022\f10\/30\/22, 9:32 AM COVID-19 Vaccine Monitoring Systems for Pregnant People | CDC\ninformation, including COVID-19 vaccination information, from people who have recently been pregnant to understand\nthe potential causes of birth defects and how to prevent them.","5674":"Although\nrespirators may be available in smaller sizes, they are typically designed to be used by adults in workplaces, and therefore\nhave not been tested for broad use in children. Selecting Masks\nMasks and respirators should not be worn by children younger than 2 years. Choose a high-quality and comfortable mask or respirator that your child can wear properly. A poorly fitting or\nuncomfortable mask or respirator might be worn incorrectly or removed often, and that would reduce its intended\nbenefits. Choose a size that fits over the child\u2019s nose and under the chin but does not impair vision.","7979":"Google searches related to the COVID-19 vaccine during\nthis reporting period remained low relative to other topics such as Uvalde, TX, and monkeypox.e According to a Meltwater\ntrends analysis, there was a 17% decrease in news coverage and 45% decrease in social media mentions of COVID-19 vaccines.f\nRecent polling indicates fewer than a third of domestic consumers report being \u201csomewhat\u201d or \u201cvery\u201d worried about contracting\nAdditionally, sources indicate vaccine uptake plateauing,g as of May 31, 2022, COVID Data Tracker reported that 77.9% of\npeople had received at least one shot60 and 66.7% were fully vaccinated.61 Reported intention to vaccinate maintains a similarly\nconsistent cadence since approximately August 2021.c,62,63\nThe FDA64 and CDC65 strengthened recommendations and expansion of booster eligibility.","6947":"Has the COVID-19 vaccine by Pfizer-BioNTech been used before? Yes. Millions of people have received this vaccine in the United States since it became available starting in\nmid-December 2020. Also, in clinical trials, approximately 23,000 people ages 12 years and older received\nat least 1 dose of the vaccine. There have been some studies in people who received the COVID-19 vaccine\nby Pfizer-BioNTech after completing a primary vaccination with a non-FDA authorized or approved COVID-\n19 vaccine or Janssen COVID-19 Vaccine. What are the risks of the COVID-19 vaccine by Pfizer-BioNTech?","1520":"Provider shall not be required to engage in any fit testing, medical evaluations, or training, regardless of\nwhether individuals obtain masks for employment or other purposes. 6. Absent willful misconduct by provider, provider shall have no responsibility for individual usage of masks or other\nconduct. Providers are not responsible for monitoring or enforcing those that choose to take masks nor confirm\nthat they are for personal versus business or other usage. 7. Providers will post a web link to a USG and\/or manufacturer URL, provided by HHS, on their websites to\ninstructions for proper fit and use.","2013":"\u2022\n\u2022\n\u2022\n\u2022\n\u2022\nLearn more about COVID-19 vaccine safety from published research and how CDC and FDA are making sure COVID-19\nvaccines used in the United States are safe. \u2022\n\uf20c\f10\/30\/22, 9:31 AM COVID-19 Vaccine Safety in Children and Teens | CDC\ndoses given of the Pfizer-BioNTech COVID-19 vaccine between November 2021 and April 2022 . In reports of myocarditis following mRNA-based COVID-19 vaccination from December 2020 to August 2021 , the risk\nof myocarditis was highest following the second dose of the Pfizer-BioNTech vaccine in adolescent and young adult\nmales.","688":"January 13, 2022: Colorado made updates to data previously submitted to CDC that resulted in an increase of\n47,260 doses administered. January 13, 2022: North Carolina made updates to data previously submitted to CDC that resulted in an increase of\n41,000 doses administered. January 13, 2022: Hawaii made updates to data previously submitted to CDC that resulted in an increase of 318,481\ndoses administered. January 11, 2022: New Jersey made updates to data previously submitted to CDC that resulted in an increase of\n31,680 doses administered. January 6, 2022: California updated 22,696,262 records previously submitted to CDC.","4345":"Vaccination providers must report COVID-19 vaccinations to their IIS\nand related systems. Your state\u2019s IIS cannot issue you a vaccination card, but they can provide a digital or\npaper copy of your vaccination record. If you need another COVID-19 vaccine dose and are unable to get a copy of your vaccination card or\nvaccination record, talk to a vaccination provider. If you have additional questions about vaccination records, please contact your state health department. Your local\nor state health department can also provide more information about the laws or regulations in your area.","1126":"CDC Privacy Policy\n\uf374 Find a vaccine near you\n\uf33f Call 1-800-232-0233\n\uf2ba Text your zip code to 438829\nGet Email Updates\nTo receive email updates about this page, enter your\nemail address:\n\uf14a\nEmail Address\nWhat's this? Submit\n\uf1e5 Add CDC web content on your site\nPut CDC syndicated pages on your website for free. Just add a small piece of web code to your page and the\ncontent will automatically update whenever CDC updates this page. Content Syndication\nLast Reviewed: May 13, 2022","4337":"Contact your vaccination provider or\nlocal health department to learn if a digital copy of your card is available to you. If you were vaccinated abroad there are ways you can update your U.S. vaccination record. To report suspicious activity involving fake CDC COVID-19 vaccination cards, please visit Fraud Alert: COVID-19 Scams\nor call 1-800-HHS-TIPS. \u2022\n\u2022\n\u2022 \uf209\nWhat if you lose your card? \uf1aa\nContact your vaccination provider directly to request a vaccination card or to get a copy of your vaccination\nrecord. If you cannot contact your vaccination provider site directly, contact your state health department\u2019s\nimmunization information system (IIS).","5305":"Under an EUA, the FDA has authorized the emergency use of the Janssen COVID-19 Vaccine to\nprevent COVID-19 in individuals 18 years of age and older for whom other FDA-authorized or\napproved COVID-19 vaccines are not accessible or clinically appropriate, and in individuals 18\nyears of age and older who elect to receive the Janssen COVID-19 Vaccine because they would\notherwise not receive a COVID-19 vaccine. For more information on EUA, see the \u201cWhat is an Emergency Use Authorization (EUA)?\u201d\nsection at the end of this Fact Sheet. WHAT SHOULD YOU MENTION TO YOUR VACCINATION PROVIDER BEFORE\nYOU GET THE JANSSEN COVID-19 VACCINE?","8011":"\u0082 COVID-19 vaccines help your body develop protection from the virus that causes COVID-19. Although vaccinated people\nsometimes get infected with the virus that causes COVID-19, staying up to date on COVID-19 vaccines significantly lowers\nthe risk of getting very sick, being hospitalized, or dying from COVID-19. CDC recommends that everyone who is eligible get\na booster and stay up to date on their COVID-19 vaccines, especially people with weakened immune systems.94\n\u0082 Layered prevention strategies \u2014 like staying up to date with vaccines and wearing masks \u2014 can help prevent COVID-19 and\nreduce the potential for strain on the healthcare system.","2237":"For the best\nprotection, everyone 6 months and older is recommended to stay up to date with their COVID-19 vaccines, which includes\ngetting boosters if eligible. Vaccine Breakthrough Infections\nCOVID-19 vaccines are effective at preventing severe disease, hospitalization, and death. However, since vaccines are not\n100% effective at preventing infection, some people who are up to date with the recommended vaccines\u202fwill still get COVID-\n19. This is called a\u202fbreakthrough infection. When people who are vaccinated develop symptoms of COVID-19, they tend to\nexperience less severe symptoms than people who are unvaccinated.","4649":"People who elect to receive Janssen COVID-19 Vaccine should be informed\nabout the risk and symptoms of TTS (see below), as well as the need to seek immediate medical care should symptoms\ndevelop. Vaccination schedule\nPeople who are not moderately or severely immunocompromised\nAdults ages 18 years and older are recommended to receive 1 primary dose and 1 booster dose at least 2 months after\nthe primary dose. A bivalent mRNA booster dose is recommended.","9602":"In 2013, the Pandemic and All-Hazards Preparedness Reauthorization Act included a new provision that\nallowed for the issuance of EUI to permit CDC to inform healthcare providers and recipients about certain uses\nof FDA-approved or cleared medical products. Specifically, EUI inform healthcare providers and recipients\nabout such products\u2019 approved, licensed, or cleared conditions of use. The CDC Director has statutory (legal)\nauthority to create, issue, and disseminate EUI before or during an emergency. 1 Comirnaty is the proprietary name for the product licensed under the Biologics License Application (BLA).","2342":"AGE GROUP\nPRIMARY SERIES PRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nChildren 5 years of age can get a\nPfizer-BioNTech booster at least\n2 months after their 3rd dose. (Children 6 months to 4 years\nare not recommended for a\nbooster.) Up to Date: Children 6 months to 4 years are up to date two weeks after completing the 3 dose of their primary\nseries. Children 5 years of age who received a Moderna primary series are up to date immediately after they have\nreceived the most recent booster recommended for them.","2735":"10\/30\/22, 9:42 AM Caring for People with Post-COVID Conditions | CDC\nEspa\u00f1ol | Other Languages\nCaring for People with Post-COVID Conditions\nHaving a post-COVID condition or supporting someone with a post-COVID condition can be challenging. It can be difficult to\ncare for yourself or loved ones, especially when there are few or no immediate answers or solutions. However, there are ways\nto help relieve some of the additional burdens of experiencing or caring for someone with a new and unknown condition. If you care for someone, remember to take steps to protect yourself and others from COVID-19. This information is intended for a general audience.","9563":"Either dose may be:\n\u0083 0.20 mL (10 mcg) of the product authorized for children ages 5\u201311 years (orange cap and label border), or\n\u0083 0.30 mL (30 mcg) of the product authorized for children ages 12\u201317 years (gray cap and label border)\nOR 3-8 weeks\nOR\fSpecial Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nInterchangeability of Moderna and Pfizer-BioNTech COVID-19 vaccines\nCOVID-19 vaccine from the same manufacturer should be used for the primary series.","7205":"The Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine,\nBivalent, or COMIRNATY (COVID-19 Vaccine, mRNA) will be given to you as an\ninjection into the muscle. Primary Series: The Pfizer-BioNTech COVID-19 Vaccine and COMIRNATY (COVID-19\nVaccine, mRNA) are given for the primary series. The vaccine is administered as a\n2-dose series, 3 weeks apart. A third primary series dose may be administered at least\n4 weeks after the second dose to individuals with certain kinds of immunocompromise.","5505":"\u2022\n\u2022\n\u2022\n\u2022\nPreventing Long COVID\nResearch suggests that people who are vaccinated but experience a breakthrough infection are less likely to report post-\nCOVID conditions, compared to people who are unvaccinated. Learn more about protecting yourself and others from COVID-19. The best way to prevent post-COVID conditions is to protect yourself and others from becoming infected. For people who\nare eligible, getting vaccinated and staying up to date with vaccines against COVID-19 can help prevent COVID-19\ninfection and protect against severe illness.","2341":"AGE GROUP\nPRIMARY SERIES PRIMARY SERIES\n4 weeks after 1st dose\nPRIMARY SERIES\nAt least 4 weeks after 2nd dose\nUPDATED (BIVALENT) BOOSTER\nChildren 5 years of age can get a\nPfizer-BioNTech booster at least\n2 months after their 3rd dose. (Children 6 months to 4 years\nare not recommended for a\nbooster.) Up to Date: Children 6 months to 4 years are up to date two weeks after completing the 3 dose of their primary\nseries. Children 5 years of age who received a Moderna primary series are up to date immediately after they have\nreceived the most recent booster recommended for them.","3719":"\u25aa Updated the eligible age of booster use of COVID-19 vaccine by Pfizer-BioNTech to 12 years and\nolder, booster dose interval to 5 months, vaccine use for those with incomplete primary dose\nseries of non-FDA-authorized or approved COVID-19 vaccines, and included the new FDA-\napproved formulation of the vaccine for persons ages 12 years and older (gray-capped multi-\ndose vials) on January 7, 2022.","8087":"However, monkeypox can spread to anyone through close, personal, often skin-to-skin contact. Anyone who has been in close contact with someone who has monkeypox is at risk.137\n\u0083 How do I know if I have monkeypox?d\n\u0082 People with monkeypox can get a rash that may be located on or near the genitals (penis, testicles, labia, and vagina) or\nanus (butthole) and could be on other areas like the hands, feet, chest, face, or mouth. \u008f The rash will go through several stages, including scabs, before healing. \u008f The rash can initially look like pimples or blisters and may be painful or itchy.","2486":"10\/30\/22, 9:39 AM COVID-19 by County | CDC\nEspa\u00f1ol | Other Languages\nCOVID-19 by County\nMany people in the United States have some protection, or immunity, against COVID-19 due to vaccination, previous\ninfection, or both. This immunity, combined with the availability of tests and treatments, has greatly reduced the risk of\nsevere illness, hospitalization, and death from COVID-19 for many people. At the same time, some people\u2014such as those who are older, are immunocompromised, have certain disabilities, or have\ncertain underlying health conditions\u2014continue to be at higher risk for serious illness.","5437":"Post-COVID conditions are found more often in people who had severe COVID-19 illness, but anyone who has\nbeen infected with the virus that causes COVID-19 can experience post-COVID conditions, even people who had\nmild illness or no symptoms from COVID-19. People who are not vaccinated against COVID-19 and become infected might also be at higher risk of developing\npost-COVID conditions compared to people who were vaccinated and had breakthrough infections. While most people with post-COVID conditions have evidence of infection or COVID-19 illness, in some cases, a\nperson with post-COVID conditions may not have tested positive for the virus or known they were infected.","5245":"Loss of taste and smell may persist for weeks or months\nafter recovery and need not delay the end of isolation. If you had no symptoms\nYou may end isolation after day 5.","3095":"People who are moderately or severely immunocompromised ages 18 years and older who received the Janssen COVID-19\nVaccine primary series dose are recommended to receive a second (additional) dose using a monovalent mRNA vaccine and 1\nbivalent mRNA booster dose (i.e., Moderna or Pfizer-BioNTech). The primary series dose and the additional dose are\nseparated by at least 4 weeks. The bivalent mRNA booster dose is administered at least 2 months after the additional dose\n(for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose. See Appendix A for additional information on Janssen COVID-19 Vaccine.","8827":"Please note: Any misrepresentation or misappropriation of the agency\u2019s materials, positions or logo\/marks in publications\nsold for profit will be referred to the HHS Office of the Inspector General (and possibly law enforcement and other entities) for\ninvestigation and possible enforcement and may be subject to civil money penalties under 42 U.S.C. Section 1320b-10. Page last reviewed: May 27 2021\f10\/30\/22, 9:25 AM Use of Agency Materials | Other | CDC\nPage last reviewed: May 27, 2021","8858":"Watch Video: Share Your COVID-19 Vaccination Experience with v-safe [00:00:31]\n\uf357\f10\/30\/22, 9:31 AM V-safe After Vaccination Health Checker | CDC\nWill I Ever be Contacted by v-safe Staff? If you enroll in v-safe and report that you are pregnant at the time of vaccination or after vaccination, the CDC COVID-19\nPregnancy Registry staff* may contact you. If you have symptoms or health problems that concern you at any time following COVID-19 vaccination, please contact your\nhealthcare professional. *Abt Associates\nhas been\ncontracted by the\nCDC to contact\nparticipants for\nCDC\u2019s v-safe COVID-\nPregnancy Registry.","4757":"*\nReceived a monovalent booster dose after completion of primary series Administer a bivalent mRNA booster dose if eligible. *\nTable B.4. Received all or some of the recommended doses of COVID-19 vaccines that are NOT FDA-authorized, FDA-\napproved, or among those listed for emergency use by WHO\nVaccination history Recommended actions\nReceived any number and combination of vaccine doses Do not count doses received toward vaccination in the US. Start primary series at least 28 days after the last dose of vaccine. Administer a bivalent mRNA booster dose if eligible.","977":"\u2022\n\u2022\n\u2022\n\u2022\n\uf6e0 COVID-19 Tests or Treatment\nCommunity-Based Testing Locations Treatment Locator\nTypes of Tests\nViral tests look for a current infection with SARS-CoV-2, the virus that causes COVID-19, by testing specimens from your nose\nor mouth. There are two main types of viral tests: nucleic acid amplification tests (NAATs) and antigen tests. In certain\ncircumstances, one test type may be recommended over the other. All tests should be performed following FDA\u2019s\nrequirements. NAATs, such as PCR-based tests, are most often performed in a laboratory. They are typically the most reliable tests for\npeople with or without symptoms.","2999":"The monovalent Novavax booster dose is administered at least 6 months after completion of any primary series and cannot be used in people\nwho previously received any booster dose(s). People ages 18 years and older who received the Janssen COVID-19 Vaccine primary series dose are recommended to receive\n1 bivalent mRNA booster dose (i.e., Moderna or Pfizer-BioNTech) at least 2 months after completion of the primary series\ndose (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose. See Appendix A for additional information on Janssen COVID-19 Vaccine.","1270":"Novavax COVID-19 vaccine for booster vaccination and Janssen COVID-19 Vaccine for primary series and booster\nvaccination should only be used in very limited situations. For more information, see COVID-19 vaccines. Is there a preferred COVID-19 vaccine? \uf1aa\nNo. You should administer the second dose as close as possible to the recommended interval after the first dose. However, if the second dose is administered after this interval, there is no need to restart the series.","6314":"\u2022\n\u2022\n\uf20c\n\u2022\n\u2022\nIf you think you or a loved one may have a post-COVID condition (new or persistent conditions occurring 4 or more weeks\nafter initial infection with SARS-CoV-2, the virus that causes COVID-19), taking a few steps to prepare for your meeting\nwith a healthcare provider can make all the difference in getting the proper medical evaluation, diagnosis, and treatment. You play a vital role in helping healthcare providers understand your or your family member\u2019s symptoms and how they\naffect your daily life.","2254":"These\nmedical conditions and living situations can make residents more likely to\nbe infected by the virus that causes COVID-19 and to become seriously ill\nfrom COVID-19. Children and adolescents with intellectual and developmental disabilities living in any type of shared setting, including\nintermediate care facilities and group homes, are also considered LTC residents. This means they are also more likely to be\ninfected or become seriously ill from COVID-19. If you live in a LTC setting, you can help protect yourself and the people around you by getting a COVID-19 vaccine as soon as\npossible.","6984":"It is your choice to receive or not receive the COVID-19 vaccine by Pfizer-BioNTech as a primary and\/or\nadditional dose. Should you decide not to receive it, it will not change your standard medical care. Will I get a vaccination card? When you are administered a primary, additional, or a booster dose of the COVID-19 vaccine by Pfizer-\nBioNTech, you will get a vaccination card to document when you received the shot. You should keep your\nvaccination card. What is the Countermeasures Injury Compensation Program?","3218":"Anaphylactic reactions have been rarely reported following receipt of COVID-19 vaccines. Administration of antihistamines\nbefore COVID-19 vaccination to prevent allergic reactions is not generally recommended. However, while antihistamines will\nnot prevent anaphylaxis, some experts advise antihistamine use as a means of preventing milder allergic reactions in patients\nwho might be at higher risk for allergic reactions. For more information on the assessment and potential management of\nanaphylaxis, see Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination. For more information on patient counseling, see Vaccine Recipient Education. Syncope (fainting) may occur in association with any injectable vaccine, especially in adolescents.","6610":"Get more information:\n\uf209\n\u2022 \uf209\n\u2022\n\u2022\n\u2022 \uf209\n\u2022\n\u2022 \uf209\n\u2022 \u00ae \uf209\n\u2022 SM\n\u2022 \uf209\n\u2022\n\u2022\n\u2022\n\u2022\n\u2022\f10\/30\/22, 9:38 AM People with Certain Medical Conditions | CDC\nGet more information:\nSmoking & Tobacco Use\nTips From Former Smokers\nHealth Benefits of Quitting Smoking\nSolid organ or blood stem cell transplant\nHaving had a solid organ or blood stem cell transplant, which includes bone marrow transplants, can make you more likely to\nget very sick from COVID-19. Get more information:\nTransplant Safety\nCOVID-19 Resources for Transplant Community\nStroke or cerebrovascular disease\nHaving cerebrovascular disease, such as having a stroke which affects blood flow to the brain, can make you more likely to get\nvery sick from COVID-19.","3943":"CDC established the COVID-19 Response Health Equity Strategy: Accelerating Progress Towards Reducing COVID-19\nDisparities and Achieving Health Equity [86KB, 5 pages] and provides additional resources to advance the vision of all\npeople having the opportunity to attain the highest level of health possible. \uf20c\n\uf20c\nLast Updated Oct. 19, 2022","3721":"\u25aa Updated on February 11, 2022, to allow an additional Pfizer-BioNTech COVID-19 vaccine dose in\npersons ages 18 years and older with certain immunocompromising conditions who received\nprimary vaccination with the Janssen COVID-19 vaccine; revaccination of certain moderately or\nseverely immunocompromised persons ages 12 years and older who received certain therapies\n(i.e., hematopoietic cell transplant (HCT) or chimeric antigen receptor (CAR)-T-cell therapy) and\nreceived COVID-19 vaccine prior to or during treatment; and the ability of healthcare providers\nto administer the Pfizer-BioNTech COVID-19 vaccine outside of the FDA-authorized or FDA-\napproved labeling and CDC recommended dosing intervals based on clinical judgment when the\nbenefits of vaccination are deemed to outweigh the potential and unknown risks.","6345":"Everyone likes to be seen on time, but it\u2019s\nimportant to remember that each patient should receive the same attention from the provider once it is their turn. The\nlist below can help you during your appointment. Printable Version: On the Day of Your Appointment | Espa\u00f1ol [PDF \u2013 372 KB]\n\uf189 \uf20c\nBring Your List of Concerns\nSince appointment time is often limited, it will help to make a list of why you are coming in for an appointment. Start\nwith your most concerning issues (sometimes called \u201cchief complaints\u201d).","2213":"Muyldermans J, De Weerdt L, De Brabandere L, Maertens K, Tommelein E. The Effects of COVID-19 Vaccination on\nLactating Women: A Systematic Review of the Literature. Front Immunol. 2022;13:852928. Published 2022 Apr 8. 26. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. COVID-19\nVaccines. [Updated 2022 Sep 19]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK565969\/\n27. Perl SH, Uzan-Yulzari A, Klainer H, et al. SARS-CoV-2\u2013Specific Antibodies in Breast Milk After COVID-19 Vaccination of\nBreastfeeding Women. 2021;325(19):2013\u20132014. DOI: https:\/\/doi.org\/10.1001\/jama.2021.5782\n28. Kelly JC, Carter EB, Raghuraman N, et al. Anti\u2013severe acute respiratory syndrome coronavirus 2 antibodies induced in\nbreast milk after Pfizer-BioNTech\/BNT162b2 vaccination.","8928":"Ensuring healthcare personnel have access to COVID-19 vaccination is critical to protect both them and their medically\nfragile patients. Page last reviewed: August 24, 2021","3138":"COVID-19 vaccination and EVUSHELD\u2122\n\u2122\n\uf20a\n\uf209 \u2122 \u2122\n\u2122 \uf20c \uf209 \u2122\nDescription of moderate and severe immunocompromising conditions\nand treatment\n\uf209\n\uf209\nSelf-attestation of immunocompromised status\nConsiderations for COVID-19 revaccination\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nRevaccination may also be considered for patients who received 1 or more doses of COVID-19 vaccine (primary series and\nbivalent booster doses) during treatment with B-cell-depleting therapies (e.g., rituximab, ocrelizumab) that were administered\nover a limited period (e.g., as part of a treatment regimen for certain malignancies). There is no revaccination for monovalent\nbooster doses received prior to or during treatment.","1388":"My patient never received a monovalent mRNA booster dose(s) and now only 1 bivalent booster\ndose is recommended for everyone ages 5 years and older. Can my patient still get the previously\nrecommended monovalent mRNA booster dose(s)? \uf1aa\nCan a child who completes a Pfizer-BioNTech primary series at ages 6 months\u20134 years get a\nbooster dose when they turn age 5 years? \uf1aa\f10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC\nYes. The child should receive 1 bivalent booster dose when they turn age 5 years, and it has been at least 2 months since\ncompleting their primary series.","3343":"Considerations for subsequent COVID-19 vaccination may include:\n\uf20c\n\uf20c\n\uf20c\nNovavax COVID-19 Vaccine\nConsiderations for COVID-19 vaccination\f10\/30\/22, 9:14 AM Clinical Guidance for COVID-19 Vaccination | CDC\nThe myocarditis or pericarditis was considered unrelated to vaccination with Moderna, Novavax, or Pfizer-BioNTech (e.g.,\ndue to SARS-CoV-2 or other viruses), especially if the myocarditis or pericarditis diagnosis occurred more than 3 weeks\nafter the most recent dose of COVID-19 vaccine\nPersonal risk of severe acute COVID-19 (e.g., age, underlying conditions)\nTiming of any immunomodulatory therapies; ACIP\u2019s general best practice guidelines for immunization can be consulted\nfor more information\nFor myocarditis associated with MIS-C or MIS-A, see COVID-19 vaccination and MIS-C and MIS-A.","8885":"Action Steps:\nEmpower vaccine recipients to share their personal stories and reasons\nfor vaccination within their circles of influence. Work with health departments and national partners to engage\ncommunities around vaccine confidence and service delivery strategies,\nincluding adaptation of vaccination provider sites to meet community\nneeds. Collaborate with trusted messengers\u2014such as faith-based and community\nleaders\u2014to tailor and share culturally relevant messages and materials\nwith diverse communities.","9562":"Either dose may be:\n\u0083 0.20 mL (10 mcg) of the product authorized for children ages 5\u201311 years (orange cap and label border), or\n\u0083 0.30 mL (30 mcg) of the product authorized for children ages 12\u201317 years (gray cap and label border)\nOR 3-8 weeks\nOR\fSpecial Situations for COVID-19 Vaccination\nof Children and Adolescents\nAge Transitions and Interchangeability\nInterchangeability of Moderna and Pfizer-BioNTech COVID-19 vaccines\nCOVID-19 vaccine from the same manufacturer should be used for the primary series.","1788":"Prepare all children and teens for the vaccination visit and use resources such as picture stories for support during and after\nvaccination. After vaccination, parents and caregivers should continue following all current\u202fprevention measures\u202frecommended by CDC. Learn more about COVID-19 Vaccines for Children and Teens. Requesting accommodations at COVID-19 vaccination sites\nWhen making an appointment or arriving for vaccination, parents and caregivers\ncan let staff and\/or volunteers know their child might need some\naccommodations.","5918":"o\no\nReceived COVID-19 vaccine dose(s) during treatment with B-cell-depleting therapies over a\nlimited period: the suggested interval to start revaccination is about 6 months after\ncompletion of the B-cell-depleting therapy\nReceived COVID-19 vaccine dose(s) prior to or during treatment with HCT or CAR-T-cell\ntherapy: revaccination at least 3 months after treatment\nRefer to CDC\u2019s Interim Clinical Considerations for specific and the latest dosing recommendations (e.g., number\nof doses, dosing intervals, revaccination) that may vary for individuals with certain medical conditions and\/or in\ncertain circumstances, which differ from or extend beyond the FDA-authorized and\/or FDA-approved labeling."},"question":{"674":"What was the decrease in doses?","6842":"Who can I report cases of suspected FRAUD?","4917":"People with a contraindication due to allergy to one type of COVID-19 vaccine are receiving another type that has been deemed what?","5394":"Where can you find information about coronavirus?","9227":"What are the 10 things you can do to manage your COVID-19 Symptoms at Home?","8418":"What are the core competencies of the EUA Fact Sheets for Healthcare Providers for the vaccine product(s) in your facility?","656":"How many doses were decreased in Illinois in February of 2022?","9903":"Where is the WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP located?","3203":"Where can people who have received dermal fillers experience temporary swelling?","9994":"What is a component of a COVID-19 vaccine?","4890":"What is Urticaria?","6855":"What may FDA issue when certain criteria are met?","148":"Who would need more information on the genetics of SARS-CoV-2 in mink, mink farm workers, and the communities around mink farms?","7371":"What does not apply to U.S. citizens?","1183":"What is the age range of people who are fully vaccinated in Texas?","7177":"What is SARS-CoV-2?","6727":"What is the name of the vaccine that children may receive?","1133":"What is the name of the website that reports COVID-19 vaccination data?","1916":"What does CDC collect from participants who report being pregnant at the time of vaccination or a positive pregnancy test after vaccination?","7490":"What is not required to board a flight to the United States?","9947":"Who is recommended to be vaccinated against COVID-19?","9726":"What did a Chilean study show about homologous boosting?","9081":"What does CDC recommend for people aged 2 years or older?","9749":"Recent studies indicate that additional doses are safe and can increase what?","6308":"What can make all the difference in getting the proper evaluation, diagnosis, and treatment?","420":"How many vaccine doses were decreased in New Jersey on June 25, 2021?","5759":"What is the suggested interval to start revaccination?","2171":"When will the MMWR Morb Mortal Wkly Rep 2022 be published?","8891":"What do you need to know about the dialysis clinics in your jurisdiction?","6513":"What percentage of COVID-19 deaths occur in people over age?","1409":"How many monovalent booster doses did your patient receive before or during treatment?","777":"What is the part of the virus that attaches to a human cell to infect it?","5636":"What are some respirators designed and tested to meet?","9948":"What is recommended for everyone 6 months of age and older?","4203":"People who already had COVID-19 and don't get vaccinated after their recovery are more likely to get what?","6790":"What has occurred in some people who have received the Pfizer-BioNTech COVID-19 Vaccine?","9589":"Who received an additional dose of the Janssen COVID-19 Vaccine in persons ages 18 and older with immunocompromising conditions?","1505":"Who approves SNS N95 masks?","2363":"What is an example of a primary immunodeficiency?","1604":"In lieu of a separate COVID-19 VIS for the licensed Moderna vaccine, what has FDA issued a combination Fact Sheet for Recipients and Caregivers?","2743":"What type of accommodations may be requested for activities outside of school?","1099":"What is important even if you receive EVUSHELD?","1553":"Who should receive a two dose dose of the Novavax COVID-19 Vaccine?","3177":"Who should be considered to have received a valid, single-dose Janssen primary series?","9166":"What can you do to help protect everyone?","3412":"What can be induced by COVID-19 vaccination or SARS-CoV-2 infection?","1161":"What are people ages 65 years or older?","1140":"Where do jurisdictions, federal agencies, and pharmacy partners order vaccines from the federal government?","2664":"Who should stay home except in limited circumstances?","6271":"Where is the site of vaccination usually located?","7714":"How many people have reported side effects after COVID-19 Vaccination?","6197":"What does active monitoring include?","7397":"What are members of the US Armed Forces?","4255":"What is the name of the virus that causes COVID-19?","6419":"What do you provide the highest level of?","749":"How many doses were decreased by a national pharmacy provider in 2021?","9651":"How many days after primary vaccination should COVID-19 be administered intramuscularly to persons ages 12 and older?","7115":"Do not delay getting emergency care because of worries about getting COVID-19.","4474":"What should you wear when you are indoors around others for a period of time?","7883":"What is the relationship between COVID-19 vaccines and monkeypox?","9121":"What does CDC recommend on school buses?","1392":"What if they are unable to receive an mRNA vaccine?","2933":"What is the maximum amount of time needed to administer the Bivalent booster?","5705":"What does EUI stand for?","2037":"What year was the interim recommendation made?","4726":"Moderna, Novavax, and Pfizer-BioNTech can be used for what?","6891":"What is the name of the coronavirus that causes Coronavirus disease 2019?","8178":"You are still up to date if you receive all the doses recommended for what disease?","6351":"What are the most important questions to ask your healthcare provider?","9831":"What types of doses do EUI's vaccines provide?","8067":"What does CDC continue to provide for clinicians who may identify hepatitis of unknown cause in children?","5650":"Where can you find lists of respirators that arenosh-approved?","5908":"How many days after the first dose of the Janssen COVID-19 Vaccine is required for an additional dose?","6965":"What could improve protection against COVID-19 for individuals who received the Janssen vaccine for primary vaccination?","2227":"Vaccines reduce the risk of what?","8502":"What is often difficult on public transportation?","8232":"How long does it take to get the Moderna COVID-19 vaccine?","6464":"What are oral antiviral and monoclonal antibody treatments available for?","3546":"Who has capped vaccination coverage at 95%?","6275":"What are the two types of vaccines authorized for use in the U.S.?","4596":"What do fans do even without an open window?","9857":"What is the name of the Joint Committee on Vaccination and Immunisation?","5221":"Who should see Ending Isolation and Precautions for People with COVID-19?","5685":"What should they use to protect themselves?","4061":"What are the same ingredients as the current COVID-19 vaccines?","5435":"Post-COVID conditions are found more often in people who had severe what?","74":"How long did it take for you to have an allergic reaction from a previous dose of the COVID-19 vaccine?","7760":"What is the name of the mRNA COVID-19 vaccine?","449":"What is the reason for the correction?","4281":"What type of medications treat autoimmune diseases?","3551":"How much coverage was previously capped by CDC?","10057":"What is Novavax?","3641":"What is the name of the CDC website that lists the community levels and prevention steps by county?","6949":"What company uses the COVID-19 vaccine as an additional primary dose?","368":"On what date was the data for Puerto Rico updated?","4658":"What is the second dose of the covid-19 vaccine?","9178":"What is COVID-19?","969":"If you test too early, you are more likely to get what?","9148":"Do not leave your home except to get medical care?","5272":"What does the Food and Drug Administration label for authorized over-the-counter antigen tests?","4080":"What tool can you use to learn if and when you can get boosters to keep up with your vaccine?","7388":"What are nonimmigrants?","4908":"Who may request a consultation from the Clinical Immunization Safety Assessment COVIDvax project?","658":"Which state made updates to data previously submitted to CDC that resulted in an increase of 12,473 doses?","1284":"For more information, see timing, spacing, interchangeability, and coadministration of what vaccines?","8091":"What type of rash can a rash look like?","3308":"What age group can be used for product comparisons?","6775":"How many people have received at least 1 dose of the Pfizer-BioNTech COVID-19 Vaccine?","5001":"What is an mRNA COVID-19 vaccine as a precaution?","3341":"What is the name of the vaccine used by Janssen?","4420":"What is the name of the Vaccine that can help with Ventilation?","5547":"What is effective at reducing transmission of SARS-CoV-2?","5506":"How can people who are eligible get vaccinated?","4791":"Where can you find a discussion on strategies to prevent errors?","6931":"What should you not get if you have a severe allergic reaction after a previous dose of the COVID-19 vaccine by Pfizer-BioNTech?","4207":"What is the name of the disease that causes me to get vaccinated?","1833":"What do CDC and other partners assess under real-world conditions after the FDA approves?","2001":"What does CDC recommend for everyone ages 6 months and older?","9435":"In addition to fatigue, headache, muscle pain, joint pain, chills, nausea and vomiting, fever, and rash, what other side effects have been reported?","7064":"What are people who are pregnant who are more likely to experience complications that can affect their pregnancy and developing baby?","1206":"What drives the information reported by CDC?","933":"What is not likely to spread the COVID-19 virus to babies?","4144":"How long has research and development on vaccines been going on?","7668":"Where can you view the total number of COVID-19 vaccinations that have been administered in the US?","7076":"Where should people wear a mask indoors in public?","5215":"What can you do if you have COVID-19?","1177":"What state provided COVID-19 vaccination administration data to CDC in aggregate format?","2321":"What is COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised?","5842":"What is the term for a hematopoietic cell transplant?","8888":"What can be done by allocating vaccines for outpatient dialysis patients and healthcare personnel?","2332":"How long after 3rd dose is it recommended to take a booster?","5927":"When did Moderna release their COVIID-19 vaccine?","1216":"When are demographic data trends expected to be released?","995":"Where can one purchase tests online?","6520":"People from racial and ethnic minority groups and people with disabilities are at higher risk of what?","7188":"What type of vaccine contains the spike protein of only the Original SARS-CoV-2?","2165":"New Engl J Med2021; 384:2273-2282.","1629":"Why was the CDC COVID-19 Vaccination Program necessary?","6948":"Who is responsible for the risks of the Janssen CoviD-19 Vaccine?","6185":"What is myocarditis inflammation of?","8566":"Crowded settings can raise your likelihood of being near someone with what?","2256":"What can you do if you live in a LTC setting?","6673":"What type of vaccination is especially important for people with underlying medical conditions?","7565":"What is the name of the vaccine product and date(s) received?","421":"How many doses of vaccine were increased in New Hampshire?","6355":"Tell your provider if there have been any changes to your symptoms?","6382":"What should you do with your provider if your tests return normal results?","3211":"What is another name for myocarditis?","1288":"How are moderna, Novavax and Pfizer-BioNTech COVID-19 vaccines administered?","850":"How Do I Find a COVID-19 Vaccine?","5235":"What should you wear if you must be around others at home and in public?","7750":"What was found to be 21 times higher after Pfizer-BioNTech or Moderna vaccinations?","6911":"What is the name of the company that provides the third primary dose of the Covid-19 vaccine?","5550":"What is the most important part of wearing a mask or respirator?","465":"When did CDC update its methodology for calculating age-based metrics for Texas?","9953":"Who can receive the Janssen COVID-19 Vaccine in limited situations?","5180":"What did CDC get your contact information from?","6653":"What type of food choices are available that meet your needs based on your medical condition?","3875":"What are the most trusted sources of health information for their patients?","4437":"What can help protect you from getting infected with and spreading the virus that causes COVID-19?","3024":"What is detailed below?","1662":"When was the HRSA COVIDR-19 Coverage Assistance Fund unavailable?","6613":"What can have a stroke that affects blood flow to the brain?","225":"What is the name of the virus that causes COVID-19?","3425":"What is recommended for people who are pregnant, trying to get pregnant, or who might become pregnant in the near future?","8980":"Who will be asked if they would be willing to provide permission for Pregnancy Registry staff to review their medical records for additional details about their pregnancies?","5817":"What is the only FDA-approved vaccine for which EUI provides information about primary and\/or additional doses following the COVID-19 vaccine that you received?","8386":"What are some nuances that healthcare professionals must become familiar with?","6251":"What can contain information that is incomplete, inaccurate, coincidental, or unverifiable?","9209":"How long should a caregiver\/other person wait?","6546":"Bronchopulmonary dysplasia affects what type of person?","4888":"What is anaphylaxis?","1077":"What must begin within 5 days of when symptoms start Taken at home by mouth (orally) Remdesivir (Veklury) Antiviral  Adults and children Start as soon as possible?","7537":"Who is required to provide proof of COVID-19 vaccination for Air Passengers?","4391":"What do you need to do to get vaccinated?","8622":"What has been studied for gene therapy, cancer, and molecular biology?","8937":"How are VAERS reports reviewed?","1690":"What does the provider agreement not specify to be recorded or reported?","4876":"What is an example of an allergic reaction after a previous dose or to a component of a Known (diagnosed) allergy?","2353":"What is active treatment for for solid tumor and hematologic malignancies?","3330":"What is a possible outcome of COVID-19?","7933":"What vaccines cause vaccine-acquired immune deficiency syndrome (VAIDS) and HIV?","3872":"What are the requirements of a COVID-19 Vaccination Provider?","5404":"What is the acronym for the CDC's COVID-19 Vaccination Program?","3230":"What is the risk of Reye's syndrome?","5832":"What is Moderna's vaccine approved for?","1663":"Why was the Uninsured Program not available?","3724":"What is another term for CAR-T-cell therapy?","433":"How many people were ages 18 and older in the census?","353":"How many people are fully vaccinated?","2863":"What are the currently FDA-approved or FDA-authorized COVID-19 vaccines?","7723":"What has been reported to the Vaccine Adverse Event Reporting System?","5338":"Is there a remote chance that the Janssen COVID-19 Vaccine could cause a severe allergic reaction?","4887":"How long after administration does anaphylaxis occur?","4120":"Who should get their child vaccinated as soon as vaccines are available to them?","7432":"What must personal identifiers match?","7454":"What is the definition of fully vaccinated if you are a noncitizen?","4103":"What are the recommendations of the CDC, ACIP, and FDA?","8443":"Who must be fully vaccinated with the primary series of an accepted COVID-19 vaccine to travel to the United States by plane?","584":"What was the net increase in doses?","3838":"What may already have completed some of the training recommended to become a COVID-19 vaccination provider?","7272":"What type of vaccine is Pfizer-BioNTech COVID-19?","4984":"How long after the first booster dose?","4260":"What is a possible reason to delay your next vaccine dose?","216":"What is the threshold for protection for antibodies for the virus that causes COVID-19?","8498":"When can I travel back home?","8838":"What is the waiting period after you get any dose of the COVID-19 vaccine?","5984":"How much mRNA did the booster dose of the Moderna COVID-19 Vaccine contain?","7678":"What are some common side effects after getting the vaccine?","4150":"What does FDA stand for?","9213":"What is COVID-19?","8026":"What do people who are vaccinated want to do?","5549":"What are some masks and respirators harder to wear?","7256":"What does V-safe do to help CDC monitor the safety of COVID-19 vaccines?","5317":"What are blood cells that help your body stop bleeding called?","432":"What was the population ages 12 and older counted as?","3464":"What are the Frequently Asked Questions?","9060":"What is a high-consequence?","10108":"What type of thrombocytopenia should not receive the Janssen COVID-19 Vaccine?","8573":"Different types of vaccines work in different ways to offer protection to what?","7736":"How many cases per one million has TTS occurred after J&J\/Janssen COVID-19 vaccination?","309":"When will the data be updated?","9402":"What is tromethamine hydrochloride?","9":"What can side effects of COVID-19 make you feel?","5023":"What is the name of the section on Contraindications and precautions that provides guidance for COVID-19 vaccination in immunocompromised people?","4471":"How long should you stay away from others?","4680":"What age group were the most likely to experience the symptoms of TTS?","8045":"Some believe infection-induced immunity protects children better than what?","305":"What are CDC and DC actively working to validate?","3514":"What poses some risk of COVID-19 transmission?","6455":"What should you do if you don't have timely access to a healthcare provider?","1944":"Who decides whether changes are needed in U.S. vaccine recommendations or clinical guidance?","7716":"What type of reactions are rare after COVID-19 vaccinations?","622":"What state made updates to data previously submitted to CDC?","2732":"What are ways to help relieve some of the additional burdens of experiencing or caring for someone with a new and unknown condition?","9405":"What is Moderna COVID-19 Vaccine, or Bivalent?","6517":"A person's risk of severe illness from COVID-19 increases as what?","3890":"What do CDC's smartphone-based after-vaccination health checker use?","9499":"What is an EUA?","7889":"What is the absence of association between COVID-19 vaccines and monkeypox?","1057":"What can you do if you test positive and are more likely to get sick from COVID- 19?","8887":"What is effective at protecting people from getting sick?","3342":"What is a possible use of Janssen COVID-19 vaccine?","2556":"How long is the recommended interval between the first and second doses of Moderna?","7612":"How old is the child of someone who is a member of the U.S. Armed Forces?","3":"How do you treat a headache?","3395":"What may also be considered for people who had MIS\/A and do not meet both criteria?","2707":"When are other surfaces in your home visibly dirty or as needed?","10133":"What is recommended for people who develop GBS within 6 weeks of Janssen Covid-19 vaccination?","6535":"What type of medical condition is COVID-19?","2286":"What is the name of the website that provides information on COVID-19 vaccines for LTC residents?","1987":"What is the most comprehensive and intense vaccine safety monitoring program in U.S. history?","2658":"How many feet away from the sick person should you try to stay?","4229":"What do some vaccination providers and health departments offer you?","5679":"What does it fit over the child's nose?","1894":"Why is no vaccine 100% effective?","1516":"Who may direct bulk quantities of the masks to long-term care facilities?","9885":"What enhances peak antibody Patamatamkul S, Thammawat S, Buranrat B?","5415":"The Janssen COVID-19 Vaccine has not undergone the same type of review as what other product?","20":"What does CDC recommend for everyone 5 years and older if eligible?","3704":"When was the COVID-19 vaccine approved by FDA?","8684":"What should you have in place in case you get sick?","3421":"What is strongly encouraged to assist with decisions about the use of COVID-19 vaccines in the setting of MIS-C?","5256":"How long do you need to isolate?","8564":"What is the Interactive Home Ventilation Tool?","5093":"What is a precaution to vaccination?","6316":"Who can make all the difference in getting the proper medical evaluation, diagnosis, and treatment?","2346":"What is the date immediately after they have received the most recent booster recommended for them?","591":"How many doses of medication did Illinois administer?","4071":"What if you have completed a COVID-19 vaccine primary series and received the most recent booster dose?","805":"When can these complications appear?","1771":"What does CDC's COVID-19 booster tool tell you about?","7208":"What may not protect everyone?","6479":"What should you do if you get exposed or develop symptoms?","4223":"What do you need to do if you have lost your CDC Vaccination card or don't have a copy of it?","1266":"What are recommended for booster vaccination?","5835":"How long does it take for SARS-CoV-2 infection to get a second dose?","5104":"Do you need to get up to date with your vaccines before you travel?","6833":"Who can you ask to learn more about your child?","5129":"Do not travel on public transportation if you won't be able to wear a high-quality mask or respirator?","809":"What can vary depending on what?","4861":"Moderna and Pfizer-BioNTech) during vaccination, see Transitioning from a younger to older age group?","8901":"Why are dialysis patients at high risk for serious illness and death related to COVID-19?","2635":"How long do symptoms last for most people?","4005":"What does COVID Data Tracker's vaccination data typically have a lag time from?","5304":"What is not accessible or clinically appropriate for individuals 18 years of age and older?","2660":"What helps remove respiratory droplets from the air?","4480":"How can you avoid contact with people who have suspected or confirmed COVID-19?","1405":"How many monovalent mRNA booster doses did the patient receive after receiving the primary series?","8918":"What is it important to vaccinate?","5595":"What can be caused by a wrong size or type of mask and when it is worn with facial hair?","6703":"What is the name of the organization that recommends safe and effective disinfectant use?","1783":"How many children are vaccinated against developmental disabilities?","1105":"What have people been seriously harmed and even died after taking products not approved for use to treat or prevent COVID-19?","10125":"Who has a history of myocarditis?","4736":"How close to the recommended time is it possible to complete primary series with the same vaccine?","6536":"What is the most common medical condition that affects children?","6892":"SARS-CoV-2 is a respiratory illness that can affect what other organ?","4170":"What is v-safe?","8481":"What is a trip that involves leaving your community?","6956":"Is myocarditis rare or rare in some people?","7012":"What were the most common side effects after two-dose shots?","9918":"What are the two types of COVID-19 vaccines?","7724":"What is rare after COVID-19 vaccination?","7844":"In most jurisdictions, what are healthcare providers required to report?","9198":"What is especially important before eating or preparing food?","7811":"Who can you call for more options?","8382":"What is critical that healthcare professionals and personnel are familiar with the specific COVID-19 vaccine product(s) in their facility's inventory?","2442":"What may be treated with acetaminophen in pregnancy?","6519":"What are some people at increased risk of getting sick or dying from COVID-19 because of where they live or work or because they can\u2019t get health care?","7212":"What is COVID-19 Vaccine, mRNA?","8164":"What are previous boosters called?","1847":"Where is St. Luke\u2019s Hospital?","9224":"What does CDC end home isolation?","6804":"Where can you report vaccine side effects?","2485":"What is another name for COVID-19?","6750":"What are symptoms of EUA?","6555":"What are some reasons people with disabilities may be more likely to get very sick?","5577":"What should a good fit provide?","2570":"How long after the previous dose should a single booster dose be given?","1066":"Who will help you decide which treatment is right for you?","5026":"What are the potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects following COVID-19 vaccination?","2320":"What is the name of the Vaccine for People Who Are Moderately or Severely Immunocompromised?","1387":"How old is the child?","7552":"What must be signed and dated before boarding a flight to the United States?","5021":"Who was included in the section on People who received the COV-19 vaccine outside of the U.S.?","1086":"What could medications be used to treat the virus?","8452":"What do you need to continue wearing?","5413":"What does HHS stand for?","6648":"What can be overwhelming and cause strong emotions?","7680":"What is a common side effect after COVID-19 vaccination?","2669":"Who should wash dishes, cups, and silverware with?","4534":"What kind of protection does the N95 provide?","8073":"How can public health and partners take action to improve vaccine confidence?","8261":"What is the name of the Vaccine that is not in the US?","9891":"What was the name of the committee meeting that took place on November 19, 2021?","8767":"What should people who are deaf or hard of hearing consider wearing?","5849":"What does EUA stand for?","585":"How many doses were increased?","6359":"What should I do next week to get my blood drawn?","2307":"Who recommends people with moderate or severe immunocompromise get an extra primary series dose if they receive the Moderna or Pfizer-BioNTech series?","9359":"How many doses does the Moderna COVID-19 Vaccine provide to individuals 6 years of age and older?","4351":"What is another name for immunization record?","9674":"How many doses does each vaccine contain?","9944":"When does this recommendation apply?","3450":"What date was the last time the Table of Contents was reviewed?","3290":"Coadministration of COVID-19 and routine vaccines on the risk of febrile seizures has not been specifically studied?","9301":"What type of daycare attendance Missed opportunities for participation in sports, playdates or other activities?","5330":"What vaccine has been shown to prevent COVID-19?","998":"What do negative results do not rule out?","6958":"Who provides information on the common and serious side effects?","1851":"Where is the University of Washington located?","8755":"What are NIOSH-approved respirators?","9799":"What is the evidence for revaccination of people who received the COVID-19 vaccine during B-cell-depleting therapy administered over a limited period?","5781":"What vaccine has been used before?","5178":"What is the acronym for Transportation Security Administration?","9766":"How many people in the UK received the Pfizer-BioNTech COVID-19 Vaccine after an extended dosing interval?","7505":"How long has it been between doses?","884":"What should you wear after your isolation period has ended?","9564":"How long should a COVID-19 vaccine last?","2695":"What are three things that you should avoid touching?","447":"What is the result of efforts to improve the data quality of records reported from Vermont?","6416":"What can provide additional layers of protection from COVID-19?","5389":"What is the name of the vaccine and the date of when you received the vaccine?","3460":"Get tested again with a COVID-19 viral test 3-5 days after your cruise?","4218":"What do people who need additional or booster doses do?","5969":"How many micrograms of the COVID-19 vaccine was used by Moderna?","4812":"What causes a higher-than-authorized dose?","3864":"What is a vaccine's expiration date?","6411":"Who is up to date with your COVID-19 vaccines?","10008":"Who may receive any currently FDA-approved or -authorized COVID-19 vaccine after the episode of myocarditis has resolved?","2774":"What can a person who feels sick long-term feel?","9156":"If you think it is an emergency, what do you do?","3496":"What are passengers at increased risk for severe illness and crew?","1204":"When was the last update of the COVID-19 vaccination data?","3442":"What does COMIRNATY stand for?","1802":"What is another term for long-term care?","49":"What is the name of the different type of COVID-19 vaccine after an allergic reaction?","9356":"What is Moderna COVID-19 Vaccine authorized for use in?","9978":"What is a previous dose OR a component of any COVIV-19 vaccine?","8389":"What is essential for healthcare professionals who will be preparing and administering vaccines?","1477":"What type of vaccines are recommended for the general population?","2539":"How long should mRNA be used for the booster dose?","7264":"What may be available under EUA?","9875":"How many doses of ChAdOx1 nCov-19 or BNT162b2 were given in the UK?","3397":"What may additional factors be considered?","3126":"Where can people receive COVID-19 vaccine doses?","7536":"Do I need to show if I am on diplomatic or official foreign government travel?","210":"When are reinfections or breakthrough infections expected?","5690":"In what year did the U.S. begin using Maximizing Fit for Cloth and Medical Procedure Masks to improve performance?","6037":"How long after infection can a person delay vaccination?","5069":"Who updated interim recommendation for the use of the Janssen (Johnson & Johnson) COVID-19 Vaccine?","9219":"What is a way to help prevent spreading COVID-19 to other people in your household?","5133":"What can lower the chances of spreading COVID-19 to others?","7270":"What is COMIRNATY?","5500":"Why can't people get health care?","3406":"What should testing include testing for?","7872":"What company makes the InteliSwab?","7749":"How much higher was the rate of GBS within the first 21 days following J&J\/Janssen COVID-19 vaccination?","4235":"What can you do to protect yourself from COVID-19?","4552":"What can you do to help reduce virus particles in your home?","6957":"What is the first week after the second dose of the COVID-19 vaccine?","4438":"Spending time outside instead of inside can help: Viral particles spread more readily between people what?","7227":"What is the name of the Omicron variant of SARS-CoV-2?","8496":"What should you do if you are in another country?","7717":"What age group is recommended to get vaccinated as soon as possible?","3647":"What should you do if you have already had COVID-19 within the past 90 days?","10141":"Who should not receive the Janssen COVID-19 Vaccine?","8842":"What does V-safe not give medical advice?","9833":"Who is responsible for reporting vaccine administration errors?","7625":"What is the name of the CDC's Interim Guidance for Ships on Managing Suspected or Confirmed Cases of Coronavirus Disease?","7449":"Who must meet the requirements in the Presidential Proclamation and CDC\u2019s Amended Order to board a plane to the United States?","5359":"What is the name of the neurological disorder in which the body's immune system damages nerve cells?","9557":"What color cap and label border should child turn 12?","800":"What can COVID-19 cause even in children?","1125":"What does Partnering for Vaccine Equity do?","6510":"What type of people may be eligible for an additional primary dose of the vaccine?","8854":"What does v-safe protect?","4236":"What should you wear if you are vaccinated?","1664":"What is the reason the HRSA COVID-19 Uninsured Program is not available?","10043":"How many doses does Monovalent Orange Orange Yes have?","3448":"The Society of Breast Imaging has developed what for patients with COVID-19 Vaccination?","5854":"What is the proprietary name for the product licensed under the Biologics License Application?","2413":"How many people were documented who completed COVID-19 vaccination before becoming pregnant?","9702":"What company provides an additional dose of the COVID-19 vaccine?","332":"What resulted in a decrease of 12,298 vaccination doses in Hawaii since December 14, 2020?","4424":"Who gets infected with the virus that causes COVID-19?","1546":"How long after receiving a primary series or prior monovalent booster dose with any COVID-19 vaccine?","2265":"What is the current rate of COVID-19 vaccination among LTC staff and residents?","8973":"What are the registry activities in addition to?","333":"How many vaccine doses have been administered in Hawaii since December 14, 2020?","6565":"What are some people immunocompromised or have a weakened immune system because of a medical condition or a treatment for?","6430":"Where can you find COVID-19 vaccine locations?","2715":"What are some symptoms of COVID-19?","4085":"How many doses of Pfizer-BioNTech vaccine are needed for people 5 years and older?","9697":"What does V-safe use to check in with people who have been vaccinated?","9299":"What is the name of the rash that occurs after a mild or severe infection?","4048":"Who is eligible for a COVID-19 vaccine?","2032":"When is the COVID-19 vaccine safety evaluated in the United States?","1525":"Who will provide the masks for free?","5173":"CDC will not enforce what order?","3396":"What do experts view as an important factor when considering COVID-19 vaccination?","7307":"What company is responsible for the manufacture of the vaccine Fact Sheet?","3806":"What is the advantage of signing up to participate as a COVID-19 vaccination provider?","10129":"What is the name of the appendix at www.cdc.gov\/vaccines\/covid-19\/clinical- considerations\/interim-considerations-us-appendix?","7779":"What is rare after COVID-19 vaccination?","9133":"How large is the image?","2471":"What does not cause sterility?","2672":"Avoid sharing personal items with who?","3698":"What was the brand name of the vaccine by Moderna?","2054":"Who is more likely to get sick from COVID-19 compared to people who are not pregnant?","7634":"What are self-tests sometimes referred to as?","7340":"What do non-U.S. citizens need to show proof of being fully vaccinated against?","6562":"What virus can make you more likely to get very sick from COVID-19?","4869":"How long is it acceptable to administer a repeat dose at an interval earlier than 8 weeks?","6189":"What are the symptoms of myocarditis?","2674":"When do people not need to wear masks when outdoors?","8936":"What are birth defects?","8344":"What may take time?","9003":"What did not identify any safety concerns for pregnant people who were vaccinated or for their babies?","4985":"What is the age range of people who are not moderately or severely immunocompromised and received Janssen COVID-19 Vaccine as both their primary series dose and booster doses?","5088":"What are the Appendices, References and Previous Updates for Use of COVID-19 Vaccines?","4169":"Who is protected from hospitalization?","7602":"What percentage of the population has been fully vaccinated against COVID-19 with any vaccine?","806":"What are the symptoms of getting a COVID-19 Vaccine?","7052":"Who is more likely to get severely ill from COVID-19 than people who are not pregnant?","2703":"Self-tests are one of what?","8929":"When was the last time the page was reviewed?","6900":"What should not be received earlier than 3 weeks?","6966":"What is the name of the Pfizer-BioNTech vaccine that may not protect everyone?","8556":"What is an example of a high-quality mask?","2747":"What are some ways to manage the stress, anxiety and uncertainty of a new illness?","2360":"What should people who were vaccinated outside of the US do?","7846":"What does the government not want to build that would deter the use of?","5057":"In what age range did the Pfizer-BioNTech Covid-19 Vaccine help adolescents?","6433":"EVUSHELD continues to be authorized for people who are moderate to severe immunocompromised and may not be able to mount an adequate response to what vaccine?","6655":"What should you avoid when possible?","1832":"What are clinical trials conducted to determine before the FDA determines whether to approve a vaccine?","8168":"How many manufacturers of COVID-19 vaccines are there?","9623":"What is the name of the vaccine that Pfizer-BioNTech provides?","6474":"Monoclonal antibodies can block what from entering cells in your body?","9451":"What is the name of the vaccine that a child can't get?","5265":"What should you wear after you have ended isolation?","8910":"What type of patients are served?","2082":"What is ongoing monitoring of the effect of COVID-19 vaccination during pregnancy?","8243":"Who does not recommend mixing products for your primary series doses?","4627":"What is the average size of a one-bedroom apartment in the United States?","587":"What was the result of the decrease in doses in Texas?","7514":"What are different formulations of vaccines considered acceptable proof of vaccination?","2826":"How many days after receiving the second dose of an mRNA COVID-19 vaccine?","3371":"What does growing epidemiologic evidence indicate?","9170":"Who may give instructions on how to care for you?","4327":"What does v-safe tell CDC about after your COVID-19 vaccination?","605":"How many administered doses were increased in Pennsylvania in 2022?","6498":"What should you do immediately after a positive test?","9672":"What is tromethamine?","3319":"In addition to myocarditis, what other condition was reported during post-authorization use outside the US?","8222":"Novavax PRIMARY SERIES 3-8 weeks after 1st dose What is the name of the booster that is recommended for you?","6086":"Buchan SA, et al. Epidemiology of myocarditis and pericardiitis following what vaccines?","616":"What state made updates to data that resulted in a net increase of 37,678 administration records?","6380":"Keep track of medications, vitamins, herbs, supplements, and what else?","8359":"What is a good way to reverse that?","9031":"What can change as more information becomes available?","7294":"What does EUA stand for?","3147":"What should be given at least 2 weeks before initiation or resumption of immunosuppressive therapies?","9913":"What should healthcare professionals be familiar with identifying?","114":"How have there been reports of infected mammalian animals spreading the virus?","414":"How many vaccine doses were given to Arizona and Puerto Rico?","8953":"Why are VAERS reports not available to the public?","3789":"Who created new web-based platforms to gather more information about the safety of COVID-19 vaccines?","6318":"How many KB is the PDF of Preparing for Your Appointment?","8995":"What does the FDA stand for?","1760":"In some jurisdictions, providers may report vaccine inventory to what?","6402":"What is CAR-T-cell therapy?","9053":"What could cause an increase in hospitalizations, put more strain on healthcare resources, and potentially lead to more deaths?","6716":"What is the Pfizer-BioNTech COVID-19 Vaccine, Bivalent?","1494":"What is the name of the program that has been used to purchase the COVID-19 vaccine?","1619":"What is prohibited by any use or unauthorized reproduction?","8217":"What is the CDC AGE GROUP 18 YEARS AND OLDER About COVID-19 Vaccines Including Boosters?","5538":"Collaborate with medical groups to develop and offer what for healthcare providers, patients, and the public?","6393":"What can help you build a plan for preventing, diagnosing and treating COVID?","4490":"What are N95's made to protect you by fitting closely on the face to filter out?","7796":"When to Take an At-Home COVID-19 Test Yourself?","4478":"How long must treatment be started after you first develop symptoms?","5098":"How long can testing be delayed for?","962":"What does the FDA recommend that you do?","6932":"What should I mention to the vaccination provider before getting the vaccine?","1713":"What are CDC instructions and timelines for disposing of?","9471":"Who should be vaccinated as appropriate?","5640":"What does a respirator filter depending on the standard they are designed to meet?","6372":"If you are confused or don't remember something your provider said, call the provider's office for clarification.","5326":"What may be administered after completing primary vaccination with a different authorized or approved COVID-19 vaccine?","134":"What type of mink was found in Utah and Oregon?","7180":"What is COVID-19 primarily a respiratory illness?","4981":"How many months after receiving the first booster dose can a person who is immune compromised have the option to receive the second dose of a booster dose of an mRNA vaccinated against a SARS-CoV-2 infection receive a supplemental dose of their second dose?","6155":"How much of the U.S. population does the participating health departments represent?","6132":"What is the acronym for WHO Strategic Advisory Group of Experts on Immunization?","1426":"What should be deferred for?","9724":"What is the Delta variant?","3871":"What is the FDA\u2019s condition of authorized use of vaccine(s)?","3675":"What is the date of CDC's January 29, 2021 Order?","1096":"How many different antibodies does EVISHELD contain?","86":"What is the name of the vaccine that is currently authorized in the United States for people with allergies?","9174":"What is the name of the condition that can cause you to have difficulty breathing?","3485":"What should you do before you board a cruise ship?","9904":"What is Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection?","3994":"How does CDC manage data from multiple sources?","10052":"What vaccine is authorized for adults ages 18 years and older?","5804":"What vaccine may help to increase immune response in people?","9782":"What has Australia, Canada, Denmark, Finland, France, Germany, Norway, Taiwan, and the United Kingdom recommended for all persons or specific sub-groups?","7238":"What should you seek medical attention for if you have any of the following symptoms after receiving the vaccine?","3532":"What is the term for deidentified data?","9196":"After blowing your nose, coughing, or sneezing, wash your hands with what?","6459":"CDC recommends that you isolate for at least how many days?","2961":"How long is the bivalent mRNA booster dose administered?","9349":"How many years old are individuals 12 years through 17 years of age?","1433":"What has not been validated to evaluate specific immunity or protection from SARS-CoV-2 infection?","8675":"What are being given to patients in real- world settings across the country?","3650":"What do I need to continue wearing?","7707":"Who can participate in safety monitoring after receiving a COVID-19 vaccine?","6072":"Who is responsible for reporting vaccine administration errors?","3231":"What is not currently recommended to assess the need for vaccination in an unvaccinated person?","468":"What are all people receiving vaccinations in Texas considered?","4856":"What is the potential for increased reactogenicity and the rare risk of myocarditis from mRNA COVID-19 vaccine?","182":"What animal was confirmed to have COVID-19 in Florida?","7387":"What is required to show proof of being fully vaccinated against COVID-19 for Air Passengers?","9228":"How many pages are in Don\u2019t Delay: Test Soon and Treat Early?","2293":"What can LTC providers recommend to vaccinated residents?","8124":"What do messengers create and disseminate graphics showing?","1782":"How do they communicate symptoms of illness?","6159":"What does COVID-NET CDC monitor rates of by vaccination status using?","2027":"What is the name of the virus that causes COVID-19?","8356":"What is the goal of getting vaccinated?","1397":"Who should not deny COVID-19 vaccination to a person because of a lack of documentation?","9445":"What is another name for Moderna COVID-19 Vaccine EUA?","4612":"What can you wear to help prevent the accumulating of virus particles in the air?","6330":"What will help you keep track of your healthcare appointment?","4205":"What is the benefit of getting a COVIV-19 vaccine?","1643":"What is a limited purpose of the Vaccination Program?","604":"In what month and year did Illinois update its database to include more doses?","911":"How much alcohol does a hand sanitizer contain?","2575":"If the vaccine product previously administered cannot be determined, is no longer available, or is contraindicated, how long after is it allowed to be administered to complete a primary series with same product?","8783":"What type of bag does the mask come in?","3597":"Who received two booster doses?","4692":"What is contraindicated to administer Janssen COVID-19 Vaccine to people with asthma?","8110":"How long after the date of exposure should vaccination be given?","8551":"What was the infected person coughing, singing, shouting or breathing heavily due to?","10109":"Who should receive an mRNA or Novavax COVID-19 vaccine booster dose?","8088":"Where is the rash located?","1656":"Who must administer COVID-19 Vaccine at no out-of-pocket cost to the recipient?","9378":"What is the name of a sore throat?","6547":"What is COPD?","4193":"Why should I get vaccinated if I'm going to get it anyway?","920":"How long have you had no fever without fever-reducing medicine?","8364":"What should patients do when asked about vaccine safety?","3365":"Who should isolate and, if symptoms do not improve by two days post-vaccination, what should they do?","27":"What does CDC recommend for everyone 6 months and older?","2830":"What do the benefits of mRNA COVID-19 vaccines outweigh the risks of?","76":"What is the CDC Monitoring Reports of Severe Allergic Reactions?","2322":"How long after the 3rd dose or last booster is the booster recommended for you?","6813":"What is the option to accept or refuse receiving any of these vaccines under the EUA?","7709":"Who can report a side effect after a vaccination?","9342":"What is EUA?","4764":"Who lists a bivalent mRNA booster dose for people ages 5 and older?","3031":"What is recommended for ages 6 months-4 years?","2365":"How many CD4 cell counts do people with HIV have?","8343":"What is the goal of a conversation with a patient?","3621":"How do you know when you can get your COVID-19 vaccine?","3476":"What does CDC During Cruise Travel do?","878":"How long will you likely not pass the virus to your newborn after your isolation period?","6286":"What can a COVID-19 vaccine make me sick with?","3738":"What is the name of the vaccine that allows revaccination for any doses received during treatment with B-cell depleting therapies over a limited period?","3920":"What increases your risk more than others?","9022":"What are some of the adverse events reported to VAERS?","3262":"What is not readily addressed by CDC guidance?","5922":"What is the name of the vaccine manufactured by Moderna?","9717":"When was the original CDC-issued 11\/17\/2021?","8118":"What makes vaccinated individuals more susceptible to monkeypox?","7202":"How many doses of the vaccine are given?","6988":"What must be submitted to the CICP within one (1) year from the date of receiving the vaccine?","382":"What was the population age in Puerto Rico?","9514":"What does CDC recommend that vaccine recipients receive based on their age?","7461":"How many doses of the COVID-19 vaccine are needed?","4252":"What is VAMS?","8778":"What can you use to wash and dry your masks?","3320":"What is the name of the vaccine that may increase the risk for these conditions?","1152":"What is another name for the Department of Defense?","6482":"What can you share with your family, friends, and healthcare providers?","95":"What is a large family of viruses?","9679":"What is the name of the Pfizer-BioNTech COVID-19 Vaccine EUI Healthcare Providers?","8736":"What do you avoid doing in public?","5292":"Who elects to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a single dose primary vaccination?","6442":"What is the Evusheld EUA Fact Sheet for Patients, Parents and Caregivers?","2358":"Talk to your healthcare provider about what?","3358":"What can people with a known or potential SARS-CoV-2 exposure receive?","1768":"What is safe and effective?","6553":"COVID-19, Alzheimer's and Dementia Diabetes (type 1 or type 2) can make you more likely to get very sick from what?","4292":"How do you prepare your child or teen for vaccination?","7605":"Who reviews other official sources of information to determine a countries\u2019 vaccination coverage?","3050":"When is the bivalent booster dose administered?","9332":"What do you need to keep track of?","9599":"What does EUA stand for?","4280":"What are non-steroidal anti-inflammatory drugs?","9016":"Who can submit a report to VAERS?","6704":"What is the name of a medical center or health department?","1616":"Who printed the COVID-19 Vaccination Record Cards?","2918":"What is recommended to people who received Janssen COVID-19 Vaccine?","8658":"What do clinical trials compare between people who are vaccinated and people not?","2233":"Public health experts see reduced protection over time against mild and moderate disease?","8020":"What do some social media user believe is causing a surge in the number of COVID-19 cases?","2621":"What is completely normal?","6055":"Efficacy data from clinical studies of 2-dose primary series supported benefit of what vaccine?","9794":"How was protection from infection or vaccination?","264":"What was the daily number of vaccine doses administered for Indiana on October 20, 2022?","2060":"Who are more likely to get very sick from COVID-19 compared to people who are not pregnant?","1168":"What are the COVID-19 Community Vulnerability Index scores from?","4611":"How many feet apart can you stay?","528":"When did the CDC release an official recommendation to use the J&J\/Janssen COVID-19 vaccine for people ages 18 and older?","2389":"What is the final dose of the primary series of an mRNA COVID-19 vaccine for people who are immunocompromised?","1222":"What is the number of people administered a dose with a Covid-19 vaccine code on or after September 1, 2022 or a CVX code?","6732":"What is COVID-19 Vaccine, mRNA?","8186":"What can you do if you have recently had or presently have COVID-19?","1872":"What is the name of the Community Regional Medical Center in Fresno, CA?","4763":"How many doses of a monovalent Novavax booster dose should people receive?","1029":"What should you do if you have symptoms of COVID-19?","2150":"People who are pregnant have not reported what?","8100":"Do not travel until you confirm that you do not have monkeypox?","8163":"Why are the updates called bivalent?","2549":"What can people with a recent SARS-CoV-2 infection consider delaying a primary series or booster dose by 3 months?","2501":"What are the recommended booster doses?","7798":"If you are going to an indoor event, what should you do?","5787":"What is the name of the non-FDA approved vaccine?","9190":"What should you cover your mouth and nose with a tissue when you cough or sneeze?","255":"What is the name of the interactive quiz that you can take to test your knowledge of the disease?","7433":"What is the name of the official source issuing the record?","673":"How many doses were decreased in Illinois in 2022?","2831":"What is a benefit of receiving mROCOVID19 vaccines?","9581":"How old are individuals ages 16 and older?","4982":"How long after the first booster dose does the mRNA COVID-19 vaccine last?","6489":"Take as many steps as you can to prevent COVID-19 and get treated quickly?","6893":"What is a wide range of symptoms?","9760":"What may reduce the risk of myocarditis and result in greater immunogenicity and effectiveness?","9972":"What type of reaction has the person to be vaccinated ever had?","6278":"What do mRNA and viral vector COVID-19 vaccines deliver to our cells to start building protection?","9662":"What are the indications for the use of the vaccine?","8782":"What can you put back on after eating?","3607":"What allows comparison between areas with different population sizes?","2330":"What is the name of the most recent booster recommended for you?","7288":"What can you not be charged for if only receiving a COVID-19 vaccination?","2343":"What is recommended for a booster?","8714":"Along with self-testing, physical distancing, and vaccination, what is a good way to protect yourself and others from spreading COVID- 19?","6571":"What can being immunocompromised make you more likely to get sick from COVID-19 or be sick for a longer period of time?","3301":"What are the most rare cases of pericardiitis in adolescent and young adult males?","9937":"What do people with mild illnesses can be vaccinated?","3754":"What age restriction was removed on similar uses?","3372":"Who should defer any COVID-19 vaccination, including booster vaccination, until recovery from acute illness?","4282":"What should you keep taking if you regularly take over-the-counter medications?","2500":"What do you need to do to stay up to date on COVID-19?","7166":"What is Pfizer-BioNTech COVID-19 Vaccine authorized for use in?","9550":"How many doses of the Pfizer-BioNTech COVID-19 Vaccine product are authorized for children ages 5-11 years?","8726":"What is a tool to help communities decide what to do?","5125":"What should you do if you have already had COVID-19 within the past 90 days?","7982":"How many shots were received?","2393":"Who can help protect you and yourself by staying up to date on their COVID-19 vaccines?","4058":"What vaccines are working well to prevent?","8046":"What do some social media users not think there is enough data to support?","7148":"What is COVID-19 VACCINE, mRNA?","6662":"What are people with moderate-to-severe asthma more likely to be?","84":"How long should you be monitored in a medical facility?","5176":"What is the name of the US State Department Travel Site?","8290":"What may change with new variants?","5493":"What is the term for post-COVID conditions?","5258":"What is the day after you end your isolation?","6065":"What is the purpose of the Moderna COVID-19 Vaccine, Bivalent?","18":"After a few days what is the rest of your body affected by?","7521":"What is necessary for these purposes?","7579":"What language is required for a humanitarian exception request to be sent to the CDC?","10077":"What is another name for monkeypoxvirus?","9916":"What is another name for monkey pox?","851":"What are the absolute risks of COVID-19 for newborns of people who have it?","8442":"How do you find a COVID-19 vaccine or booster near you?","3747":"Why is early protection important?","6304":"What is a test used to see if you have a current infection?","2764":"Eat healthy, well-balanced meals.","1179":"What did Texas and CDC collaborate on to improve?","689":"What resulted in an increase of 47,260 doses administered?","4831":"What is EVUSHELDTM?","154":"What has been done to learn more about how this virus can affect different animals?","3377":"A low risk of reinfection has been observed in the weeks to months following infection?","2950":"How long after the primary series is the bivalent booster dose administered?","298":"How many recent and historic vaccine doses did this number include?","5659":"What is important to pick a respirator that fits your face and seals well?","6181":"What is the name given to the new types of the virus?","2368":"What is another name for tumor necrosis factor blockers?","4256":"What should you do if you or your child have been vaccinated?","832":"What are the rates of COVID-19-associated hospitalizations and deaths among unvaccinated adults?","3726":"What does FDA-authorized or FDA-approved labeling and CDC recommended dosing intervals based on?","9344":"How can the moderna COVID-19 Vaccine be used?","6814":"What type of vaccines are available to prevent COVID-19?","9909":"What are the following post-vaccination observation times to monitor for?","6346":"What should each patient receive from the provider once it is their turn?","7980":"As of May 31, 2022, how many people had received at least one shot?","929":"If your newborn has one or more of these signs or symptoms, they may have what?","1052":"If you test positive, what is the most likely outcome?","8847":"Who can add a dependent to v-safe?","6097":"What is SARS-CoV-2?","7120":"What should you tell them you are pregnant or were recently pregnant and are having an emergency?","4436":"What is a term for trapping particles on a filter to remove them from the air?","7191":"What does the EUA stand for?","9186":"What should you do if you can't put on a mask?","8523":"What must pilots report all illnesses and deaths to before arriving to a U.S. destination?","7147":"How many Urgent Maternal Warning Signs were last updated?","8095":"Some people have what type of symptoms before they get a flu-like one?","7317":"What does CDC continue to do to better understand reinfections with COVID-19?","768":"What is the name of the virus that causes COVID-19?","2761":"What can be upsetting hearing about the COVID-19 pandemic repeatedly?","3169":"What is not authorized if a mixed primary series is inadvertently administered?","8125":"What are trusted messengers that show the difference in the structure of the virus particles and virions for the virus that causes monkeypox and COVID-19?","9507":"What is the FDA's decision based on?","8650":"Scientists have been working for many years to develop what?","1230":"When was the data as of 6 AM ET Wednesday?","2545":"How many days after the initial dose of a monovalent COVID-19 vaccine may a booster dose be given?","4503":"When was the last update for COVID-19 Vaccines and Vaccination?","842":"Hundreds of millions of people in the United States have received what under the most intensive safety monitoring?","4919":"What should only be undertaken in an appropriate setting under the supervision of a healthcare professional experienced in the management of COVID-19?","4696":"What may assist with decisions about booster vaccination?","8293":"What are some of the possible symptoms of being very sick?","4141":"What is it important for our child to get the vaccine made for their age group?","1200":"What may not be representative of all COVID-19 vaccinations occurring in the state?","9565":"What should be used for the primary series of vaccines?","10110":"People with a known allergy to polysorbate have a contraindication to what two vaccines?","4409":"What can you expect during and after your vaccination?","2421":"How many females were studied in a study?","2895":"How many monovalent COVID-19 vaccines are needed for primary series vaccination?","8096":"What do some people get before they get a rash?","3781":"What does the FDA stand for?","2767":"Avoid alcohol and drugs.","4854":"What results in the second dose being administered after the recommended interval between doses?","667":"What state made updates to its data that resulted in an increase of 32,976 doses?","9173":"What should you do if someone is showing any of the following signs?","2372":"How many strains of the Omicron variant are there?","10114":"What are two types of multisystem inflammatory syndrome?","8683":"Understanding the risk of COVID-19 for yourself and those around you can help you make what?","5263":"What is CDC's Travel webpage?","5895":"What is the recommended duration of the 2nd primary dose?","5111":"What are the requirements for land travel?","9570":"How many doses of vaccine should you use?","5864":"Who has independently confirmed efficacy of COVID-19 vaccines in the United States?","3346":"What is a risk factor for severe acute covid-19?","4191":"If you get sick, you are less likely to get severely ill or die?","6631":"What is important for people with medical conditions and their healthcare providers to work together and manage?","7133":"When is the last time a woman has SARS infection?","5312":"Who has authorized the emergency use of the Janssen COVID-19 Vaccine in individuals 18 years of age and older for whom other FDA-authorized or approved vaccines are not accessible or clinically appropriate?","3219":"What should be in place to prevent falling injuries and manage syncopal reactions?","5772":"How many doses of the COVID-19 vaccine did Moderna give you?","1716":"What is the VAERS?","2129":"What is the name of the vaccine that is not harmful to people who have received a vaccine?","9294":"Who is collecting data on how well COVID-19 vaccination works against MIS-C in younger children?","2892":"What is the current age of the COVID-19 vaccine?","4469":"How long can you wear a high-quality mask when you're indoors around others?","9576":"What is the name of the CDC's Emergency Use Instructions for Healthcare Providers?","4146":"What is the name of the vaccine that must go through three clinical trials?","2063":"What can a severe COVID-19 illness lead to?","8673":"What is the name of the reporting system used by the CDC and FDA to look for safety issues after vaccination?","4633":"What filter is based on one rated for MERV 13 filtration?","9275":"How can children or teens be affected?","3693":"Who can get an additional primary dose or booster dose of the COVID-19 vaccine by Pfizer-BioNTech?","8824":"What should not be used to promote or suggest endorsement of non-CDC, ATSDR or HHS companies, activities, products, events, facilities or services?","8017":"How much is the vaccine effective at preventing illness?","328":"What is the reason for the decrease in vaccination doses?","8361":"What part of the patient wants to trust that getting a vaccine is important and safe?","2384":"How many doses of mRNA COVID-19 vaccine are reported after the third primary dose?","6946":"How many doses of the COVID-19 vaccine did people receive?","9624":"What are some symptoms of the COVID-19 vaccine?","7800":"Who is at risk of severe disease?","7159":"What is the purpose of the 2-dose series?","9711":"What was used to boost those who received primary vaccination with the Pfizer-BioNTech COVID-19 vaccine?","9960":"What is a condition that makes a recipient immunocompromised?","1137":"What do public health departments and tribal health facilities use these data systems to inform?","2758":"What are experts still determining?","9652":"How long after a primary dose of the Janssen COVID-19 Vaccine should an additional dose be administered intramuscularly for persons ages 12 years and older with certain immunocompromising conditions?","785":"Scientists call viruses with these changes what?","1928":"What will be given as part of the study?","8378":"What type of vaccinators have not administered vaccines in the past 12 months or longer?","2475":"What is the name of the prospective cohort study?","5642":"What is a replacement for NIOSH-approved respiratory protection when required by your job?","9212":"What is the name of the EPA's List N: Disinfectants for Coronavirus?","7224":"What has been shown to prevent COVIDR-19?","9824":"What is the Omicron variant of SARS-CoV-2?","9615":"Who is issuing these EUI to provide information about use of the COVID-19 vaccine by Pfizer-BioNTech for primary and\/or additional doses that extend beyond its FDA-approved labeling?","5982":"What is the dose of the moderna covid-19 vaccination?","5189":"What is CDC contacting people who meet the case definition for?","1679":"What are the recommendations?","7659":"What must I do 3-5 days after arriving in the US?","4822":"What is an example of improper storage and handling?","9669":"How are the vials labeled?","409":"What is now categorized into a single race\/ethnicity group?","7111":"What can have similar symptoms to COVID-19?","3912":"What may offer less protection against certain strains of the Omicron variant?","577":"What was the net increase in doses received by Illinois in Aug. 11, 2022 compared to the previous year?","554":"What do you do with data fields that can't be updated?","4545":"What is the name of the disease that can cause you to become very sick from COVID-19?","6087":"How many mRNA vaccines are in Ontario, Canada?","9648":"What is the primary dose of the Pfizer-BioNTech vaccine?","6652":"What are non-perishable food choices?","218":"What may your immune system have cells that remember the virus that can act quickly to protect you if you become infected?","1325":"What is the minimum interval of 28 days from the last dose of COVID-19 vaccine?","5460":"What do people who experience post-COVID conditions most commonly report?","9993":"What is a precaution to COVID-19 vaccines?","8859":"How do you find COVID-19 vaccine locations near you?","6778":"How many doses of the Pfizer-BioNTech COVID-19 Vaccine did a clinical trial consist of?","5686":"What should they continue to follow to protect themselves and others?","9556":"How much of the product authorized for children ages 5-11 years should children receive?","1292":"Who can receive the orthopoxvirus vaccine without a minimum interval between vaccinations?","6788":"What is Myocarditis?","1091":"Who is best protected when you stay up to date on your COVID-19 vaccine?","5108":"What are effective at protecting people from getting seriously ill, being hospitalized, and even dying?","8003":"Healthcare settings are recommended to continue to follow what?","2817":"If you identify these symptoms, ask about prior COVID-19 vaccination.","2012":"When did the Pfizer-BioNTech COVID-19 vaccine expire?","7807":"Who may reimburse the cost of purchasing self-tests?","7420":"What must you do to board a flight to the United States?","7764":"What were the highest rates of myocarditis following the second dose of an mDNA vaccine among males?","3351":"What is another name for Moderna, Novavax, or Pfizer-BioNTech?","4232":"Who can give you a new CDC COVID-19 Vaccination card?","5880":"What is the name of the vaccine by Pfizer-BioNTech that can be used as an alternative to EUI for similar uses?","3658":"Do not travel on what type of transportation?","6112":"How many doses of COVID-19 vaccines did the UK get as a booster?","3679":"What are the most frequently asked questions about EUI?","935":"Who should get a booster shot?","7143":"How many Jurisdictions participated in the study from March 29 to October 14, 2020?","683":"How many doses were increased in Wyoming in January 2022?","3584":"What is the total number of fully vaccinated people who are eligible to receive a first booster dose of an mRNA COVID-19 vaccine?","8376":"What must be ongoing as new COVID-19 vaccines become available?","8458":"How many days after your last exposure do you need to get tested by the CDC?","6131":"Who Strategic Advisory Group of Experts on Immunization (SAGE)?","2154":"What is the name of the vaccine that can cause severe allergic reactions after receiving a COVID-19 vaccine?","2073":"Who can't make anyone sick with COVIID-19?","1403":"Patients who undergo HCT or CAR-T-cell therapy should be revaccinated for the monovalent primary series and what else?","4307":"What are allergies that are not related to vaccines or injectable medications?","3618":"When was County of Residence last updated?","303":"When did the District of Columbia upgrade its data collection and reporting system?","397":"What was the cause of some of the vaccine administration files not being ingested on August 15, 2021?","3575":"What is the total number of people who have received at least a dose of this vaccine approved or authorized for use in the United States?","9470":"Who may receive a booster dose of Moderna COVID-19 Vaccine, Bivalent?","3973":"What is the last part of the distribution process?","3232":"What should be done regardless of the antibody test result?","7903":"The findings and conclusions in this report do not necessarily represent what?","41":"What may include mucus membranes?","3527":"What does CDC estimate the number of people receiving at least one dose of COVID?","7962":"What vaccines are associated with AIDS, hepatitis, impaired immunity, and long-term effects on fertility, pregnancy, and lactation?","10031":"What is NOT considered to assess for acute SARS-CoV-2 infection or serologic testing?","5284":"What is Coronavirus Disease 2019 caused by?","1931":"What does BD-STEPS stand for?","6700":"How many steps does the Environmental Protection Agency use to label products?","251":"What would be the first thing that would need to be added to the vaccine?","6521":"What are people from racial and ethnic minority groups dying from at younger ages?","3531":"To protect the privacy of vaccine recipients, CDC receives data without what?","1597":"What is a VIS?","9704":"In the United Kingdom, how many doses of AstraZeneca, Moderna, or Pfizer-BioNTech COVID-19 vaccines successfully boosted immune responses?","6453":"What should you do if you test positive for COVID-19?","9083":"When people properly wear a high-quality mask or respirator, they protect themselves and those around them, and help keep travel safer for everyone?","2434":"What is a common symptom of COVID-19 infection?","7644":"What is required by US federal law?","9734":"Which countries have recommended heterologous dosing of COVID-19 vaccine?","8969":"What does v-safe do?","4270":"What is MIS?","7713":"When was VAERS last updated?","6383":"What are healthcare providers and patients encouraged to set achievable goals through?","6634":"What are some steps you can take based on your medical conditions and other risk factors?","9103":"Who is at high risk for getting very sick from COVID-19?","97":"What type of coronavirus does SARS-CoV-2 originate in?","8823":"What are logos and marks designed to signify?","5840":"How old are people who received certain therapies and received primary doses of COVID-19 vaccine prior to or during treatment?","589":"How many administered doses did Illinois increase?","4023":"What does the CDC COVID Data Tracker represent?","5801":"What is the name of the vaccine by Moderna?","5066":"What is a new section on people with a history of multisystem inflammatory syndrome added to considerations for vaccination of people with certain underlying medical conditions?","9548":"How many dosing errors are not considered an error?","8586":"What do many vaccines put into our bodies to trigger an immune response?","5935":"What does not apply to the Moderna COVID-19 Vaccine, Bivalent?","9987":"What is important to determine for patients who experience post-vaccination symptoms?","512":"What are reflected in national totals and in jurisdictional totals?","4052":"What do recent data suggest?","2132":"What is effective at preventing COVID-19 in people who are breastfeeding?","4084":"What depends on which vaccine you receive?","8181":"What is the most common cause of COVID-19?","8240":"What is the name of the PRIMARY SERIES Pfizer BioNTech or Moderna UPDATED (BIVALENT) BOOSTER At least 2 months after 1 dose or last booster?","538":"How many doses per vial will Pfizer-BioNTech be delivered to a jurisdiction on or after February 15, 2021?","324":"On what date were vaccination data not updated on the CDC COVID Data Tracker?","3340":"What is the term for no evidence of ongoing heart inflammation or sequelae as determined by patient's clinical team?","653":"What state made updates to data previously submitted to CDC that resulted in an increase of 16,930 doses?","862":"What does a parent do to prevent spread of the disease before and during care of the newborn?","8476":"What is CDC's primary vehicle for scientific public health information and recommendations?","9525":"What color label border does the product have?","4067":"When are people best protected?","194":"How do you make antibodies through vaccination?","1906":"CDC and the Food and Drug Administration monitor what during pregnancy?","91":"What is the risk of animals spreading SARS-CoV-2 to people?","5414":"What does the Secretary of Health and Human Services declare?","2779":"What do you feel like you want to do?","9867":"Blood Advances 2022;6(5):1537- 1546.","6003":"What may result in greater immunogenicity and effectiveness with this dosing interval?","3101":"What is the combination of two monoclonal antibodies?","5580":"What is a better way to protect yourself than a mask?","4958":"What vaccine is recommended for people ages 18 and older?","4190":"What is the risk of getting a breakthrough infection?","5551":"What type of mask provides the highest level of protection?","4715":"What should people seek medical attention for if they develop any of the following symptoms after receiving Janssen?","9258":"What is not recommended for children under 2 years and younger?","9407":"What is a third primary series dose given at least 1 month after the second dose?","6528":"What can having cancer make you more susceptible to?","253":"Studies show that people who have antibodies from an infection with the virus which causes the virus can improve their level of protection by getting vaccinated?","8528":"What is the name of the airline you booked your ticket with?","4400":"What is the zip code of the vaccine location?","5913":"How long after the booster dose does the vaccine last?","5171":"What is CDC's January 29, 2021 Order requiring masks on public transportation conveyances and at transportation hubs no longer in effect?","8230":"What may further minimize the rare risk of myocarditis and pericardiitis?","8816":"What happens when sites copy and re-post CDC materials fail to check for updates?","6031":"How long does it take to delay a second dose in people who recently had a SARS infection?","2755":"What is the RECOVER Initiative?","8374":"When was the last time the page was reviewed?","695":"What did not result in a change to the number of doses administered?","8986":"What is not paid for participation in the Vaccine Pregnancy Registry?","1296":"What is another name for COVID-19 vaccine?","379":"What is the result of updates to how pharmacies report data to CDC?","6198":"What is the name of the CDC\u2019s ongoing study of myocarditis after COVID-19 vaccination?","3507":"What should you do if your COVID-19 test results are positive?","8363":"What should a patient include in their decision about vaccines?","4066":"What is not included in the definition of fully vaccinated?","9092":"What are the names of the books that provide information about safer travel?","11":"Staff and residents should stay up to date on what?","2714":"Caregivers should stay home and monitor their health for what?","5262":"Consult your doctor before ending what?","773":"What do coronaviruses spread through droplets that you project out of your mouth or nose when you breathe, cough, sneeze, or speak?","1864":"How many participating sites are there across the US?","7046":"If you are pregnant or were recently pregnant, you are more likely to get very sick from COVID-19 compared to people who are not pregnant?","1510":"Who is responsible for shipping USG- purchased masks to agreed-upon distribution points?","5216":"What are some precautions you can take to prevent spreading the virus to others?","7606":"What percentage of the population is fully vaccinated?","7350":"What does the Amended Order clarify that parents or guardians do not need to complete on behalf of children under 2 years of age?","1888":"What is the latest CDC data on COVID-19 vaccine effectiveness?","1730":"What is a Serious AE regardless of?","1935":"When was the Last Updated?","8831":"What is the name of the app that helps you get vaccinated?","3707":"How many doses did the COVID-19 vaccine contain?","4891":"What is Angioedema?","1925":"How many medical research centers are involved in the CISA Project? What does the CISA Project provide?","2762":"What can be upsetting to hear about the COVID-19 pandemic repeatedly?","2133":"What is needed to determine what level of protection these antibodies might provide to the baby?","3520":"Cruise ships will continue to report COVID-19 cases to what agency?","61":"Which arm should you get your next COVID-19 vaccine in?","2473":"What does mRNA SARS-CoV-2 vaccine influence?","8139":"What are national and regional trends in negative attitudes toward vaccination?","1554":"What is the date of the Secretarial Directive?","6082":"Organ Transplant Recipients: A Case Series. Transplantation 2021;105(21):e280-e281.","4222":"How do you stay up to date with your COVID-19 vaccination?","5828":"Who can you contact to get a vaccination?","8500":"How can I protect myself from COVID-19 when using different types of transportation?","6603":"What is the name of the book that focuses on health, physical activity and disability?","6497":"If you test positive and are an older adult or someone who is at high risk of getting very sick, what is available?","4002":"When do vaccine data updates occur on federal holidays?","28":"What are boosters for?","10091":"What type of vaccine have a precaution to the other types of COVID-19 vaccines?","4402":"Who can you contact if you have a question about scheduling your appointment?","9925":"What should be used to identify the correct product based on the vaccine composition and recipient's age?","1686":"What is the name of the Thrombosis syndrome among Vaccine Recipients?","5928":"What is a red-capped multidose vial containing?","9368":"What is COVID-19?","1060":"What must be started within days of when you first develop symptoms to be effective?","4885":"What is urticaria?","1796":"Who can request an in-home vaccination?","5484":"What does PTSD involve?","9360":"What does the EUA mean for the vaccine?","7383":"What are the requirements for entry in the U.S.?","9036":"What is the Omicron variant made up of?","5632":"Gaps can be caused by choosing the wrong size or type of respirator or when a respirator is worn with which hair?","111":"What toolkit for Health Officials reduces risk of spreading COVID-19 between people and wildlife?","7704":"What is extremely rare following any vaccination? What does the benefits of COVIV-19 vaccination outweigh the known and potential risks?","1254":"What is a CDC Summary Document for Interim Clinical Considerations?","6588":"What may offer less protection against certain strains of the Omicron variant?","4830":"What does CDC guidance not require?","1518":"What does the USG provide for use by individuals?","8268":"How many doses of a 2-dose accepted COVID-19 vaccine are there?","3119":"What are alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, tumor necrosis factor blockers, and other biologic agents classified as?","642":"In what year did Illinois make updates to its data that resulted in a decrease in doses?","1838":"What is the list of evaluations organized by type of study?","1135":"What does CDC use to quickly collect reliable data about how many doses of COVID-19 vaccines have been distributed and how many people have been vaccinated with those doses?","5688":"What is the name of the product that reduces indoor exposure to SARS-CoV-2 aerosols?","1742":"What do providers of COVID-19 vaccines perform within the CDC's Vaccination Program?","7674":"Which vaccines will continue to undergo the most intensive safety testing?","4185":"What significantly lowers your risk of severe illness, hospitalization, and death if you get infected?","2555":"For males ages 12 to 39 years, what may reduce the small risk of myocarditis?","7960":"There is no evidence that what is true?","3217":"What is a term for a condition that can occur in association with any injectable vaccine?","3366":"What type of infection is SARS-CoV-2?","4173":"What does v-safe provide?","7867":"What company manufactures the Celltrion DiaTrustTM COVID-19 Ag Home Test?","8457":"How many days have I been exposed to a person with COV-19?","7174":"What is COMIRNATY?","5225":"If your results are positive, follow what recommendations?","8391":"What do healthcare professionals need to ensure the vaccine cold chain is protected?","9552":"What is the name of the Pfizer-BioNTech COVID-19 Vaccine product?","3364":"What should people who develop signs and symptoms that could be from COVID-19 vaccination or SRSV-2 infection?","4498":"What do you want to avoid?","2883":"What color is the cap of the Moderna COVID-19 Vaccine?","7126":"What type of milk is not likely to spread COVID-19 to babies?","3997":"Who is responsible for establishing internal operations and schedules for reporting data?","4398":"Who can call 1-800-633-4227?","9376":"Who has had a wide range of symptoms?","6539":"What is important that you talk with your healthcare provider about your risk?","4566":"What do you open as much as you can to bring in fresh, outdoor air?","4458":"Where can you order self-tests?","2480":"What is the name of the vaccine that increased menstrual disturbances in 18- to 30-year-old women after COVID-19 Vaccination?","506":"What is the name of the error that caused the daily count of doses reporting \u201cUnknown Age\u201d?","4964":"What are the names of the two vaccines used in primary series vaccination?","7273":"What may not provide full immunity to COVID-19 in people who are immunocompromised?","4416":"How often is COVID-19 County Check updated?","9997":"Deferral of vaccination and\/or consultation with an allergist-immunologist should be considered what?","5243":"If you have COVID-19, end isolation based on how serious your symptoms were?","1709":"What do providers need to maintain at all times?","6936":"What is pericarditis?","4930":"What was reported among Adult Recipients of Janssen (Johnson & Johnson) and mRNA (Pfizer-BioNTech and Moderna)?","9290":"How many of the reported MIS cases occur in children in this age group?","7055":"What does severe illness mean for a person with COVID-19?","9074":"What should you get tested for?","5613":"How do ear loops of a 3-ply mask join?","7860":"What are the available videos for using?","2907":"Who is unable to receive an mRNA vaccine?","4261":"How long does it take to get your next dose of the vaccine?","5621":"What should be worn according to the manufacturer's instructions without modifications?","8574":"How long does it take for the body to produce T-lymphocytes and B- lymphocytes after vaccination?","1840":"What is the name of the study design?","3529":"Who is fully vaccinated?","8068":"When will vaccines be available for children ages 5 years and younger?","8289":"Who can have mild to severe symptoms of COVID-19?","5186":"What does the information you provide contribute to?","5353":"What can cause easy or excessive bruising and bleeding due to low levels of platelets?","5896":"How many times should a person receive a second dose of a vaccine?","2053":"If you are pregnant or were recently pregnant, you are more likely to get very sick.","3209":"Counseling should include the need to seek care if symptoms of what after vaccination develop?","6592":"What is the BMI of an overweight person?","2857":"What is the name of the WHO's emergency use listing?","8660":"What has shown that COVID-19 vaccines are safe and effective?","378":"How many doses did reporting adjustments for Kentucky result in?","2250":"What are boosters for everyone 5 years and older?","8307":"How can you tell the difference between the two viruses?","4208":"What should you wait to be vaccinated until after you complete your isolation period?","6898":"What is the name of the vaccine by Pfizer-BioNTech?","8686":"What are the settings that make you more likely to be exposed to COVID-19?","5663":"What percentage of particles in the air are filtered by N95 respirators?","5672":"What type of masks are well-established?","3911":"What is given to help prevent COVID-19 before you are exposed?","545":"How many doses of vaccinated vaccines did Virginia transfer to the District of Columbia from December 21, 2020 to January 13, 2021?","7382":"What is advised for those seeking to enter the US by land or sea travel?","8719":"Where can you find masks?","7620":"What must crew do if they are not immediately embarking the ship?","3559":"What do data definitions for COVID-19 vaccines in the United States administration date, recipient ID, and date of submission need to be applied across multiple jurisdictions?","476":"When will the topline national totals for 12+, 18+, and 65+ be included?","8264":"What may be limited data available or reviewed on the safety or effectiveness of the COVID-19 vaccine?","1274":"How long can an interval longer than 3 or 4 weeks be?","4725":"Who is considered to be up to date with their COVID-19 vaccines when they have completed the recommended actions described below?","7309":"What is the name of the virus that causes COVID-19?","5335":"In what part of the body is tinnitus?","7228":"What could a vaccine cause?","1654":"Who is encouraged to report suspected fraud or abuse?","120":"There is no need to euthanize or otherwise harm animals infected with what virus?","5156":"What is required before you board your flight to the United States?","1386":"When should the child receive 1 bivalent booster dose when they turn age 5 years?","6846":"What is the name of the federal program that may help pay for costs of medical care?","9105":"What should I wear in travel and public transportation settings?","8593":"Which vaccine does not use any live virus?","4638":"What is the primary series dose of the Janssen COVID-19 Vaccine?","4044":"How often are COVID-19 vaccination data updated?","6253":"What has been misinterpreted and misreported?","5348":"What is the age range of individuals 18 years and older?","221":"What can a positive antibody test result help identify?","8805":"Where do copyright laws differ?","124":"What is needed to track variants and mutations and understand how SARS-CoV-2 spreads between people and animals?","8176":"How long has it been since your last dose of the vaccine?","2998":"When is the monovalent Novavax booster dose administered?","10094":"What is a history of Guillain-Barr\u00e9 syndrome?","8647":"What are distributed outside of clinical trials?","5786":"Moderna has done some studies in people who received the COVID-19 vaccine after completing what?","8394":"How long have retired healthcare professionals been licensed to administer COVID-19 vaccine but have not done so in the last 12 months?","8984":"Who can help provide this information?","1148":"What is used to populate the Immunization Data Lake?","8116":"Where is monkeypox transmission occurring?","9111":"Who might have a weakened immune system or be at increased risk for severe illness?","8160":"What is the name of the Pfizer-BioNTech Moderna Novavax Johnson & Johnson\u2019s Janssen?","5487":"Some people experience new health conditions after what illness?","6987":"How long must a claim be submitted to the CICP?","9512":"What happens after which the product may no longer be used?","5992":"What was assessed on Day 1 prior to administration of the booster dose?","2547":"How many days after the first dose to complete the primary series?","197":"What can be different for each disease, each person or influenced by other factors?","3344":"Why was the myocarditis considered non-related to COVID-19 vaccination?","1218":"What is the date of the COVID-19 Updated (Bivalent) Booster Administrations in the United States?","1933":"What is the purpose of COVID-19 vaccination information?","3100":"What is EVUSHELD?","7972":"What may be causing online discussions of current vaccine efficacy against dominant variants?","999":"Negative results should not be used as the sole basis for what?","12":"What may not fully protect you until a week or two after your final shot?","7763":"How many mRNA vaccines were given during the study period?","1252":"How old is everyone who is 6 months of age and older?","3783":"Millions of people in the United States have received what vaccines?","9884":"What does interval BNT162b2 vaccination enhance?","5839":"What is an additional dose in persons ages 18 and older who received primary vaccination with the Janssen (Johnson & Johnson) Covid-19 Vaccine?","7400":"Who is required to attest that you are not required to present Proof of Being Fully Vaccinated Against COVID-19 based on one of the exceptions?","2815":"What are some non-specific symptoms of myocarditis?","6113":"What is the name of the trial that was blinded, multicentre, randomised, controlled and phase 2?","7380":"Who is granted parole into the US?","6774":"In a clinical trial, how many individuals 5 to 11 years of age have been given the vaccines before?","3190":"When is the minimum interval between vaccinations?","3030":"What is recommended for children ages 6 months to 4 years for a 3-dose primary series?","2226":"What helps protect those who get vaccinated and the people around them?","6614":"What affects blood flow to the brain?","7029":"Who monitors everyone who receives a COVID-19 vaccine for at least 15 minutes?","939":"What should your hands be washed before breastfeeding?","1411":"What is the patient recommended to receive at least 2 months after the primary series?","6837":"What can the provider not charge you for a vaccine dose?","1785":"How much of the children and teens who participated in clinical trials had an underlying medical condition?","1919":"What does VSD monitor and evaluate?","5518":"Other than self-reported symptoms, what else do some studies collect?","2131":"What is the only vaccine that doesn't contain live virus?","3243":"What is another term for subcutaneous immunotherapy for allergies?","8975":"What is the name of the registry staff contracted by CDC?","285":"What will result in numbers and rates being under- or over-estimated for some age groups?","1199":"What state lifted its national COVID-19 emergency response declaration in May 2021?","1999":"How many confirmed reports of myocarditis were there?","772":"How do coronaviruses spread?","6237":"What can COVID-19 cause?","6199":"What are the symptoms of myocarditis?","8882":"What are Action Steps: Empower vaccine recipients to share their personal stories and reasons for vaccination within their circles of influence?","8745":"What does wearing a mask or respirator provide your child with greater protection when the COVID-19 Community Level is high?","8234":"What is the name of the vaccine that should be given to anyone wanting protection?","9306":"Why should children and teens get vaccinated against COVID-19?","7885":"What do community members and trusted messengers need to do to explain that some side effects are normal and expected?","3851":"Where can you find more information about Vaccine administration data?","8259":"How long do you have to wait to get vaccinated?","8806":"What may still be protected under the copyright laws of other countries when used in these jurisdictions?","6593":"What is a BMI under 30 kg\/m?","1732":"What is persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions A congenital anomaly\/birth defect Requirements for Reporting to VAERS?","3567":"What is the total number of vaccine doses that have been distributed to vaccine provider locations?","9496":"What is the name of the federal program that may help pay for costs of medical care?","1320":"What should a person receive for all subsequent doses if they move from a younger age group to an older age group?","2147":"What language are experts available to answer questions in?","90":"When was the last update for the COVID-19 vaccine?","7378":"What are Non-U.S. citizens admitted to the United States as?","5718":"EUI are issued to provide information about what?","6733":"What is Pfizer-BioNTech's COMIRNATY approved for use in individuals 12 years of age and older?","7435":"How many days have you been given before the day you board your flight to the US?","7320":"What is the acronym for the Council of State and Territorial Epidemiologists?","9613":"What does the FDA consider the 2-dose primary series to be?","9131":"What type of mask is recommended for indoor areas of public transportation and transportation hubs?","425":"What has been replaced with \u201cdate reported to CDC as of June 24, 2021?","6904":"Who issued the original CDC-issued fact sheet on 11\/17\/2021?","537":"When did Pfizer-BioNTech deliver to a jurisdiction?","3027":"Who should follow the COVID-19 vaccination schedule according to their age and immune status at the time of eligibility for that dose?","3748":"What is the reason for early protection?","1677":"What is the name of the Advisory Committee on Immunization Practices?","4992":"What is the current recommendation to receive?","7985":"The FDA64 and CDC65 strengthened recommendations and expanded what?","1786":"What should some children with a weakened immune system get as part of their primary COVID-19 vaccination series?","6728":"What vaccine is approved for use in individuals 5-11 years of age for doses 2 and 3?","7670":"How many participants were evaluated in clinical trials?","2122":"Who recommends that people who are breastfeeding get vaccinated and stay up to date?","1141":"What does VPOP stand for?","5364":"Difficult walking.","350":"How many incorrect census county-level population denominators did CDC update?","10090":"History of an immediate non-severe allergic reaction after a dose of one type of COVID-19 vaccine have a precaution to what type of vaccine?","6156":"What is one of the rare outcomes of COVID-19?","3550":"What is the CDC encourages people to bring with them to their appointment for vaccination?","8428":"What is the acronym for the American College of Obstetricians and Gynecologists?","755":"Where was the COVID-19 virus discovered?","3345":"How long after the most recent dose of the COVID-19 vaccine did the diagnosis of myocarditis or pericardiitis occur?","6139":"Who developed the interim recommendations for use of the inactivated COVID-19 vaccine BIBP?","3130":"Who should receive HCT or CAR-T-cell therapy?","4792":"What is the name of the chapter of Epidemiology and Prevention of Vaccine-Preventable Diseases?","9020":"What does CDC encourage reporting even if it isn\u2019t clear if the adverse event is medically important?","9631":"Persons ages 12 and older who received an incomplete primary series may receive what?","2754":"What should you do if you are experiencing a post-COVID condition?","9353":"Who may receive the Moderna COVID-19 Vaccine authorized for use in individuals 6 years through 11 years of age?","17":"What is a common side effect of HELPFUL TIPS?","2656":"Who should learn when and how to isolate?","6930":"What is a booster dose?","6870":"Who is responsible for providing information about the primary and additional doses of the COVID-19 vaccine by Pfizer-BioNTech?","5375":"What is the purpose of V-safe?","7568":"What is a personal identifier in the clinical trial documentation?","956":"What are in isolation and during their own quarantine period after you complete isolation?","4967":"What is the newer guidance on coadministration of mRNA and orthopoxvirus vaccines?","310":"How many vaccine doses did New Hampshire decrease since December 14?","1150":"What does BoP stand for?","9295":"What will CDC be able to analyze and share as more children under 12 get vaccinated?","1049":"When was the Last Updated?","2185":"What is SARS-CoV-2?","165":"What group researches and develops guidance on the connection between people and pets, wildlife, zoo animals, and livestock?","7614":"What is required for the purpose of operating a vessel or return travel?","5160":"What is the name of the virus that can be tested 3-5 days after arrival?","5795":"Is myocarditis rare or rare in some people?","9200":"How much alcohol should be in hand sanitizer?","7219":"What is used to make tromethamine and sucrose?","5695":"What should be reserved for use by healthcare workers and patients who require them?","4492":"What type of protection do respirators provide?","4639":"Why is the booster dose of Janssen approved for adults ages 18 and older?","7310":"What does it mean if a person was infected, recovered, and then became infected again?","8614":"How long have subunit vaccines been used for?","7538":"What are certain categories of persons eligible for an exception under the Proclamation and CDC's Amended Order?","6781":"Which vaccine has been shown to prevent cancer?","9253":"If you already had COVID-19 within the past 90 days, see what?","8248":"Who is not recommended to receive a booster at this time?","4881":"What is a contraindication or precaution?","1726":"What is required if a different product from the primary series is inadvertently administered for the additional or booster dose?","3482":"What are two things you should be aware of if you are traveling to remote areas?","3979":"What is the acronym for the Vaccine Administration Management System?","5403":"Who can I report CASES OF SUSPECTED FRAUD?","3053":"What is the age limit for children who receive a bivalent Pfizer-BioNTech booster?","4158":"How many monitoring systems are there for COVID-19 vaccines?","7415":"What will all airlines or other aircraft operators provide and collect on behalf of the U S Government?","5603":"What blocks light when held up to bright light source?","9417":"Who has authorized Moderna COVID-19 Vaccine, Bivalent?","8708":"How often do you wash your hands?","7826":"Why are you more likely to get very sick?","6563":"What is the acronym for Human Immunodeficiency Virus?","3414":"What should be considered for those who meet the two criteria listed below?","7696":"How does the body's immune system damage nerve cells?","3110":"What is associated with poor responses to COVID-19 vaccines regardless of current treatment status?","4547":"What may be available for COVID-19?","5989":"Who was randomly randomized 1:1:1 to receive a booster dose of one of three vaccines?","1093":"People who are boosted can be hospitalized, dying, and what else?","5117":"If you have a weakened immune system or are at increased risk for severe disease, take multiple prevention steps to provide what?","390":"Who collaborated to update how Texas submits aggregate vaccination data?","4128":"Why should parents and caregivers wait for additional vaccines?","6604":"What can make you more likely to get very sick from COVID-19?","6118":"When did Public Health Agency of Canada issue guidance on vaccine dose?","2875":"What color is Monovalent Royal blue No color?","4481":"What can having COVID-19 reduce your risk of catching the virus from them?","3430":"What is the proprietary name for the product licensed under the BLA?","7396":"When does the list for updates for the vaccine come into effect?","4382":"What has been found in untreated wastewater?","8002":"What does not apply in healthcare settings?","8632":"What are normal signs the body is building protection from?","9862":"What is JCVI's advice on third primary dose vaccination?","5110":"What is the name of the tool to help you know the requirements to board a flight to the United States?","8461":"What can lower the chances of spreading COVID-19 to others?","7661":"When was the last update updated?","4463":"What is a list of authorized tests?","3250":"What is a precaution to the other types of COVID-19 vaccines?","561":"How many doses were increased in Illinois in the 2022 update?","9485":"What does IIS stand for?","1870":"What is the Outcome of Symptomatic SARS-CoV-2 infections?","5269":"How many hours apart do you take antigen tests?","9433":"What are some of the side effects of the vaccine?","6216":"Fats, sugars, and salts are ingredients in what?","5544":"What is a critical public health tool for preventing spread of COVID-19?","8769":"What can be used to make communication possible while wearing a mask that blocks lips?","3273":"Check-ins after patients receive COVID-19 vaccination?","5572":"Layered finely woven products provide more protection, what type of surgical mask provides more?","2939":"How long is the bivalent mRNA booster dose administered?","6643":"How long are you allowed to take prescription medicines?","2452":"Which vaccines do not have an impact on fertility?","196":"What can antibodies protect you from getting if you get sick?","6441":"What is the best option for you?","4953":"How many mRNA boosters are recommended for people ages 12 and older?","752":"What did Utah make to the data previously submitted to CDC that resulted in an increase of 6,028 doses administered?","6917":"How long after the initial booster dose should people receive an additional dose of the COIVD-19 vaccination?","6805":"What is the first line of box #18 of the report form?","4145":"How many clinical trials must all vaccines in the United States go through?","2721":"How many days after the person who is sick meets the criteria to end home isolation?","2419":"What do medical organizations serving people of reproductive age, including adolescents, emphasize?","5209":"Who can submit a report to VAERS?","1038":"What is the difference between flu and COVID-19?","7743":"What did CDC scientists make available to healthcare providers and the public?","5053":"What was updated regarding mRNA vaccine dosing intervals?","2924":"What is a term for a vaccine based on the original strain of SARS-CoV-2?","9413":"How many people received a dose of a bivalent vaccine?","4388":"How do you find a COVID-19 Vaccine or Booster near you?","10015":"What is the term for a syndrome characterized by thrombosis?","4164":"What is the name of the Pfizer-BioNTech COVID-19 Vaccine Overview and Safety?","6664":"What do you take to protect yourself?","8012":"What is a mask with the best fit, protection, and comfort for you?","5339":"How long after getting a dose of the Janssen COVID-19 Vaccine?","8284":"What is the name of the Vaccine for Healthcare and Public Health Use in the United States?","8165":"What was the original virus that causes COVID-19 designed to protect against?","4465":"Where can you visit a community testing site?","5853":"Who has legal authority to create, issue, and disseminate EUI before or during an emergency?","7401":"What is fully vaccinated against COVID-19 based on one of the exceptions listed above?","8090":"The rash may be located on or near the genitals or what else?","10137":"What is contraindicated to administer Janssen COVID-19 Vaccine to persons with a history of TTS?","8808":"What must be provided in your use of CDC's public domain content?","9473":"If you are pregnant or breastfeeding, discuss the options with your healthcare provider.","8236":"How long does Novavax vaccine last 3 weeks?","2260":"What vaccine is recommended for people who are moderately or severely immunocompromised?","3646":"Where can you find a COVID-19 testing location?","2276":"What is not required by federal law for COVID-19 vaccination in the U.S.?","3573":"When was the first vaccine dose administered to a person in the United States under the Emergency Use Authorization not within a clinical trial?","7014":"What is Fatigue?","8347":"What is the goal of motivational interviewing?","4226":"What can your state's IIS provide?","9138":"What is COVID-19?","6766":"What is the name of the monovalent COVID-19 vaccine?","9678":"What are some of the adverse reactions that have been reported after administration of the vaccine?","2530":"How long does it take for BIVALENT Moderna to increase the dose?","6532":"What are the conditions on this list in alphabetical order?","3054":"How old is the child who receives a Pfizer-BioNTech booster dose?","3829":"Who must sign a COVID-19 Vaccination Provider Agreement?","8365":"What should you do if you feel competent and aware of how to answer a patient's question?","250":"What is important information for making decisions about whether or not additional vaccine doses are needed?","9722":"How many booster doses did Pfizer-BioNTech covid-19 vaccine have?","3673":"Is it Positive or You Develop COVID-19 Symptoms Isolate yourself to protect others from getting infected?","7471":"What is the difference between quarantine and isolation?","9185":"What do you need to wear if you are alone?","6186":"What is pericarditus inflammation of the outer lining of the heart?","8592":"What has cancer research used to trigger the immune system to target specific cancer cells?","3436":"What is Moderna COVID-19 Vaccine for people ages 12 years and older?","5295":"What is the name of the coronavirus that causes COVID-19?","3519":"What does CDC continue to provide for cruise ship operators to follow?","8990":"Who is currently enrolling eligible participants in the Registry?","1025":"What is it called to get very sick if you are an older adult or have an underlying medical condition?","1737":"Who is encouraged to report any additional clinically significant AEs following vaccination?","4392":"How do you find out if a vaccination appointment is available?","2425":"What is the effect of COVID-19 Vaccines on Menstrual Cycles?","5016":"What is updated guidance on dosing and administration of the vaccine in children and adolescents?","8639":"On what surface do our cells display the spike protein?","3350":"What is the name of the vaccine that people who have a history of myocarditis or pericardiitis may receive?","6165":"How many medical facilities are there in the NHSN?","1834":"What does the FDA do to assess COVID-19 vaccine effectiveness?","5779":"What is given as an injection into the muscle?","2565":"What is the primary series: Monovalent At least 3-8 weeks?","6066":"What are the original and Omicron BA.4\/BA.5 versions of the Pfizer-BioNTech Covid-19 vaccines?","9598":"The Comirnaty package insert contains information about what vaccine?","2665":"What is a safe place for a person who has been sick to be around others?","1269":"What should you administer the second dose as close as possible to the recommended interval?","9825":"What does the COVID-19 booster doses confer?","1682":"What is the name of the company that uses mRNA Vaccines after reports of adverse events?","7234":"What is COMIRNATY?","520":"What is the denominator used by the CDC to calculate national population estimates?","2975":"What is recommended for people who are not moderately or severely immunocompromised?","583":"Which state made updates to data previously submitted to CDC?","2940":"Who is NOT Moderately or Severely Immunocompromised?","254":"What can you do to protect yourself from COVID-19?","213":"How long can your level of antibodies decrease?","5259":"Who recommends you avoid being around people who are more likely to get sick from the disease?","2373":"What is the name of the medicine given to prevent COVID-19?","6672":"What is CDC reviewing this page to align with?","1953":"Who can enroll in v-safe after any dose of vaccine?","6124":"How does standard and extended dosing intervals of vaccine affect immunogenicity?","9297":"Physical and mental health complications that may occur four or more weeks after initial infection can occur after what?","3264":"What are vaccination providers required to report after COVID-19 vaccination?","2431":"Researchers found no significant changes in what after vaccination?","1375":"Dosage should be administered at least 2 months after the last monovalent booster dose?","5845":"What is the name of the vaccine used by Pfizer-BioNTech under EUI?","1127":"How do you get updates about this page?","6052":"What would allow people to develop a more sufficient immune response?","2091":"Antibodies made after pregnant people received an mmrc covid-19 vaccine have been found in their baby's umbilical cord blood?","5633":"What is the name of the international respirator?","6908":"What is the primary dose of the COVID-19 vaccine by Pfizer-BioNTech to complete the series?","3312":"What is the earliest age of children who have been reported to have had this disease?","3977":"What is the only exception to the federal delivery system?","6289":"How do the vaccines teach our immune systems to recognize and fight the virus?","3700":"How many doses did Moderna's vaccine contain?","5868":"What are the doses and intervals of the COVID-19 vaccine by Moderna for?","4962":"What vaccine is used for primary series vaccination in adults ages 18 years and older?","9740":"Who was randomly randomized to receive a booster dose?","3741":"When was the EUA updated to allow the use of Moderna COVID-19 vaccine for ages 12 years and older?","4647":"What vaccines are recommended over Janssen COVID-19 Vaccine?","4326":"How do you feel after getting a COVID-19 vaccine?","9340":"How old are individuals who receive the Moderna COVID-19 Vaccine?","1721":"What is the reporting requirements for COVID-19 vaccines?","2113":"What type of studies have shown no safety concerns for babies born to people who were vaccinated against COVID- 19 during pregnancy?","132":"How many wild mink were found to be infected with SARS-CoV-2?","8346":"What type of interviewing is an evidence-based and culturally sensitive way to speak with unvaccinated patients?","5830":"What does EUI stand for?","1646":"Communications regarding receipt of a second dose of COVID-19 vaccine Communications to vaccine recipient for public health purposes Communication to vaccine recipients involving pharmacy or clinical services of the provider, personalized to what?","7223":"What is the difference between the Pfizer-BioNTech COVID-19 Vaccine, Bivalent and COMIRNATY?","3363":"Who should be evaluated for SARS-CoV-2 infection as soon as possible?","7265":"What do bivalent vaccines contain an Omicron component of?","7090":"What should you wear to help protect yourself and others?","4212":"What is the term for a person who has had no symptoms and received a positive test?","9261":"When was the last update updated?","5763":"How long after treatment is revaccination required?","10078":"What is the name of the moderna, Novavax, or Pfizer-BioNtech COVID-19 vaccine?","4358":"What do CDC's surveillance data allow us to monitor?","6309":"What can prepare for an appointment?","8940":"What is one of the systems used by CDC and FDA to ensure vaccines used in the United States are closely monitored for safety?","7766":"How many cases of vaccines per one million doses of Pfizer-BioNTech are there?","5535":"Which group might experience different symptoms?","2690":"What do you throw out gloves into?","1645":"What is not included in the above prohibition?","9743":"What was measured by a pseudovirus neutralization assay using a lentivirus expressing the SARS-CoV-2 Spike protein with D614G mutation?","8076":"What are the benefits of vaccination compared to?","9444":"What is the name of the mRNA-containing vaccine?","3452":"What is a medical condition that weakens your immune system?","7472":"Children ages 2 to 17 years are what?","2859":"How many types of COVID-19 vaccines are currently approved?","5970":"What was the most reactogenic vaccine?","5802":"What may receiving the second primary dose of the COVID-19 vaccine by Moderna reduce the risk of?","6040":"What can impact level of protection?","7184":"What is COMIRNATY?","6744":"What is the acronym for SARS-CoV-2?","4375":"What should you do if you have pets?","499":"Which state had the most doses?","9638":"What should be revaccinated with the COVID-19 vaccine by Pfizer-BioNTech for any doses received before or during treatment?","2730":"What can be difficult to care for yourself or loved ones with a post-COVID condition?","3441":"How many FDA-approved formulations are the same?","330":"On what date did Idaho begin providing vaccine data for recipients younger than 18 years of age to CDC?","2709":"Disinfect if certain conditions apply?","1508":"The masks will be distributed to people in what country?","4712":"Who has the highest risk of GBS?","2057":"Who should stay up to date with their COVID-19 vaccines?","7413":"Why can an authorized person attest?","9443":"Where can you report vaccine side effects?","7226":"Who has authorized Pfizer-BioNTech COVID-19 Vaccine, Bivalent?","4057":"What does CDC's COVID-19 Booster Tool tell you about?","2100":"What is the name of the disease that can be used to protect babies from COVID-19?","5728":"What is Coronavirus disease 2019?","4147":"How many phases of clinical trials must vaccines go through in the US?","1393":"What is the guidance for using the monovalent Novavax COVID-19 vaccine for a booster dose?","8299":"What color is the skin, lips, or nail beds?","9688":"Do not administer the COVID-19 vaccine to persons with a known history of a severe allergic reaction to a previous dose or any component of the vaccine?","1976":"What is VAERS?","3408":"What may require a reference laboratory for SARS-CoV-2 anti-nucleocapsid antibody?","8143":"When did the COVID-19 vaccine become available?","7085":"What are people who are or were recently pregnant and those who live or visit with them urged to do?","4644":"Why would a person otherwise remain unvaccinated?","8468":"What does CBP stand for?","5172":"What will CDC not enforce the Order?","9583":"How long is the interval between the first and second dose of the Pfizer-BioNTech COVID- 19 vaccine?","5806":"Moderna's COVID-19 vaccine may not protect everyone what?","1627":"What shall be cause for immediate termination from the CDC COVID-19 Vaccination Program and criminal or civil prosecution for violation of 18 U.S.C.  1001 or other relevant federal statutes?","7804":"What are children who cannot get vaccinated yet?","3975":"Who orders vaccines from the federal government?","3671":"What should you do if your test is positive or you develop COVID-19 Symptoms?","2156":"What type of therapy can be used to treat an allergic reaction?","2253":"Children and adolescents with intellectual and developmental disabilities living in any type of shared setting are considered what?","5188":"Who is conducting surveys of patients and healthcare providers to gather information about myocarditis after COVID-19 vaccination?","1753":"What may seek appropriate reimbursement from a program or plan that covers vaccination administration fees?","5028":"What is the name of the new section on Overview of COVID-19 vaccines recommendations?","7986":"What did not positively impact Google searches?","9912":"How are COVID-19 vaccines administered?","4412":"What do you do to help protect yourself and others from severe illness from COVID-19?","6211":"What can be difficult to know which sources of information you can trust?","3630":"What should your airline require?","9305":"What can happen with a primary or booster dose?","9853":"What is the name of the Fact Sheet for Healthcare Providers Administering Vaccine?","9279":"What are some conditions that can make children more likely to get severe COVID-19?","5789":"What is available as an additional dose of the COVID-19 vaccine in people who completed their primary vaccination with a non-FDA authorized or approved covid-19 vaccine?","4933":"What year was the Interim Recommendations for Additional Primary and Booster Doses of CoviD-19 vaccines issued?","6710":"What is the name of the organization that provides information on administering asthma medication in schools?","3900":"People who are older, immunocompromised, have disabilities, or have underlying health conditions are examples of what?","9962":"Who can receive COVID-19 vaccines?","3723":"What is the term for a hematopoietic cell transplant?","1496":"What is the difference between the CDC COVID-19 Vaccination Program and the Vaccines for Children Program?","5367":"What vaccine is still being studied in clinical trials?","6705":"What can trigger an asthma attack?","1240":"What is the cost of the COVID-19 vaccine for everyone?","988":"How many hours apart should a negative antigen test be repeated?","1868":"What is the name of the Vaccine Effectiveness Research | CDC?","6964":"What could increase the immune response of people?","2278":"What should be recorded in their medical chart?","7318":"What is the risk of reinfection when there is community involvement?","5182":"What does VAERS contain?","7841":"What is needed to get an accurate result?","6666":"Avoid what?","1752":"What may not require additional medical services to receive COVID-19 vaccination?","5297":"How can you get COVID-19?","1744":"What are important for maintaining or improving providers\u2019 adherence to these requirements?","8408":"What are the core competencies of the EUA Fact Sheets for Healthcare Providers for the vaccine product(s) in your facility?","6074":"What is the acronym for Multisystem Inflammatory Syndrome?","1871":"Where is the Truman Medical Center located?","7810":"Where can you get a self-test when you need it?","7236":"Which vaccine is more commonly used in adolescents?","3157":"What should people receive on the day of vaccination?","475":"How many population groups are fully vaccinated?","4843":"What is the name of the diluent that causes a higher than authorized dose?","10099":"Whenever possible, what should be administered at least 2 weeks before initiation or resumption of immunotherapy?","7106":"What can help protect you and your baby?","8651":"SARS-CoV-2 is related to what other coronavirus?","9561":"What is the dose of COVID-19 Vaccination of Children and Adolescents Aged 5-11 years?","14":"What is the name of the person who can help you if you have side effects after a shot?","10003":"What is the personal risk of severe acute acute respiratory illness?","4713":"How long after a Janssen COVID-19 vaccination do symptoms begin?","9135":"How many pages?","6202":"Who recommends that everyone age 6 months and older get vaccinated for COVID-19?","1":"What should go away in a few days?","3083":"How many weeks NA 5 years 3 1 Pfizer-BioNTech 4 weeks At least 4 weeks at least 2 months years Ppizer-Biologics 4 weeks AT least 4 week At least 3 months Novavax primary series years 3 NA NA 3 weeks NA 3 months","6048":"Studies indicate patients do not achieve adequate seroconversion or have what?","297":"When will the data be updated?","5040":"What is a new section about Vaccination people receiving medical care unrelated to the disease?","9900":"When was CoronaVac updated?","2397":"What are people who have weakened immune systems considered to be?","5370":"What does VAERS stand for?","5274":"What should be used as the sole basis for treatment or patient management decisions?","4788":"Providers are required to report all COVID-19 errors to what?","3495":"What should passengers at increased risk for severe illness and crew do?","4114":"What may people who menstruate observe after a vaccination?","5517":"Some studies look for the presence of post-COVID conditions based on what?","2752":"What can be found at CombatCovid.hhs.gov?","975":"What is the virus that causes COVID-19?","5903":"How much of the COVID-19 vaccine should be given intramuscularly to persons ages 18 and older?","457":"What was the reason for the incorrect reporting of doses?","837":"What are the risk factors for severe COVID-19 in children published in?","6191":"What is the name of the company that vaccinates adolescents and young adult males?","4483":"What should you do when you're sick?","1466":"What does CDC's EVUSHELDTM guidance provide?","6910":"How long ago did people receive their primary vaccination with certain non-FDA authorized or approved COVID-19 vaccines?","4672":"What should people who have GBS receive a booster dose using a bivalent mRNA covid-19 vaccine?","9371":"What is SARS-CoV-2?","471":"What is the CDC's estimate of the \"at least one dose\" metric?","4991":"When did the CDC update the guidance for moderate or severely immunocompromised people?","5726":"What is the name of the Pfizer-BioNTech EUI Fact Sheet for Recipients?","10140":"How long after their dose of the Janssen COVID-19 Vaccine has their clinical condition stabilized?","1843":"What college of public health is located in Tucson, AZ?","1970":"What does VAECS stand for?","4616":"What is the name of the expanded model from the National Institute of Standards and Technology?","6018":"What did a test-negative case control study show about Pfizer-BioNTech VE?","5963":"In what country did studies show that a third dose of AstraZeneca, Moderna, or Pfizer-BioNTech COVID-19 vaccines successfully boosted immune responses?","9440":"What should you do if you or your child experience a severe allergic reaction?","8302":"What should you notify the operator of?","8106":"ACAM2000 vaccine was made available for use against what disease under an Expanded Access Investigational New Drug?","9883":"What does extended interval BNT162b2 vaccination enhance?","5523":"What percentage of people who had COVID-19 go on to experience post-COVID conditions?","9126":"How should conveyance ventilation systems be kept on when passengers?","687":"What did Illinois make to the data?","4206":"If I have already had COVID-19 and recovered, what do I still need to get?","5401":"What cannot be charged an out-of-pocket vaccine administration fee or any other fee?","4670":"Do not vaccinate with Janssen COVID-19 Vaccine?","6293":"What does COVID-19 vaccine affect?","9358":"What is Moderna COVID-19 Vaccine?","1875":"Where is the University of Mississippi Medical Center located?","845":"The benefits of COVID-19 vaccination outweigh what?","3895":"What is the name of the website that provides information on communicating with patients about COVID-19 vaccines?","6379":"Write down any issues you did not have time to talk about at the last appointment?","5714":"What do Emergency Use Instructions stand for?","6757":"What does monovalent refer to?","5":"What can you do if you have fever?","9492":"Who can I report CASES OF SUSPECTED FRAUD?","1528":"Who is responsible for the free distribution of the masks?","9392":"What is a bleeding disorder?","1248":"How many doses were administered onsite to long term care facilities in the early days of the COVID-19 vaccination program?","6689":"Quaternary ammonium compounds are known as benzalkonium chloride.","7509":"What does not have to be the same vaccine as the first dose?","8297":"When to Seek Emergency Medical Attention Look for emergency warning signs for what?","677":"What was the decrease in doses administered at the National level?","2085":"What did recent studies compare people who received an mRNA COVID-19 vaccine with pregnant people who didn't?","4300":"Novavax or J&J\/Janssen COVID-19 vaccine should not be given if youre allergic to what type of vaccine?","2948":"What is recommended for children age 5 years?","5255":"What is a moderate illness?","6140":"When was the updated recommendations updated?","4064":"What are some common side effects of smoking?","6226":"What is a safer and more reliable way to build immunity to COVID-19 than getting sick?","5987":"How long prior to enrollment were adults vaccinated with a Moderna COVID-19 Vaccine 2-dose series?","5412":"What is an EUA?","6894":"What can a severe illness lead to?","2198":"In what year was the Coronavirus disease vaccine response in pregnant and lactating women conducted?","8654":"What did the knowledge gained through past research help speed up?","6826":"What do these vaccines not contain?","8065":"What is the iCDC-INFO COVID-19 State of Vaccine Confidence Insights Report | October 10, 2022 SARS-CoV-2?","6454":"What must be started soon after you first develop symptoms to be effective?","4875":"What is the name of the appendix used for Triage of people with a history of allergies or allergic reactions?","2336":"What is the 3rd dose in primary series?","8203":"How long after your 1st dose do you need to get your 2nd dose of Pfizer-BioNTech or Moderna UPDATED (BIVALENT) BOOSTER?","1309":"What does CDC recommend if a person moves from a younger age group to an older age group during the primary series?","3309":"What is the risk of myocarditis and pericardiitis higher after vaccination with Moderna COVID-19 Vaccine compared to Pfizer-BioNTech?","5513":"What can be hard to live with when there are no immediate answers or solutions?","2491":"What helps individuals and communities decide which prevention actions to take based on the latest information?","6767":"Who should not get the PFIZER-BIONTECH COVID-19 VACCINE?","3664":"What is a good way to protect yourself and others?","8492":"What should you do if you test positive for COVID-19 during your trip?","4708":"Available evidence does not indicate that people should receive a currently FDA-approved or FDA-authorized mRNA?","5956":"What does V-safe use to check in with people who have been vaccinated?","8489":"What are some travel recommendations and requirements for domestic and international travel?","5738":"What is the second primary dose?","786":"What do scientists call the viruses with these changes?","7506":"What is the difference between a single dose and a booster dose of a accepted vaccine?","1533":"The masks provided through this initiative are what?","1947":"What can be done by scaling up existing safety monitoring systems?","8414":"What do you call the shots?","7497":"Why do many countries not offer booster doses?","1377":"Who can get a bivalent mRNA booster dose if they received the primary series but did not receive the previously recommended monovalent dose(s)?","4328":"What do you bring to your appointment whenever you get a primary series dose or booster?","9848":"What is the name of the mRNA vaccines in Ontario, Canada?","241":"What are the results of both tests for antibodies to?","8588":"What does the immune response produce?","4006":"What is shown on a state's website?","8852":"What does not require that you enter your own vaccination information or complete health check-ins for yourself?","8691":"What are new variants of the virus expected to occur?","9038":"Who has the most current data on circulating variants of Omicron?","9023":"What is the name of the meeting that discussed the safety of COVID-19 vaccines in pregnancy in the US?","3778":"How long has science been around about COVID-19 vaccines?","934":"What is the name of the person who is trying to get pregnant?","5224":"What should you do if you have test results but don't have them yet?","4466":"What should you wear if you were exposed to someone with COVID-19?","5910":"What is the recommended dose for people who receive an additional dose with a vaccine by Moderna?","5161":"Where can you find a U.S. COVID-19 testing location near you?","8596":"What is the nucleus of the cell where our DNA is located?","7663":"What does CDC recommend for everyone 6?","1162":"How many states are included in the Census Bureau Annual Estimates of the Resident Population for the United States?","9075":"How can you find tests?","6640":"Do not change your treatment plan without talking to your healthcare provider?","2396":"Who can help protect you and themselves by staying up to date on their COVID-19 vaccines?","5145":"What information will help keep the public safe?","3222":"If syncope develops, patients should be observed until symptoms resolve.","5257":"How long do you need to isolate for COVID-19?","2688":"Who should put on a mask and ask the sick person to put one before entering the room?","9034":"Staying up to date with your COVID-19 vaccines reduces what risk?","4676":"In clinical trials of Janssen COVID-19 vaccine, what was the most frequently reported local reaction among vaccine recipients?","4381":"No scientific reports of the virus that causes COVID-19 spreading to people through the water in lakes, oceans, rivers or other natural bodies of water?","7182":"How long can symptoms appear after exposure to the virus?","623":"How many doses were increased in Alaska in May of 2022?","8399":"What do you call a vaccine storage and handling training?","5079":"What is a contraindication to the Janssen COVID-19 vaccine?","6348":"What are most concerning issues sometimes called?","2297":"What is the name of a website that provides information about Medicare and the COVID-19 vaccine?","5409":"What must be submitted to the CICP within one (1) year from the date of receiving the vaccine?","9650":"Who issued the EUI Healthcare Providers Fact Sheet?","3131":"What should recipients of HCT or CAR-T-cell therapy undergo for the monovalent primary series and bivalent booster doses received prior to or during treatment?","3223":"What should providers observe for 30 minutes after COVID-19 vaccination to monitor for allergic reactions?","4590":"What can help to keep viruses from being concentrated in one place?","6358":"What did the provider tell you to do to check for understanding?","63":"Tell your vaccination provider that you experienced a rash or what after your shot?","8796":"What may be freely used or reproduced without obtaining copyright permission?","505":"When did a data synchronization error occur?","6194":"What can patients usually return to after their symptoms improve?","320":"What is still available for download when hovering over a vaccine?","4609":"How can a guest visit your home to prevent virus particles from accumulating in the air?","5018":"Who received passive antibody products?","3534":"CDC cannot use the unique person identifier to identify individuals by name?","78":"Reports of adverse events that are unexpected are followed up with what?","802":"Even people who don't have symptoms when they are first infected can have what?","6762":"How many doses are given in a 2-dose series?","6347":"What is the name of the document that will help you make a list of why you are coming in for an appointment?","6258":"What type of vaccine triggers an immune response inside your body?","2756":"Who is conducting a research project to understand how people recover from COVID-19 infection?","2026":"What do mRNA vaccines teach the body to do?","9892":"How many doses of SARS-CoV-2 vaccine did the test-negative design studies from British Columbia and Quebec show?","915":"Who should isolate and avoid caring for the newborn as much as possible?","6114":"When was the publication The Lancet published?","5226":"What can you do if your results are negative?","3952":"When was the last time a mask was updated?","2266":"What does CMS stand for?","4516":"What is an N95's nose piece?","7110":"Who should get the Tdap vaccine to protect their baby against?","6545":"What is bronchiectasis?","2315":"How long after 3rd dose or last booster did you need to be up to date?","8917":"Why are dialysis providers reporting low COVID-19 vaccination coverage among their patients?","6313":"What do you do after visiting your healthcare provider?","8331":"When was this page last reviewed?","2636":"How often do people usually feel better after a week?","1026":"What may be available for you?","1586":"Who is required to offer third primary doses or bivalent COVID-19 vaccine booster doses?","8174":"What are the three things that determine the recommendations for COVID-19 vaccines?","9232":"What is a tool to help you determine if you need to isolate or take other steps to prevent spreading COVID-19?","7853":"What is CDC How to Collect Anterior Nasal Swab Specimen for COVID-19 Testing?","9296":"What can children and teens experience after getting COVID-19?","293":"What are the dashboards Booster Vaccination Trends by?","1561":"What does the 6\/23\/22 Update replace?","2128":"What vaccines can not cause COVID-19 in pregnant people?","10034":"What type of vaccine is recommended for prophylaxis in the setting of an orthopoxvirus outbreak?","3268":"How is reporting any other clinically significant adverse event encouraged?","3548":"What was not included in census denominator data?","3391":"Who considers the benefits of COVID-19 vaccination for people with a history of MIS-C\/A to outweigh a theoretical risk of an MIS like illness or the risk of myocarditis?","9588":"What are some conditions that may require a secondary dose in persons with incomplete primary series?","887":"What is the name of the drug that can be used to treat COVID-19?","5241":"What is an example of an emergency warning sign?","9951":"Moderna and Pfizer-BioNTech are recommended for what?","1809":"What is the name of the section of the CDC website that provides strategies for obtaining and administering vaccines?","3039":"How many doses is recommended for children ages 6-11 years?","5416":"What may FDA issue when certain criteria are met?","7626":"How long must a mariner self-quarantine in shoreside accommodations?","9449":"V-safe asks questions that help CDC monitor the safety of what vaccine?","9932":"When does tachycardia develop after vaccination?","4097":"What do you do if you receive your second dose of a COVID-19 vaccine after the recommended date?","6584":"Have a history of severe allergic reactions to COVID-19 vaccines?","7574":"What are the exception criteria described in the Presidential Proclamation and CDC\u2019s Amended Order?","290":"How many dose administrations had not been reported to CDC by Indiana?","9347":"How many doses is COVID-19 approved for?","1992":"When serious reactions are reported, most often occur within what?","6937":"Are you immunocompromised or are you on a medicine that can help you?","3734":"When was the EUA-authorized for the new booster-only formulation of the Moderna Covid-19 vaccine for persons ages 18 years and older?","5419":"What does the FDA believe may be effective to prevent during the COVID-19 pandemic?","2516":"What are two ways to ensure access to testing for all people?","5764":"What is the name of the Pfizer-BioNTech COVID-19 vaccine?","8038":"What percentage of parents with children younger than 5 years will get their child vaccinated right away?","3080":"What is recommended for people who are moderately or severely immunocompromised?","7000":"Some people experience a little discomfort and can continue what?","5846":"What is the name of the Pfizer-BioNTech COVID-19 EUI Fact Sheet for Healthcare Providers?","5954":"Who provides the v-safe information sheet?","2616":"What does the mRNA in the vaccine teach your cells to do?","4767":"Who lists COVID-19 vaccines for emergency use?","3200":"What is the name of a systemic reaction?","6651":"What is a great way to reduce stress?","5119":"Who is at higher risk of getting very sick from COVID-19?","7899":"What is the major theme impacting Vaccine Confidence?","2340":"How long after 1st dose can children get a Pfizer-BioNTech booster?","9004":"Additional follow-up is needed especially among those vacccinated in the first or second trimesters of pregnancy?","4554":"What can you do to keep COVID-19 from spreading in your home?","8256":"Which vaccines are recommended only for people with moderate or severe immunocompromised?","8198":"How many months after 2nd dose or last booster can children age 5 years get a booster?","9735":"Which country has recommended using a Pfizer-BioNTech vaccine for additional primary series and\/or booster dose?","3886":"What do VAERS have to report if the error is not associated with an adverse event?","1089":"Ibuprofen is a generic name for what?","4246":"The white CDC COVID-19 vaccination cards are only issued to people who are vaccinated in what country?","4789":"Who is required to report all COVID-19 vaccine administration errors?","3276":"What type of post-vaccination reactions were similar in clinical trials of Moderna and Pfizer-BioNTech?","4310":"What should you discuss if you have an allergic reaction to a vaccine or injectable therapy for another disease?","7470":"Isolation means to separate sick people with a contagious disease from people who are not sick?","4285":"What should you talk to your healthcare provider about if you are taking medications that suppress the immune system?","5886":"What should receive a primary dose of?","9861":"What is the name of the Joint Committee on Vaccination and Immunisation (JCVI)?","58":"Who may refer you to an allergy and immunology specialist?","1247":"How many doses of COVID-19 vaccine have been administered and reported by Federal Retail Pharmacy Program participants in the US as of October 18, 2022?","6046":"What is available supporting evidence for revaccination of people who received COVID-19 vaccine during B-cell-depleting therapy administered over a limited period?","6410":"How many times a day are high-dose corticosteroids administered?","4040":"Vaccinations and Other Outcomes might be delayed due to delays in what?","1010":"What can make it hard to know if a positive test indicates a new infection?","261":"What does this section serve as an archive of for historical COVID-19 vaccine data updates?","2820":"What is an example of an inflammatory marker?","3631":"What should you do if you have a weakened immune system or are at increased risk for severe disease?","9114":"What are some people with different levels of COVID-19 able to use?","7186":"What is COMIRNATY?","4243":"What are the two main reasons for COVID-19 vaccinations?","31":"What are some people with weakened immune systems or underlying medical conditions?","5373":"How can you report side effects to Janssen Biotech, Inc.?","2677":"Low Wear a mask based on your personal preference, informed by what?","1107":"What is COVID-19?","2797":"What type of policies can employers provide to support employees?","6611":"How do former smokers benefit from quitting smoking?","2028":"What does the body get rid of within a few days after vaccination?","517":"How many doses were reported as of March 13 at 6:00 AM ET?","7879":"How many Americans died from COVID-19?","6220":"What do these pieces give to cells in your body to create an immune response?","5033":"What is new guidance on Considerations for COVID-19 revaccination?","1042":"What are the symptoms of COVID-19?","567":"How many doses were administered in Illinois in October of 2022 in comparison to the previous year?","1434":"What is the name of the organization that provides assistance with patient counseling and education regarding COVID-19 testing and vaccination?","4440":"What is one way to bring in as much outdoor air as possible?","1715":"Where can you find detailed information regarding COVID-19 Vaccine storage and handling requirements?","3093":"How old are people who received the Janssen COVID-19 Vaccine primary series dose recommended to receive a second (additional) dose using a monovalent mRNA vaccine?","34":"When was the last update?","248":"Who can learn more about which groups of people?","7421":"What is a tool to help you know the requirements to board a flight to the United States?","9432":"What are some of the side effects of the vaccine that have been reported in clinical trials?","8438":"If you are at high risk of getting sick, wear what?","1826":"What may be administered along with and on the same day as other vaccines such as the flu vaccine?","1912":"Who reviews all pregnancy reports related to COVID-19 vaccinations?","4339":"Where can you report suspicious activity involving fake vaccination cards?","7981":"How many people were fully vaccinated?","5766":"What is the name of the CDC's Interim Clinical Considerations?","8059":"What vaccine is the cause of recent hepatitis cases in children?","163":"How many federal agencies does the OH-FICC Group bring together?","2967":"How long are the primary series doses separated?","8971":"What does the v-safe COVID-19 Vaccine Pregnancy Registry do?","10014":"Who is not recommended for persons with a history of an episode of an immune-mediated syndrome?","8453":"What is the CDC's advice?","4810":"Inform the recipient of the potential for local and systemic adverse events.","8601":"What happens to the mRNA after the protein piece is made?","8911":"What is important to protect everyone in dialysis clinics?","2078":"Who received an mRNA COVID- 19 vaccine just before or during early pregnancy?","965":"What should you do if you have symptoms?","5327":"How many people have received the Janssen COVID-19 Vaccine in clinical trials?","1514":"Who should prioritize maintaining highest inventory in stores servicing high socially vulnerable populations and stores with the highest demand?","7113":"Who should be up to date with their whooping cough vaccine?","2477":"When was the study published online ahead of print?","4265":"What is the most common COVID-19 variant currently causing illness?","6508":"What are approved and authorized COVID-19 vaccines?","7037":"What is an adverse event or reaction from the COVID-19 vaccine?","6230":"How many times more likely is someone who doesn't vaccinate after they've recovered to get it?","399":"What was the name of the program that was a partnership between CDC, CVS, Walgreens, and CVS?","8321":"What are common questions and concerns about getting vaccinated?","7091":"How do you avoid crowds and poorly ventilated indoor spaces?","8759":"What should your child ask their healthcare provider before using methods to improve mask fit?","30":"Who may need to take more steps to be better protected from COVID-19?","3506":"Isolate if your test result is positive or negative?","8380":"What is important not only for those who will prepare and administer vaccine, but also for those responsible for other critical, mandatory functions?","5730":"What is a wide range of symptoms?","5011":"What was updated to alert providers of possible false positive Rapid Plasma Reagin test results in some people after COVID-19 vaccines?","2029":"There is no evidence that COVID-19 Vaccination causes any problems with becoming pregnant?","10066":"What is the week after vaccination that is most likely to cause symptoms?","5540":"What are the short- and long-term health effects associated with COVID-19?","9197":"What is particularly important after blowing your nose, coughing, or sneezing?","6690":"How do you clean and disinfect places where people with asthma might be?","6512":"Who is at highest risk of getting very sick from COVID-19?","4934":"What year was the Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years issued?","5746":"What should people who are moderately or severely immunocompromised receive?","2503":"Dosages. Maintain ventilation improvements. Avoid contact with people who have suspected or confirmed COVID-19.","6974":"What type of vaccine was developed by Pfizer-BioNTech?","1907":"How many safety monitoring systems do the CDC and the FDA have in place?","2536":"What is the name of the Pfizer-BioNTech Booster dose?","2917":"What is an additional dose of vaccine administered after the primary series?","6534":"CDC conducts ongoing reviews of what?","8194":"What is the dose of COVID-19 vaccine than teens and adults based on their age group?","3214":"Who advises antihistamine use as a means of preventing milder allergic reactions in patients at higher risk?","1712":"How long should you keep all records related to COVID-19 vaccine management?","6244":"As the virus spreads, it has more opportunities to change.","9310":"What is the purpose of the Healthcare Appointment Checklist for Post-COVID Conditions?","435":"On what date did a data synchronization error occur?","9515":"What is the name of the vaccine for Children who transition from a Younger to Older Age Group?","9323":"What do you share with your provider during the Appointment?","2468":"How many Integrated Health Care Organizations are in the United States?","5014":"Who received the dose of the vaccine as part of a clinical trial?","9696":"What is v-safe?","8585":"What do mRNA vaccines use to teach our cells how to make a protein?","7008":"Pain on the leg or arm where the shot was given Swollen lymph nodes Irritability or crying Sleepiness Loss of appetite","1046":"How many MB does How to Collect a Nasal Mid-Turbinate Swab Specimen for COVID-19 Testing take?","8772":"How do you take off your mask?","5707":"What does CDC stand for?","9379":"What is SPIKEVAX's mRNA?","6506":"How do you protect yourself from COVID-19?","7733":"When is the first dose of the Moderna COVID-19 Vaccine given in the US?","10051":"How many g of Matrix-MTM adjuvant 5 g rS?","1124":"What is the name of the program that aims to reduce disparities in disproportionately affected communities?","1647":"What type of email is used to communicate about the availability of programs to manage particular health conditions?","4597":"What can blow contaminated air directly at people?","5344":"What are blood cells that help stop bleeding?","9474":"What do these vaccines do not contain?","2644":"CDC Call their doctor if a person keeps getting sicker?","8517":"How many hours before their flight are passengers required to provide contact information?","8762":"What should you do if your symptoms do not resolve?","5379":"Is there an option to accept or refuse receiving the vaccine?","8711":"What is a critical public health tool?","398":"How many vaccine administrations were affected by this outbreak?","4678":"What was the most severe of the systemic symptoms?","8167":"What do variants of the virus have in common?","2168":"What was the date of this study published?","4258":"If you were given monoclonal antibodies or convalescent plasma while sick, you do not need to wait to get what?","2247":"What does CDC recommend for residents of long-term care?","5127":"What is the name of the organization that recommends Isolation?","5236":"Do not go places where you are unable to wear a mask?","1526":"Who will post notice at the site of any mask distribution?","668":"How many doses were increased?","3580":"How many people were fully vaccinated with Johnson & Johnson's Janssen vaccine?","8722":"What is the best way to protect yourself?","1688":"What is the name of the CDC's Interim Recommendation for Use of Moderna COVID-19 Vaccine?","748":"In 2021, what state made an increase of 11,379 doses?","6036":"What has decreased the risk of infection with antigenically similar variants by 80-93% for months after infection?","6083":"Serological responses and vaccine effectiveness for extended what?","1924":"What is the acronym for the Clinical Immunization Safety Assessment Project?","2359":"Who should complete or restart the recommended COVID-19 vaccine series in the United States?","7019":"What is not recommended to take before vaccination to try to prevent side effects?","1381":"Once a person receives 1 bivalent booster dose, what is currently recommended?","8740":"When you're sick, a respirator will provide what?","1750":"What is required of all organizations and providers participating in the CDC COVID-19 Vaccination Program?","735":"How many records were updated to CDC in Virginia?","5426":"Where is Horsham, PA 19044?","1603":"What is the age-appropriate Pfizer-BioNTech COVID-19 Vaccine Information Fact Sheet?","9870":"When will the SAGE meeting take place?","450":"How many doses were reported in New Hampshire on May 25, 2021?","4167":"Who is more likely to deliver a preterm or stillborn infant?","1324":"What should be done if the incorrect vaccine formulation is administered based on a patient's age?","4961":"What is the name of the vaccine used in adolescents ages 12-17 years?","6177":"What does Assessing How Vaccines Work in the Real World Help Us to do?","8049":"Some are concerned that immunity from vaccines decreases rapidly in adolescents?","4422":"What helps your body develop protection from the virus that causes COVID-19?","6049":"What is the odds ratio of seroconversion if a person was vaccinated during therapy?","8799":"Who developed some resources on the CDC and ATSDR websites?","7652":"How long does it take to get a viral COVID-19 test?","1578":"What is the name of the CDC's update to the booster dosages?","3820":"Providers cannot require what for a person to receive a COVID-19 vaccine?","2459":"When is the Joint Statement Regarding Vaccine in Men Desiring Fertility released?","16":"What is another name for the person that can help with side effects?","4279":"What is not a reason to avoid getting your COVID-19 vaccination?","6017":"When did VE appear to plateau?","1329":"What is the name of the vaccine product that should be used for all vaccines?","8419":"What is required for vaccine recipients?","6057":"What did Moderna determine about the effectiveness of an additional primary dose of the COVID-19 vaccine?","2390":"What are shots that enhance or restore protection against COVID-19 that may have decreased over time?","3173":"How old are children who receive different mRNA products for the first time?","3299":"What is a rare risk for myocarditis and pericardiitis observed following receipt of mRNA COVID-19 vaccines?","6866":"What is the name of the Pfizer-BioNTech COVID-19 Vaccine EUI Recipient Fact Sheet?","2495":"What is not linked to Community Levels?","572":"How many administered doses did Illinois increase in 2022?","2141":"Who is authorized for use only?","974":"What type of tests look for a current infection with SARS-CoV-2?","6978":"When was the EUI Recipient Fact Sheet issued?","8371":"Who is the author of the content that was developed in partnership with the Centers for Disease Control and Prevention?","1190":"How old are the populations on the Vaccinations in the United States site?","7128":"What is the COVID-19 Toolkit for Pregnant People and New Parents?","8607":"What is the benefit of a COVID-19 vaccine?","215":"When antibodies decrease below the threshold of protection, you may become more vulnerable to what?","9952":"People ages 5 and older are recommended to receive how many bivalent mRNA booster doses after completion of any monovalent primary series?","9084":"What is the most beneficial in crowded or poorly ventilated locations?","6123":"What is the name of the vaccine that enhances peak antibody in 2021?","2792":"What do some people want someone to listen to more often?","9837":"Where can you submit reports to VAERS?","6174":"What is a variant of COVID-19?","9015":"What collects reports of possible adverse events that happen after vaccination?","1014":"What is different for each disease and each person?","9072":"When will CDC no longer require air passengers traveling from a foreign country to the United States to show a negative COVID-19 viral test or documentation of recovery?","4355":"Who can stay up to date with COVID-19?","6109":"How many doses of SARS-CoV-2 messenger RNA-based vaccine did recipients of a solid organ transplant receive?","406":"When did CDC update its algorithm for assigning a race\/ethnicity category for vaccine recipients?","9331":"What should you keep a journal of for your next appointment?","8429":"When was this page last reviewed?","9627":"How old are people ages 12 and older?","4569":"Do not open windows and doors if doing so is unsafe for you or others?","984":"Antigen tests are less reliable than what?","7730":"What has CDC scientists conducted in regards to cases of anaphylaxis?","1460":"What type of vaccine did a mother receive before or during pregnancy?","601":"How many administered doses did Illinois increase in 2022?","6450":"What should you not do if you have COVID-19 symptoms?","3841":"What is a digital data logger?","246":"What are serological surveillance studies?","3178":"What is recommended for booster vaccination?","8221":"How long after your 2nd primary series dose or last booster did you receive the most recent booster recommended for you?","9582":"What does the EUI do?","3570":"What is the total number of doses that have been administered?","4591":"What can be turned on over your stovetop and in your bathroom if you have visitors?","7042":"What should you wear to avoid spreading the COVID-19 virus to others?","1680":"What is required of COVID-19 vaccination providers?","8674":"What are the names of the three reporting systems used by CDC, FDA, and VSD?","1607":"What are the same formulations of the Moderna Covid-19 vaccine?","5408":"How long must a claim be submitted to the CICP?","8196":"How long after 1st dose of Pfizer-BioNTech PRIMARY SERIES does it take to stay up to date?","9503":"What is supported by a Secretary of Health and Human Services declaration that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic?","5797":"What type of vaccine does Moderna have a higher risk of?","9333":"Where can you find more information on COVID conditions?","7134":"What is the name of the systematic review and meta-analysis of coronavirus disease 2019 in pregnancy?","8536":"Who has an increased risk of severe illness regardless of vaccination status?","7966":"What are the themes that continue to undermine vaccine confidence?","8136":"What is a third party report?","8182":"What is recommended for most people?","8480":"When was EPIC last updated?","7651":"When a person leaves the United States, they are no longer subject to what?","4456":"What does the tool ask a series of questions and recommend?","10073":"At a minimum interval of how many days can an age-appropriate mRNA vaccinated person with COVID-19 be given?","2072":"What does none of the COVID-19 vaccines contain?","559":"When was this option expanded to all entities? What are the historical update and delete events for reporting entities and their impacts on vaccine data reported below?","4123":"What can be immunocompromised and still healthy?","3651":"What do you need to continue wearing?","2000":"How many doses of the Pfizer-BioNTech COVID-19 vaccine were given between November 2021 and April 2022?","5658":"What seals tightly to your face when fitted properly?","2140":"What is the name of the mRNA COVID-19 vaccine?","1452":"Who recommends a bivalent mRNA vaccine for the booster dose?","6573":"What is a medium COVID-19 Community Level?","5943":"What may be an increased risk of in males under 40 years of age after the second dose of the vaccine by Moderna?","5116":"What may you be denied entry and required to return to the United States?","3314":"Dose 2 of Pfizer-BioNTech exceeded the background incidence rate for male children in what age group?","6272":"What does not contain ingredient s that can produce an electroma gnetic field?","9889":"How long is the interim analysis of the BNT162b2 booster?","597":"What was the net increase?","214":"What is this level called?","9826":"What is expected to be less favorable compared to the available alternative bivalent booster vaccines?","7686":"How many serious types of adverse events have been found following COVID-19 vaccination?","8270":"What is increasingly common in many countries outside of the US?","2631":"What should be followed when caring for people who have tested positive but are not showing symptoms?","7569":"What do you need to match with your passport or other travel documentation?","3949":"How do you find free masks in the U.S.?","6323":"What does blood work, x-rays, etc., do?","819":"What can change over time and lead to the emergence of variants?","4928":"What is the Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 years?","7816":"What do you do before and after you collect a nasal specimen for your test?","3040":"How long are the first and second doses separated from each other?","2590":"How long after the last primary series dose should the booster dose be given?","6029":"Which countries reviewed available immunological, safety, and effectiveness data?","4777":"How long after receiving the second dose of a primary series of vaccines should participants receive the third dose of an mRNA vaccine?","3848":"What does the IIS do with vaccine inventory?","6030":"What does SARS-CoV-2 infection induce a robust immune response?","1083":"What is another name for Test to Treat?","2263":"What are the recommended vaccines for COVID-19?","9377":"What is a new loss of taste or smell?","8685":"What can you do to protect yourself and others in settings that make you more likely to be exposed to exposure?","779":"Some antibodies can protect you from SARS-CoV-2 by targeting what?","6660":"When was the PDF last updated?","9922":"Novavax COVID-19 Vaccine can be administered to persons who are 12 years of age and older.","2951":"How many months after the last monovalent booster do people need to receive a booster dose?","9703":"What is the most evidence of the use of a booster dose after primary vaccination?","4442":"What is the acronym for portable high-efficiency particulate air cleaners?","7638":"What type of letter will you need to show the approval of the exception?","4139":"What do children receive a smaller and more age-appropriate dose that is right for them?","3090":"What is the bivalent booster dose given to people who previously received a monovalent dose?","6310":"What can you download to help get the most out of your healthcare appointment?","5625":"When choosing a respirator, look at how well it fits and read the manufacturer instructions?","428":"What is the net increase in vaccine administration count?","8695":"What are variations of the pandemic called?","3107":"What should providers consult for more information on the use of EVUSHELD as pre- exposure prophylaxis?","2991":"What is the most common age range for vaccination?","4449":"What type of test tells you if you have COVID-19 symptoms?","708":"What did not result in a change to number of doses administered?","9752":"What year did Kamar and Alejo publish their results?","7259":"What is another name for VACCINE?","4112":"What are the recommended boosters for people who are moderately or severely immunocompromised?","7640":"What is a requirement for proof of COVID-19 Vaccination for Air Passengers?","484":"New Hampshire and CDC are working together to correct what?","130":"What kind of animals do mink get from mink to other animals on the farm?","8412":"Who is qualified to prepare, store, handle, or transport vaccine?","4704":"What is HIT?","6227":"What vaccine causes a more predictable immune response than infection with the virus that causes COVID-19?","5680":"What do the user instructions for the mask or respirator show?","201":"What is safer than getting COVID-19?","2312":"What is the name of the CDC AGE GROUP 18 YEARS AND OLDER UPDATED (BIVALENT) BOOSTER?","3542":"What can cause CDC\u2019s dose number estimates to differ from those reported by jurisdictions?","5619":"What does PPE-Info stand for?","5784":"In clinical trials, how many people received at least 1 dose of the vaccine?","9664":"What is the age limit for administering the vaccine outside of the FDA-authorized or FDA-approved location?","5765":"Who should NOT get the COVID-19 vaccine?","7619":"How long has it taken for a ship to recover from COVID-19?","4273":"What do you need to know about getting a COVID-19 vaccine?","7734":"What is the main benefit of the moderna vaccine over the potential risks?","1257":"Who can help you find a COVID-19 Vaccine?","6821":"What age group may receive a booster dose?","9911":"How long does it take for an allergic reaction to onset?","9315":"Prepare a brief report that summarizes your experience and symptoms and describes your best and worst days.","3672":"If you are going to be around someone who is at a higher risk of getting very sick, consider what?","5662":"What is included in a US standard?","8269":"How many doses of a 2-dose accepted COVID-19 vaccine does CDC not recommend?","3045":"How long are the first and second doses separated by?","8933":"What does CDC encourage reporting?","5378":"What does the EUA allow you to accept or refuse receiving?","2357":"What is COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised?","4445":"Turning your thermostat to the \"ON\" position instead of \"AUTO\" will ensure your HVAC system provides what?","6859":"What must be met to allow for the product to be used during the COVID-19 pandemic?","6777":"What is the name of the vaccine that has been given to millions of individuals?","8206":"What is not recommended for children 6 months to 4 years of age?","9590":"How old are people who received certain therapies and received primary doses of COVID-19 vaccine prior to or during treatment?","8483":"What is not considered travel?","8568":"What do COVID-19 vaccines help our bodies develop without us having to get the illness?","2663":"What should caregivers quarantine Keep a separate bedroom and bathroom for a person who is sick?","10075":"What type of mRNA vaccine can be used?","116":"Where are white-tailed deer found?","3762":"What is the duration of vaccine-induced protection from primary vaccination?","7036":"How can you report a side effect, adverse event, or reaction from the COVID-19 vaccine?","5483":"What is post-traumatic stress disorder?","7636":"Under what supervision should self tests be conducted?","5446":"How many weeks after infection is the start of when post-COVID conditions could first be identified?","6637":"What should you do if you need emergency help?","8162":"What do the updated boosters protect against?","56":"How long after getting vaccinated did an allergic reaction start?","5041":"Who is vaccinated during SARS-CoV-2 screening?","7856":"What is the CDC Using Your Self-Test?","3018":"What vaccines are FDA-approved or FDA-authorized for a 3-week interval between the first and second doses?","4228":"If you need another COVID-19 vaccine dose, talk to a vaccination provider to find out what?","6452":"Where can you get tested?","8421":"What is another name for vaccine storage and handling?","7200":"What is given to you as an injection into the muscle?","4025":"What does CDC's COVID Data Tracker attribute dose administrations to?","6448":"What type of mask do you wear for 10 full days?","5519":"Some studies focus only on people who have been hospitalized, while others include people who were not hospitalized?","3445":"What should be read as \"through\" and the upper range includes that year?","4795":"How do you revaccinate the vaccine?","4283":"What are some examples of common medications?","3868":"What does FDA define as: Death Life-threatening AE Inpatient hospitalization or prolongation of existing hospitalization Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions?","4975":"People ages 50 and older should receive what?","3407":"What is highly recommended before any intravenous immune globulin is administered?","2361":"Who should you talk to for more information?","7917":"How old are individuals who elect to receive the Janssen COVID-19 vaccine because they would otherwise not receive the vaccine?","1103":"What is the name of the website that can help you find the right vaccine locations?","8781":"Where can you place your mask to keep it clean?","4852":"Do not administer the second dose until the person becomes eligible to receive vaccination?","4414":"What provides information about the amount of severe illness in the community where you are located?","4018":"CDC receives administration data across multiple jurisdictions with different reporting practices.","1577":"When was the last time the booster doses for this age group were changed?","1863":"What is ICATT?","7793":"What is the difference between laboratory-based tests that may take days to return your result?","1879":"Where is the University of Michigan located?","3946":"When was the last update updated?","617":"How many doses were decreased in Illinois in 2022?","4518":"What should you be sure the top end is at your fingertips?","5058":"What is the age range of the Pfizer-BioNTech COVID-19 Vaccine in adolescents?","4844":"Who should be informed of the potential for local and systemic adverse events?","9192":"How long should you wash your hands with soap and water?","5624":"What is a replacement for NIOSH-approved respiratory protection when required by your job?","539":"What does the increase in doses to fewer doses in a vial increase the number of doses delivered relative to?","9475":"What does not contain SARS-CoV-2?","5135":"How many full days after your last exposure should you get tested?","9049":"Variants of the Virus constantly change through mutation?","5909":"What should people who received 1 booster dose of the Janssen COVID-19 Vaccine receive?","2498":"What is recommended in indoor public transportation settings?","1118":"What is the name of the Vaccination Clinic Guidance?","1560":"When is the last time the vaccine was available?","5465":"What is the name of the research project conducted by the National Institutes of Health?","2269":"What does the CMS post updated information about?","3289":"Coadministration of COVID-19 and routine vaccines on the risk of what?","9612":"When was the original CDC-issued EUI healthcare providers fact sheet issued?","7089":"What do you stay up to date on?","8036":"When did the Advisory Committee on Immunization Practices (ACIP) issue interim recommendations for use of the Moderna COVID-19 vaccine in children ages 6 months to 5 years?","2182":"What is the name of the mRNA COVID-19 vaccine used in pregnancy?","4443":"Turning on exhaust fans and using other fans to improve air flow?","2432":"One study found that COVID-19 infection may be associated with a decline in what for men for up to 60 days after infection?","6405":"What is a primary immunodeficiency?","8889":"What can you do for outpatient dialysis patients and the healthcare personnel who care for them in your jurisdiction?","8893":"What can jurisdictions opt to coordinate with to reach their respective clinic sites?","4213":"What should people who have had a known COVID-19 exposure not seek vaccination until their quarantine period has ended?","5594":"What can cause gaps in a mask?","8583":"None of these vaccines can give you what?","5574":"What type of masks offer more protection?","4073":"Who can also receive a booster of an mRNA COVID-19 vaccine?","3415":"Clinical recovery has been achieved, including return to what?","1331":"What vaccines are not currently authorized to be used for the primary series?","39":"What can a severe allergic reaction cause?","1144":"What do most IISs create a centralized data repository for?","598":"When did Illinois make updates to data previously submitted to CDC?","7112":"CDC recommends all pregnant people receive what during each pregnancy?","3909":"People who are immunocompromised or taking medicines that weaken their immune system may not be as well protected as others?","2443":"What is not recommended you take these medicines before vaccination to try to prevent side effects?","2061":"What may require hospitalization, admission to an intensive care unit, or use of a medical device?","8664":"What did FDA review before granting approval for some COVID-19 vaccines?","5729":"Which coronavirus causes Coronavirus Disease?","7515":"What is the requirement for proof of COVID-19 Vaccination for Air Passengers?","6336":"How many appointments to evaluate potential post-COVID symptoms?","9847":"Buchan SA, et al. Epidemiology of myocarditis and pericardiitis following what vaccines?","8519":"Where is the address of the passenger in the US?","5929":"Who issued the EUI to Moderna in 2022?","7170":"What type of immunocompromise is the third primary series dose?","1960":"What does VSD stand for?","387":"What was the percentage of fully vaccinated people in 50+ years of age with a booster dose?","4460":"Who may reimburse the cost of purchasing self tests?","8985":"Who can still participate if you don't give your permission for CDC to access medical records?","5645":"What may not provide the level of protection indicated?","9414":"What is the difference between the Moderna COVID-19 Vaccine, Bivalent and SPIKEVAX?","3313":"Who is the most likely to have this disease after dose 2 of Pfizer BioNTech?","824":"When were COVID-19 vaccines first authorized for emergency use in the U.S.?","9282":"What is published in Pediatrics?","6023":"How long were the intervals between dose 1 and dose 2?","9984":"What type of vaccine can be administered to the same patient?","669":"What was the increase in doses?","8019":"What do social media users believe is the same as SARS-CoV-2?","5614":"Where do 3-ply masks join the edge of the mask?","3263":"What should adverse events that occur in a recipient following COVID-19 vaccination be reported to?","715":"On what date did Illinois make an update to its data?","1672":"What is the possibility of rescinding the CDC provider agreement?","671":"What did New Jersey make updates to?","2098":"Who was not vaccinated during pregnancy?","4857":"Administration error resulted in a higher-than-authorized vaccine dose, in general a subsequent dose may still be administered at what interval?","5240":"What should you do if you have COVID-19?","9594":"Moderna's COVID-19 vaccine allows similar uses as what other vaccine?","4195":"What is the recommended waiting period between getting a COVID-19 vaccine and other vaccines?","4028":"Who estimates the number of people receiving at least one dose?","2763":"Take care of your body.","4669":"What is another name for TTS?","6389":"What is a weakened immune system?","707":"What did New Mexico do to the data previously submitted to CDC?","418":"How many doses of vaccine did North Carolina receive since December 2020?","5147":"How long before travel is it recommended to get tested for COVID-19?","4194":"There is no recommended waiting period between getting a covid-19 vaccine and what else?","2195":"What is a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery?","6720":"How many doses of the COVID-19 Vaccine are available to individuals 5-11 years old?","9530":"What color is the label for the product authorized for children ages 6-11 years?","2009":"What are CDC and FDA doing to make sure COVID-19 vaccines used in the United States are safe?","2833":"Who advises patients with myocarditis to consult the American Heart Association and American College of Cardiology?","4762":"Who lists COVID-19 vaccines for emergency use?","98":"What kind of animals do some coronavisviruses infect?","8334":"How many steps to apply motivational interviewing rapidly during a patient visit?","8932":"What does FDA require healthcare providers to report to VAERS after COVID-19 vaccination?","3378":"What should be taken into account when determining whether to delay getting a COVID-19 vaccination after infection?","660":"What was the result of the increase in doses administered?","2694":"How often do you wash your hands?","494":"How many duplicate doses were there on April 13, 2021?","9872":"Who issued the EUI Healthcare Providers Fact Sheet, ver 9\/02\/2022?","4152":"What has FDA determined about COVID-19 vaccines?","5512":"Children and adolescents are less likely to have what condition than adults?","7462":"What is the name of the program that Uniting for Ukraine is a part of?","2375":"What should be used for the primary vaccination series?","8306":"What is caused by infection with SARS-CoV-2?","7603":"What does CDC consider a country to have limited?","7152":"What is the name of the Pfizer-BioNTech COVID-19 Vaccine?","7650":"What does the attestation say I have to attest to for 5 days and get a viral COVID-19 test for 3-5 days?","412":"What will the functionality allow for more accurate reporting and improved data quality?","1003":"How many days did I test positive for COVID-19?","1153":"How is federal agency data included?","4842":"How long does it take to administer a dose that is higher than the authorized dose?","4679":"How long did it take for the symptoms to resolve?","8657":"How many volunteers have been involved in the clinical trials for COVID-19 vaccines?","6254":"What is the number of deaths reported to VAERS following COVID-19 vaccination misinterpreted?","727":"What state made updates to data previously submitted to CDC?","1321":"What does FDA allow for certain age transitions?","7003":"What is the name of the virus that causes COVID- 19?","3907":"What is another name for a weakened immune system?","2354":"What is CAR-T-cell therapy?","291":"When did a data processing issue occur?","9188":"What should not be placed on young children under 2?","1938":"How have these vaccines undergone the most intensive safety monitoring in US history?","2203":"Infection. JAMA. Published online February 07, 2022.","5599":"What will you feel if the mask has a good fit?","2517":"What do you provide to encourage isolation among people who test positive?","7329":"How many U.S. healthcare facilities had SARS-CoV-2 reinfections between June 1, 2020 and February 28, 2021?","7701":"What does not necessarily mean that a vaccine caused a health problem?","6092":"Who administers the Moderna COVID-19 Vaccine to Prevent Coronavirus Disease?","2245":"What is the latest CDC data on the effectiveness of the vaccine?","4019":"To reduce potential duplication across systems, CDC reconciles what data prior to reporting?","4979":"How long after the first dose of the first COVID-19 vaccine do people who are immunocompromised get a second booster dose?","7331":"What are Variants constantly changing?","5482":"What are some of the health effects of PICS?","6620":"What type of conditions can be at increased risk for getting very sick from COVID-19?","2689":"What should you wear when you touch or have contact with a sick person's blood, stool, or body fluids?","9469":"What is Moderna COVID-19 Vaccine?","6982":"What will not change your standard medical care?","2303":"How do you stay up to date with your COVID-19 vaccines?","5230":"Who can end their isolation if they test negative?","7230":"What may your provider ask you to stay at the place where you received your vaccine?","795":"What can be protected against being hospitalized from a new infection?","8267":"What is the name of the AstraZeneca\/Oxford vaccine?","9158":"What is a tool to help you determine if you need to isolate or take other steps to prevent spreading COVID-19?","9123":"What can operators of conveyances and transportation hubs do?","1180":"What is the name of the tool used by CDC to track COVID-19 vaccinations in Texas?","2080":"What did a Chicago study show?","6636":"What can you do to manage your health and risks?","5247":"What is the first full day following the day of your test?","8177":"People who are moderately or severely immunocompromised have different recommendations for what?","8760":"What type of mask should you use if you are having trouble breathing?","2428":"There is no evidence that COVID-19 vaccines cause what?","5248":"When does the clock restart?","9436":"What is the name of the inflammation of the heart muscle?","7167":"What does COMIRNATY stand for?","4016":"What is the most complete and up-to-date data for the COVID-19 vaccine?","4333":"What is the CDC's COVID-19 vaccination card used for?","6151":"Identify signals of potential changes in what?","3266":"What is the acronym for Multisystem Inflammatory Syndrome in adults and children?","8171":"How are you up to date with your COVID-19 vaccine?","147":"What would public health officials need to do to confirm the spread of SARS to people?","3188":"What type of vaccine can be given to people who previously received COVID-19 vaccination?","827":"By what date did we see decreased vaccine effectiveness against infection?","6427":"What can you do to get tested as soon as possible?","5964":"How long earlier had people been primed with two doses of Ppfizer BioNTech or Astrazenec-BionTech or a second dose?","4347":"Who can provide more information about the laws or regulations in your area?","5866":"What is the purpose of the EUI issued by CDC?","1427":"What should be deferred for at least 2 weeks after COVID-19 vaccination?","9816":"At least how long after primary vaccination did no new safety concerns arise?","8785":"What should be thrown away after they\u2019ve been worn once?","1849":"How old are children at Baylor Scott and White Health?","7160":"How old are individuals 12 years of age and older?","6339":"What are healthcare providers still learning about?","8841":"What is not an official record of being vaccinated against COVID-19?","7303":"The benefits of the product outweigh what?","7591":"What was sought prior to application?","7813":"What do you collect to use an at-home test?","2720":"How long does it take to develop illness?","10126":"What should a person do if they decide to receive a COVID-19 vaccine dose?","4886":"What is angioedema?","6527":"What is important if you are older or have severe health conditions or more than one health condition?","9453":"What does the EUA allow you to do if your child does not receive a vaccine?","10103":"What may people who recently had SARS-CoV-2 infection consider delaying their next COVID-19 dose by 3 months from symptom onset or positive test (if infection was asymptomatic)?","3824":"What is the name of the website that provides information on reimbursement requirements?","8690":"What is COVID-19 constantly changing?","26":"What is the name of the virus that causes COVID-19?","8742":"People who are older People with certain medical conditions Pregnant and recently pregnant people People at increased risk and those who live with or visit them should Talk to what?","6850":"How long does it take for the vaccine to be submitted?","8957":"What type of information does VAERS often lack?","3255":"What is the acronym for multisystem inflammatory syndrome in children?","5062":"What was corrected in the footnote numbering?","9943":"What should be deferred until isolation has been discontinued?","5331":"What is the duration of protection against COVID-19 currently unknown?","7015":"How do you relieve pain or swelling on the arm where you got the injection?","4851":"Do not repeat the dose immediately (no minimum interval).","5587":"When working at a job where you interact with large numbers of the public, especially when not everyone is sick?","5762":"What is another name for chimeric antigen receptor-T-cell therapy?","1575":"What is the name of the CDC guidance on the use of COVID-19 Vaccines in the United States Emergency Use Instructions?","2617":"If you are exposed to the virus later, your body will recognize it and know how?","9705":"How many months earlier had people been primed with two doses?","8351":"What does 1 = never; 10 = already have an appointment to be vaccinated?","9976":"People with a known allergy to polysorbate have a contra indication to both Novavax and Janssen COVID-19 vaccines?","2864":"Which vaccine is authorized for adults ages 18 years and older?","2058":"What should pregnant women get when it's time to get one?","9586":"How long does it take for SARS-CoV-2 infection to get a second dose?","1021":"Tell people you had recent contact with that they may have been exposed to what?","3091":"How long after the last monovalent booster do people receive their monovalent novavax doses?","1428":"What can be administered any time after receipt of EVUSHELDTM?","3161":"What should the person receive for all subsequent doses?","9834":"What is VAERS?","1158":"Who calculates rate and percentage measures for vaccination among the entire population?","2654":"The caregiver should not be someone who is at higher risk for what?","3416":"How long has it been since the diagnosis of MIS-C\/A?","6424":"Know the symptoms of what?","1590":"What is the name of the emergency use instructions issued by CDC on November 17, 2021 and February 11, 2022?","2052":"What are infants ages 6 months and older born to people who were vaccinated or had a COVID-19 infection before or during pregnancy?","9795":"What was less robust than against previous variants?","747":"What state made updates to data previously submitted to CDC that resulted in a decrease of 23,325 doses administered?","2994":"How long is recommended interval for Novavasx and Pfizer-BioNTech?","444":"What may not be representative of all COVID-19 vaccination occurring in the state?","4635":"Where can you find more information about HVAC filters and portable air cleaners?","3598":"Who received one additional dose and one booster dose?","1115":"How many Things to Know About the COVID-19 Vaccine?","2972":"Who may receive a monovalent Novavax booster dose at least 6 months after completion of the primary series?","8123":"What do trusted messengers explain about the spread and outcomes of monkeypox infection?","7082":"What is the free and confidential service available Monday to Friday from 8am to 5pm?","6193":"What did patients respond well to?","5719":"What do EUI consist of?","4096":"What does COVID-19 do for people who are moderately or severely immunocompromised?","8069":"As of June 18, 2022, everyone ages 6 months and younger will be eligible for what vaccine?","7751":"After the first 42 days, what was 11 times higher?","3166":"Refer to Table 1 for information about what?","5060":"What is an update to the list of ingredients in COVID-19 vaccines?","8615":"What was the first subunit hepatitis B vaccine to be approved for use in people in the US?","8914":"What type of patients are accustomed to receiving routine vaccinations at a clinic?","2568":"What is the primary series of vaccines?","8373":"What is one of the most common questions patients have about the vaccine?","6061":"What are the available data on the safety or efficacy of a Moderna COVID-19 vaccine after receipt of?","2064":"What can protect you and others around you from getting sick from COVID-19?","9329":"Where should you record future appointments, including tests, in your calendar?","5799":"What are the benefits of the COVID-19 vaccine?","4920":"What is the supervision of a healthcare professional experienced in managing severe allergic reactions?","1355":"What type of mRNA vaccine can be used for the booster dose?","6864":"What was the name of the company that manufactured this fact sheet?","9354":"What is the name of the vaccine that children may receive for any dose in the primary series?","2528":"How many weeks does BIVALENT Moderna: Blue vial cap with gray-bordered label have?","3856":"How old is the vaccine recipient?","4034":"Data will be updated weekly on Thursday after what?","7129":"What are the Vaccines While Pregnancy or Breastfeeding?","2534":"How many weeks does MONOVALENT last?","9066":"What do the following pages cover more detailed information about?","8208":"Children 5 years old who received a Moderna primary series are what?","4125":"What is a good time to get your child a COVID-19 vaccine?","6748":"How long can symptoms appear after exposure to the virus?","670":"What state made updates to data previously submitted to CDC?","655":"What was the result of Michigan's update to data?","8109":"When should monkeypox PrEP be offered to people with the highest potential for exposure?","343":"What was provided from other entities on residents of the affected counties who were vaccinated in other states?","5733":"What symptoms may include fever or chills, cough, shortness of breath, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or run nose, nausea or vomiting, and diarrhea?","1336":"The primary and booster doses are what?","3171":"No VAERS report is required.","2879":"How many doses of monovalent blue no color No 51010 viral particles are in a Booster vaccine?","5745":"What is the primary dose of the COVID-19 vaccine by Moderna?","8582":"What does each type of vaccine prompt our bodies to recognize and help protect us from?","3179":"Who is FDA-authorized for use of a booster dose?","395":"How many doses of vaccine did Washington State receive on September 23, 2021?","5458":"What can post-COVID conditions cause for some people?","2051":"What are people who are pregnant, breastfeeding, trying to get pregnant now or those who might become pregnant in the future?","236":"What is the threshold of protection?","2456":"When was the Coronavirus Pandemic?","7566":"How do I know if the vaccine trial I participated in is on the approved list for an exception?","1401":"What type of immunocompromised patient received the primary series and the previously recommended monovalent mRNA booster dose?","1349":"What is recommended for the booster dose?","6241":"Why should you get vaccinated?","7608":"How does CDC determine if a country is designated as having limited vaccine availability?","4030":"What does the CDC include in the Total Population calculations?","1820":"What do people need to do to stay up to date with recommended vaccine doses?","3064":"How long is the bivalent mRNA booster dose administered?","1867":"How many large adult hospitals in 20 cities in 18 states are participating?","1815":"What is the acronym for State and Local Immunization Programs?","629":"How much doses were increased in the state of New Jersey in the 2022 update?","169":"How many states did CDC deploy One Health teams to?","7146":"When was MMWR Morb Mortal Wkly Rep 2021;70:1640-1645?","680":"What was the result of the decrease in doses administered in New Jersey?","1880":"What is the name of the CDC's research center for SARS-CoV-2 vaccine?","3980":"What does VAMS stand for?","6062":"What may be outweighed by the potential risks of an additional primary dose of the COVID-19 vaccine by Moderna?","5333":"What are some of the common side effects of paresthesia?","507":"What did the doses reporting \u201cUnknown Age\u201d in the COVID-19 Case Surveillance Public Use Data appear to be?","1720":"Who is required to report certain adverse events?","9341":"What is SPIKEVAX for use in individuals 12 years of age and older?","9383":"What is the name of the approved or approved COVID-19 vaccine?","4855":"What do some experts suggest delaying the second dose for 8 weeks after the invalid dose?","9350":"Who may receive this Fact Sheet even if their child is 5 years old?","2584":"How long is the recommended interval between the first and second doses for Moderna?","1245":"What does the program rely on to encourage people to go to pharmacies and get vaccinated?","2645":"What should you do if you have COVID-19?","452":"How many records were reported on May 24, 2021?","4741":"What is the name of the vaccine I received that was not approved or authorized for emergency use by WHO?","3354":"No evidence of ongoing heart inflammation or sequelae as determined by the person's clinical team?","1943":"What do experts do if there is an unexpected safety concern?","5771":"What is the name of the vaccine by Moderna?","7428":"What is an example of a non-verifiable digital record?","9938":"Do not withhold vaccination if a person is taking antibiotics?","6671":"How many days of non-prescription medications and supplies are on hand?","4572":"What can be used to move virus particles from inside your home to outside?","4269":"Are you gone (if you had symptoms) or have your isolation guidelines been met?","5611":"How many masks should you wear to have better fit and extra protection?","8094":"What is one of the symptoms that can be a result of monkey pox? What is a common symptom that can cause a rash?","4254":"Who should get a COVID-19 Vaccine Everyone 6 Months and older should get what?","2778":"What should you do if you feel overwhelmed with emotions like sadness, depression, anxiety, or thoughts of hurting yourself or others?","9796":"What may have decreased levels of protection following infection?","161":"Who has worked to improve coordination of federal, state, and other One Health partners?","5991":"What was measured by a pseudovirus neutralization assay using a lentivirus expressing the SARS-CoV-2 Spike protein with D614G mutation?","3151":"Who may administer Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines outside of the FDA and CDC dosing intervals?","1480":"What is recommended for the booster dose of the CDC vaccine?","3318":"What was identified in clinical trials of Novavax?","5950":"What is the name of the vaccine by Moderna?","4907":"What should be considered for people with these precautions?","473":"What percentage of fully vaccinated people are there in each age group?","547":"What is the name of the CDC data tracker that shows the approved transfer of doses?","9804":"What is the duration of vaccine-induced protection from primary vaccination with COVID-19 vaccines?","643":"What state made updates to data previously submitted to CDC?","5485":"What is difficult to determine for people who experience PICS after a COVID-19 diagnosis?","3993":"What do these providers report to CDC through multiple sources?","6658":"How many pages are in Test Soon and Treat Early?","2006":"How many children have already received at least one dose of a COVID-19 vaccine?","4094":"Who should you talk to about timing for the second dose in your primary series?","5902":"How many mL of the vaccine is in a red-capped multidose vial?","4987":"What is the term for multisystem inflammatory syndrome in children and adults?","5289":"Who can you talk to if you have questions?","6504":"What are some of the possible conditions that put you at higher risk of severe illness from COVID-19?","7136":"What is the name of the organization that monitors the health of pregnant women with SARS-CoV-2 infection?","5139":"How do you travel to and from the United States?","2484":"When was the last update?","3252":"Moderate or severe acute illness, with or without fever Precaution Defer vaccination until what has improved?","7902":"What do consumers have questions about the relationship between COVID-19 vaccines and monkeypox?","8212":"How long does it take to get your second dose of COVID-19?","3540":"What is another issue that poses challenges to estimating doses administered?","1058":"What can reduce your chances of being hospitalized or dying from COVID-19?","3533":"What does each jurisdiction or provider use to link records within their own systems?","9303":"Who should still get vaccinated against COVID-19?","4607":"What can small particles that people breathe out contain?","3379":"What is not recommended for the purpose of vaccine decision-making?","556":"What has CDC been working with states to do?","8253":"What is the name of the CDC Vaccination Received Outside the United States?","10059":"What vaccines are recommended over Janssen COVID-19 Vaccine?","2296":"What is a common misconception about COVID-19 Vaccines?","4568":"How many doors and windows can you open if you can?","713":"What state made updates to data that resulted in a decrease of 1,151,719 doses?","3068":"How long after completion of the primary series?","4505":"What can make it easier for people at increased risk for severe disease to get sick?","3561":"People receiving doses are attributed to which jurisdiction in which they reside?","4673":"TTS = thrombosis with what syndrome?","2139":"What is not associated with fertility problems in women or men?","9660":"What is the dose of COVID-19 vaccine by Pfizer-BioNTech?","5123":"Do you travel if your test result is positive?","2862":"What is the name of the bivalent protein subunit vaccine Novavax?","6141":"What is Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection?","6633":"What are actions you can take based on your medical conditions?","4068":"Who is best protected when they stay up to date with COVID-19 vaccinations?","7527":"Who is not eligible to get the B-1 (business) or B-2 (tourism) visa?","9839":"How do you report to VAERS?","1632":"What are terms of the COVID-19 vaccine Emergency Use Authorization eligible to be vaccinated?","8503":"How can people avoid crowding on public transport?","181":"How many animals were confirmed to be infected with COIVD-19?","7221":"How long have millions of people received the PFV under EUA since December 11, 2020?","9832":"What does VAERS stand for?","6154":"What are the rates published monthly on?","7618":"What must sea crew members follow during and after embarking a cruise ship?","3220":"What should patients be seated or lying down during during vaccination?","3656":"How many days have you been exposed to a person with the disease?","7931":"What is higher after SARS-CoV-2 infection than after mRNA COVID-19 vaccination for both males and females in all age groups?","3557":"What provides reliable data that can be reported by CDC?","7690":"What is TTS after COVID-19 vaccination?","4665":"What are people who have a history of allergic reactions urged to see?","3883":"What is the acronym for the Vaccine Adverse Event Reporting System?","6209":"When was last updated?","5081":"What was updated recommendations related to contraindications and precautions?","3113":"How long after a solid-organ transplant is given?","6985":"Who gives you a vaccination card to document when you received the shot?","6754":"What is pericarditis?","710":"What did Illinois do with the decrease in doses?","8758":"What should you do if your child has a medical condition?","5529":"What will help us better understand post-COVID conditions?","2901":"What should be used for all doses of the primary series?","5454":"How can symptoms go away or come back?","2107":"What is the name of the voluntary smartphone-based tool that provides quick and confidential health check-ins via text messages and web surveys?","8055":"What is not recommended for children ages younger than 2 years?","5418":"What is the FDA's decision based on?","89":"What is the name of the Vaccine Adverse Event Reporting System?","5876":"How long can symptoms last?","4000":"What day of the week are vaccines delivered and administered?","4348":"Who does not provide the white CDC COVID-19 vaccination card to people?","8578":"What are normal signs the body is building?","8529":"What is the name of the CDC website that provides more information about contagious diseases on flights?","5270":"How many sequential negative results do you have?","3006":"How long is the interval between the first and second doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines?","3823":"What does the CDC COVID-19 Vaccination Program Provider Requirements and Support do?","2200":"What is the name of the study that examined the vaccine response?","4862":"What is not considered an error if the dosing is in accordance with the FDA EUA?","8134":"Where is the literature review weekly published?","804":"What is the other term for post-COVID conditions?","7512":"How many doses of an accepted COVID-19 vaccine dose have I received?","1195":"When will CDC be able to attribute non-residents of Texas to their respective state or territory of residence?","4322":"What are side effects of getting a vaccine?","8533":"What does the virus spread easily between people in close quarters on board?","4108":"What are public health experts seeing decreases in?","2120":"What is important for the health of your baby during pregnancy?","2489":"What can affect your risk of getting very sick from COVID-19?","3187":"Who has no specific contraindications at the time of the healthcare visit?","8786":"What should be thrown away in the trash right away?","6830":"How can you access the latest Fact Sheets?","4581":"Who should inspect and adjust the ventilation system every year?","7843":"Who can ensure that those who tested positive for COVID-19 receive the most appropriate medical care?","2290":"What is the name of the vaccine that can cause side effects after getting it?","7365":"What is the requirement for proof of COVID-19 vaccination for Air Passengers?","7782":"What does not necessarily mean that a vaccine caused a health problem to VAERS?","6993":"What is the FDA's website for emergency preparedness and response?","4368":"What does COVID-19 spread when an infected person breathes out droplets and particles that contain the virus?","4394":"What does 211 stand for?","1050":"What does this page provide for the general public?","7557":"How much personally identifiable information must a person possess to receive a COVIDE-19 vaccine?","5004":"Who is responsible for the administration of the COVIDE-19 vaccine booster dose?","4935":"What is the name of the Janssen (Johnson & Johnson) Covid-19 vaccine?","2952":"What is the age limit for children under 5 years who are allowed to receive the Pfizer-BioNTech booster dose for?","6889":"What is the Moderna EUI Fact Sheet for Recipients?","4924":"When is Moderna COVID-19 Vaccine to be used in the United States?","2339":"What is considered up to date?","8694":"What can scientists do by comparing the branches?","3152":"What is considered to outweigh the potential and unknown risks for the recipient?","6493":"What is the Isolation and Exposure Calculator?","4330":"Who can give you another card if your vaccine card is full?","3852":"What must providers record after administering a dose of COVID-19 vaccine?","422":"What is the reason for the decrease in vaccination doses for New Jersey?","876":"What can you do to protect your newborn while in the hospital?","5137":"What should you wear when you travel?","2802":"What is the name of the organization that fights COVID?","7815":"What should you wash before and after you collect a nasal specimen for your test?","5190":"Who is contacting people who meet the case definition for myocarditis following COVID-19 vaccination?","8579":"How many main types of COVID-19 vaccines are approved or authorized for use in the United States?","9481":"Where can you find information about the vaccination provider?","8811":"ATSDR, HHS or the United States Government of you, your company, product, facility, service or enterprise?","3227":"How long does it take for a reaction to occur?","1013":"What can antibody tests help protect you from?","4613":"What type of survey did you take after using the tool below?","6486":"What can be stressful to manage if you become sick?","8320":"What is the purpose of the COVID-19 vaccines?","8309":"What is the name of the virus that can be tested for both flu and COVID-19?","7077":"What is more urgent than ever?","3478":"Be up to date with your vaccinations before travel.","6119":"Where is McMaster located?","8818":"We urge you to link directly to our resource documents rather than what?","3389":"What type of immune response does SARS-CoV-2 have?","9352":"What vaccine is approved for use in individuals 6 to 11 years of age?","8991":"As of May 2, 2022, how many pregnant people were enrolled in the CDC's registry?","2490":"What do you need to know to protect yourself and others?","5220":"If you have COVID-19, see what information?","3501":"What may cruise ships have their own requirements for?","8247":"How old is the booster age?","4159":"How do vaccine ingredients vary by manufacturer?","3899":"What are some people more likely than others to get very sick if they get COVID-19?","5812":"Moderna's vaccine was approved to prevent what?","2355":"How long after a solid organ transplant is a hematopoietic stem cell transplant needed?","7078":"What vaccines are up to date with?","2056":"What should people who are pregnant keep up to date with?","10028":"How long after symptom onset is a booster dose dose given?","963":"Who recommends that you follow the test directions?","2236":"What is a breakthrough infection?","627":"What was the increase in doses administered in New Jersey?","2003":"What is the minimum age to receive a booster?","6208":"Who should you report any health problems after vaccination to?","1313":"What does Pfizer-BioNTech do for children who transition to an older age group?","3226":"What is the onset of an allergic reaction after a previous dose of vaccinated?","6167":"What is CDC's MMWR?","7436":"When are you considered fully vaccinated?","3524":"What does the State & Territorial Health Department do?","2557":"What are adults ages 65 years and older recommended intervals for?","9593":"What is another term for CAR-T-cell therapy?","5155":"What is an attestation?","6456":"Where can you get tested, receive a prescription and have it filled?","9246":"What type of mask should you wear when you are around others?","113":"There is no evidence that animals play a significant role in spreading what?","8358":"People hesitant about vaccines usually have more practice explaining why they haven't gotten a vaccine?","5560":"What should be prioritized for healthcare settings?","1044":"What can be done if one of these tests is not available?","7544":"What must you show that you are traveling under one of the visa categories?","3769":"What did Pfizer-BioNTech and Moderna have in common?","3606":"What is the rate per 100,000 people calculated for?","3247":"Precaution Management of post-COVID-19-vaccination symptoms?","5575":"What is the highest level of protection offered by NIOSH-approved respirators?","3465":"How long ago did you test positive for COVID-19?","3349":"What is the name of the vaccine for MIS-C?","8938":"What is an early warning system used to monitor?","625":"Which state made updates to data previously submitted to CDC?","3988":"What does CDC report online on COVID Data Tracker and in vaccination datasets?","1454":"Can pregnant or breastfeeding people be vaccinated?","5546":"What does the CDC recommend you wear to protect yourself and others from COVID-19?","9193":"What should you use if soap and water aren't available?","8943":"What is VAERS especially useful for detecting?","874":"How much alcohol should be in a hand sanitizer?","4983":"What age group may choose to receive a second booster dose?","371":"What is Pfizer-BioNTech Vaccine for children ages 5 through 11 for the pediatric population?","1734":"What is pericarditis after a Pfizer-BioNTech, Moderna, or Novavax vaccine?","8422":"What are the core competencies of the EUA Fact Sheets for Healthcare Providers for the vaccine product(s) in your facility?","3419":"On a case-by-case basis, a provider may offer what if the two criteria above are met?","2905":"What is no longer authorized as a booster dose for people ages 5 and older?","3797":"What do healthcare providers need to know about VAERS COVID-19 Vaccine Safety Monitoring Systems for Pregnant People?","1359":"How old are children recommended to receive the Pfizer-BioNTech bivalent booster dose?","2308":"Use CDC's COVID-19 booster tool to learn if and when you can get boosters to stay up to date with your vaccines?","9128":"What is another way to reduce crowding on conveyances?","970":"If you are in certain high-risk settings, you may need to test as part of what program?","2045":"When will the COVID-19 vaccine be available to adolescents in the United States?","9244":"How long can it take for you to develop a cough?","3079":"What is another term for a person who is unable or unwilling to receive a booster dose?","3705":"What is the brand name of Pfizer-BioNTech?","8043":"Why do some consumers believe vaccines are unnecessary?","5813":"What is the name of the vaccine Moderna uses as an additional primary or a booster dose?","9974":"What are two types of reactions commonly observed following vaccination?","3277":"What was the most frequent local reaction?","2597":"What type of vaccines may be administered on the same day as other routinely recommended vaccines?","2728":"What is COVID19?","1277":"What is the 4-day grace period?","849":"Who Would Like to Have a Baby?","157":"What does not show whether animals can spread SARS-CoV-2 to people?","8280":"CDC does not keep vaccination records nor determine how vaccination records are used?","1950":"What does V-safe use to check in with COVID-19 vaccine recipients?","1633":"Who is required to make available and administer COVID-19 vaccine to all persons?","1893":"What happens to people who are vaccinated?","9634":"What age group should receive an additional dose of the COVID-19 vaccine by Pfizer-BioNTech?","972":"What is the risk for severe COVID-19?","2381":"How many doses of the mRNA COVID-19 vaccine did people who are moderately or severely immunocompromised receive?","7123":"What should you do if you are sick or think you were exposed to COVID-19?","5031":"Who has a history of multisystem inflammatory syndrome in children?","761":"What other parts of your body may also be affected by the disease?","10119":"Who should discuss the risks and benefits of getting a covid-19 vaccine with the recipient, guardian and clinical team?","6832":"Where can you find your child's vaccination information?","6494":"What should you wear if you are at high risk for severe illness?","4387":"When was the last update of the ASL Video Series?","3674":"What does the CDC require on public transportation conveyances and at transportation hubs?","821":"What is effective at protecting people from getting seriously ill, being hospitalized, and even dying?","1175":"What does each state or territory dictate?","341":"What is another reason residents in Massachusetts received vaccines?","7487":"What are the United States required to provide to prove COVID-19 vaccination?","4211":"How long should you delay getting your next vaccine?","4012":"How long does it take for doses delivered to be administered?","2160":"What is the name of the video about COVID-19 vaccines for people who are pregnant?","3360":"Who should be informed that vaccination is to help prevent severe COVID-19?","8295":"What should you do if you have already tested positive for COVID-19?","7997":"What can still be worn in indoor public places?","6182":"What vaccines are used in the United States to protect against severe disease, hospitalization, and death from known circulating variants?","1703":"What are measures when providing a COVID-19 vaccine?","5654":"What is the acronym for Occupational Safety and Health?","823":"What are people who have certain medical conditions or who are taking medications that weaken their immune system at increased risk of severe COVID-19 illness?","8757":"What may not have been tested for broad use in children?","2683":"How close to the time of the event is it possible?","21":"How do you find a COVID-19 vaccine near you?","52":"If you have had an immediate reaction to a vaccine other than a COVID-19 vaccine or any injectable therapy, you may still be able to get what?","490":"When did the population metrics for 65+ Texas residents drop from the metrics reported on April 18, 2021?","6531":"What may increase your risk of cancer?","1267":"Moderna and Pfizer-BioNTech are what?","3889":"What is v-safe?","8156":"What is a bivalent booster called?","6296":"What can affect menstrual cycles?","1628":"Prioritization for receipt of receipt of the vaccine was necessary given limited supplies of what?","7728":"Who can effectively and immediately treat the reaction?","7955":"What are some examples of evidence-based messaging strategies?","2179":"What vaccine is associated with SARS-CoV-2 infection in pregnant women?","1747":"What are the areas where providers are doing well and areas needing additional follow-up?","3108":"What is not a substitute for COVID-19 vaccination?","8053":"What must schools make when necessary to ensure that all students, including those with disabilities, are treated?","7323":"What is the name of the criteria for counting new infections after previous probable or confirmed infections?","3876":"What is an important factor in vaccine acceptance?","4468":"What can you do if you have COVID-19?","880":"How long has it been since symptoms first appeared?","6091":"What does the association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing with Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis do?","8718":"What are N95 respirators?","3102":"When should people who are immunocompromised be given tixagevimab\/cilgavima?","3825":"What is a private provider not required to do?","9744":"What was assessed prior to administration of the booster dose (Day 1)?","3681":"What does EUI stand for?","1957":"What is the national system that CDC & FDA use to report adverse events?","7684":"What can cause an adverse event?","9868":"What is needed for a 3rd dose of SARS-CoV-2 vaccine?","7989":"What may decrease the frequency and impact of COVID-19-specific information for consumers?","8939":"What is the frontline system of a comprehensive vaccine safety monitoring program in the US?","474":"How many doses did the population receive in Texas?","4847":"What is mixed with too much diluent?","3792":"What is another term for vaccine safety issues?","8369":"Who developed the content?","906":"Who can you ask for help with?","6200":"How long after a COVID-19 vaccination does your child have any of the symptoms?","8080":"As of September 14, 2022, how many confirmed cases of monkey pox were there?","8946":"How many reports to VAERS have been made after the vaccination?","7905":"What does the State of Vaccine Confidence Insights Report emphasize?","1588":"Who issued the Emergency Use Instructions?","6306":"What are the key things to know about COVID-19 Vaccines?","812":"How does immunity from infection decrease over time?","9665":"What does Pfizer-BioNTech do with the COVID-19 vaccine?","7812":"What is the manufacturer's instructions for using the COVID-19 test?","7247":"If you experience a severe allergic reaction, call 9-1-1 or go to the nearest hospital.","4332":"What can you do to get a copy of your vaccination record?","6802":"What is VAERS?","7756":"What will I share as it becomes available?","212":"What are some diseases where antibodies are expected to decrease or wane over time?","8216":"How long after 2nd primary series dose or last booster did you receive the most recent booster recommended for you?","404":"On what date was the Pharmacy Partnership for LTC Program archived?","6496":"What should you wear if you are in an area with a high COVID-19 Community Level?","2388":"As with the two-dose primary series, serious side effects are rare but may occur?","273":"What error was used to calculate percentage-based metrics for the U.S. population aged 18 years and older?","1250":"Who is eligible to get a COVID-19 vaccination?","5038":"Updated information in the section on Vaccinating people with what disease?","7153":"What does COMIRNATY stand for?","4526":"What must your N95 form to your face to work properly?","7540":"What is the name of the category for a noncitizen seeking entry into or transiting the United States?","7440":"What are the requirements of the Presidential Proclamation and Amended Order?","9738":"What is the immunogenicity of the Pfizer-BioNTech COVID-19 vaccine supported by?","3521":"Why was the cruise ship color-coding system removed?","1683":"What is the name of the mRNA COVID-19 Vaccine after reports of myocarditis?","7452":"What does CDC Immigrants and Other Non-affected Persons see as an exception?","9518":"What should they receive for all subsequent doses?","5736":"How long after the first primary dose of the COVID-19 vaccine should the second dose be received?","1317":"What is the minimum interval?","4399":"What website can you use to find COVID-19 vaccine locations near you?","185":"USDA Confirms SARS-CoV-2 in what animal in Utah?","2216":"Who is the author of SARS-CoV-2-Specific Antibodies in Breast Milk?","10054":"What is the name of the summary document for Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized or Approved in the United States?","9250":"How do you protect yourself and others?","6741":"Who can you talk to if you have questions?","4909":"What should only be undertaken in an appropriate setting under the supervision of a healthcare professional?","6067":"What is expected to be less favorable for booster dose use of COVID-19 vaccine by Moderna compared to the available alternative bivalent booster vaccines?","2414":"What did systems document more than 1,000 people who completed?","6579":"What is specific guidance developed?","2173":"What is the name of the Canadian National Vaccine Safety network?","9217":"What is the term for air flow at home?","5321":"What type of vaccine will be given to you as an injection into the muscle?","7277":"What do you need to discuss with your healthcare provider?","7976":"What percentage of social media mentions of the vaccine decreased?","5999":"How long after a 2-dose primary series did multiple countries implement booster doses at least 3 months after primary vaccination?","9959":"What is an increased risk for severe COVID-19 disease?","3097":"When is the bivalent mRNA booster dose administered?","6835":"What is IIS?","9641":"How long after the first dose is the approved interval for the second dose?","6740":"What vaccine may your child receive because there is currently a pandemic of?","8522":"What are pilots required to provide to airlines and aircraft operators before they board a flight to the United States?","5858":"What is Spikevax commonly referred to as?","1759":"All COVID-19 vaccination providers must report what weekly into Vaccines.gov?","6944":"When did the vaccine become available in the U.S.?","3213":"What is not generally recommended to prevent allergic reactions?","3020":"What are the intervals between the first and second primary series doses recommended for?","9067":"What type of Vaccines Masks Testing Ventilation?","2773":"What can be confusing and frustrating for people with post-COVID conditions?","6522":"What are people in racial and ethnic minority groups often younger when they develop chronic medical conditions?","288":"How many doses were administered on August 1 to August 1?","3454":"If you are taking medication that weakens your immune system, you might not be fully protected even if you are up to date with what?","6843":"What is the name of the CDC's Vaccination Program?","4577":"What type of filters are more efficient than ordinary furnace filters?","1611":"What program is responsible for the purchase of the vaccine?","6905":"Who issued the original CDC-issued vaccine on 11\/17\/2021?","3767":"What might be outweighed by the potential risks of primary, additional, and\/or booster doses of the COVID-19 vaccines by Pfizer-BioNTech?","8169":"What are the names of the two COVID-19 vaccine manufacturers?","994":"Where can you order free self-test kits?","5977":"Which countries have recommended heterologous dosing for the Moderna COVID-19 vaccine?","9967":"What is the Interim Immunization Schedule for Ages 6 Months and Older?","5009":"What was updated to alert providers of possible false positives?","7745":"What is TTS?","3574":"Who receives at least one dose of the COVID-19 vaccine?","4779":"How many doses of the Medicago COVID-19 Vaccine should people receive?","8960":"How does VAERS help to monitor vaccine safety?","8521":"What is the U.S. government requirement?","1587":"Who is required to offer third primary doses or bivalent booster doses of the Pfizer-BioNTech or Moderna COVID-19 vaccine?","7669":"What is safe and effective?","7703":"What type of events are reported after COVID-19 vaccination?","384":"How many people lived in the US?","3601":"Who receives the second dose in a two-dose COVID-19 vaccine primary series?","4290":"What type of vaccine is a flu vaccine?","1570":"What should be administered using the same mRNA COVID-19 vaccine as was administered for the 2-dose primary series to persons who are moderate to severely immunocompromised at least 28 days after completing the two dose primary series?","8086":"What can happen to someone who has been in close contact with someone who is at risk?","10062":"What is the age range of Novavax vaccine recipients?","7916":"When did the FDA limit the authorized use of the Janssen COVID-19 Vaccine to individuals ages 18 years and older?","4418":"What is one of the basic health and hygiene practices?","7210":"Who should not get COMIRNATY?","716":"What state made updates to data previously submitted to CDC that resulted in an increase of 3,433 doses administered?","2108":"How can you receive a COVID-19 vaccine?","5162":"What should you do if you have already had COVID-19 within the past 90 days?","1396":"Who should be vaccinated according to the schedule for people who are moderate or severe immunocompromised?","4749":"How long must you wait for the last WHO-EUL vaccine dose to expire?","4593":"What can help remove virus particles that might still be in the air?","9616":"What is the name of the COVID-19 vaccine by Pfizer-BioNTech for primary and\/or additional doses?","1718":"What does VAERS accept and analyze after a person has received a vaccination?","8098":"Are there any travel restrictions due to monkeypox?","7402":"What type of test will you be tested with 3-5 days after arrival in the US?","2244":"What do variants have on how well COVID-19 vaccines work in real-world conditions?","5203":"What can provide a more complete picture of your health?","7888":"How do local health departments, public health experts, and healthcare workers respond to the threat of the disease?","10146":"What is the time limit for post-vaccination observation periods?","8499":"What should my travel companions do?","8890":"How can you protect patients who are at high risk, disproportionately affected by COVID-19 or might suffer severe consequences if infected?","5796":"When is it possible to compare the risk of myocarditis in people ages 12-17?","3225":"What is a contraindication to a different type of COVID-19 vaccine?","2436":"What vaccines are undergoing the most intense safety monitoring in U.S. history?","6149":"What can be confirmed through more robust studies?","1081":"What is the most common way to take a treatment at home?","5863":"What is the name of the vaccine that is not listed for emergency use by WHO but for which a U.S. data and safety monitoring board or equivalent has independently confirmed efficacy?","7279":"When you get your first COVID-19 vaccine, you will get what?","1323":"What should all doses of the primary series be with the same product?","5904":"How many mL of the moderna vaccine is in a red-capped vial?","9055":"Which variants spread more easily and quickly than others?","5782":"How many people have received the COVID-19 vaccine since it became available?","6408":"How many mg of prednisone or equivalent per day when administered for 2 or more weeks?","6989":"How long must the vaccine be submitted?","6711":"What is the name of the school that was last updated on Apr. 7, 2022?","9175":"If someone is having trouble breathing, what should they do?","6170":"What is a measure of how well vaccination protects people against infection, symptomatic illness, hospitalization, and death?","5420":"How does the benefit of the product outweigh the risks?","7911":"High risk Moderate risk Low risk Positive sentiment  May lead to vaccine refusals and decreased uptake  Wide reach, pervasive  Potential to trigger hesitancy to vaccination  Moderate reach, modest dissemination  Concerning, but low risk to vaccine confidence  Could increase vaccine confidence, intent, or motivation  Variable reach and dissemination How has this theme\/idea changed over time?","10013":"What is HIT?","3815":"What is provided free to enrolled providers by the U.S. government?","4942":"What are the names of the companies that are listed on the fda.gov's Emergency Use Instructions for Healthcare?","1229":"What is used for population counts?","3284":"In younger children, irritability\/crying and drowsiness\/sleepiness were most common?","1658":"What is the only medical service provided to receive COVID-19 vaccination?","4801":"How long is it acceptable to administer the repeat dose at an interval earlier than 8 weeks?","1300":"What is especially important for people with underlying medical conditions associated with higher risk for severe COVID-19?","568":"What state made updates to its data that resulted in a net increase of 212,852 doses?","8930":"How many ways to report an adverse event to VAERS?","2878":"Booster vaccination 5-11 years Bivalent Orange Orange Yes 10 g 0.2 mL 12 years and older What is the name of the vaccine?","1213":"What does CDC provide administration data on in the snapshot below?","3834":"Who should complete the training module for the vaccine they will be administering?","5889":"Who should receive an additional dose of the Janssen COVID-19 Vaccine?","5933":"Where is the Moderna COVID-19 Vaccine supplied?","10079":"How long after JYNNEOS or ACAM2000 are people advised to wait?","6000":"How long after primary vaccination has the general population implemented booster doses?","9622":"How long can symptoms last?","3381":"What does not need to be delayed?","503":"What happened to the number of people who received the vaccines?","3154":"Who should not routinely administer doses of COVID-19 vaccine beyond those recommended in this guidance?","8978":"How often will participants receive calls from Abt Associates for additional health check-ins?","1291":"What is the name of the vaccine that can be given to people who previously received COVID-19 vaccination?","1915":"What is the purpose of the v-safe COVID-19 Vaccine Pregnancy Registry?","9776":"How long was the interval between dose 1 and dose 2?","902":"How many days after you last had close contact with someone with COVID-19 should you get tested?","9797":"What continues to be recommended regardless of the option for delaying vaccination after infection?","1447":"What is the purpose of vaccine decision-making?","4484":"How do you prevent a sick person?","7687":"What is a severe type of allergic reaction with symptoms such as hives, difficulty breathing, low blood pressure, or significant swelling of the tongue or lips?","0":"What can happen to some people after getting a COVID-19 Vaccine?","4318":"Where can you get a free vaccine after a vaccination?","8249":"What is the name of the booster that children under 5 years old can get?","7781":"How many doses of COVID-19 vaccines were administered in the United States from December 14 to December 14?","2234":"Who is recommended to stay up to date with their COVID-19 vaccines?","1653":"What can not be sold, for direct or indirect remuneration?","5316":"What did you have a severe allergic reaction to?","1354":"For more information, see vaccine administration errors and deviations.","1078":"How long after symptoms start Intravenous (IV) infusions at a healthcare facility for 3 consecutive days?","6105":"London (United Kingdom): Department of Health & Social Care; programme-for-winter-2021-to-2022.","7797":"How many days after your exposure should you test negative for COVID-19?","4055":"Data show that an mRNA booster increases the immune response, which improves protection against what?","5985":"What was the dose of a booster dose administered after the completion of the moderna covid-19 vaccine primary series?","3616":"How does CDC determine county of residence?","909":"Who can care for your newborn if you are well enough?","2019":"What is the name of the vaccine that can quickly provide care and call for emergency medical services?","5495":"What were people who did not get a COVID-19 vaccine exposed to?","5261":"Do not go places where you are unable to wear a mask until you can discontinue masking?","2973":"How long after completing the primary series is a child unable to receive an mRNA vaccine?","4001":"When are vaccine data in CDC's COVID Data Tracker updated weekly?","4531":"If you feel air leaking out from the edges of the N95, what is it?","5997":"What study demonstrated safety and immunogenicity of COV-BOOST and the NIH mix-and-match study?","6341":"How long do symptoms typically last?","119":"Who is more likely to get COVID-19 from other people than from animals?","2144":"What type of vaccine should pregnant people receive?","8897":"What is the median age of patients on dialysis?","1858":"What does RVTN stand for?","8510":"Who does not reimburse or help travelers get reimbursements for travel expenses?","7425":"Where is Novavax from?","8313":"What is the duration of the video?","6896":"What symptoms may include fever or chills, cough, shortness of breath, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or run nose, nausea or vomiting, and diarrhea?","9466":"If you or your child is immunocompromised, what may you receive?","1438":"Who recommends COVID-19 vaccination for all people ages 6 months and older?","3999":"What is the day of weekly reporting for vaccines?","4605":"What should you do to prevent the spread of COVID-19?","2395":"Who recommends people receive the most recent booster dose recommended for them by the CDC?","9068":"When was US & Global Variant Data last updated?","9110":"People on public transportation may not have the option to avoid being around people who are not wearing what?","6399":"Who can help protect you and themselves by staying up to date on their COVID-19 vaccines?","9721":"How many primary series doses of Sinovac COVID-19 vaccine were given to Thai HCWs?","7919":"What was the perceived lack of effectiveness of all COVID-19 vaccines?","3556":"What does CDC report online on COVID Data Tracker and in vaccination datasets?","7475":"What should a traveler do if he or she tests positive or develops symptoms?","9516":"What should a person receive if they move from a younger age group to an older age group during the primary series?","566":"What was the net increase in administered doses in California in 2022?","1390":"Who is ages 18 and older who completed primary vaccination using any COVID-19 vaccine and have not received any previous booster dose?","4999":"When is it no longer necessary to delay the vaccination?","9682":"What are some of the possible serious side effects of the Covid-19 vaccine?","5793":"What were the most common side effects reported?","3484":"How long does it take to get tested for current infection before boarding a cruise ship?","7314":"What is COVID-19 helping us understand?","7840":"Invalid results from a self test mean the test did not work properly and a new test is needed.","1068":"What can be safely taken at the same time?","1343":"What should be reported to Vaccine Adverse Event?","635":"How much doses did Illinois decrease in 2022 in addition to the data previously submitted to CDC?","1363":"What should be administered at least 2 months after the last monovalent booster dose?","535":"On what date was the COVID-19 Vaccine Tracker updated?","4013":"How do jurisdictions and federal pharmacy partners manage vaccine stock?","5362":"What is one of the symptoms that you should seek medical attention for if you develop a weakness or tingling sensation?","1986":"How were COVID-19 vaccines developed and approved?","4457":"What does your test result mean?","9488":"Where can you find more information about the IIS?","8633":"What is given in a muscle in the upper arm?","7422":"Who approves or authorizes COVID-19 Vaccines?","2119":"What can protect you from getting sick from COVID-19?","3684":"What inform healthcare providers and recipients about approved, licensed, or cleared conditions of use under circumstances that go beyond the scope of the approved labeling?","6935":"What is the term for inflammation of the heart muscle?","8620":"Several studies have focused on what other diseases?","5194":"What may people get in the mail or receive a phone call from the CDC asking about their myocarditis and medical history?","3037":"Dosage is administered at least 2 months after completion of what?","1185":"In addition to Texas, what other state included Texas in the metrics?","4126":"What website can you use to find a booster for your child?","1817":"What is the name of the disease that can be prevented in the US?","6906":"What should people ages 12 years and older receive to complete the COVID-19 vaccine?","8129":"What is OADC's Channel COVID-19 Post metrics Weekly?","4770":"What type of dose did the person receive if they had previously received a bivalent Moderna or Pfizer-BioNTech booster dose containing the original SARS-CoV-2 strain and Omicron BA.1 variant?","6016":"What was significantly higher with a longer dosing interval?","5888":"What year should an 18-year-old who received primary vaccination with the Janssen Covid-19 Vaccine receive an extra primary dose?","5959":"What is available supporting evidence for use of the COVID-19 vaccine by Moderna?","2836":"What can be used to evaluate for potential causes?","453":"What was the reason for the fewer doses reported?","8535":"Who are people who are not up to date with their COVID-19 vaccines?","462":"What was the reason for the Demographics page?","4439":"What does ventilation and filtration include?","4107":"What does the COVID-19 vaccine work well to prevent?","9272":"What can you learn about protecting your family from?","1391":"Who may receive a monovalent Novavax booster dose at least 6 months after completion of the primary series?","9351":"Who may receive the Moderna COVID-19 Vaccine for use in individuals 6 months through 5 years of age?","9501":"What is the current COVID-19 pandemic?","8665":"What are the high standards for safety, effectiveness, and manufacturing quality that the FDA requires of a vaccine?","5644":"How many of the KN95 respirators NIOSH evaluated during the COVID-19 pandemic in 2020 and 2021 did not meet the requirements that they intended to meet?","6407":"How do people with HIV and CD4 cell counts less than 200\/mm3 respond to active treatment?","488":"On what date was the total doses administered data posted to Tracker for New Hampshire the same as those reported the day before?","9409":"What is the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine?","4259":"Do you need to wait to get vaccinated?","256":"Antibodies for the virus that causes the disease are expected to decrease or wane over what time period?","4989":"How much booster dose is given for Moderna Covid-19?","1524":"Who provides the URLs for proper fit and use?","6623":"Who is at increased risk for getting very sick compared to children without underlying medical conditions?","6447":"How long after you had close contact with someone with COVID-19 do you need to get tested?","5980":"What are some of the contextual factors?","9338":"What is the name of the FDA-licensed vaccine?","3709":"What vaccine is used to authorize an additional primary dose in certain immunocompromised persons aged  12 years?","1824":"How many doses are recommended to complete their primary series?","1651":"What is considered prohibited commercial marketing?","5752":"How many days after receiving the Janssen COVID-19 Vaccine primary dose?","6045":"Numerous immunologic studies and epidemiologic studies have shown that vaccinating previously infected individuals significantly enhances their immune response and effectively reduces the risk of subsequent infection?","1687":"When is the Interim Recommendation for Use of Janssen COVID-19 vaccine?","1897":"What is CDC monitoring as part of its efforts to understand how well COVID-19 vaccines are working?","3922":"What does high blood pressure increase?","2264":"How can a loved one communicate with the LTC staff?","9736":"What are the available immunological and safety data?","1120":"What is the name of the CDC program that aims to reduce disparities in disproportionately vaccinating people?","1996":"How old are children and teens who got the Pfizer-BioNTech COVID-19 vaccine?","7768":"What do multiple studies and reviews of data from vaccine safety monitoring systems show about vaccines?","2834":"What is important to rule out other potential causes of myocarditis?","3497":"What does CDC recommend for wearing masks in travel and public transportation settings?","7069":"See the latest data on birth and infant outcomes among pregnant women with what?","2559":"What is the Interim COVID-19 Immunization Schedule for Persons 6 Months of Age and Older?","5861":"What is included in CDC\u2019s Technical Instructions for Implementing Presidential Proclamation Advancing Safe Resumption of Global Travel During the Covid-19 Pandemic and CDC's Order?","2412":"How many U.S. healthcare systems used data from eight healthcare systems?","4905":"What is the name of the company that makes the vaccines?","6696":"Do NOT mix chemical products with water?","6897":"Who can receive the primary and additional doses of the COVID-19 vaccine under the EUI?","4289":"What is the name of the vaccine that children, teens, and adults may get at the same time?","9808":"What is inferred from immunogenicity data in immunocompromised adults who received a single additional primary dose?","3286":"What is most common with high fevers?","8318":"What is the most trusted source of information on vaccines?","2784":"What does CDC understand the person's experiences might make them feel less isolated?","8768":"What type of mask can help protect you while you travel?","7149":"What is COMIRNATY?","4504":"What must N95s form to the face to work properly?","1128":"What is a way to get CDC web content on your website?","9919":"What is the age of the recipient?","3628":"What should you do if you are traveling by land?","6701":"How many steps for Safe and Effective Disinfectant Use does the EPA recommend?","355":"When did North Carolina identify an issue with linking data across different vaccine sites?","9544":"What color is the label border of the product authorized for children ages 5-11 years?","2791":"What is CDC's advice on how to start meaningful conversations?","9788":"How long has the risk of infection with antigenically similar variants been reduced?","8550":"What is more likely to result in transmission than two minutes of contact?","7469":"What is the purpose of separating and restricting the movement of people who were exposed to a contagious disease to see if they became sick?","9901":"Who developed interim recommendations for use of the inactivated COVID-19 vaccine?","1978":"How many federal and tribal sites represent IHS Areas Supports reporting to VAERS?","7975":"What was the decrease in news coverage of the COVID-19 vaccine?","581":"How many administered doses did Idaho make changes to?","1289":"What is the name of the vaccine that can be used to prevent monkey pox from getting infected?","9591":"Who received the primary dose(s) of Covid-19 vaccine during treatment with B-cell-depleting therapies?","9108":"What can involve spending long periods of time in areas that may be crowded or poorly ventilated?","6809":"What does V-safe provide if participants report a significant health impact following COVID-19 vaccination?","3164":"What are the dosing options for Moderna COVID-19 Vaccine and Pfizer-BioNTech COVIDR-19 vaccination?","8549":"What increases the risk of transmission?","6818":"What is another name for the Pfizer-BioNTech COVID-19 Vaccine?","5097":"What can be done before or at the same time as mRNA COVID-19 vaccination?","9528":"How many mcg of the product is approved for children ages 6 months-5 years?","6477":"What is the name of the disease that can cause you to get sick with COVID-19?","5564":"What does the CDC recommend that you wear?","5785":"How many people ages 12-17 years received a primary series of the vaccine?","1571":"How many doses of COVID-19 Vaccine did Pfizer-BioNTech complete?","3715":"How long is the booster dose interval?","1063":"Who are people with certain medical conditions?","178":"What is Coronavirus Disease 2019 in the United States?","1927":"Who will receive COVID-19 vaccines?","5674":"What are respirators typically designed for?","7979":"What percentage of consumers are concerned about contracting COVID-19?","6947":"What is the name of the non-FDA authorized or approved vaccine?","1520":"Who shall not be required to engage in fit testing, medical evaluations, or training?","2013":"What was the highest risk of myocarditis after the second dose of the vaccine?","688":"What state made updates to data previously submitted to CDC?","4345":"Your state's IIS cannot issue you a vaccination card, but they can provide what?","1126":"What is the CDC's Privacy Policy?","4337":"What can you do if you were vaccinated abroad?","5305":"Who elects to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a vaccine?","8011":"What can help prevent COVID-19 and reduce the potential for strain on the healthcare system?","2237":"When people who are vaccinated develop symptoms of COVID-19, they tend to experience less severe symptoms than those who are not?","4649":"Who should be informed about the risk and symptoms of TTS?","9602":"What year did the Pandemic and All-Hazards Preparedness Reauthorization Act include a new provision that allowed for the issuance of EUI to permit CDC to inform healthcare providers and recipients about certain uses of FDA-approved or cleared medical products?","2342":"Children 6 months to 4 years are not recommended for what?","2735":"What is the purpose of this information?","9563":"How long does it take to get a dose of a vaccine for a child ages 12-17?","7205":"What type of immunocompromise is the third primary series dose given to?","5505":"What is another way to protect yourself and others from becoming infected?","2341":"What is the AGE GROUP PRIMARY SERIES?","3719":"When will the vaccine be approved for adults?","8087":"Where can a rash that may be located on or near the monkey's skin be found?","2486":"What are some reasons people in the United States have some protection against?","5437":"Who is at higher risk of developing post-COVID conditions?","5245":"If you had no symptoms, you may end isolation after day 5.","3095":"What type of vaccine is recommended to be given to people with moderate or severe immune compromised ages 18 and older?","8827":"What is the penalty for misrepresentation or misappropriation of the agency's materials, positions, or logo\/marks in publications sold for profit?","8858":"Who has been contracted by the CDC to contact participants for CDC's v-safe CDC- Pregnancy Registry?","4757":"What is the name of the table in Table B.4?","977":"What is another name for acid amplification tests?","2999":"How long after completion of a primary series is the Novavasx monovalent booster dose given?","1270":"What is the recommended interval after the first dose?","6314":"What is the name of the virus that causes COVID-19?","2254":"Care facilities and group homes are also considered what?","6984":"What is the Countermeasures Injury Compensation Program?","3218":"What is an example of a vaccine that can cause syncope?","6610":"What type of transplant includes bone marrow?","3943":"How many pages is the COVID-19 Response Health Equity Strategy?","3721":"How old were the people who received the Janssen COVID-19 vaccine?","6345":"What does everyone like to be seen on time?","2213":"When was the Drugs and Lactation Database published?","8928":"What is critical to protect both healthcare personnel and their medical fragile patients?","3138":"What is not required for monovalent booster doses received prior to or during treatment?","1388":"How long has it been since the child has completed their primary series?","3343":"What was considered unrelated to vaccination with Moderna, Novavax, or Pfizer-BioNTech?","8885":"What type of messengers can you work with to tailor and share culturally relevant messages and materials with diverse communities?","9562":"What color is the label border of the product authorized for children ages 5-11?","1788":"What is the name of the CDC's vaccines for children and teens?","5918":"At least how long after treatment?"},"answer_text":{"674":"3,945","6842":"Office of the Inspector General, U.S. Department of Health and Human Services","4917":"a precaution","5394":"Visit CDC","9227":"00:01:32","8418":"Preparation requirements Storage and handling requirements","656":"20,754","9903":"Geneva","3203":"at or near the site of filler injection","9994":"non-COVID-19 vaccine or therapy has multiple components","4890":"hives) beyond the injection site","6855":"an EUA","148":"public health officials","7371":"The Presidential Proclamation and CDC\u2019s Amended Order","1183":"12 years or older, 18 years or older, and 65 years or older","7177":"coronavirus","6727":"Pfizer-BioNTech COVID-19 Vaccine authorized for use in individuals 6 months through 4 years of age, may receive the Pfizer-BioNTech COVID-19","1133":"COVID Data Tracker","1916":"health information","7490":"A booster dose","9947":"everyone 6 months of age and older","9726":"higher vaccine effectiveness (VE) against infection, symptomatic disease, and intensive care unit admission","9081":"properly wearing a high- quality mask or respirator","9749":"antibody response","6308":"Preparing for an appointment","420":"331,640","5759":"about 6 months","2171":"71:26\u2013","8891":"Make sure you are aware","6513":"81%","1409":"1 or 2","777":"The spike protein","5636":"international standards","9948":"COVID-19 vaccination","4203":"COVID-19","6790":"Myocarditis","9589":"persons ages 12 years and older who received primary or booster vaccination with certain non-FDA authorized or approved COVID-19 vaccines2. \u2022 An additional dose in persons ages 18 years and older with certain immunocompromising conditions who received primary vaccination","1505":"National Institute for Occupational Safety and Health","2363":"common variable immunodeficiency disease","1604":"Moderna COVID-19 Vaccine Fact Sheet","2743":"similar accommodations","1099":"you take multiple prevention measures","1553":"persons ages 18 years and older","3177":"People who received Janssen COVID-19 Vaccine","9166":"By letting your close contacts know they may have been exposed to COVID-19","3412":"positive test result","1161":"demographic groups","1140":"Vaccine Distribution Data Systems","2664":"Caregivers and anyone who has been in close contact with someone who has COVID-19","6271":"your arm","7714":"Many","6197":"reviewing data and medical records and evaluating the relationship to COVID-19 vaccination","7397":"or their spouses or children (under 18 years of age)","4255":"CDC Espa\u00f1ol | Other Languages Getting Your COVID-19 Vaccine Everyone 6 Months and Older","6419":"Properly fitting respirators","749":"14,187","9651":"28","7115":"Call your healthcare professional","4474":"a high-quality mask","7883":"Consumers have questions","9121":"masks","1392":"People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine and have not received any previous booster dose(s) (including any previous mRNA monovalent or bivalent booster dose[s]) may receive a monovalent Novavax booster dose","2933":"2 months","5705":"Emergency Use Instructions","2037":"2021","4726":"Age-appropriate","6891":"SARS-CoV-2","8178":"COVID-19","6351":"starting with the most important ones. Don\u2019t hesitate to ask your healthcare provider to clarify the answers","9831":"primary, additional, and\/or booster","8067":"updated reporting and laboratory guidance","5650":"- \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022","5908":"28","6965":"an additional primary or second booster dose","2227":"COVID-19","8502":"Maintaining distance between yourself and others","8232":"4 weeks","6464":"people who are more likely to get very sick","3546":"CDC","6275":"mRNA and viral vector vaccines","4596":"blowing air outside. Even without an open window, fans can improve air flow","9857":"JCVI","5221":"Healthcare professionals","5685":"regular cloth or disposable mask","4061":"COVID-19 boosters","5435":"COVID-19 illness","74":"4 hours","7760":"Moderna","449":"New Hampshire and CDC collaboratively correcting data transmission errors","4281":"Biologics or biologic response modifiers","3551":"99.9%.","10057":"www.novavaxcovidvaccine.com","3641":"COVID-19 County Check","6949":"Pfizer-BioNTech","368":"November 5, 2021","4658":"additional","9178":"\u2022 \u2022 \u2022 \u2022 \u2022","969":"an inaccurate result","9148":"illness and can recover at home without medical care. Do not leave your home, except to get medical care","5272":"negative test results do not rule out SARS-CoV-2 infection","4080":"COVID-19 Booster Tool","7388":"Noncitizens, Nonimmigrants (Covered Individuals) Noncitizens","4908":"Healthcare professionals and health departments","658":"New Jersey","1284":"COVID-19","8091":"pimples or blisters","3308":"18\u201339 years","6775":"3,100","5001":"history of myocarditis or pericarditis","3341":"COVID-19 Vaccine","4420":"COVID-19","5547":"Masks and respirators","5506":"staying up to date with vaccines against COVID-19 can help prevent COVID-19 infection and protect against severe illness","4791":"Vaccine Administration\u201d chapter of Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book).","6931":"Tell your vaccination provider the name, number of doses, and date(s)","4207":"COVID-19","1833":"COVID-19 vaccine effectiveness","2001":"COVID-19 vaccines","9435":"General","7064":"People with COVID-19","1206":"Timely and accurate reporting from jurisdictions","933":"breast milk","4144":"decades","7668":"CDC COVID Data Tracker","7076":"in areas with a high COVID-19 Community Level","5215":"spread the virus to others","1177":"Texas","2321":"CDC","5842":"HCT","8888":"you can protect patients who are at high risk, disproportionately affected by COVID-19, or might suffer severe consequences if infected","2332":"2 months","5927":"January 31, 2022","1216":"early November 2022","995":"pharmacies, and retail stores","6520":"COVID-19","7188":"Monovalent","2165":"Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons","1629":"limited supplies of vaccine","6948":"non-FDA authorized or approved COVID- 19 vaccine or Janssen COVID-19 Vaccine. What are the risks of the COVID-19 vaccine by Pfizer-BioNTech","6185":"the heart muscle","8566":"COVID-19","2256":"help protect yourself and the people around you by getting a COVID-19 vaccine","6673":"Flu","7565":"the full series of an active (non-placebo) qualifying COVID-19 vaccine candidate","421":"6,449","6355":"medications and supplements","6382":"share any test results","3211":"pericarditis","1288":"simultaneous administration of COVID-19 vaccine and other vaccines. However, there are additional considerations for Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines if administering an orthopoxvirus (monkeypox) vaccine","850":"\u2022 \u2022 \u2022 \u2022 \u2022","5235":"high-quality mask","7750":"GBS","6911":"Pfizer-BioNTech","5550":"well-fitting","465":"May 13, 2021","9953":"persons 18 years of age and older","5180":"Vaccine Adverse Event Reporting System","6653":"non-perishable","3875":"Healthcare providers","4437":"Improving ventilation and filtration","3024":"The COVID-19 vaccination schedule","1662":"April 5, 2022","6613":"cerebrovascular disease","225":"viral test","3425":"Staying up to date with COVID-19 vaccinations","8980":"Participants","5817":"Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine","8386":"all healthcare staff members need training in COVID-19 vaccination even if they are already administering routinely recommended vaccines. While many practices are the same for all vaccines, whenever a new vaccine is introduced to the U.S. market, there are nuances that healthcare professionals must become familiar with to ensure the vaccine is stored, handled, prepared, and administered correctly","6251":"VAERS reports","9209":"at least several hours","6546":"newborns","4888":"a progressive life-threatening reaction","1077":"Molnupiravir","7537":"10\/30\/22, 9:43 AM Requirement for Proof of COVID-19 Vaccination for Air Passengers | CDC","4391":"Ask your doctor, pharmacist, or community health center, or visit their website","8622":"viral vectors","8937":"Vaccine safety experts","1690":"vaccine administration data","4876":"anaphylaxis","2353":"Hematologic malignancies associated with poor responses to COVID-19 vaccines","3330":"cardiac sequelae","7933":"COVID-19 vaccines","3872":"Requirements and Support","5404":"Office of the Inspector General","3230":"aspirin is not recommended for use in children and adolescents ages 17 years and younger","5832":"prevention of COVID-19 in individuals ages 18 years and older","1663":"lack of supplemental funding","3724":"chimeric antigen receptor","433":"258,130,580 to 258,259,833","353":"189 counties","2863":"None of the currently FDA-approved or FDA-authorized COVID-19 vaccines are live-virus vaccines","7723":"Adverse events","5338":"There is a remote chance that the Janssen COVID-19 Vaccine could cause a severe allergic reaction","4887":"four hours","4120":"Parents and caregivers","7432":"the personal identifiers on the passenger\u2019s passport or other travel documents","7454":"you meet the requirements under the Presidential Proclamation and CDC\u2019s Amended Order","4103":"program requirements","8443":"Non-U.S. Citizen, Non-U.S. Immigrants","584":"37,096 administered doses. August 11, 2022: California made updates to data previously submitted to CDC that resulted in a net increase of 202,640","3838":"Providers","7272":"COMIRNATY (COVID-19 Vaccine, mRNA), the Pfizer-BioNTech COVID-19 Vaccine, or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent","4984":"4 months","4260":"If you recently had COVID-19","216":"threshold of protection","8498":"once you have ended isolation","8838":"Sign up during","5984":"0.25 mL [50 \u03bcg","7678":"affect the ability to do daily activities","4150":"Food and Drug Administration","9213":"Disinfectants for Coronavirus","8026":"support their friends and family to get the COVID-19 vaccines","5549":"consistently","7256":"asks questions","5317":"platelets","432":"+3,329,068","3464":"FAQs","9060":"Variants of High Consequence \u2013 Clear evidence of significant impact on spread and severity, and reduction of effectiveness of testing, treatment, and vaccination","10108":"people with a history of an episode of immune-mediated syndrome characterized by thrombosis and thrombocytopenia, such as spontaneous or classic HIT","8573":"COVID-19 vaccines help our bodies develop immunity to the virus that causes COVID-19","7736":"4","309":"when available","9402":"messenger ribonucleic acid (mRNA), lipids (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate trihydrate, and sucrose","9":"a little sick","5023":"Considerations","4471":"5 days","4680":"18\u201359 years","8045":"vaccines","305":"this increase","3514":"cruising","6455":"check if a Test to Treat location is in your community","1944":"Experts","7716":"severe","622":"California","2732":"there are ways to help relieve some of the additional burdens of experiencing or caring for someone with a new and unknown condition. If you care for someone, remember to take steps to protect yourself and others from COVID-19","9405":"SPIKEVAX (COVID-19 Vaccine, mRNA), Moderna COVID-19 Vaccine, or Moderna COVID- 19 Vaccine, Bivalent will be given to you or your child as an injection into the muscle","6517":"the number of underlying medical conditions they have increases","3890":"text messaging and web surveys","9499":"EMERGENCY USE AUTHORIZATION","7889":"Encourage local health departments, public health experts, and healthcare workers","1057":"treatments are available that can reduce your chances of being hospitalized or dying from the disease","8887":"COVID-19 vaccines","3342":"Appendix A","2556":"4 weeks","7612":"under 18 years of age","3":"ask a healthcare provider (or facility staff) if you can have medicine","3395":"COVID-19 vaccination","2707":"when","10133":"mRNA COVID-19 vaccine","6535":"Rare","2286":"vaccines.gov","1987":"COVID-19","2658":"6","4229":"access to a QR code or digital copy of your CDC COVID-19 Vaccination card","5679":"Choose a size","1894":"Some people who are vaccinated against COVID-19 will still get sick and have a vaccine breakthrough infection","1516":"Providers","9885":"Extended interval BNT162b2 vaccination","5415":"FDA-approved or cleared product","20":"boosters","3704":"August 2021","8684":"COVID-19 plan","3421":"A conversation between the patient and\/or their guardian(s) and their clinical team or a specialist","5256":"day 10","8564":"Being outside would be lower exposure risk than being indoors, even with good ventilation and filtration; both of those options would be lower risk than being indoors with poor ventilation or filtration","5093":"People with a reaction to a vaccine or injectable therapy that contains multiple components","6316":"a healthcare provider","2346":"Children 5 years of age who received a Moderna primary series are up to date","591":"91,864","4071":"You are up to date","805":"after mild or severe COVID-19","1771":"if and when your child or teen can get boosters to stay up to date with their COVID-19 vaccines","7208":"Pfizer-BioNTech COVID-19 Vaccine","6479":"2","4223":"contact your vaccination provider directly to request a new vaccination card","1266":"Moderna and Pfizer-BioNTech","5835":"3 months","5104":"Get up to date with your COVID-19 vaccines before you travel","6833":"vaccination provider","5129":"around others indoors for the full duration of your trip","809":"Immunity (protection) from infection can vary depending on how mild or severe someone\u2019s illness was and their age","4861":"age 11 years to 12 years","8901":"age and health status","2635":"a few days","4005":"vaccination data shown on a state\u2019s website","5304":"COVID-19 vaccines","2660":"Improving ventilation","4480":"reduce your risk of catching the virus from them","1405":"2","8918":"dialysis healthcare personnel","5595":"Gaps","6703":"EPA","1783":"1 in 6","1105":"products approved or prescribed for other uses","10125":"Persons","4736":"as close to the recommended time as possible","6536":"many conditions","6892":"Coronavirus disease 2019","4170":"CDC\u2019s smartphone-based system that provides personalized health check-ins after vaccination","8481":"Travel","6956":"rarely","7012":"mild to moderate","9918":"monovalent and bivalent","7724":"Anaphylaxis","7844":"those cases to public health","9198":"Wash your hands often with soap and water","7811":"your local health department","8382":"all healthcare staff members","2442":"Fever","6519":"racial and ethnic minority groups and people with disabilities","7212":"COMIRNATY","8164":"monovalent","1847":"Duluth, MN","9224":"10\/30\/22, 9:41 AM What to Do If You Are Sick","6804":"FDA\/CDC Vaccine Adverse Event Reporting System (VAERS).","2485":"CDC","6750":"Emergency Use Authorization","6555":"underlying medical conditions, living in congregate settings, or systemic health and social inequities","5577":"fitting closely on the face","2570":"8 weeks","1066":"A healthcare provider","5026":"Updated Appendix D","2320":"COVID-19","1387":"1 bivalent booster dose when they turn age 5 years","7552":"a letter from a licensed physician","5021":"history of myocarditis or pericarditis","1086":"other types of treatments","8452":"my mask","5413":"Health and Human Services","6648":"Fear and anxiety","7680":"affect the ability to do daily activities","2669":"gloves and hot water: Handle any dishes, cups\/glasses, or silverware used by the person who is sick with gloves","4534":"better than a cloth","8073":"Encourage primary care providers and other medical professionals who care for children to explain the benefits of COVID-19 vaccination to parents and guardians","8261":"COVID-19","9891":"Advisory Committee on Immunization Practices","8767":"a clear mask","5849":"Full Emergency Use Authorization","585":"37,096 administered doses. August 11, 2022: California made updates to data previously submitted to CDC that resulted in a net increase of 202,640","6359":"go to the lab","2307":"CDC","9359":"two","4351":"vaccine record","9674":"0.3 mL doses","9944":"regardless of whether the SARS- CoV-2 infection occurred before the recipient received an initial dose or between doses","3450":"October 27, 2022","3290":"The impact","9301":"Decreased","5330":"Janssen COVID-19 Vaccine","998":"SARS-CoV-2 infection","6958":"Pfizer-BioNTech","1851":"Seattle, WA","8755":"N95s","9799":"available supporting evidence","5781":"COVID-19","5178":"TSA","9766":"334","7505":"regardless of how long","884":"a mask","9564":"3-8 weeks","2695":"eyes, nose, and mouth","447":"a decrease in doses administered","6416":"taking multiple prevention steps","5389":"Janssen COVID-19 Vaccine","3460":"If your cruise line does not have a testing requirement, get tested for current infection","4218":"wait","5969":"100","4812":"incorrect product","3864":"answer undefined","6411":"when you have received all doses in the primary series and all boosters recommended for you, when eligible","10008":"Persons who have a history of myocarditis or pericarditis unrelated to mRNA (Moderna, Pfizer-Bio- NTech) or Novavax COVID-19 vaccination","2774":"isolated","9156":"Do not travel","3496":"Masks","1204":"Apr. 8, 2022","3442":"COVID-19 Vaccine, mRNA","1802":"LTC","49":"J&J\/Janssen COVID-19 vaccine","9356":"individuals 6 years through 11 years of age; or (2) Moderna COVID-19 Vaccine authorized for use in individuals 12 years of age and older","9978":"\u0083","8389":"training programs","1477":"mRNA (i.e., Moderna or Pfizer- BioNTech) and Novavax COVID-19","2539":"3 weeks","7264":"vaccines","9875":"two","3397":"the risk of severe COVID-19 due to age or certain medical conditions","3126":"wherever vaccines are offered","7536":"Certain categories of persons traveling to the United States","210":"When someone who is fully vaccinated gets COVID-19","5690":"2021","6037":"3 months","5069":"The Advisory Committee on Immunization Practices","9219":"Improve ventilation (air flow)","5133":"Traveling by private vehicle","7270":"COVID-19 Vaccine, mRNA","5500":"where they live or work","3406":"current or prior SARS-CoV-2 infection","7872":"OraSure Technologies","7749":"21 times higher","4235":"additional precautions","4552":"Improving ventilation","6957":"first week","4438":"indoors","7227":"COVID-19 Vaccine","8496":"follow local guidance","7717":"5 years and older","3647":"Do NOT travel","10141":"Persons with a history of heparin- induced thrombocytopenia (HIT) \u0083 Persons with a history of an episode of an immune-mediated syndrome","8842":"V-safe is not an official record of being vaccinated against COVID-19 V-safe does not give medical advice V-safe cannot schedule COVID-19 vaccination appointments","9833":"vaccination provider","7625":"COVID-19","7449":"U.S. citizens, U.S. nationals, U.S. lawful permanent residents, and immigrants, are not Covered Individuals","5359":"Guillain Barr\u00e9 syndrome","9557":"orange cap and label border) Child turns 12 0.30 mL (30 mcg) of the product authorized for children ages 12\u201317 years (gray","800":"severe illness or death","1125":"aims to reduce disparities in disproportionately affected communities by supporting a wide variety of partners","6510":"immunocompromised, or people with weakened immune systems","8854":"Your personal information","4236":"a mask","1664":"lack of supplemental funding","10043":"10 \u00b5g 0.2 mL","3448":"Recommendations for the Management of Axillary Adenopathy","5854":"Spikevax","2413":"more than 1,000","9702":"Pfizer-BioNTech","332":"data review and reporting adjustments","4424":"vaccinated people","1546":"2 months","2265":"Staying up to date\u202fmeans getting all recommended COVID-19 vaccines including boosters when eligible. If your loved one is not able to ask questions or otherwise communicate with the LTC staff, here\u2019s what to know about consent for getting a COVID-19 vaccine: Residents and their families can ask a LTC provider about the current COVID-19 vaccination rate","8973":"v-safe after vaccination health check-ins","333":"12,298","6565":"a condition","6430":"Search vaccines.gov","2715":"fever, cough, and shortness of breath","4085":"2","9697":"text messaging and web surveys","9299":"MIS-C","4048":"children of certain ages and all adults","2032":"November 3\u2013December 19, 2021","1525":"U.S. Department of Health and Human Services","5173":"CDC\u2019s January 29, 2021 Order requiring masks","3396":"clinical recovery","7307":"Pfizer Inc","3806":"Strong vaccine confidence","10129":"Appendix A","7779":"Reports of death","9133":"8.5 W x 11 H","2471":"SARS-CoV-2 spike protein seropositivity","2672":"the person who is sick","3698":"Spikevax","2054":"If you are pregnant or were recently pregnant","7634":"home tests or at-home tests","7340":"COVID-19","6562":"HIV","4869":"if the interval is not sooner than the minimal interval noted in this table","6189":"Chest pain Shortness of breath Feelings of having a fast-beating, fluttering, or pounding heart","2674":"If you are sick and need to be around others","8936":"congenital anomalies","8344":"conversations","9003":"The analyses","4985":"18\u201349 years","5088":"Interim Clinical Considerations","4169":"babies younger than 6 months old","7602":"less than 10%","806":"Cough Muscle and joint pain Headache Trouble falling or staying asleep Trouble concentrating Limitations in physical activity Feeling distressed about symptoms Mental health challenges Decreased school or daycare attendance Missed opportunities for participation in sports, playdates, or other activities \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022","7052":"If you are pregnant or were recently pregnant","2703":"several options","8929":"August 24, 2021","6900":"second dose","6966":"COVID-19","8556":"N95","2747":"different","2360":"either complete or restart the recommended COVID-19 vaccine series, including a booster, in the United States","7846":"self-tests","5057":"12\u201315 years","6433":"COVID-19","6655":"asthma triggers","1832":"vaccine efficacy","8168":"Two","9623":"COVID-19","6474":"the virus that causes COVID-19","9451":"SPIKEVAX","5265":"your mask","8910":"whether they have COVID-19 or not","2082":"vaccination of pregnant people with a COVID-19 vaccine prior to and during the first trimester was not associated with an increased risk of birth defects detectable on prenatal ultrasound","8243":"CDC","4627":"1,000 square feet","587":"a decrease in overall US figures","7514":"Yes, different formulations of COVID-19 vaccines authorized for emergency use or approved by the U.S. Food and Drug Administration\u202for listed for emergency use by WHO are accepted","2826":"7","3371":"vaccination following SARS-CoV-2 infection further increases protection from subsequent infection and hospitalization","9170":"Your local health authorities","4327":"how you\u2019re feeling","605":"14,201","6498":"Contact a healthcare provider","9672":"Tris) buffer","3319":"pericarditis","8222":"Johnson & Johnson's Janssen","6086":"mRNA","616":"California","6380":"over-the-counter drugs","8359":"Ask them to express their vaccination benefits out loud","9031":"data","7294":"EMERGENCY USE AUTHORIZATION","3147":"COVID-19 vaccines","9913":"severe allergic reactions","114":"during close contact","414":"258,590 and 465,704","8953":"to protect privacy and confidentiality they do not include information that could identify the person","3789":"CDC","6318":"372","8995":"Food and Drug Administration","1760":"the jurisdiction\u2019s IIS","6402":"chimeric antigen receptor","9053":"an increase in the total number of cases","6716":"Coronavirus Disease 2019","1494":"CDC COVID-19 Vaccination Program","1619":"COVID-19 Vaccination Cards","8217":"Moderna Vaccine Overview","5538":"clinical guidance and other educational materials","6393":"Information on this page","4490":"Respirators","7796":"If\u2026 Timing","4478":"within a few days","5098":"\u22654 weeks","962":"Follow test directions","6932":"Tell your vaccination provider the name, number of doses, and date(s)","1713":"COVID-19 vaccine and diluent","9471":"Your close contacts","5640":"varying levels of particles in the air","6372":"Work with Your Healthcare Provider","5326":"A single booster dose","134":"wild mink","7180":"virus","4981":"4","6155":"more than 70%","6132":"SAGE","1426":"Administration of EVUSHELD\u2122","9724":"Thai HCWs who received a 2-dose primary series of Sinovac (CoronaVac) COVID-19 vaccine demonstrated booster antibody responses following either AstraZeneca or Pfizer-BioNTech COVID-19 vaccines, including against the Delta variant (Patamatamkul","3871":"safety reporting requirements","3675":"April 18, 2022","1096":"two","86":"COVID-19","9174":"COVID-19","3485":"get tested for current infection with a viral test (no more than 3 days) before boarding a cruise ship, regardless of your vaccination status. Get your test results","9904":"JAMA. 2021 Dec","3994":"reconcile doses administered that are reported through more than one system","10052":"COVID-19","5804":"COVID-19 vaccine by Moderna 4\u20138 weeks after the first dose may reduce the risk of myocarditis and result in greater immune response and better protection against COVID-19. Primary, additional, and\/or booster doses of the COVID-19","9782":"extended mRNA vaccine primary series dosing","7238":"Chest pain","3532":"personally identifiable information","9196":"soap and water","6459":"10 and up to 20","2961":"2 months","9349":"two-dose series for prevention of COVID-19 in individuals 18 years of age and older","1433":"SARS-CoV-2 antibody tests","8675":"vaccines","3650":"my mask","7707":"Everyone who receives a COVID-19 vaccine can also participate in safety monitoring by enrolling themselves -or their children or dependents 6 months and older","6072":"vaccination provider","3231":"Antibody testing","468":"Texas residents of Texas","4856":"delaying the second dose for 8 weeks","182":"Ferret","7387":"Noncitizens","9228":"Your COVID-19 Symptoms at Home File Details: 484 KB, 1 page View PDF in English Other Languages \uf20c \uf20c","2293":"continue to take precautions","8124":"the difference in the structure of the virus particles","1782":"Challenges","6159":"COVID-19 hospitalizations","2027":"live virus","8356":"to help the patient become more open to moving toward higher numbers","1397":"Vaccinators and clinic administrators","9445":"SPIKEVAX","4612":"masks","6330":"Bringing your list with you","4205":"People who already had COVID-19 and do not get vaccinated after their recovery are more likely to get COVID-19 again than those who get vaccinated after their recovery","1643":"promote public health, advance positive patient outcomes, and promote health equity","604":"July 7, 2022","911":"60%","2575":"28 days","8783":"paper bag","3597":"people","4692":"Shortness of breath Chest pain Leg swelling Persistent abdominal pain Severe or persistent headaches or blurred vision Easy bruising or tiny blood spots under the skin beyond the site of the injection","8110":"between 4\u201314 days","8551":"exertion","10109":"People who develop GBS","8088":"on or near the genitals","1656":"CDC","9378":"COVID-19 is caused by a coronavirus","6547":"Chronic obstructive pulmonary disease","4193":"staying up to date with your COVID-19 vaccinations","920":"24 hours","8364":"respond within the boundaries of your competence, ethics, and scope of practice","3365":"be evaluated for SARS-CoV-2 infection","27":"COVID-19 vaccines","2830":"myocarditis and pericarditis","76":"COVID-19 vaccine. This vaccination should only be done in a health clinic, medical facility, or doctor\u2019s office. CDC Is Monitoring Reports of Severe Allergic Reactions If someone has a severe allergic reaction after getting vaccinated, their vaccination provider will send a report to the Vaccine Adverse Event Reporting System","2322":"2 months","6813":"Should you decide for your child not to receive any of these vaccines, it will not change your child\u2019s standard medical care","7709":"VAERS","9342":"Emergency Use Authorization","4764":"WHO","3031":"A 3-dose primary series","2365":"less than 200\/mm3","8343":"to understand, not to change their mind","3621":"Find out when you can get your booster and where to get a vaccine or booster","3476":"Self-monitor for COVID-19 symptoms","878":"5 days","6286":"COVID-19","3738":"COVID-19","3920":"severe heart disease","9022":"COVID 19 and Pregnancy","3262":"COVID-19 vaccine safety question","5922":"COVID-19","9717":"9\/02\/2022","8118":"COVID-19 vaccines weaken the body\u2019s immune system","7202":"2","6988":"a claim","382":"65 years","9514":"vaccine product and dosage","7461":"one","4252":"Vaccine Administration Management System","8778":"by hand or use a washer and dryer","3320":"Novavax COVID-19","1152":"DoD","6482":"COVID-19 plan","95":"Coronaviruses","9679":"Severe allergic reactions","8736":"non-essential indoor activities","5292":"individuals 18 years of age and older","6442":"TM TM TM TM TM TM","2358":"COVID-19 and your medical condition","3358":"vaccine","1768":"COVID-19 vaccination","6553":"dementia","4292":"you can support them and talk to them about what to expect","7605":"CDC","3050":"2 months after completion of the primary series","9332":"medications and supplements","9599":"Full Emergency Use Authorization","4280":"NSAIDs","9016":"patients, parents or caregivers, healthcare providers, and vaccine manufacturers","6704":"community","1616":"agents on behalf of CDC","2918":"an additional dose","8658":"how many people get sick","2233":"COVID-19 vaccines are working well","8020":"COVID-19 vaccines","2621":"Antibody","6055":"COVID-19","9794":"less robust","264":"69,965","2060":"if you are pregnant","1168":"Surgo Ventures","4611":"6","528":"February 28, 2021","2389":"third primary dose","1222":"229","6732":"COMIRNATY","8186":"delaying your next vaccine dose","1872":"UCSF","4763":"1 bivalent mRNA booster dose","1029":"Take general public health precautions","2150":"different side effects","8100":"If you have symptoms","8163":"they protect against both the original virus that causes COVID- 19 and the Omicron variant BA.4 and BA.5","2549":"symptom onset or positive test","2501":"vaccination","7798":"Immediately before the gathering, or as close to the time of the event as possible","5787":"COVID-19 vaccine or Janssen COVID-19 Vaccine","9190":"\uf277","255":"Antibody quiz","7433":"public health agency, government agency, or other authorized vaccine provider","673":"14,973","2831":"prevention of COVID-19 cases and its severe outcomes","9581":"16 years","4982":"4 months","6489":"work, childcare, and other responsibilities that may cause stress if you were to become sick. COVID-19 remains a major health concern and this can be stressful to manage. Understanding what you can do to protect yourself and what to do if you get sick can help minimize that stress. Take as many steps as you can to prevent COVID-19 and get treated quickly if you test positive for COVID-19","6893":"no symptoms to severe illness leading to death","9760":"an interval longer than 3 weeks between primary series doses","9972":"allergic","6278":"instructions","9662":"Revaccination with the COVID-19 vaccine by Pfizer-BioNTech for any primary doses received before or during treatment with certain therapies","8782":"the mask","3607":"The rate per 100,000 people is calculated for the total population and select demographic groups (such as people ages 65 years or older) using population data","2330":"Novavax","7288":"an out-of-pocket vaccine administration fee","2343":"Pfizer-BioNTech booster at least 2 months after their 3rd dose. (Children 6 months to 4 years are not recommended for a booster","8714":"Wearing a high-quality mask","6571":"medicines that weaken their immune system may not be protected even if they are up to date on their vaccines","3301":"myocarditis","9937":"Do not withhold vaccination if a person is taking antibiotics","3754":"ages 18 years and older","3372":"People with known current SARS-CoV-2 infection","4282":"before you get vaccinated","2500":"vaccination","7166":"individuals 12 years of age and older","9550":"2","8726":"COVID-19 Community Levels","5125":"see specific testing recommendations","7982":"77.9%","2393":"The people you live or spend time with","4058":"COVID-19 vaccines are working well to prevent severe illness, hospitalization, and death","8046":"vaccination against COVID-19 in children","7148":"COMIRNATY","6662":"hospitalized","84":"at least several hours","5176":"Safety and security information by country","8290":"Symptoms","5493":"long COVID","5258":"11","6065":"improving protection conferred by COVID-19 booster doses","18":"side effects","7521":"translation","7579":"English","10077":"orthopoxvirus","9916":"Orthopoxvirus","851":"low","8442":"Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233","3747":"increased concern about community transmission or risk of severe disease","6304":"viral tests","2764":"Try to eat healthy, well-balanced meals.","1179":"COVID-19","689":"Colorado made updates to data previously submitted to CDC","4831":"Tixagevimab\/cilgavimab","154":"Many studies","3377":"vaccination","2950":"2 months","298":"152,195","5659":"not all fit the same","6181":"variants","2368":"TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory","4256":"you should still get yourself or your child vaccinated","832":"substantially higher","3726":"clinical judgment","9344":"interchangeably, when used according to their respective instructions for use","6814":"bivalent vaccines","9909":"syncope and allergic reactions","6346":"the same attention","7980":"77.9%","929":"early symptoms of COVID-19 or another illness","1052":"very sick","8847":"family member, friend, or individual who relies on you for support) who is vaccinated in v-safe. Children under age 16 years must be added to a parent or guardian","6097":"Severe Acute Respiratory Syndrome Coronavirus 2","7120":"Seek medical care immediately if you experience any urgent maternal warning signs and symptoms","4436":"filtration","7191":"Emergency Use Authorization","9186":"cover your coughs and sneezes in some other way","8523":"CDC","7147":"Oct. 25, 2022","8095":"rash","7317":"to inform public health action","768":"SARS-CoV-2","2761":"Take breaks from watching, reading, or listening to news stories","3169":"A mixed primary series","8125":"Create and disseminate graphics","9507":"the totality of the scientific evidence available","8650":"vaccines against coronaviruses","1230":"Non- Hispanic Asian, Non- Hispanic Black, Non- Hispanic Hispanic \/ Latino Multiracial, Non- Hispanic NHOPI, Non- Hispanic White, Non- Hispanic Male Female \u2022 \u2022 \u2022 \uf2ff For Healthcare and Public Health COVIDVaxView: Data about Vaccination Uptake and Confidence COVID 19 Information for Health Departments\f10\/30\/22, 9:34 AM COVID-19 Vaccination Data in the United States | CDC COVID-19 Information for Health Departments Last Updated Oct. 28, 2022","2545":"28","4503":"Oct. 19, 2022","842":"COVID-19 vaccines","4919":"vaccinated","4696":"a conversation between the patient and their clinical team","8293":"Fever or chills","4141":"The smaller doses were rigorously tested and found to create the needed immune response","1200":"data submitted by New Hampshire","9565":"COVID-19 vaccine from the same manufacturer","10110":"Novavax ad Janssen COVID-19","4409":"\u2022 \u2022 Resources Related Pages Safety of COVID-19 Vaccines \u203a Stay Up to Date with Your Vaccines","2421":"more than 2,000","2895":"three","8096":"flu-like symptoms","3781":"Food and Drug Administration","2767":"Get plenty of sleep","4854":"Do not administer the second dose until the person becomes eligible to receive vaccination","667":"New Jersey","9173":"seek emergency medical care immediately","2372":"three","10114":"MIS-C and MIS-A","8683":"informed decisions","5263":"travel guidance","5895":"4\u20138 weeks","5111":"COVID-19","9570":"3","5864":"U.S. data and safety monitoring board or equivalent","3346":"age, underlying conditions","4191":"staying up to date with your COVID-19 vaccinations","6631":"those conditions carefully and safely","7133":"January 22\u2013October 3, 2020","5312":"FDA","3219":"Procedures","5772":"Tell your vaccination provider the name, number of doses, and date(s)","1716":"Vaccine Adverse Event Reporting System","2129":"COVID-19","9294":"CDC","2892":"6 months","4469":"10 days","9576":"EUI","4146":"COVID-19","2063":"death","8673":"v-safe","4633":"premium\u201d filter","9275":"Get very sick","3693":"certain people who were vaccinated outside of the United States","8824":"logos and marks","8017":"between 1 and 12 percent","328":"updates to how pharmacies report data to CDC and\/or the jurisdictions","8361":"feels hesitant","2384":"two","6946":"at least 1","9624":"fever or chills, cough, shortness of breath, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea","7800":"older adults","7159":"for prevention of COVID-19","9711":"AstraZeneca COVID-19 vaccine","9960":"health condition or undergoing treatment that makes them moderately or severely","1137":"decision-making","2758":"which types of medications or treatments","9652":"28 days","785":"variants","1928":"COVID-19 vaccines","8378":"Experienced vaccinators","2475":"COVID-19 vaccination","5642":"Do NOT wear international respirators","9212":"COVID-19","7224":"COMIRNATY","9824":"BA.4\/BA.5","9615":"CDC","5982":"0.25 mL","5189":"myocarditis","1679":"public health guidance for the safe use of vaccines and related biological products","7659":"get a test","4822":"temperature excursion","9669":"either as Comirnaty or Pfizer- BioNTech COVID-19 Vaccine","409":"vaccine recipients","7111":"whooping cough","3912":"EVUSHELD\u2122","577":"82,375","554":"delete a record","4545":"treatment may be available. Contact a healthcare provider right away after a positive test to determine if you are eligible, even if your symptoms are mild right now. You can also visit a Test to Treat","6087":"1273","9648":"30 \u03bcg in 0.3 mL","6652":"canned goods","218":"threshold of protection","1325":"The same vaccine is not available","5460":"General symptoms","9993":"A history of anaphylaxis","8859":"Search vaccines.gov","6778":"1","5686":"CDC guidance","9556":"0.20 mL","1292":"People who previously received COVID-19 vaccination (i.e. Moderna, Novavax, or Pfizer-BioNTech) may be given orthopoxvirus vaccine (either JYNNEOS or ACAM2000) without a minimum interval between vaccinations. People who previously received orthopoxvirus vaccination (either JYNNEOS or ACAM2000), particularly adolescent or young adult males","6788":"inflammation of the heart muscle","1091":"everyone who is eligible","5108":"COVID-19 vaccines","8003":"CDC\u2019s infection prevention and control recommendations for healthcare workers","2817":"Younger children who have myocarditis or pericarditis","2012":"April 2022","7807":"Private health insurance","7420":"make sure your vaccine and proof of vaccination","7764":"12\u201315 years","3351":"myocarditis or pericarditis unrelated to vaccination with Moderna, Novavax, or Pfizer-BioNTech (e.g., due to SARS-CoV-2 or other viruses","4232":"a vaccination provider","5880":"COVID-19","3658":"public","6112":"two","3679":"answers to frequently asked questions about Emergency Use Instructions (EUI). Refer to EUI for Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine","935":"everyone who is eligible","7143":"16","683":"2,761","3584":"if it has been at least 5 months since their completed Pfizer-BioNTech or Moderna primary series or at least 2 months since their completed J&J\/Janssen single-dose vaccine","8376":"Training","8458":"5","6131":"WHO","2154":"COVID-19 Vaccine","2073":"people who are pregnant or their babies","1403":"2 monovalent mRNA booster doses","4307":"food, pet, venom, environmental, or latex allergies","3618":"Aug. 17, 2022","303":"April 21, 2022","397":"a short network outage","3575":"People Receiving at Least One Dose","9470":"Individuals 6 years of age and older","3973":"Vaccine delivery to provider locations","3232":"vaccination with the primary series or a booster dose","7903":"the official position of the Centers for Disease Control and Prevention","41":"generalized rash or hives","3527":"the number of people who are fully vaccinated","7962":"COVID-19","10031":"Viral testing","5284":"SARS-CoV-2","1931":"Birth Defects Study to Evaluate Pregnancy Exposures","6700":"6","251":"boosters","6521":"COVID-19","3531":"personally identifiable information","1597":"CDC Vaccine Information Statement","9704":"third","6453":"Don\u2019t delay! Treatment must be started soon after you first develop symptoms to be effective. If you don\u2019t have timely access to a healthcare provider, check if a Test to Treat location is in your community. You can get tested, receive a prescription from a healthcare provider (either onsite or by telehealth), and have it filled all at one location","9083":"crowded or poorly ventilated locations","2434":"Fever","7644":"all airlines or other aircraft operators will provide and collect the passenger attestation on behalf of the U.S. Government prior to boarding","9734":"the United Kingdom (JCVI, 2021a-b), Canada (National Advisory Committee on Vaccination, 2021), Germany, and France","8969":"uses text messaging and web surveys to provide personalized health check-ins after you receive a COVID-19 vaccine","4270":"multisystem inflammatory syndrome","7713":"Oct. 24, 2022","6383":"shared decision-making","6634":"the following","9103":"if you live with or have social contact with someone at high risk","97":"bats","8823":"official agency products, activities, representatives, and facilities","5840":"12 years and older","589":"91,864","4023":"all vaccine partners","5801":"COVID-19","5066":"Updated recommendation for timing of COVID-19 vaccine administration","9548":"6 (maroon cap and label border) Child turns 5 of the product authorized for children ages 5\u201311 years","8586":"a weakened or inactivated germ","5935":"The EUI","9987":"whether a person can receive additional doses of the vaccine","512":"total number of doses delivered, and total number of doses administered by dialysis centers participating in the Federal Dialysis Center Program","4052":"COVID-19 vaccine effectiveness at preventing infection or severe illness wanes over time","2132":"Vaccines","4084":"The number of vaccine doses you need to complete your primary series","8181":"immunocompromised","8240":"J&J\/Janssen Vaccine Overview J&J\/Janssen","538":"six","324":"February 27, 2022","3340":"resolution of symptoms","653":"California","862":"wearing a mask and washing hands","8476":"CDC GOV","9525":"purple","4067":"when they stay up to date with COVID-19 vaccinations","194":"Your immune system","1906":"Vaccine Safety","91":"low","5414":"that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic","2779":"harm yourself or others","9867":"Haggenburg S, Lissenberg-Witte B.I, van Binnendijk RS., et al. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients","6003":"reduce the risk of myocarditis","3101":"tixagevimab\/cilgavimab","5580":"A respirator","4958":"Novavax COVID-19","4190":"less likely","5551":"properly fitting respirators","4715":"Weakness or tingling sensations","9258":"Masks","9407":"immunocompromise","6528":"get very sick from COVID-19","253":"COVID-19","8528":"exposed to a sick traveler on a flight","4400":"438829","5913":"2 months","5171":"CDC will not enforce the Order","8230":"A longer time between the 1st and 2nd primary doses","8816":"out-of-date information being offered to users","6031":"3 months","2755":"a research project","8374":"November 3, 2021","695":"Illinois made updates to data previously submitted to CDC","8986":"Participants","1296":"Moderna","379":"adjustments","6198":"Investigating Long- Term Effects of Myocarditis","3507":"contact your state, territorial, local or tribal health department","8363":"their personal values and the health needs of their family and community","4066":"COVID-19 booster","9092":"Domestic Travel During COVID-19 and International Travel","11":"COVID-19 vaccines","2714":"COVID-19 symptoms","5262":"isolation","773":"quickly","1864":"8,319","7046":"Although the overall risks are low, if you are pregnant or were recently pregnant, you are more likely to get very sick from COVID-19 compared to people who are not pregnant. Additionally, if you have COVID-19 during pregnancy, you are at increased risk of complications that can affect your pregnancy and developing baby. Having certain underlying medical conditions, and other factors, including age, can further increase the risk for getting very sick from COVID-19 during or recently after pregnancy","1510":"HHS","5216":"isolation, masking, and avoiding contact with people who are at high risk of getting very sick","7606":"less than 10%","7350":"an attestation","1888":"CDC COVID Data Tracker","1730":"causality","1935":"July 15, 2022","8831":"V-safe After Vaccination Health Checker","3707":"2","4891":"visible swelling","1925":"seven","2762":"Take breaks from watching, reading, or listening to news stories","2133":"More data","3520":"CDC","61":"the opposite arm","2473":"patients\u2019 performance during IVF-ET cycle","8139":"Project VCTR Weekly","1554":"July 21, 2022","6082":"Alejo J.,","4222":"depending on your age","5828":"Ask the vaccination provider","8500":"my travel companions","6603":"National Center","6497":"treatment","4002":"the following day","28":"everyone 5 years and older","10091":"Allergy-related contraindication to one type of COVID-19 vaccine","4402":"the vaccination provider","9925":"manufacturers' fact sheets","1686":"Thrombocytopenia Syndrome","5928":"5.5 or 7.5 mL of vaccine","9368":"SPIKEVAX","1060":"Treatment","4885":"hives","1796":"your state, territorial, local , or tribal health department","5484":"long-term reactions to a very stressful event","9360":"a two-dose primary series to individuals 6 years of age and older","7383":"COVID-19 vaccination requirements","9036":"lineages and sublineages","5632":"facial","111":"COVID-19","7704":"Serious side effects","1254":"CDC\u2019s Use of COVID-19 Vaccines in the U.S.","6588":"EVUSHELD","4830":"VAERS reporting","1518":"N95 masks","8268":"2","3119":"severely immunosuppressive","642":"2022","1838":"the evaluation\u2019s data collection platform, protocol (if available), outcome, population, and participating sites. Links to protocols that detail the evaluation designs are included when possible. The list of evaluations is organized by type of study. Choose a category below to see a description of those evaluation. Vaccine Effectiveness Evaluations by Design","1135":"multiple information technology systems","5688":"Portable Air Cleaners and Masking","1742":"vital functions","7674":"Pfizer-BioNTech, Moderna, and Johnson & Johnson\/Janssen and Novavax COVID-19","4185":"COVID-19 vaccination","2555":"An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines","7960":"XYZ","3217":"Syncope","3366":"fever, fatigue, headache, myalgia","4173":"personalized health check-ins after vaccination","7867":"Celltrion USA","8457":"10","7174":"COVID-19 Vaccine, mRNA","5225":"full isolation recommendations","8391":"trainings and competencies healthcare professionals need based on their roles and experience","9552":"A 2-dose primary series using the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 5\u201311 years (orange cap and label border)\fSpecial Situations for COVID-19 Vaccination of Children and Adolescents Age Transitions and Interchangeability Pfizer-BioNTech COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group","3364":"isolate and be evaluated for SARS-CoV-2 infection as soon as possible","4498":"crowded areas","2883":"dark blue","7126":"breast","3997":"Each state or territorial health department","4398":"Medicare recipients","9376":"People with COVID- 19","6539":"A person with a condition that is not listed may still be at greater risk of getting very sick from COVID-19","4566":"doors and windows","4458":"COVIDtests.gov","2480":"mRNA","506":"data synchronization error","4964":"Janssen COVID-19 Vaccine","7273":"Vaccinations","4416":"weekly","9997":"30 minutes after vaccination","5243":"If you have an emergency warning sign (like trouble breathing), seek emergency medical care","1709":"cold chain conditions and chain of custody","6936":"inflammation of the lining outside the heart","4930":"Adverse Events","9290":"almost half","7055":"Hospitalization Admission into an intensive care unit (ICU) A ventilator or special equipment to help them breathe","9074":"COVID-19","5613":"the edge of the mask","7860":"FDA-authorized self-tests","2907":"people ages 18 years and older","4261":"3 months","5621":"masks","8574":"a few weeks","1840":"Vaccine Effectiveness Evaluations by Design","3529":"people","8068":"126 \u0083 When will vaccines be available for children ages 5 years and younger?d \u0082 As of June 18, 2022","8289":"Anyone","5186":"what we know about the safety of COVID-19 vaccines","5353":"Immune Thrombocytopenia","5896":"4\u20138 weeks","2053":"infants ages 6 months and older born to people who were vaccinated or had a COVID-19 infection before or during pregnancy. If you are pregnant or were recently pregnant, you are more likely to get very sick from COVID-19 compared to people who are not pregnant","3209":"myocarditis or pericarditis","6592":"25 kg\/m or higher, but under 30 kg\/m","2857":"EUL","8660":"Clinical trials","378":"411,224","2250":"if eligible","8307":"by symptoms alone","4208":"COVID-19","6898":"COVID-19","8686":"extra precautions you can take to protect yourself and others","5663":"95%","5672":"The benefits of mask-wearing","3911":"EVUSHELD\u2122","545":"17,550","7382":"consult and become familiar with all applicable U.S. requirements for entry","8719":"at a participating location near you","7620":"follow the requirements of the attestation","3559":"the method used to determine dose numbers","476":"May 7, 2021","8264":"If the FDA has not approved or authorized a vaccine","1274":"8-week","4725":"People who initiated vaccination outside of the United States","7309":"Reinfection with the virus that causes COVID-19 means a person was infected, recovered, and then later became infected again. After recovering from COVID-19, most individuals will have some protection from repeat infections","5335":"the ears","7228":"severe allergic reaction","1654":"Individuals becoming aware of any suspected fraud or abuse or violations of provider agreement requirements are encouraged to report them to the Office of the Inspector General","120":"SARS-CoV-2","5156":"sign an attestation","1386":"10\/30\/22","6846":"The Countermeasures Injury Compensation Program","9105":"a mask","8593":"Protein subunit vaccines","4638":"1 booster dose","4044":"\u2022 \u2022 \u2022","6253":"the number of deaths reported to VAERS","5348":"wide","221":"someone who has had COVID-19 in the past or has been vaccinated against COVID-19","8805":"internationally","124":"More studies and surveillance","8176":"3","2998":"6 months after completion of any primary series","10094":"Janssen COVID-19 Vaccine","8647":"vaccines","5786":"a primary vaccination with a non-FDA authorized or approved COVID-19 vaccine or Janssen COVID-19 Vaccine","8394":"past 5 years","8984":"Your healthcare provider","1148":"COVID-19 Data Clearing House is a cloud-hosted data repository that receives, deduplicates, and deidentifies COVID-19 vaccination data","8116":"Sex in association with a large public event in a geographic area","9111":"Some people using public transport or working in transportation settings","8160":"J&J\/Janssen","5487":"COVID-19","6987":"within one (1) year","9512":"terminated or revoked","5992":"Neutralizing antibody titers","2547":"28","197":"How long this protection lasts","3344":"SARS-CoV-2 or other viruses","1218":"October 26, 2022","1933":"the potential causes of birth defects and how to prevent them","3100":"a combination of two monoclonal antibodies","7972":"waning COVID-19 vaccine- acquired immunity","999":"treatment or patient management decisions","12":"COVID-19 vaccines","7763":"Over 350 million","1252":"eligible to get a COVID-19 vaccination","3783":"COVID-19","9884":"peak antibody","5839":"immunocompromising conditions","7400":"Secretary of State, Secretary of Transportation, or Secretary of Homeland Security (or their designees","2815":"irritability, vomiting, poor feeding, tachypnea, or lethargy","6113":"COV-BOOST","7380":"Non-U.S. citizens","6774":"3,100","3190":"4 weeks","3030":"Moderna COVID-19 Vaccine","2226":"Vaccination can reduce the spread of disease","6614":"cerebrovascular disease, such as having a stroke","7029":"their vaccination provider","939":"soap and water","1411":"1 bivalent mRNA booster dose","6837":"out-of-pocket vaccine administration fee","1785":"20%","1919":"safety of vaccines","5518":"symptoms and conditions recorded in medical records","2131":"COVID-19","3243":"allergy shots","8975":"Abt Associates","285":"New Hampshire will only report year of birth instead of full birthdate for vaccine recipients","1199":"New Hampshire","1999":"20","772":"through droplets","6237":"severe illness or death","6199":"specific or general symptoms of myocarditis or pericarditis","8882":"Work with health departments and national partners to engage communities around vaccine confidence and service delivery strategies","8745":"Children Children ages 2 years and older","8234":"COVID-19 vaccine","9306":"Why Children and Teens Should Get Vaccinated Against COVID-19 | CDC","7885":"create and disseminate messages","3851":"Vaccines.gov","8259":"\u2022 \u2022 \u2022 \u2022","8806":"U.S. government works outside the United States, the work","6593":"Overweight","1732":"Serious AEs","3567":"COVID-19 Vaccinations Data Definitions Total Doses Distributed","9496":"The Countermeasures Injury Compensation Program","1320":"vaccine dosage for the older age group","2147":"English or Spanish","90":"July 20, 2022","7378":"refugees","5718":"emergency use of FDA-approved (licensed) medical products that may not be included in or differ in some way from the information provided in the FDA- approved labeling (package insert).","6733":"COVID-19 Vaccine, mRNA","7435":"14","7320":"CSTE","9613":"active immunization","9131":"high-quality mask or respirator","425":"Demographic Trends of People Receiving COVID-19 Vaccinations","6904":"Pfizer-BioNTech","537":"February 15, 2021","3027":"People who are or who become moderately or severely immunocompromised","3748":"increased concern about community transmission or risk of severe disease","1677":"ACIP","4992":"3-dose mRNA vaccine primary series","7985":"booster eligibility","1786":"an additional dose of vaccine","6728":"Pfizer-BioNTech COVID-19","7670":"tens of thousands","2122":"CDC","1141":"VTrckS Provider Order Portal","5364":"Guillain Barr\u00e9 Syndrome","350":"349","10090":"the same type of COVID-19 vaccine","6156":"deaths","3550":"CDC COVID-19 Vaccination record card","8428":"Vaccine Confidence Training","755":"Wuhan, China","3345":"3 weeks","6139":"China National Biotec Group (CNBG), Sinopharm","3130":"Recipients of HCT or CAR-T-cell therapy should undergo revaccination for the monovalent primary series and bivalent booster doses received prior to or during treatment","4792":"Pink Book","9020":"any medically important adverse event","9631":"a primary dose of the COVID-19 vaccine by Pfizer-BioNTech","2754":"engage in whatever coping strategies are best for your mental and physical health","9353":"Children who will turn from 11 years to 12 years of age","17":"Nausea","2656":"The person who is sick","6930":"primary","6870":"Centers for Disease Control and Prevention (CDC)","5375":"to identify potential side effects after COVID-19 vaccination","7568":"full name plus at least one other identifier such as date of birth or passport number) that match with your passport or other travel documentation","956":"Any caregiver feeding the baby","4967":"New clinical considerations","310":"62,163","1150":"Bureau of Prisons","9295":"data","1049":"Sept. 28, 2022","2185":"Severe Acute Respiratory Syndrome Coronavirus 2","165":"One Health Federal Interagency COVID-19 Coordination (OH-FICC) Group","7614":"An official letter from your employer","5160":"COVID-19","5795":"rarely","9200":"at least 60%","7219":"potassium chloride","5695":"transparent medical masks","4492":"higher","4639":"risk of thrombosis with thrombocytopenia syndrome","7310":"Reinfection with the virus that causes COVID-19","8614":"years","7538":"traveling to the United States for reasons related to official foreign government travel or because they have been invited by the United Nations","6781":"Pfizer-BioNTech COVID-19 Vaccine","9253":"specific testing recommendations","8248":"Children under age 5 years","4881":"precaution","1726":"VAERS reporting","3482":"health care and emergency evacuation","3979":"VAMS","5403":"Individuals becoming aware of any potential violations of the CDC COVID-19 Vaccination Program requirements are encouraged to report them to the Office of the Inspector General","3053":"5 years","4158":"several","7415":"the passenger attestation","5603":"Nose wire","9417":"FDA","8708":"often with soap and water","7826":"you are an older adult or have an underlying medical condition","6563":"HIV","3414":"Administration of subsequent COVID-19 vaccine dose(s","7696":"muscle weakness and sometimes paralysis","3110":"Hematologic malignancies","4547":"treatment","5989":"adults who had completed primary vaccination with a Moderna COVID-19 Vaccine 2-dose series (N=151), a Janssen COVID-19 Vaccine single dose (N=156), or a Pfizer-BioNTech COVID-19 Vaccine 2-dose series (N=151) at least 12 weeks (range 12 to 20 weeks) prior to enrollment and who reported no history of SARS-CoV-2 infection","1093":"COVID-19 vaccines","5117":"additional layers of protection from COVID-19","390":"Texas and CDC","4128":"if a child is low risk for infection","6604":"Having hemoglobin blood disorders","6118":"3 Dec 2021","2875":"5 \u00b5g rS and 50 \u00b5g of Matrix-M\u2122 adjuvant Booster vaccination 18 years and older","4481":"\u2022","3430":"SPIKEVAX","7396":"June 28, 2022","4382":"Genetic material","8002":"COVID-19 Community Levels","8632":"Many side effects from getting the vaccine","9862":"sufficient antibody response","5110":"Get Started Travel Assessment","8461":"Traveling by private vehicle","7661":"July 14, 2022","4463":"Visit FDA\u2019s website","3250":"People with an allergy-related contraindication","561":"221,933","9485":"Immunization Information System","1870":"Population: Healthcare personnel","5269":"48","9433":"fatigue, headache, muscle pain, joint pain, chills, nausea and vomiting, fever, and rash","6216":"many foods","5544":"Masking","8769":"written communication, closed captioning, or decreasing background noise","3273":"7967. In addition, CDC has developed a new voluntary, smartphone-based tool, v-safe","5572":"disposable","2939":"2 months","6643":"30-day","2452":"COVID Vaccines Do Not Impact Fertility. February 5, 2021. Available at: https:\/\/www.asrm.org\/news-and-publications\/news-and- research\/press-releases-and-bulletins\/asrm-smfm-acog-issue-joint-statement-medical-experts-continue-to-assert-that- covid","196":"severely ill","6441":"EVUSHELD","4953":"1","752":"updates","6917":"2 months","6805":"Pfizer-BioNTech COVID-19 Vaccine EUA\u201d","4145":"three","2721":"5 days","2419":"there is no evidence that COVID-19 vaccination causes problems with fertility","5209":"anyone can submit a report to VAERS, including you","1038":"You cannot tell the difference between flu and COVID-19 by symptoms alone","7743":"TTS cases","5053":"considerations","2924":"Bivalent vaccine","9413":"400","4388":"Ask your doctor, pharmacist, or community health center, or visit their website","10015":"immune- mediated syndrome","4164":"Moderna","6664":"steps","8012":"95","5339":"within a few minutes to one hour","8284":"COVID-19","8165":"Omicron variant BA.4 and BA.5","4465":"Call your healthcare provider","5853":"The CDC Director","7401":"Members of the U.S. Armed Forces","8090":"penis, testicles, labia, and vagina) or anus","10137":"following receipt of the Janssen COVID-19 Vaccine or any other adenovirus vector-based COVID-19 vaccines","8808":"Attribution to the agency that developed the material","9473":"PREGNANCY OR BREASTFEEDING","8236":"3 weeks (or 21 days) after the first dose","2260":"COVID-19","3646":"near you","2276":"written consent","3573":"December 14, 2020","7014":"tiredness","8347":"to help people manage mixed feelings and move toward healthy behavior change that is consistent with their values and needs","4226":"a digital or paper copy of your full vaccination record","9138":"treatment is available","6766":"Pfizer-BioNTech","9678":"injection site pain, fatigue, headache, muscle pain, chills, joint pain, fever, injection site swelling, injection site redness, nausea, malaise, lymphadenopathy, decreased appetite, rash, pain in extremity, diarrhea, and vomiting","2530":"8 weeks (2 months","6532":"- -","3054":"5 years","3829":"all providers participating in the program","8365":"respond with empathy and provide scientific information as needed","250":"Serological surveillance (studies that investigate antibodies in the population) provides information about how long antibody protection against COVID-19 lasts and if this protection is different among people who have antibodies from infection, compared with people who have antibodies from vaccination, or both. We can also learn more about which groups of people might not produce as many antibodies or maintain them as long as others\u2014for example, immunocompromised people compared with people who have healthy immune systems. This is important information for making decisions about whether or not additional vaccine doses or boosters are needed, when they would be recommended, and who would need them first","9722":"1","3673":"If Your Test is Positive","7471":"Isolation means to separate sick people with a contagious disease from people who are not sick","9185":"\u2022 \uf309 If you are sick, wear a well-fitting mask You should wear a mask if you must be around other people or animals, including pets (even at home). Wear a mask with the best fit, protection, and comfort for you. You don\u2019t need to wear the mask","6186":"Myocarditis","8592":"mRNA","3436":"have the same formulation","5295":"SARS-CoV-2","3519":"testing recommendations","8990":"CDC","1025":"Treatment","1737":"Healthcare providers","4392":"Check your local pharmacy\u2019s website","2425":"Limited, Temporary Impact","5016":"schedule","8639":"their surface","3350":"COVID-19","6165":"15,000","1834":"approves a vaccine","5779":"COVID-19 vaccine","2565":"Novavax","6066":"Moderna COVID-19 Vaccine, Bivalent (Original and Omicron BA.4\/BA.5) and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent","9598":"COVID-19","2665":"home isolation","1269":"after the first dose","9825":"improving protection","1682":"Janssen","7234":"COVID-19 Vaccine, mRNA","520":"a combination of: The 2019 National Census Population Estimates from the US Census Bureau Annual Estimates of the Resident Population for the United States","2975":"COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised Age group Number of primary doses Number of bivalent booster doses Recommended bivalent booster dose* Interval between 1st and 2nd primary dose Interval between 2nd and 3rd primary dose Interval between primary series and booster dose Moderna primary series years 2 NA NA 4\u20138 weeks NA NA years Pfizer-BioNTech 4\u20138 weeks NA At least 2 months Schedule: ages 12 years and older","583":"New Jersey","2940":"People","254":"getting vaccinated","213":"After a long enough period of time","5259":"Until at least day 11","2373":"EVUSHELD","6672":"updated guidance","1953":"Participants","6124":"enhances peak antibody","9297":"mild or severe COVID-19","3264":"Vaccine administration errors","2431":"sperm characteristics","1375":"bivalent booster dose","5845":"COVID-19","1127":"enter your email address","6052":"The option to be revaccinated for people who received vaccination during therapy","2091":"mRNA COVID-19 vaccine, their bodies build antibodies against COVID-19","5633":"KN95 respirators","6908":"2-dose","3312":"5\u201311 years","3977":"COVID-19 vaccines","6289":"COVID-19","3700":"two","5868":"primary and\/or additional doses","4962":"Novavax COVID-19","9740":"adults who had completed primary vaccination with a Moderna COVID-19 Vaccine 2-dose series (N=151), a Janssen COVID-19 Vaccine single-dose (N=156), or a Pfizer-BioNTech COVID-19 vaccine 2-dose series (N=151) at least 12 weeks prior to enrollment and who reported no history of SARS-CoV-2 infection","3741":"June 24, 2022","4647":"Moderna, Novavax, and Pfizer-BioNTech","4326":"side effects","9340":"6 years of age and older","1721":"the same for those authorized under emergency use (EUA) or approved under a Biologics License Application (BLA).","2113":"Scientific","132":"One","8346":"Motivational","5830":"Healthcare Providers","1646":"the vaccine recipient\u2019s medical needs","7223":"it contains a different Omicron component","3363":"People who develop signs and symptoms associated with COVID-19 (e.g., cough, shortness of breath, runny nose, sore throat, loss of taste or smell) should isolate","7265":"SARS-CoV-2","7090":"a well-fitted mask","4212":"COVID-19 Vaccination | CDC No. You should wait to be vaccinated until after you\u202fcomplete your isolation period. People who have symptoms will end isolation at a different time than people who do not have symptoms. This also applies to people who have been vaccinated","9261":"Aug. 24, 2022","5763":"3 months","10078":"JYNNEOS or ACAM2000) before receiving a Moderna, Novavax, or Pfizer-BioNtech COVID-19 vaccine because of the observed risk for myocarditis and\/or pericarditis after JYNNEOS","4358":"rates of COVID-19 cases, hospitalizations, and deaths by vaccination status","6309":"Healthcare Appointment Checklist","8940":"VAERS","7766":"70.7","5535":"different groups","2690":"a lined trash can","1645":"Communications regarding receipt of a second dose, or potential booster dose(s), of COVID-19 vaccine","9743":"Neutralizing antibody titers","8076":"infection-induced immunity","9444":"SPIKEVAX","3452":"medication","7472":"minors","2859":"three","5970":"COVID-19","5802":"myocarditis","6040":"The circulating variant","7184":"COVID-19 VACCINE, mRNA","6744":"coronavirus","4375":"COVID-19 and Animals COVID-19 can spread from people to animals in some situations. Pet cats and dogs can sometimes become infected by people with COVID-19","499":"Maine","9638":"Ages 12 years and older","2730":"there are few or no immediate answers or solutions","3441":"two","330":"January 25, 2022","2709":"COVID-19","1508":"United States","4712":"people ages 40\u201364 years","2057":"People who are pregnant","7413":"because they are too young, or because of physical or mental impairment).","9443":"FDA\/CDC Vaccine Adverse Event Reporting System (VAERS).","7226":"FDA","4057":"if and when you can get boosters to stay up to date with your COVID-19 vaccines","2100":"pregnancy","5728":"an infectious disease","4147":"three","1393":"People who are Moderately or Severely Immunocompromised","8299":"Pale, gray, or blue","9688":"Contraindications, and Warnings and Precautions sections in the Comirnaty package insert or Full EUA Prescribing Information","1976":"Vaccine Adverse Event Reporting System","3408":"serum sample","8143":"September 2, 2022","7085":"take steps to protect themselves and others from getting COVID-19","4644":"limited access to other COVID-19 vaccines","8468":"Customs and Border Protection","5172":"masks","9583":"3\u20138 weeks","5806":"COVID-19","1627":"Prioritization for receipt of COVID-19 vaccine","7804":"people who are not up to date on their COVID-19 vaccines","3975":"federal agencies, and pharmacy partners","3671":"Isolate yourself to protect others from getting infected","2156":"injectable","2253":"LTC residents","5188":"CDC","1753":"the vaccine recipient","5028":"Updated guidance in section on COVID-19 vaccine dosage and schedule. Updated guidance in section on People vaccinated for prevention of COVID-19 outside the United States","7986":"decreasing interest in booster information","9912":"by IM injection","4412":"your actions","6211":"Accurate vaccine information","3630":"testing, vaccination, or other documents","9305":"possible delay","9853":"Emergency Use Authorization of the Pfizer- BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019","9279":"Asthma or chronic lung disease","5789":"Limited data","4933":"2021","6710":"Allergy and Asthma Network Asthma and Allergy Foundation of America","3900":"COVID-19","9962":"people with underlying medical conditions","3723":"HCT","1496":"Vaccines for Children Program vs. CDC COVID-19 Vaccination Program \uf2a1 FAQs for Federal Retail Pharmacy Program Participants \uf2a1 COVID-19 vaccination providers participating in the CDC COVID-19 Vaccination Program are required to sign a CDC COVID-19 Vaccination Program Provider Agreement","5367":"Janssen COVID-19 Vaccine. Serious and unexpected effects may occur. The Janssen COVID-19","6705":"Strong emotions","1240":"free of charge","988":"48","1868":"COVID-19","6964":"Primary, additional, and\/or booster doses of the COVID-19 vaccine","2278":"vaccination card","7318":"CDC is using a range of data sources to assess how often reinfections occur, who is most at risk for reinfection, and the risk of reinfection when there is community spread of Omicron or other virus variants","5182":"information needed to check in with patients to see how they are recovering after they experience a serious event following vaccination","7841":"a new test","6666":"asthma triggers","1752":"Medicare or Medicaid reimbursement","5297":"through contact with another person who has the virus","1744":"Training, site visits, and other oversight measures","8408":"Relevant information","6074":"MIS","1871":"Kansas City, MO","7810":"community testing site","7236":"COVID-19","3157":"the recommended age-appropriate vaccine product and dosage","475":"three","4843":"No diluent","10099":"COVID-19 vaccines","7106":"Get recommended vaccines","8651":"COVID-19","9561":"0.20 mL","14":"facility healthcare provider","10003":"age, underlying conditions","4713":"42 days","9135":"1 Page","6202":"CDC","1":"Side effects","3083":"8 weeks","6048":"a decreased odds ratio of seroconversion","297":"when available","5040":"Vaccinating people undergoing SARS-CoV-2 screening","9900":"21 October 2021","2397":"up to date","5370":"Vaccine Adverse Event Reporting System","5274":"negative test results","4788":"VAERS","3495":"report your symptoms, even if they are mild, to protect others on board","4114":"small, temporary changes in menstruation","5517":"self-reported symptoms","2752":"Information about enrolling in clinical trials","975":"SARS-CoV-2","5903":"100 \u03bcg","457":"error in data processing","837":"Pediatrics","6191":"Pfizer-BioNTech","4483":"keeping your distance","1466":"People who previously received SARS-CoV-2 antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment, post-exposure prophylaxis, or pre-exposure prophylaxis can be vaccinated at any time","6910":"28 days","4672":"Janssen COVID-19 Vaccine Not recommended Do not vaccinate with Janssen COVID-19 Vaccine","9371":"coronavirus","471":"by first obtaining the percentage of the three population groups who have received \u2018at least one dose\u2019 from Texas","4991":"10\/30\/22","5726":"COVID-19 vaccine","10140":"2 months","1843":"University of Arizona","1970":"DOD Vaccine Adverse Event Clinical System","4616":"National","6018":"higher","5963":"United Kingdom","9440":"call 9-1-1, or go to the nearest hospital","8302":"you are seeking care for someone who has or may have COVID-19","8106":"monkeypox","9883":"peak antibody","5523":"Estimates of the proportion","9126":"Open windows","687":"updates","4206":"COVID-19 vaccine","5401":"if only receiving a COVID-19 vaccination","4670":"Contraindication","6293":"my fertility","9358":"supplied in vials with red caps and labels with a light blue border","1875":"Jackson, MS","845":"the known and potential risks","3895":"Vaccine Recipient Education","6379":"- - -","5714":"FDA-approved (licensed) medical products that may not be included in or differ in some way from the information provided in the FDA- approved labeling (package insert).","6757":"any authorized or approved COVID-19 vaccine","5":"Drink a lot of water","9492":"Office of the Inspector General","1528":"U.S. Department of Health and Human Services","9392":"blood thinner","1248":"8 million","6689":"Limit use of chemicals that can trigger asthma attacks, such as bleach (sodium hypochlorite) or quaternary ammonium compounds (for example, benzalkonium chloride), and do not use them in enclosed spaces","7509":"The second dose","8297":"COVID 19","677":"800,606","2085":"people who were pregnant and","4300":"other types of vaccines or injectable medications for other diseases","2948":"A 2-dose primary series and 1 bivalent Pfizer-BioNTech booster dose","5255":"you experienced shortness of breath or had difficulty breathing","6140":"28 October 2021","4064":"answer undefined","6226":"Getting a COVID-19 vaccination","5987":"12 weeks","5412":"EMERGENCY USE AUTHORIZATION","6894":"death","2198":"2019","8654":"COVID-19 vaccines","6826":"SARS-CoV-2","8065":"Further laboratory tests are being conducted to look more closely at the virus genome","6454":"Treatment","4875":"Appendix E","2336":"2 weeks","8203":"2 months","1309":"age-appropriate vaccine dosage","3309":"In age groups where product comparisons can be made (i.e., 18\u201339 years), some evidence suggests that the risk of myocarditis and pericarditis may be higher","5513":"post-COVID condition","2491":"COVID-19 Community Levels","6767":"Your child","3664":"wearing masks","8492":"do not travel","4708":"FDA","5956":"text messaging and web surveys","8489":"If you had COVID-19 in the past 90 days, see specific testing recommendations","5738":"4\u20138 weeks after the first primary dose","786":"variants","7506":"fully vaccinated","1533":"U.S. government property","1947":"CDC has expanded safety surveillance","8414":"Vaccine Administration","7497":"limits on available vaccines","1377":"people","4328":"your card","9848":"1273 SARS-CoV-2","241":"SARS-CoV-2","8588":"antibodies","4006":"vaccination data","8852":"Creating an account to add a dependent","8691":"COVID-19","9038":"CDC","9023":"ACIP","3778":"decades","934":"- - - \u2022 - \u2022 \u2022 \u2022 \u2022 \u2022","5224":"isolate","4466":"a high-quality mask","5910":"2 months","5161":"use a self-test","8596":"genetic material","7663":"COVID-19 vaccines for everyone 6 months and older","1162":"50","9075":"how","6640":"Continue your medicines","2396":"The people you live or spend time with","5145":"health and public health information","3222":"Vaccination providers, particularly when vaccinating adolescents, should consider observing vaccine recipients for 15 minutes after vaccination","5257":"day 10","2688":"Caregiver","9034":"severe illness, hospitalization, and death","4676":"pain at the injection site","4381":"rivers","7182":"2 to 14 days","623":"3,118","8399":"Vaccine Storage and Handling Or other vaccine storage and handling training offered by a worksite, state or local health department, medical professional organization, or medical\/nursing school within the last 12 months","5079":"polysorbate allergy","6348":"chief complaints","2297":"COVID-19 Vaccine Boosters","5409":"a claim","9650":"CDC","3131":"revaccination","3223":"people with the following medical histories","4590":"Exhaust fans above your stovetop and in your bathroom that vent outdoors can help move air outside. Although some stove exhaust fans","6358":"Repeat back","63":"COVID arm","8796":"Most of the information on the CDC and ATSDR websites","505":"between April 3 and 5, 2021","6194":"their normal daily activities","320":"count-based options","4609":"improving ventilation","5018":"people","3534":"CDC cannot use the unique person identifier to identify individual people by name. There are challenges in linking records when someone receives vaccine doses in different jurisdictions or from different providers. That person could receive different unique person identifiers for different doses. CDC may not be able to link multiple unique person identifiers for different jurisdictions or providers to a single person","78":"specific studies","802":"ongoing health problems, also known as long COVID or post-COVID conditions","6762":"3 weeks apart","6347":"Bring Your List of Concerns","6258":"mRNA vaccines","2756":"The National Institutes of Health","2026":"fight the virus that causes COVID-19","9892":"Two","915":"Others in your household, and caregivers who have COVID-19","6114":"2021","5226":"end your isolation","3952":"Mar. 16, 2022","2266":"Centers for Medicare and Medicaid Services","4516":"bar","7110":"whooping cough","6545":"thickening of the lungs\u2019 airways","2315":"2 months","8917":"challenges with getting vaccines","6313":"review your notes to prepare for your next appointment","8331":"April 14, 2022","2636":"a few days","1026":"Possible treatment","1586":"All providers","8174":"1. Your age 2. The vaccine you first received, and 3. The length of time since your last dose","9232":"Isolation and Exposure Calculator","7853":"customizable","9296":"a wide range of new, returning, or ongoing health problems","293":"Age, Sex, and Race\/Ethnicity among Fully Vaccinated People Ages 12 Years and Older","1561":"6\/18\/22 update","2128":"COVID-19","10034":"orthopoxvirus","3268":"even if it is uncertain whether the vaccine caused the event","3548":"part-time residents","3391":"Experts","9588":"immunocompromising conditions","887":"Quarantine and Isolation","5241":"trouble breathing","9951":"booster doses","1809":"LTC Pharmacy Partnerships","3039":"3","5416":"an EUA","7626":"5 days","9449":"COVID-19","9932":"week after vaccination","4097":"you do not have to restart the vaccine series","6584":"Do not currently have COVID-19","7574":"Individuals who fit the exception criteria described in the Presidential Proclamation and CDC\u2019s Amended Order may contact the U.S. embassy or consulate in or nearest the country from which they are departing for the United States","290":"September 2021\u2014 April 2022","9347":"two","1992":"a few days after vaccination","6937":"affects your immune system","3734":"March 29, 2022","5419":"COVID-19","2516":"point-of-care and at-home tests","5764":"B-cell-depleting therapies over a limited period: the suggested interval to start revaccination is about 6 months after completion of the B-cell-depleting therapy \u25aa Received COVID-19 vaccine dose(s) prior to or during treatment with hematopoietic cell transplant (HCT) or chimeric antigen receptor (CAR)-T-cell therapy: revaccination at least 3 months after treatment The COVID-19 vaccine by Pfizer-BioNTech can also be used under EUI for similar uses in persons ages 12 years and older","8038":"18%","3080":"COVID-19 vaccination schedule","7000":"go about their day","5846":"CDC\u2019s Interim Clinical Considerations for specific recommendations on use of the COVID-19 vaccine by Moderna","5954":"vaccine recipients\/caregivers","2616":"make copies of the spike protein","4767":"WHO","3200":"fever, fatigue\/malaise, headache, chills, myalgia, arthralgia","6651":"Getting regular exercise","5119":"If you will be visiting someone","7899":"Rumors","2340":"4 weeks","9004":"COVID-19 vaccines are safe and effective","4554":"Improving ventilation","8256":"BioNTech or Moderna) booster","8198":"2","9735":"France","3886":"COVID-19 vaccination providers","1089":"Motrin, Advil","4246":"United States","4789":"Providers","3276":"types","4310":"your doctor","7470":"quarantine","4285":"what is currently known about COVID-19 vaccine effectiveness","5886":"COVID-19 vaccine","9861":"Department of Health & Social Care","58":"Your doctor","1247":"276.4 million","6046":"Moderna COVID-19 Vaccine EUI Healthcare Providers Fact Sheet","6410":"20 or more mg of prednisone or equivalent per day","4040":"reporting","1010":"Reinfections can occur within 90 days","261":"footnotes","2820":"C-reactive protein and erythrocyte sedimentation rate","3631":"take multiple prevention steps","9114":"travel and public transportation settings","7186":"COVID-19 Vaccine, mRNA","4243":"If you have a condition or are taking medications that weaken your immune system","31":"Anyone not up to date with their COVID-19 vaccines","5373":"at the contact information provided below. e-mail Fax number","2677":"your personal level of risk","1107":"Coronavirus","2797":"flexible leave and work schedule policies","6611":"Solid organ or blood stem cell transplant Having had a solid organ or blood stem cell transplant, which includes bone marrow transplants","2028":"mRNA","517":"4,575,496","7879":"over 1 million","6220":"instructions","5033":"in the section on Considerations for COVID-19 vaccination in moderately and severely immunocompromised people","1042":"the same","567":"212,852","1434":"CDC]","4440":"opening windows","1715":"CDC Vaccine Storage and Handling Toolkit","3093":"18 years and older","34":"Jan. 24, 2022","248":"immunocompromised people","7421":"Travel Assessment","9432":"Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection, swelling (hardness), and redness \u2022 General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea and vomiting, fever, and rash","8438":"a well-fitting mask or respirator","1826":"COVID-19 vaccines","1912":"CDC clinicians","4339":"Fraud Alert: COVID-19 Scams or call 1-800-HHS-TIPS","7981":"66.7%","5766":"moderately and severely immunocompromised persons","8059":"COVID-19","163":"more than 20","2967":"3\u20138 weeks","8971":"self- identify as pregnant","10014":"Janssen COVID-19 vaccine","8453":"wearing my mask","4810":"Do not repeat dose","8601":"remove it","8911":"vaccination","2078":"pregnant people","965":"test immediately","5327":"more than 61,000","1514":"Providers","7113":"everyone who is around the baby","2477":"2022 Jan 20","4265":"\u2022 \u2022 \u2022 \u2022 \u2022","6508":"primary series and booster","7037":"side effect","6230":"2","399":"Federal Pharmacy Partnership for Long-Term Care (LTC) Program","8321":"what to expect","7091":"Know when to wear a well-fitted mask","8759":"If your child has a medical condition","30":"Some people in your family","3506":"positive","8380":"Training","5730":"People with SARS-CoV-2 infection","5011":"Updated information on vaccinating people during quarantine after a known SARS-CoV-2 exposure or during COVID- Update","2029":"There is no evidence that vaccine ingredients, including mRNA, or antibodies made following COVID-19 vaccination would cause any problems with becoming pregnant now or in the future","10066":"week following vaccination","5540":"who gets them and why","9197":"Wash your hands often with soap and water","6690":"Follow additional precautions","6512":"Older adults","4934":"2021","5746":"an additional (third) primary dose of the COVID-19 vaccine by Moderna","2503":"Stay up to date on vaccination","6974":"COVID-19","1907":"five","2536":"Bivalent","2917":"mRNA vaccine","6534":"additional underlying conditions","8194":"smaller","3214":"some experts","1712":"three years","6244":"New variants","9310":"help patients and caregivers get the most out of appointments with healthcare providers","435":"June 10, 2021","9515":"Moderna COVID-19","9323":"your medication\/supplement list","2468":"Eight","5014":"People","9696":"a voluntary smartphone-based tool that uses text messaging and web surveys to check in with people who have been vaccinated to identify potential side effects after COVID- 19 vaccination","8585":"mRNA created in a laboratory","7008":"\u2022 \u2022 \u2022","1046":"4","8772":"Correct and consistent care","5707":"Centers for Disease Control and Prevention","9379":"COVID-19 VACCINE","6506":"If you have one of these conditions, talk with your healthcare provider about how best to protect yourself from severe illness from COVID-19. The list below does not include all possible conditions that put you at higher risk of severe illness from COVID-19. If you have questions about a condition not included on this list, talk to your healthcare provider about how best to manage your condition","7733":"December 14, 2020-January 18,","10051":"50 \u00b5g","1124":"Partnering for Vaccine Equity","1647":"Clinical emails","4597":"Pointing fans","5344":"platelets","9474":"SARS-CoV-2","2644":"answer undefined","8517":"72","8762":"Consult your healthcare provider","5379":"Under the EUA","8711":"Masking","398":"66,326","4678":"mild to moderate","8167":"provide some protection against Omicron","2168":"September 8, 2021","4258":"vaccinated","2247":"COVID-19 vaccines","5127":"CDC","5236":"CDC","1526":"providers","668":"14,616","3580":"The number of people fully vaccinated with Johnson & Johnson\u2019s Janssen (J&J\/Janssen) vaccine does not equal the total number of J&J\/Janssen vaccine doses administered","8722":"Layered prevention strategies \u2014 like staying up to date on vaccines and wearing masks","1688":"Pfizer-BioNTech","748":"Colorado","6036":"Multiple large-scale studies","6083":"Amirthalingam G, Bernal, JL, Andrews, NJ, et al. Serological responses and vaccine effectiveness for extended Atmar, R.L., et al. Heterologous SARS-CoV-2 Booster Vaccinations","1924":"CISA) Project \u2014 The CISA Project","2359":"People who are moderately or severely immunocompromised","7019":"medicines","1381":"no additional booster doses","8740":"the best level of protection","1750":"must administer COVID-19 Vaccine at no out-of-pocket cost to the recipient","735":"9,172,838","5426":"USA","1603":"providers must give each vaccine recipient, adult caregiver accompanying the recipient, or other legal representative, a copy","9870":"5 October 2021","450":"7,836,063","4167":"People with COVID-19","1324":"\uf1aa \uf20c \uf20c \uf209","4961":"Novavax COVID-19","6177":"Adjust vaccine recommendations","8049":"118,119,120","4422":"COVID-19 vaccines","6049":"decreased","8799":"government contractors or grantees","7652":"3-5 days","1578":"5\/23\/22 Update","3820":"additional services","2459":"January 9, 2021","16":"facility healthcare provider","4279":"Taking one of the following medications regularly","6017":"7\u20138 week interval","1329":"COVID-19","8419":"additional information","6057":"immunogenicity data","2390":"Boosters","3173":"6 months\u20134 years","3299":"A rare risk for myocarditis and pericarditis has been observed following receipt of mRNA COVID-19 vaccines (i.e., Moderna or Pfizer-BioNTech) and Novavax COVID-19 Vaccine","6866":"9\/02\/2022","2495":"Prevention actions in healthcare facilities","572":"37,546","2141":"J&J\/Janssen","974":"Viral tests","6978":"9\/02\/2022","8371":"Jared Skillings, PhD, ABPP; Erin Swedish, PhD; Robin McLeod, PhD; Mitch Prinstein, PhD, ABPP; and Stephen Gillaspy","1190":"65 years or older","7128":"COVID-19 Vaccines While Pregnant or Breastfeeding","8607":"people get this protection from a vaccine, without ever having to risk the potentially serious consequences of getting sick with COVID-19","215":"severe illness","9952":"1","9084":"Wearing a high-quality mask or respirator","6123":"BNT162b2","2792":"their experiences","9837":"online","6174":"Viruses are constantly changing to create new types of the virus","9015":"VAERS","1014":"How long this protection lasts","9072":"June 12, 2022","4355":"Healthcare Workers","6109":"4","406":"August 31, 2021","9331":"updates or changes","8429":"April 14, 2022","9627":"Persons ages 12 years and older","4569":"young children or pets in your home, risk of falling, people in the home with asthma or other respiratory conditions, poor air quality","984":"NAATs","7730":"detailed reviews","1460":"COVID-19","601":"64,066","6450":"Stay home","3841":"DDL) to monitor vaccine storage unit temperatures and recording temperatures daily","246":"investigate antibodies in the population","3178":"bivalent mRNA vaccines","8221":"2 months","9582":"provide information for the use of this vaccine that are beyond the FDA- approved labeling","3570":"The total number of vaccine doses that have been given to people in the United States since December 14, 2020","4591":"exhaust fan","7042":"a mask","1680":"to implement all recommendations of the ACIP","8674":"Vaccine Safety Datalink (VSD), and v-safe","1607":"Moderna SPIKEVAX COVID-19 Vaccine. The vaccines have identical formulations","5408":"within one (1) year","8196":"3\u20138 weeks","9503":"An EUA","5797":"myocarditis","9333":"https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/long-term-effects.html","7134":"living","8536":"Older adults","7966":"Continuing and Evolving","8136":"Tanaq Social Listening +Media Monitoring Report","8182":"Boosters","8480":"Sept. 8, 2022","7651":"attestation","4456":"actions and resources","10073":"28","2072":"live virus","559":"August 9, 2021","4123":"A child","3651":"my mask","2000":"18.1 million","5658":"Masks and Respirators y, y y p y p p y p others","2140":"Moderna or Pfizer-BioNTech","1452":"all vaccine-eligible populations including people who are pregnant or lactating","6573":"wearing a mask","5943":"myocarditis and pericarditis","5116":"If you do not follow your destination\u2019s requirements","3314":"myocarditis in VAERS","6272":"vaccines","9889":"2 month","597":"97,219 administered doses","214":"threshold of protection","9826":"the benefit\/risk balance for the use of the COVID-19 vaccine","7686":"four","8270":"mixing COVID-19 vaccines","2631":"This information","7569":"Personal identifiers in the clinical trial documentation","3949":"Call 1-800-232-0233","6323":"prior treatments and diagnostic tests related to your post-COVID symptoms (blood work, x-rays, etc.) what makes your symptoms worse","819":"Many viruses","4928":"The Advisory Committee on Immunization Practices","7816":"Wash your hands","3040":"4 weeks","2590":"6 months","6029":"Australia, Canada, Denmark, Finland, France, Germany, Norway, Taiwan, and the United Kingdom","4777":"28 days","3848":"upload into the portal","6030":"humoral and cellular","1083":"contact your local community health center or health department","2263":"boosters","9377":"smell; sore throat; congestion or runny nose","8685":"extra precautions","779":"spike proteins","6660":"Oct. 19, 2022","9922":"\u0083","2951":"2","9703":"COVID-19 vaccine by Pfizer-BioNTech for additional primary doses in people who received a primary vaccination with non-FDA authorized or approved COVID- CDC has not systematically evaluated the safety, immunogenicity, and efficacy of an additional dose of the COVID-19 vaccine by Pfizer-BioNTech following receipt of primary vaccination with a non-FDA authorized or approved COVID-19 vaccine","4442":"HEPA","7638":"official U.S. Government letter (paper or digital","4139":"COVID-19 vaccines","3090":"2 months","6310":"Healthcare Appointment Checklist","5625":"\u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022","428":"339,047","8695":"variants","3107":"CDC\u2019s EVUSHELD guidance and current treatment guidelines","2991":"6 months\u201364 years","4449":"viral test","708":"New Mexico updated 2,213 records","9752":"2021","7259":"COMIRNATY","4112":"everyone 5 years and older","7640":"a statement, writing, entry, or other representation subject to 18 U.S.C. \u00a7 1001 that confirms that the information provided is true","484":"data transmission errors","130":"dogs, cats","8412":"Vaccination support workers","4704":"spontaneous heparin-induced thrombocytopenia","6227":"COVID-19","5680":"how to make sure the product fits properly","201":"Getting a vaccine","2312":"Moderna","3542":"CDC may lack information about a person\u2019s residence","5619":"Personal Protective Equipment Information","5784":"15,400","9664":"12 years and older","5765":"moderately and severely immunocompromised persons","7619":"90 days","4273":"Talk to your doctor","7734":"The benefits of COVID-19 vaccination continue to outweigh any potential risks","1257":"CDC\u2019s Use of COVID-19 Vaccines in the U.S. and the CDC Summary Document for Interim Clinical Considerations. To find locations that administer COVID-19 vaccinations, you can visit Vaccines.gov; text your zip code to 438829 (GETVAX); call 1-800-232-0233; or check your state health department website","6821":"5 through 11 years of age","9911":"4 hours","9315":"Healthcare Appointment Checklist","3672":"additional precautions","5662":"quality requirement","8269":"2","3045":"4 weeks","8933":"any medically important adverse event","5378":"the vaccine","2357":"CDC","4445":"continuous airflow and filtration","6859":"the known and potential benefits of the product outweigh the known and potential risks of the product","6777":"Pfizer-BioNTech COVID-19","8206":"a booster","9590":"12 years and older","8483":"Transportation within your community for errands and work transit","8568":"immunity to the virus","2663":"- -","10075":"age-appropriate mRNA COVID-19","116":"Canada","3762":"unknown","7036":"Vaccine Adverse Event Reporting System","5483":"long-term reactions to a very stressful event","7636":"tele-medicine personnel","5446":"four","6637":"call 911 right away","8162":"both the original virus that causes COVID- 19 and the Omicron variant BA.4 and BA.5","56":"4 hours","5041":"people","7856":"customizable","3018":"Novavax and Pfizer-BioNTech","4228":"your possible options","6452":"Stay home","8421":"Vaccine Storage and Handling","7200":"The Pfizer-BioNTech COVID-19 Vaccine","4025":"the jurisdiction (state, territory, tribe, or local entity) administering those doses","6448":"high quality","5519":"people","3445":"a dash","4795":"using an age-appropriate COVID-19 vaccine product","4283":"Diuretics Thyroid medications Antidepressants Metformin Diabetic medications Insulin Steroids (prednisone, etc.)","3868":"Serious AEs","4975":"a second booster dose","3407":"Obtaining a serum sample","2361":"your healthcare provider","7917":"18 years and older","1103":"vaccines.gov","8781":"your pocket, purse, or paper bag","4852":"Diluent (Pfizer-BioNTech that should not be mixed with diluent, i.e., gray cap) Vaccine is mixed with any diluent (i.e., any type or volume of diluent) Contact the manufacturer for information on the stability of the vaccine. If the manufacturer does not have information to support the stability of the vaccine, repeat the dose immediately (no minimum interval). Do not administer the second dose until the person becomes eligible to receive vaccination (either by reaching the authorized age or if the authorization is extended to include additional age groups), even if this results in the second dose being administered after the recommended interval between doses","4414":"COVID-19 Community Levels","4018":"Data quality","1577":"6\/18\/22","1863":"Increasing Community Access to Testing","7793":"They give your result in a few minutes","1879":"Ann Arbor, MI","3946":"Oct. 19, 2022","617":"31,945","4518":"use the text written on it","5058":"12\u201315 years","4844":"the recipient","9192":"20 seconds","5624":"Wear masks that meet a standard with A proper fit over your nose and mouth to prevent leaks Multiple layers of non-woven material A nose wire Do NOT wear masks that meet a standard If it is hard to breathe while wearing them If they are wet or dirty With other masks or respirators","539":"number of doses administered","9475":"VACCINES","5135":"5","9049":"Viruses constantly change through mutation and sometimes these mutations result in a new variant","5909":"an additional dose with the COVID-19 vaccine by Moderna","2498":"Masks","1118":"Operational Guidance","1560":"July 25, 2022","5465":"RECOVER Initiative","2269":"individual nursing homes","3289":"febrile seizures","9612":"11\/17\/2021","7089":"COVID-19 vaccines","8036":"June 17, 2022","2182":"BNT162b2","4443":"high-efficiency particulate air (HEPA) cleaners","2432":"fertility","6405":"common variable immunodeficiency disease","8889":"allocating vaccines","8893":"national or regional corporate leaders","4213":"avoid potentially exposing healthcare personnel and others during the vaccination visit","5594":"choosing the wrong size or type of mask","8583":"COVID-19","5574":"layered finely woven products","4073":"People (except those who are moderately or severely immunocompromised)","3415":"baseline cardiac function","1331":"bivalent mRNA vaccines","39":"difficulty breathing or wheezing, a drop in blood pressure, swelling of the tongue or throat, or a generalized rash or hives","1144":"storing vaccination\u202finformation specific to that jurisdiction","598":"July 7, 2022","7112":"Tdap vaccine","3909":"vaccines","2443":"acetaminophen","2061":"People who get very sick from COVID-19","8664":"evidence that built on the data and information submitted to support the EUA","5729":"SARS-CoV-2","7515":"10\/30\/22, 9:43 AM","6336":"more than one","9847":"mRNA","8519":"email address","5929":"FDA","7170":"certain kinds","1960":"CDC Vaccine Safety Datalink","387":"percent","4460":"Private health insurance","8985":"you can still participate in the registry","5645":"Using a poor-quality product","9414":"it contains a different Omicron component","3313":"males","824":"December 2020","9282":"data about risk factors","6023":"3\u20134 weeks","9984":"COVID-19","669":"14,616","8019":"influenza","5614":"tuck ear loops","3263":"VAERS","715":"December 16, 2021","1672":"Administering COVID-19 Vaccine at any out-of-pocket cost to the recipient","671":"data previously submitted to CDC","2098":"pregnant people","4857":"recommended interval","5240":"End isolation","9594":"COVID-19 vaccine","4195":"no","4028":"CDC","2763":"Take deep breaths, stretch, meditate , or practice mindfulness","4669":"Thrombosis with thrombocytopenia syndrome","6389":"immunocompromised","707":"updated 2,213 records","418":"621,198","5147":"no more than 3 days","4194":"vaccines","2195":"Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection","6720":"2","9530":"dark blue cap\/purple","2009":"\u2022 \u2022 \u2022 \u2022 \u2022","2833":"Advisory Committee on Immunization Practices","4762":"WHO","98":"animals","8334":"four","8932":"certain adverse events","3378":"Individual factors such as risk of COVID-19 severe disease, COVID-19 community level, or characteristics of the predominant SARS-CoV-2 strain","660":"4,251","2694":"often; avoid touching your eyes, nose, and mouth; and frequently clean and disinfect surfaces. \u2022 - Clean your hands often Wash hands: Wash your hands often with soap and water for at least 20 seconds","494":"221,081","9872":"Pfizer","4152":"meet FDA\u2019s standards","5512":"post-COVID","7462":"Department of Homeland Security (DHS) has identified health requirements as a component of the program, which include receiving measles, polio, and at least one dose of COVID-19 vaccine","2375":"the same product or brand","8306":"COVID-19","7603":"COVID-19 vaccine availability","7152":"COMIRNATY","7650":"self-quarantine","412":"CDC COVID Data Tracker","1003":"90","1153":"as part of jurisdiction, state, or territory aggregate metrics","4842":"immediately","4679":"1\u20132 days","8657":"tens of thousands","6254":"number means deaths that were proven to be caused by vaccination","727":"South Dakota","1321":"the formulation for either age group","7003":"virus","3907":"immunocompromised","2354":"chimeric antigen receptor","291":"May 9, 2022","9188":"Masks","1938":"undergone","2203":"Maternal COVID-19 Vaccination or Natural Infection","5599":"warm air","2517":"communications and messaging","7329":"238","7701":"Reports of adverse events to VAERS","6092":"Healthcare Providers","2245":"CDC COVID Data Tracker","4019":"Data quality","4979":"4 months","7331":"answer undefined","5482":"muscle weakness, problems with thinking and judgment, and symptoms of post-traumatic stress disorder","6620":"children with medical complexity, with genetic, neurologic, or metabolic conditions, or with congenital heart disease","2689":"gloves","9469":"SPIKEVAX","6982":"COVID-19 vaccine","2303":"you are protected best when you stay up to date with your COVID-19 vaccines as described below","5230":"Positive","7230":"monitoring after vaccination","795":"COVID-19 vaccines","8267":"Sinopharm Sinovac COVAXIN Covovax CanSino","9158":"Isolation and Exposure Calculator","9123":"take steps to help keep travel and public transportation safer for everyone","1180":"COVID Data Tracker","2080":"vaccination of pregnant people with a COVID-19 vaccine prior to and during the first trimester was not associated with an increased risk of birth defects detectable on prenatal ultrasound","6636":"Discuss steps","5247":"Day 1","8177":"COVID-19 vaccines","8760":"ASTM F3502","2428":"fertility problems","5248":"day 0 on the day of symptom onset","9436":"Myocarditis","7167":"COVID-19 Vaccine, mRNA","4016":"any particular county or state","4333":"proof of vaccination","6151":"vaccine effectiveness","3266":"MIS","8171":"if you have completed a COVID-19 vaccine primary series and received the most recent booster dose recommended for you by CDC","147":"more information on the epidemiology and genetics","3188":"orthopoxvirus","827":"July 2021","6427":"Order free at-home tests","5964":"3 months","4347":"Your local or state health department","5866":"to provide information about use of the COVID-19 vaccine by Moderna for primary and\/or additional booster that extend beyond its FDA-approved labeling","1427":"Administration of EVUSHELD\u2122","9816":"5 months","8785":"Disposable masks","1849":"<18 years","7160":"2-dose series for prevention of COVID-19","6339":"post-COVID conditions","8841":"V-safe","7303":"known and potential risks of the product","7591":"Information regarding any other solutions","7813":"nasal specimen","2720":"5 days","10126":"wait until after their episode has resolved","4886":"visible swelling","6527":"those on this list","9453":"accept or refuse receiving the vaccine","10103":"\u0083","3824":"CDC COVID-19 Vaccination Program Provider Requirements and Support webpage","8690":"The virus","26":"COVID-19 and the virus","8742":"their healthcare provider","6850":"one (1) year","8957":"contextual","3255":"MIS-C","5062":"Updated information for authorized age groups to include vaccination of adolescents aged 12\u201315 years with Pfizer- BioNTech COVID-19 Vaccine","9943":"Asymptomatic infection","5331":"The Janssen COVID-19 Vaccine","7015":"Apply a clean, cool, wet washcloth over the area","4851":"If the manufacturer does not have information to support the stability of the vaccine","5587":"wearing a mask","5762":"hematopoietic cell transplant","1575":"Interim Clinical Considerations","2617":"fight it off","9705":"3","8351":"how likely are you to get a COVID-19 vaccine","9976":"contraindication","2864":"Janssen COVID-19","2058":"COVID-19 booster shot","9586":"3 months","1021":"infected","3091":"2 months","1428":"COVID-19 vaccines","3161":"vaccine product and dosage for the older age group","9834":"Vaccine Adverse Event Reporting System","1158":"Census CDC","2654":"severe illness","3416":"at least 90 days","6424":"COVID-19","1590":"Pfizer EUI , Moderna EUI ,","2052":"before or during pregnancy","9795":"protection from infection or vaccination","747":"Vermont","2994":"3 weeks","444":"data submitted by New Hampshire","4635":"Ventilation in Buildings","3598":"moderately or severely immunocompromised people","1115":"6","2972":"People ages 18 years and older","8123":"what is known and what is not known","7082":"MotherToBaby","6193":"medicine and rest","5719":"fact sheets for healthcare providers and recipients","4096":"different immune response","8069":"COVID-19","7751":"the rate of GBS","3166":"age-specific vaccine products and dosages","5060":"Appendix C","8615":"hepatitis B vaccine","8914":"dialysis patients","2568":"Monovalent","8373":"Answering Patients\u2019 Questions","6061":"limited","2064":"Getting a COVID-19 vaccine","9329":"After the Appointment  Make appointments for follow up. Record future appointments, including tests, in your calendar. If others will go with you or drive you to future appointments, make sure the appointments are on their calendars","5799":"preventing COVID- 19","4920":"vaccination should only be undertaken in an appropriate setting","1355":"monovalent","6864":"Pfizer Inc","9354":"Moderna COVID-19 Vaccine","2528":"4\u20138 weeks","3856":"an asterisk below (if it is not already recorded in the vaccine recipient\u2019s record) and report the following required vaccine administration data, or other data elements if revised by CDC, to the appropriate entity noted in the agreement: 1. Administered at location\/facility name\/ID 2. Administered at location type 3. Administration address (including company)* 4. Recipient name and ID* 5. Recipient date of birth*","4034":"review and verification","7129":"COVID-19 Toolkit for Pregnant People and New Parents \u203a COVID-19","2534":"3\u20138 weeks","9066":"specific key prevention actions","8208":"up to date","4125":"as soon as possible","6748":"2 to 14 days","670":"Alaska","655":"decrease of 13,028 doses administered","8109":"October 10, 2022","343":"vaccination data","5733":"Symptoms may appear 2 to 14 days after exposure to the virus","1336":"the same","3171":"In the following exceptional situations, a different COVID-19 vaccine may be administered to complete a primary series at a minimum interval of 28 days from the last COVID-19 vaccine dose","2879":"0.5 mL","5745":"28 days ago","8582":"the virus that causes COVID-19","3179":"Any homologous or heterologous bivalent mRNA vaccine can be used if a booster dose is FDA-authorized for use in that age group","395":"473,191","5458":"disability","2051":"pregnant","236":"COVID-19","2456":"16","7566":"You will need to show official documentation","1401":"moderately or severely","1349":"A bivalent mRNA vaccine","6241":"you can spread COVID-19 to others. You can also continue to have long-term health issues","7608":"You will need to show a U.S. military identification document","4030":"all age groups","1820":"getting all recommended COVID-19 vaccine doses","3064":"2 months","1867":"21","1815":"Jurisdictions","629":"9,143","169":"multiple","7146":"March 2020\u2013September 2021","680":"increase of 34,238 doses administered","1880":"University of Pittsburgh Medical Center","3980":"Vaccine Administration Management System","6062":"its likely benefit to enhance or restore protection by the primary vaccination","5333":"headache, feeling very tired, muscle aches, nausea, and fever","507":"higher than expected","1720":"Healthcare professionals","9341":"FDA-licensed vaccine","9383":"Monovalent","4855":"minimum age","9350":"individuals 18 years of age and older","2584":"4 weeks","1245":"collaborations between public health agencies","2645":"call 911 and tell the dispatcher that the person has or might have COVID-19. \u2022 When to seek emergency medical attention Look for emergency warning signs* for COVID-19. If someone is showing any of these signs, seek emergency medical care immediately","452":"7,840,168","4741":"COVID-19","3354":"People who have a history of myocarditis or pericarditis unrelated to vaccination with Moderna, Novavax, or Pfizer-BioNTech (e.g., due to SARS-CoV-2 or other viruses) may receive any currently FDA-approved or FDA-authorized COVID-19 vaccine after the episode of myocarditis or pericarditis","1943":"quickly study it further","5771":"COVID-19","7428":"Digital photos of vaccination card or record","9938":"People with mild illnesses","6671":"30","4572":"fans","4269":"Symptoms are gone","5611":"two","8094":"flu-like symptoms","4254":"Everyone 6 Months and Older Should Get a COVID-19 Vaccine COVID-19 vaccination has many benefits and is an important tool to help protect you from severe illness, hospitalization, and death. Getting a COVID-19 vaccine after having COVID-19 Even if you or your child","2778":"Call 911","9796":"older adults","161":"CDC","5991":"Neutralizing antibody titers","3151":"providers caring for moderately or severely immunocompromised patients","1480":"COVID-19","3318":"Cases of myocarditis and pericarditis","5950":"COVID-19","4907":"referral to an allergist-immunologist","473":"the same as both the percentage of people who received at least one dose","547":"COVID Data Tracker","9804":"unknown","643":"Illinois","5485":"whether these health problems are caused by a severe illness, the virus itself, or a combination of both","3993":"COVID-19 vaccination data","6658":"1","2006":"Millions","4094":"your healthcare or vaccine provider","5902":"0.5","4987":"MIS-C","5289":"vaccination provider","6504":"any of the medical conditions","7136":"Surveillance for Emerging Threats to Mothers and Babies Network","5139":"wear a high-quality mask or respirator the entire time you are around others indoors. Traveling by private vehicle","2484":"July 14, 2022","3252":"illness","7902":"Emerging Misinformation","8212":"2 months","3540":"different jurisdictions and providers use different reporting practices","1058":"treatments","3533":"a unique person identifier","9303":"Children and Teens","4607":"virus particles","3379":"Viral testing","556":"remove duplicate or incorrect vaccination records","8253":"COVID-19 Vaccines","10059":"mRNA or Novavax","2296":"COVID-19 Vaccine Boosters","4568":"multiple","713":"Pennsylvania","3068":"2 months","4505":"seal","3561":"they reside","4673":"thrombocytopenia","2139":"COVID-19 vaccines","9660":"30 \u03bcg in 0.3 mL","5123":"Don\u2019t","2862":"COVID-19 Vaccine","6141":"JAMA. 2021 Dec","6633":"COVID-19 vaccines. If you have a medical condition, the following","4068":"People","7527":"Persons with valid visas","9839":"online","1632":"all persons","8503":"wearing a high-quality mask","181":"Two Pet Cats","7221":"1 dose of Pfizer-BioNTech COVID-19 Vaccine. Millions of individuals have received the Pfizer-BioNTech COVID-19 Vaccine under EUA since December 11, 2020. In a clinical trial, approximately 300 individuals greater than 55 years of age received one dose of a bivalent vaccine that differs from the Pfizer-BioNTech COVID-19 Vaccine, Bivalent in that it contains a different Omicron component. WHAT ARE THE BENEFITS OF THESE VACCINES? COMIRNATY (COVID-19 Vaccine, mRNA) and the Pfizer-BioNTech COVID-19 Vaccine have been shown to prevent COVID-19","9832":"Vaccine Adverse Event Reporting System","6154":"COVID Data Tracker","7618":"applicable guidance for testing and quarantine","3220":"Procedures should be in place to prevent falling injuries and manage syncopal reactions","3656":"10","7931":"the risk for cardiac complications","3557":"Timely and accurate reporting from jurisdictions","7690":"rare","4665":"Contraindications and precautions","3883":"VAERS","6209":"Sept. 27, 2022","5081":"polysorbate allergy","3113":"2 years","6985":"Pfizer- BioNTech","6754":"inflammation of the lining outside the heart","710":"made updates to data previously submitted to CDC","8758":"ask their healthcare provider before they use methods to improve mask fit or use an ASTM F3502 mask or a respirator","5529":"CDC\u2019s INSPIRE and NIH\u2019s RECOVER ,","2901":"The same vaccine product","5454":"Sometimes the symptoms can even go away or come back again","2107":"CDC\u2019s v-safe After Vaccination Health Checker","8055":"mask use","5418":"the totality of scientific evidence available","89":"VAERS","5876":"2 to 14 days","4000":"Wednesday","4348":"CDC","8578":"immunity","8529":"Protecting Travelers\u2019 Health from Airport to Community","5270":"two","3006":"8-week","3823":"reimbursement requirements","2200":"JAMA","4862":"it","8134":"\u0082PubMed, LitCovid, ProQuest Central, Altmetric","804":"long COVID","7512":"one","1195":"October 22, 2021","4322":"Adverse effects (serious safety problems) and severe allergic reactions","8533":"cruise ships","4108":"the protection COVID-19 vaccines provide over time","2120":"Keeping yourself as healthy as possible","2489":"factors","3187":"children, adolescents, and adults","8786":"Disposable masks and respirators","6830":"scan the QR code provided below","4581":"a professional","7843":"Healthcare providers","2290":"COVID-19","7365":"A person who has received only one dose of an accepted 2-dose series","7782":"Reports of adverse events to VAERS following vaccination, including deaths","6993":"https:\/\/www.fda.gov","4368":"droplets and particles can be breathed in by other people or land on their eyes, noses, or mouth","4394":"advocates","1050":"a treatment overview","7557":"full name plus at least one other identifier","5004":"Janssen (Johnson & Johnson","4935":"Pfizer-BioNTech","2952":"bivalent Pfizer-BioNTech booster dose is authorized for children age 5 years","6889":"COVID-19 vaccine by Moderna can also be used under EUI for similar uses as an alternative mRNA COVID-19 vaccine","4924":"February 2022","2339":"If you have completed your primary series","8694":"label them according to the differences","3152":"the benefits of vaccination","6493":"Monoclonal Antibody Therapy","4330":"your vaccine provider","3852":"all information marked by an asterisk below","422":"data review and reporting adjustments","876":"using a physical barrier","5137":"high-quality mask or respirator","2802":"CDC Long COVID Alliance Long COVID Kids \uf209 \uf209 Additional Resources Post-COVID Conditions Patient Tips: Healthcare Provider Appointments for Post-COVID Conditions Mental Health and Coping During COVID-19 Coping with a Disaster or Traumatic Event How Right Now | Finding What Helps Guidance for Direct Service Providers | COVID-19 Caring for Yourself When Caring for Another Connect With Patients and Families | SCCM RECOVER (recovercovid.org) Combat COVID: Information about Clinical Trials \uf209 \uf209","7815":"hands","5190":"CDC","8579":"three","9481":"Visit CDC","8811":"CDC","3227":"4 hours","1013":"infection","4613":"quick","6486":"COVID-19","8320":"helping vaccine recipients understand the importance of vaccination and that COVID-19 vaccines are safe and effective","8309":"Coronavirus","7077":"variants","3478":"Plan ahead","6119":"Hamilton","8818":"re- posting","3389":"dysregulated","9352":"Moderna COVID-19","8991":"23,779","2490":"COVID-19 Community Level","5220":"additional information on treatments that may be available to you","3501":"testing, isolation, quarantine, mask wearing, and dining","8247":"5 and older","4159":"Vaccine ingredients vary by manufacturer","3899":"people who are older, are immunocompromised, have certain disabilities, or have underlying health conditions","5812":"COVID-19","2355":"2 years","7078":"COVID-19","2056":"COVID-19 vaccines","10028":"3 months","963":"FDA","2236":"Vaccine Breakthrough Infections COVID-19 vaccines are effective at preventing severe disease, hospitalization, and death. However, since vaccines are not 100% effective at preventing infection, some people who are up to date with the recommended vaccines\u202fwill still get COVID- 19","627":"9,143","2003":"5 years and older","6208":"VAERS","1313":"Moderna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group Pfizer-BioNTech for Children who Transition from a Younger to Older Age Group Interim COVID-19 Immunization Schedule for 6 Months of Age and Older What should I do for a child who is moving from a younger age group with a lower dose formulation to an older age group with a higher dose formulation","3226":"Non-severe, immediate (onset within 4 hours","6167":"Published analyses of case surveillance data by vaccination status","7436":"14th day after the vaccination series was completed","3524":"Guidance for Cruise Ships on the Mitigation and Management of COVID-19","2557":"people who are moderately or severely immunocompromised","9593":"chimeric antigen receptor","5155":"legal statement","6456":"one location","9246":"high-quality","113":"SARS-CoV-2","8358":"reverse that","5560":"surgical N95s","1044":"many testing locations provide flu and COVID-19 tests separately","7544":"an official letter","3769":"risks of primary, additional, and\/or booster doses of the COVID-19 vaccines","3606":"the total population and select demographic groups","3247":"\u2020 * * *","5575":"well-fitting","3465":"less than 10 days","3349":"MIS-A","8938":"adverse events that happen after vaccination","625":"California","3988":"COVID-19 vaccination data","1454":"\uf1aa\f10\/30\/22, 9:15 AM COVID-19 Vaccination Interim Clinical Considerations FAQs | CDC For more information, see COVID-19 Vaccines While Pregnant or Breastfeeding.","5546":"the most protective mask","9193":"alcohol-based hand sanitizer","8943":"unusual or unexpected patterns of health problems","874":"60%","4983":"adults ages 50 years and older","371":"CDC recommended use of the Pfizer-BioNTech Vaccine for children ages 5 through 11 for the pediatric population ages 5 to 11","1734":"Cases of myocarditis","8422":"Storage and handling requirements","3419":"subsequent dose(s)","2905":"Monovalent mRNA vaccines","3797":"10 Things Healthcare Providers Need to Know about VAERS COVID-19 Vaccine Safety Monitoring Systems for Pregnant People Learn how CDC is monitoring the safety of COVID-19 vaccination in people who are pregnant. \u2022 \u2022","1359":"5 years","2308":"COVID-19 vaccines","9128":"Open windows","970":"a screening testing program","2045":"December 14, 2020\u2013July 16, 2021","9244":"up to 10 days","3079":"mRNA vaccine","3705":"Comirnaty","8043":"COVID-19 rarely affects this group","5813":"COVID-19 vaccine by Moderna? The FDA approved the COVID-19 vaccine by Moderna to prevent COVID-19 based on safety and efficacy data available from clinical trials. Additionally, the FDA issued an Emergency Use Authorization of the COVID-19","9974":"vasovagal reaction or postvaccination side effects","3277":"Pain at the injection site","2597":"COVID-19","2728":"Caring for someone at home","1277":"Doses administered up to 4 days before the minimum interval","849":"COVID-19 Vaccines for People","157":"Studies on animals","8280":"\u2022 \u2022 Proof of vaccination card in the United States \uf1aa The white CDC COVID-19 vaccination cards are issued only to people vaccinated in the United States. CDC recommends that people vaccinated outside of the United States","1950":"text messaging and web surveys","1633":"CDC COVID-19 Vaccination Program providers","1893":"Some people who are vaccinated against COVID-19 will still get sick and have a vaccine breakthrough infection","9634":"Ages 18 years and older","972":"high risk","2381":"two","7123":"contact your healthcare professional within 24 hours","5031":"People","761":"lungs and respiratory system","10119":"persons who have had MIS-C or MIS-A from SARS-CoV-2 infection who have not yet received COVID-19 vaccine or who developed MIS-C or MIS-A after COVID-19 vaccination, a conversation between the vaccine recipient, guardian, and clinical team or specialist","6832":"Immunization Information System","6494":"a mask or respirator","4387":"Aug. 11, 2022","3674":"masks","821":"COVID 19-vaccines","1175":"whether the state can collect or report demographic data","341":"small populations in these counties","7487":"all noncitizen nonimmigrant air passengers","4211":"3 months","4012":"time","2160":"ACOG","3360":"People","8295":"learn more about CDC\u2019s isolation guidance","7997":"masks","6182":"COVID-19 vaccines","1703":"COVID-19 safety measures (e.g., social distancing, mask wearing, hand hygiene","5654":"OSHA","823":"increased risk of severe COVID-19 illness and death","8757":"respirators","2683":"as close to the time of the event as possible","21":"Search vaccines.gov, text your zip code to 438829, or call 1-800-232-0233","52":"COVID-19 vaccine","490":"April 19, 2021","6531":"having a history of cancer","1267":"booster vaccination","3889":"CDC\u2019s smartphone-based after-vaccination health checker that uses text messaging and web surveys to provide personalized health check-ins","8156":"  Updated Boosters Are Recommended for Some People CDC recommends that people ages 5 years and older receive one updated (bivalent) booster if it has been at least 2 months since their last COVID-19 vaccine dose, whether that was: Their final primary series dose, or An original (monovalent) booster People who have gotten more than one original (monovalent) booster are also recommended to get an updated","6296":"stress","1628":"vaccine","7728":"healthcare providers","7955":"\u0082","2179":"BNT162b2","1747":"program requirements","3108":"monoclonal antibodies","8053":"reasonable modifications or accommodations","7323":"reinfections","3876":"A provider\u2019s recommendation","4468":"spread it to others","880":"5 days","6091":"Advisory Committee on Immunization Practices","8718":"free masks","3102":"every 6 months","3825":"provide vaccination to anyone who is not currently a patient","9744":"Neutralizing antibody titers","3681":"Emergency Use Instructions","1957":"Vaccine Adverse Event Reporting System","7684":"the vaccine","9868":"older persons who have received 2 doses of inactivated COVID-19 vaccines","7989":"Competing national events,68 continued rollback of mitigation measures,69 and consistently decreasing coverage from social media, news media, and political sources","8939":"VAERS","474":"at least one","4847":"Vaccine","3792":"adverse events","8369":"American Psychological Association","906":"your healthcare provider or your local health department","6200":"within a week","8080":"24,846","8946":"non-serious adverse events","7905":"major themes influencing COVID-19 vaccine hesitancy and uptake","1588":"CDC","6306":"Antibody tests","812":"there is still no antibody test","9665":"outside of the FDA-authorized or FDA-approved labeling","7812":"Read the complete manufacturer\u2019s instructions for use before using the test. To use an at-home test, you will collect a nasal specimen and then test that specimen. If you do not follow the manufacturer\u2019s instructions","7247":"Report vaccine side effects","4332":"contact your state health department","6802":"Vaccine Adverse Event Reporting System","7756":"more information","212":"COVID-19","8216":"2 months","404":"April 23, 2021","6496":"a mask or respirator","2388":"10\/30\/22","273":"Census denominator","1250":"Everyone 6 months of age and older","5038":"SARS-CoV-2 infection. Updated information in the section on Vaccinating people with a known COVID-19 exposure","7153":"COVID-19 Vaccine","4526":"a seal","7540":"A-1, A-2, C-2, C-3 (as a foreign government official or immediate family member of an official),","7440":"anybody who is considered a noncitizen nonimmigrant and is traveling to the United States by air","9738":"the immunogenicity data from a Phase 1\/2 open- label clinical study","3521":"CDC will continue to provide testing recommendations for cruise ship operators to follow and cruise ships will continue to report COVID-19 cases to CDC","1683":"Pfizer-BioNTech and Moderna","7452":"Requirement for Proof of COVID-19 Vaccination for Air Passengers","9518":"vaccine product and dosage for the older age group","5736":"4 weeks","1317":"no","4399":"vaccines.gov","185":"Mink","2216":"Perl SH","10054":"Appendix A","9250":"\uf426 cough shortness of breath other COVID-19 symptoms If you develop symptoms isolate immediately get tested stay home until you know the result If your test result is positive, follow the isolation recommendations. \u2022 \u2022 \u2022 \u2022 \u2022","6741":"your child\u2019s vaccination provider","4909":"vaccination","6067":"benefit\/risk balance","2414":"COVID-19 vaccination","6579":"Because the immune response following COVID-19 vaccination","2173":"CANVAS","9217":"ventilation","5321":"Janssen COVID-19 Vaccine","7277":"If you are pregnant or breastfeeding, discuss your options","7976":"45%","5999":"3 months","9959":"People with moderate or severe immunocompromising conditions","3097":"2 months","6835":"Immunization Information System","9641":"3 weeks","6740":"Pfizer-BioNTech COVID-19 Vaccine, Bivalent","8522":"contact information","5858":"Moderna COVID-19 Vaccine","1759":"COVID-19 vaccine inventory","6944":"mid-December 2020","3213":"Administration of antihistamines","3020":"4-week","9067":"\u2022 \u2022","2773":"Experiencing post-COVID conditions","6522":"younger when they develop chronic medical conditions and may be more likely to have more than one medical condition","288":"70,721","3454":"COVID-19 vaccines","6843":"COVID-19","4577":"Pleated filters","1611":"CDC COVID-19 Vaccination Program","6905":"Pfizer-BioNTech","3767":"their likely benefit","8169":"Pfizer and Moderna","994":"COVIDtests.gov","5977":"the United Kingdom (JCVI, 2021a-b), Canada (National Advisory Committee on Vaccination, 2021), Germany, and France","9967":"to schedule doses","5009":"Rapid Plasma Reagin","7745":"Thrombosis with Thrombocytopenia Syndrome","3574":"everyone who has received only one dose","4779":"third","8960":"VIDEO VAERS and Vaccine Safety: How It Works","8521":"obligation to provide complete and accurate information","1587":"All providers","7669":"COVID-19 vaccines","7703":"adverse events to VAERS following vaccination, including deaths","384":"54,833,309","3601":"People who are fully vaccinated","4290":"COVID-19","1570":"a third primary dose of an mRNA COVID-19 vaccine","8086":"monkeypox","10062":"12-39 years","7916":"May 5, 2022","4418":"handwashing","7210":"\uf0b7 completion of primary vaccination with any authorized or approved monovalent COVID-19 vaccine; or \uf0b7 receipt of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine The vaccine may not protect everyone","716":"North Dakota","2108":"without any additional documentation from your healthcare provider","5162":"see specific testing recommendations","1396":"People can self-attest to their moderately or severely immunocompromised status","4749":"28 days","4593":"exhaust fans","9616":"doses and intervals","1718":"reports of adverse events","8098":"138","7402":"COVID-19 viral test","2244":"impact","5203":"Having information on medications you take and your test results","7888":"Encourage local health departments, public health experts, and healthcare workers to explain the absence of association between COVID-19 vaccines and monkeypox","10146":"15 minutes","8499":"\uf1aa How can I protect myself from COVID-19","8890":"By allocating vaccines","5796":"not","3225":"Allergy-related","2436":"COVID-19","6149":"potential changes in vaccine effectiveness","1081":"by mouth","5863":"WHO-EUL COVID-19","7279":"a vaccination card","1323":"\uf20c \uf209","5904":"0.5","9055":"Some variants spread more easily and quickly than others, which may lead to more cases of COVID-19","5782":"Millions","6408":"20 or more","6989":"one (1) year","6711":"\u2022 \uf209 \u2022 \uf209","9175":"seek emergency medical care","6170":"Vaccine effectiveness","5420":"the known and potential benefits","7911":"uptake","10013":"heparin-induced thrombocytopenia","3815":"COVID-19 vaccination providers cannot charge vaccine recipients for the vaccine","4942":"Pfizer-BioNTech","1229":"U.S. Census Estimates (states, D.C., Puerto Rico) and 2020 U.S. Census Estimates","3284":"6\u201323 months","1658":"may not charge an office visit","4801":"if the interval is not sooner than the minimal interval noted in this table","1300":"COVID-19 vaccines","568":"Illinois","8930":"two","2878":"Monovalent Orange Orange","1213":"the percentage and number of people with an updated (bivalent) booster dose by age, sex, and racial and ethnic groups","3834":"all providers","5889":"Ages 18 years and older","5933":"in red-capped multidose vials","10079":"4 weeks","6000":"3 months","9622":"2 to 14 days","3381":"COVID-19 vaccination","503":"increase in the number of people for whom race\/ethnicity data are available","3154":"providers","8978":"several times","1291":"Moderna, Novavax, or Pfizer-BioNTech) may be given orthopoxvirus vaccine","1915":"to collect additional health information","9776":"3\u20134 weeks","902":"5","9797":"Vaccination","1447":"Laboratory testing","4484":"practicing hand hygiene, consistently and correctly wearing a high-quality mask, improving ventilation, and keeping your distance","7687":"Anaphylaxis Anaphylaxis","0":"side effects","4318":"Stay on site","8249":"Pfizer-BioNTech","7781":"632 million","2234":"everyone 6 months and older","1653":"COVID-19 vaccination registration information and vaccine administration data","5316":"any ingredient of this vaccine","1354":"\uf209","1078":"7 days","6105":"Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination","7797":"1 to 2","4055":"getting a serious COVID-19 infection","5985":"0.25 mL","3616":"by matching the county Federal Information Processing Standard State (FIPS) code to the state","909":"If a healthy caregiver is not available","2019":"COVID-19","5495":"underlying health conditions","5261":"answer undefined","2973":"6 months","4001":"Thursday","4531":"if If you cannot get a tight seal","5997":"Multiple studies, including COV-BOOST and the NIH mix-and-match study demonstrated safety and immunogenicity of a booster dose in the general population when administered at intervals as short as 3 months following a 2-dose primary series","6341":"how long","119":"people","2144":"flu vaccine","8897":"62 years","1858":"Sentinel Sentinel Protocol","8510":"CDC","7425":"Nuvaxovid","8313":"00:00:21","6896":"Symptoms may appear 2 to 14 days after exposure to the virus","9466":"a third primary series dose","1438":"CDC","3999":"Wednesday","4605":"Follow additional recommendations","2395":"COVID-19","9068":"Aug. 11, 2021","9110":"masks","6399":"The people you live or spend time with","9721":"2","7919":"discouraging vaccine uptake","3556":"COVID-19 vaccination data","7475":"they should isolate for a full 5 calendar days","9516":"vaccine product and dosage","566":"3,409","1390":"People","4999":"following receipt of monoclonal antibodies or convalescent plasma","9682":"injection site pain, fatigue, headache, muscle pain, chills, joint pain, fever, injection site swelling, injection site redness, nausea, malaise, lymphadenopathy, decreased appetite, rash, pain in extremity, diarrhea, and vomiting","5793":"mild","3484":"no more than 3 days","7314":"How often reinfections occur","7840":"CDC strongly encourages everyone who uses a self-test to report any positive results to their healthcare provider","1068":"COVID-19 treatments","1343":"vaccine administration errors","635":"13,434","1363":"bivalent booster dose","535":"February 15, 2021","4013":"to meet local demands","5362":"Difficulty walking","1986":"scientists conducted clinical trials","4457":"Viral Testing Tool","9488":"https:\/\/www.cdc.gov\/vaccines\/programs\/iis\/about.html","8633":"Viral vector COVID-19 vaccines","7422":"the U.S. Food and Drug Administration","2119":"COVID-19 vaccination","3684":"EUI","6935":"myocarditis","8620":"Zika, flu, and HIV","5194":"a letter","3037":"primary series","1185":"Texas","4126":"Search\u202fvaccines.gov","1817":"COVID-19 including severe","6906":"a primary dose","8129":"\u0082Sprout Social","4770":"second bivalent mRNA booster dose","6016":"two-dose mRNA VE","5888":"o o o Ages 12 years and older who received primary vaccination with certain non-FDA authorized or approved COVID-19 vaccines should receive an additional primary dose of the COVID-19 vaccine by Moderna. Ages 18 years and older who received primary vaccination with the Janssen COVID-19 Vaccine should receive an additional dose with the COVID-19 vaccine by Moderna","5959":"Most evidence is with use of a booster dose after primary vaccination","2836":"consultation with infectious disease and\/or rheumatology","453":"an error in data processing","8535":"answer undefined","462":"inclusion of those ages 18 years in the <18 years group","4439":"trapping particles on a filter to remove them from the air","4107":"severe illness, hospitalization, and death","9272":"COVID-19","1391":"People ages 18 years and older","9351":"Children","9501":"An EUA is a mechanism to facilitate the availability and use of medical products, including vaccines, during public health emergencies","8665":"preclinical and clinical trial data and information, as well as details of the manufacturing process, vaccine testing results to ensure vaccine quality, and inspections of the sites where the vaccine is made","5644":"60%","6407":"Advanced or untreated HIV infection","488":"May 5, 2021","9409":"receipt","4259":"If you were given monoclonal antibodies or convalescent plasma while sick with COVID-19 you do not need to wait to get vaccinated","256":"10\/30\/22, 9:37 AM Antibodies and COVID-19 | CDC Now that you\u2019ve learned about antibodies and COVID-19, test your knowledge with an interactive quiz. Test Your Knowledge Antibodies for the virus that causes COVID-19 are expected to decrease, or wane, over time. True False Next \uf29e Last Updated Nov. 10, 2021","4989":"50 \u00b5g","1524":"HHS","6623":"Children with underlying medical conditions","6447":"5 days","5980":"epidemiology of COVID-19","9338":"SPIKEVAX","3709":"Pfizer-BioNTech COVID-19","1824":"third","1651":"Communications with COVID-19 vaccine recipients","5752":"28","6045":"Vaccination continues to be recommended regardless of the option for delaying vaccination after infection. Numerous immunologic studies and a growing number of epidemiologic studies have shown that vaccinating previously infected individuals significantly enhances their immune response and effectively reduces the risk of subsequent infection, including in the setting of increased circulation of more infectious variants","1687":"February 2021","1897":"vaccine effectiveness and rates of breakthrough infections, hospitalizations, and deaths","3922":"risk","2264":"ask questions","9736":"Pfizer-BioNTech COVID-19 vaccine, for an additional primary series and\/or booster dose based on their reviews of available immunological and safety data, as well as the epidemiology of COVID-19 and other contextual factors","1120":"Partnering for Vaccine Equity","1996":"5 years and older","7768":"vaccines are safe","2834":"consultation with infectious disease and\/or rheumatology","3497":"Follow any ship-specific mask protocols","7069":"COVID-19","2559":"Table 2","5861":"A non-FDA authorized or approved COVID-19 vaccine","2412":"more than 1,000","4905":"Novavax and Janssen","6696":"Use water","6897":"People","4289":"COVID-19","9808":"Effectiveness","3286":"a fever","8318":"COVID-19 Vaccination | CDC Vaccines & Immunizations Vaccines & Immunizations Vaccines & Immunizations Home Vaccine Recipient Education Quick References for COVID-19 Vaccine Recipients Who Want More Information Many people have questions about the coronavirus disease 2019 (COVID-19) vaccines. As vaccine recipients","2784":"Caring for People with Post-COVID Conditions","8768":"high-quality mask","7149":"COVID-19 Vaccine, mRNA","4504":"a seal","1128":"Put CDC syndicated pages","9919":"6 months of age and older","3628":"check if your airline requires any testing, vaccination, or other documents","6701":"6","355":"December 10, 2021","9544":"orange","2791":"\u2022","9788":"80-93%","8550":"contact longer than 15 minutes","7469":"Quarantine","9901":"China National Biotec Group","1978":"58","7975":"17%","581":"42,051","1289":"orthopoxvirus","9591":"moderately or severely immunocompromised persons ages 12 years and older","9108":"Using public transportation and being in transportation hubs","6809":"second-dose reminders if needed and live telephone follow-up by CDC","3164":"younger to older age group","8549":"Longer exposure time","6818":"Bivalent","5097":"TB testing","9528":"25","6477":"People Who Are Immunocompromised","5564":"the most protective mask","5785":"2,500","1571":"two","3715":"5 months","1063":"people who are unvaccinated, and people with certain medical conditions, such as chronic lung disease, heart disease, or a weakened immune system","178":"USDA","1927":"pregnant people","5674":"used by adults in workplaces","7979":"fewer than a third","6947":"COVID- 19 vaccine or Janssen COVID-19 Vaccine","1520":"Provider","2013":"adolescent and young adult males","688":"Colorado","4345":"a digital or paper copy of your vaccination record","1126":"Text your zip code to 438829","4337":"update your U.S. vaccination record","5305":"individuals 18 years of age and older","8011":"Layered prevention strategies \u2014 like staying up to date with vaccines and wearing masks","2237":"unvaccinated","4649":"People who elect to receive Janssen COVID-19 Vaccine","9602":"2013","2342":"a booster","2735":"intended for a general audience","9563":"3-8 weeks","7205":"individuals with certain kinds of immunocompromise","5505":"getting vaccinated and staying up to date with vaccines","2341":"4 weeks after 1st dose","3719":"January 7, 2022","8087":"genitals","2486":"vaccination, previous infection, or both","5437":"People who are not vaccinated against COVID-19 and become infected","5245":"Loss of taste and smell may persist for weeks or months after recovery and need not delay the end of isolation","3095":"monovalent mRNA vaccine","8827":"civil money penalties","8858":"Abt Associates","4757":"Received all or some of the recommended doses of COVID-19 vaccines","977":"nucleic acid amplification tests (NAATs","2999":"6 months","1270":"second dose","6314":"SARS-CoV-2","2254":"LTC residents","6984":"When you are administered a primary, additional, or a booster dose of the COVID-19 vaccine by Pfizer- BioNTech, you will get a vaccination card","3218":"injectable vaccine","6610":"blood stem cell transplant","3943":"5","3721":"18 years and older","6345":"important to remember that each patient should receive the same attention from the provider","2213":"2022 Apr 8. 26","8928":"Ensuring healthcare personnel have access to COVID-19 vaccination","3138":"revaccination","1388":"2 months","3343":"The myocarditis or pericarditis","8885":"trusted messengers\u2014such as faith-based and community leaders","9562":"orange","1788":"COVID-19","5918":"3 months"},"answer_start":{"674":105,"6842":500,"4917":260,"5394":559,"9227":100,"8418":144,"656":108,"9903":158,"3203":313,"9994":540,"4890":428,"6855":329,"148":265,"7371":67,"1183":420,"7177":573,"6727":146,"1133":194,"1916":82,"7490":332,"9947":114,"9726":152,"9081":250,"9749":131,"6308":242,"420":425,"5759":157,"2171":221,"8891":691,"6513":526,"1409":320,"777":0,"5636":469,"9948":74,"4203":248,"6790":444,"9589":316,"1505":310,"2363":104,"1604":109,"2743":644,"1099":669,"1553":387,"3177":0,"9166":346,"3412":312,"1161":822,"1140":0,"2664":162,"6271":576,"7714":232,"6197":27,"7397":645,"4255":50,"6419":580,"749":93,"9651":616,"7115":0,"4474":321,"7883":643,"9121":98,"1392":96,"2933":213,"5705":65,"2037":495,"4726":189,"6891":395,"8178":376,"6351":367,"9831":641,"8067":83,"5650":1,"5908":423,"6965":85,"2227":495,"8502":358,"8232":298,"6464":502,"3546":352,"6275":565,"4596":455,"9857":598,"5221":53,"5685":185,"4061":201,"5435":68,"74":29,"7760":382,"449":186,"4281":0,"3551":64,"10057":823,"3641":56,"6949":61,"368":321,"4658":140,"9178":546,"969":53,"9148":126,"5272":178,"4080":10,"7388":213,"4908":0,"658":154,"1284":160,"8091":538,"3308":59,"6775":349,"5001":1066,"3341":627,"4420":677,"5547":455,"5506":429,"4791":221,"6931":337,"4207":491,"1833":335,"2001":517,"9435":463,"7064":764,"1206":274,"933":512,"4144":590,"7668":125,"7076":489,"5215":182,"1177":315,"2321":320,"5842":433,"8888":447,"2332":389,"5927":303,"1216":395,"995":81,"6520":161,"7188":307,"2165":0,"1629":317,"6948":448,"6185":203,"8566":164,"2256":502,"6673":402,"7565":321,"421":494,"6355":348,"6382":24,"3211":386,"1288":470,"850":1,"5235":536,"7750":81,"6911":348,"5550":174,"465":84,"9953":48,"5180":333,"6653":317,"3875":655,"4437":257,"3024":0,"1662":909,"6613":555,"225":413,"3425":233,"8980":58,"5817":379,"8386":295,"6251":227,"9209":536,"6546":179,"4888":57,"1077":619,"7537":2,"4391":268,"8622":32,"8937":91,"1690":45,"4876":577,"2353":194,"3330":339,"7933":46,"3872":624,"5404":455,"3230":279,"5832":450,"1663":931,"3724":414,"433":446,"353":414,"2863":500,"7723":437,"5338":377,"4887":413,"4120":323,"7432":262,"7454":171,"4103":254,"8443":383,"584":111,"3838":580,"7272":61,"4984":2777,"4260":326,"216":26,"8498":122,"8838":0,"5984":45,"7678":273,"4150":566,"9213":272,"8026":460,"5549":116,"7256":609,"5317":45,"432":357,"3464":317,"9060":451,"10108":567,"8573":8,"7736":374,"309":345,"9402":445,"9":259,"5023":3123,"4471":246,"4680":139,"8045":1596,"305":44,"3514":137,"6455":392,"1944":120,"7716":469,"622":14,"2732":373,"9405":0,"6517":183,"3890":408,"9499":461,"7889":560,"1057":231,"8887":250,"3342":649,"2556":340,"7612":289,"3":471,"3395":151,"2707":34,"10133":653,"6535":504,"2286":292,"1987":489,"2658":200,"4229":64,"5679":507,"1894":370,"1516":0,"9885":333,"5415":277,"20":209,"3704":88,"8684":33,"3421":54,"5256":283,"8564":294,"5093":136,"6316":256,"2346":420,"591":432,"4071":466,"805":396,"1771":41,"7208":14,"6479":194,"4223":445,"1266":644,"5835":112,"5104":413,"6833":323,"5129":544,"809":765,"4861":459,"8901":285,"2635":461,"4005":474,"5304":190,"2660":359,"4480":642,"1405":523,"8918":613,"5595":0,"6703":304,"1783":409,"1105":126,"10125":361,"4736":460,"6536":539,"6892":303,"4170":616,"8481":256,"6956":175,"7012":726,"9918":95,"7724":93,"7844":257,"9198":373,"7811":114,"8382":295,"2442":0,"6519":432,"7212":107,"8164":675,"1847":907,"9224":195,"6804":424,"2485":39,"6750":516,"6555":217,"5577":65,"2570":376,"1066":231,"5026":3920,"2320":3068,"1387":481,"7552":188,"5021":1066,"1086":278,"8452":58,"5413":39,"6648":540,"7680":273,"2669":152,"4534":99,"8073":751,"8261":8,"9891":325,"8767":329,"5849":335,"585":111,"6359":43,"2307":286,"9359":408,"4351":257,"9674":122,"9944":500,"3450":73,"3290":516,"9301":626,"5330":263,"998":380,"6958":428,"1851":1583,"8755":341,"9799":448,"5781":8,"5178":499,"9766":302,"7505":69,"884":59,"9564":234,"2695":107,"447":477,"6416":434,"5389":48,"3460":194,"4218":229,"5969":243,"4812":197,"3864":363,"6411":1595,"10008":638,"2774":554,"9156":130,"3496":323,"1204":461,"3442":308,"1802":420,"49":208,"9356":204,"9978":124,"8389":324,"1477":285,"2539":2226,"7264":327,"9875":340,"3397":529,"3126":713,"7536":413,"210":0,"5690":440,"6037":25,"5069":367,"9219":269,"5133":101,"7270":72,"5500":235,"3406":334,"7872":899,"7749":169,"4235":221,"4552":234,"6957":294,"4438":508,"7227":35,"8496":490,"7717":543,"3647":192,"10141":0,"8842":386,"9833":49,"7625":529,"7449":137,"5359":24,"9557":273,"800":37,"1125":521,"6510":408,"8854":460,"4236":96,"1664":931,"10043":702,"3448":363,"5854":509,"2413":290,"9702":77,"332":189,"4424":9,"1546":639,"2265":0,"8973":567,"333":253,"6565":591,"6430":287,"2715":161,"4085":0,"9697":415,"9299":366,"4048":452,"2032":69,"1525":266,"5173":133,"3396":373,"7307":390,"3806":0,"10129":246,"7779":608,"9133":372,"2471":566,"2672":532,"3698":149,"2054":516,"7634":324,"7340":550,"6562":136,"4869":83,"6189":505,"2674":92,"8936":391,"8344":430,"9003":279,"4985":3073,"5088":720,"4169":299,"7602":73,"806":281,"7052":197,"2703":167,"8929":157,"6900":245,"6966":220,"8556":378,"2747":362,"2360":189,"7846":373,"5057":374,"6433":153,"6655":74,"1832":197,"8168":293,"9623":612,"6474":229,"9451":294,"5265":154,"8910":627,"2082":345,"8243":356,"4627":26,"587":156,"7514":489,"2826":587,"3371":427,"9170":295,"4327":54,"605":111,"6498":0,"9672":592,"3319":466,"8222":388,"6086":292,"616":14,"6380":557,"8359":513,"9031":399,"7294":203,"3147":281,"9913":146,"114":636,"414":405,"8953":322,"3789":329,"6318":67,"8995":366,"1760":165,"6402":508,"9053":200,"6716":528,"1494":166,"1619":519,"8217":926,"5538":66,"6393":187,"4490":562,"7796":62,"4478":153,"5098":407,"962":239,"6932":337,"1713":217,"9471":301,"5640":12,"6372":87,"5326":255,"134":4,"7180":255,"4981":2777,"6155":558,"6132":636,"1426":342,"9724":425,"3871":279,"3675":175,"1096":197,"86":34,"9174":536,"3485":152,"9904":486,"3994":208,"10052":1958,"5804":41,"9782":128,"7238":118,"3532":549,"9196":400,"6459":90,"2961":112,"9349":20,"1433":33,"8675":546,"3650":303,"7707":0,"6072":49,"3231":459,"468":489,"4856":53,"182":711,"7387":262,"9228":163,"2293":317,"8124":342,"1782":286,"6159":265,"2027":464,"8356":133,"1397":0,"9445":23,"4612":457,"6330":272,"4205":146,"1643":309,"604":0,"911":444,"2575":658,"8783":414,"3597":544,"4692":96,"8110":9,"8551":672,"10109":196,"8088":273,"1656":220,"9378":0,"6547":189,"4193":9,"920":97,"8364":457,"3365":669,"27":230,"2830":394,"76":112,"2322":389,"6813":455,"7709":349,"9342":485,"4764":133,"3031":336,"2365":298,"8343":373,"3621":314,"3476":556,"878":357,"6286":483,"3738":82,"3920":338,"9022":71,"3262":257,"5922":600,"9717":614,"8118":1029,"7202":336,"6988":267,"382":240,"9514":383,"7461":269,"4252":205,"8778":128,"3320":725,"1152":383,"6482":372,"95":252,"9679":571,"8736":305,"5292":240,"6442":71,"2358":814,"3358":373,"1768":311,"6553":302,"4292":104,"7605":459,"3050":299,"9332":622,"9599":335,"4280":507,"9016":48,"6704":495,"1616":74,"2918":596,"8658":186,"2233":438,"8020":701,"2621":410,"6055":467,"9794":370,"264":487,"2060":74,"1168":93,"4611":422,"528":540,"2389":488,"1222":875,"6732":259,"8186":303,"1872":1459,"4763":152,"1029":411,"2150":354,"8100":0,"8163":539,"2549":263,"2501":260,"7798":334,"5787":549,"9190":384,"255":292,"7433":391,"673":375,"2831":318,"9581":553,"4982":2777,"6489":140,"6893":557,"9760":27,"9972":44,"6278":257,"9662":337,"8782":443,"3607":257,"2330":1804,"7288":357,"2343":170,"8714":335,"6571":167,"3301":14,"9937":618,"3754":175,"3372":212,"4282":244,"2500":260,"7166":358,"9550":4,"8726":49,"5125":120,"7982":538,"2393":333,"4058":570,"8046":1684,"7148":380,"6662":334,"84":62,"5176":225,"8290":354,"5493":316,"5258":532,"6065":206,"18":185,"7521":422,"7579":325,"10077":94,"9916":620,"851":317,"8442":109,"3747":301,"6304":371,"2764":417,"1179":159,"689":18,"4831":307,"154":556,"3377":61,"2950":317,"298":21,"5659":476,"6181":1160,"2368":753,"4256":395,"832":382,"3726":715,"9344":573,"6814":221,"9909":461,"6346":99,"7980":538,"929":379,"1052":365,"8847":155,"6097":579,"7120":87,"4436":119,"7191":597,"9186":72,"8523":215,"7147":501,"8095":306,"7317":427,"768":538,"2761":173,"3169":115,"8125":273,"9507":42,"8650":135,"1230":251,"2545":573,"4503":330,"842":303,"4919":29,"4696":217,"8293":186,"4141":193,"1200":618,"9565":426,"10110":155,"4409":260,"2421":276,"2895":554,"8096":277,"3781":288,"2767":512,"4854":364,"667":539,"9173":42,"2372":160,"10114":264,"8683":537,"5263":199,"5895":510,"5111":336,"9570":331,"5864":492,"3346":536,"4191":9,"6631":115,"7133":556,"5312":0,"3219":0,"5772":313,"1716":447,"2129":546,"9294":332,"2892":100,"4469":393,"9576":333,"4146":51,"2063":421,"8673":490,"4633":19,"9275":95,"3693":248,"8824":247,"8017":298,"328":465,"8361":176,"2384":624,"6946":278,"9624":405,"7800":507,"7159":34,"9711":286,"9960":387,"1137":437,"2758":557,"9652":211,"785":317,"1928":81,"8378":15,"2475":309,"5642":0,"9212":303,"7224":533,"9824":287,"9615":289,"5982":45,"5189":469,"1679":29,"7659":136,"4822":82,"9669":297,"409":213,"7111":389,"3912":512,"577":520,"554":606,"4545":211,"6087":106,"9648":516,"6652":353,"218":26,"1325":189,"5460":66,"9993":287,"8859":45,"6778":88,"5686":250,"9556":200,"1292":77,"6788":457,"1091":468,"5108":425,"8003":553,"2817":0,"2012":317,"7807":331,"7420":63,"7764":216,"3351":98,"4232":500,"5880":83,"3658":269,"6112":90,"3679":113,"935":13,"7143":148,"683":238,"3584":188,"8376":266,"8458":55,"6131":280,"2154":52,"2073":103,"1403":523,"4307":590,"3618":208,"303":316,"397":113,"3575":0,"9470":0,"3973":275,"3232":30,"7903":288,"41":589,"3527":275,"7962":77,"10031":238,"5284":108,"1931":349,"6700":310,"251":629,"6521":581,"3531":549,"1597":512,"9704":77,"6453":240,"9083":717,"2434":487,"7644":234,"9734":18,"8969":218,"4270":102,"7713":296,"6383":377,"6634":232,"9103":395,"97":729,"8823":287,"5840":73,"589":432,"4023":64,"5801":341,"5066":171,"9548":240,"8586":348,"5935":0,"9987":696,"512":365,"4052":329,"2132":0,"4084":483,"8181":192,"8240":0,"538":369,"324":34,"3340":462,"653":411,"862":213,"8476":489,"9525":358,"4067":290,"194":508,"1906":322,"91":260,"5414":83,"2779":560,"9867":688,"6003":254,"3101":194,"5580":379,"4958":1151,"4190":79,"5551":345,"4715":119,"9258":572,"9407":546,"6528":374,"253":220,"8528":119,"4400":88,"5913":326,"5171":277,"8230":188,"8816":103,"6031":128,"2755":241,"8374":708,"695":88,"8986":200,"1296":135,"379":4,"6198":218,"3507":33,"8363":255,"4066":172,"9092":554,"11":436,"2714":85,"5262":276,"773":314,"1864":478,"7046":0,"1510":0,"5216":280,"7606":73,"7350":435,"1888":126,"1730":460,"1935":13,"8831":18,"3707":105,"4891":473,"1925":532,"2762":173,"2133":248,"3520":148,"61":343,"2473":106,"8139":2281,"1554":111,"6082":202,"4222":39,"5828":107,"8500":12,"6603":326,"6497":542,"4002":148,"28":297,"10091":1181,"4402":349,"9925":8,"1686":938,"5928":133,"9368":106,"1060":13,"4885":292,"1796":359,"5484":588,"9360":406,"7383":219,"9036":499,"5632":409,"111":270,"7704":389,"1254":37,"6588":569,"4830":290,"1518":330,"8268":682,"3119":1293,"642":9,"1838":25,"1135":17,"5688":189,"1742":358,"7674":518,"4185":27,"2555":2,"7960":258,"3217":666,"3366":478,"4173":660,"7867":314,"8457":542,"7174":117,"5225":538,"8391":538,"9552":2,"3364":292,"4498":178,"2883":159,"7126":358,"3997":336,"4398":529,"9376":254,"6539":42,"4566":244,"4458":584,"2480":208,"506":486,"4964":3155,"7273":0,"4416":559,"9997":316,"5243":360,"1709":165,"6936":160,"4930":1117,"9290":552,"7055":59,"9074":528,"5613":544,"7860":220,"2907":216,"4261":434,"5621":6,"8574":395,"1840":342,"3529":289,"8068":196,"8289":263,"5186":80,"5353":382,"5896":509,"2053":393,"3209":508,"6592":250,"2857":527,"8660":131,"378":613,"2250":344,"8307":523,"4208":53,"6898":325,"8686":165,"5663":21,"5672":534,"3911":363,"545":70,"7382":287,"8719":355,"7620":74,"3559":241,"476":314,"8264":201,"1274":3,"4725":0,"7309":102,"5335":308,"7228":316,"1654":35,"120":426,"5156":128,"1386":369,"6846":0,"9105":584,"8593":473,"4638":603,"4044":50,"6253":74,"5348":266,"221":97,"8805":203,"124":0,"8176":111,"2998":61,"10094":1463,"8647":600,"5786":489,"8394":629,"8984":504,"1148":274,"8116":717,"9111":0,"8160":306,"5487":345,"6987":305,"9512":513,"5992":0,"2547":573,"197":149,"3344":330,"1218":84,"1933":803,"3100":230,"7972":336,"999":446,"12":455,"7763":0,"1252":590,"3783":593,"9884":381,"5839":514,"7400":839,"2815":93,"6113":142,"7380":530,"6774":349,"3190":612,"3030":279,"2226":273,"6614":555,"7029":74,"939":222,"1411":537,"6837":376,"1785":365,"1919":476,"5518":127,"2131":546,"3243":398,"8975":78,"285":182,"1199":412,"1999":321,"772":322,"6237":37,"6199":347,"8882":136,"8745":111,"8234":213,"9306":18,"7885":151,"3851":647,"8259":374,"8806":270,"6593":200,"1732":0,"3567":258,"9496":0,"1320":527,"2147":509,"90":876,"7378":461,"5718":348,"6733":270,"7435":593,"7320":114,"9613":213,"9131":75,"425":0,"6904":209,"537":320,"3027":462,"3748":301,"1677":755,"4992":368,"7985":801,"1786":510,"6728":262,"7670":227,"2122":260,"1141":263,"5364":0,"350":122,"10090":1145,"6156":723,"3550":266,"8428":931,"755":270,"3345":435,"6139":150,"3130":321,"4792":317,"9020":560,"9631":417,"2754":59,"9353":0,"17":326,"2656":510,"6930":72,"6870":340,"5375":138,"7568":209,"956":395,"4967":1284,"310":507,"1150":336,"9295":525,"1049":486,"2185":302,"165":14,"7614":49,"5160":370,"5795":175,"9200":97,"7219":203,"5695":6,"4492":153,"4639":659,"7310":102,"8614":420,"7538":121,"6781":279,"9253":593,"8248":0,"4881":116,"1726":121,"3482":536,"3979":290,"5403":310,"3053":13,"4158":558,"7415":108,"5603":136,"9417":0,"8708":16,"7826":107,"6563":136,"3414":122,"7696":300,"3110":159,"4547":211,"5989":15,"1093":188,"5117":472,"390":359,"4128":532,"6604":193,"6118":401,"2875":750,"4481":484,"3430":180,"7396":597,"4382":457,"8002":399,"8632":292,"9862":575,"5110":191,"8461":399,"7661":328,"4463":336,"3250":325,"561":110,"9485":117,"1870":1103,"5269":555,"9433":485,"6216":620,"5544":137,"8769":417,"3273":109,"5572":349,"2939":112,"6643":404,"2452":388,"196":72,"6441":388,"4953":73,"752":305,"6917":225,"6805":16,"4145":339,"2721":538,"2419":471,"5209":339,"1038":541,"7743":50,"5053":331,"2924":0,"9413":279,"4388":268,"10015":476,"4164":138,"6664":367,"8012":63,"5339":523,"8284":489,"8165":614,"4465":388,"5853":389,"7401":612,"8090":298,"10137":350,"8808":87,"9473":369,"8236":366,"2260":278,"3646":568,"2276":352,"3573":391,"7014":70,"8347":325,"4226":288,"9138":215,"6766":18,"9678":135,"2530":714,"6532":301,"3054":13,"3829":7,"8365":73,"250":0,"9722":328,"3673":502,"7471":0,"9185":289,"6186":172,"8592":406,"3436":227,"5295":226,"3519":29,"8990":659,"1025":422,"1737":887,"4392":387,"2425":0,"5016":3014,"8639":45,"3350":293,"6165":182,"1834":408,"5779":527,"2565":853,"6066":27,"9598":243,"2665":528,"1269":346,"9825":325,"1682":246,"7234":352,"520":204,"2975":0,"583":17,"2940":203,"254":270,"213":577,"5259":513,"2373":0,"6672":482,"1953":0,"6124":77,"9297":332,"3264":190,"2431":50,"1375":6,"5845":492,"1127":158,"6052":0,"2091":305,"5633":106,"6908":423,"3312":418,"3977":49,"6289":261,"3700":185,"5868":589,"4962":1151,"9740":15,"3741":13,"4647":1229,"4326":201,"9340":212,"1721":267,"2113":315,"132":0,"8346":146,"5830":29,"1646":331,"7223":449,"3363":138,"7265":449,"7090":18,"4212":53,"9261":129,"5763":401,"10078":139,"4358":166,"6309":440,"8940":0,"7766":229,"5535":252,"2690":469,"1645":57,"9743":0,"8076":85,"9444":23,"3452":271,"7472":189,"2859":50,"5970":257,"5802":123,"6040":249,"7184":486,"6744":539,"4375":211,"499":616,"9638":446,"2730":312,"3441":51,"330":3,"2709":169,"1508":411,"4712":38,"2057":255,"7413":107,"9443":439,"7226":0,"4057":442,"2100":551,"5728":366,"4147":339,"1393":96,"8299":393,"9688":194,"1976":98,"3408":452,"8143":309,"7085":223,"4644":1040,"8468":312,"5172":171,"9583":132,"5806":607,"1627":190,"7804":557,"3975":466,"3671":560,"2156":270,"2253":358,"5188":248,"1753":622,"5028":68,"7986":63,"9912":392,"4412":168,"6211":130,"3630":617,"9305":518,"9853":59,"9279":95,"5789":0,"4933":1652,"6710":372,"3900":385,"9962":41,"3723":406,"1496":377,"5367":230,"6705":303,"1240":34,"988":146,"1868":768,"6964":336,"2278":505,"7318":459,"5182":412,"7841":323,"6666":538,"1752":700,"5297":310,"1744":0,"8408":19,"6074":426,"1871":1361,"7810":82,"7236":395,"3157":425,"475":197,"4843":367,"10099":317,"7106":125,"8651":312,"9561":22,"14":8,"10003":402,"4713":101,"9135":400,"6202":0,"1":125,"3083":735,"6048":357,"297":406,"5040":524,"9900":642,"2397":60,"5370":39,"5274":178,"4788":691,"3495":181,"4114":230,"5517":82,"2752":326,"975":151,"5903":501,"457":131,"837":385,"6191":136,"4483":412,"1466":2,"6910":259,"4672":36,"9371":24,"471":382,"4991":114,"5726":4,"10140":588,"1843":2666,"1970":303,"4616":315,"6018":447,"5963":44,"9440":213,"8302":594,"8106":193,"9883":381,"5523":0,"9126":462,"687":540,"4206":442,"5401":542,"4670":252,"6293":295,"9358":118,"1875":1730,"845":568,"3895":321,"6379":164,"5714":365,"6757":436,"5":375,"9492":455,"1528":266,"9392":312,"1248":14,"6689":506,"7509":385,"8297":278,"677":171,"2085":350,"4300":420,"2948":126,"5255":190,"6140":205,"4064":513,"6226":539,"5987":232,"5412":459,"6894":598,"2198":282,"8654":494,"6826":481,"8065":0,"6454":253,"4875":176,"2336":2921,"8203":436,"1309":161,"3309":0,"5513":14,"2491":330,"6767":475,"3664":256,"8492":558,"4708":237,"5956":407,"8489":287,"5738":192,"786":317,"7506":299,"1533":68,"1947":500,"8414":1136,"7497":550,"1377":215,"4328":152,"9848":106,"241":605,"8588":37,"4006":474,"8852":0,"8691":92,"9038":6,"9023":95,"3778":238,"934":168,"5224":404,"4466":313,"5910":326,"5161":241,"8596":112,"7663":313,"1162":131,"9075":538,"6640":281,"2396":247,"5145":513,"3222":149,"5257":283,"2688":144,"9034":310,"4676":503,"4381":403,"7182":220,"623":362,"8399":31,"5079":405,"6348":491,"2297":112,"5409":268,"9650":349,"3131":376,"3223":50,"4590":114,"6358":529,"63":107,"8796":94,"505":513,"6194":392,"320":135,"4609":258,"5018":3211,"3534":9,"78":136,"802":289,"6762":521,"6347":291,"6258":484,"2756":187,"2026":582,"9892":437,"915":63,"6114":230,"5226":614,"3952":581,"2266":422,"4516":118,"7110":389,"6545":86,"2315":389,"8917":546,"6313":667,"8331":621,"2636":461,"1026":0,"1586":279,"8174":60,"9232":256,"7853":569,"9296":121,"293":167,"1561":25,"2128":546,"10034":8,"3268":691,"3548":649,"3391":308,"9588":241,"887":339,"5241":404,"9951":443,"1809":623,"3039":486,"5416":324,"7626":155,"9449":605,"9932":752,"4097":94,"6584":245,"7574":0,"290":66,"9347":20,"1992":377,"6937":324,"3734":254,"5419":140,"2516":469,"5764":58,"8038":973,"3080":0,"7000":511,"5846":83,"5954":264,"2616":188,"4767":55,"3200":732,"6651":79,"5119":198,"7899":87,"2340":40,"9004":564,"4554":234,"8256":596,"8198":535,"9735":126,"3886":208,"1089":102,"4246":140,"4789":564,"3276":283,"4310":297,"7470":127,"4285":113,"5886":440,"9861":122,"58":430,"1247":480,"6046":168,"6410":1099,"4040":391,"1010":0,"261":37,"2820":377,"3631":182,"9114":475,"7186":11,"4243":78,"31":103,"5373":353,"2677":308,"1107":409,"2797":443,"6611":235,"2028":31,"517":50,"7879":452,"6220":435,"5033":633,"1042":648,"567":248,"1434":301,"4440":649,"1715":359,"3093":61,"34":369,"248":450,"7421":388,"9432":319,"8438":44,"1826":0,"1912":458,"4339":302,"7981":591,"5766":187,"8059":209,"163":182,"2967":210,"8971":411,"10014":601,"8453":50,"4810":690,"8601":67,"8911":123,"2078":545,"965":472,"5327":20,"1514":386,"7113":544,"2477":401,"4265":345,"6508":336,"7037":217,"6230":401,"399":444,"8321":756,"7091":0,"8759":19,"30":0,"3506":646,"8380":391,"5730":508,"5011":1921,"2029":154,"10066":690,"5540":366,"9197":373,"6690":0,"6512":447,"4934":1828,"5746":286,"2503":241,"6974":67,"1907":416,"2536":684,"2917":624,"6534":214,"8194":493,"3214":270,"1712":77,"6244":0,"9310":213,"435":3,"9515":222,"9323":445,"2468":153,"5014":2599,"9696":371,"8585":442,"7008":217,"1046":329,"8772":90,"5707":289,"9379":18,"6506":126,"7733":328,"10051":1922,"1124":490,"1647":562,"4597":0,"5344":471,"9474":589,"2644":434,"8517":113,"8762":474,"5379":538,"8711":134,"398":408,"4678":28,"8167":10,"2168":377,"4258":287,"2247":218,"5127":382,"5236":79,"1526":13,"668":110,"3580":0,"8722":191,"1688":302,"748":426,"6036":536,"6083":371,"1924":464,"2359":56,"7019":36,"1381":546,"8740":418,"1750":156,"735":471,"5426":112,"1603":555,"9870":235,"450":282,"4167":0,"1324":428,"4961":650,"6177":813,"8049":1842,"4422":677,"6049":359,"8799":545,"7652":552,"1578":2273,"3820":619,"2459":844,"16":8,"4279":297,"6017":309,"1329":560,"8419":288,"6057":96,"2390":0,"3173":251,"3299":410,"6866":63,"2495":160,"572":109,"2141":514,"974":105,"6978":257,"8371":61,"1190":368,"7128":68,"8607":20,"215":146,"9952":515,"9084":654,"6123":56,"2792":428,"9837":557,"6174":1087,"9015":650,"1014":116,"9072":22,"4355":10,"6109":50,"406":3,"9331":548,"8429":1037,"9627":264,"4569":84,"984":478,"7730":30,"1460":610,"601":107,"6450":367,"3841":308,"246":39,"3178":214,"8221":635,"9582":593,"3570":299,"4591":386,"7042":293,"1680":44,"8674":455,"1607":278,"5408":306,"8196":422,"9503":0,"5797":410,"9333":711,"7134":138,"8536":93,"7966":433,"8136":1802,"8182":467,"8480":248,"7651":379,"4456":411,"10073":281,"2072":37,"559":434,"4123":148,"3651":303,"2000":378,"5658":296,"2140":454,"1452":202,"6573":318,"5943":446,"5116":225,"3314":558,"6272":586,"9889":299,"597":252,"214":26,"9826":14,"7686":315,"8270":832,"2631":409,"7569":151,"3949":331,"6323":241,"819":339,"4928":728,"7816":481,"3040":44,"2590":222,"6029":292,"4777":228,"3848":469,"6030":244,"1083":152,"2263":77,"9377":556,"8685":165,"779":225,"6660":396,"9922":296,"2951":431,"9703":57,"4442":253,"7638":30,"4139":6,"3090":226,"6310":440,"5625":370,"428":435,"8695":27,"3107":25,"2991":274,"4449":562,"708":557,"9752":349,"7259":266,"4112":549,"7640":369,"484":542,"130":573,"8412":749,"4704":627,"6227":0,"5680":85,"201":0,"2312":3040,"3542":179,"5619":600,"5784":220,"9664":275,"5765":187,"7619":363,"4273":282,"7734":467,"1257":37,"6821":427,"9911":617,"9315":0,"3672":476,"5662":589,"8269":682,"3045":44,"8933":601,"5378":602,"2357":771,"4445":434,"6859":192,"6777":506,"8206":54,"9590":73,"8483":313,"8568":223,"2663":94,"10075":194,"116":86,"3762":240,"7036":119,"5483":588,"7636":504,"5446":99,"6637":580,"8162":560,"56":224,"5041":536,"7856":569,"3018":283,"4228":548,"6452":367,"8421":629,"7200":0,"4025":551,"6448":172,"5519":262,"3445":194,"4795":502,"4283":419,"3868":401,"4975":2941,"3407":440,"2361":330,"7917":440,"1103":489,"8781":391,"4852":0,"4414":279,"4018":143,"1577":25,"1863":293,"7793":526,"1879":408,"3946":324,"617":504,"4518":189,"5058":374,"4844":447,"9192":205,"5624":0,"539":546,"9475":516,"5135":315,"9049":491,"5909":211,"2498":360,"1118":28,"1560":155,"5465":877,"2269":36,"3289":595,"9612":107,"7089":612,"8036":553,"2182":63,"4443":220,"2432":176,"6405":716,"8889":325,"8893":211,"4213":117,"5594":22,"8583":146,"5574":283,"4073":56,"3415":307,"1331":208,"39":490,"1144":692,"598":0,"7112":495,"3909":352,"2443":38,"2061":213,"8664":434,"5729":419,"7515":400,"6336":271,"9847":292,"8519":315,"5929":418,"7170":526,"1960":0,"387":73,"4460":257,"8985":77,"5645":464,"9414":424,"3313":513,"824":327,"9282":504,"6023":407,"9984":56,"669":110,"8019":654,"5614":497,"3263":423,"715":0,"1672":198,"671":176,"2098":267,"4857":383,"5240":515,"9594":577,"4195":474,"4028":14,"2763":352,"4669":321,"6389":196,"707":568,"418":146,"5147":127,"4194":549,"2195":429,"6720":376,"9530":709,"2009":0,"2833":215,"4762":133,"98":516,"8334":507,"8932":506,"3378":225,"660":389,"2694":80,"494":503,"9872":519,"4152":37,"5512":436,"7462":112,"2375":537,"8306":343,"7603":40,"7152":396,"7650":495,"412":79,"1003":365,"1153":492,"4842":332,"4679":77,"8657":56,"6254":195,"727":163,"1321":20,"7003":92,"3907":99,"2354":508,"291":34,"9188":219,"1938":235,"2203":550,"5599":42,"2517":560,"7329":847,"7701":0,"6092":324,"2245":473,"4019":143,"4979":2777,"7331":391,"5482":465,"6620":591,"2689":315,"9469":61,"6982":48,"2303":538,"5230":193,"7230":554,"795":0,"8267":421,"9158":223,"9123":532,"1180":202,"2080":345,"6636":492,"5247":140,"8177":245,"8760":175,"2428":422,"5248":288,"9436":680,"7167":96,"4016":605,"4333":136,"6151":388,"3266":380,"8171":474,"147":300,"3188":487,"827":481,"6427":68,"5964":300,"4347":473,"5866":284,"1427":342,"9816":263,"8785":148,"1849":1188,"7160":20,"6339":670,"8841":386,"7303":502,"7591":755,"7813":348,"2720":420,"10126":115,"4886":312,"6527":124,"9453":431,"10103":0,"3824":393,"8690":70,"26":46,"8742":326,"6850":314,"8957":25,"3255":277,"5062":358,"9943":391,"5331":259,"7015":215,"4851":226,"5587":577,"5762":291,"1575":2138,"2617":310,"9705":299,"8351":309,"9976":545,"2864":702,"2058":352,"9586":112,"1021":98,"3091":226,"1428":461,"3161":167,"9834":133,"1158":710,"2654":479,"3416":353,"6424":382,"1590":686,"2052":488,"9795":323,"747":295,"2994":20,"444":253,"4635":195,"3598":586,"1115":402,"2972":65,"8123":178,"7082":297,"6193":318,"5719":549,"4096":471,"8069":381,"7751":274,"3166":545,"5060":312,"8615":453,"8914":434,"2568":306,"8373":470,"6061":512,"2064":0,"9329":105,"5799":423,"4920":462,"1355":6,"6864":101,"9354":157,"2528":358,"3856":218,"4034":282,"7129":14,"2534":2194,"9066":552,"8208":260,"4125":267,"6748":220,"670":18,"655":623,"8109":194,"343":96,"5733":0,"1336":516,"3171":362,"2879":1578,"5745":486,"8582":78,"3179":254,"395":589,"5458":340,"2051":270,"236":495,"2456":558,"7566":0,"1401":563,"1349":170,"6241":147,"7608":99,"4030":400,"1820":306,"3064":358,"1867":698,"1815":417,"629":234,"169":309,"7146":363,"680":542,"1880":527,"3980":248,"6062":194,"5333":24,"507":662,"1720":45,"9341":278,"9383":274,"4855":19,"9350":66,"2584":20,"1245":22,"2645":25,"452":402,"4741":284,"3354":69,"1943":48,"5771":101,"7428":1073,"9938":572,"6671":281,"4572":397,"4269":537,"5611":357,"8094":277,"4254":110,"2778":522,"9796":475,"161":419,"5991":0,"3151":25,"1480":544,"3318":441,"5950":22,"4907":614,"473":164,"547":311,"9804":224,"643":16,"5485":92,"3993":570,"6658":332,"2006":108,"4094":265,"5902":70,"4987":2337,"5289":449,"6504":36,"7136":367,"5139":15,"2484":387,"3252":702,"7902":2,"8212":203,"3540":658,"1058":231,"3533":641,"9303":20,"4607":170,"3379":478,"556":143,"8253":158,"10059":28,"2296":112,"4568":422,"713":423,"3068":270,"4505":145,"3561":536,"4673":332,"2139":300,"9660":276,"5123":530,"2862":400,"6141":550,"6633":180,"4068":264,"7527":423,"9839":557,"1632":527,"8503":613,"181":1020,"7221":102,"9832":133,"6154":481,"7618":488,"3220":0,"3656":150,"7931":895,"3557":556,"7690":535,"4665":384,"3883":128,"6209":215,"5081":405,"3113":567,"6985":330,"6754":302,"710":574,"8758":91,"5529":205,"2901":93,"5454":532,"2107":138,"8055":8,"5418":42,"89":817,"5876":342,"4000":646,"4348":0,"8578":271,"8529":383,"5270":585,"3006":3,"3823":349,"2200":602,"4862":49,"8134":1623,"804":328,"7512":49,"1195":10,"4322":248,"8533":308,"4108":355,"2120":0,"2489":21,"3187":628,"8786":344,"6830":207,"4581":309,"7843":0,"2290":29,"7365":89,"7782":375,"6993":586,"4368":212,"4394":251,"1050":141,"7557":375,"5004":2274,"4935":136,"2952":500,"6889":4,"4924":2408,"2339":3152,"8694":573,"3152":251,"6493":0,"4330":325,"3852":193,"422":302,"876":81,"5137":22,"2802":257,"7815":491,"5190":4,"8579":488,"9481":457,"8811":522,"3227":522,"1013":31,"4613":585,"6486":235,"8320":438,"8309":327,"7077":558,"3478":85,"6119":749,"8818":235,"3389":623,"9352":232,"8991":45,"2490":269,"5220":582,"3501":49,"8247":672,"4159":641,"3899":409,"5812":128,"2355":601,"7078":103,"2056":313,"10028":649,"963":280,"2236":162,"627":234,"2003":613,"6208":192,"1313":25,"3226":486,"6167":585,"7436":43,"3524":515,"2557":433,"9593":441,"5155":149,"6456":578,"9246":518,"113":491,"8358":498,"5560":257,"1044":116,"7544":109,"3769":65,"3606":303,"3247":187,"5575":417,"3465":447,"3349":742,"8938":505,"625":14,"3988":467,"1454":470,"5546":370,"9193":279,"8943":393,"874":340,"4983":2835,"371":511,"1734":614,"8422":158,"3419":286,"2905":0,"3797":0,"1359":519,"2308":542,"9128":462,"970":148,"2045":1018,"9244":331,"3079":344,"3705":54,"8043":1481,"5813":39,"9974":361,"3277":343,"2597":632,"2728":78,"1277":0,"849":310,"157":0,"8280":206,"1950":384,"1633":0,"1893":370,"9634":273,"972":226,"2381":323,"7123":116,"5031":373,"761":483,"10119":6,"6832":781,"6494":208,"4387":438,"3674":231,"821":231,"1175":221,"341":635,"7487":479,"4211":472,"4012":46,"2160":420,"3360":577,"8295":153,"7997":240,"6182":32,"1703":289,"5654":710,"823":522,"8757":427,"2683":487,"21":346,"52":271,"490":3,"6531":534,"1267":622,"3889":342,"8156":3,"6296":115,"1628":337,"7728":341,"7955":495,"2179":712,"1747":337,"3108":168,"8053":217,"7323":346,"3876":182,"4468":538,"880":357,"6091":0,"8718":326,"3102":356,"3825":158,"9744":0,"3681":360,"1957":305,"7684":34,"9868":345,"7989":216,"8939":551,"474":84,"4847":520,"3792":41,"8369":25,"906":550,"6200":426,"8080":158,"8946":313,"7905":364,"1588":637,"6306":0,"812":58,"9665":349,"7812":228,"7247":364,"4332":13,"6802":432,"7756":579,"212":510,"8216":635,"404":219,"6496":208,"2388":338,"273":517,"1250":552,"5038":289,"7153":407,"4526":240,"7540":149,"7440":456,"9738":161,"3521":0,"1683":302,"7452":557,"9518":639,"5736":284,"1317":601,"4399":52,"185":931,"2216":438,"10054":157,"9250":198,"6741":263,"4909":183,"6067":456,"2414":327,"6579":647,"2173":629,"9217":277,"5321":636,"7277":272,"7976":239,"5999":450,"9959":486,"3097":436,"6835":781,"9641":559,"6740":131,"8522":5,"5858":330,"1759":47,"6944":172,"3213":89,"3020":316,"9067":651,"2773":439,"6522":54,"288":230,"3454":385,"6843":421,"4577":570,"1611":213,"6905":209,"3767":194,"8169":329,"994":37,"5977":18,"9967":503,"5009":2085,"7745":341,"3574":198,"4779":190,"8960":384,"8521":373,"1587":279,"7669":149,"7703":11,"384":532,"3601":163,"4290":143,"1570":1301,"8086":9,"10062":346,"7916":195,"4418":171,"7210":122,"716":19,"2108":62,"5162":311,"1396":548,"4749":53,"4593":9,"9616":574,"1718":630,"8098":404,"7402":113,"2244":285,"5203":383,"7888":560,"10146":71,"8499":37,"8890":322,"5796":496,"3225":171,"2436":559,"6149":367,"1081":751,"5863":394,"7279":557,"1323":431,"5904":70,"9055":535,"5782":59,"6408":1099,"6989":312,"6711":650,"9175":42,"6170":367,"5420":188,"7911":96,"10013":560,"3815":0,"4942":0,"1229":16,"3284":426,"1658":398,"4801":83,"1300":432,"568":156,"8930":182,"2878":1133,"1213":59,"3834":160,"5889":267,"5933":524,"10079":80,"6000":607,"9622":342,"3381":229,"503":316,"3154":362,"8978":292,"1291":135,"1915":61,"9776":292,"902":313,"9797":0,"1447":234,"4484":304,"7687":10,"0":96,"4318":511,"8249":172,"7781":525,"2234":25,"1653":378,"5316":585,"1354":1,"1078":343,"6105":686,"7797":252,"4055":96,"5985":320,"3616":55,"909":183,"2019":562,"5495":527,"5261":17,"2973":263,"4001":67,"4531":254,"5997":254,"6341":107,"119":275,"2144":172,"8897":268,"1858":2424,"8510":418,"7425":487,"8313":290,"6896":0,"9466":575,"1438":165,"3999":646,"4605":236,"2395":123,"9068":756,"9110":389,"6399":309,"9721":450,"7919":695,"3556":383,"7475":482,"9516":639,"566":112,"1390":96,"4999":856,"9682":135,"5793":41,"3484":204,"7314":55,"7840":415,"1068":416,"1343":285,"635":105,"1363":277,"535":3,"4013":247,"5362":668,"1986":302,"4457":310,"9488":347,"8633":104,"7422":62,"2119":542,"3684":140,"6935":96,"8620":641,"5194":15,"3037":308,"1185":499,"4126":386,"1817":711,"6906":544,"8129":641,"4770":206,"6016":123,"5888":63,"5959":434,"2836":93,"453":454,"8535":543,"462":507,"4439":131,"4107":256,"9272":631,"1391":96,"9351":0,"9501":496,"8665":15,"5644":320,"6407":837,"488":391,"9409":218,"4259":169,"256":306,"4989":3743,"1524":545,"6623":231,"6447":66,"5980":358,"9338":300,"3709":232,"1824":527,"1651":0,"5752":587,"6045":258,"1687":1093,"1897":607,"3922":375,"2264":134,"9736":193,"1120":490,"1996":582,"7768":550,"2834":93,"3497":329,"7069":303,"2559":77,"5861":2,"2412":290,"4905":192,"6696":484,"6897":376,"4289":541,"9808":417,"3286":110,"8318":46,"2784":384,"8768":579,"7149":391,"4504":143,"1128":255,"9919":445,"3628":582,"6701":310,"355":57,"9544":342,"2791":205,"9788":570,"8550":295,"7469":502,"9901":86,"1978":460,"7975":205,"581":385,"1289":663,"9591":19,"9108":86,"6809":21,"3164":412,"8549":225,"6818":126,"5097":302,"9528":31,"6477":158,"5564":302,"5785":316,"1571":1558,"3715":129,"1063":226,"178":339,"1927":23,"5674":90,"7979":325,"6947":479,"1520":0,"2013":530,"688":18,"4345":165,"1126":69,"4337":175,"5305":261,"8011":473,"2237":610,"4649":0,"9602":3,"2342":289,"2735":621,"9563":234,"7205":457,"5505":406,"2341":39,"3719":383,"8087":288,"2486":180,"5437":256,"5245":0,"3095":204,"8827":313,"8858":500,"4757":138,"977":282,"2999":61,"1270":285,"6314":159,"2254":358,"6984":236,"3218":719,"6610":305,"3943":157,"3721":109,"6345":43,"2213":206,"8928":0,"3138":635,"1388":558,"3343":202,"8885":361,"9562":95,"1788":278,"5918":341}}